PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Tang, L; Breinig, S; Stith, L; Mischel, A; Tannir, J; Kokona, B; Fairman, R; Jaffe, EK				Tang, L; Breinig, S; Stith, L; Mischel, A; Tannir, J; Kokona, B; Fairman, R; Jaffe, EK			Single amino acid mutations alter the distribution of human porphobilinogen synthase quaternary structure isoforms (morpheeins)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DEHYDRATASE; PORPHYRIA; MECHANISM; PATIENT; FORMS; GENE	Porphobilinogen synthase (PBGS) is an obligate oligomer that can exist in functionally distinct quaternary states of different stoichiometries, which are called morpheeins. The morpheein concept describes an ensemble of quaternary structure isoforms wherein different structures of the monomer dictate different multiplicities of the oligomer ( Jaffe, E. K. ( 2005) Trends Biochem. Sci. 30, 490 497). Human PBGS assembles into long-lived morpheeins and has been shown to be capable of forming either a high activity octamer or a low activity hexamer (Breinig, S., Kervinen, J., Stith, L., Wasson, A. S., Fairman, R., Wlodawer, A., Zdanov, A., and Jaffe, E. K. ( 2003) Nat. Struct. Biol. 10, 757 - 763). All PBGS monomers contain an alpha beta-barrel domain and an N-terminal arm domain. The N-terminal arm structure varies among PBGS morpheeins, and the spatial relationship between the arm and the barrel dictates the different quaternary assemblies. We have analyzed the structures of human PBGS morpheeins for key interactions that would be predicted to affect the oligomeric assembly. Examples of individual mutations that shift assembly of human PBGS away from the native octamer are R240A and W19A. The alternate morpheeins of human PBGS variants R240A and W19A are chromatographically separable from each other and kinetically distinct; their structure and dynamics have been characterized by native gel electrophoresis, dynamic light scattering, and analytical ultracentrifugation. R240A assembles into a metastable hexamer, which can undergo a reversible conversion to the octamer in the presence of substrate. The metastable nature of the R240A hexamer supports the hypothesis that octameric and hexameric morpheeins of PBGS are very close in energy. W19A assembles into a mixture of dimers, which appear to be stable.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Haverford Coll, Dept Biol, Haverford, PA 19041 USA	Fox Chase Cancer Center; Haverford College	Jaffe, EK (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Eileen.Jaffe@fccc.edu			NCI NIH HHS [CA006927] Funding Source: Medline; NIEHS NIH HHS [ES03654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akagi R, 2000, HEPATOLOGY, V31, P704, DOI 10.1002/hep.510310321; Akagi R, 2000, BLOOD, V96, P3618, DOI 10.1182/blood.V96.10.3618.h8003618_3618_3623; AKAGI R, 2006, MOL GENET METAB; Arkin M, 2001, ANAL BIOCHEM, V299, P98, DOI 10.1006/abio.2001.5396; Breinig S, 2003, NAT STRUCT BIOL, V10, P757, DOI 10.1038/nsb963; Frankenberg N, 1999, J MOL BIOL, V289, P591, DOI 10.1006/jmbi.1999.2808; Jaffe EK, 2004, BIOORG CHEM, V32, P316, DOI 10.1016/j.bioorg.2004.05.010; Jaffe EK, 2003, CHEM BIOL, V10, P25, DOI 10.1016/S1074-5521(02)00296-X; JAFFE EK, 1995, BIOCHEMISTRY-US, V34, P244, DOI 10.1021/bi00001a029; Jaffe EK, 2000, J BIOL CHEM, V275, P2619, DOI 10.1074/jbc.275.4.2619; Jaffe EK, 2005, TRENDS BIOCHEM SCI, V30, P490, DOI 10.1016/j.tibs.2005.07.003; JAFFE EK, 1990, BIOORG CHEM, V18, P381, DOI 10.1016/0045-2068(90)90022-W; JORDAN PM, 1985, BIOCHEM J, V227, P1015, DOI 10.1042/bj2271015; Kervinen J, 2001, BIOCHEMISTRY-US, V40, P8227, DOI 10.1021/bi010656k; Laue TM, 1992, BIOCH POLYM SCI, P90; Maruno M, 2001, BLOOD, V97, P2972, DOI 10.1182/blood.V97.10.2972; MILLSDAVIES NL, 2000, THESIS U SOUTHAMPTON; SASSA S, 1992, T ASSOC AM PHYSICIAN, V105, P250; Sassa S, 2000, J INTERN MED, V247, P169, DOI 10.1046/j.1365-2796.2000.00618.x; Tang L, 2005, J BIOL CHEM, V280, P15786, DOI 10.1074/jbc.M500218200; van Holde K.E., 1998, PRINCIPLES PHYS BIOC, Vsecond; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X	22	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6682	6690		10.1074/jbc.M511134200	http://dx.doi.org/10.1074/jbc.M511134200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377642	hybrid			2022-12-27	WOS:000236030800065
J	Goin, JC; Nathanson, NM				Goin, JC; Nathanson, NM			Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells - Regulation of receptor down-regulation by heterodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-TRANSFER; LIVING CELLS; PAIRED ACTIVATION; 2 COMPONENTS; M-2; OLIGOMERIZATION; INTERNALIZATION; IDENTIFICATION; SEQUESTRATION; DIMERIZATION	Although previous pharmacological and biochemical data support the notion that muscarinic acetylcholine receptors ( mAChR) form homo- and heterodimers, the existence of mAChR oligomers in live cells is still a matter of controversy. Here we used bioluminescence resonance energy transfer to demonstrate that M-1, M-2, and M-3 mAChR can form constitutive homo- and heterodimers in living HEK 293 cells. Quantitative bioluminescence resonance energy transfer analysis has revealed that the cell receptor population in cells expressing a single subtype of M-1, M-2, or M-3 mAChR is predominantly composed of high affinity homodimers. Saturation curve analysis of cells expressing two receptor subtypes demonstrates the existence of high affinity M-1/M-2, M-2/M-3, and M-1/M-3 mAChR heterodimers, although the relative affinity values were slightly lower than those for mAChR homodimers. Short term agonist treatment did not modify the oligomeric status of homo- and heterodimers. When expressed in JEG-3 cells, the M-2 receptor exhibits much higher susceptibility than the M-3 receptor to agonist-induced down-regulation. Coexpression of M-3 mAChR with increasing amounts of the M-2 subtype in JEG-3 cells resulted in an increased agonist-induced down-regulation of M-3, suggesting a novel role of heterodimerization in the mechanism of mAChR long term regulation.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Consejo Nacl Invest Cient & Tecn, Ctr Estudios Farmacol & Bot, RA-1414 Buenos Aires, DF, Argentina	University of Washington; University of Washington Seattle; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Nathanson, NM (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Box 357750, Seattle, WA 98195 USA.	nathanso@u.washington.edu			NHLBI NIH HHS [HL 44948] Funding Source: Medline; NINDS NIH HHS [NS 26920] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2004, MOL PHARMACOL, V66, P312, DOI 10.1124/mol.104.000398; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; Breitwieser GE, 2004, CIRC RES, V94, P17, DOI 10.1161/01.RES.0000110420.68526.19; Canals M, 2004, J NEUROCHEM, V88, P726, DOI 10.1046/j.1471-4159.2003.02200.x; Chidiac P, 1997, BIOCHEMISTRY-US, V36, P7361, DOI 10.1021/bi961939t; CHIDIAC P, 1992, BIOCHEMISTRY-US, V31, P10908, DOI 10.1021/bi00159a035; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; Goin JC, 2002, J NEUROCHEM, V83, P964, DOI 10.1046/j.1471-4159.2002.01209.x; GOLDMAN PS, 1994, J BIOL CHEM, V269, P15640; Goldman PS, 1996, J BIOL CHEM, V271, P4215; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Griffin MT, 2003, BIOCHEM PHARMACOL, V65, P1227, DOI 10.1016/S0006-2952(03)00068-6; HALVORSEN SW, 1981, J BIOL CHEM, V256, P7941; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; Kaykas A, 2004, NAT CELL BIOL, V6, P52, DOI 10.1038/ncb1081; Kroeger KM, 2003, FRONT NEUROENDOCRIN, V24, P254, DOI 10.1016/j.yfrne.2003.10.002; Kurogouchi F, 2002, CLIN EXP PHARMACOL P, V29, P666, DOI 10.1046/j.1440-1681.2002.03714.x; LAMEH J, 1992, J BIOL CHEM, V267, P13406; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUETJE CW, 1987, BIOCHEMISTRY-US, V26, P6892, DOI 10.1021/bi00396a003; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MCKINNON LA, 1995, J BIOL CHEM, V270, P20636, DOI 10.1074/jbc.270.35.20636; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Nadler LS, 2001, J BIOL CHEM, V276, P10539, DOI 10.1074/jbc.M007190200; Novi F, 2005, J BIOL CHEM, V280, P19768, DOI 10.1074/jbc.M411281200; Novi F, 2004, J BIOL CHEM, V279, P7476, DOI 10.1074/jbc.M306818200; Oki T, 2005, MOL BRAIN RES, V133, P6, DOI 10.1016/j.molbrainres.2004.09.012; Ostrom RS, 1997, J PHARMACOL EXP THER, V280, P189; Park PSH, 2003, BIOCHEMISTRY-US, V42, P12960, DOI 10.1021/bi034491m; Park PSH, 2004, J NEUROCHEM, V90, P537, DOI 10.1111/j.1471-4159.2004.02536.x; POTTER LT, 1991, MOL PHARMACOL, V39, P211; Ramsay D, 2004, MOL PHARMACOL, V66, P228, DOI 10.1124/mol.66.2.228; Roseberry AG, 1999, J BIOL CHEM, V274, P33671, DOI 10.1074/jbc.274.47.33671; Schlador ML, 2000, J BIOL CHEM, V275, P23295, DOI 10.1074/jbc.M002380200; Schlador ML, 1997, J BIOL CHEM, V272, P18882, DOI 10.1074/jbc.272.30.18882; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; Wang DX, 2005, MOL PHARMACOL, V67, P2173, DOI 10.1124/mol.104.010272; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Zeng FY, 2000, NEUROPSYCHOPHARMACOL, V23, pS19, DOI 10.1016/S0893-133X(00)00146-9	46	69	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5416	5425		10.1074/jbc.M507476200	http://dx.doi.org/10.1074/jbc.M507476200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16368694	hybrid, Green Published			2022-12-27	WOS:000235568900013
J	Nandigama, R; Padmasekar, M; Wartenberg, M; Sauer, H				Nandigama, R; Padmasekar, M; Wartenberg, M; Sauer, H			Feed forward cycle of hypotonic stress-induced ATP release, purinergic receptor activation, and growth stimulation of prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; INDUCED CA2+ WAVES; EXTRACELLULAR ATP; CONDUCTANCE REGULATOR; ENDOTHELIAL-CELLS; PROSTAGLANDIN E-2; NUCLEOTIDES; MECHANISMS; ASTROCYTES; TRANSPORT	ATP is released in many cell types upon mechanical strain, the physiological function of extracellular ATP is largely unknown, however. Here we report that ATP released upon hypotonic stress stimulated prostate cancer cell proliferation, activated purinergic receptors, increased intracellular [Ca2+](i), and initiated downstream signaling cascades that involved MAPKs ERK1/2 and p38 as well as phosphatidylinositol 3-kinase (PI3K). MAPK activation, the calcium response as well as induction of cell proliferation upon hypotonic stress were inhibited by preincubation with the ATP scavenger apyrase, indicating that hypotonic stress-induced signaling pathways are elicited by released ATP. Hypotonic stress increased prostaglandin E-2 (PGE(2)) synthesis. Consequently, ATP release was inhibited by antagonists of PI3K (LY294002 and wortmannin), phospholipase A(2) ( methyl arachidonyl fluorophosphonate ( MAFP)), cyclooxygenase-2 (COX-2) ( indomethacin, etodolac, NS398) and 5,8,11,14-eicosatetraynoic acid ( ETYA), which are involved in arachidonic acid metabolism. Furthermore, ATP release was abolished in the presence of the adenylate cyclase (AC) inhibitor MDL-12,330A, indicating regulation of ATP-release by cAMP. The hypotonic stress-induced ATP release was significantly blunted when the ATP-mediated signal transduction cascade was inhibited on different levels, i. e. purinergic receptors were blocked by suramin and pyridoxalphosphate-6-azophenyl- 2', 4'-disulfonic acid (PPADS), the Ca2+ response was inhibited upon chelation of intracellular Ca2+ by 1,2-bis(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid ( BAPTA), and ERK1,2 as well as p38 were inhibited by UO126 and SB203580, respectively. In summary our data demonstrate that hypotonic stress initiates a feed forward cycle of ATP release and purinergic receptor signaling resulting in proliferation of prostate cancer cells.	Univ Giessen, Dept Physiol, D-35312 Giessen, Germany; GKSS Forschungszentrum Geesthacht GmbH, Dept Cell Biol, D-14513 Teltow, Germany	Justus Liebig University Giessen; Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung	Sauer, H (corresponding author), Univ Giessen, Dept Physiol, Aulweg 129, D-35392 Giessen, Germany.	heinrich.sauer@physiologie.med.uni-giessen.de		Nandigama, Rajender/0000-0002-7344-4732; Nandigama, Manju Padmasekar/0000-0001-7060-8319				ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; Alexander LD, 2004, KIDNEY INT, V65, P551, DOI 10.1111/j.1523-1755.2004.00405.x; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bodas E, 2000, J BIOL CHEM, V275, P20268, DOI 10.1074/jbc.M000894200; Braunstein Gavin M, 2004, J Cyst Fibros, V3, P99, DOI 10.1016/j.jcf.2004.01.006; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; Brustovetsky N, 1996, P NATL ACAD SCI USA, V93, P664, DOI 10.1073/pnas.93.2.664; Burnstock G, 2002, CLIN MED, V2, P45, DOI 10.7861/clinmedicine.2-1-45; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Calvert RC, 2004, ANTICANCER RES, V24, P2853; Cohen CR, 1997, EXP CELL RES, V231, P184, DOI 10.1006/excr.1996.3450; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Coutinho-Silva R, 2005, AM J PHYSIOL-GASTR L, V288, pG1024, DOI 10.1152/ajpgi.00211.2004; FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562; Feranchak AP, 2000, J HEPATOL, V33, P174, DOI 10.1016/S0168-8278(00)80357-8; Franke H, 1999, GLIA, V28, P190, DOI 10.1002/(SICI)1098-1136(199912)28:3<190::AID-GLIA3>3.0.CO;2-0; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Hazama A, 1998, PFLUG ARCH EUR J PHY, V437, P31, DOI 10.1007/s004240050742; Insel PA, 2001, CLIN EXP PHARMACOL P, V28, P351, DOI 10.1046/j.1440-1681.2001.03452.x; Jakab M, 2002, CELL PHYSIOL BIOCHEM, V12, P235, DOI 10.1159/000067895; Janssens R, 2001, BRIT J PHARMACOL, V132, P536, DOI 10.1038/sj.bjp.0703833; Jo YH, 1999, NAT NEUROSCI, V2, P241, DOI 10.1038/6344; Lader AS, 2000, AM J PHYSIOL-CELL PH, V279, pC173, DOI 10.1152/ajpcell.2000.279.1.C173; Lundgren DW, 1997, J BIOL CHEM, V272, P20118, DOI 10.1074/jbc.272.32.20118; Matsumoto PS, 1997, J MEMBRANE BIOL, V160, P27, DOI 10.1007/s002329900292; Naumann Nora, 2005, J Cyst Fibros, V4, P157, DOI 10.1016/j.jcf.2005.05.003; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Post SR, 1996, J BIOL CHEM, V271, P2029, DOI 10.1074/jbc.271.4.2029; Randriamboavonjy V, 2004, J EXP MED, V199, P347, DOI 10.1084/jem.20030694; Roman RM, 2001, J MEMBRANE BIOL, V183, P165, DOI 10.1007/s00232-001-0064-7; Sauer H, 2000, AM J PHYSIOL-CELL PH, V279, pC295, DOI 10.1152/ajpcell.2000.279.2.C295; Sauer H, 2001, FASEB J, V15, P2539, DOI 10.1096/fj.01-0360fje; SCHULZELOHOFF E, 1992, AM J PHYSIOL, V263, pF374, DOI 10.1152/ajprenal.1992.263.3.F374; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P2674, DOI 10.1073/pnas.95.5.2674; Schwiebert EM, 2000, AM J PHYSIOL-CELL PH, V279, pC281, DOI 10.1152/ajpcell.2000.279.2.C281; Schwiebert EM, 2003, BBA-BIOMEMBRANES, V1615, P7, DOI 10.1016/S0005-2736(03)00210-4; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Schwiebert ER, 2001, CLIN EXP PHARMACOL P, V28, P340, DOI 10.1046/j.1440-1681.2001.03451.x; Stout CE, 2002, J BIOL CHEM, V277, P10482, DOI 10.1074/jbc.M109902200; Welch BD, 2003, AM J PHYSIOL-RENAL, V285, pF711, DOI 10.1152/ajprenal.00096.2003; Xing MZ, 1997, J CLIN INVEST, V99, P805, DOI 10.1172/JCI119227; Xing MZ, 1999, J BIOL CHEM, V274, P10035, DOI 10.1074/jbc.274.15.10035	45	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5686	5693		10.1074/jbc.M510452200	http://dx.doi.org/10.1074/jbc.M510452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16321972	hybrid			2022-12-27	WOS:000235568900045
J	Sun, HY; Liu, XD; Xiong, QJ; Shikano, S; Li, M				Sun, HY; Liu, XD; Xiong, QJ; Shikano, S; Li, M			Chronic inhibition of cardiac Kir2.1 and hERG potassium channels by celastrol with dual effects on both ion conductivity and protein trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; INTERVAL PROLONGATION; SURFACE EXPRESSION; MEMBRANE-RECEPTORS; MOLECULAR-BASIS; CELL-SURFACE; DRUG; RELEVANCE; DISEASE; SIGNALS	A high percentage of drugs and drug candidates has been found to cause cardiotoxicity by reducing potassium conductance, more commonly known as QT prolongation. However, some compounds do not show direct block of ionic flow, suggesting that other mechanisms may also lead to reduction of potassium currents. Using the functional recovery after chemobleaching (FRAC) assay, we have examined a collection of drugs and drug-like compounds for potential perturbation of cardiac potassium channel trafficking. Here we report that a significant number of inhibitory compounds displayed effects on channel expression on the cell surface. Further investigation of celastrol (3-hydroxy-24-nor-2-oxo-1 (10),3,5,7-friedelatetraen-29-oic acid), a cell-permeable dienonephenolic triterpene compound, revealed its potent inhibitory activity on both Kir2.1 and hERG potassium channels, causal to QT prolongation. In addition to acute block of ion conduction, celastrol also alters the rate of ion channel transport and causes a reduction of channel density on the cell surface. In contrast, celastrol has no effects on trafficking of either CD4 or CD8 membrane proteins. Furthermore, the potency for reducing surface expression is similar to 5-10-fold more effective than that for either direct acute inhibition or reported cytoprotectivity via activation of the heat shock transcription factor 1. Because the reduction of potassium channel activity is a common form of drug-induced cardiotoxicity, the potent inhibition of cell surface expression by celastrol underscores a need to evaluate drug candidates for their chronic effects on biogenesis of potassium channels. Our results suggest that chronic exposure to certain drugs may be an important aspect of acquired QT prolongation.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Li, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, BRB311,733 N Broadway, Baltimore, MD 21205 USA.	minli@jhmi.edu	Liu, Xiaodong/B-1839-2008; Liu, Xiaodong/N-3373-2019	Liu, Xiaodong/0000-0002-3171-9611; Liu, Xiaodong/0000-0002-3171-9611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070959] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 70959] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allison AC, 2001, PROG NEURO-PSYCHOPH, V25, P1341, DOI 10.1016/S0278-5846(01)00192-0; Ashcroft F.M., 2000, ION CHANNELS DIS, P67; Clancy CE, 2001, CARDIOVASC RES, V50, P301, DOI 10.1016/S0008-6363(00)00293-5; Cleren C, 2005, J NEUROCHEM, V94, P995, DOI 10.1111/j.1471-4159.2005.03253.x; Coblitz B, 2005, J BIOL CHEM, V280, P36263, DOI 10.1074/jbc.M507559200; Cordes JS, 2005, BRIT J PHARMACOL, V145, P15, DOI 10.1038/sj.bjp.0706140; Curran ME, 1998, CURR OPIN BIOTECH, V9, P565, DOI 10.1016/S0958-1669(98)80133-X; De Ponti F, 2000, EUR J CLIN PHARMACOL, V56, P1, DOI 10.1007/s002280050714; Ford John W, 2002, Prog Drug Res, V58, P133; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; Kuryshev YA, 2005, J PHARMACOL EXP THER, V312, P316, DOI 10.1124/jpet.104.073692; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Mu D, 2003, CANCER CELL, V3, P297, DOI 10.1016/S1535-6108(03)00054-0; Muhlbauer E, 2003, EUR J PHARMACOL, V459, P121, DOI 10.1016/S0014-2999(02)02855-8; NGASSAPA O, 1994, J NAT PROD, V57, P1, DOI 10.1021/np50103a001; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Redfern WS, 2003, CARDIOVASC RES, V58, P32, DOI 10.1016/S0008-6363(02)00846-5; Roden DM, 2002, ANNU REV PHYSIOL, V64, P431, DOI 10.1146/annurev.physiol.64.083101.145105; Roth BL, 1998, DRUG ALCOHOL DEPEN, V51, P73, DOI 10.1016/S0376-8716(98)00067-2; Sallette J, 2005, NEURON, V46, P595, DOI 10.1016/j.neuron.2005.03.029; Sanguinetti MC, 2005, TRENDS PHARMACOL SCI, V26, P119, DOI 10.1016/j.tips.2005.01.003; Shah M, 2005, CIRCULATION, V112, P2517, DOI 10.1161/CIRCULATIONAHA.104.494476; Shikano S, 2005, NAT CELL BIOL, V7, P985, DOI 10.1038/ncb1297; Shikano S, 2003, P NATL ACAD SCI USA, V100, P5783, DOI 10.1073/pnas.1031748100; Sun HY, 2004, P NATL ACAD SCI USA, V101, P16964, DOI 10.1073/pnas.0404178101; Taglialatela M, 1998, MOL PHARMACOL, V54, P113, DOI 10.1124/mol.54.1.113; Terstappen GC, 1999, ANAL BIOCHEM, V272, P149, DOI 10.1006/abio.1999.4179; Thomas D, 2003, BRIT J PHARMACOL, V139, P567, DOI 10.1038/sj.bjp.0705283; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Wallin E, 1998, PROTEIN SCI, V7, P1029, DOI 10.1002/pro.5560070420; Westerheide SD, 2004, J BIOL CHEM, V279, P56053, DOI 10.1074/jbc.M409267200; XU J, 2004, TARGETS, V3, P32; ZHOU BN, 1991, MEM I OSWALDO CRUZ, V86, P219, DOI 10.1590/S0074-02761991000600049; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	36	64	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5877	5884		10.1074/jbc.M600072200	http://dx.doi.org/10.1074/jbc.M600072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407206	hybrid			2022-12-27	WOS:000235568900068
J	van der Does, C; Presenti, C; Schulze, K; Dinkelaker, S; Tampe, R				van der Does, C; Presenti, C; Schulze, K; Dinkelaker, S; Tampe, R			Kinetics of the ATP hydrolysis cycle of the nucleotide-binding domain of Mdl1 studied by a novel site-specific labeling technique	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABC TRANSPORTER; P-GLYCOPROTEIN; CATALYTIC CYCLE; CASSETTE TRANSPORTERS; HISTIDINE PERMEASE; MECHANISM; MITOCHONDRIA; VISCOSITY; AFFINITY; PROTEIN	We have recently proposed a "processive clamp" model for the ATP hydrolysis cycle of the nucleotide-binding domain (NBD) of the mitochondrial ABC transporter Mdl1 ( Janas, E., Hofacker, M., Chen, M., Gompf, S., van der Does, C., and Tampe, R. ( 2003) J. Biol. Chem. 278, 26862 - 26869). In this model, ATP binding to two monomeric NBDs leads to formation of an NBD dimer that, after hydrolysis of both ATPs, dissociates and releases ADP. Here, we set out to follow the association and dissociation of NBDs using a novel minimally invasive site-specific labeling technique, which provides stable and stoichiometric attachment of fluorophores. The association and dissociation kinetics of the E599Q-NBD dimer upon addition and removal of ATP were determined by fluorescence self-quenching. Remarkably, the rate of ATP hydrolysis of the wild type NBD is determined by the rate of NBD dimerization. In the E599Q-NBD, however, in which the ATP hydrolysis is 250-fold reduced, the ATP hydrolysis reaction controls dimer dissociation and the overall ATPase cycle. These data explain contradicting observations on the rate-limiting step of various ABC proteins and further demonstrate that dimer formation is an important step in the ATP hydrolysis cycle.	Univ Frankfurt, Bioctr, Inst Biochem, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Tampe, R (corresponding author), Univ Frankfurt, Bioctr, Inst Biochem, Maie Curie Str 9, D-60439 Frankfurt, Germany.	tampe@em.uni-frankfurt.de	Tampé, Robert/H-2953-2015	Tampé, Robert/0000-0002-0403-2160				Arnold I, 2002, BBA-MOL CELL RES, V1592, P89, DOI 10.1016/S0167-4889(02)00267-7; Baykov AA, 1996, EUR J BIOCHEM, V236, P121, DOI 10.1111/j.1432-1033.1996.00121.x; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; COLE PA, 1994, J BIOL CHEM, V269, P30880; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; Fedosova NU, 2003, BIOCHEMISTRY-US, V42, P3536, DOI 10.1021/bi0268302; Gorbulev S, 2001, P NATL ACAD SCI USA, V98, P3732, DOI 10.1073/pnas.061467898; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Lata S, 2005, J AM CHEM SOC, V127, P10205, DOI 10.1021/ja050690c; Liu PQ, 1998, P NATL ACAD SCI USA, V95, P3495, DOI 10.1073/pnas.95.7.3495; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Lobau S, 1998, BIOCHEMISTRY-US, V37, P10846, DOI 10.1021/bi9807153; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Martin SF, 1999, BIOCHEMISTRY-US, V38, P4403, DOI 10.1021/bi9821216; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Rai V, 2005, BIOCHEMISTRY-US, V44, P6650, DOI 10.1021/bi0474160; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; van der Does C, 2004, BIOL CHEM, V385, P927, DOI 10.1515/BC.2004.121; Ye JQ, 2004, BBA-BIOENERGETICS, V1659, P1, DOI 10.1016/j.bbabio.2004.06.003; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; Zaitseva J, 2005, EMBO J, V24, P1901, DOI 10.1038/sj.emboj.7600657	32	25	25	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5694	5701		10.1074/jbc.M511730200	http://dx.doi.org/10.1074/jbc.M511730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16352609	hybrid			2022-12-27	WOS:000235568900046
J	Bunch, TA; Helsten, TL; Kendall, TL; Shirahatti, N; Mahadevan, D; Shattil, SJ; Brower, DL				Bunch, TA; Helsten, TL; Kendall, TL; Shirahatti, N; Mahadevan, D; Shattil, SJ; Brower, DL			Amino acid changes in Drosophila alpha PS2 beta PS integrins that affect ligand affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; EXTRACELLULAR SEGMENT; CRYSTAL-STRUCTURE; PSI DOMAIN; SUBUNIT; TIGGRIN; COMPLEX; BINDING; ALPHA-V-BETA-3; ADHESIVENESS	We developed a ligand-mimetic antibody Fab fragment specific for Drosophila alpha PS2 beta PS integrins to probe the ligand binding affinities of these invertebrate receptors. TWOW-1 was constructed by inserting a fragment of the extracellular matrix protein Tiggrin into the H-CDR3 of the alpha v beta 3 ligand-mimetic antibody WOW-1. The specificity of alpha PS2 beta PS binding to TWOW-1 was demonstrated by numerous tests used for other integrin-ligand interactions. Binding was decreased in the presence of EDTA or RGD peptides and by mutation of the TWOW-1 RGD sequence or the beta PS metal ion-dependent adhesion site ( MIDAS) motif. TWOW-1 binding was increased by mutations in the alpha PS2 membrane-proximal cytoplasmic GFFNR sequence or by exposure to Mn2+. Although Mn2+ is sometimes assumed to promote maximal integrin activity, TWOW-1 binding in Mn2+ could be increased further by the beta PS2 GFFNR -> GFANA mutation. A mutation in the beta PS I domain ( beta PS-b58; V409D) greatly increased ligand binding affinity, explaining the increased cell spreading mediated by alpha PS2 beta PS-b58. Further mutagenesis of this residue suggested that Val-409 normally stabilizes the closed head conformation. Mutations that potentially reduce interaction of the integrin beta subunit plexin-semaphorin-integrin ( PSI) and stalk domains have been shown to have activating properties. We found that complete deletion of the beta PS PSI domain enhanced TWOW-1 binding. Moreover the PSI domain is dispensable for at least some other integrin functions because beta PS-Delta PSI displayed an enhanced ability to mediate cell spreading. These studies establish a means to evaluate mechanisms and consequences of integrin affinity modulation in a tractable model genetic system.	Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Univ Arizona, Arizona Canc Ctr, Dept Biochem, Tucson, AZ 85724 USA; Univ Arizona, Arizona Canc Ctr, Dept Med, Tucson, AZ 85724 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Arizona Center Cancer Care; University of Arizona; Arizona Center Cancer Care; University of Arizona; Arizona Center Cancer Care; University of Arizona; University of California System; University of California San Diego	Bunch, TA (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Rm 0977,1515 N Campbell Ave, Tucson, AZ 85724 USA.	tbunch@u.arizona.edu			NATIONAL CANCER INSTITUTE [P30CA023074] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042474] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA023074] Funding Source: Medline; NHLBI NIH HHS [R01HL56595] Funding Source: Medline; NIGMS NIH HHS [R0GM42474] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Alahari SK, 2002, INT REV CYTOL, V220, P145; Baker SE, 2002, GENETICS, V162, P285; Barton SJ, 2004, BIOCHEM J, V380, P401, DOI 10.1042/BJ20031973; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Brower DL, 2003, CURR OPIN CELL BIOL, V15, P607, DOI 10.1016/S0955-0674(03)00102-9; BROWN NH, 1989, CELL, V59, P185, DOI 10.1016/0092-8674(89)90880-5; Bunch TA, 2004, EXP CELL RES, V294, P118, DOI 10.1016/j.yexcr.2003.11.002; BUNCH TA, 1992, DEVELOPMENT, V116, P239; Bunch TA, 1998, DEVELOPMENT, V125, P1679; Burke RD, 1999, INT REV CYTOL, V191, P257, DOI 10.1016/S0074-7696(08)60161-8; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; Dasgupta R, 2004, ONCOGENE, V23, P8359, DOI 10.1038/sj.onc.1208028; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; Graner MW, 1998, J BIOL CHEM, V273, P18235, DOI 10.1074/jbc.273.29.18235; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jannuzi AL, 2004, MOL BIOL CELL, V15, P3829, DOI 10.1091/mbc.E04-02-0085; Jannuzi AL, 2002, MOL BIOL CELL, V13, P1352, DOI 10.1091/mbc.01-08-0429; Juliano RL, 2004, BIOCHEM SOC T, V32, P443, DOI 10.1042/BST0320443; Liu SC, 2000, J CELL SCI, V113, P3563; Lu CF, 1997, J IMMUNOL, V159, P268; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; Mould AP, 2004, CURR OPIN CELL BIOL, V16, P544, DOI 10.1016/j.ceb.2004.07.003; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Springer TA, 2004, ADV PROTEIN CHEM, V68, P29; Sun QH, 2002, BLOOD, V100, P2094, DOI 10.1182/blood-2002-02-0418; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; TAUB R, 1989, J BIOL CHEM, V264, P259; Travis MA, 2003, TRENDS PHARMACOL SCI, V24, P192, DOI 10.1016/S0165-6147(03)00069-5; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xie C, 2004, P NATL ACAD SCI USA, V101, P15422, DOI 10.1073/pnas.0406680101; Xiong JP, 2004, J BIOL CHEM, V279, P40252, DOI 10.1074/jbc.C400362200; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, J THROMB HAEMOST, V1, P1642, DOI 10.1046/j.1538-7836.2003.00277.x; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Zang Q, 2001, J BIOL CHEM, V276, P6922, DOI 10.1074/jbc.M005868200; ZAVORTINK M, 1993, CELL ADHES COMMUN, V1, P251, DOI 10.3109/15419069309097258	47	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5050	5057		10.1074/jbc.M508550200	http://dx.doi.org/10.1074/jbc.M508550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371365	hybrid			2022-12-27	WOS:000235426200059
J	Miura, A; Yamagata, K; Kakei, M; Hatakeyama, H; Takahashi, N; Fukui, K; Nammo, T; Yoneda, K; Inoue, Y; Sladek, FM; Magnuson, MA; Kasai, H; Miyagawa, J; Gonzalez, FJ; Shimomura, I				Miura, A; Yamagata, K; Kakei, M; Hatakeyama, H; Takahashi, N; Fukui, K; Nammo, T; Yoneda, K; Inoue, Y; Sladek, FM; Magnuson, MA; Kasai, H; Miyagawa, J; Gonzalez, FJ; Shimomura, I			Hepatocyte nuclear factor-4 alpha is essential for glucosestimulated insulin secretion by pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HNF-4; SENSITIVE K+ CHANNELS; GLUCOSE-METABOLISM; GENE-EXPRESSION; ATP CHANNELS; YOUNG MODY1; ALPHA-GENE; MUTATIONS; RECEPTOR; MOUSE	Mutations in the hepatocyte nuclear factor (HNF)-4 alpha gene cause a form of maturity-onset diabetes of the young (MODY1) that is characterized by impairment of glucose- stimulated insulin secretion by pancreatic beta-cells. HNF-4 alpha, a transcription factor belonging to the nuclear receptor superfamily, is expressed in pancreatic islets as well as in the liver, kidney, and intestine. However, the role of HNF-4 alpha in pancreatic beta-cell is unclear. To clarify the role of HNF-4 alpha in beta-cells, we generated beta-cell-specific HNF-4 alpha knock-out (beta HNF-4 alpha KO) mice using the Cre-LoxP system. The beta HNF-4 alpha KO mice exhibited impairment of glucose- stimulated insulin secretion, which is a characteristic of MODY1. Pancreatic islet morphology, beta-cell mass, and insulin content were normal in the HNF-4 alpha mutant mice. Insulin secretion by beta HNF-4 alpha KO islets and the intracellular calcium response were impaired after stimulation by glucose or sulfonylurea but were normal after stimulation with KCl or arginine. Both NAD(P)H generation and ATP content at high glucose concentrations were normal in the beta HNF-4 alpha KO mice. Expression levels of Kir6.2 and SUR1 proteins in the beta HNF-4 alpha KO mice were unchanged as compared with control mice. Patch clamp experiments revealed that the current density was significantly increased in beta HNF-4 alpha KO mice compared with control mice. These results are suggestive of the dysfunction of K-ATP channel activity in the pancreatic beta-cells of HNF-4 alpha-deficient mice. Because the K-ATP channel is important for proper insulin secretion in beta-cells, altered K-ATP channel activity could be related to the impaired insulin secretion in the beta HNF-4 alpha KO mice.	Osaka Univ, Grad Sch Med, Dept Metab Med, Suita, Osaka 5650871, Japan; Akita Univ, Sch Med, Dept Internal Med, Div Endocrinol Metab & Geriatr Med, Akita 0108543, Japan; Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448787, Japan; Grad Univ Adv Studies, Okazaki, Aichi 4448787, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; NCI, Lab Metab, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	Osaka University; Akita University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST); University of California System; University of California Riverside; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yamagata, K (corresponding author), Osaka Univ, Grad Sch Med, Dept Metab Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kazu@imed2.med.osaka-u.ac.jp	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Inoue, Yusuke/O-6207-2018	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Inoue, Yusuke/0000-0002-9710-7482; Kasai, Haruo/0000-0003-2327-9027; YONEDA, KAZUE/0000-0001-7142-2743	NATIONAL CANCER INSTITUTE [Z01BC005561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053892] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK053892] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2001, NUCL RECEPTORS GENET; Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; BYRNE MM, 1995, DIABETES, V44, P699, DOI 10.2337/diabetes.44.6.699; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Dukes ID, 1998, J BIOL CHEM, V273, P24457, DOI 10.1074/jbc.273.38.24457; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Fukui K, 2005, CELL METAB, V2, P373, DOI 10.1016/j.cmet.2005.11.003; Gonzalez FJ, 1997, BIOCHIMIE, V79, P139, DOI 10.1016/S0300-9084(97)81506-4; Gupta RK, 2005, J CLIN INVEST, V115, P1006, DOI 10.1172/JCI22365; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Herman WH, 1997, DIABETES, V46, P1749, DOI 10.2337/diabetes.46.11.1749; Ihara A, 2005, BIOCHEM BIOPH RES CO, V329, P984, DOI 10.1016/j.bbrc.2005.02.072; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; KREYMANN B, 1987, LANCET, V2, P1300; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lausen J, 2000, NUCLEIC ACIDS RES, V28, P430, DOI 10.1093/nar/28.2.430; Love-Gregory LD, 2004, DIABETES, V53, P1134, DOI 10.2337/diabetes.53.4.1134; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; NAKAZAKI M, 1995, DIABETES, V44, P878, DOI 10.2337/diabetes.44.8.878; Noda M, 2002, J BIOL CHEM, V277, P41817, DOI 10.1074/jbc.M207690200; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; OHNOSHOSAKU T, 1987, PFLUG ARCH EUR J PHY, V408, P133, DOI 10.1007/BF00581342; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 2003, PROG BIOPHYS MOL BIO, V81, P133, DOI 10.1016/S0079-6107(02)00053-6; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; Silander K, 2004, DIABETES, V53, P1141, DOI 10.2337/diabetes.53.4.1141; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Takahashi N, 2002, SCIENCE, V297, P1349, DOI 10.1126/science.1073806; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Vaxillaire M, 2004, DIABETES, V53, P2719, DOI 10.2337/diabetes.53.10.2719; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Weedon MN, 2004, DIABETES, V53, P3002, DOI 10.2337/diabetes.53.11.3002; Wollheim CB, 2000, DIABETOLOGIA, V43, P265, DOI 10.1007/s001250050044; Yamagata K, 2002, DIABETES, V51, P114, DOI 10.2337/diabetes.51.1.114; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yang Q, 2000, DIABETOLOGIA, V43, P520, DOI 10.1007/s001250051338	45	127	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5246	5257		10.1074/jbc.M507496200	http://dx.doi.org/10.1074/jbc.M507496200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377800	hybrid			2022-12-27	WOS:000235426200079
J	Wu, SF; Yoshiko, Y; De Luca, F				Wu, SF; Yoshiko, Y; De Luca, F			Stanniocalcin 1 acts as a paracrine regulator of growth plate chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONGITUDINAL BONE-GROWTH; CHONDROCYTE MATURATION; INORGANIC-PHOSPHATE; TRANSGENIC MICE; MESSENGER-RNA; RAT; APOPTOSIS; MOUSE; EXPRESSION; PROTEIN	During embryogenesis, the expression of mammalian stanniocalcin (STC1) in the appendicular skeleton suggests its involvement in the regulation of longitudinal bone growth. Such a role is further supported by the presence of dwarfism in mice overexpressing STC1. Yet, the STC 1 inhibitory effect on growth may be related to both postnatal metabolic abnormalities and prenatal defective bone formation. In our study, we used an organ culture system to evaluate the effects of STC on growth plate chondrogenesis, which is the primary determinant of longitudinal bone growth. Fetal rat metatarsal bones were cultured in the presence of recombinant human STC (rhSTC). After 3 days, rhSTC suppressed metatarsal growth, growth plate chondrocyte proliferation and hypertrophy/differentiation, and extracellular matrix synthesis. In addition, rhSTC increased the number of apoptotic chondrocytes in the growth plate. In cultured chondrocytes, rhSTC increased phosphate uptake, reduced chondrocyte proliferation and matrix synthesis, and induced apoptosis. All these effects were reversed by culturing chondrocytes with rhSTC and phosphonoformic acid, an inhibitor of phosphate transport. The rhSTC-mediated inhibition of metatarsal growth and growth plate chondrocyte proliferation and hypertrophy/differentiation was abolished by culturing metatarsals with rhSTC and phosphonoformic acid. Taken together, our findings indicate that STC1 inhibits longitudinal bone growth directly at the growth plate. Such growth inhibition, likely mediated by an increased chondrocyte phosphate uptake, results from suppressed chondrocyte proliferation, hypertrophy/differentiation, and matrix synthesis and by increased apoptosis. Last, the expression of both STC1 and its binding site in the growth plate would support an autocrine/paracrine role for this growth factor in the regulation of growth plate chondrogenesis.	Drexel Univ, Sect Endocrinol & Diabet, St Christophers Hosp Children, Dept Pediat,Coll Med, Philadelphia, PA 19134 USA; Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral Growth & Dev Biol, Minami Ku, Hiroshima 7348553, Japan	Drexel University; Hiroshima University	De Luca, F (corresponding author), Drexel Univ, Sect Endocrinol & Diabet, St Christophers Hosp Children, Dept Pediat,Coll Med, Erie Ave & Front St, Philadelphia, PA 19134 USA.	francesco.deluca@drexel.edu						AHARINEJAD S, 1995, ANAT REC, V242, P111, DOI 10.1002/ar.1092420115; APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; BAGI C, 1989, CALCIFIED TISSUE INT, V45, P342, DOI 10.1007/BF02556004; CHANG ACM, 1995, MOL CELL ENDOCRINOL, V112, P241, DOI 10.1016/0303-7207(95)03601-3; De Niu P, 2000, MOL CELL ENDOCRINOL, V162, P131, DOI 10.1016/S0303-7207(00)00199-4; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; FARNUM CE, 1987, ANAT REC, V219, P221, DOI 10.1002/ar.1092190303; Filvaroff EH, 2002, ENDOCRINOLOGY, V143, P3681, DOI 10.1210/en.2001-211424; Fujita T, 2001, BIOCHEM BIOPH RES CO, V280, P348, DOI 10.1006/bbrc.2000.4108; Hoshi K, 1999, BONE, V25, P639, DOI 10.1016/S8756-3282(99)00223-9; HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606; IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1; Jiang WQ, 2000, J ENDOCRINOL, V165, P457, DOI 10.1677/joe.0.1650457; LU M, 1994, AM J PHYSIOL, V36, pR1356; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; Madsen KL, 1998, AM J PHYSIOL-GASTR L, V274, pG96, DOI 10.1152/ajpgi.1998.274.1.G96; Magne D, 2003, J BONE MINER RES, V18, P1430, DOI 10.1359/jbmr.2003.18.8.1430; Mansfield K, 1999, J CELL PHYSIOL, V179, P276, DOI 10.1002/(SICI)1097-4652(199906)179:3<276::AID-JCP5>3.0.CO;2-#; Mansfield K, 2001, BONE, V28, P1, DOI 10.1016/S8756-3282(00)00409-9; MCCUDDEN CR, 2002, J BIOL CHEM, V47, P4549; Meleti Z, 2000, BONE, V27, P359, DOI 10.1016/S8756-3282(00)00346-X; Naski MC, 1998, DEVELOPMENT, V125, P4977; Olsen HS, 1996, P NATL ACAD SCI USA, V93, P1792, DOI 10.1073/pnas.93.5.1792; Rajpurohit R, 1999, J CELL PHYSIOL, V179, P287, DOI 10.1002/(SICI)1097-4652(199906)179:3<287::AID-JCP6>3.0.CO;2-T; Sabbagh Y, 2005, P NATL ACAD SCI USA, V102, P9637, DOI 10.1073/pnas.0502249102; Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Stannius H, 1839, ARCH ANAT PHYSIOL, V6, P97; Stasko SE, 2001, J ENDOCRINOL, V171, P237, DOI 10.1677/joe.0.1710237; Varghese R, 1998, ENDOCRINOLOGY, V139, P4714, DOI 10.1210/en.139.11.4714; Varghese R, 2002, ENDOCRINOLOGY, V143, P868, DOI 10.1210/en.143.3.868; Venkatesan N, 2004, P NATL ACAD SCI USA, V101, P18087, DOI 10.1073/pnas.0404504102; WAGNER GF, 1995, P NATL ACAD SCI USA, V92, P1871, DOI 10.1073/pnas.92.6.1871; WAGNER GF, 1986, GEN COMP ENDOCR, V63, P481, DOI 10.1016/0016-6480(86)90149-8; Wagner GF, 1997, J BONE MINER RES, V12, P165, DOI 10.1359/jbmr.1997.12.2.165; WAGNER GF, 1991, MOL CELL ENDOCRINOL, V79, P129, DOI 10.1016/0303-7207(91)90103-Y; Wong CKC, 1998, J ENDOCRINOL, V158, P183, DOI 10.1677/joe.0.1580183; Worthington RA, 1999, ELECTROPHORESIS, V20, P2071, DOI 10.1002/(SICI)1522-2683(19990701)20:10<2071::AID-ELPS2071>3.0.CO;2-#; Wu LNY, 2002, J CELL BIOCHEM, V86, P475, DOI 10.1002/jcb.10240; Wu SF, 2004, J CHILD NEUROL, V19, P26, DOI 10.1177/088307380401900105011; Wu SF, 2004, J BIOL CHEM, V279, P4642, DOI 10.1074/jbc.M305518200; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yoshiko Y, 1999, ENDOCRINOLOGY, V140, P1869, DOI 10.1210/en.140.4.1869; Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003-0130; Yoshiko Y, 2002, J HISTOCHEM CYTOCHEM, V50, P483, DOI 10.1177/002215540205000405; Zhang KZ, 1998, AM J PATHOL, V153, P439, DOI 10.1016/S0002-9440(10)65587-3; Zhang KZ, 2000, P NATL ACAD SCI USA, V97, P3637, DOI 10.1073/pnas.070045897	47	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5120	5127		10.1074/jbc.M506667200	http://dx.doi.org/10.1074/jbc.M506667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377640	hybrid			2022-12-27	WOS:000235426200066
J	De Smet, L; Savvides, SN; Van Horen, E; Pettigrew, G; Van Beeumen, JJ				De Smet, L; Savvides, SN; Van Horen, E; Pettigrew, G; Van Beeumen, JJ			Structural and mutagenesis studies on the cytochrome c peroxidase from Rhodobacter capsulatus provide new insights into structure-function relationships of bacterial di-heme peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARACOCCUS-DENITRIFICANS; PSEUDOMONAS-AERUGINOSA; CRYSTAL-STRUCTURE; CHLOROPEROXIDASE; PURIFICATION; MECHANISM; BINDING; KINETICS; REDOX; NMR	Cytochrome c peroxidases (CCP) play a key role in cellular detoxification by catalyzing the reduction of hydrogen peroxide to water. The di-heme CCP from Rhodobacter capsulatus is the fastest enzyme (1060 s(-1)), when tested with its physiological cytochrome c substrate, among all di-heme CCPs characterized to date and has, therefore, been an attractive target to investigate structure-function relationships for this family of enzymes. Here, we combine for the first time structural studies with site-directed mutagenesis and spectroscopic studies of the mutant enzymes to investigate the roles of amino acid residues that have previously been suggested to be important for activity. The crystal structure of R. capsulatus at 2.7 angstrom in the fully oxidized state confirms the overall molecular scaffold seen in other di-heme CCPs but further reveals that a segment of about 10 amino acids near the peroxide binding site is disordered in all four molecules in the asymmetric unit of the crystal. Structural and sequence comparisons with other structurally characterized CCPs suggest that flexibility in this part of the molecular scaffold is an inherent molecular property of the R. capsulatus CCP and of CCPs in general and that it correlates with the levels of activity seen in CCPs characterized, thus, far. Mutagenesis studies support the spin switch model and the roles that Met-118, Glu-117, and Trp-97 play in this model. Our results help to clarify a number of aspects of the debate on structure-function relationships in this family of bacterial CCPs and set the stage for future studies.	Univ Ghent, Lab Prot Biochem & Prot Engn, Dept Biochem Physiol & Microbiol, B-9000 Ghent, Belgium; Univ Edinburgh, Royal Dick Sch Vet Studies, Dept Preclin Vet Sci, Edinburgh EH9 1QH, Midlothian, Scotland	Ghent University; University of Edinburgh	Van Beeumen, JJ (corresponding author), Univ Ghent, Lab Prot Biochem & Prot Engn, Dept Biochem Physiol & Microbiol, Ledeganckstr 35, B-9000 Ghent, Belgium.	jozef.vanbeeumen@ugent.be	Savvides, Savvas/E-1938-2011; De Smet, Lina/A-7354-2013	Savvides, Savvas/0000-0003-3420-5947; 				Alves T, 1999, BBA-PROTEIN STRUCT M, V1434, P248, DOI 10.1016/S0167-4838(99)00188-0; ARCIERO DM, 1994, J BIOL CHEM, V269, P11878; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; De Smet L, 2002, ACTA CRYSTALLOGR D, V58, P522, DOI 10.1107/S0907444901021710; De Smet L, 2001, EUR J BIOCHEM, V268, P6559, DOI 10.1046/j.0014-2956.2001.02610.x; Dias JM, 2004, STRUCTURE, V12, P961, DOI 10.1016/j.str.2004.03.025; ELLFOLK N, 1991, BIOCHIM BIOPHYS ACTA, V1080, P68, DOI 10.1016/0167-4838(91)90113-E; ELLFOLK N, 1983, BIOCHIM BIOPHYS ACTA, V743, P23, DOI 10.1016/0167-4838(83)90413-2; ELLFOLK N, 1984, BIOCHIM BIOPHYS ACTA, V784, P62, DOI 10.1016/0167-4838(84)90173-0; FOOTE N, 1984, BIOCHEM J, V223, P369, DOI 10.1042/bj2230369; FOOTE N, 1985, BIOCHEM J, V230, P227, DOI 10.1042/bj2300227; FOOTE N, 1992, BIOCHEM J, V283, P839, DOI 10.1042/bj2830839; FOOTE N, 1983, BIOCHEM J, V209, P701, DOI 10.1042/bj2090701; FULOP V, 1995, STRUCTURE, V3, P1225, DOI 10.1016/S0969-2126(01)00258-1; GILMOUR R, 1994, BIOCHEM J, V300, P907, DOI 10.1042/bj3000907; GILMOUR R, 1993, BIOCHEM J, V294, P745, DOI 10.1042/bj2940745; GOODHEW CF, 1990, BIOCHEM J, V271, P707, DOI 10.1042/bj2710707; HANLON SP, 1992, FEMS MICROBIOL LETT, V97, P283, DOI 10.1111/j.1574-6968.1992.tb05476.x; Hu W, 1998, EUR J BIOCHEM, V258, P29, DOI 10.1046/j.1432-1327.1998.2580029.x; Hu W, 1997, BIOCHEMISTRY-US, V36, P7958, DOI 10.1021/bi963131e; Koh M, 2003, ARCH BIOCHEM BIOPHYS, V410, P230, DOI 10.1016/S0003-9861(02)00694-X; Lopes H, 1998, J BIOL INORG CHEM, V3, P632, DOI 10.1007/s007750050277; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; McGinnity DF, 1996, J BIOL CHEM, V271, P11126, DOI 10.1074/jbc.271.19.11126; Page CC, 2003, CURR OPIN CHEM BIOL, V7, P551, DOI 10.1016/j.cbpa.2003.08.005; PETTIGREW GW, 1991, BIOCHIM BIOPHYS ACTA, V1058, P25, DOI 10.1016/S0005-2728(05)80261-0; PETTIGREW GW, 1990, CYTOCHROMES C BIOL A; Pinakoulaki E, 2003, J BIOL CHEM, V278, P18761, DOI 10.1074/jbc.M211925200; PRAZERES S, 1995, J BIOL CHEM, V270, P24264, DOI 10.1074/jbc.270.41.24264; RONNBERG M, 1979, BIOCHIM BIOPHYS ACTA, V581, P325, DOI 10.1016/0005-2795(79)90252-6; Samyn B, 1995, FEBS LETT, V377, P145, DOI 10.1016/0014-5793(95)01326-1; Shimizu H, 2001, BIOCHEMISTRY-US, V40, P13483, DOI 10.1021/bi011481h; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; Sundaramoorthy M, 1998, CHEM BIOL, V5, P461, DOI 10.1016/S1074-5521(98)90003-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VILLALAIN J, 1984, EUR J BIOCHEM, V141, P305, DOI 10.1111/j.1432-1033.1984.tb08192.x; Wagenknecht HA, 1997, CHEM BIOL, V4, P367, DOI 10.1016/S1074-5521(97)90127-7	39	36	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4371	4379		10.1074/jbc.M509582200	http://dx.doi.org/10.1074/jbc.M509582200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16314410	hybrid			2022-12-27	WOS:000235275300073
J	Kobayashi, M; Figaroa, F; Meeuwenoord, N; Jansen, LET; Siegal, G				Kobayashi, M; Figaroa, F; Meeuwenoord, N; Jansen, LET; Siegal, G			Characterization of the DNA binding and structural properties of the BRCT region of human replication factor C p140 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; LIGASE-III; SECONDARY STRUCTURE; ESCHERICHIA-COLI; TUMOR-SUPPRESSOR; DOMAIN; RECOGNITION; PROTEINS; PHOSPHOPEPTIDE; CANCER	BRCT domains, present in a large number of proteins that are involved in cell cycle regulation and/or DNA replication or repair, are primarily thought to be involved in protein-protein interactions. The large (p140) subunit of replication factor C contains a sequence of similar to 100 amino acids in the N-terminal region that binds DNA and is distantly related to known BRCT domains. Here we show that residues 375-480, which include 28 amino acids N-terminal to the BRCT domain, are required for 5'-phosphorylated double-stranded DNA binding. NMR chemical shift analysis indicated that the N-terminal extension includes an alpha-helix and confirmed the presence of a conserved BRCT domain. Sequence alignment of the BRCT region in the p140 subunit of replication factor C from various eukaryotes has identified very few absolutely conserved amino acid residues within the core BRCT domain, whereas none were found in sequences immediately N-terminal to the BRCT domain. However, mapping of the limited number of conserved, surface-exposed residues that were found onto a homology model of the BRCT domain, revealed a clustering on one side of the molecular surface. The cluster, as well as a number of amino acids in the N-terminal alpha-helix, were mutagenized to determine the importance for DNA binding. To ensure minimal structural changes because of the introduced mutations, proteins were checked using one-dimensional H-1 NMR and CD spectroscopy. Mutation of weakly conserved residues on one face of the N-terminal alpha-helix and of residues within the cluster disrupted DNA binding, suggesting a likely binding interface on the protein.	Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Siegal, G (corresponding author), Leiden Univ, Leiden Inst Chem, Postbus 9502, NL-2300 RA Leiden, Netherlands.	g.siegal@chem.leidenuniv.nl		Jansen, Lars/0000-0002-2158-0345; Siegal, Gregg/0000-0003-3806-4811				Allen BL, 1998, NUCLEIC ACIDS RES, V26, P3877, DOI 10.1093/nar/26.17.3877; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bates PA, 2001, PROTEINS, P39; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Clapperton JA, 2004, NAT STRUCT MOL BIOL, V11, P512, DOI 10.1038/nsmb775; Derbyshire DJ, 2002, EMBO J, V21, P3863, DOI 10.1093/emboj/cdf383; Dulic A, 2001, BIOCHEMISTRY-US, V40, P5906, DOI 10.1021/bi002701e; Dyson HJ, 2002, CURR OPIN STRUC BIOL, V12, P54, DOI 10.1016/S0959-440X(02)00289-0; Ekblad CMS, 2002, J MOL BIOL, V320, P431, DOI 10.1016/S0022-2836(02)00478-3; Feng H, 2004, BIOCHEMISTRY-US, V43, P12648, DOI 10.1021/bi049451c; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Joo WS, 2002, GENE DEV, V16, P583, DOI 10.1101/gad.959202; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; Karsten R., 1997, BIF FUTURA, V12, P20; Kobayashi M, 2005, J BIOMOL NMR, V31, P183, DOI 10.1007/s10858-004-7913-5; Krishnan VV, 2001, BIOCHEMISTRY-US, V40, P13158, DOI 10.1021/bi010979g; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Liu K, 2003, MOL CELL BIOL, V23, P3287, DOI 10.1128/MCB.23.9.3287-3304.2003; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Reynolds N, 1999, NUCLEIC ACIDS RES, V27, P462, DOI 10.1093/nar/27.2.462; Shiozaki EN, 2004, MOL CELL, V14, P405, DOI 10.1016/S1097-2765(04)00238-2; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wilkinson A, 2005, BBA-PROTEINS PROTEOM, V1749, P113, DOI 10.1016/j.bbapap.2005.03.003; Williams RS, 2004, NAT STRUCT MOL BIOL, V11, P519, DOI 10.1038/nsmb776; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wuthrich K., 1986, NMR PROTEINS NUCL AC, P1; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	44	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4308	4317		10.1074/jbc.M511090200	http://dx.doi.org/10.1074/jbc.M511090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361700	hybrid, Green Published			2022-12-27	WOS:000235275300065
J	Venkatesan, RN; Hsu, JJ; Lawrence, NA; Preston, BD; Loeb, LA				Venkatesan, RN; Hsu, JJ; Lawrence, NA; Preston, BD; Loeb, LA			Mutator phenotypes caused by substitution at a conserved motif A residue in eukaryotic DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; ACTIVE-SITE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; REPLICATION FIDELITY; KLENOW FRAGMENT; MISMATCH REPAIR; BUDDING YEAST; AMINO-ACID; ALPHA	Eukaryotic DNA polymerase (Pol) delta replicates chromosomal DNA and is also involved in DNA repair and genetic recombination. Motif A in Pol delta, containing the sequence DXXXLYPSI, includes a catalytically essential aspartic acid as well as other conserved residues of unknown function. Here, we used site-directed mutagenesis to create all 19 amino acid substitutions for the conserved Leu(612) in Motif A of Saccharomyces cerevisiae Pol delta. We show that substitutions at Leu612 differentially affect viability, sensitivity to genotoxic agents, cell cycle progression, and replication fidelity. The eight viable mutants contained Ile, Val, Thr, Met, Phe, Lys, Asn, or Gly substitutions. Individual substitutions varied greatly in the nature and extent of attendant phenotypic deficiencies, exhibiting mutation rates that ranged from near wild type to a 37-fold increase. The L612M mutant exhibited a 7-fold elevation of mutation rate but essentially no detectable effects on other phenotypes monitored; the L612T mutant showed a nearly wild type mutation rate together with marked hypersensitivity to genotoxic agents; and the L612G and L612N strains exhibited relatively high mutation rates and severe deficits overall. We compare our results with those for homologous substitutions in prokaryotic and eukaryotic DNA polymerases and discuss the implications of our findings for the role of Leu612 in replication fidelity.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NCI NIH HHS [R01 CA102029, R01 CA98243, R01 CA098243] Funding Source: Medline; NIA NIH HHS [P01 AG01751, P01 AG001751] Funding Source: Medline; NIEHS NIH HHS [R01 ES 09927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098243, R01CA102029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; Astatke M, 1998, P NATL ACAD SCI USA, V95, P3402, DOI 10.1073/pnas.95.7.3402; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BLANK A, 1994, P NATL ACAD SCI USA, V91, P9047, DOI 10.1073/pnas.91.19.9047; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Burke D., 2000, METHODS YEAST GENETI; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; DONG Q, 1993, J BIOL CHEM, V268, P24163; DONG Q, 1993, J BIOL CHEM, V268, P24175; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Goldsby RE, 2002, P NATL ACAD SCI USA, V99, P15560, DOI 10.1073/pnas.232340999; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Hashimoto K, 2003, BIOCHEMISTRY-US, V42, P14207, DOI 10.1021/bi0348359; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; Kokoska RJ, 2000, MOL CELL BIOL, V20, P7490, DOI 10.1128/MCB.20.20.7490-7504.2000; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; LEA DE, 1948, J GENET, V49, P248; LEE SH, 1991, J BIOL CHEM, V266, P22707; Li L, 2005, GENETICS, V170, P569, DOI 10.1534/genetics.104.040295; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Niimi A, 2004, MOL CELL BIOL, V24, P2734, DOI 10.1128/MCB.24.7.2734-2746.2004; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; Pavlov YI, 2001, GENETICS, V159, P47; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; PODUST V, 1992, CHROMOSOMA, V102, pS133, DOI 10.1007/BF02451797; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; RehaKrantz LJ, 1995, METHOD ENZYMOL, V262, P323; REHAKRANTZ LJ, 1994, J BIOL CHEM, V269, P5635; ROSENKRANZ HS, 1965, BIOCHIM BIOPHYS ACTA, V95, P181, DOI 10.1016/0005-2787(65)90225-X; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAAPER RM, 1993, J BIOL CHEM, V268, P23762; Shcherbakova PV, 2003, J BIOL CHEM, V278, P43770, DOI 10.1074/jbc.M306893200; Shimizu K, 2002, J BIOL CHEM, V277, P37422, DOI 10.1074/jbc.M204476200; Shinkai A, 2001, J BIOL CHEM, V276, P46759, DOI 10.1074/jbc.M104780200; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; Singer B., 1983, MOL BIOL MUTAGENS CA; Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 1997, J BIOL CHEM, V272, P11228; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Tran HT, 1997, MOL CELL BIOL, V17, P2859, DOI 10.1128/MCB.17.5.2859; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHOU Z, 1992, GENETICS, V131, P851	56	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4486	4494		10.1074/jbc.M510245200	http://dx.doi.org/10.1074/jbc.M510245200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16344551	hybrid			2022-12-27	WOS:000235275300084
J	Gengenbacher, M; Fitzpatrick, TB; Raschle, T; Flicker, K; Sinning, I; Muller, S; Macheroux, P; Tews, I; Kappes, B				Gengenbacher, M; Fitzpatrick, TB; Raschle, T; Flicker, K; Sinning, I; Muller, S; Macheroux, P; Tews, I; Kappes, B			Vitamin B6 biosynthesis by the malaria parasite Plasmodium falciparum - Biochemical and structural insights	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; PYRIDOXINE SYNTHESIS; PROTEIN-KINASE; SYNTHASE; GENE; PATHWAY; LOCALIZATION; EXPRESSION	Vitamin B6 is one of nature's most versatile cofactors. Most organisms synthesize vitamin B6 via a recently discovered pathway employing the proteins Pdx1 and Pdx2. Here we present an in-depth characterization of the respective orthologs from the malaria parasite, Plasmodium falciparum. Expression profiling of Pdx1 and -2 shows that blood-stage parasites indeed possess a functional vitamin B6 de novo biosynthesis. Recombinant Pdx1 and Pdx2 form a complex that functions as a glutamine amidotransferase with Pdx2 as the glutaminase and Pdx1 as pyridoxal-5'-phosphate synthase domain. Complex formation is required for catalytic activity of either domain. Pdx1 forms a chimeric bi-enzyme with the bacterial YaaE, a Pdx2 ortholog, both in vivo and in vitro, although this chimera does not attain full catalytic activity, emphasizing that species-specific structural features govern the interaction between the protein partners of the PLP synthase complexes in different organisms. To gain insight into the activation mechanism of the parasite bi-enzyme complex, the three-dimensional structure of Pdx2 was determined at 1.62 angstrom. The obstruction of the oxyanion hole indicates that Pdx2 is in a resting state and that activation occurs upon Pdx1-Pdx2 complex formation.	Heidelberg Univ, Dept Biol Struct, Biochemiezentrum, D-69120 Heidelberg, Germany; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland; Univ Klinikum Heidelberg, Abt Parasitol, D-69120 Heidelberg, Germany; ETH, Inst Pflanzenwissensch, CH-8092 Zurich, Switzerland; Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	Ruprecht Karls University Heidelberg; University of Glasgow; Ruprecht Karls University Heidelberg; Swiss Federal Institutes of Technology Domain; ETH Zurich; Graz University of Technology	Tews, I (corresponding author), Heidelberg Univ, Dept Biol Struct, Biochemiezentrum, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	ivo.tews@bzh.uni-heidelberg.de; barbara.kappes@urz.uni-heidelberg.de	Macheroux, Peter/AAB-5157-2019; Tews, Ivo/A-2750-2010; Gengenbacher, Martin/C-6876-2015; Sinning, Irmgard/A-2982-2010	Macheroux, Peter/0000-0002-0242-454X; Tews, Ivo/0000-0002-4704-1139; Gengenbacher, Martin/0000-0002-0208-5920; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bauer JA, 2004, J BIOL CHEM, V279, P2704, DOI 10.1074/jbc.M310311200; Bean LE, 2001, GENETICS, V157, P1067; Belitsky BR, 2004, J BACTERIOL, V186, P1191, DOI 10.1128/JB.186.4.1191-1196.2004; BENESCH RE, 1973, P NATL ACAD SCI USA, V70, P2595, DOI 10.1073/pnas.70.9.2595; Bhavsar AP, 2001, APPL ENVIRON MICROB, V67, P403, DOI 10.1128/AEM.67.1.403-410.2001; Burns KE, 2005, J AM CHEM SOC, V127, P3682, DOI 10.1021/ja042792t; Cassera MB, 2004, J BIOL CHEM, V279, P51749, DOI 10.1074/jbc.M408360200; Chaudhuri BN, 2003, BIOCHEMISTRY-US, V42, P7003, DOI 10.1021/bi034320h; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Chittur SV, 2000, PROTEIN EXPRES PURIF, V18, P366, DOI 10.1006/prep.2000.1207; CHULAY JD, 1983, EXP PARASITOL, V55, P138, DOI 10.1016/0014-4894(83)90007-3; DeLano W.L, PYMOL MOL GRAPHICS S; DIVO AA, 1985, J PROTOZOOL, V32, P59, DOI 10.1111/j.1550-7408.1985.tb03013.x; Dong YX, 2004, EUR J BIOCHEM, V271, P745, DOI 10.1111/j.1432-1033.2003.03973.x; Douangamath A, 2002, STRUCTURE, V10, P185, DOI 10.1016/S0969-2126(02)00702-5; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; Fitzpatrick T, 2001, MOL MICROBIOL, V40, P65, DOI 10.1046/j.1365-2958.2001.02366.x; Graeser R, 1996, MOL BIOCHEM PARASIT, V82, P37, DOI 10.1016/0166-6851(96)02716-8; INK SL, 1984, ANNU REV NUTR, V4, P455, DOI 10.1146/annurev.nu.04.070184.002323; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirk K, 2001, PHYSIOL REV, V81, P495, DOI 10.1152/physrev.2001.81.2.495; Kissinger JC, 2001, NUCLEIC ACIDS RES, V29, P66; Korolev S, 2002, PROTEINS, V49, P420, DOI 10.1002/prot.10161; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; McConkey GA, 2004, TRENDS PARASITOL, V20, P60, DOI 10.1016/j.pt.2003.11.001; Miles BW, 2002, J BIOL CHEM, V277, P4368, DOI 10.1074/jbc.M108582200; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; Mohrle JJ, 1997, BIOCHEM J, V328, P677; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ogasawara N, 2000, RES MICROBIOL, V151, P129, DOI 10.1016/S0923-2508(00)00118-2; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Raschle T, 2005, J BIOL CHEM, V280, P32291, DOI 10.1074/jbc.M501356200; Raushel FM, 1998, CURR OPIN CHEM BIOL, V2, P624, DOI 10.1016/S1367-5931(98)80094-X; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; ROSSMACDONALD PB, 1994, EUR J BIOCHEM, V220, P693, DOI 10.1111/j.1432-1033.1994.tb18670.x; Sakai A, 2002, J BIOSCI BIOENG, V93, P309, DOI 10.1263/jbb.93.309; Sakai A, 2002, J BIOSCI BIOENG, V93, P334, DOI 10.1263/jbb.93.334; Stolz J, 2005, EUKARYOT CELL, V4, P319, DOI 10.1128/EC.4.2.319-326.2005; Stolz J, 2003, J BIOL CHEM, V278, P18990, DOI 10.1074/jbc.M300949200; SUETTERLIN BW, 1991, MOL BIOCHEM PARASIT, V46, P113, DOI 10.1016/0166-6851(91)90205-K; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P8825, DOI 10.1021/bi9807761; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Wrenger C, 2005, J BIOL CHEM, V280, P5242, DOI 10.1074/jbc.M412475200; Wrenger C, 2004, MOL MICROBIOL, V53, P103, DOI 10.1111/j.1365-2958.2004.04112.x; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87; Zhu JH, 2005, J BIOL CHEM, V280, P27914, DOI 10.1074/jbc.M503642200	53	71	74	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3633	3641		10.1074/jbc.M508696200	http://dx.doi.org/10.1074/jbc.M508696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339145	hybrid, Green Published			2022-12-27	WOS:000235128200075
J	Leliveld, SR; Dame, RT; Wuite, GJL; Stitz, L; Korth, C				Leliveld, SR; Dame, RT; Wuite, GJL; Stitz, L; Korth, C			The expanded octarepeat domain selectively binds prions and disrupts homomeric prion protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRP KNOCKOUT MICE; MONOCLONAL-ANTIBODY; FULL-LENGTH; IN-VITRO; SCRAPIE; GENE; REPEATS; ENCEPHALOPATHY; SUSCEPTIBILITY	Insertion of additional octarepeats into the prion protein gene has been genetically linked to familial Creutzfeldt Jakob disease and hence to de novo generation of infectious prions. The pivotal event during prion formation is the conversion of the normal prion protein (PrPC) into the pathogenic conformer PrPSc, which subsequently induces further conversion in an autocatalytic manner. Apparently, an expanded octarepeat domain directs folding of PrP toward the PrPSc conformation and initiates a self-replicating conversion process. Here, based on three main observations, we have provided a model on how altered molecular interactions between wild-type and mutant PrP set the stage for familial Creutzfeldt Jakob disease with octarepeat insertions. First, we showed that wildtype octarepeat domains interact in a copper-dependent and reversible manner, a "copper switch." This interaction becomes irreversible upon domain expansion, possibly reflecting a loss of function. Second, expanded octarepeat domains of increasing length gradually form homogenous globular multimers of 11-21 nm in the absence of copper ions when expressed as soluble glutathione S-transferase fusion proteins. Third, octarepeat domain expansion causes a gain of function with at least 10 repeats selectively binding PrPSc in a denaturant-resistant complex in the absence of copper ions. Thus, the combination of both a loss and gain of function profoundly influences homomeric interaction behavior of PrP with an expanded octarepeat domain. A multimeric cluster of prion proteins carrying expanded octarepeat domains may therefore capture and incorporate spontaneously arising short-lived PrPSc-like conformers, thereby providing a matrix for their conversion.	Univ Dusseldorf, Inst Neuropathol, D-40225 Dusseldorf, Germany; Vrije Univ Amsterdam, Fac Exact Sci, Dept Phys & Astron, NL-1081 HV Amsterdam, Netherlands; Friedrich Loeffler Inst, Inst Immunol, D-72076 Tubingen, Germany	Heinrich Heine University Dusseldorf; Vrije Universiteit Amsterdam; Friedrich Loeffler Institute	Korth, C (corresponding author), Univ Dusseldorf, Inst Neuropathol, D-40225 Dusseldorf, Germany.	ckorth@uni-duesseldorf.de	Dame, Remus T./E-1941-2014; Dame, Remus/A-8570-2008; Dame, Remus/AAT-2989-2020; Korth, Carsten/F-7433-2010	Dame, Remus T./0000-0001-9863-1692; Dame, Remus/0000-0001-9863-1692; wuite, gijs/0000-0002-5706-043X				BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Burns CS, 2003, BIOCHEMISTRY-US, V42, P6794, DOI 10.1021/bi027138+; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Campbell TA, 1996, NEUROLOGY, V46, P761, DOI 10.1212/WNL.46.3.761; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; CHANDLER RL, 1961, LANCET, V1, P1378; Chen SG, 1997, NAT MED, V3, P1009, DOI 10.1038/nm0997-1009; Chiesa R, 2003, J VIROL, V77, P7611, DOI 10.1128/JVI.77.13.7611-7622.2003; COLLINGE J, 1992, BRAIN, V115, P687, DOI 10.1093/brain/115.3.687; Croes EA, 2004, J NEUROL NEUROSUR PS, V75, P1166, DOI 10.1136/jnnp.2003.020198; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KONG Q, 2004, PRION BIOL DIS, V41, P673; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Korth C, 1999, METHOD ENZYMOL, V309, P106; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Leliveld SR, 2003, NUCLEIC ACIDS RES, V31, P4805, DOI 10.1093/nar/gkg661; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu JJ, 1999, NATURE, V400, P573, DOI 10.1038/23048; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Moore RC, 2001, AM J HUM GENET, V69, P1385, DOI 10.1086/324414; OWEN F, 1989, LANCET, V1, P51; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Parham SN, 2001, EMBO J, V20, P2111, DOI 10.1093/emboj/20.9.2111; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RACE RE, 1987, J GEN VIROL, V68, P1391, DOI 10.1099/0022-1317-68-5-1391; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Scott Michael, 2004, VVolume 41, P435; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Sumudhu W, 2001, CURR BIOL, V11, P519, DOI 10.1016/S0960-9822(01)00147-6; Supattapone S, 2001, J VIROL, V75, P1408, DOI 10.1128/JVI.75.3.1408-1413.2001; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Zahn R, 2003, J MOL BIOL, V334, P477, DOI 10.1016/j.jmb.2003.09.048	41	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3268	3275		10.1074/jbc.M510606200	http://dx.doi.org/10.1074/jbc.M510606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16352600	Green Published, hybrid			2022-12-27	WOS:000235128200032
J	Um, JW; Min, DS; Rhim, H; Kim, J; Paik, SR; Chung, KC				Um, JW; Min, DS; Rhim, H; Kim, J; Paik, SR; Chung, KC			Parkin ubiquitinates and promotes the degradation of RanBP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEF2 TRANSCRIPTION FACTOR; HISTONE DEACETYLASES; ALPHA-SYNUCLEIN; PROTEIN LIGASE; MUSCLE DIFFERENTIATION; HDAC4 DEACETYLASE; SUBSTANTIA-NIGRA; DOPAMINE NEURONS; DOWN-REGULATION; HUMAN BRAIN	Parkinson disease (PD) is a common neurodegenerative disorder, which involves the deterioration of dopaminergic neurons in the pars compacta of the substantia nigra. The etiology of PD is still unknown, but recent identification of mutations in familial cases of PD has advanced the understanding of the molecular mechanisms of this neurological disease. Mutations in the parkin gene, which encodes for ubiquitin- protein ligase (E3), have been implicated in autosomal recessive juvenile Parkinsonism, an early onset and common familial form of PD. Here we reported that Parkin selectively binds to RanBP2, which is localized in the cytoplasmic filament of the nuclear pore complex and belongs to the small ubiquitin- related modifier E3 ligase family. We also demonstrated that RanBP2 becomes a target for Parkin E3 ubiquitin- ligase and is processed via Parkin- mediated ubiquitination and subsequent proteasomal degradation. Furthermore, Parkin controls the intracellular levels of sumoylated HDAC4, as a result of the ubiquitination and degradation of RanBP2. Our findings suggested that the intracellular levels of RanBP2 and its functional activity may be modulated by Parkin-mediated ubiquitination and proteasomal pathways.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Pusan Natl Univ, Dept Mol Biol, Coll Nat Sci, Pusan 609735, South Korea; Korea Inst Sci & Technol, Biomed Res Ctr, Seoul 136701, South Korea; Yonsei Univ, Coll Med, Dept Microbiol, Seoul 120752, South Korea; Seoul Natl Univ, Sch Chem & Biol Engn, Coll Engn, Seoul 151744, South Korea	Yonsei University; Pusan National University; Korea Institute of Science & Technology (KIST); Yonsei University; Yonsei University Health System; Seoul National University (SNU)	Chung, KC (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Shinchon Dong 134, Seoul 120749, South Korea.	kchung@yonsei.ac.kr		Kim, Jongsun/0000-0002-3149-669X				Bernad R, 2004, MOL CELL BIOL, V24, P2373, DOI 10.1128/MCB.24.6.2373-2384.2004; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Choi P, 2003, MOL BRAIN RES, V117, P179, DOI 10.1016/S0169-328X(03)00318-8; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Doss-Pepe EW, 2005, J BIOL CHEM, V280, P16619, DOI 10.1074/jbc.M413591200; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jiang HB, 2004, J BIOL CHEM, V279, P54380, DOI 10.1074/jbc.M409282200; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kim SJ, 2003, J BIOL CHEM, V278, P41890, DOI 10.1074/jbc.M306017200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lincoln S, 1999, NEUROREPORT, V10, P427, DOI 10.1097/00001756-199902050-00040; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Naoi M, 1999, MECH AGEING DEV, V111, P175, DOI 10.1016/S0047-6374(99)00064-0; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ren Y, 2003, J NEUROSCI, V23, P3316; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Saitoh H, 2002, J BIOL CHEM, V277, P4755, DOI 10.1074/jbc.M104453200; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Tsai YC, 2003, J BIOL CHEM, V278, P22044, DOI 10.1074/jbc.M212235200; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wang AH, 1999, MOL CELL BIOL, V19, P7816; YAMADA T, 1990, BRAIN RES, V526, P303, DOI 10.1016/0006-8993(90)91236-A; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	50	75	80	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3595	3603		10.1074/jbc.M504994200	http://dx.doi.org/10.1074/jbc.M504994200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332688	hybrid			2022-12-27	WOS:000235128200071
J	Shiio, Y; Suh, KS; Lee, H; Yuspa, SH; Eisenman, RN; Aebersold, R				Shiio, Y; Suh, KS; Lee, H; Yuspa, SH; Eisenman, RN; Aebersold, R			Quantitative proteomic analysis of Myc-induced apoptosis - A direct role for Myc induction of the mitochondrial chloride ion channel, mtCLIC/CLIC4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM MASS-SPECTROMETRY; CELL-CYCLE PROGRESSION; DEATH EFFECTOR DOMAIN; BCL-X-L; C-MYC; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; STATISTICAL-MODEL; PROTEIN; P53	Myc is a key regulatory protein in higher eukaryotes controlling important cellular functions such as proliferation, differentiation, and apoptosis. Myc is profoundly involved in the genesis of many human and animal cancers, and the abrogation of Myc-induced apoptosis is a critical event in cancer progression. Because the mechanisms that mediate Myc-induced apoptosis are largely unknown, we analyzed protein expression during Myc-induced apoptosis using an isotope-coded affinity tag quantitative proteomics approach and identified that a proapoptotic mitochondrial chloride ion channel, mtCLIC/CLIC4, is induced by Myc. Myc binds to the mtCLIC gene promoter and activates its transcription. Suppression of mtCLIC expression by RNA interference inhibited Myc-induced apoptosis in response to different stress conditions and abolished the cooperative induction of apoptosis by Myc and Bax. We also found that Myc reduces the expression of Bcl-2 and Bcl-xL and that the apoptosis-inducing stimuli up-regulate Bax expression. These results suggest that up-regulation of mtCLIC, together with a reduction in Bcl-2 and Bcl-xL, sensitizes Myc-expressing cells to the proapoptotic action of Bax.	Univ Texas, Hlth Sci Ctr, Childrens Canc Res Inst, San Antonio, TX 78229 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Inst Syst Biol, Seattle, WA 98103 USA; NCI, Cellular Carcinogenesis & Tumor Promot Lab, NIH, Bethesda, MD 20892 USA; Univ Zurich, Inst Mol Syst Biol, ETH, CH-8093 Zurich, Switzerland; Univ Zurich, Fac Nat Sci, CH-8093 Zurich, Switzerland	University of Texas System; University of Texas Health San Antonio; Fred Hutchinson Cancer Center; Institute for Systems Biology (ISB); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Zurich	Shiio, Y (corresponding author), Univ Texas, Hlth Sci Ctr, Childrens Canc Res Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	shiio@uthscsa.edu		Lee, Hookeun/0000-0002-0696-8421	NATIONAL CANCER INSTITUTE [Z01BC004504, ZIABC004504] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Arnould T, 2003, FASEB J, V17, P2145, DOI 10.1096/fj.03-0075fje; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; Beere HM, 2004, J CELL SCI, V117, P2641, DOI 10.1242/jcs.01284; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Chang TS, 2004, J BIOL CHEM, V279, P41975, DOI 10.1074/jbc.M407707200; CHENG NC, 1995, ONCOGENE, V10, P291; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Knuefermann P, 2002, J BIOL CHEM, V277, P23888, DOI 10.1074/jbc.M202937200; Li XJ, 2003, ANAL CHEM, V75, P6648, DOI 10.1021/ac034633i; Lucas PC, 2004, J CELL SCI, V117, P31, DOI 10.1242/jcs.00904; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; MALDE P, 1994, INT IMMUNOL, V6, P1169, DOI 10.1093/intimm/6.8.1169; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; Sakamuro D, 1995, ONCOGENE, V11, P2411; Schickling O, 2001, CELL DEATH DIFFER, V8, P1157, DOI 10.1038/sj.cdd.4400928; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; Shiio Y, 2003, J AM SOC MASS SPECTR, V14, P696, DOI 10.1016/S1044-0305(03)00204-6; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Suh KS, 2004, J BIOL CHEM, V279, P4632, DOI 10.1074/jbc.M311632200; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Weiner AM, 1999, SCIENCE, V284, P63, DOI 10.1126/science.284.5411.63; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	63	59	62	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2750	2756		10.1074/jbc.M509349200	http://dx.doi.org/10.1074/jbc.M509349200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316993	hybrid			2022-12-27	WOS:000234931800041
J	Shalev, DE; Rotem, S; Fish, A; Mor, A				Shalev, DE; Rotem, S; Fish, A; Mor, A			Consequences of N-acylation on structure and membrane binding properties of dermaseptin derivative K-4-S4-(1-13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDE; ESCHERICHIA-COLI; MACROMOLECULAR-SYNTHESIS; SELECTIVE CYTOTOXICITY; AQUEOUS-SOLUTIONS; NMR-SPECTROSCOPY; LACTOFERRICIN-B; S4 DERIVATIVES; HOST-DEFENSE; IN-VITRO	Acyl conjugation to antimicrobial peptides is known to enhance antimicrobial properties. Here, we investigated the consequences of aminolauryl (NC12) conjugation to the dermaseptin derivative K-4-S4-(1-13) (P) on binding properties to bilayer models mimicking bacterial plasma membrane, which is often cited as the ultimate site of action. Isothermal titration calorimetry revealed that acylation was responsible for enhancing the binding affinity of NC12-P compared with P (K = 13 x 10(5) and 1.5 x 10(5) M-1, respectively). Surface plasmon resonance measurements confirmed the isothermal titration calorimetry results (K-app = 12.6 x 10(5) and 1.53 x 10(5) M-1, respectively) and further indicated that enhanced adhesion affinity (K-adhesion = 3 x 10(5) and 1.5 x 10(5) M-1, respectively) was coupled to enhanced tendency to insert within the bilayer (K-insertion = 4.5 and 1.5, respectively). To gain insight into the molecular basis for these observations, we investigated the three-dimensional structures in the presence of dodecylphosphocholine using NMR. The ensemble of NMR-calculated structures ( backbone root mean square deviation <0.6 angstrom) showed that the acyl moiety was responsible for a significant molecular reorganization, possibly affecting the electrostatic potential distribution in NC12-P relative to that of P. The combined data present compelling evidence in support of the hypothesis that N-acylation affects antimicrobial properties by modifying the secondary structure of the peptide in a manner that facilitates contact with the membrane and consequently increases its disruption.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Lab Antimicrobial Peptides Invest, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, IL-91904 Jerusalem, Israel	Technion Israel Institute of Technology; Hebrew University of Jerusalem	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Lab Antimicrobial Peptides Invest, IL-32000 Haifa, Israel.	amor@tx.technion.ac.il	Shalev, Deborah E/AAY-2873-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR-01081] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ammar B, 1998, BIOCHEM BIOPH RES CO, V247, P870, DOI 10.1006/bbrc.1998.8879; Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; Balaban N, 2004, ANTIMICROB AGENTS CH, V48, P2544, DOI 10.1128/AAC.48.7.2544-2550.2004; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1989, ANNU REV BIOCHEM, V58, P223; Blazyk J, 2001, J BIOL CHEM, V276, P27899, DOI 10.1074/jbc.M102865200; Blondelle SE, 2000, BIOPOLYMERS, V55, P74, DOI 10.1002/1097-0282(2000)55:1&lt;74::AID-BIP70&gt;3.0.CO;2-S; Brul S, 1999, INT J FOOD MICROBIOL, V50, P1, DOI 10.1016/S0168-1605(99)00072-0; Chapple DS, 1998, INFECT IMMUN, V66, P2434, DOI 10.1128/IAI.66.6.2434-2440.1998; Chen J, 2000, BIOPOLYMERS, V55, P88, DOI 10.1002/1097-0282(2000)55:1<88::AID-BIP80>3.3.CO;2-B; Chicharro C, 2001, ANTIMICROB AGENTS CH, V45, P2441, DOI 10.1128/AAC.45.9.2441-2449.2001; Dathe M, 2004, BIOCHEMISTRY-US, V43, P9140, DOI 10.1021/bi035948v; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; Efron L, 2002, J BIOL CHEM, V277, P24067, DOI 10.1074/jbc.M202089200; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Elsbach P, 1998, CURR OPIN IMMUNOL, V10, P45, DOI 10.1016/S0952-7915(98)80030-7; Epand R, 2003, BIOPOLYMERS, V71, P2, DOI 10.1002/bip.10372; Feder R, 2000, J BIOL CHEM, V275, P4230, DOI 10.1074/jbc.275.6.4230; Gaidukov L, 2003, BIOCHEMISTRY-US, V42, P12866, DOI 10.1021/bi034514x; Ge YG, 1999, DIAGN MICR INFEC DIS, V35, P45, DOI 10.1016/S0732-8893(99)00056-5; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hariton-Gazal E, 2002, BIOCHEMISTRY-US, V41, P9208, DOI 10.1021/bi0201466; Haukland HH, 2001, FEBS LETT, V508, P389, DOI 10.1016/S0014-5793(01)03100-3; HAYNIE SL, 1995, ANTIMICROB AGENTS CH, V39, P301, DOI 10.1128/AAC.39.2.301; HERNANDEZ C, 1992, EUR J CELL BIOL, V59, P414; Hobta A, 2001, CELL BIOCHEM FUNCT, V19, P291, DOI 10.1002/cbf.929; HONIG B, 1993, J PHYS CHEM-US, V97, P1101, DOI 10.1021/j100108a002; Huang H W, 1999, Novartis Found Symp, V225, P188; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Kustanovich I, 2002, J BIOL CHEM, V277, P16941, DOI 10.1074/jbc.M111071200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee WJ, 1998, INFECT IMMUN, V66, P1421, DOI 10.1128/IAI.66.4.1421-1426.1998; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Levy O, 2000, BLOOD, V96, P2664; Lockwood NA, 2004, BIOCHEM J, V378, P93, DOI 10.1042/BJ20031393; Mak P, 2003, INT J ANTIMICROB AG, V21, P13, DOI 10.1016/S0924-8579(02)00245-5; MERUTKA G, 1995, J BIOMOL NMR, V5, P14, DOI 10.1007/BF00227466; Mor A, 2000, DRUG DEVELOP RES, V50, P440, DOI 10.1002/1098-2299(200007/08)50:3/4<440::AID-DDR27>3.3.CO;2-W; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, J BIOL CHEM, V269, P31635; MOR A, 1991, BIOCHEMISTRY-US, V30, P8824, DOI 10.1021/bi00100a014; Navon-Venezia S, 2002, ANTIMICROB AGENTS CH, V46, P689, DOI 10.1128/AAC.46.3.689-694.2002; NILGES M, 1991, COMPUTATIONAL ASPECT; Okumura K, 2004, CANCER LETT, V212, P185, DOI 10.1016/j.canlet.2004.04.006; Papo N, 2003, BIOCHEMISTRY-US, V42, P9346, DOI 10.1021/bi027212o; Patrzykat A, 2002, ANTIMICROB AGENTS CH, V46, P605, DOI 10.1128/AAC.46.3.605-614.2002; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peggion C, 2003, J PEPT SCI, V9, P679, DOI 10.1002/psc.500; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Radzishevsky IS, 2005, ANTIMICROB AGENTS CH, V49, P2412, DOI 10.1128/AAC.49.6.2412-2420.2005; Sal-Man N, 2002, BIOCHEMISTRY-US, V41, P11921, DOI 10.1021/bi0260482; Salzet M, 2002, TRENDS IMMUNOL, V23, P283, DOI 10.1016/S1471-4906(02)02236-6; Scott MG, 2000, J IMMUNOL, V165, P3358, DOI 10.4049/jimmunol.165.6.3358; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Shalev DE, 2002, BIOCHEMISTRY-US, V41, P7312, DOI 10.1021/bi016013m; Stark M, 2002, ANTIMICROB AGENTS CH, V46, P3585, DOI 10.1128/AAC.46.11.3585-3590.2002; Tossi A, 1997, EUR J BIOCHEM, V250, P549, DOI 10.1111/j.1432-1033.1997.0549a.x; Ulvatne H, 2004, FEMS MICROBIOL LETT, V237, P377, DOI 10.1016/j.femsle.2004.07.001; Welling MM, 2000, EUR J NUCL MED, V27, P292, DOI 10.1007/s002590050036; Wenk MR, 1998, BIOCHEMISTRY-US, V37, P3909, DOI 10.1021/bi972615n; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P13; Yaron S, 2003, PEPTIDES, V24, P1815, DOI 10.1016/j.peptides.2003.09.016; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	66	35	38	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9432	9438		10.1074/jbc.M513051200	http://dx.doi.org/10.1074/jbc.M513051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16407175	hybrid			2022-12-27	WOS:000236404700053
J	Gerard, F; Cline, K				Gerard, F; Cline, K			Efficient twin arginine translocation (Tat) pathway transport of a precursor protein covalently anchored to its initial cpTatC binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYLAKOID MEMBRANES; SIGNAL PEPTIDE; ESCHERICHIA-COLI; SEC; CHLOROPLASTS; SYSTEM; COMPLEX; REQUIREMENTS; SPECIFICITY; INTEGRATION	The thylakoid twin arginine protein translocation ( Tat) system operates by a cyclical mechanism in which precursors bind to a cpTatC-Hcf106 receptor complex, which then recruits Tha4 to form the translocase. After translocation, the translocase disassembles. Here, we fine-mapped initial interactions between precursors and the components of the receptor complex. Precursors with (Tmd) Phe substitutions in the signal peptide and early mature domain were bound to thylakoids and photo-cross-linked to components. cpTatC and Hcf106 were found to interact with different regions of the signal peptide. cpTatC cross-linked strongly to residues in the immediate vicinity of the twin arginine motif. Hcf106 cross-linked less strongly to residues in the hydrophobic core and the early mature domain. To determine whether precursors must leave their initial sites of interaction during translocation, crosslinked precursors were subjected to protein transport conditions. tOE17 cross-linked to cpTatC was efficiently translocated, indicating that the mature domain of the precursor can be translocated while the signal peptide remains anchored to the receptor complex.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cline, K (corresponding author), Univ Florida, Dept Hort Sci, 1109 Fifield Hall,Box 110690, Gainesville, FL 32611 USA.	kcline@ufl.edu	Cline, Kenneth/J-6238-2013		NIGMS NIH HHS [R01 GM48179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048179, R29GM048179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alder NN, 2003, FEBS LETT, V540, P96, DOI 10.1016/S0014-5793(03)00231-X; Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Bogsch E, 1997, EMBO J, V16, P3851, DOI 10.1093/emboj/16.13.3851; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Ma XY, 2000, J BIOL CHEM, V275, P10016, DOI 10.1074/jbc.275.14.10016; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; MOULD RM, 1991, J BIOL CHEM, V266, P17286; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Sargent F, 2002, ARCH MICROBIOL, V178, P77, DOI 10.1007/s00203-002-0434-2; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Theg SM, 2005, TRENDS PLANT SCI, V10, P153, DOI 10.1016/j.tplants.2005.02.001; Walker MB, 1999, J CELL BIOL, V147, P267, DOI 10.1083/jcb.147.2.267; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	31	86	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6130	6135		10.1074/jbc.M512733200	http://dx.doi.org/10.1074/jbc.M512733200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407185	hybrid			2022-12-27	WOS:000236030800004
J	Muroi, M; Tanamoto, K				Muroi, M; Tanamoto, K			Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; NF-KAPPA-B; BACTERIAL LIPOPOLYSACCHARIDE; MOLECULAR-MECHANISMS; CELL-SURFACE; ACTIVATION; RESPONSIVENESS; RECOGNITION; ENDOTOXIN; COMPLEX	A cell surface receptor complex consisting of CD14, Toll-like receptor (TLR4), and MD-2 recognizes lipid A, the active moiety of lipopolysaccharide (LPS). Escherichia coli-type lipid A, a typical lipid A molecule, potently activates both human and mouse macrophage cells, whereas the lipid A precursor, lipid IVa, activates mouse macrophages but is inactive and acts as an LPS antagonist in human macrophages. This animal species-specific activity of lipid IVa involves the species differences in MD-2 structure. We explored the structural region of MD-2 that determines the agonistic and antagonistic activities of lipid IVa to induce nuclear factor-kappa B activation. By expressing human/mouse chimeric MD-2 together with mouse CD14 and TLR4 in human embryonic kidney 293 cells, we found that amino acid regions 57 - 79 and 108 - 135 of MD- 2 determine the species-specific activity of lipid IVa. We also showed that the replacement of Thr(57), Val(61), and Glu(122) of mouse MD-2 with corresponding human MD- 2 sequence or alanines impaired the agonistic activity of lipid IVa, and antagonistic activity became evident. These mutations did not affect the activation of nuclear factor-kappa B, TLR4 oligomerization, and inducible phosphorylation of I kappa B alpha in response to E. coli-type lipid A. These results indicate that amino acid residues 57, 61, and 122 of mouse MD- 2 are critical to determine the agonist-antagonist activity of lipid IVa and suggest that these amino acid residues may be involved in the discrimination of lipid A structure.	Natl Inst Hlth Sci, Div Microbiol, Setagaya Ku, Tokyo 1588501, Japan	National Institute of Health Sciences - Japan	Tanamoto, K (corresponding author), Natl Inst Hlth Sci, Div Microbiol, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan.	tanamoto@nihs.go.jp						Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; DASILVA CJ, 2002, J BIOL CHEM, V277, P1845, DOI [DOI 10.1074/JBC.M109910200, 10.1074/jbc.M109910200]; Fujihara M, 2003, PHARMACOL THERAPEUT, V100, P171, DOI 10.1016/j.pharmthera.2003.08.003; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Kawasaki K, 2003, J IMMUNOL, V170, P413, DOI 10.4049/jimmunol.170.1.413; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; LUDERITZ O, 1982, CURR TOP MEMBR TRANS, V17, P79; MANEEK M, 2002, BIOCHEM BIOPH RES CO, V292, P880; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Miyake K, 2004, TRENDS MICROBIOL, V12, P186, DOI 10.1016/j.tim.2004.02.009; Muroi M, 2002, INFECT IMMUN, V70, P6043, DOI 10.1128/IAI.70.11.6043-6047.2002; Muroi M, 2002, J BIOL CHEM, V277, P42372, DOI 10.1074/jbc.M205966200; Muroi M, 2002, INFECT IMMUN, V70, P3546, DOI 10.1128/IAI.70.7.3546-3550.2002; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Re F, 2003, J IMMUNOL, V171, P5272, DOI 10.4049/jimmunol.171.10.5272; Schletter J, 1995, ARCH MICROBIOL, V164, P383, DOI 10.1007/BF02529735; Tanamoto K, 2000, J IMMUNOL, V164, P3149, DOI 10.4049/jimmunol.164.6.3149; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	28	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5484	5491		10.1074/jbc.M509193200	http://dx.doi.org/10.1074/jbc.M509193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407172	hybrid			2022-12-27	WOS:000235568900021
J	Ternes, P; Sperling, P; Albrecht, S; Franke, S; Cregg, JM; Warnecke, D; Heinz, E				Ternes, P; Sperling, P; Albrecht, S; Franke, S; Cregg, JM; Warnecke, D; Heinz, E			Identification of fungal sphingolipid C9-methyltransferases by phylogenetic profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOPROPANATED MYCOLIC ACIDS; LONG-CHAIN BASES; MYCOBACTERIUM-TUBERCULOSIS; SACCHAROMYCES-CEREVISIAE; UNCHARACTERIZED GENES; PLANT SPHINGOLIPIDS; ESCHERICHIA-COLI; PROTEIN TOPOLOGY; ACTIVE-SITE; RICE PLANTS	Fungal glucosylceramides play an important role in plant-pathogen interactions enabling plants to recognize the fungal attack and initiate specific defense responses. A prime structural feature distinguishing fungal glucosylceramides from those of plants and animals is a methyl group at the C9-position of the sphingoid base, the biosynthesis of which has never been investigated. Using information on the presence or absence of C9-methylated glucosylceramides in different fungal species, we developed a bioinformatics strategy to identify the gene responsible for the biosynthesis of this C9-methyl group. This phylogenetic profiling allowed the selection of a single candidate out of 24 - 71 methyltransferase sequences present in each of the fungal species with C9-methylated glucosylceramides. A Pichia pastoris knock-out strain lacking the candidate sphingolipid C9-methyltransferase was generated, and indeed, this strain contained only non-methylated glucosylceramides. In a complementary approach, a Saccharomyces cerevisiae strain was engineered to produce glucosylceramides suitable as a substrate for C9-methylation. C9-methylated sphingolipids were detected in this strain expressing the candidate from P. pastoris, demonstrating its function as a sphingolipid C9-methyltransferase. The enzyme belongs to the superfamily of S-adenosylmethionine-(SAM)dependent methyltransferases and shows highest sequence similarity to plant and bacterial cyclopropane fatty acid synthases. An in vitro assay showed that sphingolipid C9-methylation is membrane-bound and requires SAM and Delta 4,8-desaturated ceramide as substrates.	Univ Hamburg, Biozentrum Klein Flottbek & Bot Garten, D-22609 Hamburg, Germany; Univ Hamburg, Inst Organ Chem, D-20146 Hamburg, Germany; Keck Grad Inst, Claremont, CA 91711 USA	University of Hamburg; University of Hamburg; Claremont Colleges; Keck Graduate Institute	Ternes, P (corresponding author), Univ Utrecht, Fac Scheikunde, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	p.g.ternes@chem.uu.nl		Ternes, Philipp/0000-0003-0886-5474				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bao XM, 2002, P NATL ACAD SCI USA, V99, P7172, DOI 10.1073/pnas.092152999; Courtois F, 2005, BIOCHEMISTRY-US, V44, P13583, DOI 10.1021/bi051159x; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Dufayard JF, 2005, BIOINFORMATICS, V21, P2596, DOI 10.1093/bioinformatics/bti325; Dunn TM, 2004, ANN BOT-LONDON, V93, P483, DOI 10.1093/aob/mch071; Duran R, 1998, TETRAHEDRON, V54, P14597, DOI 10.1016/S0040-4020(98)00917-X; Eisen JA, 1998, GENOME RES, V8, P163, DOI 10.1101/gr.8.3.163; Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575; Fitch WM, 2000, TRENDS GENET, V16, P227, DOI 10.1016/S0168-9525(00)02005-9; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; Green ML, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-76; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUTIERREZ RA, 2004, GENOME BIOL; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; HEINZE FJ, 1984, ANAL BIOCHEM, V139, P126, DOI 10.1016/0003-2697(84)90397-X; Higuchi R, 1996, LIEBIGS ANN-RECL, P593; Huang CC, 2002, J BIOL CHEM, V277, P11559, DOI 10.1074/jbc.M111698200; Imai H, 1997, BIOSCI BIOTECH BIOCH, V61, P351, DOI 10.1271/bbb.61.351; IRIE A, 1990, J BIOCHEM-TOKYO, V107, P578, DOI 10.1093/oxfordjournals.jbchem.a123089; Jenkins KM, 1999, TETRAHEDRON LETT, V40, P7637, DOI 10.1016/S0040-4039(99)01562-2; JIN WZ, 1994, J ORG CHEM, V59, P144, DOI 10.1021/jo00080a023; KARLSSON KA, 1970, CHEM PHYS LIPIDS, V5, P6, DOI 10.1016/0009-3084(70)90008-3; KARLSSON KA, 1979, BIOCHIM BIOPHYS ACTA, V574, P79, DOI 10.1016/0005-2760(79)90087-0; KAWAI G, 1986, J BIOL CHEM, V261, P779; Koga J, 1998, J BIOL CHEM, V273, P31985, DOI 10.1074/jbc.273.48.31985; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Leipelt M, 2001, J BIOL CHEM, V276, P33621, DOI 10.1074/jbc.M104952200; Levesque M, 2003, CURR BIOL, V13, P129, DOI 10.1016/S0960-9822(03)00009-5; Lin N, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-154; LUNDBLAD V, 1997, CURRENT PROTOCOLS MO; Mikkelsen TS, 2005, BIOINFORMATICS, V21, P464, DOI 10.1093/bioinformatics/bti027; MORRISON WR, 1970, BIOCHIM BIOPHYS ACTA, V202, P460, DOI 10.1016/0005-2760(70)90116-5; NATORI T, 1994, TETRAHEDRON, V50, P2771, DOI 10.1016/S0040-4020(01)86991-X; Nes WD, 2000, BBA-MOL CELL BIOL L, V1529, P63, DOI 10.1016/S1388-1981(00)00138-4; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Persson B, 1997, J PROTEIN CHEM, V16, P453, DOI 10.1023/A:1026353225758; Pinto MR, 2002, GLYCOBIOLOGY, V12, P251, DOI 10.1093/glycob/12.4.251; Rodrigues ML, 2000, INFECT IMMUN, V68, P7049, DOI 10.1128/IAI.68.12.7049-7060.2000; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shevchuk NA, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh014; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Sperling P, 2004, TOP CURR GENET, V6, P337; Tan RX, 2003, NAT PROD REP, V20, P509, DOI 10.1039/b307243f; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; Thevissen K, 2004, J BIOL CHEM, V279, P3900, DOI 10.1074/jbc.M311165200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toledo MS, 2000, J LIPID RES, V41, P797; Toledo MS, 1999, BIOCHEMISTRY-US, V38, P7294, DOI 10.1021/bi982898z; TRECO DA, 1993, CURRENT PROTOCOLS MO, pCH13; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Umemura K, 2000, PLANT CELL PHYSIOL, V41, P676, DOI 10.1093/pcp/41.6.676; Umemura K, 2002, PLANT CELL PHYSIOL, V43, P778, DOI 10.1093/pcp/pcf090; WANG AY, 1992, BIOCHEMISTRY-US, V31, P11020, DOI 10.1021/bi00160a011; Warnecke D, 2003, CELL MOL LIFE SCI, V60, P919, DOI 10.1007/s00018-003-2243-4; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Zmasek CM, 2001, BIOINFORMATICS, V17, P821, DOI 10.1093/bioinformatics/17.9.821	63	55	58	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5582	5592		10.1074/jbc.M512864200	http://dx.doi.org/10.1074/jbc.M512864200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16339149	hybrid			2022-12-27	WOS:000235568900034
J	Ostheimer, GJ; Rojas, M; Hadjivassiliou, H; Barkan, A				Ostheimer, GJ; Rojas, M; Hadjivassiliou, H; Barkan, A			Formation of the CRS2-CAF2 group II intron splicing complex is mediated by a 22-amino acid motif in the COOH-terminal region of CAF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; YHBY	CRS2-associated factors 1 and 2 (CAF1 and CAF2) are closely related proteins that function in concert with chloroplast RNA splicing 2 (CRS2) to promote the splicing of specific sets of group II introns in maize chloroplasts. The CRS2-CAF complexes bind tightly to their cognate group II introns in vivo, with the CAF subunit determining the intron specificity of the complex. In this work we show that the CRS2-CAF complexes are stable in the absence of their intron targets and that CRS2 binds a 22 amino acid motif in the COOH-terminal region of CAF2 that is conserved in CAF1. Yeast two-hybrid assays and co-fractionation studies using recombinant proteins show that this motif is both necessary and sufficient to bind CRS2. The 22-amino acid motif is predicted to form an amphipathic helix whose hydrophobic surface is conserved between CAF1 and CAF2. We propose that this surface binds the hydrophobic patch on the surface of CRS2 previously shown to be necessary for the interaction between CRS2 and CAF2.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA; Univ Oregon, Dept Biol, Eugene, OR 97403 USA	University of Oregon; University of Oregon; University of Oregon	Barkan, A (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	abarkan@molbio.uoregon.edu						Barkan A., 2004, MOL BIOL BIOTECHNOLO, P281, DOI DOI 10.1007/978-1-4020-3166-3_; Bonen L, 2001, TRENDS GENET, V17, P322, DOI 10.1016/S0168-9525(01)02324-1; Dai LX, 2003, RNA, V9, P14, DOI 10.1261/rna.2126203; Dai LX, 2002, NUCLEIC ACIDS RES, V30, P1091, DOI 10.1093/nar/30.5.1091; Jenkins BD, 2001, EMBO J, V20, P872, DOI 10.1093/emboj/20.4.872; Kholod N, 2001, BIOTECHNIQUES, V31, P322, DOI 10.2144/01312st03; Lambowitz AM, 2004, ANNU REV GENET, V38, P1, DOI 10.1146/annurev.genet.38.072902.091600; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; Lambowitz AM., 1999, GROUP GROUP 2 RIBOZY, P451; Liu DJ, 2004, J BIOMOL NMR, V29, P391, DOI 10.1023/B:JNMR.0000032524.62229.93; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Ostersetzer O, 2005, PLANT CELL, V17, P241, DOI 10.1105/tpc.104.027516; Ostheimer GJ, 2005, J MOL BIOL, V345, P51, DOI 10.1016/j.jmb.2004.10.032; Ostheimer GJ, 2003, EMBO J, V22, P3919, DOI 10.1093/emboj/cdg372; Ostheimer GJ, 2002, STRUCTURE, V10, P1593, DOI 10.1016/S0969-2126(02)00886-9; Qin PZ, 1998, CURR OPIN STRUC BIOL, V8, P301, DOI 10.1016/S0959-440X(98)80062-6; Till B, 2001, RNA, V7, P1227, DOI 10.1017/S1355838201010445; Toro N, 2003, ENVIRON MICROBIOL, V5, P143, DOI 10.1046/j.1462-2920.2003.00398.x; Vogel J, 1999, NUCLEIC ACIDS RES, V27, P3866, DOI 10.1093/nar/27.19.3866; Willis MA, 2002, PROTEINS, V49, P423, DOI 10.1002/prot.10225	21	29	36	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4732	4738		10.1074/jbc.M508921200	http://dx.doi.org/10.1074/jbc.M508921200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16379013				2022-12-27	WOS:000235426200022
J	Lavillette, D; Bartosch, B; Nourrisson, D; Verney, G; Cosset, FL; Penin, F; Pecheur, EI				Lavillette, D; Bartosch, B; Nourrisson, D; Verney, G; Cosset, FL; Penin, F; Pecheur, EI			Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE GLYCOPROTEIN; INFLUENZA-VIRUS; LOW-DENSITY; CELL ENTRY; WEST-NILE; DC-SIGN; RECEPTOR; KINETICS; PROTEIN; LIPIDS	It has been suggested that the hepatitis C virus (HCV) infects host cells through a pH-dependent internalization mechanism, but the steps leading from virus attachment to the fusion of viral and cellular membranes remain uncharacterized. Here we studied the mechanism underlying the HCV fusion process in vitro using liposomes and our recently described HCV pseudoparticles (pp) bearing functional E1E2 envelope glycoproteins. The fusion of HCVpp with liposomes was monitored with fluorescent probes incorporated into either the HCVpp or the liposomes. To validate these assays, pseudoparticles bearing either the hemagglutinin of the influenza virus or the amphotropic glycoprotein of murine leukemia virus were used as models for pH-dependent and pH-independent entry, respectively. The use of assays based either on fusion-induced dequenching of fluorescent probes or on reporter systems, which produce fluorescence when the virus and liposome contents are mixed, allowed us to demonstrate that HCVpp mediated a complete fusion process, leading to the merging of both membrane leaflets and to the mixing of the internal contents of pseudoparticle and liposome. This HCVpp-mediated fusion was dependent on low pH, with a threshold of 6.3 and an optimum at about 5.5. Fusion was temperature-dependent and did not require any protein or receptor at the surface of the target liposomes. Most interestingly, fusion was facilitated by the presence of cholesterol in the target membrane. These findings clearly indicate that HCV infection is mediated by a pH-dependent membrane fusion process. This paves the way for future studies of the mechanisms underlying HCV membrane fusion.	Univ Lyon 1, CNRS, IBCP, UMR 5086,Inst Biol Chim Prot,IFR128 Biosci Lyon G, F-69367 Lyon 07, France; Ecole Normale Super Lyon, INSERM, U412, Lab Vectorol Retrovirale & Therapie Gen, F-69365 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Pecheur, EI (corresponding author), Univ Lyon 1, CNRS, IBCP, UMR 5086,Inst Biol Chim Prot,IFR128 Biosci Lyon G, 7 Passage Vercors, F-69367 Lyon 07, France.	e.pecheur@ibcp.fr	PENIN, Francois/A-7315-2008; Cosset, François-Loïc/M-5862-2019; Bartosch, Birke/I-7255-2018	Cosset, François-Loïc/0000-0001-8842-3726; Bartosch, Birke/0000-0001-6354-4660; Pecheur, Eve/0000-0002-8613-862X; Lavillette, Dimitri/0000-0002-4706-1519				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Altmeyer R, 2004, CURR PHARM DESIGN, V10, P3701, DOI 10.2174/1381612043382729; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064; Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CLAGUE MJ, 1990, BIOCHEMISTRY-US, V29, P1303, DOI 10.1021/bi00457a028; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; Corver J, 2000, VIROLOGY, V269, P37, DOI 10.1006/viro.1999.0172; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; DESPRES P, 1993, VIROLOGY, V196, P209, DOI 10.1006/viro.1993.1469; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Flint M, 2004, J VIROL, V78, P6875, DOI 10.1128/JVI.78.13.6875-6882.2004; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Gibbons DL, 2004, J VIROL, V78, P3312, DOI 10.1128/JVI.78.7.3312-3318.2004; Goffard A, 2003, BIOCHIMIE, V85, P295, DOI 10.1016/S0300-9084(03)00004-X; GOLLINS SW, 1986, J GEN VIROL, V67, P157, DOI 10.1099/0022-1317-67-1-157; Guettouche T, 2005, ANTIVIR THER, V10, P593; GUIRAKHOO F, 1991, J GEN VIROL, V72, P1323, DOI 10.1099/0022-1317-72-6-1323; Hatziioannou T, 1998, J VIROL, V72, P5313, DOI 10.1128/JVI.72.6.5313-5317.1998; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; JUSTMAN J, 1993, J VIROL, V67, P7597, DOI 10.1128/JVI.67.12.7597-7607.1993; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Keck ZY, 2004, J VIROL, V78, P7257, DOI 10.1128/JVI.78.13.7257-7263.2004; Kielian M, 2000, Subcell Biochem, V34, P409; LAPIDOT M, 1987, J BIOL CHEM, V262, P13736; Lavillette D, 2005, J VIROL, V79, P6023, DOI 10.1128/JVI.79.10.6023-6034.2005; Lavillette D, 1998, J VIROL, V72, P9955, DOI 10.1128/JVI.72.12.9955-9965.1998; LAVILLETTE D, 2005, J VIROL, V41, P265; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; LINDENBACH BD, 2001, FIELDS VIROLOGY, V1, P991; Logvinoff C, 2004, P NATL ACAD SCI USA, V101, P10149, DOI 10.1073/pnas.0403519101; Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200; Lozach PY, 2003, J BIOL CHEM, V278, P20358, DOI 10.1074/jbc.M301284200; McKeating JA, 2004, J VIROL, V78, P8496, DOI 10.1128/JVI.78.16.8496-8505.2004; Mukhopadhyay S, 2003, SCIENCE, V302, P248, DOI 10.1126/science.1089316; NEW RRC, 1990, LIPOSOMES PRACTICAL, P1; *NIH, 2002, HEPATOLOGY S1, V36, pS2; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; Pecheur EI, 2002, BIOCHEMISTRY-US, V41, P9813, DOI 10.1021/bi0259195; Pelkmans L, 2003, CURR OPIN CELL BIOL, V15, P414, DOI 10.1016/S0955-0674(03)00081-4; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Rawat SS, 2003, MOL MEMBR BIOL, V20, P243, DOI 10.1080/0968768031000104944; Sandrin V, 2005, J GEN VIROL, V86, P3189, DOI 10.1099/vir.0.81428-0; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Smit JM, 1999, J VIROL, V73, P8476, DOI 10.1128/JVI.73.10.8476-8484.1999; STEGMANN T, 1985, BIOCHEMISTRY-US, V24, P3107, DOI 10.1021/bi00334a006; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; Stiasny K, 2004, J VIROL, V78, P8536, DOI 10.1128/JVI.78.16.8536-8542.2004; Stiasny K, 2003, J VIROL, V77, P7856, DOI 10.1128/JVI.77.14.7856-7862.2003; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Voisset C, 2004, BIOL CELL, V96, P413, DOI 10.1016/j.biolcel.2004.03.008; Waarts BL, 2005, J VIROL, V79, P7942, DOI 10.1128/JVI.79.12.7942-7948.2005; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273; Yonezawa A, 2005, J VIROL, V79, P918, DOI 10.1128/JVI.79.2.918-926.2005; Zhang J, 2004, J VIROL, V78, P1448, DOI 10.1128/JVI.78.3.1448-1455.2004; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	66	113	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3909	3917		10.1074/jbc.M509747200	http://dx.doi.org/10.1074/jbc.M509747200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356932	hybrid			2022-12-27	WOS:000235275300018
J	Rosso, A; Balsamo, A; Gambino, R; Dentelli, P; Falcioni, R; Cassader, M; Pegoraro, L; Pagano, G; Brizzi, MF				Rosso, A; Balsamo, A; Gambino, R; Dentelli, P; Falcioni, R; Cassader, M; Pegoraro, L; Pagano, G; Brizzi, MF			p53 mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITORS; LOW-DENSITY LIPOPROTEINS; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; CELLULAR SENESCENCE; LIFE-SPAN; VASCULAR COMPLICATIONS; OXIDATIVE STRESS; IN-VIVO; P16	Adverse metabolic factors, including oxidized small and dense low density lipoprotein (ox-dmLDL) can contribute to the reduced number and the impaired functions of circulating endothelial progenitors (EPC) in diabetic patients. To elucidate the molecular mechanisms involved, EPC from normal donors were cultured in the presence of alpha-dmLDL. Under these experimental conditions EPC undergo to senescent-like growth arrest. This effect is associated with Akt activation, p21 expression, p53 accumulation, and retinoblastoma protein dephosphorylation and with a reduced protective effect against oxidative damage. Moreover, depletion of endogenous p53 expression by small interfering RNA demonstrates that the integrity of this pathway is essential for senescence to occur. Activation of the Akt/p53/p21 signaling pathway and accelerated onset of senescence are also detectable in EPC from diabetic patients. Finally, diabetic EPC depleted of endogenous p53 do not undergo to senescence-growth arrest and acquire the ability to form tube-like structures in vitro. These observations identify the activation of the p53 signaling pathway as a crucial event that can contribute to the impaired neovascularization in diabetes.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	University of Turin; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	Brizzi, Maria Felice/J-7882-2016; GAMBINO, Roberto/AAC-7517-2022; Falcioni, Rita/H-8869-2017	GAMBINO, Roberto/0000-0003-1902-3627; Falcioni, Rita/0000-0002-3745-4327				Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Andres V, 2004, CIRCULATION, V110, P3749, DOI 10.1161/01.CIR.0000151787.39451.BC; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Boulaire J, 2000, PATHOL BIOL, V48, P190; Brizzi MF, 1999, CIRC RES, V84, P785; Brizzi MF, 2004, FASEB J, V18, P1249, DOI 10.1096/fj.03-1053fje; Brizzi MF, 2002, DIABETES, V51, P3311, DOI 10.2337/diabetes.51.11.3311; Brizzi MF, 2002, J CLIN INVEST, V109, P111, DOI 10.1172/JCI13617; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Ceriello A, 2000, DIABETES, V49, P2170, DOI 10.2337/diabetes.49.12.2170; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dimmeler S, 2004, J MOL MED, V82, P671, DOI 10.1007/s00109-004-0580-x; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Hibbert B, 2003, TRENDS CARDIOVAS MED, V13, P322, DOI 10.1016/j.tcm.2003.09.002; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Howard Barbara V., 1994, Current Opinion in Lipidology, V5, P216, DOI 10.1097/00041433-199405030-00009; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jascur T, 2005, MOL CELL, V17, P237, DOI 10.1016/j.molcel.2004.11.049; Kontush A, 2002, FASEB J, V16, P88, DOI 10.1096/fj.02-0293fje; Krieger M, 1997, CURR OPIN LIPIDOL, V8, P275, DOI 10.1097/00041433-199710000-00006; Ladislas R, 2000, Pathol Oncol Res, V6, P3; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; Loomans CJM, 2004, DIABETES, V53, P195, DOI 10.2337/diabetes.53.1.195; Lyons TJ, 1997, CURR OPIN LIPIDOL, V8, P174, DOI 10.1097/00041433-199706000-00008; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Merched AJ, 2004, CIRCULATION, V110, P3830, DOI 10.1161/01.CIR.0000148681.01282.89; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; PENN MS, 1994, ATHEROSCLEROSIS, V108, pS21, DOI 10.1016/0021-9150(94)90150-3; Pesce M, 2003, CIRC RES, V93, pE51, DOI 10.1161/01.RES.0000090624.04507.45; REDGRAVE TG, 1979, J LIPID RES, V20, P217; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHEN MMS, 1981, J LIPID RES, V22, P236; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tanner FC, 1998, CIRC RES, V82, P396, DOI 10.1161/01.RES.82.3.396; VEDIE B, 1991, J LIPID RES, V32, P1359; Wei WY, 2003, EMBO REP, V4, P1061, DOI 10.1038/sj.embor7400001; Wong DJ, 1999, MOL CELL BIOL, V19, P5642	53	123	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4339	4347		10.1074/jbc.M509293200	http://dx.doi.org/10.1074/jbc.M509293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339764	hybrid			2022-12-27	WOS:000235275300069
J	Matsuda, N; Kitami, T; Suzuki, T; Mizuno, Y; Hattori, N; Tanaka, K				Matsuda, N; Kitami, T; Suzuki, T; Mizuno, Y; Hattori, N; Tanaka, K			Diverse effects of pathogenic mutations of parkin that catalyze multiple monoubiquitylation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; LIGASE ACTIVITY; FINGER PROTEIN; DISEASE; LOCALIZATION; COMPLEX; CHAINS; SOLUBILITY; MECHANISMS; PROTEASOME	Mutational dysfunction of PARKIN gene, which encodes a double RING finger protein and has ubiquitin ligase E3 activity, is the major cause of autosomal recessive juvenile Parkinsonism. Although many studies explored the functions of Parkin, its biochemical character is poorly understood. To address this issue, we established an E3 assay system using maltose-binding protein-fused Parkin purified from Escherichia coli. Using this recombinant Parkin, we found that not the front but the rear RING finger motif is responsible for the E3 activity of Parkin, and it catalyzes multiple monoubiquitylation. Intriguingly, for autosomal recessive juvenile Parkinsonism-causing mutations of Parkin, whereas there was loss of E3 activity in the rear RING domain, other pathogenic mutants still exhibited E3 activity equivalent to that of the wild-type Parkin. The evidence presented allows us to reconsider the function of Parkin-catalyzed ubiquitylation and to conclude that autosomal recessive juvenile Parkinsonism is not solely attributable to catalytic impairment of the E3 activity of Parkin.	Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, Tokyo 1138613, Japan; Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1130033, Japan	Tokyo Metropolitan Institute of Medical Science; Juntendo University	Tanaka, K (corresponding author), Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Bunkyo Ku, Tokyo 1138613, Japan.	tanakak@rinshoken.or.jp	Matsuda, Noriyuki/AAI-3156-2020	Matsuda, Noriyuki/0000-0001-8199-952X; Suzuki, Toshiaki/0000-0002-0650-6251				Araki K, 2003, J NEUROCHEM, V86, P749, DOI 10.1046/j.1471-4159.2003.01875.x; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cookson MR, 2003, HUM MOL GENET, V12, P2957, DOI 10.1093/hmg/ddg328; Corti O, 2003, HUM MOL GENET, V12, P1427, DOI 10.1093/hmg/ddg159; Doss-Pepe EW, 2005, J BIOL CHEM, V280, P16619, DOI 10.1074/jbc.M413591200; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Gu WJ, 2003, NEUROBIOL DIS, V14, P357, DOI 10.1016/j.nbd.2003.08.011; Hattori N, 2004, LANCET, V364, P722, DOI 10.1016/S0140-6736(04)16901-8; Henn IH, 2005, J NEUROCHEM, V92, P114, DOI 10.1111/j.1471-4159.2004.02854.x; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Imai N, 2003, J VIROL, V77, P923, DOI 10.1128/JVI.77.2.923-930.2003; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lohmann E, 2003, ANN NEUROL, V54, P176, DOI 10.1002/ana.10613; Matsuda N, 2005, DNA REPAIR, V4, P537, DOI 10.1016/j.dnarep.2004.12.012; Matsuda N, 2001, J CELL SCI, V114, P1949; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Pawlyk AC, 2003, J BIOL CHEM, V278, P48120, DOI 10.1074/jbc.M306889200; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Rankin CA, 2001, J BIOMED SCI, V8, P421; Ren Y, 2003, J NEUROSCI, V23, P3316; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Ross CA, 2004, TRENDS CELL BIOL, V14, P703, DOI 10.1016/j.tcb.2004.10.006; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Sriram SR, 2005, HUM MOL GENET, V14, P2571, DOI 10.1093/hmg/ddi292; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Takai R, 2002, PLANT J, V30, P447, DOI 10.1046/j.1365-313X.2002.01299.x; Tanaka K, 2004, BBA-MOL CELL RES, V1695, P235, DOI 10.1016/j.bbamcr.2004.09.026; Wang C, 2005, J NEUROCHEM, V93, P422, DOI 10.1111/j.1471-4159.2005.03023.x; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Zhong L, 2005, J BIOL CHEM, V280, P9425, DOI 10.1074/jbc.M408955200	32	141	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3204	3209		10.1074/jbc.M510393200	http://dx.doi.org/10.1074/jbc.M510393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339143	hybrid			2022-12-27	WOS:000235128200024
J	Watanabe, S; Matsuyama, S; Tokuda, H				Watanabe, S; Matsuyama, S; Tokuda, H			Roles of the hydrophobic cavity and lid of LolA in the lipoprotein transfer reaction in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE LIPOPROTEIN; GRAM-NEGATIVE BACTERIA; CYTOPLASMIC MEMBRANE; MOLECULAR CHAPERONE; INNER MEMBRANE; PROTEINS; LOCALIZATION; RELEASE; MUTANT; EXPRESSION	LolA, a periplasmic chaperone, binds to outer membrane-specific lipoproteins released from the inner membrane through the action of an ATP-binding cassette transporter, LolCDE and then transfers them to the outer membrane receptor LolB, thereby mediating the inner to outer membrane transport of lipoproteins. The crystal structure of free LolA revealed that it has an internal hydrophobic cavity, which is surrounded by hydrophobic residues and closed by a lid comprising alpha-helices. The hydrophobic cavity most likely represents the binding site for the lipid moiety of a lipoprotein. It is speculated that the lid undergoes opening and closing upon the binding and transfer of lipoproteins, respectively. To determine the functions of the hydrophobic cavity and lid in detail, 14 residues involved in the formation of these structures were subjected to random mutagenesis. Among the obtained 21 LolA derivatives that did not support growth, 14 were active as to the binding of lipoproteins but defective in the transfer of lipoproteins to LolB, causing the periplasmic accumulation of a lipoprotein as a complex with a LolA derivative. A LolA derivative, I93G, bound lipoproteins faster than wild-type LolA did, whereas it did not transfer associated lipoproteins to LolB. When I93G and wild type LolA co-existed, lipoproteins were bound only to I93G; which therefore exhibited a dominant negative property. Another derivative, L59R, was also defective in the transfer of lipoproteins to LolB but did not exhibit a dominant negative property. Taken together, these results indicate that both the hydrophobic cavity and the lid are critically important for not only the binding of lipoproteins but also their transfer.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Rikkyo Univ, Dept Life Sci, Toshima Ku, Tokyo 1718501, Japan	University of Tokyo; Rikkyo University	Tokuda, H (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	htokuda@iam.u-tokyo.ac.jp						Brokx SJ, 2004, J BACTERIOL, V186, P3254, DOI 10.1128/JB.186.10.3254-3258.2004; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; Hara T, 2003, J BIOL CHEM, V278, P40408, DOI 10.1074/jbc.M307836200; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HAZELBAUER GL, 1975, J BACTERIOL, V122, P206, DOI 10.1128/JB.122.1.206-214.1975; HIROTA Y, 1977, P NATL ACAD SCI USA, V74, P1417, DOI 10.1073/pnas.74.4.1417; HUSSAIN M, 1980, J BIOL CHEM, V255, P3707; Ikegami A, 2005, BIOSCI BIOTECH BIOCH, V69, P1595, DOI 10.1271/bbb.69.1595; Juncker AS, 2003, PROTEIN SCI, V12, P1652, DOI 10.1110/ps.0303703; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUYAMA S, 1993, EMBO J, V12, P265, DOI 10.1002/j.1460-2075.1993.tb05652.x; MATSUYAMA S, 1995, EMBO J, V14, P3365, DOI 10.1002/j.1460-2075.1995.tb07342.x; Matsuyama S, 1997, EMBO J, V16, P6947, DOI 10.1093/emboj/16.23.6947; Miller J. H., 1972, EXPT MOL GENETICS, P431; Miyadai H, 2004, J BIOL CHEM, V279, P39807, DOI 10.1074/jbc.M406390200; Miyamoto A, 2002, FEBS LETT, V528, P193, DOI 10.1016/S0014-5793(02)03305-7; Miyamoto A, 2001, BIOCHEM BIOPH RES CO, V287, P1125, DOI 10.1006/bbrc.2001.5705; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Seydel A, 1999, MOL MICROBIOL, V34, P810, DOI 10.1046/j.1365-2958.1999.01647.x; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Tajima T, 1998, FEBS LETT, V439, P51, DOI 10.1016/S0014-5793(98)01334-9; Takeda K, 2003, EMBO J, V22, P3199, DOI 10.1093/emboj/cdg324; Taniguchi N, 2005, J BIOL CHEM, V280, P34481, DOI 10.1074/jbc.M507388200; Terada M, 2001, J BIOL CHEM, V276, P47690, DOI 10.1074/jbc.M109307200; Yakushi T, 1998, J BIOL CHEM, V273, P32576, DOI 10.1074/jbc.273.49.32576; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6	32	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3335	3342		10.1074/jbc.M509596200	http://dx.doi.org/10.1074/jbc.M509596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354671	hybrid			2022-12-27	WOS:000235128200041
J	Benjanirut, C; Paris, M; Wang, WH; Hong, SJ; Kim, KS; Hullinger, RL; Andrisani, OM				Benjanirut, C; Paris, M; Wang, WH; Hong, SJ; Kim, KS; Hullinger, RL; Andrisani, OM			The cAMP pathway in combination with BMP2 regulates Phox2a transcription via cAMP response element binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; CIS-ACTING ELEMENTS; PHENOTYPIC MARKERS; GENE; EXPRESSION; DIFFERENTIATION; PROTEIN; CELLS; CREB; HYDROXYLASE	Combined BMP2 and cAMP signaling induces the catecholaminergic lineage in neural crest (NC) cultures by increasing expression of the proneural transcription factor Phox2a, in a cAMP response element (CRE)-binding protein (CREB)-mediated mechanism. To determine whether CREB acts directly on Phox2a transcription induced by BMP2+cAMP-elevating agent IBMX, transient transfections of hPhox2a-reporter constructs were performed in avian NC cultures and murine, catecholaminergic CAD cells. Although BMP2+IBMX increased endogenous Phox2a expression, the 7.5-kb hPhox2a reporters expressing either luciferase or DsRed1-E5 fluorescent protein were unresponsive to BMP2+IBMX, but active in both cell types. Cell sorting of fluorescence-positive NC cells expressing the 7.5-kb hPhox2a fluorescent timer reporter differentiated to equal numbers of catecholaminergic cells as fluorescence-negative cells, suggesting inappropriate transcription from the transfected hPhox2a promoter. NC or CAD cells treated with histone deacetylase inhibitor trichostatin A and BMP2+IBMX display increased endogenous Phox2a transcription and prolonged CREB phosphorylation, indicating Phox2a chromatin remodeling is linked to CREB activation. Chromatin immunoprecipitations employing CREB, CREB-binding protein, and acetylated H4 antibodies identified two CRE half-sites at -5.5 kb in the murine Phox2a promoter, which is also conserved in the human promoter. Proximal to the CRE half-sites, within a 170-bp region, are E-box and CCAAT binding sites, also conserved in mouse and human genes. This 170-bp promoter region confers cAMP, BMP2, and enhanced BMP2+cAMP regulation to Phox2a-luciferase reporters. We conclude these CREs are functional, with CREB directly activating Phox2a transcription. Because the E-box binds bHLH proteins like ASH1 induced in NC cells by BMP2, we propose this novel 170-bp cis-acting element is a composite site, mediating the synergistic regulation by BMP2+cAMP on Phox2a transcription.	Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Harvard Univ, Sch Med, McLean Hosp, Mol Neurobiol Lab, Belmont, MA 02478 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Harvard University; McLean Hospital	Andrisani, OM (corresponding author), Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.	andrisao@purdue.edu		Andrisani, Ourania/0000-0002-6230-0303				ANDERSON DJ, 1991, J NEUROSCI, V11, P3507; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; Bilodeau ML, 2005, MOL CELL NEUROSCI, V29, P394, DOI 10.1016/j.mcn.2005.03.006; Bilodeau ML, 2001, IN VITRO CELL DEV-AN, V37, P185; Bilodeau ML, 2000, MOL CELL BIOL, V20, P3004, DOI 10.1128/MCB.20.9.3004-3014.2000; Cha-Molstad H, 2004, P NATL ACAD SCI USA, V101, P13572, DOI 10.1073/pnas.0405587101; Chen CJ, 2001, MOL CELL BIOL, V21, P476, DOI 10.1128/MCB.21.2.476-487.2001; Chen SG, 2005, J BIOL CHEM, V280, P41025, DOI 10.1074/jbc.M503537200; Creaser PC, 1996, NUCLEIC ACIDS RES, V24, P2597, DOI 10.1093/nar/24.13.2597; ERNSBERGER U, 1995, MECH DEVELOP, V52, P125, DOI 10.1016/0925-4773(95)00396-I; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Ghislain J, 2003, DEVELOPMENT, V130, P941, DOI 10.1242/dev.00318; Goodman RH, 2000, GENE DEV, V14, P1553; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; Hirsch MR, 1998, DEVELOPMENT, V125, P599; Hong SJ, 2002, BIOTECHNIQUES, V33, P1236, DOI 10.2144/02336bm11; Hong SJ, 2001, J NEUROCHEM, V79, P1225, DOI 10.1046/j.1471-4159.2001.00672.x; Huber K, 2002, DEVELOPMENT, V129, P4729; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kilav R, 2001, J BIOL CHEM, V276, P8727, DOI 10.1074/jbc.M005471200; Kim HS, 1998, J NEUROSCI, V18, P8247; KWOK RP, 1994, NATURE, V370, P177; Le Douarin NM, 2004, DEVELOPMENT, V131, P4637, DOI 10.1242/dev.01350; Lee S, 2002, J BIOL CHEM, V277, P8730, DOI 10.1074/jbc.M108025200; Liu T, 2000, J MOL EVOL, V50, P22, DOI 10.1007/s002399910003; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; Lo LC, 1998, DEVELOPMENT, V125, P609; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; Mandolesi G, 2002, FEBS LETT, V510, P50, DOI 10.1016/S0014-5793(01)03227-6; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Morin X, 1997, NEURON, V18, P411, DOI 10.1016/S0896-6273(00)81242-8; Qi YP, 1997, J NEUROSCI, V17, P1217; Reissmann E, 1996, DEVELOPMENT, V122, P2079; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rowitch DH, 1998, DEVELOPMENT, V125, P2735; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; SURI C, 1993, J NEUROSCI, V13, P1280; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; VARLEY JE, 1995, DEV DYNAM, V203, P434, DOI 10.1002/aja.1002030406; Varley JE, 1996, EXP NEUROL, V140, P84, DOI 10.1006/exnr.1996.0118; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang CY, 1998, J NEUROCHEM, V71, P1813; Zellmer E, 1995, J NEUROSCI, V15, P8109; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	51	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2969	2981		10.1074/jbc.M503939200	http://dx.doi.org/10.1074/jbc.M503939200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330553	hybrid			2022-12-27	WOS:000234931800067
J	Hsieh, TS; Plank, JL				Hsieh, TS; Plank, JL			Reverse gyrase functions as a DNA renaturase - Annealing of complementary single-stranded circles and positive supercoiling of a bubble substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOPOISOMERASE-I; DROSOPHILA-MELANOGASTER; MECHANISM; HYPERTHERMOPHILE; ENERGETICS; SITE	Reverse gyrase is a hyperthermophile-specific enzyme that can positively supercoil DNA concomitant with ATP hydrolysis. However, the DNA supercoiling activity is inefficient and requires an excess amount of enzyme relative to DNA. We report here several activities that reverse gyrase can efficiently mediate with a substoichiometric amount of enzyme. In the presence of a nucleotide cofactor, reverse gyrase can readily relax negative supercoils, but not the positive ones, from a plasmid DNA substrate. Reverse gyrase can completely relax positively supercoiled DNA, provided that the DNA substrate contains a single-stranded bubble. Reverse gyrase efficiently anneals complementary single-stranded circles. A substoichiometric amount of reverse gyrase can insert positive supercoils into DNA with a single-stranded bubble, in contrast to plasmid DNA substrate. We have designed a novel method based on phage-mid DNA vectors to prepare a circular DNA substrate containing a single-stranded bubble with defined length and sequence. With these bubble DNA substrates, we demonstrated that efficient positive supercoiling by reverse gyrase requires a bubble size larger than 20 nucleotides. The activities of annealing single-stranded DNA circles and positive supercoiling of bubble substrate demonstrate that reverse gyrase can function as a DNA renaturase. These biochemical activities also suggest that reverse gyrase can have an important biological function in sensing and eliminating unpaired regions in the genome of a hyperthermophilic organism.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hsieh, TS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	hsieh@biochem.duke.edu	Plank, Jody/B-4827-2009; Wu, Wan-lin/G-8937-2012; Hsieh, Tao-shih/G-9305-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029006] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29006] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1985, J MOL BIOL, V184, P211, DOI 10.1016/0022-2836(85)90374-2; Atomi H, 2004, J BACTERIOL, V186, P4829, DOI 10.1128/JB.186.14.4829-4833.2004; BAUER WR, 1995, J MOL BIOL, V253, P438, DOI 10.1006/jmbi.1995.0565; BENHAM CJ, 1992, J MOL BIOL, V225, P835, DOI 10.1016/0022-2836(92)90404-8; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P5328, DOI 10.1073/pnas.74.12.5328; CONFALONIERI F, 1993, P NATL ACAD SCI USA, V90, P4753, DOI 10.1073/pnas.90.10.4753; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Declais AC, 2000, J BIOL CHEM, V275, P19498, DOI 10.1074/jbc.M910091199; Dekker NH, 2002, P NATL ACAD SCI USA, V99, P12126, DOI 10.1073/pnas.132378799; DUGUET M, 1993, NUCLEIC ACIDS RES, V21, P463, DOI 10.1093/nar/21.3.463; Forterre P, 2002, TRENDS GENET, V18, P236, DOI 10.1016/S0168-9525(02)02650-1; Hsieh TS, 2005, J BIOL CHEM, V280, P20467, DOI 10.1074/jbc.M502739200; HSIEH TS, 1975, BIOCHEMISTRY-US, V14, P527, DOI 10.1021/bi00674a011; HSIEH TS, 1992, NUCLEIC ACIDS RES, V20, P6177, DOI 10.1093/nar/20.23.6177; KIKUCHI A, 1984, NATURE, V309, P677, DOI 10.1038/309677a0; KIRKEGAARD K, 1978, NUCLEIC ACIDS RES, V5, P3811, DOI 10.1093/nar/5.10.3811; Krah R, 1996, P NATL ACAD SCI USA, V93, P106, DOI 10.1073/pnas.93.1.106; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Plank JL, 2005, J BIOL CHEM, V280, P3564, DOI 10.1074/jbc.M411337200; Rodriguez AC, 2002, EMBO J, V21, P418, DOI 10.1093/emboj/21.3.418; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831	24	40	44	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5640	5647		10.1074/jbc.M513252200	http://dx.doi.org/10.1074/jbc.M513252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407212	hybrid			2022-12-27	WOS:000235568900040
J	Kumar, M; Verma, R; Raghava, GPS				Kumar, M; Verma, R; Raghava, GPS			Prediction of mitochondrial proteins using support vector machine and hidden Markov model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBCELLULAR-LOCALIZATION; PROTEOME; SVM	Mitochondria are considered as one of the core organelles of eukaryotic cells hence prediction of mitochondrial proteins is one of the major challenges in the field of genome annotation. This study describes a method, MitPred, developed for predicting mitochondrial proteins with high accuracy. The data set used in this study was obtained from Guda, C., Fahy, E. & Subramaniam, S. ( 2004) Bioinformatics 20, 1785 - 1794. First support vector machine-based modules/methods were developed using amino acid and dipeptide composition of proteins and achieved accuracy of 78.37 and 79.38%, respectively. The accuracy of prediction further improved to 83.74% when split amino acid composition ( 25 N-terminal, 25 C-terminal, and remaining residues) of proteins was used. Then BLAST search and support vector machine-based method were combined to get 88.22% accuracy. Finally we developed a hybrid approach that combined hidden Markov model profiles of domains ( exclusively found in mitochondrial proteins) and the support vector machine-based method. We were able to predict mitochondrial protein with 100% specificity at a 56.36% sensitivity rate and with 80.50% specificity at 98.95% sensitivity. The method estimated 9.01, 6.35, 4.84, 3.95, and 4.25% of proteins as mitochondrial in Saccharomyces cerevisiae, Drosophila melanogaster, Caenorhabditis elegans, mouse, and human proteomes, respectively. MitPred was developed on the above hybrid approach.	Inst Microbial Technol, Bioinformat Ctr, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Raghava, GPS (corresponding author), Inst Microbial Technol, Bioinformat Ctr, Sector 39-A, Chandigarh 160036, India.	raghava@imtech.res.in	Raghava, Gajendra P.S./AAA-2413-2022; Raghava, Gajendra/B-1717-2009; Kumar, Manish/AGP-1250-2022	Raghava, Gajendra P.S./0000-0002-8902-2876; Kumar, Manish/0000-0002-7936-9892				ALBERTS B, 2000, MOL BIOL CELL, P678; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bhasin M, 2005, BIOINFORMATICS, V21, P2522, DOI 10.1093/bioinformatics/bti309; Bhasin M, 2004, NUCLEIC ACIDS RES, V32, pW414, DOI 10.1093/nar/gkh350; Bhasin M, 2004, J BIOL CHEM, V279, P23262, DOI 10.1074/jbc.M401932200; Bhasin M, 2004, BIOINFORMATICS, V20, P421, DOI 10.1093/bioinformatics/btg424; Cameron JM, 2005, BIOINFORMATICS, V21, P1825, DOI 10.1093/bioinformatics/bti280; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Gardy JL, 2003, NUCLEIC ACIDS RES, V31, P3613, DOI 10.1093/nar/gkg602; Garg A, 2005, J BIOL CHEM, V280, P14427, DOI 10.1074/jbc.M411789200; Gerbitz KD, 1996, DIABETES, V45, P113, DOI 10.2337/diabetes.45.2.113; Gottlieb RA, 2000, CRIT REV EUKAR GENE, V10, P231; Guda C, 2004, BIOINFORMATICS, V20, P1785, DOI 10.1093/bioinformatics/bth171; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; Jassem W, 2002, TRANSPLANTATION, V73, P493, DOI 10.1097/00007890-200202270-00001; Joachims T., 1999, ADV KERNEL METHODS S; Kaur H, 2003, PROTEIN SCI, V12, P627, DOI 10.1110/ps.0228903; Kumar M, 2005, NUCLEIC ACIDS RES, V33, pW154, DOI 10.1093/nar/gki588; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; Marcotte EM, 2000, P NATL ACAD SCI USA, V97, P12115, DOI 10.1073/pnas.220399497; Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3; Reinhardt A, 1998, NUCLEIC ACIDS RES, V26, P2230, DOI 10.1093/nar/26.9.2230; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Taylor SW, 2003, TRENDS BIOTECHNOL, V21, P82, DOI 10.1016/S0167-7799(02)00037-9; Wiwatwattana N, 2005, NUCLEIC ACIDS RES, V33, pD598; Xie D, 2005, NUCLEIC ACIDS RES, V33, pW105, DOI 10.1093/nar/gki359	28	87	96	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5357	5363		10.1074/jbc.M511061200	http://dx.doi.org/10.1074/jbc.M511061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16339140	hybrid			2022-12-27	WOS:000235568900006
J	Fukumoto, S; Miner, JH; Ida, H; Fukumoto, E; Yuasa, K; Miyazaki, H; Hoffman, MP; Yamada, Y				Fukumoto, S; Miner, JH; Ida, H; Fukumoto, E; Yuasa, K; Miyazaki, H; Hoffman, MP; Yamada, Y			Laminin alpha 5 is required for dental epithelium growth and polarity and the development of tooth bud and shape	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE 3-OH KINASE; EMBRYONIC SIGNALING CENTER; GLAND CELL-LINE; ALPHA-6-BETA-4 INTEGRIN; BASEMENT-MEMBRANE; ALPHA(6)BETA(4) INTEGRIN; DYSTROGLYCAN-BINDING; MOUSE TOOTH; ACTIN CYTOSKELETON; LAMELLAE FORMATION	In tooth development, the oral ectoderm and mesenchyme coordinately and reciprocally interact through the basement membrane for their growth and differentiation to form the proper shape and size of the tooth. Laminin alpha 5 subunit-containing laminin-10/11 ( LM-511/521) is the major laminin in the tooth germ basement membrane. Here, we have examined the role of laminin alpha 5 ( Lama5) in tooth development using laminin alpha 5-null mouse primary dental epithelium and tooth germ organ cultures. Lama5-null mice develop a small tooth germ with defective cusp formation and have reduced proliferation of dental epithelium. Also, cell polarity and formation of the monolayer of the inner dental epithelium are disturbed. The enamel knot, a signaling center for tooth germ development, is defective, and there is a significant reduction of Shh and Fgf4 expression in the dental epithelium. In the absence of laminin alpha 5, the basement membrane in the inner dental epithelium becomes discontinuous. In normal mice, integrin alpha 6 beta 4, a receptor for laminin alpha 5, is strongly localized at the basal layer of the epithelium, whereas in mutant mice, integrin alpha 6 beta 4 is expressed around the cell surface. In primary dental epithelium culture, laminin-10/11 promotes cell growth, spreading, and filopodia-like micro-spike formation. This promotion is inhibited by anti-integrin alpha 6 and beta 4 antibodies and by phosphatidylinositol 3-kinase inhibitors and dominant negative Rho-GTPase family proteins Cdc42 and Rac. In organ culture, anti-integrin alpha 6 antibody and wortmannin reduce tooth germ size and shape. Our studies demonstrate that laminin alpha 5 is required for the proliferation and polarity of basal epithelial cells and suggest that the interaction between laminin-10/11-integrin alpha 6 beta 4 and the phosphatidylinositol 3-kinase-Cdc42/Rac pathways play an important role in determining the size and shape of tooth germ.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Div Renal, St Louis, MO 63110 USA; Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan; Kyushu Univ, Fac Dent Sci, Fukuoka 8128582, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Washington University (WUSTL); Nagasaki University; Kyushu University	Yamada, Y (corresponding author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, 30 Convent Dr,Bldg 30,Rm 407, Bethesda, MD 20892 USA.	yoshi.yamada@nih.gov		Fukumoto, Satoshi/0000-0002-5046-6891	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000720, ZIADE000485, ZIADE000707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000707, Z01DE000720, Z01DE000485] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; BRINGAS P, 1987, SCANNING MICROSCOPY, V1, P1103; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COHN SA, 1957, AM J ANAT, V101, P295, DOI 10.1002/aja.1001010205; Dassule HR, 2000, DEVELOPMENT, V127, P4775; Deng WM, 2003, DEVELOPMENT, V130, P173, DOI 10.1242/dev.00199; Ekblom P, 2003, MATRIX BIOL, V22, P35, DOI 10.1016/S0945-053X(03)00015-5; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Fukumoto S, 2004, J CELL BIOL, V167, P973, DOI 10.1083/jcb.200409077; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gritli-Linde A, 2002, DEVELOPMENT, V129, P5323, DOI 10.1242/dev.00100; Gudjonsson T, 2002, J CELL SCI, V115, P39; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hoffman MP, 1998, J BIOL CHEM, V273, P28633, DOI 10.1074/jbc.273.44.28633; Hoffman MP, 1996, J CELL SCI, V109, P2013; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; Jernvall J, 1998, DEVELOPMENT, V125, P161; Kettunen P, 1998, DEV DYNAM, V211, P256, DOI 10.1002/(SICI)1097-0177(199803)211:3<256::AID-AJA7>3.0.CO;2-G; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kikkawa Y, 2000, J CELL SCI, V113, P869; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kleinman HK, 2005, SEMIN CANCER BIOL, V15, P378, DOI 10.1016/j.semcancer.2005.05.004; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Li J, 2003, EMBO J, V22, P2400, DOI 10.1093/emboj/cdg239; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2003, DEV CELL, V4, P613, DOI 10.1016/S1534-5807(03)00128-X; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MARTIN GR, 1988, ADV PROTEIN CHEM, V39, P1; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Moulson CL, 2001, DEV DYNAM, V222, P101, DOI 10.1002/dvdy.1169; Nguyen BP, 2000, J BIOL CHEM, V275, P31896, DOI 10.1074/jbc.M006379200; Nguyen NM, 2002, DEV BIOL, V246, P231, DOI 10.1006/dbio.2002.0658; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Ruch J V, 1987, Revis Biol Celular, V14, P1; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Salmivirta K, 1998, ANN NY ACAD SCI, V857, P279, DOI 10.1111/j.1749-6632.1998.tb10132.x; Salmivirta K, 1997, DEV DYNAM, V210, P206, DOI 10.1002/(SICI)1097-0177(199711)210:3<206::AID-AJA2>3.3.CO;2-S; Salmivirta K, 1996, DEV DYNAM, V205, P104, DOI 10.1002/(SICI)1097-0177(199602)205:2<104::AID-AJA2>3.0.CO;2-M; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tabata MJ, 1996, DEVELOPMENT, V122, P1243; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; Timpl R, 1996, CURR OPIN CELL BIOL, V8, P618, DOI 10.1016/S0955-0674(96)80102-5; Tsumaki N, 1998, J BIOL CHEM, V273, P22861, DOI 10.1074/jbc.273.36.22861; Vaahtokari A, 1996, MECH DEVELOP, V54, P39, DOI 10.1016/0925-4773(95)00459-9; Vaahtokari A, 1996, DEVELOPMENT, V122, P121; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; YAMADA M, 1980, J BIOL BUCCALE, V8, P127; Yin Y, 2003, GENESIS, V36, P114, DOI 10.1002/gene.10206; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500; Yuasa K, 2004, J BIOL CHEM, V279, P10286, DOI 10.1074/jbc.M310013200	72	88	90	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5008	5016		10.1074/jbc.M509295200	http://dx.doi.org/10.1074/jbc.M509295200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365040	hybrid			2022-12-27	WOS:000235426200053
J	Reboul, E; Klein, A; Bietrix, F; Gleize, B; Malezet-Desmoulins, C; Schneider, M; Margotat, A; Lagrost, L; Collet, X; Borel, P				Reboul, E; Klein, A; Bietrix, F; Gleize, B; Malezet-Desmoulins, C; Schneider, M; Margotat, A; Lagrost, L; Collet, X; Borel, P			Scavenger receptor class B type I (SR-BI) is involved in vitamin E transport across the enterocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TOCOPHEROL; GAMMA-TOCOPHEROL; LIPOPROTEIN METABOLISM; CHOLESTEROL ABSORPTION; INTESTINAL-ABSORPTION; CACO-2 CELLS; HUMANS; HDL; DIETARY; EXPRESSION	Although cellular uptake of vitamin E was initially described as a passive process, recent studies in the liver and brain have shown that SR-BI (scavenger receptor class B type I) is involved in this phenomenon. As SR-BI is expressed at high levels in the intestine, the present study addressed the involvement of SR-BI in vitamin E trafficking across enterocytes. Apical uptake and efflux of the main dietary forms of vitamin E were examined using Caco-2 TC-7 cell monolayers as a model of human intestinal epithelium. (R,R,R)-gamma-tocopherol bioavailability was compared between wild-type mice and mice overexpressing SR-BI in the intestine. The effect of vitamin E on enterocyte SR-BI mRNA levels was measured by real-time quantitative reverse transcription-PCR. Concentration-dependent curves for vitamin E uptake were similar for (R,R,R)-alpha-, (R,R,R)-gamma-, and DL-alpha-tocopherol. (R,R,R)-alpha-tocopherol transport was dependent on incubation temperature, with a 60% reduction in absorption at 4 C compared with 37 degrees C (p < 0.05). Vitamin E flux in enterocytes was directed from the apical to the basal side, with a relative 10-fold reduction in the transfer process when measured in the opposite direction (p < 0.05). Co-incubation with cholesterol, gamma-tocopherol, or lutein significantly impaired alpha-tocopherol absorption. Anti-human SR-BI antibodies and BLT1 (a chemical inhibitor of lipid transport via SR-BI) blocked up to 80% of vitamin E uptake and up to 30% of apical vitamin E efflux (p < 0.05), and similar results were obtained for (R,R,R)-alpha-tocopherol. SR-BI mRNA levels were not significantly modified after a 24-h incubation of Caco-2 cells with vitamin E. Finally, (R,R,R)-gamma-tocopherol bioavailability was 2.7-fold higher in mice overexpressing SR-BI than in wild-type mice (p < 0.05). The present data show for the first time that vitamin E intestinal absorption is, at least in part, mediated by SR-BI.	Univ Aix Marseille, INRA 1260, INSERM, UMR 476,Fac Med Marseille, F-13385 Marseille 5, France; Inst Physiopathol Humaine Marseille, F-13385 Marseille, France; INSERM, U498, F-21079 Dijon, France; Hop Purpan, INSERM, U563, F-31024 Toulouse, France	INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Borel, P (corresponding author), Univ Aix Marseille, INRA 1260, INSERM, UMR 476,Fac Med Marseille, 27 Bd Jean Moulin, F-13385 Marseille 5, France.	Patrick.Borel@medecine.univ-mrs.fr	Collet, Xavier/M-6938-2017; Borel, Patrick/A-4057-2015; Reboul, Emmanuelle/K-6637-2017	Borel, Patrick/0000-0001-9977-3238; Reboul, Emmanuelle/0000-0002-4576-1992				ARTURSSON P, 1991, BIOCHEM BIOPH RES CO, V175, P880, DOI 10.1016/0006-291X(91)91647-U; ARTURSSON P, 1995, EPITHELIA CELL CULTU, P111; Balazs Z, 2004, J NEUROCHEM, V89, P939, DOI 10.1111/j.1471-4159.2004.02373.x; BERNIER JJ, 1988, ALIMENTS TUBE DIGEST; BIETRIX F, 2006, J BIOL CHEM; Borel P, 2001, AM J PHYSIOL-GASTR L, V280, pG95, DOI 10.1152/ajpgi.2001.280.1.G95; Brewer HB, 2003, AM J CARDIOL, V91, p3E, DOI 10.1016/S0002-9149(02)03382-9; Burnichon V, 2003, TOXICOL LETT, V143, P155, DOI 10.1016/S0378-4274(03)00171-1; Cai L, 2004, J LIPID RES, V45, P253, DOI 10.1194/jlr.M300303-JLR200; CHANTRET I, 1994, J CELL SCI, V107, P213; CHEESEMAN KH, 1995, FREE RADICAL BIO MED, V19, P591, DOI 10.1016/0891-5849(95)00083-A; Davis HR, 2004, J BIOL CHEM, V279, P33586, DOI 10.1074/jbc.M405817200; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Hageman SH, 1999, LIPIDS, V34, P627, DOI 10.1007/s11745-999-0407-3; Huang HY, 2003, J NUTR, V133, P3137, DOI 10.1093/jn/133.10.3137; Jourdheuil-Rahmani D, 2002, BIOCHEM BIOPH RES CO, V292, P390, DOI 10.1006/bbrc.2002.6664; Kiefer C, 2002, P NATL ACAD SCI USA, V99, P10581, DOI 10.1073/pnas.162182899; KIYOSE C, 1995, LIPIDS, V30, P1015, DOI 10.1007/BF02536286; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Kramer W, 2005, J BIOL CHEM, V280, P1306, DOI 10.1074/jbc.M406309200; Levy E, 2004, J CELL SCI, V117, P327, DOI 10.1242/jcs.00856; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; Nieland TJF, 2004, J LIPID RES, V45, P1256, DOI 10.1194/jlr.M300358-JLR200; Nieland TJF, 2002, P NATL ACAD SCI USA, V99, P15422, DOI 10.1073/pnas.222421399; Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554; Salvini S, 2002, BRIT J NUTR, V87, P211, DOI 10.1079/BJN2001507; STAGGERS JE, 1990, BIOCHEMISTRY-US, V29, P2028, DOI 10.1021/bi00460a011; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; Traber MG, 2004, AM J CLIN NUTR, V80, P3; TRABER MG, 1992, J LIPID RES, V33, P1171; van Bennekum A, 2005, BIOCHEMISTRY-US, V44, P4517, DOI 10.1021/bi0484320; Violi F, 2004, ANN NY ACAD SCI, V1031, P292, DOI 10.1196/annals.1331.029; Wagner KH, 2004, ANN NUTR METAB, V48, P169, DOI 10.1159/000079555	34	189	195	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4739	4745		10.1074/jbc.M509042200	http://dx.doi.org/10.1074/jbc.M509042200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380385	Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000235426200023
J	Sato, T; Fujita, N; Yamada, A; Ooshio, T; Okamoto, R; Irie, K; Takai, Y				Sato, T; Fujita, N; Yamada, A; Ooshio, T; Okamoto, R; Irie, K; Takai, Y			Regulation of the assembly and adhesion activity of E-cadherin by nectin and afadin for the formation of adherens junctions in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL G-PROTEINS; ALPHA-CATENIN; TIGHT JUNCTIONS; EPITHELIAL-CELLS; ACTIN CYTOSKELETON; TRANS-INTERACTIONS; BINDING PROTEIN; INTERCELLULAR-JUNCTIONS; FUNCTIONAL-ANALYSIS; CYTOPLASMIC DOMAIN	The Ca2+-independent immunoglobulin-like molecule nectin first forms cell-cell adhesion and then assembles cadherin at nectin-based cell-cell adhesion sites, resulting in the formation of adherens junctions (AJs). Afadin is a nectin- and actin filament-binding protein that connects nectin to the actin cytoskeleton. Here, we studied the roles and modes of action of nectin and afadin in the formation of AJs in cultured MDCK cells. The trans-interaction of nectin assembled E-cadherin, which associated with p120(ctn), beta-catenin, and alpha-catenin, at the nectin- based cell-cell adhesion sites in an afadin-independent manner. However, the assembled E-cadherin showed weak cell-cell adhesion activity and might be the non-trans-interacting form. This assembly was mediated by the IQGAP1-dependent actin cytoskeleton, which was organized by Cdc42 and Rac small G proteins that were activated by the action of trans-interacting nectin through c-Src and Rap1 small G protein in an afadin-independent manner. However, Rap1 bound to afadin, and this Rap1-afadin complex then interacted with p120(ctn) associated with non-trans-interacting E-cadherin, thereby causing the trans-interaction of E-cadherin. Thus, nectin regulates the assembly and cell-cell adhesion activity of E-cadherin through afadin, nectin signaling, and p120(ctn) for the formation of AJs in Madin-Darby canine kidney cells.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ytakai@molbio.med.osaka-u.ac.jp		Ooshio, Takako/0000-0001-6508-8152				Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Asada M, 2003, J BIOL CHEM, V278, P4103, DOI 10.1074/jbc.M209832200; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Betson M, 2002, J BIOL CHEM, V277, P36962, DOI 10.1074/jbc.M207358200; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Ebnet K, 2000, J BIOL CHEM, V275, P27979; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; Fukuhara T, 2004, J CELL BIOL, V166, P393, DOI 10.1083/jcb.200401093; Fukuyama T, 2006, ONCOGENE, V25, P8, DOI 10.1038/sj.onc.1209010; Fukuyama T, 2005, J BIOL CHEM, V280, P815, DOI 10.1074/jbc.M411099200; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Honda T, 2003, BIOCHEM BIOPH RES CO, V306, P104, DOI 10.1016/S0006-291X(03)00919-7; Honda T, 2003, GENES CELLS, V8, P481, DOI 10.1046/j.1365-2443.2003.00649.x; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Hoshino T, 2005, J BIOL CHEM, V280, P24095, DOI 10.1074/jbc.M414447200; Hoshino T, 2004, MOL BIOL CELL, V15, P1077, DOI 10.1091/mbc.E03-05-0321; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Katata T, 2003, ONCOGENE, V22, P2097, DOI 10.1038/sj.onc.1206255; Kawakatsu T, 2005, J BIOL CHEM, V280, P4940, DOI 10.1074/jbc.M408710200; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Linnemann T, 1999, J BIOL CHEM, V274, P13556, DOI 10.1074/jbc.274.19.13556; Ma TY, 2000, AM J PHYSIOL-GASTR L, V279, pG875, DOI 10.1152/ajpgi.2000.279.5.G875; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakagawa H, 2001, J CELL SCI, V114, P1555; Nieset JE, 1997, J CELL SCI, V110, P1013; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Okamoto R, 2005, GENES CELLS, V10, P435, DOI 10.1111/j.1365-2443.2005.00846.x; Ooshio T, 2004, J BIOL CHEM, V279, P31365, DOI 10.1074/jbc.M401957200; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Pokutta S, 2002, J BIOL CHEM, V277, P18868, DOI 10.1074/jbc.M201463200; Quinlan MP, 1999, CELL GROWTH DIFFER, V10, P839; Roh MH, 2003, AM J PHYSIOL-RENAL, V285, pF377, DOI 10.1152/ajprenal.00086.2003; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Shimizu K, 2003, J BIOCHEM, V134, P631, DOI 10.1093/jb/mvg198; STEVENSON BR, 1994, J CELL SCI, V107, P367; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, CANCER SCI, V94, P655, DOI 10.1111/j.1349-7006.2003.tb01499.x; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Takenawa T, 2001, J CELL SCI, V114, P1801; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Yagi T, 2000, GENE DEV, V14, P1169; Yamada A, 2005, J BIOL CHEM, V280, P6016, DOI 10.1074/jbc.M408215200; Yamada A, 2004, GENES CELLS, V9, P843, DOI 10.1111/j.1365-2443.2004.00768.x; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	85	122	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5288	5299		10.1074/jbc.M510070200	http://dx.doi.org/10.1074/jbc.M510070200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361708	hybrid			2022-12-27	WOS:000235426200083
J	Stanasila, L; Abuin, L; Diviani, D; Cotecchia, S				Stanasila, L; Abuin, L; Diviani, D; Cotecchia, S			Ezrin directly interacts with the alpha 1b-adrenergic receptor and plays a role in receptor recycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ERM PROTEINS; ALPHA(1B)-ADRENERGIC RECEPTOR; ACTIN; BINDING; DOMAIN; PHOSPHORYLATION; ENDOCYTOSIS; INTERNALIZATION; DESENSITIZATION	Using the yeast two-hybrid system, we identified ezrin as a protein interacting with the C-tail of the alpha 1b-adrenergic receptor (AR). The interaction was shown to occur in vitro between the receptor C-tail and the N-terminal portion of ezrin, or Four-point-one ERM (FERM) domain. The alpha 1b-AR/ezrin interaction occurred inside the cells as shown by the finding that the transfected alpha 1b-AR and FERM domain or ezrin could be coimmunoprecipitated from human embryonic kidney 293 cell extracts. Mutational analysis of the alpha 1b-AR revealed that the binding site for ezrin involves a stretch of at least four arginines on the receptor C-tail. The results from both receptor biotinylation and immunofluorescence experiments indicated that the FERM domain impaired alpha 1b-AR recycling to the plasma membrane without affecting receptor internalization. The dominant negative effect of the FERM domain, which relies on its ability to mask the ezrin binding site for actin, was mimicked by treatment of cells with cytochalasin D, an actin depolymerizing agent. A receptor mutant (Delta R8) lacking its binding site in the C-tail for ezrin displayed delayed receptor recycling. These findings identify ezrin as a new protein directly interacting with a G proteincoupled receptor and demonstrate the direct implication of ezrin in GPCR trafficking via an actin-dependent mechanism.	Fac Biol & Med, Dept Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland		Cotecchia, S (corresponding author), Fac Biol & Med, Dept Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.	Susanna.Cotecchia@unil.ch		Diviani, Dario/0000-0003-4375-3718				Bockaert J, 2004, PHARMACOL THERAPEUT, V103, P203, DOI 10.1016/j.pharmthera.2004.06.004; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Cant SH, 2005, MOL BIOL CELL, V16, P3088, DOI 10.1091/mbc.E04-10-0877; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cao TT, 1998, J BIOL CHEM, V273, P24592, DOI 10.1074/jbc.273.38.24592; Chang FS, 2003, CURR BIOL, V13, P455, DOI 10.1016/S0960-9822(03)00131-3; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Denker SP, 2000, MOL CELL, V6, P1425, DOI 10.1016/S1097-2765(00)00139-8; Dickson TC, 2002, J CELL BIOL, V157, P1105, DOI 10.1083/jcb.200111076; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Diviani D, 1996, J BIOL CHEM, V271, P5049; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Hamada K, 2003, EMBO J, V22, P502, DOI 10.1093/emboj/cdg039; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Hirasawa A, 1998, BRIT J PHARMACOL, V124, P55, DOI 10.1038/sj.bjp.0701795; Laroche G, 2005, J BIOL CHEM, V280, P23215, DOI 10.1074/jbc.M414071200; LATTION AL, 1994, J BIOL CHEM, V269, P22887; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Manchanda N, 2005, J BIOL CHEM, V280, P12517, DOI 10.1074/jbc.C400583200; Mueller A, 2004, EUR J BIOCHEM, V271, P243, DOI 10.1046/j.1432-1033.2003.03918.x; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Schmieder S, 2004, J AM SOC NEPHROL, V15, P2289, DOI 10.1097/01.ASN.0000135968.49899.E8; WEINMAN EJ, 2005, ANN REV PHYSL, V68; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zhao HR, 2004, P NATL ACAD SCI USA, V101, P9485, DOI 10.1073/pnas.0308400101	30	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4354	4363		10.1074/jbc.M511989200	http://dx.doi.org/10.1074/jbc.M511989200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352594	hybrid			2022-12-27	WOS:000235275300071
J	Das, S; Ward, SV; Tacke, RS; Suske, G; Samuel, CE				Das, S; Ward, SV; Tacke, RS; Suske, G; Samuel, CE			Activation of the RNA-dependent protein kinase PKR promoter in the absence of interferon is dependent upon sp proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SP3; KCS ELEMENT; TARGETED DISRUPTION; ANTIVIRAL ACTIONS; BINDING PROTEINS; GENE-REGULATION; FACTOR FAMILY; EXPRESSION; MECHANISM; CELLS	The protein kinase regulated by RNA (PKR) is interferon (IFN)-inducible and plays important roles in many cellular processes, including virus multiplication, cell growth, and apoptosis. The TATA-less PKR promoter possesses a novel 15-bp DNA element (kinase conserved sequence (KCS)) unique to the human and mouse PKR genes that is conserved in sequence and position. We found that Sp1 and Sp3 of the Sp family of transcription factors bind at the KCS element. Their involvement was analyzed in the activation of basal and IFN-inducible PKR promoter activity. Both the small and large isoforms of Sp3 co-purified with KCS protein binding activity (KBP) by using nuclear extracts from HeLa cells not treated with IFN. Two forms of the KCS-binding protein complex were demonstrated by electrophoretic mobility shift assay analysis; one contained Sp1 and the other Sp3. In mouse cells null for all Sp3 isoforms, PKR expression was reduced to similar to 50% that of wild-type cells in the absence of IFN. The IFN-inducible expression of PKR, however, was Sp3-independent but STAT1- and JAK1-dependent. Overexpression of Sp1 in human U cells resulted in increased PKR promoter activity. In Drosophila SL2 cells lacking Sp proteins, both Sp1 and Sp3 large but not small isoforms activated PKR promoter expression, with the Sp1-mediated activation dominant. Mutational analysis of the PKR promoter region indicated a cooperative interaction between two different Sp sites, one of which is within the KCS element. These results establish that, in the absence of IFN treatment, activation of PKR basal expression is mediated by Sp1 and Sp3 proteins in a cooperative manner.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany	University of California System; University of California Santa Barbara; Philipps University Marburg	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	samuel@lifesci.ucsb.edu		Suske, Guntram/0000-0002-4807-0513	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020611] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20611] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Bouwman P, 2000, EMBO J, V19, P655, DOI 10.1093/emboj/19.4.655; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chamboredon S, 2005, ONCOGENE, V24, P2547, DOI 10.1038/sj.onc.1208489; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Das S, 2004, J BIOL CHEM, V279, P7313, DOI 10.1074/jbc.M312585200; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; Dorris DR, 2000, MOL CELL BIOL, V20, P4350, DOI 10.1128/MCB.20.12.4350-4358.2000; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; George CX, 1999, GENE, V229, P203, DOI 10.1016/S0378-1119(99)00017-7; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hilton TL, 2003, J BIOL CHEM, V278, P12992, DOI 10.1074/jbc.M300412200; ICELY PL, 1991, J BIOL CHEM, V266, P16073; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kawakami Y, 2004, DEVELOPMENT, V131, P4763, DOI 10.1242/dev.01331; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kuhen KL, 1996, GENOMICS, V36, P197, DOI 10.1006/geno.1996.0446; Kuhen KL, 1997, VIROLOGY, V227, P119, DOI 10.1006/viro.1996.8306; Kuhen KL, 1999, VIROLOGY, V254, P182, DOI 10.1006/viro.1998.9536; Kuhen KL, 1998, J VIROL, V72, P9934, DOI 10.1128/JVI.72.12.9934-9939.1998; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Samuel C E, 1981, Methods Enzymol, V79, P168; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SAMUEL CE, 1979, P NATL ACAD SCI USA, V76, P600, DOI 10.1073/pnas.76.2.600; SAMUEL CE, 1982, J BIOL CHEM, V257, P1791; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; SAMUEL CE, 1983, VIROLOGY, V130, P474, DOI 10.1016/0042-6822(83)90101-0; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Sapetschnig A, 2004, J BIOL CHEM, V279, P42095, DOI 10.1074/jbc.M404989200; Shtrichman R, 2002, INFECT IMMUN, V70, P5579, DOI 10.1128/IAI.70.10.5579-5588.2002; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suske G, 2005, GENOMICS, V85, P551, DOI 10.1016/j.ygeno.2005.01.005; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Wang J, 2005, J NEUROCHEM, V93, P474, DOI 10.1111/j.1471-4159.2005.03051.x; Ward SV, 2003, VIROLOGY, V313, P553, DOI 10.1016/S0042-6822(03)00347-7; Ward SV, 2002, VIROLOGY, V296, P136, DOI 10.1006/viro.2002.1356; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yu B, 2003, NUCLEIC ACIDS RES, V31, P5368, DOI 10.1093/nar/gkg706; Zhang XH, 2003, AM J PHYSIOL-RENAL, V284, pF82, DOI 10.1152/ajprenal.00200.2002	55	36	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3244	3253		10.1074/jbc.M510612200	http://dx.doi.org/10.1074/jbc.M510612200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339759	hybrid			2022-12-27	WOS:000235128200029
J	Hinek, A; Pshezhetsky, AV; von Itzstein, M; Starcher, B				Hinek, A; Pshezhetsky, AV; von Itzstein, M; Starcher, B			Lysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-BINDING-PROTEIN; BETA-GALACTOSIDASE; PROTECTIVE PROTEIN; MOLECULAR-CLONING; FUNCTIONAL DOMAINS; GENE; GALACTOSIALIDOSIS; EXPRESSION; DEFICIENCY; MUTATIONS	We have established previously that the 67-kDa elastin-binding protein (EBP), identical to the spliced variant of beta-galactosidase, acts as a recyclable chaperone that facilitates secretion of tropoelastin. (Hinek, A., Keeley, F. W., and Callahan, J. W. (1995) Exp. Cell Res. 220, 312-324). We now demonstrate that EBP also forms a cell surface-targeted molecular complex with protective protein/cathepsin A and sialidase (neuraminidase-1), and provide evidence that this sialidase activity is a prerequisite for the subsequent release of tropoelastin. We found that treatment with sialidase inhibitors repressed assembly of elastic fibers in cultures of human skin fibroblasts, aortic smooth muscle cells, and ear cartilage chondrocytes and caused impaired elastogenesis in developing chick embryos. Fibroblasts derived from patients with congenital sialidosis (primary deficiency of neuraminidase-1) and galactosialidosis (secondary deficiency of neuraminidase-1) demonstrated impaired elastogenesis, which could be reversed after their transduction with neuraminidase-1 cDNA or after treatment with bacterial sialidase, which has a similar substrate specificity to human neuraminidase-1. We postulate that neuraminidase-1 catalyzes removal of the terminal sialic acids from carbohydrate chains of microfibrillar glycoproteins and other adjacent matrix glycoconjugates, unmasking their penultimate galactosugars. In turn, the exposed galactosugars interact with the galectin domain of EBP, thereby inducing the release of transported tropoelastin molecules and facilitating their subsequent assembly into elastic fibers.	Hosp Sick Children, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada; Univ Montreal, Dept Med Genet, St Justine Hosp, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3T 1C5, Canada; Univ Texas Hlth Ctr, Tyler, TX 75708 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Universite de Montreal	Hinek, A (corresponding author), Hosp Sick Children, Cardiovasc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	alek.hinek@sickkids.ca	Hinek, Aleksander/V-8790-2019; von Itzstein, Mark/E-4823-2010	A, Pshezhetsky/0000-0002-6612-1062				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; AKIMOTO S, 1994, BIOCHEM BIOPH RES CO, V203, P914, DOI 10.1006/bbrc.1994.2269; Arai Y, 1999, ULTRASTRUCT PATHOL, V23, P369, DOI 10.1080/019131299281338; BACCARANICONTRI M, 1990, EUR J CELL BIOL, V53, P305; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Bonten EJ, 2000, J BIOL CHEM, V275, P37657, DOI 10.1074/jbc.M007380200; BONTEN EJ, 1995, J BIOL CHEM, V270, P26441, DOI 10.1074/jbc.270.44.26441; Bonten EJ, 2000, HUM MOL GENET, V9, P2715, DOI 10.1093/hmg/9.18.2715; BrownAugsburger P, 1996, BIOCHEM J, V318, P149, DOI 10.1042/bj3180149; Caciotti A, 2005, HUM MUTAT, V25, P285, DOI 10.1002/humu.20147; Chen XP, 1997, J IMMUNOL, V158, P3070; CHRISTIANO AM, 1994, J INVEST DERMATOL, V103, pS53, DOI 10.1111/1523-1747.ep12399044; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; DAGROSA RM, 1992, BIOCHEM J, V285, P833, DOI 10.1042/bj2850833; Davis EC, 1998, J CELL BIOL, V140, P295, DOI 10.1083/jcb.140.2.295; de Geest N, 2002, HUM MOL GENET, V11, P1455, DOI 10.1093/hmg/11.12.1455; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; Debret R, 2005, ARTERIOSCL THROM VAS, V25, P1353, DOI 10.1161/01.ATV.0000168412.50855.9f; Florio P, 1999, BIOORG MED CHEM LETT, V9, P2065, DOI 10.1016/S0960-894X(99)00331-5; Gibson MA, 1996, J BIOL CHEM, V271, P1096, DOI 10.1074/jbc.271.2.1096; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; Hinek A, 2000, AM J HUM GENET, V66, P859, DOI 10.1086/302829; Hinek A, 2000, AM J PATHOL, V156, P925, DOI 10.1016/S0002-9440(10)64961-9; HINEK A, 1994, CELL ADHES COMMUN, V2, P185, DOI 10.3109/15419069409004436; HINEK A, 1992, EXP CELL RES, V203, P344, DOI 10.1016/0014-4827(92)90008-V; HINEK A, 1991, J CLIN INVEST, V88, P2083, DOI 10.1172/JCI115538; HINEK A, 1995, EXP CELL RES, V220, P312, DOI 10.1006/excr.1995.1321; HINEK A, 1994, J CELL BIOL, V126, P563, DOI 10.1083/jcb.126.2.563; Hinek A, 2005, J DERMATOL SCI, V39, P155, DOI 10.1016/j.jdermsci.2005.04.002; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HINEK A, 1993, J CLIN INVEST, V91, P1198, DOI 10.1172/JCI116280; Hinek A, 1996, BIOL CHEM, V377, P471; HOLZER CT, 1993, GLYCOCONJUGATE J, V10, P40, DOI 10.1007/BF00731185; Hou YM, 1998, J BIOL CHEM, V273, P21386, DOI 10.1074/jbc.273.33.21386; Igdoura SA, 1998, HUM MOL GENET, V7, P115, DOI 10.1093/hmg/7.1.115; Kielty CM, 2002, PHILOS T R SOC B, V357, P207, DOI 10.1098/rstb.2001.1029; Kielty CM, 2002, J CELL SCI, V115, P2817; KNIBBS RN, 1993, J BIOL CHEM, V268, P18524; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Lukong KE, 1999, BIOCHEMISTRY-US, V38, P73, DOI 10.1021/bi981324r; Malvagia S, 2004, MOL GENET METAB, V82, P48, DOI 10.1016/j.ymgme.2004.02.007; Mann MC, 2004, BIOORG MED CHEM LETT, V14, P5555, DOI 10.1016/j.bmcl.2004.08.064; MECHAM RP, 1988, BIOCHEM BIOPH RES CO, V151, P822, DOI 10.1016/S0006-291X(88)80355-3; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; MIYAGI T, 1993, GLYCOCONJUGATE J, V10, P45, DOI 10.1007/BF00731186; Mochizuki S, 2002, J BIOL CHEM, V277, P44854, DOI 10.1074/jbc.M205630200; Monti E, 1999, GLYCOBIOLOGY, V9, P1313, DOI 10.1093/glycob/9.12.1313; Monti E, 2000, BIOCHEM J, V349, P343, DOI 10.1042/0264-6021:3490343; Monti E, 2004, GENOMICS, V83, P445, DOI 10.1016/j.ygeno.2003.08.019; Monti E, 1999, GENOMICS, V57, P137, DOI 10.1006/geno.1999.5749; Monti E, 2002, NEUROCHEM RES, V27, P649, DOI 10.1023/A:1020276000901; MORREAU H, 1989, J BIOL CHEM, V264, P20655; MORREAU H, 1992, J BIOL CHEM, V267, P17949; Morrone A, 2000, HUM MUTAT, V15, P354, DOI 10.1002/(SICI)1098-1004(200004)15:4<354::AID-HUMU8>3.3.CO;2-C; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; OBRIEN JS, 1980, CLIN GENET, V17, P35; PASQUALIRONCHETTI I, 1984, EXP MOL PATHOL, V40, P235, DOI 10.1016/0014-4800(84)90080-7; Patel MS, 1999, AM J MED GENET, V85, P38, DOI 10.1002/(SICI)1096-8628(19990702)85:1<38::AID-AJMG8>3.3.CO;2-V; Pattison S, 2004, HUM MUTAT, V23, P32, DOI 10.1002/humu.10278; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Privitera S, 1998, J BIOL CHEM, V273, P6319, DOI 10.1074/jbc.273.11.6319; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; PSHEZHETSKY AV, 1995, ANAL BIOCHEM, V230, P303, DOI 10.1006/abio.1995.1478; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Rock MJ, 2004, J BIOL CHEM, V279, P23748, DOI 10.1074/jbc.M400212200; Saito N., 1995, BIOL SIALIC ACIDS, P261; SAKURABA H, 1982, CLIN CHIM ACTA, V125, P275; SATO K, 1995, GLYCOBIOLOGY, V5, P511, DOI 10.1093/glycob/5.5.511; Seyrantepe V, 2003, HUM MUTAT, V22, P343, DOI 10.1002/humu.10268; Sherratt MJ, 2001, MICRON, V32, P185, DOI 10.1016/S0968-4328(99)00082-7; Starcher B, 1999, J INVEST DERMATOL, V112, P450, DOI 10.1046/j.1523-1747.1999.00553.x; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Uitto J, 1995, CIBA F SYMP, V192, P237; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; Vinogradova MV, 1998, BIOCHEM J, V330, P641; Vleurick L, 1999, J CELL BIOCHEM, V72, P349, DOI 10.1002/(SICI)1097-4644(19990301)72:3<349::AID-JCB4>3.0.CO;2-H; VONITZSTEIN M, 1994, CARBOHYD RES, V259, P301, DOI 10.1016/0008-6215(94)84065-2; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; WRENN DS, 1988, J BIOL CHEM, V263, P2280; Yamaguchi K, 2005, BIOCHEM J, V390, P85, DOI 10.1042/BJ20050017; ZHU L, 1994, J CLIN INVEST, V94, P1163, DOI 10.1172/JCI117432	88	129	135	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3698	3710		10.1074/jbc.M508736200	http://dx.doi.org/10.1074/jbc.M508736200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16314420	hybrid			2022-12-27	WOS:000235128200082
J	Kim, SG; Manes, NP; El-Maghrabi, MR; Lee, YH				Kim, SG; Manes, NP; El-Maghrabi, MR; Lee, YH			Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) - A possible new target for cancer therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; FRUCTOSE 2,6-BISPHOSPHATE; BIFUNCTIONAL ENZYME; 6-PHOSPHOFRUCTO-2-KINASE; FRUCTOSE-2,6-BISPHOSPHATASE; GLYCOLYSIS; ACTIVATION; EXPRESSION; GENE; PHOSPHORYLATION	The hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3) plays a crucial role in the progression of cancerous cells by enabling their glycolytic pathways even under severe hypoxic conditions. To understand its structural architecture and to provide a molecular scaffold for the design of new cancer therapeutics, the crystal structure of the human form was determined. The structure at 2.1 angstrom resolution shows that the overall folding and functional dimerization are very similar to those of the liver (PFKFB1) and testis (PFKFB4) forms, as expected from sequence homology. However, in this structure, the N-terminal regulatory domain is revealed for the first time among the PFKFB isoforms. With a beta-hairpin structure, the N terminus interacts with the 2-Pase domain to secure binding of fructose-6-phosphate to the active pocket, slowing down the release of fructose-6-phosphate from the phosphoenzyme intermediate product complex. The C-terminal regulatory domain is mostly disordered, leaving the active pocket of the fructose-2,6-bisphosphatase domain wide open. The active pocket of the 6-phosphofructo-2-kinase domain has a more rigid conformation, allowing independent bindings of substrates, fructose-6-phosphate and ATP, with higher affinities than other isoforms. Intriguingly, the structure shows an EDTA molecule bound to the fructose-6-phosphate site of the 6-phosphofructo-2-kinase active pocket despite its unfavorable liganding concentration, suggesting a high affinity. EDTA is not removable from the site with fructose-6-P alone but is with both ATP and fructose-6-P or with fructose-2,6-bisphosphate. This finding suggests that a molecule in which EDTA is covalently linked to ADP is a good starting molecule for the development of new cancer-therapeutic molecules.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	Louisiana State University System; Louisiana State University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lee, YH (corresponding author), Louisiana State Univ, Dept Biol Sci, 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.	yhlee@lsu.edu	Manes, Nathan P/E-2817-2012	Manes, Nathan P/0000-0001-6701-3314	NCI NIH HHS [R01 CA124758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA124758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atsumi T, 2002, CANCER RES, V62, P5881; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; Bertrand L, 1999, J BIOL CHEM, V274, P30927, DOI 10.1074/jbc.274.43.30927; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chesney J, 2005, BIOCHEM BIOPH RES CO, V331, P139, DOI 10.1016/j.bbrc.2005.02.193; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; El-Maghrabi MR, 2001, CURR OPIN CLIN NUTR, V4, P411, DOI 10.1097/00075197-200109000-00012; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Fukasawa M, 2004, J BIOCHEM, V136, P273, DOI 10.1093/jb/mvh137; Goren N, 2000, MOL BRAIN RES, V75, P138, DOI 10.1016/S0169-328X(99)00319-8; Hasemann CA, 1996, STRUCTURE, V4, P1017, DOI 10.1016/S0969-2126(96)00109-8; Heine-Suner D, 1998, EUR J BIOCHEM, V254, P103, DOI 10.1046/j.1432-1327.1998.2540103.x; Hirata T, 2000, BIOSCI BIOTECH BIOCH, V64, P2047, DOI 10.1271/bbb.64.2047; Hue L, 2002, J MOL CELL CARDIOL, V34, P1091, DOI 10.1006/jmcc.2002.2063; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koshland DE, 1998, NAT MED, V4, P1112, DOI 10.1038/2605; Lee YH, 1997, NAT STRUCT BIOL, V4, P615, DOI 10.1038/nsb0897-615; Lee YH, 1996, BIOCHEMISTRY-US, V35, P6010, DOI 10.1021/bi9600613; Lee YH, 2003, J BIOL CHEM, V278, P523, DOI 10.1074/jbc.M209105200; LI L, 1992, J BIOL CHEM, V267, P21588; LI L, 1992, J BIOL CHEM, V267, P16669; LIN K, 1992, J BIOL CHEM, V267, P6556; LIN K, 1994, J BIOL CHEM, V269, P16953; Manes NP, 2005, ARCH BIOCHEM BIOPHYS, V438, P125, DOI 10.1016/j.abb.2005.04.011; Manzano A, 1999, GENE, V229, P83, DOI 10.1016/S0378-1119(99)00037-2; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Minchenko OH, 2005, BIOCHIMIE, V87, P1005, DOI 10.1016/j.biochi.2005.04.007; NAVAZA J, 1993, ACTA CRYSTALLOGR D, V49, P588, DOI 10.1107/S0907444993005141; Okamura N, 1998, BIOSCI BIOTECH BIOCH, V62, P2039, DOI 10.1271/bbb.62.2039; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILKIS SJ, 1984, J BIOL CHEM, V259, P949; PILKIS SJ, 1988, ADV SEC MESS PHOSPH, V22, P175; PILKIS SJ, 1995, ANNU REV BIOCHEM, V64, P799, DOI 10.1146/annurev.bi.64.070195.004055; PILKIS SJ, 1981, J BIOL CHEM, V256, P3171; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Sakakibara R, 1999, BIOCHEM BIOPH RES CO, V257, P177, DOI 10.1006/bbrc.1999.0429; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; STEWART HB, 1986, J BIOL CHEM, V261, P8793; UYEDA K, 1981, J BIOL CHEM, V256, P8679; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yuen MH, 1999, BIOCHEMISTRY-US, V38, P12333, DOI 10.1021/bi991268+	46	36	43	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2939	2944		10.1074/jbc.M511019200	http://dx.doi.org/10.1074/jbc.M511019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316985	hybrid			2022-12-27	WOS:000234931800063
J	Salsi, V; Zappavigna, V				Salsi, V; Zappavigna, V			Hoxd13 and Hoxa13 directly control the expression of the EphA7 ephrin tyrosine kinase receptor in developing limbs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; IN-VIVO; CELL-MIGRATION; GENES; MISEXPRESSION; DOWNSTREAM; PROTEINS; HOXD-13; IDENTIFICATION; MORPHOGENESIS	Hoxa and Hoxd genes, related to the Drosophila Abd-B gene, display regionally restricted expression patterns and are necessary for the formation of the limb skeletal elements. Hox genes encode transcription factors, which are supposed to control the expression of a series of downstream target genes, whose nature has remained largely elusive. Several genes were identified that are differentially expressed in relation to Hox gene activity; few studies, however, explored their direct regulation by Hox proteins. Ephrin tyrosine kinase receptors and ephrins have been proposed as Hox targets, and recently, evidence was gained for their role in limb development. The expression of the EphA7 gene in developing limbs was shown to correlate with the expression of Hoxa13 and Hoxd13; however, its direct regulation by these genes has never been assessed. We have characterized the EphA7 promoter region and show that it contains multiple binding sites for paralog group 13 Hox proteins. We found that one of these sites is bound in vivo by HOXA13 and HOXD13 and by endogenous Hoxd13 in developing mouse limbs. Moreover, we show that HOXD13 and HOXA13 activate transcription from the EphA7 promoter and that a mutation of the HOXA13/HOXD13 binding site was sufficient to abolish activation. Conversely, the HOXD13(147L) mutation, identified in patients displaying a novel brachydactyly-polydactyly syndrome, does not bind to in vivo, and fails to transactivate the EphA7 promoter. These results establish that EphA7 is a direct downstream target of Hoxd13 and Hoxa13 during limb development, thus providing further insight into the regulatory networks that control limb patterning.	Univ Modena & Reggio Emilia, Dept Anim Biol, I-41100 Modena, Italy; Cornell Univ, Weill Med Sch, Dept Cell & Dev Biol, New York, NY 10021 USA	Universita di Modena e Reggio Emilia; Cornell University	Zappavigna, V (corresponding author), Univ Modena & Reggio Emilia, Dept Anim Biol, Via G Campi 213-D, I-41100 Modena, Italy.	zappavigna.vincenzo@unimore.it	Zappavigna, Vincenzo/D-3899-2015	Zappavigna, Vincenzo/0000-0002-7384-3207; SALSI, Valentina/0000-0002-7133-0360				BENSON GV, 1995, MOL CELL BIOL, V15, P1591; Biggin MD, 1997, DEVELOPMENT, V124, P4425; Bruhl T, 2004, CIRC RES, V94, P743, DOI 10.1161/01.RES.0000120861.27064.09; Caronia G, 2003, DEVELOPMENT, V130, P1701, DOI 10.1242/dev.00396; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Cobb J, 2005, DEVELOPMENT, V132, P3055, DOI 10.1242/dev.01885; Compagni A, 2003, DEV CELL, V5, P217, DOI 10.1016/S1534-5807(03)00198-9; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Elkon R, 2003, GENOME RES, V13, P773, DOI 10.1101/gr.947203; Favier B, 1997, MOL HUM REPROD, V3, P115, DOI 10.1093/molehr/3.2.115; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; FromentalRamain C, 1996, DEVELOPMENT, V122, P2997; Goff DJ, 1997, DEVELOPMENT, V124, P627; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Knosp WM, 2004, DEVELOPMENT, V131, P4581, DOI 10.1242/dev.01327; Kodadek T, 1998, TRENDS BIOCHEM SCI, V23, P79, DOI 10.1016/S0968-0004(97)01165-1; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lei HY, 2005, P NATL ACAD SCI USA, V102, P2420, DOI 10.1073/pnas.0409700102; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; Morgan EA, 2003, DEVELOPMENT, V130, P3095, DOI 10.1242/dev.00530; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Palmer A, 2003, GENE DEV, V17, P1429, DOI 10.1101/gad.1093703; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Stadler HS, 2001, DEVELOPMENT, V128, P4177; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; TOTH J, 2000, NUCL ACIDS RES 2000, pE4; Valerius AT, 2002, MECH DEVELOP, V112, P217; Wada N, 2003, DEV BIOL, V264, P550, DOI 10.1016/j.ydbio.2003.08.019; WALTER J, 1994, GENE DEV, V8, P1678, DOI 10.1101/gad.8.14.1678; Williams TM, 2005, DEV BIOL, V279, P462, DOI 10.1016/j.ydbio.2004.12.015; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	45	50	54	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1992	1999		10.1074/jbc.M510900200	http://dx.doi.org/10.1074/jbc.M510900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314414	hybrid			2022-12-27	WOS:000234760400019
J	Kimoto, H; Fujii, Y; Hirano, S; Yokota, Y; Taketo, A				Kimoto, H; Fujii, Y; Hirano, S; Yokota, Y; Taketo, A			Genetic and biochemical properties of streptococcal NAD-glycohydrolase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; COMPLETE GENOME SEQUENCE; STREPTOLYSIN-O; III SECRETION; HEMOLYTIC STREPTOCOCCI; M3 STRAIN; GROUP-C; PYOGENES; TOXINS; PATHOGENESIS	The gene encoding streptolysin O (slo), a cytolysin of hemolytic streptococci, is transcribed polycistronically from the promoter of the preceding NAD-glycohydrolase (NADase) gene (nga). Between nga and slo, a putative open reading frame (orf1) is located whose function has been totally unknown. Present investigation demonstrated that the orf1 encodes a protein designated as streptococcal NADase inhibitor (SNI). From its nucleotide sequence, SNI was inferred to comprise 161 amino acid residues and the deduced molecular weight was 18,800. This protein was detectable only within cells. Coexpression of SNI was essential for production of streptococcal NADase, and NADase precursor existed as an inactive complex with SNI, in recombinant Escherichia coli. Monomeric NADase and SNI rapidly formed in vitro a stable heterodimer complex in the ratio 1:1, resulting in complete suppression of the hydrolase activity. Unlike other bacterial NADase inhibitors, SNI was thermostable. This protein, coexpressed and complexed with NADase, may protect the producer cocci from exhaustion of NAD.	Univ Fukui, Fac Med, Dept Mol Genet, Fukui 9101193, Japan; Univ Fukui, Fac Med, Dept Mol Biol & Chem, Fukui 9101193, Japan; Univ Fukui, Fac Med, Dept Pediat, Fukui 9101193, Japan; Fukui Univ Technol, Dept Environm & Biotechnol Frontier Engn, Fukui 9108505, Japan	University of Fukui; University of Fukui; University of Fukui	Kimoto, H (corresponding author), Univ Fukui, Fac Med, Dept Mol Genet, 23-3 Shimoaizuki, Fukui 9101193, Japan.	hisashi@fmsrsa.fukui-med.ac.jp		Fujii, Yutaka/0000-0001-6357-3795				ALOUF JE, 1980, PHARMACOL THERAPEUT, V11, P661, DOI 10.1016/0163-7258(80)90045-5; Alouf JE, 2000, INT J MED MICROBIOL, V290, P351; Banks DJ, 2004, J INFECT DIS, V190, P727, DOI 10.1086/422697; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; BHAKDI S, 1985, INFECT IMMUN, V47, P52; Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300; Billington SJ, 2000, FEMS MICROBIOL LETT, V182, P197, DOI 10.1016/S0378-1097(99)00536-4; Blocker A, 2000, CELL MICROBIOL, V2, P387, DOI 10.1046/j.1462-5822.2000.00068.x; Buttner D, 2002, TRENDS MICROBIOL, V10, P186, DOI 10.1016/S0966-842X(02)02331-4; CARLSON AS, 1956, J EXP MED, V104, P577, DOI 10.1084/jem.104.4.577; CARLSON AS, 1957, J EXP MED, V106, P15, DOI 10.1084/jem.106.1.15; Cheng LW, 2000, TRENDS MICROBIOL, V8, P214, DOI 10.1016/S0966-842X(99)01665-0; CHRISTENSEN LR, 1945, J GEN PHYSIOL, V28, P363, DOI 10.1085/jgp.28.4.363; Coye LH, 2004, MOL MICROBIOL, V54, P89, DOI 10.1111/j.1365-2958.2004.04262.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Everse K E, 1980, Methods Enzymol, V66, P137; FEHRENBA.FJ, 1971, Z NATURFORSCH PT B, VB 26, P1336, DOI 10.1515/znb-1971-1224; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Gerlach D, 1996, FEMS MICROBIOL LETT, V136, P71; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hashikawa S, 2004, J CLIN MICROBIOL, V42, P186, DOI 10.1128/JCM.42.1.186-192.2004; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HOLM SE, 1967, ACTA PATHOL MIC SC, V69, P277; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Kimoto H, 2005, BBA-GENE STRUCT EXPR, V1681, P134, DOI 10.1016/j.bbaexp.2004.10.011; Kimoto H, 1997, J BIOCHEM, V122, P237; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Madden JC, 2001, CELL, V104, P143, DOI 10.1016/S0092-8674(01)00198-2; Mitaku S, 2002, BIOINFORMATICS, V18, P608, DOI 10.1093/bioinformatics/18.4.608; Nakagawa I, 2003, GENOME RES, V13, P1042, DOI 10.1101/gr.1096703; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Palmer M, 2001, TOXICON, V39, P1681, DOI 10.1016/S0041-0101(01)00155-6; Sachse S, 2002, FEMS IMMUNOL MED MIC, V34, P159, DOI 10.1016/S0928-8244(02)00373-5; Savic DJ, 2002, INFECT IMMUN, V70, P2730, DOI 10.1128/IAI.70.5.2730-2733.2002; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; SWARTZ MN, 1956, SCIENCE, V123, P50, DOI 10.1126/science.123.3185.50; TAKETA K, 1986, J IMMUNOL METHODS, V95, P71; TIESLER E, 1982, ZBL BAKT-INT J MED M, V253, P81; Yamamoto I, 2001, BIOSCI BIOTECH BIOCH, V65, P2682, DOI 10.1271/bbb.65.2682	39	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9181	9189		10.1074/jbc.M506879200	http://dx.doi.org/10.1074/jbc.M506879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16380378	hybrid			2022-12-27	WOS:000236404700024
J	Beahm, DL; Oshima, A; Gaietta, GM; Hand, GM; Smock, AE; Zucker, SN; Toloue, MM; Chandrasekhar, A; Nicholson, BJ; Sosinsky, GE				Beahm, DL; Oshima, A; Gaietta, GM; Hand, GM; Smock, AE; Zucker, SN; Toloue, MM; Chandrasekhar, A; Nicholson, BJ; Sosinsky, GE			Mutation of a conserved threonine in the third transmembrane helix of alpha- and beta-connexins creates a dominant-negative closed gap junction channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; MOLECULAR-CLONING; GENE-MUTATIONS; MEMBRANE; LIVER; PORE; PHENOTYPE; UNDERLIES; OLIGOMERIZATION; IDENTIFICATION	Single site mutations in connexins have provided insights about the influence specific amino acids have on gap junction synthesis, assembly, trafficking, and functionality. We have discovered a single point mutation that eliminates functionality without interfering with gap junction formation. The mutation occurs at a threonine residue located near the cytoplasmic end of the third transmembrane helix. This threonine is strictly conserved among members of the alpha- and beta-connexin subgroups but not the gamma-subgroup. In HeLa cells, connexin43 and connexin26 mutants are synthesized, traffic to the plasma membrane, and make gap junctions with the same overall appearance as wild type. We have isolated connexin26T135A gap junctions both from HeLa cells and baculovirus-infected insect Sf9 cells. By using cryoelectron microscopy and correlation averaging, difference images revealed a small but significant size change within the pore region and a slight rearrangement of the subunits between mutant and wild-type connexons expressed in Sf9 cells. Purified, detergent-solubilized mutant connexons contain both hexameric and partially disassembled structures, although wild-type connexons are almost all hexameric, suggesting that the three-dimensional mutant connexon is unstable. Mammalian cells expressing gap junction plaques composed of either connexin43T154A or connexin26T135A showed an absence of dye coupling. When expressed in Xenopus oocytes, these mutants, as well as a cysteine substitution mutant of connexin50 (connexin50T157C), failed to produce electrical coupling in homotypic and heteromeric pairings with wild type in a dominant-negative effect. This mutant may be useful as a tool for knocking down or knocking out connexin function in vitro or in vivo.	Univ Calif San Diego, Dept Neurosci, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	University of California System; University of California San Diego; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Sosinsky, GE (corresponding author), Univ Calif San Diego, Dept Neurosci, Natl Ctr Microscopy & Imaging Res, 1070 Basic Sci Bldg,MC 0608,9500 Gilman Dr, La Jolla, CA 92093 USA.	gsosinsky@ucsd.edu	Oshima, Atsunori/F-8346-2010	Nicholson, Bruce/0000-0003-1649-7173; Oshima, Atsunori/0000-0003-1174-1368	NATIONAL CANCER INSTITUTE [R01CA048049] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050, P41RR002250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072881, R01GM065937] Funding Source: NIH RePORTER; NCI NIH HHS [CA048049] Funding Source: Medline; NCRR NIH HHS [P41RR02250, RR04050] Funding Source: Medline; NIGMS NIH HHS [GM065937, GM072881, R01 GM065937, GM048773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams CK, 2000, CURR TOP MEMBR, V49, P423; Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Andreadis ST, 2001, FASEB J, V15, P898, DOI 10.1096/fj.00-0324com; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Beltramello M, 2005, NAT CELL BIOL, V7, P63, DOI 10.1038/ncb1205; BONE LJ, 1995, NEUROLOGY, V45, P1863, DOI 10.1212/WNL.45.10.1863; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; Bukauskas FF, 2004, BBA-BIOMEMBRANES, V1662, P42, DOI 10.1016/j.bbamem.2004.01.008; CROWTHER RA, 1971, J MOL BIOL, V184, P81; Cryns K, 2004, J MED GENET, V41, P147, DOI 10.1136/jmg.2003.013896; DEERINCK TJ, 1994, J CELL BIOL, V126, P901, DOI 10.1083/jcb.126.4.901; Di WL, 2001, J INVEST DERMATOL, V117, P958, DOI 10.1046/j.0022-202x.2001.01468.x; Falk MM, 2000, J CELL SCI, V113, P4109; Fleishman SJ, 2004, MOL CELL, V15, P879, DOI 10.1016/j.molcel.2004.08.016; Frei K, 2004, AUDIOL NEURO-OTOL, V9, P47, DOI 10.1159/000074186; Fuse Y, 1999, NEUROREPORT, V10, P1853, DOI 10.1097/00001756-199906230-00010; Gabriel HD, 1998, J CELL BIOL, V140, P1453, DOI 10.1083/jcb.140.6.1453; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; GILULA NB, 1972, NATURE, V235, P262, DOI 10.1038/235262a0; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Gourdie RG, 2000, CURR TOP MEMBR, V49, P581; Hand GM, 2002, J MOL BIOL, V315, P587, DOI 10.1006/jmbi.2001.5262; HENNEMANN H, 1992, J CELL BIOL, V117, P1299, DOI 10.1083/jcb.117.6.1299; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunter AW, 2003, CELL COMMUN ADHES, V10, P211, DOI 10.1080/714040429; JONGSMA HJ, 1991, BIOPHYSICS GAP JUNCT, P163; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kronengold J, 2003, J GEN PHYSIOL, V122, P389, DOI 10.1085/jgp.200308861; Krutovskikh V, 2000, MUTAT RES-REV MUTAT, V462, P197, DOI 10.1016/S1383-5742(00)00037-5; KUMAR NM, 1986, J CELL BIOL, V103, P767, DOI 10.1083/jcb.103.3.767; Kumari SS, 2001, BIOCHEM BIOPH RES CO, V280, P440, DOI 10.1006/bbrc.2000.4121; Lagree V, 2003, J CELL SCI, V116, P3189, DOI 10.1242/jcs.00604; LAL R, 1995, AM J PHYSIOL-CELL PH, V268, pC968, DOI 10.1152/ajpcell.1995.268.4.C968; Lauf U, 2002, P NATL ACAD SCI USA, V99, P10446, DOI 10.1073/pnas.162055899; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mackay D, 1999, AM J HUM GENET, V64, P1357, DOI 10.1086/302383; Martin BR, 2005, NAT BIOTECHNOL, V23, P1308, DOI 10.1038/nbt1136; Maza J, 2005, J BIOL CHEM, V280, P21115, DOI 10.1074/jbc.M412612200; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Muller DJ, 2002, EMBO J, V21, P3598, DOI 10.1093/emboj/cdf365; Nelis E, 1999, HUM MUTAT, V13, P11, DOI 10.1002/(SICI)1098-1004(1999)13:1<11::AID-HUMU2>3.0.CO;2-A; Nelles E, 1996, P NATL ACAD SCI USA, V93, P9565, DOI 10.1073/pnas.93.18.9565; Oshima A, 2003, J BIOL CHEM, V278, P1807, DOI 10.1074/jbc.M207713200; PATEL PI, 1994, TRENDS GENET, V10, P128, DOI 10.1016/0168-9525(94)90214-3; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; Paznekas WA, 2003, AM J HUM GENET, V72, P408, DOI 10.1086/346090; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Ressot C, 1996, HUM GENET, V98, P172, DOI 10.1007/s004390050183; Richard G, 1998, NAT GENET, V20, P366, DOI 10.1038/3840; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Scherer SS, 1999, NOVART FDN SYMP, V219, P175; Schonherr R, 2002, NEURON, V35, P935, DOI 10.1016/S0896-6273(02)00869-3; Shiels A, 1998, AM J HUM GENET, V62, P526, DOI 10.1086/301762; Skerrett IM, 2004, FASEB J, V18, P860, DOI 10.1096/fj.03-0763fje; Skerrett IM, 2002, J CELL BIOL, V159, P349, DOI 10.1083/jcb.200207060; Sorour E, 1998, HUM MUTAT, pS242; SOSINSKY GE, 1990, BIOPHYS J, V58, P1213, DOI 10.1016/S0006-3495(90)82462-0; Thimm J, 2005, J BIOL CHEM, V280, P10646, DOI 10.1074/jbc.M412749200; Trexler EB, 1996, P NATL ACAD SCI USA, V93, P5836, DOI 10.1073/pnas.93.12.5836; Tsien RY, 2005, FEBS LETT, V579, P927, DOI 10.1016/j.febslet.2004.11.025; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; UNWIN N, 1986, NATURE, V323, P12, DOI 10.1038/323012a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; Weber PA, 2004, BIOPHYS J, V87, P958, DOI 10.1529/biophysj.103.036350; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Zampighi GA, 1999, J GEN PHYSIOL, V113, P507, DOI 10.1085/jgp.113.4.507; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4	71	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7994	8009		10.1074/jbc.M506533200	http://dx.doi.org/10.1074/jbc.M506533200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407179	hybrid			2022-12-27	WOS:000236031000036
J	Urano, Y; Iiduka, M; Sugiyama, A; Akiyama, H; Uzawa, K; Matsumoto, G; Kawasaki, Y; Tashiro, F				Urano, Y; Iiduka, M; Sugiyama, A; Akiyama, H; Uzawa, K; Matsumoto, G; Kawasaki, Y; Tashiro, F			Involvement of the mouse Prp19 gene in neuronal/astroglial cell fate decisions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; LEUKEMIA INHIBITORY FACTOR; MAMMALIAN ACHAETE-SCUTE; CENTRAL-NERVOUS-SYSTEM; LOOP-HELIX GENES; PROMOTES NEURONAL DIFFERENTIATION; RETINOIC ACID; GLIAL-CELLS; STEM-CELLS; P19 CELLS	The molecular mechanisms involved in neuronal/astroglial cell fate decisions during the development of the mammalian central nervous system are poorly understood. Here, we report that PRP19 beta, a splice variant of mouse PRP19 alpha corresponding to the yeast PRP19 protein, can function as a neuron-astroglial switch during the retinoic acid-primed neural differentiation of P19 cells. The beta-variant possesses an additional 19 amino acid residues in-frame in the N-terminal region of the alpha-variant. The forced expression of the alpha-variant RNA caused the down-regulation of oct-3/4 and nanog mRNA expression during the 12 - 48 h of the late-early stages of neural differentiation and was sufficient to convert P19 cells into neurons ( but not glial cells) when the cells were cultured in aggregated form without retinoic acid. In contrast, the forced expression of the alpha-variant RNA suppressed neuronal differentiation and conversely stimulated astroglial cell differentiation in retinoic acid-primed P19 cells. Based on yeast two-hybrid screening, cyclophilin A was identified as a specific binding partner of the beta-variant. Luciferase reporter assay mediated by the oct-3/4 promoter revealed that cyclophilin A could act as a transcriptional activator and that its activity was suppressed by the beta-variant, suggesting that cyclophilin A takes part in the induction of oct-3/4 gene expression, which might lead to neuroectodermal otx2 expression within 12 h of the immediate-early stages of retinoic acid-primed neural differentiation. These results show that the alpha-variant gene plays a pivotal role in neural differentiation and that the beta-variant participates in neuronal/astroglial cell fate decisions.	Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2708510, Japan	Tokyo University of Science	Tashiro, F (corresponding author), Tokyo Univ Sci, Fac Ind Sci & Technol, Dept Biol Sci & Technol, Noda, Chiba 2708510, Japan.	ftashir@rs.noda.tus.ac.jp	TASHIRO, Yumiko/AAV-2054-2020	Tashiro, Yumiko/0000-0002-8328-2634				Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569; Akiyama H, 2003, DEV BRAIN RES, V140, P45, DOI 10.1016/S0165-3806(02)00574-6; Akiyama H, 2003, J BIOL CHEM, V278, P10752, DOI 10.1074/jbc.M209856200; Akiyama Y, 1996, P NATL ACAD SCI USA, V93, P14912, DOI 10.1073/pnas.93.25.14912; Altshuller Y, 1996, FEBS LETT, V393, P201, DOI 10.1016/0014-5793(96)00890-3; Anson-Cartwright L, 2000, NAT GENET, V25, P311, DOI 10.1038/77076; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Basyuk E, 1999, DEV DYNAM, V214, P303, DOI 10.1002/(SICI)1097-0177(199904)214:4<303::AID-AJA3>3.3.CO;2-2; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; Cai L, 2000, DEVELOPMENT, V127, P3021; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; CHENG SC, 1993, MOL CELL BIOL, V13, P1876, DOI 10.1128/MCB.13.3.1876; DELAMO FF, 1993, BIOCHIM BIOPHYS ACTA, V1171, P323, DOI 10.1016/0167-4781(93)90076-P; Duncan MK, 1997, DEV DYNAM, V208, P107, DOI 10.1002/(SICI)1097-0177(199701)208:1<107::AID-AJA10>3.0.CO;2-3; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Ge WH, 2002, J NEUROSCI RES, V69, P848, DOI 10.1002/jnr.10364; Goldner FM, 1996, J COMP NEUROL, V372, P283; Gunther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111; Hardy RJ, 1998, J NEUROSCI RES, V54, P46, DOI 10.1002/(SICI)1097-4547(19981001)54:1<46::AID-JNR6>3.0.CO;2-H; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; He F, 2005, NAT NEUROSCI, V8, P616, DOI 10.1038/nn1440; Hirabayashi Y, 2004, DEVELOPMENT, V131, P2791, DOI 10.1242/dev.01165; HOSOYA T, 1995, CELL, V82, P1025, DOI 10.1016/0092-8674(95)90281-3; Iwasaki Y, 2003, DEVELOPMENT, V130, P6027, DOI 10.1242/dev.00822; JOH T, 1992, CELL GROWTH DIFFER, V3, P315; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138; Kammerer M, 1999, CYTOGENET CELL GENET, V84, P43, DOI 10.1159/000015210; Kanemura Y, 1999, FEBS LETT, V442, P151, DOI 10.1016/S0014-5793(98)01650-0; Kim J, 2003, NEURON, V38, P17, DOI 10.1016/S0896-6273(03)00163-6; Kim JS, 1998, P NATL ACAD SCI USA, V95, P12364, DOI 10.1073/pnas.95.21.12364; Koblar SA, 1998, P NATL ACAD SCI USA, V95, P3178, DOI 10.1073/pnas.95.6.3178; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Makarov EM, 2002, SCIENCE, V298, P2205, DOI 10.1126/science.1077783; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mukobata Shigeki, 2000, Research Communications in Biochemistry and Cell and Molecular Biology, V4, P221; Nakashima K, 1999, J NEUROSCI, V19, P5429; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; SCHMIDT JW, 1992, J CELL BIOL, V116, P1019, DOI 10.1083/jcb.116.4.1019; Schreiber J, 2000, MOL CELL BIOL, V20, P2466, DOI 10.1128/MCB.20.7.2466-2474.2000; SHIMAZAKI T, 1993, EMBO J, V12, P4489, DOI 10.1002/j.1460-2075.1993.tb06138.x; Shimozaki K, 2003, DEVELOPMENT, V130, P2505, DOI 10.1242/dev.00476; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Song J, 2004, J BIOL CHEM, V279, P24414, DOI 10.1074/jbc.M311406200; Song MR, 2004, NAT NEUROSCI, V7, P229, DOI 10.1038/nn1192; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Sugiyama A, 2003, CARCINOGENESIS, V24, P1549, DOI 10.1093/carcin/bgg113; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Tang K, 2002, BIOCHEM BIOPH RES CO, V293, P167, DOI 10.1016/S0006-291X(02)00215-2; Teramoto S, 2005, ONCOL REP, V14, P1231; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; Vincent S, 1996, DEVELOPMENT, V122, P131; Viti J, 2003, J NEUROSCI, V23, P3385; WILLIAMS RK, 1985, J CELL BIOL, V101, P36, DOI 10.1083/jcb.101.1.36; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x	69	28	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7498	7514		10.1074/jbc.M510881200	http://dx.doi.org/10.1074/jbc.M510881200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16352598	hybrid			2022-12-27	WOS:000236030900072
J	Delettre, C; Yuste, VJ; Moubarak, RS; Bras, M; Lesbordes-Brion, JC; Petres, S; Bellalou, J; Susin, SA				Delettre, C; Yuste, VJ; Moubarak, RS; Bras, M; Lesbordes-Brion, JC; Petres, S; Bellalou, J; Susin, SA			AIFsh, a novel apoptosis-inducing factor (AIF) pro-apoptotic isoform with potential pathological relevance in human cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DNA-DEGRADATION; RELEASE; ACTIVATION; INDUCTION; CLEAVAGE; FRAGMENTATION; TRANSLOCATION; MITOCHONDRIA; DEFICIENCY	AIF is a main mediator of caspase-independent cell death. It is encoded by a single gene located on chromosome X, region q25 - 26 and A6 in humans and mice, respectively. Previous studies established that AIF codes for two isoforms of the protein, AIF and AIF-exB. Here, we identify a third AIF isoform resulting from an alternate transcriptional start site located at intron 9 of AIF. The resulting mRNA encodes a cytosolic protein that corresponds to the C-terminal domain of AIF ( amino acids 353 - 613). We named this new isoform AIFshort (AIFsh). AIFsh overexpression in HeLa cells results in nuclear translocation and caspase-independent cell death. Once in the nucleus, AIFsh provokes the same effects than AIF, namely chromatin condensation and large scale ( 50 kb) DNA fragmentation. In contrast, these apoptogenic effects are not precluded by the AIF-inhibiting protein Hsp70. These findings identify AIFsh as a new pro-apoptotic isoform of AIF, and also reveal that the first N-terminal 352 amino acids of AIF are not required for its apoptotic activity. In addition, we demonstrate that AIFsh is strongly down-regulated in tumor cells derived from kidney, vulva, skin, thyroid, and pancreas, whereas, gamma-irradiation treatment provokes AIFsh up-regulation. Overall, our results identify a novel member of the AIF-dependent pathway and shed new light on the role of caspase-independent cell death in tumor formation/suppression.	Inst Pasteur, CNRS, URA 1961, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Susin, SA (corresponding author), Inst Pasteur, CNRS, URA 1961, 25 Rue Dr Roux, F-75015 Paris, France.	susin@pasteur.fr	Yuste, Victor J./C-7071-2008; Susin, Santos A/Q-6754-2017; Delettre, Cécile/AAC-3096-2020	Yuste, Victor J./0000-0001-5322-9261; Susin, Santos A/0000-0002-3366-1628; Delettre, Cécile/0000-0003-3269-2155; petres, stephane/0000-0002-4716-565X; Moubarak, Rana/0000-0003-2096-1258				Blagosklonny MV, 2004, ONCOGENE, V23, P2967, DOI 10.1038/sj.onc.1207520; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Corbiere C, 2004, CELL RES, V14, P188, DOI 10.1038/sj.cr.7290219; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Furre IE, 2005, CANCER RES, V65, P11051, DOI 10.1158/0008-5472.CAN-05-0510; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Good PI, 2004, STAT MED, V23, P857, DOI 10.1002/sim.1738; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4; Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513; Jaattela M, 2002, ANN MED, V34, P480, DOI 10.1080/078538902321012423; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Landry JR, 2001, GENOMICS, V76, P110, DOI 10.1006/geno.2001.6604; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Liu T, 2004, ONCOGENE, V23, P39, DOI 10.1038/sj.onc.1206978; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lorenzo HK, 2004, FEBS LETT, V557, P14, DOI 10.1016/S0014-5793(03)01464-9; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Nomura M, 2004, J CELL PHYSIOL, V201, P374, DOI 10.1002/jcp.20090; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Park YC, 2005, LIFE SCI, V77, P2059, DOI 10.1016/j.lfs.2005.04.021; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schmitt E, 2003, CANCER RES, V63, P8233; Schultz DR, 2003, SEMIN ARTHRITIS RHEU, V32, P345, DOI 10.1053/sarh.2003.50005; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Urbano A, 2005, EMBO J, V24, P2815, DOI 10.1038/sj.emboj.7600746; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuste VJ, 2005, J BIOL CHEM, V280, P35670, DOI 10.1074/jbc.M504015200; Yuste VJ, 2005, CELL DEATH DIFFER, V12, P1445, DOI 10.1038/sj.cdd.4401687	51	68	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6413	6427		10.1074/jbc.M509884200	http://dx.doi.org/10.1074/jbc.M509884200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16365034	Green Submitted, hybrid			2022-12-27	WOS:000236030800035
J	Mohri, T; Fujio, Y; Maeda, M; Ito, T; Iwakura, T; Oshima, Y; Uozumi, Y; Segawa, M; Yamamoto, H; Kishimoto, T; Azuma, J				Mohri, T; Fujio, Y; Maeda, M; Ito, T; Iwakura, T; Oshima, Y; Uozumi, Y; Segawa, M; Yamamoto, H; Kishimoto, T; Azuma, J			Leukemia inhibitory factor induces endothelial differentiation in cardiac stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER; PROGENITOR CELLS; GROWTH-FACTOR; HEART-FAILURE; JAK-STAT; EXPRESSION; MYOCYTES; CARDIOMYOCYTES; ACTIVATION; GP130	The importance of interleukin 6 (IL-6)-related cytokines in cardiac homeostasis has been studied extensively; however, little is known about their biological significance in cardiac stem cells. Here we describe that leukemia inhibitory factor (LIF), a member of IL-6-related cytokines, activated STAT3 and ERK1/2 in cardiac Sca-1+ stem cells. LIF stimulation resulted in the induction of endothelial cell-specific genes, including VE-cadherin, Flk-1, and CD31, whereas neither smooth muscle nor cardiac muscle marker genes such as GATA4, GATA6, Nkx-2.5, and calponin were up-regulated. Immunocytochemical examination showed that about 25% of total cells were positively stained with anti-CD31 antibody 14 days after LIF stimulation. Immunofluorescent microscopic analyses identified the Sca-1+ cells that were also positively stained with anti-von Willebrand factor antibody, indicating the differentiating process of Sca-1+ cells into the endothelial cells. IL-6, which did not activate STAT3 and ERK1/2, failed to induce the differentiation of cardiac stem cells into the endothelial cells. In cardiac stem cells, the transduction with dominant negative STAT3 abrogated the LIF-induced endothelial differentiation. And the inhibition of ERK1/2 with the MEK1/2 inhibitor U0126 also prevented the differentiation of Sca-1+ cells into endothelial cells. Thus, both STAT3 and ERK1/2 are required for LIF-mediated endothelial differentiation in cardiac stem cells. Collectively, it is proposed that LIF regulates the commitment of cardiac stem cells into the endothelial cell lineage, contributing to neovascularization in the process of tissue remodeling and/or regeneration.	Osaka Univ, Dept Clin Evaluat Med & Therapeut, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Lab Immune Regulat, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Fujio, Y (corresponding author), Osaka Univ, Dept Clin Evaluat Med & Therapeut, 1-6 Yamadaoka, Osaka 5650871, Japan.	fujio@phs.osaka-u.ac.jp	Fujio, Yasushi/H-3421-2017; Kishimoto, Tadamitsu/C-8470-2009	Fujio, Yasushi/0000-0003-0828-2930; 				Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 2004, FEBS LETT, V573, P202, DOI 10.1016/j.febslet.2004.07.082; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Funamoto M, 2000, J MOL CELL CARDIOL, V32, P1275, DOI 10.1006/jmcc.2000.1161; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Gorski DH, 2000, CIRC RES, V87, P865, DOI 10.1161/01.RES.87.10.865; Hilfiker-Kleiner D, 2004, CIRC RES, V95, P187, DOI 10.1161/01.RES.0000134921.50377.61; Hishinuma S, 1999, BIOCHEM BIOPH RES CO, V264, P436, DOI 10.1006/bbrc.1999.1535; Jacoby JJ, 2003, P NATL ACAD SCI USA, V100, P12929, DOI 10.1073/pnas.2134694100; Jougasaki M, 2003, EUR J HEART FAIL, V5, P137, DOI 10.1016/S1388-9842(02)00236-2; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Kurdi M, 2005, MOL CELL BIOCHEM, V269, P95, DOI 10.1007/s11010-005-3085-1; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Oshima Y, 2005, CARDIOVASC RES, V65, P428, DOI 10.1016/j.cardiores.2004.10.021; Osugi T, 2002, J BIOL CHEM, V277, P6676, DOI 10.1074/jbc.M108246200; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; Podewski EK, 2003, CIRCULATION, V107, P798, DOI 10.1161/01.CIR.0000057545.82749.FF; Rossig L, 2005, J EXP MED, V201, P1825, DOI 10.1084/jem.20042097; Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162; Suganami E, 2004, DIABETES, V53, P2443, DOI 10.2337/diabetes.53.9.2443; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; WARE CB, 1995, DEVELOPMENT, V121, P1283; Zou YZ, 2003, CIRCULATION, V108, P748, DOI 10.1161/01.CIR.0000081773.76337.44	35	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6442	6447		10.1074/jbc.M508969200	http://dx.doi.org/10.1074/jbc.M508969200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407199	hybrid			2022-12-27	WOS:000236030800038
J	Xifro, X; Falluel-Morel, A; Minano, A; Aubert, N; Fado, R; Malagelada, C; Vaudry, D; Vaudry, H; Gonzalez, B; Rodriguez-Alvarez, J				Xifro, X; Falluel-Morel, A; Minano, A; Aubert, N; Fado, R; Malagelada, C; Vaudry, D; Vaudry, H; Gonzalez, B; Rodriguez-Alvarez, J			N-methyl-D-aspartate blocks activation of JNK and mitochondrial apoptotic pathway induced by potassium deprivation in cerebellar granule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; TERMINAL KINASE; CASPASE ACTIVATION; NEURON APOPTOSIS; BAX; JUN; DEATH; PROTEIN; PROMOTES; BCL-2	During the postnatal development of cerebellum, lack of excitatory innervation from the mossy fibers results in cerebellar granule cell (CGC) apoptosis during the migration of the cells toward the internal granule cell layer. Accordingly, CGCs die by apoptosis when cultured in physiological KCl concentrations (5 mM; K5), and they survive in the presence of depolarizing conditions such as high KCl concentration (25 mM; K25) or N-methyl-D-aspartate ( NMDA). We have recently shown that NMDA is able to exert a long lasting neuroprotective effect when added to immature ( 2 days in vitro) CGC cultures by inhibition of caspase-3 activity. Here we show that NMDA- and K25-mediated neuroprotection is associated with an increase in the levels of Bcl-2, an inhibition of K5-mediated increase in Bax, and the inhibition of the release of apoptogenic factors from mitochondria such as Smac/DIABLO and cytochrome c. Moreover, we have shown that similar effects are observed when c-Jun N-terminal kinases (JNKs) are inhibited and that treatment of CGC cultures with NMDA blocks K5-mediated JNK activation. These results allow us to postulate that the inhibition of JNK-mediated release of apoptogenic factors from mitochondria is involved in the NMDA protection from K5-mediated apoptosis of CGCs.	Univ Autonoma Barcelona, Inst Neurociencies, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Rouen, European Inst Peptide Res IFRMP 23, Lab Cellular & Mol Neuroendocrinol, CNRS,UA,INSERM,U413, F-76821 Mont St Aignan, France	Autonomous University of Barcelona; Autonomous University of Barcelona; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Rodriguez-Alvarez, J (corresponding author), Univ Autonoma Barcelona, Inst Neurociencies, Edifici M,Campus Bellaterra, E-08193 Barcelona, Spain.	jose.rodriguez@uab.es	Miñano-Molina, Alfredo J/C-9863-2011; Malagelada, Cristina/A-6101-2012; Malagelada, Cristina/X-6065-2019; Xifro, Xavier/ABH-2365-2020; Gonzalez, Bruno/E-6103-2016; Andrés, Fadó Fadó/L-8585-2014; VAUDRY, David/M-1454-2018; Rodriguez-Alvarez, Jose/F-8403-2011	Miñano-Molina, Alfredo J/0000-0002-7761-5682; Malagelada, Cristina/0000-0001-7185-436X; Malagelada, Cristina/0000-0001-7185-436X; Xifro, Xavier/0000-0002-7417-9475; Gonzalez, Bruno/0000-0002-7176-1320; Andrés, Fadó Fadó/0000-0002-3293-2342; VAUDRY, David/0000-0003-3567-7452; Rodriguez-Alvarez, Jose/0000-0001-8582-8082; Anthony, FALLUEL-MOREL/0000-0002-4081-6704				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Alavez S, 2003, NEUROCHEM INT, V43, P581, DOI 10.1016/S0197-0186(03)00079-2; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BALAZS R, 1988, NEUROSCIENCE, V27, P437, DOI 10.1016/0306-4522(88)90279-5; BALAZS R, 1988, DEV BRAIN RES, V40, P269, DOI 10.1016/0165-3806(88)90139-3; BURGOYNE RD, 1993, J NEUROCYTOL, V22, P689, DOI 10.1007/BF01181314; Caballero-Benitez A, 2003, J NEUROSCI RES, V71, P383, DOI 10.1002/jnr.10493; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Coffey ET, 2002, J NEUROSCI, V22, P4335, DOI 10.1523/JNEUROSCI.22-11-04335.2002; Coffey ET, 2000, J NEUROSCI, V20, P7602; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fonfria E, 2002, EUR J NEUROSCI, V16, P2013, DOI 10.1046/j.1460-9568.2002.02269.x; GALLO V, 1987, J NEUROSCI, V7, P2203; Gerhardt E, 2001, MOL CELL NEUROSCI, V17, P717, DOI 10.1006/mcne.2001.0962; Harris C, 2002, J NEUROCHEM, V83, P992, DOI 10.1046/j.1471-4159.2002.01219.x; Harris CA, 2001, J BIOL CHEM, V276, P37754; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Ikemoto H, 2000, CELL DEATH DIFFER, V7, P511, DOI 10.1038/sj.cdd.4400682; Inamura N, 2001, BRAIN RES, V904, P270, DOI 10.1016/S0006-8993(01)02472-6; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Miller TM, 1996, J NEUROSCI, V16, P7487; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MORAN J, 1989, BRAIN RES, V486, P15, DOI 10.1016/0006-8993(89)91272-9; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wadia JS, 1998, J NEUROSCI, V18, P932; Watson A, 1998, J NEUROSCI, V18, P751; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wigdal SS, 2002, J NEUROCHEM, V82, P1029, DOI 10.1046/j.1471-4159.2002.01049.x; WILLIAMS RW, 1988, ANNU REV NEUROSCI, V11, P423, DOI 10.1146/annurev.neuro.11.1.423; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xifro X, 2005, EUR J NEUROSCI, V21, P827, DOI 10.1111/j.1460-9568.2005.03935.x; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	48	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6801	6812		10.1074/jbc.M504571200	http://dx.doi.org/10.1074/jbc.M504571200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16380382	hybrid			2022-12-27	WOS:000236030800079
J	Garcia-Manyes, S; Bucior, I; Ros, R; Anselmetti, D; Sanz, F; Burger, MM; Fernandez-Busquets, X				Garcia-Manyes, S; Bucior, I; Ros, R; Anselmetti, D; Sanz, F; Burger, MM; Fernandez-Busquets, X			Proteoglycan mechanics studied by single-molecule force spectroscopy of allotypic cell adhesion glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE MICROCIONA-PROLIFERA; HEPARAN-SULFATE PROTEOGLYCANS; CARBOHYDRATE-CARBOHYDRATE INTERACTIONS; MARINE SPONGE; AGGREGATION FACTOR; CIRCULAR PROTEOGLYCANS; EXTRACELLULAR-MATRIX; SELF-RECOGNITION; MICROSCOPY; BINDING	Early Metazoans had to evolve the first cell adhesion system addressed to maintaining stable interactions between cells constituting different individuals. As the oldest extant multicellular animals, sponges are good candidates to have remnants of the molecules responsible for that crucial innovation. Sponge cells associate in a species-specific process through multivalent calcium-dependent interactions of carbohydrate structures on an extracellular membrane-bound proteoglycan termed aggregation factor. Single-molecule force spectroscopy studies of the mechanics of aggregation factor self-binding indicate the existence of intermolecular carbohydrate adhesion domains. A 200-kDa aggregation factor glycan (g200) involved in cell adhesion exhibits interindividual differences in size and epitope content which suggest the existence of allelic variants. We have purified two of these g200 distinct forms from two individuals of the same sponge species. Comparison of allotypic versus isotypic g200 binding forces reveals significant differences. Surface plasmon resonance measurements show that g200 self-adhesion is much stronger than its binding to other unrelated glycans such as chondroitin sulfate. This adhesive specificity through multiple carbohydrate binding domains is a type of cooperative interaction that can contribute to explain some functions of modular proteoglycans in general. From our results it can be deduced that the binding strength/surface area between two aggregation factor molecules is comparable with that of focal contacts in vertebrate cells, indicating that strong carbohydrate-based cell adhesions evolved at the very start of Metazoan history.	Univ Barcelona, Res Ctr Bioelect & Nanobiosci, E-08028 Barcelona, Spain; Univ Barcelona, Dept Quim Fis, E-08028 Barcelona, Spain; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Bielefeld, Dept Expt Biophys & Appl Nanosci, Fac Phys, D-33615 Bielefeld, Germany	University of Barcelona; University of Barcelona; Friedrich Miescher Institute for Biomedical Research; Marine Biological Laboratory - Woods Hole; University of Bielefeld	Fernandez-Busquets, X (corresponding author), Univ Barcelona, Res Ctr Bioelect & Nanobiosci, Barcelona Sci Pk,Josep Samitier 1-5, E-08028 Barcelona, Spain.	xfernandez_busquets@ub.edu	Fernàndez-Busquets, Xavier/K-1323-2014; Ros, Robert/G-2154-2012; Ros, Robert/X-3030-2019; Anselmetti, Dario/F-1664-2011	Fernàndez-Busquets, Xavier/0000-0002-4622-9631; Ros, Robert/0000-0001-9271-4091; Anselmetti, Dario/0000-0002-8720-4369; Garcia-Manyes, Sergi/0000-0001-5140-2606				Abu-Lail NI, 2003, J MICROSC-OXFORD, V212, P217, DOI 10.1111/j.1365-2818.2003.01261.x; ALBERTS B, 1989, MOL BIOL CELL, P805; Benoit M, 2000, NAT CELL BIOL, V2, P313, DOI 10.1038/35014000; Bershadsky AD, 2003, ANNU REV CELL DEV BI, V19, P677, DOI 10.1146/annurev.cellbio.19.111301.153011; Blackhall FH, 2001, BRIT J CANCER, V85, P1094, DOI 10.1054/bjoc.2001.2054; Bucior I, 2004, GLYCOCONJUGATE J, V21, P111, DOI 10.1023/B:GLYC.0000044843.72595.7d; Bucior I, 2004, CURR OPIN STRUC BIOL, V14, P631, DOI 10.1016/j.sbi.2004.08.006; Bucior I, 2004, J CELL BIOL, V165, P529, DOI 10.1083/jcb.200309005; Carrion-Vazquez M, 2000, PROG BIOPHYS MOL BIO, V74, P63, DOI 10.1016/S0079-6107(00)00017-1; CASSARO CMF, 1977, J BIOL CHEM, V252, P2254; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; De Cat B, 2001, SEMIN CELL DEV BIOL, V12, P117, DOI 10.1006/scdb.2000.0240; de la Fuente JM, 2004, GLYCOCONJUGATE J, V21, P149, DOI 10.1023/B:GLYC.0000044846.80014.cb; Dicko A, 2003, BBA-BIOMEMBRANES, V1613, P87, DOI 10.1016/S0005-2736(03)00141-X; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; EGGENS I, 1989, J BIOL CHEM, V264, P9476; Fernandez-Busquets X, 2003, CELL MOL LIFE SCI, V60, P88, DOI 10.1007/s000180300006; Fernandez-Busquets X, 1999, MICROSC RES TECHNIQ, V44, P204, DOI 10.1002/(SICI)1097-0029(19990215)44:4<204::AID-JEMT2>3.0.CO;2-I; Fernandez-Busquets X, 2002, DEV COMP IMMUNOL, V26, P313, DOI 10.1016/S0145-305X(01)00079-9; Fernandez-Busquets X, 1998, J BIOL CHEM, V273, P29545, DOI 10.1074/jbc.273.45.29545; FernandezBusquets X, 1997, J BIOL CHEM, V272, P27839, DOI 10.1074/jbc.272.44.27839; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Fritz J, 1997, J STRUCT BIOL, V119, P165, DOI 10.1006/jsbi.1997.3887; Grandbois M, 1999, SCIENCE, V283, P1727, DOI 10.1126/science.283.5408.1727; Guerardel Y, 2004, J BIOL CHEM, V279, P15591, DOI 10.1074/jbc.M308928200; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Haseley SR, 2001, P NATL ACAD SCI USA, V98, P9419, DOI 10.1073/pnas.151111298; HEGNER M, 1993, SURF SCI, V291, P39, DOI 10.1016/0039-6028(93)91474-4; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; HUMPHREYS S, 1977, J SUPRAMOL STR CELL, V7, P339, DOI 10.1002/jss.400070307; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; Jarchow J, 2000, J STRUCT BIOL, V132, P95, DOI 10.1006/jsbi.2000.4309; Jarchow J, 1998, CELL ADHES COMMUN, V6, P405, DOI 10.3109/15419069809109149; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; KUHNS WJ, 1995, J CELL BIOCHEM, V57, P71, DOI 10.1002/jcb.240570109; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1987, J BIOL CHEM, V262, P5870; Misevic GN, 2004, J BIOL CHEM, V279, P15579, DOI 10.1074/jbc.M308927200; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; Muller WEG, 2003, INTEGR COMP BIOL, V43, P281, DOI 10.1093/icb/43.2.281; Oberhauser AF, 2002, J MOL BIOL, V319, P433, DOI 10.1016/S0022-2836(02)00306-6; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; *PHARM BIOS AB, 1994, BIAAPPLICATIONS HDB; Pincet F, 2001, BIOPHYS J, V80, P1354, DOI 10.1016/S0006-3495(01)76108-5; Popescu O, 1997, NATURE, V386, P231, DOI 10.1038/386231b0; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Rauch U, 2001, CELL MOL LIFE SCI, V58, P1842, DOI 10.1007/PL00000822; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Roseman S, 2001, J BIOL CHEM, V276, P41527, DOI 10.1074/jbc.R100053200; Sanderson RD, 2001, SEMIN CELL DEV BIOL, V12, P89, DOI 10.1006/scdb.2000.0241; Schwartz NB, 2000, FRONT BIOSCI, V5, pD649; Selleck SB, 2001, SEMIN CELL DEV BIOL, V12, P127, DOI 10.1006/scdb.2000.0242; Seog J, 2002, MACROMOLECULES, V35, P5601, DOI 10.1021/ma0121621; Smith BL, 1999, NATURE, V399, P761, DOI 10.1038/21607; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; Spillmann D., 2000, CARBOHYDRATES CHEM B, P1061; Tan JL, 2003, P NATL ACAD SCI USA, V100, P1484, DOI 10.1073/pnas.0235407100; Tromas C, 2001, ANGEW CHEM INT EDIT, V40, P3052, DOI 10.1002/1521-3773(20010817)40:16<3052::AID-ANIE3052>3.0.CO;2-Q; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Yamaguchi Y, 2001, SEMIN CELL DEV BIOL, V12, P99, DOI 10.1006/scdb.2000.0238; Zhang XH, 2002, BIOPHYS J, V83, P2270, DOI 10.1016/S0006-3495(02)73987-8	64	30	30	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5992	5999		10.1074/jbc.M507878200	http://dx.doi.org/10.1074/jbc.M507878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373355	Green Published, hybrid			2022-12-27	WOS:000235568900080
J	Wang, B; Sun, JS; Kitamoto, S; Yang, M; Grubb, A; Chapman, HA; Kalluri, R; Shi, GP				Wang, B; Sun, JS; Kitamoto, S; Yang, M; Grubb, A; Chapman, HA; Kalluri, R; Shi, GP			Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMININ-5 GAMMA-2 CHAIN; ENDOTHELIAL-CELL PROLIFERATION; FACTOR-BETA; CYSTATIN-C; GENETIC-HETEROGENEITY; CYSTEINE PROTEASES; CANCER-CELLS; INTEGRIN; COLLAGEN; PROTEOLYSIS	The cysteine protease cathepsin S is highly expressed in malignant tissues. By using a mouse model of multistage murine pancreatic islet cell carcinogenesis in which cysteine cathepsin activity has been functionally implicated, we demonstrated that selective cathepsin S deficiency impaired angiogenesis and tumor cell proliferation, thereby impairing angiogenic islet formation and the growth of solid tumors, whereas the absence of its endogenous inhibitor cystatin C resulted in opposite phenotypes. Although mitogenic vascular endothelial growth factor, transforming growth factor-beta 1, and the anti-angiogenic endostatin levels in either serum or carcinoma tissue extracts did not change in cathepsin S- or cystatin C-null mice, tumor tissue basic fibroblast growth factor and serum type 1 insulin growth factor levels were higher in cystatin C-null mice, and serum type 1 insulin growth factor levels were also increased in cathepsin S-null mice. Furthermore, cathepsin S affected the production of type IV collagen-derived anti-angiogenic peptides and the generation of bioactive pro-angiogenic gamma 2 fragments from laminin-5, revealing a functional role for cathepsin S in angiogenesis and neoplastic progression.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; So Med Univ, Dept Nephrol, Nanfang Hosp, Guangzhou 510515, Peoples R China; Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Beth Israel Deaconess Med Ctr, Ctr Matrix Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Southern Medical University - China; Lund University; Skane University Hospital; University of California System; University of California San Francisco; Harvard University; Beth Israel Deaconess Medical Center	Shi, GP (corresponding author), NRB-7,77 Ave Louis Pasteur, Boston, MA 02115 USA.	gshi@rics.bwh.harvard.edu	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Grubb, Anders/0000-0002-0125-3662	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067283, R01HL060942] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48621, HL 60942, HL 67283] Funding Source: Medline; NIDDK NIH HHS [DK 62987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Buczek-Thomas JA, 2004, AM J RESP CELL MOL, V31, P344, DOI 10.1165/rcmb.2003-0420OC; Colorado PC, 2000, CANCER RES, V60, P2520; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fowlkes JL, 2002, CYTOKINE GROWTH F R, V13, P277, DOI 10.1016/S1359-6101(02)00005-9; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Gonzales M, 1999, MOL BIOL CELL, V10, P259, DOI 10.1091/mbc.10.2.259; Guo M, 2002, J BIOL CHEM, V277, P14829, DOI 10.1074/jbc.M108180200; Hall A, 1998, BIOCHEMISTRY-US, V37, P4071, DOI 10.1021/bi971197j; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; He GA, 2003, BIOCHEM BIOPH RES CO, V312, P801, DOI 10.1016/j.bbrc.2003.11.003; Hershberg RM, 1997, J CLIN INVEST, V100, P204, DOI 10.1172/JCI119514; Jedeszko C, 2004, BIOL CHEM, V385, P1017, DOI 10.1515/BC.2004.132; Joyce JA, 2004, CANCER CELL, V5, P443, DOI 10.1016/S1535-6108(04)00111-4; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Koshikawa N, 2003, FASEB J, V17, P364, DOI 10.1096/fj.03-0584fje; Lakka SS, 2004, ONCOGENE, V23, P4681, DOI 10.1038/sj.onc.1207616; Lee CY, 1996, ENDOCRINOLOGY, V137, P2051, DOI 10.1210/en.137.5.2051; Lin HC, 2001, INVEST OPHTH VIS SCI, V42, P2517; LIU J, 2006, IN PRESS ATHEROSCLER; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760; Martineau I, 2004, BIOMATERIALS, V25, P4489, DOI 10.1016/j.biomaterials.2003.11.013; Meara JP, 1996, J MED CHEM, V39, P3357, DOI 10.1021/jm950445b; Mook ORF, 2004, BBA-REV CANCER, V1705, P69, DOI 10.1016/j.bbcan.2004.09.006; Pasco S, 2004, EXP CELL RES, V301, P251, DOI 10.1016/j.yexcr.2004.07.036; Pepper MS, 2001, THROMB HAEMOSTASIS, V86, P346; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Sasaki T, 2001, J MOL BIOL, V314, P751, DOI 10.1006/jmbi.2001.5176; Seftor REB, 2001, CANCER RES, V61, P6322; Shaked Y, 2005, CANCER CELL, V7, P101, DOI 10.1016/j.ccr.2004.11.023; Shi GP, 2000, J EXP MED, V191, P1177, DOI 10.1084/jem.191.7.1177; Shi GP, 2003, CIRC RES, V92, P493, DOI 10.1161/01.RES.0000060485.20318.96; Siler U, 2002, BRIT J HAEMATOL, V119, P212, DOI 10.1046/j.1365-2141.2002.03800.x; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; Sokol JP, 2005, BREAST CANCER RES, V7, pR844, DOI 10.1186/bcr1312; Sokol JP, 2004, MOL CANCER RES, V2, P183; Somanna A, 2002, J BIOL CHEM, V277, P25305, DOI 10.1074/jbc.M203034200; Sukhova GK, 2005, CIRC RES, V96, P368, DOI 10.1161/01.RES.0000155964.34150.F7; Vigneswaran N, 2005, INT J ONCOL, V26, P103; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Wen W, 1999, CANCER RES, V59, P6052; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; Yanamandra N, 2004, ONCOGENE, V23, P2224, DOI 10.1038/sj.onc.1207338; Zent R, 2001, DEV BIOL, V238, P289, DOI 10.1006/dbio.2001.0391	56	209	233	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6020	6029		10.1074/jbc.M509134200	http://dx.doi.org/10.1074/jbc.M509134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16365041	Green Published, hybrid			2022-12-27	WOS:000235568900083
J	Edwin, F; Singh, R; Endersby, R; Baker, SJ; Patel, TB				Edwin, F; Singh, R; Endersby, R; Baker, SJ; Patel, TB			The tumor suppressor PTEN is necessary for human sprouty 2-mediated inhibition of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE-ACTIVITY; DROSOPHILA-SPROUTY; KINASE PATHWAY; C-TERMINUS; GROWTH; ACTIVATION; PROTEIN; MIGRATION; PHOSPHORYLATION; ARREST	Sprouty family proteins are novel regulators of growth factor actions. Human Sprouty 2 (hSPRY2) inhibits the proliferation of a number of different cell types. However, the mechanisms involved in the anti-proliferative actions of hSPRY2 remain to be elucidated. Here we have demonstrated that hSPRY2 increases the amount of the tumor suppressor phosphatase and tensin homolog deleted on chromosome 10 ( PTEN) and decreases its phosphorylation. The resultant increase in PTEN activity is reflected in decreased activation of Akt by epidermal growth factor and serum. Consistent with increased PTEN activity, in hSPRY2-expressing cells, the progression of cells from the G(1) to S phase is decreased. By using PTEN null primary mouse embryonic fibroblasts and their isogenic controls as well as small interfering RNA against PTEN, we demonstrated that PTEN is necessary for hSPRY2 to inhibit Akt activation by epidermal growth factor as well as cell proliferation. Overall, we concluded that hSPRY2 mediates its anti-proliferative actions by altering PTEN content and activity.	Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA	Loyola University Chicago; St Jude Children's Research Hospital	Patel, TB (corresponding author), Loyola Univ, Stritch Sch Med, Dept Pharmacol & Expt Therapeut, 2160 S 1st Ave, Maywood, IL 60153 USA.	tpatel7@lumc.edu	Endersby, Raelene/A-2969-2013; Baker, Suzanne J/N-8167-2018	Endersby, Raelene/0000-0003-3554-2769; 	NCI NIH HHS [CA096832] Funding Source: Medline; NHLBI NIH HHS [HL59679] Funding Source: Medline; NIGMS NIH HHS [GM073181] Funding Source: Medline; NINDS NIH HHS [NS44172] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA096832] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044172] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Furnari FB, 1998, CANCER RES, V58, P5002; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee SH, 2001, J BIOL CHEM, V276, P4128, DOI 10.1074/jbc.M006922200; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lim MA, 2004, ONCOGENE, V23, P9348, DOI 10.1038/sj.onc.1208147; Lo TL, 2004, CANCER RES, V64, P6127, DOI 10.1158/0008-5472.CAN-04-1207; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Minowada G, 1999, DEVELOPMENT, V126, P4465; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012-1606(03)00106-4; Poppleton HM, 2004, BIOCHEM BIOPH RES CO, V323, P98, DOI 10.1016/j.bbrc.2004.08.070; Reich A, 1999, DEVELOPMENT, V126, P4139; Rozen S, 2000, Methods Mol Biol, V132, P365; Rubin C, 2003, CURR BIOL, V13, P297, DOI 10.1016/S0960-9822(03)00053-8; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Taketomi T, 2005, NAT NEUROSCI, V8, P855, DOI 10.1038/nn1485; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Valiente M, 2005, J BIOL CHEM, V280, P28936, DOI 10.1074/jbc.M504761200; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Weng LP, 1999, CANCER RES, V59, P5808; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Wong ESM, 2001, J BIOL CHEM, V276, P5866, DOI 10.1074/jbc.M006945200; Yigzaw Y, 2003, J BIOL CHEM, V278, P284, DOI 10.1074/jbc.M210359200; Yigzaw Y, 2001, J BIOL CHEM, V276, P22742, DOI 10.1074/jbc.M100123200; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200; Zhang CX, 2005, ARTERIOSCL THROM VAS, V25, P533, DOI 10.1161/01.ATV.0000155461.50450.5a	49	84	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4816	4822		10.1074/jbc.M508300200	http://dx.doi.org/10.1074/jbc.M508300200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371366	hybrid			2022-12-27	WOS:000235426200032
J	Ishii, S; Yano, T; Hayashi, H				Ishii, S; Yano, T; Hayashi, H			Expression and characterization of the peptidase domain of Streptococcus pneumoniae ComA, a bifunctional ATP-binding cassette transporter involved in quorum sensing pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; GENETIC-TRANSFORMATION; BACTERIA; ENDOPEPTIDASE; FAMILY	ComA, a member of the bacteriocin ATP-binding cassette transporters, is postulated to be responsible for both the processing of the propeptide ComC and secretion of the mature competence-stimulating peptide, which regulates the competence and subsequent genetic transformation in Streptococcus pneumoniae. A recombinant N-terminal peptidase domain of ComA, designated PEP, was expressed as a soluble protein in Escherichia coli, purified to homogeneity, and characterized. Gel-filtration analysis revealed that PEP functions as a monomer. The purified PEP exhibited an efficient proteolytic activity for the substrate ComC, which was cleaved after the double glycine site. The stability of PEP was examined by circular dichroism analyses. A convenient method for analyzing the proteolytic activity of PEP was developed, and the kinetic parameters for ComC were determined (k(cat) = 1.5 +/- 0.083 min(-1) and K-m = 62 +/- 9.0 mu M). Replacements of Cys(17) of PEP with Ser or Ala and His(96) with Ala resulted in complete loss of activity, indicating that both Cys(17) and His(96) are essential for the catalysis. Together with information from a protease data base, the N-terminal domain of ComA was concluded to belong to the same clan as the papain-like cysteine proteases. Mutant substrates, in which each of the double glycines was replaced with Ala, were cleaved very poorly by PEP. The mechanism of this strict substrate specificity is discussed on the basis of the sequence alignment with other cysteine proteases.	Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan	Osaka Medical College	Hayashi, H (corresponding author), Osaka Med Coll, Dept Biochem, 2-7 Daigakumachi, Osaka 5698686, Japan.	hayashi@art.osaka-med.ac.jp						Cvitkovitch DG, 2003, J CLIN INVEST, V112, P1626, DOI 10.1172/JCI200320430; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Gabrilovac J, 2004, IMMUNOL LETT, V91, P39, DOI 10.1016/j.imlet.2003.10.006; Guarne A, 1998, EMBO J, V17, P7469, DOI 10.1093/emboj/17.24.7469; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HAVARSTEIN LS, 1995, P NATL ACAD SCI USA, V92, P11140, DOI 10.1073/pnas.92.24.11140; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kleerebezem M, 2001, PEPTIDES, V22, P1579, DOI 10.1016/S0196-9781(01)00493-4; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; Lazazzera BA, 2000, CURR OPIN MICROBIOL, V3, P177, DOI 10.1016/S1369-5274(00)00072-2; Luo P, 2004, MOL MICROBIOL, V54, P172, DOI 10.1111/j.1365-2958.2004.04254.x; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; OHARA BP, 1995, BIOCHEMISTRY-US, V34, P13190, DOI 10.1021/bi00040a034; Rawlings ND, 1999, NUCLEIC ACIDS RES, V27, P325, DOI 10.1093/nar/27.1.325; Umetsu H, 2004, BIOSCI BIOTECH BIOCH, V68, P945, DOI 10.1271/bbb.68.945; Woessner JF, 2004, HDB PROTEOLYTIC ENZY; Wu KH, 2004, J BIOL CHEM, V279, P901, DOI 10.1074/jbc.M308296200; ZOLLER H, 1993, HDB ENZYME INHIBITOR	19	31	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4726	4731		10.1074/jbc.M512516200	http://dx.doi.org/10.1074/jbc.M512516200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377622	hybrid			2022-12-27	WOS:000235426200021
J	Kreft, SG; Wang, L; Hochstrasser, M				Kreft, SG; Wang, L; Hochstrasser, M			Membrane topology of the yeast endoplasmic reticulum-localized ubiquitin ligase Doa10 and comparison with its human ortholog TEB4 (MARCH-VI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; PROTEIN-QUALITY CONTROL; HIDDEN MARKOV MODEL; I HEAVY-CHAINS; SACCHAROMYCES-CEREVISIAE; PREDICTION; DOMAIN; MEMBER	Quality control machinery in the endoplasmic reticulum (ER) helps ensure that only properly folded and assembled proteins accumulate in the ER or continue along the secretory pathway. Aberrant proteins are retrotranslocated to the cytosol and degraded by the proteasome, a process called ER-associated degradation. Doa10, a transmembrane protein of the ER/nuclear envelope, is one of the primary ubiquitin ligases (E3s) participating in ER-associated degradation in Saccharomyces cerevisiae. Here we report the membrane organization of the 1319-residue Doa10 polypeptide. The topology was determined by fusing a dual-topology reporter after 16 different Doa10 fragments. Our results indicate that Doa10 contains 14 transmembrane helices (TMs). Based on protease digestion of yeast microsomes, both the N-terminal RING-CH domain and the Cterminus face the cytosol. Notably, the experimentally derived topology was not predicted correctly by any of the generally available TM prediction algorithms. Bioinformatic analysis and in silico mutagenesis guided the topological studies through problematic regions. The conserved TD domain in Doa10 includes three TMs. These TMs might function in cofactor binding or substrate recognition, or they might be part of a retrotranslocation channel. The Derlins were previously proposed to provide such channels, but we show that the two yeast Derlins are not required for degradation of Doa10 membrane substrates, as was found before for the Sec61 translocon. Finally, we provide evidence that the likely human Doa10 ortholog, TEB4 (MARCH-VI), adopts a topology similar to that of Doa10.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Hochstrasser, M (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	mark.hochstrasser@yale.edu		Hochstrasser, Mark/0000-0002-1131-5484	NIGMS NIH HHS [GM46904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046904, R01GM046904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartee E, 2004, J VIROL, V78, P1109, DOI 10.1128/JVI.78.3.1109-1120.2004; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Dodd RB, 2004, J BIOL CHEM, V279, P53840, DOI 10.1074/jbc.M409662200; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; Hassink G, 2005, BIOCHEM J, V388, P647, DOI 10.1042/BJ20041241; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hitt R, 2004, FEMS YEAST RES, V4, P721, DOI 10.1016/j.femsyr.2004.02.003; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huyer G, 2004, J BIOL CHEM, V279, P38369, DOI 10.1074/jbc.M402468200; Kahsay RY, 2005, BIOINFORMATICS, V21, P1853, DOI 10.1093/bioinformatics/bti303; Kall L, 2005, BIOINFORMATICS, V21, pI251, DOI 10.1093/bioinformatics/bti1014; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RAVID T, 2006, IN PRESS EMBO J, V25; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Sengstag C, 2000, METHOD ENZYMOL, V327, P175, DOI 10.1016/S0076-6879(00)27275-3; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; Strahl-Bolsinger S, 1999, J BIOL CHEM, V274, P9068, DOI 10.1074/jbc.274.13.9068; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Vashist S, 2004, J CELL BIOL, V165, P41, DOI 10.1083/jcb.200309132; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; Wang QQ, 2003, EMBO J, V22, P3792, DOI 10.1093/emboj/cdg378; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656	36	112	115	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4646	4653		10.1074/jbc.M512215200	http://dx.doi.org/10.1074/jbc.M512215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373356	hybrid, Green Submitted			2022-12-27	WOS:000235426200012
J	Yamamura, Y; Lee, WL; Inoue, K; Ida, H; Ito, Y				Yamamura, Y; Lee, WL; Inoue, K; Ida, H; Ito, Y			RUNX3 cooperates with FoxO3a to induce apoptosis in gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; BCL-2 FAMILY-MEMBER; FUNCTIONAL COOPERATION; OXIDATIVE STRESS; BIM; EXPRESSION; GROWTH; GENE; PROTEINS; PROMOTER	The transcription factor RUNX3, which mediates apoptosis and cell growth inhibition in gastric epithelial cells, is a candidate tumor suppressor that is frequently lost in gastric cancer cells. Here, we found that restoration of RUNX3 expression in the cell line not expressing RUNX3 induced apoptosis and that it physically interacted with the Forkhead transcription factor FoxO3a/FKHRL1, known to be an important regulator of apoptosis and the cell cycle. Active unphosphorylated FoxO3a/FKHRL1 was expressed in the gastric cancer cell lines. RUNX3-induced apoptosis depended on the expression of Bim, a proapoptotic BH3-only protein, and both RUNX3 and FoxO3a/FKHRL1 were required for induction of Bim expression. Furthermore, we showed that interaction of RUNX3 and FoxO3a/FKHRL1 was also indispensable for Bim expression and apoptosis in mouse embryonic fibroblasts. In the Bim promoter, RUNX3 bound to two conserved RUNX-binding elements (RBE1 and RBE2), with RBE1 being immediately downstream of a FoxO-binding element. The physical interaction of RUNX3 and FoxO3a/FKHRL1 on the Bim promoter activated transcription of Bim. These findings show that RUNX3 cooperates with FoxO3a/FKHRL1 to participate in the induction of apoptosis by activating Bim and may play an important role in tumor suppression in gastric cancer.	Natl Univ Singapore, Natl Univ Med Inst, Oncol Res Inst, Clin Res Ctr, Singapore 117592, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117592, Singapore; Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117592, Singapore	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore	Ito, Y (corresponding author), Natl Univ Singapore, Natl Univ Med Inst, Oncol Res Inst, Clin Res Ctr, Block MD11,Level 5,10 Med Dr, Singapore 117592, Singapore.	itoy@imcb.a-star.edu.sg						Abrams MT, 2004, J BIOL CHEM, V279, P55809, DOI 10.1074/jbc.M411767200; Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Barnes GL, 2003, CANCER RES, V63, P2631; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Kim SG, 2001, ONCOGENE, V20, P1254, DOI 10.1038/sj.onc.1204203; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Oki E, 2005, INT J CANCER, V117, P376, DOI 10.1002/ijc.21170; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Rini D, 2001, GENE, V273, P13, DOI 10.1016/S0378-1119(01)00579-0; Sato T, 2005, IMMUNITY, V22, P317, DOI 10.1016/j.immuni.2005.01.012; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi MJ, 1998, J IMMUNOL, V161, P6751; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Viard-Leveugle I, 2003, J BIOL CHEM, V278, P16183, DOI 10.1074/jbc.M212188200; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200	44	111	123	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5267	5276		10.1074/jbc.M512151200	http://dx.doi.org/10.1074/jbc.M512151200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373335	hybrid			2022-12-27	WOS:000235426200081
J	Huo, JS; McEachin, RC; Cui, TX; Duggal, NK; Hai, T; States, DJ; Schwartz, J				Huo, JS; McEachin, RC; Cui, TX; Duggal, NK; Hai, T; States, DJ; Schwartz, J			Profiles of growth hormone (GH)-regulated genes reveal time-dependent responses and identify a mechanism for regulation of activating transcription factor 3 by GH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN-BETA; INSULIN-RECEPTOR SUBSTRATE-1; TERNARY COMPLEX FACTORS; RAT ADIPOSE-TISSUE; C-FOS; FACTOR-I; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; P85-ALPHA SUBUNIT; MESSENGER-RNA	In examination of mechanisms regulating metabolic responses to growth hormone (GH), microarray analysis identified 561 probe sets showing time-dependent patterns of expression in GH-treated 3T3-F442A adipocytes. Biological functions significantly over-represented among GH-regulated genes include regulators of transcription at early times, and lipid biosynthesis, cholesterol biosynthesis, and mediators of immune responses at later times ( 48 h). One novel GH-induced gene encodes activating transcription factor 3 (ATF3). Atf3 mRNA expression and promoter activity were stimulated by GH. Genes for ATF3 and growth arrest and DNA damage-inducible gene 45 gamma (GADD45 gamma) showed similar time-dependent patterns of responses to GH, suggesting similar regulatory mechanisms. A conserved sequence in the promoters of the Atf3 and Gadd45 gamma genes contains a CCAAT/enhancer-binding protein (C/EBP) site previously observed in the Gadd45 gamma promoter, suggesting a novel corresponding C/EBP site in the Atf3 promoter. C/EBP beta was found to bind to the predicted Atf3 C/EBP site, and C/EBP beta enhanced the activation of the wild-type Atf3 promoter. Mutation of the predicted Atf3 C/EBP site disrupted Atf3 promoter activation not only by C/EBP beta but also by GH. These findings suggest that GH regulates transcription of Atf3 through a mechanism utilizing factors, such as C/EBP beta, which bind to a novel C/EBP site.	Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Bioinformat Program, Ann Arbor, MI 48109 USA; Univ Michigan, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University System of Ohio; Ohio State University	Schwartz, J (corresponding author), Univ Michigan, Dept Mol & Integrat Physiol, 6815 Med Sci 2,1301 Catherine St, Ann Arbor, MI 48109 USA.	jeschwar@umich.edu	Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315; Huo, Jeffrey/0000-0002-0057-9118	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046072, R01DK059605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007315] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM008106] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58771, DK59605, DK46072] Funding Source: Medline; NIGMS NIH HHS [T32-GM07315] Funding Source: Medline; NLM NIH HHS [LM008106] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Allen-Jennings AE, 2002, J BIOL CHEM, V277, P20020, DOI 10.1074/jbc.M200727200; Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Assa-Kunik E, 2003, J IMMUNOL, V171, P2945, DOI 10.4049/jimmunol.171.6.2945; Barbour LA, 2004, ENDOCRINOLOGY, V145, P1144, DOI 10.1210/en.2003-1297; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chefalo PJ, 2003, J IMMUNOL, V170, P5825, DOI 10.4049/jimmunol.170.12.5825; Cheng J, 2004, BIOINFORMATICS, V20, P1462, DOI 10.1093/bioinformatics/bth087; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; Clemmons David Robert, 2002, Pituitary, V5, P181, DOI 10.1023/A:1023321421760; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Cui TX, 2005, MOL ENDOCRINOL, V19, P2175, DOI 10.1210/me.2004-0502; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; DIMITRIADIS G, 1994, EUR J CLIN INVEST, V24, P161, DOI 10.1111/j.1365-2362.1994.tb00982.x; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fasshauer M, 2004, FEBS LETT, V558, P27, DOI 10.1016/S0014-5793(03)01525-4; Fasshauer M, 2004, J ENDOCRINOL, V181, P129, DOI 10.1677/joe.0.1810129; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FOSTER CM, 1988, ENDOCRINOLOGY, V123, P1082, DOI 10.1210/endo-123-2-1082; Gong TWL, 1998, ENDOCRINOLOGY, V139, P1863, DOI 10.1210/en.139.4.1863; Greenhalgh CJ, 2004, GROWTH HORM IGF RES, V14, P200, DOI 10.1016/j.ghir.2003.12.011; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Hettiarachchi M, 1996, DIABETES, V45, P415, DOI 10.2337/diabetes.45.4.415; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jung N, 2000, EUR J BIOCHEM, V267, P6180, DOI 10.1046/j.1432-1327.2000.01692.x; Karlsson M, 2004, EUR J BIOCHEM, V271, P2471, DOI 10.1111/j.1432-1033.2004.04177.x; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; LaFleur AM, 2004, MEDIAT INFLAMM, V13, P349, DOI 10.1080/09629350400014172; LECAM A, 1994, J BIOL CHEM, V269, P21532; LeCouter J, 2003, ENDOCRINOLOGY, V144, P2606, DOI 10.1210/en.2002-0146; Leung KC, 1997, J CLIN ENDOCR METAB, V82, P4208, DOI 10.1210/jc.82.12.4208; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Liao J, 1999, J BIOL CHEM, V274, P31597, DOI 10.1074/jbc.274.44.31597; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Mauvais-Jarvis F, 2002, J CLIN INVEST, V109, P141, DOI 10.1172/JCI200213305; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Moller N, 2003, GROWTH HORM IGF RES, V13, pS18, DOI 10.1016/S1096-6374(03)00048-0; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Moraes RC, 2003, ENDOCRINOLOGY, V144, P4773, DOI 10.1210/en.2003-0456; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Olsson B, 2003, AM J PHYSIOL-ENDOC M, V285, pE504, DOI 10.1152/ajpendo.00444.2002; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Piwien-Pilipuk G, 2002, J PEDIATR ENDOCR MET, V15, P771; Piwien-Pilipuk G, 2002, J BIOL CHEM, V277, P44557, DOI 10.1074/jbc.M206886200; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Ramalingam TS, 1997, MOL BIOL CELL, V8, P2463, DOI 10.1091/mbc.8.12.2463; Rowland JE, 2005, MOL CELL BIOL, V25, P66, DOI 10.1128/MCB.25.1.66-77.2005; Ruan H, 2004, CURR OPIN LIPIDOL, V15, P297, DOI 10.1097/00041433-200406000-00009; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Sartipy P, 2003, P NATL ACAD SCI USA, V100, P7265, DOI 10.1073/pnas.1133870100; SCHWARTZ J, 1984, BIOCHEM BIOPH RES CO, V125, P237, DOI 10.1016/S0006-291X(84)80359-9; SLOOTWEG MC, 1991, J MOL ENDOCRINOL, V6, P179, DOI 10.1677/jme.0.0060179; Stahlberg Nina, 2005, BMC Physiol, V5, P8, DOI 10.1186/1472-6793-5-8; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; Thompson BJL, 2000, ENDOCRINOLOGY, V141, P4321, DOI 10.1210/en.141.11.4321; Thompson W, 2003, NUCLEIC ACIDS RES, V31, P3580, DOI 10.1093/nar/gkg608; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Tollet-Egnell P, 2004, PHYSIOL GENOMICS, V16, P261, DOI 10.1152/physiolgenomics.00093.2002; VIKMAN K, 1991, ENDOCRINOLOGY, V129, P1155, DOI 10.1210/endo-129-3-1155; VIKMAN K, 1991, J ENDOCRINOL, V131, P139, DOI 10.1677/joe.0.1310139; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Wright DE, 2004, J PERIPHER NERV SYST, V9, P242, DOI 10.1111/j.1085-9489.2004.09404.x; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Xu XQ, 2005, J BIOL CHEM, V280, P23987, DOI 10.1074/jbc.M503869200; YOUN BS, 1995, J IMMUNOL, V155, P2661; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	84	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4132	4141		10.1074/jbc.M508492200	http://dx.doi.org/10.1074/jbc.M508492200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16326703	hybrid			2022-12-27	WOS:000235275300044
J	Nakanishi-Matsui, M; Kashiwagi, S; Hosokawa, H; Cipriano, DJ; Dunn, SD; Wada, Y; Futai, M				Nakanishi-Matsui, M; Kashiwagi, S; Hosokawa, H; Cipriano, DJ; Dunn, SD; Wada, Y; Futai, M			Stochastic high-speed rotation of Escherichia coli ATP synthase F-1 sector - The epsilon subunit-sensitive rotation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CATALYTIC MECHANISM; NUCLEOTIDE-BINDING; TORQUE GENERATION; ROTARY MOTOR; NA+-ATPASE; F-ATPASE; C-RING	The gamma subunit of the ATP synthase F-1 sector rotates at the center of the alpha(3)beta(3) hexamer during ATP hydrolysis. A gold bead (40-200 nm diameter) was attached to the gamma subunit of Escherichia coli F1, and then its ATP hydrolysis-dependent rotation was studied. The rotation speeds were variable, showing stochastic fluctuation. The high-speed rates of 40- and 60-nm beads were essentially similar: 721 and 671 rps (revolutions/s), respectively. The average rate of 60-nm beads was 381 rps, which is similar to 13-fold faster than that expected from the steady-state ATPase turnover number. These results indicate that the F1 sector rotates much faster than expected from the bulk of ATPase activity, and that similar to 10% of the F1 molecules are active on the millisecond time scale. Furthermore, the real ATP turnover number ( number of ATP molecules converted to ADP and phosphate/s), as a single molecule, is variable during a short period. The epsilon subunit inhibited rotation and ATPase, whereas epsilon fused through its carboxyl terminus to cytochrome b(562) showed no effect. The epsilon subunit significantly increased the pausing time during rotation. Stochastic fluctuation of catalysis may be a general property of an enzyme, although its understanding requires combining studies of steady-state kinetics and single molecule observation.	Japan Sci & Technol Agcy, Microbial Chem Res Fdn, Futai Special Lab, Microbial Chem Res Ctr,CREST, Tokyo 1410021, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Western Ontario, Dept Biochem, London, ON N6A 5C2, Canada; Osaka Univ, ISIR, Dept Biol Sci, Osaka 5670041, Japan	Japan Science & Technology Agency (JST); University of Tokyo; Western University (University of Western Ontario); Osaka University	Futai, M (corresponding author), Japan Sci & Technol Agcy, Microbial Chem Res Fdn, Futai Special Lab, Microbial Chem Res Ctr,CREST, Tokyo 1410021, Japan.	mfutai-fsl@bikaken.or.jp	Dunn, Stanley/D-3418-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Adachi K, 2000, P NATL ACAD SCI USA, V97, P7243, DOI 10.1073/pnas.120174297; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; Diez M, 2004, NAT STRUCT MOL BIOL, V11, P135, DOI 10.1038/nsmb718; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1982, J BIOL CHEM, V257, P7354; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; Fillingame RH, 2003, FEBS LETT, V555, P29, DOI 10.1016/S0014-5793(03)01101-3; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; Futai M., 2004, HDB ATPASES BIOCH CE, P237; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; Hosokawa H, 2005, J BIOL CHEM, V280, P23797, DOI 10.1074/jbc.M502650200; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; Iko Y, 2001, J BIOL CHEM, V276, P47508, DOI 10.1074/jbc.M108803200; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 2002, FEBS LETT, V525, P156, DOI 10.1016/S0014-5793(02)03097-1; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Meier T, 2005, SCIENCE, V308, P659, DOI 10.1126/science.1111199; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Murata T, 2005, SCIENCE, V308, P654, DOI 10.1126/science.1110064; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OMOTE H, 1995, J BIOL CHEM, V270, P25656, DOI 10.1074/jbc.270.43.25656; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Ueno H, 2005, P NATL ACAD SCI USA, V102, P1333, DOI 10.1073/pnas.0407857102; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 1999, J BIOL CHEM, V274, P19124, DOI 10.1074/jbc.274.27.19124; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zimmermann B, 2005, EMBO J, V24, P2053, DOI 10.1038/sj.emboj.7600682	45	60	60	3	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4126	4131		10.1074/jbc.M510090200	http://dx.doi.org/10.1074/jbc.M510090200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352612	hybrid			2022-12-27	WOS:000235275300043
J	Okumura, AJ; Hatsuzawa, K; Tamura, T; Nagaya, H; Saeki, K; Okumura, F; Nagao, K; Nishikawa, M; Yoshimura, A; Wada, I				Okumura, AJ; Hatsuzawa, K; Tamura, T; Nagaya, H; Saeki, K; Okumura, F; Nagao, K; Nishikawa, M; Yoshimura, A; Wada, I			Involvement of a novel Q-SNARE, D12, in quality control of the endomembrane system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; INTERMEDIATE COMPARTMENT; FLUORESCENT PROTEIN; MAMMALIAN-CELLS; GOLGI TRANSPORT; YEAST; ER; LIPOFUSCIN; APOPTOSIS	The cellular endomembrane system requires the proper kinetic balance of synthesis and degradation of its individual components, which is maintained in part by a specific membrane fusion apparatus. In this study, we describe the molecular properties of D12, which was identified from a mouse expression library. This C-terminal anchored membrane protein has sequence similarity to both a yeast soluble N-ethylmaleimide-sensitive factor attachment protein (SNAP) receptor (SNARE), Use1p/Slt1p, and a recently identified human syntaxin 18-binding protein, p31. D12 formed a tight complex with syntaxin 18 as well as Sec22b and bound to alpha-SNAP, indicating that D12 is a SNARE protein. Although the majority of D12 is located in the endoplasmic reticulum and endoplasmic reticulum-Golgi intermediate compartments at steady state, overexpression or knockdown of D12 had no obvious effects on membrane trafficking in the early secretory pathway. However, suppression of D12 expression caused rapid appearance of lipofuscin granules, accompanied by apoptotic cell death without the apparent activation of the unfolded protein response. The typical cause of lipofuscin formation is the impaired degradation of mitochondria by lysosomal degradative enzymes, and, consistent with this, we found that proper post-Golgi maturation of cathepsin D was impaired in D12-deficient cells. This unexpected observation was supported by evidence that D12 associates with VAMP7, a SNARE in the endosomal-lysosomal pathway. Hence, we suggest that D12 participates in the degradative function of lysosomes.	Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Kirin Brewery Pharmaceut Res Labs, Takasaki, Gumma 3701295, Japan	Fukushima Medical University; Kyushu University	Wada, I (corresponding author), Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Cell Sci, Fukushima 9601295, Japan.	iwada@fmu.ac.jp	Yoshimura, Akihiko/K-5515-2013	Wada, Ikuo/0000-0001-5668-6994; Tamura, Taku/0000-0001-6074-9273				Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Bogdanovic A, 2002, BIOCHEM J, V368, P29, DOI 10.1042/BJ20020845; Braun V, 2004, EMBO J, V23, P4166, DOI 10.1038/sj.emboj.7600427; Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x; Burri L, 2003, P NATL ACAD SCI USA, V100, P9873, DOI 10.1073/pnas.1734000100; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dilcher M, 2003, EMBO J, V22, P3664, DOI 10.1093/emboj/cdg339; Haralampus-Grynaviski NM, 2003, P NATL ACAD SCI USA, V100, P3179, DOI 10.1073/pnas.0630280100; Hatsuzawa K, 2000, J BIOL CHEM, V275, P13713, DOI 10.1074/jbc.275.18.13713; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hirose H, 2004, EMBO J, V23, P1267, DOI 10.1038/sj.emboj.7600135; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Ishidoh K, 2002, BIOL CHEM, V383, P1827, DOI 10.1515/BC.2002.206; IVY GO, 1989, ADV EXP MED BIOL, V266, P31; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Kamada A, 2004, J BIOL CHEM, V279, P21533, DOI 10.1074/jbc.M401403200; Kaufman RJ, 2004, TRENDS BIOCHEM SCI, V29, P152, DOI 10.1016/j.tibs.2004.01.004; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 1999, MOL CELL, V4, P415, DOI 10.1016/S1097-2765(00)80343-3; Misawa K, 2000, P NATL ACAD SCI USA, V97, P3062, DOI 10.1073/pnas.060489597; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Mori K, 2002, ARCH HISTOL CYTOL, V65, P359, DOI 10.1679/aohc.65.359; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nagahama M, 2003, MOL BIOL CELL, V14, P262, DOI 10.1091/mbc.02-07-0115; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; Nakajima K, 2004, EMBO J, V23, P3216, DOI 10.1038/sj.emboj.7600333; Nakanishi H, 2003, AGEING RES REV, V2, P367, DOI 10.1016/S1568-1637(03)00027-8; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OKAZAKI I, 1992, J BIOCHEM, V111, P763, DOI 10.1093/oxfordjournals.jbchem.a123833; Paek I, 1997, J CELL BIOL, V137, P1017, DOI 10.1083/jcb.137.5.1017; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Powell SR, 2005, FREE RADICAL BIO MED, V38, P1093, DOI 10.1016/j.freeradbiomed.2005.01.003; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Pryor PR, 2004, EMBO REP, V5, P590, DOI 10.1038/sj.embor.7400150; Rayner JC, 1997, EMBO J, V16, P1832, DOI 10.1093/emboj/16.8.1832; Saeki K, 2003, EMBO J, V22, P3015, DOI 10.1093/emboj/cdg293; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; Tang BL, 1998, BIOCHEM BIOPH RES CO, V243, P885, DOI 10.1006/bbrc.1998.8194; Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zhang T, 1999, MOL BIOL CELL, V10, P435, DOI 10.1091/mbc.10.2.435	57	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4495	4506		10.1074/jbc.M509715200	http://dx.doi.org/10.1074/jbc.M509715200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354670	hybrid			2022-12-27	WOS:000235275300085
J	Kittiworakarn, J; Lecoq, A; Moine, G; Thai, R; Lajeunesse, E; Drevet, P; Vidaud, C; Menez, A; Leonetti, M				Kittiworakarn, J; Lecoq, A; Moine, G; Thai, R; Lajeunesse, E; Drevet, P; Vidaud, C; Menez, A; Leonetti, M			HIV-1 tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; VASCULAR ENDOTHELIAL-CELLS; DENDRITIC CELLS; BASIC DOMAIN; T-CELLS; TRANSACTIVATOR GENE; ANTIBODY-RESPONSE; KAPOSIS-SARCOMA	Proteins are poor immunogens that require an adjuvant to raise an immune response. Here we show that the human immunodeficiency virus, type 1 Tat protein possesses an autoadjuvant property, and we have identified the determinants and the molecular events that are associated with this unusual property. Using a series of chemically synthesized Tat101 derivatives, we show that the core region controls the autoadjuvant phenomenon independently of the B-cell recognition and T-cell stimulation that are associated with epitopes respectively located on the N-terminal region and the cysteine-rich region. We also show that cysteine-mediated oligomerization is a key molecular event of the adjuvant-free antibody response. In particular, a Tat dimer formed by the oxidation of two cysteine residues, at position 34 only, raises an adjuvant-free antibody response that is comparable with that observed with the wildtype protein. Unlike the parent protein, the Tat dimer has no transactivating activity and remains homogeneous for several weeks in solution. This construct might be of value for the design of an adjuvant-free Tat-based vaccine. Furthermore, we suggest that the specific autoadjuvanticity determinant of Tat could be used to provide other proteins with adjuvant-free immunogenicity.	CEA Saclay, Dept Ingn & Etudes Prot, F-91191 Gif Sur Yvette, France; CEA, VALRHO, Serv Biochim Post Gen & Toxicol Nucl, F-30207 Bagnols Sur Ceze, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA	Leonetti, M (corresponding author), CEA Saclay, Dept Ingn & Etudes Prot, Batiment 152, F-91191 Gif Sur Yvette, France.	michel.leonetti@cea.fr	VIDAUD, Claude/AGX-9878-2022	Thai, Robert/0000-0001-9438-4225				Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Albini A, 1998, J BIOL CHEM, V273, P15895, DOI 10.1074/jbc.273.26.15895; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; Barillari G, 2002, CLIN MICROBIOL REV, V15, P310, DOI 10.1128/CMR.15.2.310-326.2002; BATTAGLIA PA, 1994, BIOCHEM BIOPH RES CO, V201, P701, DOI 10.1006/bbrc.1994.1757; Betti M, 2001, VACCINE, V19, P3408, DOI 10.1016/S0264-410X(01)00067-6; BOGERD HP, 1993, J VIROL, V67, P5030, DOI 10.1128/JVI.67.8.5030-5034.1993; Bomford R, 1998, DEV BIOL STAND, V92, P13; Boykins RA, 1999, J IMMUNOL, V163, P15; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Caputo A, 1996, GENE THER, V3, P235; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Cohen SS, 1999, P NATL ACAD SCI USA, V96, P10842, DOI 10.1073/pnas.96.19.10842; Davis JC, 1999, BIOCHEM J, V341, P613, DOI 10.1042/0264-6021:3410613; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FROEBEL KS, 1994, AIDS RES HUM RETROV, V2, P83; GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7; GROENINK M, 1991, J VIROL, V65, P1968, DOI 10.1128/JVI.65.4.1968-1975.1991; GUTHEIL WG, 1994, P NATL ACAD SCI USA, V91, P6594, DOI 10.1073/pnas.91.14.6594; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822; Kuschel Meike, 2002, J Biomol Tech, V13, P172; LASCELLES AK, 1989, VET IMMUNOL IMMUNOP, V22, P15, DOI 10.1016/0165-2427(89)90160-8; MEYAARD L, 1992, EUR J IMMUNOL, V22, P2729, DOI 10.1002/eji.1830221038; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; Mitola S, 2000, J VIROL, V74, P344, DOI 10.1128/JVI.74.1.344-353.2000; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; Poggi A, 2004, BLOOD, V103, P2205, DOI 10.1182/blood-2003-08-2928; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; REISS P, 1990, J MED VIROL, V30, P163, DOI 10.1002/jmv.1890300303; Rothel JS, 1998, VET IMMUNOL IMMUNOP, V63, P167, DOI 10.1016/S0165-2427(98)00093-2; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Safran M, 2000, BIOCHEM J, V345, P107, DOI 10.1042/0264-6021:3450107; Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544; Tosi G, 2000, EUR J IMMUNOL, V30, P1120, DOI 10.1002/(SICI)1521-4141(200004)30:4<1120::AID-IMMU1120>3.0.CO;2-4; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vogel FR, 1998, DEV BIOL STAND, V92, P241; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wrenger S, 1997, J BIOL CHEM, V272, P30283, DOI 10.1074/jbc.272.48.30283; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466; Zagury J F, 1998, J Hum Virol, V1, P282; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823; Zocchi MR, 1997, AIDS, V11, P1227, DOI 10.1097/00002030-199710000-00005	60	27	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3105	3115		10.1074/jbc.M509899200	http://dx.doi.org/10.1074/jbc.M509899200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321975	hybrid			2022-12-27	WOS:000235128200013
J	Li, FY; Jeffrey, PD; Yu, JW; Shi, YG				Li, FY; Jeffrey, PD; Yu, JW; Shi, YG			Crystal structure of a viral FLIP - Insights into FLIP-mediated inhibition of death receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; EFFECTOR DOMAIN; CELL-DEATH; NMR STRUCTURE; APOPTOSIS; FAS; FADD; CASPASE-8; COMPLEX; ACTIVATION	Death receptor signaling is initiated by the assembly of the death-inducing signaling complex, which culminates in the activation of the initiator caspase, either caspase-8 or caspase-10. A family of viral and cellular proteins, known as FLIP, plays an essential role in the regulation of death receptor signaling. Viral FLIP (v-FLIP) and short cellular FLIP (c-FLIPS) inhibit apoptosis by interfering with death receptor signaling. The structure and mechanisms of v-FLIP and c-FLIPS remain largely unknown. Here we report a high resolution crystal structure of MC159, a v-FLIP derived from the molluscum contagiosum virus, which is a member of the human poxvirus family. Unexpectedly, the two tandem death effector domains (DEDs) of MC159 rigidly associate with each other through a hydrophobic interface. Structure-based sequence analysis suggests that this interface is conserved in the tandem DEDs from other v-FLIP, c-FLIPS, and caspase-8 and -10. Strikingly, the overall packing arrangement between the two DEDs of MC159 resembles that between the caspase recruitment domains of Apaf-1 and caspase-9. In addition, each DED of MC159 contains a highly conserved binding motif on the surface, to which loss-of-function mutations in MC159 map. These observations, in conjunction with published evidence, reveal significant insights into the function of v-FLIP and suggest a mechanism by which v-FLIP and c-FLIPS inhibit death receptor signaling.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA	Princeton University	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Washington Rd, Princeton, NJ 08544 USA.	yshi@molbio.princeton.edu		Jeffrey, Philip/0000-0002-4351-5341; Shi, Yigong/0000-0003-2030-168X				Berglund H, 2000, J MOL BIOL, V302, P171, DOI 10.1006/jmbi.2000.4011; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Garvey TL, 2002, J VIROL, V76, P697, DOI 10.1128/JVI.76.2.697-706.2002; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay BA, 2004, NAT REV GENET, V5, P911, DOI 10.1038/nrg1491; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Holler N, 2003, MOL CELL BIOL, V23, P1428, DOI 10.1128/MCB.23.4.1428-1440.2003; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; Hu SM, 1997, J BIOL CHEM, V272, P9621; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Rathmell JC, 2002, CELL, V109, pS97, DOI 10.1016/S0092-8674(02)00704-3; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Shisler JL, 2001, VIROLOGY, V282, P14, DOI 10.1006/viro.2001.0834; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 2000, CURR OPIN IMMUNOL, V12, P719, DOI 10.1016/S0952-7915(00)00168-0; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wang XD, 2001, GENE DEV, V15, P2922; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	55	71	72	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2960	2968		10.1074/jbc.M511074200	http://dx.doi.org/10.1074/jbc.M511074200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16317000	hybrid			2022-12-27	WOS:000234931800066
J	Moiseyev, G; Takahashi, Y; Chen, Y; Gentleman, S; Redmond, TM; Crouch, RK; Ma, JX				Moiseyev, G; Takahashi, Y; Chen, Y; Gentleman, S; Redmond, TM; Crouch, RK; Ma, JX			RPE65 is an iron(II)-dependent isomerohydrolase in the retinoid visual cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CAROTENE; IRON; EXPRESSION; MUTATIONS; PROTEINS; GENE; IDENTIFICATION; METABOLISM; SUBSTRATE; CLONING	The isomerization of all-trans-retinyl ester to 11-cis-retinol in the retinal pigment epithelium (RPE) is a critical step in the visual cycle and is essential for normal vision. Recently, we have established that protein RPE65 is the isomerohydrolase catalyzing this reaction. The present study investigated if metal ions are required for the isomerohydrolase activity of RPE65. The conversion of all-trans-[H-3] retinol to 11-cis-[H-3]retinol was used as the measure for isomerohydrolase activity. Metal chelators 2,2'-bipyridine and 1,10-phenanthroline both showed dose-dependent inhibitions of the isomerohydrolase activity in bovine RPE microsomes, with IC50 values of 0.5 and 0.2 mM, respectively. In the same reaction systems, however, lecithin-retinol acyltransferase (LRAT) activity was not affected by these metal chelators. The isomerohydrolase activity inhibited by the metal chelators was restored by FeSO4 but not by CuSO4, ZnCl2, or MgCl2. Moreover, addition of Fe(III) citrate or FeCl3 did not restore the activity, indicating that Fe2+ is the metal ion essential for the isomerohydrolase activity. To confirm this result in recombinant RPE65, we expressed RPE65 in a 293A cell line stably expressing LRAT. In vitro activity assay showed that both metal chelators inhibited isomerohydrolase activity of recombinant RPE65. The addition of FeSO4 restored the enzymatic activity of the recombinant RPE65. Further, two specific iron-staining methods showed that purified RPE65 contains endogenous iron. Inductively coupled plasma mass spectrometry measurements showed that bovine RPE65 binds iron ion with a stoichiometry of 0.8 +/- 0.1. These results indicate that RPE65 is an iron-dependent isomerohydrolase in the visual cycle.	Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Dept Med, Oklahoma City, OK 73104 USA; NEI, NIH, Bethesda, MD 20892 USA; Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Medical University of South Carolina; Medical University of South Carolina	Ma, JX (corresponding author), 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.	jian-xing-ma@ouhsc.edu		Redmond, T. Michael/0000-0002-1813-5291	NATIONAL EYE INSTITUTE [R24EY014793, R01EY012231, Z01EY000260, R21EY015650, ZIAEY000260, R33EY015650, R01EY004939] Funding Source: NIH RePORTER; NEI NIH HHS [EY14793, EY012231, EY15650, EY04939] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Baker HM, 2003, P NATL ACAD SCI USA, V100, P3579, DOI 10.1073/pnas.0637295100; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; Crabb JW, 1998, METH MOL B, V89, P91; Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P5809, DOI 10.1021/bi0341004; GOODMAN DS, 1967, J BIOL CHEM, V242, P3543; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Jin MH, 2005, CELL, V122, P449, DOI 10.1016/j.cell.2005.06.042; Kloer DP, 2005, SCIENCE, V308, P267, DOI 10.1126/science.1108965; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai Chooi-May, 2004, Genet Vaccines Ther, V2, P3, DOI 10.1186/1479-0556-2-3; Lange SJ, 1998, CURR OPIN CHEM BIOL, V2, P159, DOI 10.1016/S1367-5931(98)80057-4; LEONG LM, 1992, ANAL BIOCHEM, V207, P317, DOI 10.1016/0003-2697(92)90018-3; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; Ma JX, 2001, INVEST OPHTH VIS SCI, V42, P1429; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Moiseyev G, 2005, P NATL ACAD SCI USA, V102, P12413, DOI 10.1073/pnas.0503460102; Moiseyev G, 2003, BIOCHEMISTRY-US, V42, P2229, DOI 10.1021/bi026911y; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Petrat F, 2003, J BIOL CHEM, V278, P46403, DOI 10.1074/jbc.M305291200; POLIAKOV E, 2005, IN PRESS J BIOL CHEM; Rando RR, 2001, CHEM REV, V101, P1881, DOI 10.1021/cr960141c; RANDO RR, 1991, BIOCHEMISTRY-US, V30, P595, DOI 10.1021/bi00217a001; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2005, P NATL ACAD SCI USA, V102, P13658, DOI 10.1073/pnas.0504167102; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Takahashi Y, 2005, FEBS LETT, V579, P5414, DOI 10.1016/j.febslet.2005.09.002; Thompson DA, 2003, DEV OPHTHALMOL, V37, P141; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Winston A, 1998, BIOCHEMISTRY-US, V37, P2044, DOI 10.1021/bi971908d; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476	36	93	94	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2835	2840		10.1074/jbc.M508903200	http://dx.doi.org/10.1074/jbc.M508903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319067	hybrid			2022-12-27	WOS:000234931800051
J	Asensio, JG; Maia, C; Ferrer, NL; Barilone, N; Laval, F; Soto, CY; Winter, N; Daffe, M; Gicquel, B; Martin, C; Jackson, M				Asensio, JG; Maia, C; Ferrer, NL; Barilone, N; Laval, F; Soto, CY; Winter, N; Daffe, M; Gicquel, B; Martin, C; Jackson, M			The virulence-associated twocomponent PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBERCLE BACILLUS; FATTY-ACIDS; GENE; TREHALOSE; STRAINS; ACYLTREHALOSES; DEFICIENCY; SELECTION; H37RV; CELLS	Two-component regulatory signal transduction systems are important elements of the adaptative response of prokaryotes to a variety of environmental stimuli. Disruption of PhoP-PhoR in Mycobacterium tuberculosis dramatically attenuates virulence, implying that this system directly and/or indirectly coordinates the expression of important virulence factors whose identity remains to be established. Interestingly, in knocking-out the PhoP-PhoR two-component system in M. tuberculosis Mt103, dramatic changes in the colonial morphology, cording properties, and reactivity of the mutant strain to the basic dye neutral red, all intrinsic properties of tubercle bacilli known to correlate with virulence, were noted. Because deficiencies in the ability of the mutant to form serpentine cords and stain with the dye are likely the results of alterations of its cell envelope composition, we undertook to analyze the lipid content of phoP and phoP-phoR mutants constructed in two different strains of M. tuberculosis. Our results indicate that PhoP coordinately and positively regulates the synthesis of methyl-branched fatty acid-containing acyltrehaloses known to be restricted to pathogenic species of the M. tuberculosis complex, namely diacyltrehaloses, polyacyltrehaloses, and sulfolipids. Evidence is also provided that PhoP but not PhoR is required for the production of these lipids. This work represents an important step toward the functional characterization of PhoP-PhoR and the understanding of complex lipid synthesis in M. tuberculosis.	Univ Zaragoza, Dept Microbiol Med Prevent & Salud Publ, E-50009 Zaragoza, Spain; Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France; Univ Toulouse 3, Dept Mecan Mol Infect Mycobacteriennes, Inst Pharmacol Biol Struct, UMR 5089,CNRS, F-31077 Toulouse, France	University of Zaragoza; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Jackson, M (corresponding author), Univ Zaragoza, Dept Microbiol Med Prevent & Salud Publ, C Domingo Miral Sin Numero, E-50009 Zaragoza, Spain.	mjackson@pasteur.fr	LAUZERAL-VIZCAINO, Françoise/W-8898-2019; Jackson, Mary/D-5345-2017; Martin, Carlos/A-7283-2008; Winter, Nathalie/U-2690-2018; Gonzalo-Asensio, Jesús/E-4122-2013	LAUZERAL-VIZCAINO, Françoise/0000-0002-9741-3252; Jackson, Mary/0000-0002-9212-0258; Martin, Carlos/0000-0003-2993-5478; Winter, Nathalie/0000-0003-0994-7834; Gonzalo-Asensio, Jesús/0000-0001-8841-6593; Maia, Catarina/0000-0002-3010-6178; Soto Ospina, Carlos Yesid/0000-0001-8694-7489				BESRA GS, 1992, BIOCHEMISTRY-US, V31, P9832, DOI 10.1021/bi00155a040; CASON J, 1956, J BIOL CHEM, V220, P893; Converse SE, 2003, P NATL ACAD SCI USA, V100, P6121, DOI 10.1073/pnas.1030024100; DAFFE M, 1988, EUR J BIOCHEM, V172, P579, DOI 10.1111/j.1432-1033.1988.tb13928.x; Domenech P, 2004, J BIOL CHEM, V279, P21257, DOI 10.1074/jbc.M400324200; Dubey VS, 2002, MOL MICROBIOL, V45, P1451, DOI 10.1046/j.1365-2958.2002.03119.x; DUBOS RJ, 1948, AM REV TUBERC PULM, V58, P698; Fontan PA, 2004, CURR SCI INDIA, V86, P122; Gao LY, 2003, MOL MICROBIOL, V49, P1547, DOI 10.1046/j.1365-2958.2003.03667.x; Gao Q, 2004, TUBERCULOSIS, V84, P188, DOI 10.1016/j.tube.2003.12.013; Gilleron M, 2004, J EXP MED, V199, P649, DOI 10.1084/jem.20031097; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Goren M. B., 1979, TUBERCULOSIS, P63; GOREN MB, 1990, HDB LIPID RES, V6, P363; Graham JE, 1999, P NATL ACAD SCI USA, V96, P11554, DOI 10.1073/pnas.96.20.11554; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Himpens S, 2000, MICROBIOL-SGM, V146, P3091, DOI 10.1099/00221287-146-12-3091; HOWARD NS, 1995, GENE, V166, P181, DOI 10.1016/0378-1119(95)00597-X; Jackson M, 2001, Methods Mol Med, V54, P59, DOI 10.1385/1-59259-147-7:059; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; LEMASSU A, 1991, FEMS MICROBIOL LETT, V78, P171, DOI 10.1016/0378-1097(91)90153-2; Lesley JA, 2003, J BACTERIOL, V185, P2563, DOI 10.1128/JB.185.8.2563-2570.2003; Ludwiczak P, 2002, MICROBIOL-SGM, V148, P3029, DOI 10.1099/00221287-148-10-3029; Martin JF, 2004, J BACTERIOL, V186, P5197, DOI 10.1128/JB.186.16.5197-5201.2004; MIDDLEBROOK G, 1947, J EXP MED, V86, P175, DOI 10.1084/jem.86.2.175; MIDDLEBROOK G, 1959, P NATL ACAD SCI USA, V45, P1801, DOI 10.1073/pnas.45.12.1801; MINNIKIN DE, 1985, J GEN MICROBIOL, V131, P1369; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Rousseau C, 2003, INFECT IMMUN, V71, P4684, DOI 10.1128/IAI.71.8.4684-4690.2003; Rousseau C, 2003, CELL MICROBIOL, V5, P405, DOI 10.1046/j.1462-5822.2003.00289.x; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Sola-Landa A, 2003, P NATL ACAD SCI USA, V100, P6133, DOI 10.1073/pnas.0931429100; Soto CY, 2004, J CLIN MICROBIOL, V42, P212, DOI 10.1128/JCM.42.1.212-219.2004; Soto CY, 2002, J CLIN MICROBIOL, V40, P3021, DOI 10.1128/JCM.40.8.3021-3024.2002	37	157	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1313	1316		10.1074/jbc.C500388200	http://dx.doi.org/10.1074/jbc.C500388200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16326699	hybrid, Green Published			2022-12-27	WOS:000234652000004
J	Fu, ZJ; Runquist, JA; Forouhar, F; Hussain, M; Hunt, JF; Miziorko, HM; Kim, JJP				Fu, ZJ; Runquist, JA; Forouhar, F; Hussain, M; Hunt, JF; Miziorko, HM; Kim, JJP			Crystal structure of human 3-hydroxy-3-methylglutaryl-CoA lyase - Insights into catalysis and the molecular basis for hydroxymethylglutaric aciduria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A LYASE; POINT MUTATIONS; ACETYL-COENZYME; MALATE SYNTHASE; ENZYME; DEFICIENCY; IDENTIFICATION; SENSITIVITY; MECHANISM; PRODUCE	3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase is a key enzyme in the ketogenic pathway that supplies metabolic fuel to extrahepatic tissues. Enzyme deficiency may be due to a variety of human mutations and can be fatal. Diminished activity has been explained based on analyses of recombinant human mutant proteins or, more recently, in the context of structural models for the enzyme. We report the experimental determination of a crystal structure at 2.1 angstrom resolution of the recombinant human mitochondrial HMG-CoA lyase containing a bound activator cation and the dicarboxylic acid 3-hydroxyglutarate. The enzyme adopts a (beta alpha)(8) barrel fold, and the N-terminal barrel end is occluded. The structure of a physiologically relevant dimer suggests that substrate access to the active site involves binding across the cavity located at the C-terminal end of the barrel. An alternative hypothesis that involves substrate insertion through a pore proposed to extend through the barrel is not compatible with the observed structure. The activator cation ligands included Asn(275), Asp(42), His(233), and His(235); the latter three residues had been implicated previously as contributing to metal binding or enzyme activity. Arg(41), previously shown to have a major effect on catalytic efficiency, is also located at the active site. In the observed structure, this residue interacts with a carboxyl group of 3-hydroxyglutarate, the hydrolysis product of the competitive inhibitor 3-hydroxyglutaryl-CoA required for crystallization of human enzyme. The structure provides a rationale for the decrease in enzyme activity due to clinical mutations, including H233R, R41Q, D42H, and D204N, that compromise active site function or enzyme stability.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	Medical College of Wisconsin; Columbia University; University of Missouri System; University of Missouri Kansas City	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jjkim@mcw.edu			NCRR NIH HHS [S10 RR 017929, RR 07707] Funding Source: Medline; NIDDK NIH HHS [DK 21491] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anstrom DM, 2003, PROTEIN SCI, V12, P1822, DOI 10.1110/ps.03174303; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casals N, 2003, J BIOL CHEM, V278, P29016, DOI 10.1074/jbc.M304276200; COON MJ, 1955, AMINO ACID METABOLIS, P431; Forouhar F, 2006, J BIOL CHEM, V281, P7533, DOI 10.1074/jbc.M507996200; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; HIGGINS MJP, 1972, ENZYMES, V2, P407; HRUZ PW, 1992, BIOCHEMISTRY-US, V31, P6842, DOI 10.1021/bi00144a026; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; Koon N, 2004, P NATL ACAD SCI USA, V101, P8295, DOI 10.1073/pnas.0400820101; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; KRAMER PR, 1983, BIOCHEMISTRY-US, V22, P2353, DOI 10.1021/bi00279a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; Manjasetty BA, 2003, P NATL ACAD SCI USA, V100, P6992, DOI 10.1073/pnas.1236794100; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MITCHELL GA, 1993, J BIOL CHEM, V268, P4376; Mitchell GA, 1998, BIOCHEM SOC T, V26, P136, DOI 10.1042/bst0260136; Mitchell GA, 1998, AM J HUM GENET, V62, P295, DOI 10.1086/301730; Muroi J, 2000, HUM GENET, V107, P320, DOI 10.1007/s004390000363; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Roberts JR, 1997, BIOCHEMISTRY-US, V36, P7594, DOI 10.1021/bi970207d; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; Roberts JR, 1996, J BIOL CHEM, V271, P24604, DOI 10.1074/jbc.271.40.24604; ROBERTS JR, 1995, J BIOL CHEM, V270, P17311, DOI 10.1074/jbc.270.29.17311; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; ROUSSEL A, 1999, TURBOFRODO VERSION O; Smith CV, 2003, J BIOL CHEM, V278, P1735, DOI 10.1074/jbc.M209248200; STEGINK LD, 1968, J BIOL CHEM, V243, P5272; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tuinstra RL, 2004, BIOCHEMISTRY-US, V43, P5287, DOI 10.1021/bi0499765; Tuinstra RL, 2003, J BIOL CHEM, V278, P37092, DOI 10.1074/jbc.M304472200; Tuinstra RL, 2002, ARCH BIOCHEM BIOPHYS, V408, P286, DOI 10.1016/S0003-9861(02)00584-2; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629; Zapater N, 1998, ARCH BIOCHEM BIOPHYS, V358, P197, DOI 10.1006/abbi.1998.0788	42	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7526	7532		10.1074/jbc.M506880200	http://dx.doi.org/10.1074/jbc.M506880200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16330550	hybrid			2022-12-27	WOS:000236030900074
J	Kim, JK; Pedram, A; Razandi, M; Levin, ER				Kim, JK; Pedram, A; Razandi, M; Levin, ER			Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regulation of p38 kinase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; REPERFUSION INJURY; ANGIOTENSIN-II; MYOCARDIAL-INFARCTION; ELECTRON-TRANSPORT; IN-VITRO; ISCHEMIA; HEART; MITOCHONDRIA; EXPRESSION	From human and animal studies, estrogen is known to protect the myocardium from an ischemic insult. However, there is limited knowledge regarding mechanisms by which estrogen directly protects cardiomyocytes. In this report, we employed an in vitro model, in which cultured rat cardiomyocytes underwent prolonged hypoxia followed by reoxygenation (H/R), to study the cardioprotective mechanism of estrogen. 17-beta-estradiol (E2) acting via estrogen receptors inhibited H/R-induced apoptosis of cardiomyocytes. Mitochondrial reactive oxygen species (ROS) generated from H/R activated p38 alpha MAPK, and inhibition of p38 alpha with SB203580 significantly prevented H/R-induced cell death. E2 suppressed ROS formation and p38 alpha activation by H/R and concomitantly augmented the activity of p38 beta. Unlike p38 alpha, p38 beta was little affected by H/R. Dominant negative p38 beta protein expression decreased E2-mediated cardiomyocyte survival and ROS suppression during H/R stress. The prosurvival signaling molecule, phosphoinositol-3 kinase (PI3K), has previously been linked to cell survival following ischemia-reperfusion injury. Here, E2-activated PI3K was found to inhibit ROS generated from H/R injury, leading to inhibition of downstream p38 alpha. We further linked these signaling pathways in that p38 beta was activated by E2 stimulation of PI3K. Thus, E2 differentially modulated two major isoforms of p38, leading to cardiomyocyte survival. This was achieved by signaling through PI3K, integrating cell survival mediators.	Long Beach Vet Affairs Med Ctr, Div Endocrinol, Med Serv 111 1, Long Beach, CA 90822 USA; Univ Calif Irvine, Div Cardiol, Irvine, CA 92717 USA; Univ Calif Irvine, Div Endocrinol, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), Long Beach Vet Affairs Med Ctr, Div Endocrinol, Med Serv 111 1, 5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov	Levin, Ellis/J-5402-2013					Alexaki VI, 2004, FASEB J, V18, P1594, DOI 10.1096/fj.04-1495fje; *AM HEART ASS, 1997, BIOST FACT SHEETS, P1; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Cicconi S, 2003, J CELL PHYSIOL, V195, P27, DOI 10.1002/jcp.10219; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; GODSLAND IF, 1987, AM HEART J, V114, P1467, DOI 10.1016/0002-8703(87)90552-7; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; Gyulkhandanyan AV, 2004, J NEUROCHEM, V90, P405, DOI 10.1111/j.1471-4159.2004.02489.x; Hale SL, 1996, AM HEART J, V132, P258, DOI 10.1016/S0002-8703(96)90419-6; HOHL C, 1987, ARCH BIOCHEM BIOPHYS, V259, P527, DOI 10.1016/0003-9861(87)90519-4; Ichikawa H, 2004, REDOX REP, V9, P313, DOI 10.1179/135100004225006795; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Kaiser RA, 2004, J BIOL CHEM, V279, P15524, DOI 10.1074/jbc.M313717200; Kanda N, 2003, J INVEST DERMATOL, V121, P1500, DOI 10.1111/j.1523-1747.2003.12617.x; Kato K, 1994, Nagoya J Med Sci, V57, P43; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lemke LE, 2001, J MOL CELL CARDIOL, V33, P1527, DOI 10.1006/jmcc.2001.1415; Lesnefsky EJ, 2004, J BIOL CHEM, V279, P47961, DOI 10.1074/jbc.M409720200; Martin JL, 2001, CIRC RES, V89, P750, DOI 10.1161/hh2101.099504; Marushige K, 1999, ANTICANCER RES, V19, P3865; Maxwell SRJ, 1998, BASIC RES CARDIOL, V93, P79; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; Nishida M, 2005, J BIOL CHEM, V280, P18434, DOI 10.1074/jbc.M409710200; Palomeque J, 2006, AM J PHYSIOL-HEART C, V290, pH96, DOI 10.1152/ajpheart.00324.2005; Patten RD, 2004, CIRC RES, V95, P692, DOI 10.1161/01.RES.0000144126.57786.89; Pedram A, 2005, J BIOL CHEM, V280, P26339, DOI 10.1074/jbc.M414409200; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Saraste A, 1997, CIRCULATION, V95, P320; Saurin AT, 2000, FASEB J, V14, P2237, DOI 10.1096/fj.99-0671com; See F, 2004, J AM COLL CARDIOL, V44, P1679, DOI 10.1016/j.jacc.2004.07.038; Sharov VG, 2003, EUR J HEART FAIL, V5, P121, DOI 10.1016/S1388-9842(02)00254-4; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; Toyoda Y, 1998, CARDIOLOGY, V90, P149, DOI 10.1159/000006835; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; Vanden Hoek TL, 2003, AM J PHYSIOL-HEART C, V284, pH141, DOI 10.1152/ajpheart.00132.2002; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; Vilatoba M, 2005, TRANSPL P, V37, P399, DOI 10.1016/j.transproceed.2004.12.053; VITALE M, 1993, HISTOCHEMISTRY, V100, P223, DOI 10.1007/BF00269095; Wang QF, 2004, ENDOCRINOLOGY, V145, P5568, DOI 10.1210/en.2004-0807; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wenzel S, 2001, FASEB J, V15, P2291, DOI 10.1096/fj.00-0827fje; WIESNER RJ, 1989, J MOL CELL CARDIOL, V21, P49, DOI 10.1016/0022-2828(89)91492-2; WREN BG, 1992, MED J AUSTRALIA, V157, P204, DOI 10.5694/j.1326-5377.1992.tb137091.x; Zhai PY, 2000, AM J PHYSIOL-HEART C, V279, pH2766, DOI 10.1152/ajpheart.2000.279.6.H2766; Zhao ZQ, 2004, CURR OPIN PHARMACOL, V4, P159, DOI 10.1016/j.coph.2003.10.010; Zhao ZQ, 2000, CARDIOVASC RES, V45, P651, DOI 10.1016/S0008-6363(99)00354-5	53	147	169	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6760	6767		10.1074/jbc.M511024200	http://dx.doi.org/10.1074/jbc.M511024200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407188	hybrid			2022-12-27	WOS:000236030800074
J	Casas, J; Gijon, MA; Vigo, AG; Crespo, MS; Balsinde, J; Balboa, MA				Casas, J; Gijon, MA; Vigo, AG; Crespo, MS; Balsinde, J; Balboa, MA			Overexpression of cytosolic group IVA phospholipase A(2) protects cells from Ca2+-dependent death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; TUMOR-NECROSIS-FACTOR; HYDROGEN-PEROXIDE; U937 CELLS; C2 DOMAIN; MITOCHONDRIAL-MEMBRANE; HUMAN CYTOMEGALOVIRUS; PLASMA-MEMBRANE; FATTY-ACIDS; APOPTOSIS	The calcium ionophore ionomycin induces apoptosis-like events in the human embryonic kidney cell line at early times. Plasma membrane blebbing, mitochondrial depolarization, externalization of phosphatidylserine, and nuclear permeability changes can all be observed within 15 min of treatment. However, there is no activation of caspases or chromatin condensation. Expression of a fusion protein containing the enhanced green fluorescent protein (EGFP) and human cytosolic Group IVA phospholipase A(2)alpha (EGFP-cPLA(2)alpha) in these cells prevents ionomycin-induced phosphatidylserine externalization and death. Cells expressing the cPLA(2)alpha mutant D43N, which does not bind calcium, retain their susceptibility to ionomycin-induced cell death. Both nonexpressing and EGFP-D43N-cPLA(2)alpha-expressing human embryonic kidney cells can be spared from ionomycin-induced cell death by pretreating them with exogenous arachidonic acid. Moreover, during calcium overload, mitochondrial depolarization is significantly lower in the EGFP-cPLA(2)alpha-expressing cells than in cells expressing normal amounts of cPLA(2)alpha. These results suggest that early cell death events promoted by an overload of calcium can be prevented by the presence of high levels of arachidonic acid.	Univ Valladolid, Inst Biol & Genet Mol, CSIC, Sch Med, Valladolid 47003, Spain; Inst Mol Biol & Genet, Spanish Res Council, Valladolid 47003, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM)	Balboa, MA (corresponding author), Univ Valladolid, Inst Biol & Genet Mol, CSIC, Sch Med, Calle Sanz & Fores S-N, Valladolid 47003, Spain.	Miguel.Gijon@uchsc.edu; jbalsinde@ibgm.uva.es; mbalboa@ibgm.uva.es	Balboa, María A./V-9493-2018; Casas, Javier/K-7190-2015; Balsinde, Jesús/C-7833-2018	Balboa, María A./0000-0002-2130-5298; Casas, Javier/0000-0002-6413-8127; Balsinde, Jesús/0000-0002-4157-6714				Allal C, 2004, J VIROL, V78, P7717, DOI 10.1128/JVI.78.14.7717-7726.2004; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Balboa MA, 2002, J BIOL CHEM, V277, P40384, DOI 10.1074/jbc.M206155200; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonventre JV, 2004, TRENDS IMMUNOL, V25, P116, DOI 10.1016/j.it.2004.01.006; BRATTON DL, 1992, J IMMUNOL, V148, P514; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793; Doug M, 2003, CARCINOGENESIS, V24, P307, DOI 10.1093/carcin/24.2.307; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Fortunato EA, 2000, TRENDS MICROBIOL, V8, P111, DOI 10.1016/S0966-842X(00)01699-1; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Girod A, 2002, J GEN VIROL, V83, P973, DOI 10.1099/0022-1317-83-5-973; Gugliucci A, 2002, J BIOL CHEM, V277, P31789, DOI 10.1074/jbc.M204450200; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hirabayashi T, 1999, J BIOL CHEM, V274, P5163, DOI 10.1074/jbc.274.8.5163; Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jambrina E, 2003, J BIOL CHEM, V278, P14134, DOI 10.1074/jbc.M211388200; KAO JPY, 1989, J BIOL CHEM, V264, P8179; Kronke M, 2002, FEBS LETT, V531, P18, DOI 10.1016/S0014-5793(02)03407-5; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Penzo D, 2004, J BIOL CHEM, V279, P25219, DOI 10.1074/jbc.M310381200; Perez R, 2004, J BIOL CHEM, V279, P40385, DOI 10.1074/jbc.M402562200; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Roehrig S, 2003, ANAL BIOCHEM, V318, P244, DOI 10.1016/S0003-2697(03)00242-2; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001; TAIT JF, 1989, J BIOL CHEM, V264, P7944; Takadera T, 1997, EUR J BIOCHEM, V249, P8, DOI 10.1111/j.1432-1033.1997.00008.x; Tommasini I, 2002, CELL DEATH DIFFER, V9, P1368, DOI 10.1038/sj.cdd.4401123; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; Wojtczak L, 1999, J BIOENERG BIOMEMBR, V31, P447, DOI 10.1023/A:1005444322823; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Zackova M, 2003, J BIOL CHEM, V278, P20761, DOI 10.1074/jbc.M212850200	47	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6106	6116		10.1074/jbc.M505230200	http://dx.doi.org/10.1074/jbc.M505230200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407173	Green Submitted, hybrid			2022-12-27	WOS:000235568900092
J	Takada, Y; Gillenwater, A; Ichikawa, H; Aggarwal, BB				Takada, Y; Gillenwater, A; Ichikawa, H; Aggarwal, BB			Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; TUMOR-NECROSIS-FACTOR; ALPHA KINASE; CELL-DEATH; INFLAMMATORY STIMULI; ABROGATES ACTIVATION; P65 PHOSPHORYLATION; FACTOR (NF)-KAPPA-B; EXPRESSION LEVELS; GENETIC DELETION	Because of its ability to suppress tumor cell proliferation, angiogenesis, and inflammation, the histone deacetylase inhibitor suberoylanilide hydroxamic acid ( SAHA) is currently in clinical trials. How SAHA mediates its effects is poorly understood. We found that in several human cancer cell lines, SAHA potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents and inhibited TNF-induced invasion and receptor activator of NF-kappa B ligand-induced osteoclastogenesis, all of which are known to require NF-kappa B activation. These observations corresponded with the down-regulation of the expression of anti-apoptotic (IAP1, IAP2, X chromosome- linked IAP, Bcl-2, Bcl-x(L), TRAF1, FLIP, and survivin), proliferative ( cyclin D1, cyclooxygenase 2, and c-Myc), and angiogenic (ICAM-1, matrix metalloproteinase-9, and vascular endothelial growth factor) gene products. Because several of these genes are regulated by NF-kappa B, we postulated that SAHA mediates its effects by modulating NF-kappa B and found that SAHA suppressed NF-kappa B activation induced by TNF, IL-1 beta, okadaic acid, doxorubicin, lipopolysaccharide, H2O2, phorbol myristate acetate, and cigarette smoke; the suppression was not cell type-specific because both inducible and constitutive NF-kappa B activation was inhibited. We also found that SAHA had no effect on direct binding of NF-kappa B to the DNA but inhibited sequentially the TNF-induced activation of I kappa B alpha kinase, I kappa B alpha phosphorylation, I kappa B alpha ubiquitination, I kappa B alpha degradation, p65 phosphorylation, and p65 nuclear translocation. Furthermore, SAHA inhibited the NF-kappa B-dependent reporter gene expression activated by TNF, TNFR1, TRADD, TRAF2, NF-kappa B-inducing kinase, I kappa B alpha kinase, and the p65 subunit of NF-kappa B. Overall, our results indicated that NF-kappa B and NF-kappa B-regulated gene expression inhibited by SAHA can enhance apoptosis and inhibit invasion and osteoclastogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Cytokine Res Lab, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013	Gillenwater, Ann/0000-0002-0935-0037	NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 91844, P50 CA 97007] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Amin HM, 2001, BRIT J HAEMATOL, V115, P287, DOI 10.1046/j.1365-2141.2001.03123.x; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bottero V, 2001, CANCER RES, V61, P7785; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Butler LM, 2000, CANCER RES, V60, P5165; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Facchetti F, 2004, APOPTOSIS, V9, P573, DOI 10.1023/B:APPT.0000038036.31271.50; Gao N, 2004, MOL PHARMACOL, V66, P956, DOI 10.1124/mol.104.002014; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang LL, 2000, MOL MED, V6, P849, DOI 10.1007/BF03401823; Kim MS, 2003, CANCER RES, V63, P7291; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kutko MC, 2003, CLIN CANCER RES, V9, P5749; Leoni F, 2002, P NATL ACAD SCI USA, V99, P2995, DOI 10.1073/pnas.052702999; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Munster PN, 2001, CANCER RES, V61, P8492; Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830; Nakayama H, 2001, CANCER, V92, P3037, DOI 10.1002/1097-0142(20011215)92:12<3037::AID-CNCR10171>3.0.CO;2-#; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Nimmanapalli R, 2003, BLOOD, V101, P3236, DOI 10.1182/blood-2002-08-2675; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rahman MM, 2003, BLOOD, V101, P3451, DOI 10.1182/blood-2002-08-2622; Rahmani M, 2003, ONCOGENE, V22, P6231, DOI 10.1038/sj.onc.1206646; Reddy P, 2004, P NATL ACAD SCI USA, V101, P3921, DOI 10.1073/pnas.0400380101; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Richon VM, 1996, P NATL ACAD SCI USA, V93, P5705, DOI 10.1073/pnas.93.12.5705; Ruefli AA, 2002, INT J CANCER, V99, P292, DOI 10.1002/ijc.10327; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Samanta AK, 2004, J BIOL CHEM, V279, P7576, DOI 10.1074/jbc.M311659200; Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102; Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200; Shishodia S, 2004, CANCER RES, V64, P5004, DOI 10.1158/0008-5472.CAN-04-0206; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J IMMUNOL, V171, P3278, DOI 10.4049/jimmunol.171.6.3278; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Webb Y, 1999, J BIOL CHEM, V274, P14280, DOI 10.1074/jbc.274.20.14280; Xu YX, 2005, INT J MOL MED, V15, P169; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yin L, 2001, J BIOL CHEM, V276, P44641, DOI 10.1074/jbc.M105170200; Yu CR, 2003, CANCER RES, V63, P2118; Yu ZT, 2002, J AM SOC NEPHROL, V13, P2009, DOI 10.1097/01.ASN.0000024253.59665.F1	69	108	116	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5612	5622		10.1074/jbc.M507213200	http://dx.doi.org/10.1074/jbc.M507213200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377638	hybrid			2022-12-27	WOS:000235568900037
J	Hers, I; Wherlock, M; Homma, Y; Yagisawa, H; Tavare, J				Hers, I; Wherlock, M; Homma, Y; Yagisawa, H; Tavare, J			Identification of p122RhoGAP (deleted in liver cancer-1) serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in insulin-stimulated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; TUMOR-SUPPRESSOR GENE; AKT SUBSTRATE; PLC-DELTA(1)-BINDING PROTEIN; GLUCOSE-TRANSPORT; MAPKAP KINASE-1; RAT ADIPOCYTES; PHOSPHORYLATION; DLC-1; MEDIATOR	Protein kinase B (PKB or Akt) plays an essential role in the actions of insulin, cytokines, and growth factors, although the substrates for PKB that are relevant to many of its actions require identification. In this study, we have reported the identification of p122RhoGAP, a GTPase-activating protein selective for RhoA and rodent homologue of the tumor suppressor deleted in liver cancer (DLC1) as a novel insulin-stimulated phosphoprotein in primary rat adipocytes. We have demonstrated that Ser-322 is phosphorylated upon insulin stimulation of intact cells and that this site is directly phosphorylated in vitro by PKB and ribosomal S6 kinase, members of the AGC (protein kinases A, G, and C) family of insulin-stimulated protein kinases. Furthermore, expression of constitutively active mutants of PKB or mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) stimulates Ser-322 phosphorylation in intact cells, demonstrating that activation of the PKB or MEK pathway is sufficient for Ser-322 phosphorylation in vivo. Indeed, in primary adipocytes, insulin-stimulated Ser-322 phosphorylation was almost exclusively regulated by the phosphatidylinositol 3-kinase/PKB pathway, whereas in immortalized cells, insulin-stimulated phosphorylation was predominantly regulated by the MEK/extracellular signal-regulated kinase/ribosomal S6 kinase pathway, with the phosphatidylinositol 3-kinase/PKB pathway playing a minor role. These results demonstrate that p122RhoGAP Ser-322 acts as an integrator of signal transduction in a manner dependent on the cellular context.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Fukushima Med Univ, Sch Med, Inst Biomed Sci, Dept Biomol Res, Fukushima 9601295, Japan; Univ Hyogo, Grad Sch Life Sci, Harima, Hyogo 6781297, Japan	University of Bristol; Fukushima Medical University; University of Hyogo	Hers, I (corresponding author), Univ Bristol, Sch Med Sci, Bristol BS6 7TP, Avon, England.	i.hers@bris.ac.uk	Hers, Ingeborg/ABG-3357-2020; Yagisawa, Hitoshi/C-9305-2012	Yagisawa, Hitoshi/0000-0002-5365-4513; Hers, Ingeborg/0000-0002-6467-5715	Medical Research Council [G7708269] Funding Source: Medline; MRC [G7708269] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Auld GC, 2005, BIOCHEM J, V389, P775, DOI 10.1042/BJ20050733; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Berwick DC, 2004, J CELL SCI, V117, P5985, DOI 10.1242/jcs.01517; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cartlidge RA, 2005, EMBO J, V24, P1696, DOI 10.1038/sj.emboj.7600648; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; De Mesquita DD, 2001, FEBS LETT, V502, P84, DOI 10.1016/S0014-5793(01)02669-2; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gridley S, 2005, CELL SIGNAL, V17, P59, DOI 10.1016/j.cellsig.2004.05.013; Hers I, 2002, BIOCHEM J, V368, P875, DOI 10.1042/BJ20020903; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Karlsson HKR, 2005, DIABETES, V54, P1692, DOI 10.2337/diabetes.54.6.1692; Karnam P, 1997, J BIOL CHEM, V272, P6136, DOI 10.1074/jbc.272.10.6136; Kawai K, 2004, BIOCHEM SOC T, V32, P1107, DOI 10.1042/BST0321107; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; Lawlor MA, 2001, J CELL SCI, V114, P2903; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, TRENDS BIOCHEM SCI, V28, P573, DOI 10.1016/j.tibs.2003.09.003; MIINEA CP, 2005, BIOCH J; Ng IOL, 2000, CANCER RES, V60, P6581; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sano H, 2003, J BIOL CHEM, V278, P14599, DOI 10.1074/jbc.C300063200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schmid G, 1998, N-S ARCH PHARMACOL, V357, P385, DOI 10.1007/PL00005183; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Standaert M, 1998, J BIOL CHEM, V273, P7470, DOI 10.1074/jbc.273.13.7470; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; vandenBerghe N, 1996, BIOCHEM BIOPH RES CO, V229, P430, DOI 10.1006/bbrc.1996.1821; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Yamaga M, 2004, GENES CELLS, V9, P25, DOI 10.1111/j.1356-9597.2004.00698.x; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Zhao ZS, 2005, BIOCHEM J, V386, P201, DOI 10.1042/BJ20041638; Zhou QL, 2004, BIOCHEM SOC T, V32, P817, DOI 10.1042/BST0320817	51	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4762	4770		10.1074/jbc.M511008200	http://dx.doi.org/10.1074/jbc.M511008200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16338927	hybrid			2022-12-27	WOS:000235426200026
J	Kajaste-Rudnitski, A; Mashimo, T; Frenkiel, MP; Guenet, JL; Lucas, M; Despres, P				Kajaste-Rudnitski, A; Mashimo, T; Frenkiel, MP; Guenet, JL; Lucas, M; Despres, P			The 2 ',5 '-oligoadenylate synthetase 1b is a potent inhibitor of West Nile virus replication inside infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2'-5'-OLIGOADENYLATE SYNTHETASE; ALPHA/BETA-INTERFERON; GENE; ACTIVATION; FLAVIVIRUS; PROTEIN; FAMILY; SUSCEPTIBILITY; ENCEPHALITIS; RESISTANCE	The 2',5'-oligoadenylate synthetase (OAS) proteins associated with endoribonuclease RNase L are components of the interferon-regulated OAS/RNase L system, which is an RNA decay pathway known to play an important role in the innate antiviral immunity. A large body of evidence suggests a critical role for the 1b isoform of the mouse Oas gene (Oas1b) in resistance to West Nile virus (WNV) infection in vivo. WNV is a positive, single-stranded RNA virus responsible for severe encephalitis in a large range of animal species and humans. To investigate the molecular basis for the sensitivity of WNV to the Oas1b antiviral pathway, we established a stable mouse fibroblastic cell clone that up-regulates Oas1b protein expression under the control of the Tet-Off expression system. We showed that murine cells respond to Oas1b expression by efficiently inhibiting WNV replication. The antiviral action of Oas1b was essentially restricted to the early stages in virus life cycle. We found that the inability of WNV to productively infect the Oas1b-expressing cells was attributable to a dramatic reduction in positive-stranded viral RNA level. Thus, Oas1b represents an antiviral pathway that exerts its inhibitory effect on WNV replication by preventing viral RNA accumulation inside infected cells.	Inst Pasteur, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Despres, P (corresponding author), Inst Pasteur, 25 Rue Dr Roux, F-75724 Paris 15, France.	pdespres@pasteur.fr		Kajaste-Rudnitski, Anna/0000-0003-1549-2426				Best SM, 2005, J VIROL, V79, P12828, DOI 10.1128/JVI.79.20.12828-12839.2005; Brinton MA, 2002, ANNU REV MICROBIOL, V56, P371, DOI 10.1146/annurev.micro.56.012302.160654; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Ceccaldi PE, 2004, FEMS MICROBIOL LETT, V233, P1, DOI 10.1016/j.femsle.2004.01.035; Despres P, 2005, J INFECT DIS, V191, P207, DOI 10.1086/426824; Diamond MS, 2003, VIRAL IMMUNOL, V16, P259, DOI 10.1089/088282403322396082; Eskildsen S, 2002, CELL MOL LIFE SCI, V59, P1212, DOI 10.1007/s00018-002-8499-2; Fredericksen BL, 2004, J VIROL, V78, P7737, DOI 10.1128/JVI.78.14.7737-7747.2004; Guo JT, 2005, J VIROL, V79, P1343, DOI 10.1128/JVI.79.3.1343-1350.2005; Hartmann R, 2003, MOL CELL, V12, P1173, DOI 10.1016/S1097-2765(03)00433-7; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kakuta S, 2002, J INTERF CYTOK RES, V22, P981, DOI 10.1089/10799900260286696; Liu WJ, 2005, J VIROL, V79, P1934, DOI 10.1128/JVI.79.3.1934-1942.2005; Lucas M, 2003, IMMUNOL CELL BIOL, V81, P230, DOI 10.1046/j.1440-1711.2003.01166.x; Lucas M, 2004, VIROL J, V1, DOI 10.1186/1743-422X-1-9; Mashimo T, 2003, GENOMICS, V82, P537, DOI 10.1016/S0888-7543(03)00176-9; Mashimo T, 2002, P NATL ACAD SCI USA, V99, P11311, DOI 10.1073/pnas.172195399; Pantelic L, 2005, J VIROL, V79, P1753, DOI 10.1128/JVI.79.3.1753-1764.2005; Perelygin AA, 2002, P NATL ACAD SCI USA, V99, P9322, DOI 10.1073/pnas.142287799; Rogozin IB, 2003, J MOL BIOL, V326, P1449, DOI 10.1016/S0022-2836(03)00055-X; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Samuel CE, 2002, P NATL ACAD SCI USA, V99, P11555, DOI 10.1073/pnas.202448899; Samuel MA, 2005, J VIROL, V79, P13350, DOI 10.1128/JVI.79.21.13350-13361.2005; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Silvonek AL, 2004, J MIDWIFERY WOM HEAL, V49, P464, DOI 10.1016/j.jmwh.2004.04.026; Suzuki T, 1999, EMBO J, V18, P6017, DOI 10.1093/emboj/18.21.6017; Taguchi T, 2004, J GEN VIROL, V85, P959, DOI 10.1099/vir.0.19513-0; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Wang T, 2004, CURR OPIN IMMUNOL, V16, P519, DOI 10.1016/j.coi.2004.05.008; Yakub I, 2005, J INFECT DIS, V192, P1741, DOI 10.1086/497340	31	88	94	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4624	4637		10.1074/jbc.M508649200	http://dx.doi.org/10.1074/jbc.M508649200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371364	hybrid			2022-12-27	WOS:000235426200010
J	Rey, O; Papazyan, R; Waldron, RT; Young, SH; Lippincott-Schwartz, J; Jacamo, R; Rozengurt, E				Rey, O; Papazyan, R; Waldron, RT; Young, SH; Lippincott-Schwartz, J; Jacamo, R; Rozengurt, E			The nuclear import of protein kinase D3 requires its catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR ACTIVATION; PLECKSTRIN HOMOLOGY DOMAIN; CYSTEINE-RICH MOTIFS; INTRACELLULAR REDISTRIBUTION; MOLECULAR-CLONING; TYROSINE KINASE; PHORBOL ESTERS; EXPORT SIGNALS; C FAMILY; TRANSLOCATION	The protein kinase D (PKD) family consists of three serine/threonine protein kinases termed PKD, PKD2, and PKD3, which are similar in overall structure and primary amino acid sequence. However, each isozyme displays a distinctive intracellular localization. Taking advantage of the structural homology and opposite nuclear localization of PKD2 and PKD3, we generated an extensive set of chimeric proteins between both isozymes to determine which PKD3 domain(s) mediates its nuclear localization. We found that the C-terminal region of PKD3, which contains its catalytic domain, is necessary but not sufficient for its nuclear localization. Real time imaging of a photoactivatable green fluorescent protein fused to PKD3 revealed that point mutations that render PKD3 catalytically inactive completely prevented its nuclear import despite its interaction with importin alpha and beta. We also found that activation loop phosphorylation of PKD3 did not require its nuclear localization, and it was not sufficient to promote the nuclear import of PKD3. These results identify a novel function for the kinase activity of PKD3 in promoting its nuclear entry and suggest that the catalytic activity of PKD3 may regulate its nuclear import through autophosphorylation and/or interaction with another protein(s).	Univ Calif Los Angeles, Dept Med, Unit Signal Transduct & Gastrointestinal Canc, Div Digest Dis,CURE Digest Dis Res Ctr,David Geff, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA; NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Rey, O (corresponding author), Univ Calif Los Angeles, Dept Med, Unit Signal Transduct & Gastrointestinal Canc, Div Digest Dis,CURE Digest Dis Res Ctr,David Geff, 900 Vet Ave,Warren Hall Rm 11-115, Los Angeles, CA 90095 USA.	orey@mednet.ucla.edu	Waldron, Richard Taliesin/ABF-2773-2020	Waldron, Richard Taliesin/0000-0003-3151-6002; Rey, Osvaldo/0000-0003-1575-9864	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001609] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K01CA097956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, P30DK041301] Funding Source: NIH RePORTER; NCI NIH HHS [K01CA097956] Funding Source: Medline; NIDDK NIH HHS [DK 55003, DK 56930, 5 P30 DK41301] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Buchner K, 2000, J CANCER RES CLIN, V126, P1, DOI 10.1007/PL00008458; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Iglesias T, 1999, FEBS LETT, V454, P53, DOI 10.1016/S0014-5793(99)00772-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Jacamo R, 2003, J VIROL, V77, P10383, DOI 10.1128/JVI.77.19.10383-10393.2003; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lemrow SM, 2004, J BIOL CHEM, V279, P11664, DOI 10.1074/jbc.M312613200; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Lippincott-Schwartz J, 2003, NAT CELL BIOL, pS7, DOI 10.1038/ncb1032; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Patterson GH, 2004, METHODS, V32, P445, DOI 10.1016/j.ymeth.2003.10.006; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Perander M, 2001, J BIOL CHEM, V276, P13015, DOI 10.1074/jbc.M010356200; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Rey O, 2005, J BIOL CHEM, V280, P22875, DOI 10.1074/jbc.M503455200; Rey O, 2004, J BIOL CHEM, V279, P34361, DOI 10.1074/jbc.M403265200; Rey O, 2003, J CELL PHYSIOL, V196, P483, DOI 10.1002/jcp.10323; Rey O, 2003, J BIOL CHEM, V278, P23773, DOI 10.1074/jbc.M300226200; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rozengurt E, 1997, BIOCHEM SOC T, V25, P565, DOI 10.1042/bst0250565; Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; YAMAKASI L, 1992, NUCL TRAFFICKING	46	18	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5149	5157		10.1074/jbc.M508014200	http://dx.doi.org/10.1074/jbc.M508014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380377	hybrid			2022-12-27	WOS:000235426200069
J	Subramanian, VS; Marchant, JS; Said, HM				Subramanian, VS; Marchant, JS; Said, HM			Targeting and trafficking of the human thiamine transporter-2 in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDUCED FOLATE CARRIER; APICAL SORTING SIGNAL; CANINE KIDNEY-CELLS; INTRACELLULAR TRAFFICKING; TRANSMEMBRANE DOMAIN; CYTOPLASMIC TAIL; MEMBRANE; EXPRESSION; MUTATIONS; MECHANISM	Humans lack biochemical pathways for thiamine synthesis, so cellular requirements are met via specific carrier-mediated uptake pathways. Two proteins from the solute carrier SLC19A gene family have been identified as human thiamine transporters (hTHTRs), SLC19A1 (hTHTR1) and SLC19A2 (hTHTR2). Both of these transporters are co-expressed but are differentially targeted in polarized cell types that mediate vectorial thiamine transport ( e. g. renal and intestinal epithelia). It is important to understand the domain structure of these proteins, namely which regions within the polypeptide sequence are important for physiological delivery to the cell surface, in order to understand the impact of clinically relevant mutations on thiamine transport. Here we have characterized the mechanisms regulating hTHTR2 distribution by using live cell imaging methods that resolve the targeting and trafficking dynamics of full-length hTHTR2, a series of hTHTR2 truncation mutants, as well as chimeras comprising the hTHTR1 and hTHTR2 sequence. We showed the following: (i) that the cytoplasmic COOH-tail of hTHTR2 is not essential for apical targeting in polarized cells; (ii) that delivery of hTHTR2 to the cell surface is critically dependent on the integrity of the transmembrane backbone of the polypeptide so that minimal truncations abrogate cell surface expression of hTHTR2; and (iii) video rate images of hTHTR2-containing intracellular vesicles displayed rapid bi-directional trafficking events to and from the cell surface impaired by microtubule-disrupting but not microfilament-disrupting agents as well as by overexpression of the dynactin subunit dynamitin (p50). Finally, we compared the behavior of hTHTR2 with that of hTHTR1 and the human reduced folate carrier (SLC19A1) to underscore commonalities in the cell surface targeting mechanisms of the entire SLC19A gene family.	Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Physiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biophys, Irvine, CA 92697 USA; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; Dept Vet Affairs Med Ctr, Long Beach, CA 90822 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System	Said, HM (corresponding author), Dept Vet Affairs Med Ctr 151, Long Beach, CA 90822 USA.	hmsaid@uci.edu	MARCHANT, Jonathan/B-8051-2009; Marchant, Jonathan/Q-5484-2019	MARCHANT, Jonathan/0000-0001-6592-0877; Marchant, Jonathan/0000-0001-6592-0877	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK063750, R01DK056061, R01DK058057, R37DK056061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046783] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-63750, DK-58057, DK-56061] Funding Source: Medline; NINDS NIH HHS [NS-046783] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Altschuler Y, 2003, CURR OPIN CELL BIOL, V15, P423, DOI 10.1016/S0955-0674(03)00084-X; AXELROD D, 1989, METHOD CELL BIOL, V30, P245; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Berdanier CD, 1998, ADV NUTR MICRONUTRIE, P80; Boulware MJ, 2003, BIOCHEM J, V376, P43, DOI 10.1042/BJ20031220; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Callamaras N, 1999, CELL CALCIUM, V26, P271, DOI 10.1054/ceca.1999.0085; Cheng CL, 2002, J NEUROSCI, V22, P10643; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; Diaz GA, 1999, NAT GENET, V22, P309, DOI 10.1038/10385; Dudeja PK, 2001, AM J PHYSIOL-CELL PH, V281, pC786, DOI 10.1152/ajpcell.2001.281.3.C786; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Dutta B, 1999, J BIOL CHEM, V274, P31925, DOI 10.1074/jbc.274.45.31925; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eudy JD, 2000, MOL GENET METAB, V71, P581, DOI 10.1006/mgme.2000.3112; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; Gastaldi G, 2000, KIDNEY INT, V57, P2043, DOI 10.1046/j.1523-1755.2000.00053.x; GOLDSCHMIDT RB, 1989, BRAIN RES, V486, P133, DOI 10.1016/0006-8993(89)91285-7; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hou ZJ, 2005, J BIOL CHEM, V280, P36206, DOI 10.1074/jbc.M507295200; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Karim-Jimenez Z, 2000, P NATL ACAD SCI USA, V97, P2916, DOI 10.1073/pnas.97.6.2916; King SJ, 2003, MOL BIOL CELL, V14, P5089, DOI 10.1091/mbc.E03-01-0025; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Labay V, 1999, NAT GENET, V22, P300, DOI 10.1038/10372; LAFONT F, 1994, NATURE, V372, P801; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Marchant JS, 2002, J BIOL CHEM, V277, P33325, DOI 10.1074/jbc.M205955200; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/cm.970320404; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Neufeld EJ, 2001, BLOOD CELL MOL DIS, V27, P135, DOI 10.1006/bcmd.2000.0356; Reidling JC, 2002, BBA-BIOMEMBRANES, V1561, P180, DOI 10.1016/S0005-2736(02)00341-3; Said HM, 2004, AM J PHYSIOL-GASTR L, V286, pG491, DOI 10.1152/ajpgi.00361.2003; Said HM, 2001, AM J PHYSIOL-GASTR L, V281, pG144, DOI 10.1152/ajpgi.2001.281.1.G144; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; Subramanian VS, 2004, J BIOL CHEM, V279, P27719, DOI 10.1074/jbc.M400876200; Subramanian VS, 2003, J BIOL CHEM, V278, P3976, DOI 10.1074/jbc.M210717200; Subramanian VS, 2001, AM J PHYSIOL-GASTR L, V281, pG1477, DOI 10.1152/ajpgi.2001.281.6.G1477; Sun AQ, 2001, J BIOL CHEM, V276, P6825, DOI 10.1074/jbc.M008797200; Suzuki T, 2001, EUR J CELL BIOL, V80, P765, DOI 10.1078/0171-9335-00204; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; Tamura N, 2001, J BIOL CHEM, V276, P20330, DOI 10.1074/jbc.M007993200; Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X; Trinczek B, 1999, J CELL SCI, V112, P2355; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; VICTOR M, 1989, WERNICKEKORSAKOFF SY; Wang YR, 2003, J CELL SCI, V116, P2051, DOI 10.1242/jcs.00398; Welte MA, 2004, CURR BIOL, V14, pR525, DOI 10.1016/j.cub.2004.06.045; Zeng WQ, 2005, AM J HUM GENET, V77, P16, DOI 10.1086/431216	54	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5233	5245		10.1074/jbc.M512765200	http://dx.doi.org/10.1074/jbc.M512765200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371350				2022-12-27	WOS:000235426200078
J	Yamaguchi, H; Tateno, M; Yamasaki, K				Yamaguchi, H; Tateno, M; Yamasaki, K			Solution structure and DNA-binding mode of the matrix attachment region-binding domain of the transcription factor SATB1 that regulates the T-cell maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU DOMAIN; PROTEIN STRUCTURES; HOMEODOMAIN; RECOGNITION; SEQUENCE; OCT-1; DISTAMYCIN; EXPRESSION; PROGRAM; QUALITY	SATB1 is a transcriptional regulator controlling the gene expression that is essential in the maturation of the immune T-cell. SATB1 binds to the nuclear matrix attachment regions of DNA, where it recruits histone deacetylase and represses transcription through a local chromatin remodeling. Here we determined the solution structure of the matrix attachment region-binding domain, possessing similarity to the CUT DNA-binding domain, of human SATB1 by NMR spectroscopy. The structure consists of five alpha-helices, in which the N-terminal four are arranged similarly to the four-helix structure of the CUT domain of hepatocyte nuclear factor 6 alpha. By an NMR chemical shift perturbation analysis and by surface plasmon resonance analyses of SATB1 mutant proteins, an interface for DNA binding was revealed to be located at the third helix and the surrounding regions. Surface plasmon resonance experiments using groove-specific binding drugs and methylated DNAs indicated that the domain recognizes DNA from the major groove side. These observations suggested that SATB1 possesses a DNA-binding mode similar to that of the POU-specific DNA-binding domain, which is known to share structural similarity to the four-helix CUT domain.	Natl Inst Adv Ind Sci & Technol, Age Dimens Res Ctr, Tsukuba, Ibaraki 3058566, Japan; Tottori Univ, Fac Engn, Dept Mat Sci, Tottori 6808552, Japan; Univ Tsukuba, Inst Phys, Tsukuba, Ibaraki 3058571, Japan; Univ Tsukuba, Ctr Computat Sci, Tsukuba, Ibaraki 3058571, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Tottori University; University of Tsukuba; University of Tsukuba	Yamasaki, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Age Dimens Res Ctr, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	k-yamasaki@aist.go.jp	Yamaguchi, Hiroshi/A-2068-2016; Yamasaki, Kazuhiko/L-7108-2018	Yamaguchi, Hiroshi/0000-0001-9148-7990; Yamasaki, Kazuhiko/0000-0003-0320-9697				Alvarez JD, 2000, GENE DEV, V14, P521; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BAX A, 1994, CURR OPIN STRUC BIOL, V4, P738, DOI 10.1016/S0959-440X(94)90173-2; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chi YI, 2002, MOL CELL, V10, P1129, DOI 10.1016/S1097-2765(02)00704-9; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LUCK G, 1974, NUCLEIC ACIDS RES, V1, P503, DOI 10.1093/nar/1.3.503; MONDRAGON A, 1989, J MOL BIOL, V205, P180; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NORDEN B, 1977, CHEM PHYS LETT, V50, P508, DOI 10.1016/0009-2614(77)80379-5; Reay P, 2004, PROTEINS, V56, P40, DOI 10.1002/prot.20054; Seo J, 2005, J BIOL CHEM, V280, P24600, DOI 10.1074/jbc.M414076200; Sheng WY, 2004, J BIOL CHEM, V279, P33928, DOI 10.1074/jbc.M403805200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Truscott M, 2004, J BIOL CHEM, V279, P49787, DOI 10.1074/jbc.M409484200; Wen J, 2005, BLOOD, V105, P3330, DOI 10.1182/blood-2004-08-2988; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P44; Yamasaki K, 2004, PLANT CELL, V16, P3448, DOI 10.1105/tpc.104.026112; Yamasaki K, 2004, J MOL BIOL, V337, P49, DOI 10.1016/j.jmb.2004.01.015; Yamasaki T, 1998, P JPN ACAD B-PHYS, V74, P210, DOI 10.2183/pjab.74.210; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084	37	25	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5319	5327		10.1074/jbc.M510933200	http://dx.doi.org/10.1074/jbc.M510933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371359	hybrid			2022-12-27	WOS:000235426200086
J	Kamimoto, T; Shoji, S; Hidvegi, T; Mizushima, N; Umebayashi, K; Perlmutter, DH; Yoshimori, T				Kamimoto, T; Shoji, S; Hidvegi, T; Mizushima, N; Umebayashi, K; Perlmutter, DH; Yoshimori, T			Intracellular inclusions containing mutant alpha(1)-antitrypsin Z are propagated in the absence of autophagic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CONJUGATION SYSTEM; QUALITY-CONTROL; LIVER-DISEASE; DEGRADATION; PROTEIN; AGGRESOMES; MATURATION; INHIBITORS; RETENTION	Mutant alpha(1)-antitrypsin Z (alpha(1)-ATZ) protein, which has a tendency to form aggregated polymers as it accumulates within the endoplasmic reticulum of the liver cells, is associated with the development of chronic liver injury and hepatocellular carcinoma in hereditary alpha(1)-antitrypsin (alpha(1)-AT) deficiency. Previous studies have suggested that efficient intracellular degradation of alpha(1)-ATZ is correlated with protection from liver disease in alpha(1)-AT deficiency and that the ubiquitinproteasome system accounts for a major route, but not the sole route, of alpha(1)-ATZ disposal. Yet another intracellular degradation system, autophagy, has also been implicated in the pathophysiology of alpha(1)-AT deficiency. To provide genetic evidence for autophagymediated disposal of alpha(1)-ATZ, here we used cell lines deleted for the Atg5 gene that is necessary for initiation of autophagy. In the absence of autophagy, the degradation of alpha(1)-ATZ was retarded, and the characteristic cellular inclusions of alpha(1)-ATZ accumulated. In wild-type cells, colocalization of the autophagosomal membrane marker GFP-LC3 and alpha(1)-ATZ was observed, and this colocalization was enhanced when clearance of autophagosomes was prevented by inhibiting fusion between autophagosome and lysosome. By using a transgenic mouse with liver-specific inducible expression of alpha(1)-ATZ mated to the GFP-LC3 mouse, we also found that expression of alpha(1)-ATZ in the liver in vivo is sufficient to induce autophagy. These data provide definitive evidence that autophagy can participate in the quality control/degradative pathway for alpha(1)-ATZ and suggest that autophagic degradation plays a fundamental role in preventing toxic accumulation of alpha(1)-ATZ.	Natl Inst Genet, Dept Cell Genet, Shizuoka 4558540, Japan; Grad Univ Adv Studies, Dept Genet, Mishima, Shizuoka 4558540, Japan; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat Cell Biol & Physiol, Pittsburgh, PA 15213 USA; Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Tokyo 1138613, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi 3320012, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Yoshimori, T (corresponding author), Natl Inst Genet, Dept Cell Genet, Yata 1111 Mishima, Shizuoka 4558540, Japan.	tamyoshi@lab.nig.ac.jp	Shoji, Shisako/C-3690-2017; Hidvegi, Tunda/A-8041-2008; Mizushima, Noboru/C-3635-2009; Shoji, Shisako/AAJ-2654-2020	Shoji, Shisako/0000-0001-8787-2159; Mizushima, Noboru/0000-0002-6258-6444; Shoji, Shisako/0000-0001-8787-2159	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061760] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL037784] Funding Source: Medline; NIDDK NIH HHS [DK061760, DK52565] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOLENDER RP, 1973, J CELL BIOL, V56, P746, DOI 10.1083/jcb.56.3.746; Cabral CM, 2000, J BIOL CHEM, V275, P25015, DOI 10.1074/jbc.M910172199; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114; Hidvegi T, 2005, J BIOL CHEM, V280, P39002, DOI 10.1074/jbc.M508652200; Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kopito RR, 2000, EMBO REP, V1, P225, DOI 10.1093/embo-reports/kvd052; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; LE AQ, 1992, J BIOL CHEM, V267, P1072; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lin L, 2001, J BIOL CHEM, V276, P33893, DOI 10.1074/jbc.M105226200; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Marcus NY, 2000, J BIOL CHEM, V275, P1987, DOI 10.1074/jbc.275.3.1987; MASAKI R, 1987, J CELL BIOL, V104, P1207, DOI 10.1083/jcb.104.5.1207; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2003, INT J BIOCHEM CELL B, V35, P553, DOI 10.1016/S1357-2725(02)00343-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Okiyoneda T, 2004, MOL BIOL CELL, V15, P563, DOI 10.1091/mbc.E03-06-0379; Perlmutter DH, 2002, J CLIN INVEST, V110, P1579, DOI 10.1172/JCI200216787; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Rudnick DA, 2005, HEPATOLOGY, V42, P1001, DOI 10.1002/hep.20931; Rudnick DA, 2004, HEPATOLOGY, V39, P1048, DOI 10.1002/hep.20118; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V279, pG961, DOI 10.1152/ajpgi.2000.279.5.G961; Teckman JH, 2004, AM J PHYSIOL-GASTR L, V286, pG851, DOI 10.1152/ajpgi.00175.2003; Teckman JH, 2002, AM J PHYSIOL-GASTR L, V283, pG1156, DOI 10.1152/ajpgi.00041.2002; Teckman JH, 1996, HEPATOLOGY, V24, P1504, DOI 10.1002/hep.510240635; Teckman JH, 2000, AM J PHYSIOL-GASTR L, V278, pG39, DOI 10.1152/ajpgi.2000.278.1.G39; Teckman JH, 2001, J BIOL CHEM, V276, P44865, DOI 10.1074/jbc.M103703200; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yoshida Y, 2003, J BIOCHEM, V134, P183, DOI 10.1093/jb/mvg128; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	42	205	214	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4467	4476		10.1074/jbc.M509409200	http://dx.doi.org/10.1074/jbc.M509409200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365039	hybrid			2022-12-27	WOS:000235275300082
J	Kihara, A; Anada, Y; Igarashi, Y				Kihara, A; Anada, Y; Igarashi, Y			Mouse sphingosine kinase isoforms SPHK1a and SPHK1b differ in enzymatic traits including stability, localization, modification, and oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CALCIUM MOBILIZATION; MOLECULAR-CLONING; SPHINGOSINE-1-PHOSPHATE; PROTEIN; IDENTIFICATION; 1-PHOSPHATE; RECEPTOR; PHOSPHORYLATION; MEMBRANE	Sphingosine kinases catalyze the production of the bioactive lipid molecule sphingosine 1-phosphate. Mice have two isoforms of sphingosine kinase type 1, SPHK1a and SPHK1b. In addition to the previously reported difference in their enzyme activities, we have found that these isoforms differ in several enzymatic characteristics. First, SPHK1b is unstable, whereas SPHK1a is highly stable. Degradation of SPHK1b occurs at the membrane and is inhibited by a proteasome inhibitor. Second, only SPHK1b exhibits abnormal mobility on SDS-PAGE, probably due to its SDS-resistant structure. Third, SPHK1a and SPHK1b are predominantly detected in the soluble and membrane fractions, respectively, when their degradation is inhibited. Fourth, only SPHK1b is modified with lipid, on its unique Cys residues (Cys-4 and Cys-5). Site-directed mutagenesis at these Cys residues resulted in increased sphingosine kinase activity, suggesting that the modification is inhibitory to the enzyme. Finally, SPHK1b tends to form homo-oligomers, whereas most SPHK1a is presented as monomers. We have also determined that the lipid modification of SPHK1b is involved in its homo-oligomerization. Thus, although these two proteins differ only in a few N-terminal amino acid residues, their enzymatic traits are extremely different.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Hokkaido University	Kihara, A (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Kita 12-Jo,Nishi 6-Choume, Sapporo, Hokkaido 0600812, Japan.	kihara@pharm.hokudai.ac.jp	KIHARA, AKIO/A-3802-2012	KIHARA, AKIO/0000-0001-5889-0788				Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Blakey D, 2002, BIOCHEM J, V364, P527, DOI 10.1042/BJ20011761; Borgnia MJ, 1999, J MOL BIOL, V291, P1169, DOI 10.1006/jmbi.1999.3032; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Choi OH, 1996, NATURE, V380, P634; Fukata M, 2004, NEURON, V44, P987, DOI 10.1016/j.neuron.2004.12.005; Fukuda Y, 2004, BBA-MOL CELL BIOL L, V1636, P12, DOI 10.1016/j.bbalip.2003.11.006; Fukuda Y, 2003, BIOCHEM BIOPH RES CO, V309, P155, DOI 10.1016/S0006-291X(03)01551-1; Gaillard I, 1996, BIOCHEMISTRY-US, V35, P6150, DOI 10.1021/bi953005v; Hayashi S, 2002, J BIOL CHEM, V277, P33319, DOI 10.1074/jbc.M201442200; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; Hirschman JE, 1999, MOL CELL BIOL, V19, P7705; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Imai S, 2002, J BIOL CHEM, V277, P35323, DOI 10.1074/jbc.M202035200; Imamura T, 2004, J VET MED SCI, V66, P1387, DOI 10.1292/jvms.66.1387; Imamura T, 2001, GENOMICS, V76, P117, DOI 10.1006/geno.2001.6607; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kihara A, 2005, MOL CELL BIOL, V25, P9189, DOI 10.1128/MCB.25.21.9189-9197.2005; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Lacana E, 2002, J BIOL CHEM, V277, P32947, DOI 10.1074/jbc.M202841200; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lu W, 2001, J BIOL CHEM, V276, P47993, DOI 10.1074/jbc.M109674200; Maceyka M, 2004, FEBS LETT, V568, P30, DOI 10.1016/j.febslet.2004.04.093; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; MAZUREK N, 1994, BIOCHEM BIOPH RES CO, V198, P1, DOI 10.1006/bbrc.1994.1001; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Taha TA, 2004, BBA-MOL CELL BIOL L, V1682, P48, DOI 10.1016/S1388-1981(04)00023-X; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yatomi Y, 1997, J BIOCHEM, V121, P969; Yokota S, 2004, FEBS LETT, V578, P106, DOI 10.1016/j.febslet.2004.10.081	46	77	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4532	4539		10.1074/jbc.M510308200	http://dx.doi.org/10.1074/jbc.M510308200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368679	hybrid			2022-12-27	WOS:000235275300089
J	Lindermayr, C; Saalbach, G; Bahnweg, G; Durner, J				Lindermayr, C; Saalbach, G; Bahnweg, G; Durner, J			Differential inhibition of Arabidopsis methionine adenosyltransferases by protein S-nitrosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT NITRATE REDUCTASE; ACTIVE-SITE LOOP; NITRIC-OXIDE; ADENOSYLMETHIONINE SYNTHETASE; IN-VITRO; CRYSTAL-STRUCTURE; ABSCISIC-ACID; NO; IDENTIFICATION; SIGNAL	In animals, protein S-nitrosylation, the covalent attachment of NO to the thiol group of cysteine residues, is an intensively investigated posttranslational modification, which regulates many different processes. A growing body of evidence suggests that this type of redox-based regulation mechanism plays a pivotal role in plants, too. Here we report the molecular mechanism for S-nitrosylation of methionine adenosyltransferase (MAT) of Arabidopsis thaliana, thereby presenting the first detailed characterization of S-nitrosylation in plants. We cloned three MAT isoforms of Arabidopsis and tested the effect of NO on the activity of the purified, recombinant proteins. Our data showed that incubation with GSNO resulted in blunt, reversible inhibition of MAT1, whereas MAT2 and MAT3 were not significantly affected. Cys-114 of MAT1 was identified as the most promising target of NO-induced inhibition of MAT1, because this residue is absent in MAT2 and MAT3. Structural analysis of MAT1 revealed that Cys-114 is located nearby the putative substrate binding site of this enzyme. Furthermore, Cys-114 is flanked by S-nitrosylation-promoting amino acids. The inhibitory effect of GSNO was drastically reduced when Cys-114 of MAT1 was replaced by arginine, and mass spectrometric analyses of Cys-114-containing peptides obtained after chymotryptic digestion demonstrated that Cys-114 of MAT1 is indeed S-nitrosylated. Because MAT catalyzes the synthesis of the ethylene precursor S-adenosylmethionine and NO is known to influence ethylene production in plants, this enzyme probably mediates the cross-talk between ethylene and NO signaling.	GSF Munich, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, D-85764 Munich, Germany; Riso Natl Lab, Plant Res Dept, DK-4000 Roskilde, Denmark	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Technical University of Denmark	Durner, J (corresponding author), GSF Munich, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, Ingolstadter Landstr 1, D-85764 Munich, Germany.	durner@gsf.de	Lindermayr, Christian/M-7338-2014	Lindermayr, Christian/0000-0002-9343-4996				Akhand AK, 1999, J BIOL CHEM, V274, P25821, DOI 10.1074/jbc.274.36.25821; Avila MA, 1997, HEPATOLOGY, V25, P391; Beligni MV, 2002, PLANT PHYSIOL, V129, P1642, DOI 10.1104/pp.002337; Bethke PC, 2004, PLANT CELL, V16, P332, DOI 10.1105/tpc.017822; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; Castro C, 1999, FEBS LETT, V459, P319, DOI 10.1016/S0014-5793(99)01267-3; Corrales FJ, 2002, J NUTR, V132, p2377S, DOI 10.1093/jn/132.8.2377S; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Durner J, 1998, P NATL ACAD SCI USA, V95, P10328, DOI 10.1073/pnas.95.17.10328; Eu JP, 2000, CELL, V102, P499, DOI 10.1016/S0092-8674(00)00054-4; Feechan A, 2005, P NATL ACAD SCI USA, V102, P8054, DOI 10.1073/pnas.0501456102; Garcia-Mata C, 2003, TRENDS PLANT SCI, V8, P20, DOI 10.1016/S1360-1385(02)00009-2; Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253; Graziano M, 2005, TRENDS PLANT SCI, V10, P4, DOI 10.1016/j.tplants.2004.12.004; Graziano M, 2002, PLANT PHYSIOL, V130, P1852, DOI 10.1104/pp.009076; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo FQ, 2003, SCIENCE, V302, P100, DOI 10.1126/science.1086770; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; Hao G, 2004, J BIOL CHEM, V279, P36192, DOI 10.1074/jbc.M404866200; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Huang JY, 2001, NUCLEIC ACIDS RES, V29, P202, DOI 10.1093/nar/29.1.202; Kim SO, 2002, CELL, V109, P383, DOI 10.1016/S0092-8674(02)00723-7; Komoto J, 2004, BIOCHEMISTRY-US, V43, P1821, DOI 10.1021/bi035611t; Lamattina L, 2003, ANNU REV PLANT BIOL, V54, P109, DOI 10.1146/annurev.arplant.54.031902.134752; LANDY A, 1989, ANNU REV BIOCHEM, V58, P913, DOI 10.1146/annurev.biochem.58.1.913; Leshem YY, 1998, PLANT PHYSIOL BIOCH, V36, P825, DOI 10.1016/S0981-9428(99)80020-5; Leshem YY, 1996, J PLANT PHYSIOL, V148, P258, DOI 10.1016/S0176-1617(96)80251-3; Leshem YY, 2000, NITRIC OXIDE PLANTS; Lindermayr C, 2005, PLANT PHYSIOL, V137, P921, DOI 10.1104/pp.104.058719; Lindermayr C, 2003, J BIOL CHEM, V278, P2781, DOI 10.1074/jbc.M202632200; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Mannick JB, 2004, FREE RADICAL RES, V38, P1, DOI 10.1080/10715760310001629065; Martinez-Ruiz A, 2004, CARDIOVASC RES, V62, P43, DOI 10.1016/j.cardiores.2004.01.013; MATO JM, 1994, ADV EXP MED BIOL, V368, P113; Matsumoto A, 2003, SCIENCE, V301, P657, DOI 10.1126/science.1079319; Neill SJ, 2002, PLANT PHYSIOL, V128, P13, DOI 10.1104/pp.010707; Perazzolli M, 2004, PLANT CELL, V16, P2785, DOI 10.1105/tpc.104.025379; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Rockel P, 2002, J EXP BOT, V53, P103, DOI 10.1093/jexbot/53.366.103; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; Russwurm M, 2004, EMBO J, V23, P4443, DOI 10.1038/sj.emboj.7600422; Sanchez-Perez GF, 2004, J MOL BIOL, V335, P693, DOI 10.1016/j.jmb.2003.11.022; Shen B, 2002, PLANT J, V29, P371, DOI 10.1046/j.1365-313X.2002.01221.x; Sokolovski S, 2004, PLANT PHYSIOL, V136, P4275, DOI 10.1104/pp.104.050344; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; Stohr C, 2001, PLANTA, V212, P835, DOI 10.1007/s004250000447; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; Taylor JC, 2003, ARCH BIOCHEM BIOPHYS, V415, P164, DOI 10.1016/S0003-9861(03)00277-7; Taylor JC, 2002, BIOCHEMISTRY-US, V41, P9358, DOI 10.1021/bi025851t; Tedeschi G, 2005, PROTEOMICS, V5, P2422, DOI 10.1002/pmic.200401208; Tuomainen J, 1997, PLANT J, V12, P1151, DOI 10.1046/j.1365-313X.1997.12051151.x; Wang KLC, 2002, PLANT CELL, V14, pS131, DOI 10.1105/tpc.001768; Wendehenne D, 2004, CURR OPIN PLANT BIOL, V7, P449, DOI 10.1016/j.pbi.2004.04.002; Yamasaki H, 2000, FEBS LETT, V468, P89, DOI 10.1016/S0014-5793(00)01203-5; Zeidler D, 2004, P NATL ACAD SCI USA, V101, P15811, DOI 10.1073/pnas.0404536101	57	191	213	0	19	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4285	4291		10.1074/jbc.M511635200	http://dx.doi.org/10.1074/jbc.M511635200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365035	hybrid			2022-12-27	WOS:000235275300062
J	Letts, JA; Rose, NL; Fang, YR; Barry, CH; Borisova, SN; Seto, NOL; Palcic, MM; Evans, SV				Letts, JA; Rose, NL; Fang, YR; Barry, CH; Borisova, SN; Seto, NOL; Palcic, MM; Evans, SV			Differential recognition of the type I and IIH antigen acceptors by the human ABO(H) blood group A and B glycosyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-SPECIFIED GLYCOSYLTRANSFERASES; ANALOGS; ALPHA-L-FUCP-(1->2)-BETA-D-GALP-OR; BIOSYNTHESIS; SYSTEM	The human ABO( H) blood group A and B antigens are generated by the homologous glycosyltransferases A (GTA) and B (GTB), which add the monosaccharides GalNAc and Gal, respectively, to the cell-surface H antigens. In the first comprehensive structural study of the recognition by a glycosyltransferase of a panel of substrates corresponding to acceptor fragments, 14 high resolution crystal structures of GTA and GTB have been determined in the presence of oligosaccharides corresponding to different segments of the type I (alpha-L-Fucp-(1 -> 2)-beta-D-Galp-(1 -> 3)-beta-D-GlcNAcp-OR, where R is a glycoprotein or glycolipid in natural acceptors) and type II (alpha-L-Fucp-(1 -> 2)-beta-D-Galp-(1 -> 4)-beta-D-GlcNAcp-OR) H antigen trisaccharides. GTA and GTB differ in only four '' critical '' amino acid residues (Arg/Gly-176, Gly/Ser-235, Leu/Met-266, and Gly/Ala-268). As these enzymes both utilize the H antigen acceptors, the four critical residues had been thought to be involved strictly in donor recognition; however, we now report that acceptor binding and subsequent transfer are significantly influenced by two of these residues: Gly/Ser-235 and Leu/Met-266. Furthermore, these structures show that acceptor recognition is dominated by the central Gal residue despite the fact that the L-Fuc residue is required for efficient catalysis and give direct insight into the design of model inhibitors for GTA and GTB.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Victoria; University of Alberta	Evans, SV (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055 STN SCS, Victoria, BC V8W 3P6, Canada.	svevans@uvic.ca	Letts, James Anthony/AAN-6632-2020	Letts, James Anthony/0000-0002-9864-3586; Evans, Stephen/0000-0002-0366-4027				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Hakomori S, 1999, BBA-GEN SUBJECTS, V1473, P247, DOI 10.1016/S0304-4165(99)00183-X; Lazar K, 2002, CURR OPIN CHEM BIOL, V6, P786, DOI 10.1016/S1367-5931(02)00355-1; Liu Jianhua, 2001, Current Drug Targets - Infectious Disorders, V1, P159, DOI 10.2174/1568005014606107; LOWARY TL, 1993, CARBOHYD RES, V249, P163, DOI 10.1016/0008-6215(93)84068-H; LOWARY TL, 1994, CARBOHYD RES, V251, P33, DOI 10.1016/0008-6215(94)84275-2; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Nguyen HP, 2003, J BIOL CHEM, V278, P49191, DOI 10.1074/jbc.M308770200; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; SCHWYZER M, 1977, J BIOL CHEM, V252, P2346; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Seto NOL, 2000, CARBOHYD RES, V324, P161, DOI 10.1016/S0008-6215(99)00297-9; Somsak L, 2003, CURR PHARM DESIGN, V9, P1177, DOI 10.2174/1381612033454919; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1992, BIOCHEM BIOPH RES CO, V187, P366, DOI 10.1016/S0006-291X(05)81502-5	19	32	33	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3625	3632		10.1074/jbc.M507620200	http://dx.doi.org/10.1074/jbc.M507620200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326711	hybrid			2022-12-27	WOS:000235128200074
J	Pavlovic, S; Du, B; Sakamoto, K; Khan, KMF; Natarajan, C; Breyer, RM; Dannenberg, AJ; Falcone, DJ				Pavlovic, S; Du, B; Sakamoto, K; Khan, KMF; Natarajan, C; Breyer, RM; Dannenberg, AJ; Falcone, DJ			Targeting prostaglandin E-2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE-CELLS; HMG-COA REDUCTASE; PROSTANOID RECEPTORS; ATHEROSCLEROTIC PLAQUES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PLASMINOGEN ACTIVATION; MMP-9 SECRETION; MESSENGER-RNA	COX-2-dependent prostaglandin (PG) E-2 synthesis regulates macrophage MMP expression, which is thought to destabilize atherosclerotic plaques. However, the administration of selective COX-2 inhibitors paradoxically increases the frequency of adverse cardiovascular events potentially through the loss of anti-inflammatory prostanoids and/or disturbance in the balance of pro-and anti-thrombotic prostanoids. To avoid these collateral effects of COX-2 inhibition, a strategy to identify and block specific prostanoid-receptor interactions may be required. We previously reported that macrophage engagement of vascular extracellular matrix (ECM) triggers proteinase expression through a MAPK(erk1/2)-dependent increase in COX-2 expression and PGE(2) synthesis. Here we demonstrate that elicited macrophages express the PGE(2) receptors EP1-4. When plated on ECM, their expression of EP2 and EP4, receptors linked to PGE(2)-induced activation of adenylyl cyclase, is strongly stimulated. Forskolin and dibutryl cyclic-AMP stimulate macrophage matrix metalloproteinase (MMP)-9 expression in a dose-dependent manner. However, an EP2 agonist (butaprost) has no effect on MMP-9 expression, and macrophages from EP2 null mice exhibited enhanced COX-2 and MMP-9 expression when plated on ECM. In contrast, the EP4 agonist (PGE(1)-OH) stimulated macrophage MMP-9 expression, which was inhibited by the EP4 antagonist ONO-AE3-208. When compared with COX-2 silencing by small interfering RNA or inhibition by celecoxib, the EP4 antagonist was as effective in inhibiting ECM-induced proteinase expression. In addition, ECM-induced MMP-9 expression was blocked in macrophages in which EP4 was silenced by small interfering RNA. Thus, COX-2-dependent ECM-induced proteinase expression is effectively blocked by selective inhibition of EP4, a member of the PGE(2) family of receptors.	Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Vasc Biol Ctr, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA; Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Med, New York, NY 10021 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Cornell University; Cornell University; Cornell University; Cornell University; Vanderbilt University; Vanderbilt University	Falcone, DJ (corresponding author), Cornell Univ, Joan & Sanford I Weill Med Coll, Dept Pathol & Lab Med, Rm A678,1300 York Ave, New York, NY 10021 USA.	dfalcone@med.cornell.edu			NCI NIH HHS [CA089578] Funding Source: Medline; NHLBI NIH HHS [R01 HL073375, HL073375] Funding Source: Medline; NIGMS NIH HHS [GM15431, P50 GM015431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089578] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovitz M, 2000, BBA-MOL CELL BIOL L, V1483, P285, DOI 10.1016/S1388-1981(99)00164-X; Akaogi J, 2004, J LEUKOCYTE BIOL, V76, P227, DOI 10.1189/jlb.1203627; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Bayston T, 2003, J VASC SURG, V38, P354, DOI 10.1016/S0741-5214(03)00339-2; Bellosta S, 1998, ARTERIOSCL THROM VAS, V18, P1671, DOI 10.1161/01.ATV.18.11.1671; Belton O, 2000, CIRCULATION, V102, P840; Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014-2999(97)01383-6; Breyer RM, 2002, ADV EXP MED BIOL, V507, P321; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1925, DOI 10.1161/01.ATV.0000177814.41505.41; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be; Cipollone F, 2004, JAMA-J AM MED ASSOC, V291, P2221, DOI 10.1001/jama.291.18.2221; Cipollone F, 2003, CIRCULATION, V107, P1479, DOI 10.1161/01.CIR.0000056530.03783.81; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; CORCORAN ML, 1995, J BIOL CHEM, V270, P10365, DOI 10.1074/jbc.270.18.10365; de Fougerolles AR, 2000, IMMUNITY, V13, P749, DOI 10.1016/S1074-7613(00)00073-X; de Gaetano G, 2003, TRENDS PHARMACOL SCI, V24, P245, DOI 10.1016/S0165-6147(03)00077-4; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; EDELSON PJ, 1976, IN VITRO METHODS CEL, P333; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; Fujino H, 2003, TRENDS PHARMACOL SCI, V24, P335, DOI 10.1016/S0165-6147(03)00162-7; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, P NATL ACAD SCI USA, V92, P402, DOI 10.1073/pnas.92.2.402; Ganne F, 2000, THROMB HAEMOSTASIS, V84, P680, DOI 10.1055/s-0037-1614087; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003; Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016/S0021-9150(01)00547-0; Hla T, 1999, INT J BIOCHEM CELL B, V31, P551, DOI 10.1016/S1357-2725(98)00152-6; Holmes DR, 1996, J SURG RES, V63, P305, DOI 10.1006/jsre.1996.0265; Hubbard NE, 2001, PROSTAG LEUKOTR ESS, V65, P287, DOI 10.1054/plef.2001.0327; Hwang Daniel H., 2002, Neoplasia (New York), V4, P91, DOI 10.1038/sj.neo.7900226; Ikegami R, 2001, J IMMUNOL, V166, P4689, DOI 10.4049/jimmunol.166.7.4689; Kennedy CRJ, 1999, NAT MED, V5, P217, DOI 10.1038/5583; Khan KMF, 2004, J BIOL CHEM, V279, P22039, DOI 10.1074/jbc.M312735200; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Kobayashi T, 2002, PROSTAG OTH LIPID M, V68-9, P557, DOI 10.1016/S0090-6980(02)00055-2; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Ma WY, 2003, EXP NEUROL, V183, P581, DOI 10.1016/S0014-4886(03)00182-1; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528; McGeer PL, 2002, EXP GERONTOL, V37, P925, DOI 10.1016/S0531-5565(02)00028-1; MORENO PR, 1994, CIRCULATION, V90, P775, DOI 10.1161/01.CIR.90.2.775; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Narumiya S, 2003, LIFE SCI, V74, P391, DOI 10.1016/j.lfs.2003.09.025; Ottino P, 2001, CURR EYE RES, V23, P77, DOI 10.1076/ceyr.23.2.77.5471; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Ray WA, 2002, LANCET, V360, P1071, DOI 10.1016/S0140-6736(02)11131-7; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Robbie L, 2001, ANN NY ACAD SCI, V947, P167; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; SHAH PK, 1995, CIRCULATION, V92, P1565; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Stemme V, 2000, EUR J VASC ENDOVASC, V20, P146, DOI 10.1053/ejvs.2000.1145; Takayama K, 2002, J BIOL CHEM, V277, P44147, DOI 10.1074/jbc.M204810200; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; Tani K, 2001, BIOORG MED CHEM LETT, V11, P2025, DOI 10.1016/S0960-894X(01)00359-6; Treffkorn L, 2004, PROSTAG OTH LIPID M, V74, P113, DOI 10.1016/j.prostaglandins.2004.07.005; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671	68	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3321	3328		10.1074/jbc.M506846200	http://dx.doi.org/10.1074/jbc.M506846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338931	hybrid			2022-12-27	WOS:000235128200039
J	Seo, DW; Li, HM; Qu, CK; Oh, J; Kim, YS; Diaz, T; Wei, BY; Han, JW; Stetler-Stevenson, WG				Seo, DW; Li, HM; Qu, CK; Oh, J; Kim, YS; Diaz, T; Wei, BY; Han, JW; Stetler-Stevenson, WG			Shp-1 mediates the antiproliferative activity of tissue inhibitor of metalloproteinase-2 in human microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; DIFFERENTIAL REGULATION; MOTH-EATEN; P27(KIP1); INTEGRIN; ANGIOGENESIS; PROTEIN; GROWTH; CYCLE; EXPRESSION	The tissue inhibitors of metalloproteinases (TIMPs) regulate matrix metalloproteinase activity required for cell migration/invasion associated with cancer progression and angiogenesis. TIMPs also modulate cell proliferation in vitro and angiogenesis in vivo independent of their matrix metalloproteinase inhibitory activity. Here, we show that TIMP-2 mediates G(1) growth arrest in human endothelial cells through de novo synthesis of the cyclin-dependent kinase inhibitor p27(Kip1). TIMP-2-mediated inhibition of Cdk4 and Cdk2 activity is associated with increased binding of p27(Kip1) to these complexes in vivo. Protein-tyrosine phosphatase inhibitors or expression of a dominant negative Shp-1 mutant ablates TIMP-2 induction of p27(Kip1). Finally, angiogenic responses to fibroblast growth factor-2 and vascular endothelial growth factor-A in '' motheaten viable '' Shp-1-deficient mice are resistant to TIMP-2 inhibition, demonstrating that Shp-1 is an important negative regulator of angiogenesis in vivo.	NCI, NIH, Cell & Canc Biol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Pathol, Rockville, MD 20855 USA; Sungkyunkwan Univ, Coll Pharm, Dept Biochem & Mol Biol, Suwon 440746, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Sungkyunkwan University (SKKU)	Stetler-Stevenson, WG (corresponding author), NCI, NIH, Cell & Canc Biol Branch, Ctr Canc Res, Bldg 37,Rm 1062B, Bethesda, MD 20892 USA.	sstevenw@mail.nih.gov	Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Seo, Dong-Wan/0000-0003-4971-834X	Intramural NIH HHS [Z01 SC009179] Funding Source: Medline; NCI NIH HHS [Z01 SC009179-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC009179] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akahane T, 2004, EXP CELL RES, V301, P158, DOI 10.1016/j.yexcr.2004.08.002; Belkin AM, 1998, J BIOL CHEM, V273, P15234, DOI 10.1074/jbc.273.24.15234; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chen F, 2005, CELL SIGNAL, V17, P809, DOI 10.1016/j.cellsig.2004.11.002; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Guedez L, 2003, AM J PATHOL, V162, P1431, DOI 10.1016/S0002-9440(10)64276-9; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 2001, AM J PATHOL, V158, P1207, DOI 10.1016/S0002-9440(10)64070-9; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; Meredith JE, 1999, J BIOL CHEM, V274, P8111, DOI 10.1074/jbc.274.12.8111; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; Nakagami H, 2002, ARTERIOSCL THROM VAS, V22, P238, DOI 10.1161/hq0202.104001; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008-5472.CAN-04-1981; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362	37	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3711	3721		10.1074/jbc.M509932200	http://dx.doi.org/10.1074/jbc.M509932200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326706	hybrid, Green Accepted			2022-12-27	WOS:000235128200083
J	Todeschini, AL; Condon, C; Benard, L				Todeschini, AL; Condon, C; Benard, L			Sodium-induced GCN4 expression controls the accumulation of the 5 ' to 3 ' RNA degradation inhibitor, 3 '-phosphoadenosine 5 '-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SALT TOLERANCE; GENE-EXPRESSION; MESSENGER-RNAS; PROCESSING ENZYMES; STRESS CONDITIONS; MASTER REGULATOR; KINASE GCN2; YEAST; PROTEIN	Most cytoplasmic mRNAs are decapped and digested by the 5'-3'-exonuclease Xrn1p in Saccharomyces cerevisiae. The activity of Xrn1p is naturally inhibited in the presence of 3'-phosphoadenosine 5'-phosphate (pAp), a metabolite produced during sulfate assimilation that is quickly metabolized to AMP by the enzymatic activity of Hal2p. However, pAp accumulates and 5'-3' degradation decreases in the presence of ions known to inhibit Hal2p activity, such as sodium or lithium. We have shown that yeast cells can better adapt to the presence of sodium than lithium because of their ability to reduce pAp accumulation by activating HAL2 expression in a Gcn4p-dependent response, a regulatory loop that is likely to be conserved in different yeast species. We have thus identified a new role for the transcriptional activity of Gcn4p in maintaining an active mRNA degradation pathway under conditions of sodium stress. Since deregulation of proteins involved in different metabolic pathways is observed in xrn1 Delta mutants, the maintenance of mRNA degradation capacity is likely to be important for the accurate and rapid adaptation of gene expression to salt stress.	Univ Paris 07, Inst Biol Physicochim, UPR 9073, CNRS, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Benard, L (corresponding author), Univ Paris 07, Inst Biol Physicochim, UPR 9073, CNRS, 13,Rue Pierre & Marie Curie, F-75005 Paris, France.	lionel.benard@ibpc.fr	BENARD, LIONEL/E-4057-2019; Condon, Ciaran/F-6798-2011	BENARD, LIONEL/0000-0003-1745-1361; Condon, Ciaran/0000-0002-2199-9621				Adams A, 1997, METHODS YEAST GENETI; Albert A, 2000, J MOL BIOL, V295, P927, DOI 10.1006/jmbi.1999.3408; Albig AR, 2001, MOL BIOL CELL, V12, P3428, DOI 10.1091/mbc.12.11.3428; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Benard L, 2004, RNA, V10, P458, DOI 10.1261/rna.5183804; Benard L, 1998, MOL CELL BIOL, V18, P2688, DOI 10.1128/MCB.18.5.2688; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHEREST H, 1971, Journal of Bacteriology, V106, P758; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; Dichtl B, 1997, EMBO J, V16, P7184, DOI 10.1093/emboj/16.23.7184; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GLASER HU, 1993, EMBO J, V12, P3105, DOI 10.1002/j.1460-2075.1993.tb05979.x; Goossens A, 2001, J BIOL CHEM, V276, P30753, DOI 10.1074/jbc.M102960200; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HINNEBUSCH AG, 1985, MOL CELL BIOL, V5, P2349, DOI 10.1128/MCB.5.9.2349; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; HINNEBUSCH AG, 1992, MOL CELLULAR BIOL YE, V2, P409; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; JOHNSON AW, 1995, MOL CELL BIOL, V15, P2719; Johnson AW, 1997, MOL CELL BIOL, V17, P6122, DOI 10.1128/MCB.17.10.6122; Kearsey S, 1991, Trends Cell Biol, V1, P110, DOI 10.1016/0962-8924(91)90101-E; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LIM CK, 1989, J CHROMATOGR, V461, P259, DOI 10.1016/S0021-9673(00)94291-2; Mendizabal I, 1998, FEBS LETT, V425, P323, DOI 10.1016/S0014-5793(98)00249-X; MOUNTAIN HA, 1993, MOL MICROBIOL, V9, P221, DOI 10.1111/j.1365-2958.1993.tb01684.x; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1994, NATURE, V370, P578, DOI 10.1038/370578a0; MURGUIA JR, 1995, SCIENCE, V267, P232; Murguia JR, 1996, J BIOL CHEM, V271, P29029, DOI 10.1074/jbc.271.46.29029; Narasimhan J, 2004, J BIOL CHEM, V279, P22820, DOI 10.1074/jbc.M402228200; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; OCONNELL KF, 1995, MOL CELL BIOL, V15, P1879; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Pascual-Ahuir M, 2001, MOL CELL BIOL, V21, P16, DOI 10.1128/MCB.21.1.16-25.2001; Rios G, 1997, YEAST, V13, P515, DOI 10.1002/(SICI)1097-0061(199705)13:6<515::AID-YEA102>3.0.CO;2-X; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; Ros R, 1998, J BACTERIOL, V180, P3131, DOI 10.1128/JB.180.12.3131-3136.1998; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Serrano R, 1999, J EXP BOT, V50, P1023, DOI 10.1093/jexbot/50.suppl_1.1023; Serrano R, 1996, INT REV CYTOL, V165, P1, DOI 10.1016/S0074-7696(08)62219-6; Shim J, 2002, MOL CELLS, V14, P323; STEVENS A, 1991, J BACTERIOL, V173, P7024, DOI 10.1128/jb.173.21.7024-7028.1991; THOMAS D, 1989, MOL CELL BIOL, V9, P3292, DOI 10.1128/MCB.9.8.3292; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; Torchet C, 2002, MOL CELL, V9, P1285, DOI 10.1016/S1097-2765(02)00544-0; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011; Yale J, 2001, J BIOL CHEM, V276, P15996, DOI 10.1074/jbc.M008209200	58	15	16	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3276	3282		10.1074/jbc.M511688200	http://dx.doi.org/10.1074/jbc.M511688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16352596	hybrid			2022-12-27	WOS:000235128200033
J	Xie, Y; Hong, Y; Ma, XY; Ren, XR; Ackerman, S; Mei, L; Xiong, WC				Xie, Y; Hong, Y; Ma, XY; Ren, XR; Ackerman, S; Mei, L; Xiong, WC			DCC-dependent phospholipase C signaling in netrin-1-induced neurite elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; COLORECTAL-CANCER; AXON OUTGROWTH; SHORT-RANGE; LONG-RANGE; GUIDANCE; GROWTH; RECEPTORS; NETRINS; ENCODES	Netrins, a family of secreted molecules, play important roles in axon pathfinding during nervous system development. Although phosphatidylinositol signaling has been implicated in this event, how netrin-1 regulates phosphatidylinositol signaling remains poorly understood. Here we provide evidence that netrin-1 stimulates phosphatidylinositol bisphosphate hydrolysis in cortical neurons. This event appears to be mediated by DCC (deleted in colorectal cancer), but not neogenin or Unc5h2. Netrin-1 induces phospholipase C gamma (PLC gamma) tyrosine phosphorylation. Inhibition of PLC activity attenuates netrin-1-induced cortical neurite outgrowth. These results suggest that netrin-1 regulates phosphatidylinositol turnover and demonstrate a crucial role of PLC signaling in netrin-1-induced neurite elongation.	Med Coll Georgia, Dept Neurol, Augusta, GA 30809 USA; Med Coll Georgia, Inst Mol Med & Genom, Augusta, GA 30809 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Howard Hughes Med Inst, Bar Harbor, ME 04609 USA; Jackson Lab, Bar Harbor, ME 04609 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; Jackson Laboratory	Xiong, WC (corresponding author), Med Coll Georgia, Inst Mol Med & Genom, Augusta, GA 30912 USA.	wxiong@mcg.edu	Mei, Lin/G-8755-2012		NIAMS NIH HHS [AR48120] Funding Source: Medline; NIGMS NIH HHS [GM63861] Funding Source: Medline; NINDS NIH HHS [NS44521, NS045710, NS40480, R01 NS060648] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040480, R01NS045710, R01NS044521] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Brose K, 2000, CURR OPIN NEUROBIOL, V10, P95, DOI 10.1016/S0959-4388(99)00066-5; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; Cremona O, 2001, J CELL SCI, V114, P1041; Culotti JG, 1998, CURR OPIN CELL BIOL, V10, P609, DOI 10.1016/S0955-0674(98)80036-7; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Finger JH, 2002, J NEUROSCI, V22, P10346; Forcet C, 2002, NATURE, V417, P443, DOI 10.1038/nature748; Graef IA, 2003, CELL, V113, P657, DOI 10.1016/S0092-8674(03)00390-8; Hara S, 1997, J BIOL CHEM, V272, P14908, DOI 10.1074/jbc.272.23.14908; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hilpela P, 2004, CURR TOP MICROBIOL, V282, P117; Hiramoto M, 2000, NATURE, V406, P886, DOI 10.1038/35022571; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Keleman K, 2001, NEURON, V32, P605, DOI 10.1016/S0896-6273(01)00505-0; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kennedy TE, 2000, BIOCHEM CELL BIOL, V78, P569, DOI 10.1139/bcb-78-5-569; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Li WQ, 2004, NAT NEUROSCI, V7, P1213, DOI 10.1038/nn1329; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Liu GF, 2004, NAT NEUROSCI, V7, P1222, DOI 10.1038/nn1331; Livesey FJ, 1999, CELL MOL LIFE SCI, V56, P62, DOI 10.1007/s000180050006; Meriane M, 2004, J CELL BIOL, V167, P687, DOI 10.1083/jcb.200405053; Metin C, 1997, DEVELOPMENT, V124, P5063; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Ming GL, 2002, NATURE, V417, P411, DOI 10.1038/nature745; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Ren XR, 2004, NAT NEUROSCI, V7, P1204, DOI 10.1038/nn1330; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; Richards LJ, 1997, J NEUROSCI, V17, P2445; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Wenk MR, 2004, P NATL ACAD SCI USA, V101, P8262, DOI 10.1073/pnas.0401874101; Xie Y, 2005, NAT CELL BIOL, V7, P1124, DOI 10.1038/ncb1321; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	44	46	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2605	2611		10.1074/jbc.M512767200	http://dx.doi.org/10.1074/jbc.M512767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16321979	hybrid			2022-12-27	WOS:000234931800024
J	Ledford, AS; Weinberg, RB; Cook, VR; Hantgan, RR; Shelness, GS				Ledford, AS; Weinberg, RB; Cook, VR; Hantgan, RR; Shelness, GS			Self-association and lipid binding properties of the lipoprotein initiating domain of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; N-TERMINAL 17-PERCENT; INTERFACIAL PROPERTIES; SUBCELLULAR-LOCALIZATION; A-IV; SECRETION; MODEL; LIPOVITELLIN; SOLUBILIZATION; BIOSYNTHESIS	The amino-terminal 20.1% of apolipoprotein B (apoB20.1; residues 1-912) is sufficient to initiate and direct the formation of nascent apoB-containing lipoprotein particles. To investigate the mechanism of initial lipid acquisition by apoB, we examined the lipid binding and interfacial properties of a carboxyl-terminal His6-tagged form of apoB20.1 (apoB20.1H). ApoB20.1H was expressed in Sf9 cells and purified by nickel affinity chromatography. ApoB20.1H was produced in a folded state as characterized by formation of intramolecular disulfide bonds and resistance to chemical reduction. Dynamic light scattering in physiological buffer indicated that purified apoB20.1H formed multimers, which were readily dissociable upon the addition of nonionic detergent (0.1% Triton X-100). ApoB20.1H was incapable of binding dimyristoylphosphatidylcholine multilamellar vesicles, unless its multimeric structure was first disrupted by guanidine hydrochloride. However, apoB20.1H multimers spontaneously dissociated and bound to the interface of naked and phospholipid-coated triolein droplets. These data reveal that the initiating domain of apoB contains solvent-accessible hydrophobic sequences, which, in the absence of a hydrophobic lipid interface or detergent, engage in self-association. The high affinity of apoB20.1H for neutral lipid is consistent with the membrane binding and desorption model of apoB-containing lipoprotein assembly.	Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Shelness, GS (corresponding author), Wake Forest Univ, Sch Med, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	gshelnes@wfubmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030897, R23HL030897, P01HL049373] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL030897-23, HL49373, HL30897, R01 HL030897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Burch WL, 2000, J BIOL CHEM, V275, P16267, DOI 10.1074/jbc.M000446200; Chu B., 1983, MEASUREMENT SUSPENDE, P81; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; DeLozier JA, 2001, J LIPID RES, V42, P399; GIBBONS GF, 1990, BIOCHEM J, V268, P1; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Gusarova V, 2003, J BIOL CHEM, V278, P48051, DOI 10.1074/jbc.M306898200; HAMILTON JA, 1983, J BIOL CHEM, V258, P2821; HAMILTON JA, 1981, P NATL ACAD SCI-BIOL, V78, P6878, DOI 10.1073/pnas.78.11.6878; Hamilton RL, 1998, J LIPID RES, V39, P1543; HANTGAN RR, 1993, BIOCHEMISTRY-US, V32, P3935, DOI 10.1021/bi00066a013; Harazono A, 2005, GLYCOBIOLOGY, V15, P447, DOI 10.1093/glycob/cwi033; HERSCOVITZ H, 1991, P NATL ACAD SCI USA, V88, P7313, DOI 10.1073/pnas.88.16.7313; Herscovitz H, 2001, J LIPID RES, V42, P51; Hockey KJ, 2001, J LIPID RES, V42, P211; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 2005, CURR OPIN LIPIDOL, V16, P281, DOI 10.1097/01.mol.0000169347.53568.5a; Ingram MF, 1997, J BIOL CHEM, V272, P10279; Jiang ZG, 2005, BIOCHEMISTRY-US, V44, P1163, DOI 10.1021/bi048286y; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Levy E, 2002, J BIOL CHEM, V277, P16470, DOI 10.1074/jbc.M102385200; Manchekar M, 2004, J BIOL CHEM, V279, P39757, DOI 10.1074/jbc.M406302200; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; McLachlin DT, 1996, PROTEIN EXPRES PURIF, V7, P275, DOI 10.1006/prep.1996.0039; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; Richardson PE, 2005, BIOPHYS J, V88, P2789, DOI 10.1529/biophysj.104.046235; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 1999, J LIPID RES, V40, P1401; Segrest JP, 2001, J LIPID RES, V42, P1346; Shelness GS, 2005, CURR OPIN LIPIDOL, V16, P325, DOI 10.1097/01.mol.0000169353.12772.eb; Shelness GS, 2003, J BIOL CHEM, V278, P44702, DOI 10.1074/jbc.M307562200; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; Swift LL, 2003, J LIPID RES, V44, P1841, DOI 10.1194/jlr.M300276-JLR200; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Thompson JR, 2002, BIOCHEMISTRY-US, V41, P9398, DOI 10.1021/bi025674w; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; Wang LB, 2004, J LIPID RES, V45, P1704, DOI 10.1194/jlr.M400106-JLR200; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; Weinberg RB, 2003, J BIOL CHEM, V278, P34438, DOI 10.1074/jbc.M303784200; Weinberg RB, 2000, J LIPID RES, V41, P1419; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96	50	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8871	8876		10.1074/jbc.M507657200	http://dx.doi.org/10.1074/jbc.M507657200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407215	hybrid			2022-12-27	WOS:000236247100067
J	Stefanic, S; Palm, D; Svard, SG; Hehl, AB				Stefanic, S; Palm, D; Svard, SG; Hehl, AB			Organelle proteomics reveals cargo maturation mechanisms associated with Golgi-like encystation vesicles in the early-diverged protozoan Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYST WALL; ENDOPLASMIC-RETICULUM; PRIMITIVE EUKARYOTE; SECRETORY APPARATUS; PROTEIN TRAFFICKING; ENTAMOEBA-INVADENS; QUALITY-CONTROL; INTESTINALIS; GENE; IDENTIFICATION	During encystation Giardia trophozoites secrete a fibrillar extracellular matrix of glycans and cyst wall proteins on the cell surface. The cyst wall material is accumulated in encystation-specific vesicles (ESVs), specialized Golgi-like compartments generated de novo, after export from the endoplasmic reticulum (ER) and before secretion. These large post-ER vesicles neither have the morphological characteristics of Golgi cisternae nor sorting functions, but may represent an evolutionary early form of the Golgi-like maturation compartment. Because little is known about the genesis and maturation of ESVs, we used a limited proteomics approach to discover novel proteins that are specific for developing ESVs or associated peripherally with these organelles. Unexpectedly, we identified cytoplasmic and luminal factors of the ER quality control system on two-dimensional electrophoresis gels, i.e. several proteasome subunits and HSP70-BiP. We show that BiP is exported to ESVs and retrieved via its C-terminal KDEL signal from ESVs. In contrast, cytoplasmic proteasome complexes undergo a developmentally regulated re-localization to ESVs during encystation. This suggests that maturation of bulk exported cyst wall material in the Golgi-like ESVs involves both continuous activity of ER-associated quality control mechanisms and retrograde Golgi to ER transport.	Univ Zurich, Inst Parasitol, CH-8057 Zurich, Switzerland; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Uppsala Univ, BMC, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden	University of Zurich; Karolinska Institutet; Uppsala University	Hehl, AB (corresponding author), Univ Zurich, Inst Parasitol, Winterthurerstr 266A, CH-8057 Zurich, Switzerland.	Adrian.Hehl@access.unizh.ch	Stefanic, Sasa/AAF-3063-2020	Stefanic, Sasa/0000-0001-7367-1831; Hehl, Adrian/0000-0002-2110-4445; Svard, Staffan/0000-0002-7392-1746				Adam RD, 2001, CLIN MICROBIOL REV, V14, P447, DOI 10.1128/CMR.14.3.447-475.2001; ARROYOBEGOVICH A, 1980, J PARASITOL, V66, P735, DOI 10.2307/3280662; Benedetti C, 2000, BIOCHEM BIOPH RES CO, V278, P530, DOI 10.1006/bbrc.2000.3838; Davids BJ, 2004, MOL BIOCHEM PARASIT, V136, P173, DOI 10.1016/j.molbiopara.2004.03.011; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Emmerlich V, 2001, PARASITOL RES, V87, P112, DOI 10.1007/s004360000332; Enenkel C, 1998, EMBO J, V17, P6144, DOI 10.1093/emboj/17.21.6144; Ferguson DJP, 2003, INT J PARASITOL, V33, P1329, DOI 10.1016/S0020-7519(03)00185-1; Frisardi M, 2000, INFECT IMMUN, V68, P4217, DOI 10.1128/IAI.68.7.4217-4224.2000; Gaechter V, 2005, INT J PARASITOL, V35, P1359, DOI 10.1016/j.ijpara.2005.06.007; Gerwig GJ, 2002, GLYCOBIOLOGY, V12, P499, DOI 10.1093/glycob/cwf059; GILLIN FD, 1989, EXP PARASITOL, V69, P164, DOI 10.1016/0014-4894(89)90185-9; Gonzalez J, 1999, EUR J BIOCHEM, V264, P897, DOI 10.1046/j.1432-1327.1999.00682.x; GUPTA RS, 1994, P NATL ACAD SCI USA, V91, P2895, DOI 10.1073/pnas.91.8.2895; Hehl AB, 2000, MOL BIOL CELL, V11, P1789, DOI 10.1091/mbc.11.5.1789; Hehl AB, 2004, MOL MICROBIOL, V53, P19, DOI 10.1111/j.1365-2958.2004.04115.x; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Lanfredi-Rangel A, 2003, J STRUCT BIOL, V143, P153, DOI 10.1016/S1047-8477(03)00123-0; Lujan HD, 1996, BIOL CELL, V86, P11, DOI 10.1016/0248-4900(96)89519-0; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lujan HD, 2003, CELL MICROBIOL, V5, P427, DOI 10.1046/j.1462-5822.2003.00284.x; Marti M, 2003, TRENDS PARASITOL, V19, P440, DOI 10.1016/S1471-4922(03)00201-0; Marti M, 2003, J BIOL CHEM, V278, P24837, DOI 10.1074/jbc.M302082200; Marti M, 2003, MOL BIOL CELL, V14, P1433, DOI 10.1091/mbc.E02-08-0467; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Pal A, 2002, J BIOL CHEM, V277, P9529, DOI 10.1074/jbc.M110055200; Petri WA, 2002, CURR OPIN MICROBIOL, V5, P443, DOI 10.1016/S1369-5274(02)00335-1; RAJAS F, 1993, BIOCHEM J, V295, P447, DOI 10.1042/bj2950447; Regoes A, 2005, J BIOL CHEM, V280, P30557, DOI 10.1074/jbc.M500787200; Reiner DS, 2001, CELL MICROBIOL, V3, P459, DOI 10.1046/j.1462-5822.2001.00129.x; Roger AJ, 1999, J MOL EVOL, V48, P750, DOI 10.1007/PL00006519; Slavin I, 2002, MOL BIOCHEM PARASIT, V122, P95, DOI 10.1016/S0166-6851(02)00065-8; Snapp EL, 2003, J CELL BIOL, V163, P257, DOI 10.1083/jcb.200306020; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Soltys BJ, 1996, J CELL SCI, V109, P1909; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; Van Horssen AM, 1998, J NEUROCHEM, V71, P402; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Weiland MEL, 2005, INT J PARASITOL, V35, P617, DOI 10.1016/j.ijpara.2004.12.009	42	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7595	7604		10.1074/jbc.M510940200	http://dx.doi.org/10.1074/jbc.M510940200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407213	hybrid			2022-12-27	WOS:000236030900081
J	Piscitelli, CL; Angel, BE; Bailey, BW; Hargrave, P; Dratz, EA; Lawrence, CM				Piscitelli, CL; Angel, BE; Bailey, BW; Hargrave, P; Dratz, EA; Lawrence, CM			Equilibrium between metarhodopsin-I and metarhodopsin-II is dependent on the conformation of the third cytoplasmic loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; INITIAL RATE ANALYSIS; TRANSDUCIN ACTIVATION; CRYSTAL-STRUCTURE; STRUCTURAL FEATURES; INTRINSIC DISORDER; EXCITED RHODOPSIN; BOVINE RHODOPSIN; PHAGE-DISPLAY; ALPHA-SUBUNIT	Rhodopsin is a G-protein-coupled receptor ( GPCR) that is the light detector in the rod cells of the eye. Rhodopsin is the best understood member of the large GPCR superfamily and is the only GPCR for which atomic resolution structures have been determined. However, these structures are for the inactive, dark-adapted form. Characterization of the conformational changes in rhodopsin caused by light-induced activation is of wide importance, because the metarhodopsin-II photoproduct is analogous to the agonist-occupied conformation of other GPCRs, and metarhodopsin-I may be similar to antagonist-occupied GPCR conformations. In this work we characterize the interaction of antibody K42-41L with the metarhodopsin photoproducts. K42-41L is shown to inhibit formation of metarhodopsin-II while it stabilizes the metarhodopsin-I state. Thus, K42-41L recognizes an epitope accessible in dark-adapted rhodopsin and metarhodopsin-I that is lost upon formation of metarhodopsin-II. Previous work has shown that the peptide TGALQERSK is able to mimic the K42-41L epitope, and we have now determined the structure of the K42-41L-peptide complex. The structure demonstrates a central role for elements of the rhodopsin C3 loop, particularly Gln(238) and Glu(239), in the interaction with K42-41L. Geometric constraints taken from the antibody-bound peptide were used to model the epitope on the rhodopsin surface. The resulting model suggests that K42-41L locks the C3 loop into an extended conformation that is intermediate between two compact conformations seen in crystal structures of dark-adapted rhodopsin. Together, the structural and functional data strongly suggest that the equilibrium between metarhodopsin-I and metarhodopsin-II is dependent upon the conformation of the C3 loop. The biological implications of this model and its possible relations to dimeric and multimeric complexes of rhodopsin are discussed.	Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA; NCI, NIH, Rockville, MD 20852 USA; Univ Florida, Coll Med, Dept Ophthalmol, Gainesville, FL 32610 USA	Montana State University System; Montana State University Bozeman; Montana State University System; Montana State University Bozeman; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida	Lawrence, CM (corresponding author), Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA.	lawrence@chemistry.montana.edu	Bailey, Brian/B-1732-2009; Lawrence, C. Martin/AAH-3420-2020	Lawrence, C. Martin/0000-0002-5398-466X	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062547] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ADAMUS G, 1988, Peptide Research, V1, P42; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Aris L, 2001, J BIOL CHEM, V276, P2333, DOI 10.1074/jbc.M002533200; Bailey BW, 2003, PROTEIN SCI, V12, P2453, DOI 10.1110/ps.03233703; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breit A, 2004, J BIOL CHEM, V279, P28756, DOI 10.1074/jbc.M313310200; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burritt JB, 1998, J BIOL CHEM, V273, P24847, DOI 10.1074/jbc.273.38.24847; Burritt JB, 1996, ANAL BIOCHEM, V238, P1, DOI 10.1006/abio.1996.0241; Burritt JB, 2000, EUR J HAEMATOL, V65, P407, DOI 10.1034/j.1600-0609.2000.065006407.x; Chabre M, 2005, BIOCHEMISTRY-US, V44, P9395, DOI 10.1021/bi050720o; Collis AVJ, 2003, J MOL BIOL, V325, P337, DOI 10.1016/S0022-2836(02)01222-6; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Echols N, 2003, NUCLEIC ACIDS RES, V31, P478, DOI 10.1093/nar/gkg104; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; FARAHBAKHSH ZT, 1993, SCIENCE, V262, P1416, DOI 10.1126/science.8248781; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Im WP, 2003, J COMPUT CHEM, V24, P1691, DOI 10.1002/jcc.10321; Ishiguro M, 2004, CHEMBIOCHEM, V5, P298, DOI 10.1002/cbic.200300668; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE; Jastrzebska B, 2004, J BIOL CHEM, V279, P54663, DOI 10.1074/jbc.M408691200; Jesaitis AJ, 1999, PROTEIN SCI, V8, P760; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; Koenig BW, 2002, J MOL BIOL, V322, P441, DOI 10.1016/S0022-2836(02)00745-3; KONIG B, 1989, FEBS LETT, V257, P163, DOI 10.1016/0014-5793(89)81811-3; Krebs WG, 2000, NUCLEIC ACIDS RES, V28, P1665, DOI 10.1093/nar/28.8.1665; KUHN H, 1981, P NATL ACAD SCI-BIOL, V78, P6873, DOI 10.1073/pnas.78.11.6873; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVER WG, 1990, CELL, V61, P553, DOI 10.1016/0092-8674(90)90464-P; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; Medina R, 2004, J BIOL CHEM, V279, P39565, DOI 10.1074/jbc.M402446200; Mumey BM, 2003, J COMPUT BIOL, V10, P555, DOI 10.1089/10665270360688183; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; Nikiforovich GV, 2003, BIOCHEMISTRY-US, V42, P9110, DOI 10.1021/bi034586o; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t	72	12	12	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6813	6825		10.1074/jbc.M510175200	http://dx.doi.org/10.1074/jbc.M510175200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407202	hybrid			2022-12-27	WOS:000236030800080
J	Ida, M; Shuo, T; Hirano, K; Tokita, Y; Nakanishi, K; Matsui, F; Aono, S; Fujita, H; Fujiwara, Y; Kaji, T; Oohira, A				Ida, M; Shuo, T; Hirano, K; Tokita, Y; Nakanishi, K; Matsui, F; Aono, S; Fujita, H; Fujiwara, Y; Kaji, T; Oohira, A			Identification and functions of chondroitin sulfate in the milieu of neural stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH FACTOR-2; TYROSINE-PHOSPHATASE-BETA; CENTRAL-NERVOUS-SYSTEM; EMBRYONIC PIG BRAIN; HEPARAN-SULFATE; DERMATAN SULFATE; NEUROGLYCAN-C; NEURONAL DIFFERENTIATION; MOLECULAR-INTERACTIONS; PROTEOGLYCAN	The behavior of cells is generally considered to be regulated by environmental factors, but the molecules in the milieu of neural stem cells have been little studied. We found by immunohistochemistry that chondroitin sulfate (CS) existed in the surroundings of nestin-positive cells or neural stem/progenitor cells in the rat ventricular zone of the telencephalon at embryonic day 14. Brain-specific chondroitin sulfate proteoglycans (CSPGs), including neurocan, phosphacan/receptor-type protein-tyrosine phosphatase beta, and neuroglycan C, were detected in the ventricular zone. Neurospheres formed by cells from the fetal telencephalon also expressed these CSPGs and NG2 proteoglycan. To examine the structural features and functions of CS polysaccharides in the milieu of neural stem cells, we isolated and purified CS from embryonic day 14 telencephalons. The CS preparation consisted of two fractions differing in size and extent of sulfation: small CS polysaccharides with low sulfation and large CS polysaccharides with high sulfation. Interestingly, both CS polysaccharides and commercial preparations of dermatan sulfate CS-B and an E-type of highly sulfated CS promoted the fibroblast growth factor-2-mediated proliferation of neural stem/progenitor cells. None of these CS preparations promoted the epidermal growth factor-mediated neural stem cell proliferation. These results suggest that these CSPGs are involved in the proliferation of neural stem cells as a group of cell microenvironmental factors.	Aichi Human Serv Ctr, Dept Perinatol, Inst Dev Res, Aichi 4800392, Japan; Nagoya Univ, Dept Neurochem, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Hokuriku Univ, Fac Pharmaceut Sci, Dept Environm Hlth, Kanazawa, Ishikawa 9201181, Japan; Seikagaku Corp, Kanagawa 2390831, Japan	Nagoya University; Hokuriku University; Seikagaku Corporation	Oohira, A (corresponding author), Aichi Human Serv Ctr, Dept Perinatol & Neuroglycosci, Inst Dev Res, Aichi 4800392, Japan.	oohira@inst-hsc.jp	Fujiwara, Yasuyuki/AAB-8775-2020	Fujiwara, Yasuyuki/0000-0003-0028-0658; Ida-Eto, Michiru/0000-0002-2469-4006				Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Aono S, 2006, J NEUROSCI RES, V83, P110, DOI 10.1002/jnr.20698; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bao XF, 2004, J BIOL CHEM, V279, P9765, DOI 10.1074/jbc.M310877200; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Brakebusch C, 2002, MOL CELL BIOL, V22, P7417, DOI 10.1128/MCB.22.21.7417-7427.2002; Campos LS, 2004, J NEUROSCI RES, V78, P761, DOI 10.1002/jnr.20333; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Engel M, 1996, J COMP NEUROL, V366, P34; Ford-Perriss M, 2003, DEV DYNAM, V227, P170, DOI 10.1002/dvdy.10298; Fukuda T, 1997, J COMP NEUROL, V382, P141; Gabay L, 2003, NEURON, V40, P485, DOI 10.1016/S0896-6273(03)00637-8; Garwood J, 2003, J BIOL CHEM, V278, P24164, DOI 10.1074/jbc.M211721200; Hagihara K, 2000, DEV DYNAM, V219, P353, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1059>3.0.CO;2-#; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; Joseph SJ, 1996, DEVELOPMENT, V122, P3443; Kabos P, 2004, BIOCHEM BIOPH RES CO, V318, P955, DOI 10.1016/j.bbrc.2004.04.114; Kappler J, 1997, EUR J NEUROSCI, V9, P306, DOI 10.1111/j.1460-9568.1997.tb01401.x; LEVY JB, 1993, J BIOL CHEM, V268, P10573; Li WW, 1998, J NEUROSCI, V18, P8853; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Margolis RU, 1997, CELL TISSUE RES, V290, P343, DOI 10.1007/s004410050939; MATSUI F, 1994, NEUROCHEM INT, V25, P425, DOI 10.1016/0197-0186(94)90018-3; Matsuno Y, 2004, J PHARMACEUT BIOMED, V36, P9, DOI 10.1016/j.jpba.2004.05.020; Milev P, 1998, J BIOL CHEM, V273, P21439, DOI 10.1074/jbc.273.34.21439; Milev P, 1998, BIOCHEM BIOPH RES CO, V247, P207, DOI 10.1006/bbrc.1998.8759; Muroyama Y, 2004, BIOCHEM BIOPH RES CO, V313, P915, DOI 10.1016/j.bbrc.2003.12.023; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; OOHIRA A, 1986, J NEUROCHEM, V47, P588; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Popp S, 2003, DEV DYNAM, V227, P143, DOI 10.1002/dvdy.10282; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Sakurai T, 1996, J NEUROSCI RES, V43, P694, DOI 10.1002/(SICI)1097-4547(19960315)43:6<694::AID-JNR6>3.3.CO;2-9; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schmalfeldt M, 2000, J CELL SCI, V113, P807; Shuo T, 2003, GLYCOCONJUGATE J, V20, P267, DOI 10.1023/B:GLYC.0000025821.22618.33; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; TEKOTTE H, 1994, J NEUROCHEM, V62, P1126; Villena J, 2004, J CELL PHYSIOL, V198, P169, DOI 10.1002/jcp.10422; Yamauchi S, 2002, J BIOL CHEM, V277, P20583, DOI 10.1074/jbc.M200909200; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	53	105	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5982	5991		10.1074/jbc.M507130200	http://dx.doi.org/10.1074/jbc.M507130200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373347	hybrid			2022-12-27	WOS:000235568900079
J	Palma, AS; Feizi, T; Zhang, YB; Stoll, MS; Lawson, AM; Diaz-Rodriguez, E; Campanero-Rhodes, MA; Costa, J; Gordon, S; Brown, GD; Chai, WG				Palma, AS; Feizi, T; Zhang, YB; Stoll, MS; Lawson, AM; Diaz-Rodriguez, E; Campanero-Rhodes, MA; Costa, J; Gordon, S; Brown, GD; Chai, WG			Ligands for the beta-glucan receptor, Dectin-1, assigned using "designer" microarrays of oligosaccharide probes (neoglycolipids) generated from glucan polysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-LINKED OLIGOSACCHARIDES; C-TYPE LECTIN; CARBOHYDRATE MICROARRAYS; E-SELECTIN; RECOGNITION; CELLS; TECHNOLOGY; BINDING; IDENTIFICATION; SPECIFICITY	Dectin- 1 is a C- type lectin- like receptor on leukocytes that mediates phagocytosis and inflammatory mediator production in innate immunity to fungal pathogens. Dectin- 1 lacks residues involved in calcium ligation that mediates carbohydrate- binding by classical C- type lectins; nevertheless, it binds zymosan, a particulate beta- glucan-rich extract of Saccharomyces cerevisiae, and binding is inhibited by polysaccharides rich in beta 1,3- or both beta 1,3- and beta 1,6- linked glucose. The oligosaccharide ligands on glucans recognized by Dectin-1 have not yet been delineated precisely. It is also not known whether Dectin- 1 can interact with other types of carbohydrates. We have investigated this, since Dectin- 1 shows glucan- independent binding to a subset of T- lymphocytes and is involved in triggering their proliferation. Here we assign oligosaccharide ligands for Dectin- 1 using the neoglycolipid- based oligosaccharide microarray technology, a unique approach for constructing microarrays of lipid-linked oligosaccharide probes from desired sources. We generate " designer" microarrays from three glucan polysaccharides, a neutral soluble glucan isolated from S. cerevisiae and two bacterial glucans, curdlan from Alcaligenes faecalis and pustulan from Umbilicaria papullosa, and use these in conjunction with 187 diverse, sequence- defined, predominantly mammalian- type, oligosaccharide probes. Among these, Dectin- 1 binding is detected exclusively to 1,3- linked glucose oligomers, the minimum length required for detectable binding being a 10- or 11- mer. Thus, the ligands assigned so far are exogenous rather than endogenous. We further show that Dectin- 1 ligands, 11 - 13 gluco- oligomers, in clustered form ( displayed on liposomes), mimic the macromolecular beta- glucans and compete with zymosan binding and triggering of tumor necrosis factor-alpha secretion by a Dectin- 1- expressing macrophage cell line.	Imperial Coll London, Fac Med, Glycosci Lab, Harrow HA1 3UJ, Middx, England; Univ Nova Lisboa, Inst Tecnol Quim & Biol, Lab Glicobiol, P-2781901 Oeiras, Portugal; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa	Imperial College London; Universidade Nova de Lisboa; University of Oxford; University of Cape Town	Feizi, T (corresponding author), Imperial Coll London, Fac Med, Glycosci Lab, Northwick Pk & St Marks Campus,Watford Rd, Harrow HA1 3UJ, Middx, England.	t.feizi@imperial.ac.uk	Costa, Júlia C/B-7131-2008; brown, gordon/B-4249-2012; Campanero-Rhodes, María Asunción/M-3158-2014; Palma, Angelina S/D-2052-2013	Costa, Júlia C/0000-0001-7782-6319; Campanero-Rhodes, María Asunción/0000-0002-3373-0064; Palma, Angelina S/0000-0001-5797-6555; brown, gordon/0000-0002-0287-5383; Feizi, Ten/0000-0001-6495-0329	MRC [G9601454] Funding Source: UKRI; Engineering and Physical Sciences Research Council [GR/S79268/02] Funding Source: researchfish; Medical Research Council [G9601454] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adachi Y, 2004, INFECT IMMUN, V72, P4159, DOI 10.1128/IAI.72.7.4159-4171.2004; Ariizumi K, 2000, J BIOL CHEM, V275, P20157, DOI 10.1074/jbc.M909512199; BLACK WAP, 1951, J APPL CHEM, V1, P505, DOI 10.1002/jctb.5010011112; Blixt O, 2004, P NATL ACAD SCI USA, V101, P17033, DOI 10.1073/pnas.0407902101; Bohn JA, 1995, CARBOHYD POLYM, V28, P3, DOI 10.1016/0144-8617(95)00076-3; BRISSON JR, 1992, BIOCHEMISTRY-US, V31, P4996, DOI 10.1021/bi00136a012; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4; Chai WG, 2003, METHOD ENZYMOL, V362, P160; Chai WG, 1997, GLYCOBIOLOGY, V7, P861, DOI 10.1093/glycob/7.6.861; CHAI WG, 1992, EUR J BIOCHEM, V203, P257, DOI 10.1111/j.1432-1033.1992.tb19855.x; CHANDA NB, 1957, J CHEM SOC, P1951, DOI 10.1039/jr9570001951; DELACRUZ J, 1995, J BACTERIOL, V177, P1864, DOI 10.1128/jb.177.7.1864-1871.1995; Ettinger R, 1996, P NATL ACAD SCI USA, V93, P13102, DOI 10.1073/pnas.93.23.13102; Feizi T, 2004, NAT REV MOL CELL BIO, V5, P582, DOI 10.1038/nrm1428; Feizi T, 2003, CURR OPIN STRUC BIOL, V13, P637, DOI 10.1016/j.sbi.2003.09.002; FEIZI T, 1979, J EXP MED, V149, P975, DOI 10.1084/jem.149.4.975; Fukui S, 2002, NAT BIOTECHNOL, V20, P1011, DOI 10.1038/nbt735; Galustian C, 2004, INT IMMUNOL, V16, P853, DOI 10.1093/intimm/dxh089; Galustian C, 1997, BIOCHEMISTRY-US, V36, P5260, DOI 10.1021/bi962887a; Gantner BN, 2005, EMBO J, V24, P1277, DOI 10.1038/sj.emboj.7600594; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Grunebach F, 2002, EXP HEMATOL, V30, P1309, DOI 10.1016/S0301-472X(02)00928-1; Haworth W. N., 1937, J CHEM SOC, P748; HER GR, 1987, J CARBOHYD CHEM, V6, P129, DOI 10.1080/07328308708058864; Herre J, 2004, CRIT REV IMMUNOL, V24, P193, DOI 10.1615/CritRevImmunol.v24.i3.30; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Hong F, 2003, CANCER RES, V63, P9023; JAMAS S, 1991, ACS SYM SER, V469, P44; Lindberg B., 1975, ADV CARBOHYD CHEM BI, V31, P185, DOI [10.1016/s0065-2318(08)60297-8, DOI 10.1016/S0065-2318(08)60297-8]; McCleary B V, 1986, Adv Carbohydr Chem Biochem, V44, P147; Ratner DM, 2004, CHEMBIOCHEM, V5, P1375, DOI 10.1002/cbic.200400106; Reddy ST, 2004, J BIOL CHEM, V279, P38658, DOI 10.1074/jbc.M407474200; Reid DM, 2004, J LEUKOCYTE BIOL, V76, P86, DOI 10.1189/jlb.0104031; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Shin I, 2005, CHEM-EUR J, V11, P2894, DOI 10.1002/chem.200401030; Sobanov Y, 2001, EUR J IMMUNOL, V31, P3493, DOI 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9; Steele C, 2003, J EXP MED, V198, P1677, DOI 10.1084/jem.20030932; Stoll MS, 2000, EUR J BIOCHEM, V267, P1795, DOI 10.1046/j.1432-1327.2000.01178.x; STOLL MS, 1997, PREPARATION NEOGLYCO, V9, P329; Taylor PR, 2002, J IMMUNOL, V169, P3876, DOI 10.4049/jimmunol.169.7.3876; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Willment JA, 2005, EUR J IMMUNOL, V35, P1539, DOI 10.1002/eji.200425725; Willment JA, 2001, J BIOL CHEM, V276, P43818, DOI 10.1074/jbc.M107715200; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003	49	272	292	0	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5771	5779		10.1074/jbc.M511461200	http://dx.doi.org/10.1074/jbc.M511461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371356	hybrid			2022-12-27	WOS:000235568900055
J	Sirokmany, G; Szidonya, L; Kaldi, K; Gaborik, Z; Ligeti, E; Geiszt, M				Sirokmany, G; Szidonya, L; Kaldi, K; Gaborik, Z; Ligeti, E; Geiszt, M			Sec14 homology domain targets p50RhoGAP to endosomes and provides a link between Rab and Rho GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; ENDOCYTOSIS; RECEPTORS; DYNAMICS; GOLGI; GAPS	Sec14 protein was first identified in Saccharomyces cerevisiae, where it serves as a phosphatidylinositol transfer protein that is essential for the transport of secretory proteins from the Golgi complex. A protein domain homologous to Sec14 was identified in several mammalian proteins that regulates Rho GTPases, including exchange factors and GTPase activating proteins. P50RhoGAP, the first identified GTPase activating protein for Rho GTPases, is composed of a Sec14-like domain and a Rho-GTPase activating protein (GAP) domain. The biological function of its Sec14-like domain is still unknown. Here we show that p50RhoGAP is present on endosomal membranes, where it colocalizes with internalized transferrin receptor. We demonstrate that the Sec14-like domain of P50RhoGAP is responsible for the endosomal targeting of the protein. We also show that overexpression of p50RhoGAP or its Sec14-like domain inhibits transferrin uptake. Furthermore, both P50RhoGAP and its Sec14-like domain show colocalization with small GTPases Rab11 and Rab5. We measured bioluminescence resonance energy transfer between p50RhoGAP and Rab11, indicating that these proteins form molecular complex in vivo on endosomal membranes. The interaction was mediated by the Sec 14-like domain of p50RhoGAP. Our results indicate that Sec14-like domain, which was previously considered as a phospholipid binding module, may have a role in the mediation of protein-protein interactions. We suggest that p50RhoGAP provides a link between Rab and Rho GTPases in the regulation of receptor-mediated endocytosis.	Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary	Semmelweis University	Geiszt, M (corresponding author), Semmelweis Univ, Dept Physiol, POB 259, H-1444 Budapest, Hungary.	geiszt@puskin.sote.u	Káldi, Krisztina/X-4080-2019; Szidonya, Laszlo/A-2271-2010	Kaldi, Krisztina/0000-0002-5724-0182	FIC NIH HHS [R03 TW 006421-01A1] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW006421] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; Gaborik Z, 2004, TRENDS ENDOCRIN MET, V15, P286, DOI 10.1016/j.tem.2004.06.009; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; Geyer M, 1997, CURR OPIN STRUC BIOL, V7, P786, DOI 10.1016/S0959-440X(97)80147-9; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Kostenko EV, 2005, J BIOL CHEM, V280, P2807, DOI 10.1074/jbc.M411139200; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Moskwa P, 2005, J BIOL CHEM, V280, P6716, DOI 10.1074/jbc.M412563200; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Qualmann B, 2003, BIOCHEM J, V371, P233, DOI 10.1042/bj20030139; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Ueda S, 2004, CELL SIGNAL, V16, P899, DOI 10.1016/j.cellsig.2004.01.007; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Wang L, 2005, P NATL ACAD SCI USA, V102, P13484, DOI 10.1073/pnas.0504420102; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	39	46	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6096	6105		10.1074/jbc.M510619200	http://dx.doi.org/10.1074/jbc.M510619200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16380373	hybrid			2022-12-27	WOS:000235568900091
J	Yehezkel, G; Hadad, N; Zaid, H; Sivan, S; Shoshan-Barmatz, V				Yehezkel, G; Hadad, N; Zaid, H; Sivan, S; Shoshan-Barmatz, V			Nucleotide-binding sites in the voltage-dependent anion channel - Characterization and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; MITOCHONDRIAL OUTER-MEMBRANE; RAT-HEART MITOCHONDRIA; VDAC CHANNELS; CELL-DEATH; MAMMALIAN PORIN; HIGH-AFFINITY; ATP BINDING; TRANSPORT; MODULATION	In this study, we addressed the presence and location of nucleotide-binding sites in the voltage-dependent anion channel (VDAC). VDAC bound to reactive red 120-agarose, from which it was eluted by ATP, less effectively by ADP and AMP, but not by NADH. The photoreactive ATP analog, benzoyl-benzoyl-ATP (BzATP), was used to identify and characterize the ATP-binding sites in VDAC. [alpha-P-32] BzATP bound to purified VDAC at two or more binding sites with apparent high and low binding affinities. Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) analysis of BzATP-labeled VDAC confirmed the binding of at least two BzATP molecules to VDAC. The VDAC BzATP-binding sites showed higher specificity for purine than for pyrimidine nucleotides and higher affinity for negatively charged nucleotide species. VDAC treatment with the lysyl residue modifying reagent, fluorescein 5'-isothiocyanate, markedly inhibited VDAC labeling with BzATP. The VDAC nucleotide-binding sites were localized using chemical and enzymatic cleavage. Digestion of [alpha-P-32] BzATP-labeled VDAC with CNBr or V8 protease resulted in the appearance of similar to 17- and similar to 14-kDa labeled fragments. Further digestion, high performance liquid chromatography separation, and sequencing of the selected V8 peptides suggested that the labeled fragments originated from two different regions of the VDAC molecule. MALDI-TOF analysis of BzATP-labeled, tryptic VDAC fragments indicated and localized three nucleotide binding sites, two of which were at the N and C termini of VDAC. Thus, the presence of two or more nucleotide-binding sites in VDAC is suggested, and their possible function in the control of VDAC activity, and, thereby, of outer mitochondrial membrane permeability is discussed.	Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel	Ben Gurion University	Shoshan-Barmatz, V (corresponding author), Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel.	vardasb@bgu.ac.il						ADAMS V, 1991, BIOCHEM MED METAB B, V45, P271, DOI 10.1016/0885-4505(91)90032-G; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; BATHORI G, 1993, BIOCHIM BIOPHYS ACTA, V1145, P168, DOI 10.1016/0005-2736(93)90394-F; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BERA AK, 1995, BIOCHEM BIOPH RES CO, V209, P213, DOI 10.1006/bbrc.1995.1491; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRDICZKA D, 1994, BBA-BIOENERGETICS, V1187, P264, DOI 10.1016/0005-2728(94)90124-4; BROWN GC, 1992, BIOCHEM J, V284, P1; Casadio R, 2002, FEBS LETT, V520, P1, DOI 10.1016/S0014-5793(02)02758-8; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLL RJ, 1984, J BIOL CHEM, V259, P4249; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; FLORKE H, 1994, BIOL CHEM H-S, V375, P513, DOI 10.1515/bchm3.1994.375.8.513; GARLID KD, 1980, J BIOL CHEM, V255, P1273; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Haworth RA, 2000, J BIOENERG BIOMEMBR, V32, P91, DOI 10.1023/A:1005568630151; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Hishida T, 1999, J BIOL CHEM, V274, P25335, DOI 10.1074/jbc.274.36.25335; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Huizing M, 1998, J BIOENERG BIOMEMBR, V30, P277, DOI 10.1023/A:1020501021222; Imagawa T, 2003, ANN NY ACAD SCI, V986, P240, DOI 10.1111/j.1749-6632.2003.tb07170.x; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; LAPIDUS RG, 1994, J BIOL CHEM, V269, P18931; Lee AC, 1996, J BIOL CHEM, V271, P26724, DOI 10.1074/jbc.271.43.26724; Liberatori S, 2004, PROTEOMICS, V4, P1335, DOI 10.1002/pmic.200300734; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; Majima E, 2001, J BIOL CHEM, V276, P9792, DOI 10.1074/jbc.M007222200; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; REYMANN S, 1995, BIOCHEM MOL MED, V54, P75, DOI 10.1006/bmme.1995.1011; Rodriguez-Zavala JS, 1998, J BIOL CHEM, V273, P7850, DOI 10.1074/jbc.273.14.7850; Rostovtseva T, 1997, BIOPHYS J, V72, P1954, DOI 10.1016/S0006-3495(97)78841-6; Rostovtseva TK, 1998, BIOPHYS J, V74, P2365, DOI 10.1016/S0006-3495(98)77945-7; Rostovtseva TK, 2002, BIOPHYS J, V82, P193, DOI 10.1016/S0006-3495(02)75386-1; Rudel T, 1996, CELL, V85, P391, DOI 10.1016/S0092-8674(00)81117-4; RUTTER GA, 1990, BIOCHEM J, V271, P627, DOI 10.1042/bj2710627; Shoshan-Barmatz V, 2005, J MEMBRANE BIOL, V204, P57, DOI 10.1007/s00232-005-0749-4; Shoshan-Barmatz V, 2003, CELL BIOCHEM BIOPHYS, V39, P279, DOI 10.1385/CBB:39:3:279; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WILLIAMS N, 1982, J BIOL CHEM, V257, P2834; ZIZI M, 1994, J BIOL CHEM, V269, P1614; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	51	49	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5938	5946		10.1074/jbc.M510104200	http://dx.doi.org/10.1074/jbc.M510104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16354668	hybrid			2022-12-27	WOS:000235568900074
J	Orlichenko, L; Huang, B; Krueger, E; McNiven, MA				Orlichenko, L; Huang, B; Krueger, E; McNiven, MA			Epithelial growth factor-induced phosphorylation of caveolin 1 at tyrosine 14 stimulates caveolae formation in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FACTOR RECEPTOR; ELECTROPHORETIC TRANSFER; POLYACRYLAMIDE-GELS; PHOSPHOLIPASE D1; BETA-CATENIN; E-CADHERIN; ENDOCYTOSIS; INTERNALIZATION; MEMBRANE	Caveolae are flask-shaped endocytic structures composed primarily of caveolin-1 (Cav1) and caveolin-2 (Cav2) proteins. Interestingly, a cytoplasmic accumulation of Cav1 protein does not always result in a large number of assembled caveolae organelles, suggesting a regulatory mechanism that controls caveolae assembly. In this study we report that stimulation of epithelial cells with epithelial growth factor (EGF) results in a profound increase in the number of caveolar structures at the plasma membrane. Human pancreatic tumor cells (PANC-1) and normal rat kidney cells (NRK), as a control, were treated with 30 ng/ml EGF for 0, 5, and 20 min before fixation and viewing by electron microscopy. Cells fixed without EGF treatment exhibited modest numbers of plasma membrane-associated caveolae. Cells treated with EGF for 5 or 20 min showed an 8-10-fold increase in caveolar structures, some forming long, pronounced caveolar "towers" at the cell-cell borders. It is known that Cav1 is Src-phosphorylated on tyrosine 14 in response to EGF treatment, although the significance of this modification is unknown. We postulated that phosphorylation could provide the stimulus for caveolae assembly. To this end, we transfected cells with mutant forms of Cav1 that could not be phosphorylated (Cav1Y14F) and tested if this altered protein reduced the number of EGF-induced caveolae. We observed that EGF-stimulated PANC-1 cells expressing the mutant Cav1Y14F protein exhibited a 90-95% reduction in caveolae number compared with cells expressing wild type Cav1. This study provides novel insights into how cells regulate caveolae formation and implicates EGF-based signaling cascades in the phosphorylation of Cav1 as a stimulus for caveolae assembly.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Mayo Clin, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	McNiven, MA (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Guggenheim 1637,200 1st St SW, Rochester, MN 55905 USA.	mcniven.mark@mayo.edu						Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Beardsley A, 2005, J BIOL CHEM, V280, P3541, DOI 10.1074/jbc.M409040200; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Crescioli C, 2002, PROSTATE, V50, P15, DOI 10.1002/pros.10028; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Gonzalez-Cabrera J, 2003, INSECT BIOCHEM MOLEC, V33, P929, DOI 10.1016/S0965-1748(03)00099-7; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kim YN, 2002, EXP CELL RES, V280, P134, DOI 10.1006/excr.2002.5623; KORC M, 1986, P NATL ACAD SCI USA, V83, P5141, DOI 10.1073/pnas.83.14.5141; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahtinen U, 2003, FEBS LETT, V538, P85, DOI 10.1016/S0014-5793(03)00135-2; Lamb ME, 2001, BIOCHEM J, V355, P741, DOI 10.1042/bj3550741; Li SW, 1996, J BIOL CHEM, V271, P3863; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Navarro A, 2004, FASEB J, V18, P1801, DOI 10.1096/fj.04-2516rev; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pawson AJ, 2003, ENDOCRINOLOGY, V144, P3860, DOI 10.1210/en.2003-0028; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Sowa G, 2003, P NATL ACAD SCI USA, V100, P6511, DOI 10.1073/pnas.1031672100; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yamamoto M, 1999, EXP CELL RES, V247, P380, DOI 10.1006/excr.1998.4379	50	93	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4570	4579		10.1074/jbc.M512088200	http://dx.doi.org/10.1074/jbc.M512088200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16332692	hybrid			2022-12-27	WOS:000235426200004
J	Twiddy, D; Cohen, GM; MacFarlane, M; Cain, K				Twiddy, D; Cohen, GM; MacFarlane, M; Cain, K			Caspase-7 is directly activated by the similar to 700-kDa apoptosome complex and is released as a stable XIAP-caspase-7 similar to 200-kDa complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; INHIBITOR-INDUCED APOPTOSIS; CHEMICAL-INDUCED APOPTOSIS; BREAST-CANCER CELLS; CYTOCHROME-C; APAF-1 APOPTOSOME; DEATH; PROTEASOME; MECHANISM; MODEL	MCF-7 cells lack caspase-3 but undergo mitochondrial-dependent apoptosis via caspase-7 activation. It is assumed that the Apaf-1-caspase-9 apoptosome processes caspase-7 in an analogous manner to that described for caspase-3. However, this has not been validated experimentally, and we have now characterized the caspase-7 activating apoptosome complex in MCF-7 cell lysates activated with dATP/cytochrome c. Apaf-1 oligomerizes to produce similar to 1.4-MDa and similar to 700-kDa apoptosome complexes, and the latter complex directly cleaves/activates procaspase-7. This similar to 700-kDa apoptosome complex, which is also formed in apoptotic MCF-7 cells, is assembled by rapid oligomerization of Apaf-1 and followed by a slower process of procaspase-9 recruitment and cleavage to form the p35/34 forms. However, procaspase-9 recruitment and processing are accelerated in lysates supplemented with caspase-3. In lysates containing very low levels of Smac and Omi/HtrA2, XIAP (X-linked inhibitor of apoptosis) binds tightly to caspase-9 in the apoptosome complex, and as a result caspase-7 processing is abrogated. In contrast, in MCF-7 lysates containing Smac and Omi/HtrA2, active caspase-7 is released from the apoptosome and forms a stable similar to 200-kDa XIAP-caspase-7 complex, which apparently does not contain cIAP1 or cIAP2. Thus, in comparison to caspase-3-containing cells, XIAP appears to have a more significant antiapoptotic role in MCF-7 cells because it directly inhibits caspase-7 activation by the apoptosome and also forms a stable similar to 200-kDa complex with active caspase-7.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester	Cain, K (corresponding author), Univ Leicester, MRC, Toxicol Unit, Lancaster Rd, Leicester LE1 9HN, Leics, England.	kc5@le.ac.uk	Cohen, Gerald M/A-1687-2008		Medical Research Council [MC_U132685863] Funding Source: Medline; MRC [MC_U132685863] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Bratton SB, 2001, CELL DEATH DIFFER, V8, P425, DOI 10.1038/sj.cdd.4400834; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7; Cain K, 2003, DRUG METAB REV, V35, P337, DOI 10.1081/DMR-120026497; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Denault JB, 2003, J BIOL CHEM, V278, P34042, DOI 10.1074/jbc.M305110200; Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hengartner M, 1998, SCIENCE, V281, P1298, DOI 10.1126/science.281.5381.1298; Hill MM, 2004, EMBO J, V23, P2134, DOI 10.1038/sj.emboj.7600210; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kurokawa H, 1999, ONCOL REP, V6, P33; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; MacFarlane M, 1997, J CELL BIOL, V137, P469, DOI 10.1083/jcb.137.2.469; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tenev T, 2005, NAT CELL BIOL, V7, P70, DOI 10.1038/ncb1204; Twiddy D, 2004, J BIOL CHEM, V279, P19665, DOI 10.1074/jbc.M311388200; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yang XH, 2001, CANCER RES, V61, P348; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	53	41	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3876	3888		10.1074/jbc.M507393200	http://dx.doi.org/10.1074/jbc.M507393200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352606	hybrid			2022-12-27	WOS:000235275300015
J	Mareninova, OA; Sung, KF; Hong, P; Lugea, A; Pandol, SJ; Gukovsky, I; Gukovskaya, AS				Mareninova, OA; Sung, KF; Hong, P; Lugea, A; Pandol, SJ; Gukovsky, I; Gukovskaya, AS			Cell death in pancreatitis - Caspases protect from necrotizing pancreatitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INTERACTING PROTEIN; ACINAR-CELLS; APAF-1 APOPTOSOME; CYTOCHROME-C; KINASE RIP; ACTIVATION; NECROSIS; MITOCHONDRIAL; INHIBITION; NEUTROPHILS	Mechanisms of cell death in pancreatitis remain unknown. Parenchymal necrosis is a major complication of pancreatitis; also, the severity of experimental pancreatitis correlates directly with necrosis and inversely with apoptosis. Thus, shifting death responses from necrosis to apoptosis may have a therapeutic value. To determine cell death pathways in pancreatitis and the possibility of necrosis/apoptosis switch, we utilized the differences between the rat model of cerulein pancreatitis, with relatively high apoptosis and low necrosis, and the mouse model, with little apoptosis and high necrosis. We found that caspases were greatly activated during cerulein pancreatitis in the rat but not mouse. Endogenous caspase inhibitor X-linked inhibitor of apoptosis protein (XIAP) underwent complete degradation in the rat but remained intact in the mouse model. Furthermore, XIAP inhibition with embelin triggered caspase activation in the mouse model, implicating XIAP in caspase blockade in pancreatitis. Caspase inhibitors decreased apoptosis and markedly stimulated necrosis in the rat model, worsening pancreatitis parameters. Conversely, caspase induction with embelin stimulated apoptosis and decreased necrosis in mouse model. Thus, caspases not only mediate apoptosis but also protect from necrosis in pancreatitis. One protective mechanism is through degradation of receptor-interacting protein (RIP), a key mediator of "programmed" necrosis. We found that RIP was cleaved (i.e. inactivated) in the rat but not the mouse model. Caspase inhibition restored RIP levels; conversely, caspase induction with embelin triggered RIP cleavage. Our results indicate key roles for caspases, XIAP, and RIP in the regulation of cell death in pancreatitis. Manipulating these signals to change the pattern of death responses presents a therapeutic strategy for treatment of pancreatitis.	Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90073 USA; Chang Gung Mem Hosp, Dept HepatoGastroenterol, Taipei 333, Taiwan	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Chang Gung Memorial Hospital	Gukovskaya, AS (corresponding author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,Bldg 258,Rm 340, Los Angeles, CA 90073 USA.	agukovsk@ucla.edu		Gukovskaya, Anna/0000-0003-3737-5335	NIDDK NIH HHS [DK59936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Alvarado-Kristensson M, 2005, J BIOL CHEM, V280, P6238, DOI 10.1074/jbc.M409718200; Bassi C, 2003, PANCREATOLOGY, V3, P128, DOI 10.1159/000070080; Bhatia M, 2000, J PATHOL, V190, P117; Bhatia M, 2004, AM J PHYSIOL-GASTR L, V286, pG189, DOI 10.1152/ajpgi.00304.2003; Bhatia M, 1998, BIOCHEM BIOPH RES CO, V246, P476, DOI 10.1006/bbrc.1998.8519; Blinman TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1993, DOI 10.1152/ajpcell.2000.279.6.C1993; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Caserta TM, 2003, APOPTOSIS, V8, P345, DOI 10.1023/A:1024116916932; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Chen XQ, 2002, GASTROENTEROLOGY, V122, P448, DOI 10.1053/gast.2002.31060; CHITRA M, 1994, CHEMOTHERAPY, V40, P109, DOI 10.1159/000239181; Connor S, 2004, WORLD J GASTROENTERO, V10, P1697; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; GORELICK PS, 1993, PANCREAS BIOL PATHOL, P64; Guimaraes CA, 2004, EUR J BIOCHEM, V271, P1638, DOI 10.1111/j.1432-1033.2004.04084.x; Gukovsaya AS, 1996, GASTROENTEROLOGY, V110, P875, DOI 10.1053/gast.1996.v110.pm8608898; Gukovskaya AS, 2002, J BIOL CHEM, V277, P22595, DOI 10.1074/jbc.M202929200; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; Gukovskaya AS, 2004, PANCREATOLOGY, V4, P567, DOI 10.1159/000082182; Gukovskaya AS, 2002, GASTROENTEROLOGY, V122, P974, DOI 10.1053/gast.2002.32409; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; GUPTA S, 1989, CONTRACEPTION, V39, P307, DOI 10.1016/0010-7824(89)90063-2; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hayakawa K, 2003, CIRCULATION, V108, P104, DOI 10.1161/01.CIR.0000074225.62168.68; Hegyi P, 2004, WORLD J GASTROENTERO, V10, P2003, DOI 10.3748/wjg.v10.i14.2003; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; Johnson CR, 2004, APOPTOSIS, V9, P423, DOI 10.1023/B:APPT.0000031457.90890.13; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; Kakimura J, 2001, EUR J PHARMACOL, V417, P59, DOI 10.1016/S0014-2999(01)00902-5; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Krieser RJ, 2002, CURR OPIN CELL BIOL, V14, P734, DOI 10.1016/S0955-0674(02)00390-3; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lee HC, 2000, J BIOMED SCI, V7, P2, DOI 10.1007/BF02255913; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; LERCH MM, 1994, INT J PANCREATOL, V15, P159; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; LUTHEN R, 1995, AM J PHYSIOL-GASTR L, V268, pG592, DOI 10.1152/ajpgi.1995.268.4.G592; LUTHEN RE, 1995, PANCREAS, V11, P141; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Melnikov VY, 2002, J CLIN INVEST, V110, P1083, DOI 10.1172/JCI200215623; Nikolovska-Coleska Z, 2004, J MED CHEM, V47, P2430, DOI 10.1021/jm030420+; Norman J, 1998, AM J SURG, V175, P76, DOI 10.1016/S0002-9610(97)00240-7; Norman JG, 1999, DIGESTION, V60, P57, DOI 10.1159/000051455; Peter Marcus E, 2004, Biochem J, V382, pe1; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Raraty Michael G T, 2004, Curr Gastroenterol Rep, V6, P99, DOI 10.1007/s11894-004-0035-0; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; Reed JC, 2005, BLOOD, V106, P408, DOI 10.1182/blood-2004-07-2761; Saluja A, 1996, BIOCHEM BIOPH RES CO, V220, P875, DOI 10.1006/bbrc.1996.0498; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Soares RV, 2002, ARCH ORAL BIOL, V47, P591, DOI 10.1016/S0003-9969(02)00047-X; Steer ML, 1999, BEST PRACT RES CL GA, V13, P213, DOI 10.1053/bega.1999.0020; Sumino M, 2002, CHEM PHARM BULL, V50, P1484, DOI 10.1248/cpb.50.1484; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tashiro M, 2001, GUT, V49, P241, DOI 10.1136/gut.49.2.241; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Vaquero EC, 2003, GASTROENTEROLOGY, V125, P1188, DOI 10.1016/S0016-5085(03)01203-4; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; von Harsdorf R, 2004, CIRC RES, V95, P554, DOI 10.1161/01.RES.0000143717.70275.8f; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049	78	229	249	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3370	3381		10.1074/jbc.M511276200	http://dx.doi.org/10.1074/jbc.M511276200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339139	hybrid			2022-12-27	WOS:000235128200045
J	Olivera, A; Urtz, N; Mizugishi, K; Yamashita, Y; Gilfillan, AM; Furumoto, Y; Gu, HH; Proia, RL; Baumruker, T; Rivera, J				Olivera, A; Urtz, N; Mizugishi, K; Yamashita, Y; Gilfillan, AM; Furumoto, Y; Gu, HH; Proia, RL; Baumruker, T; Rivera, J			IgE-dependent activation of sphingosine kinases 1 and 2 and secretion of sphingosine 1-phosphate requires Fyn kinase and contributes to mast cell responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; PROTEIN-COUPLED RECEPTORS; STRESS FIBER FORMATION; ALLERGIC RESPONSE; FUNCTIONAL-CHARACTERIZATION; CALCIUM MOBILIZATION; MOLECULAR-CLONING; PLASMA-MEMBRANE; SPHINGOSINE-1-PHOSPHATE; SIGNALS	Engagement of the high affinity receptor for IgE (Fc epsilon RI) on mast cells results in the production and secretion of sphingosine 1-phosphate (S1P), a lipid metabolite present in the lungs of allergen-challenged asthmatics. Herein we report that two isoforms of sphingosine kinase (SphK1 and SphK2) are expressed and activated upon Fc epsilon RI engagement of bone marrow-derived mast cells (BMMC). Fyn kinase is required for Fc epsilon RI coupling to SphK1 and -2 and for subsequent S1P production. Normal activation of SphK1 and -2 was restored by expression of wild type Fyn but only partly with a kinase-defective Fyn, indicating that induction of SphK1 and SphK2 depended on both catalytic and noncatalytic properties of Fyn. Downstream of Fyn, the requirements for SphK1 activation differed from that of SphK2. Whereas SphK1 was considerably dependent on the adapter Grb2-associated binder 2 and phosphatidylinositol 3-OH kinase, SphK2 showed minimal dependence on these molecules. Fyn-deficient BMMC were defective in chemotaxis and, as previously reported, in degranulation. These functional responses were partly reconstituted by the addition of exogenous S1P to Fc epsilon RI-stimulated cells. Taken together with our previous study, which demonstrated delayed SphK activation in Lyn-deficient BMMC, we propose a cooperative role between Fyn and Lyn kinases in the activation of SphKs, which contributes to mast cell responses.	NIAMS, NIH, Mol Inflammat Sect, Mol Immunol & Inflammat Branch, Bethesda, MD 20892 USA; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIDDK, Gen Dev & Dis Branch, Bethesda, MD 20892 USA; Novartis Inst Biomed Res Vienna, A-1235 Vienna, Austria; Harvard Univ, Sch Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol & Oncol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Novartis; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Olivera, A (corresponding author), NIAMS, NIH, Mol Inflammat Sect, Mol Immunol & Inflammat Branch, Bldg 10,Rm 9N228, Bethesda, MD 20892 USA.	oliveraa@mail.nih.gov; juan_rivera@nih.gov	Proia, Richard L/A-7908-2012	Proia, Richard/0000-0003-0456-1270	NIAID NIH HHS [AI51612] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051612, Z01AI000850] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041155, Z01AR041101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000, Z01DK056015] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Burton EA, 1997, J BIOL CHEM, V272, P16189, DOI 10.1074/jbc.272.26.16189; Choi OH, 1996, NATURE, V380, P634; Edsall L, 2000, METHOD ENZYMOL, V312, P9; Gordon JR, 2000, CELL IMMUNOL, V205, P128, DOI 10.1006/cimm.2000.1714; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hanna AN, 2001, MOL BIOL CELL, V12, P3618, DOI 10.1091/mbc.12.11.3618; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2002, J BIOL CHEM, V277, P17255, DOI 10.1074/jbc.M110944200; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 2005, J IMMUNOL, V174, P1153, DOI 10.4049/jimmunol.174.3.1153; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Saba JD, 2004, CIRC RES, V94, P724, DOI 10.1161/01.RES.0000122383.60368.24; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Smith RE, 2003, BLOOD, V102, P2532, DOI 10.1182/blood-2002-11-3596; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2000, ANN NY ACAD SCI, V905, P54; Tan BL, 2003, BLOOD, V101, P4725, DOI 10.1182/blood-2002-08-2521; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Urtz N, 2004, MOL CELL BIOL, V24, P8765, DOI 10.1128/MCB.24.19.8765-8777.2004; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352; Young KW, 2003, CELL CALCIUM, V33, P119, DOI 10.1016/S0143-4160(02)00205-1	42	117	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2515	2525		10.1074/jbc.M508931200	http://dx.doi.org/10.1074/jbc.M508931200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316995	hybrid			2022-12-27	WOS:000234931800014
J	Kulp, MS; Frickel, EM; Ellgaard, L; Weissman, JS				Kulp, MS; Frickel, EM; Ellgaard, L; Weissman, JS			Domain architecture of protein-disulfide isomerase facilitates its dual role as an oxidase and an isomerase in Ero1p-mediated disulfide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE PANCREATIC RIBONUCLEASE; ENDOPLASMIC-RETICULUM; BOND FORMATION; FUNCTIONAL-PROPERTIES; ACTIVE-SITES; LIVING CELLS; ER STRESS; IN-VITRO; YEAST; ERP57	Native disulfide bond formation in eukaryotes is dependent on protein-disulfide isomerase (PDI) and its homologs, which contain varying combinations of catalytically active and inactive thioredoxin domains. However, the specific contribution of PDI to the formation of new disulfides versus reduction/rearrangement of non-native disulfides is poorly understood. We analyzed the role of individual PDI domains in disulfide bond formation in a reaction driven by their natural oxidant, Ero1p. We found that Ero1p oxidizes the isolated PDI catalytic thioredoxin domains, A and A' at the same rate. In contrast, we found that in the context of full-length PDI, there is an asymmetry in the rate of oxidation of the two active sites. This asymmetry is the result of a dual effect: an enhanced rate of oxidation of the second catalytic (A') domain and the substrate-mediated inhibition of oxidation of the first catalytic (A) domain. The specific order of thioredoxin domains in PDI is important in establishing the asymmetry in the rate of oxidation of the two active sites thus allowing A and A', two thioredoxin domains that are similar in sequence and structure, to serve opposing functional roles as a disulfide isomerase and disulfide oxidase, respectively. These findings reveal how native disulfide folding is accomplished in the endoplasmic reticulum and provide a context for understanding the proliferation of PDI homologs with combinatorial arrangements of thioredoxin domains.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94158 USA; ETH, Inst Biochem, CH-8093 Zurich, Switzerland	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Swiss Federal Institutes of Technology Domain; ETH Zurich	Weissman, JS (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, 1700 4th St, San Francisco, CA 94158 USA.	weissman@cmp.ucsf.edu	Ellgaard, Lars/I-9034-2014	Ellgaard, Lars/0000-0002-7018-0137; Weissman, Jonathan/0000-0003-2445-670X				Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; Cunnea PM, 2003, J BIOL CHEM, V278, P1059, DOI 10.1074/jbc.M206995200; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Gross E, 2004, CELL, V117, P601, DOI 10.1016/S0092-8674(04)00418-0; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; Hosoda A, 2003, J BIOL CHEM, V278, P2669, DOI 10.1074/jbc.M208346200; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Mossner E, 1998, PROTEIN SCI, V7, P1233; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Pagani M, 2000, J BIOL CHEM, V275, P23685, DOI 10.1074/jbc.M003061200; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Shin HC, 2000, J MOL BIOL, V300, P995, DOI 10.1006/jmbi.2000.3928; Silvennoinen L, 2004, J BIOL CHEM, V279, P13607, DOI 10.1074/jbc.M313054200; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Tachikawa H, 1997, BIOCHEM BIOPH RES CO, V239, P710, DOI 10.1006/bbrc.1997.7426; TACHIKAWA H, 1995, FEBS LETT, V369, P212, DOI 10.1016/0014-5793(95)00750-4; Tsai M, 2002, J CELL BIOL, V159, P207, DOI 10.1083/jcb.200207120; Tu BP, 2000, SCIENCE, V290, P1571, DOI 10.1126/science.290.5496.1571; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Tu BP, 2002, MOL CELL, V10, P983, DOI 10.1016/S1097-2765(02)00696-2; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Westphal V, 1999, J MOL BIOL, V286, P1229, DOI 10.1006/jmbi.1999.2560; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Xiao RY, 2004, J BIOL CHEM, V279, P49780, DOI 10.1074/jbc.M409210200; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	46	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 13	2006	281	2					876	884		10.1074/jbc.M511764200	http://dx.doi.org/10.1074/jbc.M511764200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	000FV	16368681	hybrid, Green Published			2022-12-27	WOS:000234447200026
J	Guo, K; Lukacik, P; Papagrigoriou, E; Meier, M; Lee, WH; Adamski, J; Oppermann, U				Guo, K; Lukacik, P; Papagrigoriou, E; Meier, M; Lee, WH; Adamski, J; Oppermann, U			Characterization of human DHRS6, an orphan short chain dehydrogenase/reductase enzyme - A novel, cytosolic type 2 R-beta-hydroxybutyrate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; (R)-3-HYDROXYBUTYRATE DEHYDROGENASE; ALCOHOL-DEHYDROGENASE; KETONE-BODY; HUMAN HEART; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; 3-HYDROXYBUTYRATE DEHYDROGENASE; 3-DIMENSIONAL STRUCTURE; RAT-LIVER; FAMILY	Human DHRS6 is a previously uncharacterized member of the short chain dehydrogenases/reductase family and displays significant homologies to bacterial hydroxybutyrate dehydrogenases. Substrate screening reveals sole NAD(+)-dependent conversion of (R)-hydroxybutyrate to acetoacetate with K-m values of about 10 mM, consistent with plasma levels of circulating ketone bodies in situations of starvation or ketoacidosis. The structure of human DHRS6 was determined at a resolution of 1.8 angstrom in complex with NAD(H) and reveals a tetrameric organization with a short chain dehydrogenases/ reductase-typical folding pattern. A highly conserved triad of Arg residues ("triple R" motif consisting of Arg(144), Arg(188), and Arg(205)) was found to bind a sulfate molecule at the active site. Docking analysis of R-beta-hydroxybutyrate into the active site reveals an experimentally consistent model of substrate carboxylate binding and catalytically competent orientation. GFP reporter gene analysis reveals a cytosolic localization upon transfection into mammalian cells. These data establish DHRS6 as a novel, cytosolic type 2 ( R)hydroxybutyrate dehydrogenase, distinct from its well characterized mitochondrial type 1 counterpart. The properties determined for DHRS6 suggest a possible physiological role in cytosolic ketone body utilization, either as a secondary system for energy supply in starvation or to generate precursors for lipid and sterol synthesis.	Univ Oxford, Struct Genom Consortium, Oxford OX3 7LD, England; GSF, Natl Res Ctr, Inst Expt Genet, D-85764 Neuherberg, Germany	University of Oxford; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Oppermann, U (corresponding author), Univ Oxford, Struct Genom Consortium, Oxford OX3 7LD, England.	Udo.Oppermann@sgc.ox.ac.uk	Lukacik, Petra/AAY-3775-2021; Lee, Wen Hwa/GZA-8183-2022; Lee, Wen Hwa/G-1250-2013	Lukacik, Petra/0000-0002-3179-7273; Lee, Wen Hwa/0000-0002-4098-5225; Lee, Wen Hwa/0000-0002-4098-5225; Adamski, Jerzy/0000-0001-9259-0199	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aneja P, 1999, J BACTERIOL, V181, P849, DOI 10.1128/JB.181.3.849-857.1999; Benach J, 1999, J MOL BIOL, V289, P335, DOI 10.1006/jmbi.1999.2765; Breitkreuz KE, 2003, J BIOL CHEM, V278, P41552, DOI 10.1074/jbc.M305717200; Chelius D, 2000, BIOCHEMISTRY-US, V39, P9687, DOI 10.1021/bi000274z; CHURCHILL P, 1992, BIOCHEMISTRY-US, V31, P3793, DOI 10.1021/bi00130a009; DALTON LA, 1993, BIOCHEM J, V296, P563, DOI 10.1042/bj2960563; ENDEMANN G, 1982, J BIOL CHEM, V257, P3434; Filling C, 2002, J BIOL CHEM, V277, P25677, DOI 10.1074/jbc.M202160200; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Green D, 1996, BIOCHEMISTRY-US, V35, P8158, DOI 10.1021/bi952807n; Hawes JW, 2000, METHOD ENZYMOL, V324, P218; Hawes JW, 1997, ADV EXP MED BIOL, V414, P395; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; KOUNDAKJIAN PP, 1970, BIOCHEM J, V119, P49, DOI 10.1042/bj1190049; LeBlanc PJ, 2000, J EXP ZOOL, V286, P434, DOI 10.1002/(SICI)1097-010X(20000301)286:4<434::AID-JEZ11>3.3.CO;2-X; MARKS AR, 1992, J BIOL CHEM, V267, P15459; Ohnuki M, 2005, BBA-GENE STRUCT EXPR, V1729, P147, DOI 10.1016/j.bbaexp.2005.05.006; Oppermann U, 2003, CHEM-BIOL INTERACT, V143, P247, DOI 10.1016/S0009-2797(02)00164-3; Oppermann UCT, 2001, CHEM-BIOL INTERACT, V130, P699, DOI 10.1016/S0009-2797(00)00301-X; Oppermann UCT, 1997, BIOCHEMISTRY-US, V36, P34, DOI 10.1021/bi961803v; Powell AJ, 2000, J MOL BIOL, V303, P311, DOI 10.1006/jmbi.2000.4139; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Totrov M, 1997, PROTEINS, P215	25	52	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10291	10297		10.1074/jbc.M511346200	http://dx.doi.org/10.1074/jbc.M511346200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16380372	hybrid			2022-12-27	WOS:000236594300057
J	Buchse, T; Prietzsch, H; Sasse, T; Korbel, S; Stigge, G; Bogdanow, S; Brock, J; Bittorf, T				Buchse, T; Prietzsch, H; Sasse, T; Korbel, S; Stigge, G; Bogdanow, S; Brock, J; Bittorf, T			Profiling of early gene expression induced by erythropoietin receptor structural variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; MESSENGER-RNA; EPO RECEPTOR; PROTHYMOSIN-ALPHA; GROWTH-HORMONE; DIFFERENTIATION; ACTIVATION; STAT5; JAK2	The development of erythroid progenitor cells is triggered via the expression of the erythropoietin receptor ( EPOR) and its activation by erythropoietin. The function of the resulting receptor complex depends critically on the presence of activated JAK2, and the complex contains a large number of signaling molecules recruited to eight phosphorylated tyrosine residues. Studies using mutant receptor forms have demonstrated that truncated receptors lacking all tyrosines are able to support red blood cell development with low efficiency, whereas add-back mutants containing either Tyr(343) or Tyr(479) reconstitute EPOR signaling and erythropoiesis in vivo. To study the contribution of tyrosines to receptor function, we analyzed the activation of essential signaling pathways and early gene induction promoted by different receptor structural variants using human epidermal growth factor receptor/murine EPOR hybrids. In our experiments, receptors lacking all tyrosine residues or the JAK2-binding site did not induce mitogenic and anti-apoptotic signaling, whereas add-back mutant receptors containing single tyrosine residues (Try(343) and Tyr(479)) supported the activation of these functions efficiently. Profiling of early gene expression using cDNA array hybridization revealed that ( i) the high redundancy in the activation of signaling pathways is continued at the level of transcription; (ii) the expression of many genes targeted by the wild-type receptor is not supported by add-back mutants; and (iii) a small set of genes are exclusively induced by add-back receptors. We report the identification of several early genes that have not been implicated in the EPOR-dependent response so far.	Univ Rostock, Fac Med, Inst Med Biochem & Mol Biol, D-18057 Rostock, Germany	University of Rostock	Bittorf, T (corresponding author), Univ Rostock, Fac Med, Inst Med Biochem & Mol Biol, Schillingallee 70, D-18057 Rostock, Germany.	thomas.bittorf@med.uni-rostock.de						Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Berridge MV, 2000, ANTIOXID REDOX SIGN, V2, P231, DOI 10.1089/ars.2000.2.2-231; BITTORF T, 1994, CELL SIGNAL, V6, P305, DOI 10.1016/0898-6568(94)90035-3; Bittorf T, 2001, CELL SIGNAL, V13, P673, DOI 10.1016/S0898-6568(01)00189-9; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Karetsou Z, 2004, FEBS LETT, V577, P496, DOI 10.1016/j.febslet.2004.09.091; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Korbel S, 2005, PROTEOMICS, V5, P91, DOI 10.1002/pmic.200400883; KRANTZ SB, 1991, BLOOD, V77, P419; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Li K, 2003, BLOOD, V102, P3147, DOI 10.1182/blood-2003-01-0078; Li K, 2003, J BIOL CHEM, V278, P40702, DOI 10.1074/jbc.M307182200; Li WP, 2004, ANN NEUROL, V56, P767, DOI 10.1002/ana.20274; Liu L, 1997, LEUKEMIA, V11, P181, DOI 10.1038/sj.leu.2400559; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; Miller CP, 2002, BLOOD, V99, P898, DOI 10.1182/blood.V99.3.898; MIURA O, 1994, BLOOD, V84, P1501; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; REN HY, 1994, J BIOL CHEM, V269, P19633; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Sarna MK, 2003, ONCOGENE, V22, P3221, DOI 10.1038/sj.onc.1206381; Segade F, 1999, INT J BIOCHEM CELL B, V31, P1243, DOI 10.1016/S1357-2725(99)00094-1; Seubert N, 2003, MOL CELL, V12, P1239, DOI 10.1016/S1097-2765(03)00389-7; Shimizu R, 1996, BIOCHEM BIOPH RES CO, V222, P1, DOI 10.1006/bbrc.1996.0688; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Tian SS, 1996, BLOOD, V88, P4435, DOI 10.1182/blood.V88.12.4435.bloodjournal88124435; Vareli K, 2004, BIOL CELL, V96, P421, DOI 10.1016/j.biolcel.2004.04.002; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yang CH, 2004, EXP CELL RES, V298, P197, DOI 10.1016/j.yexcr.2004.04.008; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; Yoon DH, 2003, EXP HEMATOL, V31, P1310, DOI 10.1016/j.exphem.2003.08.009; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156	52	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7697	7707		10.1074/jbc.M508481200	http://dx.doi.org/10.1074/jbc.M508481200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16380376	hybrid			2022-12-27	WOS:000236031000002
J	Yi, MK; Tong, X; Skelton, A; Chase, R; Chen, T; Prongay, A; Bogen, SL; Saksena, AK; Njoroge, FG; Veselenak, RL; Pyles, RB; Bourne, N; Malcolm, BA; Lemon, SM				Yi, MK; Tong, X; Skelton, A; Chase, R; Chen, T; Prongay, A; Bogen, SL; Saksena, AK; Njoroge, FG; Veselenak, RL; Pyles, RB; Bourne, N; Malcolm, BA; Lemon, SM			Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor - Reduced rna replication fitness and partial rescue by second-site mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; VIRAL FITNESS; ACTIVE-SITE; IN-VIVO; EXPRESSION; TYPE-1; VARIANTS; GAG	Drug resistance is a major issue in the development and use of specific antiviral therapies. Here we report the isolation and characterization of hepatitis C virus RNA replicons resistant to a novel ketoamide inhibitor of the NS3/4A protease, SCH6 ( originally SCH446211). Resistant replicon RNAs were generated by G418 selection in the presence of SCH6 in a dose-dependent fashion, with the emergence of resistance reduced at higher SCH6 concentrations. Sequencing demonstrated remarkable consistency in the mutations conferring SCH6 resistance in genotype 1b replicons derived from two different strains of hepatitis C virus, A156T/ A156V and R109K. R109K, a novel mutation not reported previously to cause resistance to NS3/4A inhibitors, conferred moderate resistance only to SCH6. Structural analysis indicated that this reflects unique interactions of SCH6 with P'-side residues in the protease active site. In contrast, A156T conferred high level resistance to SCH6 and a related ketoamide, SCH503034, as well as BILN 2061 and VX-950. Unlike R109K, which had minimal impact on NS3/4A enzymatic function, A156T significantly reduced NS3/4A catalytic efficiency, polyprotein processing, and replicon fitness. However, three separate second-site mutations, P89L, Q86R, and G162R, were capable of partially reversing A156T-associated defects in polyprotein processing and/or replicon fitness, without significantly reducing resistance to the protease inhibitor.	Schering Plough Corp, Res Inst, Dept Virol, Kenilworth, NJ 07033 USA; Univ Texas, Med Branch, Inst Human Infect & Immun, Ctr Hepatitis Res, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77555 USA; Schering Plough Corp, Res Inst, Dept Struct Chem, Kenilworth, NJ 07033 USA; Schering Plough Corp, Res Inst, Dept Med Chem, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Merck & Company; Schering Plough Corporation; Merck & Company; Schering Plough Corporation	Tong, X (corresponding author), Schering Plough Corp, Res Inst, Dept Virol, Kenilworth, NJ 07033 USA.	xiao.tong@spcorp.com; smlemon@utmb.edu			NIAID NIH HHS [N01-AI25488, R21-AI063451, U19-AI40035] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI063451, U19AI040035] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arasappan A, 2005, BIOORG MED CHEM LETT, V15, P4180, DOI 10.1016/j.bmcl.2005.06.091; Back SH, 2000, PROTEIN EXPRES PURIF, V20, P196, DOI 10.1006/prep.2000.1301; BERGER A, 1970, PHILOS T R SOC B, V257, P249, DOI 10.1098/rstb.1970.0024; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bourne N, 2005, ANTIVIR RES, V67, P76, DOI 10.1016/j.antiviral.2005.03.006; Cabot B, 2001, J VIROL, V75, P12005, DOI 10.1128/JVI.75.24.12005-12013.2001; Croteau G, 1997, J VIROL, V71, P1089, DOI 10.1128/JVI.71.2.1089-1096.1997; CRUMPACKER C, 2001, FIELDS VIROLOGY, P393; Farci P, 2002, P NATL ACAD SCI USA, V99, P3081, DOI 10.1073/pnas.052712599; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Johnson Victoria A, 2004, Top HIV Med, V12, P119; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Kuzmic P, 2000, ANAL BIOCHEM, V281, P62, DOI 10.1006/abio.2000.4501; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lin C, 2004, J BIOL CHEM, V279, P17508, DOI 10.1074/jbc.M313020200; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lu LJ, 2004, ANTIMICROB AGENTS CH, V48, P2260, DOI 10.1128/AAC.48.6.2260-2266.2004; Maguire MF, 2002, J VIROL, V76, P7398, DOI 10.1128/JVI.76.15.7398-7406.2002; Mammano F, 1998, J VIROL, V72, P7632, DOI 10.1128/JVI.72.9.7632-7637.1998; MARTELL M, 1992, J VIROL, V66, P3225, DOI 10.1128/JVI.66.5.3225-3229.1992; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nijhuis M, 2001, CURR OPIN INFECT DIS, V14, P23, DOI 10.1097/00001432-200102000-00005; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; REESINK HW, 2005, 36 ANN DIG DIS WEEK; Taremi SS, 1998, PROTEIN SCI, V7, P2143, DOI 10.1002/pro.5560071011; Trozzi C, 2003, J VIROL, V77, P3669, DOI 10.1128/JVI.77.6.3669-3679.2003; Wang WY, 2004, J VIROL, V78, P700, DOI 10.1128/JVI.78.2.700-709.2004; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yi MK, 2004, J VIROL, V78, P7904, DOI 10.1128/JVI.78.15.7904-7915.2004; Yi MK, 2002, VIROLOGY, V304, P197, DOI 10.1006/viro.2002.1652; Yusa K, 2004, CURR PHARM DESIGN, V10, P4055, DOI 10.2174/1381612043382477; Zhang RM, 1999, ANAL BIOCHEM, V270, P268, DOI 10.1006/abio.1999.4109	37	89	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8205	8215		10.1074/jbc.M510246200	http://dx.doi.org/10.1074/jbc.M510246200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16352601	hybrid			2022-12-27	WOS:000236031000060
J	Sarg, B; Helliger, W; Talasz, H; Forg, B; Lindner, HH				Sarg, B; Helliger, W; Talasz, H; Forg, B; Lindner, HH			Histone H1 phosphorylation occurs site-specifically during interphase and mitosis - Identification of a novel phosphorylation site on histone H1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMATURE CHROMOSOME CONDENSATION; INTERACTION LIQUID-CHROMATOGRAPHY; TRANSFORMED MOUSE FIBROBLASTS; C-TERMINAL DOMAIN; CELL-CYCLE; CHROMATIN-STRUCTURE; IN-VIVO; H3 PHOSPHORYLATION; LINKER HISTONES; TETRAHYMENA	H1 histones, isolated from logarithmically growing and mitotically enriched human lymphoblastic T-cells (CCRF-CEM), were fractionated by reversed phase and hydrophilic interaction liquid chromatography, subjected to enzymatic digestion, and analyzed by amino acid sequencing and mass spectrometry. During interphase the four H1 subtypes present in these cells differ in their maximum phosphorylation levels: histone H1.5 is tri-, H1.4 di-, and H1.3 and H1.2, only monophosphorylated. The phosphorylation is site-specific and occurs exclusively on serine residues of SP(K/A) K motifs. The phosphorylation sites of histone H1.5 from mitotically enriched cells were also examined. In contrast to the situation in interphase, at mitosis there were additional phosphorylations, exclusively at threonine residues. Whereas the tetraphosphorylated H1.5 arises from the triphosphosphorylated form by phosphorylation of one of two TPKK motifs in the C-terminal domain, namely Thr(137) and Thr(154), the pentaphosphorylated H1.5 was the result of phosphorylation of one of the tetraphosphorylated forms at a novel nonconsensus motif at Thr(10) in the N-terminal tail. Despite the fact that histone H1.5 has five (S/T) P(K/A) K motifs, all of these motifs were never found to be phosphorylated simultaneously. Our data suggest that phosphorylation of human H1 variants occurs nonrandomly during both interphase and mitosis and that distinct serine- or threonine-specific kinases are involved in different cell cycle phases. The order of increased phosphorylation and the position of modification might be necessary for regulated chromatin decondensation, thus facilitating processes of replication and transcription as well as of mitotic chromosome condensation.	Innsbruck Med Univ, Bioctr, Div Clin Biochem, A-6020 Innsbruck, Austria	Medical University of Innsbruck	Lindner, HH (corresponding author), Innsbruck Med Univ, Bioctr, Div Clin Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	herbert.lindner@i-med.ac.at						AJIRO K, 1985, J BIOL CHEM, V260, P5379; AJIRO K, 1983, J BIOL CHEM, V258, P4534; ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; BRADBURY EM, 1992, BIOESSAYS, V14, P9; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Chadee DN, 2002, ONCOGENE, V21, P8397, DOI 10.1038/sj.onc.1206029; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; GURLEY LR, 1995, J BIOL CHEM, V270, P27653, DOI 10.1074/jbc.270.46.27653; Halmer L, 1996, NUCLEIC ACIDS RES, V24, P1420, DOI 10.1093/nar/24.8.1420; Hendzel MJ, 2004, J BIOL CHEM, V279, P20028, DOI 10.1074/jbc.M400070200; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Herrera RE, 1996, P NATL ACAD SCI USA, V93, P11510, DOI 10.1073/pnas.93.21.11510; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; JERZMANOWSKI A, 1992, J BIOL CHEM, V267, P8514; Katayama Hiroshi, 2003, Cancer and Metastasis Reviews, V22, P451, DOI 10.1023/A:1023789416385; LENNOX RW, 1982, J BIOL CHEM, V257, P5183; LENNOX RW, 1984, HISTONE GENES, V3, P3; Lindner H, 1996, J CHROMATOGR A, V743, P137, DOI 10.1016/0021-9673(96)00131-8; Lindner H, 1997, J CHROMATOGR A, V782, P55, DOI 10.1016/S0021-9673(97)00468-8; Lindner Herbert, 2004, Methods Mol Biol, V251, P75; Mizzen CA, 1999, J BIOL CHEM, V274, P14533, DOI 10.1074/jbc.274.21.14533; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; Ota T, 2002, CANCER RES, V62, P5168; Paulson JR, 1996, J CELL SCI, V109, P1437; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Roque A, 2004, NUCLEIC ACIDS RES, V32, P6111, DOI 10.1093/nar/gkh945; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sarg B, 2004, J BIOL CHEM, V279, P53458, DOI 10.1074/jbc.M409099200; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Swank RA, 1997, BIOCHEMISTRY-US, V36, P13761, DOI 10.1021/bi9714363; Talasz H, 1996, BIOCHEMISTRY-US, V35, P1761, DOI 10.1021/bi951914e; Van Holde K.A., 1988, CHROMATIN, P69; VANHOLDE K, 1995, ELEMENTS CHROMATIN S, V9, P1; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; YASUDA H, 1981, BIOCHEMISTRY-US, V20, P4414, DOI 10.1021/bi00518a028	42	100	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6573	6580		10.1074/jbc.M508957200	http://dx.doi.org/10.1074/jbc.M508957200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377619	hybrid			2022-12-27	WOS:000236030800053
J	Bergeron, A; Jorquera, R; Orejuela, D; Tanguay, RM				Bergeron, A; Jorquera, R; Orejuela, D; Tanguay, RM			Involvement of endoplasmic reticulum stress in hereditary tyrosinemia type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; INDUCED GENE-EXPRESSION; CELL-DEATH PROGRAM; FUMARYLACETOACETATE; APOPTOSIS; ACTIVATION; INDUCTION; MOUSE; LIVER; ER	Hereditary tyrosinemia type I ( HTI) is the most severe disease of the tyrosine degradation pathway. HTI is caused by a deficiency of fumarylacetoacetate hydrolase ( FAH), the enzyme responsible for the hydrolysis of fumarylacetoacetate ( FAA). As a result, there is an accumulation of metabolites such as maleylacetoacetate, succinylacetone, and FAA. The latter was shown to display mutagenic, cytostatic, and apoptogenic activities and to cause chromosomal instability. Herein, we demonstrate that FAA also causes a cellular insult leading to the endoplasmic reticulum ( ER) stress signaling. Treatment of V79 Chinese hamster lung cells with an apoptogenic dose of FAA ( 100 mu M) causes an early induction of the ER resident chaperone GRP78/BiP and a simultaneous phosphorylation of the eIF2 alpha. FAA treatment also causes a subsequent induction of the proapoptotic CHOP ( CEBP homologous protein) transcription factor as well as a late activation of caspase-12. Data obtained from fah(-)/ - mice taken off the therapeutic 2-(2-nitro-4-trifluoromethylbenzoyl)1,3 cyclohexanedione drug are similar. However, in this mouse model, there is also an increase in proteasome activity indicative of ER-associated degradation. This difference observed between the two models may be due to the fact that the murine model measures the effects of all metabolites accumulating in hereditary tyrosinemia type I as opposed to the cellular model that only measures the effects of exogenous FAA.	Univ Laval, Ctr Rech Fonct Struct & Ingn Prot, Dept Med, Lab Cell & Dev Genet, Ste Foy, PQ G1K 7P4, Canada	Laval University	Tanguay, RM (corresponding author), Univ Laval, Ctr Rech Fonct Struct & Ingn Prot, Dept Med, Lab Cell & Dev Genet, Pavillon Marchand, Ste Foy, PQ G1K 7P4, Canada.	robert.tanguay@rsvs.ulaval.ca						BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BERGER R, 1987, PEDIATR RES, V22, P394, DOI 10.1203/00006450-198710000-00005; Bloom D, 2002, ONCOGENE, V21, P2191, DOI 10.1038/sj.onc.1205288; Castano JG, 1996, BIOCHEMISTRY-US, V35, P3782, DOI 10.1021/bi952540s; Chang JY, 1996, EXP NEUROL, V137, P201, DOI 10.1006/exnr.1996.0019; Dieter MZ, 2003, FREE RADICAL BIO MED, V35, P351, DOI 10.1016/S0891-5849(03)00273-9; EDWARDS SW, 1955, METHOD ENZYMOL, V2, P292; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; FALLSTROM SP, 1979, PEDIATR RES, V13, P78, DOI 10.1203/00006450-197901000-00056; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GROMPE M, 1993, GENE DEV, V7, P2298, DOI 10.1101/gad.7.12a.2298; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Ito H, 2005, J CELL BIOCHEM, V95, P932, DOI 10.1002/jcb.20445; Jorquera R, 1999, FASEB J, V13, P2284, DOI 10.1096/fasebj.13.15.2284; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; Jorquera R, 2001, HUM MOL GENET, V10, P1741, DOI 10.1093/hmg/10.17.1741; Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KVITTINGEN EA, 1981, CLIN CHIM ACTA, V115, P311, DOI 10.1016/0009-8981(81)90244-8; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; Liu XM, 2005, J BIOL CHEM, V280, P872, DOI 10.1074/jbc.M410413200; Luijerink MC, 2003, J HEPATOL, V39, P901, DOI 10.1016/S0168-8278(03)00433-1; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; PEREZSALA D, 1995, J CELL PHYSIOL, V163, P523, DOI 10.1002/jcp.1041630312; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RICE WR, 1989, EVOLUTION, V43, P223, DOI 10.1111/j.1558-5646.1989.tb04220.x; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Sokal R.R, 1995, BIOMETRY PRINCIPLES, P392; Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032; Tanguay RM, 1996, ACTA BIOCHIM POL, V43, P209; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; TANGUAY RM, 1984, ADV GENE TECHNOLOGY, P256; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Vogel A, 2004, HEPATOLOGY, V39, P433, DOI 10.1002/hep.20077; Yan LJ, 2005, ANTIOXID REDOX SIGN, V7, P465, DOI 10.1089/ars.2005.7.465; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; ZAR JH, 1984, BIOSTAT ANAL, P122; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200	53	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5329	5334		10.1074/jbc.M506804200	http://dx.doi.org/10.1074/jbc.M506804200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16317004	hybrid			2022-12-27	WOS:000235568900002
J	Lai, AL; Park, H; White, JM; Tamm, LK				Lai, AL; Park, H; White, JM; Tamm, LK			Fusion peptide of influenza hemagglutinin requires a fixed angle boomerang structure for activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; LIPID-BILAYERS; VIRUS HEMAGGLUTININ; SECONDARY STRUCTURE; HEMIFUSION; MECHANISM; MUTANTS; SPECTROSCOPY; PROTEINS; PROGRAM	The fusion peptide of influenza hemagglutinin is crucial for cell entry of this virus. Previous studies showed that this peptide adopts a boomerang- shaped structure in lipid model membranes at the pH of membrane fusion. To examine the role of the boomerang in fusion, we changed several residues proposed to stabilize the kink in this structure and measured fusion. Among these, mutants E11A and W14A expressed hemagglutinins with hemifusion and no fusion activities, and F9A and N12A had no effect on fusion, respectively. Binding enthalpies and free energies of mutant peptides to model membranes and their ability to perturb lipid bilayer structures correlated well with the fusion activities of the parent full-length molecules. The structure of W14A determined by NMR and site- directed spin labeling features a flexible kink that points out of the membrane, in sharp contrast to the more ordered boomerang of the wild- type, which points into the membrane. A specific fixed angle boomerang structure is thus required to support membrane fusion.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Tamm, LK (corresponding author), Univ Virginia Hlth Syst, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.	lkt2e@virginia.edu	Lai, Alex/G-8668-2014		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030557, R01AI022470] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI 30557, R01 AI 22470, R37 AI030557, R01 AI022470] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Chen J, 1999, P NATL ACAD SCI USA, V96, P8967, DOI 10.1073/pnas.96.16.8967; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; Gray C, 1996, BIOPHYS J, V70, P2275, DOI 10.1016/S0006-3495(96)79793-X; Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097; Han X, 1999, BIOCHEMISTRY-US, V38, P15052, DOI 10.1021/bi991232h; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Han X, 2000, J MOL BIOL, V304, P953, DOI 10.1006/jmbi.2000.4251; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Lai AL, 2005, PROTEIN-LIPID INTERACTIONS: FROM MEMBRANE DOMAINS TO CELLULAR NETWORKS, P279; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; Li YL, 2005, J VIROL, V79, P12065, DOI 10.1128/JVI.79.18.12065-12076.2005; Li YL, 2003, BIOCHEMISTRY-US, V42, P7245, DOI 10.1021/bi0341760; Luginbuhl P, 1996, J BIOMOL NMR, V8, P136; Qiao H, 1999, MOL BIOL CELL, V10, P2759, DOI 10.1091/mbc.10.8.2759; SCHOCH C, 1993, J BIOL CHEM, V268, P9267; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; STEINHAUER DA, 1995, J VIROL, V69, P6643, DOI 10.1128/JVI.69.11.6643-6651.1995; Tamm LK, 2003, BBA-BIOMEMBRANES, V1614, P14, DOI 10.1016/S0005-2736(03)00159-7; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Zaitseva E, 2005, J CELL BIOL, V169, P167, DOI 10.1083/jcb.200412059	25	112	115	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5760	5770		10.1074/jbc.M512280200	http://dx.doi.org/10.1074/jbc.M512280200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407195	hybrid			2022-12-27	WOS:000235568900054
J	Bai, JX; Cederbaum, AI				Bai, JX; Cederbaum, AI			Overexpression of CYP2E1 in mitochondria sensitizes HepG2 cells to the toxicity caused by depletion of glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED OVEREXPRESSION; CYTOCHROME-P450 2E1; PERMEABILITY TRANSITION; CHRONIC ETHANOL; RAT-LIVER; COMPARTMENT PROTECTS; LIPID-PEROXIDATION; HEPATIC GLUTATHIONE; FISH-OIL; APOPTOSIS	Induction of CYP2E1 by ethanol is one mechanism by which ethanol causes oxidative stress and alcohol liver disease. Although CYP2E1 is predominantly found in the endoplasmic reticulum, it is also located in rat hepatic mitochondria. In the current study, chronic alcohol consumption induced rat hepatic mitochondrial CYP2E1. To study the role of mitochondrial targeted CYP2E1 in generating oxidative stress and causing damage to mitochondria, HepG2 lines overexpressing CYP2E1 in mitochondria (mE10 and mE27 cells) were established by transfecting a plasmid containing human CYP2E1 cDNA lacking the hydrophobic endoplasmic reticulum targeting signal sequence into HepG2 cells followed by G418 selection. A 40-kDa catalytically active NH2-terminally truncated form of CYP2E1 (mtCYP2E1) was detected in the mitochondrial compartment in these cells by Western blot analysis. Cell death caused by depletion of GSH by buthionine sulfoximine (BSO) was increased in mE10 and mE27 cells as compared with cells transfected with empty vector (pCI-neo). Antioxidants were able to abolish the loss of cell viability. Increased levels of reactive oxygen species and mitochondrial 3-nitrotyrosine and 4-hydroxynonenal protein adducts and decreased mitochondrial aconitase activity and mitochondrial membrane potential were observed in mE10 and mE27 cells treated with BSO. The mitochondrial membrane stabilizer, cyclosporine A, was also able to protect these cells from BSO toxicity. These results revealed that CYP2E1 in the mitochondrial compartment could induce oxidative stress in the mitochondria, damage mitochondria membrane potential, and cause a loss of cell viability. The accumulation of CYP2E1 in hepatic mitochondria induced by ethanol consumption might play an important role in alcohol liver disease.	Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, Box 1603,1 Gustave L Levy Pl, New York, NY 10029 USA.	arthur.cederbaum@mssm.edu			NIAAA NIH HHS [AA 03312] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA003312, R01AA003312] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Bai JX, 2001, J BIOL CHEM, V276, P4315, DOI 10.1074/jbc.M008895200; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9; Eliasson E, 1996, MOL PHARMACOL, V50, P573; Fang C, 1998, HEPATOLOGY, V27, P1304, DOI 10.1002/hep.510270516; FERNANDEZCHECA JC, 1991, J CLIN INVEST, V87, P397, DOI 10.1172/JCI115010; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; GORSKY LD, 1984, J BIOL CHEM, V259, P6812; Hall AG, 1999, ADV EXP MED BIOL, V457, P199; Hirokawa M, 1998, ALCOHOL CLIN EXP RES, V22, p111S, DOI 10.1111/acer.1998.22.s3_part1.111s; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Iimuro Y, 2000, HEPATOLOGY, V31, P391, DOI 10.1002/hep.510310219; INGELMANSUNDBERG M, 1993, ALCOHOL, V10, P447, DOI 10.1016/0741-8329(93)90063-T; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Lemasters JJ, 1997, BIOSCIENCE REP, V17, P281, DOI 10.1023/A:1027332611839; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Mari M, 2002, J PHARMACOL EXP THER, V301, P111, DOI 10.1124/jpet.301.1.111; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; MORTON S, 1985, BIOCHEM PHARMACOL, V34, P1559, DOI 10.1016/0006-2952(85)90699-9; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; Neve EPA, 1999, FEBS LETT, V460, P309, DOI 10.1016/S0014-5793(99)01361-7; Neve EPA, 2000, J BIOL CHEM, V275, P17130, DOI 10.1074/jbc.M000957200; Neve EPA, 2003, BIOCHEMISTRY-US, V42, P14566, DOI 10.1021/bi035193s; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; Neve EPA, 2001, J BIOL CHEM, V276, P11317, DOI 10.1074/jbc.M008640200; Oh SI, 1998, J NUTR, V128, P758, DOI 10.1093/jn/128.4.758; Pahan K, 1997, FREE RADICAL BIO MED, V23, P963, DOI 10.1016/S0891-5849(97)00017-8; Perez MJ, 2003, HEPATOLOGY, V38, P1146, DOI 10.1053/jhep.2003.50479; Raza H, 2004, DIABETES, V53, P185, DOI 10.2337/diabetes.53.1.185; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Robin MA, 2001, J BIOL CHEM, V276, P24680, DOI 10.1074/jbc.M100363200; RONIS MJJ, 1991, EUR J BIOCHEM, V198, P383, DOI 10.1111/j.1432-1033.1991.tb16026.x; SADRZADEH SMH, 1994, J PHARMACOL EXP THER, V269, P632; SPEISKY H, 1985, BIOCHEM J, V225, P565, DOI 10.1042/bj2250565; Tada-Oikawa S, 1998, BIOCHEM BIOPH RES CO, V247, P693, DOI 10.1006/bbrc.1998.8869; TSUKAMOTO H, 1995, J CLIN INVEST, V96, P620, DOI 10.1172/JCI118077; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Wu DF, 2001, ALCOHOL CLIN EXP RES, V25, P619, DOI 10.1097/00000374-200104000-00021; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	50	60	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5128	5136		10.1074/jbc.M510484200	http://dx.doi.org/10.1074/jbc.M510484200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380384	hybrid			2022-12-27	WOS:000235426200067
J	Kang, HW; Park, JY; Jeong, SW; Kim, JA; Moon, HJ; Perez-Reyes, E; Lee, JH				Kang, HW; Park, JY; Jeong, SW; Kim, JA; Moon, HJ; Perez-Reyes, E; Lee, JH			A molecular determinant of nickel inhibition in Ca(v)3.2 T-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ CHANNELS; SENSORY NEURONS; SCORPION TOXIN; AMINO-ACIDS; BLOCK; SELECTIVITY; BINDING; FAMILY; CELLS; GENE	Molecular cloning studies have revealed that heterogeneity of T-type Ca2+ currents in native tissues arises from the three isoforms of Ca(v)3 channels: Ca(v)3.1, Ca(v)3.2, and Ca(v)3.3. From pharmacological analysis of the recombinant T-type channels, low concentrations ( < 50 mu M) of nickel were found to selectively block the Ca(v)3.2 over the other isoforms. To date, however, the structural element(s) responsible for the nickel block on the Ca(v)3.2 T-type Ca2+ channel remain unknown. Thus, we constructed chimeric channels between the nickel-sensitive Ca(v)3.2 and the nickel-insensitive Ca(v)3.1 to localize the region interacting with nickel. Systematic assaying of serial chimeras suggests that the region preceding domain I S4 of Ca(v)3.2 contributes to nickel block. Point mutations of potential nickel-interacting sites revealed that H191Q in the S3-S4 loop of domain I significantly attenuated the nickel block of Ca(v)3.2, mimicking the nickel-insensitive blocking potency of Ca(v)3.1. These findings indicate that His-191 in the S3-S4 loop is a critical residue conferring nickel block to Ca(v)3.2 and reveal a novel role for the S3-S4 loop to control ion permeation through T-type Ca2+ channels.	Sogang Univ, Dept Life Sci, Mapo Gu, Seoul 121742, South Korea; Sogang Univ, Interdisciplinary Program Biotechnol, Seoul 121742, South Korea; Yonsei Univ, Coll Med, Inst Basic Med Sci, Dept Physiol, Kangwon Do, South Korea; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	Sogang University; Sogang University; Yonsei University; Yonsei University Health System; University of Virginia	Lee, JH (corresponding author), Sogang Univ, Dept Life Sci, Mapo Gu, Shinsu Dong 1, Seoul 121742, South Korea.	jhleem@sogang.ac.kr			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038691] Funding Source: NIH RePORTER; NINDS NIH HHS [NS038691] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBRACCHIO MP, 1982, BIOL TRACE ELEM RES, V4, P289, DOI 10.1007/BF02786543; Bal W, 1998, CHEM RES TOXICOL, V11, P1014, DOI 10.1021/tx980051y; Bourinet E, 2005, EMBO J, V24, P315, DOI 10.1038/sj.emboj.7600515; Brueggemann LI, 2005, AM J PHYSIOL-HEART C, V288, pH923, DOI 10.1152/ajpheart.01126.2003; Chakrabarti SK, 2001, TOXICOL APPL PHARM, V170, P153, DOI 10.1006/taap.2000.9097; Chemin J, 2002, J PHYSIOL-LONDON, V540, P3, DOI 10.1113/jphysiol.2001.013269; Chen HJ, 2000, PFLUG ARCH EUR J PHY, V439, P423, DOI 10.1007/s004240050959; Chen XL, 1999, AM J PHYSIOL-RENAL, V276, pF674, DOI 10.1152/ajprenal.1999.276.5.F674; Chuang RSI, 1998, NAT NEUROSCI, V1, P668, DOI 10.1038/3669; Clozel JP, 1999, P ASSOC AM PHYSICIAN, V111, P429, DOI 10.1111/paa.1999.111.5.429; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Durell SR, 2004, BIOPHYS J, V87, P2116, DOI 10.1529/biophysj.104.040618; ELLINOR PT, 1995, NEURON, V15, P1121, DOI 10.1016/0896-6273(95)90100-0; GORDON SE, 1995, NEURON, V14, P177; HAGIWARA N, 1988, J PHYSIOL-LONDON, V395, P233, DOI 10.1113/jphysiol.1988.sp016916; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; Jeong SW, 2003, NEUROREPORT, V14, P1537, DOI 10.1097/00001756-200308060-00028; Lee JH, 1999, BIOPHYS J, V77, P3034, DOI 10.1016/S0006-3495(99)77134-1; Lee JH, 1999, J NEUROSCI, V19, P1912; Martinez ML, 1999, J MOL CELL CARDIOL, V31, P1617, DOI 10.1006/jmcc.1999.0998; Park JY, 2003, EXP MOL MED, V35, P285, DOI 10.1038/emm.2003.39; Park JY, 2004, J BIOL CHEM, V279, P21707, DOI 10.1074/jbc.M400684200; Peng SQ, 2002, MOL PHARMACOL, V62, P1418, DOI 10.1124/mol.62.6.1418; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; Sillen L.G., 1971, STABILITY CONSTANTS; Talavera K, 2001, J BIOL CHEM, V276, P45628, DOI 10.1074/jbc.M103047200; Todorovic SM, 1998, J NEUROPHYSIOL, V79, P240, DOI 10.1152/jn.1998.79.1.240; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; Van Horn JD, 2003, J BIOL INORG CHEM, V8, P601, DOI 10.1007/s00775-003-0454-7; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; Zamponi GW, 1996, J MEMBRANE BIOL, V151, P77, DOI 10.1007/s002329900059	33	89	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4823	4830		10.1074/jbc.M510197200	http://dx.doi.org/10.1074/jbc.M510197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377633	hybrid			2022-12-27	WOS:000235426200033
J	Dastur, A; Beaudenon, S; Kelley, M; Krug, RM; Huibregtse, JM				Dastur, A; Beaudenon, S; Kelley, M; Krug, RM; Huibregtse, JM			Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN PROTEIN LIGASE; FAMILY; E2; INSIGHTS; COMPLEX; TARGETS	ISG15 is an interferon (IFN)-alpha/beta-induced ubiquitin-like protein that is conjugated to cellular proteins during innate immune responses to viral and bacterial infections. A recent proteomics study identified 158 human proteins targeted for ISG15 conjugation, including the ISG15 E1 and E2 enzymes (Ube1L and UbcH8, respectively) and a HECT E3 enzyme, Herc5. Like the genes encoding Ube1L and UbcH8, expression of Herc5 was also induced by IFN-beta, suggesting that Herc5 might be a component of the ISG15 conjugation system. Consistent with this, small interfering RNAs targeting Herc5 had a dramatic effect on overall ISG15 conjugation in human cells, abrogating conjugation to the vast majority of ISG15 target proteins in vivo. In addition, co-transfection of plasmids expressing ISG15, Ube1L, UbcH8, and Herc5 resulted in robust ISG15 conjugation in non-IFN-treated cells, while the active-site cysteine mutant of Herc5 or a mutant lacking the RCC1 repeat region did not support ISG15 conjugation. These results demonstrate that Herc5 is required for conjugation of ISG15 to a broad spectrum of target proteins in human cells.	Univ Texas, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Huibregtse, JM (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Austin, TX 78712 USA.	huibreg@mail.utexas.edu			NATIONAL CANCER INSTITUTE [R01CA072943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011772, R01AI011772] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA072943-11, R01 CA072943, CA72943] Funding Source: Medline; NIAID NIH HHS [AI11772] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Biron C.A., 2001, FIELDS VIROLOGY, P321; Denison C, 2005, MOL CELL PROTEOMICS, V4, P246, DOI 10.1074/mcp.M400154-MCP200; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hochrainer K, 2005, GENOMICS, V85, P153, DOI 10.1016/j.ygeno.2004.10.006; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Liu MJ, 2003, J BIOL CHEM, V278, P1594, DOI 10.1074/jbc.M208123200; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V266, P115, DOI 10.1006/bbrc.1999.1777; Nuber U, 1999, J BIOL CHEM, V274, P7576, DOI 10.1074/jbc.274.11.7576; Nyman TA, 2000, EUR J BIOCHEM, V267, P4011, DOI 10.1046/j.1432-1327.2000.01433.x; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Salvat C, 2004, J BIOL CHEM, V279, P18935, DOI 10.1074/jbc.M312201200; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Xu LX, 2003, EXP CELL RES, V288, P84, DOI 10.1016/S0014-4827(03)00187-3; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102	24	192	200	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4334	4338		10.1074/jbc.M512830200	http://dx.doi.org/10.1074/jbc.M512830200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16407192	hybrid			2022-12-27	WOS:000235275300068
J	Gibbs, GM; Scanlon, MJ; Swarbrick, J; Curtis, S; Gallant, E; Dulhunty, AF; O'Bryan, MK				Gibbs, GM; Scanlon, MJ; Swarbrick, J; Curtis, S; Gallant, E; Dulhunty, AF; O'Bryan, MK			The cysteine-rich secretory protein domain of Tpx-1 is related to ion channel toxins and regulates ryanodine receptor Ca2+ signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEIN; TESTIS-SPECIFIC GENE; TORSION ANGLE DYNAMICS; II-III-LOOP; CRISP FAMILY; SNAKE-VENOM; DIHYDROPYRIDINE RECEPTOR; SARCOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; LIZARD VENOM	The cysteine-rich secretory proteins (Crisp) are predominantly found in the mammalian male reproductive tract as well as in the venom of reptiles. Crisps are two domain proteins with a structurally similar yet evolutionary diverse N-terminal domain and a characteristic cysteine- rich C-terminal domain, which we refer to as the Crisp domain. We presented the NMR solution structure of the Crisp domain of mouse Tpx-1, and we showed that it contains two subdomains, one of which has a similar fold to the ion channel regulators BgK and ShK. Furthermore, we have demonstrated for the first time that the ion channel regulatory activity of Crisp proteins is attributed to the Crisp domain. Specifically, the Tpx-1 Crisp domain inhibited cardiac ryanodine receptor (RyR) 2 with an IC50 between 0.5 and 1.0 mu M and activated the skeletal RyR1 with an AC(50) between 1 and 10 mu M when added to the cytoplasmic domain of the receptor. This activity was nonvoltage-dependent and weakly voltage-dependent, respectively. Furthermore, the Tpx-1 Crisp domain activated both RyR forms at negative bilayer potentials and showed no effect at positive bilayer potentials when added to the luminal domain of the receptor. These data show that the Tpx-1 Crisp domain on its own can regulate ion channel activity and provide compelling evidence for a role for Tpx-1 in the regulation of Ca2+ fluxes observed during sperm capacitation.	Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia; Monash Univ, Australian Res Council, Ctr Excellence Biotechnol & Dev, Clayton, Vic 3168, Australia; Monash Univ, Dept Med Chem, Clayton, Vic 3168, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Monash University; Monash University; Monash University; Australian National University; John Curtin School of Medical Research	O'Bryan, MK (corresponding author), Monash Univ, Monash Inst Med Res, 27-31 Wright St, Clayton, Vic 3168, Australia.	Moira.OBryan@med.monash.edu.au	Dulhunty, Angela/AAO-5421-2020; O'Bryan, Moira K/F-8256-2012	O'Bryan, Moira K/0000-0001-7298-4940; Dulhunty, Angela/0000-0001-9493-4944; Scanlon, Martin/0000-0002-9230-7506				BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brown RL, 2003, J GEN PHYSIOL, V122, P749, DOI 10.1085/jgp.200308823; Busso D, 2003, CELL MOL BIOL, V49, P407; Chang TY, 1997, TOXICON, V35, P879, DOI 10.1016/S0041-0101(96)00192-4; Chiarella P, 2004, J CELL SCI, V117, P4127, DOI 10.1242/jcs.01283; Cohen DJ, 2001, BIOL REPROD, V65, P1000, DOI 10.1095/biolreprod65.4.1000; CRAIK DJ, 2000, ENCY ANAL CHEM, P12390; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Dulhunty AF, 2004, BIOCHEM J, V379, P161, DOI 10.1042/BJ20031096; Dulhunty AF, 2004, J BIOL CHEM, V279, P11853, DOI 10.1074/jbc.M310466200; EBERSPAECHER U, 1995, MOL REPROD DEV, V42, P157, DOI 10.1002/mrd.1080420205; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; Fernandez C, 1997, J MOL BIOL, V266, P576, DOI 10.1006/jmbi.1996.0772; Foster JA, 1996, MOL REPROD DEV, V44, P221, DOI 10.1002/(SICI)1098-2795(199606)44:2&lt;221::AID-MRD11&gt;3.0.CO;2-5; GIANNINI G, 1995, J CELL BIOL, V128, P893, DOI 10.1083/jcb.128.5.893; Giese A, 2002, GENE, V299, P101, DOI 10.1016/S0378-1119(02)01018-1; Goddard T. D., 1999, SPARKY 3; Guo M, 2005, J BIOL CHEM, V280, P12405, DOI 10.1074/jbc.M413566200; Haarmann CS, 2003, BIOCHEM J, V372, P305, DOI 10.1042/BJ20021763; HAENDLER B, 1993, ENDOCRINOLOGY, V133, P192, DOI 10.1210/en.133.1.192; Harper CV, 2004, J BIOL CHEM, V279, P46315, DOI 10.1074/jbc.M401194200; Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jalkanen J, 2005, BIOL REPROD, V72, P1268, DOI 10.1095/biolreprod.104.035758; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jin Y, 2003, TOXICON, V42, P539, DOI 10.1016/S0041-0101(03)00234-4; KASAHARA M, 1989, IMMUNOGENETICS, V29, P61, DOI 10.1007/BF02341616; KASAHARA M, 1989, GENOMICS, V5, P527, DOI 10.1016/0888-7543(89)90019-0; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; Kitajima S, 1999, J BIOCHEM, V125, P1, DOI 10.1093/oxfordjournals.jbchem.a022244; KLAUS W, 1993, J MOL BIOL, V232, P897, DOI 10.1006/jmbi.1993.1438; Kratzschmar J, 1996, EUR J BIOCHEM, V236, P827, DOI 10.1111/j.1432-1033.1996.t01-1-00827.x; Maeda T, 1999, DEV GROWTH DIFFER, V41, P715; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; MOCHCAMORALES J, 1990, TOXICON, V28, P299, DOI 10.1016/0041-0101(90)90065-F; MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8; MURPHY EV, 1995, GENE, V159, P131, DOI 10.1016/0378-1119(95)00061-A; NIXON B, 2005, BIOL REPROD; NOBILE M, 1994, J MEMBRANE BIOL, V139, P49; Nobile M, 1996, EXP BRAIN RES, V110, P15; O'Bryan MK, 1998, MOL REPROD DEV, V50, P313, DOI 10.1002/(SICI)1098-2795(199807)50:3&lt;313::AID-MRD7&gt;3.0.CO;2-M; O'Bryan MK, 2001, MOL REPROD DEV, V58, P116, DOI 10.1002/1098-2795(200101)58:1&lt;116::AID-MRD14&gt;3.0.CO;2-8; O'Leary JM, 2004, J BIOL CHEM, V279, P53857, DOI 10.1074/jbc.M409225200; OTSU K, 1990, J BIOL CHEM, V265, P13472; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Roberts KP, 2003, BIOL REPROD, V69, P572, DOI 10.1095/biolreprod.102.013771; Rosengren KJ, 2001, BIOCHEMISTRY-US, V40, P4601, DOI 10.1021/bi002623v; Schambony A, 2003, MECH DEVELOP, V120, P937, DOI 10.1016/S0925-4773(03)00162-X; Schreiber MC, 1997, GENE, V191, P135, DOI 10.1016/S0378-1119(97)00010-3; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Serrano RL, 2004, J MOL BIOL, V339, P173, DOI 10.1016/j.jmb.2004.03.015; Shikamoto Y, 2005, J MOL BIOL, V350, P735, DOI 10.1016/j.jmb.2005.05.020; Sleight SB, 2005, BIOL REPROD, V73, P721, DOI 10.1095/biolreprod.105.041533; Trevino CL, 1998, ZYGOTE, V6, P159, DOI 10.1017/S0967199498000094; Tudor JE, 1996, NAT STRUCT BIOL, V3, P317, DOI 10.1038/nsb0496-317; Udby L, 2004, BIOCHEMISTRY-US, V43, P12877, DOI 10.1021/bi048823e; Udby L, 2002, J LEUKOCYTE BIOL, V72, P462; Westhoff JH, 2003, CELL CALCIUM, V34, P261, DOI 10.1016/S0143-4160(03)00112-X; Yamazaki Y, 2004, TOXICON, V44, P227, DOI 10.1016/j.toxicon.2004.05.023; Yamazaki Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P133, DOI 10.1016/S0003-9861(03)00028-6; Yamazaki Y, 2002, EUR J BIOCHEM, V269, P2708, DOI 10.1046/j.1432-1033.2002.02940.x; Yamazaki Y, 2002, BIOCHEMISTRY-US, V41, P11331, DOI 10.1021/bi026132h	66	107	114	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4156	4163		10.1074/jbc.M506849200	http://dx.doi.org/10.1074/jbc.M506849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339766	hybrid			2022-12-27	WOS:000235275300047
J	Gross, CH; Abdul-Manan, N; Fulghum, J; Lippke, J; Liu, X; Prabhakar, P; Brennan, D; Willis, MS; Faerman, C; Connelly, P; Raybuck, S; Moore, J				Gross, CH; Abdul-Manan, N; Fulghum, J; Lippke, J; Liu, X; Prabhakar, P; Brennan, D; Willis, MS; Faerman, C; Connelly, P; Raybuck, S; Moore, J			Nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator, an ABC transporter, catalyze adenylate kinase activity but not ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-DOMAIN; CFTR; 2ND; PROTEIN; CHANNELS; SEQUENCE; COMPLEX; FOLD; HETERODIMER; MUTATIONS	The cystic fibrosis transmembrane conductance regulator (CFTR) is an anion channel in the ATP-binding cassette (ABC) transporter family. CFTR consists of two transmembrane domains, two nucleotide-binding domains (NBD1 and NBD2), and a regulatory domain. Previous biochemical reports suggest NBD1 is a site of stable nucleotide interaction with low ATPase activity, whereas NBD2 is the site of active ATP hydrolysis. It has also been reported that NBD2 additionally possessed adenylate kinase (AK) activity. Knowledge about the intrinsic biochemical activities of the NBDs is essential to understanding the Cl- ion gating mechanism. We find that purified mouse NBD1, human NBD1, and human NBD2 function as adenylate kinases but not as ATPases. AK activity is strictly dependent on the addition of the adenosine monophosphate ( AMP) substrate. No liberation of [P-33] phosphate is observed from the gamma-P-33-labeled ATP substrate in the presence or absence of AMP. AK activity is intrinsic to both human NBDs, as the Walker A box lysine mutations abolish this activity. At low protein concentration, the NBDs display an initial slower nonlinear phase in AK activity, suggesting that the activity results from homodimerization. Interestingly, the G551D gating mutation has an exaggerated nonlinear phase compared with the wild type and may indicate this mutation affects the ability of NBD1 to dimerize. hNBD1 and hNBD2 mixing experiments resulted in an 8-57-fold synergistic enhancement in AK activity suggesting heterodimer formation, which supports a common theme in ABC transporter models. A CFTR gating mechanism model based on adenylate kinase activity is proposed.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	Gross, CH (corresponding author), Vertex Pharmaceut Inc, 130 Waverly St, Cambridge, MA 02139 USA.	Christian_Gross@vrtx.com	Willis, Monte S/J-9994-2015	Willis, Monte S/0000-0002-0769-5816; Moore, Jonathan/0000-0001-8633-3313				ALBERTY RA, 1992, BIOCHEMISTRY-US, V31, P10610, DOI 10.1021/bi00158a025; Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Annereau JP, 2003, BIOCHEM J, V371, P451, DOI 10.1042/BJ20021318; Balakrishnan L, 2004, J BIOL CHEM, V279, P11273, DOI 10.1074/jbc.M308494200; Berger AL, 2005, P NATL ACAD SCI USA, V102, P455, DOI 10.1073/pnas.0408575102; Berry MB, 1998, PROTEINS, V32, P276, DOI 10.1002/(SICI)1097-0134(19980815)32:3<276::AID-PROT3>3.0.CO;2-G; Callebaut I, 2004, CELL MOL LIFE SCI, V61, P230, DOI 10.1007/s00018-003-3386-z; Chappe V, 2005, EMBO J, V24, P2730, DOI 10.1038/sj.emboj.7600747; Chen JH, 2002, J MEMBRANE BIOL, V188, P55, DOI 10.1007/s00232-001-0174-2; CUTTING GR, 1990, NATURE, V346, P366, DOI 10.1038/346366a0; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Howell LD, 2004, BIOCHEM J, V378, P151, DOI 10.1042/BJ20021428; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Kidd JF, 2004, J BIOL CHEM, V279, P41664, DOI 10.1074/jbc.M407666200; Krishnamurthy H, 2005, PROTEINS, V58, P88, DOI 10.1002/prot.20301; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; Lu NT, 2000, ARCH BIOCHEM BIOPHYS, V375, P7, DOI 10.1006/abbi.1999.1656; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Ostedgaard LS, 2001, J BIOL CHEM, V276, P7689, DOI 10.1074/jbc.R100001200; Ramaen O, 2005, BIOCHEM J, V391, P481, DOI 10.1042/BJ20050897; Ramjeesingh M, 1997, BIOCHEM J, V327, P17, DOI 10.1042/bj3270017; Ramjeesingh M, 2003, BIOCHEM J, V375, P633, DOI 10.1042/BJ20030774; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Randak C, 2003, CELL, V115, P837, DOI 10.1016/S0092-8674(03)00983-8; Randak C, 1999, BIOCHEM J, V340, P227, DOI 10.1042/0264-6021:3400227; Randak CO, 2005, J BIOL CHEM, V280, P34385, DOI 10.1074/jbc.R500009200; Randak CO, 2005, P NATL ACAD SCI USA, V102, P2216, DOI 10.1073/pnas.0409787102; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SHUTZGESHWENDER A, 2004, LICOR BIOSCIENCES; Stefkova J, 2004, PHYSIOL RES, V53, P235; SWOPE MW, 2005, PROTEIN SCI, V14, P1818; Verdon G, 2003, J MOL BIOL, V334, P255, DOI 10.1016/j.jmb.2003.08.065; Vonrhein C, 1998, J MOL BIOL, V282, P167, DOI 10.1006/jmbi.1998.2003; Wang WL, 2002, AM J PHYSIOL-CELL PH, V282, pC1170, DOI 10.1152/ajpcell.00337.2001; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Winter MC, 1997, NATURE, V389, P294, DOI 10.1038/38514; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	43	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4058	4068		10.1074/jbc.M511113200	http://dx.doi.org/10.1074/jbc.M511113200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361259	hybrid			2022-12-27	WOS:000235275300035
J	Knauf, JA; Ouyang, B; Knudsen, ES; Fukasawa, K; Babcock, G; Fagin, JA				Knauf, JA; Ouyang, B; Knudsen, ES; Fukasawa, K; Babcock, G; Fagin, JA			Oncogenic RAS induces accelerated transition through G(2)/M and promotes defects in the G(2) DNA damage and mitotic spindle checkpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID PCCL3 CELLS; SIGNAL-REGULATED KINASE; GENOMIC INSTABILITY; MAP KINASE; HA-RAS; GENETIC INSTABILITY; METASTATIC ABILITY; MUTATOR PHENOTYPE; PATHWAY; PROTEIN	Activating mutations of RAS are prevalent in thyroid follicular neoplasms, which commonly have chromosomal losses and gains. In thyroid cells, acute expression of HRAS(V12) increases the frequency of chromosomal abnormalities within one or two cell cycles, suggesting that RAS oncoproteins may interfere with cell cycle checkpoints required for maintenance of a stable genome. To explore this, PCCL3 thyroid cells with conditional expression of HRAS(V12) or HRAS(V12) effector mutants were presynchronized at the G(1)/S boundary, followed by activation of expression of RAS mutants and release from the cell cycle block. Expression of HRAS(V12) accelerated the G(2)/M phase by similar to 4 h and promoted bypass of the G(2) DNA damage and mitotic spindle checkpoints. Accelerated passage through G(2)/M and bypass of the G(2) DNA damage checkpoint, but not bypass of the mitotic spindle checkpoint, required activation of mitogen-activated protein kinase (MAPK). However, selective activation of the MAPK pathway was not sufficient to disrupt the G(2) DNA damage checkpoint, because cells arrested appropriately in G(2) despite conditional expression of HRAS(V12,S35) or BRAF(V600E). By contrast to the MAPK requirement for radiation-induced G(2) arrest, RAS-induced bypass of the mitotic spindle checkpoint was not prevented by pretreatment with MEK inhibitors. These data support a direct role for the MAPK pathway in control of G(2) progression and regulation of the G(2) DNA damage checkpoint. We propose that oncogenic RAS activation may predispose cells to genomic instability through both MAPK-dependent and independent pathways that affect critical checkpoints in G(2)/M.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Shriners Burns Inst, Div Burn Surg, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Fagin, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, 231 Bethesda Ave,Rm 5564, Cincinnati, OH 45267 USA.	James.Fagin@uc.edu		Knauf, Jeffrey/0000-0003-4456-8792	NCI NIH HHS [CA72597] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072597] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; AESCHIMANN S, 1993, J CLIN ENDOCR METAB, V77, P846, DOI 10.1210/jc.77.3.846; Agapova LS, 2004, J BIOL CHEM, V279, P36382, DOI 10.1074/jbc.M405007200; Agapova LS, 1999, ONCOGENE, V18, P3135, DOI 10.1038/sj.onc.1202386; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BOS JL, 1989, CANCER RES, V49, P4682; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; Chen CR, 1999, P NATL ACAD SCI USA, V96, P517, DOI 10.1073/pnas.96.2.517; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DEVRIES JE, 1993, CANCER GENET CYTOGEN, V67, P35, DOI 10.1016/0165-4608(93)90041-J; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; FEY MF, 1992, J CLIN INVEST, V89, P1438, DOI 10.1172/JCI115733; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; ICHIKAWA T, 1990, CANCER RES, V50, P6349; ICHIKAWA T, 1991, PROSTATE, V18, P163, DOI 10.1002/pros.2990180209; Jesch SA, 2001, MOL BIOL CELL, V12, P1811, DOI 10.1091/mbc.12.6.1811; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; Knauf JA, 1999, J BIOL CHEM, V274, P23414, DOI 10.1074/jbc.274.33.23414; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; Li YC, 2000, GENETICS, V156, P995; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; NAMBA H, 1990, J CLIN INVEST, V86, P120, DOI 10.1172/JCI114673; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Norppa H, 2003, MUTAGENESIS, V18, P221, DOI 10.1093/mutage/18.3.221; OLLER AR, 1989, MUTAT RES, V216, P149, DOI 10.1016/0165-1161(89)90001-0; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Sebolt-Leopold JS, 2004, CURR PHARM DESIGN, V10, P1907, DOI 10.2174/1381612043384439; Segal M, 2001, BIOESSAYS, V23, P307, DOI 10.1002/bies.1044; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SUAREZ HG, 1990, ONCOGENE, V5, P565; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; THACKER J, 1985, MUTAT RES, V150, P431, DOI 10.1016/0027-5107(85)90140-X; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; WANI MA, 1994, CANCER RES, V54, P2504; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	59	75	75	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3800	3809		10.1074/jbc.M511690200	http://dx.doi.org/10.1074/jbc.M511690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16316983	hybrid			2022-12-27	WOS:000235275300008
J	El-Guindy, AS; Paek, SY; Countryman, J; Miller, G				El-Guindy, AS; Paek, SY; Countryman, J; Miller, G			Identification of constitutive phosphorylation sites on the Epstein-Barr virus ZEBRA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CREB-BINDING-PROTEIN; LYTIC CYCLE GENES; NF-KAPPA-B; DNA-BINDING; C-JUN; TRANSCRIPTION FACTOR; PRODUCTIVE CYCLE; BZLF1 PROTEIN; CELL-CYCLE	ZEBRA, the product of the Epstein-Barr virus gene bzlf1, and a member of the AP-1 subfamily of basic zipper ( bZIP) transcription factors, is necessary and sufficient to disrupt viral latency and to initiate the viral lytic cycle. Two serine residues of ZEBRA, Ser(167) and Ser(173), are substrates for casein kinase 2 ( CK2) and are constitutively phosphorylated in vivo. Phosphorylation of ZEBRA at its CK2 sites is required for proper temporal regulation of viral gene expression. Phosphopeptide analysis indicated that ZEBRA contains additional constitutive phosphorylation sites. Here we employed a co-migration strategy to map these sites in vivo. The cornerstone of this strategy was to correlate the migration of P-32- and S-35- labeled tryptic peptides of ZEBRA. The identity of the peptides was revealed by mutagenesis of methionine and cysteine residues present in each peptide. Phosphorylation sites within the peptide were identified by mutagenesis of serines and threonines. ZEBRA was shown to be phosphorylated at serine and threonine residues, but not tyrosine. Two previously unrecognized phosphorylation sites of ZEBRA were identified in the NH2-terminal region of the transactivation domain: a cluster of weak phosphorylation sites at Ser(6), Thr(7), and Ser(8) and a strong phosphorylation site at Thr(14). Thr(14) was embedded in a MAP kinase consensus sequence and could be phosphorylated in vitro by JNK, despite the absence of a canonical JNK docking site. Thus ZEBRA is now known to be constitutively phosphorylated at three distinct sites.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Miller, G (corresponding author), Rm 420 LSOG,333 Cedar St,POB 208064, New Haven, CT 06520 USA.	George.Miller@yale.edu		Paek, So Yeon/0000-0002-1598-5928	NCI NIH HHS [CA12055, CA16038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012055, R37CA012055, P01CA016038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson AL, 1999, J VIROL, V73, P6551, DOI 10.1128/JVI.73.8.6551-6558.1999; Adamson AL, 2000, J VIROL, V74, P1224, DOI 10.1128/JVI.74.3.1224-1233.2000; Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1995, ONCOGENE, V11, P2509; Baumann M, 1998, J VIROL, V72, P8105, DOI 10.1128/JVI.72.10.8105-8114.1998; Baumann M, 1999, EMBO J, V18, P6095, DOI 10.1093/emboj/18.21.6095; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Bhende PM, 2004, NAT GENET, V36, P1099, DOI 10.1038/ng1424; Cayrol C, 1996, EMBO J, V15, P2748, DOI 10.1002/j.1460-2075.1996.tb00635.x; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; COUNTRYMAN J, 1985, P NATL ACAD SCI USA, V82, P4085, DOI 10.1073/pnas.82.12.4085; DAI TN, 1995, ONCOGENE, V10, P849; DAIBATA M, 1992, VIROLOGY, V188, P916, DOI 10.1016/0042-6822(92)90553-2; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DAVIS MG, 1988, BIOTECHNOL APPL BIOC, V10, P6; Deng Z, 2003, MOL CELL BIOL, V23, P2633, DOI 10.1128/MCB.23.8.2633-2644.2003; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; El-Guindy AS, 2004, J VIROL, V78, P7634, DOI 10.1128/JVI.78.14.7634-7644.2004; El-Guindy AS, 2002, J VIROL, V76, P11199, DOI 10.1128/JVI.76.22.11199-11208.2002; ELGUINDY A, 2003, THESIS YALE U NEW HA; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; Feederle R, 2004, J VIROL, V78, P12082, DOI 10.1128/JVI.78.21.12082-12084.2004; FIXMAN ED, 1992, J VIROL, V66, P5030, DOI 10.1128/JVI.66.8.5030-5039.1992; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; Flemington EK, 2001, J VIROL, V75, P4475, DOI 10.1128/JVI.75.10.4475-4481.2001; Francis A, 1999, J VIROL, V73, P4543, DOI 10.1128/JVI.73.6.4543-4551.1999; Francis AL, 1997, J VIROL, V71, P3054, DOI 10.1128/JVI.71.4.3054-3061.1997; Gao ZG, 1998, J VIROL, V72, P8559, DOI 10.1128/JVI.72.11.8559-8567.1998; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; HESTON L, 1982, NATURE, V295, P160, DOI 10.1038/295160a0; HOLLEYGUTHRIE EA, 1990, J VIROL, V64, P3753, DOI 10.1128/JVI.64.8.3753-3759.1990; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KOLMAN JL, 1993, P NATL ACAD SCI USA, V90, P10115, DOI 10.1073/pnas.90.21.10115; Kolman JL, 1996, J VIROL, V70, P1493, DOI 10.1128/JVI.70.3.1493-1504.1996; KOUZARIDES T, 1991, ONCOGENE, V6, P195; LeRoux F, 1996, J GEN VIROL, V77, P501, DOI 10.1099/0022-1317-77-3-501; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Ragoczy T, 1999, J VIROL, V73, P9858, DOI 10.1128/JVI.73.12.9858-9866.1999; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; SCHEPERS A, 1993, J VIROL, V67, P4237, DOI 10.1128/JVI.67.7.4237-4245.1993; SCHEPERS A, 1993, EMBO J, V12, P3921, DOI 10.1002/j.1460-2075.1993.tb06070.x; SINCLAIR AJ, 1991, J VIROL, V65, P2237, DOI 10.1128/JVI.65.5.2237-2244.1991; TAYLOR N, 1991, J VIROL, V65, P4033, DOI 10.1128/JVI.65.8.4033-4041.1991; TAYLOR N, 1989, J VIROL, V63, P1721, DOI 10.1128/JVI.63.4.1721-1728.1989; URIER G, 1989, EMBO J, V8, P1447, DOI 10.1002/j.1460-2075.1989.tb03527.x; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Wu FY, 2003, J VIROL, V77, P1481, DOI 10.1128/JVI.77.2.1481-1500.2003; Zerby D, 1999, MOL CELL BIOL, V19, P1617; Zhang Q, 1996, J VIROL, V70, P5131, DOI 10.1128/JVI.70.8.5131-5142.1996; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	67	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3085	3095		10.1074/jbc.M506076200	http://dx.doi.org/10.1074/jbc.M506076200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321978	hybrid			2022-12-27	WOS:000235128200011
J	Gonzalez, E; Kou, RQ; Michel, T				Gonzalez, E; Kou, RQ; Michel, T			Rac1 modulates sphingosine 1-phosphate-mediated activation of phosphoinositide 3-kinase/Akt signaling pathways in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; NITRIC-OXIDE SYNTHASE; DIFFERENTIAL REGULATION; LYSOPHOSPHATIDIC ACID; BINDING-PROTEINS; KINASE; EDG-1; AKT; RHO; PHOSPHORYLATION	Sphingosine 1-phosphate (S1P) is a platelet-derived sphingolipid that activates G protein-coupled S1P receptors and initiates a broad range of responses in vascular endothelial cells. The small GTPase Rac1 is implicated in diverse S1P-modulated cellular responses in endothelial cells, yet the molecular mechanisms involved in S1P-mediated Rac1 activation are incompletely understood. We studied the pathways involved in S1P-mediated Rac1 activation in bovine aortic endothelial cells (BAEC) and found that S1P-induced Rac1 activation is impaired following chelation of G protein beta gamma subunits by transfection of beta ARKct. Treatment with the Src tyrosine kinase inhibitor PP2 completely attenuated S1P-mediated Rac1 activation; however, pretreatment of BAEC with wortmannin, an inhibitor of phosphoinositide (PI) 3-kinase, had no effect on Rac1 activation while completely blocking S1P-induced Akt phosphorylation. We used Rac1-specific small interfering RNA (siRNA) duplexes to "knock down" endogenous Rac1 expression and found that siRNA-mediated Rac1 knockdown significantly impaired basal as well as S1P-induced phosphorylation of protein kinase Akt, as well as several downstream targets of Akt including endothelial nitric-oxide synthase and glycogen synthase kinase 3 beta. By contrast, S1P-induced phosphorylation of the mitogen-activated protein kinases ERK1/2 was unperturbed by siRNA-mediated Rac1 knockdown. We found that overexpression of the Rac1 guanine nucleotide exchange factor (GEF) Tiam1 markedly enhanced Rac1 activity, whereas a dominant negative Tiam1 mutant significantly attenuated S1P-mediated Rac1 activation. Taken together, these studies identify G protein beta gamma subunits, Src kinase and the GEF Tiam1 as upstream modulators of S1P-mediated Rac1 activation, and establish a central role for Rac1 in S1P- mediated activation of PI3-kinase/Akt/endothelial nitric-oxide synthase signaling in vascular endothelial cells.	Harvard Univ, Div Cardiovasc, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Michel, T (corresponding author), Harvard Univ, Div Cardiovasc, Brigham & Womens Hosp, Sch Med, 75 Francis St, Boston, MA 02115 USA.	tmichel@research.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046457, R29HL046457] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46457] Funding Source: Medline; NIGMS NIH HHS [GM36259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chan ASL, 2004, CELL SIGNAL, V16, P823, DOI 10.1016/j.cellsig.2003.12.007; Dantas APV, 2003, AM J PHYSIOL-HEART C, V284, pH2045, DOI 10.1152/ajpheart.01089.2002; Ehler E, 1997, MOL CELL NEUROSCI, V9, P1, DOI 10.1006/mcne.1997.0602; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Erickson JW, 2004, BIOCHEMISTRY-US, V43, P837, DOI 10.1021/bi036026v; Eriksson A, 2003, CIRCULATION, V107, P1532, DOI 10.1161/01.CIR.0000055324.34758.32; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Gonzalez E, 2004, J BIOL CHEM, V279, P40659, DOI 10.1074/jbc.M407051200; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; HLA T, 1990, J BIOL CHEM, V265, P9308; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Igarashi J, 2001, J BIOL CHEM, V276, P36281, DOI 10.1074/jbc.M105628200; Igarashi J, 2000, J BIOL CHEM, V275, P32363, DOI 10.1074/jbc.M003075200; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kou RQ, 2005, BIOCHEMISTRY-US, V44, P15064, DOI 10.1021/bi0509898; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Mehta D, 2005, J BIOL CHEM, V280, P17320, DOI 10.1074/jbc.M411674200; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Singleton PA, 2005, FASEB J, V19, P1646, DOI 10.1096/fj.05-3928com; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797	38	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3210	3216		10.1074/jbc.M510434200	http://dx.doi.org/10.1074/jbc.M510434200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339142	hybrid			2022-12-27	WOS:000235128200025
J	Hoe, HS; Pocivavsek, A; Chakraborty, G; Fu, ZY; Vicini, S; Ehlers, MD; Rebeck, GW				Hoe, HS; Pocivavsek, A; Chakraborty, G; Fu, ZY; Vicini, S; Ehlers, MD; Rebeck, GW			Apolipoprotein E receptor 2 interactions with the N-methyl-D-aspartate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; PSD-95; MICE; NEURONS; REELIN; FAMILY	In our previous studies we showed that apoE treatment of neurons activated ERK 1/2 signaling, and activation was blocked by treatment with inhibitors of the low density lipoprotein receptor family, the N-methyl-D-aspartate (NMDA) receptor antagonist MK 801, and calcium channel blockers. We hypothesized an interaction between the low density lipoprotein receptor family members and the NMDA receptor. In the present study, we confirmed through co-immunoprecipitation experiments an interaction between the apoE receptor, ApoEr2, and NMDAR1 through their extracellular domains. We also found that the PDZ1 domain of PSD95, a postsynaptic scaffolding protein, interacted with the C terminus of ApoEr2 via an alternatively spliced, intracellular exon. This interaction between ApoEr2 and PSD95 in neurons was modulated by NMDA receptor activation and an ApoEr2 ligand. We also found that the PDZ2 domain of PSD95 interacted with the NR2A and NR2B subunits of NMDA receptors. Full-length PSD95 increased cell surface levels of ApoEr2 and its cleavage, resulting in increases in secreted ApoEr2 and C-terminal fragments of ApoEr2. These studies suggest that ApoEr2 can form a multiprotein complex with NMDA receptor subunits and PSD95.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Physiol & Biophys, Washington, DC 20057 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Georgetown University; Georgetown University; Duke University	Rebeck, GW (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA.	gwr2@georgetown.edu	Pocivavsek, Ana/AAW-8923-2020; Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X; Vicini, Stefano/0000-0001-8671-5194; Pocivavsek, Ana/0000-0002-3817-3201				Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; El-Hussein AE, 2000, SCIENCE, V290, P1364; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Grootendorst J, 2005, BEHAV BRAIN RES, V159, P1, DOI 10.1016/j.bbr.2004.09.019; Hoe HS, 2005, MOL CELL BIOL, V25, P9259, DOI 10.1128/MCB.25.21.9259-9268.2005; Hoe HS, 2005, MOL BRAIN RES, V137, P31, DOI 10.1016/j.molbrainres.2005.02.013; Hoe HS, 2005, J NEUROCHEM, V93, P145, DOI 10.1111/j.1471-4159.2004.03007.x; Li YH, 2001, MOL NEUROBIOL, V23, P53; May P, 2004, MOL CELL BIOL, V24, P8872, DOI 10.1128/MCB.24.20.8872-8883.2004; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Niethammer M, 1996, J NEUROSCI, V16, P2157; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; QUI Z, 2004, J BIOL CHEM, V279, P34948; QUI Z, 2003, NEUROSCIENCE, V122, P291; Sala C, 2001, NEURON, V31, P115, DOI 10.1016/S0896-6273(01)00339-7; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Trommer BL, 2004, NEUROREPORT, V15, P2655, DOI 10.1097/00001756-200412030-00020; Watson PG, 1998, RAT BRAIN STEREOTAXI; Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803	26	69	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3425	3431		10.1074/jbc.M509380200	http://dx.doi.org/10.1074/jbc.M509380200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332682	hybrid			2022-12-27	WOS:000235128200051
J	Khalil, IA; Kogure, K; Futaki, S; Harashima, H				Khalil, IA; Kogure, K; Futaki, S; Harashima, H			High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PENETRATING PEPTIDES; ARGININE-RICH PEPTIDES; TAT-FUSION PROTEINS; TRANSDUCTION DOMAINS; MODIFIED LIPOSOMES; MAMMALIAN-CELLS; MEDIATED UPTAKE; DRUG-DELIVERY; IN-VIVO; ENDOCYTOSIS	The mechanism of the arginine-rich peptide-mediated cellular uptake is currently a controversial issue. Several factors, including the type of peptide, the nature of the cargo, and the linker between them, appear to affect uptake. One of the less studied factors, which may affect the uptake mechanism, is the effect of peptide density on the surface of the cargo. Here, we examined the mechanism of cellular uptake and intracellular trafficking of liposomes modified with different densities of the octaarginine (R8) peptide. Liposomes modified with a low R8 density were taken up mainly through clathrin- mediated endocytosis, leading to extensive lysosomal degradation, whereas those modified with a high R8 density were taken up mainly through macropinocytosis and were less subject to lysosomal degradation. Furthermore, the high density R8-liposomes were able to stimulate the macropinocytosis- mediated uptake of other particles. When plasmid DNA was condensed and encapsulated in R8-liposomes, the levels of gene expression were three orders of magnitude higher for the high density liposomes. The enhanced gene expression by the high density R8- liposomes was highly impaired by blocking uptake through macropinocytosis. The different extents of gene expression from different densities of the R8 peptide on the liposomes could be explained principally by the existence of an intracellular trafficking route, but not by the uptake amount, of internalized liposomes. These results show that the density of the R8 peptide on liposomes determines the uptake mechanism and that this is directly linked to intracellular trafficking, resulting in different levels of gene expression.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Shibuya Ku, Tokyo 1500002, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Shibuya Ku, Tokyo 1500002, Japan; Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan	Hokkaido University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Kyoto University	Harashima, H (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	harasima@pharm.hokudai.ac.jp	Harashima, Hideyoshi/D-8390-2012; khalil, ikramy A./T-7523-2019	khalil, ikramy A./0000-0001-9417-7437; Futaki, Shiroh/0000-0002-0124-4002				Akita H, 2004, MOL THER, V9, P443, DOI 10.1016/j.ymthe.2004.01.005; Almofti MR, 2003, ARCH BIOCHEM BIOPHYS, V410, P246, DOI 10.1016/S0003-9861(02)00725-7; Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9; Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200; Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022; Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X; Hafez IM, 2000, BBA-BIOMEMBRANES, V1463, P107, DOI 10.1016/S0005-2736(99)00186-8; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128; Kogure K, 2004, J CONTROL RELEASE, V98, P317, DOI 10.1016/j.jconrel.2004.04.024; Kopatz I, 2004, J GENE MED, V6, P769, DOI 10.1002/jgm.558; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0; Meier O, 2002, J CELL BIOL, V158, P1119, DOI 10.1083/jcb.200112067; Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Singh M, 1999, CURR PHARM DESIGN, V5, P443; Snyder EL, 2004, PHARM RES-DORDR, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Trehin R, 2004, EUR J PHARM BIOPHARM, V58, P209, DOI 10.1016/j.ejpb.2004.02.018; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996; Yoneda A, 2003, MATRIX BIOL, V22, P25, DOI 10.1016/S0945-053X(03)00010-6; Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200	42	325	334	3	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3544	3551		10.1074/jbc.M503202200	http://dx.doi.org/10.1074/jbc.M503202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326716	hybrid			2022-12-27	WOS:000235128200065
J	Stanitsa, ES; Arps, L; Traktman, P				Stanitsa, ES; Arps, L; Traktman, P			Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; TO-ALANINE MUTAGENESIS; BASE EXCISION-REPAIR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GENETIC-ANALYSIS; BINDING PROTEIN; III HOLOENZYME; REPLICATION; UL42	The vaccinia virus E9 protein, the catalytic subunit of the DNA polymerase holoenzyme, is inherently distributive under physiological conditions, although infected cells contain a highly processive form of the enzyme. The viral A20 protein was previously characterized as a stoichiometric component of the processivity factor, and an interaction between A20 and E9 was documented in vivo. A20 has been shown to interact with D4, the virally encoded uracil DNA glycosylase (UDG), by yeast-two hybrid and in vitro analysis. Here we confirm that UDG and A20 interact in vivo and show that temperature-sensitive viruses with lesions in the D4R gene show a profound defect in DNA synthesis at the non-permissive temperature. Moreover, cytoplasmic extracts prepared from these infections lack processive polymerase activity in vitro, implicating D4 in the assembly or activity of the processive polymerase. Upon overexpression of 3 x FLAG-UDG, A20, and E9 in various combinations, we purified dimeric and trimeric UDG-A20 and UDG-A20-polymerase complexes, respectively. These complexes are stable in 750 mM NaCl and can be further purified by Mono Q chromatography. Notably, the trimeric complex displays robust processive polymerase activity, and the dimeric complex can confer processivity on purified E9. Consistent with previous reports that the catalytic activity of UDG is dispensable for virus replication in tissue culture, we find that the role of UDG role in the polymerase complex is not diminished by mutations targeting residues involved in uracil recognition or excision. Our cumulative data support the conclusion that A20 and UDG form a heterodimeric processivity factor that associates with E9 to comprise the processive polymerase holoenzyme.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Traktman, P (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd,BSB-273, Milwaukee, WI 53226 USA.	ptrakt@mcw.edu		Traktman, Paula/0000-0002-6517-0225	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021758] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI-21758] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akbari M, 2004, NUCLEIC ACIDS RES, V32, P5486, DOI 10.1093/nar/gkh872; Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018; Beaud G, 1995, BIOCHIMIE, V77, P774, DOI 10.1016/0300-9084(96)88195-8; BRUCKI, 2001, GENOME BIOL; Chaudhuri M, 2002, J VIROL, V76, P10270, DOI 10.1128/JVI.76.20.10270-10281.2002; De Silva FS, 2003, J VIROL, V77, P159, DOI 10.1128/JVI.77.1.159-166.2003; DeMasi J, 2000, J VIROL, V74, P2393, DOI 10.1128/JVI.74.5.2393-2405.2000; EVANS E, 1987, J VIROL, V61, P3152, DOI 10.1128/JVI.61.10.3152-3162.1987; FRANKE CA, 1985, MOL CELL BIOL, V5, P1918, DOI 10.1128/MCB.5.8.1918; Garcia AD, 2000, P NATL ACAD SCI USA, V97, P8926, DOI 10.1073/pnas.150238697; Grubisha O, 2003, J VIROL, V77, P10929, DOI 10.1128/JVI.77.20.10929-10942.2003; Ishii K, 2002, VIROLOGY, V303, P232, DOI 10.1006/viro.2002.1721; Ishii K, 2001, J VIROL, V75, P1656, DOI 10.1128/JVI.75.4.1656-1663.2001; Johnson DE, 2003, J BIOL CHEM, V278, P23762, DOI 10.1074/jbc.M301366200; Kelman Z, 1998, STRUCTURE, V6, P121, DOI 10.1016/S0969-2126(98)00014-8; Klemperer N, 2001, J VIROL, V75, P12298, DOI 10.1128/JVI.75.24.12298-12307.2001; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lackner CA, 2003, VIROLOGY, V305, P240, DOI 10.1006/viro.2002.1745; McConnell M, 1996, BIOCHEMISTRY-US, V35, P8268, DOI 10.1021/bi9530649; McCraith S, 2000, P NATL ACAD SCI USA, V97, P4879, DOI 10.1073/pnas.080078197; McDonald WF, 1997, VIROLOGY, V234, P168, DOI 10.1006/viro.1997.8639; MCDONALD WF, 1994, PROTEIN EXPRES PURIF, V5, P409, DOI 10.1006/prep.1994.1059; MCDONALD WF, 1994, J BIOL CHEM, V269, P31190; MCFADDEN G, 1980, VIROLOGY, V103, P68, DOI 10.1016/0042-6822(80)90126-9; McIntosh AAG, 1996, J VIROL, V70, P272, DOI 10.1128/JVI.70.1.272-281.1996; MILLNS AK, 1994, VIROLOGY, V198, P504, DOI 10.1006/viro.1994.1061; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; Prichard MN, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-55; Prichard MN, 1996, J VIROL, V70, P3018, DOI 10.1128/JVI.70.5.3018-3025.1996; Punjabi A, 2005, J VIROL, V79, P2171, DOI 10.1128/JVI.79.4.2171-2190.2005; Punjabi A, 2001, J VIROL, V75, P12308, DOI 10.1128/JVI.75.24.12308-12318.2001; Randell JC, 2001, MOL CELL, V8, P911, DOI 10.1016/S1097-2765(01)00355-0; Randell JCW, 2005, J VIROL, V79, P12025, DOI 10.1128/JVI.79.18.12025-12034.2005; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Thornton KE, 2000, VIROLOGY, V275, P373, DOI 10.1006/viro.2000.0506; Trakselis MA, 2001, STRUCTURE, V9, P999, DOI 10.1016/S0969-2126(01)00676-1; TRAKTMAN P, 1996, POXVIRUS DNA REPLICA, P775; Traktman Paula, 2004, Methods Mol Biol, V269, P169; Trego KS, 2005, NUCLEIC ACIDS RES, V33, P536, DOI 10.1093/nar/gki196; UPTON C, 1993, P NATL ACAD SCI USA, V90, P4518, DOI 10.1073/pnas.90.10.4518; Weisshart K, 1999, J VIROL, V73, P55, DOI 10.1128/JVI.73.1.55-66.1999; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	48	73	82	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3439	3451		10.1074/jbc.M511239200	http://dx.doi.org/10.1074/jbc.M511239200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326701	hybrid			2022-12-27	WOS:000235128200053
J	Bernier, M; Kwon, YK; Pandey, SK; Zhu, TN; Zhao, RJ; Maciuk, A; He, HJ; DeCabo, R; Kole, S				Bernier, M; Kwon, YK; Pandey, SK; Zhu, TN; Zhao, RJ; Maciuk, A; He, HJ; DeCabo, R; Kole, S			Binding of manumycin A inhibits I kappa B kinase beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; ACTIVATION; IKK; COMPLEX; ALPHA; ANGIOGENESIS; SUBUNIT; TNF; INFLAMMATION; ASSOCIATION	I kappa B kinase (IKK) catalytic subunits play a key role in cytokine-mediated nuclear factor (NF)-kappa B signaling, and a loss of NF-kappa B function appears to inhibit inflammation and oncogenesis. Manumycin A is a potent and selective farnesyltransferase inhibitor with antitumor activity. We found that manumycin A caused a rapid and potent inhibition of IKK activity induced by tumor necrosis factor alpha in a number of cell types. Most unexpectedly, other classes of farnesyltransferase inhibitors had no inhibitory effect. To identify the molecular mechanisms of manumycin A action, cultured human HepG2 hepatoma cells were transiently transfected with various IKK alpha and IKK beta constructs, and a striking difference in manumycin A sensitivity was observed. Furthermore, cells expressing wild-type IKK beta and IKK beta mutated in the activation loop at Cys-179 exhibited covalent homotypic dimerization of IKK beta in response to manumycin A, whereas substitution of Cys-662 and -716 conferred protection against dimer formation. Direct inhibition of IKK activity and formation of stable IKK beta dimers were observed in the presence of manumycin A that could be blocked by dithiothreitol. IKK interaction with the adaptor protein IKK gamma/NEMO was disrupted in manumycin A-treated cells. Most importantly, administration of manumycin A to mice xenografted with murine B16F10 tumors caused potent IKK-suppressive effects. Thus, manumycin A with its epoxyquinoid moieties plays an important regulatory function in IKK signaling through pathways distinct from its role as a protein farnesylation inhibitor.	NIA, Diabet Sect, NIH, Baltimore, MD 21224 USA; NIA, Bioanalyt Chem & Drug Discovery Sect, Lab Clin Invest, Baltimore, MD 21224 USA; NIA, Bioanalyt Chem & Drug Discovery Sect, Lab Clin Invest, NIH, Baltimore, MD 21224 USA; NIA, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University	Bernier, M (corresponding author), NIA, Diabet Sect, NIH, Box 23,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	Bernierm@grc.nia.nih.gov	de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/E-7996-2010; Bernier, Michel/AAO-3983-2021; Bernier, Michel/Y-7139-2019; de Cabo, Rafael/J-5230-2016; Maciuk, Alexandre/J-2270-2018	de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0003-2830-5693; Bernier, Michel/0000-0002-5948-368X; de Cabo, Rafael/0000-0002-3354-2442; Maciuk, Alexandre/0000-0003-1436-6436	NATIONAL INSTITUTE ON AGING [ZIAAG000368, Z01AG000368, ZIAAG000302, Z01AG000302, Z01AG000886] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Auer J, 2002, CURR MED CHEM, V9, P1831, DOI 10.2174/0929867023369024; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Carcamo JM, 2004, MOL CELL BIOL, V24, P6645, DOI 10.1128/mcb.24.15.6645-6652.2004; Carter RS, 2003, J BIOL CHEM, V278, P48903, DOI 10.1074/jbc.M310686200; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; de Cabo R, 2003, EXP GERONTOL, V38, P631, DOI 10.1016/S0531-5565(03)00055-X; Finder JD, 2001, AM J PHYSIOL-LUNG C, V281, pL816, DOI 10.1152/ajplung.2001.281.4.L816; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Gnad R, 2001, EXP CELL RES, V264, P244, DOI 10.1006/excr.2001.5165; Goalstone ML, 2001, J BIOL CHEM, V276, P12805, DOI 10.1074/jbc.M009443200; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Higuchi Y, 2003, J BIOL CHEM, V278, P20770, DOI 10.1074/jbc.M213203200; Hu YB, 2001, ORG LETT, V3, P1649, DOI 10.1021/ol0159367; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ito T, 1996, JPN J CANCER RES, V87, P113, DOI 10.1111/j.1349-7006.1996.tb03146.x; Jeon KI, 2000, J IMMUNOL, V164, P5981, DOI 10.4049/jimmunol.164.11.5981; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Klein S, 2002, MOL CELL BIOL, V22, P5912, DOI 10.1128/MCB.22.16.5912-5922.2002; Knaus UG, 2000, IMMUNOL RES, V21, P103, DOI 10.1385/IR:21:2-3:103; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Li CM, 2002, ORG LETT, V4, P3267, DOI 10.1021/ol026513n; Li CM, 2001, J AM CHEM SOC, V123, P11308, DOI 10.1021/ja0169769; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsuzaki J, 2000, J NUTR, V130, P111; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Pandey SK, 2002, ENDOCRINOLOGY, V143, P375, DOI 10.1210/en.143.2.375; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Segain JP, 2003, GASTROENTEROLOGY, V124, P1180, DOI 10.1016/S0016-5085(03)00283-X; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tang ED, 2003, J BIOL CHEM, V278, P38566, DOI 10.1074/jbc.M304374200; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Umezawa K, 2000, ANTI-CANCER DRUG DES, V15, P239; Werner N, 2002, BASIC RES CARDIOL, V97, P105, DOI 10.1007/s003950200000; Wipf P, 1998, BIOORG MED CHEM LETT, V8, P351, DOI 10.1016/S0960-894X(98)00026-2; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wurzer G, 2001, J CELL BIOCHEM, P1; Xu GP, 2001, J CLIN ENDOCR METAB, V86, P1769, DOI 10.1210/jc.86.4.1769; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhao DZ, 2003, AM J PHYSIOL-CELL PH, V284, pC1397, DOI 10.1152/ajpcell.00328.2002; Zhou JM, 2003, INT J MOL MED, V12, P955	58	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2551	2561		10.1074/jbc.M511878200	http://dx.doi.org/10.1074/jbc.M511878200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319058	hybrid			2022-12-27	WOS:000234931800018
J	Lee, JY; Ristow, M; Lin, XY; White, MF; Magnuson, MA; Hennighausen, L				Lee, JY; Ristow, M; Lin, XY; White, MF; Magnuson, MA; Hennighausen, L			RIP-Cre revisited, evidence for impairments of pancreatic beta-cell function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-2; TETRACYCLINE-RESPONSIVE PROMOTER; TISSUE-SPECIFIC KNOCKOUT; ALTERED GENE-EXPRESSION; GLUCOSE-HOMEOSTASIS; TEMPORAL CONTROL; TRANSGENIC MICE; SECRETION; RECOMBINASE; LEADS	The Cre/loxP recombinase system for performing conditional gene targeting experiments has been very useful in exploring genetic pathways that control both the development and function of pancreatic beta-cells. One particular line of transgenic mice (B6.Cg-Tg(Ins2-cre)25Mgn/J), commonly called RIP-Cre, in which expression of Cre recombinase is controlled by a short fragment of the rat insulin II gene promoter has been used in at least 21 studies on at least 17 genes. In most of these studies inactivation of the gene of interest was associated with either glucose intolerance or frank diabetes. Experimental evidence has been gradually emerging to suggest that RIP-Cre mice alone display glucose intolerance. In this study experiments from three laboratories demonstrate that RIP-Cre mice, in the absence of genes targeted by loxP sites, are glucose intolerant, possibly due to impaired insulin secretion. In addition, we review the use of RIP-Cre mice and discuss possible molecular underpinnings and ramifications of our findings.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; Univ Jena, Dept Human Nutr, D-07743 Jena, Germany; German Inst Human Potsdam Rehbruecke, Potsdam, Germany; Harvard Univ, Sch Med, Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Friedrich Schiller University of Jena; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Vanderbilt University	Magnuson, MA (corresponding author), NIDDK, Lab Genet & Physiol, NIH, 8 Ctr Dr,Rm 101, Bethesda, MD 20892 USA.	mark.magnuson@vanderbilt.edu	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Ristow, Michael/O-9858-2014	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Ristow, Michael/0000-0003-2109-2453; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardoux P, 2005, DIABETES, V54, P1357, DOI 10.2337/diabetes.54.5.1357; Biondi CA, 2004, MOL CELL BIOL, V24, P3125, DOI 10.1128/MCB.24.8.3125-3131.2004; Choudhury AI, 2005, J CLIN INVEST, V115, P940; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Cui YX, 2004, MOL CELL BIOL, V24, P258, DOI 10.1128/MCB.24.1.258-269.2004; Dai CS, 2005, AM J PATHOL, V167, P429, DOI 10.1016/S0002-9440(10)62987-2; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gannon M, 2000, GENESIS, V26, P139, DOI 10.1002/(SICI)1526-968X(200002)26:2<139::AID-GENE12>3.0.CO;2-7; Gesina E, 2004, DIABETES, V53, P2322, DOI 10.2337/diabetes.53.9.2322; Glaser S, 2005, NAT GENET, V37, P1187, DOI 10.1038/ng1668; Gorogawa S, 2004, BIOCHEM BIOPH RES CO, V319, P1159, DOI 10.1016/j.bbrc.2004.05.095; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Gupta RK, 2005, J CLIN INVEST, V115, P1006, DOI 10.1172/JCI22365; Hashimoto N, 2005, J CLIN INVEST, V115, P138, DOI 10.1172/JCI200522232; Kubota N, 2004, J CLIN INVEST, V114, P917, DOI 10.1172/JCI200421484; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6; Lee JY, 2005, BIOCHEM BIOPH RES CO, V334, P764, DOI 10.1016/j.bbrc.2005.06.162; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Ristow M, 2003, J CLIN INVEST, V112, P527, DOI 10.1172/JCI200318107; Rosen ED, 2003, MOL CELL BIOL, V23, P7222, DOI 10.1128/MCB.23.20.7222-7229.2003; Schmidt EE, 2000, P NATL ACAD SCI USA, V97, P13702, DOI 10.1073/pnas.240471297; Schulla V, 2003, EMBO J, V22, P3844, DOI 10.1093/emboj/cdg389; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; StOnge L, 1996, NUCLEIC ACIDS RES, V24, P3875, DOI 10.1093/nar/24.19.3875; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Thyagarajan B, 2000, GENE, V244, P47, DOI 10.1016/S0378-1119(00)00008-1; Wang L, 2004, ENDOCRINOLOGY, V145, P3941, DOI 10.1210/en.2004-0281; Wang XP, 2005, FEBS LETT, V579, P3107, DOI 10.1016/j.febslet.2005.04.069	34	187	192	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2649	2653		10.1074/jbc.M512373200	http://dx.doi.org/10.1074/jbc.M512373200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326700	hybrid			2022-12-27	WOS:000234931800029
J	Chen, SY; Crawford, M; Day, RM; Briones, VR; Leader, JE; Jose, PA; Lechleider, RJ				Chen, SY; Crawford, M; Day, RM; Briones, VR; Leader, JE; Jose, PA; Lechleider, RJ			RhoA modulates smad signaling during transforming growth factor-beta-induced smooth muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; DEPENDENT MECHANISM; MARKER GENES; CELLS; EXPRESSION; KINASE; ACTIVATION; INDUCTION; MIGRATION; FEATURES	We recently reported that transforming growth factor (TGF)-beta induced the neural crest stem cell line Monc-1 to differentiate into a spindle-like contractile smooth muscle cell (SMC) phenotype and that Smad signaling played an important role in this phenomenon. In addition to Smad signaling, other pathways such as mitogen-activated protein kinase (MAPK), phosphoinositol-3 kinase, and RhoA have also been shown to mediate TGF-beta actions. The objectives of this study were to examine whether these signaling pathways contribute to TGF-beta-induced SMC development and to test whether Smad signaling cross-talks with other pathway(s) during SMC differentiation induced by TGF-beta. We demonstrate here that RhoA signaling is critical to TGF-beta-induced SMC differentiation. RhoA kinase ( ROCK) inhibitor Y27632 significantly blocks the expression of multiple SMC markers such as smooth muscle alpha-actin, SM22 alpha, and calponin in TGF-beta-treated Monc-1 cells. In addition, Y27632 reversed the cell morphology and abolished the contractility of TGF-beta-treated cells. RhoA signaling was activated as early as 5 min following TGF-beta addition. Dominant negative RhoA blocked nuclear translocation of Smad2 and Smad3 because of the inhibition of phosphorylation of both Smads and inhibited Smad-dependent SBE promoter activity, whereas constitutively active RhoA significantly enhanced SBE promoter activity. Consistent with these results, C3 exotoxin, an inhibitor of RhoA activation, significantly attenuated SBE promoter activity and inhibited Smad nuclear translocation. Taken together, these data point to a new role for RhoA as a modulator of Smad activation while regulating TGF-beta-induced SMC differentiation.	Georgetown Univ, Dept Pediat, Sch Med, Washington, DC 20057 USA; Georgetown Univ, Dept Cell Biol, Sch Med, Washington, DC 20057 USA; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Georgetown University; Georgetown University; Uniformed Services University of the Health Sciences - USA	Chen, SY (corresponding author), Georgetown Univ, Dept Pediat, Sch Med, Bldg D Rm 63,4000 Reservoir Rd NW, Washington, DC 20057 USA.	sc229@Georgetown.edu			NCI NIH HHS [T32 CA009686] Funding Source: Medline; NHLBI NIH HHS [R01 HL065681, R01HL65681, R01HL073929-01, R01 HL073929-02, R01 HL073929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073929, R01HL065681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bi D, 2005, CIRC RES, V96, P890, DOI 10.1161/01.RES.0000163018.66460.85; Blindt R, 2004, CARDIOVASC RES, V62, P212, DOI 10.1016/j.cardiores.2004.01.004; Bostrom K, 2000, J CELL BIOCHEM, V78, P210, DOI 10.1002/(SICI)1097-4644(20000801)78:2<210::AID-JCB4>3.0.CO;2-Z; Chen SY, 2004, CIRC RES, V94, P1195, DOI 10.1161/01.RES.0000126897.41658.81; Chen SY, 2003, NUCLEIC ACIDS RES, V31, P1302, DOI 10.1093/nar/gkg224; Christiansen JH, 2000, CURR OPIN CELL BIOL, V12, P719, DOI 10.1016/S0955-0674(00)00158-7; Deaton RA, 2005, J BIOL CHEM, V280, P31172, DOI 10.1074/jbc.M504774200; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Desai LP, 2004, AM J PHYSIOL-LUNG C, V287, pL1134, DOI 10.1152/ajplung.00022.2004; Edlund S, 2004, J CELL SCI, V117, P1835, DOI 10.1242/jcs.01036; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Goumans MJ, 2000, INT J DEV BIOL, V44, P253; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Hungerford JE, 1999, J VASC RES, V36, P2, DOI 10.1159/000025622; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Jain MK, 1998, J BIOL CHEM, V273, P5993, DOI 10.1074/jbc.273.11.5993; Kamaraju SK, 2005, J BIOL CHEM, V280, P1024, DOI 10.1074/jbc.M403960200; Klesse LJ, 1998, J NEUROSCI, V18, P10420; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, HUM PATHOL, V17, P875, DOI 10.1016/S0046-8177(86)80637-2; Liu YL, 2004, CIRC RES, V95, P579, DOI 10.1161/01.RES.0000141428.53262.a4; Lu J, 2001, DEV BIOL, V240, P404, DOI 10.1006/dbio.2001.0403; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nawshad A, 2004, ARCH ORAL BIOL, V49, P675, DOI 10.1016/j.archoralbio.2004.05.007; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sauzeau V, 2003, CIRC RES, V93, P630, DOI 10.1161/01.RES.0000093220.90027.D9; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Wamhoff BR, 2004, CIRC RES, V95, P406, DOI 10.1161/01.RES.0000138582.36921.9e; Watts KL, 2004, AM J PHYSIOL-LUNG C, V287, pL1323, DOI 10.1152/ajplung.00447.2003; Worth NF, 2001, ANN NY ACAD SCI, V947, P316	34	117	121	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1765	1770		10.1074/jbc.M507771200	http://dx.doi.org/10.1074/jbc.M507771200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16317010	Green Accepted, hybrid			2022-12-27	WOS:000234652000057
J	Appel, N; Schaller, T; Penin, F; Bartenschlager, R				Appel, N; Schaller, T; Penin, F; Bartenschlager, R			From structure to function: New insights into hepatitis C virus RNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NONSTRUCTURAL PROTEIN 5A; MAJOR PHOSPHORYLATION SITE; CRYSTAL-STRUCTURE; MEMBRANE ASSOCIATION; VIRAL REPLICATION; ADAPTER PROTEIN; NS5A PROTEIN; POLYMERASE; NS3; BINDING		Heidelberg Univ, Dept Mol Virol, D-69120 Heidelberg, Germany; Univ Lyon 1, IFR BioSci Lyon Gerland 128, Inst Biol & Chim Prot, CNRS,UMR 5086, F-69367 Lyon, France	Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Bartenschlager, R (corresponding author), Heidelberg Univ, Dept Mol Virol, Neuenheimer Feld 345, D-69120 Heidelberg, Germany.	Ralf_Bartenschlager@med.uni-heidelberg.de	Schaller, Torsten/ABC-9153-2020; PENIN, Francois/A-7315-2008; Bartenschlager, Ralf/L-2582-2015	Schaller, Torsten/0000-0001-9597-4112; Bartenschlager, Ralf/0000-0001-5601-9307				Appel N, 2005, J VIROL, V79, P3187, DOI 10.1128/JVI.79.5.3187-3194.2005; Banerjee R, 2001, J VIROL, V75, P1708, DOI 10.1128/JVI.75.4.1708-1721.2001; Bartenschlager R, 2004, ADV VIRUS RES, V63, P71, DOI 10.1016/S0065-3527(04)63002-8; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Branch AD, 2005, SEMIN LIVER DIS, V25, P105, DOI 10.1055/s-2005-864786; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Einav S, 2004, J VIROL, V78, P11288, DOI 10.1128/JVI.78.20.11288-11295.2004; Evans MJ, 2004, P NATL ACAD SCI USA, V101, P13038, DOI 10.1073/pnas.0405152101; Frick DN, 2004, J BIOL CHEM, V279, P1269, DOI 10.1074/jbc.M310630200; Friebe P, 2005, J VIROL, V79, P380, DOI 10.1128/JVI.79.1.380-392.2005; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gao L, 2004, J VIROL, V78, P3480, DOI 10.1128/JVI.78.7.3480-3488.2004; Hamamoto I, 2005, J VIROL, V79, P13473, DOI 10.1128/JVI.79.21.13473-13482.2005; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Huang LY, 2005, J BIOL CHEM, V280, P36417, DOI 10.1074/jbc.M508175200; Kapadia SB, 2005, P NATL ACAD SCI USA, V102, P2561, DOI 10.1073/pnas.0409834102; Katze MG, 2000, VIROLOGY, V278, P501, DOI 10.1006/viro.2000.0662; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Lee H, 2004, J VIROL, V78, P10865, DOI 10.1128/JVI.78.20.10865-10877.2004; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Levin MK, 2005, NAT STRUCT MOL BIOL, V12, P429, DOI 10.1038/nsmb920; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Lundin M, 2003, J VIROL, V77, P5428, DOI 10.1128/JVI.77.9.5428-5438.2003; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Moradpour D, 2004, J VIROL, V78, P13278, DOI 10.1128/JVI.78.23.13278-13284.2004; Moradpour D, 2004, J VIROL, V78, P7400, DOI 10.1128/JVI.78.14.7400-7409.2004; Neddermann P, 2004, J VIROL, V78, P13306, DOI 10.1128/JVI.78.23.13306-13314.2004; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Penin F, 2004, J BIOL CHEM, V279, P40835, DOI 10.1074/jbc.M404761200; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Pisarev AV, 2005, CR BIOL, V328, P589, DOI 10.1016/j.crvi.2005.02.004; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Reed KE, 1998, J VIROL, V72, P6199, DOI 10.1128/JVI.72.7.6199-6206.1998; Reed KE, 1999, J BIOL CHEM, V274, P28011, DOI 10.1074/jbc.274.39.28011; Serebrov V, 2004, NATURE, V430, P476, DOI 10.1038/nature02704; Siridechadilok B, 2005, SCIENCE, V310, P1513, DOI 10.1126/science.1118977; Spahn CMT, 2001, SCIENCE, V291, P1959, DOI 10.1126/science.1058409; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; Tellinghuisen TL, 2005, NATURE, V435, P374, DOI 10.1038/nature03580; Tellinghuisen TL, 2004, J BIOL CHEM, V279, P48576, DOI 10.1074/jbc.M407787200; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Watashi K, 2003, HEPATOLOGY, V38, P1282, DOI 10.1053/jhep.2003.50449; Watashi K, 2005, MOL CELL, V19, P111, DOI 10.1016/j.molcel.2005.05.014; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; Ye J, 2003, P NATL ACAD SCI USA, V100, P15865, DOI 10.1073/pnas.2237238100; You SY, 2004, J VIROL, V78, P1352, DOI 10.1128/JVI.78.3.1352-1366.2004; Zhang J, 2004, VIROLOGY, V320, P135, DOI 10.1016/j.virol.2003.11.023; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000	63	162	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					9833	9836		10.1074/jbc.R500026200	http://dx.doi.org/10.1074/jbc.R500026200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16407182	hybrid			2022-12-27	WOS:000236594300002
J	Haupt, M; Bramkamp, M; Heller, M; Coles, M; Deckers-Hebestreit, G; Herkenhoff-Hesselmann, B; Altendorf, K; Kessler, H				Haupt, M; Bramkamp, M; Heller, M; Coles, M; Deckers-Hebestreit, G; Herkenhoff-Hesselmann, B; Altendorf, K; Kessler, H			The Holo-form of the nucleotide binding domain of the KdpFABC complex from Escherichia coli reveals a new binding mode	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; AMINO-ACID SUBSTITUTIONS; P-TYPE ATPASES; KDP-ATPASE; CALCIUM-PUMP; N-DOMAIN; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; CHEMICAL-SHIFT	P-type ATPases are ubiquitously abundant enzymes involved in active transport of charged residues across biological membranes. The KdpB subunit of the prokaryotic Kdp-ATPase (KdpFABC complex) shares characteristic regions of homology with class II - IV P-type ATPases and has been shown previously to be misgrouped as a class IA P-type ATPase. Here, we present the NMR structure of the AMP-PNP-bound nucleotide binding domain KdpBN of the Escherichia coli Kdp-ATPase at high resolution. The aromatic moiety of the nucleotide is clipped into the binding pocket by Phe(377) and Lys(395) via a pi-pi stacking and a cation-pi interaction, respectively. Charged residues at the outer rim of the binding pocket (Arg(317), Arg(382), Asp(399), and Glu(348)) stabilize and direct the triphosphate group via electrostatic attraction and repulsion toward the phosphorylation domain. The nucleotide binding mode was corroborated by the replacement of critical residues. The conservative mutation F377Y produced a high residual nucleotide binding capacity, whereas replacement by alanine resulted in low nucleotide binding capacities and a considerable loss of ATPase activity. Similarly, mutation K395A resulted in loss of ATPase activity and nucleotide binding affinity, even though the protein was properly folded. We present a schematic model of the nucleotide binding mode that allows for both high selectivity and a low nucleotide binding constant, necessary for the fast and effective turnover rate realized in the reaction cycle of the Kdp-ATPase.	Tech Univ Munich, Dept Chem, D-85747 Garching, Germany; Univ Osnabruck, Fachbereich Biol Chem, Abt Mikrobiol, D-49069 Osnabruck, Germany	Technical University of Munich; University Osnabruck	Kessler, H (corresponding author), Tech Univ Munich, Dept Chem, Lichtenbergstr 4, D-85747 Garching, Germany.	horst.kessler@ch.tum.de	Kessler, Horst/C-1178-2010	Bramkamp, Marc/0000-0002-7704-3266				Abu-Abed M, 2002, BIOCHEMISTRY-US, V41, P1156, DOI 10.1021/bi015703n; Altendorf K, 1998, ACTA PHYSIOL SCAND, V163, P137; ALTENDORF K, 1996, BIOMEMBR, V5, P403; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bertrand J, 2004, J BACTERIOL, V186, P5519, DOI 10.1128/JB.186.16.5519-5522.2004; Bramkamp M, 2005, BIOCHEMISTRY-US, V44, P8260, DOI 10.1021/bi050135n; Bramkamp M, 2004, BIOCHEMISTRY-US, V43, P12289, DOI 10.1021/bi048727d; Bramkamp M, 2004, BIOCHEMISTRY-US, V43, P4559, DOI 10.1021/bi030198a; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Cole R, 2003, J BIOMOL NMR, V26, P203, DOI 10.1023/A:1023808801134; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dalvit C, 2001, J BIOMOL NMR, V21, P349, DOI 10.1023/A:1013302231549; DeLano W. L., 2002, PYMOL MOL GRAPHICS S; Diercks T, 1999, J BIOMOL NMR, V15, P177, DOI 10.1023/A:1008367912535; Dorus S, 2001, J BIOL CHEM, V276, P9590, DOI 10.1074/jbc.M009365200; EPSTEIN W, 1971, J BACTERIOL, V108, P639, DOI 10.1128/JB.108.2.639-644.1971; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Hakansson KO, 2003, J MOL BIOL, V332, P1175, DOI 10.1016/j.jmb.2003.07.012; Haupt M, 2005, J MOL MICROB BIOTECH, V10, P120, DOI 10.1159/000091559; Haupt M, 2004, J MOL BIOL, V342, P1547, DOI 10.1016/j.jmb.2004.07.060; Haupt M, 2004, J BIOMOL NMR, V29, P437, DOI 10.1023/B:JNMR.0000032512.08757.8b; HENKEL RD, 1988, ANAL BIOCHEM, V169, P312, DOI 10.1016/0003-2697(88)90290-4; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Loria JP, 1999, J AM CHEM SOC, V121, P2331, DOI 10.1021/ja983961a; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; McIntosh DB, 2003, ANN NY ACAD SCI, V986, P101, DOI 10.1111/j.1749-6632.2003.tb07145.x; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Mulder FAA, 2002, J AM CHEM SOC, V124, P1443, DOI 10.1021/ja0119806; Sambrock J, 1989, MOL CLONING LAB MANU; Skrynnikov NR, 2001, J AM CHEM SOC, V123, P4556, DOI 10.1021/ja004179p; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Tollinger M, 2001, J AM CHEM SOC, V123, P11341, DOI 10.1021/ja011300z; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Truffault V, 2001, J MOL BIOL, V309, P949, DOI 10.1006/jmbi.2001.4683; van der Laan M, 2002, J BACTERIOL, V184, P5491, DOI 10.1128/JB.184.19.5491-5494.2002; WISHART DS, 1994, J BIOMOL NMR, V4, P171	44	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9641	9649		10.1074/jbc.M508290200	http://dx.doi.org/10.1074/jbc.M508290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16354672	hybrid			2022-12-27	WOS:000236404700076
J	Calkins, CC; Setzer, SV; Jennings, JM; Summers, S; Tsunoda, K; Amagai, M; Kowalczyk, AP				Calkins, CC; Setzer, SV; Jennings, JM; Summers, S; Tsunoda, K; Amagai, M; Kowalczyk, AP			Desmoglein endocytosis and desmosome disassembly are coordinated responses to pemphigus autoantibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; CELL-ADHESION; VULGARIS-IGG; ADHERENS JUNCTIONS; DISEASE; ANTIGEN; DSG3; KERATINOCYTES; PLAKOGLOBIN; ANTIBODIES	Desmosomes are adhesive intercellular junctions prominent in the skin and heart. Loss of desmosome function is associated with severe congenital and acquired disorders characterized by tissue fragility. Pemphigus vulgaris (PV) is an autoimmune disorder in which antibodies are directed against the desmosomal adhesion molecule Dsg3, resulting in severe mucosal erosions and epidermal blistering. To define the mechanisms by which Dsg3 autoantibodies disrupt keratinocyte adhesion, the fate of PV IgG and various desmosomal components was monitored in primary human keratinocytes exposed to PV patient IgG. PV IgG initially bound to keratinocyte cell surfaces and colocalized with desmosomal markers. Within 6 h after PV IgG binding to Dsg3, electron microscopy revealed that desmosomes were dramatically disrupted and keratinocyte adhesion was severely compromised. Immunofluorescence analysis indicated that PV IgG and Dsg3 were rapidly internalized from the cell surface in a complex with plakoglobin but not desmoplakin. Dsg3 internalization was associated with retraction of keratin filaments from cell-cell borders. Furthermore, the internalized PV IgG-Dsg3 complex colocalized with markers for both endosomes and lysosomes, suggesting that Dsg3 was targeted for degradation. Consistent with this possibility, biotinylation experiments demonstrated that soluble Dsg3 cell surface pools were rapidly depleted followed by loss of detergent-insoluble Dsg3. These findings demonstrate that Dsg3 endocytosis, keratin filament retraction, and the loss of keratinocyte cell-cell adhesion are coordinated responses to PV IgG.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, Tokyo 1608582, Japan	Emory University; Emory University; Keio University	Kowalczyk, AP (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Whitehead Biomed Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	akowalc@emory.edu	tsunoda, kazuyuki/GLR-8745-2022; Amagai, Masayuki/K-5325-2013	Amagai, Masayuki/0000-0003-3314-7052	NIAMS NIH HHS [R21 AR 050779, T32 AR 007587, R01 AR 048266] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050779, T32AR007587, R01AR048266] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1995, J INVEST DERMATOL, V105, P243, DOI 10.1111/1523-1747.ep12317587; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Angst BD, 2001, J CELL SCI, V114, P629; Anhalt GJ, 2004, J AM ACAD DERMATOL, V51, pS20, DOI 10.1016/j.jaad.2004.01.011; Aoyama Y, 1999, J INVEST DERMATOL, V112, P67, DOI 10.1046/j.1523-1747.1999.00463.x; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Caldelari R, 2001, J CELL BIOL, V153, P823, DOI 10.1083/jcb.153.4.823; Cheng X, 2004, J DERMATOL, V31, P171, DOI 10.1111/j.1346-8138.2004.tb00654.x; Chidgey M, 2002, HISTOL HISTOPATHOL, V17, P1179, DOI 10.14670/HH-17.1179; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Gloushankova NA, 2003, CELL TISSUE RES, V314, P399, DOI 10.1007/s00441-003-0812-3; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; IWATSUKI K, 1989, J AM ACAD DERMATOL, V20, P578, DOI 10.1016/S0190-9622(89)70066-9; Iwatsuki K, 1999, BRIT J DERMATOL, V140, P35; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kitajima Y, 2002, CLIN EXP DERMATOL, V27, P684, DOI 10.1046/j.1365-2230.2002.01116.x; Koch AW, 2004, CELL MOL LIFE SCI, V61, P1884, DOI 10.1007/s00018-004-4006-2; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; KOWALCZYK AP, 1995, J INVEST DERMATOL, V105, P147, DOI 10.1111/1523-1747.ep12316680; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; MILNER Y, 1989, J CELL PHYSIOL, V139, P441, DOI 10.1002/jcp.1041390229; Muller E, 2000, J INVEST DERMATOL, V115, P332, DOI 10.1046/j.1523-1747.2000.00abs-2.x; Nguyen VT, 2004, J BIOL CHEM, V279, P2135, DOI 10.1074/jbc.M309000200; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Palka HL, 1997, J CELL SCI, V110, P2359; PATEL HP, 1984, J INVEST DERMATOL, V83, P409, DOI 10.1111/1523-1747.ep12273480; Payne AS, 2004, CURR OPIN CELL BIOL, V16, P536, DOI 10.1016/j.ceb.2004.07.006; Reynolds AB, 2004, SEMIN CELL DEV BIOL, V15, P657, DOI 10.1016/j.semcdb.2004.09.003; Robinson MS, 2004, TRENDS CELL BIOL, V14, P167, DOI 10.1016/j.tcb.2004.02.002; Sato M, 2000, LAB INVEST, V80, P1583, DOI 10.1038/labinvest.3780168; Shimizu A, 2004, J INVEST DERMATOL, V122, P1145, DOI 10.1111/j.0022-202X.2004.22426.x; Stanley JR, 2001, J INVEST DERMATOL, V116, P489, DOI 10.1046/j.1523-1747.2001.01307.x; Tsunoda K, 2003, J IMMUNOL, V170, P2170, DOI 10.4049/jimmunol.170.4.2170; Vincent PA, 2004, AM J PHYSIOL-CELL PH, V286, pC987, DOI 10.1152/ajpcell.00522.2003; Waschke J, 2005, J CLIN INVEST, V115, P3157, DOI 10.1172/JCI23475; Windoffer R, 2002, J CELL SCI, V115, P1717; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yin TF, 2004, SEMIN CELL DEV BIOL, V15, P665, DOI 10.1016/j.semcdb.2004.09.005	48	169	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7623	7634		10.1074/jbc.M512447200	http://dx.doi.org/10.1074/jbc.M512447200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16377623	hybrid			2022-12-27	WOS:000236030900084
J	Cenas, N; Prast, S; Nivinskas, H; Sarlauskas, J; Arner, ESJ				Cenas, N; Prast, S; Nivinskas, H; Sarlauskas, J; Arner, ESJ			Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGOLENSE TRYPANOTHIONE REDUCTASE; EARLY EMBRYONIC LETHALITY; GLUTATHIONE-REDUCTASE; LIPOAMIDE DEHYDROGENASE; ELECTRON-TRANSFER; ESCHERICHIA-COLI; OXIDATIVE STRESS; HUMAN PLACENTA; MECHANISM; SELENOCYSTEINE	Here we described novel interactions of the mammalian selenoprotein thioredoxin reductase (TrxR) with nitroaromatic environmental pollutants and drugs. We found that TrxR could catalyze nitroreductase reactions with either one- or two-electron reduction, using its selenocysteine-containing active site and another redox active center, presumably the FAD. Tetryl and p-dinitrobenzene were the most efficient nitroaromatic substrates with a k(cat) of 1.8 and 2.8 s(-1), respectively, at pH 7.0 and 25 degrees C using 50 mu M NADPH. As a nitroreductase, TrxR cycled between four- and two-electron-reduced states. The one- electron reactions led to superoxide formation as detected by cytochrome c reduction and, interestingly, reductive N-denitration of tetryl or 2,4-dinitrophenyl-N-methylnitramine, resulting in the release of nitrite. Most nitroaromatics were uncompetitive and noncompetitive inhibitors with regard to NADPH and the disulfide substrate 5,5'-dithiobis(2-nitrobenzoic acid), respectively. Tetryl and 4,6-dinitrobenzofuroxan were, however, competitive inhibitors with respect to 5,5'-dithiobis( 2-nitrobenzoic acid) and were clearly substrates for the selenolthiol motif of the enzyme. Furthermore, tetryl and 4,6-dinitrobenzofuroxan efficiently inactivated TrxR, likely by alkylation of the selenolthiol motif as in the inhibition of TrxR by 1-chloro-2,4-dinitrobenzene/ dinitrochlorobenzene ( DNCB) or juglone. The latter compounds were the most efficient inhibitors of TrxR activity in a cellular context. DNCB, juglone, and tetryl were highly cytotoxic and induced caspase-3/7 activation in HeLa cells. Furthermore, DNCB and juglone were potent inducers of apoptosis also in Bcl2 overexpressing HeLa cells or in A549 cells. Based on these findings, we suggested that targeting of intracellular TrxR by alkylating nitroaromatic or quinone compounds may contribute to the induction of apoptosis in exposed human cancer cells.	Inst Biochem, LT-08662 Vilnius, Lithuania; Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Vilnius University; Karolinska Institutet	Cenas, N (corresponding author), Inst Biochem, Mokslininku 12, LT-08662 Vilnius, Lithuania.	ncenas@bchi.lt; Elias.Arner@ki.se	Arnér, Elias S.J./J-5832-2012; Prast-Nielsen, Stefanie/W-6946-2019; Sarlauskas, Jonas/ACX-5314-2022; Arnér, Elias/K-6737-2019	Arnér, Elias S.J./0000-0002-4807-6114; Prast-Nielsen, Stefanie/0000-0001-5877-7988; Arnér, Elias/0000-0002-4807-6114; Sarlauskas, Jonas/0000-0003-4268-1716				Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; ARNER ESJ, 2000, CURRENT PROTOCOLS TO; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Bauer H, 2003, J BIOL CHEM, V278, P33020, DOI 10.1074/jbc.M303762200; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i; BEREZIN IV, 1976, PRACTICAL COURSE CHE; BIRONAITE DA, 1991, BIOCHIM BIOPHYS ACTA, V1060, P203, DOI 10.1016/S0005-2728(09)91008-8; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; Blumenstiel K, 1999, BIOCHEM PHARMACOL, V58, P1791, DOI 10.1016/S0006-2952(99)00264-6; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Cenas N, 2004, J BIOL CHEM, V279, P2583, DOI 10.1074/jbc.M310292200; Cenas N, 2001, BBA-GEN SUBJECTS, V1528, P31, DOI 10.1016/S0304-4165(01)00169-6; CENAS N, 1994, BIOCHEM BIOPH RES CO, V204, P224, DOI 10.1006/bbrc.1994.2448; CENAS N, 1994, ARCH BIOCHEM BIOPHYS, V315, P400, DOI 10.1006/abbi.1994.1517; CENAS N, 2006, ECOTOXICOLOGY EXPLOS; CENAS NK, 1994, BIOCHEMISTRY-US, V33, P2509, DOI 10.1021/bi00175a021; CENAS NK, 1989, BIOCHIM BIOPHYS ACTA, V973, P399, DOI 10.1016/S0005-2728(89)80381-0; Conrad M, 2004, MOL CELL BIOL, V24, P9414, DOI 10.1128/MCB.24.21.9414-9423.2004; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Grellier P, 2001, ARCH BIOCHEM BIOPHYS, V393, P199, DOI 10.1006/abbi.2001.2487; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; Jakupoglu C, 2005, MOL CELL BIOL, V25, P1980, DOI 10.1128/MCB.25.5.1980-1988.2005; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Johansson L, 2004, NAT METHODS, V1, P61, DOI 10.1038/NMETH707; Johansson L, 2005, BBA-GEN SUBJECTS, V1726, P1, DOI 10.1016/j.bbagen.2005.05.010; Knox RJ, 2004, METHOD ENZYMOL, V382, P194; Koder RL, 1998, BBA-PROTEIN STRUCT M, V1387, P395, DOI 10.1016/S0167-4838(98)00151-4; Maroziene A, 2001, Z NATURFORSCH C, V56, P1157; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Maurice MM, 1999, ARTHRITIS RHEUM, V42, P2430, DOI 10.1002/1529-0131(199911)42:11<2430::AID-ANR22>3.0.CO;2-6; Miskiniene V, 1999, CANCER LETT, V146, P217, DOI 10.1016/S0304-3835(99)00271-2; Miskiniene V, 1998, BBA-BIOENERGETICS, V1366, P275, DOI 10.1016/S0005-2728(98)00128-5; Nemeikaie-Ceniene A, 2004, ACTA BIOCHIM POL, V51, P1081; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Paul C, 2000, EXP GERONTOL, V35, P757, DOI 10.1016/S0531-5565(00)00150-9; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; Purohit V, 2000, CHEM RES TOXICOL, V13, P673, DOI 10.1021/tx000002x; Rengby O, 2004, APPL ENVIRON MICROB, V70, P5159, DOI 10.1128/AEM.70.9.5159-5167.2004; Riefler RG, 2002, APPL ENVIRON MICROB, V68, P1690, DOI 10.1128/AEM.68.4.1690-1696.2002; Rossa MM, 2003, PHARMACOL RES, V48, P369, DOI 10.1016/S1043-6618(03)00183-X; Rundlof AK, 2004, ANTIOXID REDOX SIGN, V6, P41, DOI 10.1089/152308604771978336; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Sasada T, 1999, FREE RADICAL BIO MED, V27, P504, DOI 10.1016/S0891-5849(99)00101-X; Seo T, 2005, ANTICANCER RES, V25, P991; SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515; Tchounwou Paul B, 2003, Rev Environ Health, V18, P203; Tocher JH, 1997, GEN PHARMACOL, V28, P485, DOI 10.1016/S0306-3623(96)00283-2; Viode C, 1999, BIOCHEM PHARMACOL, V57, P549, DOI 10.1016/S0006-2952(98)00324-4; WARDMAN P, 1990, FREE RADICAL RES COM, V8, P219, DOI 10.3109/10715769009053355; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843; Wardman P, 2001, CURR MED CHEM, V8, P739, DOI 10.2174/0929867013372959; Wardman P, 1995, BIOCHEM SOC SYMP, P171, DOI 10.1042/bss0610171; Watanabe N, 2002, AM J PHYSIOL-LUNG C, V283, pL726, DOI 10.1152/ajplung.00025.2002; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	67	102	106	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5593	5603		10.1074/jbc.M511972200	http://dx.doi.org/10.1074/jbc.M511972200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16354662	hybrid			2022-12-27	WOS:000235568900035
J	Do, AT; Smeds, E; Spillmann, D; Kusche-Gullberg, M				Do, AT; Smeds, E; Spillmann, D; Kusche-Gullberg, M			Overexpression of heparan sulfate 6-O-sulfotransferases in human embryonic kidney 293 cells results in increased N-acetylglucosaminyl 6-O-sulfation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; SUBSTRATE-SPECIFICITY; O-SULFOTRANSFERASES; EXPRESSION PATTERNS; MOLECULAR-CLONING; IDURONIC ACID; HUMAN CDNAS; MOUSE; ISOFORMS; 2-O-SULFATION	Heparan sulfate (HS) interacts with a variety of proteins and thus mediates numerous complex biological processes. These interactions critically depend on the patterns of O-sulfate groups within the HS chains that determine binding sites for proteins. In particular the distribution of 6-O-sulfated glucosamine residues influences binding and activity of HS-dependent signaling molecules. The protein binding domains of HS show large structural variability, potentially because of differential expression patterns of HS biosynthetic enzymes along with differences in substrate specificity. To investigate whether different isoforms of HS glucosaminyl 6-O-sulfotransferase (6-OST) give rise to differently sulfated domains, we have introduced mouse 6-OST1, 6-OST2, and 6-OST3 in human embryonic kidney 293 cells and compared the effects of overexpression on HS structure. High expression of any one of the 6-OST enzymes resulted in appreciably increased 6-O-sulfation of N-sulfated as well as N-acetylated glucosamine units. The increased 6-O-sulfation was accompanied by a decrease in nonsulfated as well as in iduronic acid 2-O-sulfated disaccharide structures. Furthermore, overexpression led to an altered HS domain structure, the most striking effect was the formation of extended 6-O-sulfated predominantly N-acetylated HS domains. Although the effect was most noticeable in 6-OST3-expressing cells, these results were largely independent of the particular 6-OST isoform expressed and mainly influenced by the level of overexpression.	Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden; Univ Bergen, Dept Biomed, Div Physiol, N-5009 Bergen, Norway	Uppsala University; University of Bergen	Kusche-Gullberg, M (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Marion.Kusche@biomed.uib.no	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695				Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Bai XM, 1997, J BIOL CHEM, V272, P23172, DOI 10.1074/jbc.272.37.23172; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bink RJ, 2003, J BIOL CHEM, V278, P31118, DOI 10.1074/jbc.M213124200; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bulow HE, 2004, NEURON, V41, P723, DOI 10.1016/S0896-6273(04)00084-4; Chen E, 2005, DEV BIOL, V284, P364, DOI 10.1016/j.ydbio.2005.05.032; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Crawford BE, 2001, J BIOL CHEM, V276, P21538, DOI 10.1074/jbc.M100880200; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Ford-Perriss M, 2002, GLYCOBIOLOGY, V12, P721, DOI 10.1093/glycob/cwf072; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Habuchi H, 2003, BIOCHEM J, V371, P131, DOI 10.1042/BJ20021259; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Holmborn K, 2004, J BIOL CHEM, V279, P42355, DOI 10.1074/jbc.C400373200; Irie A, 2002, DEVELOPMENT, V129, P61; Jemth P, 2003, J BIOL CHEM, V278, P24371, DOI 10.1074/jbc.M212155200; Kamimura K, 2001, J BIOL CHEM, V276, P17014, DOI 10.1074/jbc.M011354200; Kobayashi M, 1997, J BIOL CHEM, V272, P13980, DOI 10.1074/jbc.272.21.13980; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; Li JP, 2001, J BIOL CHEM, V276, P20069, DOI 10.1074/jbc.M011783200; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LYON M, 1991, BIOCHEM J, V273, P415, DOI 10.1042/bj2730415; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2001, J BIOL CHEM, V276, P35429, DOI 10.1074/jbc.M100379200; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nogami K, 2004, J BIOL CHEM, V279, P8219, DOI 10.1074/jbc.M307304200; Pikas DS, 2000, BIOCHEMISTRY-US, V39, P4552, DOI 10.1021/bi992524l; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Rong JH, 2000, BIOCHEM J, V346, P463, DOI 10.1042/0264-6021:3460463; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANDERSON PN, 1983, BIOCHEM J, V211, P677, DOI 10.1042/bj2110677; Sedita J, 2004, DEV DYNAM, V231, P782, DOI 10.1002/dvdy.20173; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Smeds E, 2003, BIOCHEM J, V372, P371, DOI 10.1042/BJ20021665; Turnbull J, 2003, BIOCHEM SOC T, V31, P343, DOI 10.1042/BST0310343; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; WLAD H, 1994, J BIOL CHEM, V269, P24538; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200	46	9	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5348	5356		10.1074/jbc.M509584200	http://dx.doi.org/10.1074/jbc.M509584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16326709	hybrid			2022-12-27	WOS:000235568900005
J	Tirosh, B; Iwakoshi, NN; Glimcher, LH; Ploegh, HL				Tirosh, B; Iwakoshi, NN; Glimcher, LH; Ploegh, HL			Rapid turnover of unspliced Xbp-1 as a factor that modulates the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I MEMBRANE-PROTEIN; KAPPA-B-ALPHA; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; PROTEASOMAL DEGRADATION; TRANSCRIPTION FACTOR; STRESS; US11; INDUCTION; DOMAIN	The mammalian and yeast unfolded protein responses (UPR) share the characteristic of rapid elimination of unspliced Xbp-1 (Xbp-1u) and unspliced Hac1p, respectively. These polypeptides derive from mRNAs, whose splicing is induced upon onset of the UPR, so as to allow synthesis of transcription factors essential for execution of the UPR itself. Whereas in yeast translation of unspliced Hac1p is blocked, mammalian Xbp-1u is synthesized constitutively and eliminated by rapid proteasomal degradation. Here we show that the rate of Xbp-1u degradation approaches its rate of synthesis. The C terminus of XBP-1u ensures its trafficking to the cytoplasm, and is sufficient to impose rapid degradation. Degradation of XBP-1u involves both ubiquitin-dependent and ubiquitin-independent mechanisms, which might explain its unusually rapid turnover. Xbp-1(-/-) mouse embryonic fibroblasts reconstituted with mutants of XBP-1u that show improved stability differentially activate UPR target genes. Unexpectedly, we found that one of the mutants activates transcription of both Xbp-1-specific and non-Xbp-1-dependent UPR targets in response to tunicamycin treatment, even more potently than does wild type Xbp-1. We suggest that the degradation of Xbp-1u is required to prevent uncontrolled activation of the UPR while allowing short dwell times for initiation of this response.	Harvard Univ, Sch Publ Hlth, Whitehead Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard T.H. Chan School of Public Health	Ploegh, HL (corresponding author), 9 Cambridge Ctr, Cambridge, MA 02142 USA.	ploegh@wi.mit.edu	Longo, Kenneth A/A-5631-2010		NIAID NIH HHS [AI 32412, 5R37 AI 33456] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032412, R37AI033456] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asher G, 2005, MOL CELL, V17, P645, DOI 10.1016/j.molcel.2005.01.020; Asher G, 2002, P NATL ACAD SCI USA, V99, P13125, DOI 10.1073/pnas.202480499; Baumeister P, 2005, MOL CELL BIOL, V25, P4529, DOI 10.1128/MCB.25.11.4529-4540.2005; Beauparlant P, 1996, J BIOL CHEM, V271, P10690, DOI 10.1074/jbc.271.18.10690; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Dantuma NP, 2000, NAT BIOTECHNOL, V18, P538, DOI 10.1038/75406; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FAIRWELL T, 1984, FEBS LETT, V170, P281, DOI 10.1016/0014-5793(84)81329-0; Furman MH, 2003, J BIOL CHEM, V278, P34804, DOI 10.1074/jbc.M300913200; Iwakoshi NN, 2003, IMMUNOL REV, V194, P29, DOI 10.1034/j.1600-065X.2003.00057.x; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Ma YJ, 2004, J BIOL CHEM, V279, P13792, DOI 10.1074/jbc.M313724200; Papa FR, 2003, SCIENCE, V302, P1533, DOI 10.1126/science.1090031; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Ruegsegger U, 2001, CELL, V107, P103, DOI 10.1016/S0092-8674(01)00505-0; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Shen XH, 2005, PLOS GENET, V1, P355, DOI 10.1371/journal.pgen.0010037; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Tirosh B, 2005, J VIROL, V79, P2768, DOI 10.1128/JVI.79.5.2768-2779.2005; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0	26	92	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5852	5860		10.1074/jbc.M509061200	http://dx.doi.org/10.1074/jbc.M509061200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16332684	hybrid			2022-12-27	WOS:000235568900065
J	Torrents, E; Trevisiol, C; Rotte, C; Hellman, U; Martin, W; Reichard, P				Torrents, E; Trevisiol, C; Rotte, C; Hellman, U; Martin, W; Reichard, P			Euglena gracilis ribonucleotide reductase - The eukaryote class II enzyme and the possible antiquity of eukaryote B12 dependence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; ESCHERICHIA-COLI; LACTOBACILLUS-LEICHMANNII; EVOLUTION; ADENOSYLCOBALAMIN; MECHANISM; VITAMIN-B-12; EXPRESSION; PROTEIN; ASSAY	Ribonucleotide reductases provide the building blocks for DNA synthesis. Three classes of enzymes are known, differing widely in amino acid sequence but with similar structural motives and allosteric regulation. Class I occurs in eukaryotes and aerobic prokaryotes, class II occurs in aerobic and anaerobic prokaryotes, and class III occurs in anaerobic prokaryotes. The eukaryote Euglena gracilis contains a class II enzyme ( Gleason, F. K., and Hogenkamp, H. P. ( 1970) J. Biol. Chem. 245, 4894 - 4899) and, thus, forms an exception. Class II enzymes depend on vitamin B-12 for their activity. We purified the reductase from Euglena cells, determined partial peptide sequences, identified its cDNA, and purified the recombinant enzyme. Its amino acid sequence and general properties, including its allosteric behavior, were similar to the class II reductase from Lactobacillus leichmannii. Both enzymes belong to a distinct small group of reductases that unlike all other homodimeric reductases are monomeric. They compensate the loss of the second polypeptide of dimeric enzymes by a large insertion in the monomeric chain. Data base searching and sequence comparison revealed a homolog from the eukaryote Dictyostelium discoideum as the closest relative to the Euglena reductase, suggesting that the class II enzyme was present in a common, B-12-dependent, eukaryote ancestor.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Stockholm Univ, Arrhenius Labs Nat Sci, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden; Univ Dusseldorf, Inst Bot 3, DE-40225 Dusseldorf, Germany; Ludwig Inst Canc Res, Ctr Biomed, SE-75124 Uppsala, Sweden; Karolinska Inst, Dept Biochem, S-17177 Stockholm, Sweden	University of Padua; Stockholm University; Heinrich Heine University Dusseldorf; Ludwig Institute for Cancer Research; Karolinska Institutet	Reichard, P (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	reichard@mail.bio.unipd.it	Martin, William F./O-5446-2015; Torrents, Eduard/C-7184-2008; Trevisiol, Chiara/AAX-5369-2020; Trevisiol, Chiara/AAB-9554-2020; Martin, William/C-5680-2008	Martin, William F./0000-0003-1478-6449; Torrents, Eduard/0000-0002-3010-1609; Trevisiol, Chiara/0000-0002-6063-7930; 				Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryant D, 2004, MOL BIOL EVOL, V21, P255, DOI 10.1093/molbev/msh018; CARELL EF, 1980, BIOCHEM J, V188, P573, DOI 10.1042/bj1880573; Croft MT, 2005, NATURE, V438, P90, DOI 10.1038/nature04056; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Eliasson R, 1999, J BIOL CHEM, V274, P7182, DOI 10.1074/jbc.274.11.7182; Gleason FK, 2002, J BACTERIOL, V184, P6544, DOI 10.1128/JB.184.23.6544-6550.2002; GLEASON FK, 1970, J BIOL CHEM, V245, P4894; HAMILTON FD, 1974, J BIOL CHEM, V249, P4428; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hoffmeister M, 2005, J BIOL CHEM, V280, P4329, DOI 10.1074/jbc.M411010200; Hoffmeister M, 2004, J BIOL CHEM, V279, P22422, DOI 10.1074/jbc.M400913200; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUNTER SH, 1964, ANNU REV PLANT PHYS, V15, P37, DOI DOI 10.1146/ANNUREV.PP.15.060164.000345; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838; Lawrence CC, 1998, CURR OPIN CHEM BIOL, V2, P650, DOI 10.1016/S1367-5931(98)80097-5; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MOLLIN DL, 1976, CLIN HAEMATOL, V5, P521; Parle-McDermott A, 2003, MOL GENET METAB, V80, P463, DOI 10.1016/j.ymgme.2003.09.009; POSTON JM, 1977, SCIENCE, V195, P301, DOI 10.1126/science.195.4275.301; PRINGSHEIM EG, 1962, NATURE, V195, P604, DOI 10.1038/195604a0; REICHARD P, 1993, J BIOL CHEM, V268, P8383; Reichard P, 2002, ARCH BIOCHEM BIOPHYS, V397, P149, DOI 10.1006/abbi.2001.2637; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Richards TA, 2005, NATURE, V436, P1113, DOI 10.1038/nature03949; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Sjoberg BM, 1997, STRUCT BOND, V88, P139; SJOBERG BM, 1978, J BIOL CHEM, V253, P6863; Stubble J, 2003, CURR OPIN CHEM BIOL, V7, P183, DOI 10.1016/S1367-5931(03)00025-5; STUTZENBERGER F, 1973, ANAL BIOCHEM, V56, P294, DOI 10.1016/0003-2697(73)90193-0; Thelander L, 1978, Methods Enzymol, V51, P227; Thollesson M, 2004, BIOINFORMATICS, V20, P416, DOI 10.1093/bioinformatics/btg422; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torrents E, 2002, J MOL EVOL, V55, P138, DOI 10.1007/s00239-002-2311-7; Torrents E, 2001, J BIOL CHEM, V276, P33488, DOI 10.1074/jbc.M103743200; Watanabe F, 1996, MICROBIOL-SGM, V142, P2631, DOI 10.1099/00221287-142-9-2631; WOLKEN JJ, 1967, EUGLENA, P174	42	20	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5604	5611		10.1074/jbc.M512962200	http://dx.doi.org/10.1074/jbc.M512962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16368684	hybrid			2022-12-27	WOS:000235568900036
J	Leonard, R; Rendic, D; Rabouille, C; Wilson, IBH; Preat, T; Altmann, F				Leonard, R; Rendic, D; Rabouille, C; Wilson, IBH; Preat, T; Altmann, F			The Drosophila fused lobes gene encodes an N-acetylglucosaminidase involved in N-glycan processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; ACETYL-D-GLUCOSAMINIDASE; ALPHA-MANNOSIDASE-II; BOMBYX-MORI LARVAE; INSECT CELLS; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; GLYCOPROTEIN-BIOSYNTHESIS; SPODOPTERA-FRUGIPERDA	Most processed, e. g. fucosylated, N-glycans on insect glycoproteins terminate in mannose, yet the relevant modifying enzymes require the prior action of N-acetylglucosaminyltransferase I. This led to the hypothesis that a hexosaminidase acts during the course of N-glycan maturation. To determine whether the Drosophila melanogaster genome indeed encodes such an enzyme, a cDNAcorresponding to fused lobes (fdl), a putative beta-N-acetylglucosaminidase with a potential transmembrane domain, was cloned. When expressed in Pichia pastoris, the enzyme exhibited a substrate specificity similar to that previously described for a hexosaminidase activity from Sf-9 cells, i.e. it hydrolyzed exclusively the GlcNAc residue attached to the alpha 1,3-linked mannose of the core pentasaccharide of N-glycans. It also hydrolyzed p-nitrophenyl-N-acetyl-beta-glucosaminide, but not chitooligosaccharides; in contrast, Drosophila HEXO1 and HEXO2 expressed in Pichia cleaved both these substrates but not N-glycans. The localization of recombinant FDL tagged with green fluorescent protein in Drosophila S2 cells by immunoelectron microscopy showed that this enzyme transits through the Golgi, is present on the plasma membrane and in multivesicular bodies, and is secreted. Finally, the N-glycans of two lines of fdl mutant flies were analyzed by mass spectrometry and reversed-phase high-performance liquid chromatography. The ratio of structures with terminal GlcNAc over those without (i.e. paucimannosidic N-glycans) was drastically increased in the fdl-deficient flies. Therefore, we conclude that the fdl gene encodes a novel hexosaminidase responsible for the occurrence of paucimannosidic N-glycans in Drosophila.	Univ Nat Resources & Appl Life Sci, Dept Chem, Glycobiol Grp, A-1190 Vienna, Austria; Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands; CNRS, F-91190 Gif Sur Yvette, France	University of Natural Resources & Life Sciences, Vienna; Utrecht University; Utrecht University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Leonard, R (corresponding author), Univ Nat Resources & Appl Life Sci, Dept Chem, Glycobiol Grp, Muthgasse 18, A-1190 Vienna, Austria.	renaud.leonard@boku.ac.at	Wilson, Iain/B-3326-2009; Rendic, Dubravko/A-9368-2010	Wilson, Iain/0000-0001-8996-1518; Leonard, Renaud/0000-0001-5023-1032; Altmann, Friedrich/0000-0002-0112-7877; Preat, Thomas/0000-0001-9976-1763				Ailor E, 2000, GLYCOBIOLOGY, V10, P837, DOI 10.1093/glycob/10.8.837; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P150, DOI 10.1007/BF00731359; Ayyar S, 2003, DEVELOPMENT, V130, P2841, DOI 10.1242/dev.00513; Bencurova M, 2003, BIOCHIMIE, V85, P413, DOI 10.1016/S0300-9084(03)00072-5; Boisson M, 2001, EMBO J, V20, P1010, DOI 10.1093/emboj/20.5.1010; Boquet I, 2000, J NEUROBIOL, V42, P33; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Cattaneo F, 2002, INSECT BIOCHEM MOLEC, V32, P929, DOI 10.1016/S0965-1748(02)00031-0; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Ding HB, 2003, PROTEIN EXPRES PURIF, V31, P34, DOI 10.1016/S1046-5928(03)00138-4; Donaldson M, 1999, BIOTECHNOL PROGR, V15, P168, DOI 10.1021/bp9900211; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Fitchette-Laine AC, 1997, PLANT J, V12, P1411, DOI 10.1046/j.1365-313x.1997.12061411.x; Haines N, 2005, GLYCOBIOLOGY, V15, P335, DOI 10.1093/glycob/cwi017; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; Hollister JR, 1998, GLYCOBIOLOGY, V8, P473, DOI 10.1093/glycob/8.5.473; Hsu TA, 1997, J BIOL CHEM, V272, P9062; Kawar Z, 2001, J BIOL CHEM, V276, P16335, DOI 10.1074/jbc.M100119200; Kim YK, 2005, BIOTECHNOL BIOENG, V92, P452, DOI 10.1002/bit.20605; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; Landis G, 2001, GENETICS, V158, P1167; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Mahuran DJ, 1999, BBA-MOL BASIS DIS, V1455, P105, DOI 10.1016/S0925-4439(99)00074-5; Marchal I, 1999, GLYCOBIOLOGY, V9, P645, DOI 10.1093/glycob/9.7.645; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; Matsuo I, 2003, BIOSCI BIOTECH BIOCH, V67, P646, DOI 10.1271/bbb.67.646; Misaki R, 2003, BIOCHEM BIOPH RES CO, V311, P979, DOI 10.1016/j.bbrc.2003.10.094; Morton CL, 2000, MOL BIOTECHNOL, V16, P193, DOI 10.1385/MB:16:3:193; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; NAGAMATSU Y, 1995, BIOSCI BIOTECH BIOCH, V59, P219, DOI 10.1271/bbb.59.219; OGONAH OW, 1995, BIOCHEM SOC T, V23, pS100, DOI 10.1042/bst023100s; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Rabouille C, 1999, J CELL SCI, V112, P3319; RABOUILLE C, 1995, J CELL SCI, V108, P1617; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SOMMER U, 1991, ARCH INSECT BIOCHEM, V17, P3, DOI 10.1002/arch.940170103; SOMMER U, 1991, ARCH INSECT BIOCHEM, V18, P45, DOI 10.1002/arch.940180105; Staudacher E, 1998, GLYCOCONJUGATE J, V15, P355, DOI 10.1023/A:1006969701231; Tan J, 1996, AM J HUM GENET, V59, P810; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; Tomiya N, 2003, ACCOUNTS CHEM RES, V36, P613, DOI 10.1021/ar020202v; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; Vadaie N, 2004, J BIOL CHEM, V279, P33501, DOI 10.1074/jbc.M404925200; Vadaie N, 2002, GLYCOBIOLOGY, V12, P589, DOI 10.1093/glycob/cwf074; VITALE A, 1984, J CELL BIOL, V99, P133, DOI 10.1083/jcb.99.1.133; Wagner R, 1996, GLYCOBIOLOGY, V6, P165, DOI 10.1093/glycob/6.2.165; Wagner R, 1996, J VIROL, V70, P4103, DOI 10.1128/JVI.70.6.4103-4109.1996; WANG AM, 1990, J BIOL CHEM, V265, P21859; Wang Y, 2002, BBA-GEN SUBJECTS, V1573, P301, DOI 10.1016/S0304-4165(02)00397-5; Watanabe S, 2002, J BIOL CHEM, V277, P5090, DOI 10.1074/jbc.M110548200; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; [No title captured]	64	122	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4867	4875		10.1074/jbc.M511023200	http://dx.doi.org/10.1074/jbc.M511023200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16339150	hybrid			2022-12-27	WOS:000235426200037
J	Piccirella, S; Czegle, I; Lizak, B; Margittai, E; Senesi, S; Papp, E; Csala, M; Fulceri, R; Csermely, P; Mandl, J; Benedetti, A; Banhegyi, G				Piccirella, S; Czegle, I; Lizak, B; Margittai, E; Senesi, S; Papp, E; Csala, M; Fulceri, R; Csermely, P; Mandl, J; Benedetti, A; Banhegyi, G			Uncoupled redox systems in the lumen of the endoplasmic reticulum - Pyridine nucleotides stay reduced in an oxidative environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; MICROSOMAL HEXOSE-6-PHOSPHATE DEHYDROGENASE; FUNCTIONAL-RELATIONSHIP; LIVER-MICROSOMES; PROTEIN; GLUTATHIONE; REDUCTASE; DISULFIDE; TRANSPORT; DEHYDROASCORBATE	The redox state of the intraluminal pyridine nucleotide pool was investigated in rat liver microsomal vesicles. The vesicles showed cortisone reductase activity in the absence of added reductants, which was dependent on the integrity of the membrane. The intraluminal pyridine nucleotide pool could be oxidized by the addition of cortisone or metyrapone but not of glutathione. On the other hand, intraluminal pyridine nucleotides were slightly reduced by cortisol or glucose 6-phosphate, although glutathione was completely ineffective. Redox state of microsomal protein thiols/disulfides was not altered either by manipulations affecting the redox state of pyridine nucleotides or by the addition of NAD(P)(+) or NAD(P)H. The uncoupling of the thiol/disulfide and NAD(P)(+)/NAD(P)H redox couples was not because of their subcompartmentation, because enzymes responsible for the intraluminal oxidoreduction of pyridine nucleotides were distributed equally in smooth and rough microsomal subfractions. Instead, the phenomenon can be explained by the negligible representation of glutathione reductase in the endoplasmic reticulum lumen. The results demonstrated the separate existence of two redox systems in the endoplasmic reticulum lumen, which explains the contemporary functioning of oxidative folding and of powerful reductive reactions.	Semmelweis Univ, Dept Med Chem Mol Biol & Pathobiochem, H-1444 Budapest, Hungary; Hungarian Acad Sci, Endoplasm Reticulum Res Grp, H-1444 Budapest, Hungary; Univ Siena, Dept Pathophysiol Expt Med & Publ Hlth, I-53100 Siena, Italy; Santa Maria Scotte Hosp, Unit Dev Biomed Res, I-53100 Siena, Italy	Semmelweis University; Hungarian Academy of Sciences; University of Siena	Banhegyi, G (corresponding author), Semmelweis Univ, Dept Med Chem, PO 260, H-1444 Budapest, Hungary.	banhegyi@puskin.sote.hu	Bánhegyi, Gábor/A-1476-2014; Csermely, Peter/J-2067-2017; Czegle, Ibolya/Y-3365-2019; Csala, Miklos/H-5369-2011	Csermely, Peter/0000-0001-9234-0659; Csala, Miklos/0000-0002-3829-4361; Czegle, Ibolya/0000-0001-7240-4678				Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; Banhegyi G, 1998, J BIOL CHEM, V273, P2758, DOI 10.1074/jbc.273.5.2758; Banhegyi G, 1997, J BIOL CHEM, V272, P13584, DOI 10.1074/jbc.272.21.13584; Banhegyi G, 1999, J BIOL CHEM, V274, P12213, DOI 10.1074/jbc.274.18.12213; Banhegyi G, 2004, J BIOL CHEM, V279, P27017, DOI 10.1074/jbc.M404159200; Bannenberg G, 2003, CHEM-BIOL INTERACT, V143, P449, DOI 10.1016/S0009-2797(02)00183-7; Bass R, 2004, J BIOL CHEM, V279, P5257, DOI 10.1074/jbc.M304951200; BENEDETTI A, 1988, J BIOL CHEM, V263, P3466; BENEDETTI A, 2005, NATO SCI SERIES LIFE, V363; Benham AM, 2000, EMBO J, V19, P4493, DOI 10.1093/emboj/19.17.4493; BUBLITZ C, 1988, BIOCHIM BIOPHYS ACTA, V965, P90, DOI 10.1016/0304-4165(88)90155-9; BUBLITZ C, 1987, BIOCHEM J, V245, P263, DOI 10.1042/bj2450263; BUBLITZ C, 1987, ARCH BIOCHEM BIOPHYS, V259, P22, DOI 10.1016/0003-9861(87)90465-6; BURCHELL A, 1988, CLIN CHIM ACTA, V173, P183, DOI 10.1016/0009-8981(88)90256-2; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Clarke JL, 2003, ARCH BIOCHEM BIOPHYS, V415, P229, DOI 10.1016/S0003-9861(03)00229-7; Csala M, 2004, BIOCHEM PHARMACOL, V68, P1353, DOI 10.1016/j.bcp.2004.05.055; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; FULCERI R, 1994, ARCH BIOCHEM BIOPHYS, V309, P43, DOI 10.1006/abbi.1994.1081; Herling AW, 1998, AM J PHYSIOL-GASTR L, V274, pG1087, DOI 10.1152/ajpgi.1998.274.6.G1087; Hewitt KN, 2005, ENDOCRINOLOGY, V146, P2539, DOI 10.1210/en.2005-0117; HINO Y, 1982, J BIOCHEM, V92, P547, DOI 10.1093/oxfordjournals.jbchem.a133963; HINO Y, 1987, EUR J BIOCHEM, V165, P195, DOI 10.1111/j.1432-1033.1987.tb11211.x; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KEHRER JP, 1994, FREE RADICAL BIO MED, V17, P65, DOI 10.1016/0891-5849(94)90008-6; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; KULKARNI AP, 1982, BIOCHEM PHARMACOL, V31, P1131, DOI 10.1016/0006-2952(82)90353-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWRY OH, 1957, J BIOL CHEM, V224, P1047; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; Marcolongo P, 1996, BIOCHEM BIOPH RES CO, V219, P916, DOI 10.1006/bbrc.1996.0333; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Mezghrani A, 2001, EMBO J, V20, P6288, DOI 10.1093/emboj/20.22.6288; Molteni SN, 2004, J BIOL CHEM, V279, P32667, DOI 10.1074/jbc.M404992200; Ogg D, 2005, J BIOL CHEM, V280, P3789, DOI 10.1074/jbc.M412463200; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; Papp E, 2005, BIOCHEM BIOPH RES CO, V338, P938, DOI 10.1016/j.bbrc.2005.10.027; SAWADA H, 1981, J BIOCHEM-TOKYO, V90, P1077, DOI 10.1093/oxfordjournals.jbchem.a133559; SAWADA H, 1980, J BIOCHEM-TOKYO, V87, P985, DOI 10.1093/oxfordjournals.jbchem.a132829; Senesi S, 2005, BIOCHEM J, V389, P57, DOI 10.1042/BJ20050213; SOUTE BAM, 1992, BIOCHEM J, V281, P255, DOI 10.1042/bj2810255; Szarka A, 2002, J BIOENERG BIOMEMBR, V34, P317, DOI 10.1023/A:1020212720330; TAKAHASHI T, 1978, BIOCHIM BIOPHYS ACTA, V524, P262, DOI 10.1016/0005-2744(78)90163-8; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; Varsanyi M, 2004, J BIOL CHEM, V279, P3370, DOI 10.1074/jbc.M307783200; Zhang JY, 2003, J BIOL CHEM, V278, P7459, DOI 10.1074/jbc.M207976200	50	73	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4671	4677		10.1074/jbc.M509406200	http://dx.doi.org/10.1074/jbc.M509406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373343	hybrid			2022-12-27	WOS:000235426200015
J	Bouakaz, L; Bouakaz, E; Murgola, EJ; Ehrenberg, M; Sanyal, S				Bouakaz, L; Bouakaz, E; Murgola, EJ; Ehrenberg, M; Sanyal, S			The role of ribosomal protein L11 in class I release factor-mediated translation termination and translational accuracy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-CHAIN TERMINATION; ESCHERICHIA-COLI RIBOSOME; CONSERVED GTPASE CENTER; RECYCLING FACTOR RRF; FACTOR RF3; CODON RECOGNITION; MESSENGER-RNAS; EF-G; COMPLEX; SUBUNIT	It has been suggested from in vivo and cryoelectron micrographic studies that the large ribosomal subunit protein L11 and its N-terminal domain play an important role in peptide release by, in particular, the class I release factor RF1. In this work, we have studied in vitro the role of L11 in translation termination with ribosomes from a wild type strain (WT-L11), an L11 knocked-out strain (Delta L11), and an L11 N terminus truncated strain (Cter-L11). Our data show 4-6fold reductions in termination efficiency (k(cat)/K-m) of RF1, but not of RF2, on Delta L11 and Cter-L11 ribosomes compared with wild type. There is, at the same time, no effect of these L11 alterations on the maximal rate of ester bond cleavage by either RF1 or RF2. The rates of dissociation of RF2 but not of RF1 from the ribosome after peptide release are somewhat reduced by the L11 changes irrespective of the presence of RF3, and they cause a 2-fold decrease in the missense error. Our results suggest that the L11 modifications increase nonsense suppression at UAG codons because of the reduced termination efficiency of RF1 and that they decrease nonsense suppression at UGA codons because of a decreased missense error level.	Uppsala Univ, Inst Cell & Mol Biol, S-75124 Uppsala, Sweden; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Uppsala University; University of Texas System; UTMD Anderson Cancer Center	Sanyal, S (corresponding author), Uppsala Univ, Inst Cell & Mol Biol, BMC,Box 596, S-75124 Uppsala, Sweden.	Suparna.sanyal@icm.uu.se			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021499] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21499, GM70768] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2001, J MOL BIOL, V311, P777, DOI 10.1006/jmbi.2001.4907; ARMSTRONG IL, 1978, J MOL BIOL, V120, P155, DOI 10.1016/0022-2836(78)90062-1; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNEL C, 1993, BIOCHIMIE, V75, P1167, DOI 10.1016/0300-9084(93)90016-L; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; Freistroffer DV, 2000, P NATL ACAD SCI USA, V97, P2046, DOI 10.1073/pnas.030541097; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Jemiolo DK, 1995, P NATL ACAD SCI USA, V92, P12309, DOI 10.1073/pnas.92.26.12309; KAZEMIE M, 1975, EUR J BIOCHEM, V58, P501, DOI 10.1111/j.1432-1033.1975.tb02398.x; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; McCaughan KK, 1998, BIOL CHEM, V379, P857, DOI 10.1515/bchm.1998.379.7.857; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOFFAT JG, 1991, BIOCHIMIE, V73, P1113, DOI 10.1016/0300-9084(91)90154-S; Mora L, 2003, MOL MICROBIOL, V50, P1467, DOI 10.1046/j.1365-2958.2003.03799.x; Pavlov MY, 1996, ARCH BIOCHEM BIOPHYS, V328, P9, DOI 10.1006/abbi.1996.0136; Pavlov MY, 1997, EMBO J, V16, P4134, DOI 10.1093/emboj/16.13.4134; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; Pedersen K, 2003, CELL, V112, P131, DOI 10.1016/S0092-8674(02)01248-5; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; RYAN PC, 1991, J MOL BIOL, V221, P1257, DOI 10.1016/0022-2836(91)80125-E; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; SENO T, 1968, BIOCHIM BIOPHYS ACTA, V169, P80, DOI 10.1016/0005-2787(68)90010-5; STOFFLER G, 1980, J BIOL CHEM, V255, P517; TATE WP, 1983, J BIOL CHEM, V258, P2816; TATE WP, 1975, J MOL BIOL, V93, P375, DOI 10.1016/0022-2836(75)90284-3; TATE WP, 1984, J BIOL CHEM, V259, P7317; TATE WP, 1986, J BIOL CHEM, V261, P2289; Tenson T, 2003, J MOL BIOL, V330, P1005, DOI 10.1016/S0022-2836(03)00662-4; Van Dyke N, 2003, J MOL BIOL, V330, P9, DOI 10.1016/S0022-2836(03)00537-0; Van Dyke N, 2002, J MOL BIOL, V319, P329, DOI 10.1016/S0022-2836(02)00304-2; WOLLENZIEN P, 1991, BIOCHEMISTRY-US, V30, P1788, DOI 10.1021/bi00221a009; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6	39	22	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4548	4556		10.1074/jbc.M510433200	http://dx.doi.org/10.1074/jbc.M510433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16371360	hybrid			2022-12-27	WOS:000235275300091
J	Tang, HB; Veldman, MB; Goldman, D				Tang, HB; Veldman, MB; Goldman, D			Characterization of a muscle-specific enhancer in human MuSK promoter reveals the essential role of myogenin in controlling activity-dependent gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; DELTA-SUBUNIT PROMOTER; ELECTRICAL-ACTIVITY; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; IN-VIVO; EXPRESSION; TRANSCRIPTION; PATHWAY; SYNAPSE	Neuromuscular synaptogenesis is initiated by the release of agrin from motor neurons and the activation of the receptor tyrosine kinase, MuSK, in the postsynaptic membrane. MuSK gene expression is regulated by nerve-derived agrin and muscle activity. Agrin stimulates synapse-specific MuSK gene expression by activating GABP(alpha beta) transcription factors in endplate-associated myonuclei. In contrast, the mechanism by which muscle activity regulates MuSK gene expression is not known. We report on a 60-bp MuSK enhancer that confers promoter regulation by muscle differentiation, changes in intracellular calcium, and muscle activity. Within this enhancer, we identified a single E-box that is essential for this regulation. This E-box binds myogenin, and we showed that myogenin is necessary for not only MuSK but also nAChR gene regulation by muscle activity. Surprisingly, the same E-box functions in vivo to mediate muscle-specific and differentiation-dependent gene induction in zebrafish, suggesting an evolutionary conserved mechanism of regulation of synaptic protein gene expression.	Univ Michigan, Mol & Behav Neurosci Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldman, D (corresponding author), Univ Michigan, Mol & Behav Neurosci Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	neuroman@umich.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025153] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS25153] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams L, 1998, J NEUROBIOL, V35, P245, DOI 10.1002/(SICI)1097-4695(19980605)35:3<245::AID-NEU2>3.0.CO;2-Z; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; BESSEREAU JL, 1994, P NATL ACAD SCI USA, V91, P1304, DOI 10.1073/pnas.91.4.1304; Bessereau JL, 1998, J BIOL CHEM, V273, P12786, DOI 10.1074/jbc.273.21.12786; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Bowen DC, 1998, DEV BIOL, V199, P309, DOI 10.1006/dbio.1998.8936; BRAUN T, 1995, EMBO J, V14, P1176, DOI 10.1002/j.1460-2075.1995.tb07101.x; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; Goldman D, 2001, TRANSGENIC RES, V10, P21, DOI 10.1023/A:1008998832552; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Kim CH, 2005, MOL CELL BIOL, V25, P5329, DOI 10.1128/MCB.25.13.5329-5338.2005; Kim CH, 2003, J BIOL CHEM, V278, P38522, DOI 10.1074/jbc.M305058200; Lacazette E, 2003, J CELL BIOL, V161, P727, DOI 10.1083/jcb.200210156; Liu SH, 2000, J BIOL CHEM, V275, P41364, DOI 10.1074/jbc.M004172200; Macpherson P, 2002, J BIOL CHEM, V277, P15638, DOI 10.1074/jbc.M109864200; Macpherson PCD, 2004, J CELL BIOCHEM, V91, P821, DOI 10.1002/jcb.10784; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Steinke JW, 2000, NUCLEIC ACIDS RES, V28, P2726, DOI 10.1093/nar/28.14.2726; SU CT, 1995, FEBS LETT, V366, P131, DOI 10.1016/0014-5793(95)00496-V; Sunesen M, 2003, J NEUROCYTOL, V32, P677, DOI 10.1023/B:NEUR.0000020616.53664.80; Tang HB, 2004, CELL SIGNAL, V16, P551, DOI 10.1016/j.cellsig.2003.09.006; Tang HB, 2001, J BIOL CHEM, V276, P26057, DOI 10.1074/jbc.M101670200; TANG JC, 1994, DEVELOPMENT, V120, P1799; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Walke W, 1996, J NEUROSCI, V16, P3641; Wang ZZ, 2003, J NEUROSCI, V23, P5161	31	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3943	3953		10.1074/jbc.M511317200	http://dx.doi.org/10.1074/jbc.M511317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361705	hybrid			2022-12-27	WOS:000235275300022
J	Hirao, J; Arakawa, S; Watanabe, K; Ito, K; Furukawa, T				Hirao, J; Arakawa, S; Watanabe, K; Ito, K; Furukawa, T			Effects of restricted feeding on daily fluctuations of hepatic functions including P450 monooxygenase activities in rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-DEALKYLASE ACTIVITIES; SUPRACHIASMATIC NUCLEUS; GROWTH-HORMONE; CIRCADIAN OSCILLATORS; PERIPHERAL-TISSUES; LIVER-MICROSOMES; METABOLISM; GHRELIN; 7-ALKOXYCOUMARIN; RHYTHM	Hepatic P450 monooxygenase activities, assessed by measurement of 7-alkoxycoumarin O-dealkylase ( ACD) activities, show obvious daily fluctuations in male rats with high values during the dark period and low values during the light period. We have already confirmed that the ACD activities are controlled by the suprachiasmatic nucleus ( SCN), which is well known as the oscillator of circadian rhythm. Recently, it is reported that circadian oscillators exist not only in the SCN but also in peripheral organs. To date, it is unclear which circadian oscillators predominantly drive the daily fluctuations of hepatic ACD activities. To address this question, we examined the effects of restricted feeding, which uncouples the circadian oscillators in the liver from the central pacemaker in the SCN, on the daily fluctuations in hepatic ACD activities in male rats. Here we show that restricted feeding inverts the oscillation phase of the daily fluctuations in hepatic ACD activities. Regarding the hepatic P450 content, there were no fluctuations between the light and dark periods under ad libitum and restricted feeding conditions. Therefore, it is considered that the daily fluctuations in hepatic ACD activities are predominantly driven by the circadian factors in peripheral organs rather than by the oscillator in the SCN directly.	Sankyo Co Ltd, Med Safety Res Labs, Shizuoka 4370065, Japan	Daiichi Sankyo Company Limited	Hirao, J (corresponding author), Sankyo Co Ltd, Med Safety Res Labs, 717,Horikoshi, Shizuoka 4370065, Japan.	jhirao@sankyo.co.jp						Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Davis RA, 2002, J LIPID RES, V43, P533; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Furukawa T, 1999, TOXICOL LETT, V108, P11, DOI 10.1016/S0378-4274(99)00065-X; Furukawa T, 1999, ARCH TOXICOL, V73, P367, DOI 10.1007/s002040050675; Furukawa T, 1999, TOXICOL APPL PHARM, V161, P219, DOI 10.1006/taap.1999.8808; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirota T, 2004, ZOOL SCI, V21, P359, DOI 10.2108/zsj.21.359; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; INOUYE SIT, 1994, NEUROSCI RES, V20, P109, DOI 10.1016/0168-0102(94)90029-9; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Lewis DFV, 2004, PHARMACOGENOMICS, V5, P305, DOI 10.1517/phgs.5.3.305.29827; LopezMolina L, 1997, EMBO J, V16, P6762, DOI 10.1093/emboj/16.22.6762; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU AYH, 1969, J BIOL CHEM, V244, P3714; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; MATSUBARA T, 1983, JPN J PHARMACOL, V33, P41, DOI 10.1254/jjp.33.41; Meier U, 2004, CLIN CHEM, V50, P1511, DOI 10.1373/clinchem.2004.032482; Mugford CA, 1998, DRUG METAB REV, V30, P441, DOI 10.3109/03602539808996322; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; NOSHIRO M, 1990, J BIOL CHEM, V265, P10036; Noshiro M, 2004, GENES CELLS, V9, P317, DOI 10.1111/j.1356-9597.2004.00722.x; OKUNO H, 1989, JPN J PHARMACOL, V50, P1, DOI 10.1254/jjp.50.1; OMURA T, 1964, J BIOL CHEM, V239, P2379; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; RUSAK B, 1979, PHYSIOL REV, V59, P449, DOI 10.1152/physrev.1979.59.3.449; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; SHARMA C, 1963, J BIOL CHEM, V238, P3840; Smid M, 2003, BIOINFORMATICS, V19, P2065, DOI 10.1093/bioinformatics/btg282; SOUCEK P, 1992, XENOBIOTICA, V22, P83; St Pierre DH, 2003, NEWS PHYSIOL SCI, V18, P242; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Van Schaftingen E, 2002, BIOCHEM J, V362, P513, DOI 10.1042/0264-6021:3620513; VanSchaftingen E, 1997, BIOCHEM SOC T, V25, P136, DOI 10.1042/bst0250136; Yabe D, 2003, P NATL ACAD SCI USA, V100, P3155, DOI 10.1073/pnas.0130116100; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; YOSHIMURA J, 1987, STAT ANAL TOXICITY D, P28	42	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3165	3171		10.1074/jbc.M511194200	http://dx.doi.org/10.1074/jbc.M511194200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332680	hybrid			2022-12-27	WOS:000235128200019
J	Harikumar, KG; Hosohata, K; Pinon, DI; Miller, LJ				Harikumar, KG; Hosohata, K; Pinon, DI; Miller, LJ			Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; AMINO-TERMINAL TAIL; SPATIAL APPROXIMATION; CHOLECYSTOKININ RECEPTOR; MOLECULAR PHARMACOLOGY; CONFORMATIONAL-CHANGES; TRANSMEMBRANE HELICES; EXTRACELLULAR DOMAIN; CALCITONIN RECEPTOR; DISULFIDE PATTERN	Fluorescence techniques can provide insight into the environment of fluorescence indicators situated at distinct sites within a ligand as it is bound to its receptor. Here, we have developed a series of analogues of the 27-amino acid hormone, secretin, that incorporate a fluorescent Alexa Fluor 488 into the amino terminus, the carboxyl terminus, and positions 13 and 22. Each probe bound with high affinity and was biologically active, stimulating full cAMP responses in receptor-bearing Chinese hamster ovary-SecR cells. Treatment with 10 mu M guanosine 5'-(beta, gamma-imido) triphosphate (GppNHp) shifted the agonist-bound receptor into a G protein-uncoupled low affinity state. Fluorescence spectra for the probes in solution and bound to the receptor demonstrated maximal emission at 521 nm after excitation at 481 nm. Collisional quenching of fluorescence with potassium iodide revealed that Alexa at the amino terminus of secretin was more accessible than at the other three positions within the probes. Of note, quenching constants for each probe were higher when bound in the active state than in the G protein-uncoupled, low affinity state of the receptor, with the most marked changes occurring for the two midregion probes. Anisotropy values and fluorescence lifetimes confirmed this, with higher anisotropy and longer lifetimes observed for position 13 and 22 probes bound to the receptor in its uncoupled state than in its active state. These observations suggest that the amino terminus of secretin as docked to the receptor is most exposed to the hydrophilic aqueous milieu, and that the major changes in conformation and exposure to the medium occur in the midregion of secretin. Photoaffinity labeling studies have demonstrated approximation of each of these ligand residues with distinct receptor residues. Combining the fluorescence data with photoaffinity labeling data provides insights into the conformation and dynamics of a natural peptide ligand docked to a Family B G protein-coupled receptor.	Mayo Clin, Ctr Canc, Scottsdale, AZ 85259 USA; Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Miller, LJ (corresponding author), 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	miller@mayo.edu			NIDDK NIH HHS [DK46577] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046577] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Asmann YW, 2000, MOL PHARMACOL, V58, P911, DOI 10.1124/mol.58.5.911; Bazarsuren A, 2002, BIOPHYS CHEM, V96, P305, DOI 10.1016/S0301-4622(02)00023-6; Dong MQ, 2000, J BIOL CHEM, V275, P26032, DOI 10.1074/jbc.M000612200; Dong MQ, 2004, J BIOL CHEM, V279, P2894, DOI 10.1074/jbc.M310407200; Dong MQ, 2003, J BIOL CHEM, V278, P48300, DOI 10.1074/jbc.M309166200; Dong MQ, 1999, J BIOL CHEM, V274, P19161, DOI 10.1074/jbc.274.27.19161; Dong MQ, 2002, MOL ENDOCRINOL, V16, P2490, DOI 10.1210/me.2002-0111; Dong MQ, 2002, RECEPTOR CHANNEL, V8, P189, DOI 10.1080/10606820213686; Dong MQ, 2000, ANN NY ACAD SCI, V921, P381; Dong MQ, 1999, J BIOL CHEM, V274, P903, DOI 10.1074/jbc.274.2.903; Donnelly D, 1997, FEBS LETT, V409, P431, DOI 10.1016/S0014-5793(97)00546-2; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Grace CRR, 2004, P NATL ACAD SCI USA, V101, P12836, DOI 10.1073/pnas.0404702101; Grauschopf U, 2000, BIOCHEMISTRY-US, V39, P8878, DOI 10.1021/bi0001426; Harikumar KG, 2005, J BIOL CHEM, V280, P1044, DOI 10.1074/jbc.M409480200; Harikumar KG, 2004, MOL PHARMACOL, V65, P28, DOI 10.1124/mol.65.1.28; Harikumar KG, 2002, J BIOL CHEM, V277, P18552, DOI 10.1074/jbc.M201164200; Holtmann MH, 1996, J PHARMACOL EXP THER, V279, P555; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Kobilka B, 2004, MOL PHARMACOL, V65, P1060, DOI 10.1124/mol.65.5.1060; Laburthe M, 1996, ANN NY ACAD SCI, V805, P94; Laburthe M, 2002, RECEPTOR CHANNEL, V8, P137, DOI 10.1080/10606820290005191; Lisenbee CS, 2005, J BIOL CHEM, V280, P12330, DOI 10.1074/jbc.M414016200; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perrin MH, 2001, J BIOL CHEM, V276, P31528, DOI 10.1074/jbc.M101838200; Pham V, 2005, J BIOL CHEM, V280, P28610, DOI 10.1074/jbc.M503272200; Purdue BW, 2002, RECEPTOR CHANNEL, V8, P243, DOI 10.1080/10606820213681; Qi LJ, 1997, BIOCHEMISTRY-US, V36, P12442, DOI 10.1021/bi970997r; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; ULRICH CD, 1993, BIOCHEM BIOPH RES CO, V193, P204, DOI 10.1006/bbrc.1993.1610; Zang MW, 2003, MOL PHARMACOL, V63, P993, DOI 10.1124/mol.63.5.993	39	22	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2543	2550		10.1074/jbc.M509197200	http://dx.doi.org/10.1074/jbc.M509197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319066	hybrid			2022-12-27	WOS:000234931800017
J	Polevoda, B; Span, L; Sherman, F				Polevoda, B; Span, L; Sherman, F			The yeast translation release factors Mrf1p and Sup45p (eRF1) are methylated, respectively, by the methyltransferases Mtq1p and Mtq2p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE-CHAIN TERMINATION; ESCHERICHIA-COLI; GGQ MOTIF; SACCHAROMYCES-CEREVISIAE; PROTEIN METHYLATION; SEQUENCE MOTIFS; GTPASE ACTIVITY; MUTANT LACKING; IN-VIVO; GENE	The translation release factors (RFs) RF1 and RF2 of Escherichia coli are methylated at the N-5-glutamine of the GGQ motif by PrmC methyltransferase. This motif is conserved in organisms from bacteria to higher eukaryotes. The Saccharomyces cerevisiae RFs, mitochondrial Mrf1p and cytoplasmic Sup45p (eRF1), have sequence similarities to the bacterial RFs, including the potential site of glutamine methylation in the GGQ motif. A computational analysis revealed two yeast proteins, Mtq1p and Mtq2p, that have strong sequence similarity to PrmC. Mass spectrometric analysis demonstrated that Mtq1p and Mtq2p methylate Mrf1p and Sup45p, respectively, in vivo. A tryptic peptide of Mrf1p, GGQHVNTTD-SAVR, containing the GGQ motif was found to be similar to 50% methylated at the glutamine residue in the normal strain but completely unmodified in the peptide from mtq1-Delta. Moreover, Mtq1p methyltransferase activity was observed in an in vitro assay. In similar experiments, it was determined that Mtq2p methylates Sup45p. The Sup45p methylation by Mtq2p was recently confirmed independently (Heurgue-Hamard, V., Champ, S., Mora, L., Merkulova-Rainon, T., Kisselev, L. L., and Buckingham, R. H. (2005) J. Biol. Chem. 280, 2439 - 2445). Analysis of the deletion mutants showed that although mtq1-Delta had only moderate growth defects on nonfermentable carbon sources, the mtq2-Delta had multiple phenotypes, including cold sensitivity and sensitivity to translation fidelity antibiotics paromomycin and geneticin, to high salt and calcium concentrations, to polymyxin B, and to caffeine. Also, the mitochondrial mit(-) mutation, cox2-V25, containing a premature stop mutation, was suppressed by mtq1-Delta. Most interestingly, the mtq2-Delta was significantly more resistant to the anti-microtubule drugs thiabendazole and benomyl, suggesting that Mtq2p may also methylate certain microtubule-related proteins.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Sherman, F (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	Fred_Sherman@urmc.rochester.edu	Polevoda, Bogdan/A-4880-2008		NIGMS NIH HHS [GM12702] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askarian-Amiri ME, 2000, J BIOL CHEM, V275, P17241, DOI 10.1074/jbc.M910448199; BEAUDET AL, 1971, P NATL ACAD SCI USA, V68, P619, DOI 10.1073/pnas.68.3.619; BOGUSLAWSKI G, 1985, MOL GEN GENET, V199, P401, DOI 10.1007/BF00330749; BOGUTA M, 1986, J GEN MICROBIOL, V132, P2087; Bonnefoy N, 2000, MOL GEN GENET, V262, P1036, DOI 10.1007/PL00008646; Borchsenius AS, 2000, CURR GENET, V37, P285, DOI 10.1007/s002940050529; Clarke S, 2002, P NATL ACAD SCI USA, V99, P1104, DOI 10.1073/pnas.042004099; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Dincbas-Renqvist V, 2000, EMBO J, V19, P6900, DOI 10.1093/emboj/19.24.6900; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; Frolova LY, 2000, RNA, V6, P381, DOI 10.1017/S135583820099143X; Grant PA, 2001, GENOME BIOL, V2; Heurgue-Hamard V, 2005, J BIOL CHEM, V280, P2439, DOI 10.1074/jbc.M407252200; Heurgue-Hamard V, 2002, EMBO J, V21, P769, DOI 10.1093/emboj/21.4.769; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Inge-Vechtomov S, 2003, BIOL CELL, V95, P195, DOI 10.1016/S0248-4900(03)00035-2; JUKES TH, 1993, COMP BIOCHEM PHYS B, V106, P489, DOI 10.1016/0305-0491(93)90122-L; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; Kim C, 2001, J MOL BIOL, V307, P119, DOI 10.1006/jmbi.2000.4389; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; LHOEST J, 1981, EUR J BIOCHEM, V121, P33, DOI 10.1111/j.1432-1033.1981.tb06425.x; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; LHOEST J, 1977, MOL GEN GENET, V154, P175, DOI 10.1007/BF00330833; LHOEST J, 1990, PROTEIN METHYLATION, P61; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; MILMAN G, 1969, P NATL ACAD SCI USA, V63, P183, DOI 10.1073/pnas.63.1.183; Mora L, 2003, MOL MICROBIOL, V47, P267, DOI 10.1046/j.1365-2958.2003.03301.x; Nakahigashi K, 2002, P NATL ACAD SCI USA, V99, P1473, DOI 10.1073/pnas.032488499; PAIK WK, 1990, PROTEIN METHYLATION, P1; PEL HJ, 1992, NUCLEIC ACIDS RES, V20, P6339, DOI 10.1093/nar/20.23.6339; Polevoda B, 2003, J BIOL CHEM, V278, P30686, DOI 10.1074/jbc.M304690200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schubert HL, 2003, BIOCHEMISTRY-US, V42, P5592, DOI 10.1021/bi034026p; SCOLNICK E, 1968, P NATL ACAD SCI USA, V61, P768, DOI 10.1073/pnas.61.2.768; Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; STANSFIELD I, 1995, TRENDS BIOCHEM SCI, V20, P489, DOI 10.1016/S0968-0004(00)89113-6; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Tate WP, 1996, PROG NUCLEIC ACID RE, V52, P293, DOI 10.1016/S0079-6603(08)60970-8; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Towpik J, 2004, J BIOL CHEM, V279, P14096, DOI 10.1074/jbc.M312856200; Valouev IA, 2004, MOL MICROBIOL, V53, P687, DOI 10.1111/j.1365-2958.2004.04157.x; Valouev IA, 2002, CELL MOTIL CYTOSKEL, V52, P161, DOI 10.1002/cm.10040; Yang Z, 2004, J MOL BIOL, V340, P695, DOI 10.1016/j.jmb.2004.05.019; Zavialov AV, 2002, MOL CELL, V10, P789, DOI 10.1016/S1097-2765(02)00691-3; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6; Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	51	43	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2562	2571		10.1074/jbc.M507651200	http://dx.doi.org/10.1074/jbc.M507651200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16321977	hybrid			2022-12-27	WOS:000234931800019
J	Li, L; Li, ZG; Howley, PM; Sacks, DB				Li, L; Li, ZG; Howley, PM; Sacks, DB			E6AP and calmodulin reciprocally regulate estrogen receptor stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; PROTEIN; PROTEASOME; ESTRADIOL; ASSOCIATION; CANCER; INHIBITION; FAMILY; ALPHA; E6-AP	Estrogen promotes the proliferation of human breast epithelial cells by interacting with the estrogen receptor ( ER). Physiological responses of cells to estrogen are regulated in part by degradation of the ER. Previous studies revealed that calmodulin binds directly to the ER, thereby enhancing its stability. Consistent with these findings, cell-permeable calmodulin antagonists dramatically reduced the number of ER in MCF-7 human breast epithelial cells. Here we investigated the molecular mechanism by which calmodulin attenuates ER degradation. MG132 and lactacystin, inhibitors of the ubiquitin-proteasome pathway, prevented the calmodulin antagonist CGS9343B from reducing the amount of ER in MCF-7 cells. In contrast, protease inhibitors afforded no protection. Moreover, CGS9343B enhanced ER ubiquitination. A point mutant ER construct that is unable to bind calmodulin, termed ER Delta CaM, is ubiquitinated to a greater extent than wild type ER. The ubiquitin-protein isopeptide ligase E6-associated protein (E6AP) associated with and promoted the degradation of ER. The possible convergence of calmodulin and E6AP on ER degradation was examined. ER Delta CaM bound E6AP with higher affinity than that of wild type ER. Moreover, calmodulin attenuated the in vitro interaction between ER and E6AP in a Ca2+-dependent manner. Collectively, our data reveal that E6AP is a component of ER degradation via the ubiquitin-proteasome pathway and that Ca2+/calmodulin modulates this degradation mechanism. These results have potential implications for the development of selectively targeted therapeutic agents for breast cancer.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, DB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Thom 530,75 Francis St, Boston, MA 02115 USA.	dsacks@rics.bwh.harvard.edu		Sacks, David/0000-0003-3100-0735; Howley, Peter/0000-0002-8668-9579	NATIONAL CANCER INSTITUTE [R01CA093645, R37CA064888] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA 64888, CA 93645] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Biswas DK, 1998, J BIOL CHEM, V273, P33817, DOI 10.1074/jbc.273.50.33817; BOUHOUTE A, 1995, BIOCHEM BIOPH RES CO, V208, P748, DOI 10.1006/bbrc.1995.1401; BOUHOUTE A, 1992, BIOCHEM BIOPH RES CO, V184, P1432, DOI 10.1016/S0006-291X(05)80043-9; BOUHOUTE A, 1994, BIOCHEM PHARMACOL, V47, P748, DOI 10.1016/0006-2952(94)90140-6; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; CASTORIA G, 1988, MOL ENDOCRINOL, V2, P167, DOI 10.1210/mend-2-2-167; Cohen P, 1988, CALMODULIN; Das SK, 2000, J BIOL CHEM, V275, P28834, DOI 10.1074/jbc.M003827200; Dickson R B, 2000, J Natl Cancer Inst Monogr, P135; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200; Hatakeyama S, 1997, J BIOL CHEM, V272, P15085, DOI 10.1074/jbc.272.24.15085; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HORIGOME T, 1988, ENDOCRINOLOGY, V123, P2540, DOI 10.1210/endo-123-5-2540; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Li L, 2005, J BIOL CHEM, V280, P13097, DOI 10.1074/jbc.M410642200; Li L, 2003, J BIOL CHEM, V278, P1195, DOI 10.1074/jbc.M210708200; Li ZG, 2001, J BIOL CHEM, V276, P17354, DOI 10.1074/jbc.M010238200; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MIGLIACCIO A, 1984, P NATL ACAD SCI-BIOL, V81, P5921, DOI 10.1073/pnas.81.19.5921; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Newton CJ, 2000, J STEROID BIOCHEM, V73, P29, DOI 10.1016/S0960-0760(00)00047-9; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Pedrero JMG, 2002, MOL ENDOCRINOL, V16, P947; Shao WL, 2004, P NATL ACAD SCI USA, V101, P11599, DOI 10.1073/pnas.0402997101; SINGER AL, 1976, CANCER RES, V36, P60; STROBL JS, 1992, J PHARMACOL EXP THER, V263, P186; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	46	71	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1978	1985		10.1074/jbc.M508545200	http://dx.doi.org/10.1074/jbc.M508545200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314411	hybrid			2022-12-27	WOS:000234760400017
J	Kelly, AE; Kranitz, H; Dotsch, V; Mullins, RD				Kelly, AE; Kranitz, H; Dotsch, V; Mullins, RD			Actin binding to the central domain of WASP/Scar proteins plays a critical role in the activation of the arp2/3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WASP-FAMILY PROTEINS; CONFORMATIONAL-CHANGES; STRUCTURAL BASIS; N-WASP; MOTILITY; THYMOSIN-BETA-4; IDENTIFICATION; NUCLEOTIDE; NUCLEATION; SIGNALS	The Arp2/3 complex nucleates and cross-links actin filaments at the leading edge of motile cells, and its activity is stimulated by C-terminal regions of WASP/Scar proteins, called VCA domains. VCA domains contain a verprolin homology sequence (V) that binds monomeric actin and central (C) and acidic sequences (A) that bind the Arp2/3 complex. Here we show that the C domain binds to monomeric actin with higher affinity (K-d = 10 mu M) than to the Arp2/3 complex (K-d > 200 mu M). Nuclear magnetic resonance spectroscopy reveals that actin binds to the N-terminal half of the C domain and that both the V and C domains can bind actin independently and simultaneously, indicating that they interact with different sites. Mutation of conserved hydrophobic residues in the actin-binding interface of the C domain disrupts activation of the Arp2/3 complex but does not alter affinity for the complex. By chemical cross-linking the C domain interacts with the p40 subunit of the Arp2/3 complex and, by fluorescence polarization anisotropy, the binding of actin and the Arp2/3 complex are mutually exclusive. Our results indicate that both actin and Arp2/3 binding are important for C domain function but that the C domain does not form a static bridge between the two. We propose a model for activation of the Arp2/3 complex in which the C domain first primes the complex by inducing a necessary conformational change and then initiates nucleus assembly by bringing an actin monomer into proximity of the primed complex.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Goethe Univ Frankfurt, Inst Biophys Chem, D-60439 Frankfurt, Germany; Goethe Univ Frankfurt, Ctr Biomol Magnet Resonance, D-60439 Frankfurt, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Goethe University Frankfurt; Goethe University Frankfurt	Mullins, RD (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	dyche@mullinslab.ucsf.edu	Kelly, Alexander/AAZ-8425-2021; Doetsch, Volker/D-5697-2011	Dotsch, Volker/0000-0001-5720-212X; KELLY, ALEXANDER/0000-0002-3395-6012	NIGMS NIH HHS [R01 GM061010, R01 GM 61010, R01 GM061010-06] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Beltzner CC, 2004, J MOL BIOL, V336, P551, DOI 10.1016/j.jmb.2003.12.017; Boquet I, 2000, CELL, V102, P797, DOI 10.1016/S0092-8674(00)00068-4; Chereau D, 2005, P NATL ACAD SCI USA, V102, P16644, DOI 10.1073/pnas.0507021102; DAYEL MJ, 2004, PLOS BIOL; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Domanski M, 2004, J BIOL CHEM, V279, P23637, DOI 10.1074/jbc.M311413200; Eadie JS, 2000, J CELL BIOCHEM, V77, P277, DOI 10.1002/(SICI)1097-4644(20000501)77:2<277::AID-JCB10>3.0.CO;2-Q; EGILE C, 2005, PLOS BIOL; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Goley ED, 2004, MOL CELL, V16, P269, DOI 10.1016/j.molcel.2004.09.018; Gouin E, 2005, CURR OPIN MICROBIOL, V8, P35, DOI 10.1016/j.mib.2004.12.013; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Hufner K, 2001, J BIOL CHEM, V276, P35761, DOI 10.1074/jbc.M106520200; Irobi E, 2004, EMBO J, V23, P3599, DOI 10.1038/sj.emboj.7600372; KELLEHER JF, 1995, J CELL BIOL, V131, P385, DOI 10.1083/jcb.131.2.385; Kelly AE, 2002, J AM CHEM SOC, V124, P12013, DOI 10.1021/ja026121b; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MACLEANFLETCHER S, 1980, BIOCHEM BIOPH RES CO, V96, P18, DOI 10.1016/0006-291X(80)91175-4; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Martin AC, 2005, J CELL BIOL, V168, P315, DOI 10.1083/jcb.200408177; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Mullins RD, 2000, CURR OPIN CELL BIOL, V12, P91, DOI 10.1016/S0955-0674(99)00061-7; Pan F, 2004, J BIOL CHEM, V279, P54629, DOI 10.1074/jbc.M402357200; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Riek R, 2002, J AM CHEM SOC, V124, P12144, DOI 10.1021/ja026763z; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Sept D, 2001, BIOPHYS J, V81, P667, DOI 10.1016/S0006-3495(01)75731-1; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Zalevsky J, 2001, CURR BIOL, V11, P1903, DOI 10.1016/S0960-9822(01)00603-0	39	54	57	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10589	10597		10.1074/jbc.M507470200	http://dx.doi.org/10.1074/jbc.M507470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16403731	Green Accepted, hybrid			2022-12-27	WOS:000236594300091
J	Schumacher, MA; Seidel, G; Hillen, W; Brennan, RG				Schumacher, MA; Seidel, G; Hillen, W; Brennan, RG			Phosphoprotein Crh-Ser(46)-P displays altered binding to CcpA to effect carbon catabolite regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS-HUT; CONTROL PROTEIN CCPA; DNA-BINDING; RESPONSIVE ELEMENTS; CRYSTAL-STRUCTURE; REPRESSION; HPR; CRH; COREPRESSOR; OPERON	In Gram-positive bacteria, the catabolite control protein A (CcpA) functions as the master transcriptional regulator of carbon catabolite repression/regulation (CCR). To effect CCR, CcpA binds a phosphoprotein, either HPr-Ser(46)-P or Crh-Ser(46)-P. Although Crh and histidine-containing protein (HPr) are structurally homologous, CcpA binds Crh-Ser(46)-P more weakly than HPr-Ser(46)-P. Moreover, Crh can form domain-swapped dimers, which have been hypothesized to be functionally relevant in CCR. To understand the molecular mechanism of Crh-Ser(46)-P regulation of CCR, we determined the structure of a CcpA-(Crh-Ser(46)-P)-DNA complex. The structure reveals that Crh-Ser(46)-P does not bind CcpA as a dimer but rather interacts with CcpA as amonomer in a manner similar to that of HPr-Ser(46)-P. The reduced affinity of Crh-Ser(46)-P for CcpA as compared with that of HPr-Ser(46)P is explained by weaker Crh-Ser(46)-P interactions in its contact region I to CcpA, which causes this region to shift away from CcpA. Nonetheless, the interface between CcpA and helix alpha 2 of the second contact region ( contact region II) of Crh-Ser(46)-P is maintained. This latter finding demonstrates that this contact region is necessary and sufficient to throw the allosteric switch to activate cre binding by CcpA.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, Houston, TX 77030 USA; Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Inst Mikrobiol Biochem & Genet, D-91058 Erlangen, Germany	University of Texas System; UTMD Anderson Cancer Center; University of Erlangen Nuremberg	Brennan, RG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rgbrenna@mdanderson.org		Brennan, Richard/0000-0001-7647-485X				Audette GF, 2000, J MOL BIOL, V303, P545, DOI 10.1006/jmbi.2000.4166; Aung-Hilbrich LM, 2002, J MOL BIOL, V319, P77, DOI 10.1016/S0022-2836(02)00245-0; Bell CE, 2000, NAT STRUCT BIOL, V7, P209; Bell CE, 2001, J MOL BIOL, V312, P921, DOI 10.1006/jmbi.2001.5024; Bruckner R, 2002, FEMS MICROBIOL LETT, V209, P141; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; Darbon E, 2001, J MOL MICROB BIOTECH, V3, P439; Favier A, 2002, J MOL BIOL, V317, P131, DOI 10.1006/jmbi.2002.5397; FUJITA Y, 1995, MOL MICROBIOL, V17, P953, DOI 10.1111/j.1365-2958.1995.mmi_17050953.x; Galinier A, 1999, J MOL BIOL, V286, P307, DOI 10.1006/jmbi.1998.2492; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; Gorke B, 2004, J BACTERIOL, V186, P2992, DOI 10.1128/JB.186.10.2992-2995.2004; Gosseringer R, 1997, J MOL BIOL, V266, P665, DOI 10.1006/jmbi.1996.0820; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Henkin TM, 1996, FEMS MICROBIOL LETT, V135, P9; HUECK CJ, 1994, RES MICROBIOL, V145, P503, DOI 10.1016/0923-2508(94)90028-0; Jones BE, 1997, J BIOL CHEM, V272, P26530, DOI 10.1074/jbc.272.42.26530; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Juy M, 2003, J MOL BIOL, V332, P767, DOI 10.1016/S0022-2836(03)00918-5; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; Kalodimos CG, 2002, EMBO J, V21, P2866, DOI 10.1093/emboj/cdf318; Kim JH, 2005, MOL MICROBIOL, V56, P155, DOI 10.1111/j.1365-2958.2005.04496.x; Kim JH, 1998, P NATL ACAD SCI USA, V95, P9590, DOI 10.1073/pnas.95.16.9590; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Miwa Y, 1997, MOL MICROBIOL, V23, P1203, DOI 10.1046/j.1365-2958.1997.2921662.x; Miwa Y, 2001, J BACTERIOL, V183, P5877, DOI 10.1128/JB.183.20.5877-5884.2001; Miwa Y, 2000, NUCLEIC ACIDS RES, V28, P1206, DOI 10.1093/nar/28.5.1206; Moreno MS, 2001, MOL MICROBIOL, V39, P1366, DOI 10.1046/j.1365-2958.2001.02328.x; Poncet S, 2004, BBA-PROTEINS PROTEOM, V1697, P123, DOI 10.1016/j.bbapap.2003.11.018; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; SAIER MH, 1995, TRENDS BIOCHEM SCI, V20, P267, DOI 10.1016/S0968-0004(00)89041-6; Schumacher MA, 2004, CELL, V118, P731, DOI 10.1016/j.cell.2004.08.027; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Seidel G, 2005, FEBS J, V272, P2566, DOI 10.1111/j.1742-4658.2005.04682.x; Stulke J, 2000, ANNU REV MICROBIOL, V54, P849, DOI 10.1146/annurev.micro.54.1.849; STULKE J, 1998, J MOL BIOL, V303, P545; Turinsky AJ, 1998, J BACTERIOL, V180, P5961, DOI 10.1128/JB.180.22.5961-5967.1998; WEICKERT MJ, 1990, P NATL ACAD SCI USA, V87, P6238, DOI 10.1073/pnas.87.16.6238; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; WRAY LV, 1994, J BACTERIOL, V176, P1894, DOI 10.1128/jb.176.7.1894-1902.1994; Zalieckas JM, 1998, MOL MICROBIOL, V27, P1031, DOI 10.1046/j.1365-2958.1998.00751.x; Zalieckas JM, 1999, J BACTERIOL, V181, P2883, DOI 10.1128/JB.181.9.2883-2888.1999	46	18	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6793	6800		10.1074/jbc.M509977200	http://dx.doi.org/10.1074/jbc.M509977200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16316990	hybrid			2022-12-27	WOS:000236030800078
J	Clohessy, JG; Zhuang, JG; de Boer, J; Gil-Gomez, G; Brady, HJM				Clohessy, JG; Zhuang, JG; de Boer, J; Gil-Gomez, G; Brady, HJM			Mcl-1 interacts with truncated bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBERS; BH3-ONLY PROTEINS; IMMUNOHISTOCHEMICAL ANALYSIS; MITOCHONDRIAL-MEMBRANE; CONFORMATIONAL-CHANGE; DEATH RECEPTORS; BH3 DOMAINS; CELL-DEATH; T-CELLS; BAX	Engagement of death receptors such as tumor necrosis factor-R1 and Fas brings about the cleavage of cytosolic Bid to truncated Bid (tBid), which translocates to mitochondria to activate Bax/Bak, resulting in the release of cytochrome c. The mechanism underlying the activation, however, is not fully understood. Here, we have identified the anti-apoptotic Bcl-2 family member Mcl-1 as a potent tBid-binding partner. Site-directed mutagenesis reveals that the Bcl-2 homology (BH) 3 domain of tBid is essential for binding to Mcl-1, whereas all threeBHdomains (BH1, BH2, and BH3) of Mcl-1 are required for interaction with tBid. In vitro studies using isolated mitochondria and recombinant proteins demonstrate that Mcl-1 strongly inhibits tBid-induced cytochrome c release. In addition to its ability to interact directly with Bax and Bak, tBid also binds Mcl-1 and displaces Bak from the Mcl-1-Bak complex. Importantly, overexpression of Mcl-1 confers resistance to the induction of apoptosis by both TRAIL and tumor necrosis factor-alpha in HeLa cells, whereas targeting Mcl-1 by RNA interference sensitizes HeLa cells to TRAIL-induced apoptosis. Therefore, our study demonstrates a novel regulation of tBid by Mcl-1 through protein-protein interaction in apoptotic signaling from death receptors to mitochondria.	Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; UCL, Great Ormond St Hosp Children, London WC1N 1EH, England; Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-03003 Barcelona, Spain	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Pompeu Fabra University	Brady, HJM (corresponding author), Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	h.brady@ich.ucl.ac.uk	de Boer, Jasper/B-5067-2013; Gil-Gomez, G/H-6307-2014	de Boer, Jasper/0000-0002-3220-8776; Gil-Gomez, G/0000-0002-9790-7308; Clohessy, John/0000-0001-5186-9775; Zhuang, Jianguo/0000-0003-3245-0789; Brady, Hugh/0000-0002-3152-067X				Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clohessy JG, 2004, BRIT J HAEMATOL, V125, P655, DOI 10.1111/j.1365-2141.2004.04949.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Edwards SW, 2004, BIOCHEM SOC T, V32, P489, DOI 10.1042/BST0320489; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Okita H, 1998, BBA-GENE STRUCT EXPR, V1398, P335, DOI 10.1016/S0167-4781(98)00059-1; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Rinkenberger JL, 2000, GENE DEV, V14, P23; Schulze-Bergkamen H, 2004, HEPATOLOGY, V39, P645, DOI 10.1002/hep.20138; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Seol DW, 2001, CANCER RES, V61, P1138; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weng CJ, 2005, J BIOL CHEM, V280, P10491, DOI 10.1074/jbc.M412819200; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	46	149	158	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5750	5759		10.1074/jbc.M505688200	http://dx.doi.org/10.1074/jbc.M505688200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16380381	hybrid			2022-12-27	WOS:000235568900053
J	Lalle, M; Salzano, AM; Crescenzi, M; Pozio, E				Lalle, M; Salzano, AM; Crescenzi, M; Pozio, E			The Giardia duodenalis 14-3-3 protein is post-translationally modified by phosphorylation and polyglycylation of the C-terminal tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TUBULIN; SUBCELLULAR-LOCALIZATION; FUNCTIONAL SPECIFICITY; 14-3-3-PROTEIN FAMILY; AMPHIPATHIC GROOVE; TOXOPLASMA-GONDII; CRYSTAL-STRUCTURE; ALPHA-TUBULIN; LAMBLIA; ISOFORM	The flagellated protozoan Giardia duodenalis (syn. lamblia or intestinalis) has been chosen as a model parasite to further investigate the multifunctional 14-3-3s, a family of highly conserved eukaryotic proteins involved in many cellular processes, such as cell cycle, differentiation, apoptosis, and signal transduction pathways. We confirmed the presence of a single 14-3-3 homolog gene (g14-3-3) by an in silico screening of the complete genome of Giardia, and we demonstrated its constitutive transcription throughout the life stages of the parasite. We cloned and expressed the g14-3-3 in bacteria, and by protein-protein interaction assays we demonstrated that it is a functional 14-3-3. Using an anti-peptide antibody raised against a unique 18-amino acid sequence at the N terminus, we observed variations both in the intracellular localization and in the molecular size of the native g14-3-3 during the conversion of Giardia from trophozoites to the cyst stage. An affinity chromatography, based on the 14-3-3 binding to the polypeptide difopein, was set to purify the native g14-3-3. By matrix-assisted laser desorption ionization mass spectroscopy analysis, we showed that polyglycylation, an unusual post-translational modification described only for tubulin, occurred at the extreme C terminus of the native g14-3-3 on Glu(246), Glu(247), or both and that the Thr(214), located in the loop between helices 8 and 9, is phosphorylated. We propose that the addition of the polyglycine chain can promote the binding of g14-3-3 to alternative ligands and that the differential rate of polyglycylation/deglycylation during the encystation process can act as a novel mechanism to regulate the intracellular localization of g14-3-3.	Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, I-00161 Rome, Italy; Ist Super Sanita, Dept Environm & Primary Prevent, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Lalle, M (corresponding author), Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.	marco.lalle@iss.it	Salzano, Anna Maria/C-7139-2012; Crescenzi, Marco/J-3603-2018; Lalle, Marco/O-2287-2015	Salzano, Anna Maria/0000-0001-7192-8760; Crescenzi, Marco/0000-0003-0156-1494; Lalle, Marco/0000-0001-5168-2150				Aducci P, 2002, IUBMB LIFE, V53, P49, DOI 10.1080/15216540210813; Aitken A, 2002, PLANT MOL BIOL, V50, P993, DOI 10.1023/A:1021261931561; Al-Khedery B, 1999, MOL BIOCHEM PARASIT, V102, P117, DOI 10.1016/S0166-6851(99)00090-0; Assossou O, 2003, FEMS MICROBIOL LETT, V224, P161, DOI 10.1016/S0378-1097(03)00479-8; Athwal GS, 2002, PLANT J, V29, P119, DOI 10.1046/j.0960-7412.2001.01200.x; Benzinger A, 2005, CELL RES, V15, P219, DOI 10.1038/sj.cr.7290290; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bre MH, 1996, J CELL SCI, V109, P727; Campanati L, 1999, BIOL CELL, V91, P499, DOI 10.1016/S0248-4900(00)88206-4; Ellis JG, 2003, J BIOL CHEM, V278, P1936, DOI 10.1074/jbc.M209274200; Hedges SB, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-2; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; KANE AV, 1991, J PARASITOL, V77, P974, DOI 10.2307/3282752; Kjellstrom S, 2004, ANAL CHEM, V76, P5109, DOI 10.1021/ac0400257; Koyama T, 2001, VET PARASITOL, V96, P65, DOI 10.1016/S0304-4017(00)00424-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalle M, 2005, PLANT MOL BIOL, V59, P713, DOI 10.1007/s11103-005-0862-x; Lally NC, 1996, MOL BIOCHEM PARASIT, V75, P169, DOI 10.1016/0166-6851(95)02530-8; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Lloyd D, 2002, TRENDS MICROBIOL, V10, P122, DOI 10.1016/S0966-842X(02)02306-5; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; McArthur AG, 2000, FEMS MICROBIOL LETT, V189, P271, DOI 10.1111/j.1574-6968.2000.tb09242.x; Moorhead G, 1999, PLANT J, V18, P1, DOI 10.1046/j.1365-313X.1999.00417.x; MOSS DM, 1990, J CLIN MICROBIOL, V28, P254, DOI 10.1128/JCM.28.2.254-257.1990; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Pan SQ, 1999, PLANT CELL, V11, P1591, DOI 10.1105/tpc.11.8.1591; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Redeker V, 2005, J BIOL CHEM, V280, P596, DOI 10.1074/jbc.M408324200; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; Rubio MP, 2004, BIOCHEM J, V379, P395, DOI 10.1042/bj20031797; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Siles-Lucas MD, 2003, TRENDS PARASITOL, V19, P575, DOI 10.1016/j.pt.2003.10.003; Slavin I, 2002, MOL BIOCHEM PARASIT, V122, P95, DOI 10.1016/S0166-6851(02)00065-8; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Testerink C, 2002, PLANT MOL BIOL, V50, P535, DOI 10.1023/A:1019869900285; Thazhath R, 2002, NAT CELL BIOL, V4, P256, DOI 10.1038/ncb764; Thompson RCA, 2000, INT J PARASITOL, V30, P1259, DOI 10.1016/S0020-7519(00)00127-2; van Hemert MJ, 2004, J CELL SCI, V117, P1411, DOI 10.1242/jcs.00990; Vinh J, 1999, BIOCHEMISTRY-US, V38, P3133, DOI 10.1021/bi982304s; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Wang WF, 1996, J MOL EVOL, V43, P384; Weber K, 1997, FEBS LETT, V419, P87, DOI 10.1016/S0014-5793(97)01436-1; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Xia L, 2000, J CELL BIOL, V149, P1097, DOI 10.1083/jcb.149.5.1097; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang H, 2003, MOL BIOCHEM PARASIT, V128, P167, DOI 10.1016/S0166-6851(03)00072-0	52	42	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5137	5148		10.1074/jbc.M509673200	http://dx.doi.org/10.1074/jbc.M509673200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368691	hybrid			2022-12-27	WOS:000235426200068
J	Phillips-Mason, PJ; Gates, TJ; Major, DL; Sacks, DB; Brady-Kalnay, SM				Phillips-Mason, PJ; Gates, TJ; Major, DL; Sacks, DB; Brady-Kalnay, SM			The receptor protein-tyrosine phosphatase PTP mu interacts with IQGAP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; HOMOPHILIC BINDING-SITE; RASGAP-RELATED PROTEIN; ACTIN STRESS FIBERS; RHO-FAMILY GTPASES; NEURITE OUTGROWTH; RPTP-MU; BETA-CATENIN; PKC-DELTA; IN-VIVO	The receptor protein-tyrosine phosphatase PTP mu is a member of the Ig superfamily of cell adhesion molecules. The extracellular domain of PTP mu contains motifs commonly found in cell adhesion molecules. The intracellular domain of PTP mu contains two conserved catalytic domains, only the membrane-proximal domain has catalytic activity. The unique features of PTP mu make it an attractive molecule to transduce signals upon cell-cell contact. PTP mu has been shown to regulate cadherin-mediated cell adhesion, neurite outgrowth, and axon guidance. Protein kinase C is a component of the PTP mu signaling pathway utilized to regulate these events. To aid in the further characterization of PTP mu signaling pathways, we used a series of GST-PTP mu fusion proteins, including catalytically inactive and substrate trapping mutants, to identify PTP mu-interacting proteins. We identified IQGAP1, a known regulator of the Rho GTPases, Cdc42 and Rac1, as a novel PTP mu-interacting protein. We show that this interaction is due to direct binding. In addition, we demonstrate that amino acid residues 765-958 of PTP mu, which include the juxtamembrane domain and 35 residues of the first phosphatase domain, mediate the binding to IQGAP1. Furthermore, we demonstrate that constitutively active Cdc42, and to a lesser extent Rac1, enhances the interaction of PTP mu and IQGAP1. These data indicate PTP mu may regulate Rho-GTPase-dependent functions of IQGAP1 and suggest that IQGAP1 is a component of the PTP mu signaling pathway. In support of this, we show that a peptide that competes IQGAP1 binding to Rho GTPases blocks PTP mu-mediated neurite outgrowth.	Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Case Western Reserve University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Brady-Kalnay, SM (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	susann.brady-kalnay@case.edu		Sacks, David/0000-0003-3100-0735	NATIONAL CANCER INSTITUTE [R01CA093645] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY011373, R01EY012251] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA93645] Funding Source: Medline; NEI NIH HHS [R01-EY12251, P0-EY11373, R01 EY012251] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Blanchetot C, 2005, METHODS, V35, P44, DOI 10.1016/j.ymeth.2004.07.007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Burden-Gulley SM, 2002, J NEUROSCI, V22, P3615; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chattopadhyay N, 2003, J CELL BIOL, V163, P1351, DOI 10.1083/jcb.200306067; Cismasiu VB, 2004, J BIOL CHEM, V279, P26922, DOI 10.1074/jbc.M313115200; Ensslen SE, 2004, MOL CELL NEUROSCI, V25, P558, DOI 10.1016/j.mcn.2003.12.003; Ensslen-Craig SE, 2005, MOL CELL NEUROSCI, V28, P177, DOI 10.1016/j.mcn.2004.08.011; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fukada M, 2005, METHODS, V35, P54, DOI 10.1016/j.ymeth.2004.07.008; Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Grohmanova K, 2004, J BIOL CHEM, V279, P48495, DOI 10.1074/jbc.M408113200; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hellberg CB, 2002, J BIOL CHEM, V277, P11165, DOI 10.1074/jbc.M112157200; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; Holsinger LJ, 2002, ONCOGENE, V21, P7067, DOI 10.1038/sj.onc.1205858; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; Li ZG, 2005, J BIOL CHEM, V280, P13871, DOI 10.1074/jbc.M413482200; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lui WY, 2005, J CELL PHYSIOL, V202, P49, DOI 10.1002/jcp.20098; Mataraza JM, 2003, J BIOL CHEM, V278, P41237, DOI 10.1074/jbc.M304838200; Mataraza JM, 2003, BIOCHEM BIOPH RES CO, V305, P315, DOI 10.1016/S0006-291X(03)00759-9; Mateer SC, 2002, J BIOL CHEM, V277, P12324, DOI 10.1074/jbc.M109535200; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rosdahl JA, 2003, J NEUROBIOL, V56, P199, DOI 10.1002/neu.10231; Rosdahl JA, 2002, MOL CELL NEUROSCI, V19, P292, DOI 10.1006/mcne.2001.1071; Roy M, 2004, J BIOL CHEM, V279, P17329, DOI 10.1074/jbc.M308405200; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VIELMETTER J, 1990, EXP BRAIN RES, V81, P283; WALTER J, 1987, DEVELOPMENT, V101, P909; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	66	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4903	4910		10.1074/jbc.M506414200	http://dx.doi.org/10.1074/jbc.M506414200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380380	hybrid			2022-12-27	WOS:000235426200041
J	Tanemura, K; Chui, DH; Fukuda, T; Murayama, M; Park, JM; Akagi, T; Tatebayashi, Y; Miyasaka, T; Kimura, T; Hashikawa, T; Nakano, Y; Kudo, T; Takeda, M; Takashima, A				Tanemura, K; Chui, DH; Fukuda, T; Murayama, M; Park, JM; Akagi, T; Tatebayashi, Y; Miyasaka, T; Kimura, T; Hashikawa, T; Nakano, Y; Kudo, T; Takeda, M; Takashima, A			Formation of Tau inclusions in knock-in mice with familial Alzheimer disease (FAD) mutation of presenilin 1 (PS1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED HELICAL FILAMENTS; FRONTOTEMPORAL DEMENTIA; AMYLOID DEPOSITION; CELL-LINES; A-BETA; NEURODEGENERATION; ACCUMULATION; ACTIVATION; PROTEIN	Mutations in the presenilin 1 ( PS1) gene are responsible for the early onset of familial Alzheimer disease ( FAD). Accumulating evidence shows that PS1 is involved in gamma-secretase activity and that FAD-associated mutations of PS1 commonly accelerate A beta(1-42) production, which causes Alzheimer disease ( AD). Recent studies suggest, however, that PS1 is involved not only in A beta production but also in other processes that lead to neurodegeneration. To better understand the causes of neurodegeneration linked to the PS1 mutation, we analyzed the development of tau pathology, another key feature of AD, in PS1 knock-in mice. Hippocampal samples taken from FAD mutant ( I213T) PS1 knock-in mice contained hyperphosphorylated tau that reacted with various phosphodependent tau antibodies and with Alz50, which recognizes the conformational change of PHF tau. Some neurons exhibited Congo red birefringence and Thioflavin T reactivity, both of which are histological criteria for neurofibrillary tangles ( NFTs). Biochemical analysis of the samples revealed SDS-insoluble tau, which under electron microscopy examination, resembled tau fibrils. These results indicate that our mutant PS1 knock-in mice exhibited NFT-like tau pathology in the absence of A beta deposition, suggesting that PS1 mutations contribute to the onset of AD not only by enhancing A beta(1-42) production but by also accelerating the formation and accumulation of filamentous tau.	RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama 3510198, Japan; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan; Osaka Univ, Grad Sch Med, Dept Psychiat & Behav Sci & Environm Med, Suita, Osaka 5650871, Japan	RIKEN; RIKEN; Osaka University	Takashima, A (corresponding author), RIKEN, Brain Sci Inst, Lab Alzheimers Dis, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	kenneth@brain.riken.jp						Amtul Z, 2002, NEUROBIOL DIS, V9, P269, DOI 10.1006/nbdi.2001.0473; Baki L, 2004, EMBO J, V23, P2586, DOI 10.1038/sj.emboj.7600251; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Chang PT, 2000, BRAIN RES PROTOC, V6, P6, DOI 10.1016/S1385-299X(00)00031-3; CRUTS M, 1995, HUM MOL GENET, V4, P2363, DOI 10.1093/hmg/4.12.2363; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dermaut B, 2004, ANN NEUROL, V55, P617, DOI 10.1002/ana.20083; Evin G, 2002, NEUROREPORT, V13, P719, DOI 10.1097/00001756-200204160-00036; Gomez-Isla T, 1999, BRAIN, V122, P1709, DOI 10.1093/brain/122.9.1709; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; IQBAL K, 1991, NEUROBIOL AGING, V12, P357, DOI 10.1016/0197-4580(91)90022-C; Kang DE, 2005, J BIOL CHEM, V280, P31537, DOI 10.1074/jbc.M500833200; Klein AM, 1999, ANN NY ACAD SCI, V893, P314, DOI 10.1111/j.1749-6632.1999.tb07845.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Morelli L, 1999, CELL TISSUE RES, V298, P225, DOI 10.1007/s004419900109; Murayama O, 1997, NEUROSCI LETT, V229, P61, DOI 10.1016/S0304-3940(97)00417-5; Nakano Y, 1999, EUR J NEUROSCI, V11, P2577, DOI 10.1046/j.1460-9568.1999.00698.x; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Siman R, 2000, J NEUROSCI, V20, P8717; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; St George-Hyslop PH, 2005, CR BIOL, V328, P119, DOI 10.1016/j.crvi.2004.10.013; Sun XY, 2002, NEUROBIOL AGING, V23, P195, DOI 10.1016/S0197-4580(01)00265-2; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tanemura K, 2002, J NEUROSCI, V22, P133, DOI 10.1523/JNEUROSCI.22-01-00133.2002; Tang-Wai D, 2002, DEMENT GERIATR COGN, V14, P13, DOI 10.1159/000058328; Tatebayashi Y, 2002, P NATL ACAD SCI USA, V99, P13896, DOI 10.1073/pnas.202205599; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; Yoshiyama Y, 2001, Curr Neurol Neurosci Rep, V1, P413, DOI 10.1007/s11910-001-0100-0; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2	33	43	48	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5037	5041		10.1074/jbc.M509145200	http://dx.doi.org/10.1074/jbc.M509145200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377636	hybrid			2022-12-27	WOS:000235426200057
J	Ulrichts, H; Udvardy, MS; Lenting, PJ; Pareyn, I; Vandeputte, N; Vanhoorelbeke, K; Deckmyn, H				Ulrichts, H; Udvardy, MS; Lenting, PJ; Pareyn, I; Vandeputte, N; Vanhoorelbeke, K; Deckmyn, H			Shielding of the A1 domain by the D ' D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR DOMAIN; MONOCLONAL-ANTIBODY; FACTOR-VIII; BINDING DOMAIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ALPHA-CHAIN; AMINO-ACIDS; COLLAGEN; COMPLEX	Soluble von Willebrand factor (VWF) has a low affinity for platelet glycoprotein (GP) Ib alpha and needs immobilization and/or high shear stress to enable binding of its A1 domain to the receptor. The previously described anti-VWF monoclonal antibody 1C1E7 enhances VWF/GPIb alpha binding and recognizes an epitope in the amino acids 764-1035 region in the N-terminal D'D3 domains. In this study we demonstrated that the D'D3 region negatively modulates the VWF/GPIb-IX-V interaction; (i) deletion of the D'D3 region in VWF augmented binding to GPIb alpha, suggesting an inhibitory role for this region, (ii) the isolated D'D3 region inhibited the GPIb alpha interaction of a VWF deletion mutant lacking this region, indicating that intramolecular interactions limit the accessibility of the A1 domain, (iii) using a panel of anti-VWF monoclonal antibodies, we next showed that the D'D3 region is in close proximity with the A1 domain in soluble VWF but not when VWF was immobilized; (iv) destroying the epitope of 1C1E7 resulted in a mutant VWF with an increased affinity for GPIb alpha. Our results support a model of domain translocation in VWF that allows interaction with GPIb alpha. The suggested shielding interaction of the A1 domain by the D'D3 region then becomes disrupted by VWF immobilization.	Katholieke Univ Leuven, Lab Thrombosis Res, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium; Univ Debrecen, Fac Med, Dept Clin Biochem & Mol Pathol, H-4012 Debrecen, Hungary; Univ Utrecht, Med Ctr, Dept Haematol, Lab Thrombosis & Haemostasis, NL-3584 CX Utrecht, Netherlands	KU Leuven; University of Debrecen; Utrecht University	Deckmyn, H (corresponding author), Katholieke Univ Leuven, Lab Thrombosis Res, Interdisciplinary Res Ctr, Campus Kortrijk,E Sabbelaan 53, B-8500 Kortrijk, Belgium.	Hans.Deckmyn@kuleuven-kortrijk.br	Lenting, Peter/AAH-5663-2019; Deckmyn, Hans/L-9434-2015; Deckmyn, Hans/N-8932-2019; Lenting, Peter/F-8269-2013	Lenting, Peter/0000-0002-7937-3429; Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; Lenting, Peter/0000-0002-7937-3429; Udvardy, Miklos Laszlo/0000-0002-0021-1225; Vanhoorelbeke, Karen/0000-0003-2288-8277				ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; Bendetowicz AV, 1999, J BIOL CHEM, V274, P12300, DOI 10.1074/jbc.274.18.12300; Depraetere H, 1998, BLOOD, V91, P3792; Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Esch JSA, 1997, BLOOD, V90, P4425, DOI 10.1182/blood.V90.11.4425.4425_4425_4437; ESCH SA, 2005, BRIT J HAEMATOL, V128, P82; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; GOUDEMAND J, 1977, PATHOL BIOL, V25, P241; GRALNICK HR, 1992, P NATL ACAD SCI USA, V89, P7880, DOI 10.1073/pnas.89.17.7880; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; LANKHOF H, 1995, BLOOD, V86, P1035, DOI 10.1182/blood.V86.3.1035.bloodjournal8631035; Lenting PJ, 2004, J BIOL CHEM, V279, P12102, DOI 10.1074/jbc.M310436200; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; MATSUSHITA T, 1995, J BIOL CHEM, V270, P13406, DOI 10.1074/jbc.270.22.13406; Meyer D, 2001, BEST PRACT RES CL HA, V14, P349, DOI 10.1053/beha.2001.0137; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; MOHRI H, 1988, J BIOL CHEM, V263, P17901; Nakayama T, 2002, J BIOL CHEM, V277, P22063, DOI 10.1074/jbc.M201327200; Novak L, 2002, BLOOD, V99, P2070, DOI 10.1182/blood.V99.6.2070; Obert B, 1999, BLOOD, V93, P1959, DOI 10.1182/blood.V93.6.1959.406k01_1959_1968; PIETU G, 1989, BIOCHEM BIOPH RES CO, V163, P618, DOI 10.1016/0006-291X(89)92182-7; READ MS, 1989, BLOOD, V74, P1031; Ruggeri ZM, 2002, NAT MED, V8, P1227, DOI 10.1038/nm1102-1227; RUGGERI ZM, 1981, BLOOD, V57, P1140; Sblattero D, 1998, IMMUNOTECHNOLOGY, V3, P271, DOI 10.1016/S1380-2933(97)10004-5; Siedlecki CA, 1996, BLOOD, V88, P2939, DOI 10.1182/blood.V88.8.2939.bloodjournal8882939; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; STAELENS S, 2005, IN PRESS MOL IMMUNOL; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; SUGIMOTO M, 1991, BIOCHEMISTRY-US, V30, P5202, DOI 10.1021/bi00235a013; SUGIMOTO M, 1993, J BIOL CHEM, V268, P12185; TORNAI I, 1993, J CLIN INVEST, V91, P273, DOI 10.1172/JCI116181; Ulrichts H, 2005, J THROMB HAEMOST, V3, P552, DOI 10.1111/j.1538-7836.2005.01209.x; Ulrichts H, 2004, J THROMB HAEMOST, V2, P1622, DOI 10.1111/j.1538-7836.2004.00865.x; Ulrichts H, 2003, ARTERIOSCL THROM VAS, V23, P1302, DOI 10.1161/01.ATV.0000079510.23517.43; van der Plas RM, 2000, THROMB HAEMOSTASIS, V84, P1005; Vanhoorelbeke K, 2003, J BIOL CHEM, V278, P37815, DOI 10.1074/jbc.M304289200; Vanhoorelbeke K, 2000, THROMB HAEMOSTASIS, V83, P107; VERMYLEN J, 1973, NATURE, V244, P167, DOI 10.1038/244167a0; VICENTE V, 1990, J BIOL CHEM, V265, P274	43	101	109	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4699	4707		10.1074/jbc.M513314200	http://dx.doi.org/10.1074/jbc.M513314200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373331	Green Published, hybrid			2022-12-27	WOS:000235426200018
J	Vos, MD; Dallol, A; Eckfeld, K; Allen, NPC; Donninger, H; Hesson, LB; Calvisi, D; Latif, F; Clark, GJ				Vos, MD; Dallol, A; Eckfeld, K; Allen, NPC; Donninger, H; Hesson, LB; Calvisi, D; Latif, F; Clark, GJ			The RASSF1A tumor suppressor activates Bax via MOAP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIGENETIC INACTIVATION; RAS; FAMILY; PROTEIN; BREAST; NORE1; GENE; IDENTIFICATION; EFFECTOR; KINASE	The novel tumor suppressor RASSF1A is frequently inactivated during human tumorigenesis by promoter methylation. RASSF1A may serve as a node in the integration of signaling pathways controlling a range of critical cellular functions including cell cycle, genomic instability, and apoptosis. The mechanism of action of RASSF1A remains under investigation. We now identify a novel pathway connecting RASSF1A to Bax via the Bax binding protein MOAP-1. RASSF1A and MOAP-1 interact directly, and this interaction is enhanced by the presence of activated K-Ras. RASSF1A can activate Bax via MOAP-1. Moreover, activated K-Ras, RASSF1A, and MOAP-1 synergize to induce Bax activation and cell death. Analysis of a tumor-derived point mutant of RASSF1A showed that the mutant was defective for the MOAP-1 interaction and for Bax activation. Moreover, inhibition of RASSF1A by shRNA impaired the ability of K-Ras to activate Bax. Thus, we identify a novel pro-apoptotic pathway linking K-Ras, RASSF1A and Bax that is specifically impaired in some human tumors.	NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA; Univ Sassari, Dept Biomed Sci, I-07110 Sassari, Italy; Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Sassari; University of Birmingham	Clark, GJ (corresponding author), NCI, Dept Cell & Canc Biol, 9610 Med Ctr Dr, Rockville, MD 20850 USA.	gclark@mail.nih.gov	Donninger, Howard/I-9874-2019; Dallol, Ashraf/H-8661-2012	Donninger, Howard/0000-0002-8589-1660; Dallol, Ashraf/0000-0002-8803-228X				Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Choi JA, 2004, ONCOGENE, V23, P9, DOI 10.1038/sj.onc.1206982; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Ke HN, 2004, EXP CELL RES, V298, P329, DOI 10.1016/j.yexcr.2004.04.031; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kiel C, 2005, J MOL BIOL, V348, P759, DOI 10.1016/j.jmb.2005.02.046; Kuzmin I, 2002, CANCER RES, V62, P3498; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tan KO, 2001, J BIOL CHEM, V276, P2802, DOI 10.1074/jbc.M008955200; Tommasi S, 2005, CANCER RES, V65, P92; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174	39	101	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4557	4563		10.1074/jbc.M512128200	http://dx.doi.org/10.1074/jbc.M512128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16344548	hybrid			2022-12-27	WOS:000235426200002
J	Woollhead, AM; Baines, DL				Woollhead, AM; Baines, DL			Forskolin-induced cell shrinkage and apical translocation of functional enhanced green fluorescent protein-human alpha ENaC in H441 lung epithelial cell monolayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; SODIUM-CHANNEL; LIQUID CLEARANCE; GUINEA-PIGS; II CELLS; CAMP; EXPRESSION; TRANSPORT; ABSORPTION; MEMBRANE	Elevation of intracellular cAMP increases fluid re-absorption in the lung by raising amiloride-sensitive Na+ transport through the apically localized epithelial, amiloride-sensitive Na+ channel (ENaC). However, the signaling pathways mediating this response are still not fully understood. We show that inhibition of protein-tyrosine kinase (PTK) with Genistein and protein kinase A (PKA) with KT5720, decreased forskolin-stimulated amiloride-sensitive short circuit current (I-sc) across H441 adult human lung epithelial cell monolayers. KT5720 also decreased basal Isc. Stable expression of green fluorescent protein (GFP)-labeled human alpha ENaC in H441 cells was used to investigate dynamic changes in the cellular localization of this protein in response to forskolin. Reverse transcription-PCR and immunoblotting analysis revealed two clones expressing a truncated (alpha C3-5) and full-length (alpha C3-3) EGFP-h alpha ENaC protein. Only the alpha C3-3 clone displayed dome formation and exhibited a 50% increase in basal and forskolin-stimulated amiloride-sensitive I-sc indicating that the full-length protein was required for functional activity. Apical surface biotinylation and real-time confocal microscopy demonstrated that EGFP-h alpha ENaC (alpha C3-3) translocated to the apical membrane in response to forskolin in a Brefeldin A-sensitive manner. This effect was completely inhibited by Genistein but only partially inhibited by KT5720. Forskolin also induced a reduction in the height of cells within alpha C3-3 monolayers, indicative of cell shrinkage. This effect was inhibited by KT5720 but not by Genistein or Brefeldin A. These data show that forskolin activates PKA-sensitive cell shrinkage in adult human H441 lung epithelial cell monolayers, which induces a PTK-sensitive translocation of EGFP-h alpha ENaC subunits to the apical membrane and increases amiloride-sensitive Na+ transport.	St Georges Univ London, Div Basic Med Sci, Ion Channels & Cell Signaling Ctr, London SW17 0RE, England	St Georges University London	Baines, DL (corresponding author), St Georges Univ London, Div Basic Med Sci, Ion Channels & Cell Signaling Ctr, Cranmer Terrace, London SW17 0RE, England.	d.baines@sgul.ac.uk		Baines, Deborah/0000-0001-7229-0244	Wellcome Trust [068674/Z/02/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blazer-Yost BL, 2004, AM J PHYSIOL-CELL PH, V287, pC1569, DOI 10.1152/ajpcell.00226.2004; Blazer-Yost BL, 2001, AM J PHYSIOL-CELL PH, V281, pC624, DOI 10.1152/ajpcell.2001.281.2.C624; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; BONNY O, 1997, J AM SOC NEPHROL, V8, pM572; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chraibi A, 2001, CELL PHYSIOL BIOCHEM, V11, P115, DOI 10.1159/000047799; Finley N, 1998, J CLIN INVEST, V101, P972, DOI 10.1172/JCI1478; GOODMAN BE, 1989, AM J PHYSIOL, V257, pL86, DOI 10.1152/ajplung.1989.257.2.L86; Helve O, 2004, PEDIATRICS, V113, P1267, DOI 10.1542/peds.113.5.1267; Hosoi K, 2002, JPN J PHYSIOL, V52, P561, DOI 10.2170/jjphysiol.52.561; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Itani OA, 2002, AM J PHYSIOL-LUNG C, V282, pL631, DOI 10.1152/ajplung.00085.2001; Ito Y, 1997, PFLUG ARCH EUR J PHY, V434, P492, DOI 10.1007/s004240050425; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Jain L, 1999, AM J PHYSIOL-LUNG C, V276, pL1046, DOI 10.1152/ajplung.1999.276.6.L1046; Koh G, 2005, ARCH BIOCHEM BIOPHYS, V438, P70, DOI 10.1016/j.abb.2005.03.018; Lazrak A, 2003, AM J PHYSIOL-LUNG C, V285, pL443, DOI 10.1152/ajplung.00412.2002; Marunaka Y, 2000, J KOREAN MED SCI, V15, pS42, DOI 10.3346/jkms.2000.15.S.S42; Moran O, 2005, FEBS LETT, V579, P3979, DOI 10.1016/j.febslet.2005.06.026; Niisato N, 1997, PFLUG ARCH EUR J PHY, V434, P227, DOI 10.1007/s004240050389; Niisato N, 1999, AM J PHYSIOL-LUNG C, V277, pL727, DOI 10.1152/ajplung.1999.277.4.L727; Norlin A, 1999, J PHYSIOL-LONDON, V519, P261, DOI 10.1111/j.1469-7793.1999.0261o.x; OBRODOVICH H, 1991, AM J PHYSIOL, V261, P555; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Ramminger SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL411, DOI 10.1152/ajplung.00407.2003; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SAUMON G, 1987, PFLUG ARCH EUR J PHY, V410, P464, DOI 10.1007/BF00586526; Shlyonsky V, 2005, J BIOL CHEM, V280, P24181, DOI 10.1074/jbc.M413823200; Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200; Thomas CP, 2004, AM J PHYSIOL-LUNG C, V287, pL843, DOI 10.1152/ajplung.00340.2003; WALTERS DV, 1990, J APPL PHYSIOL, V68, P2054, DOI 10.1152/jappl.1990.68.5.2054; WALTERS DV, 1978, PEDIATR RES, V12, P239, DOI 10.1203/00006450-197803000-00017; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; Woollhead AM, 2005, J PHYSIOL-LONDON, V566, P781, DOI 10.1113/jphysiol.2005.088674	35	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5158	5168		10.1074/jbc.M509947200	http://dx.doi.org/10.1074/jbc.M509947200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373340	hybrid			2022-12-27	WOS:000235426200070
J	Brown, L; Benchimol, S				Brown, L; Benchimol, S			The involvement of MAPK signaling pathways in determining the cellular response to p53 activation - Cell cycle arrest or apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCUS-FORMING VIRUS; RECEPTOR TYROSINE KINASE; P53-MEDIATED APOPTOSIS; PROTEIN-KINASE; GROWTH ARREST; FRIEND-VIRUS; PHOSPHATIDYLINOSITOL 3-KINASE; P53-DEPENDENT APOPTOSIS; CONSTITUTIVE ACTIVATION; ERYTHROPOIETIN RECEPTOR	The effect of ERK, p38, and JNK signaling on p53-dependent apoptosis and cell cycle arrest was investigated using a Friend murine erythroleukemia virus (FVP)-transformed cell line that expresses a temperature-sensitive p53 allele, DP16.1/p53ts. In response to p53 activation at 32 degrees C, DP16.1/p53ts cells undergo p53-dependent G(1) cell cycle arrest and apoptosis. As a result of viral transformation, these cells express the spleen focus forming env-related glycoprotein gp55, which can bind to the erythropoietin receptor (EPO-R) and mimics many aspects of EPO-induced EPO-R signaling. We demonstrate that ERK, p38 and JNK mitogen-activated protein kinases (MAPKs) are constitutively active in DP16.1/p53ts cells. Constitutive MEK activity contributes to p53-dependent apoptosis and phosphorylation of p53 on serine residue 15. The pro-apoptotic effect of this MAPK kinase signal likely reflects an aberrant Ras proliferative signal arising from FVP-induced viral transformation. Inhibition of MEK alters the p53-dependent cellular response of DP16.1/p53ts from apoptosis to G(1) cell cycle arrest, with a concomitant increase in p21(WAF1), suggesting that the Ras/MEK pathway may influence the cellular response to p53 activation. p38 and JNK activity in DP16.1/p53ts cells is anti-apoptotic and capable of limiting p53-dependent apoptosis at 32 degrees C. Moreover, JNK facilitates p53 protein turnover, which could account for the enhanced apoptotic effects of inhibiting this MAPK pathway in DP16.1/p53ts cells. Overall, these data show that intrinsic MAPK signaling pathways, active in transformed cells, can both positively and negatively influence p53-dependent apoptosis, and illustrate their potential to affect cancer therapies aimed at reconstituting or activating p53 function.	Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Benchimol, S (corresponding author), Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	benchimo@uhnres.utoronto.ca		Benchimol, Samuel/0000-0003-3433-890X				ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Benchimol S, 2001, CELL DEATH DIFFER, V8, P1049, DOI 10.1038/sj.cdd.4400918; Bergmann A, 2002, DEV CELL, V2, P159, DOI 10.1016/S1534-5807(02)00116-8; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Finkelstein LD, 2002, ONCOGENE, V21, P3562, DOI 10.1038/sj.onc.1205442; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; FUKUNAGAJOHNSON N, 1995, CARCINOGENESIS, V16, P1761, DOI 10.1093/carcin/16.8.1761; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JOHNSON P, 1992, CANCER SURV, V12, P137; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lin YP, 2002, BLOOD, V100, P3990, DOI 10.1182/blood-2002-02-0504; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Lotem J, 1999, APOPTOSIS, V4, P187, DOI 10.1023/A:1009614723237; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Muszynski KW, 2000, J VIROL, V74, P8444, DOI 10.1128/JVI.74.18.8444-8451.2000; Nagata Y, 1997, BLOOD, V89, P2664, DOI 10.1182/blood.V89.8.2664; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Ney PA, 2000, BLOOD, V96, P3675, DOI 10.1182/blood.V96.12.3675.h8003675_3675_3680; Nishigaki K, 2001, J VIROL, V75, P7893, DOI 10.1128/JVI.75.17.7893-7903.2001; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Parrizas M, 1997, J BIOL CHEM, V272, P154; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle FW, 1998, GENE DEV, V12, P1099, DOI 10.1101/gad.12.8.1099; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Schmitt CA, 1999, J PATHOL, V187, P127; SCHOTT AF, 1995, ONCOGENE, V11, P1389; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Tian H, 2000, CANCER RES, V60, P679; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang S, 2004, BRIT J CANCER, V91, P178, DOI 10.1038/sj.bjc.6601902	66	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3832	3840		10.1074/jbc.M507951200	http://dx.doi.org/10.1074/jbc.M507951200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16330547	hybrid			2022-12-27	WOS:000235275300011
J	Cai, CL; Li, H; Rivera, C; Keinanen, K				Cai, CL; Li, H; Rivera, C; Keinanen, K			Interaction between SAP97 and PSD-95, two Maguk proteins involved in synaptic trafficking of AMPA receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY; EXCITATORY SYNAPSES; DISTINCT MECHANISMS; PDZ DOMAINS; MYOSIN-VI; PLASTICITY; SUBUNIT; L27; ORGANIZATION	Synapse-associated protein 97 (SAP97) and postsynaptic density 95 (PSD-95) are closely related membrane-associated guanylate kinase homologs (Maguks) implicated in the synaptic targeting and anchoring of alpha-amino-5-methyl-3-hydroxy-4-isoxazolepropionic acid (AMPA)-selective glutamate receptors. Prompted by accumulating evidence for an oligomeric nature of Maguks, we examined the potential of SAP97 and PSD-95 to form heteromeric complexes. SAP97 and PSD-95 coimmunoprecipitated from rat brain detergent extracts and subsequent glutathione S-transferase pull-down and immunoprecipitation experiments showed that the interaction is mediated by binding of the N-terminal segment of SAP97 (SAP97(NTD)) to the Src homology 3 domain of PSD-95 (PSD-95(SH3)). In cultured hippocampal neurons, expression of green fluorescent protein-tagged PSD-95 triggered accumulation of SAP97 in synaptic spines, which was totally inhibited by coexpression of PSD95(SH3). Furthermore, overexpression of green fluorescent proteinPSD-95 induced dendritic clustering of GluR-A subunit-containing AMPA receptors, which was strongly inhibited by cotransfection with SAP97(NTD) and PSD-95(SH3) constructs. Our results demonstrated a direct interaction between SAP97 and PSD-95 and suggested that this association may play a functional role in the trafficking and clustering of AMPA receptors.	Univ Helsinki, Viikki Bioctr, Dept Biol & Environm Sci, FI-00014 Helsinki, Finland; Univ Helsinki, Viikki Bioctr, Div Biochem, FI-00014 Helsinki, Finland; Univ Helsinki, Viikki Bioctr, Div Physiol, FI-00014 Helsinki, Finland; Univ Helsinki, Viikki Bioctr, Inst Biotechnol, FI-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki	Keinanen, K (corresponding author), Univ Helsinki, Viikki Bioctr, Dept Biol & Environm Sci, POB 56, FI-00014 Helsinki, Finland.	kari.keinanen@helsinki.fi	Keinanen, Kari/E-9122-2010; Rivera, Claudio/ABE-2499-2021	Rivera, Claudio/0000-0003-2462-6561				Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; Cai C, 2002, J BIOL CHEM, V277, P31484, DOI 10.1074/jbc.M204354200; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Contro N, 2002, ARCH PEDIAT ADOL MED, V156, P14, DOI 10.1001/archpedi.156.1.14; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; El-Hussein AE, 2000, SCIENCE, V290, P1364; Feng W, 2004, NAT STRUCT MOL BIOL, V11, P475, DOI 10.1038/nsmb751; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hata Y, 1999, CELL MOL LIFE SCI, V56, P461, DOI 10.1007/s000180050445; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Li YH, 2004, EMBO J, V23, P2723, DOI 10.1038/sj.emboj.7600294; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Marfatia SM, 2000, J BIOL CHEM, V275, P13759, DOI 10.1074/jbc.275.18.13759; Masuko N, 1999, J BIOL CHEM, V274, P5782, DOI 10.1074/jbc.274.9.5782; Mauceri D, 2004, J BIOL CHEM, V279, P23813, DOI 10.1074/jbc.M402796200; McGee AW, 2003, CURR OPIN NEUROBIOL, V13, P111, DOI 10.1016/S0959-4388(03)00008-4; McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Mehta S, 2001, J BIOL CHEM, V276, P16092, DOI 10.1074/jbc.M100643200; Montgomery JM, 2004, CELL MOL LIFE SCI, V61, P911, DOI 10.1007/s00018-003-3364-5; Nakagawa T, 2004, NEURON, V44, P453, DOI 10.1016/j.neuron.2004.10.012; Osterweil E, 2005, J CELL BIOL, V168, P329, DOI 10.1083/jcb.200410091; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Piccini A, 2002, J NEUROSCI, V22, P5387; Rumbaugh G, 2003, J NEUROSCI, V23, P4567; Sans N, 2001, J NEUROSCI, V21, P7506, DOI 10.1523/JNEUROSCI.21-19-07506.2001; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheng M, 2003, NEUROSCI RES, V46, P127, DOI 10.1016/S0168-0102(03)00040-3; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Stein V, 2003, J NEUROSCI, V23, P5503; Tavares GA, 2001, MOL CELL, V8, P1313, DOI 10.1016/S1097-2765(01)00416-6; Tomita S, 2003, J CELL BIOL, V161, P805, DOI 10.1083/jcb.200212116; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Vinade L, 2003, J NEUROCHEM, V87, P1255, DOI 10.1046/j.1471-4159.2003.02091.x; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200	45	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4267	4273		10.1074/jbc.M505886200	http://dx.doi.org/10.1074/jbc.M505886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16332687	hybrid			2022-12-27	WOS:000235275300060
J	Field, MS; Szebenyi, DME; Stover, PJ				Field, MS; Szebenyi, DME; Stover, PJ			Regulation of de novo purine biosynthesis by methenyltetrahydrofolate synthetase in neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							5,10-METHENYLTETRAHYDROFOLATE SYNTHETASE; SERINE HYDROXYMETHYLTRANSFERASE; RABBIT LIVER; BINDING-SITE; FOLATE; 5-FORMYLTETRAHYDROFOLATE; PURIFICATION; HOMOCYSTEINE; INHIBITION; HYDROLYSIS	5-Formyltetrahydrofolate (5-formylTHF) is the only folate derivative that does not serve as a cofactor in folate-dependent one-carbon metabolism. Two metabolic roles have been ascribed to this folate derivative. It has been proposed to 1) serve as a storage form of folate because it is chemically stable and accumulates in seeds and spores and 2) regulate folate-dependent one-carbon metabolism by inhibiting folate-dependent enzymes, specifically targeting folate-dependent de novo purine biosynthesis. Methenyltetrahydrofolate synthetase (MTHFS) is the only enzyme that metabolizes 5-formylTHF and catalyzes its ATP-dependent conversion to 5,10-methenylTHF. This reaction determines intracellular 5-formylTHF concentrations and converts 5-formylTHF into an enzyme cofactor. The regulation and metabolic role of MTHFS in one-carbon metabolism was investigated in vitro and in human neuroblastoma cells. Steady-state kinetic studies revealed that 10-formylTHF, which exists in chemical equilibrium with 5,10-methenylTHF, acts as a tight binding inhibitor of mouse MTHFS. [6R]-10-formylTHF inhibited MTHFS with a K-i of 150 nM, and [6R, S]-10-formylTHF triglutamate inhibited MTHFS with a Ki of 30 nM. MTHFS is the first identified 10-formylTHF tight-binding protein. Isotope tracer studies in neuroblastoma demonstrate that MTHFS enhances de novo purine biosynthesis, indicating that MTHFS-bound 10-formylTHF facilitates de novo purine biosynthesis. Feedback metabolic regulation of MTHFS by 10-formylTHF indicates that 5-formylTHF can only accumulate in the presence of 10-formylTHF, providing the first evidence that 5-formylTHF is a storage form of excess formylated folates in mammalian cells. The sequestration of 10-formylTHF by MTHFS may explain why de novo purine biosynthesis is protected from common disruptions in the folate-dependent one-carbon network.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Cornell Univ, Grad Field Biochem Mol & Cell Biol, Ithaca, NY 14853 USA; Cornell Univ, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 127 Savage Hall, Ithaca, NY 14853 USA.	pjs13@cornell.edu	Szebenyi, Marian/GMX-2709-2022	Field, Martha/0000-0001-7547-5180	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035687] Funding Source: NIH RePORTER; NICHD NIH HHS [HD35687] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anguera MC, 2004, PROTEIN EXPRES PURIF, V35, P276, DOI 10.1016/j.pep.2004.02.010; Anguera MC, 2003, J BIOL CHEM, V278, P29856, DOI 10.1074/jbc.M302883200; Bailey LB, 1999, J NUTR, V129, P919, DOI 10.1093/jn/129.5.919; BERTRAND R, 1987, BIOCHIM BIOPHYS ACTA, V911, P154, DOI 10.1016/0167-4838(87)90004-5; BERTRAND R, 1989, J BIOL CHEM, V264, P8843; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Chen SF, 2005, PROTEINS, V61, P433, DOI 10.1002/prot.20591; Chen SF, 2004, PROTEINS, V56, P839, DOI 10.1002/prot.20214; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; Finkelstein JD, 2000, SEMIN THROMB HEMOST, V26, P219, DOI 10.1055/s-2000-8466; Finkelstein JD, 2000, NUTR REV, V58, P193, DOI 10.1111/j.1753-4887.2000.tb01862.x; Friso S, 2002, ANAL CHEM, V74, P4526, DOI 10.1021/ac020050h; Fu TF, 1999, ARCH BIOCHEM BIOPHYS, V367, P161, DOI 10.1006/abbi.1999.1262; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holmes WB, 2002, J BIOL CHEM, V277, P20205, DOI 10.1074/jbc.M201242200; HOPKINS S, 1984, J BIOL CHEM, V259, P5618; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kisliuk RL, 2003, CURR PHARM DESIGN, V9, P2615, DOI 10.2174/1381612033453695; Kisliuk RL, 2000, PHARMACOL THERAPEUT, V85, P183, DOI 10.1016/S0163-7258(99)00056-X; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSCHWITZ HL, 1994, J BIOL CHEM, V269, P28757; MARAS B, 1994, J BIOL CHEM, V269, P18429; Marsilje TH, 2002, BIOORGAN MED CHEM, V10, P2739, DOI 10.1016/S0968-0896(02)00102-5; McGuire JJ, 2003, CURR PHARM DESIGN, V9, P2593, DOI 10.2174/1381612033453712; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORAN RG, 1986, METHOD ENZYMOL, V122, P309; Moran RG, 1999, SEMIN ONCOL, V26, P24; Roje S, 2002, J BIOL CHEM, V277, P42748, DOI 10.1074/jbc.M205632200; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shane B., 1995, FOLATE HLTH DIS, V2, P1; STOVER P, 1993, TRENDS BIOCHEM SCI, V18, P102, DOI 10.1016/0968-0004(93)90162-G; STOVER P, 1992, ANAL BIOCHEM, V202, P82, DOI 10.1016/0003-2697(92)90210-X; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2148, DOI 10.1021/bi00122a036; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; STOVER P, 1990, J BIOL CHEM, V265, P14227; Stover PJ, 2004, NUTR REV, V62, pS3, DOI 10.1111/j.1753-4887.2004.tb00070.x; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Wagner C, 1995, FOLATE HLTH DIS, P23; Yeo EJ, 1999, J BIOL CHEM, V274, P37559, DOI 10.1074/jbc.274.53.37559; Zhao RB, 2003, ONCOGENE, V22, P7431, DOI 10.1038/sj.onc.1206946	45	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4215	4221		10.1074/jbc.M510624200	http://dx.doi.org/10.1074/jbc.M510624200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365037	hybrid			2022-12-27	WOS:000235275300054
J	Okamoto, M; Yoko-o, T; Umemura, M; Nakayama, K; Jigami, Y				Okamoto, M; Yoko-o, T; Umemura, M; Nakayama, K; Jigami, Y			Glycosylphosphatidylinositol-anchored proteins are required for the transport of detergent-resistant microdomain-associated membrane proteins Tat2p and Fur4p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST URACIL PERMEASE; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; TRYPTOPHAN PERMEASE; CELL-WALL; INOSITOL ACYLATION; LIPID RAFTS; STRUCTURAL-CHARACTERIZATION; MAMMALIAN-CELLS; HIGH-PRESSURE	In eukaryotic cells many cell surface proteins are attached to the membrane via the glycosylphosphatidylinositol (GPI) moiety. In yeast, GPI also plays important roles in the production of manno-protein in the cell wall. We previously isolated gwt1 mutants and found that GWT1 is required for inositol acylation in the GPI bio-synthetic pathway. In this study we isolated a new gwt1 mutant allele, gwt1-10, that shows not only high temperature sensitivity but also low temperature sensitivity. The gwt1-10 cells show impaired acyltransferase activity and attachment of GPI to proteins even at the permissive temperature. We identified TAT2, which encodes a high affinity tryptophan permease, as a multicopy suppressor of cold sensitivity in gwt1-10 cells. The gwt1-10 cells were also defective in the import of tryptophan, and a lack of tryptophan caused low temperature sensitivity. Microscopic observation revealed that Tat2p is not transported to the plasma membrane but is retained in the endoplasmic reticulum in gwt1-10 cells grown under tryptophan-poor conditions. We found that Tat2p was not associated with detergent-resistant membranes (DRMs), which are required for the recruitment of Tat2p to the plasma membrane. A similar result was obtained for Fur4p, a uracil permease localized in the DRMs of the plasma membrane. These results indicate that GPI-anchored proteins are required for the recruitment of membrane proteins Tat2p and Fur4p to the plasma membrane via DRMs, suggesting that some membrane proteins are redistributed in the cell in response to environmental and nutritional conditions due to an association with DRMs that is dependent on GPI-anchored proteins.	AIST, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Jigami, Y (corresponding author), AIST, Res Ctr Glycosci, Tsukuba Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	jigami.yoshi@aist.go.jp	Yoko-o, Takehiko/L-7093-2018	Yoko-o, Takehiko/0000-0003-0291-8299; Okamoto, michiyo/0000-0003-4280-6048				Abe F, 2000, MOL CELL BIOL, V20, P8093, DOI 10.1128/MCB.20.21.8093-8102.2000; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Blondel MO, 2004, MOL BIOL CELL, V15, P883, DOI 10.1091/mbc.E03-04-0202; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; Dupre S, 2003, TRAFFIC, V4, P83, DOI 10.1034/j.1600-0854.2003.40204.x; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fujita M, 2004, J BIOL CHEM, V279, P51869, DOI 10.1074/jbc.M405232200; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; Hearn JD, 2003, J BIOL CHEM, V278, P3679, DOI 10.1074/jbc.M209170200; HEITMAN J, 1993, MOL CELL BIOL, V13, P5010, DOI 10.1128/MCB.13.8.5010; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; HORVATH A, 1994, EMBO J, V13, P3687, DOI 10.1002/j.1460-2075.1994.tb06678.x; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Kapteyn JC, 1999, BBA-GEN SUBJECTS, V1426, P373, DOI 10.1016/S0304-4165(98)00137-8; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LISANTI MP, 1990, J MEMBRANE BIOL, V117, P1, DOI 10.1007/BF01871561; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Malinska K, 2004, J CELL SCI, V117, P6031, DOI 10.1242/jcs.01493; Malinska K, 2003, MOL BIOL CELL, V14, P4427, DOI 10.1091/mbc.E03-04-0221; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Murakami Y, 2003, MOL BIOL CELL, V14, P4285, DOI 10.1091/mbc.E03-03-0193; Nagayama A, 2004, EXTREMOPHILES, V8, P143, DOI 10.1007/s00792-003-0373-0; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; PUOTI A, 1992, J BIOL CHEM, V267, P22673; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; SCHMIDT A, 1994, MOL CELL BIOL, V14, P6597, DOI 10.1128/MCB.14.10.6597; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sievi E, 2001, TRAFFIC, V2, P896, DOI 10.1034/j.1600-0854.2001.21205.x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Sutterlin C, 1997, J CELL SCI, V110, P2703; Tsukahara K, 2003, MOL MICROBIOL, V48, P1029, DOI 10.1046/j.1365-2958.2003.03481.x; Umebayashi K, 2003, J CELL BIOL, V161, P1117, DOI 10.1083/jcb.200303088; Umemura M, 2003, J BIOL CHEM, V278, P23639, DOI 10.1074/jbc.M301044200; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; Watanabe R, 2002, J BIOL CHEM, V277, P49538, DOI 10.1074/jbc.M206209200; Yashiroda H, 1998, GENE, V225, P39, DOI 10.1016/S0378-1119(98)00535-6	62	39	40	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4013	4023		10.1074/jbc.M504684200	http://dx.doi.org/10.1074/jbc.M504684200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361252	hybrid			2022-12-27	WOS:000235275300030
J	Saerens, SMG; Verstrepen, KJ; Van Laere, SDM; Voet, ARD; Van Dijck, P; Delvaux, FR; Thevelein, JM				Saerens, SMG; Verstrepen, KJ; Van Laere, SDM; Voet, ARD; Van Dijck, P; Delvaux, FR; Thevelein, JM			The Saccharomyces cerevisiae EHT1 and EEB1 genes encode novel enzymes with medium-chain fatty acid ethyl ester synthesis and hydrolysis capacity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLASE; GENOME; GENTHREADER; EFFICIENT; SEQUENCE; CELLS	Fatty acid ethyl esters are secondary metabolites produced by Saccharomyces cerevisiae and many other fungi. Their natural physiological role is not known but in fermentations of alcoholic beverages and other food products they play a key role as flavor compounds. Information about the metabolic pathways and enzymology of fatty acid ethyl ester biosynthesis, however, is very limited. In this work, we have investigated the role of a three-member S. cerevisiae gene family with moderately divergent sequences (YBR177c/EHT1,YPL095c/EEB1, and YMR210w). We demonstrate that two family members encode an acyl-coenzymeA: ethanol O-acyltransferase, an enzyme required for the synthesis of medium-chain fatty acid ethyl esters. Deletion of either one or both of these genes resulted in severely reduced medium-chain fatty acid ethyl ester production. Purified glutathione S-transferase-tagged Eht1 and Eeb1 proteins both exhibited acyl-coenzymeA: ethanol O-acyltransferase activity in vitro, as well as esterase activity. Overexpression of Eht1 and Eeb1 did not enhance medium-chain fatty acid ethyl ester content, which is probably due to the bifunctional synthesis and hydrolysis activity. Molecular modeling of Eht1 and Eeb1 revealed the presence of a alpha/beta-hydrolase fold, which is generally present in the substrate-binding site of esterase enzymes. Hence, our results identify Eht1 and Eeb1 as novel acyl- coenzymeA: ethanol O-acyltransferases/esterases, whereas the third family member, Ymr210w, does not seem to play an important role in medium-chain fatty acid ethyl ester formation.	Katholieke Univ Leuven, Inst Bot & Microbiol, Mol Cell Biol Lab, B-3001 Heverlee, Belgium; Flemish Interuniv Inst Biotechnol, Dept Mol Microbiol, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Dept Microbial & Mol Syst, Ctr Food & Microbial Technol, B-3001 Heverlee, Belgium; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA; Katholieke Univ Leuven, Dept Chem, Lab Biomol Modeling, B-3001 Heverlee, Belgium	KU Leuven; KU Leuven; Harvard University; KU Leuven	Thevelein, JM (corresponding author), Katholieke Univ Leuven, Inst Bot & Microbiol, Mol Cell Biol Lab, Kastellpk Arenberg 31, B-3001 Heverlee, Belgium.	Johan.Thevelein@bio.kuleuven.be	Thevelein, Johan M./AAK-4203-2021; Verstrepen, Kevin/AAA-4343-2021; Thevelein, Johan M./A-7897-2013; voet, arnout/O-5248-2014	Thevelein, Johan M./0000-0002-2626-0180; voet, arnout/0000-0002-3329-2703; Verstrepen, Kevin/0000-0002-3077-6219				ANSARI GAS, 1995, TOXICOL LETT, V75, P1, DOI 10.1016/0378-4274(94)03171-3; Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Balakrishnan R, 2005, NUCLEIC ACIDS RES, V33, pD374, DOI 10.1093/nar/gki023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Criddle DN, 2004, P NATL ACAD SCI USA, V101, P10738, DOI 10.1073/pnas.0403431101; DELHAISE P, 1984, J MOL GRAPHICS, V2, P103, DOI 10.1016/0263-7855(84)80002-8; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; Diczfalusy MA, 2001, J LIPID RES, V42, P1025; Dietrich FS, 2004, SCIENCE, V304, P304, DOI 10.1126/science.1095781; Dujon B, 2004, NATURE, V430, P35, DOI 10.1038/nature02579; Fushinobu S, 2005, BIOSCI BIOTECH BIOCH, V69, P491, DOI 10.1271/bbb.69.491; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gilham D, 2005, METHODS, V36, P139, DOI 10.1016/j.ymeth.2004.11.003; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Holmquist M, 2000, CURR PROTEIN PEPT SC, V1, P209, DOI 10.2174/1389203003381405; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones T, 2004, P NATL ACAD SCI USA, V101, P7329, DOI 10.1073/pnas.0401648101; Laposata M, 1998, PROG LIPID RES, V37, P307, DOI 10.1016/S0163-7827(98)00013-7; Lilly M, 2000, APPL ENVIRON MICROB, V66, P744, DOI 10.1128/AEM.66.2.744-753.2000; Liu SQ, 2004, INT DAIRY J, V14, P923, DOI 10.1016/j.idairyj.2004.02.010; MALCORPS P, 1992, EUR J BIOCHEM, V210, P1015, DOI 10.1111/j.1432-1033.1992.tb17507.x; Manolis K., 2004, NATURE, V428, P617; Mason AB, 2000, YEAST, V16, P1287, DOI 10.1002/1097-0061(200010)16:14<1287::AID-YEA613>3.0.CO;2-I; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; Nandhagopal N, 1997, P JPN ACAD B-PHYS, V73, P154, DOI 10.2183/pjab.73.154; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; SHERMAN F, 1991, METHODS YEAST GENETI; Soderberg BL, 2003, AM J CLIN PATHOL, V119, P94; Stratford M, 1996, FEMS MICROBIOL LETT, V142, P53, DOI 10.1016/0378-1097(96)00242-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verstrepen KJ, 2004, YEAST, V21, P367, DOI 10.1002/yea.1100; Verstrepen KJ, 2003, J BIOSCI BIOENG, V96, P110, DOI [10.1016/S1389-1723(03)90112-5, 10.1263/jbb.96.110]; Verstrepen KJ, 2003, APPL ENVIRON MICROB, V69, P5228, DOI 10.1128/AEM.69.9.5228-5237.2003; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541	35	192	216	11	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4446	4456		10.1074/jbc.M512028200	http://dx.doi.org/10.1074/jbc.M512028200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361250	hybrid, Green Published			2022-12-27	WOS:000235275300080
J	Zhao, LJ; Subramanian, T; Zhou, Y; Chinnadurai, G				Zhao, LJ; Subramanian, T; Zhou, Y; Chinnadurai, G			Acetylation by p300 regulates nuclear localization and function of the transcriptional corepressor CtBP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-BINDING-PROTEIN; ADENOVIRUS E1A; MOLECULAR-CLONING; CO-REPRESSOR; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; MEMBRANE FISSION; SYNAPTIC RIBBONS; DROSOPHILA CTBP; INTERACTS	CtBP family members, CtBP1 and CtBP2, are unique transcriptional regulators that adapt a metabolic enzyme fold, and their activities are regulated by NAD(H)- binding. CtBP1 is both cytoplasmic and nuclear, and its subcellular localization is regulated by sumoylation, phosphorylation, and binding to a PDZ protein. In contrast, we showed that CtBP2 is exclusively nuclear. CtBP1 and CtBP2 are highly similar, but differ at the N-terminal 20 amino acid region. Substitution of the N-terminal domain of CtBP1 with the corresponding CtBP2 domain confers a dominant nuclear localization pattern to CtBP1. The N-terminal domain of CtBP2 contains three Lys residues. Our results show that these Lys residues are acetylated by the nuclear acetylase p300. Although all three Lys residues of CtBP2 (Lys-6, Lys-8, and Lys-10) appear to be acetylated, acetylation of Lys-10 is critical for nuclear localization. CtBP2 with a single amino acid substitution at Lys-10 (K10R) is predominantly localized in the cytoplasm. The cytoplasmic localization of the K10R mutant is correlated with enhanced nuclear export that is inhibited by leptomycin B. Furthermore, lack of acetylation at Lys-10 renders CtBP2 to be more efficient in repression of the E-cadherin promoter. Our studies have revealed the important roles of acetylation in regulating subcellular localization and transcriptional activity of CtBP2.	St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Hlth Sci Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NCI NIH HHS [CA-84941] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084941] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balasubramanian P, 2003, FEBS LETT, V537, P157, DOI 10.1016/S0014-5793(03)00119-4; Barnes CJ, 2003, NAT STRUCT BIOL, V10, P622, DOI 10.1038/nsb957; Bonazzi M, 2005, NAT CELL BIOL, V7, P570, DOI 10.1038/ncb1260; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Brannon M, 1999, DEVELOPMENT, V126, P3159; Carcedo CH, 2004, SCIENCE, V305, P93, DOI 10.1126/science.1097775; Chinnadurai G, 2003, BIOESSAYS, V25, P9, DOI 10.1002/bies.10212; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Dieck ST, 2005, J CELL BIOL, V168, P825, DOI 10.1083/jcb.200408157; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fjeld CC, 2003, P NATL ACAD SCI USA, V100, P9202, DOI 10.1073/pnas.1633591100; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gallop JL, 2005, NATURE, V438, P675, DOI 10.1038/nature04136; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Katsanis N, 1998, GENOMICS, V47, P294, DOI 10.1006/geno.1997.5115; Kim JH, 2005, NAT STRUCT MOL BIOL, V12, P423, DOI 10.1038/nsmb924; Kumar V, 2002, MOL CELL, V10, P857, DOI 10.1016/S1097-2765(02)00650-0; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Meloni AR, 2005, MOL CANCER RES, V3, P575, DOI 10.1158/1541-7786.MCR-05-0088; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schmitz F, 2000, NEURON, V28, P857, DOI 10.1016/S0896-6273(00)00159-8; Senyuk V, 2005, ARCH BIOCHEM BIOPHYS, V441, P168, DOI 10.1016/j.abb.2005.06.024; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Subramanian T, 2003, FEBS LETT, V540, P255, DOI 10.1016/S0014-5793(03)00275-8; Sundqvist A, 1998, FEBS LETT, V429, P183, DOI 10.1016/S0014-5793(98)00588-2; Sutrias-Grau M, 2004, MOL CELL BIOL, V24, P5953, DOI 10.1128/MCB.24.13.5953-5966.2004; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Xu WT, 1998, MOL CELL BIOL, V18, P5659, DOI 10.1128/MCB.18.10.5659; Zenisek D, 2004, J NEUROSCI, V24, P9752, DOI 10.1523/JNEUROSCI.2886-04.2004; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2002, SCIENCE, V295, P1895	51	63	67	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4183	4189		10.1074/jbc.M509051200	http://dx.doi.org/10.1074/jbc.M509051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356938	hybrid			2022-12-27	WOS:000235275300050
J	Barros, MH; Myers, AM; Van Driesche, S; Tzagoloff, A				Barros, MH; Myers, AM; Van Driesche, S; Tzagoloff, A			COX24 codes for a mitochondrial protein required for processing of the COX1 transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; GROUP-I INTRON; PRE-MESSENGER RNA; SACCHAROMYCES-CEREVISIAE; MEMBRANE SYSTEM; YEAST MITOCHONDRIA; CBP2 PROTEIN; BOX PROTEIN; B GENE; MATURASE	In most strains of Saccharomyces cerevisiae the mitochondrial gene COX1, for subunit 1 of cytochrome oxidase, contains multiple exons and introns. Processing of COX1 primary transcript requires accessory proteins factors, some of which are encoded by nuclear genes and others by reading frames residing in some of the introns of the COX1 and COB genes. Here we show that the low molecular weight protein product of open reading frame YLR204W, for which we propose the name COX24, is also involved in processing of COX1 RNA intermediates. The growth defect of cox24 mutants is partially rescued in strains harboring mitochondrial DNA lacking introns. Northern blot analyses of mitochondrial transcripts indicate cox24 null mutants to be blocked in processing of introns aI2 and aI3. The dependence of intron aI3 excision on Cox24p is also supported by the growth properties of the cox24 mutant harboring mitochondrial DNA with different intron compositions. The intermediate phenotype of the cox24 mutant in the background of intronless mitochondrial DNA, however, suggests that in addition to its role in splicing of the COX1 pre-mRNA, Cox24p still has another function. Based on the analysis of a cox14-cox24 double mutant, we propose that the other function of Cox24p is related to translation of the COX1 mRNA.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu	Barros, Mario H/B-8118-2012; Barros, Mario/Q-6358-2019	Barros, Mario/0000-0003-2977-9815; Myers, Alan/0000-0002-9619-4692	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952, R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45952, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Barros MH, 2002, J BIOL CHEM, V277, P9997, DOI 10.1074/jbc.M112025200; BEGGS JD, 1978, NATURE, V275, P104, DOI 10.1038/275104a0; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BOUSQUET I, 1990, CURR GENET, V18, P117, DOI 10.1007/BF00312599; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; COSTANZO MC, 1988, P NATL ACAD SCI USA, V85, P2677, DOI 10.1073/pnas.85.8.2677; DECOSTER E, 1993, J MOL BIOL, V232, P79, DOI 10.1006/jmbi.1993.1371; DUJON B, 1989, GENE, V82, P91, DOI 10.1016/0378-1119(89)90034-6; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAMPEL A, 1989, MOL CELL BIOL, V9, P5424, DOI 10.1128/MCB.9.12.5424; GAMPEL A, 1991, GENE DEV, V5, P1870, DOI 10.1101/gad.5.10.1870; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Golik P, 2004, FEMS YEAST RES, V4, P477, DOI 10.1016/S1567-1356(03)00160-0; GUO WW, 1995, J BIOL CHEM, V270, P15563, DOI 10.1074/jbc.270.26.15563; HERBERT CJ, 1988, EMBO J, V7, P473, DOI 10.1002/j.1460-2075.1988.tb02835.x; HILL J, 1985, J BIOL CHEM, V260, P3235; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Huang HR, 2005, P NATL ACAD SCI USA, V102, P163, DOI 10.1073/pnas.0407896101; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; Krause K, 2004, MOL BIOL CELL, V15, P2674, DOI 10.1091/mbc.E04-02-0126; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABOUESSE M, 1983, EMBO J, V2, P269, DOI 10.1002/j.1460-2075.1983.tb01416.x; LABOUESSE M, 1990, MOL GEN GENET, V224, P209, DOI 10.1007/BF00271554; LAZOWSKA J, 1989, J MOL BIOL, V205, P275, DOI 10.1016/0022-2836(89)90341-0; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANON S, 1989, BIOCHIM BIOPHYS ACTA, V985, P127, DOI 10.1016/0005-2736(89)90356-8; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MAXAM AM, 1980, METHOD ENZYMOL, V65, P49; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCGRAW P, 1983, J BIOL CHEM, V258, P9459; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; MUROFF I, 1990, EMBO J, V9, P2765, DOI 10.1002/j.1460-2075.1990.tb07464.x; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SERAPHIN B, 1987, P NATL ACAD SCI USA, V84, P6810, DOI 10.1073/pnas.84.19.6810; SERAPHIN B, 1992, GENE, V113, P1, DOI 10.1016/0378-1119(92)90663-A; SIMON M, 1992, YEAST, V8, P559, DOI 10.1002/yea.320080707; STEPIEN PP, 1992, P NATL ACAD SCI USA, V89, P6813, DOI 10.1073/pnas.89.15.6813; SZCZEPANEK T, 1994, GENE, V139, P1, DOI 10.1016/0378-1119(94)90516-9; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; VALENCIK ML, 1989, EMBO J, V8, P3899, DOI 10.1002/j.1460-2075.1989.tb08569.x; WENZLAU JM, 1989, CELL, V56, P421, DOI 10.1016/0092-8674(89)90245-6	59	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3743	3751		10.1074/jbc.M510778200	http://dx.doi.org/10.1074/jbc.M510778200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339141	hybrid			2022-12-27	WOS:000235128200087
J	Korzeniewski, B				Korzeniewski, B			AMP deamination delays muscle acidification during heavy exercise and hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKELETAL-MUSCLE; OXIDATIVE-PHOSPHORYLATION; ADENINE-NUCLEOTIDE; EXHAUSTIVE EXERCISE; AMMONIA METABOLISM; PROTON LEAK; ATP; CONTRACTION; HUMANS; KINETICS	In silico studies carried out by using a computer model of oxidative phosphorylation and anaerobic glycolysis in skeletal muscle demonstrated that deamination of AMP to IMP during heavy short term exercise and/or hypoxia lessens the acidification of myocytes. The concerted action of adenylate kinase and AMP deaminase, leading to a decrease in the total adenine nucleotide pool, constitutes an additional process consuming ADP and producing ATP. It diminishes the amount of ADP that must be converted to ATP by other processes in order to meet the rate of ADP production by ATPases ( because the adenylate kinase + AMP deaminase system produces only 1 ATP per 2 ADPs used, ATP consumption is not matched by ATP production, and the reduction of the total adenine nucleotide pool occurs mostly at the cost of [ ATP]). As a result, the rate of ADP consumption by other processes may be lowered. This effect concerns mostly ADP consumption by anaerobic glycolysis that is inhibited by AMP deamination-induced decrease in [ ADP] and [ AMP], and not oxidative phosphorylation, because during heavy exercise and/or hypoxia [ ADP] is significantly greater than the K-m value of this process for ADP. The resultant reduction of proton production by anaerobic glycolysis enables us to delay the termination of exercise because of fatigue and/or to diminish cell damage.	Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland	Jagiellonian University	Korzeniewski, B (corresponding author), Jagiellonian Univ, Fac Biotechnol, Ul Gronostajowa 7, PL-30387 Krakow, Poland.	benio@mol.uj.edu.pl						ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794; BANGSBO J, 1992, J PHYSIOL-LONDON, V451, P205, DOI 10.1113/jphysiol.1992.sp019161; Blomstrand E, 1997, J PHYSIOL-LONDON, V501, P455, DOI 10.1111/j.1469-7793.1997.455bn.x; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; BRINDLE KM, 1987, BIOCHIM BIOPHYS ACTA, V928, P45, DOI 10.1016/0167-4889(87)90084-X; BROBERG S, 1989, J APPL PHYSIOL, V67, P116, DOI 10.1152/jappl.1989.67.1.116; DUDLEY GA, 1985, AM J PHYSIOL, V248, pC37, DOI 10.1152/ajpcell.1985.248.1.C37; Garnier A, 1996, J MOL CELL CARDIOL, V28, P1671, DOI 10.1006/jmcc.1996.0157; GRAHAM TE, 1990, AM J PHYSIOL, V259, pE170, DOI 10.1152/ajpendo.1990.259.2.E170; Hancock CR, 2005, AM J PHYSIOL-CELL PH, V288, pC1298, DOI 10.1152/ajpcell.00621.2004; HARRIS RC, 1991, EUR J APPL PHYSIOL O, V62, P235, DOI 10.1007/BF00571546; Hellsten Y, 1999, J PHYSIOL-LONDON, V520, P909, DOI 10.1111/j.1469-7793.1999.00909.x; KATZ A, 1986, AM J PHYSIOL, V250, pC834, DOI 10.1152/ajpcell.1986.250.6.C834; Kay L, 1997, J MOL CELL CARDIOL, V29, P3399, DOI 10.1006/jmcc.1997.0564; Kobara M, 1996, J MOL CELL CARDIOL, V28, P417, DOI 10.1006/jmcc.1996.0038; Korzeniewski B, 2003, BIOCHEM J, V375, P799, DOI 10.1042/BJ20030882; Korzeniewski B, 1998, BIOCHEM J, V330, P1189, DOI 10.1042/bj3301189; Korzeniewski B, 2001, BIOPHYS CHEM, V92, P17, DOI 10.1016/S0301-4622(01)00184-3; Korzeniewski B, 2004, BIOPHYS CHEM, V110, P147, DOI 10.1016/j.bpc.2004.01.011; Kushmerick MJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1739, DOI 10.1152/ajpcell.1997.272.5.C1739; Lambeth MJ, 2002, ANN BIOMED ENG, V30, P808, DOI 10.1114/1.1492813; LOWENBRAUN S, 1990, REM SPEC EDUC, V11, P37, DOI 10.1177/074193259001100408; REN JM, 1992, J APPL PHYSIOL, V73, P2713, DOI 10.1152/jappl.1992.73.6.2713; Rolfe DFS, 1996, BBA-BIOENERGETICS, V1276, P45, DOI 10.1016/0005-2728(96)00029-1; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; SABINA RL, 1984, J CLIN INVEST, V73, P720, DOI 10.1172/JCI111265; SAHLIN K, 1990, INT J SPORTS MED, V11, pS62, DOI 10.1055/s-2007-1024856; SAHLIN K, 1978, PFLUG ARCH EUR J PHY, V374, P193, DOI 10.1007/BF00581301; SAHLIN K, 1992, MED SPORTS SCI, V43, P54; SALTIN B, 1985, AM J CARDIOL, V55, pD42, DOI 10.1016/0002-9149(85)91054-9; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SODERLUND K, 1991, AM J PHYSIOL, V261, pE737, DOI 10.1152/ajpendo.1991.261.6.E737; Tonkonogi M, 1997, ACTA PHYSIOL SCAND, V161, P345, DOI 10.1046/j.1365-201X.1997.00222.x; Tullson P C, 1991, Exerc Sport Sci Rev, V19, P507; TULLSON PC, 1995, J APPL PHYSIOL, V78, P146, DOI 10.1152/jappl.1995.78.1.146; Tullson PC, 1998, AM J PHYSIOL-CELL PH, V274, pC1411, DOI 10.1152/ajpcell.1998.274.5.C1411; TULLSON PC, 1990, INT J SPORTS MED, V11, pS47, DOI 10.1055/s-2007-1024854; Turner D, 1999, PHYSL DETERMINANTS E, P29; WHIPP BJ, 1969, J APPL PHYSIOL, V26, P644, DOI 10.1152/jappl.1969.26.5.644; Zhao S, 2000, J APPL PHYSIOL, V88, P1513, DOI 10.1152/jappl.2000.88.5.1513	40	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3057	3066		10.1074/jbc.M510418200	http://dx.doi.org/10.1074/jbc.M510418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16314416	hybrid			2022-12-27	WOS:000235128200008
J	McGuire, JR; Rong, J; Li, SH; Li, XJ				McGuire, JR; Rong, J; Li, SH; Li, XJ			Interaction of huntingtin-associated protein-1 with kinesin light chain - Implications in intracellular trafficking in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; BOVINE BRAIN KINESIN; AXONAL-TRANSPORT; ACTIN CYTOSKELETON; MUTANT HUNTINGTIN; IN-VITRO; DISEASE; HAP1; CELLS; IDENTIFICATION	Huntingtin-associated protein-1 ( HAP1) was initially identified as an interacting partner of huntingtin, the Huntington disease protein. Unlike huntingtin that is ubiquitously expressed throughout the brain and body, HAP1 is enriched in neurons, suggesting that its dysfunction could contribute to Huntington disease neuropathology. Growing evidence has demonstrated that HAP1 and huntingtin are anterogradely transported in axons and that the abnormal interaction between mutant huntingtin and HAP1 may impair axonal transport. However, the exact role of HAP1 in anterograde transport remains unclear. Here we report that HAP1 interacts with kinesin light chain, a subunit of the kinesin motor complex that drives anterograde transport along microtubules in neuronal processes. The interaction of HAP1 with kinesin light chain is demonstrated via a yeast two-hybrid assay, glutathione S-transferase pull down, and coimmunoprecipitation. Furthermore, HAP1 is colocalized with kinesin in growth cones of neuronal cells. We also demonstrated that knocking down HAP1 via small interfering RNA suppresses neurite outgrowth of PC12 cells. Analysis of live neuronal cells with fluorescence microscopy and fluorescence recovery after photobleaching demonstrates that suppressing the expression of HAP1 or deleting the HAP1 gene inhibits the kinesin- dependent transport of amyloid precursor protein vesicles. These studies provide amolecular basis for the participation of HAP1 in anterograde transport in neuronal cells.	Emory Clin, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA	Emory University	Li, XJ (corresponding author), Emory Clin, Sch Med, Dept Human Genet, 615 Michael St, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu						Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x; Bananis E, 2004, MOL BIOL CELL, V15, P3688, DOI 10.1091/mbc.E04-04-0278; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; BLOOM GS, 1988, BIOCHEMISTRY-US, V27, P3409, DOI 10.1021/bi00409a043; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cha BY, 2004, J CELL SCI, V117, P3353, DOI 10.1242/jcs.01180; Chan EYW, 2002, HUM MOL GENET, V11, P945, DOI 10.1093/hmg/11.8.945; DRAGATSIS I, 2004, HUM MOL GENET, V20, P20; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; Hames RS, 2005, MOL BIOL CELL, V16, P1711, DOI 10.1091/mbc.E04-08-0688; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; Kaether C, 2000, MOL BIOL CELL, V11, P1213, DOI 10.1091/mbc.11.4.1213; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KREMER HPH, 1990, J NEUROPATH EXP NEUR, V49, P371, DOI 10.1097/00005072-199007000-00002; KUZNETSOV SA, 1988, EMBO J, V7, P353, DOI 10.1002/j.1460-2075.1988.tb02820.x; Lazarov O, 2005, J NEUROSCI, V25, P2386, DOI 10.1523/JNEUROSCI.3089-04.2005; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Li SH, 2004, TRENDS GENET, V20, P146, DOI 10.1016/j.tig.2004.01.008; Li SH, 2003, J NEUROSCI, V23, P6956; Li SH, 1998, J NEUROCHEM, V71, P2178; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; Li SH, 2000, MOL CELL NEUROSCI, V16, P168, DOI 10.1006/mcne.2000.0858; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li XJ, 2005, TRENDS PHARMACOL SCI, V26, P1, DOI 10.1016/j.tips.2004.11.001; Li YK, 2002, J BIOL CHEM, V277, P28212, DOI 10.1074/jbc.M111612200; Lin SX, 2002, MOL BIOL CELL, V13, P96, DOI 10.1091/mbc.01-05-0224; Martin EJ, 1999, J COMP NEUROL, V403, P421; McGuire JR, 2005, CURR GENOMICS, V6, P189, DOI 10.2174/1389202053971938; Meyvis TKL, 1999, PHARM RES-DORDR, V16, P1153, DOI 10.1023/A:1011924909138; Morfini G, 1997, J CELL BIOL, V138, P657, DOI 10.1083/jcb.138.3.657; Muller U, 2002, TRENDS MOL MED, V8, P152, DOI 10.1016/S1471-4914(02)02320-1; Niu TK, 2005, MOL BIOL CELL, V16, P1213, DOI 10.1091/mbc.E04-07-0599; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Satpute-Krishnan P, 2003, AGING CELL, V2, P305, DOI 10.1046/j.1474-9728.2003.00069.x; Schmidt K, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-43; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Tang TS, 2004, EUR J NEUROSCI, V20, P1779, DOI 10.1111/j.1460-9568.2004.03633.x; Tang TS, 2003, NEURON, V39, P227, DOI 10.1016/S0896-6273(03)00366-0; Trushina E, 2004, MOL CELL BIOL, V24, P8195, DOI 10.1128/MCB.24.18.8195-8209.2004; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; Zhang HL, 2001, NEURON, V31, P261, DOI 10.1016/S0896-6273(01)00357-9	54	198	208	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3552	3559		10.1074/jbc.M509806200	http://dx.doi.org/10.1074/jbc.M509806200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339760	hybrid			2022-12-27	WOS:000235128200066
J	Moreau, K; Dizin, E; Ray, H; Luquain, C; Lefai, E; Foufelle, F; Billaud, M; Lenoir, GM; Dalla Venezia, N				Moreau, K; Dizin, E; Ray, H; Luquain, C; Lefai, E; Foufelle, F; Billaud, M; Lenoir, GM; Dalla Venezia, N			BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FATTY-ACID SYNTHASE; BREAST-CANCER; DNA-DAMAGE; SYNTHESIS PATHWAY; PROSTATE-CANCER; ALPHA-GENE; CELL-CYCLE; PHOSPHORYLATION; SUSCEPTIBILITY	Germ line alterations in BRCA1 ( breast cancer susceptibility gene 1) are associated with an increased susceptibility to breast and ovarian cancer. BRCA1 acts as a scaffold protein implicated in multiple cellular functions, such as transcription, DNA repair, and ubiquitination. However, the molecular mechanisms responsible for tumorigenesis are not yet fully understood. We have recently demonstrated that BRCA1 interacts in vivo with acetyl coenzyme A carboxylase alpha (ACCA) through its tandem of BRCA1 C terminus (BRCT) domains. To understand the biological function of the BRCA1 center dot ACCA complex, we sought to determine whether BRCA1 is a regulator of lipogenesis through its interaction with ACCA. We showed here that RNA inhibition-mediated down-regulation of BRCA1 expression induced a marked increase in the fatty acid synthesis. We then delineated the biochemical characteristics of the complex and found that BRCA1 interacts solely with the phosphorylated and inactive form of ACCA (P-ACCA). Finally, we demonstrated that BRCA1 affects lipid synthesis by preventing P-ACCA dephosphorylation. These results suggest that BRCA1 affects lipogenesis through binding to P-ACCA, providing a new mechanism by which BRCA1 may exert a tumor suppressor function.	CNRS, UMR 5201, Genet Mol Lab, Fac Med Rockefeller, F-69373 Lyon 08, France; Fac Med Laennec, INSERM, U449, INRA 1235, F-69372 Lyon 08, France; Univ Paris 06, INSERM, U671, Ctr Biomed Cordeliers, F-75270 Paris 06, France; Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Dalla Venezia, N (corresponding author), CNRS, UMR 5201, Genet Mol Lab, Fac Med Rockefeller, 8 Ave Rockefeller, F-69373 Lyon 08, France.	dalla@rockefeller.univ-lyon1.fr	Lefai, Etienne/L-7961-2019; Lefai, Etienne/E-9615-2019; Billaud, Marc N/M-6954-2013; VENEZIA, Nicole DALLA/C-6542-2017; Moreau, Karen L/L-9903-2014	Lefai, Etienne/0000-0002-3042-7801; Lefai, Etienne/0000-0002-3042-7801; VENEZIA, Nicole DALLA/0000-0002-4553-3535; Moreau, Karen L/0000-0001-6297-3543; FOUFELLE, Fabienne/0000-0002-0752-622X				Alli PM, 2005, ONCOGENE, V24, P39, DOI 10.1038/sj.onc.1208174; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; CALLEBAUT L, 1997, FEBS LETT, V400, P25; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; DAVIES SP, 1990, EUR J BIOCHEM, V187, P183, DOI 10.1111/j.1432-1033.1990.tb15293.x; De Schrijver E, 2003, CANCER RES, V63, P3799; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gosmain Y, 2005, J LIPID RES, V46, P697, DOI 10.1194/jlr.M400261-JLR200; HA J, 1994, J BIOL CHEM, V269, P22162; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Kim KS, 1997, BIOCHEM SOC T, V25, P1211, DOI 10.1042/bst0251211; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010-JLR200; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magnard C, 2002, ONCOGENE, V21, P6729, DOI 10.1038/sj.onc.1205915; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Pizer ES, 1996, CANCER RES, V56, P2745; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sinilnikova OM, 2004, CARCINOGENESIS, V25, P2417, DOI 10.1093/carcin/bgh273; Starita LM, 2003, CURR OPIN CELL BIOL, V15, P345, DOI 10.1016/S0955-0674(03)00042-5; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Winder WW, 1997, J APPL PHYSIOL, V82, P219, DOI 10.1152/jappl.1997.82.1.219; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhou WB, 2003, CANCER RES, V63, P7330	37	93	100	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3172	3181		10.1074/jbc.M504652200	http://dx.doi.org/10.1074/jbc.M504652200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326698	hybrid			2022-12-27	WOS:000235128200020
J	Roberts, MT; Phelan, R; Erlichman, BS; Pillai, RN; Ma, L; Lopreato, GF; Mihic, SJ				Roberts, MT; Phelan, R; Erlichman, BS; Pillai, RN; Ma, L; Lopreato, GF; Mihic, SJ			Occupancy of a single anesthetic binding pocket is sufficient to enhance glycine receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; GENERAL-ANESTHETICS; ALCOHOLS; GABA(A); ETHANOL; MUTANT; SITES; MECHANISM; MICE	Alcohols and volatile anesthetics enhance the function of inhibitory glycine receptors (GlyRs). This is hypothesized to occur by their binding to a pocket formed between the transmembrane domains of individual alpha 1 GlyR subunits. Because GlyRs are pentameric, it follows that each GlyR contains up to five alcohol/anesthetic binding sites, with one in each subunit. We asked how many subunits per pentamer need be bound by drug in order to enhance receptor-mediated currents. A cysteine mutation was introduced at amino acid serine 267 (S267C) in the transmembrane 2 domain as a tool to block GlyR potentiation by some anesthetic drugs and to provide a means for covalent binding by the small, anesthetic-like thiol reagent propyl methanethiosulfonate. Xenopus laevis oocytes were co-injected with various ratios of wild-type (wt) to S267C alpha 1 GlyR cDNAs in order to express heteromeric receptors with a range of wt: mutant subunit stoichiometries. The enhancement of GlyR currents by 200 mM ethanol and 1.5 mM chloroform was positively correlated with the number of wt subunits found in heteromeric receptors. Furthermore, currents from oocytes injected with high ratios of wt to S267C cDNAs (up to 200:1) were significantly and irreversibly enhanced following propyl methanethiosulfonate labeling and washout, demonstrating that drug binding to a single subunit in the receptor pentamer is sufficient to induce enhancement of GlyR currents.	Univ Texas, Univ Stn 1, Waggoner Ctr Alcohol & Addict Res, Sect Neurobiol,Inst Neurosci, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Waggoner Ctr Alcohol & Addict Res, Neurobiol Sect, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Mihic, SJ (corresponding author), Univ Texas, Univ Stn 1, Waggoner Ctr Alcohol & Addict Res, Sect Neurobiol,Inst Neurosci, A4800, Austin, TX 78712 USA.	mihic@mail.utexas.edu		Roberts, Michael/0000-0003-2835-8752	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA011525, F31AA014454] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA11525, F31 AA14454] Funding Source: Medline; NIGMS NIH HHS [P01 GM47818] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguayo Luis G., 2002, Current Topics in Medicinal Chemistry, V2, P869, DOI 10.2174/1568026023393426; Beato M, 2004, J NEUROSCI, V24, P895, DOI 10.1523/JNEUROSCI.4420-03.2004; Beckstead MJ, 2000, MOL PHARMACOL, V57, P1199; Beckstead MJ, 2001, J BIOL CHEM, V276, P24959, DOI 10.1074/jbc.M011627200; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Breitinger HG, 2002, NEUROSCI LETT, V331, P21, DOI 10.1016/S0304-3940(02)00773-5; Burzomato V, 2004, J NEUROSCI, V24, P10924, DOI 10.1523/JNEUROSCI.3424-04.2004; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Daniels S, 1998, TOXICOL LETT, V101, P71, DOI 10.1016/S0378-4274(98)00167-2; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; Eger EI, 1999, ANESTH ANALG, V88, P867, DOI 10.1097/00000539-199904000-00035; Findlay GS, 2003, J NEUROSCI, V23, P8051; Findlay GS, 2002, J PHARMACOL EXP THER, V300, P526, DOI 10.1124/jpet.300.2.526; Franks NP, 1998, BIOPHYS J, V75, P2205, DOI 10.1016/S0006-3495(98)77664-7; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kruse SW, 2003, NAT STRUCT BIOL, V10, P694, DOI 10.1038/nsb960; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; Lobo IA, 2004, J BIOL CHEM, V279, P33919, DOI 10.1074/jbc.M313941200; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; Mascia MP, 2000, P NATL ACAD SCI USA, V97, P9305, DOI 10.1073/pnas.160128797; Mascia MP, 1996, BRIT J PHARMACOL, V119, P1331, DOI 10.1111/j.1476-5381.1996.tb16042.x; Mascia MP, 1998, BRIT J PHARMACOL, V125, P263; Mihic SJ, 1999, NEUROCHEM INT, V35, P115, DOI 10.1016/S0197-0186(99)00053-4; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Zhang Y, 2003, ANESTH ANALG, V96, P97, DOI 10.1097/00000539-200301000-00021	31	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3305	3311		10.1074/jbc.M502000200	http://dx.doi.org/10.1074/jbc.M502000200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16361257	hybrid			2022-12-27	WOS:000235128200037
J	Li, Y; Asuri, S; Rebhun, JF; Castro, AF; Paranavitana, NC; Quilliam, LA				Li, Y; Asuri, S; Rebhun, JF; Castro, AF; Paranavitana, NC; Quilliam, LA			The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; DISSOCIATION STIMULATOR; BIOCHEMICAL-ANALYSIS; PHOSPHOLIPASE-C; BINDING PROTEIN; FAMILY GTPASES; GOLGI-COMPLEX; R-RAS; ACTIVATION; CAMP	Epac-1 and -2 ( exchange proteins directly activated by cyclic AMP) are guanine-nucleotide exchange factors for the GTPases Rap1 and -2. Epac2 but not Epac1 was found to possess a RA (Ras association) domain similar to that found in the Ras effector Ral-GDS. This domain specifically bound Ras-GTP, enabling oncogenic Ras to translocate Epac2 from the cytosol to the plasma membrane. Consequently, a small pool of plasma membrane-bound Rap1 was activated at the expense of bulk Rap1 located on intracellular organelles. Whereas translocation of Epac2 was not mimicked by challenge with epidermal growth factor alone, costimulation with forskolin, prostaglandin E-2, or an Epac-selective cyclic AMP analog-induced rapid relocation of GFP-Epac2 but not -Epac1 to the plasma membrane in a Ras-dependent manner. Deletion of the cyclic AMP-binding domain overcame the need for nucleotide, suggesting that this domain normally masked the RA domain in the resting GEF. Thus, Epac2 can respond to costimulation by agonists that jointly elevate Ras-GTP and cyclic AMP levels, activating a specific pool of Rap1 at the plasma membrane. Therefore, despite its previous description as a Ras antagonist or independently functioning GTPase, Rap1/Krev-1 may additionally act downstream of Ras in cells that express the cyclic AMP-regulated GEF, Epac2.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Quilliam, LA (corresponding author), 635 Barnhill Dr,MS-4053, Indianapolis, IN 46202 USA.	lquillia@iupui.edu	Quilliam, Lawrence/B-6447-2015; Rebhun, John F/H-7235-2019; Quilliam, Lawrence/Q-4987-2019	Rebhun, John F/0000-0002-0764-5210; 	NATIONAL CANCER INSTITUTE [R01CA108647] Funding Source: NIH RePORTER; NCI NIH HHS [CA108647, R01 CA108647-02, R01 CA108647] Funding Source: Medline; PHS HHS [T32-H07774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bivona TG, 2004, J CELL BIOL, V164, P461, DOI 10.1083/jcb.200311093; Boettner B, 2000, P NATL ACAD SCI USA, V97, P9064, DOI 10.1073/pnas.97.16.9064; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Caloca MJ, 2004, J BIOL CHEM, V279, P20435, DOI 10.1074/jbc.M313013200; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Caron E, 2003, J CELL SCI, V116, P435, DOI 10.1242/jcs.00238; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; de Hoog CL, 2001, MOL CELL BIOL, V21, P2107, DOI 10.1128/MCB.21.6.2107-2117.2001; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DSilva NJ, 1997, J HISTOCHEM CYTOCHEM, V45, P965, DOI 10.1177/002215549704500706; Elmendorf Jeffrey S, 2003, Methods Mol Med, V83, P105; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; KAPLON T, 1995, J BIOL CHEM, V270, P20742, DOI 10.1074/jbc.270.35.20742; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Knox AL, 2002, SCIENCE, V295, P1285, DOI 10.1126/science.1067549; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kuiperij HB, 2003, BBA-MOL CELL RES, V1593, P141, DOI 10.1016/S0167-4889(02)00365-8; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Laroche-Joubert N, 2002, J BIOL CHEM, V277, P18598, DOI 10.1074/jbc.M201868200; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Matsubara K, 1999, ONCOGENE, V18, P1303, DOI 10.1038/sj.onc.1202425; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200; PIZON V, 1994, J CELL SCI, V107, P1661; Qiao JB, 2002, J BIOL CHEM, V277, P26581, DOI 10.1074/jbc.M203571200; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Quilliam LA, 2001, METHOD ENZYMOL, V333, P187; Rangarajan S, 2003, J CELL BIOL, V160, P487, DOI 10.1083/jcb.200209105; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rehmann H, 2003, J BIOL CHEM, V278, P23508, DOI 10.1074/jbc.M301680200; Rehmann H, 2003, J BIOL CHEM, V278, P38548, DOI 10.1074/jbc.M306292200; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Shibasaki T, 2004, J BIOL CHEM, V279, P7956, DOI 10.1074/jbc.M309068200; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000	67	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2506	2514		10.1074/jbc.M508165200	http://dx.doi.org/10.1074/jbc.M508165200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316996	hybrid			2022-12-27	WOS:000234931800013
J	Valentin, G; Schwob, E; Della Seta, F				Valentin, G; Schwob, E; Della Seta, F			Dual role of the Cdc7-regulatory protein Dbf4 during yeast meiosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREMEIOTIC DNA-REPLICATION; KINASE REGULATORY SUBUNIT; MEIOTIC S PHASE; SACCHAROMYCES-CEREVISIAE; CDC7 KINASE; CELL-CYCLE; CHROMOSOME SEGREGATION; FISSION YEAST; CHECKPOINT; INITIATION	The Dbf4-dependent Cdc7 kinase (DDK) is essential for chromosome duplication in all eukaryotes, but was proposed to be dispensable for yeast pre-meiotic DNA replication. This discrepancy led us to investigate the role of the unstable Cdc7-regulatory protein Dbf4 in meiosis. We show that, when Dbf4 is depleted at the time of meiotic induction, cells enter the meiotic program but do not replicate their chromosomes. Surprisingly when Dbf4 is depleted after the initiation of DNA synthesis, S phase goes to completion, but most cells arrest before anaphase I. Deletion of the cohesin Rec8 suppresses this phenotype, suggesting a distinct role of DDK for meiotic chromosome segregation. As after Cdc5 depletion, a fraction of cells undergo a single equational division suggesting a failure to mono-orient sister kinetochores. Our results demonstrate that Dbf4 is essential for DNA replication during meiosis like in vegetative cells and provide evidence for an additional role in setting up the reductional division of meiosis I.	Inst Mol Genet, F-34293 Montpellier 5, France; Univ Montpellier 2, CNRS, UMR5535, F-34293 Montpellier 5, France	Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Schwob, E (corresponding author), Inst Mol Genet, 1919,Route Mende, F-34293 Montpellier 5, France.	etienne.schwob@igmm.cnrs.fr; flavio.dellaseta@igmm.fr	Valentin, Guillaume/AAL-9185-2020; Schwob, Etienne/H-4678-2015; Schwob, Etienne/AAC-3050-2020	Schwob, Etienne/0000-0002-9369-6419; Valentin, Guillaume/0000-0003-4596-6282				Bailis JM, 2003, NAT CELL BIOL, V5, P1111, DOI 10.1038/ncb1069; Benjamin KR, 2003, GENE DEV, V17, P1524, DOI 10.1101/gad.1101503; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brott BK, 2005, DEV CELL, V8, P703, DOI 10.1016/j.devcel.2005.02.012; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Cha RS, 2000, GENE DEV, V14, P493; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; COLLINS I, 1994, MOL CELL BIOL, V14, P3524, DOI 10.1128/MCB.14.5.3524; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; Dirick L, 1998, SCIENCE, V281, P1854, DOI 10.1126/science.281.5384.1854; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Duncker BP, 2003, MUTAT RES-FUND MOL M, V532, P21, DOI 10.1016/j.mrfmmm.2003.08.007; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Forsburg SL, 2000, NAT GENET, V25, P263, DOI 10.1038/77015; Guttmann-Raviv N, 2001, GENETICS, V159, P1547; HOLLINGSWORTH RE, 1993, CHROMOSOMA, V102, P415, DOI 10.1007/BF00360406; Honigberg SM, 2004, J CELL BIOCHEM, V92, P1025, DOI 10.1002/jcb.20131; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; KLAPHOLZ S, 1985, GENETICS, V110, P187; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lengronne A, 2001, NUCLEIC ACIDS RES, V29, P1433, DOI 10.1093/nar/29.7.1433; Lindner K, 2002, MOL BIOL CELL, V13, P435, DOI 10.1091/mbc.01-11-0537; Marston AL, 2004, NAT REV MOL CELL BIO, V5, P983, DOI 10.1038/nrm1526; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Montagnoli A, 2002, EMBO J, V21, P3171, DOI 10.1093/emboj/cdf290; Murakami H, 2001, NAT GENET, V28, P290, DOI 10.1038/90142; Nakamura T, 2002, MOL CELL BIOL, V22, P309, DOI 10.1128/MCB.22.1.309-320.2002; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Ofir Y, 2004, MOL BIOL CELL, V15, P2230, DOI 10.1091/mbc.E03-08-0617; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; SCHILD D, 1978, CHROMOSOMA, V70, P109, DOI 10.1007/BF00292220; Shonn MA, 2000, SCIENCE, V289, P300, DOI 10.1126/science.289.5477.300; SIMCHEN G, 1974, GENETICS, V76, P745; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Stuart D, 1998, GENE DEV, V12, P2698, DOI 10.1101/gad.12.17.2698; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; XU LZ, 1995, MOL CELL BIOL, V15, P6572; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yoshizawa-Sugata N, 2005, J BIOL CHEM, V280, P13062, DOI 10.1074/jbc.M411653200	43	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2828	2834		10.1074/jbc.M510626200	http://dx.doi.org/10.1074/jbc.M510626200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319063	Green Published, hybrid			2022-12-27	WOS:000234931800050
J	Baars, L; Ytterberg, AJ; Drew, D; Wagner, S; Thilo, C; van Wijk, KJ; de Gier, JW				Baars, L; Ytterberg, AJ; Drew, D; Wagner, S; Thilo, C; van Wijk, KJ; de Gier, JW			Defining the role of the Escherichia coli chaperone SecB using comparative proteomics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; HEAT-SHOCK RESPONSE; OUTER-MEMBRANE; PROTEIN-TRANSLOCATION; SALMONELLA-TYPHIMURIUM; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; PLASMA-MEMBRANE; BINDING PROTEIN; FLOW-CYTOMETRY	To improve understanding and identify novel substrates of the cytoplasmic chaperone SecB in Escherichia coli, we analyzed a secB null mutant using comparative proteomics. The secB null mutation did not affect cell growth but caused significant differences at the proteome level. In the absence of SecB, dynamic protein aggregates containing predominantly secretory proteins accumulated in the cytoplasm. Unprocessed secretory proteins were detected in radiolabeled whole cell lysates. Furthermore, the assembly of a large fraction of the outer membrane proteome was slowed down, whereas its steady state composition was hardly affected. In response to aggregation and delayed sorting of secretory proteins, cytoplasmic chaperones DnaK, GroEL/ES, ClpB, IbpA/B, and HslU were up-regulated severalfold, most likely to stabilize secretory proteins during their delayed translocation and/or rescue aggregated secretory proteins. The SecB/A dependence of 12 secretory proteins affected by the secB null mutation ( DegP, FhuA, FkpA, OmpT, OmpX, OppA, TolB, TolC, YbgF, YcgK, YgiW, and YncE) was confirmed by "classical" pulse-labeling experiments. Our study more than triples the number of known SecB-dependent secretory proteins and shows that the primary role of SecB is to facilitate the targeting of secretory proteins to the Sec-translocase.	Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; Karolinska Univ Hosp Huddinge, Karolinska Inst, Ctr Infect Dis, SE-14186 Stockholm, Sweden	Stockholm University; Cornell University; Karolinska Institutet; Karolinska University Hospital	de Gier, JW (corresponding author), Stockholm Univ, Arrhenius Labs, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden.	degier@dbb.su.se	Drew, David/D-3243-2018; Ytterberg, Anders/E-1773-2016; Drew, David/AAY-3455-2020	Ytterberg, Anders/0000-0002-1485-2314; Drew, David/0000-0001-8866-6349; Wagner, Claudia/0000-0002-7311-2236				Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3; Berven FS, 2003, ELECTROPHORESIS, V24, P757, DOI 10.1002/elps.200390091; Carrio MM, 2003, FEBS LETT, V537, P215, DOI 10.1016/S0014-5793(03)00126-1; Darwin AJ, 2005, MOL MICROBIOL, V57, P621, DOI 10.1111/j.1365-2958.2005.04694.x; Davey HM, 1996, MICROBIOL REV, V60, P641, DOI 10.1128/MMBR.60.4.641-696.1996; Dekker C, 2003, J STRUCT BIOL, V144, P313, DOI 10.1016/j.jsb.2003.09.012; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Duguay AR, 2004, BBA-MOL CELL RES, V1694, P121, DOI 10.1016/j.bbamcr.2004.04.012; FEKKES P, 1995, BIOCHEMISTRY-US, V34, P10078, DOI 10.1021/bi00031a032; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Froderberg L, 2004, J BIOL CHEM, V279, P31026, DOI 10.1074/jbc.M403229200; Froderberg L, 2003, MOL MICROBIOL, V47, P1015, DOI 10.1046/j.1365-2958.2003.03346.x; Froderberg L, 2001, FEBS LETT, V498, P52, DOI 10.1016/S0014-5793(01)02494-2; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hewitt CJ, 2004, ADV BIOCHEM ENG BIOT, V89, P197; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; LAMINET AA, 1991, MOL MICROBIOL, V5, P117, DOI 10.1111/j.1365-2958.1991.tb01832.x; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Mogk A, 2003, MOL MICROBIOL, V50, P585, DOI 10.1046/j.1365-2958.2003.03710.x; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OSBORN MJ, 1972, J BIOL CHEM, V247, P3973; Peltier JB, 2000, PLANT CELL, V12, P319, DOI 10.1105/tpc.12.3.319; Peltier JB, 2002, PLANT CELL, V14, P211, DOI 10.1105/tpc.010304; Peterson JH, 2003, J BIOL CHEM, V278, P46155, DOI 10.1074/jbc.M309082200; POWERS EL, 1995, J BACTERIOL, V177, P1906, DOI 10.1128/jb.177.7.1906-1907.1995; Randall LL, 2002, CELL MOL LIFE SCI, V59, P1617, DOI 10.1007/PL00012488; Rosen R, 2002, MASS SPECTROM REV, V21, P244, DOI 10.1002/mas.10031; Ruiz N, 2005, CELL, V121, P307, DOI 10.1016/j.cell.2005.02.014; SCHAGGER H, 1988, ANAL BIOCHEM, V173, P201, DOI 10.1016/0003-2697(88)90179-0; Schierle CF, 2003, J BACTERIOL, V185, P5706, DOI 10.1128/JB.185.19.5706-5713.2003; Seol JH, 1997, EUR J BIOCHEM, V247, P1143, DOI 10.1111/j.1432-1033.1997.01143.x; Seong IS, 2000, FEBS LETT, V477, P224, DOI 10.1016/S0014-5793(00)01808-1; Shimizu H, 1997, MOL MICROBIOL, V26, P1013, DOI 10.1046/j.1365-2958.1997.6392003.x; Sijbrandi R, 2003, J BIOL CHEM, V278, P4654, DOI 10.1074/jbc.M211630200; Smith VF, 1997, PROTEIN SCI, V6, P1746, DOI 10.1002/pro.5560060815; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ullers RS, 2004, P NATL ACAD SCI USA, V101, P7583, DOI 10.1073/pnas.0402398101; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VanBogelen RA, 1999, METH MOL B, V112, P21; Vorderwulbecke S, 2004, FEBS LETT, V559, P181, DOI 10.1016/S0014-5793(04)00052-3; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WILD J, 1993, J BACTERIOL, V175, P3992, DOI 10.1128/JB.175.13.3992-3997.1993; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Xu ZH, 2000, NAT STRUCT BIOL, V7, P1172, DOI 10.1038/82040; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	55	65	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 14	2006	281	15					10024	10034		10.1074/jbc.M509929200	http://dx.doi.org/10.1074/jbc.M509929200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	029WE	16352602	hybrid			2022-12-27	WOS:000236594300026
J	Abdi, KM; Mohler, PJ; Davis, JQ; Bennett, V				Abdi, KM; Mohler, PJ; Davis, JQ; Bennett, V			Isoform specificity of ankyrin-B - A site in the divergent C-terminal domain is required for intramolecular association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; NEONATAL CARDIOMYOCYTES; CARDIAC-ARRHYTHMIA; REGULATORY DOMAIN; MEMBRANE SKELETON; CRYSTAL-STRUCTURE; BINDING; PROTEINS; SPECTRIN; LOCALIZATION	Ankyrins contain significant amino acid identity and are co-expressed in many cell types yet maintain unique functions in vivo. Recent studies have identified the highly divergent C-terminal domain in ankyrin-B as the key domain for driving ankyrin-B-specific functions in cardiomyocytes. Here we identify an intramolecular interaction between the C-terminal domain and the membrane-binding domain of ankyrin- B using pure proteins in solution and the yeast two-hybrid assay. Through extensive deletion and alanine-scanning mutagenesis we have mapped key residues for interaction in both domains. Amino acids (EED1599)-E-1597 located in the ankyrin- B C-terminal domain and amino acids Arg(37)/Arg(40) located in ANK repeat 1 are necessary for inter-domain interactions in yeast two-hybrid assays. Furthermore, conversion of amino acids EED1597 to AAA(1597) leads to a loss of function in the localization of inositol 1,4,5-trisphosphate receptors in ankyrin- B mutant cardiomyocytes. Physical properties of the ankyrin- B C-terminal domain determined by circular dichroism spectroscopy and hydrodynamic parameters reveal it is unstructured and highly extended in solution. Similar structural studies performed on full-length 220-kDa ankyrin- B harboring alanine substitutions, (1597)AAA(1599), reveal a more extended conformation compared with wild-type ankyrin- B. Taken together these results suggest a model of an extended and unstructured C-terminal domain folding back to bind and potentially regulate the membrane-binding domain of ankyrin- B.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurosci, Durham, NC 27710 USA; Duke Univ, Howard Hughes Med Inst, Durham, NC 27710 USA; Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA	Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute; Vanderbilt University	Bennett, V (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, 355 CARL Bldg, Durham, NC 27710 USA.	v.bennett@cellbio.duke.edu						Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; CHAN W, 1993, J CELL BIOL, V123, P1463, DOI 10.1083/jcb.123.6.1463; Chang SH, 2003, J BIOL CHEM, V278, P6879, DOI 10.1074/jbc.M211137200; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; Eber S, 2004, SEMIN HEMATOL, V41, P118, DOI 10.1053/j.seminhematol.2004.01.002; Garver TD, 1997, J CELL BIOL, V137, P703, DOI 10.1083/jcb.137.3.703; HALL TG, 1987, J BIOL CHEM, V262, P10537; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kontrogianni-Konstantopoulos A, 2003, MOL BIOL CELL, V14, P1138, DOI 10.1091/mbc.E02-07-0411; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Michaely P, 2002, EMBO J, V21, P6387, DOI 10.1093/emboj/cdf651; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P17533, DOI 10.1073/pnas.0403711101; Mohler PJ, 2004, P NATL ACAD SCI USA, V101, P9137, DOI 10.1073/pnas.0402546101; Mohler PJ, 2004, J BIOL CHEM, V279, P25798, DOI 10.1074/jbc.M401296200; Mohler PJ, 2004, J BIOL CHEM, V279, P12980, DOI 10.1074/jbc.M313979200; Mohler PJ, 2003, NATURE, V421, P634, DOI 10.1038/nature01335; Mohler PJ, 2002, J BIOL CHEM, V277, P10599, DOI 10.1074/jbc.M110958200; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Tuvia S, 1999, J CELL BIOL, V147, P995, DOI 10.1083/jcb.147.5.995; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Zhang X, 1998, J BIOL CHEM, V273, P30785, DOI 10.1074/jbc.273.46.30785	24	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5741	5749		10.1074/jbc.M506697200	http://dx.doi.org/10.1074/jbc.M506697200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16368689	hybrid			2022-12-27	WOS:000235568900052
J	Huang, LS; Sun, G; Cobessi, D; Wang, AC; Shen, JT; Tung, EY; Anderson, VE; Berry, EA				Huang, LS; Sun, G; Cobessi, D; Wang, AC; Shen, JT; Tung, EY; Anderson, VE; Berry, EA			3-Nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by Complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WOLINELLA-SUCCINOGENES QUINOL; FUMARATE REDUCTASE; SUCCINATE-DEHYDROGENASE; HUNTINGTONS-DISEASE; PROTEIN; IDENTIFICATION; MUTATIONS; MECHANISM; RESIDUES; MODELS	We report three new structures of mitochondrial respiratory Complex II (succinate ubiquinone oxidoreductase, E.C. 1.3.5.1) at up to 2.1 angstrom resolution, with various inhibitors. The structures define the conformation of the bound inhibitors and suggest the residues involved in substrate binding and catalysis at the dicarboxylate site. In particular they support the role of Arg(297) as a general base catalyst accepting a proton in the dehydrogenation of succinate. The dicarboxylate ligand in oxaloacetate-containing crystals appears to be the same as that reported for Shewanella flavocytochrome c treated with fumarate. The plant and fungal toxin 3-nitropropionic acid, an irreversible inactivator of succinate dehydrogenase, forms a covalent adduct with the side chain of Arg(297). The modification eliminates a trypsin cleavage site in the flavoprotein, and tandem mass spectroscopic analysis of the new fragment shows the mass of Arg(297) to be increased by 83 Da and to have the potential of losing 44 Da, consistent with decarboxylation, during fragmentation.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Case Western Reserve University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Anderson, VE (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA.	vea@cwru.edu; EABerry@LBL.gov	wang, andy/GRJ-8724-2022; Anderson, Vernon/W-2673-2019	Huang, Li-Shar/0000-0003-1427-2544; Anderson, Vernon Emmett/0000-0002-1699-7621	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG015885] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG 15885, P01 AG015885] Funding Source: Medline; NIDDK NIH HHS [DK 44842, R01 DK044842] Funding Source: Medline; NIGMS NIH HHS [R01 GM062563, R01 GM 62563] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; ACKRELL BAC, 1975, J BIOL CHEM, V250, P7114; Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2; ALSTON TA, 1977, P NATL ACAD SCI USA, V74, P3767, DOI 10.1073/pnas.74.9.3767; ANDERSON RC, 1993, APPL ENVIRON MICROB, V59, P3056, DOI 10.1128/AEM.59.9.3056-3061.1993; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; BEAL MF, 1993, J NEUROSCI, V13, P4181; BELIKOVA YO, 1988, BIOCHIM BIOPHYS ACTA, V936, P1, DOI 10.1016/0005-2728(88)90245-9; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P289, DOI 10.1016/S0149-7634(96)00027-9; Borlongan CV, 1997, BRAIN RES PROTOC, V1, P253, DOI 10.1016/S1385-299X(96)00037-2; Brambrink AM, 2004, ACT NEUR S, V89, P63; Browne SE, 1997, ANN NEUROL, V41, P646, DOI 10.1002/ana.410410514; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; COLES CJ, 1979, J BIOL CHEM, V254, P5161; DERVARTANIAN D. V., 1965, BIOCHIM BIOPHYS ACTA, V105, P424; Doherty MK, 2000, BIOCHEMISTRY-US, V39, P10695, DOI 10.1021/bi000871l; GILBERT HF, 1975, BIOCHEMISTRY-US, V14, P5194, DOI 10.1021/bi00694a027; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Huang LS, 2005, ACTA CRYSTALLOGR D, V61, P380, DOI 10.1107/S0907444905000181; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOTLYAR AB, 1984, BIOCHIM BIOPHYS ACTA, V784, P24, DOI 10.1016/0167-4838(84)90168-7; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2003, FEBS LETT, V555, P21, DOI 10.1016/S0014-5793(03)01100-1; Lancaster CRD, 2001, EUR J BIOCHEM, V268, P1820, DOI 10.1046/j.1432-1327.2001.02053.x; Liu X, 1992, Biomed Environ Sci, V5, P161; MING L, 1995, J TOXICOL-CLIN TOXIC, V33, P363, DOI 10.3109/15563659509028924; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oya T, 1999, J BIOL CHEM, V274, P18492, DOI 10.1074/jbc.274.26.18492; PANCHENKO MV, 1991, FEBS LETT, V286, P76, DOI 10.1016/0014-5793(91)80944-X; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Senoo-Matsuda N, 2003, J BIOL CHEM, V278, P22031, DOI 10.1074/jbc.M211377200; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Sun G, 2003, J MASS SPECTROM, V38, P531, DOI 10.1002/jms.467; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; TOI K, 1967, J BIOL CHEM, V242, P1036; Urbanska EM, 2000, POL J PHARMACOL, V52, P55; Walker FA, 2004, CHEM REV, V104, P589, DOI 10.1021/cr020634j; WESTWOOD ME, 1995, J PROTEIN CHEM, V14, P359, DOI 10.1007/BF01886793; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	47	221	233	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5965	5972		10.1074/jbc.M511270200	http://dx.doi.org/10.1074/jbc.M511270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371358	Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000235568900077
J	Khoshnoodi, J; Sigmundsson, K; Cartailler, JP; Bondar, O; Sundaramoorthy, M; Hudson, BG				Khoshnoodi, J; Sigmundsson, K; Cartailler, JP; Bondar, O; Sundaramoorthy, M; Hudson, BG			Mechanism of chain selection in the assembly of collagen IV - A prominent role for the alpha 2 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR-BASEMENT-MEMBRANE; GROWTH IN-VIVO; NONCOLLAGENOUS DOMAIN; CRYSTAL-STRUCTURE; MASS-TRANSPORT; TRIPLE-HELIX; NC1 DOMAINS; CROSS-LINK; PROCOLLAGEN; IDENTIFICATION	Collagens comprise a large superfamily of extracellular matrix proteins that play diverse roles in tissue function. The mechanism by which newly synthesized collagen chains recognize each other and assemble into specific triple-helical molecules is a fundamental question that remains unanswered. Emerging evidence suggests a role for the non-collagenous domain (NC1) located at the C-terminal end of each chain. In this study, we have investigated the molecular mechanism underlying chain selection in the assembly of collagen IV. Using surface plasmon resonance, we have determined the kinetics of interaction and assembly of the alpha 1(IV) and alpha 2(IV) NC1 domains. We show that the differential affinity of alpha 2(IV) NC1 domain for dimer formation underlies the driving force in the mechanism of chain discrimination. Given its characteristic domain recognition and affinity for the alpha 1(IV) NC1 domain, we conclude that the alpha 2(IV) chain plays a regulatory role in directing chain composition in the assembly of (alpha 1)(2)alpha 2 triple-helical molecule. Detailed crystal structure analysis of the [(alpha 1)(2)alpha 2](2) NC1 hexamer and sequence alignments of the NC1 domains of all six alpha-chains from mammalian species revealed the residues involved in the molecular recognition of NC1 domains. We further identified a hypervariable region of 15 residues and a beta-hairpin structural motif of 13 residues as two prominent regions that mediate chain selection in the assembly of collagen IV. To our knowledge, this report is the first to combine kinetics and structural data to describe molecular basis for chain selection in the assembly of a collagen molecule.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Novo Nordisk AS, DK-2760 Malov, Denmark	Vanderbilt University; Novo Nordisk	Khoshnoodi, J (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, S-3223 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	Jamshid.Khoshnoodi@vanderbilt.edu	Cartailler, Jean-Philippe/D-2543-2010	Cartailler, Jean-Philippe/0000-0002-0312-2391; Hudson, Billy/0000-0002-5420-4100	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, P01DK065123] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68485] Funding Source: Medline; NIDDK NIH HHS [P01 DK 065123, R37 DK 18381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHINGER HP, 1981, J BIOL CHEM, V256, P3193; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Bernocco S, 2001, J BIOL CHEM, V276, P48930, DOI 10.1074/jbc.M108611200; Borza DB, 2001, J BIOL CHEM, V276, P28532, DOI 10.1074/jbc.M103690200; Boutaud A, 2000, J BIOL CHEM, V275, P30716, DOI 10.1074/jbc.M004569200; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HUDSON BG, 1994, CONTRIB NEPHROL, V107, P163; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; Hulmes DJS, 2002, J STRUCT BIOL, V137, P2, DOI 10.1006/jsbi.2002.4450; LANGEVELD JPM, 1988, J BIOL CHEM, V263, P10481; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McLaughlin SH, 1999, J BIOL CHEM, V274, P7570, DOI 10.1074/jbc.274.11.7570; Myers JK, 2001, BIOCHEMISTRY-US, V40, P8479, DOI 10.1021/bi0027884; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Myszka DG, 1997, BIOPHYS CHEM, V64, P127, DOI 10.1016/S0301-4622(96)02230-2; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; PIHLAJANIEMI T, 1985, J BIOL CHEM, V260, P7681; Press W. H., 1999, NUMERICAL RECIPES C; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Rogers KS, 1997, BIOCHEM MOL MED, V61, P114, DOI 10.1006/bmme.1997.2596; Roth JM, 2005, AM J PATHOL, V166, P901, DOI 10.1016/S0002-9440(10)62310-3; Sigmundsson K, 2002, BIOCHEMISTRY-US, V41, P8263, DOI 10.1021/bi020099h; Soder S, 2004, BIOCHEM BIOPH RES CO, V325, P276, DOI 10.1016/j.bbrc.2004.10.034; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Than ME, 2002, P NATL ACAD SCI USA, V99, P6607, DOI 10.1073/pnas.062183499; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; Vanacore RM, 2005, J BIOL CHEM, V280, P29300, DOI 10.1074/jbc.M502752200; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575	32	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6058	6069		10.1074/jbc.M506555200	http://dx.doi.org/10.1074/jbc.M506555200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373348	hybrid			2022-12-27	WOS:000235568900087
J	Sugahara, KN; Hirata, T; Hayasaka, H; Stern, R; Murai, T; Miyasaka, M				Sugahara, KN; Hirata, T; Hayasaka, H; Stern, R; Murai, T; Miyasaka, M			Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; UP-REGULATION; URINE MARKER; OLIGOSACCHARIDES; GROWTH; SERUM; ACID; HYALURONIDASE-2; PURIFICATION; ACTIVATION	Hyaluronan (HA) is an extracellular matrix glycosaminoglycan that interacts with cell-surface receptors, including CD44. Although HA usually exists as a high molecular mass polymer, HA of a much lower molecular mass that shows a variety of biological activities can be detected under certain pathological conditions, particularly in tumors. We previously reported that low molecular weight HAs (LMW-HAs) of a certain size range induce the proteolytic cleavage of CD44 from the surface of tumor cells and promote tumor cell migration in a CD44-dependent manner. Here, we show that MIA PaCa-2, a human pancreatic carcinoma cell line, secreted hyaluronidases abundantly and generated readily detectable levels of LMW-HAs ranging from similar to 10- to 40-mers. This occurred in the absence of any exogenous stimulation. The tumor-derived HA oligosaccharides were able to enhance CD44 cleavage and tumor cell motility. Inhibition of the CD44-HA interaction resulted in the complete abrogation of these cellular events. These results are consistent with the concept that tumor cells generate HA oligosaccharides that bind to tumor cell CD44 through the expression of their own constitutive hyaluronidases. This enhances their own CD44 cleavage and cell motility, which would subsequently promote tumor progression. Such an autocrine/paracrine-like process may represent a novel activation mechanism that would facilitate and promote the malignant potential of tumor cells.	Osaka Univ, Grad Sch Med, Dept Microbiol & Immunol, Lab Immunodynam, Suita, Osaka 5650871, Japan; Osaka Univ, Microbial Dis Res Inst, 21st Century COE Program, Suita, Osaka 5650871, Japan; Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA	Osaka University; Osaka University; University of California System; University of California San Francisco	Miyasaka, M (corresponding author), Osaka Univ, Grad Sch Med C8, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mmiyasak@orgctl.med.osaka-u.ac.jp	Miyasaka, Masayuki/AAM-6343-2020	Hirata, Takako/0000-0002-1740-6168				AFIFY AM, 1993, ARCH BIOCHEM BIOPHYS, V305, P434, DOI 10.1006/abbi.1993.1443; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; DAHL IMS, 1988, CANCER-AM CANCER SOC, V62, P326, DOI 10.1002/1097-0142(19880715)62:2<326::AID-CNCR2820620217>3.0.CO;2-Y; Fieber C, 2004, J CELL SCI, V117, P359, DOI 10.1242/jcs.00831; FOSANG AJ, 1990, MATRIX, V10, P306, DOI 10.1016/S0934-8832(11)80186-1; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Fujisaki T, 1999, CANCER RES, V59, P4427; Ghatak S, 2005, J BIOL CHEM, V280, P8875, DOI 10.1074/jbc.M410882200; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; GUO YJ, 1994, CANCER RES, V54, P422; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106; KUMAR S, 1989, INT J CANCER, V44, P445, DOI 10.1002/ijc.2910440311; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lokeshwar VB, 2000, J UROLOGY, V163, P348, DOI 10.1016/S0022-5347(05)68050-0; Lokeshwar VB, 1997, CANCER RES, V57, P773; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Novak U, 1999, CANCER RES, V59, P6246; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Pham HT, 1997, CANCER RES, V57, P778; Ropponen K, 1998, CANCER RES, V58, P342; Shi M, 2001, J IMMUNOL, V167, P123, DOI 10.4049/jimmunol.167.1.123; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; STERN M, 1992, MATRIX, V12, P397, DOI 10.1016/S0934-8832(11)80036-3; Stern R, 2004, EUR J CELL BIOL, V83, P317, DOI 10.1078/0171-9335-00392; Sugahara KN, 2004, TRENDS GLYCOSCI GLYC, V16, P187, DOI 10.4052/tigg.16.187; Sugahara KN, 2003, J BIOL CHEM, V278, P32259, DOI 10.1074/jbc.M300347200; Tawada A, 2002, GLYCOBIOLOGY, V12, P421, DOI 10.1093/glycob/cwf048; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Toole BP, 2000, J CLIN INVEST, V106, P335, DOI 10.1172/JCI10706; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, GLYCOBIOLOGY, V12, p37R, DOI 10.1093/glycob/12.3.37R; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Zeng CX, 1998, INT J CANCER, V77, P396	52	100	105	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5861	5868		10.1074/jbc.M506740200	http://dx.doi.org/10.1074/jbc.M506740200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407205	hybrid			2022-12-27	WOS:000235568900066
J	Civas, A; Genin, P; Morin, P; Lin, RT; Hiscott, J				Civas, A; Genin, P; Morin, P; Lin, RT; Hiscott, J			Promoter organization of the interferon-A genes differentially affects virus-induced expression and responsiveness to TBK1 and IKK epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED RNA; NF-KAPPA-B; TRANSCRIPTION FACTOR; RIG-I; REGULATORY FACTOR-3; ANTIVIRAL RESPONSES; POSITIVE FEEDBACK; CRYSTAL-STRUCTURE; ALPHA PRODUCTION; ADAPTER PROTEIN	Virus-induced expression of interferon (IFN)-A genes is regulated by two members of the IFN regulatory factor (IRF) family, IRF-3 and IRF-7, which are activated by phosphorylation during viral infection by the IKK-related serine/threonine kinases TBK1 and I kappa B kinase epsilon (IKK epsilon). In this study, we demonstrate that three IRF- binding sites located in the virus-responsive element mediate the transcriptional activation of the IFN-A4 promoter by IRF-3. The precise arrangement of these IRF elements is required for synergistic activation of the IFN-A4 promoter following Newcastle disease virus infection or activation by TBK1 or IKK epsilon. The ordered assembly of IRF- 3 multimers on the promoter also determines cooperative recruitment of IRF-3 and CREB-binding protein and differential virus-induced expression of IFN-A4 gene promoter compared with IFN-A11. Naturally occurring nucleotide substitutions disrupt two of the IRF elements in the IFN-A11 gene promoter, leading to a dramatic decrease in IRF-3 and CREB-binding protein recruitment and in IRF-3-dependent transcription. Transcription of the IFN-A4 promoter by IRF- 7 is mediated by two IRF elements; promoter mutants that carry a reversed IRF element retain the ability to respond to IKK epsilon or TBK1 expression in the presence of IRF- 7 but lose the capacity to respond to virus or kinase-induced IRF-3. Interestingly, IKK epsilon or TBK1 stimulates the IRF-7-mediated transcription of IFN-A11, although at a lesser extent compared with IFN-A4. Our data indicate that virus-induced expression of IFN-A genes is dictated by the organization of IRF elements within the IFN-A promoters and that the differential IFN-A gene expression, based on the IRF- 3 responsiveness, is partially compensated in the presence of IRF-7 when both factors are activated by IKK epsilon or TBK1.	Univ Paris 05, CNRS, UPR 2228, Lab Regulat Transcript & Malad Genet, F-75270 Paris 06, France; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Civas, A (corresponding author), Univ Paris 05, CNRS, UPR 2228, Lab Regulat Transcript & Malad Genet, 45 Rue St Peres, F-75270 Paris 06, France.	ahmet.civas@univ-paris5.fr	Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503; Genin, Pierre/0000-0002-7502-3851				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; AU WC, 1993, J BIOL CHEM, V268, P24032; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Barchet W, 2002, J EXP MED, V195, P507, DOI 10.1084/jem.20011666; Braganca J, 1997, J BIOL CHEM, V272, P22154, DOI 10.1074/jbc.272.35.22154; CIVAS A, 1991, NUCLEIC ACIDS RES, V19, P4497, DOI 10.1093/nar/19.16.4497; Civas A, 2002, BIOCHIMIE, V84, P643, DOI 10.1016/S0300-9084(02)01431-1; Coccia EM, 2004, EUR J IMMUNOL, V34, P796, DOI 10.1002/eji.200324610; Colonna M, 2002, CURR OPIN IMMUNOL, V14, P373, DOI 10.1016/S0952-7915(02)00349-7; COULOMBEL C, 1991, GENE, V104, P187, DOI 10.1016/0378-1119(91)90249-B; Dalod M, 2003, J EXP MED, V197, P885, DOI 10.1084/jem.20021522; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Harlow E., 1988, ANTIBODIES LAB MANUA; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; HOSSHOMFELD A, 1989, VIROLOGY, V173, P539, DOI 10.1016/0042-6822(89)90566-7; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P825, DOI 10.1093/nar/13.3.825; KELLEY KA, 1985, NUCLEIC ACIDS RES, V13, P805, DOI 10.1093/nar/13.3.805; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 2000, J BIOL CHEM, V275, P34320, DOI 10.1074/jbc.M002814200; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Morin P, 2002, J MOL BIOL, V316, P1009, DOI 10.1006/jmbi.2001.5401; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Ning SB, 2005, J BIOL CHEM, V280, P12262, DOI 10.1074/jbc.M404260200; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Panne D, 2004, EMBO J, V23, P4384, DOI 10.1038/sj.emboj.7600453; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Suhara W, 2002, J BIOL CHEM, V277, P22304, DOI 10.1074/jbc.M200192200; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yang HM, 2003, J BIOL CHEM, V278, P15495, DOI 10.1074/jbc.M212940200; Yie JM, 1999, P NATL ACAD SCI USA, V96, P13108, DOI 10.1073/pnas.96.23.13108; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; ZWARTHOFF EC, 1985, NUCLEIC ACIDS RES, V13, P791, DOI 10.1093/nar/13.3.791	65	32	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4856	4866		10.1074/jbc.M506812200	http://dx.doi.org/10.1074/jbc.M506812200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16380379	hybrid			2022-12-27	WOS:000235426200036
J	Schonichen, A; Alexander, M; Gasteier, JE; Cuesta, FE; Fackler, OT; Geyer, M				Schonichen, A; Alexander, M; Gasteier, JE; Cuesta, FE; Fackler, OT; Geyer, M			Biochemical characterization of the diaphanous autoregulatory interaction in the formin homology protein FHOD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SRC TYROSINE KINASE; ACTIN NUCLEATION; FH2 DOMAIN; CYTOSKELETAL CONTROL; STRUCTURAL BASIS; BINDING PROTEIN; RHO-GTPASE; F-ACTIN; MDIA1	Diaphanous related formins ( DRFs) are cytoskeleton remodeling proteins that mediate specific upstream GTPase signals to regulate cellular processes such as cytokinesis, cell polarity, and organelle motility. Previous work on the Rho-interacting DRF mDia has established that the biological activity of DRFs is regulated by an autoinhibitory interaction of a C-terminal diaphanous autoregulatory domain ( DAD) with the DRFN terminus. This autoinhibition is released upon competitive binding of an activated GTPase to the N terminus of the DRF. Analyzing autoregulation of the Rac1-interacting DRF FHOD1, we utilized in vitro binding studies to identify a 60-amino acid DAD at the protein C terminus that recognizes an N-terminal formin homology ( FH) 3 domain. Importantly, the FH3 domain of FHOD1 does not overlap with the proposed Rac1-binding domain. The FHOD1 DAD was found to contain one functional hydrophobic autoregulatory motif, while a previously uncharacterized basic cluster that is conserved in all DRF family DADs also contributed to the FH3-DAD interaction. Simultaneous mutation of both motifs efficiently released autoinhibition of FHOD1 in NIH3T3 cells resulting in the formation of actin stress fibers and increased serum response element transcription. A second putative hydrophobic autoregulatory motif N-terminal of the DAD belongs to a unique FHOD subdomain of yet undefined function. NMR structural analysis and size exclusion chromatography experiments revealed that the FHOD1 DAD is intrinsically unstructured with a tendency for a helical conformation in the hydrophobic autoregulation motif. Together, these data suggest that in FHOD1, DAD acts as signal sequence for binding to the well folded and monomeric FH3 domain and imply an activation mechanism that differs from competitive binding of Rac1 and DAD to one interaction site.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany; Univ Heidelberg, Dept Virol, D-69120 Heidelberg, Germany	Max Planck Society; Ruprecht Karls University Heidelberg	Geyer, M (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.	matthias.geyer@mpi-dortmund.mpg.de		Fackler, Oliver Till/0000-0003-2982-4209; Geyer, Matthias/0000-0002-7718-5002				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Copeland JW, 2004, J BIOL CHEM, V279, P50250, DOI 10.1074/jbc.M404429200; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Gasteier JE, 2005, EXP CELL RES, V306, P192, DOI 10.1016/j.yexcr.2005.02.006; Gasteier JE, 2003, J BIOL CHEM, V278, P38902, DOI 10.1074/jbc.M306229200; Geyer M, 1999, J MOL BIOL, V289, P123, DOI 10.1006/jmbi.1999.2740; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Higashida C, 2004, SCIENCE, V303, P2007, DOI 10.1126/science.1093923; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Kanaya H, 2005, GENES CELLS, V10, P665, DOI 10.1111/j.1365-2443.2005.00867.x; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Madrid R, 2005, FEBS LETT, V579, P441, DOI 10.1016/j.febslet.2004.12.009; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Petersen J, 1998, J CELL BIOL, V141, P1217, DOI 10.1083/jcb.141.5.1217; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Schulte A, 2005, J BIOL CHEM, V280, P24968, DOI 10.1074/jbc.M501431200; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Takeya R, 2003, J CELL SCI, V116, P4567, DOI 10.1242/jcs.00769; Tanaka K, 2000, BIOCHEM BIOPH RES CO, V267, P479, DOI 10.1006/bbrc.1999.1707; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 2004, EXP CELL RES, V301, P16, DOI 10.1016/j.yexcr.2004.08.020; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	43	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5084	5093		10.1074/jbc.M509226200	http://dx.doi.org/10.1074/jbc.M509226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361249	hybrid			2022-12-27	WOS:000235426200063
J	Takahashi, E; Wraight, CA				Takahashi, E; Wraight, CA			Small weak acids reactivate proton transfer in reaction centers from Rhodobacter sphaeroides mutated at Asp(L210) and Asp(M17)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL REACTION CENTERS; PHOTOSYNTHETIC REACTION CENTERS; ACCEPTOR QUINONE COMPLEX; SITE-DIRECTED MUTANTS; 2 IONIZABLE RESIDUES; INDUCED H+ BINDING; ELECTRON-TRANSFER; SECONDARY QUINONE; MEMBRANE-PROTEINS; TRANSFER PATHWAYS	In reaction centers of Rhodobacter sphaeroides, site-directed mutagenesis has implicated several acidic residues in the delivery of protons to the secondary quinone (Q(B)) during reduction to quinol. In a double mutant (Asp(L210) -> Asn + Asp(M17) -> Asn) that is severely impaired in proton transfer capability over a wide pH range, proton transfer was "rescued" by added weak acids. For low pK(a) acids the total concentration of salt required near neutral pH was high. The ionic strength effect of added salts stimulated the rate of proton-coupled electron transfer at pH < 7, but decreased it at pH > 7.5, indicating an effective isoelectric point between these limits. In this region, a substantial rate enhancement by weak acids was clearly evident. A Bronsted plot of activity versus pK(a) of the rescuing acids was linear, with a slope of -1, and extrapolated to a diffusion-limited rate at pK(a)(app) approximate to 1. However, the maximum rate at saturating concentrations of acid did not correlate with pKa, indicating that the acid and anion species compete for binding, both with weak affinity. This model predicts that pK(a)(app) corresponds to a true pK(a) = 4-5, similar to that for a carboxylic acid or Q(B)(-), itself. Only rather small, neutral acids were active, indicating a need to access a small internal volume, suggested to be a proton channel to theQB domain. However, the on-rates were near the diffusion limit. The implications for intraprotein proton transfer pathway design are discussed.	Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Wraight, CA (corresponding author), Univ Illinois, Ctr Biophys & Computat Biol, MC-147,607 S Mathews Ave, Urbana, IL 61801 USA.	cwraight@uiuc.edu						Abresch EC, 1998, PHOTOSYNTH RES, V55, P119, DOI 10.1023/A:1006047519260; Adelroth P, 2000, P NATL ACAD SCI USA, V97, P13086, DOI 10.1073/pnas.230439597; Adelroth P, 2001, BIOCHEMISTRY-US, V40, P14538, DOI 10.1021/bi011585s; Alexov E, 2000, BIOCHEMISTRY-US, V39, P5940, DOI 10.1021/bi9929498; Alexov EG, 1999, BIOCHEMISTRY-US, V38, P8253, DOI 10.1021/bi982700a; Axelrod HL, 2000, P NATL ACAD SCI USA, V97, P1542, DOI 10.1073/pnas.97.4.1542; BEROZA P, 1995, BIOPHYS J, V68, P2233, DOI 10.1016/S0006-3495(95)80406-6; BUDIL DE, 1987, ANNU REV PHYS CHEM, V38, P561, DOI 10.1146/annurev.pc.38.100187.003021; Chelikani P, 2003, J BIOL CHEM, V278, P31290, DOI 10.1074/jbc.M304076200; Cherepanov DA, 2000, BBA-BIOENERGETICS, V1459, P10, DOI 10.1016/S0005-2728(00)00110-9; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Deisenhofer J., 1993, PHOTOSYNTHETIC REACT, VII, P49; FEHER G, 1989, NATURE, V339, P111, DOI 10.1038/339111a0; Gerencser L, 2001, BIOCHEMISTRY-US, V40, P1850, DOI 10.1021/bi0021636; Graige MS, 1999, BIOCHEMISTRY-US, V38, P11465, DOI 10.1021/bi990708u; Graige MS, 1996, J AM CHEM SOC, V118, P9005, DOI 10.1021/ja960056m; Graige MS, 1998, P NATL ACAD SCI USA, V95, P11679, DOI 10.1073/pnas.95.20.11679; HANSON DK, 1993, P NATL ACAD SCI USA, V90, P8929, DOI 10.1073/pnas.90.19.8929; Jenkins HDB, 1999, INORG CHEM, V38, P3609, DOI 10.1021/ic9812961; KEMPSTER CJ, 1972, ACTA CRYSTALLOGR B, V28, P3674, DOI 10.1107/S056774087200857X; KRISHTALIK LI, 1995, FEBS LETT, V369, P140, DOI 10.1016/0014-5793(95)00756-Y; Lancaster CRD, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL I, P903; LEE JK, 1989, J BACTERIOL, V171, P3391, DOI 10.1128/jb.171.6.3391-3405.1989; Li JL, 1998, BIOCHEMISTRY-US, V37, P2818, DOI 10.1021/bi971699x; Maniatis T., 1982, MOL CLONING; MAROTI P, 1994, P NATL ACAD SCI USA, V91, P5617, DOI 10.1073/pnas.91.12.5617; MAROTI P, 1995, NAT STRUCT BIOL, V2, P1057, DOI 10.1038/nsb1295-1057; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P329, DOI 10.1016/0005-2728(88)90092-8; Maroti P, 1997, BIOPHYS J, V73, P367, DOI 10.1016/S0006-3495(97)78077-9; MAROTI P, 1988, BIOCHIM BIOPHYS ACTA, V934, P314, DOI 10.1016/0005-2728(88)90091-6; MCPHERSON PH, 1988, BIOCHIM BIOPHYS ACTA, V934, P348, DOI 10.1016/0005-2728(88)90093-X; Miksovska J, 1997, BIOCHEMISTRY-US, V36, P12216, DOI 10.1021/bi970442w; MITCHELL P, 1979, SCIENCE, V206, P1148, DOI 10.1126/science.388618; Moser CC, 2003, ADV PROTEIN CHEM, V63, P71; NAIR HK, 1994, BIOCHEMISTRY-US, V33, P8566, DOI 10.1021/bi00194a023; Nicholls P, 2001, ADV INORG CHEM, V51, P51; Okamura MY, 2000, BBA-BIOENERGETICS, V1458, P148, DOI 10.1016/S0005-2728(00)00065-7; Paddock M, 2004, BIOPHYS J, V86, p11A; PADDOCK ML, 1995, BIOCHEMISTRY-US, V34, P15742, DOI 10.1021/bi00048a019; Paddock ML, 2003, FEBS LETT, V555, P45, DOI 10.1016/S0014-5793(03)01149-9; Paddock ML, 2003, BIOCHEMISTRY-US, V42, P9626, DOI 10.1021/bi0346648; Paddock ML, 1998, PHOTOSYNTH RES, V55, P281, DOI 10.1023/A:1005953615604; Paddock ML, 1999, P NATL ACAD SCI USA, V96, P6183, DOI 10.1073/pnas.96.11.6183; PADDOCK ML, 1990, P NATL ACAD SCI USA, V87, P6803, DOI 10.1073/pnas.87.17.6803; Paddock ML, 2000, P NATL ACAD SCI USA, V97, P1548, DOI 10.1073/pnas.97.4.1548; Paddock ML, 2002, BIOCHEMISTRY-US, V41, P14716, DOI 10.1021/bi020419x; PADDOCK ML, 1989, P NATL ACAD SCI USA, V86, P6602, DOI 10.1073/pnas.86.17.6602; Paddock ML, 2001, BIOCHEMISTRY-US, V40, P6893, DOI 10.1021/bi010280a; PRINCE RC, 1974, BIOCH BIOPHYS ACTA, V347; RADIC Z, 1992, BIOCHEMISTRY-US, V31, P9760, DOI 10.1021/bi00155a032; RONGEY SH, 1993, P NATL ACAD SCI USA, V90, P1325, DOI 10.1073/pnas.90.4.1325; SEBBAN P, 1995, BIOCHEMISTRY-US, V34, P8390, DOI 10.1021/bi00026a021; Shinkarev VP, 1993, PHOTOSYNTHETIC REACT, V1, P193; SISTROM WR, 1962, J GEN MICROBIOL, V28, P607, DOI 10.1099/00221287-28-4-607; TAKAHASHI E, 1990, BIOCHIM BIOPHYS ACTA, V1020, P107, DOI 10.1016/0005-2728(90)90100-I; TAKAHASHI E, 1992, BIOCHEMISTRY-US, V31, P855, DOI 10.1021/bi00118a031; TAKAHASHI E, 1991, FEBS LETT, V283, P140, DOI 10.1016/0014-5793(91)80572-K; Takahashi E., 1990, CURRENT RES PHOTOSYN, V1, P169; TAKAHASHI E, 1992, ELECT PROTON TRANSFE, V78, P219; Utschig LM, 1998, BIOCHEMISTRY-US, V37, P8278, DOI 10.1021/bi980395n; Utschig LM, 2000, BIOCHEMISTRY-US, V39, P2961, DOI 10.1021/bi991800t; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Woodbury NW, 1995, ANOXYGENIC PHOTOSYNT, P527, DOI [DOI 10.1007/0-306-47954-0_24, 10.1007/0-306-47954-0_24]; Wraight CA, 2004, FRONT BIOSCI-LANDMRK, V9, P309, DOI 10.2741/1236; WRAIGHT CA, 1982, FUNCTION QUINONES EN, P11; Zhou HX, 1996, J AM CHEM SOC, V118, P13069, DOI 10.1021/ja963134e; Zhu ZY, 2005, BIOCHEMISTRY-US, V44, P82, DOI 10.1021/bi048348k	67	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4413	4422		10.1074/jbc.M511359200	http://dx.doi.org/10.1074/jbc.M511359200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354664	hybrid			2022-12-27	WOS:000235275300077
J	Bylund, J; Burgess, LA; Cescutti, P; Ernst, RK; Speert, DP				Bylund, J; Burgess, LA; Cescutti, P; Ernst, RK; Speert, DP			Exopolysaccharides from Burkholderia cenocepacia inhibit neutrophil chemotaxis and scavenge reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOID PSEUDOMONAS-AERUGINOSA; CHRONIC GRANULOMATOUS-DISEASE; CYSTIC-FIBROSIS; MOUSE MODEL; MICROBIAL PATHOGENESIS; RESPIRATORY BURST; CLINICAL ISOLATE; CEPACIA COMPLEX; LIPOPOLYSACCHARIDE; ALGINATE	Bacteria belonging to the Burkholderia cepacia complex are important opportunistic pathogens in compromised hosts, particularly patients with cystic fibrosis or chronic granulomatous disease. Isolates of B. cepacia complex may produce large amounts of exopolysaccharides (EPS) that endow the bacteria with a mucoid phenotype and appear to facilitate bacterial persistence during infection. We showed that EPS from a clinical B. cenocepacia isolate interfered with the function of human neutrophils in vitro; it inhibited chemotaxis and production of reactive oxygen species (ROS), both essential components of innate neutrophil-mediated host defenses. These inhibitory effects were not due to cytotoxicity or interference with intracellular calcium signaling. EPS also inhibited enzymatic generation of ROS in cell-free systems, indicating that it scavenges these bactericidal products. B. cenocepacia EPS is structurally distinct from Pseudomonas aeruginosa alginate, yet they share the capacity to scavenge ROS and inhibit chemotaxis. These properties could explain why the two bacterial species resist clearance from the infected cystic fibrosis lung.	Univ British Columbia, Dept Paediat, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Trieste, Dept Biochem Biophys & Macromol Chem, I-34127 Trieste, Italy	Child & Family Research Institute; University of British Columbia; University of Washington; University of Washington Seattle; University of Trieste	Speert, DP (corresponding author), Univ British Columbia, Dept Paediat, Child & Family Res Inst, Rm 377,950 W 238th Ave, Vancouver, BC V5Z 4H4, Canada.	dspeert@cw.bc.ca		Ernst, Robert/0000-0001-5016-8694; Cescutti, Paola/0000-0003-3744-2198	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057141] Funding Source: NIH RePORTER; NIAID NIH HHS [U54AI057141] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aaron SD, 2000, AM J RESP CRIT CARE, V161, P1206, DOI 10.1164/ajrccm.161.4.9907147; BIGNOLD LP, 1991, INFECT IMMUN, V59, P4255, DOI 10.1128/IAI.59.11.4255-4258.1991; Borges F, 2002, CURR MED CHEM, V9, P195, DOI 10.2174/0929867023371229; Boucher JC, 1997, INFECT IMMUN, V65, P3838, DOI 10.1128/IAI.65.9.3838-3846.1997; BOYUM A, 1991, SCAND J IMMUNOL, V34, P697, DOI 10.1111/j.1365-3083.1991.tb01594.x; BURKHOLDER WH, 1950, PHYTOPATHOLOGY, V40, P115; Bylund J, 2002, INFECT IMMUN, V70, P2908, DOI 10.1128/IAI.70.6.2908-2914.2002; Bylund J, 2005, ADV EXP MED BIOL, V568, P67; Bylund J, 2005, J IMMUNOL, V174, P3562, DOI 10.4049/jimmunol.174.6.3562; Cerantola S, 1999, EUR J BIOCHEM, V260, P373, DOI 10.1046/j.1432-1327.1999.00171.x; Cerantola S, 1996, CARBOHYD RES, V285, P59, DOI 10.1016/0008-6215(96)00014-6; Cerantola S, 2000, FEMS MICROBIOL LETT, V185, P243, DOI 10.1016/S0378-1097(00)00099-9; Cescutti P, 2000, BIOCHEM BIOPH RES CO, V273, P1088, DOI 10.1006/bbrc.2000.3059; Clark RA, 1999, J INFECT DIS, V179, pS309, DOI 10.1086/513849; Conway BAD, 2004, J INFECT DIS, V190, P957, DOI 10.1086/423141; Cunha MV, 2004, J CLIN MICROBIOL, V42, P3052, DOI 10.1128/JCM.42.7.3052-3058.2004; Cunha MV, 2003, J CLIN MICROBIOL, V41, P4113, DOI 10.1128/JCM.41.9.4113-4120.2003; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Eberl L, 2004, INT J MED MICROBIOL, V294, P123, DOI 10.1016/j.ijmm.2004.06.022; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Gudmundsson GH, 1999, J IMMUNOL METHODS, V232, P45, DOI 10.1016/S0022-1759(99)00152-0; GUTHRIE LA, 1984, J EXP MED, V160, P1656, DOI 10.1084/jem.160.6.1656; HANCOCK REW, 1983, INFECT IMMUN, V42, P170, DOI 10.1128/IAI.42.1.170-177.1983; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hoffmann N, 2005, INFECT IMMUN, V73, P2504, DOI 10.1128/IAI.73.4.2504-2514.2005; Hudson VM, 2001, FREE RADICAL BIO MED, V30, P1440, DOI 10.1016/S0891-5849(01)00530-5; Hughes JE, 1997, INFECT IMMUN, V65, P4281, DOI 10.1128/IAI.65.10.4281-4287.1997; ISLES A, 1984, J PEDIATR-US, V104, P206, DOI 10.1016/S0022-3476(84)80993-2; Karlsson A, 2002, ANTIOXID REDOX SIGN, V4, P49, DOI 10.1089/152308602753625852; KONIG B, 1992, INT ARCH ALLERGY IMM, V99, P98, DOI 10.1159/000236341; Krause KH, 2004, JPN J INFECT DIS, V57, pS28; Lagatolla C, 2002, FEMS MICROBIOL LETT, V209, P99, DOI 10.1111/j.1574-6968.2002.tb11116.x; LEARN DB, 1987, INFECT IMMUN, V55, P1813, DOI 10.1128/IAI.55.8.1813-1818.1987; LEW PD, 1990, AM REV RESPIR DIS, V141, pS127, DOI 10.1164/ajrccm/141.3_Pt_2.S127; Linker A, 2001, CARBOHYD RES, V335, P45, DOI 10.1016/S0008-6215(01)00205-1; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; MRSNY RJ, 1994, PULM PHARMACOL, V7, P357, DOI 10.1006/pulp.1994.1042; Pasquier C, 1997, FEMS MICROBIOL LETT, V147, P195, DOI 10.1016/S0378-1097(96)00523-X; PEDERSEN SS, 1990, INFECT IMMUN, V58, P3363, DOI 10.1128/IAI.58.10.3363-3368.1990; Richau JA, 2000, J CLIN MICROBIOL, V38, P1651, DOI 10.1128/JCM.38.4.1651-1655.2000; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Roos D, 2003, MICROBES INFECT, V5, P1307, DOI 10.1016/j.micinf.2003.09.009; SHERBROCKCOX V, 1984, CARBOHYD RES, V135, P147, DOI 10.1016/0008-6215(84)85012-0; Shimomura H, 2003, INFECT IMMUN, V71, P5225, DOI 10.1128/IAI.71.9.5225-5230.2003; SIMPSON JA, 1989, FREE RADICAL BIO MED, V6, P347, DOI 10.1016/0891-5849(89)90078-6; Sist P, 2003, CARBOHYD RES, V338, P1861, DOI 10.1016/S0008-6215(03)00306-9; Speert David Paul, 2002, Paediatr Respir Rev, V3, P230, DOI 10.1016/S1526-0542(02)00185-9; SPEERT DP, 1994, J INFECT DIS, V170, P1524, DOI 10.1093/infdis/170.6.1524; STOKES DC, 1989, J INFECT DIS, V160, P52, DOI 10.1093/infdis/160.1.52; Yu H, 1998, INFECT IMMUN, V66, P280, DOI 10.1128/IAI.66.1.280-288.1998	51	106	107	1	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2526	2532		10.1074/jbc.M510692200	http://dx.doi.org/10.1074/jbc.M510692200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316987	hybrid			2022-12-27	WOS:000234931800015
J	Manna, T; Thrower, D; Miller, HP; Curmi, P; Wilson, L				Manna, T; Thrower, D; Miller, HP; Curmi, P; Wilson, L			Stathmin strongly increases the minus end catastrophe frequency and induces rapid treadmilling of bovine brain microtubules at steady state in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINESIN-RELATED PROTEIN; STAGE-SPECIFIC EXPRESSION; DYNAMIC INSTABILITY; INTRACELLULAR PH; ONCOPROTEIN 18; PHOSPHOPROTEIN P19; LIGHT-MICROSCOPY; MITOTIC SPINDLES; TUBULIN; OP18/STATHMIN	Stathmin is a ubiquitous microtubule destabilizing protein that is believed to play an important role linking cell signaling to the regulation of microtubule dynamics. Here we show that stathmin strongly destabilizes microtubule minus ends in vitro at steady state, conditions in which the soluble tubulin and microtubule levels remain constant. Stathmin increased the minus end catastrophe frequency similar to 13-fold at a stathmin: tubulin molar ratio of 1:5. Stathmin steady-state catastrophe-promoting activity was considerably stronger at the minus ends than at the plus ends. Consistent with its ability to destabilize minus ends, stathmin strongly increased the treadmilling rate of bovine brain microtubules. By immunofluorescence microscopy, we also found that stathmin binds to purified microtubules along their lengths in vitro. Co-sedimentation of purified microtubules polymerized in the presence of a 1: 5 initial molar ratio of stathmin to tubulin yielded a binding stoichiometry of 1 mol of stathmin per similar to 14.7 mol of tubulin in the microtubules. The results firmly establish that stathmin can increase the steady-state catastrophe frequency by a direct action on microtubules, and furthermore, they indicate that an important regulatory action of stathmin in cells may be to destabilize microtubule minus ends.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Evry Val Essonne, Lab Struct & Reconnaissance Biomol, EA3637, F-91025 Evry, France	University of California System; University of California Santa Barbara; UDICE-French Research Universities; Universite Paris Saclay	Wilson, L (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	Wilson@lifesci.ucsb.edu		CURMI, Patrick A./0000-0001-5045-8501; Manna, Tapas/0000-0002-2213-6246	NINDS NIH HHS [NS 13560] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS013560] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bieche I, 2003, GENOMICS, V81, P400, DOI 10.1016/S0888-7543(03)00031-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLER KJ, 1990, PFLUG ARCH EUR J PHY, V417, P234, DOI 10.1007/BF00370705; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; CHAILLET JR, 1986, P NATL ACAD SCI USA, V83, P522, DOI 10.1073/pnas.83.2.522; Chen W, 2004, NAT CELL BIOL, V6, P227, DOI 10.1038/ncb1104; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; Dammermann A, 2003, CURR BIOL, V13, pR614, DOI 10.1016/S0960-9822(03)00530-X; Derry WB, 1998, CANCER RES, V58, P1177; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; DOYE V, 1989, J BIOL CHEM, V264, P12134; FARRELL KW, 1987, J CELL BIOL, V104, P1035, DOI 10.1083/jcb.104.4.1035; GAMBLIN TC, 1995, ANAL BIOCHEM, V232, P43; Gavet O, 1998, J CELL SCI, V111, P3333; GELFAND VI, 1991, ANNU REV CELL BIOL, V7, P93, DOI 10.1146/annurev.cb.07.110191.000521; GERBOTH GD, 1993, AM J PHYSIOL, V264, pL448, DOI 10.1152/ajplung.1993.264.5.L448; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Grego S, 2001, BIOPHYS J, V81, P66, DOI 10.1016/S0006-3495(01)75680-9; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Howell B, 1999, J CELL SCI, V112, P3713; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; Keating TJ, 1997, P NATL ACAD SCI USA, V94, P5078, DOI 10.1073/pnas.94.10.5078; Kuntziger T, 2001, J BIOL CHEM, V276, P22979, DOI 10.1074/jbc.M101466200; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Leem CH, 1999, J PHYSIOL-LONDON, V517, P159, DOI 10.1111/j.1469-7793.1999.0159z.x; MALINOWSKA I, 2002, MED SCI MONITOR, V8, P441; MARGOLIS RL, 1981, NATURE, V293, P705, DOI 10.1038/293705a0; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; MCBEATH E, 1990, EUR J CELL BIOL, V52, P1; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; Muller-Borer BJ, 1998, AM J PHYSIOL-HEART C, V275, pH1937, DOI 10.1152/ajpheart.1998.275.6.H1937; Newton CN, 2004, FEBS LETT, V572, P80, DOI 10.1016/j.febslet.2004.06.093; Ozon S, 2002, MOL BIOL CELL, V13, P698, DOI 10.1091/mbc.01-07-0362; Panda D, 1996, J BIOL CHEM, V271, P29807, DOI 10.1074/jbc.271.47.29807; Panda D, 2000, BIOCHEMISTRY-US, V39, P5075, DOI 10.1021/bi992217f; Panda D, 1999, P NATL ACAD SCI USA, V96, P12459, DOI 10.1073/pnas.96.22.12459; Panda D, 2003, P NATL ACAD SCI USA, V100, P9548, DOI 10.1073/pnas.1633508100; Popov AV, 2002, CURR BIOL, V12, P1326, DOI 10.1016/S0960-9822(02)01033-3; Ravelli RBG, 2004, NATURE, V428, P198, DOI 10.1038/nature02393; Rodionov V, 1999, P NATL ACAD SCI USA, V96, P115, DOI 10.1073/pnas.96.1.115; Rodionov VI, 1997, SCIENCE, V275, P215, DOI 10.1126/science.275.5297.215; Rogers GC, 2005, J CELL SCI, V118, P1105, DOI 10.1242/jcs.02284; Rogers GC, 2004, NATURE, V427, P364, DOI 10.1038/nature02256; ROOS G, 1993, LEUKEMIA, V7, P1538; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SEKSEK O, 1991, ANAL BIOCHEM, V193, P49, DOI 10.1016/0003-2697(91)90042-R; Shaw SL, 2003, SCIENCE, V300, P1715, DOI 10.1126/science.1083529; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Srivastava A, 1997, ANAL BIOCHEM, V249, P140, DOI 10.1006/abio.1997.2164; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Stewart AK, 1999, J PHYSIOL-LONDON, V516, P209, DOI 10.1111/j.1469-7793.1999.209aa.x; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; Trzaskawka E, 2000, EUR J ORAL SCI, V108, P54, DOI 10.1034/j.1600-0722.2000.00670.x; Vorobjev IA, 1997, J CELL SCI, V110, P2635; Vorobjev IA, 1999, J CELL SCI, V112, P2277; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417; Wilson L, 1999, CELL STRUCT FUNCT, V24, P329, DOI 10.1247/csf.24.329; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Wittmann T, 2001, J CELL SCI, V114, P3795; Wong P, 2002, BRIT J CANCER, V87, P238, DOI 10.1038/sj.bjc.6600424; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95	74	38	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2071	2078		10.1074/jbc.M510661200	http://dx.doi.org/10.1074/jbc.M510661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16317007	hybrid			2022-12-27	WOS:000234760400028
J	Cantini, F; Savino, S; Scarselli, M; Masignani, V; Pizza, M; Romagnoli, G; Swennen, E; Veggi, D; Banci, L; Rappuoli, R				Cantini, F; Savino, S; Scarselli, M; Masignani, V; Pizza, M; Romagnoli, G; Swennen, E; Veggi, D; Banci, L; Rappuoli, R			Solution structure of the immunodominant domain of protective antigen GNA1870 of Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-B; OUTER-MEMBRANE PROTEIN; ELICITS BACTERICIDAL ANTIBODIES; MENINGOCOCCAL VACCINES; CRYSTAL-STRUCTURE; NMR RELAXATION; TRANSFERRIN; IMMUNOGENICITY; IDENTIFICATION; COMPLEXES	GNA1870, a 28-kDa surface-exposed lipoprotein of Neisseria meningitidis recently discovered by reverse vaccinology, is one of the most potent antigens of Meningococcus and a promising candidate for a universal vaccine against a devastating disease. Previous studies of epitope mapping and genetic characterization identified residues critical for bactericidal response within the C-terminal domain of the molecule. To elucidate the conformation of protective epitopes, we used NMR spectroscopy to obtain the solution structure of the immunodominant 18-kDa C-terminal portion of GNA1870. The structure consists of an eight-stranded antiparallel beta-barrel overlaid by a short alpha-helix with an unstructured N-terminal end. Residues previously shown to be important for antibody recognition were mapped on loops facing the same ridge of the molecule. The sequence similarity of GNA1870 with members of the bacterial transferrin receptor family allows one to predict the folding of this class of well known bacterial antigens, providing the basis for the rational engineering of high affinity B cell epitopes.	Univ Florence, Ctr Risonanze Magnet CERM, I-50019 Sesto Fiorentino, Italy; CHIRON Vaccines Res Ctr, I-53100 Siena, Italy	University of Florence; Novartis	Rappuoli, R (corresponding author), IRIS Res Ctr, Chiron Srl Via Fiorentina 1, I-53100 Siena, Italy.	rino_rappuoli@chiron.com	Cantini, Francesca/O-1220-2015	Cantini, Francesca/0000-0003-0526-6732; BANCI, LUCIA/0000-0003-0562-5774				AlaAldeen DAA, 1996, VACCINE, V14, P49, DOI 10.1016/0264-410X(95)00136-O; Banci L, 1998, J AM CHEM SOC, V120, P12903, DOI 10.1021/ja981791w; BAX A, 1994, METHOD ENZYMOL, V239, P79; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BRANHAM SE, 1953, BACTERIOL REV, V17, P175, DOI 10.1128/MMBR.17.3.175-188.1953; Datta S, 2001, P NATL ACAD SCI USA, V98, P14268, DOI 10.1073/pnas.241429098; Decanniere K, 2001, J MOL BIOL, V313, P473, DOI 10.1006/jmbi.2001.5075; DEMORAES JC, 1992, LANCET, V340, P1074; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FRASCH CE, 1989, CLIN MICROBIOL REV S, V2, P134; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; Giuliani MM, 2005, INFECT IMMUN, V73, P1151, DOI 10.1128/IAI.73.2.1151-1160.2005; GOTSCHLICH EC, 1969, J EXP MED, V129, P1349, DOI 10.1084/jem.129.6.1349; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guntert Peter, 2004, Methods Mol Biol, V278, P353; Holm L, 1998, PROTEINS, V33, P88, DOI 10.1002/(SICI)1097-0134(19981001)33:1<88::AID-PROT8>3.0.CO;2-H; Kahler CM, 2001, INFECT IMMUN, V69, P1687, DOI 10.1128/IAI.69.3.1687-1696.2001; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; LISSOLO L, 1995, INFECT IMMUN, V63, P884, DOI 10.1128/IAI.63.3.884-890.1995; Martin D, 1997, J EXP MED, V185, P1173, DOI 10.1084/jem.185.7.1173; Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911; Myers LE, 1998, INFECT IMMUN, V66, P4183; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Pearl F, 2005, NUCLEIC ACIDS RES, V33, pD247, DOI 10.1093/nar/gki024; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; Perkins BA, 1998, J INFECT DIS, V177, P683, DOI 10.1086/514232; Prince SM, 2002, P NATL ACAD SCI USA, V99, P3417, DOI 10.1073/pnas.062630899; Renauld-Mongenie G, 2004, J BACTERIOL, V186, P850, DOI 10.1128/JB.186.3.850-857.2004; Retzer MD, 1999, MOL MICROBIOL, V32, P111, DOI 10.1046/j.1365-2958.1999.01331.x; ROSENQVIST E, 1995, INFECT IMMUN, V63, P4642, DOI 10.1128/IAI.63.12.4642-4652.1995; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; Takagi K, 2001, EUR J BIOCHEM, V268, P470, DOI 10.1046/j.1432-1033.2001.01912.x; Tappero JW, 1999, JAMA-J AM MED ASSOC, V281, P1520, DOI 10.1001/jama.281.16.1520; Vandeputte-Rutten L, 2003, J BIOL CHEM, V278, P24825, DOI 10.1074/jbc.M302803200; VEDROS NA, 1987, EVOLUTION MENINGOCOC; Webb DC, 1999, INFECT IMMUN, V67, P2138, DOI 10.1128/IAI.67.5.2138-2144.1999; Welsch JA, 2004, J IMMUNOL, V172, P5606, DOI 10.4049/jimmunol.172.9.5606	44	38	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7220	7227		10.1074/jbc.M508595200	http://dx.doi.org/10.1074/jbc.M508595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407174	hybrid			2022-12-27	WOS:000236030900039
J	Rabah, N; Gauthier, D; Wilkes, BC; Gauthier, DJ; Lazure, C				Rabah, N; Gauthier, D; Wilkes, BC; Gauthier, DJ; Lazure, C			Single amino acid substitution in the PC1/3 propeptide can induce significant modifications of its inhibitory profile toward its cognate enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIGHT-BINDING INHIBITORS; PRO-PROTEIN CONVERTASES; PROPROTEIN CONVERTASES; PROHORMONE CONVERTASES; CRYSTAL-STRUCTURE; INTRAMOLECULAR CHAPERONE; POTENT INHIBITORS; INSECT CELLS; HUMAN FURIN; IN-VITRO	The proprotein convertase PC1/3 is synthesized as a large precursor that undergoes proteolytic processing of the signal peptide, the propeptide and ultimately the COOH-terminal tail, to generate the mature form. The propeptide is essential for protease folding, and, although cleaved by an autocatalytic process, it remains associated with the mature form acting as an auto-inhibitor of PC1/3. To further assess the role of certain residues in its interaction with its cognate enzyme, we performed an alanine scan on two PC1/3 propeptide potential cleavable sites ((RRSRR54)-R-50 and (KR62)-K-61) and an acidic region (DDD67)-D-65 conserved among species. Upon incubation with PC1/3, the ensuing peptides exhibit equal inhibitory potency, lower potency, or higher potency than the wild-type propeptide. The K-i values calculated varied between 0.15 and 16.5 nM. All but one mutant exhibited a tight binding behavior. To examine the specificity of mutants, we studied their reactivity toward furin, a closely related convertase. The mutation of certain residues also affects the inhibition behavior toward furin yielding propeptides exhibiting K-i ranging from 0.2 to 24 nM. Mutant propeptides exhibited against each enzyme either different mode of inhibition, enhanced selectivity in the order of 40-fold for one enzyme, or high potency with no discrimination. Hence, we demonstrate through single amino acid substitution that it is feasible to modify the inhibitory behavior of propeptides toward convertases in such away as to increase or decrease their potency, modify their inhibitory mechanisms, as well as increase their selectivity.	Univ Montreal, Inst Rech Clin Montreal, Neuropeptides Struct & Metab Res Lab, Neuropeptides Struct & Metab Res Unit, Montreal, PQ H2W 1R7, Canada; Clin Res Inst Montreal, Chem Biol & Peptide Res Unit, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Lazure, C (corresponding author), Univ Montreal, Inst Rech Clin Montreal, Neuropeptides Struct & Metab Res Lab, Neuropeptides Struct & Metab Res Unit, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	lazurec@ircm.qc.ca						Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; Basak A, 2003, BIOCHEM J, V373, P231, DOI 10.1042/BJ20030120; Basak A, 1999, PEPTIDES: FRONTIERS OF PEPTIDES SCIENCE, P676; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Bhattacharjya S, 2000, BIOCHEMISTRY-US, V39, P2868, DOI 10.1021/bi9923961; Bissonnette L, 2004, BIOCHEM J, V379, P757, DOI 10.1042/BJ20031902; Boudreault A, 1998, PROTEIN EXPRES PURIF, V14, P353, DOI 10.1006/prep.1998.0964; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; BRENNAN SO, 1994, FEBS LETT, V347, P80, DOI 10.1016/0014-5793(94)00511-7; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; Chapman RL, 1997, J BIOL CHEM, V272, P8808, DOI 10.1074/jbc.272.13.8808; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; EGGELKRAUTGOTTA.R, 2004, CURR MED CHEM, V11, P2651; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; Fu X, 2000, J BIOL CHEM, V275, P16871, DOI 10.1074/jbc.275.22.16871; Fugere M, 2002, CURR PHARM DESIGN, V8, P549, DOI 10.2174/1381612023395736; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Holyoak T, 2004, BIOCHEMISTRY-US, V43, P2412, DOI 10.1021/bi035849h; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; JEAN F, 1993, BIOCHEM J, V292, P891, DOI 10.1042/bj2920891; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; Lazure C, 2002, CURR PHARM DESIGN, V8, P511, DOI 10.2174/1381612023395691; Lesage G, 2001, FEBS LETT, V508, P332, DOI 10.1016/S0014-5793(01)03096-4; Marie-Claire C, 2001, J MOL BIOL, V305, P151, DOI 10.1006/jmbi.2000.4233; Muller L, 2000, J BIOL CHEM, V275, P39213, DOI 10.1074/jbc.M003547200; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; Powner D, 1998, MOL CELL BIOL, V18, P400, DOI 10.1128/MCB.18.1.400; Rabah N, 2004, PROTEIN EXPRES PURIF, V37, P377, DOI 10.1016/j.pep.2004.06.014; Rockwell NC, 2004, TRENDS BIOCHEM SCI, V29, P80, DOI 10.1016/j.tibs.2003.12.006; Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i; Sauter NK, 1998, NAT STRUCT BIOL, V5, P945, DOI 10.1038/2919; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; Takagi H, 2003, APPL MICROBIOL BIOT, V63, P1, DOI 10.1007/s00253-003-1352-1; Tangrea MA, 2002, J MOL BIOL, V320, P801, DOI 10.1016/S0022-2836(02)00543-0; Tangrea MA, 2001, BIOCHEMISTRY-US, V40, P5488, DOI 10.1021/bi0026472; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Villemure M, 2003, BIOCHEMISTRY-US, V42, P9659, DOI 10.1021/bi034418w; Weiss GA, 2000, P NATL ACAD SCI USA, V97, P8950, DOI 10.1073/pnas.160252097; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509	56	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7556	7567		10.1074/jbc.M510607200	http://dx.doi.org/10.1074/jbc.M510607200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407210	hybrid			2022-12-27	WOS:000236030900077
J	Wilkinson, BM; Purswani, J; Stirling, CJ				Wilkinson, BM; Purswani, J; Stirling, CJ			Yeast GTB1 encodes a subunit of glucosidase II required for glycoprotein processing in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYSTIC LIVER-DISEASE; SACCHAROMYCES-CEREVISIAE; IN-VIVO; HETERODIMERIC STRUCTURE; PROTEIN TRANSLOCATION; MEMBRANE-PROTEIN; DISTINCT DOMAINS; GENE DELETION; RAT-LIVER; MUTATIONS	Glucosidase II is essential for sequential removal of two glucose residues from N-linked glycans during glycoprotein biogenesis in the endoplasmic reticulum. The enzyme is a heterodimer whose alpha-subunit contains the glycosyl hydrolase active site. The function of the beta-subunit has yet to be defined, but mutations in the human gene have been linked to an autosomal dominant form of polycystic liver disease. Here we report the identification and characterization of a Saccharomyces cerevisiae gene, GTB1, encoding a polypeptide with 21% sequence similarity to the beta-subunit of human glucosidase II. The Gtb1 protein was shown to be a soluble glycoprotein ( 96 102 kDa) localized to the endoplasmic reticulum lumen where it was present in a complex together with the yeast alpha-subunit homologue Gls2p. Surprisingly, we found that Delta gtb1 mutant cells were specifically defective in the processing of monoglucosylated glycans. Thus, although Gls2p is sufficient for cleavage of the penultimate glucose residue, Gtb1p is essential for cleavage of the final glucose. Our data demonstrate that Gtb1p is required for normal glycoprotein biogenesis and reveal that the final two glucose-trimming steps in N-glycan processing are mechanistically distinct.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Stirling, CJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	colin.stirling@manchester.ac.uk	Purswani, Jessica/M-8038-2018; , Jessica/T-7459-2019	Purswani, Jessica/0000-0001-7846-9368; , Jessica/0000-0001-7846-9368	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALONSO JM, 1993, EUR J BIOCHEM, V215, P37, DOI 10.1111/j.1432-1033.1993.tb18004.x; Arendt CW, 2000, GLYCOBIOLOGY, V10, P487, DOI 10.1093/glycob/10.5.487; Brachmann CB, 1998, YEAST, V14, P115; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; D'Alessio C, 1999, J BIOL CHEM, V274, P25899, DOI 10.1074/jbc.274.36.25899; Deprez P, 2005, MOL CELL, V19, P183, DOI 10.1016/j.molcel.2005.05.029; Drenth JPH, 2004, GASTROENTEROLOGY, V126, P1819, DOI 10.1053/j.gastro.2004.02.023; Drenth JPH, 2004, HEPATOLOGY, V39, P924, DOI 10.1002/hep.20141; Drenth JPH, 2003, NAT GENET, V33, P345, DOI 10.1038/ng1104; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; Jakob CA, 1998, GLYCOBIOLOGY, V8, P155, DOI 10.1093/glycob/8.2.155; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Levinson JN, 2002, YEAST, V19, P1243, DOI 10.1002/yea.908; Li AR, 2003, AM J HUM GENET, V72, P691, DOI 10.1086/368295; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Munro S, 2001, CURR BIOL, V11, pR499, DOI 10.1016/S0960-9822(01)00302-5; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; Pelletier MF, 2000, GLYCOBIOLOGY, V10, P815, DOI 10.1093/glycob/10.8.815; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; SHAILUBHAI K, 1991, J BIOL CHEM, V266, P16587; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; Treml K, 2000, GLYCOBIOLOGY, V10, P493, DOI 10.1093/glycob/10.5.493; Trombetta ES, 1996, J BIOL CHEM, V271, P27509, DOI 10.1074/jbc.271.44.27509; Trombetta ES, 2001, BIOCHEMISTRY-US, V40, P10717, DOI 10.1021/bi010629u; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; Wilkinson BM, 2000, J BIOL CHEM, V275, P521, DOI 10.1074/jbc.275.1.521; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Xu XH, 2004, FEBS LETT, V570, P155, DOI 10.1016/j.febslet.2004.06.039; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262	43	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6325	6333		10.1074/jbc.M510455200	http://dx.doi.org/10.1074/jbc.M510455200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16373354	hybrid			2022-12-27	WOS:000236030800026
J	Choudhary, S; Doherty, KM; Handy, CJ; Sayer, JM; Yagi, H; Jerina, DM; Brosh, RM				Choudhary, S; Doherty, KM; Handy, CJ; Sayer, JM; Yagi, H; Jerina, DM; Brosh, RM			Inhibition of Werner syndrome helicase activity by benzo[a]pyrene diol epoxide adducts can be overcome by replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							7,8-DIOL 9,10-EPOXIDE ADDUCTS; CODON 61 SEQUENCE; DNA DUPLEX; SYNDROME CELLS; SOLUTION CONFORMATION; HOMOLOGOUS RECOMBINATION; MODIFIED DEOXYGUANOSINE; TRANSLESION SYNTHESIS; RECQ HELICASES; WRN HELICASE	RecQ helicases are believed to function in repairing replication forks stalled by DNA damage and may also play a role in the intra-S-phase checkpoint, which delays the replication of damaged DNA, thus permitting repair to occur. Since little is known regarding the effects of DNA damage on RecQ helicases, and because the replication and recombination defects in Werner syndrome cells may reflect abnormal processing of damaged DNA associated with the replication fork, we examined the effects of specific bulky, covalent adducts at N-6 of deoxyadenosine (dA) or N-2 of deoxyguanosine (dG) on Werner (WRN) syndrome helicase activity. The adducts are derived from the optically active 7,8-diol 9,10-epoxide (DE) metabolites of the carcinogen benzo[a]pyrene (BaP). The results demonstrate that WRN helicase activity is inhibited in a strand-specific manner by BaP DE-dG adducts only when on the translocating strand. These adducts either occupy the minor groove without significant perturbation of DNA structure (trans adducts) or cause base displacement at the adduct site (cis adducts). In contrast, helicase activity is only mildly affected by intercalating BaP DE-dA adducts that locally perturb DNA double helical structure. This differs from our previous observation that intercalating dA adducts derived from benzo[c]phenanthrene (BcPh) DEs inhibit WRN activity in a strand-and stereospecific manner. Partial unwinding of the DNA helix at BaP DE-dA adduct sites may make such adducted DNAs more susceptible to the action of helicase than DNA containing the corresponding BcPh DE-dA adducts, which cause little or no destabilization of duplex DNA. The single-stranded DNA binding protein RPA, an auxiliary factor for WRN helicase, enabled the DNA unwinding enzyme to overcome inhibition by either the trans-R or cis-R BaP DE-dG adduct, suggesting that WRN and RPA may function together to unwind duplex DNA harboring specific covalent adducts that otherwise block WRN helicase acting alone.	NIDDK, Bioorgan Chem Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; NIA, Lab Mol Gerontol, NIH, Dept Hlth & Human Serv, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Brosh, RM (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA.	broshr@grc.nia.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000741, ZIAAG000741] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Blank A, 2004, DNA REPAIR, V3, P629, DOI 10.1016/j.dnarep.2004.02.003; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Buterin T, 2000, CANCER RES, V60, P1849; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; Choudhary S, 2004, J BIOL CHEM, V279, P34603, DOI 10.1074/jbc.M401901200; Committee on Biologic Effects of Atmospheric Pollutants, 1972, PART POL ORG MATT; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cosman M, 1996, BIOCHEMISTRY-US, V35, P9850, DOI 10.1021/bi9605346; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P4145, DOI 10.1021/bi00067a001; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Cui S, 2004, NUCLEIC ACIDS RES, V32, P2158, DOI 10.1093/nar/gkh540; Custer L, 1999, BIOCHEMISTRY-US, V38, P569, DOI 10.1021/bi9813330; Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5245, DOI 10.1021/bi00138a002; Driscoll HC, 2003, J BIOL CHEM, V278, P41126, DOI 10.1074/jbc.M304798200; FOUNTAIN MA, 1995, BIOCHEMISTRY-US, V34, P3152, DOI 10.1021/bi00010a004; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Garcia PL, 2004, NUCLEIC ACIDS RES, V32, P3771, DOI 10.1093/nar/gkh709; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Graziewicz MA, 2004, NUCLEIC ACIDS RES, V32, P397, DOI 10.1093/nar/gkh213; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Huang XW, 2003, BIOCHEMISTRY-US, V42, P2456, DOI 10.1021/bi026912q; Hussain SP, 2001, CANCER RES, V61, P6350; Jerina D M, 1991, Adv Exp Med Biol, V283, P533; Khakhar RR, 2003, TRENDS CELL BIOL, V13, P493, DOI 10.1016/S0962-8924(03)00171-5; Khan QA, 2003, P NATL ACAD SCI USA, V100, P12498, DOI 10.1073/pnas.2032456100; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; Kroth H, 2000, J ORG CHEM, V65, P5558, DOI 10.1021/jo000522x; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Mao B, 1999, BIOCHEMISTRY-US, V38, P10831, DOI 10.1021/bi991212f; Marians KJ, 2000, STRUCTURE, V8, pR227, DOI 10.1016/S0969-2126(00)00539-6; Opresko PL, 2004, J BIOL CHEM, V279, P18099, DOI 10.1074/jbc.R300034200; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Perlow RA, 2003, J MOL BIOL, V327, P797, DOI 10.1016/S0022-2836(03)00187-6; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; Pilcher AS, 1998, J AM CHEM SOC, V120, P3520, DOI 10.1021/ja980176p; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; Rechkoblit O, 2002, J BIOL CHEM, V277, P30488, DOI 10.1074/jbc.M201167200; Rodriguez-Lopez AM, 2002, AGING CELL, V1, P30, DOI 10.1046/j.1474-9728.2002.00002.x; Ruan Q, 2002, CHEM RES TOXICOL, V15, P249, DOI 10.1021/tx010157k; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Sayer JM, 1999, POLYCYCL AROMAT COMP, V17, P95, DOI 10.1080/10406639908020605; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; THAKKER DR, 1977, CHEM-BIOL INTERACT, V16, P281, DOI 10.1016/0009-2797(77)90108-9; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Villani G, 2000, J BIOL CHEM, V275, P33185, DOI 10.1074/jbc.R000011200; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; Volk DE, 2003, BIOCHEMISTRY-US, V42, P1410, DOI 10.1021/bi026745u; YEH HJC, 1995, BIOCHEMISTRY-US, V34, P13570, DOI 10.1021/bi00041a037; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; Zegar IS, 1998, BIOCHEMISTRY-US, V37, P16516, DOI 10.1021/bi9817616; Zegar IS, 1996, BIOCHEMISTRY-US, V35, P6212, DOI 10.1021/bi9524732; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	69	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6000	6009		10.1074/jbc.M510122200	http://dx.doi.org/10.1074/jbc.M510122200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16380375	hybrid			2022-12-27	WOS:000235568900081
J	Sanchez-Magraner, L; Cortajarena, AL; Goni, FM; Ostolaza, H				Sanchez-Magraner, L; Cortajarena, AL; Goni, FM; Ostolaza, H			Membrane insertion of Escherichia coli alpha-hemolysin is independent from membrane lysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TOXIN; PHOSPHOLIPID MONOLAYERS; SELF-AGGREGATION; LIPID MONOLAYERS; BINDING; ADSORPTION; PURIFICATION; INTERFACES; MECHANISM; VESICLES	Escherichia coli alpha-hemolysin ( HlyA) is a protein exotoxin that binds and lyses eukaryotic cell and model membranes in the presence of calcium. Previous studies have been able to distinguish between reversible toxin binding to the membrane and irreversible insertion into the lipid matrix. Membrane lysis occurs as the combined effect of protein insertion plus a transient perturbation of the membrane bilayer structure. In the past, insertion and bilayer perturbation have not been experimentally dissected. This has now been achieved by studying HlyA penetration into lipid monolayers at the air-water interface, in which three-dimensional effects ( of the kind required to break down the bilayer permeability barrier) cannot occur. The study of native HlyA, together with the nonlytic precursor pro-HlyA, and of different mutants demonstrates that although some nonlytic variants ( e. g. pro-HlyA) exhibit very low levels of insertion, others ( e. g. the nonlytic mutant HlyA H859N) insert even more strongly than the lytic wild type. These results show that insertion does not necessarily lead to membrane lysis, i.e. that insertion and lysis are not "coupled" phenomena. Millimolar levels of Ca2+, which are essential for the lytic activity, cause an extra degree of insertion but only in the case of the lytic forms of HlyA.	Univ Basque Country, Consejo Super Invest Cient, Unidad Biofis, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country	Ostolaza, H (corresponding author), Univ Basque Country, Consejo Super Invest Cient, Unidad Biofis, Aptdo 644, E-48080 Bilbao, Spain.	gbzoseth@lg.ehu.es	Goni, Felix M/M-5425-2015; Cortajarena, Aitziber L/J-6202-2012	Goni, Felix M/0000-0001-6270-9216; Cortajarena, Aitziber L/0000-0002-5331-114X; OSTOLAZA ECHABE, ELENA AMAYA/0000-0003-2933-9975				Adamson A.W., 1997, PHYS CHEM SURFACES, P390; Bakas L, 1998, BBA-BIOMEMBRANES, V1368, P225, DOI 10.1016/S0005-2736(97)00181-8; Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; Barlic A, 2004, J BIOL CHEM, V279, P34209, DOI 10.1074/jbc.M313817200; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BENZ R, 1989, INFECT IMMUN, V57, P887, DOI 10.1128/IAI.57.3.887-895.1989; BHAKOO M, 1982, BIOCHEMISTRY-US, V21, P6879, DOI 10.1021/bi00269a039; Brockman H, 1999, CURR OPIN STRUC BIOL, V9, P438, DOI 10.1016/S0959-440X(99)80061-X; Cornec M, 1999, J COLLOID INTERF SCI, V214, P129, DOI 10.1006/jcis.1999.6230; Cortajarena AL, 2003, FEBS LETT, V546, P271, DOI 10.1016/S0014-5793(03)00595-7; Cortajarena AL, 2003, J BIOL CHEM, V278, P19159, DOI 10.1074/jbc.M208552200; Cortajarena AL, 2002, J BIOL CHEM, V277, P23223, DOI 10.1074/jbc.M202028200; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FIDELIO GD, 1982, BIOCHEM J, V203, P717, DOI 10.1042/bj2030717; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; GRAHAM DE, 1980, J COLLOID INTERF SCI, V76, P227, DOI 10.1016/0021-9797(80)90289-1; Herlax V, 2003, CHEM PHYS LIPIDS, V122, P185, DOI 10.1016/S0009-3084(02)00191-3; Holland IB, 2005, MOL MEMBR BIOL, V22, P29, DOI 10.1080/09687860500042013; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; KSENZHEK O S, 1978, Molekulyarnaya Biologiya (Moscow), V12, P1057; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Maget-Dana R, 1999, BBA-BIOMEMBRANES, V1462, P109, DOI 10.1016/S0005-2736(99)00203-5; MagetDana R, 1997, BIOPHYS J, V73, P2527, DOI 10.1016/S0006-3495(97)78281-X; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; Netz RR, 1996, J PHYS II, V6, P1023, DOI 10.1051/jp2:1996114; OSTOLAZA H, 1993, BIOCHIM BIOPHYS ACTA, V1147, P81, DOI 10.1016/0005-2736(93)90318-T; OSTOLAZA H, 1995, FEBS LETT, V371, P303, DOI 10.1016/0014-5793(95)00927-2; OSTOLAZA H, 1995, EUR J BIOCHEM, V228, P39, DOI 10.1111/j.1432-1033.1995.tb20225.x; OSTOLAZA H, 1991, FEBS LETT, V280, P195, DOI 10.1016/0014-5793(91)80291-A; Schindel C, 2001, EUR J BIOCHEM, V268, P800, DOI 10.1046/j.1432-1327.2001.01937.x; Soloaga A, 1998, BIOCHEMISTRY-US, V37, P6387, DOI 10.1021/bi9730994; Soloaga A, 1999, MOL MICROBIOL, V31, P1013, DOI 10.1046/j.1365-2958.1999.01225.x; Soloaga A, 1996, EUR J BIOCHEM, V238, P418, DOI 10.1111/j.1432-1033.1996.0418z.x; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Wang SX, 1998, BIOCHEM J, V335, P225, DOI 10.1042/bj3350225; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85; Xia XF, 2001, BBA-BIOMEMBRANES, V1515, P1, DOI 10.1016/S0005-2736(01)00348-0	41	28	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5461	5467		10.1074/jbc.M512897200	http://dx.doi.org/10.1074/jbc.M512897200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377616	hybrid			2022-12-27	WOS:000235568900018
J	Zhao, YH; White, MA; Muralidhara, BK; Sun, L; Halpert, JR; Stout, CD				Zhao, YH; White, MA; Muralidhara, BK; Sun, L; Halpert, JR; Stout, CD			Structure of microsomal cytochrome P4502B4 complexed with the antifungal drug bifonazole - Insight into p450 conformational plasticity and membrane interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; DENSITY MODIFICATION; ANGSTROM RESOLUTION; SUBSTRATE-BINDING; DIFFRACTION DATA; CRYSTALLOGRAPHY; MONOOXYGENASES; ASSOCIATION; DIVERSITY; MECHANISM	To better understand ligand-induced structural transitions in cytochrome P450 2B4, protein-ligand interactions were investigated using a bulky inhibitor. Bifonazole, a broad spectrum antifungal agent, inhibits monooxygenase activity and induces a type II binding spectrum in 2B4dH(H226Y), a modified enzyme previously crystallized in the presence of 4-(4-chlorophenyl)imidazole (CPI). Isothermal titration calorimetry and tryptophan fluorescence quenching indicate no significant burial of protein apolar surface nor altered accessibility of Trp-121 upon bifonazole binding, in contrast to recent results with CPI. A 2.3 angstrom crystal structure of 2B4-bifonazole reveals a novel open conformation with ligand bound in the active site, which is significantly different from either the U-shaped cleft of ligand-free 2B4 or the small active site pocket of 2B4-CPI. The O-shaped active site cleft of 2B4-bifonazole is widely open in the middle but narrow at the top. A bifonazole molecule occupies the bottom of the active site cleft, where helix I is bent similar to 15 degrees to accommodate the bulky ligand. The structure also defines unanticipated interactions between helix C residues and bifonazole, suggesting an important role of helix C in azole recognition by mammalian P450s. Comparison of the ligand-free 2B4 structure, the 2B4-CPI structure, and the 2B4-bifonazole structure identifies structurally plastic regions that undergo correlated conformational changes in response to ligand binding. The most plastic regions are putative membrane-binding motifs involved in substrate access or substrate binding. The results allow us to model the membrane-associated state of P450 and provide insight into how lipophilic substrates access the buried active site.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Scripps Research Institute	Zhao, YH (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA.	yozhao@utmb.edu	White, Mark Andrew/B-1723-2012	White, Mark Andrew/0000-0003-1057-4203	NIEHS NIH HHS [ES 06676, ES 03619] Funding Source: Medline; NIGMS NIH HHS [GM 61545] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES003619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061545] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayburt TH, 2002, P NATL ACAD SCI USA, V99, P6725, DOI 10.1073/pnas.062565599; BOSSCHE HV, 1995, PHARMACOL THERAPEUT, V67, P79; Bracey MH, 2004, FEBS LETT, V567, P159, DOI 10.1016/j.febslet.2004.04.084; Bridges A, 1998, J BIOL CHEM, V273, P17036, DOI 10.1074/jbc.273.27.17036; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COON MJ, 1973, ANN NY ACAD SCI, V212, P449, DOI 10.1111/j.1749-6632.1973.tb47613.x; DELEMOSCHIARANDINI C, 1987, J CELL BIOL, V104, P209, DOI 10.1083/jcb.104.2.209; Domanski TL, 2001, CURR DRUG METAB, V2, P117, DOI 10.2174/1389200013338612; Garavito RM, 2002, PROSTAG OTH LIPID M, V68-9, P129; GOTOH O, 1992, J BIOL CHEM, V267, P83; Hernandez-Guzman FG, 2003, J BIOL CHEM, V278, P22989, DOI 10.1074/jbc.M211497200; Im YJ, 2005, NATURE, V437, P154, DOI 10.1038/nature03923; Johnson EF, 2005, BIOCHEM BIOPH RES CO, V338, P331, DOI 10.1016/j.bbrc.2005.08.190; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leavitt S, 2001, CURR OPIN STRUC BIOL, V11, P560, DOI 10.1016/S0959-440X(00)00248-7; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Li HY, 2004, CURR TOP MED CHEM, V4, P1789, DOI 10.2174/1568026043387205; Matsuura K, 2005, J BIOL CHEM, V280, P9088, DOI 10.1074/jbc.M413042200; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mueller Ernest J., 1995, P83; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poulos TL, 2005, DRUG METAB DISPOS, V33, P10, DOI 10.1124/dmd.104.002071; Rendic S, 2002, DRUG METAB REV, V34, P83, DOI 10.1081/DMR-120001392; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Scott EE, 2001, ARCH BIOCHEM BIOPHYS, V395, P57, DOI 10.1006/abbi.2001.2574; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Tanaka T, 2004, CHEM PHARM BULL, V52, P830, DOI 10.1248/cpb.52.830; Tanaka T, 2004, CHEM PHARM BULL, V52, P836, DOI 10.1248/cpb.52.836; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; van Tiel CM, 2002, FEBS LETT, V531, P69, DOI 10.1016/S0014-5793(02)03403-8; Wade RC, 2004, J INORG BIOCHEM, V98, P1175, DOI 10.1016/j.jinorgbio.2004.02.007; Waterman MR, 2005, BIOCHEM BIOPH RES CO, V338, P418, DOI 10.1016/j.bbrc.2005.08.118; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2003, BIOCHEMISTRY-US, V42, P6370, DOI 10.1021/bi0273922; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200	47	143	148	3	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5973	5981		10.1074/jbc.M511464200	http://dx.doi.org/10.1074/jbc.M511464200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373351	hybrid, Green Submitted			2022-12-27	WOS:000235568900078
J	Chen, KQ; Iribarren, P; Hu, JY; Chen, JH; Gong, WH; Cho, EH; Lockett, S; Dunlop, NM; Wang, JM				Chen, KQ; Iribarren, P; Hu, JY; Chen, JH; Gong, WH; Cho, EH; Lockett, S; Dunlop, NM; Wang, JM			Activation of toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; CENTRAL-NERVOUS-SYSTEM; STAPHYLOCOCCUS-AUREUS; IMMUNE-RESPONSES; PROTEIN; INFLAMMATION; MECHANISMS; EXPRESSION; BRAIN; PHAGOCYTOSIS	The human G-protein-coupled formyl peptide receptor-like 1 (FPRL1) and its mouse homologue mFPR2 mediate the chemotactic activity of a variety of polypeptides associated with inflammation and bacterial infection, including the 42-amino acid form of amyloid beta peptide (A beta(42)), a pathogenic factor in Alzheimer disease. Because mFPR2 was inducible in mouse microglial cells by proinflammatory stimulants, such as bacterial lipopolysaccharide, a ligand for the Toll-like receptor 4 (TLR4), we investigated the role of TLR2 in the regulation of mFPR2. We found that a TLR2 agonist, peptidoglycan (PGN) derived from Gram-positive bacterium Staphylococcus aureus, induced considerable mFpr2 mRNA expression in a mouse microglial cell line and primary microglial cells. This was associated with a markedly increased chemotaxis of the cells in response to mFPR2 agonist peptides. In addition, activation of TLR2 markedly enhanced mFPR2-mediated uptake of A beta(42) by microglia. Studies of the mechanistic basis showed that PGN activates MAPK and I kappa Ba, and the effect of PGN on induction of mFPR2 was dependent on signaling pathways via ERK1/2 and p38 MAPKs. The use of TLR2 on microglial cells by PGN was supported by the fact that N9 cells transfected with short interfering RNA targeting mouse TLR2 failed to show increased expression of functional mFPR2 after stimulation with PGN. Our results demonstrated a potentially important role for TLR2 in microglial cells of promoting cell responses to chemoattractants produced in lesions of inflammatory and neurodegenerative diseases in the brain.	NCI, Lab Mol Immunoregulat, Ctr Canc Res, NIH, Frederick, MD 21702 USA; NCI, Image Anal Lab, SAIC, NIH, Frederick, MD 21702 USA; NCI, Basic Res Program, SAIC, NIH, Frederick, MD 21702 USA; Shanghai Jiao Tong Univ, Sch Agr & Biol, Shanghai 201101, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Shanghai Jiao Tong University	Wang, JM (corresponding author), NCI, Lab Mol Immunoregulat, Ctr Canc Res, NIH, Bldg 560,Rm 31-40, Frederick, MD 21702 USA.	wangji@mail.ncifcrf.gov	Cho, Edward/B-3727-2012	Cho, Edward/0000-0002-0278-334X	NATIONAL CANCER INSTITUTE [ZIABC010015, Z01BC010015, Z01BC010723] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ard MD, 1996, J NEUROSCI RES, V43, P190, DOI 10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Carl VS, 2002, J BIOL CHEM, V277, P17448, DOI 10.1074/jbc.M111847200; Cotter RL, 1999, J LEUKOCYTE BIOL, V65, P416, DOI 10.1002/jlb.65.4.416; Cui YH, 2002, J LEUKOCYTE BIOL, V72, P628; Cui YH, 2002, NEUROBIOL DIS, V10, P366, DOI 10.1006/nbdi.2002.0517; Cui YH, 2002, J IMMUNOL, V168, P434, DOI 10.4049/jimmunol.168.1.434; Eikelenboom P, 1998, EXP NEUROL, V154, P89, DOI 10.1006/exnr.1998.6920; ElKhoury J, 1996, NATURE, V382, P716; FRACKOWIAK J, 1992, ACTA NEUROPATHOL, V84, P225; Frautschy SA, 1998, AM J PATHOL, V152, P307; FRAUTSCHY SA, 1992, AM J PATHOL, V140, P1389; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Grabiec A, 2004, J BIOL CHEM, V279, P48004, DOI 10.1074/jbc.M405311200; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; Iribarren P, 2003, J IMMUNOL, V171, P5482, DOI 10.4049/jimmunol.171.10.5482; Iribarren P, 2005, IMMUNOL RES, V31, P165, DOI 10.1385/IR:31:3:165; Kalaria R N, 1999, Curr Opin Hematol, V6, P15, DOI 10.1097/00062752-199901000-00004; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kielian T, 2005, INFECT IMMUN, V73, P7428, DOI 10.1128/IAI.73.11.7428-7435.2005; Kielian T, 2002, J NEUROIMMUNOL, V130, P86, DOI 10.1016/S0165-5728(02)00216-3; Kielian T, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-16; Laflamme N, 2003, EUR J IMMUNOL, V33, P1127, DOI 10.1002/eji.200323821; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Le YY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-02-j0003.2001; Lombardo JA, 2003, J NEUROSCI, V23, P10879, DOI 10.1523/jneurosci.23-34-10879.2003; McGeer PL, 1999, J LEUKOCYTE BIOL, V65, P409, DOI 10.1002/jlb.65.4.409; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Morgan C, 2004, PROG NEUROBIOL, V74, P323, DOI 10.1016/j.pneurobio.2004.10.004; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Pocock JM, 2002, E SCHERING RES FDN W, V39, P105; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Rogers J, 2002, E SCHERING RES FDN W, V39, P25; Rogers J, 2001, NEUROCHEM INT, V39, P333, DOI 10.1016/S0197-0186(01)00040-7; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Vabulas RM, 2002, J BIOL CHEM, V277, P15107, DOI 10.1074/jbc.M111204200; Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Weldon DT, 1998, J NEUROSCI, V18, P2161; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; WISNIEWSKI HM, 1994, NEUROPATH APPL NEURO, V20, P192; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yazawa H, 2001, FASEB J, V15, P2454, DOI 10.1096/fj.01-0251com; Ying GG, 2004, J IMMUNOL, V172, P7078, DOI 10.4049/jimmunol.172.11.7078; Zekki H, 2002, BRAIN PATHOL, V12, P308	53	180	182	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3651	3659		10.1074/jbc.M508125200	http://dx.doi.org/10.1074/jbc.M508125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339765	hybrid			2022-12-27	WOS:000235128200077
J	He, JQ; Bellini, M; Inuzuka, H; Xu, JG; Xiong, Y; Yang, XM; Castleberry, AM; Hall, RA				He, JQ; Bellini, M; Inuzuka, H; Xu, JG; Xiong, Y; Yang, XM; Castleberry, AM; Hall, RA			Proteomic analysis of beta(1)-adrenergic receptor interactions with PDZ scaffold proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGER REGULATORY FACTOR; BETA-ADRENERGIC-RECEPTORS; RAT VENTRICULAR MYOCYTES; BETA(2)-ADRENERGIC RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; CARDIAC MYOCYTES; GUANYLATE KINASE; BETA-2-ADRENERGIC RECEPTORS; BINDING; INTERNALIZATION	Many G protein-coupled receptors possess carboxyl-terminal motifs ideal for interaction with PDZ scaffold proteins, which can control receptor trafficking and signaling in a cell-specific manner. To gain a panoramic view of beta(1)-adrenergic receptor (beta(1)AR) interactions with PDZ scaffolds, the beta 1AR carboxyl terminus was screened against a newly developed proteomic array of PDZ domains. These screens confirmed beta(1)AR associations with several previously identified PDZ partners, such as PSD-95, MAGI-2, GIPC, and CAL. Moreover, two novel beta(1)AR- interacting proteins, SAP97 and MAGI-3, were also identified. The beta(1)AR carboxyl terminus was found to bind specifically to the first PDZ domain of MAGI-3, with the last four amino acids (E-S-K-V) of beta(1)AR being the key determinants of the interaction. Full-length beta(1)AR robustly associated with full-length MAGI-3 in cells, and this association was abolished by mutation of the beta(1)AR terminal valine residue to alanine (V477A), as determined by co-immunoprecipitation experiments and immunofluorescence co-localization studies. MAGI-3 co-expression with beta(1)AR profoundly impaired beta(1)AR-mediated ERK1/2 activation but had no apparent effect on beta(1)AR-mediated cyclic AMP generation or agonist-promoted beta(1)AR internalization. These findings revealed that the interaction of MAGI-3 with beta(1)AR can selectively regulate specific aspects of receptor signaling. Moreover, the screens of the PDZ domain proteomic array provide a comprehensive view of beta(1)AR interactions with PDZ scaffolds, thereby shedding light on the molecular mechanisms by which beta(1)AR signaling and trafficking can be regulated in a cell-specific manner.	Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, Atlanta, GA 30322 USA; Capital Univ Med Sci, Dept Biochem & Mol Biol, Beijing 100054, Peoples R China	Emory University; Capital Medical University	Hall, RA (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, 1510 Clifton Rd, Atlanta, GA 30322 USA.	rhall@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728				Adamsky K, 2003, J CELL SCI, V116, P1279, DOI 10.1242/jcs.00302; Balasubramanian S, 2004, J BIOL CHEM, V279, P18840, DOI 10.1074/jbc.M313470200; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cesetti T, 2003, J NEUROSCI, V23, P73; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Devic E, 2001, MOL PHARMACOL, V60, P577; Fam SR, 2005, P NATL ACAD SCI USA, V102, P8042, DOI 10.1073/pnas.0408818102; GREEN SA, 1994, J BIOL CHEM, V269, P26215; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 2004, SEMIN CELL DEV BIOL, V15, P281, DOI 10.1016/j.semcdb.2003.12.017; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; He JQ, 2004, J BIOL CHEM, V279, P50190, DOI 10.1074/jbc.M404876200; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hu LA, 2002, J BIOL CHEM, V277, P1607, DOI 10.1074/jbc.M107297200; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hu LYA, 2003, J BIOL CHEM, V278, P26295, DOI 10.1074/jbc.M212352200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Pak Y, 2002, MOL CELL BIOL, V22, P7942, DOI 10.1128/MCB.22.22.7942-7952.2002; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shizukuda Y, 2002, J MOL CELL CARDIOL, V34, P823, DOI 10.1006/jmcc.2002.2020; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Wang GS, 2004, NEURON, V42, P113, DOI 10.1016/S0896-6273(04)00139-4; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; XIAO RP, 1994, J BIOL CHEM, V269, P19151; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Zaugg M, 2000, CIRCULATION, V102, P344	32	97	105	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2820	2827		10.1074/jbc.M509503200	http://dx.doi.org/10.1074/jbc.M509503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316992	hybrid			2022-12-27	WOS:000234931800049
J	Taylor, J; Grote, SK; Xia, JR; Vandelft, M; Graczyk, J; Ellerby, LM; La Spada, AR; Truant, R				Taylor, J; Grote, SK; Xia, JR; Vandelft, M; Graczyk, J; Ellerby, LM; La Spada, AR; Truant, R			Ataxin-7 can export from the nucleus via a conserved exportin-dependent signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; DOMINANT CEREBELLAR-ATAXIA; TATA-BINDING PROTEIN; EXPANDED POLYGLUTAMINE; RETINAL DEGENERATION; CELLULAR TOXICITY; ANDROGEN RECEPTOR; MUTANT ATAXIN-7; BETA-ARRESTINS; MESSENGER-RNA	Spinocerebellar ataxia type 7 is a progressive neurodegenerative disorder caused by a CAG DNA triplet repeat expansion leading to an expanded polyglutamine tract in the ataxin-7 protein. Ataxin-7 appears to be a transcription factor and a component of the STAGA transcription coactivator complex. Here, using live cell imaging and inverted fluorescence recovery after photobleaching, we demonstrate that ataxin-7 has the ability to export from the nucleus via the CRM-1/exportin pathway and that ataxin-7 contains a classic leucine-type nuclear export signal (NES). We have precisely defined the location of this NES in ataxin-7 and found it to be fully conserved in all vertebrate species. Polyglutamine expansion was seen to reduce the nuclear export rate of mutant ataxin-7 relative to wildtype ataxin-7. Subtle point mutation of the NES in polyglutamine expanded ataxin-7 increased toxicity in primary cerebellar neurons in a polyglutamine length-dependent manner in the context of full-length ataxin-7. Our results add ataxin-7 to a growing list of polyglutamine disease proteins that are capable of nuclear shuttling, and we define an activity of ataxin-7 in the STAGA complex of trafficking between the nucleus and cytoplasm.	McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; Univ Washington, Med Ctr, Dept Lab Med Med & Neurol, Seattle, WA 98195 USA; Univ Washington, Med Ctr, Ctr Neurogenet & Neurotherapeut, Seattle, WA 98195 USA; Buck Inst Age Res, Novato, CA 94945 USA	McMaster University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Buck Institute for Research on Aging	Truant, R (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, HSC4H45, Hamilton, ON L8N 3Z5, Canada.	truantr@mcmaster.ca	La Spada, Albert/AAG-8809-2020	Achenbach, Jillian/0000-0002-1054-3784; van Delft, Mark/0000-0002-3866-4318	NEI NIH HHS [EY14061] Funding Source: Medline; NINDS NIH HHS [NS40251A] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY014061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040251] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abdullah AAR, 1998, HUM MOL GENET, V7, P379, DOI 10.1093/hmg/7.3.379; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Bowman AB, 2005, HUM MOL GENET, V14, P679, DOI 10.1093/hmg/ddi064; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Cancel G, 2000, BRAIN, V123, P2519, DOI 10.1093/brain/123.12.2519; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Chen SM, 2004, HUM MOL GENET, V13, P53, DOI 10.1093/hmg/ddh005; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; ENEVOLDSON TP, 1994, BRAIN, V117, P445, DOI 10.1093/brain/117.3.445; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod Maarten, 2002, Results Probl Cell Differ, V35, P67; GAO WQ, 1991, NEURON, V6, P705, DOI 10.1016/0896-6273(91)90168-Y; Garden GA, 2002, J NEUROSCI, V22, P4897, DOI 10.1523/JNEUROSCI.22-12-04897.2002; Grote SK, 2003, CYTOGENET GENOME RES, V100, P164, DOI 10.1159/000072851; Helmlinger D, 2004, HUM MOL GENET, V13, P1257, DOI 10.1093/hmg/ddh139; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Howell JL, 2002, BIOTECHNIQUES, V32, P80, DOI 10.2144/02321st04; Irwin S, 2005, J CELL SCI, V118, P233, DOI 10.1242/jcs.01611; Jacob AL, 2001, J BIOL CHEM, V276, P37659, DOI 10.1074/jbc.M104427200; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kaytor MD, 1999, HUM MOL GENET, V8, P1657, DOI 10.1093/hmg/8.9.1657; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Lebre AS, 2003, CYTOGENET GENOME RES, V100, P154, DOI 10.1159/000072850; Lee JH, 2003, MOL CELLS, V16, P78; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Matilla A, 2001, HUM MOL GENET, V10, P2821, DOI 10.1093/hmg/10.24.2821; Mauger C, 1999, MOL BRAIN RES, V74, P35, DOI 10.1016/S0169-328X(99)00256-9; McMahon SJ, 2005, P NATL ACAD SCI USA, V102, P8478, DOI 10.1073/pnas.0503493102; Mushegian AR, 2000, BIOCHEMISTRY-US, V39, P6809, DOI 10.1021/bi992694y; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Nucifora FC, 2003, J BIOL CHEM, V278, P13047, DOI 10.1074/jbc.M211224200; Palhan VB, 2005, P NATL ACAD SCI USA, V102, P8472, DOI 10.1073/pnas.0503505102; Ralser M, 2005, J MOL BIOL, V346, P203, DOI 10.1016/j.jmb.2004.11.024; Rashevsky-Finkel A, 2001, J BIOL CHEM, V276, P44963, DOI 10.1074/jbc.M106112200; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Saporita AJ, 2003, J BIOL CHEM, V278, P41998, DOI 10.1074/jbc.M302460200; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Slow EJ, 2005, CLIN GENET, V67, P228, DOI 10.1111/j.1399-0004.2005.00416.x; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; TO KW, 1993, OPHTHALMOLOGY, V100, P15; Truant R, 2003, CLIN NEUROSCI RES, V3, P157, DOI 10.1016/S1566-2772(03)00058-6; Turpin P, 1999, FEBS LETT, V452, P82, DOI 10.1016/S0014-5793(99)00533-5; Voss TC, 2005, BIOTECHNIQUES, V38, P413, DOI 10.2144/05383RV01; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xia JR, 2003, HUM MOL GENET, V12, P1393, DOI 10.1093/hmg/ddg156; Yoo SY, 2003, NEURON, V37, P383, DOI 10.1016/S0896-6273(02)01190-X; Yvert G, 2001, HUM MOL GENET, V10, P1679, DOI 10.1093/hmg/10.16.1679; Zander C, 2001, HUM MOL GENET, V10, P2569, DOI 10.1093/hmg/10.22.2569	56	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2730	2739		10.1074/jbc.M506751200	http://dx.doi.org/10.1074/jbc.M506751200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16314424	hybrid			2022-12-27	WOS:000234931800039
J	Najmudin, S; Guerreiro, CIPD; Carvalho, AL; Prates, JAM; Correia, MAS; Alves, VD; Ferreira, LMA; Romao, MJ; Gilbert, HJ; Bolam, DN; Fontes, CMGA				Najmudin, S; Guerreiro, CIPD; Carvalho, AL; Prates, JAM; Correia, MAS; Alves, VD; Ferreira, LMA; Romao, MJ; Gilbert, HJ; Bolam, DN; Fontes, CMGA			Xyloglucan is recognized by carbohydrate-binding modules that interact with beta-glucan chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULOMONAS-FIMI; LIGAND-BINDING; CRYSTAL-STRUCTURE; AFFINITY ELECTROPHORESIS; DOMAIN; FAMILY; CELLULASE; COMPLEX; IDENTIFICATION; SPECIFICITY	Enzyme systems that attack the plant cell wall contain noncatalytic carbohydrate-binding modules (CBMs) that mediate attachment to this composite structure and play a pivotal role in maximizing the hydrolytic process. Although xyloglucan, which includes a backbone of beta-1,4-glucan decorated primarily with xylose residues, is a key component of the plant cell wall, CBMs that bind to this polymer have not been identified. Here we showed that the C-terminal domain of the modular Clostridium thermocellum enzyme CtCel9D-Cel44A (formerly known as CelJ) comprises a novel CBM (designated CBM44) that binds with equal affinity to cellulose and xyloglucan. We also showed that accommodation of xyloglucan side chains is a general feature of CBMs that bind to single cellulose chains. The crystal structures of CBM44 and the other CBM (CBM30) in CtCel9D-Cel44A display a beta-sandwich fold. The concave face of both CBMs contains a hydrophobic platform comprising three tryptophan residues that can accommodate up to five glucose residues. The orientation of these aromatic residues is such that the bound ligand would adopt the twisted conformation displayed by cello-oligosaccharides in solution. Mutagenesis studies confirmed that the hydrophobic platform located on the concave face of both CBMs mediates ligand recognition. In contrast to other CBMs that bind to single polysaccharide chains, the polar residues in the binding cleft of CBM44 play only a minor role in ligand recognition. The mechanism by which these proteins are able to recognize linear and decorated beta-1,4-glucans is discussed based on the structures of CBM44 and the other CBMs that bind single cellulose chains.	Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal; Univ Tecn Lisboa, Fac Med Vet, CIISA, P-1300477 Lisbon, Portugal	Newcastle University - UK; Universidade Nova de Lisboa; Universidade de Lisboa	Bolam, DN (corresponding author), Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	D.N.Bolam@newcastle.ac.uk; cafontes@fmv.utl.pt	Correia, Márcia/D-2077-2013; Romao, Maria J/A-4115-2013; Prates, José A M/K-9934-2013; Carvalho, Ana Luísa/G-5638-2011; UCIBIO, U Cienc Biom Apl/F-7948-2017	Correia, Márcia/0000-0003-0636-8095; Romao, Maria J/0000-0002-3004-0543; Prates, José A M/0000-0003-1032-5987; Carvalho, Ana Luísa/0000-0002-3824-0240; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Alves, Victor Diogo/0000-0002-8430-4380; Bolam, David/0000-0003-0314-3122; Najmudin, Shabir/0000-0002-0429-5454; Ferreira, Luis/0000-0002-3543-9166; Fontes, Carlos/0000-0002-1219-9753	Biotechnology and Biological Sciences Research Council [BB/C005074/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abou-Hachem M, 2002, BIOCHEMISTRY-US, V41, P5720, DOI 10.1021/bi012094a; Ahsan MM, 1996, J BACTERIOL, V178, P5732, DOI 10.1128/jb.178.19.5732-5740.1996; Arai T, 2003, J BACTERIOL, V185, P504, DOI 10.1128/JB.185.2.504-512.2003; ATKINS EDT, 1992, 3 DIMENSIONAL STRUCT; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BESKROVNAYA OI, 2000, HUM MOL GENET, V9, P1641, DOI DOI 10.1093/HMG/9.11.1641; Bolam DN, 2004, J BIOL CHEM, V279, P22953, DOI 10.1074/jbc.M313317200; Bolam DN, 1998, BIOCHEM J, V331, P775, DOI 10.1042/bj3310775; Boraston AB, 2003, STRUCTURE, V11, P665, DOI 10.1016/S0969-2126(03)00100-X; Boraston AB, 2002, J MOL BIOL, V319, P1143, DOI 10.1016/S0022-2836(02)00374-1; Boraston AB, 2002, BIOCHEM J, V361, P35, DOI 10.1042/0264-6021:3610035; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Boraston AB, 2000, BIOCHEMISTRY-US, V39, P11129, DOI 10.1021/bi0007728; BUEREN AL, 2005, J BIOL CHEM, V280, P530; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Carvalho AL, 2004, J BIOL CHEM, V279, P34785, DOI 10.1074/jbc.M405867200; Charnock SJ, 2002, P NATL ACAD SCI USA, V99, P14077, DOI 10.1073/pnas.212516199; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; COUGHLAN MP, 1985, BIOTECHNOL GENET ENG, V3, P39, DOI 10.1080/02648725.1985.10647809; Coutinho PM, 1999, ROY SOC CH, P3; Czjzek M, 2001, J BIOL CHEM, V276, P48580, DOI 10.1074/jbc.M109142200; Dias FMV, 2004, J BIOL CHEM, V279, P25517, DOI 10.1074/jbc.M401647200; Flint J, 2005, J BIOL CHEM, V280, P23718, DOI 10.1074/jbc.M501551200; Flint J, 2004, J MOL BIOL, V337, P417, DOI 10.1016/j.jmb.2003.12.081; Gill J, 1999, BIOCHEM J, V342, P473, DOI 10.1042/0264-6021:3420473; Henrissat B, 1998, BIOCHEM SOC T, V26, P153, DOI 10.1042/bst0260153; Henshaw JL, 2004, J BIOL CHEM, V279, P21552, DOI 10.1074/jbc.M401620200; Jamal-Talabani S, 2004, STRUCTURE, V12, P1177, DOI 10.1016/j.str.2004.04.022; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P13895, DOI 10.1021/bi961186a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kormos J, 2000, BIOCHEMISTRY-US, V39, P8844, DOI 10.1021/bi000607s; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; Leslie AGW, 1992, PROTEIN CRYSTALLOGR, V26, P27; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Najmudin S, 2005, ACTA CRYSTALLOGR F, V61, P1043, DOI 10.1107/S1744309105035670; Notenboom V, 2001, J MOL BIOL, V314, P797, DOI 10.1006/jmbi.2001.5153; Orikoshi H, 2005, J APPL MICROBIOL, V99, P551, DOI 10.1111/j.1365-2672.2005.02630.x; Pell G, 2003, BIOCHEMISTRY-US, V42, P9316, DOI 10.1021/bi0347510; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pires VMR, 2004, J BIOL CHEM, V279, P21560, DOI 10.1074/jbc.M401599200; Raghothama S, 2000, BIOCHEMISTRY-US, V39, P978, DOI 10.1021/bi992163+; ROUSSEL A, 1991, TURBO FRODO SILICON, P86; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; Szabo L, 2001, J BIOL CHEM, V276, P49061, DOI 10.1074/jbc.M109558200; TAKEO K, 1984, ELECTROPHORESIS, V5, P187, DOI 10.1002/elps.1150050402; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tomme P, 2000, ENZYME MICROB TECH, V27, P453, DOI 10.1016/S0141-0229(00)00246-5; Tormo J, 1996, EMBO J, V15, P5739, DOI 10.1002/j.1460-2075.1996.tb00960.x; Tunnicliffe RB, 2005, J MOL BIOL, V347, P287, DOI 10.1016/j.jmb.2005.01.038; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WOOD TM, 1988, METHOD ENZYMOL, V160, P19; Xie HF, 2001, BIOCHEMISTRY-US, V40, P5700, DOI 10.1021/bi010034z; Xie HF, 2001, BIOCHEMISTRY-US, V40, P9167, DOI 10.1021/bi0106742; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011	60	94	94	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8815	8828		10.1074/jbc.M510559200	http://dx.doi.org/10.1074/jbc.M510559200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16314409	Green Published, hybrid			2022-12-27	WOS:000236247100061
J	Lindzen, M; Gottschalk, KE; Fuzesi, M; Garty, H; Karlish, SJD				Lindzen, M; Gottschalk, KE; Fuzesi, M; Garty, H; Karlish, SJD			Structural interactions between FXYD proteins and Na+,K+-ATPase - alpha/beta/FXYD subunit stoichiometry and cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; ALPHA-SUBUNIT; FUNCTIONAL INTERACTION; NA+/K+-ATPASE; OLIGOMERIC STRUCTURE; RENAL NA,K-ATPASE; K-ATPASE; CHIF; EXPRESSION; AFFINITY	Interactions of rat FXYD4 (corticosteroid hormone-induced factor (CHIF)), FXYD2 (gamma), or FXYD1 (phospholemman (PLM)) proteins with rat alpha 1 subunits of Na+,K+-ATPase have been analyzed by co-immunoprecipitation and covalent cross-linking. In detergent-solubilized membranes from HeLa cells expressing both gamma and CHIF or CHIF and hemagglutinin A-tagged CHIF, mixed complexes of CHIF and gamma or CHIF and hemagglutinin A-tagged CHIF with alpha/beta subunits are undetectable. This implies that the alpha/beta/FXYD protomer is the major species in detergent solution. A lipid-soluble cysteine-cysteine bifunctional reagent, dibromobimane, cross-links CHIF to alpha in colonic membranes but not gamma or PLM to alpha in kidney or heart membranes, respectively. Sequence comparisons of the FXYD proteins suggested that Cys-49 in the trans-membrane segment of CHIF could be involved. In detergent-solubilized HeLa cell membranes, dibromobimane cross-links wild-type CHIF to alpha but not the C49F mutant, and also the corresponding F36C mutant but not wild-type gamma b, and F48C but not wild-type PLM. C140S, C338A, C804A, and C966S mutants of the alpha subunit have been expressed. Only the C140S mutant prevents cross-linking with CHIF. The data demonstrated the proximity of trans-membrane segments of CHIF, gamma, and PLM to M2 of alpha. Molecular modeling is consistent with location of the trans-membrane segment of all FXYD proteins between M2, M6, and M9 and the proximity of Cys-49 of CHIF or Phe-36 of gamma with Cys-140 of M2. Cross-linking also demonstrated CHIF-alpha and CHIF-beta proximities in extra-membrane regions, similar to the evidence for gamma-alpha and gamma-beta cross-links.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Karlish, SJD (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Steven.Karlish@weizmann.ac.il	Gottschalk, Kay/D-6503-2012	Gottschalk, Kay/0000-0002-7951-0972				Aizman R, 2002, AM J PHYSIOL-RENAL, V283, pF569, DOI 10.1152/ajprenal.00376.2001; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Asahi M, 2003, P NATL ACAD SCI USA, V100, P5040, DOI 10.1073/pnas.0330962100; Askari A, 2000, INT CONGR SER, V1207, P17; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen E, 2005, J BIOL CHEM, V280, P16610, DOI 10.1074/jbc.M414290200; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE, pRE1; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Fuzesi M, 2005, J BIOL CHEM, V280, P18291, DOI 10.1074/jbc.M500080200; Garty H, 2005, SEMIN NEPHROL, V25, P304, DOI 10.1016/j.semnephrol.2005.03.005; Garty H, 2003, ANN NY ACAD SCI, V986, P395, DOI 10.1111/j.1749-6632.2003.tb07220.x; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; Garty H, 2006, ANNU REV PHYSIOL, V68, P431, DOI 10.1146/annurev.physiol.68.040104.131852; Geering K, 2003, ANN NY ACAD SCI, V986, P388, DOI 10.1111/j.1749-6632.2003.tb07219.x; Gottschalk KE, 2004, J MOL GRAPH MODEL, V23, P99, DOI 10.1016/j.jmgm.2004.02.002; Gottschalk KE, 2004, BIOPHYS J, V86, P3335, DOI 10.1529/biophysj.103.034546; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; HAYASHI Y, 1989, BIOCHIM BIOPHYS ACTA, V983, P217, DOI 10.1016/0005-2736(89)90237-X; Hayashi Y, 1997, ANN NY ACAD SCI, V834, P19, DOI 10.1111/j.1749-6632.1997.tb52222.x; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Hu YK, 2000, J BIOL CHEM, V275, P30734, DOI 10.1074/jbc.M003737200; Jones DH, 2005, J BIOL CHEM, V280, P19003, DOI 10.1074/jbc.M500697200; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KIM JS, 1995, ANAL BIOCHEM, V225, P174, DOI 10.1006/abio.1995.1131; KOSOWER EM, 1995, METHOD ENZYMOL, V251, P133, DOI 10.1016/0076-6879(95)51117-2; Koster JC, 1997, ANN NY ACAD SCI, V834, P135, DOI 10.1111/j.1749-6632.1997.tb52240.x; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; Laughery M, 2004, J BIOL CHEM, V279, P36339, DOI 10.1074/jbc.M402778200; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; LINDZEN M, 2005, J GEN PHYSIOL, V126, pA51; MacLennan DH, 2003, ANN NY ACAD SCI, V986, P472, DOI 10.1111/j.1749-6632.2003.tb07231.x; Mahmmoud YA, 2005, J BIOL CHEM, V280, P27776, DOI 10.1074/jbc.M503150200; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; Martin DW, 2000, P NATL ACAD SCI USA, V97, P3195, DOI 10.1073/pnas.050558397; Martin DW, 2000, J BIOL CHEM, V275, P24512, DOI 10.1074/jbc.M003179200; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MIMURA K, 1993, BIOCHIM BIOPHYS ACTA, V1145, P63, DOI 10.1016/0005-2736(93)90382-A; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Strugatsky D, 2005, BIOCHEMISTRY-US, V44, P15961, DOI 10.1021/bi051921v; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Taniguchi K, 2001, J BIOCHEM, V129, P335, DOI 10.1093/oxfordjournals.jbchem.a002862; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2001, J BIOENERG BIOMEMBR, V33, P407, DOI 10.1023/A:1010619623841; Wald H, 1996, AM J PHYSIOL-RENAL, V271, pF322, DOI 10.1152/ajprenal.1996.271.2.F322; Wald H, 1997, AM J PHYSIOL-RENAL, V272, pF617, DOI 10.1152/ajprenal.1997.272.5.F617; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; Wetzel RK, 2004, J BIOL CHEM, V279, P41750, DOI 10.1074/jbc.M405622200; Zouzoulas A, 2005, J MEMBRANE BIOL, V204, P49, DOI 10.1007/s00232-005-0746-7; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	58	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5947	5955		10.1074/jbc.M512063200	http://dx.doi.org/10.1074/jbc.M512063200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373350	hybrid			2022-12-27	WOS:000235568900075
J	Constantinidou, C; Hobman, JL; Griffiths, L; Patel, MD; Penn, CW; Cole, JA; Overton, TW				Constantinidou, C; Hobman, JL; Griffiths, L; Patel, MD; Penn, CW; Cole, JA; Overton, TW			A reassessment of the FNR regulon and transcriptomic analysis of the effects of nitrate, nitrite, NarXL, and NarQP as Escherichia coli K12 adapts from aerobic to anaerobic growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR GENETIC-ANALYSIS; OXIDE REDUCTASE GENE; COLI NIR PROMOTER; OPERON EXPRESSION; IN-VITRO; RESPONSIVE REGULATOR; DEPENDENT ACTIVATION; OXYGEN AVAILABILITY; ELECTRON-ACCEPTORS; PROTEIN	The transcription factor FNR, the regulator of fumarate and nitrate reduction, regulates major changes as Escherichia coli adapts from aerobic to anaerobic growth. In an anaerobic glycerol/ trimethylamine N-oxide/fumarate medium, the fnr mutant grew as well as the parental strain, E. coli K12 MG1655, enabling us to reveal the response to oxygen, nitrate, and nitrite in the absence of glucose repression or artifacts because of variations in growth rate. Hence, many of the discrepancies between previous microarray studies of the E. coli FNR regulon were resolved. The current microarray data confirmed 31 of the previously characterized FNR-regulated operons. Forty four operons not previously known to be included in the FNR regulon were activated by FNR, and a further 28 operons appeared to be repressed. For each of these operons, a match to the consensus FNR-binding site sequence was identified. The FNR regulon therefore minimally includes at least 103, and possibly as many as 115, operons. Comparison of transcripts in the parental strain and a narXL deletion mutant revealed that transcription of 51 operons is activated, directly or indirectly, by NarL, and a further 41 operons are repressed. The narP gene was also deleted from the narXL mutant to reveal the extent of regulation by phosphorylated NarP. Fourteen promoters were more active in the narP(+) strain than in the mutant, and a further 37 were strongly repressed. This is the first report that NarP might function as a global repressor as well as a transcription activator. The data also revealed possible new defense mechanisms against reactive nitrogen species.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Overton, TW (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.	t.w.overton@bham.ac.uk	Overton, Tim W/F-3284-2011	Overton, Tim W/0000-0003-3050-2549; Hobman, Jon/0000-0003-0998-9444				Anderson LA, 2000, J BACTERIOL, V182, P7035, DOI 10.1128/JB.182.24.7035-7043.2000; Anjum MF, 2000, MICROBIOL-SGM, V146, P3157, DOI 10.1099/00221287-146-12-3157; APARICIO O, 2005, CURRENT PROTOCOLS MO; BEARSON SM, 2002, BMC MICROBIOL, V12, P2; BEAUMONT MD, 1993, J GEN MICROBIOL, V139, P2677, DOI 10.1099/00221287-139-11-2677; BELL AI, 1990, MOL MICROBIOL, V4, P1753, DOI 10.1111/j.1365-2958.1990.tb00553.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bodenmiller DM, 2006, J BACTERIOL, V188, P874, DOI 10.1128/JB.188.3.874-881.2006; BONNEFOY V, 1992, MOL MICROBIOL, V6, P3595; Boston T, 2003, J BACTERIOL, V185, P5310, DOI 10.1128/JB.185.17.5310-5313.2003; Browning DF, 2000, MOL MICROBIOL, V37, P1258, DOI 10.1046/j.1365-2958.2000.02087.x; Browning DF, 2005, MOL MICROBIOL, V57, P496, DOI 10.1111/j.1365-2958.2005.04701.x; Browning DF, 2004, MOL MICROBIOL, V53, P203, DOI 10.1111/j.1365-2958.2004.04104.x; COMPAN I, 1994, MOL MICROBIOL, V11, P955, DOI 10.1111/j.1365-2958.1994.tb00374.x; Cook GM, 1997, J BACTERIOL, V179, P6525, DOI 10.1128/jb.179.20.6525-6530.1997; COTTER PA, 1989, J BACTERIOL, V171, P3817, DOI 10.1128/jb.171.7.3817-3823.1989; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; Cunningham L, 1997, MICROBIOL-UK, V143, P3795, DOI 10.1099/00221287-143-12-3795; da Costa PN, 2003, FEMS MICROBIOL LETT, V218, P385, DOI 10.1016/S0378-1097(02)01186-2; DARIE S, 1994, J BACTERIOL, V176, P5270, DOI 10.1128/JB.176.17.5270-5276.1994; Darwin AJ, 1998, J BACTERIOL, V180, P4192, DOI 10.1128/JB.180.16.4192-4198.1998; Darwin AJ, 1996, MOL MICROBIOL, V20, P621, DOI 10.1046/j.1365-2958.1996.5491074.x; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; DRAPAL N, 1995, J BACTERIOL, V177, P5338, DOI 10.1128/jb.177.18.5338-5341.1995; Eichler K, 1996, J BACTERIOL, V178, P1248, DOI 10.1128/jb.178.5.1248-1257.1996; EIGLMEIER K, 1989, MOL MICROBIOL, V3, P869, DOI 10.1111/j.1365-2958.1989.tb00236.x; Filenko NA, 2005, BIOCHEM SOC T, V33, P195, DOI 10.1042/BST0330195; Flatley J, 2005, J BIOL CHEM, V280, P10065, DOI 10.1074/jbc.M410393200; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Golby P, 1998, J BACTERIOL, V180, P6586, DOI 10.1128/JB.180.24.6586-6596.1998; Govantes F, 2000, MOL MICROBIOL, V38, P1061, DOI 10.1046/j.1365-2958.2000.02215.x; Grainger DC, 2004, J BACTERIOL, V186, P6938, DOI 10.1128/JB.186.20.6938-6943.2004; GREEN J, 1994, MOL MICROBIOL, V12, P433, DOI 10.1111/j.1365-2958.1994.tb01032.x; Green J, 1996, MOL MICROBIOL, V19, P125, DOI 10.1046/j.1365-2958.1996.353884.x; Green J, 1997, MOL MICROBIOL, V24, P593, DOI 10.1046/j.1365-2958.1997.3801737.x; GUNSALUS RP, 1994, RES MICROBIOL, V145, P437, DOI 10.1016/0923-2508(94)90092-2; Hasona A, 2001, ARCH MICROBIOL, V175, P178, DOI 10.1007/s002030100252; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; IUCHI S, 1990, J BACTERIOL, V172, P179, DOI 10.1128/JB.172.1.179-184.1990; JENNINGS MP, 1993, MOL MICROBIOL, V9, P155, DOI 10.1111/j.1365-2958.1993.tb01677.x; JONES HM, 1987, J BACTERIOL, V169, P3340, DOI 10.1128/jb.169.7.3340-3349.1987; Jourlin C, 1997, J MOL BIOL, V267, P770, DOI 10.1006/jmbi.1997.0919; Jourlin C, 1996, J BACTERIOL, V178, P1219, DOI 10.1128/jb.178.4.1219-1223.1996; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; Kim SJ, 1999, IUBMB LIFE, V48, P215, DOI 10.1080/152165499307251; LAMBDEN PR, 1976, J GEN MICROBIOL, V97, P145, DOI 10.1099/00221287-97-2-145; Lamberg KE, 2000, MOL MICROBIOL, V38, P817, DOI 10.1046/j.1365-2958.2000.02172.x; LI J, 1992, J BACTERIOL, V174, P4935, DOI 10.1128/JB.174.15.4935-4942.1992; Malpica R, 2004, P NATL ACAD SCI USA, V101, P13318, DOI 10.1073/pnas.0403064101; Marshall FA, 2001, MOL MICROBIOL, V39, P747, DOI 10.1046/j.1365-2958.2001.02262.x; McNicholas PM, 1998, MOL MICROBIOL, V27, P197, DOI 10.1046/j.1365-2958.1998.00675.x; Melville SB, 1996, P NATL ACAD SCI USA, V93, P1226, DOI 10.1073/pnas.93.3.1226; Membrillo-Hernandez J, 1999, J BACTERIOL, V181, P7571; Messenger SL, 2003, FEMS MICROBIOL LETT, V228, P81, DOI 10.1016/S0378-1097(03)00726-2; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Notley L, 1996, J BACTERIOL, V178, P1465, DOI 10.1128/jb.178.5.1465-1468.1996; Notley-McRobb L, 2002, J BACTERIOL, V184, P806, DOI 10.1128/JB.184.3.806-811.2002; Poock SR, 2002, J BIOL CHEM, V277, P23664, DOI 10.1074/jbc.M200731200; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POPE NR, 1982, J GEN MICROBIOL, V128, P219; Potter LC, 1999, BIOCHEM J, V344, P77, DOI 10.1042/0264-6021:3440077; RABIN RS, 1993, J BACTERIOL, V175, P3259, DOI 10.1128/jb.175.11.3259-3268.1993; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; Rodionov DA, 2006, PLOS COMPUT BIOL, V2, P1568, DOI 10.1371/journal.pcbi.0020163; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAWERS G, 1992, J BACTERIOL, V174, P3474, DOI 10.1128/JB.174.11.3474-3478.1992; SAWERS RG, 1988, ARCH MICROBIOL, V149, P240, DOI 10.1007/BF00422011; Scott C, 2003, FEBS LETT, V541, P97, DOI 10.1016/S0014-5793(03)00312-0; Soballe B, 1997, FEBS LETT, V414, P373, DOI 10.1016/S0014-5793(97)01041-7; SPIRO S, 1987, J GEN MICROBIOL, V133, P3279; SPIRO S, 1991, TRENDS BIOCHEM SCI, V16, P310, DOI 10.1016/0968-0004(91)90125-F; Stewart V, 2003, J BACTERIOL, V185, P5862, DOI 10.1128/JB.185.19.5862-5870.2003; STEWART V, 1993, MOL MICROBIOL, V9, P425, DOI 10.1111/j.1365-2958.1993.tb01704.x; TAKAHASHI K, 1994, FEBS LETT, V340, P59, DOI 10.1016/0014-5793(94)80173-8; Tyson K, 1997, ARCH MICROBIOL, V168, P240, DOI 10.1007/s002030050494; WALKER MS, 1991, MOL MICROBIOL, V5, P353, DOI 10.1111/j.1365-2958.1991.tb02116.x; Wang HN, 1999, J BACTERIOL, V181, P5303, DOI 10.1128/JB.181.17.5303-5308.1999; WONG KK, 1992, FEMS MICROBIOL LETT, V94, P15; Wu HC, 1998, MOL MICROBIOL, V27, P493, DOI 10.1046/j.1365-2958.1998.00699.x; Wyborn NR, 2004, MICROBIOL-SGM, V150, P1495, DOI 10.1099/mic.0.26877-0; Zheng DL, 2004, NUCLEIC ACIDS RES, V32, P5874, DOI 10.1093/nar/gkh908; Zientz E, 1999, J BACTERIOL, V181, P3716, DOI 10.1128/JB.181.12.3716-3720.1999; Zientz E, 1996, J BACTERIOL, V178, P7241, DOI 10.1128/jb.178.24.7241-7247.1996	88	218	224	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4802	4815		10.1074/jbc.M512312200	http://dx.doi.org/10.1074/jbc.M512312200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377617	hybrid			2022-12-27	WOS:000235426200031
J	Flemming, PK; Dedman, AM; Xu, SZ; Li, J; Zeng, FN; Naylor, J; Benham, CD; Bateson, AN; Muraki, K; Beech, DJ				Flemming, PK; Dedman, AM; Xu, SZ; Li, J; Zeng, FN; Naylor, J; Benham, CD; Bateson, AN; Muraki, K; Beech, DJ			Sensing of lysophospholipids by TRPC5 calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIFUNCTIONAL CATION CHANNELS; SMOOTH-MUSCLE; RECEPTOR; LYSOPHOSPHATIDYLCHOLINE; ENTRY; IDENTIFICATION; ACTIVATION; MECHANISM; PATHWAY; INFLUX	TRPC calcium channels are emerging as a ubiquitous feature of vertebrate cells, but understanding of them is hampered by limited knowledge of the mechanisms of activation and identity of endogenous regulators. We have revealed that one of the TRPC channels, TRPC5, is strongly activated by common endogenous lysophospholipids including lysophosphatidylcholine ( LPC) but, by contrast, not arachidonic acid. Although TRPC5 was stimulated by agonists at G-protein-coupled receptors, TRPC5 activation by LPC occurred downstream and independently of G-protein signaling. The effect was not due to the generation of reactive oxygen species or because of a detergent effect of LPC. LPC activated TRPC5 when applied to excised membrane patches and thus has a relatively direct action on the channel structure, either because of a phospholipid binding site on the channel or because of sensitivity of the channel to perturbation of the bilayer by certain lipids. Activation showed dependence on side-chain length and the chemical head-group. The data revealed a previously unrecognized lysophospholipid-sensing capability of TRPC5 that confers the property of a lipid ionotropic receptor.	Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England; Aichi Gakuin Univ, Sch Pharm, Chikusa Ku, Nagoya, Aichi 4678650, Japan; GlaxoSmithKline Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of Leeds; Aichi Gakuin University; GlaxoSmithKline	Beech, DJ (corresponding author), Univ Leeds, Inst Membrane & Syst Biol, Leeds LS2 9JT, W Yorkshire, England.	d.j.beech@leeds.ac.uk	Xu, Shang-Zhong/P-2807-2015	Xu, Shang-Zhong/0000-0002-7295-9347; Beech, David/0000-0002-7683-9422	Wellcome Trust [060988] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beech DJ, 2004, J PHYSIOL-LONDON, V559, P685, DOI 10.1113/jphysiol.2004.068734; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Facemire CS, 2004, AM J PHYSIOL-RENAL, V286, pF546, DOI 10.1152/ajprenal.00338.2003; FELDER CC, 1990, J PHARMACOL EXP THER, V255, P1140; Freichel M, 2005, J PHYSIOL-LONDON, V567, P59, DOI 10.1113/jphysiol.2005.092999; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Ishii I, 2004, ANNU REV BIOCHEM, V73, P321, DOI 10.1146/annurev.biochem.73.011303.073731; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Nilius B, 2005, PFLUG ARCH EUR J PHY, V451, P1, DOI 10.1007/s00424-005-1462-y; Obukhov AG, 2005, J NEUROSCI, V25, P1234, DOI 10.1523/JNEUROSCI.4451-04.2005; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; Ordaz B, 2005, J BIOL CHEM, V280, P30788, DOI 10.1074/jbc.M504745200; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Plant TD, 2003, CELL CALCIUM, V33, P441, DOI 10.1016/S0143-4160(03)00055-1; Putney JW, 2004, TRENDS CELL BIOL, V14, P282, DOI 10.1016/j.tcb.2004.04.002; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Smani T, 2004, NAT CELL BIOL, V6, P113, DOI 10.1038/ncb1089; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Takeshita S, 2000, J Atheroscler Thromb, V7, P238; Thukkani AK, 2003, CIRCULATION, V108, P3128, DOI 10.1161/01.CIR.0000104564.01539.6A; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Yan JJ, 2004, NAT MED, V10, P161, DOI 10.1038/nm989; ZENG F, 2004, J PHYSIOL-LONDON, V15, P739; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	29	100	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4977	4982		10.1074/jbc.M510301200	http://dx.doi.org/10.1074/jbc.M510301200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368680	hybrid			2022-12-27	WOS:000235426200049
J	Kambara, T; Ikebe, M				Kambara, T; Ikebe, M			A unique ATP hydrolysis mechanism of single-headed processive myosin, myosin IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; PHOSPHORYLATION-DEPENDENT REGULATION; ACTIN-BINDING LOOP; KINETIC MECHANISM; MOTOR DOMAIN; CHIMERIC SUBSTITUTIONS; CONFORMATIONAL-CHANGES; NUCLEOTIDE-BINDING; FREE-ENERGY; TRYPTOPHAN	Recent studies have revealed that myosin IX is a single-headed processive myosin, yet it is unclear how myosin IX can achieve the processive movement. Here we studied the mechanism of ATP hydrolysis cycle of actomyosin IXb. We found that myosin IXb has a rate-limiting ATP hydrolysis step unlike other known myosins, thus populating the prehydrolysis intermediate (M(.)ATP). M(.)ATP has a high affinity for actin, and, unlike other myosins, the dissociation of M(.)ATP from actin was extremely slow, thus preventing myosin from dissociating away from actin. The ADP dissociation step was 10-fold faster than the overall ATP hydrolysis cycle rate and thus not rate-limiting. We propose the following model for single-headed processive myosin. Upon the formation of the M(.)ATP intermediate, the tight binding of actomyosin IX at the interface is weakened. However, the head is kept in close proximity to actin due to the tethering role of loop 2/large unique insertion of myosin IX. There is enough freedom for the myosin head to find the next location of the binding site along with the actin filament before complete dissociation from the filament. After ATP hydrolysis, P-i is quickly released to form a strong actin binding form, and a power stroke takes place.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave N, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048898, R01AR048526, R01AR041653] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 41653, AR 048898, AR 048526] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; BERGER CL, 1991, BIOCHEMISTRY-US, V30, P11036, DOI 10.1021/bi00110a005; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Forkey JN, 2003, NATURE, V422, P399, DOI 10.1038/nature01529; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Homma K, 2005, J BIOL CHEM, V280, P29381, DOI 10.1074/jbc.M504779200; IKEBE M, 1985, J BIOL CHEM, V260, P3146; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774; Kambara T, 1999, J BIOL CHEM, V274, P16400, DOI 10.1074/jbc.274.23.16400; Knetsch MLW, 1999, J BIOL CHEM, V274, P20133, DOI 10.1074/jbc.274.29.20133; KONRAD M, 1982, EUR J BIOCHEM, V128, P547; Kovacs M, 2002, J BIOL CHEM, V277, P28459, DOI 10.1074/jbc.M202180200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Malnasi-Csizmadia A, 2000, BIOCHEMISTRY-US, V39, P16135, DOI 10.1021/bi001125j; MARUTA H, 1981, J BIOL CHEM, V256, P499; Murphy CT, 1999, BIOCHEMISTRY-US, V38, P3785, DOI 10.1021/bi9826815; Nalavadi V, 2005, J BIOL CHEM, V280, P38957, DOI 10.1074/jbc.M507161200; O'Connell CB, 2003, NAT CELL BIOL, V5, P171, DOI 10.1038/ncb924; Park S, 1997, BIOCHEMISTRY-US, V36, P3368, DOI 10.1021/bi9624999; Post PL, 1998, J CELL SCI, V111, P941; Post PL, 2002, J BIOL CHEM, V277, P11679, DOI 10.1074/jbc.M111173200; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Resetar AM, 1995, BIOCHEMISTRY-US, V34, P16039, DOI 10.1021/bi00049a018; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; Rovner AS, 1998, J BIOL CHEM, V273, P27939, DOI 10.1074/jbc.273.43.27939; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Saeki N, 2005, J BIOL CHEM, V280, P10128, DOI 10.1074/jbc.M413415200; Sato O, 2004, J BIOL CHEM, V279, P28844, DOI 10.1074/jbc.M314332200; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Trybus KM, 1999, J BIOL CHEM, V274, P27448, DOI 10.1074/jbc.274.39.27448; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WHITE HD, 1993, J BIOL CHEM, V268, P10039; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Yengo CM, 1999, BIOCHEMISTRY-US, V38, P14515, DOI 10.1021/bi991226l; Yengo CM, 1998, P NATL ACAD SCI USA, V95, P12944, DOI 10.1073/pnas.95.22.12944; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u; Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398; Yoshimura M, 2001, J BIOL CHEM, V276, P39600, DOI 10.1074/jbc.M105080200	44	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4949	4957		10.1074/jbc.M509141200	http://dx.doi.org/10.1074/jbc.M509141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16338935	hybrid			2022-12-27	WOS:000235426200046
J	Westerberg, R; Mansson, JE; Golozoubova, V; Shabalina, IG; Backlund, EC; Tvrdik, P; Retterstol, K; Capecchi, MR; Jacobsson, A				Westerberg, R; Mansson, JE; Golozoubova, V; Shabalina, IG; Backlund, EC; Tvrdik, P; Retterstol, K; Capecchi, MR; Jacobsson, A			ELOVL3 is an important component for early onset of lipid recruitment in brown adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; FATTY-ACIDS; NONSHIVERING THERMOGENESIS; COLD-ACCLIMATION; CHAIN ELONGATION; IDENTIFICATION; ADIPOCYTES; ADAPTATION; EXPRESSION; REGULATORS	During the recruitment process of brown adipose tissue, the mRNA level of the fatty acyl chain elongase Elovl3 is elevated more than 200-fold in cold-stressed mice. We have obtained Elovl3-ablated mice and report here that, although cold-acclimated Elovl3-ablated mice experienced an increased heat loss due to impaired skin barrier, they were unable to hyperrecruit their brown adipose tissue. Instead, they used muscle shivering in order to maintain body temperature. Lack of Elovl3 resulted in a transient decrease in the capacity to elongate saturated fatty acyl-CoAs into very long chain fatty acids, concomitantly with the occurrence of reduced levels of arachidic acid (C20:0) and behenic acid (C22:0) in brown adipose tissue during the initial cold stress. This effect on very long chain fatty acid synthesis could be illustrated as a decrease in the condensation activity of the elongation enzyme. In addition, warm-acclimated Elovl3-ablated mice showed diminished ability to accumulate fat and reduced metabolic capacity within the brown fat cells. This points to ELOVL3 as an important regulator of endogenous synthesis of saturated very long chain fatty acids and triglyceride formation in brown adipose tissue during the early phase of the tissue recruitment.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden; Sahlgrens Univ Hosp, Lab Med Clin Chem, SE-43180 Molndal, Sweden; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT 84112 USA; Univ Oslo, Rikshosp, Inst Clin Biochem, N-0027 Oslo, Norway	Stockholm University; Sahlgrenska University Hospital; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; University of Oslo; National Hospital Norway	Jacobsson, A (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	anders.jacobsson@wgi.su.se	Shabalina, Irina/AAC-3720-2019; Shabalina, Irina G/A-4225-2011; Tvrdik, Petr/AAK-4398-2021	Shabalina, Irina/0000-0002-2915-6450; Shabalina, Irina G/0000-0002-2915-6450; Tvrdik, Petr/0000-0002-8750-9672				ALBERTS P, 2005, CURRENT PROTOCOLS PH; BAHT HS, 1989, BIOCHEM J, V258, P369, DOI 10.1042/bj2580369; BERNERT JT, 1979, J NEUROCHEM, V32, P85, DOI 10.1111/j.1471-4159.1979.tb04513.x; BERNERT JT, 1977, J BIOL CHEM, V252, P6736; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS BJ, 1983, BIOSCIENCE REP, V3, P263, DOI 10.1007/BF01122458; BUKOWIECKI L, 1982, AM J PHYSIOL, V242, pE353, DOI 10.1152/ajpendo.1982.242.6.E353; CAMERON IL, 1964, J CELL BIOL, V23, P89, DOI 10.1083/jcb.23.1.89; Cannon B, 1996, INT J OBESITY, V20, pS36; Cannon B, 2004, PHYSIOL REV, V84, P277, DOI 10.1152/physrev.00015.2003; Cannon B, 2000, METH MOL B, V155, P295; CANNON B, 1975, ARCH BIOCHEM BIOPHYS, V167, P505, DOI 10.1016/0003-9861(75)90493-2; CARNEHEIM C, 1989, AM J PHYSIOL, V256, pR146, DOI 10.1152/ajpregu.1989.256.1.R146; DICKER A, 1995, AM J PHYSIOL-REG I, V269, pR767, DOI 10.1152/ajpregu.1995.269.4.R767; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fluhr JW, 2003, J INVEST DERMATOL, V120, P728, DOI 10.1046/j.1523-1747.2003.12134.x; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; GELOEN A, 1988, AM J PHYSIOL, V254, pC175, DOI 10.1152/ajpcell.1988.254.1.C175; Golozoubova V, 2001, FASEB J, V15, P2048, DOI 10.1096/fj.00-0536fje; HOHTOLA E, 1982, COMP BIOCHEM PHYS A, V73, P159, DOI 10.1016/0300-9629(82)90049-4; Inagaki K, 2002, BIOSCI BIOTECH BIOCH, V66, P613, DOI 10.1271/bbb.66.613; JACOBSSON A, 1994, AM J PHYSIOL-REG I, V267, pR999, DOI 10.1152/ajpregu.1994.267.4.R999; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Jakobsson A, 2005, AM J PHYSIOL-ENDOC M, V289, pE517, DOI 10.1152/ajpendo.00045.2005; JANSKY L, 1973, BIOL REV, V48, P85; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; Leonard AE, 2002, LIPIDS, V37, P733, DOI 10.1007/s11745-002-0955-6; Moon YA, 2001, J BIOL CHEM, V276, P45358, DOI 10.1074/jbc.M108413200; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NUGTEREN DH, 1965, BIOCHIM BIOPHYS ACTA, V106, P280, DOI 10.1016/0005-2760(65)90036-6; OGAWA K, 1992, JPN J PHYSIOL, V42, P63, DOI 10.2170/jjphysiol.42.63; OGAWA K, 1987, JPN J PHYSIOL, V37, P783, DOI 10.2170/jjphysiol.37.783; Raclot T, 2003, PROG LIPID RES, V42, P257, DOI 10.1016/S0163-7827(02)00066-8; REHNMARK S, 1989, EXP CELL RES, V180, P574, DOI 10.1016/0014-4827(89)90086-4; RICQUIER D, 1979, CAN J BIOCHEM CELL B, V57, P1262, DOI 10.1139/o79-167; SENAULT C, 1975, ANN NUTR ALIMENT, V29, P67; Shabalina IG, 2004, J BIOL CHEM, V279, P38236, DOI 10.1074/jbc.M402375200; Silve S, 1996, MOL CELL BIOL, V16, P2719; SMITH RE, 1969, PHYSIOL REV, V49, P330, DOI 10.1152/physrev.1969.49.2.330; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SUNEJA SK, 1991, J NEUROCHEM, V57, P140, DOI 10.1111/j.1471-4159.1991.tb02108.x; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TRAYHURN P, 1987, P NUTR SOC, V46, P135, DOI 10.1079/PNS19870017; Trayhurn P., 1986, BROWN ADIPOSE TISSUE, P299; TRVDIK P, 2000, J CELL BIOL, V149, P707; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Westerberg R, 2004, J BIOL CHEM, V279, P5621, DOI 10.1074/jbc.M310529200; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817; [No title captured]	51	100	103	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4958	4968		10.1074/jbc.M511588200	http://dx.doi.org/10.1074/jbc.M511588200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16326704	hybrid			2022-12-27	WOS:000235426200047
J	Liu, LJ; Song, X; He, DD; Komma, C; Kita, A; Virbasius, JV; Huang, GQ; Bellamy, HD; Miki, K; Czech, MP; Zhou, GW				Liu, LJ; Song, X; He, DD; Komma, C; Kita, A; Virbasius, JV; Huang, GQ; Bellamy, HD; Miki, K; Czech, MP; Zhou, GW			Crystal structure of the C2 domain of class II phosphatidylinositide 3-kinase C2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PHOSPHOINOSITIDE 3-KINASE; KINASE-C; SIGNAL-TRANSDUCTION; ALPHA-ISOFORM; CDNA CLONING; BINDING; PROTEIN; SYNAPTOTAGMIN; CALCIUM; DIMERIZATION	Phosphatidylinositide (PtdIns) 3-kinase catalyzes the addition of a phosphate group to the 3'-position of phosphatidyl inositol. Accumulated evidence shows that PtdIns 3-kinase can provide a critical signal for cell proliferation, cell survival, membrane trafficking, glucose transport, and membrane ruffling. Mammalian PtdIns 3-kinases are divided into three classes based on structure and substrate specificity. A unique characteristic of class II PtdIns 3-kinases is the presence of both a phox homolog domain and a C2 domain at the C terminus. The biological function of the C2 domain of the class II PtdIns 3-kinases remains to be determined. We have determined the crystal structure of the mCPK-C2 domain, which is the first three-dimensional structural model of a C2 domain of class II PtdIns 3-kinases. Structural studies reveal that the mCPK-C2 domain has a typical anti-parallel beta-sandwich fold. Scrutiny of the surface of this C2 domain has identified three small, shallow sulfate-binding sites. On the basis of the structural features of these sulfate-binding sites, we have studied the lipid binding properties of the mCPK-C2 domain by site-directed mutagenesis. Our results show that this C2 domain binds specifically to PtdIns(3,4)P-2 and PtdIns(4,5)P-2 and that three lysine residues at SBS I site, Lys-1420, Lys-1432, and Lys-1434, are responsible for the phospholipid binding affinity.	Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA; Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Louisiana State Univ, Ctr Adv Microstruct & Devices, Baton Rouge, LA 70806 USA	Louisiana State University System; Louisiana State University; Kyoto University; University of Massachusetts System; University of Massachusetts Worcester; Louisiana State University System; Louisiana State University	Zhou, GW (corresponding author), Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA.	zhouw@lsu.edu		Virbasius, Joseph/0000-0003-1784-6793				Anderson KE, 2003, INT J BIOCHEM CELL B, V35, P1028, DOI 10.1016/S1357-2725(02)00270-4; Arcaro A, 1998, J BIOL CHEM, V273, P33082, DOI 10.1074/jbc.273.49.33082; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; Brown RA, 1997, BIOCHEM BIOPH RES CO, V233, P537, DOI 10.1006/bbrc.1997.6495; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Corbalan-Garcia S, 2003, BIOCHEMISTRY-US, V42, P11661, DOI 10.1021/bi034850d; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gaidarov I, 2001, MOL CELL, V7, P443, DOI 10.1016/S1097-2765(01)00191-5; Garcia-Garcia J, 1999, BIOCHEMISTRY-US, V38, P9667, DOI 10.1021/bi9905765; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Jimenez JL, 2003, J MOL BIOL, V333, P621, DOI 10.1016/j.jmb.2003.08.052; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; Layton MJ, 1998, J BIOL CHEM, V273, P33379, DOI 10.1074/jbc.273.50.33379; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Misra S, 2001, CELL, V107, P559, DOI 10.1016/S0092-8674(01)00594-3; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; Murray D, 2002, MOL CELL, V9, P145, DOI 10.1016/S1097-2765(01)00426-9; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pepio AM, 1998, BIOCHEMISTRY-US, V37, P1256, DOI 10.1021/bi971841u; Rozycka M, 1998, GENOMICS, V54, P569, DOI 10.1006/geno.1998.5621; Song X, 2001, BIOCHEMISTRY-US, V40, P8940, DOI 10.1021/bi0155100; Sutton RB, 1998, STRUCTURE, V6, P1395, DOI 10.1016/S0969-2126(98)00139-7; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Urso B, 1999, FEBS LETT, V460, P423, DOI 10.1016/S0014-5793(99)01388-5; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; Zhan Y, 2002, J BIOL CHEM, V277, P4512, DOI 10.1074/jbc.M109520200; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081; [No title captured]	45	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4254	4260		10.1074/jbc.M510791200	http://dx.doi.org/10.1074/jbc.M510791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16338929	hybrid			2022-12-27	WOS:000235275300058
J	van Oevelen, CJC; van Teeffelen, HAAM; van Werven, FJ; Timmers, HTM				van Oevelen, CJC; van Teeffelen, HAAM; van Werven, FJ; Timmers, HTM			Snf1p-dependent Spt-Ada-Gcn5-acetyltransferase (SAGA) recruitment and chromatin remodeling activities on the HXT2 and HXT4 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL TRANSCRIPTIONAL REGULATORS; IN-VIVO; GLUCOSE REPRESSION; HISTONE ACETYLTRANSFERASE; TBP RECRUITMENT; MIG1 REPRESSOR; YEAST GCN5P; SWI-SNF; GENE; PROTEIN	We previously showed that the Spt-Ada-Gcn5-acetyltransferase ( SAGA) complex is recruited to the activated HXT2 and HXT4 genes and plays a role in the association of TBP-associated factors. Using the HXT2 and HXT4 genes, we now present evidence for a functional link between Snf1p-dependent activation, recruitment of the SAGA complex, histone H3 removal, and H3 acetylation. Recruitment of the SAGA complex is dependent on the release of Ssn6p-Tup1p repression by Snf1p. In addition, we found that the Gcn5p subunit of the SAGA complex preferentially acetylates histone H3K18 on the HXT2 and HXT4 promoters and that Gcn5p activity is required for removal of histone H3 from the HXT4 promoter TATA region. In contrast, histone H3 removal from the HXT2 promoter does not require Gcn5p. In conclusion, although similar protein complexes are involved, induction of HXT2 and HXT4 displays important mechanistic differences.	Univ Utrecht, Ctr Med, Dept Physiol Chem, Div Biomed Genet, NL-3584 CG Utrecht, Netherlands	Utrecht University	Timmers, HTM (corresponding author), Univ Utrecht, Ctr Med, Dept Physiol Chem, Div Biomed Genet, Universiteitsweg 100, NL-3584 CG Utrecht, Netherlands.	h.t.m.timmers@med.uu.nl		van Werven, Folkert/0000-0002-6685-2084				Andrau JC, 2002, EMBO J, V21, P5173, DOI 10.1093/emboj/cdf485; Bai Y, 1997, MOL CELL BIOL, V17, P3081, DOI 10.1128/MCB.17.6.3081; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BURKE D, METHODS YEAST GENETI; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; Carlson M, 1997, ANNU REV CELL DEV BI, V13, P1, DOI 10.1146/annurev.cellbio.13.1.1; CELENZA JL, 1984, MOL CELL BIOL, V4, P49, DOI 10.1128/MCB.4.1.49; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Diderich JA, 1999, J BIOL CHEM, V274, P15350, DOI 10.1074/jbc.274.22.15350; Ducker CE, 2000, EMBO J, V19, P400, DOI 10.1093/emboj/19.3.400; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; EISENMANN DM, 1994, GENETICS, V137, P647; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; Fleming AB, 2001, EMBO J, V20, P5219, DOI 10.1093/emboj/20.18.5219; Gavin IM, 1997, EMBO J, V16, P6263, DOI 10.1093/emboj/16.20.6263; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Kuchin S, 1998, MOL CELL BIOL, V18, P1163, DOI 10.1128/MCB.18.3.1163; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Li B, 2001, J BIOL CHEM, V276, P33788, DOI 10.1074/jbc.M104220200; Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9; Lo WS, 2005, EMBO J, V24, P997, DOI 10.1038/sj.emboj.7600577; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Papamichos-Chronakis M, 2004, EMBO REP, V5, P368, DOI 10.1038/sj.embor.7400120; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; POON D, 1994, J BIOL CHEM, V269, P23135; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Reid RJD, 2002, METHOD ENZYMOL, V350, P258; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Timmers HTM, 2005, TRENDS BIOCHEM SCI, V30, P7, DOI 10.1016/j.tibs.2004.11.007; Topalidou I, 2004, EMBO J, V23, P1943, DOI 10.1038/sj.emboj.7600199; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VALLIER LG, 1994, GENETICS, V137, P49; van Oevelen CJC, 2005, MOL CELL BIOL, V25, P4863, DOI 10.1128/MCB.25.12.4863-4872.2005; WAHI M, 1995, GENETICS, V140, P79; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Wu PYJ, 2004, MOL CELL, V15, P199, DOI 10.1016/j.molcel.2004.06.005	57	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4523	4531		10.1074/jbc.M509330200	http://dx.doi.org/10.1074/jbc.M509330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368692	hybrid			2022-12-27	WOS:000235275300088
J	Dementiev, A; Dobo, J; Gettins, PGW				Dementiev, A; Dobo, J; Gettins, PGW			Active site distortion is sufficient for proteinase inhibition by serpins - Structure of the covalent complex of alpha(1)-proteinase inhibitor with porcine pancreatic elastase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE COMPLEX; TERNARY COMPLEX; MECHANISM; ANTITHROMBIN; PITTSBURGH; REVEALS; HEPARIN; TRYPSIN; NMR; STABILIZATION	We report here the x-ray structure of a covalent serpin-proteinase complex, alpha(1)-proteinase inhibitor (alpha 1PI) with porcine pancreatic elastase (PPE), which differs from the only other x-ray structure of such a complex, that of alpha 1PI with trypsin, in showing nearly complete definition of the proteinase. alpha 1PI complexes with trypsin, PPE, and human neutrophil elastase (HNE) showed similar rates of deacylation and enhanced susceptibility to proteolysis by exogenous proteinases in solution. The differences between the two x-ray structures therefore cannot arise from intrinsic differences in the inhibition mechanism. However, self-proteolysis of purified complex resulted in rapid cleavage of the trypsin complex, slower cleavage of the PPE complex, and only minimal cleavage of the HNE complex. This suggests that the earlier alpha 1PI-trypsin complex may have been proteolyzed and that the present structure is more likely to be representative of serpin-proteinase complexes. The present structure shows that active site distortion alone is sufficient for inhibition and suggests that enhanced proteolysis is not necessarily exploited in vivo.	Univ Illinois, Dept Biochem & Mol Genet, M-C 669,900 S Ashland, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, M-C 669,900 S Ashland, Chicago, IL 60607 USA.	pgettins@uic.edu	Dobo, Jozsef/C-7331-2014	Dobo, Jozsef/0000-0001-9187-8502	NHLBI NIH HHS [P01HL64013, R37HL49234] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064013, R01HL049234, R37HL049234] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Backovic M, 2002, PROTEIN SCI, V11, P1182, DOI 10.1110/ps.4320102; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calugaru SV, 2001, J BIOL CHEM, V276, P32446, DOI 10.1074/jbc.M104731200; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; Dementiev A, 2003, J BIOL CHEM, V278, P37881, DOI 10.1074/jbc.M305195200; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Dobo J, 2004, J BIOL CHEM, V279, P9264, DOI 10.1074/jbc.M311731200; Egelund R, 2001, EUR J BIOCHEM, V268, P673, DOI 10.1046/j.1432-1327.2001.01921.x; Fa M, 2000, STRUCT FOLD DES, V8, P397, DOI 10.1016/S0969-2126(00)00121-0; FISH WW, 1979, EUR J BIOCHEM, V101, P39, DOI 10.1111/j.1432-1033.1979.tb04213.x; Futamura A, 1998, BIOCHEMISTRY-US, V37, P13110, DOI 10.1021/bi981234m; Gettins PGW, 2002, FEBS LETT, V523, P2, DOI 10.1016/S0014-5793(02)02924-1; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HERVE M, 1991, ARCH BIOCHEM BIOPHYS, V285, P142, DOI 10.1016/0003-9861(91)90341-F; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; KASLIK G, 1995, FEBS LETT, V370, P179, DOI 10.1016/0014-5793(95)00816-R; Kaslik G, 1997, BIOCHEMISTRY-US, V36, P5455, DOI 10.1021/bi962931m; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lee FT, 1996, ACAD RADIOL, V3, pS500, DOI 10.1016/S1076-6332(05)80366-6; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peterson FC, 2000, BIOCHEMISTRY-US, V39, P11884, DOI 10.1021/bi001152+; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6284, DOI 10.1021/bi010100x; Stavridi ES, 1996, BIOCHEMISTRY-US, V35, P10608, DOI 10.1021/bi9605806; Stratikos E, 1998, J BIOL CHEM, V273, P15582, DOI 10.1074/jbc.273.25.15582; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979	28	110	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3452	3457		10.1074/jbc.M510564200	http://dx.doi.org/10.1074/jbc.M510564200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321984	hybrid			2022-12-27	WOS:000235128200054
J	Dode, L; Andersen, JP; Vanoevelen, J; Raeymaekers, L; Missiaen, L; Vilsen, B; Wuytack, F				Dode, L; Andersen, JP; Vanoevelen, J; Raeymaekers, L; Missiaen, L; Vilsen, B; Wuytack, F			Dissection of the functional differences between human secretory pathway Ca2+/Mn2+-ATPase (SPCA) 1 and 2 isoenzymes by steady-state and transient kinetic analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; HAILEY-HAILEY-DISEASE; CA2&-DEPENDENT ATP HYDROLYSIS; ALKALI-METAL SALTS; SKELETAL-MUSCLE; CALCIUM-PUMP; CA2+ PUMP; ADENOSINE-TRIPHOSPHATASE; REACTION-MECHANISM; CRYSTAL-STRUCTURE	Human secretory pathway Ca2+/Mn2+-ATPase (SPCA) 2 encoded by ATP2C2 is only expressed in a limited number of tissues, unlike the ubiquitously expressed SPCA1 pump (encoded by ATP2C1, the gene defective in Hailey-Hailey disease). It has not been determined whether there are significant functional differences between SPCA1 and SPCA2 pump enzymes. Therefore, steady-state and transient kinetic approaches were used to characterize the overall and partial reactions of the Ca2+ transport cycle mediated by the human SPCA2 enzyme upon heterologous expression in HEK-293 cells. The catalytic turnover rate of SPCA2 was found enhanced relative to SPCA1 pumps. SPCA2 displayed a very high apparent affinity for cytosolic Ca2+ (K-0.(5) = 0.025 mu M) in activation of the phosphorylation activity but still 2.5- fold lower than that of SPCA1d. Our kinetic analysis traced both differences to the increased rate characterizing the E-1 similar to P(Ca) to E-2-P transition of SPCA2. Moreover, the reduced rate of the E-2 to E-1 transition seems to contribute in determining the lower apparent Ca2+ affinity and the increased sensitivity to thapsigargin inhibition, relative to SPCA1d. SPCA2 also displayed a reduced apparent affinity for inorganic phosphate, which could be explained by the observed enhanced rate of the E-2-P dephosphorylation. The insensitivity to modulation by pH and K+ concentration of the constitutively enhanced E-2-P dephosphorylation of SPCA2 is similar to SPCA1d and possibly represents a novel SPCA-specific feature, which is not shared by sarco(endo) plasmic reticulum Ca2+-ATPases.	Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark; Catholic Univ Louvain, Physiol Lab, B-3000 Louvain, Belgium	Aarhus University; Universite Catholique Louvain	Andersen, JP (corresponding author), Univ Aarhus, Dept Physiol, Inst Physiol & Biophys, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	jpa@fi.au.dk	Vanoevelen, Jo M/F-2686-2013	Vanoevelen, Jo M/0000-0003-1830-8858; Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Dode L, 2005, J BIOL CHEM, V280, P39124, DOI 10.1074/jbc.M506181200; Dode L, 2003, J BIOL CHEM, V278, P47877, DOI 10.1074/jbc.M306784200; Dode L, 2002, J BIOL CHEM, V277, P45579, DOI 10.1074/jbc.M207778200; Fairclough RJ, 2003, J BIOL CHEM, V278, P24721, DOI 10.1074/jbc.M300509200; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Hu ZL, 2000, NAT GENET, V24, P61, DOI 10.1038/71701; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Sorensen TLM, 2004, J BIOL CHEM, V279, P46355, DOI 10.1074/jbc.C400414200; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; Sorin A, 1997, J BIOL CHEM, V272, P9895; Sudbrak R, 2000, HUM MOL GENET, V9, P1131, DOI 10.1093/hmg/9.7.1131; Sugita Y, 2005, J AM CHEM SOC, V127, P6150, DOI 10.1021/ja0427505; Ton VK, 2004, AM J PHYSIOL-CELL PH, V287, pC580, DOI 10.1152/ajpcell.00135.2004; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Van Baelen K, 2004, BBA-MOL CELL RES, V1742, P103, DOI 10.1016/j.bbamcr.2004.08.018; Van Baelen K, 2001, J BIOL CHEM, V276, P10683, DOI 10.1074/jbc.M010553200; Vanoevelen J, 2005, J BIOL CHEM, V280, P22800, DOI 10.1074/jbc.M501026200; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P9121; Xiang MH, 2005, J BIOL CHEM, V280, P11608, DOI 10.1074/jbc.M413116200; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m	33	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3182	3189		10.1074/jbc.M511547200	http://dx.doi.org/10.1074/jbc.M511547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332677	hybrid			2022-12-27	WOS:000235128200021
J	Wicher, D; Agricola, HJ; Schonherr, R; Heinemann, SH; Derst, C				Wicher, D; Agricola, HJ; Schonherr, R; Heinemann, SH; Derst, C			TRP gamma channels are inhibited by cAMP and contribute to pacemaking in neurosecretory insect neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; PERIPLANETA-AMERICANA; CALCIUM-ENTRY; DROSOPHILA; COCKROACH; RELEASE; CELLS; CURRENTS	From a neuronal cDNA library of the cockroach Periplaneta americana we isolated a 3585-bp cDNA sequence encoding Periplaneta transient receptor potential gamma (pTRP gamma), a protein of 1194 amino acids showing 65% identity to the orthologous Drosophila channel protein dTRP gamma. Heterologous expression of pTRP gamma in HEK293 cells produced a constitutively active, non-selective cation channel with a Ca2(+):Na+ permeability ratio of 2. In contrast to dTRP gamma-mediated currents, pTRP gamma currents were partially inhibited by 8-bromo-cAMP, and this effect was not mediated by protein kinase A (PKA) activation. pTRP gamma b, a truncated pTRP gamma splice variant missing most of the C terminus, was insensitive to 8-bromo-cAMP. Thus, the critical cAMP-binding site seems to be located in the C-terminal part of pTRP gamma, although there is no common cAMP-binding consensus sequence. While dTRP gamma is only expressed in the photoreceptors, pTRP gamma is expressed throughout the nervous system. In particular it is expressed in dorsal unpaired median (DUM) neurons. In these octopamine-releasing, neurosecretory cells a Ca2+ background current contributing to pacemaker activity was found to be up-regulated by the reduction of cAMP level. In addition, the Ca2+ background current was inhibited by LOE-908, 2-APB, and La3+, which similarly affected the pTRP gamma current. We thus propose that the pTRP gamma protein is involved in forming the channel passing the Ca2+ pakemaking background current in DUM neurons.	Saxon Acad Sci, Dept Neurohormones, D-07743 Jena, Germany; Univ Jena, Inst Zool, D-6900 Jena, Germany; Univ Jena, Inst Mol Cell Biol, D-6900 Jena, Germany; Charite, Ctr Anat, Berlin, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Wicher, D (corresponding author), Max Planck Inst Chem Ecol, Hans Knoll Str 8, D-07745 Jena, Germany.	dwicher@ice.mpg.de	Schönherr, Roland/K-8713-2013	Schönherr, Roland/0000-0003-0633-0775; Heinemann, Stefan H./0000-0002-4144-0251				Achenbach H, 1997, NEUROREPORT, V8, P3737, DOI 10.1097/00001756-199712010-00016; BAUMANN E, 1984, BIOMED BIOCHIM ACTA, V43, P13; Bezzerides VJ, 2004, NAT CELL BIOL, V6, P709, DOI 10.1038/ncb1150; Bugaj V, 2005, J BIOL CHEM, V280, P16790, DOI 10.1074/jbc.M500192200; Clapham DE, 2003, PHARMACOL REV, V55, P591, DOI 10.1124/pr.55.4.6; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Derst C, 2003, EUR J NEUROSCI, V17, P1197, DOI 10.1046/j.1460-9568.2003.02550.x; Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0; Grolleau F, 2000, J EXP BIOL, V203, P1633; Heine M, 1998, NEUROREPORT, V9, P3309, DOI 10.1097/00001756-199810050-00029; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Messutat S, 2001, CELL CALCIUM, V30, P199, DOI 10.1054/ceca.2001.0227; MINKE B, 1977, BIOPHYS STRUCT MECH, V3, P59, DOI 10.1007/BF00536455; Moneer Z, 2002, BIOCHEM J, V362, P13, DOI 10.1042/0264-6021:3620013; Montell C, 1999, ANNU REV CELL DEV BI, V15, P231, DOI 10.1146/annurev.cellbio.15.1.231; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Predel R, 2004, EUR J NEUROSCI, V20, P1499, DOI 10.1111/j.1460-9568.2004.03598.x; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; WICHER D, 1994, J COMP PHYSIOL A, V174, P507; Wicher D, 2006, J NEUROPHYSIOL, V95, P311, DOI 10.1152/jn.00904.2005; Wicher D, 2004, J BIOL CHEM, V279, P50410, DOI 10.1074/jbc.M405800200; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Zagranichnaya TK, 2005, J BIOL CHEM, V280, P29559, DOI 10.1074/jbc.M505842200	25	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3227	3236		10.1074/jbc.M511741200	http://dx.doi.org/10.1074/jbc.M511741200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16319060	hybrid			2022-12-27	WOS:000235128200027
J	Chen, B; Nelson, DM; Sadovsky, Y				Chen, B; Nelson, DM; Sadovsky, Y			N-Myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; VASCULAR ENDOTHELIAL-CELLS; EMBRYONIC STEM-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; CALORIE RESTRICTION; IN-VITRO; EXPRESSION; DIFFERENTIATION; GROWTH; PROTEIN	The placenta is susceptible to diverse insults during human pregnancy. The expression of the protein N-myc down-regulated gene 1 (NDRG1) is regulated during cell proliferation, differentiation, and in response to stress. Nevertheless, the function of this protein in humans remains unknown. We tested the hypothesis that NDRG1 is up-regulated in hypoxic primary human trophoblasts and that NDRG1 modulates trophoblast response to hypoxia. We initially demonstrated that the expression of NDRG1 is enhanced in primary human trophoblasts exposed to hypoxia. Importantly, we found a similar increase in NDRG1 expression in placental samples derived from either singleton gestations complicated by intrauterine growth restriction or from dizygotic twin gestation where one twin exhibited growth restriction. Having established efficient lentivirus-mediated transfection of primary human trophoblasts, we overexpressed NDRG1 in trophoblasts, which resulted in enhanced trophoblast differentiation. In contrast, lentivirus-driven short interfering RNA-mediated silencing of NDRG1 diminished trophoblast viability and differentiation. Consistent with these results, NDRG1 reduced the expression level of p53 in trophoblasts cultured in standard or hypoxic conditions. Furthermore, NDRG1 expression was regulated by the activity of SIRT1 (Sir2 like protein 1), which promotes cell survival. Together, our data indicate that NDRG1 interacts with SIRT1/p53 signaling to attenuate hypoxic injury in human trophoblasts.	Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Sadovsky, Y (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, Campus Box 8064,4566 Scott Ave, St Louis, MO 63110 USA.	ysadovsky@wustl.edu		Sadovsky, Yoel/0000-0003-2969-6737				Ahmed A, 2000, PLACENTA, V21, pS16, DOI 10.1053/plac.1999.0524; Alarcon R, 1999, CANCER RES, V59, P6046; Alcendor RR, 2004, CIRC RES, V95, P971, DOI 10.1161/01.RES.0000147557.75257.ff; Alsat E, 1996, J CELL PHYSIOL, V168, P346, DOI 10.1002/(SICI)1097-4652(199608)168:2<346::AID-JCP13>3.0.CO;2-1; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bandyopadhyay S, 2003, CANCER RES, V63, P1731; BENIRSCHKE K, 2000, PATHOLOGY HUMAN PLAC, P452; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Budhraja V, 2003, BMC BIOL, V1, DOI 10.1186/1741-7007-1-1; BURNS DPW, 1993, J VIROL, V67, P4104, DOI 10.1128/JVI.67.7.4104-4113.1993; Caniggia I, 2002, PLACENTA, V23, pS47, DOI 10.1053/plac.2002.0815; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Di Santo S, 2003, PLACENTA, V24, P882, DOI 10.1016/S0143-4004(03)00142-5; Dong YS, 2001, J IMMUNOL, V167, P311, DOI 10.4049/jimmunol.167.1.311; DOUGLAS GC, 1990, J CELL SCI, V96, P131; Esterman A, 1996, PLACENTA, V17, P217, DOI 10.1016/S0143-4004(96)90041-7; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Genbacev O, 1997, SCIENCE, V277, P1669, DOI 10.1126/science.277.5332.1669; Graham CH, 2000, PLACENTA, V21, P443, DOI 10.1053/plac.2000.0543; Gratton RJ, 2004, PLACENTA, V25, P62, DOI 10.1016/S0143-4004(03)00216-9; Gropp M, 2003, MOL THER, V7, P281, DOI 10.1016/S1525-0016(02)00047-3; Guang RJ, 2000, CANCER RES, V60, P749; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Kale VP, 2004, STEM CELLS DEV, V13, P536, DOI 10.1089/1547328042417390; Kilani RT, 1997, J VIROL, V71, P6359, DOI 10.1128/JVI.71.9.6359-6372.1997; Kilani RT, 2003, PLACENTA, V24, P826, DOI 10.1016/S0143-4004(03)00129-2; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; Klimatcheva E, 1999, FRONT BIOSCI-LANDMRK, V4, P481; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kordower JH, 1999, EXP NEUROL, V160, P1, DOI 10.1006/exnr.1999.7178; Korin YD, 1999, J VIROL, V73, P6526, DOI 10.1128/JVI.73.8.6526-6532.1999; Kudo Y, 2003, BBA-MOL BASIS DIS, V1638, P63, DOI 10.1016/S0925-4439(03)00043-7; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lachat P, 2002, HISTOCHEM CELL BIOL, V118, P399, DOI 10.1007/s00418-002-0460-9; Levy R, 2002, AM J OBSTET GYNECOL, V186, P1056, DOI 10.1067/mob.2002.122250; Levy R, 2000, AM J PHYSIOL-CELL PH, V278, pC982, DOI 10.1152/ajpcell.2000.278.5.C982; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; Lin TM, 1997, P NATL ACAD SCI USA, V94, P4988, DOI 10.1073/pnas.94.10.4988; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Ma Y, 2003, STEM CELLS, V21, P111, DOI 10.1634/stemcells.21-1-111; MARTIN AW, 1992, HUM PATHOL, V23, P411, DOI 10.1016/0046-8177(92)90088-K; MATTERN CFT, 1992, PEDIATRICS, V89, P207; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Mi S, 2000, NATURE, V403, P785, DOI 10.1038/35001608; Morrish DW, 2001, CURR PROTEIN PEPT SC, V2, P245, DOI 10.2174/1389203013381116; Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057; Nagata M, 2003, J GENE MED, V5, P921, DOI 10.1002/jgm.431; Nelson DM, 1999, AM J OBSTET GYNECOL, V180, P896, DOI 10.1016/S0002-9378(99)70661-7; Okuda T, 2004, MOL CELL BIOL, V24, P3949, DOI 10.1128/MCB.24.9.3949-3956.2004; OMURA T, 1995, J STEROID BIOCHEM, V53, P19, DOI 10.1016/0960-0760(95)00036-Y; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Piquemal D, 1999, BBA-MOL CELL RES, V1450, P364, DOI 10.1016/S0167-4889(99)00056-7; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Qu XH, 2002, MOL CELL BIOCHEM, V229, P35, DOI 10.1023/A:1017934810825; Resnik R, 2002, OBSTET GYNECOL, V99, P490, DOI 10.1016/S0029-7844(01)01780-X; Roh CR, 2005, PLACENTA, V26, P319, DOI 10.1016/j.placenta.2004.06.013; Salnikow K, 2000, CANCER RES, V60, P5630; Salnikow K, 1999, TOXICOL APPL PHARM, V160, P127, DOI 10.1006/taap.1999.8759; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; Schmid T, 2004, J CELL MOL MED, V8, P423, DOI 10.1111/j.1582-4934.2004.tb00467.x; Shaw E, 2002, PROTEINS, V47, P163, DOI 10.1002/prot.10083; Shimono A, 1999, MECH DEVELOP, V83, P39, DOI 10.1016/S0925-4773(99)00025-8; Stein S, 2004, J BIOL CHEM, V279, P48930, DOI 10.1074/jbc.M400386200; Sugiki T, 2004, BIOL PHARM BULL, V27, P628, DOI 10.1248/bpb.27.628; Takahashi Masayo, 2004, Methods Mol Biol, V246, P439; TANG SB, 1995, J VIROL, V69, P5659, DOI 10.1128/JVI.69.9.5659-5665.1995; Taylor CM, 1997, PLACENTA, V18, P451, DOI 10.1016/S0143-4004(97)80047-1; Totsugawa T, 2003, ASAIO J, V49, P635, DOI 10.1097/01.MAT.0000093747.89681.4C; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; vanBelzen N, 1997, LAB INVEST, V77, P85; Vidricaire G, 2003, J BIOL CHEM, V278, P15832, DOI 10.1074/jbc.M210470200; WHEELER T, 1995, PLACENTA, V16, P289, DOI 10.1016/0143-4004(95)90115-9; Xu B, 1999, BIOL REPROD, V61, P681, DOI 10.1095/biolreprod61.3.681; Zhang G, 2003, J NEUROSCI RES, V72, P33, DOI 10.1002/jnr.10559; Zhou DJ, 1998, CANCER RES, V58, P2182; Zhou RH, 2001, GENOMICS, V73, P86, DOI 10.1006/geno.2000.6496; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	83	113	119	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2764	2772		10.1074/jbc.M507330200	http://dx.doi.org/10.1074/jbc.M507330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16314423	hybrid			2022-12-27	WOS:000234931800043
J	Di Sano, F; Ferraro, E; Tufi, R; Achsel, T; Piacentini, M; Cecconi, F				Di Sano, F; Ferraro, E; Tufi, R; Achsel, T; Piacentini, M; Cecconi, F			Endoplasmic reticulum stress induces apoptosis by an apoptosome-dependent but caspase 12-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH PROGRAM; UNFOLDED PROTEIN RESPONSE; ER STRESS; MITOCHONDRIAL RELEASE; ACTIVATION; APAF1; PATHWAYS; CED-4	The endoplasmic reticulum (ER) is the cellular site of polypeptide folding and modification. When these processes are hampered, an unfolded protein response (UPR) is activated. If the damage is too broad, the mammalian UPR launches the apoptotic program. As a consequence, mobilization of ER calcium stores sensitizes mitochondria to direct proapoptotic stimuli. We make use of a mouse Apaf1-deficient cell system of proneural origin to understand the roles played in this context by the apoptosome, the most studied apoptotic machinery along the mitochondrial pathway of death. We show here that in the absence of the apoptosome ER stress induces cytochrome c release from the mitochondria but that apoptosis cannot occur. Under these circumstances, Grp78/BiP and GADD153/CHOP, both hallmarks of UPR, are canonically up-regulated, and calcium is properly released from ER stores. We also demonstrate that caspase 12, a protease until now believed to play a central role in the initiation of ER stress-induced cell death in the mouse system, is dispensable for the mitochondrial pathway of death to take place.	Univ Roma Tor Vergata, Dulbecco Telethon Inst, Dept Biol, I-00133 Rome, Italy; Fdn Santa Lucia, IRCCS, I-00100 Rome, Italy; IRCCS L Spallanzani, Natl Inst Infect Dis, I-00100 Rome, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); University of Rome Tor Vergata; IRCCS Santa Lucia; IRCCS Lazzaro Spallanzani	Cecconi, F (corresponding author), Univ Roma Tor Vergata, Dulbecco Telethon Inst, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	fcecconi@dti.telethon.it	Ferraro, Elisabetta/AAS-4975-2020; Cecconi, Francesco/K-3969-2016; Piacentini, Mauro/I-2411-2016; ferraro, elisabetta/K-3904-2016	Cecconi, Francesco/0000-0002-5614-4359; Piacentini, Mauro/0000-0003-2919-1296; ferraro, elisabetta/0000-0002-9596-4624; Di Sano, Federica/0000-0002-5048-3966	Telethon [TCP99038] Funding Source: Medline	Telethon(Fondazione Telethon)		Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Arnoult D, 2003, CELL DEATH DIFFER, V10, P845, DOI 10.1038/sj.cdd.4401240; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cecconi F, 2001, CELL MOL LIFE SCI, V58, P1688, DOI 10.1007/PL00000806; Chen LZ, 2002, NEUROCHEM RES, V27, P891, DOI 10.1023/A:1020387414086; Cozzolino M, 2004, CELL DEATH DIFFER, V11, P1179, DOI 10.1038/sj.cdd.4401476; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Salvesen GS, 2002, DEV CELL, V2, P256, DOI 10.1016/S1534-5807(02)00137-5; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	28	108	110	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2693	2700		10.1074/jbc.M509110200	http://dx.doi.org/10.1074/jbc.M509110200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16317003	hybrid, Green Published			2022-12-27	WOS:000234931800035
J	Proia, DA; Nannenga, BW; Donehower, LA; Weigel, NL				Proia, DA; Nannenga, BW; Donehower, LA; Weigel, NL			Dual roles for the phosphatase PPM1D in regulating progesterone receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LIGAND-INDEPENDENT ACTIVATION; PHOSPHORYLATION SITES; ANDROGEN RECEPTOR; WIP1; TRANSCRIPTION; COACTIVATOR; HORMONE; P38; PROMOTER	Although protein phosphatase magnesium-dependent 1 delta (PPM1D) was initially characterized as a p53-regulated phosphatase responsible for inactivation of p38 MAPK and consequent inactivation of p53, its overexpression and amplification in human breast cancers led us to assess its role in steroid hormone action. We found that PPM1D stimulated the activity of several nuclear receptors including the progesterone receptor ( PR) and estrogen receptor. Although p38 MAPK inhibited PR activity, PPM1D stimulation of PR activity was greater than that achieved by a chemical inhibitor of p38 MAPK, SB202190. This suggests an additional novel function for PPM1D. Consistent with this, the transcriptional activity of endogenous PR in MCF-7 breast cancer cells was preferentially inhibited by small interfering RNA for PPM1D; SB202190 failed to reverse the inhibition. Although PPM1D phosphatase activity was required for stimulation of transcriptional activity, the activity of a PR phosphorylation site null mutant was enhanced by PPM1D, indicating that PR is not the direct target. Additional studies revealed that PPM1D enhanced the intrinsic activity of p160 coactivators such as steroid receptor coactivator-1 and promoted the interaction between PR and steroid receptor coactivator-1 in a mammalian two-hybrid assay. Neither activity was induced by SB202190. Although PPM1D stimulated PR activity in part through inhibition of p38 MAPK, its primary action is novel and independent of p38 MAPK. Thus, we speculate that PPM1D promotes breast tumor growth both by inhibiting p53 activity and by enhancing steroid hormone receptor action.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Microbiol & Virol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Weigel, NL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	nweigel@bcm.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA057539, R55CA057539, R01CA100420] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 100420, CA 57539] Funding Source: Medline; NICHD NIH HHS [T32 HD 07165] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Agoulnik IU, 2003, J BIOL CHEM, V278, P31136, DOI 10.1074/jbc.M305153200; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Bai WL, 1996, J BIOL CHEM, V271, P12801, DOI 10.1074/jbc.271.22.12801; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Cheng SW, 2000, COMB OPT (SER), V6, P137; Choi J, 2000, GENOMICS, V64, P298, DOI 10.1006/geno.2000.6134; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; KASTNER P, 1990, J BIOL CHEM, V265, P12163; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; Knotts TA, 2001, J BIOL CHEM, V276, P8475, DOI 10.1074/jbc.M009805200; Lange CA, 2000, P NATL ACAD SCI USA, V97, P1032, DOI 10.1073/pnas.97.3.1032; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Ma ZQ, 2001, MOL CELL BIOL, V21, P8056, DOI 10.1128/MCB.21.23.8056-8067.2001; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; MEYER ME, 1992, J BIOL CHEM, V267, P10882; Mulac-Jericevic B, 2000, SCIENCE, V289, P1751, DOI 10.1126/science.289.5485.1751; Mulac-Jericevic B, 2003, P NATL ACAD SCI USA, V100, P9744, DOI 10.1073/pnas.1732707100; Narayanan R, 2005, MOL CELL BIOL, V25, P2885, DOI 10.1128/MCB.25.8.2885-2898.2005; Narayanan R, 2005, MOL CELL BIOL, V25, P264, DOI 10.1128/MCB.25.1.264-277.2005; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yeh SY, 2002, P NATL ACAD SCI USA, V99, P13498, DOI 10.1073/pnas.212474399; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; Zhang YX, 1997, MOL ENDOCRINOL, V11, P823, DOI 10.1210/me.11.6.823; Zou AH, 1997, J BIOL CHEM, V272, P19027, DOI 10.1074/jbc.272.30.19027; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	52	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7089	7101		10.1074/jbc.M511839200	http://dx.doi.org/10.1074/jbc.M511839200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16352595	hybrid			2022-12-27	WOS:000236030900023
J	Jordens, J; Janssens, V; Longin, S; Stevens, I; Martens, E; Bultynck, G; Engelborghs, Y; Lescrinier, E; Waelkens, E; Goris, J; Van Hoof, C				Jordens, J; Janssens, V; Longin, S; Stevens, I; Martens, E; Bultynck, G; Engelborghs, Y; Lescrinier, E; Waelkens, E; Goris, J; Van Hoof, C			The protein phosphatase 2A phosphatase activator is a novel peptidyl-prolyl cis/trans-isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS ISOMERASE; RABBIT SKELETAL-MUSCLE; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL-ANALYSIS; CATALYTIC SUBUNIT; BOVINE BRAIN; IMMUNOSUPPRESSANT FK506; METHYL ESTERIFICATION; REGULATORY MECHANISM; BINDING-PROTEIN	The protein phosphatase 2A (PP2A) phosphatase activator ( PTPA) is an essential protein involved in the regulation of PP2A and the PP2A-like enzymes. In this study we demonstrate that PTPA and its yeast homologues Ypa1 and Ypa2 can induce a conformational change in some model substrates. Using these model substrates in different assays with and without helper proteases, this isomerase activity is similar to the isomerase activity of FKBP12, the human cyclophilin A, and one of its yeast homologs Cpr7 but dissimilar to the isomerase activity of Pin1. However, neither FKBP12 nor Cpr7 can reactivate the inactive form of PP2A. Therefore, PTPA belongs to a novel peptidyl-prolyl cis/trans-isomerase ( PPIase) family. The PPIase activity of PTPA correlates with its activating activity since both are stimulated by the presence of Mg2+ ATP, and a PTPA mutant ( Delta 208-213) with 400-fold less activity in the activation reaction of PP2A also showed almost no PPIase activity. The point mutant Asp(205) --> Gly ( in Ypa1) identified this amino acid as essential for both activities. Moreover, PTPA dissociates the inactive form from the complex with the PP2A methylesterase. Finally, Pro(190) in the catalytic subunit of PP2A ( PP2A(C)) could be identified as the target Pro isomerized by PTPA/Mg2+ ATP since among the 14 Pro residues present in 12 synthesized peptides representing the microenvironments of these prolines in PP2A(C), only Pro(190) could be isomerized by PTPA/Mg2+ ATP. This Pro(190) is present in a predicted loop structure near the catalytic center of PP2AC and, if mutated into a Phe, the phosphatase is inactive and can no longer be activated by PTPA/Mg2+ ATP.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Wetenschappen, Lab Biomol Dynam, B-3001 Heverlee, Belgium; Katholieke Univ Leuven, Med Chem Lab, B-3000 Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven	Goris, J (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Jozef.Goris@med.kuleuven.be	Lescrinier, Eveline/G-9339-2016; Janssens, Veerle/I-7059-2016	Lescrinier, Eveline/0000-0001-7066-4329; Janssens, Veerle/0000-0002-6772-8448; Bultynck, Geert/0000-0002-5968-4828				BACHINGER HP, 1987, J BIOL CHEM, V262, P17144; BATON G, 1994, EUR J BIOCHEM, V220, P225; Brandts J F, 1986, Methods Enzymol, V131, P107; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Bukrinsky MI, 2002, TRENDS IMMUNOL, V23, P323, DOI 10.1016/S1471-4906(02)02237-8; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CAYLA X, 1994, J BIOL CHEM, V269, P15668; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; De Baere I, 1999, BIOCHEMISTRY-US, V38, P16539, DOI 10.1021/bi991646a; Dolinski K, 1997, P NATL ACAD SCI USA, V94, P13093, DOI 10.1073/pnas.94.24.13093; Duina AA, 1996, YEAST, V12, P943, DOI 10.1002/(SICI)1097-0061(199608)12:10<943::AID-YEA997>3.0.CO;2-3; EGLOFF MP, 1995, J MOL BIOL, V254, P942, DOI 10.1006/jmbi.1995.0667; Evans DRH, 1999, J BIOL CHEM, V274, P24038, DOI 10.1074/jbc.274.34.24038; Fellner T, 2003, GENE DEV, V17, P2138, DOI 10.1101/gad.259903; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HUBNER D, 1991, FEBS LETT, V284, P79, DOI 10.1016/0014-5793(91)80766-V; Janssens V, 2000, J BIOL CHEM, V275, P20488, DOI 10.1074/jbc.M909370199; Janssens V, 2000, EUR J BIOCHEM, V267, P4406, DOI 10.1046/j.1432-1327.2000.01486.x; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 1999, BIOCHEM J, V344, P755, DOI 10.1042/0264-6021:3440755; LEE J, 1993, J BIOL CHEM, V268, P19192; Lee J, 1996, P NATL ACAD SCI USA, V93, P6043, DOI 10.1073/pnas.93.12.6043; Longin S, 2004, BIOCHEM J, V380, P111, DOI 10.1042/BJ20031643; Lu K P, 2000, Prog Cell Cycle Res, V4, P83; Lu KP, 1996, NATURE, V380, P544; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mayr C, 2000, J BIOL CHEM, V275, P34140, DOI 10.1074/jbc.M005251200; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; Rempola B, 2000, MOL GEN GENET, V262, P1081, DOI 10.1007/PL00008651; Schiene C, 1998, FEBS LETT, V432, P202, DOI 10.1016/S0014-5793(98)00871-0; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Van Hoof C, 2005, BIOCHEM J, V386, P93, DOI 10.1042/BJ20040887; Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6; Van Hoof C, 2001, EXP CELL RES, V264, P372, DOI 10.1006/excr.2000.5144; Van Hoof C, 1998, BIOCHEMISTRY-US, V37, P12899, DOI 10.1021/bi980496l; Van Hoof C, 2000, J MOL BIOL, V302, P103, DOI 10.1006/jmbi.2000.4062; VANHOOF C, 1994, EUR J BIOCHEM, V226, P899; VANHOOF C, 1995, GENOMICS, V28, P261, DOI 10.1006/geno.1995.1140; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; Winkler KE, 2000, SCIENCE, V287, P1644, DOI 10.1126/science.287.5458.1644; XIE HY, 1994, BIOCHEM BIOPH RES CO, V203, P1710, DOI 10.1006/bbrc.1994.2383; XIE HY, 1993, J BIOL CHEM, V268, P13364; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120	59	78	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6349	6357		10.1074/jbc.M507760200	http://dx.doi.org/10.1074/jbc.M507760200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16380387	Green Published, hybrid			2022-12-27	WOS:000236030800028
J	Zhang, X; Emerald, BS; Mukhina, S; Mohankumar, KM; Kraemer, A; Yap, AS; Gluckman, PD; Lee, KO; Lobie, PE				Zhang, X; Emerald, BS; Mukhina, S; Mohankumar, KM; Kraemer, A; Yap, AS; Gluckman, PD; Lee, KO; Lobie, PE			HOXA1 is required for E-cadherin-dependent anchorage-independent survival of human mammary carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; HUMAN BREAST-CANCER; EPITHELIAL-CELLS; CYTOSKELETAL ORGANIZATION; ADHESIVE CONTACTS; GENE-EXPRESSION; HOMEOBOX GENES; BETA-CATENIN; P-CADHERIN; APOPTOSIS	Forced expression of HOXA1 is sufficient to stimulate oncogenic transformation of immortalized human mammary epithelial cells and subsequent tumor formation. We report here that the expression and transcriptional activity of HOXA1 are increased in mammary carcinoma cells at full confluence. This confluence-dependent expression of HOXA1 was abrogated by incubation of cells with EGTA to produce loss of intercellular contact and rescued by extracellular addition of Ca2+. Increased HOXA1 expression at full confluence was prevented by an E-cadherin function-blocking antibody and attachment of non-confluent cells to a substrate by homophilic ligation of E-cadherin increased HOXA1 expression. E-cadherin-directed signaling increased HOXA1 expression through Rac1. Increased HOXA1 expression consequent to E-cadherin-activated signaling decreased apoptotic cell death and was required for E-cadherin-dependent anchorage-independent proliferation of human mammary carcinoma cells. HOXA1 is therefore a downstream effector of E-cadherin-directed signaling required for anchorage-independent proliferation of mammary carcinoma cells.	Univ Auckland, Liggins Inst, Auckland 1001, New Zealand; Natl Univ Singapore, Dept Med, Singapore 117609, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Univ Queensland, Inst Mol Biosci, Div Mol Cell Biol, St Lucia, Qld 4072, Australia; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1001, New Zealand	University of Auckland; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of Queensland; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave,Private Bag 92019, Auckland 1001, New Zealand.	p.lobie@auckland.ac.nz	Lee, Kok-Onn/E-9874-2011; David, Starling Emerald Bright/R-6034-2019; Kumarasamypet Murugesan, Mohankumar/F-4231-2012; Yap, Alpha S./J-1554-2014	Lee, Kok-Onn/0000-0002-3040-1185; David, Starling Emerald Bright/0000-0001-6875-2258; Yap, Alpha S./0000-0002-1038-8956; KM, Mohankumar/0000-0001-9407-1800				Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Bissell MJ, 2003, CURR OPIN CELL BIOL, V15, P753, DOI 10.1016/j.ceb.2003.10.016; Boersma C J, 1999, Mol Cell Biol Res Commun, V1, P117, DOI 10.1006/mcbr.1999.0115; Boussadia O, 2002, MECH DEVELOP, V115, P53, DOI 10.1016/S0925-4773(02)00090-4; BRACKE ME, 1994, CANCER RES, V54, P4607; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Chariot A, 1996, BIOCHEM BIOPH RES CO, V222, P292, DOI 10.1006/bbrc.1996.0737; CHARIOT A, 1995, BIOCHEM BIOPH RES CO, V215, P713, DOI 10.1006/bbrc.1995.2522; Charpin C, 1997, J PATHOL, V181, P294; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525; Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004; Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; Frankel A, 1997, CANCER RES, V57, P2388; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; GAMALLO C, 1993, AM J PATHOL, V142, P987; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; GEHRING WJ, 1986, ANNU REV GENET, V20, P147, DOI 10.1146/annurev.ge.20.120186.001051; Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hashizume R, 1996, HISTOPATHOLOGY, V29, P139, DOI 10.1046/j.1365-2559.1996.d01-499.x; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Heiser D, 2004, EXP GERONTOL, V39, P1125, DOI 10.1016/j.exger.2004.04.011; Irving C, 2000, DEVELOPMENT, V127, P177; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Li G, 2001, CANCER RES, V61, P3819; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; Maroulakou IG, 2003, ANTICANCER RES, V23, P2101; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Meniel V, 2003, J MAMMARY GLAND BIOL, V8, P435, DOI 10.1023/B:JOMG.0000017430.12210.37; Meredith JE, 1996, ENDOCR REV, V17, P207, DOI 10.1210/er.17.3.207; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; MOLL R, 1993, AM J PATHOL, V143, P1731; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nakamura T, 2003, INT J MOL MED, V12, P693; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Ohsugi M, 1997, DEV BIOL, V185, P261, DOI 10.1006/dbio.1997.8560; OKA H, 1993, CANCER RES, V53, P1696; Peluso JJ, 1996, ENDOCRINOLOGY, V137, P1196, DOI 10.1210/en.137.4.1196; Peluso JJ, 2001, BIOL REPROD, V64, P1183, DOI 10.1095/biolreprod64.4.1183; Pujuguet P, 2003, MOL BIOL CELL, V14, P2181, DOI 10.1091/mbc.E02-07-0410; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; Rios-Doria J, 2005, PROSTATE, V63, P259, DOI 10.1002/pros.20179; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Shen XD, 2004, AM J PATHOL, V165, P1315, DOI 10.1016/S0002-9440(10)63390-1; Srebrow A, 1998, J CELL BIOCHEM, V69, P377, DOI 10.1002/(SICI)1097-4644(19980615)69:4<377::AID-JCB1>3.0.CO;2-K; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317	63	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6471	6481		10.1074/jbc.M512666200	http://dx.doi.org/10.1074/jbc.M512666200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16373333	hybrid			2022-12-27	WOS:000236030800042
J	Baechle, D; Flad, T; Cansier, A; Steffen, H; Schittek, B; Tolson, J; Herrmann, T; Dihazi, H; Beck, A; Mueller, GA; Mueller, M; Stevanovic, S; Garbe, C; Mueller, CA; Kalbacher, H				Baechle, D; Flad, T; Cansier, A; Steffen, H; Schittek, B; Tolson, J; Herrmann, T; Dihazi, H; Beck, A; Mueller, GA; Mueller, M; Stevanovic, S; Garbe, C; Mueller, CA; Kalbacher, H			Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTATIN M/E EXPRESSION; HUMAN SKIN; ATOPIC-DERMATITIS; INNATE DEFENSE; GLANDS; KERATINOCYTES; CATHELICIDINS; INFECTION; DERMCIDIN; PURIFICATION	The protein pattern of healthy human eccrine sweat was investigated and 10 major proteins were detected from which apolipoprotein D, lipophilin B, and cathepsin D ( CatD) were identified for the first time in human eccrine sweat. We focused our studies on the function of the aspartate protease CatD in sweat. In vitro digestion experiments using a specific fluorescent CatD substrate showed that CatD is enzymatically active in human sweat. To identify potential substrates of CatD in human eccrine sweat LL-37 and DCD-1L, two antimicrobial peptides present in sweat, were digested in vitro with purified CatD. LL-37 was not significantly digested by CatD, whereas DCD-1L was cleaved between Leu(44) and Asp(45) and between Leu(29) and Glu(30) almost completely. The DCD-1L-derived peptides generated in vitro by CatD were also found in vivo in human sweat as determined by surface-enhanced laser desorption/ ionization (SELDI) mass spectrometry. Furthermore, besides the CatD-processed peptides we identified additionally DCD-1L-derived peptides that are generated upon cleavage with a 1,10-phenanthroline- sensitive carboxypeptidase and an endoprotease. Taken together, proteolytic processing generates 12 DCD-1L-derived peptides. To elucidate the functional significance of postsecretory processing the antimicrobial activity of three CatD-processed DCD-1L peptides was tested. Whereas two of these peptides showed no activity against Gram-positive and Gram-negative bacteria, one DCD-1L-derived peptide showed an even higher activity against Escherichia coli than DCD-1L. Functional analysis indicated that proteolytic processing of DCD-1L by CatD in human sweat modulates the innate immune defense of human skin.	Univ Tubingen, Med & Nat Sci Res Ctr, D-72074 Tubingen, Germany; Univ Tubingen, Sect Transplantat Immunol & Immunohematol, D-72072 Tubingen, Germany; Univ Tubingen, Dept Dermatol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Immunol, D-72076 Tubingen, Germany; Univ Hosp Gottingen, Dept Nephrol & Rheumatol, D-37075 Gottingen, Germany; Univ Tubingen Hosp, Dept Internal Med 4, Div Clin Chem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; University of Gottingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Kalbacher, H (corresponding author), Ob Himmelreich 7, D-72074 Tubingen, Germany.	kalbacher@uni-tuebingen.de	Garbe, Claus/ABH-2128-2021	Garbe, Claus/0000-0001-8530-780X; Schittek, Birgit/0000-0003-0081-2001				Algermissen B, 1996, ARCH DERMATOL RES, V288, P426, DOI 10.1007/BF02505229; Ali RS, 2001, J INVEST DERMATOL, V117, P106; Baechle D, 2005, J PEPT SCI, V11, P166, DOI 10.1002/psc.607; Chen SH, 2000, FASEB J, V14, P565, DOI 10.1096/fasebj.14.3.565; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; FIELDS C G, 1991, Peptide Research, V4, P95; Flad T, 2002, J IMMUNOL METHODS, V270, P53, DOI 10.1016/S0022-1759(02)00229-6; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HIBINO T, 1994, J INVEST DERMATOL, V102, P214, DOI 10.1111/1523-1747.ep12371765; HORIE N, 1986, AM J PHYSIOL, V250, pR691, DOI 10.1152/ajpregu.1986.250.4.R691; Kishi T, 2004, CLIN CHEM, V50, P709, DOI 10.1373/clinchem.2003.029538; Langbein L, 2005, J INVEST DERMATOL, V125, P428, DOI 10.1111/j.0022-202X.2005.23860.x; Lopez-Garcia B, 2005, J INVEST DERMATOL, V125, P108, DOI 10.1111/j.0022-202X.2005.23713.x; Miranda E, 2003, J SURG ONCOL, V83, P99, DOI 10.1002/jso.10245; Murakami M, 2002, J INVEST DERMATOL, V119, P1090, DOI 10.1046/j.1523-1747.2002.19507.x; Murakami M, 2004, J IMMUNOL, V172, P3070, DOI 10.4049/jimmunol.172.5.3070; MYAL Y, 1991, MOL CELL ENDOCRINOL, V80, P165, DOI 10.1016/0303-7207(91)90153-J; NAKAYASHIKI N, 1990, TOHOKU J EXP MED, V161, P25, DOI 10.1620/tjem.161.25; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PETERSON LM, 1976, BIOCHEMISTRY-US, V15, P2501, DOI 10.1021/bi00657a001; Rieg S, 2005, J IMMUNOL, V174, P8003, DOI 10.4049/jimmunol.174.12.8003; Rieg S, 2004, BRIT J DERMATOL, V151, P534, DOI 10.1111/j.1365-2133.2004.06081.x; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; VALORE EV, 1992, BLOOD, V79, P1538; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; VANNOORT JM, 1989, J BIOL CHEM, V264, P14159; Wright George L Jr, 2002, Expert Rev Mol Diagn, V2, P549, DOI 10.1586/14737159.2.6.549; YOKOZEKI H, 1987, AM J PHYSIOL, V252, pR1119; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x	37	74	82	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5406	5415		10.1074/jbc.M504670200	http://dx.doi.org/10.1074/jbc.M504670200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16354654	hybrid			2022-12-27	WOS:000235568900012
J	Dabney-Smith, C; Mori, H; Cline, K				Dabney-Smith, C; Mori, H; Cline, K			Oligomers of Tha4 organize at the thylakoid Tat translocase during protein transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE SIGNAL PEPTIDE; ESCHERICHIA-COLI; ANTIMICROBIAL PEPTIDES; CRYSTAL-STRUCTURE; PHOTOSYSTEM-II; PATHWAY; MEMBRANE; SYSTEM; SEC; CHLOROPLASTS	The Tat ( twin arginine translocation) systems of thylakoids and bacteria transport fully folded protein substrates without breaching the permeability barrier of the membrane. Two components of the thylakoid system, cpTatC and Hcf106, compose a precursor-bound receptor complex. The third component, Tha4, assembles with the precursor-bound receptor complex for the translocation step and is thought to compose at least part of the protein-conducting channel. Here, we used two different cross-linking approaches to explore the organization of Tha4 in the translocase. These cross-linking techniques showed that transition to an active protein transport state resulted in an alignment of the Tha4 amphipathic helix and C-terminal tail domains to form Tha4 oligomers. Oligomerization required functional Tha4, a twin arginine signal peptide, and an active cpTatC-Hcf106 receptor complex. The spectrum of oligomers obtained was independent of the mature folded domain of the precursor. We propose a trapdoor mechanism for translocation whereby aligned oligomers of Tha4 amphipathic helices fold into the membrane to allow formfitting passage of precursor proteins.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA; Shujitsu Univ, Sch Pharm, Okayama 7038516, Japan	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Cline, K (corresponding author), Univ Florida, Dept Hort Sci, 1109 Fifield Hall,POB 110690, Gainesville, FL 32611 USA.	kcline@ufl.edu	Dabney-Smith, Carole/C-2432-2008; Cline, Kenneth/J-6238-2013	Dabney-Smith, Carole/0000-0003-1347-3870; 	NIGMS NIH HHS [R01 GM 48179] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alami M, 2003, MOL CELL, V12, P937, DOI 10.1016/S1097-2765(03)00398-8; Alder NN, 2003, FEBS LETT, V540, P96, DOI 10.1016/S0014-5793(03)00231-X; Alder NN, 2003, CELL, V112, P231, DOI 10.1016/S0092-8674(03)00032-1; Berks BC, 2005, CURR OPIN MICROBIOL, V8, P174, DOI 10.1016/j.mib.2005.02.010; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Bruser T, 2003, MICROBIOL RES, V158, P7, DOI 10.1078/0944-5013-00176; Calderone V, 2003, EMBO REP, V4, P900, DOI 10.1038/sj.embor.embor923; CAREAGA CL, 1992, J MOL BIOL, V226, P1219, DOI 10.1016/0022-2836(92)91063-U; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1986, J BIOL CHEM, V261, P4804; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; Cline K, 2003, ADV PHOTOSYNTHESIS R, V13, P353; Dabney-Smith C, 2003, J BIOL CHEM, V278, P43027, DOI 10.1074/jbc.M307923200; de Keyzer J, 2003, CELL MOL LIFE SCI, V60, P2034, DOI 10.1007/s00018-003-3006-y; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fincher V, 2003, EUR J BIOCHEM, V270, P4930, DOI 10.1046/j.1432-1033.2003.03894.x; Gohlke U, 2005, P NATL ACAD SCI USA, V102, P10482, DOI 10.1073/pnas.0503558102; Gouffi K, 2004, J BIOL CHEM, V279, P11608, DOI 10.1074/jbc.M313187200; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Ifuku K, 2004, EMBO REP, V5, P362, DOI 10.1038/sj.embor.7400113; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, FEBS LETT, V501, P65, DOI 10.1016/S0014-5793(01)02626-6; Muller M, 2005, MOL MEMBR BIOL, V22, P113, DOI 10.1080/09687860500041809; Oates J, 2005, J MOL BIOL, V346, P295, DOI 10.1016/j.jmb.2004.11.047; Oates J, 2003, J MOL BIOL, V330, P277, DOI 10.1016/S0022-2836(03)00621-1; Palmer T, 2003, MICROBIOL-SGM, V149, P547, DOI 10.1099/mic.0.25900-0; Pop OI, 2003, J BIOL CHEM, V278, P38428, DOI 10.1074/jbc.M306516200; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Reddy KVR, 2004, INT J ANTIMICROB AG, V24, P536, DOI 10.1016/j.ijantimicag.2004.09.005; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Teter SA, 1998, P NATL ACAD SCI USA, V95, P1590, DOI 10.1073/pnas.95.4.1590; Theg SM, 2005, TRENDS PLANT SCI, V10, P153, DOI 10.1016/j.tplants.2005.02.001; Tossi A, 2000, BIOPOLYMERS, V55, P4; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4; YUAN JG, 1994, SCIENCE, V266, P796, DOI 10.1126/science.7973633	45	108	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5476	5483		10.1074/jbc.M512453200	http://dx.doi.org/10.1074/jbc.M512453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407186	hybrid			2022-12-27	WOS:000235568900020
J	Ward, MW; Rehm, M; Duessmann, H; Kacmar, S; Concannon, CG; Prehn, JHM				Ward, MW; Rehm, M; Duessmann, H; Kacmar, S; Concannon, CG; Prehn, JHM			Real time single cell analysis of Bid cleavage and Bid translocation during caspase-dependent and neuronal caspase-independent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; CEREBELLAR GRANULE CELLS; ACUTE GLUTAMATE EXCITOTOXICITY; FOCAL CEREBRAL-ISCHEMIA; PERMEABILITY TRANSITION; BH3-ONLY PROTEINS; DNA FRAGMENTATION; BCL-2 FAMILY; DEATH	Bcl- 2 homology domain ( BH) 3- only proteins couple stress signals to evolutionarily conserved mitochondrial apoptotic pathways. Caspase 8- mediated cleavage of the BH3- only protein Bid into a truncated protein ( tBid) and subsequent translocation of tBid to mitochondria has been implicated in death receptor signaling. We utilized a recombinant fluorescence resonance energy transfer ( FRET) Bid probe to determine the kinetics of Bid cleavage and tBid translocation during death receptor- induced apoptosis in caspase 3- deficient MCF- 7 cells. Cells treated with tumor necrosis factor-alpha ( 200 ng/ ml) showed a rapid cleavage of the Bid- FRET probe occurring 75.4 +/- 12.6 min after onset of the tumor necrosis factor-alpha exposure. Cleavage of the Bid- FRET probe coincided with a translocation of tBid to the mitochondria and a collapse of the mitochondrial membrane potential ( Delta Psi m). We next investigated the role of Bid cleavage in a model of caspase- independent, glutamate- induced excitotoxic apoptosis. Rat cerebellar granule neurons were transfected with the Bid- FRET probe and exposed to glutamate for 5 min. In contrast to death receptor- induced apoptosis, neurons showed a translocation of full- length Bid to the mitochondria. This translocation occurred 5.6 +/- 1.7 h after the termination of the glutamate exposure and was also paralleled with a collapse of the Delta Psi m. Proteolytic cleavage of the FRET probe also occurred, however, only 25.2 +/- 3.5 min after its translocation to the mitochondria. Subfractionation experiments confirmed a translocation of full- length Bid from the cytosolic to the mitochondrial fraction during excitotoxic apoptosis. Our data demonstrate that both tBid and full- length Bid have the capacity to translocate to mitochondria during apoptosis.	Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; Royal Coll Surgeons Ireland, RCSI Neurosci Res Ctr, Dublin 2, Ireland	Royal College of Surgeons - Ireland; Royal College of Surgeons - Ireland	Prehn, JHM (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	Prehn@rcsi.ie	Concannon, Caoimhin/B-2075-2010; Rehm, Markus/C-3398-2012; Prehn, Jochen HM/A-3928-2010	Rehm, Markus/0000-0001-6149-9261; Prehn, Jochen HM/0000-0003-3479-7794; Dussmann, Heiko/0000-0002-3582-8057; Ward, Manus/0000-0002-7085-9668				Armstrong RC, 1997, J NEUROSCI, V17, P553; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bouillet P, 2002, J CELL SCI, V115, P1567; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Budd SL, 1996, J NEUROCHEM, V67, P2282; Cao J, 2004, J BIOL CHEM, V279, P35903, DOI 10.1074/jbc.M402353200; Castilho RF, 1999, J NEUROCHEM, V72, P1394, DOI 10.1046/j.1471-4159.1999.721394.x; Castilho RF, 1998, J NEUROSCI, V18, P10277; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Dussmann H, 2003, J CELL SCI, V116, P525, DOI 10.1242/jcs.00236; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Gasull T, 2000, J BIOL CHEM, V275, P18350, DOI 10.1074/jbc.M910468199; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goonesinghe A, 2005, BIOCHEM J, V387, P109, DOI 10.1042/BJ20041389; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; INOMATA M, 1985, J BIOCHEM-TOKYO, V98, P407, DOI 10.1093/oxfordjournals.jbchem.a135295; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson MD, 1999, J NEUROSCI, V19, P2996; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Onuki R, 2002, P NATL ACAD SCI USA, V99, P14716, DOI 10.1073/pnas.232177599; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Rehm M, 2003, J CELL BIOL, V162, P1031, DOI 10.1083/jcb.200303123; Rehm M, 2002, J BIOL CHEM, V277, P24506, DOI 10.1074/jbc.M110789200; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Tafani M, 2002, J BIOL CHEM, V277, P10073, DOI 10.1074/jbc.M111350200; Takano J, 2005, J BIOL CHEM, V280, P16175, DOI 10.1074/jbc.M414552200; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Villunger A, 2004, Cell Death Differ, V11, P790, DOI 10.1038/sj.cdd.4401460; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Ward MW, 2005, J NEUROCHEM, V92, P1081, DOI 10.1111/j.1471-4159.2004.02928.x; Ward MW, 2000, J NEUROSCI, V20, P7208; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 2002, J BIOL CHEM, V277, P42074, DOI 10.1074/jbc.M204991200; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	69	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5837	5844		10.1074/jbc.M511562200	http://dx.doi.org/10.1074/jbc.M511562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407197	hybrid, Green Published			2022-12-27	WOS:000235568900063
J	Ferrara, C; Stuart, F; Sondermann, P; Brukner, P; Umana, P				Ferrara, C; Stuart, F; Sondermann, P; Brukner, P; Umana, P			The carbohydrate at Fc gamma RIIIa Asn-162 - an element required for high affinity binding to non-fucosylated IgG glycoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CELLULAR CYTOTOXICITY; EFFECTOR FUNCTIONS; INTERACTION SITES; RECEPTOR; ANTIBODY; OLIGOSACCHARIDES; GLYCOSYLATION; POLYMORPHISM; SPECIFICITY; EXPRESSION	Fc gamma RIIIa plays a prominent role in the elimination of tumor cells by antibody-based cancer therapies. Non-fucosylated bisected IgGs bind this receptor with increased affinity and trigger Fc gamma RIII-mediated effector functions more efficiently than native, fucosylated antibodies. In this study the contribution of the carbohydrates of both binding partners to the strength of the complex was analyzed. Glycoengineering of the antibody increased affinity for two polymorphic forms of soluble human Fc gamma RIIIa ( by up to 50-fold) but did not affect binding to the inhibitory Fc gamma RIIb receptor. While the absence of carbohydrate at Fc gamma RIIIa's Asn-162 increased affinity for native IgG, presumably due to the removal of steric hindrance caused by the bulky sugars, it unexpectedly reduced affinity for glycoengineered ( GE) antibodies by over one order of magnitude, bringing the affinity down to the same level as for native IgG. We conclude that the high affinity between GE antibodies and Fc gamma RIII is mediated by productive interactions formed between the receptor carbohydrate attached at Asn-162 and regions of the Fc that are only accessible when it is nonfucosylated. As Fc gamma RIIIa and Fc gamma RIIIb are the only human Fc gamma receptors glycosylated at this position, the proposed interactions explain the observed selective affinity increase of GE antibodies for only these receptors. Furthermore, we predict from our structural model that only one of the two Fc-fucose residues needs to be absent for increased binding affinity toward Fc gamma RIII. This information can be exploited for the design of new antibodies with altered Fc receptor binding affinity and enhanced therapeutic potential.	GLYCART Bioterchnol aG, Roche Grp, CH-8952 Schlieren, Switzerland; ETH, Dept Biotechnol, CH-8093 Zurich, Switzerland	Roche Holding; Swiss Federal Institutes of Technology Domain; ETH Zurich	Umana, P (corresponding author), GLYCART Bioterchnol aG, Roche Grp, Wagistr 18, CH-8952 Schlieren, Switzerland.	pablo.umana@roche.com						BRAAKMAN E, 1992, CELL IMMUNOL, V143, P97, DOI 10.1016/0008-8749(92)90008-D; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Deo YM, 1997, IMMUNOL TODAY, V18, P127, DOI 10.1016/S0167-5699(97)01007-4; Drescher B, 2003, IMMUNOLOGY, V110, P335, DOI 10.1046/j.1365-2567.2003.01743.x; Edberg JC, 1997, J IMMUNOL, V159, P3849; FERRARA C, 2006, IN PRESS BIOTECHNOL; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Mechetina LV, 2002, IMMUNOGENETICS, V54, P463, DOI 10.1007/s00251-002-0486-0; Mimura Y, 2001, J BIOL CHEM, V276, P45539, DOI 10.1074/jbc.M107478200; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Okazaki A, 2004, J MOL BIOL, V336, P1239, DOI 10.1016/j.jmb.2004.01.007; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Sondermann P, 1999, BIOL CHEM, V380, P717, DOI 10.1515/BC.1999.090; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; TAO MH, 1989, J IMMUNOL, V143, P2595; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; Weng WK, 2004, J CLIN ONCOL, V22, P4717, DOI 10.1200/JCO.2004.06.003; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087	27	269	303	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5032	5036		10.1074/jbc.M510171200	http://dx.doi.org/10.1074/jbc.M510171200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16330541	hybrid			2022-12-27	WOS:000235426200056
J	Segarra, J; Balenci, L; Drenth, T; Maina, F; Lamballe, F				Segarra, J; Balenci, L; Drenth, T; Maina, F; Lamballe, F			Combined signaling through ERK, PI3K/AKT, and RAC1/p38 is required for Met-triggered cortical neuron migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; MUSCLE-CELL-MIGRATION; FACTOR SCATTER FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR/SCATTER FACTOR; ACTIN REORGANIZATION; ENDOTHELIAL-CELLS; MAMMALIAN TARGET	Cell migration is a complex biological process playing a key role in physiological and pathological conditions. During central nervous system development, positioning and function of cortical neurons is tightly regulated by cell migration. Recently, signaling events involving the urokinase-type plasminogen activator receptor, which is a key regulator for the activation of hepatocyte growth factor (HGF), have been implicated in modulating cortical neuron migration. However, the intracellular pathways controlling neuronal migration triggered by the HGF receptor Met have not been elucidated. By combining pharmacological and genetic approaches, we show here that the Ras/ERK pathway and phosphatidylinositol 3-kinase (PI3K) are both required for cortical neuron migration. By dissecting the downstream signals necessary for this event, we found that Rac1/p38 and Akt are required, whereas the c-Jun N-terminal kinase (JNK) and mTOR/p70(s6k) pathways are dispensable. This study demonstrates that concomitant activation of the Ras/ERK, PI3K/Akt, and Rac1/p38 pathways is required to achieve full capacity of cortical neurons to migrate upon HGF stimulation.	Univ Mediterranee, CNRS, UMR623, Dev Biol Inst Marseille,INSERM, F-13288 Marseille 09, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Lamballe, F (corresponding author), Univ Mediterranee, CNRS, UMR623, Dev Biol Inst Marseille,INSERM, Campus Luminy,Case 907, F-13288 Marseille 09, France.	lamballe@ibdm.univ-mrs.fr	Maina, Flavio/J-9962-2019; Lamballe, Fabienne/GLT-0820-2022; Lamballe, Fabienne/P-4293-2017	Maina, Flavio/0000-0001-6100-4695; Lamballe, Fabienne/0000-0001-7631-942X; 				Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; ALASEK P, 2005, DEVELOPMENT CAMB, V132, P447; Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Bielas S, 2004, ANNU REV CELL DEV BI, V20, P593, DOI 10.1146/annurev.cellbio.20.082503.103047; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Brunstrom JE, 1997, NEURON, V18, P505, DOI 10.1016/S0896-6273(00)81250-7; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Cacci E, 2003, J NEUROSCI RES, V74, P760, DOI 10.1002/jnr.10799; Coltella N, 2003, FASEB J, V17, P1162, DOI 10.1096/fj.02-0576fje; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Delehedde M, 2001, EUR J BIOCHEM, V268, P4423, DOI 10.1046/j.1432-1327.2001.02363.x; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Dubrulle J, 2001, CELL, V106, P219, DOI 10.1016/S0092-8674(01)00437-8; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ebens A, 1996, NEURON, V17, P1157, DOI 10.1016/S0896-6273(00)80247-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gomez-Cambronero J, 2003, J IMMUNOL, V171, P6846, DOI 10.4049/jimmunol.171.12.6846; Gomez-Cambronero J, 2003, FEBS LETT, V550, P94, DOI 10.1016/S0014-5793(03)00828-7; Guay J, 1997, J CELL SCI, V110, P357; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Helmbacher F, 2003, NEURON, V39, P767, DOI 10.1016/S0896-6273(03)00493-8; Huang SL, 2003, CANCER BIOL THER, V2, P222, DOI 10.4161/cbt.2.3.360; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; JUN T, 1999, SCI STKE, V13, pPE1; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kawamura K, 2004, J BIOL CHEM, V279, P54862, DOI 10.1074/jbc.M408057200; Kawauchi T, 2003, EMBO J, V22, P4190, DOI 10.1093/emboj/cdg413; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Konno D, 2005, J BIOL CHEM, V280, P5082, DOI 10.1074/jbc.M408251200; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Maina F, 1998, NEURON, V20, P835, DOI 10.1016/S0896-6273(00)80466-3; Maina F, 2001, MOL CELL, V7, P1293, DOI 10.1016/S1097-2765(01)00261-1; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Medina DL, 2004, EMBO J, V23, P3803, DOI 10.1038/sj.emboj.7600399; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; NOBES CD, 1995, J CELL SCI, V108, P225; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Powell EM, 2003, J NEUROSCI, V23, P622, DOI 10.1523/JNEUROSCI.23-02-00622.2003; Powell EM, 2001, NEURON, V30, P79, DOI 10.1016/S0896-6273(01)00264-1; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rice DS, 1999, GENE DEV, V13, P2758, DOI 10.1101/gad.13.21.2758; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Ross ME, 2001, ANNU REV NEUROSCI, V24, P1041, DOI 10.1146/annurev.neuro.24.1.1041; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Sun YX, 2003, MICROW OPT TECHN LET, V36, P48, DOI 10.1002/mop.10667; Taher TEI, 2002, BIOCHEM BIOPH RES CO, V298, P80, DOI 10.1016/S0006-291X(02)02397-5; Tai YT, 2003, BLOOD, V101, P2762, DOI 10.1182/blood-2002-09-2813; Takeda K, 2002, GENES CELLS, V7, P1099, DOI 10.1046/j.1365-2443.2002.00591.x; Tanski WJ, 2005, J VASC SURG, V41, P91, DOI 10.1016/j.jvs.2004.08.058; Thompson J, 2004, MOL CELL NEUROSCI, V27, P441, DOI 10.1016/j.mcn.2004.07.007; Tokumaru S, 2005, BIOCHEM BIOPH RES CO, V327, P100, DOI 10.1016/j.bbrc.2004.11.145; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; Yamamoto Y, 1997, DEVELOPMENT, V124, P2903; Yang XM, 1998, J NEUROSCI, V18, P8369; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	76	94	96	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4771	4778		10.1074/jbc.M508298200	http://dx.doi.org/10.1074/jbc.M508298200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361255	hybrid			2022-12-27	WOS:000235426200027
J	ten Dam, GB; Kurup, S; van De Westerlo, EMA; Versteeg, EMM; Lindahl, U; Spillmann, D; van Kuppevelt, TH				ten Dam, GB; Kurup, S; van De Westerlo, EMA; Versteeg, EMM; Lindahl, U; Spillmann, D; van Kuppevelt, TH			3-O-sulfated oligosaccharide structures are recognized by anti-heparan sulfate antibody HS4C3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; ANTITHROMBIN-BINDING-SITE; HERPES-SIMPLEX-VIRUS; GLOMERULAR-BASEMENT-MEMBRANE; GROWTH-FACTOR FGF; HEPARIN/HEPARAN SULFATE; SUBSTRATE-SPECIFICITY; NEONATAL LETHALITY; HUMAN CDNAS; DOMAIN	Antibodies against heparan sulfate (HS) are useful tools to study the structural diversity of HS. They demonstrate the large sequential variation within HS and show the distribution of HS oligosaccharide sequences within their natural environment. We analyzed the distribution and the structural characteristics of the oligosaccharide epitope recognized by anti-HS antibody HS4C3. Biosynthetic and synthetic heparin-related oligosaccharide libraries were used in affinity chromatography, immunoprecipitation, and enzyme-linked immunosorbent assay to identify this epitope as a 3-O-sulfated motif with antithrombin binding capacity. The antibody binds weakly to any N-sulfated, 2-O- and 6-O-sulfated hexa- to octasaccharide fragment but strongly to the corresponding oligosaccharide when there is a 3-O-sulfated glucosamine residue present in the sequence. This difference was highlighted by affinity interaction and immunohistochemistry at salt concentrations from 500 mM. At physiological salt conditions the antibody strongly recognized basal lamina of epithelia and endothelia. At 500 mM salt conditions, when 3-O sulfation is required for binding, antibody recognition was more restricted and selective. Antibody HS4C3 bound similar tissue structures as antithrombin in rat kidney. Furthermore, antithrombin and antibody HS4C3 could compete with one another for binding to heparin. Antibody HS4C3 was also able to inhibit the anti-coagulant activities of heparin and Arixtra as demonstrated using the activated partial thromboplastin time clotting and the anti-factor Xa assays. In summary, antibody HS4C3 selectively detects 3-O-sulfated HS structures and interferes with the coagulation activities of heparin by association with the antithrombin binding pentasaccharide sequence.	Radboud Univ, Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Biochem 280, NL-6500 HB Nijmegen, Netherlands; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Radboud University Nijmegen; Uppsala University	van Kuppevelt, TH (corresponding author), Radboud Univ, Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Biochem 280, POB 9101, NL-6500 HB Nijmegen, Netherlands.	a.vankuppevelt@ncmls.ru.nl	van Kuppevelt, A.H.M.S.M./L-4463-2015	Versteeg, Elly/0000-0001-7047-5173				Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Chen JH, 2003, GLYCOBIOLOGY, V13, P785, DOI 10.1093/glycob/cwg101; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Duncan MB, 2004, BBA-GEN SUBJECTS, V1671, P34, DOI 10.1016/j.bbagen.2003.12.010; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; Edge ASB, 2000, DIABETOLOGIA, V43, P1056, DOI 10.1007/s001250051489; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Feyzi E, 1997, J BIOL CHEM, V272, P24850, DOI 10.1074/jbc.272.40.24850; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HajMohammadi S, 2003, J CLIN INVEST, V111, P989, DOI 10.1172/JCI200315809; Jemth P, 2003, J BIOL CHEM, V278, P24371, DOI 10.1074/jbc.M212155200; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; Kreuger J, 2001, J BIOL CHEM, V276, P30744, DOI 10.1074/jbc.M102628200; Kreuger J, 2002, EMBO J, V21, P6303, DOI 10.1093/emboj/cdf638; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; Kusche-Gullberg M, 2003, CURR OPIN STRUC BIOL, V13, P605, DOI 10.1016/j.sbi.2003.08.002; Li JP, 2003, J BIOL CHEM, V278, P28363, DOI 10.1074/jbc.C300219200; LINDAHL U, 1979, P NATL ACAD SCI USA, V76, P3198, DOI 10.1073/pnas.76.7.3198; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Loo BM, 2001, J BIOL CHEM, V276, P16868, DOI 10.1074/jbc.M011226200; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; Merry CLR, 2002, BBA-GEN SUBJECTS, V1573, P319, DOI 10.1016/S0304-4165(02)00399-9; Miyamoto K, 2003, ONCOGENE, V22, P274, DOI 10.1038/sj.onc.1206146; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; Petitou M, 2003, BIOCHIMIE, V85, P83, DOI 10.1016/S0300-9084(03)00078-6; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Smits NC, 2004, AM J RESP CELL MOL, V30, P166, DOI 10.1165/rcmb.2003-0198OC; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; ten Dam GB, 2004, J BIOL CHEM, V279, P38346, DOI 10.1074/jbc.M404166200; ten Dam GB, 2003, J HISTOCHEM CYTOCHEM, V51, P727; Tiwari V, 2004, J GEN VIROL, V85, P805, DOI 10.1099/vir.0.19641-0; Turnbull JE, 1999, P NATL ACAD SCI USA, V96, P2698, DOI 10.1073/pnas.96.6.2698; van de Westerlo EMA, 2002, BLOOD, V99, P2427, DOI 10.1182/blood.V99.7.2427; van den Born J, 2005, J BIOL CHEM, V280, P20516, DOI 10.1074/jbc.M502065200; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; VANBOECKEL CAA, 1993, ANGEW CHEM INT EDIT, V32, P1671, DOI 10.1002/anie.199316713; VANDELEST CHA, 1994, ANAL BIOCHEM, V221, P356, DOI 10.1006/abio.1994.1425; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; Xia GQ, 2002, J BIOL CHEM, V277, P37912, DOI 10.1074/jbc.M204209200; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200	53	89	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4654	4662		10.1074/jbc.M506357200	http://dx.doi.org/10.1074/jbc.M506357200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373349	hybrid, Green Published			2022-12-27	WOS:000235426200013
J	Fan, JS; Matsumoto, Y; Wilson, DM				Fan, JS; Matsumoto, Y; Wilson, DM			Nucleotide sequence and DNA secondary structure, as well as replication protein A, modulate the single-stranded abasic endonuclease activity of APE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; HUMAN APURINIC ENDONUCLEASE; ANTIGEN-DEPENDENT REPAIR; DAMAGE-RECOGNITION; MAJOR HUMAN; FUNCTIONAL-CHARACTERIZATION; OXIDATIVE DAMAGE; BINDING-PROTEIN; T7 ENDONUCLEASE	A major role of the multifunctional human Ape1 protein is to incise at apurinic/apyrimidinic (AP) sites in DNA via site-specific endonuclease activity. This nuclease function has been well characterized on double-stranded (ds) DNA substrates, where the complementary strand provides a template for subsequent base excision repair events. Recently, Ape1 was found to incise efficiently at AP sites positioned within the single-stranded (ss) regions of various biologically relevant DNA configurations. The studies within indicated that the ss endonuclease activity of Ape1 is poorly active on ss AP site-containing polyadenine or polythymine oligonucleotides, suggesting a requirement for some form of DNA secondary structure for efficient cleavage. Computational, footprinting, and biochemical analyses indicated that the nature of the secondary structure and the proximity of the AP site influence Ape1 incision efficiency significantly. Replication protein A (RPA), the major ssDNA-binding protein in mammalian cells, was found to bind ss AP-DNA with similar affinity as unmodified ssDNA and ds AP-DNA with lower affinity. Consistent with their known relative DNA binding affinities, RPA blocks/inhibits the ss, but not ds, AP endonuclease function of Ape1. Moreover, RPA inactivates Ape1 incision activity at an AP site within the ss region of a fork duplex, but not a transcription-like bubble intermediate. The data herein suggested a model whereby RPA selectively suppresses the nontemplated ss cleavage activity of Ape1 in vivo, particularly at sites of ongoing replication/recombination, by coating the ssDNA.	NIA, Lab Mol Gerontol, NIH, GRC, Baltimore, MD 21224 USA; Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Fox Chase Cancer Center	Wilson, DM (corresponding author), NIA, Lab Mol Gerontol, NIH, GRC, 2D-13,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	wilsonda@grc.nia.nih.gov	Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395; Matsumoto, Yoshihiro/0000-0001-6580-7188	NATIONAL INSTITUTE ON AGING [ZIAAG000743, Z01AG000743] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; Beard BC, 2003, P NATL ACAD SCI USA, V100, P7465, DOI 10.1073/pnas.1330328100; Beloglazova NG, 2004, NUCLEIC ACIDS RES, V32, P5134, DOI 10.1093/nar/gkh846; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bochkareva E, 2001, EMBO J, V20, P612, DOI 10.1093/emboj/20.3.612; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CLUGSTON CK, 1992, CANCER RES, V52, P6375; Declais AC, 2003, EMBO J, V22, P1398, DOI 10.1093/emboj/cdg132; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; Erzberger JP, 1999, J MOL BIOL, V290, P447, DOI 10.1006/jmbi.1999.2888; Erzberger JP, 1998, NUCLEIC ACIDS RES, V26, P2771, DOI 10.1093/nar/26.11.2771; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; Fortini P, 2003, BIOCHIMIE, V85, P1053, DOI 10.1016/j.biochi.2003.11.003; Fung H, 2005, MOL CELL, V17, P463, DOI 10.1016/j.molcel.2004.12.029; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; Hadi MZ, 2000, NUCLEIC ACIDS RES, V28, P3871, DOI 10.1093/nar/28.20.3871; Hadi MZ, 2002, J MOL BIOL, V316, P853, DOI 10.1006/jmbi.2001.5382; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hey T, 2001, BIOCHEMISTRY-US, V40, P2901, DOI 10.1021/bi002166i; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Huamani J, 2004, MOL CELL BIOL, V24, P8145, DOI 10.1128/MCB.24.18.8145-8153.2004; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Lao Y, 2000, BIOCHEMISTRY-US, V39, P850, DOI 10.1021/bi991704s; Larson ED, 2005, MOL CELL, V20, P367, DOI 10.1016/j.molcel.2005.09.018; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu YY, 2005, BIOCHEM J, V385, P519, DOI 10.1042/BJ20041151; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Marenstein DR, 2004, DNA REPAIR, V3, P527, DOI 10.1016/j.dnarep.2004.01.010; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Meira LB, 2001, CANCER RES, V61, P5552; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nguyen LH, 2000, J MOL BIOL, V298, P447, DOI 10.1006/jmbi.2000.3653; Nilsen H, 2002, EMBO J, V21, P5943, DOI 10.1093/emboj/cdf581; Opresko PL, 2005, NUCLEIC ACIDS RES, V33, P1230, DOI 10.1093/nar/gki273; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Parkinson MJ, 1997, J MOL BIOL, V270, P169, DOI 10.1006/jmbi.1997.1128; Parsian AJ, 2002, MUTAT RES-FUND MOL M, V501, P105, DOI 10.1016/S0027-5107(02)00016-7; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; Ranalli TA, 2002, J BIOL CHEM, V277, P1719, DOI 10.1074/jbc.M109053200; Stivers JT, 2003, CHEM REV, V103, P2729, DOI 10.1021/cr010219b; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Thoma BS, 2003, MOL CARCINOGEN, V38, P1, DOI 10.1002/mc.10143; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Wilson DM, 2001, MUTAT RES-DNA REPAIR, V485, P283, DOI 10.1016/S0921-8777(01)00063-5; Wilson DM, 2005, J MOL BIOL, V345, P1003, DOI 10.1016/j.jmb.2004.11.028; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	62	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3889	3898		10.1074/jbc.M511004200	http://dx.doi.org/10.1074/jbc.M511004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356936	hybrid			2022-12-27	WOS:000235275300016
J	Gao, ZG; He, Q; Peng, BL; Chiao, PJ; Ye, JP				Gao, ZG; He, Q; Peng, BL; Chiao, PJ; Ye, JP			Regulation of nuclear translocation of HDAC3 by I kappa B alpha is required for tumor necrosis factor inhibition of peroxisome proliferator-activated receptor gamma function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; FIBROBLAST-GROWTH-FACTOR; GENE-EXPRESSION; PPAR-GAMMA; TRANSCRIPTIONAL ACTIVITY; PROTEIN-KINASE; ADIPOCYTE DIFFERENTIATION; DEPENDENT REPRESSION; 3T3-L1 ADIPOCYTES; BINDING PROTEIN	dInhibition of peroxisome proliferator-activated receptor gamma (PPAR gamma) function by TNF-alpha contributes to glucose and fatty acid metabolic disorders in inflammation and cancer, although the molecular mechanism is not fully understood. In this study, we demonstrate that nuclear translocation of HDAC3 is regulated by TNF-alpha, and this event is required for inhibition of transcriptional activity of PPAR gamma by TNF-alpha. HDAC3 is associated with I kappa B alpha in the cytoplasm. After I kappa B alpha degradation in response to TNF-alpha, HDAC3 is subject to nuclear translocation, leading to an increase in HDAC3 activity in the nucleus. This event leads to subcellular redistribution of HDAC3. Knock-out of I kappa B alpha, but not p65 or p50, leads to disappearance of HDAC3 in the cytoplasm, which is associated with HDAC3 enrichment in the nucleus. These data suggest that inhibition of PPAR gamma by TNF-alpha is not associated with a reduction in the DNA binding activity of PPAR gamma. Rather, these results suggest that I kappa B alpha-dependent nuclear translocation of HDAC3 is responsible for PPAR gamma inhibition by TNF-alpha.	Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Texas System; UTMD Anderson Cancer Center	Ye, JP (corresponding author), Louisiana State Univ Syst, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	yej@pbrc.edu	Ye, Jianping/N-1998-2017	Ye, Jianping/0000-0003-3875-365X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068036, R56DK068036] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK068036, DK068036, R56 DK068036] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; Gao ZG, 2005, J BIOL CHEM, V280, P21091, DOI 10.1074/jbc.M500754200; Gao ZG, 2004, MOL ENDOCRINOL, V18, P2024, DOI 10.1210/me.2003-0383; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Ge K, 2002, NATURE, V417, P563, DOI 10.1038/417563a; GRAVES RA, 1992, MOL CELL BIOL, V12, P3313; Guan HP, 2005, GENE DEV, V19, P453, DOI 10.1101/gad.1263305; Guenther MG, 2001, MOL CELL BIOL, V21, P6091, DOI 10.1128/MCB.21.18.6091-6101.2001; Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02-06-0356; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Krogsdam AM, 2002, BIOCHEM J, V363, P157, DOI 10.1042/0264-6021:3630157; Lazar MA, 2001, NAT MED, V7, P23, DOI 10.1038/83301; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; NAVRE M, 1989, J CELL BIOL, V109, P1857, DOI 10.1083/jcb.109.4.1857; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Ruan H, 2002, DIABETES, V51, P1319, DOI 10.2337/diabetes.51.5.1319; SERRERO G, 1991, P NATL ACAD SCI USA, V88, P3912, DOI 10.1073/pnas.88.9.3912; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; SUZAWA M, 2003, NAT CELL BIOL; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Viatour P, 2003, J BIOL CHEM, V278, P46541, DOI 10.1074/jbc.M306381200; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Yang WM, 2002, J BIOL CHEM, V277, P9447, DOI 10.1074/jbc.M105993200; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang B, 1996, MOL ENDOCRINOL, V10, P1457, DOI 10.1210/me.10.11.1457; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	61	118	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4540	4547		10.1074/jbc.M507784200	http://dx.doi.org/10.1074/jbc.M507784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16371367	Green Accepted, hybrid			2022-12-27	WOS:000235275300090
J	Goetz, JA; Singh, S; Suber, LM; Kull, FJ; Robbins, DJ				Goetz, JA; Singh, S; Suber, LM; Kull, FJ; Robbins, DJ			A highly conserved amino-terminal region of sonic hedgehog is required for the formation of its freely diffusible multimeric form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NEURON INDUCTION; SCLEROTOME INDUCTION; CLEAVAGE PRODUCT; FLOOR PLATE; PROTEIN; ACYLTRANSFERASE; PALMITOYLATION; ASSOCIATION; ECTODERM; COMPLEX	Although members of the Hedgehog (Hh) family were initially described as morphogens, many of these early conclusions were based on experiments that used non-physiologically relevant forms of Hh. Native Hh is modified by cholesterol (HhNp) and palmitate. These hydrophobic modifications are responsible for the ability of Hh to associate with cellular membranes, a property that initially appeared inconsistent with its ability to act far from its site of synthesis. Although it is now clear that Hh family members are capable of acting directly in long-range signaling, the form of Hh capable of this activity remains controversial. We have previously provided evidence for a freely diffusible multimeric form of Sonic Hedgehog (Shh) termed s-ShhNp, which is capable of accumulating in a gradient fashion through a morphogenic field. Here, we provide further evidence that s-ShhNp is the physiologically relevant form of Shh. We show that the biological activity of freely diffusible ShhNp resides in its multimeric form and that this multimeric form is exceedingly stable, even to high concentrations of salt and detergent. Furthermore, we now validate the Shh-Shh interactions previously observed in the crystal structure of human Shh, showing that a highly conserved amino-terminal domain of Shh is important for the formation of s-ShhNp. We also conclusively show that palmi-toylation is required for s-ShhNp formation. Thus, our results identify both protein-protein and protein-lipid interactions that are required for s-ShhNp formation, and provide the first structural analyses supporting the existence of Shh multimers.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45249 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; University System of Ohio; University of Cincinnati	Robbins, DJ (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	David.J.Robbins@Dartmouth.edu	Singh, Samer/H-8468-2013	Singh, Samer/0000-0002-0921-1686	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064011] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM64011] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amanai K, 2001, DEVELOPMENT, V128, P5119; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BUMCROT DA, 1995, MOL CELL BIOL, V15, P2294; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; DeLano WL, 2002, PYMOL USERS MANUAL; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Feng J, 2004, DEVELOPMENT, V131, P4357, DOI 10.1242/dev.01301; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Goetz JA, 2002, BIOESSAYS, V24, P157, DOI 10.1002/bies.10056; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; LAI CJ, 1995, DEVELOPMENT, V121, P2349; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Micchelli CA, 2002, DEVELOPMENT, V129, P843; Pepinsky RB, 2000, J BIOL CHEM, V275, P10995, DOI 10.1074/jbc.275.15.10995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Robbins DJ, 2005, CURR CANCER THER REV, V1, P277, DOI 10.2174/157339405774574243; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Rubin JB, 2002, DEVELOPMENT, V129, P2223; Sanchez P, 2005, CANCER RES, V65, P2990, DOI 10.1158/0008-5472.CAN-05-0439; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taylor FR, 2001, BIOCHEMISTRY-US, V40, P4359, DOI 10.1021/bi002487u; Torroja C, 2005, J NEUROBIOL, V64, P334, DOI 10.1002/neu.20168; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648	36	107	111	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4087	4093		10.1074/jbc.M511427200	http://dx.doi.org/10.1074/jbc.M511427200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339763	hybrid			2022-12-27	WOS:000235275300038
J	Yamaguchi, Y; Takatsuka, Y; Matsufuji, S; Murakami, Y; Kamio, Y				Yamaguchi, Y; Takatsuka, Y; Matsufuji, S; Murakami, Y; Kamio, Y			Characterization of a counterpart to mammalian ornithine decarboxylase antizyme in prokaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; RUMINANTIUM LYSINE DECARBOXYLASE; SELENOMONAS-RUMINANTIUM; ESCHERICHIA-COLI; VEILLONELLA-ALCALESCENS; OVERLAP EXTENSION; CELL-GROWTH; PEPTIDOGLYCAN; CADAVERINE; PROTEIN	The degradation of mammalian ornithine decarboxylase (ODC) (EC 4.1.1.17) by 26 S proteasome, is accelerated by the ODC antizyme (AZ), a trigger protein involved in the specific degradation of eukaryotic ODC. In prokaryotes, AZ has not been found. Previously, we found that in Selenomonas ruminantium, a strictly anaerobic and Gram-negative bacterium, a drastic degradation of lysine decarboxylase (LDC; EC 4.1.1.18), which has decarboxylase activities toward both L-lysine and L-ornithine with similar K-m values, occurs upon entry into the stationary phase of cell growth by protease together with a protein of 22 kDa (P22). Here, we show that P22 is a direct counterpart of eukaryotic AZ by the following evidence. (i) P22 synthesis is induced by putrescine but not cadaverine. (ii) P22 enhances the degradation of both mouse ODC and S. ruminantium LDC by a 26 S proteasome. (iii) S. ruminantium LDC degradation is also enhanced by mouse AZ replacing P22 in a cell-free extract from S. ruminantium. (iv) Both P22 and mouse AZ bind to S. ruminantium LDC but not to the LDC mutated in its binding site for P22 and AZ. In this report, we also show that P22 is a ribosomal protein of S. ruminantium.	Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Appl Microbiol Lab,Aoba Ku, Sendai, Miyagi 9818555, Japan; Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, Tokyo 1058461, Japan	Tohoku University; Jikei University	Kamio, Y (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Appl Microbiol Lab,Aoba Ku, 1-1 Tsutsumi Dori, Sendai, Miyagi 9818555, Japan.	ykamio@biochem.tohoku.ac.jp		Yamaguchi, Yoshihiro/0000-0003-4663-6963				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P9786, DOI 10.1073/pnas.0402521101; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ivanov IP, 1998, MOL MICROBIOL, V29, P1521, DOI 10.1046/j.1365-2958.1998.01032.x; KAMIO Y, 1986, J BIOL CHEM, V261, P6585; KAMIO Y, 1981, J BACTERIOL, V146, P49, DOI 10.1128/JB.146.1.49-53.1981; KAMIO Y, 1987, J BACTERIOL, V169, P4837, DOI 10.1128/jb.169.10.4837-4840.1987; KAMIO Y, 1982, J BIOL CHEM, V257, P3326; KAMIO Y, 1987, J BACTERIOL, V169, P2881, DOI 10.1128/jb.169.6.2881-2884.1987; KAMIO Y, 1983, J BACTERIOL, V153, P658, DOI 10.1128/JB.153.2.658-664.1983; KANEGASAKI S, 1967, J BACTERIOL, V93, P456, DOI 10.1128/JB.93.1.456-463.1967; KASHIWAGI K, 1987, BIOCHIM BIOPHYS ACTA, V911, P180, DOI 10.1016/0167-4838(87)90007-0; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; KITANI T, 1984, J BIOL CHEM, V259, P36; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINEHAN B, 1978, APPL ENVIRON MICROB, V35, P317, DOI 10.1128/AEM.35.2.317-322.1978; Murakami Y, 2000, BIOCHEM BIOPH RES CO, V267, P1, DOI 10.1006/bbrc.1999.1706; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; PANAGIOTIDIS CA, 1984, J BIOL CHEM, V259, P5025; Persson L, 2003, BIOCHEM SOC T, V31, P411, DOI 10.1042/BST0310411; PHAN APH, 1982, ANAL BIOCHEM, V120, P193, DOI 10.1016/0003-2697(82)90336-0; POSO H, 1984, BIOCHEM BIOPH RES CO, V125, P205, DOI 10.1016/S0006-291X(84)80355-1; POST LE, 1979, P NATL ACAD SCI USA, V76, P1697, DOI 10.1073/pnas.76.4.1697; Saito T, 2000, BIOCHEM J, V345, P99, DOI 10.1042/0264-6021:3450099; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Takatsuka Y, 1999, BIOSCI BIOTECH BIOCH, V63, P1063, DOI 10.1271/bbb.63.1063; Takatsuka Y, 2000, J BACTERIOL, V182, P6732, DOI 10.1128/JB.182.23.6732-6741.2000; Welch RA, 2002, P NATL ACAD SCI USA, V99, P17020, DOI 10.1073/pnas.252529799; Yamaguchi Y, 2002, BIOSCI BIOTECH BIOCH, V66, P1431, DOI 10.1271/bbb.66.1431; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	36	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3995	4001		10.1074/jbc.M507545200	http://dx.doi.org/10.1074/jbc.M507545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354653	hybrid			2022-12-27	WOS:000235275300028
J	Bhanumathy, CD; Nakao, SK; Joseph, SK				Bhanumathy, CD; Nakao, SK; Joseph, SK			Mechanism of proteasomal degradation of inositol trisphosphate receptors in CHO-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-ASSOCIATED DEGRADATION; INDUCED DOWN-REGULATION; LIVER EPITHELIAL-CELLS; 1,4,5-TRISPHOSPHATE RECEPTOR; LIGAND-BINDING; MAMMALIAN UBC7; MOUSE OOCYTES; EARLY EMBRYOS; ACTIVATION; UBIQUITINATION	myo-Inositol 1,4,5-trisphosphate receptor (IP3R) degradation occurs in response to carbachol (Cch) stimulation of CHO-K1 cells. The response was mediated by endogenous muscarinic receptors and was blocked by atropine or proteasomal inhibitors. We have used these cells to identify the sites of ubiquitination on IP(3)Rs and study the role of Ca2+ and substrate recognition properties of the degradation system using exogenously expressed IP3R constructs. Employing caspase-3 for IP3R cleavage, we show that Cch promotes polyubiquitination in the N-terminal domain and monoubiquitination in the C-terminal domain. The addition of extracellular Ca2+ to Ca2+-depleted Chinese hamster ovary (CHO) cells initiates IP3R degradation provided Cch is present. This effect is inhibited by thapsigargin. The data suggest that both a sustained elevation of IP3 and a minimal content of Ca2+ in the endoplasmic reticulum lumen is required to initiate IP3R degradation. Transient transfection of IP3R constructs into CHO cells indicated the selective degradation of only the SI(+) splice variant of the type I IP3R. This was also the splice form present endogenously in these cells. A pore-defective, nonfunctional SI(+) IP3R mutant (D2550A) was also degraded in Cch-stimulated cells. The Cch-mediated response in CHO cells provides a convenient model system to further analyze the Ca2+ dependence and structural requirements of the IP3R proteasomal degradation pathway.	Thomas Jefferson Univ, Dept Pathol, Sch Med, Philadelphia, PA 19107 USA	Jefferson University	Joseph, SK (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Rm 230A,JAH,1020 Locust St, Philadelphia, PA 19107 USA.	suresh.joseph@mail.tju.edu			NIDDK NIH HHS [DK34804] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alzayady KJ, 2005, BIOCHEM J, V392, P601, DOI 10.1042/BJ20050949; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Bokkala S, 1999, ALCOHOL CLIN EXP RES, V23, P1875, DOI 10.1097/00000374-199912000-00004; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hamada K, 2003, J BIOL CHEM, V278, P52881, DOI 10.1074/jbc.M309743200; Hang LS, 2000, J NEUROCHEM, V75, P1852; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Joseph SK, 2006, BIOCHEM J, V393, P575, DOI 10.1042/BJ20050889; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; Khan MT, 2003, BIOCHEM J, V375, P603, DOI 10.1042/BJ20030828; Kim BW, 2003, MOL ENDOCRINOL, V17, P2603, DOI 10.1210/me.2003-0082; Kume S, 2000, DEV GROWTH DIFFER, V42, P327; Lee B, 2001, ENDOCRINOLOGY, V142, P1744, DOI 10.1210/en.142.5.1744; McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; Parrington J, 1998, DEV BIOL, V203, P451, DOI 10.1006/dbio.1998.9071; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Ramos-Franco J, 1998, BIOPHYS J, V75, P2783, DOI 10.1016/S0006-3495(98)77721-5; Regan MR, 2005, PROTEINS, V59, P312, DOI 10.1002/prot.20225; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; Sharma K, 1997, J BIOL CHEM, V272, P14617, DOI 10.1074/jbc.272.23.14617; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Tovey SC, 2001, J CELL SCI, V114, P3979; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WANG SZ, 1995, EUR J PHARM-MOLEC PH, V291, pR1; Webster JM, 2003, J BIOL CHEM, V278, P38238, DOI 10.1074/jbc.M305600200; Willars GB, 2001, J BIOL CHEM, V276, P3123, DOI 10.1074/jbc.M008916200; WOJCIKIEWICZ RJH, 1992, J NEUROCHEM, V59, P383, DOI 10.1111/j.1471-4159.1992.tb08916.x; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; Yoshikawa F, 1999, J BIOL CHEM, V274, P316, DOI 10.1074/jbc.274.1.316; Young KW, 2003, J BIOL CHEM, V278, P20753, DOI 10.1074/jbc.M211555200; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	45	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3722	3730		10.1074/jbc.M509966200	http://dx.doi.org/10.1074/jbc.M509966200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16316991	hybrid			2022-12-27	WOS:000235128200084
J	Handy, DE; Hang, GZ; Scolaro, J; Metes, N; Razaq, N; Yang, Y; Loscalzo, J				Handy, DE; Hang, GZ; Scolaro, J; Metes, N; Razaq, N; Yang, Y; Loscalzo, J			Aminoglycosides decrease glutathione peroxidase-1 activity by interfering with selenocysteine incorporation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN THIOREDOXIN REDUCTASE; NONSENSE-MEDIATED DECAY; MESSENGER-RNA; INSERTION-SEQUENCE; GENE-EXPRESSION; SELENOPROTEIN SYNTHESIS; BINDING PROTEIN; STOP MUTATIONS; FUNCTIONAL-CHARACTERIZATION; GENTAMICIN-NEPHROTOXICITY	Cellular glutathione peroxidase is a key intracellular antioxidant enzyme that contains a selenocysteine residue at its active site. Selenium, a selenocysteine incorporation sequence in the 3'-untranslated region of the glutathione peroxidase mRNA, and other translational cofactors are necessary for "read-through" of a UGA stop codon that specifies selenocysteine incorporation. Aminoglycoside antibiotics facilitate read-through of premature stop codons in prokayotes and eukaryotes. We studied the effects of G418, an aminoglycoside, on cellular glutathione peroxidase expression and function in mammalian cells. Insertion of a selenocysteine incorporation element along with a UGA codon into a reporter construct allows for read-through only in the presence of selenium. G418 increased read-through in selenium-replete cells as well as in the absence of selenium. G418 treatment increased immunodetectable endogenous or recombinant glutathione peroxidase but reduced the specific activity of the enzyme. Tandem mass spectrometry experiments indicated that G418 caused a substitution of L-arginine for selenocysteine. These data show that G418 can affect the biosynthesis of this key antioxidant enzyme by promoting substitution at the UGA codon.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Handy, DE (corresponding author), Brigham & Womens Hosp, Dept Med, HMS-NRB 0630,77 Ave Louis Pasteur, Boston, MA 02115 USA.	dhandy@rics.bwh.harvard.edu	Loscalzo, Joseph/ABD-8980-2021; Yang, Yi/C-1297-2013	Yang, Yi/0000-0001-7896-1184; Sutton, Nadia/0000-0002-0968-3085; Handy, Diane/0000-0002-4310-8527	NHLBI NIH HHS [P50 HL055993, N01 HV028178, N01 HV28178, P01 HL81587, R01 HL058976, HL61795, R01 HL59876] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081587, R37HL061795, R01HL058976, R01HL061795, P50HL055993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ali BH, 2003, FOOD CHEM TOXICOL, V41, P1447, DOI 10.1016/S0278-6915(03)00186-8; Atessahin A, 2003, PHARMACOL RES, V48, P637, DOI 10.1016/S1043-6618(03)00227-5; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; Behne D, 2001, ANNU REV NUTR, V21, P453, DOI 10.1146/annurev.nutr.21.1.453; BERRY MJ, 1992, ENDOCRINOLOGY, V131, P1848, DOI 10.1210/en.131.4.1848; BERRY MJ, 1994, NUCLEIC ACIDS RES, V22, P3753, DOI 10.1093/nar/22.18.3753; BERRY MJ, 1993, EMBO J, V12, P3315, DOI 10.1002/j.1460-2075.1993.tb06001.x; CHADA S, 1989, BLOOD, V74, P2535; Copeland PR, 2003, GENE, V312, P17, DOI 10.1016/S0378-1119(03)00588-2; Copeland PR, 1999, J BIOL CHEM, V274, P25447, DOI 10.1074/jbc.274.36.25447; Cuzzocrea S, 2002, EUR J PHARMACOL, V450, P67, DOI 10.1016/S0014-2999(02)01749-1; DAVIES J, 1965, MOL PHARMACOL, V1, P93; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Erdem A, 2000, NEPHROL DIAL TRANSPL, V15, P1175, DOI 10.1093/ndt/15.8.1175; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; Fletcher JE, 2001, RNA, V7, P1442; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; GORINI L, 1964, P NATL ACAD SCI USA, V51, P995, DOI 10.1073/pnas.51.6.995; Grundner-Culemann E, 2001, J MOL BIOL, V310, P699, DOI 10.1006/jmbi.2001.4809; Handy DE, 2005, J BIOL CHEM, V280, P15518, DOI 10.1074/jbc.M501452200; Hoppe G, 2003, ARCH BIOCHEM BIOPHYS, V414, P19, DOI 10.1016/S0003-9861(03)00144-9; Howard M, 1996, NAT MED, V2, P467, DOI 10.1038/nm0496-467; Howard MT, 2004, ANN NEUROL, V55, P422, DOI 10.1002/ana.20052; Keeling KM, 2001, HUM MOL GENET, V10, P291, DOI 10.1093/hmg/10.3.291; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Kotra LP, 2000, ANTIMICROB AGENTS CH, V44, P3249, DOI 10.1128/AAC.44.12.3249-3256.2000; Kuiper GGJM, 2003, ENDOCRINOLOGY, V144, P2505, DOI 10.1210/en.2003-0084; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; LEINFELDER W, 1988, NATURE, V331, P723, DOI 10.1038/331723a0; Leonard JL, 1996, J CELL BIOCHEM, V61, P410, DOI 10.1002/(SICI)1097-4644(19960601)61:3<410::AID-JCB8>3.0.CO;2-W; Lesoon A, 1997, MOL CELL BIOL, V17, P1977, DOI 10.1128/MCB.17.4.1977; Lin CL, 2002, ELECTROPHORESIS, V23, P513, DOI 10.1002/1522-2683(200202)23:4<513::AID-ELPS513>3.0.CO;2-J; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Maiorino M, 1998, Z ERNAHRUNGSWISS, V37, P118; Manuvakhova M, 2000, RNA, V6, P1044, DOI 10.1017/S1355838200000716; MARTIN R, 1989, MOL GEN GENET, V217, P411, DOI 10.1007/BF02464911; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; Mehta A, 2004, J BIOL CHEM, V279, P37852, DOI 10.1074/jbc.M404639200; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Namy O, 2004, MOL CELL, V13, P157, DOI 10.1016/S1097-2765(04)00031-0; Ozawa Y, 2002, GENE, V300, P79, DOI 10.1016/S0378-1119(02)01042-9; Pedraza-Chaverri J, 2000, FREE RADICAL BIO MED, V29, P602, DOI 10.1016/S0891-5849(00)00354-3; Sachdev SW, 2001, BIOCHEM J, V357, P851; Schulz A, 2002, J CLIN ENDOCR METAB, V87, P5247, DOI 10.1210/jc.2002-020286; Shen QC, 1998, J BIOL CHEM, V273, P5443, DOI 10.1074/jbc.273.10.5443; SINGH A, 1979, NATURE, V277, P146, DOI 10.1038/277146a0; Soejima A, 1998, NEPHRON, V80, P331, DOI 10.1159/000045194; Stadtman TC, 2000, ANN NY ACAD SCI, V899, P399, DOI 10.1111/j.1749-6632.2000.tb06203.x; Sun XL, 2000, EMBO J, V19, P4734, DOI 10.1093/emboj/19.17.4734; Tujebajeva RM, 2000, EMBO REP, V1, P158, DOI 10.1093/embo-reports/kvd033; URSINI F, 1995, METHOD ENZYMOL, V252, P38; Weiss N, 2001, P NATL ACAD SCI USA, V98, P12503, DOI 10.1073/pnas.231428998; Wilschanski M, 2003, NEW ENGL J MED, V349, P1433, DOI 10.1056/NEJMoa022170; Wingler K, 1999, EUR J BIOCHEM, V259, P149, DOI 10.1046/j.1432-1327.1999.00012.x; Wu WJ, 2002, AUDIOL NEURO-OTOL, V7, P171, DOI 10.1159/000058305; Yazar E, 2003, CAN J VET RES, V67, P239; Zavacki AM, 2003, MOL CELL, V11, P773, DOI 10.1016/S1097-2765(03)00064-9; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200; Zsembery A, 2002, HEPATOLOGY, V35, P95, DOI 10.1053/jhep.2002.30423	59	31	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3382	3388		10.1074/jbc.M511295200	http://dx.doi.org/10.1074/jbc.M511295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354666	Green Published, hybrid, Green Accepted			2022-12-27	WOS:000235128200046
J	Jurkuvenaite, A; Varga, K; Nowotarski, K; Kirk, KL; Sorscher, EJ; Li, Y; Clancy, JP; Bebok, Z; Collawn, JF				Jurkuvenaite, A; Varga, K; Nowotarski, K; Kirk, KL; Sorscher, EJ; Li, Y; Clancy, JP; Bebok, Z; Collawn, JF			Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNALIZATION SEQUENCE; CHLORIDE CHANNELS; CFTR; DOMAIN; PROTEIN; IDENTIFICATION; DETERMINANT; DEGRADATION; MEMBRANE; SIGNALS	Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator (CFTR) is mediated by a tyrosine-based internalization signal in the CFTR carboxyl-terminal tail (YDSI1427)-Y-1424. In the present studies, two naturally occurring cystic fibrosis mutations in the amino terminus of CFTR, R31C, and R31L were examined. To determine the defect that these mutations cause, the Arg-31 mutants were expressed in COS-7 cells and their biogenesis and trafficking to the cell surface tested in metabolic pulse-chase and surface biotinylation assays, respectively. The results indicated that both Arg-31 mutants were processed to band C at similar to 50% the efficiency of the wild-type protein. However, once processed and delivered to the cell surface, their half-lives were the same as wildtype protein. Interestingly, indirect immunofluorescence and cell surface biotinylation indicated that the surface pool was much smaller than could be accounted for based on the biogenesis defect alone. Therefore, the Arg-31 mutants were tested in internalization assays and found to be internalized at 2x the rate of the wild-type protein. Patch clamp and 6-methoxy-N-(3-sulfopropyl) quinolinium analysis confirmed reduced amounts of functional Arg-31 channels at the cell surface. Together, the results suggest that both R31C and R31L mutations compromise biogenesis and enhance internalization of CFTR. These two additive effects contribute to the loss of surface expression and the associated defect in chloride conductance that is consistent with a disease phenotype.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Gregory Fleming James Cyst Fibrosis Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Collawn, JF (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, 1918 Univ Blvd,MCLM 350, Birmingham, AL 35294 USA.	jcollawn@uab.edu		Jurkuvenaite, Asta/0000-0002-9193-5797; Sorscher, Eric J./0000-0001-9341-3354; Collawn, James/0000-0002-2528-2759	NHLBI NIH HHS [HL076587] Funding Source: Medline; NIDDK NIH HHS [DK60065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060065] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; Clancy JP, 1998, BIOCHEMISTRY-US, V37, P15222, DOI 10.1021/bi980436f; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Cormet-Boyaka E, 2004, P NATL ACAD SCI USA, V101, P8221, DOI 10.1073/pnas.0400459101; DEMOLOMBE S, 1994, EUR J CELL BIOL, V65, P214; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Gentzsch M, 2004, MOL BIOL CELL, V15, P2684, DOI 10.1091/mbc.E04-03-0176; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Lukacs GL, 1997, BIOCHEM J, V328, P353; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; Naren AP, 1999, SCIENCE, V286, P544, DOI 10.1126/science.286.5439.544; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Peter K, 2002, J BIOL CHEM, V277, P49952, DOI 10.1074/jbc.M209275200; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; Rowntree RK, 2003, ANN HUM GENET, V67, P471, DOI 10.1046/j.1469-1809.2003.00028.x; Schultz BD, 1996, AM J PHYSIOL-LUNG C, V271, pL192, DOI 10.1152/ajplung.1996.271.2.L192; Sharma M, 2004, J CELL BIOL, V164, P923, DOI 10.1083/jcb.200312018; Silvis MR, 2003, J BIOL CHEM, V278, P11554, DOI 10.1074/jbc.M212843200; Straley KS, 1998, MOL BIOL CELL, V9, P1683, DOI 10.1091/mbc.9.7.1683; Swiatecka-Urban A, 2005, J BIOL CHEM, V280, P36762, DOI 10.1074/jbc.M508944200; Varga K, 2004, J BIOL CHEM, V279, P22578, DOI 10.1074/jbc.M401522200; Wang W, 2005, J BIOL CHEM, V280, P23622, DOI 10.1074/jbc.M503118200; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340; Weixel KM, 2001, PFLUG ARCH EUR J PHY, V443, pS70; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; ZIELENSKI J, 1995, HUM MUTAT, V5, P43, DOI 10.1002/humu.1380050106	34	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3329	3334		10.1074/jbc.M508131200	http://dx.doi.org/10.1074/jbc.M508131200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339147	hybrid			2022-12-27	WOS:000235128200040
J	Kwon, G; Marshall, CA; Liu, H; Pappan, KL; Remedi, MS; McDaniel, ML				Kwon, G; Marshall, CA; Liu, H; Pappan, KL; Remedi, MS; McDaniel, ML			Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by K-ATP channels - Effects on cell cycle progression in rodent islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; METABOLIC-REGULATION; SIGNALING PATHWAY; IN-VIVO; MASS; PROLIFERATION; MITOCHONDRIA; ACTIVATION; DIAZOXIDE; APOPTOSIS	The aim of this study was to define metabolic signaling pathways that mediate DNA synthesis and cell cycle progression in adult rodent islets to devise strategies to enhance survival, growth, and proliferation. Since previous studies indicated that glucose-stimulated activation of mammalian target of rapamycin (mTOR) leads to [H-3]thymidine incorporation and that mTOR activation is mediated, in part, through the K-ATP channel and changes in cytosolic Ca2+, we determined whether glyburide, an inhibitor of KATP channels that stimulates Ca2+ influx, modulates [H-3]thymidine incorporation. Glyburide (10-100 nM) at basal glucose stimulated [H-3]thymidine incorporation to the same magnitude as elevated glucose and further enhanced the ability of elevated glucose to increase [H-3]thymidine incorporation. Diazoxide (250 mu M), an activator of KATP channels, paradoxically potentiated glucose-stimulated [H-3]thymidine incorporation 2-4-fold above elevated glucose alone. Cell cycle analysis demonstrated that chronic exposure of islets to basal glucose resulted in a typical cell cycle progression pattern that is consistent with a low level of proliferation. In contrast, chronic exposure to elevated glucose or glyburide resulted in progression from G(0)/G(1) to an accumulation in S phase and a reduction in G(2)/M phase. Rapamycin (100 nM) resulted in an similar to 62% reduction of S phase accumulation. The enhanced [H-3]thymidine incorporation with chronic elevated glucose or glyburide therefore appears to be associated with S phase accumulation. Since diazoxide significantly enhanced [H-3]thymidine incorporation without altering S phase accumulation under chronic elevated glucose, this increase in DNA synthesis also appears to be primarily related to an arrest in S phase and not cell proliferation.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; So Illinois Univ, Sch Pharm, Edwardsville, IL 62026 USA	Washington University (WUSTL); Washington University (WUSTL); Southern Illinois University System; Southern Illinois University Edwardsville	McDaniel, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.	mmcdaniel@wustl.edu	Pappan, Kirk/AAV-5946-2021	Pappan, Kirk/0000-0002-2341-8798	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK006181, R01DK006181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-06181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belanger S, 2005, GYNECOL ONCOL, V97, P796, DOI 10.1016/j.ygyno.2005.02.018; Bjorklund A, 2000, DIABETES, V49, P1840, DOI 10.2337/diabetes.49.11.1840; BRADLEY LM, 1980, SELECTED METHODS CEL, P156; Briaud I, 2005, J BIOL CHEM, V280, P2282, DOI 10.1074/jbc.M412179200; Briaud I, 2003, DIABETES, V52, P974, DOI 10.2337/diabetes.52.4.974; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Fikaris AJ, 2005, J BIOL CHEM, V280, P32107, DOI 10.1074/jbc.M504432200; Grimmsmann T, 1998, BRIT J PHARMACOL, V123, P781, DOI 10.1038/sj.bjp.0701663; GUIOT Y, 1994, EUR J PHARMACOL, V261, P157, DOI 10.1016/0014-2999(94)90314-X; Hannan KM, 2003, BIOCHEM J, V370, P469, DOI 10.1042/BJ20021709; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holmuhamedov E, 2002, FASEB J, V16, P1010, DOI 10.1096/fj.01-0996com; Holmuhamedov EL, 1999, J PHYSIOL-LONDON, V519, P347, DOI 10.1111/j.1469-7793.1999.0347m.x; Kullin M, 2003, DIABETOLOGIA, V46, P80, DOI 10.1007/s00125-002-0997-0; Kwon G, 2004, DIABETES, V53, pS225, DOI 10.2337/diabetes.53.suppl_3.S225; Laybutt DR, 2003, J BIOL CHEM, V278, P2997, DOI 10.1074/jbc.M210581200; Laybutt DR, 2002, DIABETES, V51, P413, DOI 10.2337/diabetes.51.2.413; Lipsett M, 2002, DIABETES, V51, P1834, DOI 10.2337/diabetes.51.6.1834; Maedler K, 2005, J CLIN ENDOCR METAB, V90, P501, DOI 10.1210/jc.2004-0699; Maedler K, 2001, DIABETES, V50, P1683, DOI 10.2337/diabetes.50.8.1683; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; McDaniel ML, 2002, DIABETES, V51, P2877, DOI 10.2337/diabetes.51.10.2877; Montanya E, 2000, DIABETES, V49, P1341, DOI 10.2337/diabetes.49.8.1341; Namkung Y, 2001, J CLIN INVEST, V108, P1015, DOI 10.1172/JCI13310; Ozcan C, 2001, J THORAC CARDIOV SUR, V121, P298, DOI 10.1067/mtc.2001.111421; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Paris M, 2003, ENDOCRINOLOGY, V144, P2717, DOI 10.1210/en.2002-221112; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Rother KI, 2004, J CLIN INVEST, V114, P877, DOI 10.1172/JC1200423235; Steil GM, 2001, AM J PHYSIOL-ENDOC M, V280, pE788, DOI 10.1152/ajpendo.2001.280.5.E788; Xu G, 2001, DIABETES, V50, P353, DOI 10.2337/diabetes.50.2.353; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Yarosh DB, 2002, METHODS, V28, P55, DOI 10.1016/S1046-2023(02)00209-8; Yoshikawa H, 2004, AM J PHYSIOL-ENDOC M, V287, pE1202, DOI 10.1152/ajpendo.00255.2004	36	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3261	3267		10.1074/jbc.M508821200	http://dx.doi.org/10.1074/jbc.M508821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16344552	hybrid			2022-12-27	WOS:000235128200031
J	Sanderson-Smith, M; Batzloff, M; Sriprakash, KS; Dowton, M; Ranson, M; Walker, MJ				Sanderson-Smith, M; Batzloff, M; Sriprakash, KS; Dowton, M; Ranson, M; Walker, MJ			Divergence in the plasminogen-binding group A streptococcal M protein family - Functional conservation of binding site and potential role for immune selection of variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POPULATION GENETIC-STRUCTURE; BACTERIAL SURFACE PROTEIN; ESCHERICHIA-COLI; KRINGLE-2 DOMAIN; ALPHA-ENOLASE; PYOGENES; PAM; EVOLUTION; REGION; STREPTOKINASE	Group A streptococci ( GAS) display receptors for the human zymogen plasminogen on the cell surface, one of which is the plasminogen-binding group A streptococcal M protein (PAM). Characterization of PAM genes from 12 GAS isolates showed significant variation within the plasminogen-binding repeat motifs (a1/a2) of this protein. To determine the impact of sequence variation on protein function, recombinant proteins representing five naturally occurring variants of PAM, together with a recombinant M1 protein, were expressed and purified. Equilibrium dissociation constants for the interaction of PAM variants with biotinylated Glu-plasminogen ranged from 1.58 to 4.99 nM. Effective concentrations of prototype PAM required for 50% inhibition of plasminogen binding to immobilized PAM variants ranged from 0.68 to 22.06 nM. These results suggest that although variation in the a1/a2 region of the PAM protein does affect the comparative affinity of PAM variants, the functional capacity to bind plasminogen is conserved. Additionally, a potential role for the a1 region of PAM in eliciting a protective immune response was investigated by using a mouse model for GAS infection. The a1 region of PAM was found to protect immunized mice challenged with a PAM-positive GAS strain. These data suggest a link between selective immune pressure against the plasminogen-binding repeats and the functional conservation of the binding domain in PAM variants.	Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia; Queensland Inst Med Res, Herston, Qld 4006, Australia	University of Wollongong; QIMR Berghofer Medical Research Institute	Walker, MJ (corresponding author), Univ Wollongong, Sch Biol Sci, Wollongong, NSW 2522, Australia.	mwalker@uow.edu.au	Dowton, Mark/A-7766-2012; Ranson, Marie/A-6324-2008; Sanderson-Smith, Martina/O-9387-2019; Sanderson-Smith, Martina L/H-9614-2013; Ranson, Marie/GRO-5792-2022; Walker, Mark J./F-6940-2011; Ranson, Marie/AAC-4468-2019	Dowton, Mark/0000-0003-3180-2922; Ranson, Marie/0000-0002-5570-9645; Sanderson-Smith, Martina L/0000-0002-6366-4993; Ranson, Marie/0000-0002-5570-9645; Ranson, Marie/0000-0002-5570-9645; Walker, Mark/0000-0001-7423-2769				Andronicos NM, 1997, BBA-PROTEIN STRUCT M, V1337, P27, DOI 10.1016/S0167-4838(96)00146-X; BEACHEY EH, 1977, J EXP MED, V145, P1469, DOI 10.1084/jem.145.6.1469; BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862; BENNASR A, 1994, EUR J BIOCHEM, V222, P267, DOI 10.1111/j.1432-1033.1994.tb18865.x; Beres SB, 2004, P NATL ACAD SCI USA, V101, P11833, DOI 10.1073/pnas.0404163101; BERGE A, 1993, J BIOL CHEM, V268, P25417; Bessen DE, 1996, J INFECT DIS, V173, P896, DOI 10.1093/infdis/173.4.896; Brandt ER, 1996, IMMUNOLOGY, V89, P331, DOI 10.1046/j.1365-2567.1996.d01-754.x; Cedervall T, 1997, BIOCHEMISTRY-US, V36, P4987, DOI 10.1021/bi962971q; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; HARBAUGH MP, 1993, MOL MICROBIOL, V8, P981, DOI 10.1111/j.1365-2958.1993.tb01642.x; Hayman WA, 1997, INT IMMUNOL, V9, P1723, DOI 10.1093/intimm/9.11.1723; HOLLINGSHEAD SK, 1993, MOL MICROBIOL, V8, P707, DOI 10.1111/j.1365-2958.1993.tb01614.x; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JONES KF, 1988, P NATL ACAD SCI USA, V85, P8271, DOI 10.1073/pnas.85.21.8271; Kalia A, 2004, J BACTERIOL, V186, P110, DOI 10.1128/JB.186.1.110-121.2004; Kalia A, 2002, INFECT IMMUN, V70, P1971, DOI 10.1128/IAI.70.4.1971-1983.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lahteenmaki K, 2001, FEMS MICROBIOL REV, V25, P531, DOI 10.1111/j.1574-6976.2001.tb00590.x; LOTTENBERG R, 1992, J INFECT DIS, V166, P436, DOI 10.1093/infdis/166.2.436; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; McKay FC, 2004, INFECT IMMUN, V72, P364, DOI 10.1128/IAI.72.1.364-370.2004; Olive C, 2002, INFECT IMMUN, V70, P2734, DOI 10.1128/IAI.70.5.2734-2738.2002; Pancholi V, 1998, J BIOL CHEM, V273, P14503, DOI 10.1074/jbc.273.23.14503; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; Ramachandran V, 2004, J BACTERIOL, V186, P7601, DOI 10.1128/JB.186.22.7601-7609.2004; RELF WA, 1994, GENE, V144, P25, DOI 10.1016/0378-1119(94)90198-8; Ringdahl U, 1998, J BIOL CHEM, V273, P6424, DOI 10.1074/jbc.273.11.6424; Rios-Steiner JL, 2001, J MOL BIOL, V308, P705, DOI 10.1006/jmbi.2001.4646; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Sambrook J., 1989, MOL CLONING LAB MANU, P74; Schenone MM, 2000, J PEPT RES, V56, P438, DOI 10.1034/j.1399-3011.2000.00810.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sun HM, 2004, SCIENCE, V305, P1283, DOI 10.1126/science.1101245; Svensson MD, 1999, INFECT IMMUN, V67, P3915, DOI 10.1128/IAI.67.8.3915-3920.1999; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Walker MJ, 2005, TRENDS MICROBIOL, V13, P308, DOI 10.1016/j.tim.2005.05.006; WHATMORE AM, 1994, MOL MICROBIOL, V14, P619, DOI 10.1111/j.1365-2958.1994.tb01301.x; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WISTEDT AC, 1995, MOL MICROBIOL, V18, P569, DOI 10.1111/j.1365-2958.1995.mmi_18030569.x; Wistedt AC, 1998, J BIOL CHEM, V273, P24420, DOI 10.1074/jbc.273.38.24420	44	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3217	3226		10.1074/jbc.M508758200	http://dx.doi.org/10.1074/jbc.M508758200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16319056	hybrid			2022-12-27	WOS:000235128200026
J	Gross-Langenhoff, M; Hofbauer, K; Weber, J; Schultz, A; Schultz, JE				Gross-Langenhoff, M; Hofbauer, K; Weber, J; Schultz, A; Schultz, JE			cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROSTATIC STROMAL CELLS; ADENYLYL-CYCLASE; EVOLUTIONARY RELATEDNESS; GENOMIC ORGANIZATION; GENE FAMILY; A DOMAIN; BINDING; PDE11A; DIMERIZATION	N-terminal tandem GAF domains are present in 5 out of 11 mammalian phosphodiesterase (PDE) families. The ligand for the GAF domains of PDEs 2, 5, and 6 is cGMP, whereas those for PDEs 10 and 11 remained enigmatic for years. Here we used the cyanobacterial cyaB1 adenylyl cyclase, which has an N-terminal tandem GAF domain closely related to those of the mammalian PDEs, as an assay system to identify the ligands for the human PDEs 10 and 11 GAF domains. We report that a chimera between the PDE10 GAF domain and the cyanobacterial cyclase was 9-fold stimulated by cAMP (EC50 = 19.8 mu M), whereas cGMP had only low activity. cAMP increased V-max in a non-cooperative manner and did not affect the Km for ATP of 27 mu M. In an analogous chimeric construct with the tandem GAF domain of human PDE11A4, cGMP was identified as an allosteric activator (EC50 = 72.5 mu M) that increased V-max of the cyclase non-cooperatively 4-fold. GAF-B of PDE10 and GAF-A of PDE11A4 contain an invariant NKFDE motif present in all mammalian PDE GAF ensembles. We mutated the aspartates within this motif in both regions and found that intramolecular signaling was considerably reduced or abolished. This was in line with all data concerning GAF domains with an NKFDE motif as far as they have been tested. The data appeared to define those GAF domains as a distinct subclass within the > 3100 annotated GAF domains for which we propose a tentative classification scheme.	Univ Tubingen, Abt Pharmazeut Biochem, Fak Chem & Pharm, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schultz, JE (corresponding author), Univ Tubingen, Abt Pharmazeut Biochem, Fak Chem & Pharm, Morgenstelle 8, D-72076 Tubingen, Germany.	joachim.schultz@uni-tuebingen.de						Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bruder S, 2005, P NATL ACAD SCI USA, V102, P3088, DOI 10.1073/pnas.0409917102; Cook ALM, 2004, CELL SIGNAL, V16, P253, DOI 10.1016/S0898-6568(03)00134-7; Cook ALM, 2002, CELL SIGNAL, V14, P1023, DOI 10.1016/S0898-6568(02)00050-5; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; ERNEUX C, 1981, EUR J BIOCHEM, V115, P503; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Fujishige K, 2000, EUR J BIOCHEM, V267, P5943, DOI 10.1046/j.1432-1327.2000.01661.x; Hetman JM, 2000, P NATL ACAD SCI USA, V97, P12891, DOI 10.1073/pnas.200355397; Houslay MD, 2003, BIOCHEM J, V370, P1, DOI 10.1042/BJ20021698; HURLEY JH, 2003, SCI STKE, pPE1; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; Laxman S, 2005, J BIOL CHEM, V280, P3771, DOI 10.1074/jbc.M408111200; Little R, 2003, J BIOL CHEM, V278, P28711, DOI 10.1074/jbc.M301992200; Loughney K, 2005, INT J IMPOT RES, V17, P320, DOI 10.1038/sj.ijir.3901317; Martinez SE, 2005, P NATL ACAD SCI USA, V102, P3082, DOI 10.1073/pnas.0409913102; Martinez SE, 2002, P NATL ACAD SCI USA, V99, P13260, DOI 10.1073/pnas.192374899; Martinez Sergio E, 2002, Mol Interv, V2, P317, DOI 10.1124/mi.2.5.317; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Mullershausen F, 2003, J CELL BIOL, V160, P719, DOI 10.1083/jcb.200211041; Rascon A, 2002, P NATL ACAD SCI USA, V99, P4714, DOI 10.1073/pnas.002031599; Rybalkin SD, 2003, EMBO J, V22, P469, DOI 10.1093/emboj/cdg051; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Seeger TF, 2003, BRAIN RES, V985, P113, DOI 10.1016/S0006-8993(03)02754-9; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Sopory S, 2003, FEBS LETT, V539, P161, DOI 10.1016/S0014-5793(03)00219-9; Wayman C, 2005, INT J IMPOT RES, V17, P216, DOI 10.1038/sj.ijir.3901307; Wu AY, 2004, J BIOL CHEM, V279, P37928, DOI 10.1074/jbc.M404287200; Yuasa K, 2000, J BIOL CHEM, V275, P31469, DOI 10.1074/jbc.M003041200; Yuasa K, 2001, EUR J BIOCHEM, V268, P4440, DOI 10.1046/j.1432-1327.2001.02366.x; Yuasa K, 2001, EUR J BIOCHEM, V268, P168, DOI 10.1046/j.1432-1327.2001.01866.x; Zoraghi R, 2004, MOL PHARMACOL, V65, P267, DOI 10.1124/mol.65.2.267; Zoraghi R, 2005, J BIOL CHEM, V280, P12051, DOI 10.1074/jbc.M413611200	40	86	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2841	2846		10.1074/jbc.M511468200	http://dx.doi.org/10.1074/jbc.M511468200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330539	hybrid			2022-12-27	WOS:000234931800052
J	Lin, YW; MacMullen, C; Ganguly, A; Stanley, CA; Shyng, SL				Lin, YW; MacMullen, C; Ganguly, A; Stanley, CA; Shyng, SL			A novel KCNJ11 mutation associated with congenital hyperinsulinism reduces the intrinsic open probability of beta-cell ATP-sensitive potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR GENE; COENZYME-A ESTERS; ACYL-COA ESTERS; FAMILIAL HYPERINSULINISM; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INSULIN-SECRETION; K+ CHANNELS; KIR6.2; HYPOGLYCEMIA; INHIBITION	The beta-cell ATP-sensitive potassium (KATP) channel controls insulin secretion by linking glucose metabolism to membrane excitability. Loss of K-ATP channel function due to mutations in ABCC8 or KCNJ11, genes that encode the sulfonylurea receptor 1 or the inward rectifier Kir6.2 subunit of the channel, is a major cause of congenital hyperinsulinism. Here, we report identification of a novel KCNJ11 mutation associated with the disease that renders a missense mutation, F55L, in the Kir6.2 protein. Mutant channels reconstituted in COS cells exhibited a wild-type-like surface expression level and normal sensitivity to ATP, MgADP, and diazoxide. However, the intrinsic open probability of the mutant channel was greatly reduced, by similar to 10-fold. This low open probability defect could be reversed by application of phosphatidylinositol 4,5-bisphosphates or oleoyl-CoA to the cytoplasmic face of the channel, indicating that reduced channel response to membrane phospholipids and/or long chain acyl-CoAs underlies the low intrinsic open probability in the mutant. Our findings reveal a novel molecular mechanism for loss of K-ATP channel function and congenital hyperinsulinism and support the importance of phospholipids and/or long chain acyl-CoAs in setting the physiological activity of beta-cell K-ATP channels. The F55L mutation is located in the slide helix of Kir6.2. Several permanent neonatal diabetes-associated mutations found in the same structure have the opposite effect of increasing intrinsic channel open probability. Our results also highlight the critical role of the Kir6.2 slide helix in determining the intrinsic open probability of K-ATP channels.	Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97239 USA; Childrens Hosp Philadelphia, Div Endocrinol Diabet, Philadelphia, PA 19104 USA	Oregon Health & Science University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Stanley, CA (corresponding author), Childrens Hosp Philadelphia, Div Endocrinol Diabet, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	stanleyc@email.chop.edu; shyngs@ohsu.edu		STANLEY, CHARLES/0000-0003-4881-9392	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066485, R01DK057699] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000240] Funding Source: Medline; NIDDK NIH HHS [R01 DK057699, R01 DK066485, R01 DK056268] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aguilar-Bryan L, 2001, RECENT PROG HORM RES, V56, P47, DOI 10.1210/rp.56.1.47; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Branstrom R, 2004, DIABETOLOGIA, V47, P277, DOI 10.1007/s00125-003-1299-x; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; COLLINS JE, 1990, ARCH DIS CHILD, V65, P1118, DOI 10.1136/adc.65.10.1118; COLLINS JE, 1984, LANCET, V2, P311; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; Crane A, 2004, J BIOL CHEM, V279, P9080, DOI 10.1074/jbc.M311079200; Cukras CA, 2002, J GEN PHYSIOL, V120, P437, DOI 10.1085/jgp.20028621; Drain P, 1998, P NATL ACAD SCI USA, V95, P13953, DOI 10.1073/pnas.95.23.13953; Dunne MJ, 2004, PHYSIOL REV, V84, P239, DOI 10.1152/physrev.00022.2003; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; Fox JEM, 2004, MOL ENDOCRINOL, V18, P679, DOI 10.1210/me.2003-0431; Glaser B, 2000, SEMIN PERINATOL, V24, P150, DOI 10.1053/sp.2000.6365; Gribble FM, 1998, J BIOL CHEM, V273, P26383, DOI 10.1074/jbc.273.41.26383; Henwood MJ, 2005, J CLIN ENDOCR METAB, V90, P789, DOI 10.1210/jc.2004-1604; Huopio H, 2002, AM J PHYSIOL-ENDOC M, V283, pE207, DOI 10.1152/ajpendo.00047.2002; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; John SA, 2001, J GEN PHYSIOL, V118, P391, DOI 10.1085/jgp.118.4.391; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; Larsson O, 2000, DIABETES, V49, P1409, DOI 10.2337/diabetes.49.9.1409; Lin CW, 2005, DIABETES, V54, P2852, DOI 10.2337/diabetes.54.10.2852; Lin YW, 2003, J GEN PHYSIOL, V122, P225, DOI 10.1085/jgp.200308822; Magge SN, 2004, J CLIN ENDOCR METAB, V89, P4450, DOI 10.1210/jc.2004-0441; Matsuo M, 2000, J BIOL CHEM, V275, P41184, DOI 10.1074/jbc.M006503200; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; Nestorowicz A, 1998, HUM MOL GENET, V7, P1119, DOI 10.1093/hmg/7.7.1119; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Proks P, 2005, EMBO REP, V6, P470, DOI 10.1038/sj.embor.7400393; Proks P, 2001, J GEN PHYSIOL, V118, P341, DOI 10.1085/jgp.118.4.341; Proks P, 2004, P NATL ACAD SCI USA, V101, P17539, DOI 10.1073/pnas.0404756101; Riedel MJ, 2005, DIABETES, V54, P2070, DOI 10.2337/diabetes.54.7.2070; Riedel MJ, 2003, DIABETES, V52, P2630, DOI 10.2337/diabetes.52.10.2630; Riedel MJ, 2005, HUM GENET, V116, P133, DOI 10.1007/s00439-004-1216-5; Schulze D, 2003, J BIOL CHEM, V278, P10500, DOI 10.1074/jbc.M208413200; Schulze D, 2003, J PHYSIOL-LONDON, V552, P357, DOI 10.1113/jphysiol.2003.047035; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; SIGWORTH FJ, 1980, J PHYSIOL-LONDON, V307, P97, DOI 10.1113/jphysiol.1980.sp013426; Stanley CA, 2002, J CLIN ENDOCR METAB, V87, P4857, DOI 10.1210/jc.2002-021403; Tarasov A, 2004, DIABETES, V53, pS113, DOI 10.2337/diabetes.53.suppl_3.S113; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548	54	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					3006	3012		10.1074/jbc.M511875200	http://dx.doi.org/10.1074/jbc.M511875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16332676	Green Accepted, hybrid			2022-12-27	WOS:000234931800071
J	McDowell, LM; Frazier, BA; Studelska, DR; Giljum, K; Chen, JH; Liu, J; Yu, K; Ornitz, DM; Zhang, LJ				McDowell, LM; Frazier, BA; Studelska, DR; Giljum, K; Chen, JH; Liu, J; Yu, K; Ornitz, DM; Zhang, LJ			Inhibition or activation of Apert syndrome FGFR2 (S252W) signaling by specific glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; LIGAND-BINDING SPECIFICITY; DERMATAN SULFATE; CHONDROITIN SULFATE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; RECEPTOR KINASE; MICE DEFICIENT; CELL-SURFACE	Most Apert syndrome patients harbor a single amino acid mutation (S252W) in fibroblast growth factor (FGF) receptor 2 (FGFR2), which leads to abnormal FGF/FGFR2 signaling. Here we show that specific combinations of FGFs and glycosaminoglycans activate both alternative splice forms of the mutant but not of the wild-type FGF receptors. More importantly, 2-O- and N-sulfated heparan sulfate, prepared by a combined chemical and enzymatic synthesis, antagonized the over-activated FGFR2b ( S252W) to basal levels at nanomolar concentrations. These studies demonstrated that specific glycosaminoglycans could be useful in treating ligand-dependent FGFR signaling-related diseases, such as Apert syndrome and cancer.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of North Carolina; University of North Carolina Chapel Hill	Zhang, LJ (corresponding author), Washington Univ, Sch Med, Dept Pathol, Campus Box 8118, St Louis, MO 63110 USA.	ljzhang@wustl.edu		Ornitz, David/0000-0003-1592-7629	NIAID NIH HHS [R01 AI 50050] Funding Source: Medline; NICHD NIH HHS [R01 HD 39952] Funding Source: Medline; NIGMS NIH HHS [R01 GM 69968] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069968] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Bergefall K, 2005, J BIOL CHEM, V280, P32193, DOI 10.1074/jbc.M503645200; Chen JH, 2005, J BIOL CHEM, V280, P42817, DOI 10.1074/jbc.M504338200; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; Garcia-Garcia MJ, 2003, CELL, V114, P727, DOI 10.1016/S0092-8674(03)00715-3; Grobe K, 2005, DEVELOPMENT, V132, P3777, DOI 10.1242/dev.01935; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Ibrahimi OA, 2005, PLAST RECONSTR SURG, V115, P264, DOI 10.1097/01.PRS.0000146703.08958.95; Ibrahimi OA, 2004, HUM MOL GENET, V13, P2313, DOI 10.1093/hmg/ddh235; Ibrahimi OA, 2004, BIOCHEMISTRY-US, V43, P4724, DOI 10.1021/bi0352320; Ibrahimi OA, 2001, P NATL ACAD SCI USA, V98, P7182, DOI 10.1073/pnas.121183798; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kariya Y, 2000, J BIOL CHEM, V275, P25949, DOI 10.1074/jbc.M004140200; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lundin L, 2000, J BIOL CHEM, V275, P24653, DOI 10.1074/jbc.M908930199; Mohammadi M, 2005, CURR OPIN STRUC BIOL, V15, P506, DOI 10.1016/j.sbi.2005.09.002; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Oldridge M, 1999, AM J HUM GENET, V64, P446, DOI 10.1086/302245; OLSON ST, 1994, SEMIN THROMB HEMOST, V20, P373, DOI 10.1055/s-2007-1001928; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Ostrovsky O, 2002, J BIOL CHEM, V277, P2444, DOI 10.1074/jbc.M108540200; PARK WJ, 1995, AM J HUM GENET, V57, P321; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Robinson CJ, 2005, J BIOL CHEM, V280, P42274, DOI 10.1074/jbc.M505720200; Rusnati M, 2002, P NATL ACAD SCI USA, V99, P4367, DOI 10.1073/pnas.072651899; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Shworak N W, 2001, Methods Mol Biol, V171, P79; Slaney SF, 1996, AM J HUM GENET, V58, P923; Stickens D, 2005, DEVELOPMENT, V132, P5055, DOI 10.1242/dev.02088; Studelska DR, 2006, GLYCOBIOLOGY, V16, P65, DOI 10.1093/glycob/cwj037; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Taylor KR, 2005, J BIOL CHEM, V280, P5300, DOI 10.1074/jbc.m410412200; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; von Gernet S, 2000, CLIN GENET, V57, P137, DOI 10.1034/j.1399-0004.2000.570208.x; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101; Wang YL, 2005, DEVELOPMENT, V132, P3537, DOI 10.1242/dev.01914; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; Wu ZLL, 2003, J BIOL CHEM, V278, P17121, DOI 10.1074/jbc.M212590200; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yeh BK, 2002, MOL CELL BIOL, V22, P7184, DOI 10.1128/MCB.22.20.7184-7192.2002; Yu K, 2001, P NATL ACAD SCI USA, V98, P3641, DOI 10.1073/pnas.081082498; Yu K, 2000, P NATL ACAD SCI USA, V97, P14536, DOI 10.1073/pnas.97.26.14536	60	40	43	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6924	6930		10.1074/jbc.M512932200	http://dx.doi.org/10.1074/jbc.M512932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16373332	hybrid			2022-12-27	WOS:000236030900004
J	Fuh, G; Wu, P; Liang, WC; Ultsch, M; Lee, CV; Moffat, B; Wiesmann, C				Fuh, G; Wu, P; Liang, WC; Ultsch, M; Lee, CV; Moffat, B; Wiesmann, C			Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the AVASTIN (TM) Fab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN RECEPTOR; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; TYROSINE KINASE; BINDING; VEGF; ANGIOGENESIS; ANTIBODY; COMPLEX; TUMOR	In the quest to discover new research tools and to develop better agents in the fight against cancer, two antibodies, G6 and B20 - 4, were isolated from synthetic antibody phage libraries. Unlike the AVASTIN(TM) antibody, a recently approved agent for the treatment of patients with colorectal cancer, B20 - 4 and G6 bind and block both human and murine vascular endothelial growth factor ( VEGF). Here we have analyzed and compared the binding epitopes on VEGF for these three antibodies using alanine-scanning mutagenesis and structural analyses. The epitopes recognized by both synthetic antibodies are conserved between human and mouse VEGF, and they match closely to the receptor epitopes both structurally and functionally. In contrast, the Avastin epitope overlaps minimally with the receptor binding surface and centers around a residue that is not conserved in mouse. Our structural and functional analyses elucidate the cross-species reactivity of all three antibodies and emphasize the potential advantages of antibody generation using phage display as the resulting antibodies do not depend on sequence differences across species and preferentially target natural protein-protein interaction surfaces.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Fuh, G (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	gml@gene.com; chw@gene.com		Wiesmann, Christian/0000-0002-4092-9880				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Caffrey DR, 2004, PROTEIN SCI, V13, P190, DOI 10.1110/ps.03323604; Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192; Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO;2-E; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; EIGENBROT C, 1993, J MOL BIOL, V229, P969, DOI 10.1006/jmbi.1993.1099; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Gerber HP, 2000, CANCER RES, V60, P6253; GRISHIN NV, 1994, PROTEIN SCI, V3, P2455, DOI 10.1002/pro.5560031231; Halperin I, 2004, STRUCTURE, V12, P1027, DOI 10.1016/j.str.2004.04.009; Hurwitz Herbert, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS62, DOI 10.3816/CCC.2004.s.010; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; Johnson G, 2000, NUCLEIC ACIDS RES, V28, P214, DOI 10.1093/nar/28.1.214; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joukov V, 1996, EMBO J, V15, P290; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KONNER J, 2004, CLIN COLORECTAL C S2, V4, pS281; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee CV, 2004, J MOL BIOL, V340, P1073, DOI 10.1016/j.jmb.2004.05.051; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Marx J, 2003, SCIENCE, V301, P452, DOI 10.1126/science.301.5632.452; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAJUSOLA K, 1992, CANCER RES, V52, P5738; Pan B, 2002, J MOL BIOL, V316, P769, DOI 10.1006/jmbi.2001.5370; Prewett M, 1999, CANCER RES, V59, P5209; SHIBUYA M, 1990, ONCOGENE, V5, P519; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Valdar WSJ, 2001, J MOL BIOL, V313, P399, DOI 10.1006/jmbi.2001.5034; Wiesmann C, 1998, BIOCHEMISTRY-US, V37, P17765, DOI 10.1021/bi9819327; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0	44	146	185	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6625	6631		10.1074/jbc.M507783200	http://dx.doi.org/10.1074/jbc.M507783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16373345	hybrid			2022-12-27	WOS:000236030800059
J	Li, SJ; Hong, XG; Shi, YY; Li, H; Wang, CC				Li, SJ; Hong, XG; Shi, YY; Li, H; Wang, CC			Annular arrangement and collaborative actions of four domains of protein-disulfide isomerase - A small angle X-ray scattering study in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; ALPHA-SYNUCLEIN; PROLYL 4-HYDROXYLASE; ESCHERICHIA-COLI; FOLDING CATALYST; FUNCTIONAL-PROPERTIES; CHAPERONE ACTIVITIES; SHAPE DETERMINATION; TERMINAL DOMAIN; BINDING SITE	We presented for the first time a small angle x-ray scattering study of intact protein-disulfide isomerase (PDI) in solution. The restored model revealed that PDI is a short and roughly elliptical cylinder with a molecular mass of 69 kDa and dimensions of 105 x 65 x 40 angstrom, and the four thioredoxin-fold domains in the order a-b-b'-a' are arranged in an annular fashion. Atomic force microscope imaging also supported the finding that PDI appears as an approximately flat elliptical cylinder. A PDI species with apparent molecular mass of 116 kDa measured by using size-exclusion chromatography, previously assumed to be a dimer, was determined to exist mainly as a monomer by using analytical ultracentrifugation. The C-terminal fragment 441 - 491 contributed to the anomalous molecular mass determination of PDI by size-exclusion chromatography. The annular model of PDI accounted for the cooperative properties of the four domains in both the isomerase and chaperone functions of PDI.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Biophys, Ctr Syst Biol, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst High Energy Phys, Beijing 100039, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100049, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of High Energy Physics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Wang, CC (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	chihwang@sun5.ibp.ac.cn	li, shengjian/B-4866-2013	Hong, Xinguo/0000-0001-8994-219X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1994, J BIOL CHEM, V269, P24550; Chacon P, 1998, BIOPHYS J, V74, P2760, DOI 10.1016/S0006-3495(98)77984-6; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Choi JY, 2002, BIOTECHNOL APPL BIOC, V36, P33, DOI 10.1042/BA20020004; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Darby NJ, 1996, BIOCHEMISTRY-US, V35, P10517, DOI 10.1021/bi960763s; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fleming KG, 1998, J BIOL CHEM, V273, P15675, DOI 10.1074/jbc.273.25.15675; Fournet G., 1955, SMALL ANGLE SCATTERI, V24; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; Huang CJ, 2005, PROTEIN EXPRES PURIF, V42, P173, DOI 10.1016/j.pep.2005.02.014; Izumi Y, 2001, FEBS LETT, V495, P126, DOI 10.1016/S0014-5793(01)02375-4; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KELLER D, 1991, SURF SCI, V253, P353, DOI 10.1016/0039-6028(91)90606-S; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1999, J BIOMOL NMR, V13, P357, DOI 10.1023/A:1008341820489; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Koivunen P, 2005, J BIOL CHEM, V280, P5227, DOI 10.1074/jbc.M412480200; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702; Martin SL, 2003, P NATL ACAD SCI USA, V100, P13815, DOI 10.1073/pnas.2336221100; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; Nielsen MS, 2001, J BIOL CHEM, V276, P22680, DOI 10.1074/jbc.M101181200; Noiva R, 1999, SEMIN CELL DEV BIOL, V10, P481, DOI 10.1006/scdb.1999.0319; OHBA H, 1981, J BIOCHEM, V89, P889, DOI 10.1093/oxfordjournals.jbchem.a133272; Pan XM, 2001, PROTEINS, V43, P256, DOI 10.1002/prot.1036; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pirneskoski A, 2001, J BIOL CHEM, V276, P11287, DOI 10.1074/jbc.M010656200; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; PUIG A, 1994, J BIOL CHEM, V269, P7764; Puig A, 1997, J BIOL CHEM, V272, P32988, DOI 10.1074/jbc.272.52.32988; Sanchez-Puig N, 2005, PROTEIN SCI, V14, P1410, DOI 10.1110/ps.051368005; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Solovyov A, 2004, PROTEIN SCI, V13, P1902, DOI 10.1110/ps.04716104; Sun XX, 2000, BBA-PROTEIN STRUCT M, V1481, P45, DOI 10.1016/S0167-4838(00)00122-9; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; TOJO H, 1994, J BIOTECHNOL, V33, P55, DOI 10.1016/0168-1656(94)90098-1; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651	54	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6581	6588		10.1074/jbc.M508422200	http://dx.doi.org/10.1074/jbc.M508422200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407203	hybrid			2022-12-27	WOS:000236030800054
J	Matsubara, T; Shirai, Y; Miyasaka, K; Murakami, T; Yamaguchi, Y; Ueyama, T; Kai, M; Sakane, F; Kanoh, H; Hashimoto, T; Kamada, S; Kikkawa, U; Saito, N				Matsubara, T; Shirai, Y; Miyasaka, K; Murakami, T; Yamaguchi, Y; Ueyama, T; Kai, M; Sakane, F; Kanoh, H; Hashimoto, T; Kamada, S; Kikkawa, U; Saito, N			Nuclear transportation of diacylglycerol kinase gamma and its possible function in the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; CYSTEINE-RICH DOMAINS; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 5-KINASE; PLECKSTRIN HOMOLOGY DOMAIN; MOLECULAR-CLONING; PHOSPHATIDIC-ACID; CELL-CYCLE; HUMAN-PLATELETS; I-ALPHA; ACTIVATION	Diacylglycerol kinases (DGKs) convert diacylglycerol (DG) to phosphatidic acid, and both lipids are known to play important roles in lipid signal transduction. Thereby, DGKs are considered to be a one of the key players in lipid signaling, but its physiological function remains to be solved. In an effort to investigate one of nine subtypes, we found that DGK gamma came to be localized in the nucleus with time in all cell lines tested while seen only in the cytoplasm at the early stage of culture, indicating that DGK gamma is transported from the cytoplasm to the nucleus. The nuclear transportation of DGK gamma didn't necessarily need DGK activity, but its C1 domain was indispensable, suggesting that the C1 domain of DGK gamma acts as a nuclear transport signal. Furthermore, to address the function of DGK gamma in the nucleus, we produced stable cell lines of wild-type DGK gamma and mutants, including kinase negative, and investigated their cell size, growth rate, and cell cycle. The cells expressing the kinase-negative mutant of DGK gamma were larger in size and showed slower growth rate, and the S phase of the cells was extended. These findings implicate that nuclear DGK gamma regulates cell cycle.	Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Biosignal Res Ctr, Biochem Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Sapporo Med Univ, Sch Med, Dept Biochem, Chuo Ku, Sapporo, Hokkaido 0608556, Japan	Sapporo Medical University	Shirai, Y (corresponding author), Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Rokkodai Cho 1-1, Kobe, Hyogo 6578501, Japan.	shirai@kobe-u.ac.jp; naosaito@kobe-u.ac.jp	Shirai, Yasuhito/O-3255-2018; Kanoh, Hiroko/GOG-8672-2022; Kanoh, Hiroko/GWU-7640-2022; Sakane, Fumio/H-2693-2017	Kanoh, Hiroko/0000-0002-8765-1249; Sakane, Fumio/0000-0003-0857-0377				BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; Batista EL, 2005, J CELL BIOCHEM, V94, P774, DOI 10.1002/jcb.20356; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; Bregoli L, 2002, ADV ENZYME REGUL, V42, P213, DOI 10.1016/S0065-2571(01)00032-2; Bregoli L, 2001, J BIOL CHEM, V276, P23288, DOI 10.1074/jbc.M101501200; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; Deacon EM, 2002, J CELL SCI, V115, P983; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; Divecha N, 1997, SEMIN CELL DEV BIOL, V8, P323, DOI 10.1006/scdb.1997.0154; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Flores I, 1999, J IMMUNOL, V163, P708; Gorlich D, 1995, COLD SPRING HARB SYM, V60, P695, DOI 10.1101/SQB.1995.060.01.075; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; Goto K, 1999, CHEM PHYS LIPIDS, V98, P109, DOI 10.1016/S0009-3084(99)00023-7; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Houssa B, 1997, J BIOL CHEM, V272, P10422; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Jiang Y, 2000, J BIOL CHEM, V275, P34092, DOI 10.1074/jbc.M004914200; Jones DR, 2000, FEBS LETT, V476, P160, DOI 10.1016/S0014-5793(00)01702-6; KAI M, 1994, J BIOL CHEM, V269, P18492; Kanoh H, 2002, J BIOCHEM, V131, P629, DOI 10.1093/oxfordjournals.jbchem.a003144; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Klauck TM, 1996, J BIOL CHEM, V271, P19781, DOI 10.1074/jbc.271.33.19781; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Luo B, 2004, CELL SIGNAL, V16, P891, DOI 10.1016/j.cellsig.2004.01.010; Moriyama T, 1999, J BIOCHEM, V125, P1077, DOI 10.1093/oxfordjournals.jbchem.a022389; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; POWERS MA, 1994, CELL, V79, P931, DOI 10.1016/0092-8674(94)90024-8; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Shindo M, 2003, J BIOL CHEM, V278, P18448, DOI 10.1074/jbc.M300400200; Shindo M, 2001, BIOORGAN MED CHEM, V9, P2073, DOI 10.1016/S0968-0896(01)00100-6; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; Tsushima S, 2004, J BIOL CHEM, V279, P28603, DOI 10.1074/jbc.M314031200; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; Yamada K, 2003, BIOCHEM BIOPH RES CO, V305, P101, DOI 10.1016/S0006-291X(03)00713-7; YORK JD, 1994, J BIOL CHEM, V269, P7847	45	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6152	6164		10.1074/jbc.M509873200	http://dx.doi.org/10.1074/jbc.M509873200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407189	hybrid			2022-12-27	WOS:000236030800007
J	Zhang, W; Anger, T; Su, JL; Hao, JM; Xu, XM; Zhu, M; Gach, A; Cui, L; Liao, RL; Mende, U				Zhang, W; Anger, T; Su, JL; Hao, JM; Xu, XM; Zhu, M; Gach, A; Cui, L; Liao, RL; Mende, U			Selective loss of fine tuning of G(q/11) signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT CARDIAC EXPRESSION; GTPASE-ACTIVATING PROTEINS; PRESSURE-OVERLOAD; HEART-FAILURE; 3RD-INTRACELLULAR LOOP; VENTRICULAR MYOCYTES; BLOOD-PRESSURE; REGULATOR; RNA; TRANSLOCATION	Alterations in cardiac G protein- mediated signaling, most prominently G(q/ 11) signaling, are centrally involved in hypertrophy and heart failure development. Several RGS proteins that can act as negative regulators of G protein signaling are expressed in the heart, but their functional roles are still poorly understood. RGS expression changes have been described in hypertrophic and failing hearts. In this study, we report a marked decrease in RGS2 ( but not other major cardiac RGS proteins ( RGS3 - RGS5)) that occurs prior to hypertrophy development in different models with enhanced G(q/11) signaling ( transgenic expression of activated G alpha(q)* and pressure overload due to aortic constriction). To assess functional consequences of selective down- regulation of endogenous RGS2, we identified targeting sequences for effective RGS2 RNA interference and used lipid- based transfection to achieve uptake of fluorescently labeled RGS2 small interfering RNA in > 90% of neonatal and adult ventricular myocytes. Endogenous RGS2 expression was dose- dependently suppressed ( up to 90%) with no major change in RGS3 RGS5. RGS2 knockdown increased phenylephrine- and endothelin-1- induced phospholipase C beta stimulation in both cell types and exacerbated the hypertrophic effect ( increase in cell size and radiolabeled protein) in neonatal myocytes, with no major change in G(q/11)- mediated ERK1/ 2, p38, or JNK activation. Taken together, this study demonstrates that endogenous RGS2 exerts functionally important inhibitory restraint on G(q/ 11)- mediated phospholipase C beta activation and hypertrophy in ventricular myocytes. Our findings point toward a potential pathophysiological role of loss of fine tuning due to selective RGS2 down- regulation in G(q/ 11)- mediated remodeling. Furthermore, this study shows the feasibility of effective RNA interference in cardiomyocytes using lipid- based small interfering RNA transfection.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Mende, U (corresponding author), Rhode Isl Hosp, SW Pavil 2nd Floor,593 Eddy St, Providence, RI 02903 USA.	UMende@Lifespan.org		Gach, Agnieszka/0000-0002-6590-5797; Anger, Thomas/0000-0001-9071-6405; Liao, Ronglih/0000-0002-9598-9020	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072174, P50HL052320, R01HL080127] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 52320, HL 72174, R01 HL072174, R01 HL080127] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Anger T, 2004, J BIOL CHEM, V279, P3906, DOI 10.1074/jbc.M309496200; Bernstein LS, 2004, J BIOL CHEM, V279, P21248, DOI 10.1074/jbc.M312407200; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Deng XF, 2000, CIRC RES, V87, P781, DOI 10.1161/01.RES.87.9.781; Dorn GW, 2004, ANN NY ACAD SCI, V1015, P225, DOI 10.1196/annals.1302.019; Doupnik CA, 2001, BBA-GENE STRUCT EXPR, V1522, P97, DOI 10.1016/S0167-4781(01)00342-6; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; ELLINGSEN O, 1993, AM J PHYSIOL, V265, pH747, DOI 10.1152/ajpheart.1993.265.2.H747; Frey N, 2003, ANNU REV PHYSIOL, V65, P45, DOI 10.1146/annurev.physiol.65.092101.142243; Frey N, 2004, CIRCULATION, V109, P1580, DOI 10.1161/01.CIR.0000120390.68287.BB; Gross V, 2005, AM J PHYSIOL-REG I, V288, pR1134, DOI 10.1152/ajpregu.00246.2004; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Hao JM, 2005, CIRCULATION, V111, P1724; Hardt SE, 2004, CARDIOVASC RES, V63, P500, DOI 10.1016/j.cardiores.2004.03.015; Hepler JR, 2003, MOL PHARMACOL, V64, P547, DOI 10.1124/mol.64.3.547; Heximer SP, 2003, J CLIN INVEST, V111, P445, DOI 10.1172/JC1200315598; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jalili T, 1999, AM J PHYSIOL-HEART C, V277, pH2298, DOI 10.1152/ajpheart.1999.277.6.H2298; Jin Y, 2004, J PEPT RES, V63, P141, DOI 10.1111/j.1399-3011.2003.00114.x; Kardestuncer T, 1998, FEBS LETT, V438, P285, DOI 10.1016/S0014-5793(98)01319-2; Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001; Liao RL, 2002, CIRCULATION, V106, P2125, DOI 10.1161/01.CIR.0000034049.61181.F3; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Mende U, 1999, CIRC RES, V85, P1085; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; MENDE U, 2000, MOL CELL CARDIOL, V33, P1477; Mittmann C, 2002, CARDIOVASC RES, V55, P778, DOI 10.1016/S0008-6363(02)00459-5; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Owen VJ, 2001, EUR HEART J, V22, P1015, DOI 10.1053/euhj.2000.2578; Pasumarthi KBS, 1996, CIRC RES, V78, P126, DOI 10.1161/01.RES.78.1.126; Pedram A, 2005, J BIOL CHEM, V280, P26339, DOI 10.1074/jbc.M414409200; Peterson DJ, 1999, CARDIOVASC RES, V41, P575, DOI 10.1016/S0008-6363(98)00264-8; Petrich BG, 2004, TRENDS CARDIOVAS MED, V14, P50, DOI 10.1016/j.tcm.2003.11.002; Riddle EL, 2005, CIRC RES, V96, P401, DOI 10.1161/01.RES.0000158287.49872.4e; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Seth M, 2004, P NATL ACAD SCI USA, V101, P16683, DOI 10.1073/pnas.0407537101; SIMPSON P, 1982, CIRC RES, V51, P787, DOI 10.1161/01.RES.51.6.787; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Sun XG, 2005, MOL PHARMACOL, V67, P631, DOI 10.1124/mol.104.007724; Tamirisa P, 1999, CIRCULATION, V99, P441, DOI 10.1161/01.CIR.99.3.441; Tang M, 2003, NAT MED, V9, P1506, DOI 10.1038/nm958; VOLZ A, 1991, J MOL CELL CARDIOL, V23, P161, DOI 10.1016/0022-2828(91)90103-S; Wang Q, 2004, METHOD ENZYMOL, V389, P244; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; Wang XH, 2004, J BIOL CHEM, V279, P133, DOI 10.1074/jbc.M310040200; Watanabe A, 2004, J MOL CELL CARDIOL, V37, P691, DOI 10.1016/j.yjmcc.2004.06.009; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Yue YZ, 2004, J BIOL CHEM, V279, P12883, DOI 10.1074/jbc.M312308200; Zhang SA, 1998, J MOL CELL CARDIOL, V30, P269, DOI 10.1006/jmcc.1997.0591	54	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5811	5820		10.1074/jbc.M507871200	http://dx.doi.org/10.1074/jbc.M507871200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16380388	hybrid			2022-12-27	WOS:000235568900060
J	Ai, XB; Do, AT; Kusche-Gullberg, M; Lindahl, U; Lu, K; Emerson, CP				Ai, XB; Do, AT; Kusche-Gullberg, M; Lindahl, U; Lu, K; Emerson, CP			Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BINDING; IDENTIFICATION; PROTEOGLYCAN; DIVERSITY; CANCER	The extracellular sulfatases (Sulfs) are an evolutionally conserved family of heparan sulfate (HS)-specific 6-O-endosulfatases. These enzymes remodel the 6-O-sulfation of cell surface HS chains to promote Wnt signaling and inhibit growth factor signaling for embryonic tissue patterning and control of tumor growth. In this study we demonstrate that the avian HS endosulfatases, QSulf1 and QSulf2, exhibit the same substrate specificity toward a subset of trisulfated disaccharides internal to HS chains. Further, we show that both QSulfs associate exclusively with cell membrane and are enzymatically active on the cell surface to desulfate both cell surface and cell matrix HS. Mutagenesis studies reveal that conserved amino acid regions in the hydrophilic domains of QSulf1 and QSulf2 have multiple functions, to anchor Sulf to the cell surface, bind to HS substrates, and to mediate HS 6-O-endosulfatase enzymatic activity. Results of our current studies establish the hydrophilic domain (HD) of Sulf enzymes as an essential multifunctional domain for their unique endosulfatase activities and also demonstrate the extracellular activity of Sulfs for desulfation of cell surface and cell matrix HS in the control of extracellular signaling for embryonic development and tumor progression.	Boston Biomed Res Inst, Watertown, MA 02472 USA; Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ Bergen, Div Physiol, Dept Biomed, N-5009 Bergen, Norway	Boston Biomedical Research Institute; Uppsala University; University of Bergen	Emerson, CP (corresponding author), Boston Biomed Res Inst, Watertown, MA 02472 USA.	emersonc@bbri.org	Kusche-Gullberg, Marion/P-4466-2016	Kusche-Gullberg, Marion/0000-0002-5636-1695; Ai, Xingbin/0000-0002-2178-0080	NINDS NIH HHS [F32 NS043891] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS043891] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ai XB, 2003, J CELL BIOL, V162, P341, DOI 10.1083/jcb.200212083; Braquart-Varnier C, 2004, MOL CELL NEUROSCI, V25, P612, DOI 10.1016/j.mcn.2003.11.013; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Goerges AL, 2003, J BIOL CHEM, V278, P19518, DOI 10.1074/jbc.M211208200; KRESSE H, 1980, P NATL ACAD SCI-BIOL, V77, P6822, DOI 10.1073/pnas.77.11.6822; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; Merry CLR, 1999, J BIOL CHEM, V274, P18455, DOI 10.1074/jbc.274.26.18455; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nybakken K, 2002, BBA-GEN SUBJECTS, V1573, P280, DOI 10.1016/S0304-4165(02)00395-1; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; Rapraeger AC, 2002, METHOD CELL BIOL, V69, P83, DOI 10.1016/S0091-679X(02)69009-0; Rong JH, 2001, BIOCHEMISTRY-US, V40, P5548, DOI 10.1021/bi002926p; Safaiyan F, 2000, BIOCHEMISTRY-US, V39, P10823, DOI 10.1021/bi000411s; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Viviano BL, 2004, J BIOL CHEM, V279, P5604, DOI 10.1074/jbc.M310691200; Wang SW, 2004, P NATL ACAD SCI USA, V101, P4833, DOI 10.1073/pnas.0401028101	23	122	124	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4969	4976		10.1074/jbc.M511902200	http://dx.doi.org/10.1074/jbc.M511902200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377625	hybrid			2022-12-27	WOS:000235426200048
J	Raynal, N; Hamaia, SW; Siljander, PRM; Maddox, B; Peachey, AR; Fernandez, R; Foley, LJ; Slatter, DA; Jarvis, GE; Farndale, RW				Raynal, N; Hamaia, SW; Siljander, PRM; Maddox, B; Peachey, AR; Fernandez, R; Foley, LJ; Slatter, DA; Jarvis, GE; Farndale, RW			Use of synthetic peptides to locate novel integrin alpha(2)beta(1)-binding motifs in human collagen III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELICAL PEPTIDES; ALPHA-2 VWFA DOMAIN; PLATELET-ADHESION; GLYCOPROTEIN-VI; BINDING-SITE; I-DOMAIN; IDENTIFICATION; SEQUENCE; RECOGNITION; ACTIVATION	A set of 57 synthetic peptides encompassing the entire triple-helical domain of human collagen III was used to locate binding sites for the collagen-binding integrin alpha(2)beta(1). The capacity of the peptides to support Mg2+-dependent binding of several integrin preparations was examined. Wild-type integrins (recombinant alpha(2) I-domain, alpha(2)beta(1) purified from platelet membranes, and recombinant soluble alpha(2)beta(1) expressed as an alpha(2)-Fos/beta(1)-Jun heterodimer) bound well to only three peptides, two containing GXX'GER motifs (GROGER and GMOGER, where O is hydroxyproline) and one containing two adjacent GXX'GEN motifs (GLKGEN and GLOGEN). Two mutant alpha(2) I-domains were tested: the inactive T221A mutant, which recognized no peptides, and the constitutively active E318W mutant, which bound a larger subset of peptides. Adhesion of activated human platelets to GER-containing peptides was greater than that of resting platelets, and HT1080 cells bound well to more of the peptides compared with platelets. Binding of cells and recombinant proteins was abolished by anti-alpha(2) monoclonal antibody 6F1 and by chelation of Mg2+. We describe two novel high affinity integrin-binding motifs in human collagen III (GROGER and GLOGEN) and a third motif (GLKGEN) that displays intermediate activity. Each motif was verified using shorter synthetic peptides.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Farndale, RW (corresponding author), Univ Cambridge, Dept Biochem, Bldg O,Dowling Site, Cambridge CB2 1QW, England.	rwf10@cam.ac.uk	Slatter, David/AAW-6938-2021; Jarvis, Gavin/A-1903-2013; Slatter, David/AAV-5771-2020	Siljander, Pia/0000-0003-2326-5821; Jarvis, Gavin/0000-0003-4362-1133	Medical Research Council [G0400701, G0601378] Funding Source: Medline; MRC [G0400701] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Aquilina A, 2002, EUR J BIOCHEM, V269, P1136, DOI 10.1046/j.0014-2956.2001.02740.x; Bella J, 2000, STRUCTURE, V8, pR121, DOI 10.1016/S0969-2126(00)00153-2; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; COLLER BS, 1989, BLOOD, V74, P182; Eble JA, 1998, BIOCHEMISTRY-US, V37, P10945, DOI 10.1021/bi980175+; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Farndale RW, 2004, J THROMB HAEMOST, V2, P561, DOI 10.1111/j.1538-7836.2004.00665.x; Glattauer V, 1997, BIOCHEM J, V323, P45, DOI 10.1042/bj3230045; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Jin M, 2004, STRUCTURE, V12, P2137, DOI 10.1016/j.str.2004.10.005; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Kapyla J, 2004, J BIOL CHEM, V279, P51677, DOI 10.1074/jbc.M409412200; Kim JK, 2005, J BIOL CHEM, V280, P32512, DOI 10.1074/jbc.M502431200; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; Ramshaw JAM, 1998, J STRUCT BIOL, V122, P86, DOI 10.1006/jsbi.1998.3977; SAELMAN EUM, 1994, BLOOD, V83, P1244; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; Siljander PRM, 2004, J BIOL CHEM, V279, P47763, DOI 10.1074/jbc.M404685200; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; SILJANDER PRM, 2002, PLATELETS THROMBOTIC, P158; Smethurst PA, 2004, BLOOD, V103, P903, DOI 10.1182/blood-2003-01-0308; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell DS, 2000, BIOCHEM J, V350, P485, DOI 10.1042/0264-6021:3500485; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	33	142	150	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3821	3831		10.1074/jbc.M509818200	http://dx.doi.org/10.1074/jbc.M509818200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16326707	hybrid			2022-12-27	WOS:000235275300010
J	Li, LW; Sampat, K; Hu, N; Zakari, J; Yuspa, SH				Li, LW; Sampat, K; Hu, N; Zakari, J; Yuspa, SH			Protein kinase C negatively regulates Akt activity and modifies UVC-induced apoptosis in mouse keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; INDUCED ACTIVATION; PHOSPHATASE 2A; HUMAN SKIN; B AKT; PHOSPHORYLATION; DIFFERENTIATION; INHIBITION; DELTA; EXPRESSION	Skin keratinocytes are subject to frequent chemical and physical injury and have developed elaborate cell survival mechanisms to compensate. Among these, the Akt/protein kinase B (PKB) pathway protects keratinocytes from the toxic effects of ultraviolet light (UV). In contrast, the protein kinase C (PKC) family is involved in several keratinocyte death pathways. During an examination of potential interactions among these two pathways, we found that the insulin-like growth factor (IGF-1) activates both the PKC and the Akt signaling pathways in cultured primary mouse keratinocytes as indicated by increased phospho-PKC and phospho-Ser-473-Akt. IGF-1 also selectively induced translocation of PKC delta and PKC delta from soluble to particulate fractions in mouse keratinocytes. Furthermore, the PKC-specific inhibitor, GF109203X, increased IGF-1-induced phospho-Ser-473-Akt and Akt kinase activity and enhanced IGF-1 protection from UVC-induced apoptosis. Selective activation of PKC by 12-O-tetradecanoylphorbol-13-acetate (TPA) reduced phospho-Ser-473-Akt, suggesting that activation of PKC inhibits Akt activity. TPA also attenuated IGF-1 and epidermal growth factor-induced phospho-Ser-473-Akt, reduced Akt kinase activity, and blocked IGF-1 protection from UVC-induced apoptosis. The inhibition of Akt activity by TPA was reduced by inhibitors of protein phosphatase 2A, and TPA stimulated the association of phosphatase 2A with Akt. Individual PKC isoforms were overexpressed in cultured keratinocytes by transduction with adenoviral vectors or inhibited with PKC-selective inhibitors. These studies indicated that PKC alpha and PKC epsilon were selectively potent at causing dephosphorylation of Akt and modifying cell survival, whereas PKC alpha enhanced phosphorylation of Akt on Ser-473. Our results suggested that activation of PKC delta and PKC epsilon provide a negative regulation for Akt phosphorylation and kinase activity in mouse keratinocytes and serve as modulators of cell survival pathways in response to external stimuli.	NCI, Lab Cellular Carcinogenesis & Tumor Promot, Canc Res Ctr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, LW (corresponding author), NCI, Lab Cellular Carcinogenesis & Tumor Promot, Canc Res Ctr, NIH, Bldg 37,Rm 4600,37 Convent Dr, Bethesda, MD 20892 USA.	lilu@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC004504, Z01BC004504] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; BLUMBERG PM, 1980, CRC CR REV TOXICOL, V8, P153, DOI 10.3109/10408448009037493; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Cooper SJ, 2003, MOL CANCER RES, V1, P848; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; DiGiovanni J, 2000, CANCER RES, V60, P1561; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; Doornbos RP, 1999, J BIOL CHEM, V274, P8589, DOI 10.1074/jbc.274.13.8589; FARESE RV, 1989, BIOCHEM J, V261, P927, DOI 10.1042/bj2610927; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gliki G, 2002, CELL BIOL INT, V26, P751, DOI 10.1016/S1065-6995(02)90926-1; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1998, FEBS LETT, V421, P165, DOI 10.1016/S0014-5793(97)01530-5; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 2001, J BIOL CHEM, V276, P40234, DOI 10.1074/jbc.M103684200; Itoh N, 2002, CANCER, V94, P3127, DOI 10.1002/cncr.10591; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jansen AP, 2001, INT J CANCER, V93, P635, DOI 10.1002/ijc.1395; Kampfer S, 1998, ADV ENZYME REGUL, V38, P35, DOI 10.1016/S0065-2571(97)00005-8; KOIZUMI H, 1993, J INVEST DERMATOL, V101, P858, DOI 10.1111/1523-1747.ep12371707; KOJIMA I, 1993, J BIOL CHEM, V268, P10003; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Letiges M, 2002, MOL ENDOCRINOL, V16, P847, DOI 10.1210/me.16.4.847; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; Matsumoto M, 2001, J BIOL CHEM, V276, P14400, DOI 10.1074/jbc.M011093200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Miyata Y, 2004, MOL CANCER THER, V3, P839; NERI LM, 1994, FEBS LETT, V347, P63, DOI 10.1016/0014-5793(94)00508-7; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; STRICKLAND JE, 1988, CANCER RES, V48, P165; Suzuki A, 2003, CANCER RES, V63, P674; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; TRANQUE PA, 1992, ENDOCRINOLOGY, V131, P1948, DOI 10.1210/en.131.4.1948; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wen HC, 2003, CELL SIGNAL, V15, P37, DOI 10.1016/S0898-6568(02)00047-5; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; Xu WP, 2003, CANCER RES, V63, P7777; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zheng WH, 2000, J BIOL CHEM, V275, P13377, DOI 10.1074/jbc.275.18.13377; Zheng WH, 2002, MOL PHARMACOL, V62, P225, DOI 10.1124/mol.62.2.225; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	68	88	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3237	3243		10.1074/jbc.M512167200	http://dx.doi.org/10.1074/jbc.M512167200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338928	hybrid			2022-12-27	WOS:000235128200028
J	Lu, S; Yao, Y; Cheng, XY; Mitchell, S; Leng, SY; Meng, SM; Gallagher, JW; Shelness, GS; Morris, GS; Mahan, J; Frase, S; Mansbach, CM; Weinberg, RB; Black, DD				Lu, S; Yao, Y; Cheng, XY; Mitchell, S; Leng, SY; Meng, SM; Gallagher, JW; Shelness, GS; Morris, GS; Mahan, J; Frase, S; Mansbach, CM; Weinberg, RB; Black, DD			Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL EPITHELIAL-CELLS; NEWBORN SWINE; INTERFACIAL PROPERTIES; FEEDING-BEHAVIOR; FATTY-ACIDS; C-III; CHOLESTEROL; EXPRESSION; RAT; ABSORPTION	Intestinal apolipoprotein A- IV expression is highly regulated by dietary lipid in newborn swine, suggesting a role in lipid absorption. Constitutive overexpression of apoA- IV in newborn swine enterocytes enhances basolateral secretion of triacylglycerol ( TG) in TG-rich lipoproteins 4.9- fold ( Lu, S., Yao, Y., Meng, S., Cheng, X., and Black, D. D. ( 2002) J. Biol. Chem. 277, 31929 - 31937). To investigate the mechanism of this enhancement, IPEC- 1 cells were transfected with a tetracycline- regulatable expression system ( Tet- On). In cells incubated with oleic acid, a dose response relationship was observed between medium doxycycline concentration and basolateral apoA- IV and TG secretion. Similarly regulated expression of apoA- I did not enhance lipid secretion. The mean diameter of TG-rich lipoproteins secreted from doxycycline- treated cells was larger than from untreated cells ( 87.0 nm versus 53.4 nm). Basolateral apoB secretion decreased. Using the same expression system, full-length human apoA-IV ( 376 amino acids); a " pig- like" human apoA-IV, lacking the C- terminal EQQQ repeats ( 361 amino acids); and a " chicken- like" apoA- IV, further truncated to 343 amino acids, were expressed in IPEC- 1 cells. With increasing protein secretion, cells expressing the full- length human apoA- IV displayed a 2- fold increase in TG secretion; in sharp contrast, cells expressing the piglike human apoA- IV displayed a 25- fold increase in TG secretion and a 27- fold increase in lipoprotein diameter. When human apoA- IV was further truncated to yield a chicken- like protein, TG secretion was inhibited. We conclude that overexpression of swine apoA- IV enhances basolateral TG secretion in a dose- dependent manner by increasing the size of secreted lipoproteins. These data suggest that the region in the human apoA- IV protein from residues 344 to 354 is critical to its ability to enhance lipid secretion, perhaps by enabling the packaging of additional core TG into chylomicron particles. The EQQQ- rich region may play an inhibitory or modulatory role in chylomicron packaging in humans.	Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Paediat, Memphis, TN 38103 USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38103 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Pharmacol, Winston Salem, NC 27157 USA; Vet Adm Med Ctr, Memphis, TN 38104 USA; Univ Memphis, Integrated Microscopy Ctr, Memphis, TN 38152 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Memphis	Black, DD (corresponding author), Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Rm 401,W Patient Tower ,50 N Dunlap, Memphis, TN 38103 USA.	dblack@utmem.edu	Black, Dennis/AAD-9809-2020		NHLBI NIH HHS [R01 HL030897, HL30897, HL49373, R01 HL030897-23] Funding Source: Medline; NICHD NIH HHS [R01 HD022551-14A1, R01 HD022551-17, R01 HD022551-11, R01 HD022551-09A1, R01 HD022551-08, R01 HD022551-16, R01 HD022551-12, R01 HD022551, R01 HD022551-13, R01 HD022551-15, R01 HD022551-18, HD22551] Funding Source: Medline; NIDDK NIH HHS [DK38760] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD022551, R23HD022551, R29HD022551] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R23HL030897, R01HL030897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038760] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOSETALA K, 1994, J CLIN INVEST, V93, P1776, DOI 10.1172/JCI117163; APFELBAUM TF, 1987, AM J PHYSIOL, V252, pG662, DOI 10.1152/ajpgi.1987.252.5.G662; BLACK DD, 1990, J LIPID RES, V31, P497; BLACK DD, 1989, J LIPID RES, V30, P207; Black DD, 1996, BIOCHEM BIOPH RES CO, V221, P619, DOI 10.1006/bbrc.1996.0645; Chauhan V, 1998, BIOCHEMISTRY-US, V37, P3735, DOI 10.1021/bi9718853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Cohen RD, 1997, J CLIN INVEST, V99, P1906, DOI 10.1172/JCI119358; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; DVORIN E, 1986, J BIOL CHEM, V261, P5714; Ee LC, 2000, AM J PHYSIOL-GASTR L, V279, pG325, DOI 10.1152/ajpgi.2000.279.2.G325; ELSHOURBAGY NA, 1987, J BIOL CHEM, V262, P7973; EMMANUEL F, 1994, J BIOL CHEM, V269, P29883; FUJIMOTO K, 1992, AM J PHYSIOL, V262, pG1002, DOI 10.1152/ajpgi.1992.262.6.G1002; FUJIMOTO K, 1993, J CLIN INVEST, V91, P1830, DOI 10.1172/JCI116395; Gallagher JW, 2004, J LIPID RES, V45, P1826, DOI 10.1194/jlr.M400188-JLR200; GonzalezVallina R, 1996, AM J PHYSIOL-GASTR L, V271, pG249, DOI 10.1152/ajpgi.1996.271.2.G249; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; INNIS SM, 1993, J NUTR, V123, P386, DOI 10.1093/jn/123.suppl_2.386; Kalogeris TJ, 1997, J NUTR, V127, pS537, DOI 10.1093/jn/127.3.537S; Kumar NS, 1999, AM J PHYSIOL-GASTR L, V276, pG378, DOI 10.1152/ajpgi.1999.276.2.G378; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu S, 2002, J BIOL CHEM, V277, P31929, DOI 10.1074/jbc.M201418200; MURTHY S, 1992, ARTERIOSCLER THROMB, V12, P691, DOI 10.1161/01.ATV.12.6.691; Navarro MA, 2004, GENE, V325, P157, DOI 10.1016/j.gene.2003.10.007; Pearson K, 2005, J BIOL CHEM, V280, P38576, DOI 10.1074/jbc.M506802200; Pearson K, 2004, BIOCHEMISTRY-US, V43, P10719, DOI 10.1021/bi048978m; Phillips ML, 1997, J LIPID RES, V38, P1170; Qin XF, 1998, AM J PHYSIOL-HEART C, V274, pH1836, DOI 10.1152/ajpheart.1998.274.5.H1836; SMITH MW, 1988, COMP BIOCHEM PHYS A, V90, P577, DOI 10.1016/0300-9629(88)90670-6; STEIN O, 1986, BIOCHIM BIOPHYS ACTA, V878, P7, DOI 10.1016/0005-2760(86)90337-1; Steinmetz A, 1998, J BIOL CHEM, V273, P10543, DOI 10.1074/jbc.273.17.10543; Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233; Wang H, 1999, AM J PHYSIOL-GASTR L, V276, pG353, DOI 10.1152/ajpgi.1999.276.2.G353; Wang H, 2001, AM J PHYSIOL-GASTR L, V280, pG1137, DOI 10.1152/ajpgi.2001.280.6.G1137; Wang H, 1997, AM J PHYSIOL-GASTR L, V272, pG935, DOI 10.1152/ajpgi.1997.272.5.G935; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; Weinberg RB, 2002, J BIOL CHEM, V277, P21549, DOI 10.1074/jbc.M202197200; Weinberg RB, 2000, J LIPID RES, V41, P2035; Weinberg RB, 2000, J LIPID RES, V41, P1419; Weinberg RB, 2000, J LIPID RES, V41, P1410; Weinstock PH, 1997, J LIPID RES, V38, P1782	44	67	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3473	3483		10.1074/jbc.M502501200	http://dx.doi.org/10.1074/jbc.M502501200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338933	hybrid			2022-12-27	WOS:000235128200057
J	Morten, KJ; Ackrell, BAC; Melov, S				Morten, KJ; Ackrell, BAC; Melov, S			Mitochondrial reactive oxygen species in mice lacking superoxide dismutase 2 - Attenuation via antioxidant treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; ELECTRON-TRANSPORT CHAIN; DEVELOPMENTAL-CHANGES; ENERGY-METABOLISM; DILATED CARDIOMYOPATHY; HEART-MITOCHONDRIA; HYDROGEN-PEROXIDE; ALZHEIMER-DISEASE; OXIDATIVE STRESS; CYTOCHROME-C	Mice that lack the mitochondrial form of superoxide dismutase (SOD2) incur severe pathologies and mitochondrial deficiencies, including major depletion of complex II, as a consequence of buildup of endogenous reactive oxygen species (Melov, S., Coskun, P., Patel, M., Tuinstra, R., Cottrell, B., Jun, A. S., Zastawny, T. H., Dizdaroglu, M., Goodman, S. I., Huang, T. T., Miziorko, H., Epstein, C. J., and Wallace, D. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 846-851 and Li, Y., Huang, T. T., Carlson, E. J., Melov, S., Ursell, P. C., Olson, J. L., Noble, L. J., Yoshimura, M. P., Berger, C., Chan, P. H., Wallace, D. C., and Epstein, C. J. (1995) Nat. Genet. 11, 376-381). These problems can be greatly attenuated or rescued by synthetic antioxidant treatment, such as with the catalytic antioxidant EUK189 (Hinerfeld, D., Traini, M. D., Weinberger, R. P., Cochran, B., Doctrow, S. R., Harry, J., and Melov, S. (2004) J. Neurochem. 88, 657-667). We have used heart mitochondria from sod2 null mice to better understand mitochondrial reactive oxygen species production both in the absence of SOD2 and following in vivo antioxidant treatment. Isolated heart mitochondria from 5-day-old sod2 null animals respiring on the complex II substrate succinate exhibited statistically significant higher levels of mitochondrial O-2(.). (157%, p < 0.01) but significantly less H2O2 (33%, p < 0.001) than wild type littermates. Treatment of sod2 nullizygous mice with EUK189 proportionately increased the levels of complex II and H2O2. Increased production of O-2(.). resulting from complex II normalization had no effect on steady state levels due to the rapid conversion to H2O2, a process presumably aided by the presence of the EUK189, an SOD mimetic.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Melov, S (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	smelov@buckinstitute.org	Melov, Simon/AAC-9469-2020; MORTEN, Karl/GXM-6291-2022	Morten, Karl/0000-0001-6926-6550; Melov, Simon/0000-0001-8554-2834	NIA NIH HHS [AG18679] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG018679] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bass A, 2001, PHYSIOL RES, V50, P237; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Beal MF, 2004, J BIOENERG BIOMEMBR, V36, P381, DOI 10.1023/B:JOBB.0000041772.74810.92; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264; DOCTROW SR, 2002, CRITCAL REV OXIDATIV, P1324; DOCTROW SR, 2005, MED INORGANIC CHEM, P301; Drahota Z, 2004, PHYSIOL RES, V53, P119; ELCHURI S, 2004, ONCOGENE; Fink B, 2004, AM J PHYSIOL-CELL PH, V287, pC895, DOI 10.1152/ajpcell.00028.2004; Friedman JS, 2004, BLOOD, V104, P2565, DOI 10.1182/blood-2003-11-3858; Friedman JS, 2001, J EXP MED, V193, P925, DOI 10.1084/jem.193.8.925; GOLDEN TR, 2005, RADIC BIOL MED, V39, P162; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Hinerfeld D, 2004, J NEUROCHEM, V88, P657, DOI 10.1046/j.1471-4159.2003.02195.x; Huang TT, 2001, FREE RADICAL BIO MED, V31, P1101, DOI 10.1016/S0891-5849(01)00694-3; HUET O, 1992, CYTOMETRY, V13, P532, DOI 10.1002/cyto.990130513; Kalous M, 2001, PHYSIOL RES, V50, P315; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 2005, FREE RADICAL BIO MED, V38, P258, DOI 10.1016/j.freeradbiomed.2004.10.023; Melov S, 2001, J NEUROSCI, V21, P8348, DOI 10.1523/JNEUROSCI.21-21-08348.2001; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Miwa S, 2003, FREE RADICAL BIO MED, V35, P938, DOI 10.1016/S0891-5849(03)00464-7; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200; Nakai A, 2000, DEV BRAIN RES, V121, P67, DOI 10.1016/S0165-3806(00)00025-0; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; Rapoport SI, 1996, NEURODEGENERATION, V5, P473, DOI 10.1006/neur.1996.0065; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Samper E, 2003, AGING CELL, V2, P277, DOI 10.1046/j.1474-9728.2003.00062.x; SCHNEIDER SH, 1984, DIABETOLOGIA, V26, P355, DOI 10.1007/BF00266036; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Strassburger M, 2005, FREE RADICAL BIO MED, V38, P1458, DOI 10.1016/j.freeradbiomed.2005.02.009; STURTZ LA, 2001, J BIOL CHEM, V10, P10; Tiivel T, 2000, MOL CELL BIOCHEM, V208, P119, DOI 10.1023/A:1007002323492; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4	49	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3354	3359		10.1074/jbc.M509261200	http://dx.doi.org/10.1074/jbc.M509261200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326710	hybrid			2022-12-27	WOS:000235128200043
J	Picard, M; Toyoshima, C; Champeil, P				Picard, M; Toyoshima, C; Champeil, P			Effects of inhibitors on luminal opening of Ca2+ binding sites in an E2P-like complex of sarcoplasmic reticulum Ca2+-ATPase with Be2+-fluoride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSENSITIVE PHOSPHOENZYME INTERMEDIATE; CALCIUM-PUMP; TRANSPORT SITES; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL-CHANGES; INORGANIC-PHOSPHATE; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; HYDROGEN-ION; LOW-AFFINITY	We document here the intrinsic fluorescence and Ca-45(2+) binding properties of putative "E2P-related" complexes of Ca2+-free ATPase with fluoride, formed in the presence of magnesium, aluminum, or beryllium. Intrinsic fluorescence measurements suggest that in the absence of inhibitors, the ATPase complex with beryllium fluoride ( but not those with magnesium or aluminum fluoride) does constitute an appropriate analog of the "ADP-insensitive" phosphorylated form of Ca2+-ATPase, the so-called "E2P" state. Ca-45(2+) binding measurements, performed in the presence of 100 mM KCl, 5 mM Mg2+, and 20% Me2SO at pH 8, demonstrate that this ATPase complex with beryllium fluoride ( but again not those with magnesium or aluminum fluoride) has its Ca2+ binding sites accessible for rapid, low affinity (submillimolar) binding of Ca2+ from the luminal side of SR. In addition, we specifically demonstrate that in this E2P-like form of ATPase, the presence of thapsigargin, 2,5-ditertbutyl-1,4-dihydroxybenzene, or cyclopiazonic acid prevents Ca-45(2+) binding (i.e. presumably prevents opening of the Ca-45(2+) binding sites on the SR luminal side). Since crystals of E2P-related forms of ATPase have up to now been described in the presence of thapsigargin only, these results suggest that crystallizing an inhibitor-free E2P-like form of ATPase ( like its complex with beryllium fluoride) would be highly desirable, to unambiguously confirm previous predictions about the exit pathway from the ATPase transmembrane Ca2+ binding sites to the SR luminal medium.	CEA Saclay, CNRS, URA 2096, Serv Biophys Fonct Membranaires,CEA, F-91191 Gif Sur Yvette, France; Univ Paris Sud, Dept Biol Joliot Curie, CEA Saclay, Inst Federat Rech 46, F-91191 Gif Sur Yvette, France; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Tokyo	Champeil, P (corresponding author), CEA Saclay, CNRS, URA 2096, Serv Biophys Fonct Membranaires,CEA, F-91191 Gif Sur Yvette, France.	champeil@dsvidf.cea.fr	Picard, Martin/A-3236-2016; Toyoshima, Chikashi/R-4153-2019	Picard, Martin/0000-0002-6518-8900; Toyoshima, Chikashi/0000-0001-9640-0778				BONNET JP, 1978, ARCH BIOCHEM BIOPHYS, V191, P32, DOI 10.1016/0003-9861(78)90064-4; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, FEBS LETT, V206, P93, DOI 10.1016/0014-5793(86)81347-3; Champeil P., 1996, BIOMEMBR, V5, P43; CUENDA A, 1994, BBA-BIOMEMBRANES, V1194, P35, DOI 10.1016/0005-2736(94)90200-3; Danko S, 2004, J BIOL CHEM, V279, P14991, DOI 10.1074/jbc.M313363200; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; Davidson GA, 1996, BBA-GEN SUBJECTS, V1289, P187, DOI 10.1016/0304-4165(95)00155-7; DEFORESTA B, 1990, EUR J BIOCHEM, V194, P383; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FERNANDEZBELDA F, 1985, BIOCHIM BIOPHYS ACTA, V854, P257; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; GUILLAIN F, 1982, J BIOL CHEM, V257, P7366; HASSELBACH W, 1983, Z NATURFORSCH C, V38, P1015; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; INESI G, 1980, J BIOL CHEM, V255, P3025; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; KHAN YM, 1995, BIOCHEMISTRY-US, V34, P14385, DOI 10.1021/bi00044a015; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; LACAPERE JJ, 1981, J BIOL CHEM, V256, P2302; Logan-Smith MJ, 2002, BIOCHEMISTRY-US, V41, P2869, DOI 10.1021/bi011938n; LUND S, 1989, J BIOL CHEM, V264, P4907; MAKINOSE M, 1972, FEBS LETT, V25, P113, DOI 10.1016/0014-5793(72)80466-6; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MURPHY AJ, 1993, J BIOL CHEM, V268, P23307; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; MYUNG J, 1994, BIOCHEMISTRY-US, V33, P8775, DOI 10.1021/bi00195a020; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; Picard M, 2005, J BIOL CHEM, V280, P18745, DOI 10.1074/jbc.M501596200; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SCALES DJ, 1984, Z NATURFORSCH C, V39, P177; Seekoe T, 2001, J BIOL CHEM, V276, P46737, DOI 10.1074/jbc.M106320200; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; TROULLIER A, 1992, J BIOL CHEM, V267, P22821; VERJOVSKIALMEIDA S, 1977, BIOCHEMISTRY-US, V16, P329, DOI 10.1021/bi00621a026; VIEYRA A, 2005, BIOCHIM BIOPHYS ACTA, V1667, P103; Webb RJ, 2000, J BIOL CHEM, V275, P977, DOI 10.1074/jbc.275.2.977; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WICTOME M, 1995, BIOCHEM J, V310, P859, DOI 10.1042/bj3100859; WICTOME M, 1992, BIOCHEM J, V283, P525, DOI 10.1042/bj2830525; Xu C, 2004, J BIOL CHEM, V279, P17973, DOI 10.1074/jbc.M313263200; Yamasaki K, 2002, J BIOL CHEM, V277, P13615, DOI 10.1074/jbc.M200625200; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	59	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3360	3369		10.1074/jbc.M511385200	http://dx.doi.org/10.1074/jbc.M511385200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332689	hybrid			2022-12-27	WOS:000235128200044
J	Yang, CK; Kim, JH; Li, HW; Stallcup, MR				Yang, CK; Kim, JH; Li, HW; Stallcup, MR			Differential use of functional domains by coiled-coil coactivator in its synergistic coactivator function with beta-catenin or GRIP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR COACTIVATOR; ARYL-HYDROCARBON RECEPTOR; ANDROGEN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; ARGININE METHYLTRANSFERASE; MUSCLE DIFFERENTIATION; PROSTATE-CANCER; CARCINOMA-CELLS; CYCLIN D1	beta-Catenin, a pivotal component of the Wnt-signaling pathway, binds to and serves as a transcriptional coactivator for the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcriptional activator proteins and for the androgen receptor (AR), a nuclear receptor. Three components of the p160 nuclear receptor coactivator complex, including CARM1, p300/CBP, and GRIP1 (one of the p160 coactivators), bind to and cooperate with beta-catenin to enhance transcriptional activation by TCF/LEF and AR. Here we report that another component of the p160 nuclear receptor coactivator complex, the coiled-coil coactivator (CoCoA), directly binds to and cooperates synergistically with beta-catenin as a coactivator for AR and TCF/LEF. CoCoA uses different domains to bind GRIP1 and beta-catenin, and it uses different domains to transmit the activating signal to the transcription machinery, depending on whether it is bound to GRIP1 or beta-catenin. CoCoA associated specifically with the promoters of transiently transfected and endogenous target genes of TCF/LEF, and reduction of the endogenous CoCoA level decreased the ability of TCF/LEF and beta-catenin to activate transcription of transient and endogenous target genes. Thus, CoCoA uses different combinations of functional domains to serve as a physiologically relevant component of the Wnt/beta-catenin signaling pathway and the androgen signaling pathway.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.	stallcup@usc.edu			NIDDK NIH HHS [R01 DK043093, DK43093] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brannon M, 1999, DEVELOPMENT, V126, P3159; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2000, GENE DEV, V14, P1209; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Glass CK, 2000, GENE DEV, V14, P121; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Jenster G, 1999, SEMIN ONCOL, V26, P407; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JH, 2004, J BIOL CHEM, V279, P49842, DOI 10.1074/jbc.M408535200; Kim JH, 2003, MOL CELL, V12, P1537, DOI 10.1016/S1097-2765(03)00450-7; Kizu R, 2003, ARCH TOXICOL, V77, P335, DOI 10.1007/s00204-003-0454-y; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Li HW, 2004, J BIOL CHEM, V279, P4212, DOI 10.1074/jbc.M311374200; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Ma H, 1999, MOL CELL BIOL, V19, P6164; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MILLER JR, 2001, GENOME BIOL; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morrow D, 2004, J STEROID BIOCHEM, V88, P27, DOI 10.1016/j.jsbmb.2003.10.005; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Romagnolo B, 1999, CANCER RES, V59, P3875; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674-1687.2003; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Stallcup MR, 2003, J STEROID BIOCHEM, V85, P139, DOI 10.1016/S0960-0760(03)00222-X; Stallcup MR, 2000, BIOCHEM SOC T, V28, P415, DOI 10.1042/0300-5127:0280415; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Truica CI, 2000, CANCER RES, V60, P4709; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Xu JM, 2003, MOL ENDOCRINOL, V17, P1681, DOI 10.1210/me.2003-0116; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	51	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3389	3397		10.1074/jbc.M510403200	http://dx.doi.org/10.1074/jbc.M510403200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16344550	Green Accepted, hybrid			2022-12-27	WOS:000235128200047
J	Liu, BF; Liang, JJN				Liu, BF; Liang, JJN			Domain interaction sites of human lens beta b2-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; CRYSTALLIN; DIMERIZATION; TRYPTOPHAN	beta B2- crystallin, the major component of beta-crystallin, is a dimer at low concentrations but can form oligomers under physiological conditions. The interaction domains have been speculated to be the beta-sheets, each of which is formed by two or more beta-strands. beta B2-crystallin consists of 16 beta-strands, 8 in the N-terminal domain and 8 in the C-terminal domain. Domain interaction sites may be removed by destroying the beta-strands, which can be done by site-specific mutations, substituting the beta-formers (Val, Phe, Leu) with Glu or Asn, strong beta-breakers. We have cloned the following beta-strand-deleted mutants, I20E, L34E, V54E, V60E, V73E, L97E, I109E, I124E, V144E, V152E, L162E, L165E, and V187E and their corresponding X -> Asn mutants. We also made two mutants, V46E and V129E, that were not on the beta-strand as controls. Disruption of protein-protein interactions was screened by a mammalian two-hybrid system assay. Protein-protein interactions decreased for all beta-strand-deleted mutants except I20E, L34E, and L162E mutants; this effect was not seen in the two mutant controls, V46E and V129E. The sequences around Val-54, Val-60, Val-73, and Leu-97 in the N-terminal region and Ile-109, Ile-124, Val-144, Val-152, Leu-165, and Val-187 in the C-terminal region that formed beta-strands appear to be important in dimerization. Some selected mutant proteins that showed strong ( V46E and V129E) and reduced ( V60E, V144E, V60N, and V144N) interactions were expressed in bacterial culture and were studied with spectroscopy and chromatography. The V60E and V144E mutants were found to be partially unfolded and incapable of forming a complete dimer.	Brigham & Womens Hosp, Ctr Ophthalm Res Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liang, JJN (corresponding author), Brigham & Womens Hosp, Ctr Ophthalm Res Surg, 221 Longwood Ave, Boston, MA 02115 USA.	jliang@rics.bwh.harvard.edu			NATIONAL EYE INSTITUTE [R01EY013968] Funding Source: NIH RePORTER; NEI NIH HHS [EY13968] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAX B, 1989, J MOL BIOL, V208, P715, DOI 10.1016/0022-2836(89)90162-9; BAX B, 1990, NATURE, V347, P776, DOI 10.1038/347776a0; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CHOU PY, 1989, PREDICTION PROTEIN S, P549; DRIESSEN HPC, 1991, ACTA CRYSTALLOGR B, V47, P987, DOI 10.1107/S0108768191009163; Fu L, 2003, INVEST OPHTH VIS SCI, V44, P1155, DOI 10.1167/iovs.02-0950; Fu L, 2002, J BIOL CHEM, V277, P4255, DOI 10.1074/jbc.M110027200; Fu L, 2001, MOL VIS, V7, P178; Ghosh JG, 2005, PROTEIN SCI, V14, P684, DOI 10.1110/ps.041152805; Hejtmancik JF, 2004, EXP EYE RES, V79, P377, DOI 10.1016/j.exer.2004.06.011; Kosinski-Collins MS, 2004, PROTEIN SCI, V13, P2223, DOI 10.1110/ps.04627004; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Kumaraswamy VS, 1996, ACTA CRYSTALLOGR D, V52, P611, DOI 10.1107/S0907444995014302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampi KJ, 1997, J BIOL CHEM, V272, P2268; Liu BF, 2005, MOL VIS, V11, P321; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; NALINI V, 1994, J MOL BIOL, V236, P1250, DOI 10.1016/0022-2836(94)90025-6; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sergeev YV, 2004, BIOCHEMISTRY-US, V43, P415, DOI 10.1021/bi034617f; Sreelakshmi Y, 2004, BIOCHEMISTRY-US, V43, P15785, DOI 10.1021/bi048151s; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905	22	21	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2624	2630		10.1074/jbc.M509017200	http://dx.doi.org/10.1074/jbc.M509017200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319073	hybrid			2022-12-27	WOS:000234931800026
J	Rastogi, S; Joshi, B; Fusaro, G; Chellappan, S				Rastogi, S; Joshi, B; Fusaro, G; Chellappan, S			Camptothecin induces nuclear export of prohibitin preferentially in transformed cells through a CRM-1-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR ACTIVITY; NUCLEOCYTOPLASMIC TRANSPORT; REPRESSES TRANSCRIPTION; MITOCHONDRIAL PROTEINS; 3'-UNTRANSLATED REGION; POTENTIAL ROLE; P53; RB; TARGET; CANCER	Prohibitin is a growth-suppressive protein that has multiple functions in the nucleus and the mitochondria. Our earlier studies had shown that prohibitin represses the activity of E2F transcription factors while enhancing p53-mediated transcription. At the same time, prohibitin has been implicated in mediating the proper folding of mitochondrial proteins. We had found that treatment of cells with camptothecin, a topoisomerase 1 inhibitor, led to the export of prohibitin and p53 from the nucleus to the mitochondria. Here we show that the camptothecin-induced export of prohibitin occurs preferentially in transformed cell lines, but not in untransformed or primary cells. Cells that did not display the translocation of prohibitin were refractive to the apoptotic effects of camptothecin. The translocation was mediated by a putative nuclear export signal at the C-terminal region of prohibitin; fusion of the nuclear export signal (NES) of prohibitin to green fluorescence protein led to its export from the nucleus. Leptomycin B could inhibit the nuclear export of prohibitin showing that it was a CRM-1-dependent event driven by Ran GTPase. Confirming this, prohibitin was found to physically interact with CRM-1, and this interaction was significantly higher in transformed cells. Delivery of a peptide corresponding to the NES of prohibitin prevented the export of prohibitin to cytoplasm and protected cells from apoptosis. These results suggest that the regulated translocation of prohibitin from the nucleus to the mitochondria facilitates its pleiotropic functions and might contribute to its anti-proliferative and tumor suppressive properties.	Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Drug Discovery Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Chellappan, S (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Chellasp@moffitt.usf.edu	Rastogi, Shipra/L-1209-2015; Rastogi, Shipra/F-5109-2012	Rastogi, Shipra/0000-0003-3296-4405; 	NCI NIH HHS [CA77301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077301] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bednenko J, 2003, TRAFFIC, V4, P127, DOI 10.1034/j.1600-0854.2003.00109.x; Berger KH, 1998, MOL CELL BIOL, V18, P4043, DOI 10.1128/MCB.18.7.4043; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chipuk JE, 2004, CELL CYCLE, V3, P429; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Duriez PJ, 1997, BIOCHEM CELL BIOL, V75, P337, DOI 10.1139/bcb-75-4-337; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fahrenkrog B, 2003, NAT REV MOL CELL BIO, V4, P757, DOI 10.1038/nrm1230; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; Gasiorowski JZ, 2003, ADV DRUG DELIVER REV, V55, P703, DOI 10.1016/S0169-409X(03)00048-6; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harel A, 2004, MOL CELL, V16, P319, DOI 10.1016/S1097-2765(04)00647-1; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hipfner DR, 2004, NAT REV MOL CELL BIO, V5, P805, DOI 10.1038/nrm1491; Joseph TW, 2003, FASEB J, V17, P1622, DOI 10.1096/fj.02-0931com; Joshi B, 2003, BIOCHEM BIOPH RES CO, V312, P459, DOI 10.1016/j.bbrc.2003.10.148; Jupe ER, 2001, LANCET, V357, P1588, DOI 10.1016/S0140-6736(00)04747-4; Jupe ER, 1996, CELL GROWTH DIFFER, V7, P871; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Koster M, 2003, EXP CELL RES, V286, P321, DOI 10.1016/S0014-4827(03)00100-9; Kurtev V, 2004, J BIOL CHEM, V279, P24834, DOI 10.1074/jbc.M312300200; Li CP, 2004, PHARM RES-DORDR, V21, P93, DOI 10.1023/B:PHAM.0000012166.44521.1f; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Manjeshwar S, 2003, CANCER RES, V63, P5251; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Matsuyama S, 1997, J VET MED SCI, V59, P201, DOI 10.1292/jvms.59.201; MCCLUNG JK, 1995, EXP GERONTOL, V30, P99, DOI 10.1016/0531-5565(94)00069-7; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Ossareh-Nazari B, 1999, EXP CELL RES, V252, P236, DOI 10.1006/excr.1999.4599; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Park SE, 2005, MOL CELL BIOL, V25, P1989, DOI 10.1128/MCB.25.5.1989-1999.2005; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Santamaria E, 2003, P NATL ACAD SCI USA, V100, P3065, DOI 10.1073/pnas.0536625100; SATO T, 1992, CANCER RES, V52, P1643; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Spurdle AB, 2002, LANCET, V360, P925, DOI 10.1016/S0140-6736(02)11043-9; Stevens C, 2003, ARCH BIOCHEM BIOPHYS, V412, P157, DOI 10.1016/S0003-9861(03)00054-7; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Sun LG, 2004, J CELL SCI, V117, P3021, DOI 10.1242/jcs.01142; Thompson WE, 2004, BIOL REPROD, V71, P282, DOI 10.1095/biolreprod.103.024125; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Vander Heiden MG, 2002, J BIOL CHEM, V277, P44870, DOI 10.1074/jbc.M204888200; Wang S, 2002, EMBO J, V21, P3019, DOI 10.1093/emboj/cdf302; Wang S, 1999, MOL CELL BIOL, V19, P7447; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Yamasaki Lili, 2003, Cancer Treat Res, V115, P209; Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791; Yoneda Y, 1999, CELL STRUCT FUNCT, V24, P425, DOI 10.1247/csf.24.425; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	68	62	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2951	2959		10.1074/jbc.M508669200	http://dx.doi.org/10.1074/jbc.M508669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319068	hybrid			2022-12-27	WOS:000234931800065
J	Sheehan, JH; Bunick, CG; Hu, HT; Fagan, PA; Meyn, SM; Chazin, WJ				Sheehan, JH; Bunick, CG; Hu, HT; Fagan, PA; Meyn, SM; Chazin, WJ			Structure of the N-terminal calcium sensor domain of centrin reveals the biochemical basis for domain-specific function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; NUCLEOTIDE EXCISION-REPAIR; EF-HAND DOMAIN; YEAST CENTRIN; BINDING-SITES; CALMODULIN; DYNAMICS; CDC31P; KAR1P; NMR	Centrin is an essential component of microtubule-organizing centers in organisms ranging from algae and yeast to humans. It is an EF-hand calcium-binding protein with homology to calmodulin but distinct calcium binding properties. In a previously proposed model, the C-terminal domain of centrin serves as a constitutive anchor to target proteins, and the N-terminal domain serves as the sensor of calcium signals. The three-dimensional structure of the N-terminal domain of Chlamydomonas rheinhardtii centrin has been determined in the presence of calcium by solution NMR spectroscopy. The domain is found to occupy an open conformation typical of EF-hand calcium sensors. Comparison of the N- and C-terminal domains of centrin reveals a structural and biochemical basis for the domain specificity of interactions with its cellular targets and the distinct nature of centrin relative to other EF-hand proteins. An NMR titration of the centrin N-terminal domain with a fragment of the known centrin target Sfi1 reveals binding of the peptide to a discrete site on the protein, which supports the proposal that the N-terminal domain serves as a calcium sensor in centrin.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Phys, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37232 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92307 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Scripps Research Institute	Chazin, WJ (corresponding author), Vanderbilt Univ, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	walter.chazin@vanderbilt.edu	Bunick, Christopher/AAD-3842-2021	Bunick, Christopher/0000-0002-4011-8308; Sheehan, Jonathan/0000-0002-9641-7577; Hu, Haitao/0000-0002-0312-1954; Meyn, Susan/0000-0002-0894-0721	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040120, T32GM008320, R01GM065484] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES0000267] Funding Source: Medline; NIGMS NIH HHS [GM-65484, R01 GM-40120, T32 GM008320] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKKE M, 1993, BIOCHEMISTRY-US, V32, P9832, DOI 10.1021/bi00088a039; Araki M, 2001, J BIOL CHEM, V276, P18665, DOI 10.1074/jbc.M100855200; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; Bhattacharya S, 2004, BBA-MOL CELL RES, V1742, P69, DOI 10.1016/j.bbamcr.2004.09.002; BIGGINS S, 1994, J CELL BIOL, V125, P843, DOI 10.1083/jcb.125.4.843; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Duggan BM, 2001, J BIOMOL NMR, V19, P321, DOI 10.1023/A:1011227824104; Durussel I, 2000, FEBS LETT, V472, P208, DOI 10.1016/S0014-5793(00)01452-6; Fischer T, 2004, NAT CELL BIOL, V6, P840, DOI 10.1038/ncb1163; Geier BM, 1996, J BIOL CHEM, V271, P28366, DOI 10.1074/jbc.271.45.28366; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Hu HT, 2004, J BIOL CHEM, V279, P50895, DOI 10.1074/jbc.M404233200; Hu HT, 2003, J MOL BIOL, V330, P473, DOI 10.1016/S0022-2836(03)00619-3; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; Ivanovska I, 2001, GENETICS, V157, P503; Jasperson SL, 2002, J CELL BIOL, V159, P945, DOI 10.1083/jcb.200208169; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LINSE S, 1991, J BIOL CHEM, V266, P8050; Matei E, 2003, BIOCHEMISTRY-US, V42, P1439, DOI 10.1021/bi0269714; Molinier J, 2004, PLANT CELL, V16, P1633, DOI 10.1105/tpc.021378; Nelson MR, 2002, PROTEIN SCI, V11, P198, DOI 10.1110/ps.33302; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Ortiz M, 2005, BIOCHEMISTRY-US, V44, P2409, DOI 10.1021/bi0484419; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Popescu A, 2003, J BIOL CHEM, V278, P40252, DOI 10.1074/jbc.M302546200; Salisbury JL, 2004, CURR BIOL, V14, pR27, DOI 10.1016/j.cub.2003.12.019; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SMITH JA, 1996, MAGN RESON CHEM, V34, P147; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; Sullivan DS, 1998, J CELL BIOL, V143, P751, DOI 10.1083/jcb.143.3.751; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tourbez M, 2004, J BIOL CHEM, V279, P47672, DOI 10.1074/jbc.M404996200; Veeraraghavan S, 2002, J BIOL CHEM, V277, P28564, DOI 10.1074/jbc.M112232200; WEBER C, 1994, J BIOL CHEM, V269, P15795; Yuan T, 1999, PROTEIN SCI, V8, P113	44	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2876	2881		10.1074/jbc.M509886200	http://dx.doi.org/10.1074/jbc.M509886200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16317001	hybrid			2022-12-27	WOS:000234931800056
J	McManus, KJ; Biron, VL; Heit, R; Underhill, DA; Hendzel, MJ				McManus, KJ; Biron, VL; Heit, R; Underhill, DA; Hendzel, MJ			Dynamic changes in histone H3 lysine 9 methylations - Identification of a mitosis-specific function for dynamic methylation in chromosome congression and segregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIGENETIC REGULATION; ARGININE METHYLATION; GENE-EXPRESSION; FISSION YEAST; IN-VIVO; CHROMATIN; DOMAIN; HETEROCHROMATIN; BINDING; CELLS	Histone methylation is unique among post-translational histone modifications by virtue of its stability. It is thought to be a relatively stable and heritable epigenetic mark for gene-specific regulation. In this study, we use quantitative in situ approaches to investigate the cell cycle dynamics of methylated isoforms of histone H3 lysine 9. Contrary to the expected stability of trimethylated lysines, our results for trimethylated lysine 9 (tMeK9) of H3 demonstrate that the genomic content of this methylation undergoes significant changes as cells progress through mitosis. Unexpectedly, there is a loss of tMeK9 that appears to reflect a robust demethylase activity that is active during the period between anaphase and cytokinesis. Subsequent investigations of mitoses in tMeK9-deficient cells revealed defects in chromosome congression and segregation that are distinct from the increased cohesion at centromeres previously reported in association with the loss of tMeK9. Collectively, these results identify a mitosis-specific trimethylation of Lys(9) in pericentromeric heterochromatin that functions in the faithful segregation of chromosomes.	Univ Alberta, Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada	University of Alberta; University of Alberta	Hendzel, MJ (corresponding author), Univ Alberta, Cross Canc Inst, Dept Oncol, 11560 Univ Ave,Rm 3332, Edmonton, AB T6G 1Z2, Canada.	michaelh@cancerboard.ab.ca	McManus, Kirk J./AAE-3521-2020; Hendzel, Michael/C-3391-2009	McManus, Kirk J./0000-0003-0081-8737; Hendzel, Michael/0000-0002-9603-7945; Underhill, Darrell/0000-0003-0957-7407				Aagaard L, 2000, J CELL SCI, V113, P817; Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; BICKAR D, 1992, ANAL BIOCHEM, V203, P109, DOI 10.1016/0003-2697(92)90049-D; Biron VL, 2004, DEV BIOL, V276, P337, DOI 10.1016/j.ydbio.2004.08.038; BORUN TW, 1972, J BIOL CHEM, V247, P4288; BOSCH A, 1995, EUR J CELL BIOL, V68, P220; Brehm A, 2004, BIOESSAYS, V26, P133, DOI 10.1002/bies.10392; BYVOET P, 1972, ARCH BIOCHEM BIOPHYS, V148, P558, DOI 10.1016/0003-9861(72)90174-9; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; DUERRE JA, 1974, J NEUROCHEM, V23, P541, DOI 10.1111/j.1471-4159.1974.tb06057.x; Eissenberg JC, 2001, GENE, V275, P19, DOI 10.1016/S0378-1119(01)00628-X; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Goll MG, 2002, GENE DEV, V16, P1739, DOI 10.1101/gad.1013902; Gonzalo S, 2005, NAT CELL BIOL, V7, P420, DOI 10.1038/ncb1235; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kiekhaefer CM, 2002, P NATL ACAD SCI USA, V99, P14309, DOI 10.1073/pnas.212389499; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; McManus KJ, 2005, METHODS, V36, P351, DOI 10.1016/j.ymeth.2005.03.010; McManus KJ, 2003, MOL CELL BIOL, V23, P7611, DOI 10.1128/MCB.23.21.7611-7627.2003; Melcher M, 2000, MOL CELL BIOL, V20, P3728, DOI 10.1128/MCB.20.10.3728-3741.2000; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; MURRAY K, 1964, BIOCHEMISTRY-US, V3, P10, DOI 10.1021/bi00889a003; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; Partridge JF, 2002, CURR BIOL, V12, P1652, DOI 10.1016/S0960-9822(02)01177-6; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; RUSSANOVA V, 1989, MOL CELL BIOCHEM, V90, P1; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Thiriet C, 2005, GENE DEV, V19, P677, DOI 10.1101/gad.1265205; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Volpe T, 2003, CHROMOSOME RES, V11, P137, DOI 10.1023/A:1022815931524; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; WATERBORG JH, 1993, J BIOL CHEM, V268, P4918; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	59	72	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8888	8897		10.1074/jbc.M505323200	http://dx.doi.org/10.1074/jbc.M505323200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16373353	hybrid			2022-12-27	WOS:000236247100069
J	Soyombo, AA; Tjon-Kon-Sang, S; Rbaibi, Y; Bashllari, E; Bisceglia, J; Muallem, S; Kiselyov, K				Soyombo, AA; Tjon-Kon-Sang, S; Rbaibi, Y; Bashllari, E; Bisceglia, J; Muallem, S; Kiselyov, K			TRP-ML1 regulates lysosomal pH and acidic lysosomal lipid hydrolytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCOLIPIDOSIS TYPE-IV; ABNORMAL TRANSPORT; IDENTIFICATION; PROTEIN; CELLS; PHOSPHOLIPIDS; ACCUMULATION; COMPARTMENT; CURRENTS; CALCIUM	Mucolipidosis type IV (MLIV) is caused by mutations in the ion channel mucolipin 1 (TRP-ML1). MLIV is typified by accumulation of lipids and membranous materials in intracellular organelles, which was hypothesized to be caused by the altered membrane fusion and fission events. How mutations in TRP-ML1 lead to aberrant lipolysis is not known. Here we present evidence that MLIV is a metabolic disorder that is not associated with aberrant membrane fusion/ fission events. Thus, measurement of lysosomal pH revealed that the lysosomes in TRP-ML1(-/-) cells obtained from the patients with MLIV are over-acidified. TRP-ML1 can function as a H+ channel, and the increased lysosomal acidification in TRP-ML1(-/-) cells is likely caused by the loss of TRP-ML1-mediated H+ leak. Measurement of lipase activity using several substrates revealed a marked reduction in lipid hydrolysis in TRP-ML1(-/-) cells, which was rescued by the expression of TRP-ML1. Cell fractionation indicated specific loss of acidic lipase activity in TRP-ML1(-/-) cells. Furthermore, dissipation of the acidic lysosomal pH of TRP-ML1(-/-) cells by nigericin or chloroquine reversed the lysosomal storage disease phenotype. These findings provide a new mechanism to account for the pathogenesis of MLIV.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	shmuel.muallem@utsouthwestern.edu	Dembowski, Jill/Y-2500-2019	Dembowski, Jill/0000-0002-0309-8053; Kiselyov, Kirill/0000-0001-6683-2895; Soyombo, Abigail/0000-0003-0850-2593	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 12309] Funding Source: Medline; NIDDK NIH HHS [DK 38938] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACH G, 1979, BIOCHEM BIOPH RES CO, V90, P1341, DOI 10.1016/0006-291X(79)91183-5; Bach G, 1999, CLIN CHIM ACTA, V280, P173, DOI 10.1016/S0009-8981(98)00183-1; Bach G, 2001, MOL GENET METAB, V73, P197, DOI 10.1006/mgme.2001.3195; Bach G, 2005, PFLUG ARCH EUR J PHY, V451, P313, DOI 10.1007/s00424-004-1361-7; BACH G, 1988, ENZYME, V40, P40, DOI 10.1159/000469140; Bargal R, 1997, J INHERIT METAB DIS, V20, P625, DOI 10.1023/A:1005362123443; BARGAL R, 1989, CLIN CHIM ACTA, V181, P167, DOI 10.1016/0009-8981(89)90184-8; Bassi MT, 2000, AM J HUM GENET, V67, P1110, DOI 10.1016/S0002-9297(07)62941-3; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BURTON BK, 1980, CLIN CHIM ACTA, V101, P25, DOI 10.1016/0009-8981(80)90052-2; Chen CS, 1998, P NATL ACAD SCI USA, V95, P6373, DOI 10.1073/pnas.95.11.6373; DeCoursey TE, 1996, BIOPHYS J, V71, P182, DOI 10.1016/S0006-3495(96)79215-9; DECOURSEY TE, 1991, BIOPHYS J, V60, P1243, DOI 10.1016/S0006-3495(91)82158-0; DeCoursey TE, 1998, FRONT BIOSCI, V3, P477; Duncan JA, 1996, J BIOL CHEM, V271, P23594, DOI 10.1074/jbc.271.38.23594; Fares H, 2001, NAT GENET, V28, P64, DOI 10.1038/ng0501-64; Goldin E, 1999, P NATL ACAD SCI USA, V96, P8562, DOI 10.1073/pnas.96.15.8562; Haller T, 1996, CELL CALCIUM, V19, P157, DOI 10.1016/S0143-4160(96)90084-6; Kim J J, 2001, Results Probl Cell Differ, V33, P39; Kiselyov K, 2005, J BIOL CHEM, V280, P43218, DOI 10.1074/jbc.M508210200; LAKE JR, 1987, GASTROENTEROLOGY, V92, P1251, DOI 10.1016/S0016-5085(87)91085-7; LaPlante JM, 2002, FEBS LETT, V532, P183, DOI 10.1016/S0014-5793(02)03670-0; LaPlante JM, 2004, BIOCHEM BIOPH RES CO, V322, P1384, DOI 10.1016/j.bbrc.2004.08.045; Luzio JP, 2005, BIOCHEM SOC SYMP, V72, P77, DOI 10.1042/bss0720077; Luzio JP, 2003, MOL MEMBR BIOL, V20, P141, DOI 10.1080/0968768031000089546; Manzoni M, 2004, FEBS LETT, V567, P219, DOI 10.1016/j.febslet.2004.04.080; Morgan D, 2003, FRONT BIOSCI, V8, pS1266, DOI 10.2741/1191; Mullins C, 2001, BIOESSAYS, V23, P333, DOI 10.1002/bies.1048; Ostrowska H, 2003, CELL MOL BIOL LETT, V8, P19; Pillay CS, 2002, BIOCHEM J, V363, P417, DOI 10.1042/0264-6021:3630417; Piper RC, 2004, TRENDS CELL BIOL, V14, P471, DOI 10.1016/j.tcb.2004.07.010; Pshezhetsky AV, 2001, PROG NUCLEIC ACID RE, V69, P81, DOI 10.1016/S0079-6603(01)69045-7; Raychowdhury MK, 2004, HUM MOL GENET, V13, P617, DOI 10.1093/hmg/ddh067; Slaugenhaupt Susan A., 2002, Current Molecular Medicine (Hilversum), V2, P445, DOI 10.2174/1566524023362276; Srinivas SP, 2002, INVEST OPHTH VIS SCI, V43, P2341; Treusch S, 2004, P NATL ACAD SCI USA, V101, P4483, DOI 10.1073/pnas.0400709101; Tzagoloff A, 2004, J BIOL CHEM, V279, P19775, DOI 10.1074/jbc.M401506200; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; ZEIGLER M, 1992, PRENATAL DIAG, V12, P1037, DOI 10.1002/pd.1970121209	39	174	178	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7294	7301		10.1074/jbc.M508211200	http://dx.doi.org/10.1074/jbc.M508211200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16361256	hybrid			2022-12-27	WOS:000236030900047
J	Liu, JY; Timm, DE; Hurley, TD				Liu, JY; Timm, DE; Hurley, TD			Pyrithiamine as a substrate for thiamine pyrophosphokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RAT-TISSUES; TRIPHOSPHATE; METABOLISM; ANTAGONISTS; DEFICIENCY; BRAIN	Thiamine pyrophosphokinase transfers a pyrophosphate group from a nucleoside triphosphate, such as ATP, to the hydroxyl group of thiamine to produce thiamine pyrophosphate. Deficiencies in thiamine can result in the development of the neurological disorder Wernicke-Korsakoff Syndrome as well as the potentially fatal cardiovascular disease wet beriberi. Pyrithiamine is an inhibitor of thiamine metabolism that induces neurological symptoms similar to that of Wernicke-Korsakoff Syndrome in animals. However, the mechanism by which pyrithiamine interferes with cellular thiamine phosphoester homeostasis is not entirely clear. We used kinetic assays coupled with mass spectrometry of the reaction products and x-ray crystallography of an equilibrium reaction mixture of thiamine pyrophosphokinase, pyrithiamine, and Mg2+/ATP to elucidate the mechanism by which pyrithiamine inhibits the enzymatic production of thiamine pyrophosphate. Three lines of evidence support the ability of thiamine pyrophosphokinase to form pyrithiamine pyrophosphate. First, a coupled enzyme assay clearly demonstrated the ability of thiamine pyrophosphokinase to produce AMP when pyrithiamine was used as substrate. Second, an analysis of the reaction mixture by mass spectrometry directly identified pyrithiamine pyrophosphate in the reaction mixture. Last, the structure of thiamine pyrophosphokinase crystallized from an equilibrium substrate/product mixture shows clear electron density for pyrithiamine pyrophosphate bound in the enzyme active site. This structure also provides the first clear picture of the binding pocket for the nucleoside triphosphate and permits the first detailed understanding of the catalytic requirements for catalysis in this enzyme.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly	Hurley, TD (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	thurley@iupui.edu		HURLEY, THOMAS/0000-0002-5942-1163				Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, P2127; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Blaszczyk J, 2000, STRUCTURE, V8, P1049, DOI 10.1016/S0969-2126(00)00502-5; Brunger AT, 1997, NAT STRUCT BIOL, V4, P862; D'Amour ML, 2000, ADDICT BIOL, V5, P71, DOI 10.1080/13556210071298; Gasteiger J., 1990, TETRAHEDRON COMPUT M, V3, P537, DOI DOI 10.1016/0898-5529(90)90156-3; GUBLER CJ, 1982, J NUTR SCI VITAMINOL, V28, P217, DOI 10.3177/jnsv.28.217; GUBLER CJ, 1961, J BIOL CHEM, V236, P3112; Hennig M, 1999, J MOL BIOL, V287, P211, DOI 10.1006/jmbi.1999.2623; Homewood J, 1999, ALCOHOL, V19, P75, DOI 10.1016/S0741-8329(99)00027-0; IWASHIMA A, 1976, J BIOCHEM-TOKYO, V79, P845, DOI 10.1093/oxfordjournals.jbchem.a131138; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lakaye B, 2004, J BIOL CHEM, V279, P17142, DOI 10.1074/jbc.M313569200; Lakaye B, 2002, J BIOL CHEM, V277, P13771, DOI 10.1074/jbc.M111241200; LIU JY, 2002, THIAMINE CATALYTIC M, P29; MACHLIN LJ, 1991, HDB VITAMINS, P233; Makarchikov AF, 2003, CELL MOL LIFE SCI, V60, P1477, DOI 10.1007/s00018-003-3098-4; Nghiem HO, 2000, FASEB J, V14, P543, DOI 10.1096/fasebj.14.3.543; NOSAKA K, 1993, J BIOL CHEM, V268, P17440; NOSAKA K, 1989, FEMS MICROBIOL LETT, V51, P55; Onozuka M, 2003, J NUTR SCI VITAMINOL, V49, P156, DOI 10.3177/jnsv.49.156; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PLETCHER J, 1972, J AM CHEM SOC, V94, P3998, DOI 10.1021/ja00766a058; Rindi G, 2003, METAB BRAIN DIS, V18, P245, DOI 10.1023/B:MEBR.0000020187.98238.58; RINDI G, 1963, J NUTR, V81, P47; SADOWSKI J, 1992, ANAL CHIM ACTA, V265, P233, DOI 10.1016/0003-2670(92)85029-6; Schellenberger A, 1998, BBA-PROTEIN STRUCT M, V1385, P177, DOI 10.1016/S0167-4838(98)00067-3; SHIKATA H, 1989, BIOCHEM INT, V18, P943; Timm DE, 2001, J MOL BIOL, V310, P195, DOI 10.1006/jmbi.2001.4727; VOSKOBOYEV AI, 1982, ANN NY ACAD SCI, V378, P161, DOI 10.1111/j.1749-6632.1982.tb31195.x; 1994, ACTA CRYSTALLOGR D, V50, P60	31	38	41	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6601	6607		10.1074/jbc.M510951200	http://dx.doi.org/10.1074/jbc.M510951200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16365036	hybrid			2022-12-27	WOS:000236030800056
J	Yu, LQ; Bharadwaj, S; Brown, JM; Ma, YY; Du, W; Davis, MA; Michaely, P; Liu, PS; Willingham, MC; Rudel, LL				Yu, LQ; Bharadwaj, S; Brown, JM; Ma, YY; Du, W; Davis, MA; Michaely, P; Liu, PS; Willingham, MC; Rudel, LL			Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL-SENSING DOMAIN; POLARIZED HEPATIC CELLS; PICK C1 PROTEIN; ABSORPTION INHIBITOR; BILE CANALICULI; LIVING CELLS; EZETIMIBE; TRANSPORT; HOMEOSTASIS; MEMBRANE	Although NPC1L1 is required for intestinal cholesterol absorption, data demonstrating mechanisms by which this protein facilitates the process are few. In this study, a hepatoma cell line stably expressing human NPC1L1 was established, and cholesterol uptake was studied. A relationship between NPC1L1 intracellular trafficking and cholesterol uptake was apparent. At steady state, NPC1L1 proteins localized predominantly to the transferrin-positive endocytic recycling compartment, where free cholesterol also accumulated as revealed by filipin staining. Interestingly, acute cholesterol depletion induced with methyl-beta-cyclodextrin stimulated relocation of NPC1L1 to the plasma membrane, preferentially to a newly formed "apical-like" subdomain. This translocation was associated with a remarkable increase in cellular cholesterol uptake, which in turn was dose-dependently inhibited by ezetimibe, a novel cholesterol absorption inhibitor that specifically binds to NPC1L1. These findings define a cholesterol-regulated endocytic recycling of NPC1L1 as a novel mechanism regulating cellular cholesterol uptake.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Sect Lipid Sci, Winston Salem, NC 27157 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, LQ (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Sect Lipid Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.	lyu@wfubmc.edu	Liu, Pingsheng/B-7124-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [S15HL043973, R00HL096166] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R00 HL096166, HL-43973] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altmann SW, 2004, SCIENCE, V303, P1201, DOI 10.1126/science.1093131; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORNIG H, 1974, ACTA HISTOCHEM, V50, P110; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHIU JH, 1990, HEPATOLOGY, V11, P834, DOI 10.1002/hep.1840110519; Davies JP, 2005, J BIOL CHEM, V280, P12710, DOI 10.1074/jbc.M409110200; Davies JP, 2000, GENOMICS, V65, P137, DOI 10.1006/geno.2000.6151; Davis HR, 2004, J BIOL CHEM, V279, P33586, DOI 10.1074/jbc.M405817200; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Garcia-Calvo M, 2005, P NATL ACAD SCI USA, V102, P8132, DOI 10.1073/pnas.0500269102; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOTTARDI CJ, 1995, AM J PHYSIOL, V268, P285; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; Hao MM, 2002, J BIOL CHEM, V277, P609, DOI 10.1074/jbc.M108861200; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; IHRKE G, 1993, J CELL BIOL, V123, P1761, DOI 10.1083/jcb.123.6.1761; Iyer SPN, 2005, BBA-GEN SUBJECTS, V1722, P282, DOI 10.1016/j.bbagen.2004.12.021; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; Kramer W, 2005, J BIOL CHEM, V280, P1306, DOI 10.1074/jbc.M406309200; Kuwabara PE, 2002, TRENDS GENET, V18, P193, DOI 10.1016/S0168-9525(02)02640-9; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Michaely P, 2004, J BIOL CHEM, V279, P34023, DOI 10.1074/jbc.M405242200; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Ohgami N, 2004, P NATL ACAD SCI USA, V101, P12473, DOI 10.1073/pnas.0405255101; OSHIO C, 1981, SCIENCE, V212, P1041, DOI 10.1126/science.7015506; Radhakrishnan A, 2004, MOL CELL, V15, P259, DOI 10.1016/j.molcel.2004.06.019; Smart EJ, 2004, P NATL ACAD SCI USA, V101, P3450, DOI 10.1073/pnas.0400441101; SORMUNEN R, 1993, LAB INVEST, V68, P652; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Sudhop T, 2002, CIRCULATION, V106, P1943, DOI 10.1161/01.CIR.0000034044.95911.DC; Tuma PL, 1999, J CELL BIOL, V145, P1089, DOI 10.1083/jcb.145.5.1089; Valasek MA, 2005, J BIOL CHEM, V280, P28103, DOI 10.1074/jbc.M504609200; van Heek M, 2001, BRIT J PHARMACOL, V134, P409, DOI 10.1038/sj.bjp.0704260; VanHeek M, 1997, J PHARMACOL EXP THER, V283, P157; Wustner D, 2002, J BIOL CHEM, V277, P30325, DOI 10.1074/jbc.M202626200; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zhang M, 2001, P NATL ACAD SCI USA, V98, P4466, DOI 10.1073/pnas.081070898	40	156	174	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6616	6624		10.1074/jbc.M511123200	http://dx.doi.org/10.1074/jbc.M511123200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407187	hybrid			2022-12-27	WOS:000236030800058
J	Baum, J; Richard, D; Healer, J; Rug, M; Krnajski, Z; Gilberger, TW; Green, JL; Holder, AA; Cowman, AF				Baum, J; Richard, D; Healer, J; Rug, M; Krnajski, Z; Gilberger, TW; Green, JL; Holder, AA; Cowman, AF			A conserved molecular motor drives cell invasion and gliding motility across malaria life cycle stages and other apicomplexan parasites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM MEROZOITES; TOXOPLASMA-GONDII; ANONYMOUS PROTEIN; DIVERSIFYING SELECTION; CRYPTOSPORIDIUM-PARVUM; ERYTHROCYTE INVASION; GENOME SEQUENCE; THEILERIA-PARVA; HOST-CELLS; MYOSIN-A	Apicomplexan parasites constitute one of the most significant groups of pathogens infecting humans and animals. The liver stage sporozoites of Plasmodium spp. and tachyzoites of Toxoplasma gondii, the causative agents of malaria and toxoplasmosis, respectively, use a unique mode of locomotion termed gliding motility to invade host cells and cross cell substrates. This amoeboid-like movement uses a parasite adhesin from the thrombospondin-related anonymous protein (TRAP) family and a set of proteins linking the extracellular adhesin, via an actin-myosin motor, to the inner membrane complex. The Plasmodium blood stage merozoite, however, does not exhibit gliding motility. Here we show that homologues of the key proteins that make up the motor complex, including the recently identified glideosome-associated proteins 45 and 50 (GAP40 and GAP50), are present in P. falciparum merozoites and appear to function in erythrocyte invasion. Furthermore, we identify a merozoite TRAP homologue, termed MTRAP, a micronemal protein that shares key features with TRAP, including a thrombospondin repeat domain, a putative rhomboid-protease cleavage site, and a cytoplasmic tail that, in vitro, binds the actin-binding protein aldolase. Analysis of other parasite genomes shows that the components of this motor complex are conserved across diverse Apicomplexan genera. Conservation of the motor complex suggests that a common molecular mechanism underlies all Apicomplexan motility, which, given its unique properties, highlights a number of novel targets for drug intervention to treat major diseases of humans and livestock.	Walter & Eliza Hall Inst Med Res, Div Infect & Immun, Parkville, Vic 3050, Australia; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany; Natl Inst Med Res, London NW7 1AA, England	Walter & Eliza Hall Institute; Bernhard Nocht Institut fur Tropenmedizin; MRC National Institute for Medical Research	Cowman, AF (corresponding author), Walter & Eliza Hall Inst Med Res, Div Infect & Immun, Parkville, Vic 3050, Australia.	cowman@wehi.edu.au	Rug, Melanie/A-9504-2011; Holder, Anthony A/A-7554-2013; Rug, Melanie/B-5417-2015; Cowman, Alan F/C-7642-2013	Holder, Anthony A/0000-0002-8490-6058; Cowman, Alan F/0000-0001-5145-9004; Baum, Jake/0000-0002-0275-352X; Green, Judith/0000-0001-6825-9404; Gilberger, Tim-Wolf/0000-0002-7965-8272	Medical Research Council [MC_U117532067] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [MC_U117532067] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahamsen MS, 2004, SCIENCE, V304, P441, DOI 10.1126/science.1094786; Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1; Alexander DL, 2005, PLOS PATHOG, V1, P137, DOI 10.1371/journal.ppat.0010017; Baldi DL, 2000, EMBO J, V19, P2435, DOI 10.1093/emboj/19.11.2435; Baldi DL, 2002, INFECT IMMUN, V70, P5236, DOI 10.1128/IAI.70.9.5236-5245.2002; Baum J, 2003, GENETICS, V163, P1327; Bergman LW, 2003, J CELL SCI, V116, P39, DOI 10.1242/jcs.00194; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Brossier F, 2005, INT J BIOCHEM CELL B, V37, P2266, DOI 10.1016/j.biocel.2005.06.006; Brossier F, 2005, P NATL ACAD SCI USA, V102, P4146, DOI 10.1073/pnas.0407918102; Buscaglia CA, 2003, MOL BIOL CELL, V14, P4947, DOI 10.1091/mbc.E03-06-0355; Carreno RA, 1999, PARASITOL RES, V85, P899, DOI 10.1007/s004360050655; Carruthers VB, 1997, EUR J CELL BIOL, V73, P114; Chattopadhyay R, 2003, J BIOL CHEM, V278, P25977, DOI 10.1074/jbc.M300865200; Dowse TJ, 2005, INT J PARASITOL, V35, P747, DOI 10.1016/j.ijpara.2005.04.001; Duraisingh MT, 2003, EMBO J, V22, P1047, DOI 10.1093/emboj/cdg096; Duraisingh MT, 2002, INT J PARASITOL, V32, P81, DOI 10.1016/S0020-7519(01)00345-9; FIELD SJ, 1993, CELL MOTIL CYTOSKEL, V25, P43, DOI 10.1002/cm.970250106; Gantt S, 2000, INFECT IMMUN, V68, P3667, DOI 10.1128/IAI.68.6.3667-3673.2000; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gaskins E, 2004, J CELL BIOL, V165, P383, DOI 10.1083/jcb.200311137; Gilberger TW, 2003, J CELL BIOL, V162, P317, DOI 10.1083/jcb.200301046; Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002; Herm-Gotz A, 2002, EMBO J, V21, P2149, DOI 10.1093/emboj/21.9.2149; Hettmann C, 2000, MOL BIOL CELL, V11, P1385, DOI 10.1091/mbc.11.4.1385; Huynh MH, 2004, CELL MICROBIOL, V6, P771, DOI 10.1111/j.1462-5822.2004.00403.x; Huynh MH, 2003, EMBO J, V22, P2082, DOI 10.1093/emboj/cdg217; Jewett TJ, 2003, MOL CELL, V11, P885, DOI 10.1016/S1097-2765(03)00113-8; Kappe S, 1999, J CELL BIOL, V147, P937, DOI 10.1083/jcb.147.5.937; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lebrun M, 2005, CELL MICROBIOL, V7, P1823, DOI 10.1111/j.1462-5822.2005.00646.x; Lew AE, 2002, CELL MOTIL CYTOSKEL, V52, P202, DOI 10.1002/cm.10046; Margos G, 2004, PARASITOLOGY, V129, P273, DOI 10.1017/S0031182004005657; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Menard R, 2001, CELL MICROBIOL, V3, P63, DOI 10.1046/j.1462-5822.2001.00097.x; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5; Opitz C, 2002, EMBO J, V21, P1577, DOI 10.1093/emboj/21.7.1577; Pain A, 2005, SCIENCE, V309, P131, DOI 10.1126/science.1110418; Pinder JC, 1998, J CELL SCI, V111, P1831; Polley SD, 2001, GENETICS, V158, P1505; Rabenau KE, 2001, MOL MICROBIOL, V41, P537, DOI 10.1046/j.1365-2958.2001.02513.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Rug M, 2004, INFECT IMMUN, V72, P6095, DOI 10.1128/IAI.72.10.6095-6105.2004; SCHOFIELD L, 1986, MOL BIOCHEM PARASIT, V18, P183, DOI 10.1016/0166-6851(86)90037-X; Shaw MK, 1999, EXP PARASITOL, V92, P24, DOI 10.1006/expr.1998.4393; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Soldati D, 2004, TRENDS PARASITOL, V20, P567, DOI 10.1016/j.pt.2004.09.009; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; Thompson J, 2004, MOL BIOCHEM PARASIT, V134, P225, DOI 10.1016/j.molbiopara.2003.12.003; Tonkin CJ, 2004, MOL BIOCHEM PARASIT, V137, P13, DOI 10.1016/j.molbiopara.2004.05.009; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x; Trottein F, 1995, MOL BIOCHEM PARASIT, V74, P129, DOI 10.1016/0166-6851(95)02489-1; Urban S, 2003, MOL CELL, V11, P1425, DOI 10.1016/S1097-2765(03)00181-3; van Dooren GG, 2005, MOL MICROBIOL, V57, P405, DOI 10.1111/j.1365-2958.2005.04699.x; Wetzel DM, 2005, INFECT IMMUN, V73, P5379, DOI 10.1128/IAI.73.9.5379-5387.2005; Yuda M, 1999, J EXP MED, V190, P1711, DOI 10.1084/jem.190.11.1711; Zhou XW, 2004, MOL CELL PROTEOMICS, V3, P565, DOI 10.1074/mcp.M300123-MCP200	62	263	282	0	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5197	5208		10.1074/jbc.M509807200	http://dx.doi.org/10.1074/jbc.M509807200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16321976	hybrid			2022-12-27	WOS:000235426200074
J	Panadero, J; Pallotti, C; Rodriguez-Vargas, S; Randez-Gil, F; Prieto, JA				Panadero, J; Pallotti, C; Rodriguez-Vargas, S; Randez-Gil, F; Prieto, JA			A downshift in temperature activates the high osmolarity glycerol (HOG) pathway, which determines freeze tolerance in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PATHWAY; ABC-TRANSPORT-SYSTEM; HEAT-SHOCK RESPONSE; MEMBRANE-FLUIDITY; OSMOTIC-STRESS; PHYSICAL STATE; YEAST-CELLS; COLD-SHOCK; SIGNAL-TRANSDUCTION; GENE	The molecular mechanisms that enable yeast cells to detect and transmit cold signals and their physiological significance in the adaptive response to low temperatures are unknown. Here, we have demonstrated that the MAPK Hog1p is specifically activated in response to cold. Phosphorylation of Hog1p was dependent on Pbs2p, the MAPK kinase ( MAPKK) of the high osmolarity glycerol (HOG) pathway, and Ssk1p, the response regulator of the two-component system Sln1p-Ypd1p. However, Sho1p was not required. Interestingly, phosphorylation of Hog1p was stimulated at 30 degrees C in cells exposed to the membrane rigidifier agent dimethyl sulfoxide. Moreover, Hog1p activation occurred specifically through the Sln1 branch. This suggests that Sln1p monitors changes in membrane fluidity caused by cold. Quite remarkably, activation of Hog1p at low temperatures affected the transcriptional response to cold shock. Indeed, the absence of Hog1p impaired the cold-instigated expression of genes for trehalose- and glycerol-synthesizing enzymes and small chaperones. Moreover, a downward transfer to 12 or 4 degrees C stimulated the overproduction of glycerol in a Hog1p-dependent manner. However, hog1 Delta mutant cells showed no growth defects at 12 degrees C as compared with the wild type. On the contrary, deletion of HOG1 or GPD1 decreased tolerance to freezing of wildtype cells preincubated at a low temperature, whereas no differences could be detected in cells shifted directly from 30 to -20 degrees C. Thus, exposure to low temperatures triggered a Hog1p-dependent accumulation of glycerol, which is essential for freeze protection.	CSIC, Inst Agroquim & Tecnol Alimentos, Dept Biotechnol, E-46100 Burjassot, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Prieto, JA (corresponding author), CSIC, Inst Agroquim & Tecnol Alimentos, Dept Biotechnol, POB 73, E-46100 Burjassot, Spain.	prieto@iata.csic.es	Prieto, Jose A/H-4646-2012; Randez-Gil, Francisca/H-2868-2012; pallotti, claudia/F-5489-2016	Prieto, Jose A/0000-0001-9677-0023; Randez-Gil, Francisca/0000-0001-8217-3156; pallotti, claudia/0000-0002-5231-4285; Panadero, Joaquin/0000-0002-8039-6505				Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; Aguilera J, 2005, MOL MICROBIOL, V56, P228, DOI 10.1111/j.1365-2958.2005.04533.x; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; BELL W, 1992, EUR J BIOCHEM, V209, P951, DOI 10.1111/j.1432-1033.1992.tb17368.x; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Browse J, 2001, CURR OPIN PLANT BIOL, V4, P241, DOI 10.1016/S1369-5266(00)00167-9; Carratu L, 1996, P NATL ACAD SCI USA, V93, P3870, DOI 10.1073/pnas.93.9.3870; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Gacto M, 2003, INT MICROBIOL, V6, P211, DOI 10.1007/s10123-003-0136-x; Garcia-Rodriguez LJ, 2000, J BACTERIOL, V182, P2428, DOI 10.1128/JB.182.9.2428-2437.2000; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Horvath I, 1998, P NATL ACAD SCI USA, V95, P3513, DOI 10.1073/pnas.95.7.3513; Inaba M, 2003, J BIOL CHEM, V278, P12191, DOI 10.1074/jbc.M212204200; Inoue Y, 1996, J BIOL CHEM, V271, P25958, DOI 10.1074/jbc.271.42.25958; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Izawa S, 2004, APPL MICROBIOL BIOT, V66, P303, DOI 10.1007/s00253-004-1688-1; Kandror O, 2004, MOL CELL, V13, P771, DOI 10.1016/S1097-2765(04)00148-0; KONDO K, 1991, J BIOL CHEM, V266, P17537; KONDO K, 1992, J BIOL CHEM, V267, P16252; KOWALSKI LRZ, 1995, MOL MICROBIOL, V15, P341, DOI 10.1111/j.1365-2958.1995.tb02248.x; Laroche C, 2001, APPL MICROBIOL BIOT, V56, P249, DOI 10.1007/s002530000583; Lawrence CL, 2004, MOL CELL BIOL, V24, P3307, DOI 10.1128/MCB.24.8.3307-3323.2004; Lopez CS, 2000, INT J FOOD MICROBIOL, V55, P137, DOI 10.1016/S0168-1605(00)00171-9; Los DA, 2004, BBA-BIOMEMBRANES, V1666, P142, DOI 10.1016/j.bbamem.2004.08.002; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Mikami K, 2002, MOL MICROBIOL, V46, P905, DOI 10.1046/j.1365-2958.2002.03202.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Murata N, 1997, PLANT PHYSIOL, V115, P875, DOI 10.1104/pp.115.3.875; O'Rourke SM, 2002, MOL CELL BIOL, V22, P4739, DOI 10.1128/MCB.22.13.4739-4749.2002; Ohsaka Y, 2002, CELL PHYSIOL BIOCHEM, V12, P111, DOI 10.1159/000063787; Orvar BL, 2000, PLANT J, V23, P785, DOI 10.1046/j.1365-313x.2000.00845.x; Perraud AL, 1999, TRENDS MICROBIOL, V7, P115, DOI 10.1016/S0966-842X(99)01458-4; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; Randez-Gil F, 2003, TOP CURR GENET, V2, P57; Reiser V, 2003, J CELL BIOL, V161, P1035, DOI 10.1083/jcb.200301099; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Reynolds TB, 1998, J CELL BIOL, V143, P935, DOI 10.1083/jcb.143.4.935; Sahara T, 2002, J BIOL CHEM, V277, P50015, DOI 10.1074/jbc.M209258200; Sangwan V, 2002, PLANT J, V31, P629, DOI 10.1046/j.1365-313X.2002.01384.x; Sherman F., 1986, METHODS YEAST GENETI; Soto T, 2002, EUR J BIOCHEM, V269, P5056, DOI 10.1046/j.1432-1033.2002.03214.x; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; Suzuki I, 2001, MOL MICROBIOL, V40, P235, DOI 10.1046/j.1365-2958.2001.02379.x; Suzuki I, 2000, EMBO J, V19, P1327, DOI 10.1093/emboj/19.6.1327; Szalontai B, 2000, BBA-BIOMEMBRANES, V1509, P409, DOI 10.1016/S0005-2736(00)00323-0; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Thieringer HA, 1998, BIOESSAYS, V20, P49; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TOKISHITA S, 1994, MOL MICROBIOL, V13, P435, DOI 10.1111/j.1365-2958.1994.tb00438.x; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; van der Heide T, 2001, EMBO J, V20, P7022, DOI 10.1093/emboj/20.24.7022; Van Wuytswinkel O, 2000, MOL MICROBIOL, V37, P382, DOI 10.1046/j.1365-2958.2000.02002.x; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; Westfall PJ, 2004, SCIENCE, V306, P1511, DOI 10.1126/science.1104879; Winkler A, 2002, EUKARYOT CELL, V1, P163, DOI 10.1128/EC.1.2.163-173.2002; Wolfe J, 1999, CRYOBIOLOGY, V39, P103, DOI 10.1006/cryo.1999.2195; Zhang L, 2001, BIOCHEM BIOPH RES CO, V283, P531, DOI 10.1006/bbrc.2001.4776	65	140	155	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4638	4645		10.1074/jbc.M512736200	http://dx.doi.org/10.1074/jbc.M512736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371351	Green Submitted, hybrid			2022-12-27	WOS:000235426200011
J	Babu, GJ; Bhupathy, P; Petrashevskaya, NN; Wang, HL; Raman, S; Wheeler, D; Jagatheesan, G; Wieczorek, D; Schwartz, A; Janssen, PML; Ziolo, MT; Periasamy, M				Babu, GJ; Bhupathy, P; Petrashevskaya, NN; Wang, HL; Raman, S; Wheeler, D; Jagatheesan, G; Wieczorek, D; Schwartz, A; Janssen, PML; Ziolo, MT; Periasamy, M			Targeted overexpression of sarcolipin in the mouse heart decreases sarcoplasmic reticulum calcium transport and cardiac contractility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PHOSPHOLAMBAN; SERCA; CA2+-ATPASE; EXPRESSION; ATPASE; RYANODINE; MYOCYTES; INCREASE; PUMPS	The role of sarcolipin (SLN) in cardiac physiology was critically evaluated by generating a transgenic (TG) mouse model in which the SLN to sarco(endoplasmic) reticulum (SR) Ca2+ ATPase (SERCA) ratio was increased in the ventricle. Overexpression of SLN decreases SR calcium transport function and results in decreased calcium transient amplitude and rate of relaxation. SLN TG hearts exhibit a significant decrease in rates of contraction and relaxation when assessed by ex vivo work-performing heart preparations. Similar results were also observed with muscle preparations and myocytes from SLN TG ventricles. Interestingly, the inhibitory effect of SLN was partially relieved upon high dose of isoproterenol treatment and stimulation at high frequency. Biochemical analyses show that an increase in SLN level does not affect PLB levels, monomer to pentamer ratio, or its phosphorylation status. No compensatory changes were seen in the expression of other calcium-handling proteins. These studies suggest that the SLN effect on SERCA pump is direct and is not mediated through increased monomerization of PLB or by a change in PLB phosphorylation status. We conclude that SLN is a novel regulator of SERCA pump activity, and its inhibitory effect can be reversed by beta-adrenergic agonists.	Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet & Biochem, Cincinnati, OH 45267 USA	University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Periasamy, M (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Physiol & Cell Biol, 304 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	periasamy.1@osu.edu	Janssen, Paul ML/E-3307-2011; Babu, Gopal/AAB-7787-2021; Ziolo, Mark/E-4371-2011	Babu, Gopal/0000-0001-7833-5300; Periasamy, Muthu/0000-0001-8834-5975; Janssen, Paul/0000-0002-9682-3014	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064140] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64140] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahi M, 2004, P NATL ACAD SCI USA, V101, P9199, DOI 10.1073/pnas.0402596101; Asahi M, 2003, TRENDS CARDIOVAS MED, V13, P152, DOI 10.1016/S1050-1738(03)00037-9; Asahi M, 2003, P NATL ACAD SCI USA, V100, P5040, DOI 10.1073/pnas.0330962100; Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; Babu GJ, 2005, CARDIOVASC RES, V65, P177, DOI 10.1016/j.cardiores.2004.08.012; BERS DM, 1987, AM J PHYSIOL, V253, pC408, DOI 10.1152/ajpcell.1987.253.3.C408; Bers DR, 1999, CARDIOVASC RES, V42, P339, DOI 10.1016/S0008-6363(99)00038-3; Frank KF, 2003, CARDIOVASC RES, V57, P20, DOI 10.1016/S0008-6363(02)00694-6; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; Greene AL, 2000, J BIOL CHEM, V275, P24722, DOI 10.1074/jbc.M001783200; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; Hellstern S, 2001, J BIOL CHEM, V276, P30845, DOI 10.1074/jbc.M102495200; Ji Y, 1999, ANAL BIOCHEM, V269, P236, DOI 10.1006/abio.1999.4059; Kimura Y, 1996, J BIOL CHEM, V271, P21726, DOI 10.1074/jbc.271.36.21726; Li L, 1998, AM J PHYSIOL-HEART C, V274, pH1335, DOI 10.1152/ajpheart.1998.274.4.H1335; Luss I, 1999, J MOL CELL CARDIOL, V31, P1299, DOI 10.1006/jmcc.1999.0962; MacLennan DH, 2003, ANN NY ACAD SCI, V986, P472, DOI 10.1111/j.1749-6632.2003.tb07231.x; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; MacLennan DH, 2002, J MOL CELL CARDIOL, V34, P897, DOI 10.1006/jmcc.2002.2031; Minamisawa S, 2003, J BIOL CHEM, V278, P9570, DOI 10.1074/jbc.M213132200; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Pan BS, 1999, J MOL CELL CARDIOL, V31, P159, DOI 10.1006/jmcc.1998.0854; Pashmforoush M, 2004, CELL, V117, P373, DOI 10.1016/S0092-8674(04)00405-2; Periasamy M, 2001, J MOL CELL CARDIOL, V33, P1053, DOI 10.1006/jmcc.2001.1366; Reed TD, 2000, J MOL CELL CARDIOL, V32, P453, DOI 10.1006/jmcc.1999.1095; Stokes DL, 2000, EUR J BIOCHEM, V267, P5274, DOI 10.1046/j.1432-1327.2000.01569.x; Stull LB, 2002, J MOL CELL CARDIOL, V34, P1367, DOI 10.1006/jmcc.2002.2065; Uemura N, 2004, EUR J CLIN INVEST, V34, P723, DOI 10.1111/j.1365-2362.2004.01422.x; Valverde CA, 2005, J PHYSIOL-LONDON, V562, P801, DOI 10.1113/jphysiol.2004.075432; Ziolo MT, 2005, CIRC RES, V96, P815, DOI 10.1161/01.RES.0000163981.97262.3b	31	57	58	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3972	3979		10.1074/jbc.M508998200	http://dx.doi.org/10.1074/jbc.M508998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365042	hybrid			2022-12-27	WOS:000235275300025
J	Zou, WG; Zhang, DE				Zou, WG; Zhang, DE			The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RING-FINGER PROTEIN; SIGNALING PROTEINS; CRYSTAL-STRUCTURE; BINDING-PROTEINS; CELLS; E2; ISGYLATION; EXPRESSION; PATHWAYS; TARGETS	The expression of the ubiquitin-like protein ISG15 and protein modification by ISG15 (ISGylation) are strongly activated by interferons. Accordingly, ISG15 expression and protein ISGylation are strongly activated upon viral and bacterial infections and during other stress conditions, suggesting important roles for the ISG15 system in innate immune responses. Here, we report the identification of the ubiquitin-protein isopeptide ligase (E3) EFP (estrogen-responsive finger protein) as the ISG15 E3 ligase for 14-3-3 sigma protein. Like other known components of the protein ISGylation system (ISG15, UBE1L, UBP43, and UBC8), EFP is also an interferon-inducible protein. Expression of EFP small interfering RNA decreased the ISGylation of 14-3-3 sigma in the 293T cell ISGylation system as well as in MCF-7 cells upon interferon treatment. Furthermore, the ISGylation enzyme activity of EFP was RING domain-dependent. These findings indicate that EFP is an ISG15 E3 ligase for 14-3-3 sigma in vivo. The fact that both UBC8 and EFP are common components in the ubiquitin and ISG15 conjugation pathways suggests a mechanism whereby a limited set of enzymes accomplishes diverse post-translational modifications of their substrates in response to changes in environmental stimulations.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Zhang, DE (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Mail Drop MEM-L51,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dzhang@scripps.edu			NCI NIH HHS [CA079849] Funding Source: Medline; NIGMS NIH HHS [GM066955] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Bridges D, 2004, SCI STKE, pre10; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chin LS, 2002, J BIOL CHEM, V277, P35071, DOI 10.1074/jbc.M203300200; Dao CT, 2005, FRONT BIOSCI-LANDMRK, V10, P2701, DOI 10.2741/1730; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hamerman JA, 2002, J IMMUNOL, V168, P2415, DOI 10.4049/jimmunol.168.5.2415; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Ikeda K, 1997, BIOCHEM BIOPH RES CO, V236, P765, DOI 10.1006/bbrc.1997.7046; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004; Kim KI, 2006, MOL CELL BIOL, V26, P472, DOI 10.1128/MCB.26.2.472-479.2006; Kim KI, 2003, BIOCHEM BIOPH RES CO, V307, P431, DOI 10.1016/S0006-291X(03)01216-6; Kim KI, 2005, J IMMUNOL, V175, P847, DOI 10.4049/jimmunol.175.2.847; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KORANT BD, 1984, J BIOL CHEM, V259, P4835; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Kumar S, 1997, J BIOL CHEM, V272, P13548, DOI 10.1074/jbc.272.21.13548; Leaman DW, 2003, J INTERF CYTOK RES, V23, P745, DOI 10.1089/107999003772084860; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Narasimhan J, 2005, J BIOL CHEM, V280, P27356, DOI 10.1074/jbc.M502814200; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Osiak A, 2005, MOL CELL BIOL, V25, P6338, DOI 10.1128/MCB.25.15.6338-6345.2005; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Shimada N, 2004, MOL CELL ENDOCRINOL, V218, P147, DOI 10.1016/j.mce.2003.12.008; Urano T, 2002, NATURE, V417, P871, DOI 10.1038/nature00826; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2004, CELL, V119, P741, DOI 10.1016/S0092-8674(04)01154-7; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102; Zou WG, 2005, BIOCHEM BIOPH RES CO, V336, P61, DOI 10.1016/j.bbrc.2005.08.038	50	194	206	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3989	3994		10.1074/jbc.M510787200	http://dx.doi.org/10.1074/jbc.M510787200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352599	hybrid			2022-12-27	WOS:000235275300027
J	McGee, DJ; Kumar, S; Viator, RJ; Bolland, JR; Ruiz, J; Spadafora, D; Testerman, TL; Kelly, DJ; Pannell, LK; Windle, HJ				McGee, DJ; Kumar, S; Viator, RJ; Bolland, JR; Ruiz, J; Spadafora, D; Testerman, TL; Kelly, DJ; Pannell, LK; Windle, HJ			Helicobacter pylori thioredoxin is an arginase chaperone and guardian against oxidative and nitrosative stresses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; GNOTOBIOTIC PIGLETS; UREASE ACTIVITY; SYSTEM; COLONIZATION; PATHOGENESIS; PATHWAYS; SEQUENCE; ARTICLE; ACID	The gastric human pathogen Helicobacter pylori faces formidable challenges in the stomach including reactive oxygen and nitrogen intermediates. Here we demonstrate that arginase activity, which inhibits host nitric oxide production, is post-translationally stimulated by H. pylori thioredoxin (Trx) 1 but not the homologous Trx2. Trx1 has chaperone activity that renatures urea- or heat-denatured arginase back to the catalytically active state. Most reactive oxygen and nitrogen intermediates inhibit arginase activity; this damage is reversed by Trx1, but not Trx2. Trx1 and arginase equip H. pylori with a "renox guardian" to overcome abundant nitrosative and oxidative stresses encountered during the persistence of the bacterium in the hostile gastric environment.	Univ S Alabama, Coll Med, Inst Canc Res, Dept Microbiol & Immunol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Inst Canc Res, Dept Biol Sci, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Inst Canc Res, Prote & Mass Spectrometry Res Facil, Mobile, AL 36688 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; St Jamess Univ Hosp, Trinity Coll, Trinity Ctr Hlth Sci, Dept Clin Med, Dublin 8, Ireland	University of South Alabama; University of South Alabama; University of South Alabama; University of Sheffield; Trinity College Dublin	McGee, DJ (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, 1501 Kings Highway, Shreveport, LA 71130 USA.	dmcgee@lsuhsc.edu	Testerman, Traci L/AAI-1506-2020	Testerman, Traci L/0000-0002-3883-6407; McGee, David/0000-0003-0592-7836	NATIONAL CANCER INSTITUTE [R01CA101931] Funding Source: NIH RePORTER; NCI NIH HHS [CA101931] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Baker LMS, 2001, J BACTERIOL, V183, P1961, DOI 10.1128/JB.183.6.1961-1973.2001; Bauerfeind P, 1997, GUT, V40, P25, DOI 10.1136/gut.40.1.25; Comtois SL, 2003, MICROBIOL-SGM, V149, P121, DOI 10.1099/mic.0.25896-0; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; EATON KA, 1991, INFECT IMMUN, V59, P2470, DOI 10.1128/IAI.59.7.2470-2475.1991; Ernst P, 1999, ALIMENT PHARM THER, V13, P13, DOI 10.1046/j.1365-2036.1999.00003.x; Gobert AP, 2001, P NATL ACAD SCI USA, V98, P13844, DOI 10.1073/pnas.241443798; Kern R, 2003, BIOCHEM J, V371, P965, DOI 10.1042/BJ20030093; MARSHALL BJ, 1990, GASTROENTEROLOGY, V99, P697, DOI 10.1016/0016-5085(90)90957-3; McGee DJ, 2004, EUR J BIOCHEM, V271, P1952, DOI 10.1111/j.1432-1033.2004.04105.x; McGee DJ, 1999, J BACTERIOL, V181, P2477, DOI 10.1128/JB.181.8.2477-2484.1999; McGee DJ, 1999, J BACTERIOL, V181, P7314, DOI 10.1128/JB.181.23.7314-7322.1999; Nardone G, 2004, ALIMENT PHARM THER, V20, P261, DOI 10.1111/j.1365-2036.2004.02075.x; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Satriano J, 2004, AMINO ACIDS, V26, P321, DOI 10.1007/s00726-004-0078-4; Slonczewski JL, 2000, HELICOBACTER, V5, P240, DOI 10.1046/j.1523-5378.2000.00037.x; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Windle HJ, 2000, J BIOL CHEM, V275, P5081, DOI 10.1074/jbc.275.7.5081; Zabaleta J, 2004, J IMMUNOL, V173, P586, DOI 10.4049/jimmunol.173.1.586	21	31	37	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3290	3296		10.1074/jbc.M506139200	http://dx.doi.org/10.1074/jbc.M506139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354674	hybrid			2022-12-27	WOS:000235128200035
J	Friedman, JE; Watson, JA; Lam, DWH; Rokita, SE				Friedman, JE; Watson, JA; Lam, DWH; Rokita, SE			Iodotyrosine deiodinase is the first mammalian member of the NADH oxidase/flavin reductase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IODOTHYRONINE DEIODINASE; TETRACHLOROHYDROQUINONE DEHALOGENASE; THERMUS-THERMOPHILUS; PROTEIN STRUCTURES; IODINE-METABOLISM; MONO-IODOTYROSINE; CRYSTAL-STRUCTURE; FLAVIN REDUCTASE; DI-IODOTYROSINE; REDUCED FLAVIN	The enzyme responsible for iodide salvage in the thyroid, iodotyrosine deiodinase, was solubilized from porcine thyroid microsomes by limited proteolysis with trypsin. The resulting protein retained deiodinase activity and was purified using anion exchange, dye, and hydrophobic chromatography successively. Peptide sequencing of the final isolate identified the gene responsible for the deiodinase. The amino acid sequence of the porcine enzyme is highly homologous to corresponding genes in a variety of mammals including humans, and the mouse gene was expressed in human embryonic kidney 293 cells to confirm its identity. The amino acid sequence of the deiodinase suggests the presence of three domains. The N-terminal domain provides a membrane anchor. The intermediate domain contains the highest sequence variability and lacks homology to structural motifs available in the common databases. The C-terminal domain is highly conserved and resembles bacterial enzymes of the NADH oxidase/flavin reductase superfamily. A three-dimensional model of the deiodinase based on the coordinates of the minor nitroreductase of Escherichia coli indicates that a Cys common to all of the mammal sequences is located adjacent to bound FMN. However, the deiodinase is not structurally related to other known flavoproteins containing redox-active cysteines or the iodothyronine deiodinases containing an active site selenocysteine.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	Rokita, SE (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	rokita@umd.edu	Rokita, Steven E/C-4793-2009					Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Callebaut I, 2003, J BIOL CHEM, V278, P36887, DOI 10.1074/jbc.M305725200; Cavalieri RR, 1997, THYROID, V7, P177, DOI 10.1089/thy.1997.7.177; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Copley S.D., 1999, COMPREHENSIVE NATURA, P401, DOI 10.1016/b978-0-08-091283-7.00122-3; Copley SD, 2003, CURR OPIN CHEM BIOL, V7, P265, DOI 10.1016/S1367-5931(03)00032-2; Coppock DL, 1998, GENOMICS, V54, P460, DOI 10.1006/geno.1998.5605; Dunn CR, 1996, NAT STRUCT BIOL, V3, P912, DOI 10.1038/nsb1196-912; Dunn JT, 2001, THYROID, V11, P407, DOI 10.1089/105072501300176363; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; Fetzner S, 1998, APPL MICROBIOL BIOT, V50, P633, DOI 10.1007/s002530051346; Fischer D, 1999, PROTEINS, P209; Gnidehou S, 2004, FASEB J, V18, P1574, DOI 10.1096/fj.04-2023fje; GOSWAMI A, 1977, ENDOCRINOLOGY, V101, P331, DOI 10.1210/endo-101-2-331; GOSWAMI A, 1979, J BIOL CHEM, V254, P2326; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; GREEN WL, 1968, ENDOCRINOLOGY, V83, P336, DOI 10.1210/endo-83-2-336; Gross E, 2002, NAT STRUCT BIOL, V9, P61, DOI 10.1038/nsb740; HECHT HJ, 1995, NAT STRUCT BIOL, V2, P1109, DOI 10.1038/nsb1295-1109; Hoober KL, 1999, J BIOL CHEM, V274, P31759, DOI 10.1074/jbc.274.45.31759; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JANSSEN DB, 1994, ANNU REV MICROBIOL, V48, P163, DOI 10.1146/annurev.mi.48.100194.001115; Jeffers CE, 2001, BIOCHEMISTRY-US, V40, P1749, DOI 10.1021/bi0024310; Kiefer PM, 2002, BIOCHEMISTRY-US, V41, P1308, DOI 10.1021/bi0117495; Kiefer PM, 2002, BIOCHEMISTRY-US, V41, P1315, DOI 10.1021/bi0117504; Koder RL, 2002, BIOCHEMISTRY-US, V41, P14197, DOI 10.1021/bi025805t; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kuiper GGJM, 2005, J MOL ENDOCRINOL, V34, P865, DOI 10.1677/jme.1.01770; Kunishima M, 1999, J AM CHEM SOC, V121, P4722, DOI 10.1021/ja990693n; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lei BF, 2005, BIOCHEMISTRY-US, V44, P261, DOI 10.1021/bi047952s; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; McCarthy DL, 1996, BIOCHEMISTRY-US, V35, P14634, DOI 10.1021/bi961730f; MILLER H, 1995, BIOCHEMISTRY-US, V34, P5180, DOI 10.1021/bi00015a032; Moreno JC, 2003, TRENDS ENDOCRIN MET, V14, P318, DOI 10.1016/S1043-2760(03)00137-1; Moreno JC, 2002, J ENDOCRINOL INVE S7, V25, P23; NOVOA WB, 1959, J BIOL CHEM, V234, P1143; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; Parkinson GN, 2000, J MED CHEM, V43, P3624, DOI 10.1021/jm000159m; Parry RJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P47, DOI 10.1006/abbi.1996.9857; PESCE A, 1967, J BIOL CHEM, V242, P2151; Poelarends GJ, 2004, BIOORG CHEM, V32, P376, DOI 10.1016/j.bioorg.2004.05.006; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; ROSENBERG IN, 1984, METHOD ENZYMOL, V107, P488; ROSENBERG IN, 1979, J BIOL CHEM, V254, P2318; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1994, PROTEIN STRUCTURE BY DISTANCE ANALYSIS, P64; Solis-S JC, 2004, J ENDOCRINOL, V181, P385, DOI 10.1677/joe.0.1810385; STANBURY JB, 1956, J CLIN ENDOCR METAB, V16, P735, DOI 10.1210/jcem-16-6-735; STANBURY JB, 1957, J BIOL CHEM, V228, P801; STANBURY JB, 1956, J CLIN ENDOCR METAB, V16, P848, DOI 10.1210/jcem-16-7-848; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Sun BC, 1997, ENDOCRINOLOGY, V138, P5452, DOI 10.1210/en.138.12.5452; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; Taurog AM, 2000, WERNER INGBARS THYRO, P61; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tu SC, 2001, ANTIOXID REDOX SIGN, V3, P881, DOI 10.1089/15230860152665046; Valverde-R C, 2004, INT REV CYTOL, V234, P143, DOI 10.1016/S0074-7696(04)34004-0; Vasil'ev AA, 1998, J ORG CHEM, V63, P3911, DOI 10.1021/jo972240b; Wackett LP, 2004, J BIOL CHEM, V279, P41259, DOI 10.1074/jbc.R400014200; Wang SC, 2003, J AM CHEM SOC, V125, P14282, DOI 10.1021/ja0370948; WHITAKER JR, 1994, FOOD SCI TECHNOL, V61, P521; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996	68	47	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2812	2819		10.1074/jbc.M510365200	http://dx.doi.org/10.1074/jbc.M510365200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316988	hybrid			2022-12-27	WOS:000234931800048
J	Nawrocki, AR; Rajala, MW; Tomas, E; Pajvani, UB; Saha, AK; Trumbauer, ME; Pang, Z; Chen, AS; Ruderman, NB; Chen, H; Rossetti, L; Scherer, PE				Nawrocki, AR; Rajala, MW; Tomas, E; Pajvani, UB; Saha, AK; Trumbauer, ME; Pang, Z; Chen, AS; Ruderman, NB; Chen, H; Rossetti, L; Scherer, PE			Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; ADIPOSE-TISSUE; PROTEIN-KINASE; RESISTANCE; OXIDATION; MUSCLE; MOUSE; LIVER; MECHANISMS; EXPRESSION	The adipose tissue-derived hormone adiponectin improves insulin sensitivity and its circulating levels are decreased in obesity-induced insulin resistance. Here, we report the generation of a mouse line with a genomic disruption of the adiponectin locus. We aimed to identify whether these mice develop insulin resistance and which are the primary target tissues affected in this model. Using euglycemic/insulin clamp studies, we demonstrate that these mice display severe hepatic but not peripheral insulin resistance. Furthermore, we wanted to test whether the lack of adiponectin magnifies the impairments of glucose homeostasis in the context of a dietary challenge. When exposed to high fat diet, adiponectin null mice rapidly develop glucose intolerance. Specific PPAR gamma agonists such as thiazolidinediones (TZDs) improve insulin sensitivity by mechanisms largely unknown. Circulating adiponectin levels are significantly up-regulated in vivo upon activation of PPAR gamma. Both TZDs and adiponectin have been shown to activate AMP-activated protein kinase (AMPK) in the same target tissues. We wanted to address whether the ability of TZDs to improve glucose tolerance is dependent on adiponectin and whether this improvement involved AMPK activation. We demonstrate that the ability of PPAR gamma agonists to improve glucose tolerance in ob/ob mice lacking adiponectin is diminished. Adiponectin is required for the activation of AMPK upon TZD administration in both liver and muscle. In summary, adiponectin is an important contributor to PPAR gamma-mediated improvements in glucose tolerance through mechanisms that involve the activation of the AMPK pathway.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Boston Univ, Med Ctr, Dept Physiol & Med Biophys, Boston, MA 02118 USA; Boston Univ, Med Ctr, Diabet Unit, Boston, MA 02118 USA; Merck Res Labs, Rahway, NJ 07065 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Boston University; Boston University; Merck & Company	Scherer, PE (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	scherer@aecom.yu.edu	Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392; Ruderman, Neil/0000-0002-6589-6587; Saha, Asish/0000-0003-1001-5110	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073163, P01HL068758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019514, R01DK049147, R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL68758, R01-HL073163-01] Funding Source: Medline; NIDDK NIH HHS [R01-DK55758, DK 19514, DK 49147] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; Berger J, 1996, ENDOCRINOLOGY, V137, P4189, DOI 10.1210/en.137.10.4189; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Combs TP, 2004, ENDOCRINOLOGY, V145, P367, DOI 10.1210/en.2003-1068; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Fasshauer M, 2002, BIOCHEM BIOPH RES CO, V290, P1084, DOI 10.1006/bbrc.2001.6307; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Kim JK, 2003, DIABETES, V52, P1311, DOI 10.2337/diabetes.52.6.1311; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Lee CH, 2003, ENDOCRINOLOGY, V144, P2201, DOI 10.1210/en.2003-0288; Ma K, 2002, J BIOL CHEM, V277, P34658, DOI 10.1074/jbc.C200362200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Namae M, 1998, LAB ANIM SCI, V48, P103; Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani Utpal B, 2003, Curr Diab Rep, V3, P207, DOI 10.1007/s11892-003-0065-2; Rajala MW, 2003, J CLIN INVEST, V111, P225, DOI 10.1172/JCI200316521; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Ruderman NB, 2003, ACTA PHYSIOL SCAND, V178, P435, DOI 10.1046/j.1365-201X.2003.01164.x; Saha AK, 2004, BIOCHEM BIOPH RES CO, V314, P580, DOI 10.1016/j.bbrc.2003.12.120; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Vincent MF, 1996, DIABETOLOGIA, V39, P1148, DOI 10.1007/BF02658500; Wellen KE, 2004, ENDOCRINOLOGY, V145, P2214, DOI 10.1210/en.2003-1580; Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200; Yang WS, 2001, J CLIN ENDOCR METAB, V86, P3815, DOI 10.1210/jc.86.8.3815	35	495	514	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2654	2660		10.1074/jbc.M505311200	http://dx.doi.org/10.1074/jbc.M505311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326714	hybrid			2022-12-27	WOS:000234931800030
J	Vetting, MW; Yu, M; Rendle, PM; Blanchard, JS				Vetting, MW; Yu, M; Rendle, PM; Blanchard, JS			The substrate-induced conformational change of Mycobacterium tuberculosis mycothiol synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMEGMATIS MUTANTS; GNAT SUPERFAMILY; ACETYLTRANSFERASES; THIOLS	The structure of the ternary complex of mycothiol synthase from Mycobacterium tuberculosis with bound desacetylmycothiol and CoA was determined to 1.8 angstrom resolution. The structure of the acety-lCoA-binary complex had shown an active site groove that was several times larger than its substrate. The structure of the ternary complex reveals that mycothiol synthase undergoes a large conformational change in which the two acetyltransferase domains are brought together through shared interactions with the functional groups of desacetylmycothiol, thereby decreasing the size of this large central groove. A comparison of the binary and ternary structures illustrates many of the features that promote catalysis. Desacetylmycothiol is positioned with its primary amine in close proximity and in the proper orientation for direct nucleophilic attack on the si-face of the acetyl group of acetyl-CoA. Glu-234 and Tyr-294 are positioned to act as a general base and general acid to promote acetyl transfer. In addition, this structure provides further evidence that the N-terminal acetyltransferase domain no longer has enzymatic activity and is vestigial in nature.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Ind Res Ltd, Carbohydrate Chem, Lower Hutt, New Zealand	Yeshiva University; Albert Einstein College of Medicine; Callaghan Innovation	Blanchard, JS (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	blanchar@aecom.yu.edu		Rendle, Phillip/0000-0002-2825-8746	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033696, T32AI007501, R01AI060899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIAID NIH HHS [T32 AI07501, AI60899, AI33696] Funding Source: Medline; NIGMS NIH HHS [T32 GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burk DL, 2003, PROTEIN SCI, V12, P426, DOI 10.1110/ps.0233503; DELANO WL, 2002, PYMOL 0 97; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Knapp S, 2002, ORG LETT, V4, P4337, DOI 10.1021/ol0269796; Koledin T, 2002, ARCH MICROBIOL, V178, P331, DOI 10.1007/s00203-002-0462-y; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEWTON GL, 1995, EUR J BIOCHEM, V230, P821; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; NEWTON GL, 1993, J BACTERIOL, V175, P2734, DOI 10.1128/JB.175.9.2734-2742.1993; Newton GL, 1999, BIOCHEM BIOPH RES CO, V255, P239, DOI 10.1006/bbrc.1999.0156; Newton GL, 2000, BIOCHEMISTRY-US, V39, P10739, DOI 10.1021/bi000356n; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel MP, 2001, BIOCHEMISTRY-US, V40, P5119, DOI 10.1021/bi0029144; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; SWEENEY AM, 2002, J APPL CRYSTALLOGR, V36, P165; Vetting MW, 2005, J BIOL CHEM, V280, P22108, DOI 10.1074/jbc.M502401200; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; Vetting MW, 2003, PROTEIN SCI, V12, P1954, DOI 10.1110/ps.03153703	19	20	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2795	2802		10.1074/jbc.M510798200	http://dx.doi.org/10.1074/jbc.M510798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326705	hybrid			2022-12-27	WOS:000234931800046
J	Lee, YH; Naider, F; Becker, JM				Lee, YH; Naider, F; Becker, JM			Interacting residues in an activated state of a G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; CEREVISIAE TRIDECAPEPTIDE PHEROMONE; MUSCARINIC ACETYLCHOLINE-RECEPTOR; DOMINANT-NEGATIVE MUTATIONS; TRANSMEMBRANE DOMAINS III; DISULFIDE CROSS-LINKING; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL-CHANGES; LIGAND SPECIFICITY; EXTRACELLULAR ENDS	Ste2p, the G protein-coupled receptor ( GPCR) for the tridecapeptide pheromone alpha- factor of Saccharomyces cerevisiae, was used as a model GPCR to investigate the role of specific residues in the resting and activated states of the receptor. Using a series of biological and biochemical analyses of wild-type and site-directed mutant receptors, we identified Asn(205) as a potential interacting partner with the Tyr(266) residue. An N205H/Y266H double mutant showed pH-dependent functional activity, whereas the N205H receptor was non-functional and the Y266H receptor was partially active indicating that the histidine 205 and 266 residues interact in an activated state of the receptor. The introduction of N205K or Y266D mutations into the P258L/S259L constitutively active receptor suppressed the constitutive activity; in contrast, the N205K/ Y266D/P258L/S259L quadruple mutant was fully constitutively active, again indicating an interaction between residues at the 205 and 206 positions in the receptor-active state. To further test this interaction, we introduced the N205C/Y266C, F204C/Y266C, and N205C/A265C double mutations into wild-type and P258L/S259L constitutively active receptors. After trypsin digestion, we found that a disulfide-cross-linked product, with the molecular weight expected for a receptor fragment with a cross-link between N205C and Y266C, formed only in the N205C/ Y266C constitutively activated receptor. This study represents the first experimental demonstration of an interaction between specific residues in an active state, but not the resting state, of Ste2p. The information gained from this study should contribute to an understanding of the conformational differences between resting and active states in GPCRs.	Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA; Univ Tennessee, Grad Sch Genome Sci & Technol, Knoxville, TN 37996 USA; CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA; CUNY Coll Staten Isl, Macromol Assemblies Inst, Staten Isl, NY 10314 USA; CUNY Grad Sch & Univ Ctr, Staten Isl, NY 10314 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) Graduate School	Becker, JM (corresponding author), Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA.	jbecker@utk.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM022087, R56GM022086, R01GM022086, R01GM022087] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22086, GM 22087] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MG, 1998, BBA-MOL CELL RES, V1448, P12, DOI 10.1016/S0167-4889(98)00109-8; Abel MG, 1998, J PEPT RES, V52, P95; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; Cai KW, 1997, P NATL ACAD SCI USA, V94, P14267, DOI 10.1073/pnas.94.26.14267; Chen QJ, 1996, MOL CELL BIOL, V16, P247; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Ding FX, 2002, J PEPT RES, V60, P65, DOI 10.1034/j.1399-3011.2002.21004.x; Ding FX, 2001, BIOCHEMISTRY-US, V40, P1102, DOI 10.1021/bi0021535; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dosil M, 2000, MOL CELL BIOL, V20, P5321, DOI 10.1128/MCB.20.14.5321-5329.2000; Dosil M, 1998, MOL CELL BIOL, V18, P5981, DOI 10.1128/MCB.18.10.5981; Dube P, 1998, MOL CELL BIOL, V18, P7205, DOI 10.1128/MCB.18.12.7205; Dube P, 2000, J BIOL CHEM, V275, P26492, DOI 10.1074/jbc.M002767200; Eilers M, 2005, BIOCHEMISTRY-US, V44, P8959, DOI 10.1021/bi047316u; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Han SJ, 2005, J BIOL CHEM, V280, P34849, DOI 10.1074/jbc.M506711200; Han SJ, 2005, J BIOL CHEM, V280, P24870, DOI 10.1074/jbc.M500379200; Henry LK, 2002, BIOCHEMISTRY-US, V41, P6128, DOI 10.1021/bi015863z; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; Hunyady L, 2003, TRENDS PHARMACOL SCI, V24, P81, DOI 10.1016/S0165-6147(02)00050-0; JENNESS DD, 1986, MOL CELL BIOL, V6, P318, DOI 10.1128/MCB.6.1.318; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; Kristiansen K, 2004, PHARMACOL THERAPEUT, V103, P21, DOI 10.1016/j.pharmthera.2004.05.002; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Leavitt LM, 1999, MOL GEN GENET, V261, P917, DOI 10.1007/s004380051039; Lee BK, 2002, BIOCHEMISTRY-US, V41, P13681, DOI 10.1021/bi026100u; Lee BK, 2001, J BIOL CHEM, V276, P37950; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; Lin JC, 2004, MOL CELL BIOL, V24, P2041, DOI 10.1128/MCB.24.5.2041-2051.2004; Lin JC, 2003, BIOCHEMISTRY-US, V42, P293, DOI 10.1021/bi026766o; Overton MC, 2003, J BIOL CHEM, V278, P49369, DOI 10.1074/jbc.M308654200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parrish W, 2002, GENETICS, V160, P429; RATHS SK, 1988, J BIOL CHEM, V263, P17333; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SEN M, 1994, J BIOL CHEM, V269, P968; Sen M, 1997, CURR GENET, V31, P235, DOI 10.1007/s002940050200; Shah A, 1996, BIOCHEM BIOPH RES CO, V226, P242, DOI 10.1006/bbrc.1996.1340; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Sommers CM, 1997, J MOL BIOL, V266, P559, DOI 10.1006/jmbi.1996.0816; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2003, J BIOL CHEM, V278, P352, DOI 10.1074/jbc.M206424200; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; Yu BM, 2004, J BIOL CHEM, V279, P40972, DOI 10.1074/jbc.M405300200; Yu HB, 1999, BIOCHEMISTRY-US, V38, P12028, DOI 10.1021/bi990948+; Zhang YL, 1997, J PEPT RES, V50, P319	57	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2263	2272		10.1074/jbc.M509987200	http://dx.doi.org/10.1074/jbc.M509987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314417	hybrid			2022-12-27	WOS:000234760400051
J	Horsefield, R; Yankovskaya, V; Sexton, G; Whittingham, W; Shiomi, K; Omura, S; Byrne, B; Cecchini, G; Iwata, S				Horsefield, R; Yankovskaya, V; Sexton, G; Whittingham, W; Shiomi, K; Omura, S; Byrne, B; Cecchini, G; Iwata, S			Structural and computational analysis of the quinone-binding site of complex II (succinate-ubiquinone oxidoreductase) - A mechanism of electron transfer and proton conduction during ubiquinone reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION-CENTER; COLI FUMARATE REDUCTASE; BACTERIAL REACTION CENTERS; CYTOCHROME BC(1) COMPLEX; SULFUR PROTEIN SUBUNIT; ESCHERICHIA-COLI; RESPIRATORY-CHAIN; WOLINELLA-SUCCINOGENES; ANGSTROM RESOLUTION; CONFERS RESISTANCE	The transfer of electrons and protons between membrane-bound respiratory complexes is facilitated by lipid-soluble redox-active quinone molecules ( Q). This work presents a structural analysis of the quinone- binding site (Q-site) identified in succinate: ubiquinone oxidoreductase (SQR) from Escherichia coli. SQR, often referred to as Complex II or succinate dehydrogenase, is a functional member of the Krebs cycle and the aerobic respiratory chain and couples the oxidation of succinate to fumarate with the reduction of quinone to quinol (QH(2)). The interaction between ubiquinone and the Q-site of the protein appears to be mediated solely by hydrogen bonding between the O1 carbonyl group of the quinone and the side chain of a conserved tyrosine residue. In this work, SQR was co-crystallized with the ubiquinone binding-site inhibitor Atpenin A5 (AA5) to confirm the binding position of the inhibitor and reveal additional structural details of the Q-site. The electron density for AA5 was located within the same hydrophobic pocket as ubiquinone at, however, a different position within the pocket. AA5 was bound deeper into the site prompting further assessment using protein-ligand docking experiments in silico. The initial interpretation of the Q-site was re-evaluated in the light of the new SQR-AA5 structure and protein-ligand docking data. Two binding positions, the Q1-site and Q(2)-site, are proposed for the E. coli SQR quinone- binding site to explain these data. At the Q(2)-site, the side chains of a serine and histidine residue are suitably positioned to provide hydrogen bonding partners to the O4 carbonyl and methoxy groups of ubiquinone, respectively. This allows us to propose a mechanism for the reduction of ubiquinone during the catalytic turnover of the enzyme.	Univ London Imperial Coll Sci Technol & Med, Div Mol Biosci, London SW7 2AZ, England; Dept Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Syngenta, Jealotts Hill Int Res Ctr, Bracknell RG42 6EY, Berks, England; Kitasato Univ, Sch Pharmaceut Sci, Tokyo 1088641, Japan; Kitasato Inst, Minato Ku, Tokyo 1088642, Japan	Imperial College London; University of California System; University of California San Francisco; Syngenta; Kitasato University	Cecchini, G (corresponding author), Vet Affairs Med Ctr, San Francisco, CA 94121 USA.	ceccini@itsa.ucsf.edu; s.iwata@imperial.ac.uk	Horsefield, Rob/B-1378-2010	Shiomi, Kazuro/0000-0003-1264-5116; Byrne, Bernadette/0000-0001-9598-9832	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061606] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BB/C505116/1] Funding Source: Medline; NIGMS NIH HHS [GM 61606] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baysal BE, 2001, J MOL MED, V79, P495, DOI 10.1007/s001090100267; Berry EA, 2003, FEBS LETT, V555, P13, DOI 10.1016/S0014-5793(03)01099-8; BROOMFIELD PLE, 1992, CURR GENET, V22, P117, DOI 10.1007/BF00351470; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; Cecchini G, 2002, BBA-BIOENERGETICS, V1553, P140, DOI 10.1016/S0005-2728(01)00238-9; CRANE FL, 1966, PHYSIOL REV, V46, P662, DOI 10.1152/physrev.1966.46.4.662; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; Dikanov SA, 2004, J BIOL CHEM, V279, P15814, DOI 10.1074/jbc.M313417200; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Fisher N, 2000, J MOL BIOL, V296, P1153, DOI 10.1006/jmbi.2000.3509; GRIVENNIKOVA VG, 1982, BIOCHIM BIOPHYS ACTA, V682, P491, DOI 10.1016/0005-2728(82)90065-2; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Horsefield R, 2004, CURR PROTEIN PEPT SC, V5, P107, DOI 10.2174/1389203043486847; Horsefield R, 2003, ACTA CRYSTALLOGR D, V59, P600, DOI 10.1107/S0907444903002075; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; INGLEDEW WJ, 1977, BIOCHEM J, V164, P617, DOI 10.1042/bj1640617; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii T, 2005, CANCER RES, V65, P203; Ishikita H, 2004, J AM CHEM SOC, V126, P8059, DOI 10.1021/ja038092q; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; KEON JPR, 1994, BIOCHEM SOC T, V22, P234, DOI 10.1042/bst0220234; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Lancaster CRD, 2002, BBA-BIOENERGETICS, V1553, P1, DOI 10.1016/S0005-2728(01)00240-7; Lancaster CRD, 2000, P NATL ACAD SCI USA, V97, P13051, DOI 10.1073/pnas.220425797; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; Matsson M, 2001, J BIOENERG BIOMEMBR, V33, P99, DOI 10.1023/A:1010744330092; Miyadera H, 2003, P NATL ACAD SCI USA, V100, P473, DOI 10.1073/pnas.0237315100; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; OMURA S, 1988, J ANTIBIOT, V41, P1769, DOI 10.7164/antibiotics.41.1769; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oyedotun KS, 2004, J BIOL CHEM, V279, P9424, DOI 10.1074/jbc.M311876200; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Paddock ML, 2003, FEBS LETT, V555, P45, DOI 10.1016/S0014-5793(03)01149-9; PADDOCK ML, 1990, P NATL ACAD SCI USA, V87, P6803, DOI 10.1073/pnas.87.17.6803; Parfait B, 2000, HUM GENET, V106, P236, DOI 10.1007/s004390051033; Pedretti A, 2002, J MOL GRAPH MODEL, V21, P47, DOI 10.1016/S1093-3263(02)00123-7; RAMSAY RR, 1981, P NATL ACAD SCI-BIOL, V78, P825, DOI 10.1073/pnas.78.2.825; Rothery RA, 2005, FEBS J, V272, P313, DOI 10.1111/j.1742-4658.2004.04469.x; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; Sobolev V, 1999, BIOINFORMATICS, V15, P327, DOI 10.1093/bioinformatics/15.4.327; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Verdonk ML, 1999, J MOL BIOL, V289, P1093, DOI 10.1006/jmbi.1999.2809; Verdonk ML, 2003, PROTEINS, V52, P609, DOI 10.1002/prot.10465; WARNCKE K, 1994, BIOCHEMISTRY-US, V33, P7830, DOI 10.1021/bi00191a010; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020	53	214	229	2	61	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7309	7316		10.1074/jbc.M508173200	http://dx.doi.org/10.1074/jbc.M508173200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407191	hybrid			2022-12-27	WOS:000236030900049
J	Akasaki, Y; Liu, GT; Matundan, HH; Ng, HS; Yuan, XP; Zeng, ZH; Black, KL; Yu, JS				Akasaki, Y; Liu, GT; Matundan, HH; Ng, HS; Yuan, XP; Zeng, ZH; Black, KL; Yu, JS			A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and-9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED APOPTOSIS; GLIOBLASTOMA CELLS; CYTOCHROME-C; INDUCTION; KINASE; RESISTANCE; INHIBITION; GROWTH; THIAZOLIDINEDIONES; EXPRESSION	Despite dramatic advances in adjuvant therapies, patients with malignant glioma face a bleak prognosis. Because many adjuvant therapies seek to induce glioma apoptosis, strategies that lower thresholds for the induction of apoptosis may improve patient outcomes. Therefore, elucidation of the biological mechanisms that underlie resistance to current therapies is needed to develop new therapeutic strategies. Here we proposed a novel mechanism of proapoptotic effect induced by a pharmacological peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonist, troglitazone, that facilitates caspase signaling in human glioma cells. Troglitazone activates protein-tyrosine phosphatase (PTP)-1B, which subsequently reduces phosphotyrosine 705 STAT3 (pY705-STAT3) via a PPAR gamma-independent pathway. Reduction of pY705-STAT3 in glioma cells caused down-regulation of FLIP (FADD-like IL-1 beta-converting enzyme-inhibitory protein) and Bcl-2. Furthermore, troglitazone induced Ser-392 phosphorylation of p53 via a PPAR gamma-dependent pathway and up-regulation of Bax in a p53 wild-type glioma. When given with tumor necrosis factor-related apoptosis-inducing ligand or caspase-dependent chemotherapeutic agents, such as etoposide and paclitaxel, troglitazone exhibited a synergistic effect by facilitating caspase-8/9 activities. A PPAR gamma antagonist, GW9662, did not block this effect, although a PTP inhibitor abrogated it. Knockdown of STAT3 by STAT3-small interfering RNA negated the inhibitory effect of PTP inhibitor on troglitazone, indicating that troglitazone uses a STAT3 inactivation mechanism that makes caspase-8/9 activities susceptible to cytotoxic agents in glioma cells and that PTP1B plays a critical role in the down-regulation of activated STAT3, as well as FLIP and Bcl-2. When taken with caspase-dependent anti-neoplastic agents, troglitazone may be a promising drug for use against malignant gliomas because it facilitates the caspase cascade, thereby lowering thresholds for the apoptosis induction of glioma cells.	Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Yu, JS (corresponding author), Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, 800 E,8631 W 3rd St, Los Angeles, CA 90048 USA.	yuj@cshs.org		Yu, John/0000-0003-1230-8494; Black, Keith/0000-0002-0546-4934				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akasaki Y, 2004, J IMMUNOL, V173, P4352, DOI 10.4049/jimmunol.173.7.4352; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; Arabaci G, 1999, J AM CHEM SOC, V121, P5085, DOI 10.1021/ja9906756; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bobola MS, 2004, CLIN CANCER RES, V10, P7875, DOI 10.1158/1078-0432.CCR-04-1161; Bousquet C, 1999, J CLIN INVEST, V104, P1277, DOI 10.1172/JCI7924; Chakravarti A, 2004, ONCOGENE, V23, P7494, DOI 10.1038/sj.onc.1208049; Charest A, 2003, P NATL ACAD SCI USA, V100, P916, DOI 10.1073/pnas.242741799; Chen CW, 2003, J IMMUNOL, V171, P979, DOI 10.4049/jimmunol.171.2.979; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970; Hao CH, 2001, CANCER RES, V61, P1162; Hsu S, 2003, CELL SIGNAL, V15, P1149, DOI 10.1016/S0898-6568(03)00088-3; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kaszubska W, 2002, MOL CELL ENDOCRINOL, V195, P109, DOI 10.1016/S0303-7207(02)00178-8; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Koeffler HP, 2003, CLIN CANCER RES, V9, P1; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Konnikova L, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-23; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Li B, 2003, CANCER RES, V63, P7443; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin CF, 2004, J BIOL CHEM, V279, P40755, DOI 10.1074/jbc.M404726200; Liu GT, 2004, EUR J IMMUNOL, V34, P1680, DOI 10.1002/eji.200425081; Nikitakis NG, 2002, BRIT J CANCER, V87, P1396, DOI 10.1038/sj.bjc.6600618; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Palakurthi SS, 2001, CANCER RES, V61, P6213; Park EJ, 2003, J BIOL CHEM, V278, P14747, DOI 10.1074/jbc.M210819200; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Perkins CL, 2000, CANCER RES, V60, P1645; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Rippo MR, 2004, ONCOGENE, V23, P7753, DOI 10.1038/sj.onc.1208051; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Shiau CW, 2005, CANCER RES, V65, P1561, DOI 10.1158/0008-5472.CAN-04-1677; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Teixeira JE, 2002, INFECT IMMUN, V70, P1816, DOI 10.1128/IAI.70.4.1816-1823.2002; Thomas CY, 2003, INT J CANCER, V104, P19, DOI 10.1002/ijc.10880; Thomas LR, 2004, J BIOL CHEM, V279, P32780, DOI 10.1074/jbc.M401680200; VAN MEIR EG, 1994, CANCER RES, V54, P649; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Yoon G, 2002, J NEURO-ONCOL, V60, P135, DOI 10.1023/A:1020604705831; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	50	63	65	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6165	6174		10.1074/jbc.M505266200	http://dx.doi.org/10.1074/jbc.M505266200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16319070	hybrid			2022-12-27	WOS:000236030800008
J	Bienert, R; Baier, K; Volkmer, R; Lockau, W; Heinemann, U				Bienert, R; Baier, K; Volkmer, R; Lockau, W; Heinemann, U			Crystal structure of NblA from Anabaena sp PCC 7120, a small protein playing a key role in phycobilisome degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MACROMOLECULAR STRUCTURES; CYANOBACTERIUM ANABAENA; SPIRULINA-PLATENSIS; DIFFRACTION DATA; STRAIN PCC-6803; PHYCOCYANIN; EXPRESSION; NITROGEN; REFINEMENT	Cyanobacterial light-harvesting complexes, the phycobilisomes, are proteolytically degraded when the organisms are starved for combined nitrogen, a process referred to as chlorosis or bleaching. Gene nblA, present in all phycobilisome-containing organisms, encodes a protein of about 7 kDa that plays a key role in phycobilisome degradation. The mode of action of NblA in this degradation process is poorly understood. Here we presented the 1.8-angstrom crystal structure of NblA from Anabaena sp. PCC 7120. In the crystal, NblA is present as a four-helix bundle formed by dimers, the basic structural units. By using pull-down assays with immobilized NblA and peptide scanning, we showed that NblA specifically binds to the alpha-subunits of phycocyanin and phycoerythrocyanin, the main building blocks of the phycobilisome rod structure. By site-directed mutagenesis, we identified amino acid residues in NblA that are involved in phycobilisome binding. The results provided evidence that NblA is directly involved in phycobilisome degradation, and the results allowed us to present a model that gives insight into the interaction of this small protein with the phycobilisomes.	Max Delbruck Ctr Mol Med, Crystallog Grp, D-13125 Berlin, Germany; Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; CCM Univ Med Berlin, Mol Lib, Inst Med Immunol, D-10115 Berlin, Germany; Free Univ Berlin, Inst Chem Crystallog, D-14195 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Baier, K (corresponding author), Max Delbruck Ctr Mol Med, Crystallog Grp, FG Kristallog,Robert Rossle Str 10, D-13125 Berlin, Germany.	kerstin.baier@biologie.hu-berlin.de	Heinemann, Udo/S-3379-2016; Heinemann, Udo/AAH-4766-2019	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850; Volkmer, Rudolf/0000-0003-4710-1143				ALLEN MM, 1969, ARCH MIKROBIOL, V69, P114, DOI 10.1007/BF00409755; Baier K, 2004, MICROBIOL-SGM, V150, P2739, DOI 10.1099/mic.0.27153-0; Baier K, 2001, FEMS MICROBIOL LETT, V195, P35, DOI 10.1111/j.1574-6968.2001.tb10494.x; Boisguerin P, 2004, CHEM BIOL, V11, P449, DOI 10.1016/j.chembiol.2004.03.010; BOUSSIBA S, 1980, ARCH MICROBIOL, V125, P143, DOI 10.1007/BF00403211; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; COLLIER JL, 1994, EMBO J, V13, P1039, DOI 10.1002/j.1460-2075.1994.tb06352.x; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Dolganov N, 1999, J BACTERIOL, V181, P610, DOI 10.1128/JB.181.2.610-617.1999; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FOULDS IJ, 1977, FEMS MICROBIOL LETT, V2, P117; GLAZER AN, 1982, ANNU REV MICROBIOL, V36, P173, DOI 10.1146/annurev.mi.36.100182.001133; Grossman AR, 2001, J BIOL CHEM, V276, P11449, DOI 10.1074/jbc.R100003200; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landgraf C, 2004, PLOS BIOL, V2, P94, DOI 10.1371/journal.pbio.0020014; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 2002, ARCH MICROBIOL, V178, P256, DOI 10.1007/s00203-002-0446-y; LOCKAU W, 1988, EUR J BIOCHEM, V172, P433, DOI 10.1111/j.1432-1033.1988.tb13906.x; Luque I, 2003, MOL MICROBIOL, V50, P1043, DOI 10.1046/j.1365-2958.2003.03768.x; MALDENER I, 1991, MOL GEN GENET, V225, P113, DOI 10.1007/BF00282649; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nanni B, 2001, MICROBIOL RES, V156, P259, DOI 10.1078/0944-5013-00110; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Piven I, 2005, J BIOL CHEM, V280, P21667, DOI 10.1074/jbc.m412967200; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Richaud C, 2001, J BACTERIOL, V183, P2989, DOI 10.1128/JB.183.10.2989-2994.2001; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; Strauss H, 2002, EUR J BIOCHEM, V269, P4617, DOI 10.1046/j.1432-1033.2002.03161.x; Studemann A, 2003, EMBO J, V22, P4111, DOI 10.1093/emboj/cdg411; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toole CM, 1998, MOL MICROBIOL, V30, P475, DOI 10.1046/j.1365-2958.1998.01082.x; Weiser AA, 2005, ANAL BIOCHEM, V342, P300, DOI 10.1016/j.ab.2005.04.033; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; WOOD NB, 1979, LTD PROTEOLYSIS MICR, P159	49	38	40	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5216	5223		10.1074/jbc.M507243200	http://dx.doi.org/10.1074/jbc.M507243200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16356935	hybrid			2022-12-27	WOS:000235426200076
J	Song, G; Lazar, GA; Kortemme, T; Shimaoka, M; Desjarlais, JR; Baker, D; Springer, TA				Song, G; Lazar, GA; Kortemme, T; Shimaoka, M; Desjarlais, JR; Baker, D; Springer, TA			Rational design of intercellular adhesion molecule-1 (ICAM-1) variants for antagonizing integrin lymphocyte function-associated antigen-1-dependent adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN COMPLEXES; HIGH-LEVEL EXPRESSION; I-LIKE DOMAIN; CONFORMATIONAL REGULATION; COMPUTATIONAL DESIGN; BINDING-ENERGY; HIGH-AFFINITY; SUBUNIT; RECOGNITION; PREDICTION	The interaction between integrin lymphocyte function-associated antigen-1 ( LFA-1) and its ligand intercellular adhesion molecule-1 ( ICAM-1) is critical in immunological and inflammatory reactions but, like other adhesive interactions, is of low affinity. Here, multiple rational design methods were used to engineer ICAM-1 mutants with enhanced affinity for LFA-1. Five amino acid substitutions 1) enhance the hydrophobicity and packing of residues surrounding Glu-34 of ICAM-1, which coordinates to a Mg2+ in the LFA-1 I domain, and 2) alter associations at the edges of the binding interface. The affinity of the most improved ICAM-1 mutant for intermediate-and high-affinity LFA-1 I domains was increased by 19-fold and 22-fold, respectively, relative to wild type. Moreover, potency was similarly enhanced for inhibition of LFA-1-dependent ligand binding and cell adhesion. Thus, rational design can be used to engineer novel adhesion molecules with high monomeric affinity; furthermore, the ICAM-1 mutant holds promise for targeting LFA-1-ICAM-1 interaction for biological studies and therapeutic purposes.	Harvard Univ, Sch Med, CBR Inst Biochem Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Xencor, Monrovia, CA 91016 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Springer, TA (corresponding author), Harvard Univ, Sch Med, CBR Inst Biochem Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu	Kortemme, Tanja/AAN-3180-2021; Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Kortemme, Tanja/0000-0002-8494-680X; Lazar, Greg/0000-0003-2169-8703	NCI NIH HHS [R01 CA031798, CA31798, R37 CA031798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; Crawford F, 1998, IMMUNITY, V8, P675, DOI 10.1016/S1074-7613(00)80572-5; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; Dahiyat BI, 1996, PROTEIN SCI, V5, P895, DOI 10.1002/pro.5560050511; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Dunbrack RL, 1997, PROTEIN SCI, V6, P1661, DOI 10.1002/pro.5560060807; DUSTIN ML, 1999, GUIDEBOOK EXTRACELLU, P216; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Jun CD, 2001, P NATL ACAD SCI USA, V98, P6830, DOI 10.1073/pnas.121186998; Kim M, 2004, J CELL BIOL, V167, P1241, DOI 10.1083/jcb.200404160; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; Kortemme T, 2004, CURR OPIN CHEM BIOL, V8, P91, DOI 10.1016/j.cbpa.2003.12.008; Kortemme T, 2003, J MOL BIOL, V326, P1239, DOI 10.1016/S0022-2836(03)00021-4; Kortemme T, 2002, P NATL ACAD SCI USA, V99, P14116, DOI 10.1073/pnas.202485799; Kuhlman B, 2000, P NATL ACAD SCI USA, V97, P10383, DOI 10.1073/pnas.97.19.10383; Lazar GA, 2003, CURR OPIN STRUC BIOL, V13, P513, DOI 10.1016/S0959-440X(03)00104-0; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Lu CF, 1997, J IMMUNOL, V159, P268; Luo P, 2002, PROTEIN SCI, V11, P1218, DOI 10.1110/ps.4580102; Marshall SA, 2003, DRUG DISCOV TODAY, V8, P212, DOI 10.1016/S1359-6446(03)02610-2; Martin L, 2003, NAT BIOTECHNOL, V21, P71, DOI 10.1038/nbt768; Mendes J, 1999, PROTEINS, V37, P530; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Raha K, 2000, PROTEIN SCI, V9, P1106, DOI 10.1110/ps.9.6.1106; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13413, DOI 10.1073/pnas.212519199; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Sarkar CA, 2002, NAT BIOTECHNOL, V20, P908, DOI 10.1038/nbt725; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Selzer T, 2000, NAT STRUCT BIOL, V7, P537; Selzer T, 1999, J MOL BIOL, V287, P409, DOI 10.1006/jmbi.1999.2615; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2003, IMMUNITY, V19, P391, DOI 10.1016/S1074-7613(03)00238-3; Shimaoka M, 2003, NAT REV DRUG DISCOV, V2, P703, DOI 10.1038/nrd1174; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; Song G, 2005, P NATL ACAD SCI USA, V102, P3366, DOI 10.1073/pnas.0500200102; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Tamada A, 1998, NEUROSCI LETT, V240, P163, DOI 10.1016/S0304-3940(97)00951-8; Tian L, 1997, J IMMUNOL, V158, P928; Wang JH, 2002, TRENDS BIOCHEM SCI, V27, P122, DOI 10.1016/S0968-0004(01)02038-2; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920	47	42	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5042	5049		10.1074/jbc.M510454200	http://dx.doi.org/10.1074/jbc.M510454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16354667	hybrid, Green Accepted			2022-12-27	WOS:000235426200058
J	Xu, DR; Wang, SQ; Liu, W; Liu, JZ; Feng, X				Xu, DR; Wang, SQ; Liu, W; Liu, JZ; Feng, X			A novel receptor activator of NF-kappa B (RANK) cytoplasmic motif plays an essential role in osteoclastogenesis by committing macrophages to the osteoclast lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF FAMILY-MEMBER; ALPHA-INDUCED OSTEOCLASTOGENESIS; LYMPH-NODE ORGANOGENESIS; OSTEOPROTEGERIN-LIGAND; DIFFERENTIATION FACTOR; TERMINAL KINASE; BONE-RESORPTION; DENDRITIC-CELL; KEY REGULATOR	Receptor activator of NF-kappa B (RANK) ligand (RANKL) and its receptor RANK play an essential role in osteoclastogenesis and osteoclast function by activating several signaling pathways. However, several lines of evidence suggest that RANK also transmits an unidentified signaling pathway(s) essential for osteoclastogenesis. To identify the novel pathway(s), we carried out a detailed structure/function study of the RANK cytoplasmic domain. A series of studies using numerous deletion/point mutants elucidated a specific 4-amino acid motif ((IVVY538)-I-535) essential for osteoclastogenesis. This novel motif plays a crucial role in committing macrophages to the osteoclast lineage but is not implicated in osteoclast function or survival. Moreover, this motif does not activate the known RANK signaling pathways, indicating that it initiates a novel pathway(s). The identification of the novel motif not only provides critical insight into RANK signaling in osteoclastogenesis, but more importantly, the RANK motif and its downstream signaling pathways may represent specific therapeutic targets for various bone diseases, including postmenopausal osteoporosis.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Feng, X (corresponding author), Univ Alabama, Dept Pathol, 1670 Univ Blvd,VH G046B, Birmingham, AL 35294 USA.	xfeng@path.uab.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046031, R01AR047830] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 47830, P30AR46031] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Barnhart KN, 1999, BIOTECHNIQUES, V26, P624, DOI 10.2144/99264bm06; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527; Chung JY, 2002, J CELL SCI, V115, P679; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Doggrell SA, 2003, DRUG TODAY, V39, P633, DOI 10.1358/dot.2003.39.8.799409; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Eghbali-Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669; Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733; Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200; Jimi E, 1999, J IMMUNOL, V163, P434; Jin Y, 1998, BLOOD, V92, P2777, DOI 10.1182/blood.V92.8.2777.420k27_2777_2790; Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225; Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Kitazawa S, 2002, J PATHOL, V198, P228, DOI 10.1002/path.1199; Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176; Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566; Liu W, 2004, J BIOL CHEM, V279, P54759, DOI 10.1074/jbc.M404687200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Walsh MC, 2003, CYTOKINE GROWTH F R, V14, P251, DOI 10.1016/S1359-6101(03)00027-3; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Wong BR, 1999, J LEUKOCYTE BIOL, V65, P715, DOI 10.1002/jlb.65.6.715; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yeh WC, 1999, IMMUNOL REV, V169, P283, DOI 10.1111/j.1600-065X.1999.tb01323.x; Zhang J, 2003, CANCER RES, V63, P7883	60	35	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4678	4690		10.1074/jbc.M510383200	http://dx.doi.org/10.1074/jbc.M510383200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373338	hybrid			2022-12-27	WOS:000235426200016
J	Bauman, AT; Yukl, ET; Alkevich, K; McCormack, AL; Blackburn, NJ				Bauman, AT; Yukl, ET; Alkevich, K; McCormack, AL; Blackburn, NJ			The hydrogen peroxide reactivity of peptidylglycine monooxygenase supports a Cu(II)-superoxo catalytic intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HYDROXYLATING MONOOXYGENASE; BINUCLEAR COPPER SITE; AMIDATING ENZYME; OXYGEN ACTIVATION; ELECTRON-TRANSFER; MONONUCLEAR COPPER; PEPTIDE AMIDATION; ACTIVE-SITE; MECHANISM; MUTAGENESIS	We have investigated the reaction of peptidylglycine monooxygenase with hydrogen peroxide to determine whether Cu(II)-peroxo is a likely intermediate. When the oxidized enzyme was reacted with the dansyl-YVG substrate and H2O2, the alpha-hydroxyglycine product was formed. The reaction was catalytic and did not require the presence of additional reductant. When O-18-labeled H2O2 was reacted with peptidylglycine monooxygenase and substrate anaerobically, oxygen in the product was labeled with O-18 and must therefore be derived from H2O2. However, when the reaction was carried out with H-2 O-16(2) in the presence of O-18(2), 60% of the product contained the O-18 label. Therefore, the reaction must proceed via an intermediate that can react directly with dioxygen and thus scramble the label. Under strictly anaerobic conditions ( in the presence of glucose and glucose oxidase, where no oxygen was released into the medium from nonenzymatic peroxide decomposition), product formation and peroxide consumption were tightly coupled, and the rate of product formation was identical to that measured under aerobic conditions. Peroxide reactivity was eliminated by amutation at the Cu-H center, which should not be involved in the peroxide shunt. Our data lend support to recent proposals that Cu(II)-superoxide is the active species.	Oregon Hlth Sci Univ, OGI Sch Sci & Engn, Dept Environm & Biomol Syst, Beaverton, OR 97006 USA; Oregon Hlth Sci Univ, Mass Spectrometry Lab, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA	Oregon Health & Science University; Oregon Health & Science University	Blackburn, NJ (corresponding author), Oregon Hlth Sci Univ, OGI Sch Sci & Engn, Dept Environm & Biomol Syst, 20000 NW Walker Rd, Beaverton, OR 97006 USA.	ninian@ebs.ogi.edu		Yukl, Erik/0000-0001-6519-6938	NINDS NIH HHS [NS-27583] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027583] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bell J, 2003, BIOCHEMISTRY-US, V42, P7133, DOI 10.1021/bi034247v; Blackburn NJ, 2000, J BIOL INORG CHEM, V5, P341, DOI 10.1007/PL00010663; Boswell JS, 1996, BIOCHEMISTRY-US, V35, P12241, DOI 10.1021/bi960742y; Chen P, 2004, P NATL ACAD SCI USA, V101, P13105, DOI 10.1073/pnas.0402114101; Chen P, 2004, J AM CHEM SOC, V126, P4991, DOI 10.1021/ja031564g; Chen P, 2004, BIOCHEMISTRY-US, V43, P5735, DOI 10.1021/bi0362830; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; EIPPER BA, 1995, BIOCHEMISTRY-US, V34, P2857, DOI 10.1021/bi00009a016; Evans JP, 2003, J BIOL CHEM, V278, P49691, DOI 10.1074/jbc.M300797200; Francisco WA, 2004, J AM CHEM SOC, V126, P13168, DOI 10.1021/ja046888z; Francisco WA, 2002, J AM CHEM SOC, V124, P8194, DOI 10.1021/ja025758s; Francisco WA, 1998, BIOCHEMISTRY-US, V37, P8244, DOI 10.1021/bi973004y; FREEMAN JC, 1993, J AM CHEM SOC, V115, P4923, DOI 10.1021/ja00064a077; FROLAND WA, 1992, J BIOL CHEM, V267, P17588; HRYCAY EG, 1976, EUR J BIOCHEM, V61, P43, DOI 10.1111/j.1432-1033.1976.tb09995.x; Jaron S, 2002, BIOCHEMISTRY-US, V41, P13274, DOI 10.1021/bi020404z; Jaron S, 1999, BIOCHEMISTRY-US, V38, P15086, DOI 10.1021/bi991341w; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KULATHILA R, 1994, ARCH BIOCHEM BIOPHYS, V311, P191, DOI 10.1006/abbi.1994.1225; LI CZ, 1994, BIOCHEM J, V300, P31, DOI 10.1042/bj3000031; MERKLER DJ, 1992, BIOCHEMISTRY-US, V31, P7282, DOI 10.1021/bi00147a011; Prigge ST, 2004, SCIENCE, V304, P864, DOI 10.1126/science.1094583; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Prigge ST, 1997, SCIENCE, V278, P1300, DOI 10.1126/science.278.5341.1300; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Su QJ, 1999, BIOCHEMISTRY-US, V38, P8572, DOI 10.1021/bi990044o; Wolfe MD, 2003, J BIOL CHEM, V278, P829, DOI 10.1074/jbc.M209604200	27	44	45	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4190	4198		10.1074/jbc.M511199200	http://dx.doi.org/10.1074/jbc.M511199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16330540	hybrid			2022-12-27	WOS:000235275300051
J	Klumpp, K; Leveque, V; Le Pogam, S; Ma, H; Jiang, WR; Kang, HS; Granycome, C; Singer, M; Laxton, C; Hang, JQ; Sarma, K; Smith, DB; Heindl, D; Hobbs, CJ; Merrett, JH; Symons, J; Cammack, N; Martin, JA; Devos, R; Najera, I				Klumpp, K; Leveque, V; Le Pogam, S; Ma, H; Jiang, WR; Kang, HS; Granycome, C; Singer, M; Laxton, C; Hang, JQ; Sarma, K; Smith, DB; Heindl, D; Hobbs, CJ; Merrett, JH; Symons, J; Cammack, N; Martin, JA; Devos, R; Najera, I			The novel nucleoside analog R1479 (4 '-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2A PLUS RIBAVIRIN; SPECTRUM ANTIVIRAL ACTIVITY; REPLICON	Hepatitis C virus (HCV) polymerase activity is essential for HCV replication. Targeted screening of nucleoside analogs identified R1479 (4'-azidocytidine) as a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC50 = 1.28 mu M) with similar potency compared with 2'-C-methylcytidine (IC50 = 1.13 mu M). R1479 showed no effect on cell viability or proliferation of HCV replicon or Huh-7 cells at concentrations up to 2 mM. HCV replicon RNA could be fully cleared from replicon cells after prolonged incubation with R1479. The corresponding 5'-triphosphate derivative (R1479-TP) is a potent inhibitor of native HCV replicase isolated from replicon cells and of recombinant HCV polymerase (NS5B)-mediated RNA synthesis activity. R1479-TP inhibited RNA synthesis as a CTP-competitive inhibitor with a K-i of 40 nM. On an HCV RNA-derived template substrate (complementary internal ribosome entry site), R1479-TP showed similar potency of NS5B inhibition compared with 3'-dCTP. R1479-TP was incorporated into nascent RNA by HCV polymerase and reduced further elongation with similar efficiency compared with 3'-dCTP under the reaction conditions. The S282T point mutation in the coding sequence of NS5B confers resistance to inhibition by 2'-C-MeATP and other 2'-methyl-nucleotides. In contrast, the S282T mutation did not confer cross-resistance to R1479.	Roche Palo Alto LLC, Palo Alto, CA 94304 USA; Roche Diagnost GmbH, D-82377 Penzberg, Germany	Roche Holding; Roche Holding	Klumpp, K (corresponding author), Roche Palo Alto LLC, 3431 Hillview Ave, Palo Alto, CA 94304 USA.	klaus.klumpp@roche.com						[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Beaulieu Pierre L, 2004, Curr Opin Investig Drugs, V5, P838; Carroll SS, 2003, J BIOL CHEM, V278, P11979, DOI 10.1074/jbc.M210914200; Chung RT, 2004, NEW ENGL J MED, V351, P451, DOI 10.1056/NEJMoa032653; Crotty S, 2000, NAT MED, V6, P1375, DOI 10.1038/82191; Eldrup AB, 2004, J MED CHEM, V47, P5284, DOI 10.1021/jm040068f; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Frese M, 2002, HEPATOLOGY, V35, P694, DOI 10.1053/jhep.2002.31770; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; Krieger N, 2001, J VIROL, V75, P4614, DOI 10.1128/JVI.75.10.4614-4624.2001; Lau JYN, 2002, HEPATOLOGY, V35, P1002, DOI 10.1053/jhep.2002.32672; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Ma H, 2005, VIROLOGY, V332, P8, DOI 10.1016/j.virol.2004.11.024; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Migliaccio G, 2003, J BIOL CHEM, V278, P49164, DOI 10.1074/jbc.M305041200; Moradpour D, 2003, ANTIVIR RES, V60, P103, DOI 10.1016/j.antiviral.2003.08.017; Olsen DB, 2004, ANTIMICROB AGENTS CH, V48, P3944, DOI 10.1128/AAC.48.10.3944-3953.2004; Pawlotsky JM, 2004, NEW ENGL J MED, V351, P422, DOI 10.1056/NEJMp048068; Pietschmann T, 2001, J VIROL, V75, P1252, DOI 10.1128/JVI.75.3.1252-1264.2001; Shim J, 2003, ANTIVIR RES, V58, P243, DOI 10.1016/S0166-3542(03)00007-X; SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705; Stuyver LJ, 2004, ANTIMICROB AGENTS CH, V48, P651, DOI 10.1128/AAC.48.2.651-654.2004; Thomson BJ, 2005, CLIN MICROBIOL INFEC, V11, P86, DOI 10.1111/j.1469-0691.2004.01061.x; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P2454, DOI 10.1128/AAC.39.11.2454; Torriani FJ, 2004, NEW ENGL J MED, V351, P438, DOI 10.1056/NEJMoa040842; Vrolijk JM, 2003, J VIROL METHODS, V110, P201, DOI 10.1016/S0166-0934(03)00134-4; WITKOWSKI JT, 1972, J MED CHEM, V15, P1150, DOI 10.1021/jm00281a014	27	175	220	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3793	3799		10.1074/jbc.M510195200	http://dx.doi.org/10.1074/jbc.M510195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16316989	hybrid			2022-12-27	WOS:000235275300007
J	Matsumoto, G; Kim, S; Morimoto, RI				Matsumoto, G; Kim, S; Morimoto, RI			Huntingtin and mutant SOD1 form aggregate structures with distinct molecular properties in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; NEURONAL INTRANUCLEAR INCLUSIONS; TATA-BINDING PROTEIN; NEURODEGENERATIVE DISEASES; POLYGLUTAMINE AGGREGATION; EXPANDED POLYGLUTAMINE; SUPEROXIDE-DISMUTASE; CELLULAR TOXICITY; AMYLOID FORMATION; COACTIVATOR CBP	Expression of many proteins associated with neurodegenerative disease results in the appearance of misfolded species that readily adopt alternate folded states. In vivo, these appear as punctated subcellular structures typically referred to as aggregates or inclusion bodies. Whereas groupings of these distinct proteins into a common morphological class have been useful conceptually, there is some suggestion that aggregates are not homogeneous and can exhibit a range of biological properties. In this study, we use dynamic imaging analysis of living cells to compare the aggregation and growth properties of mutant huntingtin with polyglutamine expansions or mutant SOD1 (G85R/G93A) to examine the formation of aggregate structures and interactions with other cellular proteins. Using a dual conditional expression system for sequential expression of fluorescence- tagged proteins, we show that mutant huntingtin forms multiple intracellular cytoplasmic and nuclear structures composed of a dense core inaccessible to nascent polypeptides surrounded by a surface that stably sequesters certain transcription factors and interacts transiently with molecular chaperones. In contrast, mutant SOD1 (G85R/G93A) forms a distinct aggregate structure that is porous, through which nascent proteins diffuse. These results reveal that protein aggregates do not correspond to a single common class of subcellular structures, and rather that there may be a wide range of aggregate structures, perhaps each corresponding to the specific disease-associated protein with distinct consequences on the biochemical state of the cell.	Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Morimoto, RI (corresponding author), Northwestern Univ, Rice Inst Biomed Res, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	r-morimoto@northwestern.edu		Matsumoto, Gen/0000-0002-9339-1682	NIGMS NIH HHS [R37 GM038109] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apostol BL, 2003, P NATL ACAD SCI USA, V100, P5950, DOI 10.1073/pnas.2628045100; Becker M, 2000, J CELL BIOL, V149, P255, DOI 10.1083/jcb.149.2.255; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; Bossy-Wetzel E, 2004, NAT MED, V10, pS2, DOI 10.1038/nm1067; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chen DY, 2002, MOL BIOL CELL, V13, P276, DOI 10.1091/mbc.01-10-0523; Chen HK, 2003, CELL, V113, P457, DOI 10.1016/S0092-8674(03)00349-0; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chong JA, 2005, MOL CELL BIOL, V25, P2632, DOI 10.1128/MCB.25.7.2632-2643.2005; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Emamian ES, 2003, NEURON, V38, P375, DOI 10.1016/S0896-6273(03)00258-7; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Hazeki N, 2002, BIOCHEM BIOPH RES CO, V294, P429, DOI 10.1016/S0006-291X(02)00498-9; Holmberg CI, 2004, EMBO J, V23, P4307, DOI 10.1038/sj.emboj.7600426; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Hughes RE, 2001, NAT MED, V7, P419, DOI 10.1038/86486; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Martin-Aparicio E, 2001, J NEUROSCI, V21, P8772, DOI 10.1523/JNEUROSCI.21-22-08772.2001; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; Muchowskil PJ, 2002, NEURON, V35, P9, DOI 10.1016/S0896-6273(02)00761-4; Nagai Y, 1999, EXP NEUROL, V155, P195, DOI 10.1006/exnr.1998.6991; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; OKAMOTO K, 1991, NEUROSCI LETT, V129, P233, DOI 10.1016/0304-3940(91)90469-A; Patterson GH, 1998, YEAST, V14, P813, DOI 10.1002/(SICI)1097-0061(19980630)14:9<813::AID-YEA280>3.0.CO;2-2; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Qin ZH, 2004, J NEUROSCI, V24, P269, DOI 10.1523/JNEUROSCI.1409-03.2004; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reid SJ, 2004, MOL BRAIN RES, V125, P120, DOI 10.1016/j.molbrainres.2004.03.018; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schmidt T, 2002, ANN NEUROL, V51, P302, DOI 10.1002/ana.10101; Shimizu N, 2000, J NEURAL TRANSM-SUPP, P19; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Stenoien DL, 2002, NAT CELL BIOL, V4, P806, DOI 10.1038/ncb859; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Suhr ST, 2001, J CELL BIOL, V153, P283, DOI 10.1083/jcb.153.2.283; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Urushitani M, 2004, J NEUROCHEM, V90, P231, DOI 10.1111/j.1471-4159.2004.02486.x; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	60	84	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4477	4485		10.1074/jbc.M509201200	http://dx.doi.org/10.1074/jbc.M509201200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16371362				2022-12-27	WOS:000235275300083
J	Huang, IC; Bosch, BJ; Li, F; Li, WH; Lee, KH; Ghiran, S; Vasilieva, N; Dermody, TS; Harrison, SC; Dormitzer, PR; Farzan, M; Rottier, PJM; Choe, H				Huang, IC; Bosch, BJ; Li, F; Li, WH; Lee, KH; Ghiran, S; Vasilieva, N; Dermody, TS; Harrison, SC; Dormitzer, PR; Farzan, M; Rottier, PJM; Choe, H			SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-RESPIRATORY-SYNDROME; ANGIOTENSIN-CONVERTING ENZYME-2; SPIKE GLYCOPROTEIN; RECEPTOR SPECIFICITY; FUNCTIONAL RECEPTOR; TISSUE DISTRIBUTION; REOVIRUS INFECTION; AMINOPEPTIDASE-N; YOUNG-CHILDREN; TRACT DISEASE	Viruses require specific cellular receptors to infect their target cells. Angiotensin-converting enzyme 2 ( ACE2) is a cellular receptor for two divergent coronaviruses, SARS coronavirus (SARS-CoV) and human coronavirus NL63 (HCoV-NL63). In addition to host-cell receptors, lysosomal cysteine proteases are required for productive infection by some viruses. Here we show that SARS-CoV, but not HCoV-NL63, utilizes the enzymatic activity of the cysteine protease cathepsin L to infect ACE2-expressing cells. Inhibitors of cathepsin L blocked infection by SARS-CoV and by a retrovirus pseudotyped with the SARS-CoV spike ( S) protein but not infection by HCoV-NL63 or a retrovirus pseudotyped with the HCoV-NL63 S protein. Expression of exogenous cathepsin L substantially enhanced infection mediated by the SARS-CoV S protein and by filovirus GP proteins but not by the HCoV-NL63 S protein or the vesicular stomatitis virus G protein. Finally, an inhibitor of endosomal acidification had substantially less effect on infection mediated by the HCoV-NL63 S protein than on that mediated by the SARS-CoV S protein. Our data indicate that two coronaviruses that utilize a common receptor nonetheless enter cells through distinct mechanisms.	Univ Utrecht, Div Virol, Dept Infect Dis & Immunol, Fac Vet Med, NL-3584 CL Utrecht, Netherlands; Univ Utrecht, Biomembrane Inst, NL-3584 CL Utrecht, Netherlands; Harvard Univ, Sch Med, Div Pulm, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, New England Reg Primate Res Ctr, Southborough, MA 01772 USA; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA	Utrecht University; Utrecht University; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Vanderbilt University	Rottier, PJM (corresponding author), Univ Utrecht, Div Virol, Dept Infect Dis & Immunol, Fac Vet Med, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.	p.j.m.rottier@vet.uu.nl; hyeryun.choe@childrens.harvard.edu	Bosch, Berend/ABD-8740-2021	Li, Wenhui/0000-0003-1305-7404; Farzan, Michael/0000-0002-2990-5319	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43891, AI0616101] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288; Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869; Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003; Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656; Chandran K, 2003, J VIROL, V77, P13361, DOI 10.1128/JVI.77.24.13361-13375.2003; Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002; Chiu SS, 2005, CLIN INFECT DIS, V40, P1721, DOI 10.1086/430301; Dimitrov DS, 2004, NAT REV MICROBIOL, V2, P109, DOI 10.1038/nrmicro817; Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Ebert DH, 2002, J BIOL CHEM, V277, P24609, DOI 10.1074/jbc.M201107200; Ebihara T, 2005, J MED VIROL, V75, P463, DOI 10.1002/jmv.20289; Esper F, 2005, J INFECT DIS, V191, P492, DOI 10.1086/428138; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P6212, DOI 10.1073/pnas.0400762101; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Golden JW, 2004, J BIOL CHEM, V279, P8547, DOI 10.1074/jbc.M309758200; Golden JW, 2002, J VIROL, V76, P7430, DOI 10.1128/JVI.76.15.7430-7443.2002; Guan Y, 2004, LANCET, V363, P99, DOI 10.1016/S0140-6736(03)15259-2; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Hofmann H, 2005, P NATL ACAD SCI USA, V102, P7988, DOI 10.1073/pnas.0409465102; HOLMES KV, 1993, ADV EXP MED BIOL, V342, P261; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; Jane-Valbuena J, 2002, J VIROL, V76, P5184, DOI 10.1128/JVI.76.10.5184-5197.2002; Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267; KUBO H, 1994, J VIROL, V68, P5403, DOI 10.1128/JVI.68.9.5403-5410.1994; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6; Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004; Odegard AL, 2003, J VIROL, V77, P5389, DOI 10.1128/JVI.77.9.5389-5400.2003; Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101; Snijder EJ, 2003, J MOL BIOL, V331, P991, DOI 10.1016/S0022-2836(03)00865-9; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597; Tresnan DB, 1998, ADV EXP MED BIOL, V440, P69; Tsai JC, 2003, J VIROL, V77, P841, DOI 10.1128/JVI.77.2.841-850.2003; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; Urbich C, 2005, NAT MED, V11, P206, DOI 10.1038/nm1182; van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024; Wei BDL, 2005, J VIROL, V79, P5705, DOI 10.1128/JVI.79.9.5705-5712.2005; Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200; Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005; Xiao X, 2004, CELL MOL LIFE SCI, V61, P2428, DOI 10.1007/s00018-004-4257-y; YEAGER CL, 1992, NATURE, V357, P420, DOI 10.1038/357420a0	49	245	258	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3198	3203		10.1074/jbc.M508381200	http://dx.doi.org/10.1074/jbc.M508381200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339146	Green Published, hybrid			2022-12-27	WOS:000235128200023
J	Krones-Herzig, A; Mesaros, A; Metzger, D; Ziegler, A; Lemke, U; Bruning, JC; Herzig, S				Krones-Herzig, A; Mesaros, A; Metzger, D; Ziegler, A; Lemke, U; Bruning, JC; Herzig, S			Signal-dependent control of gluconeogenic key enzyme genes through coactivator-associated arginine methyltransferase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; CCAAT/ENHANCER-BINDING PROTEIN; CAMP RESPONSE ELEMENT; TRANSCRIPTIONAL REGULATION; PROMOTER; EXPRESSION; CARM1; GLUCOCORTICOIDS; IDENTIFICATION; METHYLATION	Together with impaired glucose uptake in skeletal muscle, elevated hepatic gluconeogenesis is largely responsible for the hyperglycemic phenotype in type II diabetic patients. Intracellular glucocorticoid and cyclic adenosine monophosphate ( cAMP)/protein kinase A-dependent signaling pathways contribute to aberrant hepatic glucose production through the induction of gluconeogenic enzyme gene expression. Here we show that the coactivator-associated arginine methyltransferase 1 ( CARM1) is required for cAMP-mediated activation of rate-limiting gluconeogenic phosphoenolpyruvate carboxykinase ( PEPCK; EC 4.1.1.32) and glucose-6-phosphatase genes. Mutational analysis showed that CARM1 mediates its effect via the cAMP-responsive element within the PEPCK promoter, which is identified here as a CARM1 target in vivo. In hepatocytes, endogenous CARM1 physically interacts with cAMP-responsive element binding factor CREB and is recruited to the PEPCK and glucose-6-phosphatase promoters in a cAMP-dependent manner associated with increased promoter methylation. CARM1 might, therefore, represent a critical component of cAMP-dependent glucose metabolism in the liver.	German Canc Res Ctr, Dept Mol Metab Control, D-69120 Heidelberg, Germany; Univ Cologne, Dept Mouse Genet & Metab, Inst Genet, D-50674 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50674 Cologne, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne; University of Cologne	Herzig, S (corresponding author), German Canc Res Ctr, Dept Mol Metab Control, A170,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	s.herzig@dkfz.de		Herzig, Stephan/0000-0003-3950-3652				Amos AF, 1997, DIABETIC MED, V14, pS7, DOI 10.1002/(SICI)1096-9136(199712)14:5+<S7::AID-DIA522>3.3.CO;2-I; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Barthel A, 2003, AM J PHYSIOL-ENDOC M, V285, pE685, DOI 10.1152/ajpendo.00253.2003; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Chakravarty K, 2005, CRIT REV BIOCHEM MOL, V40, P129, DOI 10.1080/10409230590935479; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; Friedman JE, 1997, J BIOL CHEM, V272, P31475, DOI 10.1074/jbc.272.50.31475; Gautier-Stein A, 2005, MOL ENDOCRINOL, V19, P163, DOI 10.1210/me.2004-0105; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Herzig S, 2000, J BIOL CHEM, V275, P27989; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; IMAI E, 1993, J BIOL CHEM, V268, P5353; Koh SS, 2002, J BIOL CHEM, V277, P26031, DOI 10.1074/jbc.M110865200; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kopelman PG, 1998, LANCET, V352, P5; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; LIU JS, 1991, J BIOL CHEM, V266, P19095; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Postic C, 2004, DIABETES METAB, V30, P398, DOI 10.1016/S1262-3636(07)70133-7; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; SHORT JM, 1986, J BIOL CHEM, V261, P9721; Wang XHL, 2004, J BIOL CHEM, V279, P34191, DOI 10.1074/jbc.M403455200; Wilson HL, 2002, J BIOL CHEM, V277, P43895, DOI 10.1074/jbc.M203169200; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yadav N, 2003, P NATL ACAD SCI USA, V100, P6464, DOI 10.1073/pnas.1232272100	40	35	36	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3025	3029		10.1074/jbc.M509770200	http://dx.doi.org/10.1074/jbc.M509770200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330542	hybrid			2022-12-27	WOS:000235128200004
J	Tu, SL; Sughrue, W; Britt, RD; Lagarias, JC				Tu, SL; Sughrue, W; Britt, RD; Lagarias, JC			A conserved histidine-aspartate pair is required for exovinyl reduction of biliverdin by a cyanobacterial phycocyanobilin : ferredoxin oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANABAENA PCC 7119; ELECTRON-TRANSFER; BINDING; BIOSYNTHESIS; SURFACE; COMPLEX	Phycocyanobilin: ferredoxin oxidoreductase is a member of the ferredoxin-dependent bilin reductase family and catalyzes two vinyl reductions of biliverdin IX alpha to produce phycocyanobilin, the pigment precursor of both phytochrome and phycobiliprotein chromophores in cyanobacteria. Atypically for ferredoxin-dependent enzymes, phycocyanobilin: ferredoxin oxidoreductase mediates direct electron transfers from reduced ferredoxin to its tetrapyrrole substrate without metal ion or organic cofactors. We previously showed that bound bilin radical intermediates could be detected by low temperature electron paramagnetic resonance and absorption spectroscopies ( Tu, S., Gunn, A., Toney, M. D., Britt, R. D., and Lagarias, J. C. ( 2004) J. Am. Chem. Soc. 126, 8682 - 8693). On the basis of these studies, a mechanism involving sequential electron-coupled proton transfers to protonated bilin substrates buried within the phycocyanobilin: ferredoxin oxidoreductase protein scaffold was proposed. The present investigation was undertaken to identify catalytic residues in phycocyanobilin: ferredoxin oxidoreductase from the cyanobacterium Nostoc sp. PCC7120 through site-specific chemical modification and mutagenesis of candidate proton-donating residues. These studies identified conserved histidine and aspartate residues essential for the catalytic activity of phycocyanobilin: ferredoxin oxidoreductase. Spectroscopic evidence for the formation of stable enzyme-bound biliverdin radicals for the H85Q and D102N mutants support their role as a "coupled" protondonating pair during the reduction of the biliverdin exovinyl group.	Univ Calif Davis, Coll Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Univ Calif Davis, Dept Chem, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Lagarias, JC (corresponding author), Univ Calif Davis, Coll Biol Sci, Sect Mol & Cellular Biol, Davis, CA 95616 USA.	jclagarias@ucdavis.edu	Lagarias, John Clark/L-3139-2013; Tu, Shih-Long/ABF-5446-2021	Lagarias, John Clark/0000-0002-2093-0403; Tu, Shih-Long/0000-0001-9436-278X				Akashi T, 1999, J BIOL CHEM, V274, P29399, DOI 10.1074/jbc.274.41.29399; BEALE SI, 1993, CHEM REV, V93, P785, DOI 10.1021/cr00018a008; DEPASCALIS AR, 1993, PROTEIN SCI, V2, P1126, DOI 10.1002/pro.5560020707; Dose MM, 1997, PLANT PHYSIOL, V114, P1047, DOI 10.1104/pp.114.3.1047; ELICH TD, 1989, J BIOL CHEM, V264, P183; Frankenberg N, 2003, J BIOL CHEM, V278, P9219, DOI 10.1074/jbc.M211643200; Frankenberg N, 2001, PLANT CELL, V13, P965, DOI 10.1105/tpc.13.4.965; Frankenberg N., 2003, PORPHYRIN HDB, P211; Glazer A. N., 1999, CHEM MICROALGAE, P261; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Lundblad RL., 2005, CHEM REAGENTS PROTEI; Martinez-Julvez M, 1998, BIOCHEMISTRY-US, V37, P17680, DOI 10.1021/bi981718i; McDowell MT, 2001, PLANT PHYSIOL, V126, P1546, DOI 10.1104/pp.126.4.1546; Medina M, 1998, BIOCHEMISTRY-US, V37, P2715, DOI 10.1021/bi971795y; Prisner T, 2001, ANNU REV PHYS CHEM, V52, P279, DOI 10.1146/annurev.physchem.52.1.279; SCHLUCHTER WM, 1994, THESIS PENNSYLVANIA; Tu SL, 2004, J AM CHEM SOC, V126, P8682, DOI 10.1021/ja049280z	18	22	22	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3127	3136		10.1074/jbc.M510126200	http://dx.doi.org/10.1074/jbc.M510126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16327013	hybrid			2022-12-27	WOS:000235128200015
J	Khan, EM; Heidinger, JM; Levy, M; Lisanti, MP; Ravid, T; Goldkorn, T				Khan, Elaine M.; Heidinger, Jill M.; Levy, Michal; Lisanti, Michael P.; Ravid, Tommer; Goldkorn, Tzipora			Epidermal Growth Factor Receptor Exposed to Oxidative Stress Undergoes Src- and Caveolin-1-dependent Perinuclear Trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The epidermal growth factor (EGF) receptor (EGFR) has been found to be overexpressed in several types of cancer cells, and the regulation of its oncogenic potential has been widely studied. The paradigm for EGFR down-regulation involves the trafficking of activated receptor molecules from the plasma membrane, through clathrin-coated pits, and into the cell for lysosomal degradation. We have previously shown that oxidative stress generated by H2O2 results in aberrant phosphorylation of the EGFR. This leads to the loss of c-Cbl-mediated ubiquitination of the EGFR and, consequently, prevents its degradation. However, we have found that c-Cbl-mediated ubiquitination is required solely for degradation but not for internalization of the EGFR under oxidative stress. To further examine the fate of the EGFR under oxidative stress, we used confocal analysis to show that the receptor not only remains colocalized with caveolin-1 at the plasma membrane, but at longer time points, is also sorted to a perinuclear compartment via a clathrin-independent, caveolae-mediated pathway. Our findings indicate that although the EGFR associates with caveolin-1 constitutively, caveolin-1 is hyperphosphorylated only under oxidative stress, which is essential in transporting the EGFR to a perinuclear location, where it is not degraded and remains active. Thus, oxidative stress may have a role in tumorigenesis by not only activating the EGFR but also by promoting prolonged activation of the receptor both at the plasma membrane and within the cell.	[Goldkorn, Tzipora] Univ Calif Davis, Genome & Biomed Sci Facil, Dept Internal Med, Signal Transduct Lab,Sch Med, Davis, CA 95616 USA; [Lisanti, Michael P.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; [Lisanti, Michael P.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Lisanti, Michael P.] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; [Ravid, Tommer] Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University of California System; University of California Davis; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yale University	Goldkorn, T (corresponding author), Univ Calif Davis, Genome & Biomed Sci Facil, Dept Internal Med, Signal Transduct Lab,Sch Med, Rm 6321,451 E Hlth Sci Dr, Davis, CA 95616 USA.	ttgoldkorn@ucdavis.edu	高, 雨莉/HGU-8187-2022; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 	Tobacco-Related Disease Research Program [13FT-0126]; National Institutes of Health [HL-71871, HL-66189]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066189, R01HL071871] Funding Source: NIH RePORTER	Tobacco-Related Disease Research Program(University of California System); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Tobacco-Related Disease Research Program Grant 13FT-0126 (to E. M. K.) and National Institutes of Health Grants HL-71871 and HL-66189 (to T. G.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; de Melker AA, 2001, J CELL SCI, V114, P2167; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; ECCLES SA, 1994, INVAS METAST, V14, P337; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Goldkorn T, 1998, AM J RESP CELL MOL, V19, P786, DOI 10.1165/ajrcmb.19.5.3249; Huang FT, 2005, MOL BIOL CELL, V16, P1268, DOI 10.1091/mbc.E04-09-0832; Huang RP, 2001, MOL CARCINOGEN, V30, P209, DOI 10.1002/mc.1030; Laude AJ, 2004, MOL MEMBR BIOL, V21, P193, DOI 10.1080/09687680410001700517; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2004, CELL, V118, P767, DOI 10.1016/j.cell.2004.09.003; Quest AFG, 2004, BIOCHEM CELL BIOL, V82, P129, DOI 10.1139/o03-071; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; Ravid T, 2002, J BIOL CHEM, V277, P31214, DOI 10.1074/jbc.M204677200; Sanguinetti AR, 2003, BIOCHEM J, V376, P159, DOI 10.1042/BJ20030336; Sanguinetti AR, 2003, CELL SIGNAL, V15, P289, DOI 10.1016/S0898-6568(02)00090-6; Shajahan AN, 2004, J BIOL CHEM, V279, P48055, DOI 10.1074/jbc.M405837200; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2	41	129	134	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	2006	281	20					14486	14493		10.1074/jbc.M509332200	http://dx.doi.org/10.1074/jbc.M509332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	V06FK	16407214	hybrid			2022-12-27	WOS:000207179300007
J	Gyulkhandanyan, AV; Lee, SC; Bikopoulos, G; Dai, FH; Wheeler, MB				Gyulkhandanyan, AV; Lee, SC; Bikopoulos, G; Dai, FH; Wheeler, MB			The Zn2+-transporting pathways in pancreatic beta-cells - A role for the L-type voltage-gated Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETORY GRANULES; MAMMALIAN ZINC TRANSPORTER; CALCIUM-CHANNELS; CORTICAL-NEURONS; K+ CHANNELS; MITOCHONDRIAL DYSFUNCTION; POTASSIUM CHANNELS; GLUCAGON-RELEASE; HEAVY-METALS; ALPHA-CELLS	In pancreatic beta-cells Zn2+ is crucial for insulin biosynthesis and exocytosis. Despite this, little is known about mechanisms of Zn2+ transport into beta-cells or the regulation and compartmentalization of Zn2+ within this cell type. Evidence suggests that Zn2+ in part enters neurons and myocytes through specific voltage-gated calcium channels (VGCC). Using a Zn2+-selective fluorescent dye with high affinity and quantum yield, FluoZin-3 AM and the plasma membrane potential dye DiBAC(4)(3) we applied fluorescent microscopy techniques for analysis of Zn2+-accumulating pathways in mouse islets, dispersed islet cells, and beta-cell lines (MIN6 and beta-TC6f7 cells). Because the stimulation of insulin secretion is associated with cell depolarization, Zn2+ (5-10 mu M) uptake was analyzed under basal (1 mM glucose) and stimulatory (10-20 mM glucose, tolbutamide, tetraethylammonium, and high K+) conditions. Under both basal and depolarized states, beta-cells were capable of Zn2+ uptake, and switching from basal to depolarizing conditions resulted in a marked increase in the rate of Zn2+ accumulation. Importantly, L-type VGCC (L-VGCC) blockers (verapamil, nitrendipine, and nifedipine) as well as nonspecific inhibitors of Ca2+ channels, Gd3+ and La3+, inhibited Zn2+ uptake in beta-cells under stimulatory conditions with little or no change in Zn2+ accumulation under low glucose conditions. To determine the mechanism of VGCC-independent Zn2+ uptake the expression of a number of ZIP family Zn2+ transporter mRNAs in islets and beta-cells was investigated. In conclusion, we demonstrate for the first time that, in part, Zn2+ transport into beta-cells takes place through the L-VGCC. Our investigation demonstrates direct Zn2+ accumulation in insulin-secreting cells by two pathways and suggests that the rate of Zn2+ transport across the plasma membrane is dependent upon the metabolic status of the cell.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle,Rm 3352, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca		Wheeler, Michael B./0000-0002-7480-7267				Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; ARSLAN P, 1985, J BIOL CHEM, V260, P2719; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; BAETENS D, 1979, SCIENCE, V206, P1323, DOI 10.1126/science.390711; Bancila V, 2004, J NEUROCHEM, V90, P1243, DOI 10.1111/j.1471-4159.2004.02587.x; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Brissova M, 2005, J HISTOCHEM CYTOCHEM, V53, P1087, DOI 10.1369/jhc.5C6684.2005; Chausmer AB, 1998, J AM COLL NUTR, V17, P109, DOI 10.1080/07315724.1998.10718735; Chimienti F, 2004, DIABETES, V53, P2330, DOI 10.2337/diabetes.53.9.2330; Colvin RA, 2003, EUR J PHARMACOL, V479, P171, DOI 10.1016/j.ejphar.2003.08.067; Colvin RA, 1998, NEUROSCI LETT, V247, P147, DOI 10.1016/S0304-3940(98)00302-4; Dineley KE, 2005, MITOCHONDRION, V5, P55, DOI 10.1016/j.mito.2004.11.001; Dufner-Beattie J, 2004, J BIOL CHEM, V279, P49082, DOI 10.1074/jbc.M409962200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P50142, DOI 10.1074/jbc.M304163200; Eide DJ, 2004, PFLUG ARCH EUR J PHY, V447, P796, DOI 10.1007/s00424-003-1074-3; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; Falkmer S, 1968, Diabetologia, V4, P239, DOI 10.1007/BF00430102; FIGLEWICZ DP, 1980, DIABETES, V29, P767, DOI 10.2337/diacare.20.10.767; FORMBY B, 1984, DIABETES, V33, P229, DOI 10.2337/diabetes.33.3.229; FOSTER MC, 1993, BIOPHYS J, V64, P525, DOI 10.1016/S0006-3495(93)81397-3; Franklin I, 2005, DIABETES, V54, P1808, DOI 10.2337/diabetes.54.6.1808; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; FREUND WD, 1994, BRAIN RES, V654, P257, DOI 10.1016/0006-8993(94)90487-1; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Gee KR, 2002, CELL CALCIUM, V31, P245, DOI 10.1016/S0143-4160(02)00053-2; GOLD G, 1984, EXPERIENTIA, V40, P1105, DOI 10.1007/BF01971458; Gromada J, 1997, J GEN PHYSIOL, V110, P217, DOI 10.1085/jgp.110.3.217; Guan ZX, 2003, J INORG BIOCHEM, V97, P199, DOI 10.1016/S0162-0134(03)00291-5; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; Henquin JC, 2004, DIABETES, V53, pS48, DOI 10.2337/diabetes.53.suppl_3.S48; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kim BJ, 2000, DIABETES, V49, P367, DOI 10.2337/diabetes.49.3.367; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402; LUDVIGSEN C, 1979, DIABETES, V28, P570, DOI 10.2337/diab.28.6.570; Ma XS, 2005, MOL ENDOCRINOL, V19, P198, DOI 10.1210/me.2004-0059; MacDonald PE, 2003, DIABETOLOGIA, V46, P1046, DOI 10.1007/s00125-003-1159-8; Malaiyandi LM, 2005, J NEUROCHEM, V93, P1242, DOI 10.1111/j.1471-4159.2005.03116.x; Malaiyandi LM, 2004, GLIA, V45, P346, DOI 10.1002/glia.10332; Ohana E, 2004, J BIOL CHEM, V279, P4278, DOI 10.1074/jbc.M309229200; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; PRASAD AS, 1995, NUTRITION, V11, P93; Qian WJ, 2003, ANAL CHEM, V75, P3468, DOI 10.1021/ac0341057; Reyes JG, 1996, AM J PHYSIOL-CELL PH, V270, pC401, DOI 10.1152/ajpcell.1996.270.2.C401; Segal D, 2004, BIOCHEM BIOPH RES CO, V323, P1145, DOI 10.1016/j.bbrc.2004.08.211; Sensi SL, 2000, EUR J NEUROSCI, V12, P3813, DOI 10.1046/j.1460-9568.2000.00277.x; Sensi SL, 2004, CURR MOL MED, V4, P87, DOI 10.2174/1566524043479211; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sensi SL, 1999, P NATL ACAD SCI USA, V96, P2414, DOI 10.1073/pnas.96.5.2414; Straub SG, 2004, DIABETES, V53, P3179, DOI 10.2337/diabetes.53.12.3179; Taylor KM, 2003, BIOCHEM J, V375, P51, DOI 10.1042/BJ20030478; Truong-Tran AQ, 2001, BIOMETALS, V14, P315, DOI 10.1023/A:1012993017026; VEGA MT, 1994, PFLUG ARCH EUR J PHY, V429, P231, DOI 10.1007/BF00374317; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Wang FD, 2004, J BIOL CHEM, V279, P24631, DOI 10.1074/jbc.M400680200; Yin HZ, 1995, NEUROREPORT, V6, P2553, DOI 10.1097/00001756-199512150-00025; YOKOH S, 1969, DIABETOLOGIA, V5, P137, DOI 10.1007/BF01213670; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	75	77	79	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9361	9372		10.1074/jbc.M508542200	http://dx.doi.org/10.1074/jbc.M508542200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16407176	hybrid			2022-12-27	WOS:000236404700045
J	Neumann, S; Schobel, S; Jager, S; Trautwein, A; Haass, C; Pietrzik, CU; Lichtenthaler, SF				Neumann, S; Schobel, S; Jager, S; Trautwein, A; Haass, C; Pietrzik, CU; Lichtenthaler, SF			Amyloid precursor-like protein 1 influences endocytosis and proteolytic processing of the amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; HUMAN NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; BETA-PROTEIN; CYTOPLASMIC DOMAIN; BINDING PROTEIN; TRANSGENIC MICE; FAMILY-MEMBERS; RETINOIC ACID; FE65 PROTEIN	Ectodomain shedding of the amyloid precursor protein (APP) is a key regulatory step in the generation of the Alzheimer disease amyloid beta peptide (A beta). The molecular mechanisms underlying the control of APP shedding remain little understood but are in part dependent on the low density lipoprotein receptor-related protein (LRP), which is involved in APP endocytosis. Here, we show that the APP homolog APLP1 (amyloid precursor-like protein 1) influences APP shedding. In human embryonic kidney 293 cells expression of APLP1 strongly activated APP shedding by alpha-secretase and slightly reduced beta-secretase cleavage. As revealed by domain deletion analysis, the increase in APP shedding required the NPTY amino acid motif within the cytoplasmic domain of APLP1. This motif is conserved in APP and is essential for the endocytosis of APP and APLP1. Unrelated membrane proteins containing similar endocytic motifs did not affect APP shedding, showing that the increase in APP shedding was specific to APLP1. In LRP-deficient cells APLP1 no longer induced APP shedding, suggesting that in wild-type cells APLP1 interferes with the LRP-dependent endocytosis of APP and thereby increases APP alpha-cleavage. In fact, an antibody uptake assay revealed that expression of APLP1 reduced the rate of APP endocytosis. In summary, our study provides a novel mechanism for APP shedding, in which APLP1 affects the endocytosis of APP and makes more APP available for alpha-secretase cleavage.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55128 Mainz, Germany	University of Munich; Johannes Gutenberg University of Mainz	Lichtenthaler, SF (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	Stefan.Lichtenthaler@med.uni-muenchen.de	Lichtenthaler, Stefan F/B-6587-2016	Lichtenthaler, Stefan F/0000-0003-2211-2575				Adlerz L, 2003, MOL BRAIN RES, V119, P62, DOI 10.1016/j.molbrainres.2003.08.014; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Araki Y, 2003, J BIOL CHEM, V278, P49448, DOI 10.1074/jbc.M306024200; Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Bayer TA, 1997, ACTA NEUROPATHOL, V94, P519, DOI 10.1007/s004010050745; Beckman M, 1997, NEUROSCI LETT, V221, P73, DOI 10.1016/S0304-3940(96)13292-4; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Cam JA, 2004, J BIOL CHEM, V279, P29639, DOI 10.1074/jbc.M313893200; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chyung JH, 2003, J BIOL CHEM, V278, P51035, DOI 10.1074/jbc.M304989200; Citron M, 2004, TRENDS PHARMACOL SCI, V25, P92, DOI 10.1016/j.tips.2003.12.004; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kummer C, 2002, EXP CELL RES, V280, P222, DOI 10.1006/excr.2002.5631; Lee JH, 2004, J BIOL CHEM, V279, P49099, DOI 10.1074/jbc.M405602200; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Russo C, 2005, BRAIN RES REV, V48, P257, DOI 10.1016/j.brainresrev.2004.12.016; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Santiard-Baron D, 2005, J NEUROCHEM, V93, P330, DOI 10.1111/j.1471-4159.2005.03026.x; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; Ting Adrian, 2005, Novartis Found Symp, V267, P219; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Walsh DM, 2003, BIOCHEMISTRY-US, V42, P6664, DOI 10.1021/bi027375c; Xie ZC, 2005, J BIOL CHEM, V280, P15413, DOI 10.1074/jbc.M414353200	55	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7583	7594		10.1074/jbc.M508340200	http://dx.doi.org/10.1074/jbc.M508340200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16344553				2022-12-27	WOS:000236030900080
J	Lorenzen, I; Dingley, AJ; Jacques, Y; Grotzinger, J				Lorenzen, I; Dingley, AJ; Jacques, Y; Grotzinger, J			The structure of the interleukin-15 alpha receptor and its implications for ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; ALPHA-CHAIN; BETA-CHAIN; NATURAL-KILLER; GAMMA-CHAIN; IL-15; CYTOKINE; PROTEIN; INDUCTION; IDENTIFICATION	Interleukin (IL)-15 is a member of the small four alpha-helix bundle family of cytokines. IL-15 was discovered by its ability to mimic IL-2-mediated T-cell proliferation. Both cytokines share the beta and gamma receptor chains of the IL-2 receptor for signal transduction. However, in addition, they target specific alpha chain receptors IL-15R alpha and IL-2R alpha, respectively. The exceptionally high affinity binding of IL-15 to IL-15R alpha is mediated by its sushi domain. Here we present the solution structure of the IL-15R alpha sushi domain solved by NMR spectroscopy and a model of its complex with IL-15. The model shows that, rather than the familiar hydrophobic forces dominating the interaction interface between cytokines and their cognate receptors, the interaction between the IL-15 and IL-15R alpha complex involves a large network of ionic interactions. This type of interaction explains the exceptionally high affinity of the IL-15 . IL-15R alpha complex, which is essential for the biological effects of this important cytokine and which is not observed in other cytokine/cytokine receptor complexes.	Univ Kiel, Inst Biochem, D-24118 Kiel, Germany; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; INSERM, UMR 601, Grp Rech Cytokines & Recepteurs, Inst Biol, F-44093 Nantes, France	University of Kiel; University of London; University College London; Institut National de la Sante et de la Recherche Medicale (Inserm)	Grotzinger, J (corresponding author), Univ Kiel, Inst Biochem, Olshaussenstr 40, D-24118 Kiel, Germany.	jgroetzinger@biochem.uni-kiel.de	Dingley, Andrew/G-6427-2013	Dingley, Andrew/0000-0002-6838-5803				ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; Bernard J, 2004, J BIOL CHEM, V279, P24313, DOI 10.1074/jbc.M312458200; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Budagian V, 2004, J BIOL CHEM, V279, P40368, DOI 10.1074/jbc.M404125200; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Cordier F, 1999, J AM CHEM SOC, V121, P1601, DOI 10.1021/ja983945d; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; Grotzinger J, 2002, BBA-MOL CELL RES, V1592, P215, DOI 10.1016/S0167-4889(02)00316-6; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hage T, 1999, CELL, V97, P271, DOI 10.1016/S0092-8674(00)80736-9; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; KUNDIG TM, 1993, SCIENCE, V262, P1059, DOI 10.1126/science.8235625; Liparoto SF, 2002, BIOCHEMISTRY-US, V41, P2543, DOI 10.1021/bi011692m; Liu AZ, 2000, J BIOMOL NMR, V17, P79, DOI 10.1023/A:1008373501591; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Markley JL, 1998, J BIOMOL NMR, V12, P1, DOI 10.1023/A:1008290618449; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; Matsumoto M, 2003, PROTEIN EXPRES PURIF, V31, P64, DOI 10.1016/S1046-5928(03)00143-8; McInnes IB, 2004, CURR OPIN PHARMACOL, V4, P392, DOI 10.1016/j.coph.2004.04.003; Mortier E, 2006, J BIOL CHEM, V281, P1612, DOI 10.1074/jbc.M508624200; Mortier E, 2004, J IMMUNOL, V173, P1681, DOI 10.4049/jimmunol.173.3.1681; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishimura H, 2005, FASEB J, V19, P19, DOI 10.1096/fj.04-2633com; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; PERKINS SJ, 1988, BIOCHEMISTRY-US, V27, P4004, DOI 10.1021/bi00411a017; Pettit DK, 1997, J BIOL CHEM, V272, P2312; Rickert M, 2005, SCIENCE, V308, P1477, DOI 10.1126/science.1109745; Ruchatz H, 1998, J IMMUNOL, V160, P5654; Ruckert R, 2005, J IMMUNOL, V174, P5507, DOI 10.4049/jimmunol.174.9.5507; Shen BJ, 1996, EUR J BIOCHEM, V240, P252, DOI 10.1111/j.1432-1033.1996.0252h.x; Smith XG, 2000, J IMMUNOL, V165, P3444, DOI 10.4049/jimmunol.165.6.3444; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Waldmann TA, 2004, ARTHRITIS RES THER, V6, P174, DOI 10.1186/ar1202; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Wang XQ, 2005, SCIENCE, V310, P1159, DOI 10.1126/science.1117893; Wei XQ, 2001, J IMMUNOL, V167, P277, DOI 10.4049/jimmunol.167.1.277; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9	50	43	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6642	6647		10.1074/jbc.M513118200	http://dx.doi.org/10.1074/jbc.M513118200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377614	hybrid			2022-12-27	WOS:000236030800061
J	Horman, S; Vertommen, D; Heath, R; Neumann, D; Mouton, V; Woods, A; Schlattner, U; Walliman, T; Carling, D; Hue, L; Rider, MH				Horman, S; Vertommen, D; Heath, R; Neumann, D; Mouton, V; Woods, A; Schlattner, U; Walliman, T; Carling, D; Hue, L; Rider, MH			Insulin antagonizes ischemia-induced Thr(172) phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser(485/491)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-ISCHEMIA; GLUCOSE-UPTAKE; INHIBITION; COMPLEXES; SUBFAMILY; ISOFORMS; GLUT-4; ROLES; SNF1; LKB1	Previous studies showed that insulin antagonizes AMP-activated protein kinase activation by ischemia and that protein kinase B might be implicated. Here we investigated whether the direct phosphorylation of AMP-activated protein kinase by protein kinase B might participate in this effect. Protein kinase B phosphorylated recombinant bacterially expressed AMP-activated protein kinase heterotrimers at Ser(485) of the alpha 1-subunits. In perfused rat hearts, phosphorylation of the alpha 1/alpha 2 AMP-activated protein kinase subunits on Ser(485)/Ser(491) was increased by insulin and insulin pretreatment decreased the phosphorylation of the alpha-subunits at Thr(172) in a subsequent ischemic episode. It is proposed that the effect of insulin to antagonize AMP-activated protein kinase activation involves a hierarchical mechanism whereby Ser(485)/Ser(491) phosphorylation by protein kinase B reduces subsequent phosphorylation of Thr(172) by LKB1 and the resulting activation of AMP-activated protein kinase.	Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, B-1200 Brussels, Belgium; Hammersmith Hosp, Imperial Coll, Cellular Stress Grp, MRC,Clin Sci Ctr, London W12 0NN, England; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland	Universite Catholique Louvain; Imperial College London; Swiss Federal Institutes of Technology Domain; ETH Zurich	Horman, S (corresponding author), Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, Ave Hippocrate 75, B-1200 Brussels, Belgium.	sandrine.horman@horm.ucl.ac.be	Wallimann, Theo/C-6047-2008; Schlattner, Uwe/D-1267-2009; Carling, David/F-1943-2014	Wallimann, Theo/0000-0003-4957-5836; Schlattner, Uwe/0000-0003-1159-5911; Carling, David/0000-0002-2316-1830; Vertommen, Didier/0000-0001-7648-8282; Neumann, Dietbert/0000-0002-4316-684X	Medical Research Council [MC_U120027537] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Baron SJ, 2005, CIRC RES, V96, P337, DOI 10.1161/01.RES.0000155723.53868.d2; Beauloye C, 2001, FEBS LETT, V505, P348, DOI 10.1016/S0014-5793(01)02788-0; Beauloye C, 2001, CIRC RES, V88, P513, DOI 10.1161/01.RES.88.5.513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; Clark H, 2004, EUR J BIOCHEM, V271, P2215, DOI 10.1111/j.1432-1033.2004.04151.x; DeGnore JP, 1998, J AM SOC MASS SPECTR, V9, P1175, DOI 10.1016/S1044-0305(98)00088-9; Deprez J, 2000, BIOCHEM J, V347, P305, DOI 10.1042/0264-6021:3470305; Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Horman S, 2003, J BIOL CHEM, V278, P41970, DOI 10.1074/jbc.M302403200; Jessen N, 2003, J APPL PHYSIOL, V94, P1373, DOI 10.1152/japplphysiol.00250.2002; Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200; Krause U, 2002, EUR J BIOCHEM, V269, P3742, DOI 10.1046/j.1432-1033.2002.03069.x; Lefebvre V, 1996, J BIOL CHEM, V271, P22289, DOI 10.1074/jbc.271.37.22289; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Russell RR, 1999, AM J PHYSIOL-HEART C, V277, pH643, DOI 10.1152/ajpheart.1999.277.2.H643; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; Sugden C, 1999, PLANT J, V19, P433, DOI 10.1046/j.1365-313X.1999.00532.x; Sutherland CM, 2003, CURR BIOL, V13, P1299, DOI 10.1016/S0960-9822(03)00459-7; WITTERS LA, 1992, J BIOL CHEM, V267, P2864; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 1996, FEBS LETT, V397, P347, DOI 10.1016/S0014-5793(96)01209-4; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200	36	272	278	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5335	5340		10.1074/jbc.M506850200	http://dx.doi.org/10.1074/jbc.M506850200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16340011	hybrid			2022-12-27	WOS:000235568900003
J	Franco, MC; Arciuch, VGA; Peralta, JG; Galli, S; Levisman, D; Lopez, LM; Romorini, L; Poderoso, JJ; Carreras, MC				Franco, MC; Arciuch, VGA; Peralta, JG; Galli, S; Levisman, D; Lopez, LM; Romorini, L; Poderoso, JJ; Carreras, MC			Hypothyroid phenotype is contributed by mitochondrial complex I inactivation due to translocated neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; SPATIAL CONFINEMENT; RADICAL PRODUCTION; PROTEIN COMPLEXES; LIVER; OXYGEN; MODULATION; IDENTIFICATION; PROLIFERATION; INHIBITION	Although transcriptional effects of thyroid hormones have substantial influence on oxidative metabolism, how thyroid sets basal metabolic rate remains obscure. Compartmental localization of nitric-oxide synthases is important for nitric oxide signaling. We therefore examined liver neuronal nitric-oxide synthase-alpha( nNOS) subcellular distribution as a putative mechanism for thyroid effects on rat metabolic rate. At low 3,3',5-triiodo-L-thyronine levels, nNOS mRNA increased by 3-fold, protein expression by one-fold, and nNOS was selectively translocated to mitochondria without changes in other isoforms. In contrast, under thyroid hormone administration, mRNA level did not change and nNOS remained predominantly localized in cytosol. In hypothyroidism, nNOS translocation resulted in enhanced mitochondrial nitric-oxide synthase activity with low O-2 uptake. In this context, NO utilization increased active O-2 species and peroxynitrite yields and tyrosine nitration of complex I proteins that reduced complex activity. Hypothyroidism was also associated to high phospho-p38 mitogen-activated protein kinase and decreased phospho-extracellular signal-regulated kinase 1/2 and cyclin D1 levels. Similarly to thyroid hormones, but without changing thyroid status, nitric-oxide synthase inhibitor N-omega-nitro-L-arginine methyl ester increased basal metabolic rate, prevented mitochondrial nitration and complex I derangement, and turned mitogen-activated protein kinase signaling and cyclin D1 expression back to control pattern. We surmise that nNOS spatial confinement in mitochondria is a significant downstream effector of thyroid hormone and hypothyroid phenotype.	Univ Buenos Aires, Univ Hosp, Lab Oxygen Metab, RA-1120 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencia Prof Eduardo Rob, RA-1120 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1120 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Farm & Bioquim, Dept Bioquim Clin, RA-1120 Buenos Aires, DF, Argentina	University of Buenos Aires; University of Buenos Aires; University of Buenos Aires; University of Buenos Aires	Carreras, MC (corresponding author), Univ Buenos Aires, Univ Hosp, Lab Oxygen Metab, Cordoba 2351, RA-1120 Buenos Aires, DF, Argentina.	ccarreras@hospitaldeclinicas.uba.ar	Franco, Maria/O-7862-2015					Alvarez MJ, 2000, ANAL BIOCHEM, V287, P87, DOI 10.1006/abio.2000.4823; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; Bianchi MS, 2004, NEUROENDOCRINOLOGY, V80, P129, DOI 10.1159/000082527; Brookes PS, 2003, J BIOL CHEM, V278, P31603, DOI 10.1074/jbc.M211784200; Carreras Maria C., 2004, Molecular Aspects of Medicine, V25, P125, DOI 10.1016/j.mam.2004.02.014; Carreras MC, 2004, HEPATOLOGY, V40, P157, DOI 10.1002/hep.20255; Carreras MC, 2001, AM J PHYSIOL-HEART C, V281, pH2282, DOI 10.1152/ajpheart.2001.281.6.H2282; Cymeryng CB, 2002, ENDOCRINOLOGY, V143, P1235, DOI 10.1210/en.143.4.1235; Das K, 2001, BBA-MOL BASIS DIS, V1537, P1, DOI 10.1016/S0925-4439(01)00048-5; Dougherty CJ, 2004, FASEB J, V18, P1060, DOI 10.1096/fj.04-1505com; Elfering SL, 2004, AM J PHYSIOL-HEART C, V286, pH22, DOI 10.1152/ajpheart.00766.2003; Fulton D, 2004, J BIOL CHEM, V279, P30349, DOI 10.1074/jbc.M402155200; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Hare JM, 2004, LANCET, V363, P1338, DOI 10.1016/S0140-6736(04)16083-2; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Jope RS, 2000, ARCH BIOCHEM BIOPHYS, V376, P365, DOI 10.1006/abbi.2000.1728; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Koeck T, 2004, J BIOL CHEM, V279, P27257, DOI 10.1074/jbc.M401586200; Liggett SB, 2004, NAT MED, V10, P582, DOI 10.1038/nm0604-582; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Lopez-Torres M, 2000, MOL CELL ENDOCRINOL, V168, P127, DOI 10.1016/S0303-7207(00)00302-6; Moro L, 2004, ENDOCRINOLOGY, V145, P5121, DOI 10.1210/en.2004-0909; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; OGILVIE P, 1995, FASEB J, V9, P799, DOI 10.1096/fasebj.9.9.7541381; Peralta JG, 2003, AM J PHYSIOL-HEART C, V284, pH2375, DOI 10.1152/ajpheart.00785.2002; Persichini T, 2005, NEUROSCI LETT, V384, P254, DOI 10.1016/j.neulet.2005.04.085; Pibiri M, 2001, FASEB J, V15, P1006, DOI 10.1096/fj.00-0416com; Pillar TM, 1997, EUR J ENDOCRINOL, V136, P231, DOI 10.1530/eje.0.1360231; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Riobo NA, 2002, J BIOL CHEM, V277, P42447, DOI 10.1074/jbc.M204580200; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; Sato Y, 2004, J BIOL CHEM, V279, P8827, DOI 10.1074/jbc.M310327200; Scanlan TS, 2004, NAT MED, V10, P638, DOI 10.1038/nm1051; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Souza JM, 2000, ARCH BIOCHEM BIOPHYS, V380, P360, DOI 10.1006/abbi.2000.1940; Valdez Laura B., 2004, Molecular Aspects of Medicine, V25, P49, DOI 10.1016/j.mam.2004.02.008; Valdez LB, 2005, METHOD ENZYMOL, V396, P444, DOI 10.1016/S0076-6879(05)96037-0; Venditti P, 2003, MOL CELL ENDOCRINOL, V205, P185, DOI 10.1016/S0303-7207(02)00332-5; Venkatraman A, 2004, HEPATOLOGY, V40, P565, DOI 10.1002/hep.20326; Zhang JL, 2005, AM J PHYSIOL-CELL PH, V288, pC840, DOI 10.1152/ajpcell.00325.2004	48	65	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4779	4786		10.1074/jbc.M512080200	http://dx.doi.org/10.1074/jbc.M512080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361261	hybrid, Green Published			2022-12-27	WOS:000235426200028
J	Maeda, N; Fukazawa, N; Hata, T				Maeda, N; Fukazawa, N; Hata, T			The binding of chondroitin sulfate to pleiotrophin/heparin-binding growth-associated molecule is regulated by chain length and oversulfated structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; OUTGROWTH-PROMOTING ACTIVITY; HB-GAM; NEURITE-OUTGROWTH; ZETA/RPTP-BETA; 6B4 PROTEOGLYCAN/PHOSPHACAN; EXTRACELLULAR VARIANT; FACTOR MIDKINE; HYBRID CHAINS; CELL-ADHESION	Pleiotrophin is an 18-kDa heparin-binding growth factor, which uses chondroitin sulfate (CS) proteoglycan, PTP zeta as a receptor. It has been suggested that the D-type structure (GlcA(2S)beta 1-3GalNAc(6S)) in CS contributes to the high affinity binding between PTP zeta and pleiotrophin. Here, we analyzed the interaction of shark cartilage CS-D with pleiotrophin using a surface plasmon resonance biosensor to reveal the importance of D-type structure. CS-D was partially digested with chondroitinase ABC, and fractionated using a Superdex 75pg column. The >= 18-mer CS fractions showed significant binding to pleiotrophin, and the longer fractions had stronger affinity for pleiotrophin than the shorter ones. The similar to 46-mer CS fraction bound to densely immobilized pleiotrophin with high affinity (K-D = similar to 30 nM), and the binding reactions fitted the bivalent analyte model. However, when the density of the immobilized pleiotrophin was lowered, the strength of affinity remarkably decreased (K-D = similar to 2.5 mu M), and the reactions no longer fitted the model and were considered to be monovalent binding. The 20 similar to 24-mer fractions showed low affinity binding to densely immobilized pleiotrophin (K-D = 3 similar to 20 mu M), which seemed to be monovalent. When similar to 22-mer CS oligosaccharides were fractionated by strong anion exchange HPLC, each fraction differed in affinity for pleiotrophin (K-D = 0.36 similar to > 10 mu M), and the affinity correlated with the amounts of D- and E- (GlcA beta 1-3GalNAc(4S, 6S)) type oversulfated structures. These results suggest that the binding of pleiotrophin to CS is regulated by multivalency with CS similar to 20 mer as a unit and by the amounts of oversulfated structures.	Tokyo Metropolitan Inst Neurosci, Dept Dev Neurosci, Tokyo 1838526, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science	Maeda, N (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Dev Neurosci, 2-6 Musashidai, Tokyo 1838526, Japan.	maedan@tmin.ac.jp						Bao XF, 2005, J BIOL CHEM, V280, P35318, DOI 10.1074/jbc.M507304200; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Bernard-Pierrot I, 1999, BIOCHEM BIOPH RES CO, V266, P437, DOI 10.1006/bbrc.1999.1835; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Fath M, 1999, FEBS LETT, V454, P105, DOI 10.1016/S0014-5793(99)00785-1; Hikino M, 2003, J BIOL CHEM, V278, P43744, DOI 10.1074/jbc.M308169200; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Kaneda N, 1996, BIOCHEM BIOPH RES CO, V220, P108, DOI 10.1006/bbrc.1996.0365; Kawachi H, 2001, P NATL ACAD SCI USA, V98, P6593, DOI 10.1073/pnas.041608698; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; Kinnunen T, 1996, J BIOL CHEM, V271, P2243, DOI 10.1074/jbc.271.4.2243; Kojima S, 1997, J BIOL CHEM, V272, P9410; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; Maeda N, 1996, J BIOL CHEM, V271, P21446, DOI 10.1074/jbc.271.35.21446; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; Maeda N, 1998, J CELL BIOL, V142, P203, DOI 10.1083/jcb.142.1.203; Mahoney SA, 1996, BIOCHEM BIOPH RES CO, V224, P147, DOI 10.1006/bbrc.1996.0998; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; Polykratis A, 2005, J BIOL CHEM, V280, P22454, DOI 10.1074/jbc.M414407200; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; RAULO E, 1994, J BIOL CHEM, V269, P12999; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; Shimazaki Y, 2005, J NEUROSCI RES, V82, P172, DOI 10.1002/jnr.20639; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Tanaka M, 2003, J NEUROSCI, V23, P2804, DOI 10.1523/jneurosci.23-07-02804.2003; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Zou P, 2003, GLYCOBIOLOGY, V13, P35, DOI 10.1093/glycob/cwg001	33	40	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4894	4902		10.1074/jbc.M507750200	http://dx.doi.org/10.1074/jbc.M507750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373346	hybrid			2022-12-27	WOS:000235426200040
J	Osibow, K; Malli, R; Kostner, GM; Graier, WF				Osibow, K; Malli, R; Kostner, GM; Graier, WF			A new type of non-Ca2+-buffering Apo(a)-based fluorescent indicator for intraluminal Ca2+ in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM; MITOCHONDRIA; PROTEINS; CALRETICULIN; DYNAMICS; RELEASE; ENTRY	Genetically encoded Ca2+ indicators are outstanding tools for the assessment of intracellular/organelle Ca2+ dynamics. Basically, most indicators contain the Ca2+-binding site of a ( mutated) cytosolic protein that interacts with its natural ( mutated) interaction partner upon binding of Ca2+. Consequently, a change in the structure of the sensor occurs that, in turn, alters the fluorescent properties of the sensor. Herein, we present a new type of genetically encoded Ca2+ indicator for the endoplasmic reticulum ( ER) ( apoK1-er ( W. F. Graier, K. Osibow, R. Malli, and G. M. Kostner, patent application number 05450006.1 at the European patent office)) that is based on a single kringle domain from apolipoprotein( a), which is flanked by yellow and cyan fluorescent protein at the 3'- and 5'- ends, respectively. Notably, apoK1-er does not interact with Ca2+ itself but serves as a substrate for calreticulin, the main constitutive Ca2+-binding protein in the ER. ApoK1- er assembles with calreticulin and the protein disulfide isomerase ERp57 and undergoes a conformational shift in a Ca2+-dependent manner that allows fluorescence resonance energy transfer between the two fluorophores. This construct primarily offers three major advantages compared with the already existing probes: ( i) it resolves perfectly the physiological range of the free Ca2+ concentration in the ER, ( ii) expression of apoK1-er does not affect the Ca2+ buffering capacity of the ER, and ( iii) apoK1-er is not inactivated by binding of constitutive interaction partners that prevent Ca2+-dependent conformational changes. These unique characteristics of apoK1-er make this sensor particularly attractive for studies on ER Ca2+ signaling and dynamics in which alteration of Ca2+ fluctuations by expression of any additional Ca2+ buffer essentially has to be avoided.	Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, A-8010 Graz, Austria	Medical University of Graz	Graier, WF (corresponding author), Med Univ Graz, Ctr Mol Med, Inst Mol Biol & Biochem, Harrachgasse 21-3, A-8010 Graz, Austria.	wolfgang.graier@meduni-graz.at	Malli, Roland/B-7369-2008; Graier, Wolfgang F./B-7052-2008	Graier, Wolfgang F./0000-0003-1871-3298; Osibow, Karin/0000-0002-9703-595X; Malli, Roland/0000-0001-6327-8729	Austrian Science Fund FWF [P 16860] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Arnaudeau S, 2002, J BIOL CHEM, V277, P46696, DOI 10.1074/jbc.M202395200; Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Demaurex N, 2003, CELL CALCIUM, V34, P109, DOI 10.1016/S0143-4160(03)00081-2; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Frieden M, 2000, J PHYSIOL-LONDON, V524, P715, DOI 10.1111/j.1469-7793.2000.00715.x; Frieden M, 2002, J PHYSIOL-LONDON, V540, P73, DOI 10.1113/jphysiol.2002.017053; Graier WF, 1997, HORM METAB RES, V29, P622, DOI 10.1055/s-2007-979113; Graier WF, 1995, EUR J PHARMACOL, V294, P221; Heim N, 2004, J BIOL CHEM, V279, P14280, DOI 10.1074/jbc.M312751200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Kostner GM, 1999, J LIPID RES, V40, P2255; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Malli R, 2005, J BIOL CHEM, V280, P12114, DOI 10.1074/jbc.M409353200; Malli R, 2003, J BIOL CHEM, V278, P10807, DOI 10.1074/jbc.M212971200; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nilius B, 2003, CELL CALCIUM, V33, P293, DOI 10.1016/S0143-4160(03)00042-3; Nilius B, 2003, ENDOTHELIUM-J ENDOTH, V10, P5, DOI 10.1080/10623320303356; Nilius B, 1993, EXS, V66, P269; Palmer AE, 2004, P NATL ACAD SCI USA, V101, P17404, DOI 10.1073/pnas.0408030101; Paltauf-Doburzynska J, 2000, J PHYSIOL-LONDON, V524, P701, DOI 10.1111/j.1469-7793.2000.00701.x; Paltauf-Doburzynska J, 2004, J CARDIOVASC PHARM, V44, P423, DOI 10.1097/01.fjc.0000139449.64337.1b; Persechini A, 1997, CELL CALCIUM, V22, P209, DOI 10.1016/S0143-4160(97)90014-2; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; SOMMER A, 1991, BIOCHEMISTRY-US, V30, P11245, DOI 10.1021/bi00111a008; Szabadkai G, 2004, FEBS LETT, V567, P111, DOI 10.1016/j.febslet.2004.04.059; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; White AL, 1997, J BIOL CHEM, V272, P5048, DOI 10.1074/jbc.272.8.5048; Zoratti C, 2003, BRIT J PHARMACOL, V140, P1351, DOI 10.1038/sj.bjp.0705529	38	26	26	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5017	5025		10.1074/jbc.M508583200	http://dx.doi.org/10.1074/jbc.M508583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368693	Green Accepted, hybrid			2022-12-27	WOS:000235426200054
J	Xu, LJ; Deng, XM				Xu, LJ; Deng, XM			Protein kinase C iota promotes nicotine-induced migration and invasion of cancer cells via phosphorylation of mu- and m-calpains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PULMONARY NEUROENDOCRINE CELLS; DRUG-INDUCED APOPTOSIS; LUNG-CARCINOMA CELLS; ACETYLCHOLINE-RECEPTOR; CIGARETTE-SMOKING; SURVIVAL FUNCTION; ACTIVATION; METASTASIS; MOTILITY	Nicotine is a major component in cigarette smoke that activates the growth-promoting pathways to facilitate the development of lung cancer. However, it is not clear whether nicotine affects cell motility to facilitate tumor metastasis. Here we discovered that nicotine potently induces phosphorylation of both mu- and m-calpains via activation of protein kinase C iota( PKC iota), which is associated with accelerated migration and invasion of human lung cancer cells. Purified PKC iota directly phosphorylates mu- and m-calpains in vitro. Overexpression of PKC iota results in increased phosphorylation of both mu- and m-calpains in vivo. Nicotine also induces activation of c-Src, which is a known PKC iota upstream kinase. Treatment of cells with the alpha(7) nicotinic acetylcholine receptor inhibitor alpha-bungarotoxin can block nicotine-induced calpain phosphorylation with suppression of calpain activity, wound healing, cell migration, and invasion, indicating that nicotine-induced calpain phosphorylation occurs, at least in part, through a signaling pathway involving the upstream alpha(7) nicotinic acetylcholine receptor. Intriguingly, depletion of PKC iota by RNA interference suppresses nicotine-induced calpain phosphorylation, calpain activity, cell migration, and invasion, indicating that PKC iota is a necessary component in nicotine-mediated cell motility signaling. Importantly, nicotine potently induces secretion of mu- and m-calpains from lung cancer cells into culture medium, which may have potential to cleave substrates in the extracellular matrix. These findings reveal a novel role for PKC iota as a nicotine-activated, physiological calpain kinase that directly phosphorylates and activates calpains, leading to enhanced migration and invasion of human lung cancer cells.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1600 SW Archer Rd,Acad Res Bldg,R4-216,POB 100232, Gainesville, FL 32610 USA.	xdeng@ufscc.ufl.edu			NCI NIH HHS [R01CA112183-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT RK, 2004, CLIN RESPIRATORY MED, P519; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; Bhatt A, 2002, J CELL SCI, V115, P3415; Carragher NO, 2004, NEOPLASIA, V6, P53, DOI 10.1016/S1476-5586(04)80053-8; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200; DUMONT JA, 1994, BIOCHEM BIOPH RES CO, V204, P264, DOI 10.1006/bbrc.1994.2454; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Glading A, 2001, J BIOL CHEM, V276, P23341, DOI 10.1074/jbc.M008847200; Gomez DE, 1999, ONCOL REP, V6, P1363; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; Hecht SS, 1999, JNCI-J NATL CANCER I, V91, P1194, DOI 10.1093/jnci/91.14.1194; Heino J, 2002, CELL INVASION MED IN, P1; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Itier V, 2001, FEBS LETT, V504, P118, DOI 10.1016/S0014-5793(01)02702-8; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Jeong HW, 2005, CANCER RES, V65, P507; Jin ZJ, 2005, J BIOL CHEM, V280, P16045, DOI 10.1074/jbc.M413488200; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Krajewska M, 1997, CANCER RES, V57, P1605; Lopez MG, 1998, P NATL ACAD SCI USA, V95, P14184, DOI 10.1073/pnas.95.24.14184; Mamoune A, 2003, CANCER RES, V63, P4632; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Minna JD, 2003, J CLIN INVEST, V111, P31, DOI 10.1172/JCI200317492; Murin S, 2001, CHEST, V119, P1635, DOI 10.1378/chest.119.6.1635; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Nishihara H, 2001, BIOCHEM BIOPH RES CO, V285, P845, DOI 10.1006/bbrc.2001.5242; Palecek SP, 1998, J CELL SCI, V111, P929; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; SALVATERRA PM, 1976, J BIOL CHEM, V251, P6327; Schuller HM, 2003, ANAT REC PART A, V270A, P51, DOI 10.1002/ar.a.10019; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shiraha H, 2002, MOL CELL BIOL, V22, P2716, DOI 10.1128/MCB.22.8.2716-2727.2002; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Smith SD, 2003, FEBS LETT, V542, P115, DOI 10.1016/S0014-5793(03)00361-2; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Wells A, 2002, ACTA ONCOL, V41, P124, DOI 10.1080/028418602753669481; Witkowski JM, 2002, BLOOD, V100, P1802, DOI 10.1182/blood-2001-11-0073; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Xu LJ, 2004, J BIOL CHEM, V279, P53683, DOI 10.1074/jbc.M409889200	47	102	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4457	4466		10.1074/jbc.M510721200	http://dx.doi.org/10.1074/jbc.M510721200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361262	hybrid			2022-12-27	WOS:000235275300081
J	Gasser, A; Glassmeier, G; Fliegert, R; Langhorst, MF; Meinke, S; Hein, D; Kruger, S; Weber, K; Heiner, I; Oppenheimer, N; Schwarz, JR; Guse, AH				Gasser, A; Glassmeier, G; Fliegert, R; Langhorst, MF; Meinke, S; Hein, D; Kruger, S; Weber, K; Heiner, I; Oppenheimer, N; Schwarz, JR; Guse, AH			Activation of T cell calcium influx by the second messenger ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-PEROXIDE; NAD GLYCOHYDROLASE; REVERSED-PHASE; CA2+ RELEASE; CHANNEL; TRPM2; LTRPC2; LYMPHOCYTES; INHIBITOR; APOPTOSIS	Stimulation of Jurkat T cells by high concentrations of concanavalin A (ConA) induced an elevation of the endogenous adenosine diphosphoribose (ADPR) concentration and an inward current significantly different from the Ca2+ release-activated Ca2+ current (I-CRAC). Electrophysiological characterization and activation of a similar current by infusion of ADPR indicated that the ConA-induced current is carried by TRPM2. Expression of TRPM2 in the plasma membrane of Jurkat T cells was demonstrated by reverse transcription-PCR, Western blot, and immunofluorescence. Inhibition of ADPR formation reduced ConA-mediated, but not store-operated, Ca2+ entry and prevented ConA-induced cell death of Jurkat cells. Moreover, gene silencing of TRPM2 abolished the ADPR- and ConA-mediated inward current. Thus, ADPR is a novel second messenger significantly involved in ConA-mediated cell death in T cells.	Univ Hamburg, Med Ctr, Ctr Med Expt, Inst Biochem & Mol Biol 1, D-20246 Hamburg, Germany; Inst Appl Physiol, D-20246 Hamburg, Germany; Univ Hosp Aachen, Rhein Westfal TH Aachen, Inst Physiol, D-52057 Aachen, Germany; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of Hamburg; RWTH Aachen University; RWTH Aachen University Hospital; University of California System; University of California San Francisco	Guse, AH (corresponding author), Univ Hamburg, Med Ctr, Ctr Med Expt, Inst Biochem & Mol Biol 1, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de		Meinke, Stephan/0000-0003-4489-9727	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ayub K, 2004, FASEB J, V18, P1335, DOI 10.1096/fj.04-1888hyp; Bastide B, 2002, BIOCHEM BIOPH RES CO, V296, P1267, DOI 10.1016/S0006-291X(02)02073-9; BEHL B, 1987, BIOCHEM BIOPH RES CO, V144, P1303, DOI 10.1016/0006-291X(87)91452-5; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; da Silva CP, 1998, J CHROMATOGR B, V707, P43, DOI 10.1016/S0378-4347(97)00622-1; De Flora A, 2000, CHEM IMMUNOL, V75, P79; Fonfria E, 2005, J NEUROCHEM, V95, P715, DOI 10.1111/j.1471-4159.2005.03396.x; Fonfria E, 2004, BRIT J PHARMACOL, V143, P186, DOI 10.1038/sj.bjp.0705914; Gasser A, 2005, J CHROMATOGR B, V821, P181, DOI 10.1016/j.jchromb.2005.05.002; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Guse AH, 1998, CRIT REV IMMUNOL, V18, P419, DOI 10.1615/CritRevImmunol.v18.i5.20; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; GUSE AH, 1995, J IMMUNOL, V155, P3353; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; Huang D, 2003, J CHROMATOGR B, V784, P101, DOI 10.1016/S1570-0232(02)00780-8; KIM UH, 1993, BIOCHIM BIOPHYS ACTA, V1178, P121, DOI 10.1016/0167-4889(93)90001-6; Kolisek M, 2005, MOL CELL, V18, P61, DOI 10.1016/j.molcel.2005.02.033; Kuhn FJP, 2004, J BIOL CHEM, V279, P46431, DOI 10.1074/jbc.M407263200; Kunerth S, 2004, J CELL SCI, V117, P2141, DOI 10.1242/jcs.01063; Kunerth S, 2003, CELL SIGNAL, V15, P783, DOI 10.1016/S0898-6568(03)00015-9; Langhorst MF, 2004, CELL SIGNAL, V16, P1283, DOI 10.1016/j.cellsig.2004.03.013; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Li PL, 2002, AM J PHYSIOL-HEART C, V282, pH1229, DOI 10.1152/ajpheart.00736.2001; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; MULLERSTEFFNER HM, 1992, J BIOL CHEM, V267, P9606; Nagase F, 1998, MICROBIOL IMMUNOL, V42, P567, DOI 10.1111/j.1348-0421.1998.tb02325.x; Perraud AL, 2004, MOL IMMUNOL, V41, P657, DOI 10.1016/j.molimm.2004.04.013; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; ROSS PE, 1995, J GEN PHYSIOL, V106, P415, DOI 10.1085/jgp.106.3.415; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; Suen YK, 2000, APOPTOSIS, V5, P369, DOI 10.1023/A:1009691727077; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Uemura T, 2005, BIOCHEM BIOPH RES CO, V328, P1232, DOI 10.1016/j.bbrc.2005.01.086; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; WERNER A, 1993, J CHROMATOGR-BIOMED, V618, P3, DOI 10.1016/0378-4347(93)80024-X; YOST DA, 1981, J BIOL CHEM, V256, P3647; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	46	95	101	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2489	2496		10.1074/jbc.M506525200	http://dx.doi.org/10.1074/jbc.M506525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316998	hybrid			2022-12-27	WOS:000234931800011
J	Horcajada, C; Guinovart, JJ; Fita, I; Ferrer, JC				Horcajada, C; Guinovart, JJ; Fita, I; Ferrer, JC			Crystal structure of an archaeal glycogen synthase - Insights into oligomerization and substrate binding of eukaryotic glycogen synthases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE; CLASSIFICATION; IDENTIFICATION; PURIFICATION; METABOLISM; MECHANISM; RESIDUES; MUSCLE	Glycogen and starch synthases are retaining glycosyltransferases that catalyze the transfer of glucosyl residues to the non-reducing end of a growing alpha-1,4-glucan chain, a central process of the carbon/energy metabolism present in almost all living organisms. The crystal structure of the glycogen synthase from Pyrococcus abyssi, the smallest known member of this family of enzymes, revealed that its subunits possess a fold common to other glycosyltransferases, a pair of beta/alpha/beta Rossmann fold-type domains with the catalytic site at their interface. Nevertheless, the archaeal enzyme presents an unprecedented homotrimeric molecular arrangement both in solution, as determined by analytical ultracentrifugation, and in the crystal. The C-domains are not involved in intersubunit interactions of the trimeric molecule, thus allowing for movements, likely required for catalysis, across the narrow hinge that connects the Nand C-domains. The radial disposition of the subunits confers on the molecule a distinct triangular shape, clearly visible with negative staining electron microscopy, in which the upper and lower faces present a sharp asymmetry. Comparison of bacterial and eukaryotic glycogen synthases, which use, respectively, ADP or UDP glucose as donor substrates, with the archaeal enzyme, which can utilize both molecules, allowed us to propose the residues that determine glucosyl donor specificity.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Inst Recerca Biomed, E-08028 Barcelona, Spain; CSIC, Inst Biol Mol Barcelona, E-08028 Barcelona, Spain	University of Barcelona; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Ferrer, JC (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Av Diagonal 645, E-08028 Barcelona, Spain.	ferrer@bq.ub.es	Fita, Ignasi/R-4515-2019; Ferrer, Joan C./AAP-2145-2021	Fita, Ignasi/0000-0002-7521-2679; Ferrer, Joan C./0000-0003-1212-5161				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROWN NE, 1971, BIOCHIM BIOPHYS ACTA, V242, P69, DOI 10.1016/0005-2744(71)90088-X; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; Cid E, 2002, FEBS LETT, V528, P5, DOI 10.1016/S0014-5793(02)03313-6; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Geremia S, 2002, J MOL BIOL, V322, P413, DOI 10.1016/S0022-2836(02)00771-4; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gruyer S, 2002, CURR MICROBIOL, V44, P206, DOI 10.1007/s00284-001-0029-1; Henrissat B, 2002, TRENDS GENET, V18, P437, DOI 10.1016/S0168-9525(02)02734-8; Horcajada C, 2003, ACTA CRYSTALLOGR D, V59, P2322, DOI 10.1107/S0907444903021279; JETT MF, 1979, J BIOL CHEM, V254, P6739; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN DC, 1973, J BIOL CHEM, V248, P7007; Mitchell EP, 1996, BIOCHEMISTRY-US, V35, P7341, DOI 10.1021/bi960072w; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pederson BA, 2000, J BIOL CHEM, V275, P27753; Prats C, 2005, J BIOL CHEM, V280, P23165, DOI 10.1074/jbc.M502713200; Schwarz A, 2005, BIOCHEM J, V387, P437, DOI 10.1042/BJ20041593; TAKAHARA H, 1978, BIOCHIM BIOPHYS ACTA, V522, P363, DOI 10.1016/0005-2744(78)90070-0; TAKEDA Y, 1975, J BIOL CHEM, V250, P8943; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tong L, 1997, METHOD ENZYMOL, V276, P594, DOI 10.1016/S0076-6879(97)76080-4; Watson KA, 1999, EMBO J, V18, P4619, DOI 10.1093/emboj/18.17.4619; WITITSUWANNAKUL D, 1977, J BIOL CHEM, V252, P7812; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zea CJ, 2003, J AM CHEM SOC, V125, P13666, DOI 10.1021/ja037298o	30	55	55	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2923	2931		10.1074/jbc.M507394200	http://dx.doi.org/10.1074/jbc.M507394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319074	hybrid			2022-12-27	WOS:000234931800061
J	Marion, S; Oakley, RH; Kim, KM; Caron, MG; Barak, LS				Marion, S; Oakley, RH; Kim, KM; Caron, MG; Barak, LS			A beta-arrestin binding determinant common to the second intracellular loops of rhodopsin family G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIOID RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; VASOPRESSIN RECEPTOR; ADRENERGIC-RECEPTOR; 48-KDA PROTEIN; DESENSITIZATION; PHOSPHORYLATION; LIGHT; MUTANTS	beta-Arrestins have been shown to inhibit competitively G protein-dependent signaling and to mediate endocytosis for many of the hundreds of nonvisual rhodopsin family G protein-coupled receptors ( GPCR). An open question of fundamental importance concerning the regulation of signal transduction of several hundred rhodopsin-like GPCRs is how these receptors of limited sequence homology, when considered in toto, can all recruit and activate the two highly conserved beta-arrestin proteins as part of their signaling/desensitization process. Although the serine and threonine residues that form GPCR kinase phosphorylation sites are common beta-arrestin-associated receptor determinants regulating receptor desensitization and internalization, the agonist-activated conformation of a GPCR probably reveals the most fundamental determinant mediating the GPCR and arrestin interaction. Here we identified a beta-arrestin binding determinant common to the rhodopsin family GPCRs formed from the proximal 10 residues of the second intracellular loop. We demonstrated by both gain and loss of function studies for the serotonin 2C, beta(2)-adrenergic, alpha(2a)-adrenergic, and neuropeptide Y type 2 receptors that the highly conserved amino acids, proline and alanine, naturally occurring in rhodopsin family receptors six residues distal to the highly conserved second loop DRY motif regulate beta-arrestin binding and beta-arrestin-mediated internalization. In particular, as demonstrated for the beta(2)AR, this occurs independently of changes in GPCR kinase phosphorylation. These results suggest that a GPCR conformation directed by the second intracellular loop, likely using the loop itself as a binding patch, may function as a switch for transitioning beta-arrestin from its inactive form to its active receptor-binding state.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.	caron002@mc.duke.edu; l.barak@cellbio.duke.edu		Marion, Sebastien/0000-0002-3302-3845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061635] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barak LS, 2003, ASSAY DRUG DEV TECHN, V1, P339, DOI 10.1089/15406580360545152; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Berglund MM, 2003, J PHARMACOL EXP THER, V306, P147, DOI 10.1124/jpet.103.051227; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; CHANG MS, 2000, SCI STKE 2000, pPL1; Chung DA, 2002, BIOCHEMISTRY-US, V41, P3596, DOI 10.1021/bi015811+; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Demene H, 2003, BIOCHEMISTRY-US, V42, P8204, DOI 10.1021/bi027358n; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Filipek S, 2005, J MOL MODEL, V11, P385, DOI 10.1007/s00894-005-0268-3; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gibson SK, 2000, BIOCHEMISTRY-US, V39, P5738, DOI 10.1021/bi991857f; GUEX N, 2001, DEEP VIEW SWISS PDBV; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; Luttrell LM, 2002, J CELL SCI, V115, P455; Marion S, 2004, J BIOL CHEM, V279, P2945, DOI 10.1074/jbc.M308742200; MORO O, 1993, J BIOL CHEM, V268, P22273; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Niswender CM, 1999, J BIOL CHEM, V274, P9472, DOI 10.1074/jbc.274.14.9472; Niswender CM, 1998, ANN NY ACAD SCI, V861, P38, DOI 10.1111/j.1749-6632.1998.tb10171.x; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Parker SL, 2001, EUR J BIOCHEM, V268, P877, DOI 10.1046/j.1432-1327.2001.01966.x; Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200; Raman D, 1999, BIOCHEMISTRY-US, V38, P5117, DOI 10.1021/bi9824588; Raman D, 2003, J NEUROCHEM, V84, P1040, DOI 10.1046/j.1471-4159.2003.01598.x; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Scheer A, 2000, MOL PHARMACOL, V57, P219; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Seibold A, 2000, MOL PHARMACOL, V58, P1162, DOI 10.1124/mol.58.5.1162; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shi W, 1998, BIOCHEMISTRY-US, V37, P4869, DOI 10.1021/bi9731100; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Wilbanks AM, 2002, BIOCHEMISTRY-US, V41, P11981, DOI 10.1021/bi020275m	48	85	89	1	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2932	2938		10.1074/jbc.M508074200	http://dx.doi.org/10.1074/jbc.M508074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319069	hybrid			2022-12-27	WOS:000234931800062
J	Watanabe, S; Kodak, T; Makino, K				Watanabe, S; Kodak, T; Makino, K			Cloning, expression, and characterization of bacterial L-arabinose 1-dehydrogenase involved in an alternative pathway of L-arabinose metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-FRUCTOSE OXIDOREDUCTASE; D-GALACTOSE DEHYDROGENASE; L-XYLULOSE REDUCTASE; ZYMOMONAS-MOBILIS; 2-KETO-3-DEOXYGLUCONATE ALDOLASE; PSEUDOMONAS-FLUORESCENS; SULFOLOBUS-SOLFATARICUS; CATABOLIC PATHWAY; ASPERGILLUS-NIGER; GENE	Azospirillum brasiliense converts L-arabinose to alpha-ketoglutarate via five hypothetical enzymatic steps. We purified and characterized L-arabinose 1-dehydrogenase (EC 1.1.1.46), catalyzing the conversion of L-arabinose to L-arabino-gamma-lactone as an enzyme responsible for the first step of this alternative pathway of L-arabinose metabolism. The purified enzyme preferred NADP(+) to NAD(+) as a coenzyme. Kinetic analysis revealed that the enzyme had high catalytic efficiency for both L-arabinose and D-galactose. The gene encoding L-arabinose 1-dehydrogenase was cloned using a partial peptide sequence of the purified enzyme and was overexpressed in Escherichia coli as a fully active enzyme. The enzyme consists of 308 amino acids and has a calculated molecular mass of 33,663.92 Da. The deduced amino acid sequence had some similarity to glucose-fructose oxidoreductase, D-xylose 1-dehydrogenase, and D-galactose 1-dehydrogenase. Site-directed mutagenesis revealed that the enzyme possesses unique catalytic amino acid residues. Northern blot analysis showed that this gene was induced by L-arabinose but not by D-galactose. Furthermore, a disruptant of the L-arabinose 1-dehydrogenase gene did not grow on L-arabinose but grew on D-galactose at the same growth rate as the wild-type strain. There was a partial gene for L-arabinose transport in the flanking region of the L-arabinose 1-dehydrogenase gene. These results indicated that the enzyme is involved in the metabolism of L-arabinose but not D-galactose. This is the first identification of a gene involved in an alternative pathway of L-arabinose metabolism in bacterium.	Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan; Kyoto Univ, Fac Engn, Saikyo Ku, Kyoto 6158530, Japan; Japan Sci & Technol Agcy, CREST, Uji, Kyoto 6110011, Japan; Kyoto Univ, Int Innovat Ctr, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University; Japan Science & Technology Agency (JST); Kyoto University	Makino, K (corresponding author), Kyoto Univ, Inst Adv Energy, Uji, Kyoto 6110011, Japan.	kmak@iae.kyoto-u.ac.jp						Angelov A, 2005, FEBS J, V272, P1054, DOI 10.1111/j.1742-4658.2004.04539.x; Aoki S, 2001, CHEM-BIOL INTERACT, V130, P775, DOI 10.1016/S0009-2797(00)00307-0; Arimitsu E, 1999, BIOCHEM J, V342, P721, DOI 10.1042/0264-6021:3420721; Asada Y, 2000, BIOCHEM BIOPH RES CO, V278, P333, DOI 10.1006/bbrc.2000.3796; BLACHNITZKY EO, 1974, EUR J BIOCHEM, V47, P235, DOI 10.1111/j.1432-1033.1974.tb03687.x; Bonete MJ, 1996, FEBS LETT, V383, P227, DOI 10.1016/0014-5793(96)00235-9; Cosgrove MS, 1998, BIOCHEMISTRY-US, V37, P2759, DOI 10.1021/bi972069y; Cosgrove MS, 2000, BIOCHEMISTRY-US, V39, P15002, DOI 10.1021/bi0014608; DAGLEY S, 1965, BIOCHEM J, V95, P48, DOI 10.1042/bj0950048; DAHMS AS, 1969, BIOCHEM BIOPH RES CO, V36, P809, DOI 10.1016/0006-291X(69)90681-0; DUNCAN MJ, 1979, J GEN MICROBIOL, V113, P177, DOI 10.1099/00221287-113-1-177; DUNCAN MJ, 1979, J BACTERIOL, V137, P415, DOI 10.1128/JB.137.1.415-419.1979; Edwards KJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P173, DOI 10.1006/abbi.1996.0158; Elshafei AM, 2001, ENZYME MICROB TECH, V29, P76, DOI 10.1016/S0141-0229(01)00346-5; ELZAINY TA, 1973, J BACTERIOL, V114, P457, DOI 10.1128/JB.114.1.457-459.1973; Galbraith MP, 1998, MICROBIOL-SGM, V144, P2915, DOI 10.1099/00221287-144-10-2915; GENNADY PM, 2002, HDB DETECTION ENZYME, P27; Gros E., 1967, METHOD ENZYMOL, V11, P238; Johnsen U, 2004, J BACTERIOL, V186, P6198, DOI 10.1128/JB.186.18.6198-6207.2004; Kemner JM, 1997, J BACTERIOL, V179, P2452, DOI 10.1128/jb.179.7.2452-2458.1997; Kim ST, 1998, BBA-PROTEIN STRUCT M, V1429, P29, DOI 10.1016/S0167-4838(98)00217-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamble FJ, 2004, FEBS LETT, V576, P133, DOI 10.1016/j.febslet.2004.08.074; Lamble HJ, 2003, J BIOL CHEM, V278, P34066, DOI 10.1074/jbc.M305818200; Lott JS, 2000, J MOL BIOL, V304, P575, DOI 10.1006/jmbi.2000.4245; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHIAS AL, 1989, J BACTERIOL, V171, P5206, DOI 10.1128/jb.171.9.5206-5209.1989; Moore RA, 2004, INFECT IMMUN, V72, P4172, DOI 10.1128/IAI.72.7.4172-4187.2004; Moore S, 1940, J BIOL CHEM, V133, P293; NOVICK NJ, 1982, J BACTERIOL, V149, P364, DOI 10.1128/JB.149.1.364-367.1982; Nurizzo D, 2001, BIOCHEMISTRY-US, V40, P13857, DOI 10.1021/bi011355d; PEDROSA FO, 1974, J BACTERIOL, V119, P336, DOI 10.1128/JB.119.1.336-338.1974; Penning TM, 2001, CHEM REV, V101, P3027, DOI 10.1021/cr000049n; Richard P, 2002, BIOCHEMISTRY-US, V41, P6432, DOI 10.1021/bi025529i; Richard P, 2001, J BIOL CHEM, V276, P40631, DOI 10.1074/jbc.M104022200; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; Sambrook J., 2001, MOL CLONING LAB MANU; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SPERKA S, 1989, NUCLEIC ACIDS RES, V17, P5402, DOI 10.1093/nar/17.13.5402; STRYER L, 1988, BIOCHEMISTRY-US, P805; TARRAND JJ, 1978, CAN J MICROBIOL, V24, P967, DOI 10.1139/m78-160; Theodossis A, 2004, J BIOL CHEM, V279, P43886, DOI 10.1074/jbc.M407702200; Van Bastelaere E, 1999, MOL MICROBIOL, V32, P703, DOI 10.1046/j.1365-2958.1999.01384.x; Verho R, 2004, J BIOL CHEM, V279, P14746, DOI 10.1074/jbc.M312533200; WELMBERG R, 1961, J BIOL CHEM, V236, P629; WELMBERG R, 1955, J BIOL CHEM, V217, P607; WENGENMA.F, 1973, EUR J BIOCHEM, V40, P49, DOI 10.1111/j.1432-1033.1973.tb03168.x; Wiegert T, 1997, J BIOL CHEM, V272, P13126, DOI 10.1074/jbc.272.20.13126; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; ZACHARIOU M, 1986, J BACTERIOL, V167, P863, DOI 10.1128/jb.167.3.863-869.1986; Zaldivar J, 2001, APPL MICROBIOL BIOT, V56, P17, DOI 10.1007/s002530100624	52	61	68	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2612	2623		10.1074/jbc.M506477200	http://dx.doi.org/10.1074/jbc.M506477200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326697	hybrid			2022-12-27	WOS:000234931800025
J	Wegrzyn, RD; Hofmann, D; Merz, F; Nikolay, R; Rauch, T; Graf, C; Deuerling, E				Wegrzyn, RD; Hofmann, D; Merz, F; Nikolay, R; Rauch, T; Graf, C; Deuerling, E			A conserved motif is prerequisite for the interaction of NAC with ribosomal protein L23 and nascent chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-ASSOCIATED COMPLEX; SIGNAL RECOGNITION PARTICLE; MULTIPLE SEQUENCE ALIGNMENT; NEWLY SYNTHESIZED PROTEINS; COLI TRIGGER FACTOR; ESCHERICHIA-COLI; IN-VIVO; SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; FUNCTIONAL DISSECTION	In eukaryotes, newly synthesized proteins interact co-translationally with a multitude of different ribosome-bound factors and chaperones including the conserved heterodimeric nascent polypeptide-associated complex (NAC) and a Hsp40/70-based chaperone system. These factors are thought to play an important role in protein folding and targeting, yet their specific ribosomal localizations, which are prerequisite for their functions, remain elusive. This study describes the ribosomal localization of NAC and the molecular details by which NAC is able to contact the ribosome and gain access to nascent polypeptides. We identified a conserved RRK(X)(n)KK ribosome binding motif within the beta-subunit of NAC that is essential for the entire NAC complex to attach to ribosomes and allow for its interaction with nascent polypeptide chains. The motif localizes within a potential loop region between two predicted alpha-helices in the N terminus of beta NAC. This N-terminal beta NAC ribosome-binding domain was completely portable and sufficient to target an otherwise cytosolic protein to the ribosome. NAC modified with a UV-activatable cross-linker within its ribosome binding motif specifically cross-linked to L23 ribosomal protein family members at the exit site of the ribosome, providing the first evidence of NAC-L23 interaction in the context of the ribosome. Mutations of L23 reduced NAC ribosome binding in vivo and in vitro, whereas other eukaryotic ribosome-associated factors such as the Hsp70/40 chaperones Ssb or Zuotin were unaffected. We conclude that NAC employs a conserved ribosome binding domain to position itself on the L23 ribosomal protein adjacent to the nascent polypeptide exit site.	Univ Heidelberg, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Deuerling, E (corresponding author), Univ Heidelberg, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	e.deuerling@zmbh.uni-heidelberg.de		Nikolay, Rainer/0000-0003-4713-2548				AMANN E, 1988, GENE, V69, P3001; Baram D, 2005, P NATL ACAD SCI USA, V102, P12017, DOI 10.1073/pnas.0505581102; Beatrix B, 2000, J BIOL CHEM, V275, P37838, DOI 10.1074/jbc.M006368200; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Bloss TA, 2003, NATURE, V424, P1066, DOI 10.1038/nature01920; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Cheng ZL, 2005, J CELL BIOL, V168, P67, DOI 10.1083/jcb.200408188; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; Clamp M, 2004, BIOINFORMATICS, V20, P426, DOI 10.1093/bioinformatics/btg430; Cuff JA, 2000, PROTEINS, V40, P502, DOI 10.1002/1097-0134(20000815)40:3<502::AID-PROT170>3.0.CO;2-Q; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; DENG JM, 1995, TRANSGENIC RES, V4, P264, DOI 10.1007/BF01969120; Deuerling E, 2003, MOL MICROBIOL, V47, P1317, DOI 10.1046/j.1365-2958.2003.03370.x; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Franke J, 2001, J CELL SCI, V114, P2641; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; Gautschi M, 2001, P NATL ACAD SCI USA, V98, P3762, DOI 10.1073/pnas.071057198; Gautschi M, 2003, MOL CELL BIOL, V23, P7403, DOI 10.1128/MCB.23.20.7403-7414.2003; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GRALLATH S, 2005, EMBO REPORTS; Gu SQ, 2003, RNA, V9, P566, DOI 10.1261/rna.2196403; GUTHRIE C, 2004, METHODS ENZYMOLOGY G, V194; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hundley H, 2002, P NATL ACAD SCI USA, V99, P4203, DOI 10.1073/pnas.062048399; Hundley HA, 2005, SCIENCE, V308, P1032, DOI 10.1126/science.1109247; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Kristensen O, 2003, STRUCTURE, V11, P1547, DOI 10.1016/j.str.2003.11.003; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LAURING B, 1995, P NATL ACAD SCI USA, V92, P5411, DOI 10.1073/pnas.92.12.5411; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Markesich DC, 2000, DEVELOPMENT, V127, P559; Moller I, 1998, FEBS LETT, V441, P1, DOI 10.1016/S0014-5793(98)01440-9; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Nikolay R, 2004, J BIOL CHEM, V279, P2673, DOI 10.1074/jbc.M311112200; Otto H, 2005, P NATL ACAD SCI USA, V102, P10064, DOI 10.1073/pnas.0504400102; Pool MR, 2002, SCIENCE, V297, P1345, DOI 10.1126/science.1072366; Powers T, 1996, CURR BIOL, V6, P331, DOI 10.1016/S0960-9822(02)00484-0; Rauch T, 2005, MOL MICROBIOL, V57, P357, DOI 10.1111/j.1365-2958.2005.04690.x; Reimann B, 1999, YEAST, V15, P397, DOI 10.1002/(SICI)1097-0061(19990330)15:5<397::AID-YEA384>3.3.CO;2-L; Rist W, 2005, ANAL BIOCHEM, V342, P160, DOI 10.1016/j.ab.2004.11.043; Rospert S, 2002, CELL MOL LIFE SCI, V59, P1632, DOI 10.1007/PL00012490; Schaffitzel E, 2001, BIOL CHEM, V382, P1235, DOI 10.1515/BC.2001.154; Schlunzen F, 2005, STRUCTURE, V13, P1685, DOI 10.1016/j.str.2005.08.007; SIKORSKI RS, 1989, GENETICS, V122, P19; Spreter T, 2005, J BIOL CHEM, V280, P15849, DOI 10.1074/jbc.M500160200; Wegrzyn RD, 2005, CELL MOL LIFE SCI, V62, P2727, DOI 10.1007/s00018-005-5292-z; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	53	61	61	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2847	2857		10.1074/jbc.M511420200	http://dx.doi.org/10.1074/jbc.M511420200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316984	hybrid			2022-12-27	WOS:000234931800053
J	Xiao, YJ; Cai, YB; Bommineni, YR; Fernando, SC; Prakash, O; Gilliland, SE; Zhang, GL				Xiao, YJ; Cai, YB; Bommineni, YR; Fernando, SC; Prakash, O; Gilliland, SE; Zhang, GL			Identification and functional characterization of three chicken cathelicidins with potent antimicrobial activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNITY; HOST-DEFENSE; PEPTIDE PROTECTS; RAPID METHOD; EXPRESSION; INFECTION; SKIN; SEQUENCES; EVOLUTION; ALIGNMENT	Cathelicidins comprise a family of antimicrobial peptides sharing a highly conserved cathelin domain. Here we report that the entire chicken genome encodes three cathelicidins, namely fowlicidin-1 to -3, which are densely clustered within a 7.5-kb distance at the proximal end of chromosome 2p. Each fowlicidin gene adopts a four-exon, three-intron structure, typical for a mammalian cathelicidin. Phylogenetic analysis revealed that fowlicidins and a group of distantly related mammalian cathelicidins known as neutrophilic granule proteins are likely to originate from a common ancestral gene prior to the separation of birds from mammals, whereas other classic mammalian cathelicidins may have been duplicated from the primordial gene for neutrophilic granule proteins after mammals and birds are diverged. Similar to ovine cathelicidin SMAP-29, putatively mature fowlicidins displayed potent and salt-independent activities against a range of Gram-negative and Gram-positive bacteria, including antibiotic-resistant strains, with minimum inhibitory concentrations in the range of 0.4-2.0 mu M for most strains. Fowlicidin-1 and -2 also showed cytotoxicity, with 50% killing of mammalian erythrocytes or epithelial cells in the range of 6-40 mu M. In addition, two fowlicidins demonstrated a strong positive cooperativity in binding lipopolysaccharide (LPS), resulting in nearly complete blockage of LPS-mediated proinflammatory gene expression in RAW264.7 cells. Taken together, fowlicidin-1 and -2 are clearly among the most potent cathelicidins that have been reported. Their broad spectrum and salt-insensitive antibacterial activities, coupled with their potent LPS-neutralizing activity, make fowlicidins excellent candidates for novel antimicrobial and antisepsis agents.	Oklahoma State Univ, Dept Anim Sci, Stillwater, OK 74078 USA; Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Oklahoma State University System; Oklahoma State University - Stillwater; Kansas State University	Zhang, GL (corresponding author), Oklahoma State Univ, Dept Anim Sci, Stillwater, OK 74078 USA.	zguolon@okstate.edu	Zhang, Guolong/HCI-5587-2022; Zhang, Guolong/AAU-8197-2020	Zhang, Guolong/0000-0003-4781-5816				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bals R, 1999, J CLIN INVEST, V103, P1113, DOI 10.1172/JCI6570; Bals R, 1999, INFECT IMMUN, V67, P6084, DOI 10.1128/IAI.67.11.6084-6089.1999; Bartlett KH, 2003, ANTIMICROB AGENTS CH, V47, P3901, DOI 10.1128/AAC.47.12.3901-3906.2003; Brogden KA, 2003, INT J ANTIMICROB AG, V22, P465, DOI 10.1016/S0924-8579(03)00180-8; Carretero M, 2004, FASEB J, V18, P1931, DOI 10.1096/fj.04-1515fje; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Harmon BG, 1998, POULTRY SCI, V77, P972, DOI 10.1093/ps/77.7.972; Hettinger AM, 2001, BIOL REPROD, V65, P507, DOI 10.1095/biolreprod65.2.507; Iimura M, 2005, J IMMUNOL, V174, P4901, DOI 10.4049/jimmunol.174.8.4901; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; Lee PHA, 2005, P NATL ACAD SCI USA, V102, P3750, DOI 10.1073/pnas.0500268102; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; LEVY O, 1993, J BIOL CHEM, V268, P6058; Lynn DJ, 2004, IMMUNOGENETICS, V56, P170, DOI 10.1007/s00251-004-0675-0; Moscinski LC, 1995, J CELL BIOCHEM, V59, P431, DOI 10.1002/jcb.240590404; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Nociari MM, 1998, J IMMUNOL METHODS, V213, P157, DOI 10.1016/S0022-1759(98)00028-3; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Panyutich A, 1997, INFECT IMMUN, V65, P978, DOI 10.1128/IAI.65.3.978-985.1997; Patil A, 2004, PHYSIOL GENOMICS, V20, P1, DOI 10.1152/physiolgenomics.00150.2004; Patil AA, 2005, PHYSIOL GENOMICS, V23, P5, DOI 10.1152/physiolgenomics.00104.2005; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; Putsep K, 2002, LANCET, V360, P1144, DOI 10.1016/S0140-6736(02)11201-3; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCOCCHI M, 1992, EUR J BIOCHEM, V209, P589, DOI 10.1111/j.1432-1033.1992.tb17324.x; Scott MG, 2000, CRIT REV IMMUNOL, V20, P407; Shai Y, 2002, CURR PHARM DESIGN, V8, P715, DOI 10.2174/1381612023395367; Shi JS, 1999, INFECT IMMUN, V67, P3121, DOI 10.1128/IAI.67.6.3121-3127.1999; Shin SY, 2001, BIOCHEM BIOPH RES CO, V285, P1046, DOI 10.1006/bbrc.2001.5280; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Tack BF, 2002, EUR J BIOCHEM, V269, P1181, DOI 10.1046/j.0014-2956.2002.02751.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Travis SM, 2000, INFECT IMMUN, V68, P2748, DOI 10.1128/IAI.68.5.2748-2755.2000; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Uzzell T, 2003, PEPTIDES, V24, P1655, DOI 10.1016/j.peptides.2003.08.024; van Dijk A, 2005, VET IMMUNOL IMMUNOP, V106, P321, DOI 10.1016/j.vetimm.2005.03.003; Wehkamp Jan, 2005, V86, P42, DOI 10.1159/000086672; Xiao YJ, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-56; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Yeh RF, 2001, GENOME RES, V11, P803, DOI 10.1101/gr.175701; Yu K, 2002, J PEPT RES, V60, P1, DOI 10.1034/j.1399-3011.2002.01968.x; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zaiou M, 2002, J MOL MED, V80, P549, DOI 10.1007/s00109-002-0350-6; Zanetti M, 2002, CURR PHARM DESIGN, V8, P779, DOI 10.2174/1381612023395457; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; Zarember KA, 2002, INFECT IMMUN, V70, P569, DOI 10.1128/IAI.70.2.569-576.2002; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	51	179	203	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2858	2867		10.1074/jbc.M507180200	http://dx.doi.org/10.1074/jbc.M507180200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16326712	hybrid			2022-12-27	WOS:000234931800054
J	Lee, SJ; Kim, DC; Choi, BH; Ha, HJ; Kim, KT				Lee, SJ; Kim, DC; Choi, BH; Ha, HJ; Kim, KT			Regulation of p53 by activated protein kinase C-delta during nitric oxide-induced dopaminergic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; TYROSINE NITRATION; OXIDATIVE STRESS; INDUCED PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; ALPHA; INHIBITION; PEROXYNITRITE; TRANSLOCATION; MECHANISM	Selective cell death of dopaminergic neurons in the substantia nigra is the major cause of Parkinson disease. Current evidence suggests that this cell death could be mediated by nitric oxide by-products such as nitrate and peroxynitrite. Because protein kinase C (PKC)-delta is implicated in apoptosis of various cell types, we studied its roles and activation mechanisms in nitric oxide (NO)-induced apoptosis of SN4741 dopaminergic cells. When cells were treated with sodium nitroprusside (SNP), a NO donor, endogenous PKC-delta was nitrated and activated. Immunoprecipitation revealed that p53 co-immunoprecipitated with PKC-delta and was phosphorylated at the 15th serine residue in SNP-treated cells. An in vitro kinase assay revealed that p53 was directly phosphorylated by SNP-activated PKC-delta. The p53 Ser-15 phosphorylation was suppressed in SNP-treated cells when the NO-mediated activation of PKC-delta was inhibited by rottlerin or (-)-epigallocatechin gallate. Within 3 h of p53 phosphorylation, its protein levels increased because of decreased ubiquitin-dependent proteosomal proteolysis, whereas the protein levels of MDM2, ubiquitin-protein isopeptide ligase, were down-regulated in a p53 phosphorylation-dependent fashion. Taken together, these results demonstrate that nitration-mediated activation of PKC-delta induces the phosphorylation of the Ser-15 residue in p53, which increases its protein stability, thereby contributing to the nitric oxide-mediated apoptosis-like cell death pathway. These findings may be expanded to provide new insight into the cellular mechanisms of Parkinson disease.	POSTECH, Dept Life Sci, Div Mol & Life Sci, Syst BioDynam NCRC, Pohang 790784, South Korea; Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Cheongju 361763, South Korea	Pohang University of Science & Technology (POSTECH); Chungbuk National University	Kim, KT (corresponding author), POSTECH, Dept Life Sci, Div Mol & Life Sci, Syst BioDynam NCRC, Pohang 790784, South Korea.	ktk@postech.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627				Achanta G, 2001, CANCER RES, V61, P8723; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bal-Price A, 2000, J NEUROCHEM, V75, P1455, DOI 10.1046/j.1471-4159.2000.0751455.x; Balafanova Z, 2002, J BIOL CHEM, V277, P15021, DOI 10.1074/jbc.M112451200; BASHIR M, 2002, J BIOL CHEM, V277, P2330; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chakraborti T, 2005, BIOCHEMISTRY-US, V44, P5246, DOI 10.1021/bi0477889; Chan P, 1998, NEUROLOGY, V50, P513, DOI 10.1212/WNL.50.2.513; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Choi BH, 2004, J NEUROCHEM, V90, P442, DOI 10.1111/j.1471-4159.2004.02495.x; Choi SH, 2003, J NEUROSCI, V23, P5877; de Bernardo S, 2004, J NEUROCHEM, V91, P667, DOI 10.1111/j.1471-4159.2004.02744.x; DeVries TA, 2004, J BIOL CHEM, V279, P45603, DOI 10.1074/jbc.M407448200; El-Remessy AB, 2005, J CELL SCI, V118, P243, DOI 10.1242/jcs.01612; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; Gorell JM, 1997, NEUROLOGY, V48, P650, DOI 10.1212/WNL.48.3.650; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Hodara R, 2004, J BIOL CHEM, V279, P47746, DOI 10.1074/jbc.M408906200; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kim DC, 2005, BIOCHEM BIOPH RES CO, V337, P110, DOI 10.1016/j.bbrc.2005.09.009; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Knapp LT, 2001, BIOCHEM BIOPH RES CO, V286, P764, DOI 10.1006/bbrc.2001.5448; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leist M, 1999, EXP CELL RES, V249, P396, DOI 10.1006/excr.1999.4514; Li BJ, 2004, GENE DEV, V18, P1824, DOI 10.1101/gad.1223504; Li L, 2004, J BIOL CHEM, V279, P4058, DOI 10.1074/jbc.M310415200; Liu YB, 1997, J NEUROCHEM, V69, P581, DOI 10.1046/j.1471-4159.1997.69020581.x; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; Matassa A, 2003, CELL DEATH DIFFER, V10, P269, DOI 10.1038/sj.cdd.4401149; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Murphy S, 2000, GLIA, V29, P1, DOI 10.1002/(SICI)1098-1136(20000101)29:1<1::AID-GLIA1>3.0.CO;2-N; Murriel CL, 2004, J BIOL CHEM, V279, P47985, DOI 10.1074/jbc.M405071200; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Oh-hashi K, 1999, BIOCHEM BIOPH RES CO, V263, P504, DOI 10.1006/bbrc.1999.1237; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tang Y, 1999, IMMUNOLOGY, V96, P171; Vaughan JR, 2001, ANN HUM GENET, V65, P111, DOI 10.1017/S0003480001008557; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; Zhang YM, 2004, J NEUROSCI, V24, P10616, DOI 10.1523/JNEUROSCI.2469-04.2004	58	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2215	2224		10.1074/jbc.M509509200	http://dx.doi.org/10.1074/jbc.M509509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314418	hybrid			2022-12-27	WOS:000234760400045
J	Sudhamsu, J; Crane, BR				Sudhamsu, J; Crane, BR			Structure and reactivity of a thermostable prokaryotic nitric-oxide synthase that forms a long-lived oxy-heme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIWAVELENGTH SPECTROSCOPIC DATA; FERROUS DIOXYGEN COMPLEX; LIGAND-PROTEIN INTERACTIONS; COMPLETE GENOME SEQUENCE; COMPOUND-I FORMATION; N-G-HYDROXYARGININE; CYTOCHROME P450CAM; EQUILIBRIUM-CONSTANTS; BACILLUS-SUBTILIS; L-ARGININE	In an effort to generate more stable reaction intermediates involved in substrate oxidation by nitric-oxide synthases (NOSs), we have cloned, expressed, and characterized a thermostable NOS homolog from the thermophilic bacterium Geobacillus stearothermophilus (gsNOS). As expected, gsNOS forms nitric oxide ( NO) from L-arginine via the stable intermediate N-hydroxy L-arginine ( NOHA). The addition of oxygen to ferrous gsNOS results in long-lived heme-oxy complexes in the presence (Soret peak 427 nm) and absence ( Soret peak 413 nm) of substrates L-arginine and NOHA. The substrate-induced red shift correlates with hydrogen bonding between substrate and heme-bound oxygen resulting in conversion to a ferric heme-superoxy species. In single turnover experiments with NOHA, NO forms only in the presence of H4B. The crystal structure of gsNOS at 3.2 angstrom of resolution reveals great similarity to other known bacterial NOS structures, with the exception of differences in the distal heme pocket, close to the oxygen binding site. In particular, a Lys-356 ( Bacillus subtilis NOS) to Arg-365 ( gsNOS) substitution alters the conformation of a conserved Asp carboxylate, resulting in movement of an Ile residue toward the heme. Thus, a more constrained heme pocket may slow ligand dissociation and increase the lifetime of heme-bound oxygen to seconds at 4 degrees C. Similarly, the ferric-heme NO complex is also stabilized in gsNOS. The slow kinetics of gsNOS offer promise for studying downstream intermediates involved in substrate oxidation.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	Crane, BR (corresponding author), Cornell Univ, Dept Chem & Biol Chem, G 60 ST Olin, Ithaca, NY 14853 USA.	bc69@cornell.edu	Sudhamsu, Jawahar/A-8751-2012					AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Benson DE, 1997, BIOCHEMISTRY-US, V36, P5104, DOI 10.1021/bi963170q; Berka V, 2004, BIOCHEMISTRY-US, V43, P13137, DOI 10.1021/bi049026j; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; BLAKE RC, 1981, J BIOL CHEM, V256, P2127; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; BONFILS C, 1979, BIOCHEM BIOPH RES CO, V88, P1301, DOI 10.1016/0006-291X(79)91122-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buddha MR, 2004, J BIOL CHEM, V279, P49567, DOI 10.1074/jbc.C400418200; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Davydov R, 2002, BIOCHEMISTRY-US, V41, P10375, DOI 10.1021/bi0260637; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Davydov R, 2002, J AM CHEM SOC, V124, P1798, DOI 10.1021/ja0122391; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Denisov IG, 2002, J BIOL CHEM, V277, P42706, DOI 10.1074/jbc.M207949200; Denisov IG, 2002, METHOD ENZYMOL, V357, P103; Denisov IG, 2001, J BIOL CHEM, V276, P11648, DOI 10.1074/jbc.M010219200; EGAWA T, 1994, BIOCHEM BIOPH RES CO, V201, P1464, DOI 10.1006/bbrc.1994.1868; GAMPP H, 1986, TALANTA, V33, P943, DOI 10.1016/0039-9140(86)80233-8; GAMPP H, 1985, TALANTA, V32, P1133, DOI 10.1016/0039-9140(85)80238-1; GAMPP H, 1985, TALANTA, V32, P257, DOI 10.1016/0039-9140(85)80077-1; GAMPP H, 1985, TALANTA, V32, P95, DOI 10.1016/0039-9140(85)80035-7; Golderer G, 2001, GENE DEV, V15, P1299, DOI 10.1101/gad.890501; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRINSTAFF MW, 1995, INORG CHEM, V34, P4896, DOI 10.1021/ic00123a026; Huang H, 2001, J AM CHEM SOC, V123, P2674, DOI 10.1021/ja005900u; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Hurshman AR, 2003, BIOCHEMISTRY-US, V42, P13287, DOI 10.1021/bi035491p; ISHIMURA Y, 1971, BIOCHEM BIOPH RES CO, V42, P140, DOI 10.1016/0006-291X(71)90373-1; Kellner DG, 2002, J BIOL CHEM, V277, P9641, DOI 10.1074/jbc.C100745200; Kers JA, 2004, NATURE, V429, P79, DOI 10.1038/nature02504; Klessig DF, 2000, P NATL ACAD SCI USA, V97, P8849, DOI 10.1073/pnas.97.16.8849; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAMBEIR AM, 1985, BIOCHIM BIOPHYS ACTA, V828, P144, DOI 10.1016/0167-4838(85)90050-0; LAMBEIR AM, 1985, EUR J BIOCHEM, V147, P93, DOI 10.1111/j.1432-1033.1985.tb08723.x; LARROQUE C, 1980, FEBS LETT, V115, P175, DOI 10.1016/0014-5793(80)81161-6; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li D, 2004, J BIOL CHEM, V279, P26489, DOI 10.1074/jbc.M400968200; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; Marchal S, 2004, J BIOL CHEM, V279, P19824, DOI 10.1074/jbc.M313587200; Midha S, 2005, BIOCHEM BIOPH RES CO, V336, P346, DOI 10.1016/j.bbrc.2005.08.083; Muller U, 1997, PROG NEUROBIOL, V51, P363, DOI 10.1016/S0301-0082(96)00067-6; Nagano S, 2005, J BIOL CHEM, V280, P22102, DOI 10.1074/jbc.M501732200; Nagano S, 2005, J BIOL CHEM, V280, P31659, DOI 10.1074/jbc.M505261200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ninnemann H, 1996, PHOTOCHEM PHOTOBIOL, V64, P393, DOI 10.1111/j.1751-1097.1996.tb02477.x; OPRIAN DD, 1983, J BIOL CHEM, V258, P8684; Ost TWB, 2003, J AM CHEM SOC, V125, P15010, DOI 10.1021/ja035731o; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALCIC MM, 1980, BIOCHEM BIOPH RES CO, V94, P1123, DOI 10.1016/0006-291X(80)90535-5; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; PETERSON JA, 1972, ARCH BIOCHEM BIOPHYS, V149, P197, DOI 10.1016/0003-9861(72)90315-3; POMPON D, 1984, J BIOL CHEM, V259, P5377; Roach MP, 1999, J AM CHEM SOC, V121, P12088, DOI 10.1021/ja9915504; Rousseau DL, 2005, J INORG BIOCHEM, V99, P306, DOI 10.1016/j.jinorgbio.2004.11.007; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sato H, 1998, BIOCHEM BIOPH RES CO, V253, P845, DOI 10.1006/bbrc.1998.9851; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; Schunemann V, 2002, J INORG BIOCHEM, V91, P586, DOI 10.1016/S0162-0134(02)00476-2; Schunemann V, 2000, FEBS LETT, V479, P149, DOI 10.1016/S0014-5793(00)01886-X; SONO M, 1985, J BIOL CHEM, V260, P5530; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Sorlie M, 2003, J BIOL CHEM, V278, P48602, DOI 10.1074/jbc.M305682200; Spolitak T, 2005, J BIOL CHEM, V280, P20300, DOI 10.1074/jbc.M501761200; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Stuehr DJ, 2004, J BIOL CHEM, V279, P36167, DOI 10.1074/jbc.R400017200; Takami H, 2004, NUCLEIC ACIDS RES, V32, P6292, DOI 10.1093/nar/gkh970; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; TUCKEY RC, 1982, J BIOL CHEM, V257, P9309; TYSON CA, 1972, J BIOL CHEM, V247, P5777; Wang ZQ, 2004, J BIOL CHEM, V279, P19018, DOI 10.1074/jbc.M311663200; Wei CC, 2003, J BIOL CHEM, V278, P46668, DOI 10.1074/jbc.M307682200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wei CC, 2003, CHEM REV, V103, P2365, DOI 10.1021/cr0204350; WEISS RF, 1970, DEEP-SEA RES, V17, P721, DOI 10.1016/0011-7471(70)90037-9	84	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					9623	9632		10.1074/jbc.M510062200	http://dx.doi.org/10.1074/jbc.M510062200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16407211	hybrid			2022-12-27	WOS:000236404700074
J	Sentman, ML; Granstrom, M; Jakobson, H; Reaume, A; Basu, S; Marklund, SL				Sentman, ML; Granstrom, M; Jakobson, H; Reaume, A; Basu, S; Marklund, SL			Phenotypes of mice lacking extracellular superoxide dismutase and copper- and zinc-containing superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE; LIPID-PEROXIDATION; OXIDATIVE STRESS; MUTANT MICE; NEONATAL LETHALITY; HYDROGEN-PEROXIDE; XANTHINE-OXIDASE; DEFICIENT MICE; NITRIC-OXIDE; PEROXYNITRITE	Mice lacking the secreted extracellular superoxide dismutase (EC-SOD) or the cytosolic copper- and zinc-containing SOD (CuZn-SOD) show relatively mild phenotypes. To explore the possibility that the isoenzymes have partly overlapping functions, single and double knockout mice were examined. The absence of EC-SOD was found to be without effect on the lifespan of mice, and the reduced lifespan of CuZn-SOD knockouts was not further shortened by EC-SOD deficiency. The urinary excretion of isoprostanes was increased in CuZn-SOD knockout mice, and plasma thiobarbituric acid-reactive substances levels were elevated in EC-SOD knockout mice. These oxidant stress markers showed potentiated increases in the absence of both isoenzymes. Other alterations were mainly found in CuZn-SOD knockout mice, such as halved glutathione peroxidase activity in the tissues examined and increased glutathione and iron in the liver. There were no changes in tissue content of the alternative superoxide scavenger ascorbate, but there was a 25% reduction in ascorbate in blood plasma in mice lacking CuZn-SOD. No increase was found in the urinary excretion of the terminal metabolites of NO, nitrite, and nitrate in any of the genotypes. In conclusion, apart from the increases in the global urinary and plasma oxidant stress markers, our phenotype studies revealed no other evidence that the copper- and zinc-containing SOD isoenzymes have overlapping roles.	Univ Umea Hosp, Dept Med Biosci, SE-90185 Umea, Sweden; Natl Def Res Estab, SE-90182 Umea, Sweden; Melior Discovery Inc, Malvern, PA 19355 USA; Uppsala Univ, Fac Med, Dept Geriatr, SE-75125 Uppsala, Sweden	Umea University; Uppsala University	Marklund, SL (corresponding author), Univ Umea Hosp, Dept Med Biosci, SE-90185 Umea, Sweden.	Stefan.Marklund@medbio.umu.se		Granstrom, Micael/0000-0003-4563-7403				Attieh ZK, 1999, J BIOL CHEM, V274, P1116, DOI 10.1074/jbc.274.2.1116; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Basu S, 1998, PROSTAG LEUKOTR ESS, V58, P319, DOI 10.1016/S0952-3278(98)90042-4; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BIEMOND P, 1986, BIOCHEM J, V239, P169, DOI 10.1042/bj2390169; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; Copin JC, 2000, FREE RADICAL BIO MED, V28, P1571, DOI 10.1016/S0891-5849(00)00280-X; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; HALL MA, 1999, N AM ACTUARIAL J, V3, P34; HALLIWELL B, 1978, FEBS LETT, V92, P321, DOI 10.1016/0014-5793(78)80779-0; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; Ho YS, 1998, J BIOL CHEM, V273, P7765, DOI 10.1074/jbc.273.13.7765; Huang TT, 2002, METHOD ENZYMOL, V349, P191, DOI 10.1016/S0076-6879(02)49335-4; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KARLSSON K, 1988, BIOCHEM J, V255, P223; KARLSSON K, 1994, LAB INVEST, V70, P705; KOJIMA T, 1990, CHEM PHARM BULL, V38, P3414, DOI 10.1248/cpb.38.3414; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Landis GN, 2005, MECH AGEING DEV, V126, P365, DOI 10.1016/j.mad.2004.08.012; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Levy MA, 2001, AM J PHYSIOL-LUNG C, V281, pL172, DOI 10.1152/ajplung.2001.281.1.L172; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MARKLUND S, 1976, J BIOL CHEM, V251, P7504; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1984, BIOCHEM J, V222, P649, DOI 10.1042/bj2220649; MARKLUND SL, 1981, CLIN CHIM ACTA, V116, P191, DOI 10.1016/0009-8981(81)90022-X; Marklund SL, 2002, METHOD ENZYMOL, V349, P74, DOI 10.1016/S0076-6879(02)49322-6; MARKLUND SL, 1982, CANCER RES, V42, P1955; Marklund SL, 1997, J NEUROCHEM, V69, P675; Marklund SL, 1985, HDB METHODS OXYGEN R, P249; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Missirlis F, 2003, J BIOL CHEM, V278, P47365, DOI 10.1074/jbc.M307700200; Moore K, 1998, FREE RADICAL RES, V28, P659, DOI 10.3109/10715769809065821; NISHIKIMI M, 1975, BIOCHEM BIOPH RES CO, V63, P463, DOI 10.1016/0006-291X(75)90710-X; Ookawara T, 2002, BIOCHEM BIOPH RES CO, V296, P54, DOI 10.1016/S0006-291X(02)00804-5; Oury TD, 1999, BRAIN RES, V850, P96, DOI 10.1016/S0006-8993(99)02103-4; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rohrdanz E, 2001, ARCH TOXICOL, V75, P150, DOI 10.1007/s002040000206; RUBBO H, 1994, J BIOL CHEM, V269, P26066; Starzynski RR, 2005, J BIOL CHEM, V280, P4207, DOI 10.1074/jbc.M411055200; Stralin P, 2003, BBA-GEN SUBJECTS, V1619, P1, DOI 10.1016/S0304-4165(02)00419-1; Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003; Vulpe CD, 1999, NAT GENET, V21, P195, DOI 10.1038/5979; WEISIGER RA, 1973, J BIOL CHEM, V248, P3582; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WINTERBOURN CC, 1987, J CLIN INVEST, V80, P1486, DOI 10.1172/JCI113230	51	113	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6904	6909		10.1074/jbc.M510764200	http://dx.doi.org/10.1074/jbc.M510764200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16377630	hybrid			2022-12-27	WOS:000236030900002
J	Stevens, JM; Uchida, T; Daltrop, O; Kitagawa, T; Ferguson, SJ				Stevens, JM; Uchida, T; Daltrop, O; Kitagawa, T; Ferguson, SJ			Dynamic Ligation properties of the Escherichia coli heme chaperone CcmE to non-covalently bound heme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C MATURATION; RESONANCE RAMAN-SPECTRA; PROXIMAL HISTIDINE; PROTEIN CCME; ACTIVE-SITE; LIGAND; BIOGENESIS; MYOGLOBIN; COMPLEX; COOA	The cytochrome c maturation protein CcmE is an essential membrane-anchored heme chaperone involved in the post-translational covalent attachment of heme to c-type cytochromes in Gram-negative bacteria such as Escherichia coli. Previous in vitro studies have shown that CcmE can bind heme both covalently ( via a histidine residue) and non-covalently. In this work we present results on the latter form of heme binding to a soluble form of CcmE. Examination of a number of site-directed mutants of E. coli CcmE by resonance Raman spectroscopy has identified ligands of the heme iron and provided insight into the initial steps of heme binding by CcmE before it binds the heme covalently. The heme binding histidine (His-130) appears to ligate the heme iron in the ferric oxidation state, but two other residues ligate the iron in the ferrous form, thereby freeing His-130 to undergo covalent attachment to a heme vinyl group. It appears that the heme ligation in the non-covalent form is different from that in the holo-form, suggesting that a change in ligation could act as a trigger for the formation of the covalent bond and showing the dynamic and oxidation state-sensitive ligation properties of CcmE.	Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); University of Oxford	Kitagawa, T (corresponding author), Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Okazaki, Aichi 4448787, Japan.	teizo@ims.ac.jp; stuart.ferguson@bioch.ox.ac.uk	Uchida, Takeshi/A-6455-2017	Uchida, Takeshi/0000-0001-9270-8329	Biotechnology and Biological Sciences Research Council [C20071] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Ahuja U, 2005, J BIOL CHEM, V280, P236, DOI 10.1074/jbc.M410912200; Aki M, 2000, J PHYS CHEM B, V104, P10765, DOI 10.1021/jp000357p; Allen JWA, 2005, BIOCHEM J, V389, P587, DOI 10.1042/BJ20041894; Allen JWA, 2003, PHILOS T ROY SOC B, V358, P255, DOI 10.1098/rstb.2002.1192; ANDERSSON LA, 1992, NEW J CHEM, V16, P569; ANDERSSON LA, 1989, J BIOL CHEM, V264, P19099; ANZENBACHER P, 1989, BIOCHEM BIOPH RES CO, V162, P921, DOI 10.1016/0006-291X(89)90760-2; Aono S, 2003, ACCOUNTS CHEM RES, V36, P825, DOI 10.1021/ar020097p; Arnesano F, 2002, BIOCHEMISTRY-US, V41, P13587, DOI 10.1021/bi026362w; Cerda-Colon JF, 1998, J AM CHEM SOC, V120, P9312, DOI 10.1021/ja972654m; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P9703, DOI 10.1073/pnas.152120699; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DESBOIS A, 1992, EUR BIOPHYS J BIOPHY, V20, P321, DOI 10.1007/BF00196591; Enggist E, 2003, J BACTERIOL, V185, P3821, DOI 10.1128/JB.185.13.3821-3827.2003; Enggist E, 2002, STRUCTURE, V10, P1551, DOI 10.1016/S0969-2126(02)00885-7; Fabianek RA, 2000, FEMS MICROBIOL REV, V24, P303, DOI 10.1111/j.1574-6976.2000.tb00544.x; Harvat EM, 2005, J BIOL CHEM, V280, P36747, DOI 10.1074/jbc.M508355200; HU SZ, 1993, J AM CHEM SOC, V115, P12446, DOI 10.1021/ja00079a028; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Jayaraman V, 1996, BIOSPECTROSCOPY, V2, P311, DOI 10.1002/(SICI)1520-6343(1996)2:5<311::AID-BSPY4>3.3.CO;2-L; Lee DH, 2005, J AM CHEM SOC, V127, P3716, DOI 10.1021/ja044658e; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Liu Y, 1999, BIOCHEMISTRY-US, V38, P3733, DOI 10.1021/bi982707s; Mowat CG, 2005, DALTON T, P3381, DOI 10.1039/b505184c; OSAWA Y, 1990, J BIOL CHEM, V265, P10340; OSAWA Y, 1991, J BIOL CHEM, V266, P3208; RAVA RP, 1985, BIOCHEMISTRY-US, V24, P1861, DOI 10.1021/bi00329a009; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; Stevens JM, 2004, ACCOUNTS CHEM RES, V37, P999, DOI 10.1021/ar030266l; Stevens JM, 2003, J BIOL CHEM, V278, P20500, DOI 10.1074/jbc.M212925200; Stroebel D, 2003, NATURE, V426, P413, DOI 10.1038/nature02155; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Uchida T, 2004, J BIOL CHEM, V279, P51981, DOI 10.1074/jbc.M408963200; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	42	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6144	6151		10.1074/jbc.M508765200	http://dx.doi.org/10.1074/jbc.M508765200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16373344	hybrid			2022-12-27	WOS:000236030800006
J	Dewilde, S; Ebner, B; Vinck, E; Gilany, K; Hankeln, T; Burmester, T; Kreiling, J; Reinisch, C; Vanfleteren, JR; Kiger, L; Marden, MC; Hundahl, C; Fago, A; Van Doorslaer, S; Moens, L				Dewilde, S; Ebner, B; Vinck, E; Gilany, K; Hankeln, T; Burmester, T; Kreiling, J; Reinisch, C; Vanfleteren, JR; Kiger, L; Marden, MC; Hundahl, C; Fago, A; Van Doorslaer, S; Moens, L			The nerve hemoglobin of the bivalve mollusc Spisula solidissima - Molecular cloning, ligand binding studies, and phylogenetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBRO-VISCERAL CONNECTIVES; VERTEBRATE GLOBIN FAMILY; HIGH-PRESSURE; TEMPERATURE-DEPENDENCE; HUMAN NEUROGLOBIN; HEME ENVIRONMENT; OXYGEN-AFFINITY; CYTOGLOBIN; BRAIN; PROTEIN	Members of the hemoglobin (Hb) superfamily are present in nerve tissue of several vertebrate and invertebrate species. In vertebrates they display hexacoordinate heme iron atoms and are typically expressed at low levels (mu M). Their function is still a matter of debate. In invertebrates they have a hexa- or pentacoordinate heme iron, are mostly expressed at high levels ( mM), and have been suggested to have a myoglobin-like function. The native Hb of the surf clam, Spisula solidissima, composed of 162 amino acids, does not show specific deviations from the globin templates. UV-visible and resonance Raman spectroscopy demonstrate a hexacoordinate heme iron. Based on the sequence analogy, the histidine E7 is proposed as a sixth ligand. Kinetic and equilibrium measurements show amoderate oxygen affinity (P-50 similar to 0.6 torr) and no cooperativity. The histidine binding affinity is 100-fold lower than in neuroglobin. Phylogenetic analysis demonstrates a clustering of the S. solidissima nerve Hb with mollusc Hbs and myoglobins, but not with the vertebrate neuroglobins. We conclude that invertebrate nerve Hbs expressed at high levels are, despite the hexacoordinate nature of their heme iron, not essentially different from other intracellular Hbs. They most likely fulfill a myoglobin-like function and enhance oxygen supply to the neurons.	Univ Antwerp, Dept Biomed Sci, B-2610 Antwerp, Belgium; Univ Antwerp, Dept Phys, B-2610 Antwerp, Belgium; Johannes Gutenberg Univ Mainz, Inst Mol Genet, D-55099 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany; Marine Biol Lab, Woods Hole, MA 02543 USA; Univ Ghent, Dept Biol, B-9000 Ghent, Belgium; INSERM, U779, F-94276 Le Kremlin Bicetre, France; Aarhus Univ, Inst Biol Sci, DK-8000 Aarhus C, Denmark	University of Antwerp; University of Antwerp; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; Marine Biological Laboratory - Woods Hole; Ghent University; Institut National de la Sante et de la Recherche Medicale (Inserm); Aarhus University	Moens, L (corresponding author), Univ Antwerp, Dept Biomed Sci, Campus Drie Eiken,Univ Pl 1, B-2610 Antwerp, Belgium.	luc.moens@ua.ac.be	Marden, Michael/AAA-5923-2020; Kiger, Laurent/Q-1686-2018; Hundahl, Christian Ansgar/H-3938-2015; Van Doorslaer, Sabine/E-5050-2017; Gilany, Kambiz/F-3271-2017; Fago, Angela/J-5946-2013; Burmester, Thorsten/I-7225-2013; Marden, Michael C/G-3139-2012	Van Doorslaer, Sabine/0000-0002-1685-9202; Gilany, Kambiz/0000-0003-2916-7245; Fago, Angela/0000-0001-7315-2628; Burmester, Thorsten/0000-0002-5772-7863; Marden, Michael C/0000-0002-5254-6385; Kreiling, Jill/0000-0003-4440-2039; Vinck, Evi/0000-0001-6167-1068; Gilany, Kambiz/0000-0002-6729-5566				ALDEN RG, 1989, J BIOL CHEM, V264, P1933; [Anonymous], 2005, PHYLIP PHYLOGENY INF; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; ARVANITAKI A., 1960, BULL INST OCEANOGR [MONACO], V1164, P1; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BOISSEL JP, 1985, P NATL ACAD SCI USA, V82, P8448, DOI 10.1073/pnas.82.24.8448; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; Burmester T, 2004, IUBMB LIFE, V56, P703, DOI 10.1080/15216540500037257; CHALAZON.N, 1966, CR SOC BIOL, V160, P1020; Couture M, 2001, J BIOL CHEM, V276, P36377, DOI 10.1074/jbc.M103907200; Das TK, 1999, J BIOL CHEM, V274, P4207, DOI 10.1074/jbc.274.7.4207; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dewilde S, 1996, J BIOL CHEM, V271, P19865, DOI 10.1074/jbc.271.33.19865; DOELLER JE, 1988, BIOL BULL, V174, P67, DOI 10.2307/1541760; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Ebner B, 2003, MOL BIOL EVOL, V20, P1521, DOI 10.1093/molbev/msg164; Fago A, 2004, J BIOL CHEM, V279, P44417, DOI 10.1074/jbc.M407126200; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Geuens E, 2003, J BIOL CHEM, V278, P30417, DOI 10.1074/jbc.C300203200; Hamdane D, 2005, J BIOL CHEM, V280, P36809, DOI 10.1074/jbc.M506253200; Hamdane D, 2004, MICRON, V35, P59, DOI 10.1016/j.micron.2003.10.019; Hankeln T, 2005, J INORG BIOCHEM, V99, P110, DOI 10.1016/j.jinorgbio.2004.11.009; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; KEILIN J, 1949, BIOCHEM J, V45, P440, DOI 10.1042/bj0450440; Kiger L, 2004, IUBMB LIFE, V56, P709, DOI 10.1080/15216540500037711; KRAUS DW, 1986, SCIENCE, V232, P90, DOI 10.1126/science.232.4746.90; KRAUS DW, 1988, BIOL BULL, V174, P346, DOI 10.2307/1541960; KRAUS DW, 1988, BIOL BULL, V174, P54, DOI 10.2307/1541759; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lacan P, 2002, AM J HEMATOL, V69, P214, DOI 10.1002/ajh.10051; LANKESTER ER, 1872, ADV COMP ENV PHYSL, V21, P70; Laufs TL, 2004, NEUROSCI LETT, V362, P83, DOI 10.1016/j.neulet.2004.02.072; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; Moens L, 2000, NATURE, V407, P461, DOI 10.1038/35035181; MORISHIMA I, 1980, BIOCHEMISTRY-US, V19, P1569, DOI 10.1021/bi00549a006; Pesce A, 2003, STRUCTURE, V11, P1087, DOI 10.1016/S0969-2126(03)00166-7; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Polevoda B, 2000, J BIOL CHEM, V275, P36479, DOI 10.1074/jbc.R000023200; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; Roesner A, 2005, MOL BIOL EVOL, V22, P12, DOI 10.1093/molbev/msh258; SAGE JT, 1991, BIOCHEMISTRY-US, V30, P1227, DOI 10.1021/bi00219a010; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sawai H, 2003, BIOCHEMISTRY-US, V42, P5133, DOI 10.1021/bi027067e; SCHINDELMEISER I, 1979, COMP BIOCHEM PHYS B, V64, P149, DOI 10.1016/0305-0491(79)90153-6; SCHMIDT ER, 1980, CHROMOSOMA, V76, P35, DOI 10.1007/BF00292224; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; STRITTMATTER P, 1963, BIOCHIM BIOPHYS ACTA, V78, P562, DOI 10.1016/0006-3002(63)90928-4; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Uzan J, 2004, BIOPHYS J, V87, P1196, DOI 10.1529/biophysj.104.042168; Vandergon TL, 1998, J BIOL CHEM, V273, P16998, DOI 10.1074/jbc.273.27.16998; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; Whelan S, 2001, MOL BIOL EVOL, V18, P691, DOI 10.1093/oxfordjournals.molbev.a003851; WITTENBERG BA, 1965, BIOCHEM J, V96, P363, DOI 10.1042/bj0960363; WITTENBERG JB, 1992, ADV COMP ENV PHYSL, P59; Wystub S, 2003, NEUROSCI LETT, V346, P114, DOI 10.1016/S0304-3940(03)00563-9	61	24	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5364	5372		10.1074/jbc.M509486200	http://dx.doi.org/10.1074/jbc.M509486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16352603	Green Published, hybrid			2022-12-27	WOS:000235568900007
J	Matsuo, N; Tanaka, S; Gordon, MK; Koch, M; Yoshioka, H; Ramirez, F				Matsuo, N; Tanaka, S; Gordon, MK; Koch, M; Yoshioka, H; Ramirez, F			CREB-AP1 protein complexes regulate transcription of the collagen XXIV gene (Col24a1) in Osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE FIBRILLAR COLLAGEN; CHONDROCYTE-SPECIFIC ENHANCER; BONE-FORMATION; V COLLAGEN; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; PROMOTER; SOX9; SEQUENCE	Collagen XXIV is a newly discovered and poorly characterized member of the fibril-forming family of collagen molecules, which displays unique structural features of invertebrate fibrillar collagens and is expressed predominantly in bone tissue. Here we report the characterization of the proximal promoter of the mouse gene (Col24a1) and its regulation in osteoblastic cells. Using well characterized murine models of osteoblast differentiation, we found that the Col24a1 gene is activated sometime before onset of the late differentiation marker osteocalcin. Additional analyses revealed that Col24a1 produces equal amounts of two alternatively spliced products with different 5'-untranslated sequences that originate from distinct transcriptional start sites. Cell transfection experiments in combination with DNA binding assays demonstrated that Col24a1 promoter activity in ROS17/2.8 osteosarcoma cells is under the control of an upstream cis-acting element, which is shared by both transcripts and is recognized by specific combinations of c-Jun, CREB1, ATF1, and ATF2 dimers. Consistent with these results, overexpression of c-Jun, ATF1, ATF2, or CREB1 in transiently transfected osteoblastic cells stimulated transcription from reporter gene constructs driven by the Col24a1 promoter to different degrees. Moreover, chromatin immunoprecipitation experiments showed that these nuclear factors bind the same upstream sequence of the endogenous Col24a1 gene. Collectively these data provide new information about transcriptional control of collagen fibrillogenesis, in addition to implicating for the first time CREB-AP1 protein complexes in the regulation of collagen gene expression in osteoblasts.	Hosp Special Surg, Div Res, Lab Genet & Organogenesis, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; Oita Univ, Dept Anat Biol & Med, Oita 8795593, Japan; Rutgers State Univ, Ernest Mario Sch Pharm, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Univ Cologne, Inst Biochem 2, D-50931 Cologne, Germany; CEINGE Biotecnol Avanzate, I-80131 Naples, Italy	Cornell University; Oita University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Cologne; CEINGE Biotecnologie Avanzate	Ramirez, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, 89 French St, New Brunswick, NJ 08901 USA.	ramirefr@umdnj.edu	Koch, Manuel/AAG-9914-2021	Koch, Manuel/0000-0002-2962-7814	NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY009056, EY 09056] Funding Source: Medline; NIAMS NIH HHS [AR 38648] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; Aouacheria A, 2004, J BIOL CHEM, V279, P47711, DOI 10.1074/jbc.M408950200; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; Chanut-Delalande H, 2004, MOL CELL BIOL, V24, P6049, DOI 10.1128/MCB.24.13.6049-6057.2004; Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004-1343; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; Long FX, 2001, DEVELOPMENT, V128, P541; Luvalle P, 2003, J BONE JOINT SURG AM, V85A, P133, DOI 10.2106/00004623-200300002-00018; MAJESKA RJ, 1982, J BIOL CHEM, V257, P3362; Matsuo N, 2003, J BIOL CHEM, V278, P32763, DOI 10.1074/jbc.M305599200; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Murshed M, 2005, GENE DEV, V19, P1093, DOI 10.1101/gad.1276205; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Okazaki K, 2004, CLIN ORTHOP RELAT R, pS123, DOI 10.1097/01.blo.0000144478.51284.f3; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; Ricard-Blum S, 2005, PATHOL BIOL, V53, P430, DOI 10.1016/j.patbio.2004.12.024; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Sakamoto MK, 1998, J BIOCHEM-TOKYO, V123, P399; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; Tanaka S, 2004, J BIOL CHEM, V279, P56024, DOI 10.1074/jbc.M411406200; Terraz C, 2001, J BIOL CHEM, V276, P37011, DOI 10.1074/jbc.M104185200; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Wagner EF, 2002, ANN RHEUM DIS, V61, P40, DOI 10.1136/ard.61.suppl_2.ii40; Wenstrup RJ, 2004, J BIOL CHEM, V279, P53331, DOI 10.1074/jbc.M409622200; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yang XL, 2004, J BIOL CHEM, V279, P47109, DOI 10.1074/jbc.M410010200; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	49	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5445	5452		10.1074/jbc.M509923200	http://dx.doi.org/10.1074/jbc.M509923200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373341	hybrid			2022-12-27	WOS:000235568900016
J	Hsu, MC; Chang, HC; Hung, WC				Hsu, MC; Chang, HC; Hung, WC			HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; BREAST-CANCER; GENE-EXPRESSION; DOWN-REGULATION; PANCREATIC-CANCER; NEU PROTOONCOGENE; ACTIVATION; PROTEIN; PHOSPHORYLATION	Matrix metalloproteinase (MMP) inhibitory proteins may negatively regulate MMP activity to suppress tumor metastasis. In this study, we demonstrate that the HER-2/neu oncogene inhibits the expression of the MMP inhibitor RECK to promote cell invasion. RECK was inhibited via transcriptional repression in B104-1-1 cells, which express constitutively active HER-2/neu. Overexpression of HER-2/neu in NIH/3T3 or HaCaT cells also suppressed RECK expression. Deletion and mutation assays showed that HER-2/neu repressed RECK via the Sp1-binding site localized in the -82/-71 region from the translational start site. DNA affinity precipitation and chromatin immunoprecipitation assays indicated that binding of Sp1 and Sp3 to this consensus site was increased in B104-1-1 cells. We also found that HER-2/neu inhibited RECK via the ERK signaling pathway. Sp1 proteins phosphorylated at Thr(453) and Thr(739) by ERK bound preferentially to the RECK promoter, and this binding was reversed by HER-2/neu and ERK inhibitors. Furthermore, our data indicate that HER-2/neu obviously increased HDAC1 binding to the Sp1-binding site localized in the -72/-71 region of the RECK promoter. The histone deacetylase inhibitor trichostatin A reversed HER-2/neu-induced inhibition of RECK. HER-2/neu activation was associated with increased MMP-9 secretion and activation. Re-expression of RECK in HER-2/neu-overexpressing cells inhibited MMP-9 secretion and cell invasion. Taken together, our results suggest that HER-2/neu induces the binding of Sp proteins and HDAC1 to the RECK promoter to inhibit RECK expression and to promote cell invasion. Restoration of RECK provides a novel strategy for the inhibition of HER-2/neu-induced metastasis.	Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Fukuoka 804, Taiwan; Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct, Tainan 701, Taiwan	National Sun Yat Sen University; Kaohsiung Medical University; National Cheng Kung University	Hung, WC (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, 70 Lien Hai Rd, Kaohsiung, Fukuoka 804, Taiwan.	hung1228@ms10.hinet.net	Hsu, MC/AAE-5310-2020; Hung, Wen-Chun/F-4846-2011					Alroy I, 1999, MOL CELL BIOL, V19, P1961; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Bosc DG, 2001, ONCOGENE, V20, P6215, DOI 10.1038/sj.onc.1204820; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; Chadjichristos C, 2002, J BIOL CHEM, V277, P43903, DOI 10.1074/jbc.M206111200; Chang HC, 2004, CELL SIGNAL, V16, P675, DOI 10.1016/j.cellsig.2003.11.001; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DOUGALL WC, 1993, J CELL BIOCHEM, V53, P61, DOI 10.1002/jcb.240530108; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; Finkenzeller Gunter, 2004, Angiogenesis, V7, P59, DOI 10.1023/B:AGEN.0000037332.66411.f0; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; Harris VK, 2000, J BIOL CHEM, V275, P10802, DOI 10.1074/jbc.275.15.10802; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; Howe LR, 2002, CANCER RES, V62, P5405; Huang YC, 2004, ONCOGENE, V23, P4856, DOI 10.1038/sj.onc.1207621; Hung MC, 1999, SEMIN ONCOL, V26, P51; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; KING BL, 1992, AM J PATHOL, V140, P23; Konecny G, 2001, CLIN CANCER RES, V7, P2448; La Rocca G, 2004, BRIT J CANCER, V90, P1414, DOI 10.1038/sj.bjc.6601725; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li T, 2003, CIRC RES, V93, P1202, DOI 10.1161/01.RES.0000104085.76261.02; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Liu LT, 2003, CANCER RES, V63, P3069; Masui T, 2003, CLIN CANCER RES, V9, P1779; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; MITRA AB, 1994, CANCER RES, V54, P637; Nguyen DX, 2002, J VIROL, V76, P619, DOI 10.1128/JVI.76.2.619-632.2002; Noda M, 2003, CANCER METAST REV, V22, P167, DOI 10.1023/A:1023043315031; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Pang RTK, 2004, MOL ENDOCRINOL, V18, P471, DOI 10.1210/me.2003-0245; Petit AMV, 1997, AM J PATHOL, V151, P1523; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; SLEBOS RJC, 1989, BRIT J CANCER, V59, P76, DOI 10.1038/bjc.1989.14; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; VARLEY JM, 1987, ONCOGENE, V1, P423; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Wong WK, 2003, J BIOL CHEM, V278, P36227, DOI 10.1074/jbc.M305549200; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zhao SJ, 2003, CANCER RES, V63, P2624; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	46	97	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4718	4725		10.1074/jbc.M510937200	http://dx.doi.org/10.1074/jbc.M510937200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377629	hybrid			2022-12-27	WOS:000235426200020
J	Montalibet, J; Skorey, K; McKay, D; Scapin, G; Asante-Appiah, E; Kennedy, BP				Montalibet, J; Skorey, K; McKay, D; Scapin, G; Asante-Appiah, E; Kennedy, BP			Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PHOSPHODIESTERASE; PTP-1B INHIBITORS; POTENT; DESIGN; YEAST; SPECIFICITY; IDENTIFICATION; SELECTIVITY; SUBSTRATE; SCREEN	Regions of protein-tyrosine phosphatase (PTP) 1B that are distant from the active site yet affect inhibitor binding were identified by a novel library screen. This screen was based on the observation that expression of v-Src in yeast leads to lethality, which can be rescued by the coexpression of PTP1B. However, this rescue is lost when yeast are grown in the presence of PTP1B inhibitors. To identify regions of PTP1B (amino acids 1-400, catalytic domain plus 80-amino acid C-terminal tail) that can affect the binding of the difluoromethyl phosphonate (DFMP) inhibitor 7-bromo-6-difluoromethyl phosphonate 3-naphthalenenitrile, a library coexpressing PTP1B mutants and v-Src was generated, and the ability of yeast to grow in the presence of the inhibitor was evaluated. PTP1B inhibitor-resistant mutations were found to concentrate on helix alpha 7 and its surrounding region, but not in the active site. No resistant amino acid substitutions were found to occur in the C-terminal tail, suggesting that this region has little effect on active-site inhibitor binding. An in-depth characterization of a resistant substitution localizing to region alpha 7 (S295F) revealed that this change minimally affected enzyme catalytic activity, but significantly reduced the potency of a panel of structurally diverse DFMP PTP1B inhibitors. This loss of inhibitor potency was found to be due to the difluoro moiety of these inhibitors because only the difluoro inhibitors were shifted. For example, the inhibitor potency of a monofluorinated or non-fluorinated analog of one of these DFMP inhibitors was only minimally affected. Using this type of library screen, which can scan the nearly full-length PTP1B sequence (catalytic domain and C-terminal tail) for effects on inhibitor binding, we have been able to identify novel regions of PTP1B that specifically affect the binding of DFMP inhibitors.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Chem, Pointe Claire, PQ H9R 4P8, Canada; Concordia Univ, Dept Chem & Biochem, Montreal, PQ H4B 1R6, Canada; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Concordia University - Canada; Merck & Company	Kennedy, BP (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005,16711 Trans Canada Hwy, Pointe Claire, PQ H9R 4P8, Canada.	brian_kennedy@merck.com						Asante-Appiah E, 2001, J BIOL CHEM, V276, P26036, DOI 10.1074/jbc.M011697200; Atienza JM, 1999, J BIOL CHEM, V274, P4839, DOI 10.1074/jbc.274.8.4839; Burke TR, 2003, ACCOUNTS CHEM RES, V36, P426, DOI 10.1021/ar020127o; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CHEN L, 1995, BIOCHEM BIOPH RES CO, V216, P976, DOI 10.1006/bbrc.1995.2716; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME; Desmarais S, 1999, BIOCHEM J, V337, P219, DOI 10.1042/0264-6021:3370219; Dufresne C, 2004, BIOORG MED CHEM LETT, V14, P1039, DOI 10.1016/j.bmcl.2003.11.048; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Goldstein Barry J., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P265, DOI 10.2174/1568008013341163; Guo XL, 2002, J BIOL CHEM, V277, P41014, DOI 10.1074/jbc.M207347200; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Lau CK, 2004, BIOORG MED CHEM LETT, V14, P1043, DOI 10.1016/j.bmcl.2003.11.076; Leslie AGW, 1990, CRYSTALLOGRAPHIC COM; Montalibet J, 2005, METHODS, V35, P2, DOI 10.1016/j.ymeth.2004.07.002; Montalibet J, 2004, BIOCHEM PHARMACOL, V68, P1807, DOI 10.1016/j.bcp.2004.06.024; Montalibet J., 2005, DRUG DISCOV TODAY TH, V2, P129, DOI DOI 10.1016/J.DDSTR.2005.05.002; NELSON Z, 2004, F HUTCHINSON CANC RE; Ohtaka H, 2004, INT J BIOCHEM CELL B, V36, P1787, DOI 10.1016/j.biocel.2004.02.021; PILLAI R, 1993, P NATL ACAD SCI USA, V90, P11970, DOI 10.1073/pnas.90.24.11970; Prejdova Jana, 2004, Current Drug Targets - Infectious Disorders, V4, P137, DOI 10.2174/1568005043340984; Puius YA, 1997, P NATL ACAD SCI USA, V94, P13420, DOI 10.1073/pnas.94.25.13420; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Scapin G, 2003, BIOCHEMISTRY-US, V42, P11451, DOI 10.1021/bi035098j; SupertiFurga G, 1996, NAT BIOTECHNOL, V14, P600, DOI 10.1038/nbt0596-600; Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/eoid.13.3.199.27347; Wang QP, 1998, BIOORG MED CHEM LETT, V8, P345, DOI 10.1016/S0960-894X(98)00027-4; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803; Xu RX, 2004, J MOL BIOL, V337, P355, DOI 10.1016/j.jmb.2004.01.040; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616	32	52	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5258	5266		10.1074/jbc.M511546200	http://dx.doi.org/10.1074/jbc.M511546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16332678	hybrid			2022-12-27	WOS:000235426200080
J	Yoshida, R; Umezawa, T; Mizoguchi, T; Takahashi, S; Takahashi, F; Shinozaki, K				Yoshida, R; Umezawa, T; Mizoguchi, T; Takahashi, S; Takahashi, F; Shinozaki, K			The regulatory domain of SRK2E/OST1/SnRK2.6 interacts with ABI1 and integrates abscisic acid (ABA) and osmotic stress signals controlling stomatal closure in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE 2C; HYPEROSMOTIC STRESS; DROUGHT TOLERANCE; GENE-EXPRESSION; KINASE; ACTIVATION; CHANNELS; TRANSDUCTION; RESPONSES; UPSTREAM	ABI1 and ABI2 encode PP2C-type protein phosphatases and are thought to negatively regulate many aspects of abscisic acid (ABA) signaling, including stomatal closure in Arabidopsis. In contrast, SRK2E/OST1/SnRK2.6 encodes an Arabidopsis SnRK2 protein kinase and acts as a positive regulator in the ABA-induced stomatal closure. SRK2E/OST1 is activated by osmotic stress as well as by ABA, but the independence of the two activation processes has not yet been determined. Additionally, interaction between SRK2E/OST1 and PP2C-type phosphatases (ABI1 and ABI2) is not understood. In the present study, we demonstrated that the abi1-1 mutation, but not the abi2-1 mutation, strongly inhibited ABA-dependent SRK2E/OST1 activation. In contrast, osmotic stress activated SRK2E/OST1 even in abi1-1 and aba2-1 plants. The C-terminal regulatory domain of SRK2E/OST1 was required for its activation by both ABA and osmotic stress in Arabidopsis. The C-terminal domain was functionally divided into Domains I and II. Domain II was required only for the ABA-dependent activation of SRK2E/OST1, whereas Domain I was responsible for the ABA-independent activation. Full-length SRK2E/OST1 completely complemented the wilty phenotype of the srk2e mutant, but SRK2E/OST1 lacking Domain II did not. Domain II interacted with the ABI1 protein in a yeast two-hybrid assay. Our results suggested that the direct interaction between SRK2E/OST1 and ABI1 through Domain II plays a critical role in the control of stomatal closure.	RIKEN, Tsukuba Inst, Plant Mol Biol Lab, Tsukuba, Ibaraki 3050074, Japan; RIKEN, Genom Sci Ctr, Plant Mutat Explorat Team, Plant Funct Genom Res Grp,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; RIKEN, Plant Sci Ctr, Gene Discovery Res Grp, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	RIKEN; RIKEN; University of Tsukuba; RIKEN	Shinozaki, K (corresponding author), RIKEN, Tsukuba Inst, Plant Mol Biol Lab, 3-1-1,Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sinozaki@rtc.riken.jp	Umezawa, Taishi/E-3028-2010; Takahashi, Fuminori/D-6200-2017; Takahashi, Seiji/AAE-1509-2019; Shinozaki, Kazuo/G-4202-2013	Umezawa, Taishi/0000-0003-3750-0503; Takahashi, Fuminori/0000-0001-8817-8652; Takahashi, Seiji/0000-0002-2288-4340; Shinozaki, Kazuo/0000-0002-6317-9867				ANDERBERG RJ, 1992, P NATL ACAD SCI USA, V89, P10183, DOI 10.1073/pnas.89.21.10183; Bonetta D, 1998, TRENDS PLANT SCI, V3, P231, DOI 10.1016/S1360-1385(98)01241-2; Boudsocq M, 2004, J BIOL CHEM, V279, P41758, DOI 10.1074/jbc.M405259200; Bray EA, 1997, TRENDS PLANT SCI, V2, P48, DOI 10.1016/S1360-1385(97)82562-9; Finkelstein Ruth R., 2002, Plant Cell, V14, pS15; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; Guo Y, 2002, DEV CELL, V3, P233, DOI 10.1016/S1534-5807(02)00229-0; Halford NG, 2000, ADV BOT RES, V32, P405, DOI 10.1016/S0065-2296(00)32031-6; Himmelbach A, 2002, EMBO J, V21, P3029, DOI 10.1093/emboj/cdf316; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Hrabak EM, 2003, PLANT PHYSIOL, V132, P666, DOI 10.1104/pp.102.011999; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; Kelner A, 2004, PLANT PHYSIOL, V136, P3255, DOI 10.1104/pp.104.046151; Kobayashi Y, 2004, PLANT CELL, V16, P1163, DOI 10.1105/tpc.019943; Lemichez E, 2001, GENE DEV, V15, P1808, DOI 10.1101/gad.900401; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Li JX, 2000, SCIENCE, V287, P300, DOI 10.1126/science.287.5451.300; Liu K, 1998, PLANT CELL, V10, P1957, DOI 10.1105/tpc.10.11.1957; Luan S, 2002, PLANT CELL ENVIRON, V25, P229, DOI 10.1046/j.1365-3040.2002.00758.x; Mikolajczyk M, 2000, PLANT CELL, V12, P165, DOI 10.1105/tpc.12.1.165; Mitsuhara I, 1996, PLANT CELL PHYSIOL, V37, P49, DOI 10.1093/oxfordjournals.pcp.a028913; Monks DE, 2001, PLANT CELL, V13, P1205, DOI 10.1105/tpc.13.5.1205; Mustilli AC, 2002, PLANT CELL, V14, P3089, DOI 10.1105/tpc.007906; Nath N, 2003, MOL CELL BIOL, V23, P3909, DOI 10.1128/MCB.23.11.3909-3917.2003; Ohta M, 2003, P NATL ACAD SCI USA, V100, P11771, DOI 10.1073/pnas.2034853100; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Seo M, 2002, TRENDS PLANT SCI, V7, P41, DOI 10.1016/S1360-1385(01)02187-2; Shinozaki K, 2003, CURR OPIN PLANT BIOL, V6, P410, DOI 10.1016/S1369-5266(03)00092-X; Taji T, 2002, PLANT J, V29, P417, DOI 10.1046/j.0960-7412.2001.01227.x; Umezawa T, 2004, P NATL ACAD SCI USA, V101, P17306, DOI 10.1073/pnas.0407758101; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Yamaguchi-Shinozaki K, 2005, TRENDS PLANT SCI, V10, P88, DOI 10.1016/j.tplants.2004.12.012; Yoshida R, 2002, PLANT CELL PHYSIOL, V43, P1473, DOI 10.1093/pcp/pcf188; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P9508, DOI 10.1073/pnas.0402112101; Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329	38	381	437	9	100	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5310	5318		10.1074/jbc.M509820200	http://dx.doi.org/10.1074/jbc.M509820200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365038	hybrid			2022-12-27	WOS:000235426200085
J	Iwata, J; Ezaki, J; Komatsu, M; Yokota, S; Ueno, T; Tanida, I; Chiba, T; Tanaka, K; Kominami, E				Iwata, J; Ezaki, J; Komatsu, M; Yokota, S; Ueno, T; Tanida, I; Chiba, T; Tanaka, K; Kominami, E			Excess peroxisomes are degraded by autophagic machinery in mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATING ENZYME; VACUOLE TARGETING PATHWAY; SACCHAROMYCES-CEREVISIAE; SELECTIVE DEGRADATION; PICHIA-PASTORIS; RAT-LIVER; BIOGENESIS; PROLIFERATORS; PEXOPHAGY; CYTOPLASM	Peroxisomes are degraded by autophagic machinery termed "pexophagy" in yeast; however, whether this is essential for peroxisome degradation in mammals remains unknown. Here we have shown that Atg7, an essential gene for autophagy, plays a pivotal role in the degradation of excess peroxisomes in mammals. Following induction of peroxisomes by a 2-week treatment with phthalate esters in control and Atg7-deficient livers, peroxisomal degradation was monitored within 1 week after discontinuation of phthalate esters. Although most of the excess peroxisomes in the control liver were selectively degraded within 1 week, this rapid removal was exclusively impaired in the mutant liver. Furthermore, morphological analysis revealed that surplus peroxisomes, but not mutant hepatocytes, were surrounded by autophagosomes in the control. Our results indicated that the autophagic machinery is essential for the selective clearance of excess peroxisomes in mammals. This is the first direct evidence for the contribution of autophagic machinery in peroxisomal degradation in mammals.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Tokyo 1138613, Japan; Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Biol Lab, Tamaho, Yamanashi 40938, Japan	Juntendo University; Tokyo Metropolitan Institute of Medical Science; University of Yamanashi	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	komilabo@med.juntendo.ac.jp	Kominami, Eiki/D-3802-2009; Komatsu, Masaaki/B-8321-2011; Tanida, Isei/C-8277-2009	Komatsu, Masaaki/0000-0001-7672-7722; Tanida, Isei/0000-0001-8999-3990				Ano Y, 2005, MOL BIOL CELL, V16, P446, DOI 10.1091/mbc.E04-09-0842; Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Bellu AR, 2003, MICROSC RES TECHNIQ, V61, P161, DOI 10.1002/jemt.10325; Bellu AR, 2001, J BIOL CHEM, V276, P44570, DOI 10.1074/jbc.M107599200; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; EZAKI J, 1995, J NEUROCHEM, V64, P733; Farre JC, 2004, TRENDS CELL BIOL, V14, P515, DOI 10.1016/j.tcb.2004.07.014; Heiland I, 2005, FEBS J, V272, P2362, DOI 10.1111/j.1742-4658.2005.04690.x; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; NICHOLLSGRZEMSK.FA, 1992, BIOCHEM PHARMACOL, V7, P1395; Onodera J, 2004, J BIOL CHEM, V279, P16071, DOI 10.1074/jbc.M312706200; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; Shintani T, 2004, J BIOL CHEM, V279, P29889, DOI 10.1074/jbc.M404399200; Stromhaug PE, 2001, J BIOL CHEM, V276, P42422, DOI 10.1074/jbc.M104087200; Subramani S, 1998, PHYSIOL REV, V78, P171, DOI 10.1152/physrev.1998.78.1.171; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, BIOCHEM BIOPH RES CO, V292, P256, DOI 10.1006/bbrc.2002.6645; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; USUDA N, 1991, J HISTOCHEM CYTOCHEM, V39, P95, DOI 10.1177/39.1.1670581; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; YOKOTA S, 1993, EUR J CELL BIOL, V61, P67; Yokota S, 2003, MICROSC RES TECHNIQ, V61, P151, DOI 10.1002/jemt.10324; Yokota S, 2001, J HISTOCHEM CYTOCHEM, V49, P613, DOI 10.1177/002215540104900508; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	38	184	195	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4035	4041		10.1074/jbc.M512283200	http://dx.doi.org/10.1074/jbc.M512283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16332691	hybrid			2022-12-27	WOS:000235275300032
J	Karten, B; Campenot, RB; Vance, DE; Vance, JE				Karten, B; Campenot, RB; Vance, DE; Vance, JE			Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; APOLIPOPROTEIN-E; CELLULAR CHOLESTEROL; CONTAINING LIPOPROTEINS; ASTROCYTES SYNTHESIZE; DENSITY-LIPOPROTEIN; CEREBROSPINAL-FLUID; LIPID EFFLUX; WILD-TYPE; IN-VITRO	Central nervous system lipoproteins mediate the exchange of cholesterol between cells and support synaptogenesis and neuronal growth. The primary source of lipoproteins in the brain is astroglia cells that synthesize and secrete apolipoprotein (apo) E in high density lipoprotein-like particles. Small quantities of apoA1, derived from the peripheral circulation, are also present in the brain. In addition to the direct secretion of apoE-containing lipoproteins from astroglia, glia-derived lipoproteins are thought to be formed by cholesterol efflux to extracellular apolipoproteins via ATP-binding cassette (ABC) transporters. We used cultured cerebellar murine astroglia to investigate the relationship among cholesterol availability, apoE secretion, expression of ABCA1 and ABCG1, and cholesterol efflux. In many cell types, cholesterol content, ABCA1 expression, and cholesterol efflux are closely correlated. In contrast, cholesterol enrichment of glia failed to increase ABCA1 expression, although ABCG1 expression and cholesterol efflux to apoA1 were increased. Moreover, the liver X receptor (LXR) agonist TO901317 up-regulated ABCA1 and ABCG1 expression in glia without stimulating cholesterol efflux. Larger lipoproteins were generated when glia were enriched with cholesterol, whereas treatment with the LXR agonist produced smaller particles that were eliminated when the glia were loaded with cholesterol. We also used glia from ApoE(-/-) mice to distinguish between direct lipoprotein secretion and the extracellular generation of lipoproteins. Our observations indicate that partially lipidated apoE, secreted directly by glia, is likely to be the major extracellular acceptor of cholesterol released from glia in a process mediated by ABCG1.	Univ Alberta, Canadian Inst Hlth Res, Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada	Institute for Work & Health; University of Alberta; University of Alberta; University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Canadian Inst Hlth Res, Res Grp Mol & Cell Biol Lipids, 328 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	jean.vance@ualberta.ca		Karten, Barbara/0000-0003-2395-3333				Choi HY, 2003, J BIOL CHEM, V278, P32569, DOI 10.1074/jbc.M304553200; Costet P, 2000, J BIOL CHEM, V275, P28240; DeMattos RB, 2001, NEUROCHEM INT, V39, P415, DOI 10.1016/S0197-0186(01)00049-3; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Hayashi H, 2004, J BIOL CHEM, V279, P14009, DOI 10.1074/jbc.M313828200; Hirsch-Reinshagen V, 2004, J BIOL CHEM, V279, P41197, DOI 10.1074/jbc.M407962200; Ito T, 2003, DRUG NEWS PERSPECT, V16, P490, DOI 10.1358/dnp.2003.16.8.829346; Karten B, 2005, BIOCHEM J, V387, P779, DOI 10.1042/BJ20041694; Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Koch S, 2001, J LIPID RES, V42, P1143; Koudinov AR, 2005, J NEUROL SCI, V229, P233, DOI 10.1016/j.jns.2004.11.036; Krimbou L, 2004, J LIPID RES, V45, P839, DOI 10.1194/jlr.M300418-JLR200; LaDu MJ, 2000, J BIOL CHEM, V275, P33974, DOI 10.1074/jbc.M000602200; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lee JY, 2005, CURR OPIN LIPIDOL, V16, P19, DOI 10.1097/00041433-200502000-00005; Lordkipanidze T, 2005, GLIA, V51, P229, DOI 10.1002/glia.20200; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; MOCKEL B, 1994, J NEUROCHEM, V62, P788; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; Nakamura K, 2004, J BIOL CHEM, V279, P45980, DOI 10.1074/jbc.M408652200; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Oram JF, 2001, J LIPID RES, V42, P1173; Panzenboeck U, 2002, J BIOL CHEM, V277, P42781, DOI 10.1074/jbc.M207601200; PATEL SC, 1995, NEUROREPORT, V6, P653, DOI 10.1097/00001756-199503000-00017; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Schmitz G, 2001, J LIPID RES, V42, P1513; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; STITT TN, 1991, ANN NY ACAD SCI, V633, P113; Turley SD, 1996, J LIPID RES, V37, P1953; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wahrle SE, 2004, J BIOL CHEM, V279, P40987, DOI 10.1074/jbc.M407963200; Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101; Yamada Keiko, 2002, Anatomical Science International, V77, P94, DOI 10.1046/j.0022-7722.2002.00021.x	45	100	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4049	4057		10.1074/jbc.M508915200	http://dx.doi.org/10.1074/jbc.M508915200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352604	hybrid			2022-12-27	WOS:000235275300034
J	Ma, JL; Lee, SJ; Duong, JK; Stern, DF				Ma, JL; Lee, SJ; Duong, JK; Stern, DF			Activation of the checkpoint kinase Rad53 by the phosphatidyl inositol kinase-like kinase Mec1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; DOUBLE-STRAND BREAKS; CHK2 PROTEIN-KINASE; BUDDING YEAST RAD9; SACCHAROMYCES-CEREVISIAE; S-PHASE; REPLICATION STRESS; MRE11 COMPLEX; PHOSPHORYLATION; PATHWAYS	Saccharomyces cerevisiae Rad53, the ortholog of mammalian Chk2, is an essential protein kinase in DNA damage and DNA replication checkpoint pathways. Consecutive phosphatidyl inositol kinase-like kinase (PIKK)-dependent and PIKK-independent steps in activation of Rad53 are key steps for controlling and transmitting diverse downstream responses to DNA damage. However, these activities have not been demonstrated in vitro in defined systems. Here, we have shown that enzymatically dephosphorylated purified Rad53 autoactivates in vitro through a phosphorylation-dependent mechanism. Kinetic analysis demonstrated that autophosphorylation results in a more than 9-fold increase in protein kinase activity. Autophosphorylation was Rad53 concentration-dependent, indicating that the reaction follows an intermolecular mechanism. DNA damage induced oligomerization of a subset of Rad53 molecules in vivo. At low concentrations of Rad53, preincubation of Rad53 with immune complexes containing the Mec1/Ddc2 complex can activate Rad53 kinase activity. Our findings showed that Mec1/Ddc2 complexes can directly activate Rad53 through a phosphorylation-dependent mechanism, and more generally, supported the hypothesis that PIKKs regulate Chk2 orthologs through phosphorylation. Moreover, this work has substantiated a model for PIKK-independent amplification of Rad53 activation (and by extension, activation of other Chk2 orthologs) mediated by inter-Rad53 phosphorylation.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.	DF.Stern@yale.edu	Ma, Nianhan/AAB-9869-2020	Ma, Nianhan/0000-0003-1800-2306	NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA82257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; AHN JY, 2002, J BIOL CHEM, V18, P18; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Amours D, 2001, GENE DEV, V15, P2238, DOI 10.1101/gad.208701; de la Torre-Ruiz MA, 1998, EMBO J, V17, P2687, DOI 10.1093/emboj/17.9.2687; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Emili A, 1998, MOL CELL, V2, P183, DOI 10.1016/S1097-2765(00)80128-8; Gardner R, 1999, EMBO J, V18, P3173, DOI 10.1093/emboj/18.11.3173; Gilbert CS, 2003, EMBO REP, V4, P953, DOI 10.1038/sj.embor.embor935; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee SJ, 2004, MOL BIOL CELL, V15, P5443, DOI 10.1091/mbc.E04-07-0608; Lee SJ, 2003, MOL CELL BIOL, V23, P6300, DOI 10.1128/MCB.23.17.6300-6314.2003; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mochida S, 2004, EMBO J, V23, P418, DOI 10.1038/sj.emboj.7600018; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Naiki T, 2004, MOL CELL BIOL, V24, P3277, DOI 10.1128/MCB.24.8.3277-3285.2004; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Pellicioli A, 2005, CURR BIOL, V15, pR769, DOI 10.1016/j.cub.2005.08.057; Ruiz MAD, 2000, FEBS LETT, V485, P205, DOI 10.1016/S0014-5793(00)02198-0; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schwartz MF, 2003, CELL CYCLE, V2, P384, DOI 10.4161/cc.2.4.457; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Smolka MB, 2005, MOL CELL PROTEOMICS, V4, P1358, DOI 10.1074/mcp.M500115-MCP200; Soulier J, 1999, CURR BIOL, V9, P551, DOI 10.1016/S0960-9822(99)80242-5; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Sweeney FD, 2005, CURR BIOL, V15, P1364, DOI 10.1016/j.cub.2005.06.063; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829	50	37	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3954	3963		10.1074/jbc.M507508200	http://dx.doi.org/10.1074/jbc.M507508200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365046	hybrid			2022-12-27	WOS:000235275300023
J	Macauley, MS; Errington, WJ; Scharpf, M; Mackereth, CD; Blaszczak, AG; Graves, BJ; McIntosh, LP				Macauley, MS; Errington, WJ; Scharpf, M; Mackereth, CD; Blaszczak, AG; Graves, BJ; McIntosh, LP			Beads-on-a-string, characterization of Ets-1 sumoylated within its flexible N-terminal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; SUMO-1 MODIFICATION; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; POINTED DOMAIN; DNA-BINDING; PROTEIN; IDENTIFICATION; MOTIF; SITE	Sumoylation regulates the activities of several members of the ETS transcription factor family. To provide a molecular framework for understanding this regulation, we have characterized the conjugation of Ets-1 with SUMO-1. Ets-1 is modified in vivo predominantly at a consensus sumoylation motif containing Lys-15. This lysine is located within the unstructured N-terminal segment of Ets-1 preceding its PNT domain. Using NMR spectroscopy, we demonstrate that the Ets-1 sumoylation motif associates with the substrate binding site on the SUMO-conjugating enzyme UBC9 (K-d similar to 400 mu M) and that the PNT domain is not involved in this interaction. Ets-1 with Lys-15 mutated to an arginine still binds UBC9 with an affinity similar to the wild type protein, but is no longer sumoylated. NMR chemical shift and relaxation measurements reveal that the covalent attachment of mature SUMO-1, via its flexible C-terminal Gly-97, to Lys-15 of Ets-1 does not perturb the structure or dynamic properties of either protein. Therefore sumoylated Ets-1 behaves as "beads-on-a-string" with the two proteins tethered by flexible polypeptide segments containing the isopeptide linkage. Accordingly, SUMO-1 may mediate interactions of Ets-1 with signaling or transcriptional regulatory macromolecules by acting as a structurally independent docking module, rather than through the induction of a conformational change in either protein upon their covalent linkage. We also hypothesize that the flexibility of the linking polypeptide sequence may be a general feature contributing to the recognition of SUMO-modified proteins by their downstream effectors.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z3, Canada; Univ Utah, Dept Oncol Sci, Huntsman Canc Inst, Salt Lake City, UT 84112 USA	University of British Columbia; University of British Columbia; University of British Columbia; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	McIntosh, LP (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintosh@chem.ubc.ca	Mackereth, Cameron D./F-7946-2013	Mackereth, Cameron D./0000-0002-0776-7947; Macauley, Matthew/0000-0003-4579-1048	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038663] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038663] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baba D, 2005, NATURE, V435, P979, DOI 10.1038/nature03634; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Chang CC, 2005, J BIOL CHEM, V280, P10164, DOI 10.1074/jbc.M409161200; Cowley DO, 2000, GENE DEV, V14, P366; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Eskiw CH, 2002, BIOCHEM CELL BIOL, V80, P301, DOI 10.1139/O02-079; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Foulds CE, 2004, MOL CELL BIOL, V24, P10954, DOI 10.1128/MCB.24.24.10954-10964.2004; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gocke CB, 2005, J BIOL CHEM, V280, P5004, DOI 10.1074/jbc.M411718200; Goddard T. D., 1999, SPARKY 3; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hannich JT, 2005, J BIOL CHEM, V280, P4102, DOI 10.1074/jbc.M413209200; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hilgarth RS, 2004, J BIOL CHEM, V279, P53899, DOI 10.1074/jbc.R400021200; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson PE, 1996, BIOCHEMISTRY-US, V35, P13895, DOI 10.1021/bi961186a; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Lee GM, 2005, J BIOL CHEM, V280, P7088, DOI 10.1074/jbc.M410722200; Leight ER, 2005, DEVELOPMENT, V132, P1047, DOI 10.1242/dev.01664; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Macauley MS, 2004, J BIOL CHEM, V279, P49131, DOI 10.1074/jbc.M408705200; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Pichler A, 2005, NAT STRUCT MOL BIOL, V12, P264, DOI 10.1038/nsmb903; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Salinas S, 2004, J CELL BIOL, V165, P767, DOI 10.1083/jcb.200310136; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tatham MH, 2003, BIOCHEMISTRY-US, V42, P9959, DOI 10.1021/bi0345283; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wasylyk C, 2005, ONCOGENE, V24, P820, DOI 10.1038/sj.onc.1208226; Wohlschlegel JA, 2004, J BIOL CHEM, V279, P45662, DOI 10.1074/jbc.M409203200; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Wykoff DD, 2005, MOL CELL PROTEOMICS, V4, P73, DOI 10.1074/mcp.M400166-MCP200; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	62	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4164	4172		10.1074/jbc.M510488200	http://dx.doi.org/10.1074/jbc.M510488200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16319071	hybrid			2022-12-27	WOS:000235275300048
J	Swift, S; Leger, AJ; Talavera, J; Lei, Z; Bohm, A; Kuliopulos, A				Swift, S; Leger, AJ; Talavera, J; Lei, Z; Bohm, A; Kuliopulos, A			Role of the PAR1 receptor 8th helix in signaling - The 7-8-1 receptor activation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; LIGHT-DEPENDENT CHANGES; 4TH CYTOPLASMIC LOOP; THROMBIN-RECEPTOR; INTRACELLULAR TRAFFICKING; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE; RHODOPSIN; BINDING; TRANSDUCIN	The protease-activated receptors are tethered ligand G protein-coupled receptors that are activated by proteolytic cleavage of the extracellular domain of the receptor. The archetypic protease-activated receptor PAR1 strongly activates G(q) signaling pathways, but very little is known regarding the mechanism of signal transference between receptor and internally located G protein. The recent x-ray structure of rhodopsin revealed the presence of a highly conserved amphipathic 8th helix that is likely to be physically interposed between receptor and G protein. We found that the analogous 8th helix region of PAR1 was critical for activation of Gq-dependent signaling. Engineering an 8th helix alpha-aneurysm with a downwards-directed alanine residue markedly interfered with signal transference to Gq. The 8th helix-anchoring cysteine palmitoylation sites were important for the affinity of ligand-dependent G protein coupling but did not affect the maximal signal. A network of H-bond and ionic interactions was found to connect the N-terminal portion of the 8th helix to the nearby NPXXY motif on transmembrane helix 7 and also to the adjacent intracellular loop-1. Disruption of these pairwise interactions caused additive defects in coupling to G protein, indicating that the transmembrane 7-8th helix-i1 loop may move in a coordinated manner to transfer the signal from PAR1 to G protein. This "7-8-1" interaction network was found to be prevalent in G protein-coupled receptors involved in endothelial signaling and angiogenesis.	Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Div Hematol & Oncol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts University	Kuliopulos, A (corresponding author), Tufts Univ, New England Med Ctr, Mol Oncol Res Inst, Box 7510,750 Washington St, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu		Swift, Steven/0000-0002-3840-4401	NHLBI NIH HHS [F32HL10296, R01-HL57905, R01-HL64701] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010296, R01HL057905, R01HL064701] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1984, EUR J BIOCHEM, V145, P333, DOI 10.1111/j.1432-1033.1984.tb08558.x; Al-Ani B, 2004, MOL PHARMACOL, V65, P149, DOI 10.1124/mol.65.1.149; Al-Ani B, 1999, BRIT J PHARMACOL, V128, P1105, DOI 10.1038/sj.bjp.0702834; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Blackhart BD, 2000, MOL PHARMACOL, V58, P1178, DOI 10.1124/mol.58.6.1178; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Compton SJ, 2000, J BIOL CHEM, V275, P39207, DOI 10.1074/jbc.M007215200; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P9308, DOI 10.1021/bi9902236; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Imamoto Y, 2000, BIOCHEMISTRY-US, V39, P15225, DOI 10.1021/bi0018685; ISHII K, 1994, J BIOL CHEM, V269, P1125; Kaneider NC, 2005, NAT MED, V11, P661, DOI 10.1038/nm1245; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; Krishna AG, 2002, BIOCHEMISTRY-US, V41, P8298, DOI 10.1021/bi025534m; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; McLaughlin JN, 2005, J BIOL CHEM, V280, P25048, DOI 10.1074/jbc.M414090200; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; Natochin M, 2003, J BIOL CHEM, V278, P37574, DOI 10.1074/jbc.M305136200; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Okuno T, 2003, J BIOL CHEM, V278, P41500, DOI 10.1074/jbc.M307335200; Paing MM, 2004, J BIOL CHEM, V279, P21938, DOI 10.1074/jbc.M401672200; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Seeley S, 2003, CHEM BIOL, V10, P1033, DOI 10.1016/j.chembiol.2003.10.014; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; SHORTLE D, 1995, CURR OPIN BIOTECH, V6, P387, DOI 10.1016/0958-1669(95)80067-0; Swift S, 2000, J BIOL CHEM, V275, P2627, DOI 10.1074/jbc.275.4.2627; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Verrall S, 1997, J BIOL CHEM, V272, P6898, DOI 10.1074/jbc.272.11.6898; VOURETCRAVIARI V, 1992, MOL BIOL CELL, V3, P95, DOI 10.1091/mbc.3.1.95; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Woulfe D, 2004, J CLIN INVEST, V113, P441, DOI 10.1172/JCI200420267; Zain J, 2000, BLOOD, V95, P3133	55	76	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4109	4116		10.1074/jbc.M509525200	http://dx.doi.org/10.1074/jbc.M509525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354660	hybrid			2022-12-27	WOS:000235275300041
J	Veit, G; Kobbe, B; Keene, DR; Paulsson, M; Koch, M; Wagener, R				Veit, G; Kobbe, B; Keene, DR; Paulsson, M; Koch, M; Wagener, R			Collagen XXVIII, a novel von Willebrand factor A domain-containing protein with many imperfections in the collagenous domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CRYSTAL-STRUCTURE; PROCOLLAGEN-VII; SCHWANN-CELLS; C5 DOMAIN; BINDING; IDENTIFICATION; EXPRESSION; PREDICTION; MUTATIONS	Here we describe a novel collagen belonging to the class of von Willebrand factor A ( VWA) domain- containing proteins. This novel protein was identified by screening the EST data base and was subsequently recombinantly expressed and characterized as an authentic tissue component. The COL28A1 gene on human chromosome 7p21.3 and on mouse chromosome 6A1 encodes a novel protein that structurally resembles the beaded filament- forming collagens. The collagenous domain contains several very short interruptions arranged in a repeat pattern. As shown for other novel minor collagens, the expression of collagen XXVIII protein in mouse is very restricted. In addition to small amounts in skin and calvaria, the major signals were in dorsal root ganglia and peripheral nerves. By immunoelectron microscopy, collagen XXVIII was detected in the sciatic nerve, at the basement membrane of certain Schwann cells surrounding the nerve fibers. Even though the protein is present in the adult sciatic nerve, collagen XXVIII mRNA was only detected in sciatic nerve of newborn mice, indicating that the protein persists for an extended period after synthesis.	Univ Cologne, Inst Biochem 2, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med, Fac Med, D-50931 Cologne, Germany; Univ Cologne, Dept Dermatol, Fac Med, D-50931 Cologne, Germany; Shriners Hosp Crippled Children, Childrens Res Ctr, Portland, OR 97239 USA	University of Cologne; University of Cologne; University of Cologne	Wagener, R (corresponding author), Univ Cologne, Inst Biochem 2, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	raimund.wagener@uni-koeln.de	Veit, Guido/C-9596-2009; Koch, Manuel/AAG-9914-2021	Veit, Guido/0000-0002-6758-2696; Koch, Manuel/0000-0002-2962-7814				Abril JF, 2005, GENOME RES, V15, P111, DOI 10.1101/gr.3108805; Aigner T, 2002, BIOCHEM BIOPH RES CO, V290, P743, DOI 10.1006/bbrc.2001.6227; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUCKNERTUDERMAN L, 1995, J CELL BIOL, V131, P551, DOI 10.1083/jcb.131.2.551; CHU ML, 1988, J BIOL CHEM, V263, P18601; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Farrer T, 2002, NUCLEIC ACIDS RES, V30, P3360, DOI 10.1093/nar/gkf465; Feltri ML, 2005, J PERIPHER NERV SYST, V10, P128, DOI 10.1111/j.1085-9489.2005.0010204.x; Knupp C, 2001, EMBO J, V20, P372, DOI 10.1093/emboj/20.3.372; Ko YP, 2004, MOL CELL BIOL, V24, P1691, DOI 10.1128/MCB.24.4.1691-1699.2004; Kohfeldt E, 1996, EUR J BIOCHEM, V238, P333, DOI 10.1111/j.1432-1033.1996.0333z.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LI K, 1993, GENOMICS, V16, P733, DOI 10.1006/geno.1993.1255; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; Persikov AV, 2005, J BIOL CHEM, V280, P19343, DOI 10.1074/jbc.M501657200; Persikov AV, 2005, BIOCHEMISTRY-US, V44, P1414, DOI 10.1021/bi048216r; POSCHL E, 1994, EMBO J, V13, P3741, DOI 10.1002/j.1460-2075.1994.tb06683.x; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Ries A, 2001, EUR J BIOCHEM, V268, P5119, DOI 10.1046/j.0014-2956.2001.02437.x; Rothblum K, 2004, J BIOL CHEM, V279, P51282, DOI 10.1074/jbc.M408837200; Sengle G, 2003, J BIOL CHEM, V278, P50240, DOI 10.1074/jbc.M307794200; SIBLEY MH, 1993, J CELL BIOL, V123, P255, DOI 10.1083/jcb.123.1.255; Smyth N, 2000, METH MOL B, V139, P49; TRYGGVASON K, 1990, ANN NY ACAD SCI, V580, P97, DOI 10.1111/j.1749-6632.1990.tb17922.x; Uschkureit T, 2000, J NEUROSCI, V20, P5225, DOI 10.1523/JNEUROSCI.20-14-05225.2000; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259	32	130	142	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3494	3504		10.1074/jbc.M509333200	http://dx.doi.org/10.1074/jbc.M509333200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330543	hybrid			2022-12-27	WOS:000235128200059
J	Galinier, A; Carriere, A; Fernandez, Y; Carpene, C; Andre, M; Caspar-Bauguil, S; Thouvenot, JP; Periquet, B; Penicaud, L; Casteilla, L				Galinier, A; Carriere, A; Fernandez, Y; Carpene, C; Andre, M; Caspar-Bauguil, S; Thouvenot, JP; Periquet, B; Penicaud, L; Casteilla, L			Adipose tissue proadipogenic redox changes in obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; INSULIN-RESISTANCE; GENE-EXPRESSION; PLASMA; BLOOD; MICE; SUPPLEMENTATION; DIFFERENTIATION; ANTIOXIDANTS; ADIPOCYTES	The role of inflammation and oxidative stress in the development of obesity and associated metabolic disorders is under debate. We investigated the redox metabolism in a non-diabetic obesity model, i.e. 11-week-old obese Zucker rats. Antioxidant enzyme activities, lipophilic antioxidant (alpha-tocopherol, coenzymes Q) and hydrophilic antioxidant ( glutathione, vitamin C) contents and their redox state (% oxidized form), were studied in inguinal white fat and compared with blood and liver. The adipose tissues of obese animals showed a specific higher content of hydrophilic molecules in a lower redox state than those of lean animals, which were associated with lower lipophilic molecule content and lipid peroxidation. Conversely and as expected, glutathione content decreased and its redox state increased in adipose tissues of rats subjected to lipowpolysaccharide-induced systemic oxidative stress. In these in vivo models, oxidative stress and obesity thus had opposite effects on adipose tissue redox state. Moreover, the increase in glutathione content and the decrease of its redox state by antioxidant treatment promoted in vitro the accumulation of triglycerides in preadipocytes. Taken together and contrary to the emergent view, our results suggest that obesity is associated with an intracellular reduced redox state that promotes on its own the development of a deleterious proadipogenic process.	Univ Toulouse 3, CNRS, UMR 5018, Inst Fed Rech 31,Inst Louis Bugnard, F-31432 Toulouse 4, France; Hop Purpan, Lab Biochim Gen & Nutr, F-31059 Toulouse 9, France; Inst Louis Bugnard, Unite 586, IFR 31, F-31432 Toulouse 4, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Casteilla, L (corresponding author), Univ Toulouse 3, CNRS, UMR 5018, Inst Fed Rech 31,Inst Louis Bugnard, BP 84225, F-31432 Toulouse 4, France.	casteil@toulouse.inserm.fr	Carpéné, Christian/S-3279-2019	Carriere, Audrey/0000-0002-4277-7905; Galinier, Anne/0000-0003-2454-5681; Casteilla, Louis/0000-0001-9647-3248; Caspar-Bauguil, Sylvie/0000-0003-2682-0704				Ben-Shaul V, 2001, TOXICOL LETT, V123, P1, DOI 10.1016/S0378-4274(01)00369-1; Carriere A, 2004, J BIOL CHEM, V279, P40462, DOI 10.1074/jbc.M407258200; Carriere A, 2003, FEBS LETT, V550, P163, DOI 10.1016/S0014-5793(03)00862-7; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; Deveaud C, 2005, BIOCHEM PHARMACOL, V70, P90, DOI 10.1016/j.bcp.2005.04.015; Douillet C, 1998, BIOL TRACE ELEM RES, V65, P221, DOI 10.1007/BF02789098; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Esposito LA, 2000, FREE RADICAL BIO MED, V28, P754, DOI 10.1016/S0891-5849(00)00161-1; FABREGAT I, 1987, BIOCHEM BIOPH RES CO, V146, P920, DOI 10.1016/0006-291X(87)90618-8; Faure P, 2004, EUR J CLIN INVEST, V34, P475, DOI 10.1111/j.1365-2362.2004.01362.x; Ford ES, 2003, DIABETES, V52, P2346, DOI 10.2337/diabetes.52.9.2346; Froyland L, 1996, LIPIDS, V31, P169, DOI 10.1007/BF02522617; Fujita A, 2005, DIABETES RES CLIN PR, V69, P113, DOI 10.1016/j.diabres.2004.11.016; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]; Galinier A, 2004, FEBS LETT, V578, P53, DOI 10.1016/j.febslet.2004.10.067; GUNZLER WA, 1974, Z KLIN CHEM KLIN BIO, V12, P444; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; McClung JP, 2004, P NATL ACAD SCI USA, V101, P8852, DOI 10.1073/pnas.0308096101; Melnyk S, 1999, J NUTR BIOCHEM, V10, P490, DOI 10.1016/S0955-2863(99)00033-9; Molnar D, 2004, INT J OBESITY, V28, P1197, DOI 10.1038/sj.ijo.0802719; Morin N, 2001, J PHARMACOL EXP THER, V297, P563; Ogihara T, 2004, DIABETOLOGIA, V47, P794, DOI 10.1007/s00125-004-1391-x; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Prunet-Marcassus B, 1999, FEBS LETT, V464, P184, DOI 10.1016/S0014-5793(99)01710-X; RAMIREZZACARIAS JL, 1992, HISTOCHEMISTRY, V97, P493, DOI 10.1007/BF00316069; Reitman A, 2002, ISRAEL MED ASSOC J, V4, P590; Rosen ED, 2000, GENE DEV, V14, P1293; SPEEK AJ, 1984, J CHROMATOGR, V305, P53, DOI 10.1016/S0378-4347(00)83313-7; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; Tofovic SP, 2003, METH MOLEC MED, V86, P29; Touyz RM, 2004, HISTOCHEM CELL BIOL, V122, P339, DOI 10.1007/s00418-004-0696-7; Urakawa H, 2003, J CLIN ENDOCR METAB, V88, P4673, DOI 10.1210/jc.2003-030202; Visentin V, 2004, OBES RES, V12, P547, DOI 10.1038/oby.2004.62; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YAGI K, 1984, METHOD ENZYMOL, V105, P328; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829	37	79	83	1	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12682	12687		10.1074/jbc.M506949200	http://dx.doi.org/10.1074/jbc.M506949200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16377639	hybrid			2022-12-27	WOS:000237134700059
J	Carta, L; Pereira, L; Arteaga-Solis, E; Lee-Arteaga, SY; Lenart, B; Starcher, B; Merkel, CA; Sukoyan, M; Kerkis, A; Hazeki, N; Keene, DR; Sakai, LY; Ramirez, F				Carta, L; Pereira, L; Arteaga-Solis, E; Lee-Arteaga, SY; Lenart, B; Starcher, B; Merkel, CA; Sukoyan, M; Kerkis, A; Hazeki, N; Keene, DR; Sakai, LY; Ramirez, F			Fibrillins 1 and 2 perform partially overlapping functions during aortic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE; EXTRACELLULAR MICROFIBRILS; VASCULAR MORPHOGENESIS; LYSYL OXIDASE; EXPRESSION; ELASTIN; CYR61; MICE; PATHOGENESIS; FIBULIN-5	Fibrillin-rich microfibrils are extracellular assemblies that impart structural properties to the connective tissue. To elucidate the contribution of fibrillin-rich microfibrils to organogenesis, we have examined the vascular phenotype of a newly created strain of mice that completely lacks fibrillin-1 and the consequences of combined deficiency of fibrillins 1 and 2 on tissue formation. The results demonstrated that fibrillins 1 and 2 perform partially overlapping functions during aortic development. Fbn1(-/-) mice died soon after birth from ruptured aortic aneurysm, impaired pulmonary function, and/or diaphragmatic collapse. Analysis of the neonatal Fbn1(-/-) aorta documented a disorganized and poorly developed medial layer but normal levels of elastin cross-links. Transcriptional profiling revealed that aneurysm progression in Fbn1 null mice is accompanied by unproductive up-regulation of gene products normally involved in tissue repair and vascular integrity, such as plasminogen activator inhibitor-1, activin A, and cysteine-rich angiogenic protein 61. In contrast to Fbn1(-/-) mice, Fbn2 null mice had a well developed and morphologically normal aortic wall. However, virtually all Fbn1(-/-); Fbn2(-/-) embryos and about half of the Fbn1(+/-); Fbn2(-/-) embryos died in utero and displayed a significantly more severe vascular phenotype than Fbn1(-/-) mice. Consistent with a specialized function of fibrillin-2, electron microscopy visualized ultrastructurally different microfibrils in Fbn1 null compared with control cell cultures. Collectively, these data demonstrate that involvement of fibrillin-2 in the initial assembly of the aortic matrix overlaps in part with fibrillin-1 and that continued fibrillin-1 deposition is absolutely required for the maturation and function of the vessel during neonatal life.	CEINGE Biotecnol Avanzate, I-80131 Naples, Italy; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Shriners Hosp Children, Portland, OR 97239 USA; Univ Texas, Hlth Sci Ctr, Tyler, TX 75708 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Univ Sao Paulo, Inst Biociencias, Dept Genet & Biol Evolut, BR-05508900 Sao Paulo, Brazil; Cornell Univ, Hosp Special Surg, Weill Med Coll, Lab Genet & Organogenesis, New York, NY 10021 USA	CEINGE Biotecnologie Avanzate; Oregon Health & Science University; Oregon Health & Science University; University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Universidade de Sao Paulo; Cornell University	Ramirez, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Inst Child Hlth, 89 French St, New Brunswick, NJ 08901 USA.	ramirefr@umdnj.edu	Merkel, Christian/K-7057-2012		NIAMS NIH HHS [R01 AR042044-13, R01 AR042044, P01 AR049698] Funding Source: Medline; NIGMS NIH HHS [F31 GM018511-04, F31 GM018511] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042044, P01AR049698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM018511] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arteaga-Solis E, 2001, J CELL BIOL, V154, P275, DOI 10.1083/jcb.200105046; Bonewald LF, 1999, CRIT REV EUKAR GENE, V9, P33, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.30; Brooke BS, 2003, TRENDS CELL BIOL, V13, P51, DOI 10.1016/S0962-8924(02)00007-7; Bunton TE, 2001, CIRC RES, V88, P37, DOI 10.1161/01.RES.88.1.37; Charbonneau Noe L, 2004, Birth Defects Res C Embryo Today, V72, P37, DOI 10.1002/bdrc.20000; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; DAVIS EC, 1994, J CELL SCI, V107, P727; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Faury G, 2001, PATHOL BIOL, V49, P310, DOI 10.1016/S0369-8114(01)00147-X; Gayraud B, 2000, J CELL BIOL, V150, P667, DOI 10.1083/jcb.150.3.667; Gelb BD, 2004, CURR OPIN CARDIOL, V19, P110, DOI 10.1097/00001573-200403000-00007; Handford PA, 2000, MATRIX BIOL, V19, P457, DOI 10.1016/S0945-053X(00)00100-1; Hornstra IK, 2003, J BIOL CHEM, V278, P14387, DOI 10.1074/jbc.M210144200; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Judge DP, 2004, J CLIN INVEST, V114, P172, DOI 10.1172/JCI200420641; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Kelleher CM, 2004, CURR TOP DEV BIOL, V62, P153; Kielty CM, 2002, J CELL SCI, V115, P2817; KUROO M, 1991, J BIOL CHEM, V266, P3768; Li DY, 1998, J CLIN INVEST, V102, P1783, DOI 10.1172/JCI4487; Liu XQ, 2004, NAT GENET, V36, P178, DOI 10.1038/ng1297; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maki JM, 2002, CIRCULATION, V106, P2503, DOI 10.1161/01.CIR.0000038109.84500.1E; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Molloy CJ, 1999, J ENDOCRINOL, V161, P179, DOI 10.1677/joe.0.1610179; Nakamura T, 2002, NATURE, V415, P171, DOI 10.1038/415171a; Neptune ER, 2003, NAT GENET, V33, P407, DOI 10.1038/ng1116; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; Pereira L, 1999, P NATL ACAD SCI USA, V96, P3819, DOI 10.1073/pnas.96.7.3819; Pyeritz RE, 2002, PRINCIPLES PRACTICE, P3977; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Spencer JA, 2005, P NATL ACAD SCI USA, V102, P2946, DOI 10.1073/pnas.0500058102; STARCHER B, 1995, CONNECT TISSUE RES, V31, P133, DOI 10.3109/03008209509028401; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; Zou YZ, 2004, NAT CELL BIOL, V6, P499, DOI 10.1038/ncb1137	38	179	193	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8016	8023		10.1074/jbc.M511599200	http://dx.doi.org/10.1074/jbc.M511599200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16407178	Green Accepted, hybrid			2022-12-27	WOS:000236031000038
J	Kono, M; Dreier, JL; Ellis, JM; Allende, ML; Kalkofen, DN; Sanders, KM; Bielawski, J; Bielawska, A; Hannun, YA; Proia, RL				Kono, M; Dreier, JL; Ellis, JM; Allende, ML; Kalkofen, DN; Sanders, KM; Bielawski, J; Bielawska, A; Hannun, YA; Proia, RL			Neutral ceramidase encoded by the Asah2 gene is essential for the intestinal degradation of sphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,2-DIMETHYLHYDRAZINE-TREATED CF1 MICE; ALKALINE SPHINGOMYELINASE ACTIVITY; HUMAN ACID CERAMIDASE; FULL-LENGTH CDNA; MOLECULAR-CLONING; GASTROINTESTINAL-TRACT; COLON-CANCER; CRYPT FOCI; METABOLISM; RAT	Complex sphingolipids are abundant as eukaryotic cell membrane components, whereas their metabolites, in particular ceramide, sphingosine, and sphingosine 1-phosphate, are involved in diverse cell signaling processes. In mammals, degradation of ceramide by ceramidase yields sphingosine, which is phosphorylated by the action of sphingosine kinase to generate sphingosine 1-phosphate. Therefore, ceramidases are key enzymes in the regulation of the cellular levels of ceramide, sphingosine, and sphingosine 1-phosphate. To explore the physiological functions of a neutral ceramidase with diverse cellular locations, we disrupted the Asah2 gene in mice. Asah2 null mice have a normal life span and do not show obvious abnormalities or major alterations in total ceramide levels in tissues. The Asah2-encoded neutral ceramidase is highly expressed in the small intestine along the brush border, suggesting that the neutral ceramidase may be involved in a pathway for the digestion of dietary sphingolipids. Indeed, Asah2 null mice were deficient in the intestinal degradation of ceramide. Thus, the results indicate that the Asah2-encoded neutral ceramidase is a key enzyme for the catabolism of dietary sphingolipids and regulates the levels of bioactive sphingolipid metabolites in the intestinal tract.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Medical University of South Carolina	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012	Kono, Mari/0000-0003-2447-4350; Stephanos, Kathleen/0000-0001-7170-0627; Proia, Richard/0000-0003-0456-1270	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK059340, Z01DK056017, Z01DK056000] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [DK 59340] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIELAWSKI J, 2006, IN PRESS METHODS; Choi MS, 2003, GENE, V315, P113, DOI 10.1016/S0378-1119(03)00721-2; DILLEHAY DL, 1994, J NUTR, V124, P615, DOI 10.1093/jn/124.5.615; Duan RD, 2003, J BIOL CHEM, V278, P38528, DOI 10.1074/jbc.M305437200; Duan RD, 1996, DIGEST DIS SCI, V41, P1801, DOI 10.1007/BF02088748; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Kirby RJ, 2002, J BIOL CHEM, V277, P4104, DOI 10.1074/jbc.M107549200; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Liu H, 2002, PROG NUCLEIC ACID RE, V71, P493, DOI 10.1016/S0079-6603(02)71049-0; Liu YJ, 1999, J CLIN INVEST, V103, P497, DOI 10.1172/JCI5542; Lundgren P, 2001, DIGEST DIS SCI, V46, P765, DOI 10.1023/A:1010792031910; Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; MOSER HW, 2001, METABOLIC MOL BASES, V3, P3573; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; NILSSON A, 1968, BIOCHIM BIOPHYS ACTA, V164, P575, DOI 10.1016/0005-2760(68)90187-2; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V187, P113, DOI 10.1016/0005-2760(69)90138-6; Nilsson A, 1999, CHEM PHYS LIPIDS, V102, P97, DOI 10.1016/S0009-3084(99)00078-X; Okino N, 2002, BIOCHEM BIOPH RES CO, V299, P160, DOI 10.1016/S0006-291X(02)02540-8; Okino N, 1999, J BIOL CHEM, V274, P36616, DOI 10.1074/jbc.274.51.36616; Olivera A, 2001, PROSTAG OTH LIPID M, V64, P123, DOI 10.1016/S0090-6980(01)00108-3; Schmelz EM, 2004, FRONT BIOSCI-LANDMRK, V9, P2632, DOI 10.2741/1422; Schmelz EM, 2000, J NUTR, V130, P522, DOI 10.1093/jn/130.3.522; SCHMELZ EM, 1994, J NUTR, V124, P702, DOI 10.1093/jn/124.5.702; Schmelz EM, 1996, CANCER RES, V56, P4936; Schmelz EM, 2001, CANCER RES, V61, P6723; Smith WL, 2002, J BIOL CHEM, V277, P25841, DOI 10.1074/jbc.R200011200; SULLARDS MC, 2001, SCI STKE, V67, P1; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; Symolon H, 2004, J NUTR, V134, P1157, DOI 10.1093/jn/134.5.1157; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; Tani M, 2003, J BIOL CHEM, V278, P10523, DOI 10.1074/jbc.M207932200; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Vesper H, 1999, J NUTR, V129, P1239, DOI 10.1093/jn/129.7.1239; Wada R, 2000, P NATL ACAD SCI USA, V97, P10954, DOI 10.1073/pnas.97.20.10954; Yoshimura Y, 2004, J BIOL CHEM, V279, P44012, DOI 10.1074/jbc.M405598200; Yoshimura Y, 2002, J BIOCHEM, V132, P229, DOI 10.1093/oxfordjournals.jbchem.a003215	43	111	115	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7324	7331		10.1074/jbc.M508382200	http://dx.doi.org/10.1074/jbc.M508382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16380386	hybrid			2022-12-27	WOS:000236030900051
J	Adibhatla, RM; Hatcher, JF; Larsen, EC; Chen, XZ; Sun, DD; Tsao, FHC				Adibhatla, RM; Hatcher, JF; Larsen, EC; Chen, XZ; Sun, DD; Tsao, FHC			CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A(2) and CTP: Phosphocholine cytidylyltransferase after stroke	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT CEREBRAL-ISCHEMIA; EXPERIMENTAL FOCAL ISCHEMIA; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; FOREBRAIN ISCHEMIA; ARACHIDONIC-ACID; ISCHEMIA/REPERFUSION INJURY; CYTIDINE TRIPHOSPHATE; LIPID-PEROXIDATION; INDUCED APOPTOSIS	Phosphatidylcholine (PtdCho) is a major membrane phospholipid, and its loss is sufficient in itself to induce cell death. PtdCho homeostasis is regulated by the balance between hydrolysis and synthesis. PtdCho is hydrolyzed by phospholipase A(2) (PLA(2)), PtdCho-specific phospholipase C (PtdCho-PLC), and phospholipase D (PLD). PtdCho synthesis is rate-limited by CTP: phosphocholine cytidylyltransferase (CCT), which makes CDP-choline. The final step of PtdCho synthesis is catalyzed by CDP-choline: 1,2-diacylglycerol cholinephosphotransferase. PtdCho synthesis in the brain is predominantly through the CDP-choline pathway. Transient middle cerebral artery occlusion (tMCAO) significantly increased PLA(2) activity, secretory PLA(2) (sPLA(2))-IIA mRNA and protein levels, PtdCho-PLC activity, and PLD2 protein expression following reperfusion. CDP-choline treatment significantly attenuated PLA(2) activity, sPLA(2)-IIA mRNA and protein levels, and PtdCho-PLC activity, but did not affect PLD2 protein expression. tMCAO also resulted in loss of CCT activity and CCT alpha protein, which were partially restored by CDP-choline. No changes were observed in cytosolic PLA(2) or calcium-independent PLA(2) protein levels after tMCAO. Up-regulation of PLA(2), PtdCho-PLC, and PLD and down-regulation of CCT collectively resulted in loss of PtdCho, which was significantly restored by CDP-choline treatment. CDP-choline treatment significantly attenuated the infarction volume by 55 +/- 5% after 1 h of tMCAO and 1 day of reperfusion. Taken together, these results suggest that CDP-choline significantly restores PtdCho levels by differentially affecting sPLA(2)-IIA, PtdCho-PLC, and CCT alpha after transient focal cerebral ischemia. A hypothetical scheme is proposed integrating results from this study and from other reports in the literature.	Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, Madison, WI 53792 USA; Univ Wisconsin, Cardiovasc Res Ctr, Madison, WI 53792 USA; Vet Affairs Med Ctr, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Adibhatla, RM (corresponding author), Univ Wisconsin, Ctr Clin Sci, Dept Neurol Surg, H4-330,600 Highland Ave, Madison, WI 53792 USA.	adibhatl@neurosurg.wisc.edu	Chen, X. Richard/A-7141-2012		NINDS NIH HHS [NS42008] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042008] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adibhatla R, 2005, NEUROCHEM RES, V30, P15, DOI 10.1007/s11064-004-9681-8; Adibhatla R.H., 1999, RRD NEUROCHEMISTRY 2, V2, P533; Adibhatla RM, 2006, FREE RADICAL BIO MED, V40, P376, DOI 10.1016/j.freeradbiomed.2005.08.044; Adibhatla RM, 2005, BRAIN RES, V1058, P193, DOI 10.1016/j.brainres.2005.07.067; Adibhatla RM, 2004, J NEUROSCI RES, V76, P390, DOI 10.1002/jnr.20078; Adibhatla RM, 2003, ANTIOXID REDOX SIGN, V5, P647, DOI 10.1089/152308603770310329; Adibhatla RM, 2003, J NEUROSCI RES, V73, P308, DOI 10.1002/jnr.10672; Adibhatla RM, 2002, J NEUROSCI RES, V70, P133, DOI 10.1002/jnr.10403; Adibhatla RM, 2001, STROKE, V32, P2376, DOI 10.1161/hs1001.096010; Akiba S, 2004, BIOL PHARM BULL, V27, P1174, DOI 10.1248/bpb.27.1174; ALBERGHINA M, 1981, J NEUROSCI RES, V6, P421, DOI 10.1002/jnr.490060316; ALBERGHINA M, 1981, J NEUROSCI RES, V6, P719, DOI 10.1002/jnr.490060605; Aronowski J, 1996, NEUROL RES, V18, P570; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Balboa MA, 2002, FEBS LETT, V531, P12, DOI 10.1016/S0014-5793(02)03481-6; Balsinde J, 2002, FEBS LETT, V531, P2, DOI 10.1016/S0014-5793(02)03413-0; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Carrol JE, 2000, NEUROREPORT, V11, pR1; Clemens JA, 1996, STROKE, V27, P527, DOI 10.1161/01.STR.27.3.527; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; Davalos A, 2002, STROKE, V33, P2850, DOI 10.1161/01.STR.0000038691.03334.71; De Valck D, 1998, J CELL BIOCHEM, V71, P392, DOI 10.1002/(SICI)1097-4644(19981201)71:3<392::AID-JCB8>3.0.CO;2-N; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Fujiki M, 2005, BRAIN RES, V1043, P236, DOI 10.1016/j.brainres.2005.02.063; Gimenez R, 1999, NEUROSCI LETT, V273, P163, DOI 10.1016/S0304-3940(99)00660-6; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168; Jin JK, 2005, J NEUROCHEM, V92, P452, DOI 10.1111/j.1471-4159.2004.02881.x; KAKIHANA M, 1988, STROKE, V19, P217, DOI 10.1161/01.STR.19.2.217; Kalluri HSG, 2005, NEUROREPORT, V16, P835, DOI 10.1097/00001756-200505310-00011; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; Klein J, 2005, J NEUROCHEM, V94, P1473, DOI 10.1111/j.1471-4159.2005.03315.x; Klein J, 2000, J NEURAL TRANSM, V107, P1027, DOI 10.1007/s007020070051; Krupinski J, 2005, NEUROCHEM RES, V30, P1067, DOI 10.1007/s11064-005-7201-0; Krupinski J, 2002, NEUROPHARMACOLOGY, V42, P846, DOI 10.1016/S0028-3908(02)00032-1; Lagace TA, 2002, MOL CELL BIOL, V22, P4851, DOI 10.1128/MCB.22.13.4851-4862.2002; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; Li ZY, 2005, J BIOL CHEM, V280, P37798, DOI 10.1074/jbc.M508575200; Lin TN, 2004, J NEUROCHEM, V90, P637, DOI 10.1111/j.1471-4159.2004.02540.x; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; LOPEZ G, 1987, NEUROCHEM INT, V11, P293; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; McMaster CR, 1997, BBA-LIPID LIPID MET, V1348, P100, DOI 10.1016/S0005-2760(97)00097-0; MILLINGTON WR, 1982, J NEUROCHEM, V38, P1748, DOI 10.1111/j.1471-4159.1982.tb06658.x; Murakami M, 2004, BIOL PHARM BULL, V27, P1158, DOI 10.1248/bpb.27.1158; Murakami M, 2002, J BIOCHEM, V131, P285, DOI 10.1093/oxfordjournals.jbchem.a003101; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; Narita K, 2000, NEUROL RES, V22, P393, DOI 10.1080/01616412.2000.11740689; Pfeilschifter J, 1997, PROG SURG, V24, P31, DOI 10.1159/000075465; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Pomerantsev AP, 2003, INFECT IMMUN, V71, P6591, DOI 10.1128/IAI.71.11.6591-6606.2003; Ramoni C, 2004, EXP CELL RES, V299, P370, DOI 10.1016/j.yexcr.2004.05.037; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rao AM, 1999, J NEUROSCI RES, V58, P697, DOI 10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.3.CO;2-2; Savci V, 2003, EUR J PHARMACOL, V468, P129, DOI 10.1016/S0014-2999(03)01602-9; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Schabitz WR, 1999, STROKE, V30, P427, DOI 10.1161/01.STR.30.2.427; Secades JJ, 2002, METHODS FIND EXP SB, V24, P1; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Sun ZW, 2002, SHOCK, V18, P99, DOI 10.1097/00024382-200208000-00001; Svensson CI, 2005, NEUROSCIENCE, V133, P543, DOI 10.1016/j.neuroscience.2005.01.024; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tabuchi S, 2003, ACT NEUR S, V86, P169; TERHORST G, 1997, CLIN PHARM CEREBRAL; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Wang LM, 2005, MOL CELL BIOL, V25, P3357, DOI 10.1128/MCB.25.8.3357-3363.2005; WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8; Xiong Y, 2000, NEUROSCI LETT, V283, P129, DOI 10.1016/S0304-3940(00)00929-0; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yoshikawa T, 2001, J HISTOCHEM CYTOCHEM, V49, P777, DOI 10.1177/002215540104900611	81	83	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6718	6725		10.1074/jbc.M512112200	http://dx.doi.org/10.1074/jbc.M512112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16380371	hybrid, Green Published			2022-12-27	WOS:000236030800069
J	Covarrubias, AS; Bergfors, T; Jones, TA; Hogbom, M				Covarrubias, AS; Bergfors, T; Jones, TA; Hogbom, M			Structural mechanics of the pH-dependent activity of beta-carbonic anhydrase from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; METHANOBACTERIUM-THERMOAUTOTROPHICUM; ALCOHOL-DEHYDROGENASE; STRUCTURE REFINEMENT; TERNARY COMPLEX; ANCIENT ENZYME; PISUM-SATIVUM; CO2 HYDRATION; CATALYSIS	Carbonic anhydrases catalyze the reversible hydration of carbon dioxide to form bicarbonate, a reaction required for many functions, including carbon assimilation and pH homeostasis. Carbonic anhydrases are divided into at least three classes and are believed to share a zinc-hydroxide mechanism for carbon dioxide hydration. beta-carbonic anhydrases are broadly spread among the domains of life, and existing structures from different organisms show two distinct active site setups, one with three protein coordinations to the zinc ( accessible) and the other with four ( blocked). The latter is believed to be inconsistent with the zinc-hydroxide mechanism. The Mycobacterium tuberculosis Rv3588c gene, shown to be required for in vivo growth of the pathogen, encodes a beta-carbonic anhydrase with a steep pH dependence of its activity, being active at pH 8.4 but not at pH 7.5. We have recently solved the structure of this protein, which was a dimeric protein with a blocked active site. Here we present the structure of the thiocyanate complexed protein in a different crystal form. The protein now forms distinct tetramers and shows large structural changes, including a carboxylate shift yielding the accessible active site. This structure demonstrated for the first time that a beta-carbonic anhydrase can switch between the two states. A pH-dependent dimer to tetramer equilibrium was also demonstrated by dynamic light scattering measurements. The data presented here, therefore, suggest a carboxylate shift on/off switch for the enzyme, which may, in turn, be controlled by a dimer-to-tetramer equilibrium.	Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden	Uppsala University	Hogbom, M (corresponding author), Uppsala Univ, Ctr Biomed, Dept Cell & Mol Biol, Box 596, S-75124 Uppsala, Sweden.	hogbom@xray.bmc.uu.se		Hogbom, Martin/0000-0001-5574-9383				BADGER MR, 1994, ANNU REV PLANT PHYS, V45, P369, DOI 10.1146/annurev.pp.45.060194.002101; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chegwidden W. R., 2000, CARBONIC ANHYDRASES, DOI [10.1007/978-3-0348-8446-4_9, DOI 10.1007/978-3-0348-8446-4_9]; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Covarrubias AS, 2005, J BIOL CHEM, V280, P18782, DOI 10.1074/jbc.M414348200; Cox EH, 2000, BIOCHEMISTRY-US, V39, P12128, DOI 10.1021/bi001416s; Cronk JD, 2001, PROTEIN SCI, V10, P911, DOI 10.1110/ps.46301; Ducruix A, 1999, CRYSTALLIZATION NUCL; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esposito L, 2003, BIOCHEMISTRY-US, V42, P14397, DOI 10.1021/bi035271b; Flynn JL, 2003, CURR OPIN IMMUNOL, V15, P450, DOI 10.1016/S0952-7915(03)00075-X; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; FUKUZAWA H, 1992, P NATL ACAD SCI USA, V89, P4437, DOI 10.1073/pnas.89.10.4437; GUILLOTON MB, 1992, J BIOL CHEM, V267, P3731; GUILLOTON MB, 1993, J BACTERIOL, V175, P1443, DOI 10.1128/JB.175.5.1443-1451.1993; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; Hiltonen T, 1998, PLANT PHYSIOL, V117, P1341, DOI 10.1104/pp.117.4.1341; Hogbom M, 2001, J BIOL INORG CHEM, V6, P315, DOI 10.1007/s007750000205; JOHANSSON IM, 1993, EUR J BIOCHEM, V218, P439, DOI 10.1111/j.1432-1033.1993.tb18394.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANDEL M, 1978, J BIOL CHEM, V253, P679; Karlsson A, 2003, CHEM-BIOL INTERACT, V143, P239, DOI 10.1016/S0009-2797(02)00222-3; Kimber MS, 2000, EMBO J, V19, P1407, DOI 10.1093/emboj/19.7.1407; KISIEL W, 1972, PHYTOCHEMISTRY, V11, P113, DOI 10.1016/S0031-9422(00)89975-6; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 2004, ACTA CRYSTALLOGR D, V60, P2240, DOI 10.1107/S0907444904013253; LINDSKOG S, 1993, CURR OPIN STRUC BIOL, V3, P915, DOI 10.1016/0959-440X(93)90156-F; MELDRUM N. IT., 1933, JOUR PHYSIOL, V80, P113; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'Neill JW, 2001, ACTA CRYSTALLOGR D, V57, P480, DOI 10.1107/S0907444901000373; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrin CL, 1997, ANNU REV PHYS CHEM, V48, P511, DOI 10.1146/annurev.physchem.48.1.511; Roberts SB, 1997, J PHYCOL, V33, P845, DOI 10.1111/j.0022-3646.1997.00845.x; Rowlett RS, 2004, ARCH BIOCHEM BIOPHYS, V425, P25, DOI 10.1016/j.abb.2004.02.033; ROWLETT RS, 1994, BIOCHEMISTRY-US, V33, P13967, DOI 10.1021/bi00251a003; Rumeau D, 1996, PLANTA, V199, P79, DOI 10.1007/BF00196884; Sanghani PC, 2002, BIOCHEMISTRY-US, V41, P15189, DOI 10.1021/bi026705q; Sassetti CM, 2003, P NATL ACAD SCI USA, V100, P12989, DOI 10.1073/pnas.2134250100; Smith KS, 2002, J BACTERIOL, V184, P4240, DOI 10.1128/JB.184.15.4240-4245.2002; Smith KS, 1999, J BACTERIOL, V181, P6247, DOI 10.1128/JB.181.20.6247-6253.1999; Smith KS, 1999, P NATL ACAD SCI USA, V96, P15184, DOI 10.1073/pnas.96.26.15184; Smith KS, 2000, J BACTERIOL, V182, P6605, DOI 10.1128/JB.182.23.6605-6613.2000; Smith KS, 2000, FEMS MICROBIOL REV, V24, P335, DOI 10.1016/S0168-6445(00)00030-9; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; SoltesRak E, 1997, J BACTERIOL, V179, P769, DOI 10.1128/jb.179.3.769-774.1997; Stadie WC, 1933, J BIOL CHEM, V103, P521; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Strop P, 2001, J BIOL CHEM, V276, P10299, DOI 10.1074/jbc.M009182200; TOBIN AJ, 1970, J BIOL CHEM, V245, P2656; Tripp BC, 2001, J BIOL CHEM, V276, P48615, DOI 10.1074/jbc.R100045200	57	114	119	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4993	4999		10.1074/jbc.M510756200	http://dx.doi.org/10.1074/jbc.M510756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16321983	hybrid			2022-12-27	WOS:000235426200051
J	Cai, J; Jiang, WG; Grant, MB; Boulton, M				Cai, J; Jiang, WG; Grant, MB; Boulton, M			Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1 (Withdrawn Publication. See vol. 298, 2021)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Withdrawn Publication							TYROSINE KINASE; GAMMA-SECRETASE; EXPRESSION; CLEAVAGE; PRESENILIN; PROTEIN; CELLS; TRAFFICKING; DEFICIENCY; ACTIVATION	Pigment epithelium-derived factor ( PEDF) has been identified as one of the most potent of endogenous negative regulators of blood vessel growth in the body. Here we report that PEDF is able to inhibit growth factor-induced angiogenesis in microvascular endothelial cells through a novel pathway requiring cleavage and intracellular translocation of the transmembrane domain of the VEGFR-1. Analysis of the subcellular distribution of VEGFR-1 revealed the appearance of an 80-kDa C-terminal domain in the cytosol of cells treated with VEGF and PEDF that correlated with a decrease of the full-length receptor in the nuclear and cytoskeletal fractions. This regulated intramembrane proteolysis is dependent on gamma-secretase because inhibition of gamma-secretase abolished the inhibitory effect of PEDF on VEGF-induced angiogenesis as well as VEGFR-1 cleavage. The addition of PEDF to microvascular endothelial cells significantly increases gamma-secretase activity even in the absence of VEGF, showing that VEGF binding to VEGF-R1 is essential for substrate availability. This increase in activity was associated with translocation of presenilin 1 from the perinuclear region to the cell membrane. PEDF was also able to inhibit VEGF-induced phosphorylation of VEGFR-1. Taken together we have identified two novel pathways by which PEDF inhibits VEGF-induced angiogenesis: regulated intramembrane proteolysis and inhibition of phosphorylation. This confirms the importance of PEDF and VEGFR-1 in the negative regulation of angiogenesis.	Cardiff Univ, Cell & Mol Biol Grp, Sch Optometry & Vis Sci, Cardiff CF10 3NB, Wales; Cardiff Univ, Dept Surg, Metastasis Res Grp, Cardiff CF10 3NB, Wales; Cardiff Univ, Cardiff Inst Tissue Engn & Repair, Cardiff CF10 3NB, Wales; Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA	Cardiff University; Cardiff University; Cardiff University; State University System of Florida; University of Florida	Boulton, M (corresponding author), Cardiff Univ, Cell & Mol Biol Grp, Sch Optometry & Vis Sci, Cardiff CF10 3NB, Wales.	boultonm@cardiff.ac.uk	jiang, wen/GYI-9662-2022; Jiang, Wen G./AAF-1876-2020; Jiang, Wen G/B-1293-2010	Jiang, Wen G./0000-0002-3283-1111; Jiang, Wen G/0000-0002-3283-1111				Aymerich MS, 2001, INVEST OPHTH VIS SCI, V42, P3287; Blat Y, 2002, BIOCHEM BIOPH RES CO, V299, P569, DOI 10.1016/S0006-291X(02)02705-5; Bocci G, 2001, MOL HUM REPROD, V7, P771, DOI 10.1093/molehr/7.8.771; Bouck N, 2002, TRENDS MOL MED, V8, P330, DOI 10.1016/S1471-4914(02)02362-6; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Brunkan AL, 2005, J NEUROCHEM, V93, P769, DOI 10.1111/j.1471-4159.2005.03099.x; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Cai J, 1999, BIOCHEM BIOPH RES CO, V258, P113, DOI 10.1006/bbrc.1999.0596; Cai J, 2003, DIABETES, V52, P2959, DOI 10.2337/diabetes.52.12.2959; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Chan CK, 2005, LAB INVEST, V85, P721, DOI 10.1038/labinvest.3700277; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; DE SB, 1999, NATURE, V398, P518; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Haas IG, 2005, J BIOL CHEM, V280, P9313, DOI 10.1074/jbc.M412909200; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2001, CANCER RES, V61, P1207; Ilan N, 2003, LAB INVEST, V83, P1105, DOI 10.1097/01.LAB.0000083531.84403.8B; Itokawa T, 2002, MOL CANCER THER, V1, P295; Kaiser S, 2001, J VASC RES, V38, P133, DOI 10.1159/000051040; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; LARA L, 2003, INVESTIG OPTHALMOL V, V44; Liao YF, 2004, J BIOL CHEM, V279, P49523, DOI 10.1074/jbc.M402034200; Liu H, 2004, P NATL ACAD SCI USA, V101, P6605, DOI 10.1073/pnas.0308342101; Myers JM, 2003, J CELL BIOCHEM, V88, P1273, DOI 10.1002/jcb.10476; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Ogata N, 2002, AM J OPHTHALMOL, V133, P851, DOI 10.1016/S0002-9394(02)01406-X; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Roberts DM, 2004, AM J PATHOL, V164, P1531, DOI 10.1016/S0002-9440(10)63711-X; Ruggeri B, 2003, CANCER RES, V63, P5978; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHIBUYA M, 1990, ONCOGENE, V5, P519; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tombran-Tink J, 1996, Mol Vis, V2, P11; TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200	47	202	212	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3604	3613		10.1074/jbc.M507401200	http://dx.doi.org/10.1074/jbc.M507401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339148	hybrid			2022-12-27	WOS:000235128200072
J	Cheong, R; Bergmann, A; Werner, SL; Regal, J; Hoffmann, A; Levchenko, A				Cheong, R; Bergmann, A; Werner, SL; Regal, J; Hoffmann, A; Levchenko, A			Transient I kappa B kinase activity mediates temporal NF-kappa B dynamics in response to a wide range of tumor necrosis factor-alpha doses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-ALPHA; ESCHERICHIA-COLI; IKK-BETA; ACTIVATION; TRANSCRIPTION; MACROPHAGES; APOPTOSIS; NETWORK; MODULE; PHOSPHORYLATION	Dynamic properties of signaling pathways control their behavior and function. We undertook an iterative computational and experimental investigation of the dynamic properties of tumor necrosis factor (TNF)alpha-mediated activation of the transcription factor NF-kappa B. Surprisingly, we found that the temporal profile of the NF-kappa B activity is invariant to the TNF alpha dose. We reverse engineered a computational model of the signaling pathway to identify mechanisms that impart this important response characteristic, thus predicting that the IKK activity profile must transiently peak at all TNF alpha doses to generate the observed NF-kappa B dynamics. Experimental confirmation of this prediction emphasizes the importance of mechanisms that rapidly down-regulate IKK following TNF alpha activation. A refined computational model further revealed signaling characteristics that ensure robust TNF alpha-mediated cell-cell communication over considerable distances, allowing for fidelity of cellular inflammatory responses in infected tissue.	Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; Univ Calif San Diego, Dept Chem & Biochem, Signaling Syst Lab, La Jolla, CA 92093 USA	Johns Hopkins University; University of California System; University of California San Diego	Levchenko, A (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, 208C Clark Hall,3400 N Charles St, Baltimore, MD 21218 USA.	alev@jhu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM069013, R33GM069013, R01GM072024] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM072024-01, GM69013-01/B270JA] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALON R, 1994, J IMMUNOL, V152, P1304; Aupperle KR, 1999, J IMMUNOL, V163, P427; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; Banzhaf W., 1998, GENETIC PROGRAMMING; Barken D, 2005, SCIENCE, V308, DOI 10.1126/science.1107904; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cheng H, 2005, MOL CELL BIOL, V25, P44, DOI 10.1128/MCB.25.1.44-59.2005; CHEONG R, 2005, ENCY MOL CELL BIOL M, V14, P437; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Francis K, 1997, P NATL ACAD SCI USA, V94, P12258, DOI 10.1073/pnas.94.23.12258; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goodhill GJ, 1997, EUR J NEUROSCI, V9, P1414, DOI 10.1111/j.1460-9568.1997.tb01496.x; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Klein DE, 2004, NATURE, V430, P1040, DOI 10.1038/nature02840; Klein RD, 2000, J SURG RES, V94, P159, DOI 10.1006/jsre.2000.5975; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lipniacki T, 2004, J THEOR BIOL, V228, P195, DOI 10.1016/j.jtbi.2004.01.001; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; REEVES R, 1990, PROG NUCLEIC ACID RE, V38, P241; Sasagawa S, 2005, NAT CELL BIOL, V7, P365, DOI 10.1038/ncb1233; Shapiro BE, 2003, BIOINFORMATICS, V19, P677, DOI 10.1093/bioinformatics/btg042; Stoecklin G, 2003, MOL CELL BIOL, V23, P3506, DOI 10.1128/MCB.23.10.3506-3515.2003; Swameye I, 2003, P NATL ACAD SCI USA, V100, P1028, DOI 10.1073/pnas.0237333100; TRACEY KJ, 1992, P SOC EXP BIOL MED, V200, P233; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xaus J, 2000, BLOOD, V95, P3823; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	44	99	101	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2945	2950		10.1074/jbc.M510085200	http://dx.doi.org/10.1074/jbc.M510085200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16321974	hybrid			2022-12-27	WOS:000234931800064
J	O'Hayre, M; Taylor, L; Andratsch, M; Feifel, E; Gstraunthaler, G; Curthoys, NP				O'Hayre, M; Taylor, L; Andratsch, M; Feifel, E; Gstraunthaler, G; Curthoys, NP			Effects of constitutively active and dominant negative MAPK kinase (MKK) 3 and MKK6 on the pH-responsive increase in phosphoenolpyruvate carboxykinase mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BASE-BALANCE; GENE-EXPRESSION; LLC-PK1-FBPASE(+) CELLS; GLUTAMINE-METABOLISM; RENAL GLUTAMINASE; MAMMALIAN-CELLS; PROTEIN-KINASES; RAT; PATHWAYS; GLUCONEOGENESIS	Metabolic acidosis is partially compensated by a pronounced increase in renal catabolism of glutamine. This adaptive response is sustained, in part, through increased expression of phosphoenolpyruvate carboxykinase ( PEPCK). Previous inhibitor studies suggested that the pH-responsive increase in PEPCK mRNA in LLCPK1-FBPase(+) cells is mediated by a p38 mitogen-activated protein kinase ( MAPK). These cells express high levels of the upstream kinase MAPK kinase (MKK) 3 but relatively low levels of the alternative upstream kinase MKK6. To firmly establish the role of the p38 MAPK signaling pathway, clonal lines of LLC-PK1-FBPase(+) cells that express constitutively active (ca) and dominant negative (dn) forms of MKK3 and MKK6 from a tetracycline-responsive promoter were developed. Western blot analyses confirmed that 0.5 mu g/ml doxycycline was sufficient to block transcription and that removal of doxycycline led to pronounced and sustained expression of the caMKKs and dnMKKs. Expression of caMKK6 ( but not caMKK3) caused an increase in phosphorylation of p38 MAPK and an increase in the level of PEPCK mRNA that closely mimicked the effect of treatment with acidic medium (pH 6.9, 10 mM HCO3-). Only caMKK6 activated transcription of a PEPCK-luciferase reporter construct. Co-expression of both dnMKKs blocked the increases in phosphorylation of p38 MAPK and PEPCK mRNA. The latter effect closely mimicked that of the p38 MAPK inhibitor SB203580. The expression of either dnMKK3 or dnMKK6 was less effective than co-expression of both dnMKKs. Thus, the pH-responsive increase in PEPCK mRNA in the kidney is mediated by the p38 MAPK signaling pathway and involves activation of MKK3 and/or MKK6.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA; Innsbruck Med Univ, Dept Phys & Med Phys, A-6010 Innsbruck, Austria	Colorado State University; Medical University of Innsbruck	Curthoys, NP (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.	Norman.Curthoys@ColoState.edu			NIDDK NIH HHS [DK-43704, DK-37124] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043704, R01DK037124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROSNAN JT, 1987, CAN J PHYSIOL PHARM, V65, P489, DOI 10.1139/y87-084; BURCH HB, 1978, AM J PHYSIOL, V235, pF246, DOI 10.1152/ajprenal.1978.235.3.F246; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheong J, 1998, J BIOL CHEM, V273, P22714, DOI 10.1074/jbc.273.35.22714; Cowan KJ, 2003, J EXP BIOL, V206, P1107, DOI 10.1242/jeb.00220; Curthoys NP, 2001, AM J PHYSIOL-RENAL, V281, pF381, DOI 10.1152/ajprenal.2001.281.3.F381; DALESSIO JM, 1981, BIOCHEMISTRY-US, V20, P3822, DOI 10.1021/bi00516a024; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHAKRAS PS, 2006, IN PRESS AM J PHYSL; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Feifel E, 2002, AM J PHYSIOL-RENAL, V283, pF678, DOI 10.1152/ajprenal.00097.2002; Gerich JE, 2001, DIABETES CARE, V24, P382, DOI 10.2337/diacare.24.2.382; Gstraunthaler G, 2000, AM J PHYSIOL-RENAL, V278, pF227, DOI 10.1152/ajprenal.2000.278.2.F227; GSTRAUNTHALER G, 1987, AM J PHYSIOL, V252, pC232, DOI 10.1152/ajpcell.1987.252.2.C232; Hajarnis S, 2005, J BIOL CHEM, V280, P28272, DOI 10.1074/jbc.M501204200; HALPERIN ML, 1993, CLIN INVEST MED, V16, P294; Hansen WR, 1996, AM J PHYSIOL-RENAL, V271, pF126, DOI 10.1152/ajprenal.1996.271.1.F126; HOLCOMB T, 1995, AM J PHYSIOL-CELL PH, V268, pC449, DOI 10.1152/ajpcell.1995.268.2.C449; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; HWANG JJ, 1991, BIOCHEMISTRY-US, V30, P7522, DOI 10.1021/bi00244a022; IYNEDJIAN PB, 1975, J BIOL CHEM, V250, P5596; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Liu NS, 1996, J BIOL CHEM, V271, P355, DOI 10.1074/jbc.271.1.355; Loflin PT, 1999, METHODS, V17, P11, DOI 10.1006/meth.1998.0702; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Morel C, 2005, J BIOL CHEM, V280, P21384, DOI 10.1074/jbc.M408851200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHOOLWERTH AC, 1994, AM J PHYSIOL, V267, pF400, DOI 10.1152/ajprenal.1994.267.3.F400; SCHROEDER JM, 2006, IN PRESS AM J PHYSL; TANNEN RL, 1990, MINER ELECTROL METAB, V16, P249; Taylor L, 2004, BIOCHEM MOL BIOL EDU, V32, P291, DOI 10.1002/bmb.2004.494032050388; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	36	8	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2982	2988		10.1074/jbc.M510084200	http://dx.doi.org/10.1074/jbc.M510084200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319064	hybrid			2022-12-27	WOS:000234931800068
J	Xie, LL; Boyle, D; Sanford, D; Scherer, PE; Pessin, JE; Mora, S				Xie, LL; Boyle, D; Sanford, D; Scherer, PE; Pessin, JE; Mora, S			Intracellular trafficking and secretion of adiponectin is dependent on GGA-coated vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ADIPOSE-SPECIFIC PROTEIN; FATTY-ACID OXIDATION; EAR HOMOLOGY DOMAIN; INSULIN-RESISTANCE; BREFELDIN-A; GLOBULAR DOMAIN; GAMMA-ADAPTIN; VHS DOMAIN; GLUCOSE	Adiponectin (Acrp30) is an insulin-sensitizing hormone produced and secreted exclusively by adipose tissue. Confocal fluorescent microscopy demonstrated the colocalization of adiponectin with the Golgi membrane markers p115, beta-COP, and the trans-Golgi network marker, syntaxin 6. Treatment of cells with brefeldin A redistributed adiponectin to the endoplasmic reticulum where it colocalized with the chaperone protein BIP and inhibited secretion of adiponectin demonstrating a requirement for a functional Golgi apparatus for adiponectin release. Confocal fluorescent microscopy also demonstrated a colocalization of endogenous adiponectin with that of expressed GGA1myc (Golgi-localizing gamma-adaptin ear homology ARF-binding protein) but with no significant overlap between adiponectin and the GGA2myc or GGA3myc isoforms. Consistent with confocal fluorescent microscopy, transmission electron microscopy demonstrated the colocalization of GGA1 with adiponectin. Although GGA1 did not directly interact with the adiponectin protein, the adiponectin enriched membrane compartments of adipocyte were precipitated by a GST-GGA1 cargo binding domain (VHS) fusion protein but not with a GST-GGA2 VHS or GST-GGA3 VHS fusion proteins. Moreover, co-expression of adiponectin with a GGA1 dominant-interfering mutant (GGA1-VHS GAT domain) resulted in a marked inhibition of adiponectin secretion in both 3T3L1 adipocytes and HEK293 cells, whereas no inhibition was detected with the truncated mutants GGA2-VHSGAT or GGA3-VHSGAT. Moreover, co-expression of wild type GGA1 with adiponectin enhanced secretion of adiponectin. Interestingly, leptin secretion was unaffected by neither the wild type form or GGA1 mutant. Taken together these data demonstrate that the trafficking of adiponectin through its secretory pathway is dependent on GGA-coated vesicles.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	Kansas State University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Mora, S (corresponding author), Kansas State Univ, Div Biol, 231 Ackert Hall, Manhattan, KS 66506 USA.	mora@ksu.edu	Mora, Silvia/Y-3131-2019; Scherer, Philipp E/K-7819-2012	Scherer, Philipp E/0000-0003-0680-3392; Mora, Silvia/0000-0002-8473-1497	NCRR NIH HHS [P20 RR 17708, P20 RR 017686] Funding Source: Medline; NIDDK NIH HHS [DK 55811, DK 63332] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017708, P20RR017686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063332, R01DK055811] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Beltowski J, 2003, MED SCI MONITOR, V9, P55; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Bogan JS, 1999, J CELL BIOL, V146, P609, DOI 10.1083/jcb.146.3.609; Boman AL, 2001, J CELL SCI, V114, P3413; Bradley RL, 2001, RECENT PROG HORM RES, V56, P329, DOI 10.1210/rp.56.1.329; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Fisher FM, 2002, HORM METAB RES, V34, P650, DOI 10.1055/s-2002-38246; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Guerre-Millo M, 2002, J ENDOCRINOL INVEST, V25, P855, DOI 10.1007/BF03344048; He XY, 2002, FEBS LETT, V524, P183, DOI 10.1016/S0014-5793(02)03052-1; Heilbronn LK, 2003, CURR PHARM DESIGN, V9, P1411, DOI 10.2174/1381612033454766; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Li LV, 2005, MOL ENDOCRINOL, V19, P2145, DOI 10.1210/me.2005-0032; Lihn AS, 2003, AM J PHYSIOL-ENDOC M, V284, pE443, DOI 10.1152/ajpendo.00358.2002; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Mattera R, 2003, EMBO J, V22, P78, DOI 10.1093/emboj/cdg015; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Pajvani Utpal B, 2003, Curr Diab Rep, V3, P207, DOI 10.1007/s11892-003-0065-2; Puertollano R, 2003, MOL BIOL CELL, V14, P1545, DOI 10.1091/mbc.02-07-0109; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SHAPIRO L, 1998, CURR BIOL, V276, P3628; Shuldiner AR, 2001, NEW ENGL J MED, V345, P1345, DOI 10.1056/NEJM200111013451814; Simon JP, 2000, METHODS, V20, P437, DOI 10.1006/meth.2000.0957; Statnick M A, 2000, Int J Exp Diabetes Res, V1, P81, DOI 10.1155/EDR.2000.81; Steppan CM, 2002, TRENDS ENDOCRIN MET, V13, P18, DOI 10.1016/S1043-2760(01)00522-7; Takatsu H, 2002, BIOCHEM J, V365, P369, DOI 10.1042/BJ20020428; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tschritter O, 2003, DIABETES, V52, P239, DOI 10.2337/diabetes.52.2.239; Ukkola O, 2002, J MOL MED, V80, P696, DOI 10.1007/s00109-002-0378-7; Wasiak S, 2002, J CELL BIOL, V158, P855, DOI 10.1083/jcb.200205078; Watson RT, 2004, EMBO J, V23, P2059, DOI 10.1038/sj.emboj.7600159; Weiss R, 2003, J CLIN ENDOCR METAB, V88, P2014, DOI 10.1210/jc.2002-021711; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zhu GY, 2003, FEBS LETT, V537, P171, DOI 10.1016/S0014-5793(03)00095-4; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	57	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7253	7259		10.1074/jbc.M511313200	http://dx.doi.org/10.1074/jbc.M511313200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407204	hybrid, Green Published			2022-12-27	WOS:000236030900043
J	Li, YK; Gerbod-Giannone, MC; Seitz, H; Cui, DY; Thorp, E; Tall, AR; Matsushima, GK; Tabas, I				Li, YK; Gerbod-Giannone, MC; Seitz, H; Cui, DY; Thorp, E; Tall, AR; Matsushima, GK; Tabas, I			Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CELL-SURFACE CALRETICULIN; TYROSINE KINASE; IN-VITRO; ATHEROSCLEROTIC PLAQUE; ENDOPLASMIC-RETICULUM; LOADED MACROPHAGES; DEFICIENT MICE; CLEARANCE; BETA	Macrophage apoptosis and the ability of phagocytes to clear these apoptotic cells are important processes in advanced atherosclerosis. Phagocytic clearance not only disposes of dead cells but usually elicits an anti-inflammatory response. To study this process in a model of advanced lesional macrophage death, macrophages rendered apoptotic by free cholesterol loading (FC-AMs) were incubated briefly with fresh macrophages ("phagocytes"). FC-AMs were promptly ingested by the phagocytes, which was dependent upon actin polymerization and the phagocyte Mer receptor. Surprisingly, this brief exposure to FC-AMs triggered a modest proinflammatory response in the phagocytes: tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 beta were induced, whereas the levels of transforming growth factor-beta and IL-10 were not increased. This response required cell contact between the FC-AMs and phagocytes but not FC-AM ingestion. TNF-alpha and IL-1 beta induction required one or more proteins on the FC-AM surface and was dependent on signaling through extracellular signal-regulated kinase-1/2 mitogen-activated protein kinase and nuclear factor-kappa B in the phagocytes. TNF-alpha production was markedly greater when Mer-defective phagocytes were used, indicating that Mer attenuated the inflammatory response. Interestingly, a more typical anti-inflammatory response was elicited when phagocytes were exposed to macrophages rendered apoptotic by oxidized low density lipoprotein or UV radiation. Thus, the proinflammatory milieu of advanced atherosclerotic lesions may be promoted, or at least not dampened, by contact between FC-induced apoptotic macrophages and neighboring phagocytes prior to apoptotic cell ingestion.	Columbia Univ, Dept Med, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Physiol & Cellular Biophys, New York, NY 10032 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA	Columbia University; Columbia University; Columbia University; University of North Carolina; University of North Carolina Chapel Hill	Tabas, I (corresponding author), Columbia Univ, Dept Med, 630 W 168th St, New York, NY 10032 USA.	iat1@columbia.edu	Tall, Alan/AAT-8528-2021	Thorp, Edward/0000-0003-1387-7058	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075662, P01HL054591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL75662, HL54591] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa M, 2004, CARDIOVASC PATHOL, V13, P125, DOI 10.1016/S1054-8807(04)00004-3; Arai S, 2005, CELL METAB, V1, P201, DOI 10.1016/j.cmet.2005.02.002; BALL RY, 1995, ATHEROSCLEROSIS, V114, P45, DOI 10.1016/0021-9150(94)05463-S; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Caligiuri G, 2003, MOL MED, V9, P10, DOI 10.1007/BF03402102; Camenisch TD, 1999, J IMMUNOL, V162, P3498; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 1998, J IMMUNOL, V161, P6250; Feng B, 2003, P NATL ACAD SCI USA, V100, P10423, DOI 10.1073/pnas.1732494100; Feng B, 2003, NAT CELL BIOL, V5, P781, DOI 10.1038/ncb1035; Fleetwood AJ, 2005, CRIT REV IMMUNOL, V25, P405, DOI 10.1615/CritRevImmunol.v25.i5.50; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Grainger DJ, 2004, J IMMUNOL, V173, P6366, DOI 10.4049/jimmunol.173.10.6366; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hinson RM, 1996, P NATL ACAD SCI USA, V93, P4885, DOI 10.1073/pnas.93.10.4885; Ishimoto Y, 2000, J BIOCHEM-TOKYO, V127, P411, DOI 10.1093/oxfordjournals.jbchem.a022622; Khan M, 2003, ATHEROSCLEROSIS, V171, P21, DOI 10.1016/j.atherosclerosis.2003.07.001; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; KRUTH HS, 1984, AM J PATHOL, V114, P201; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Li YK, 2005, J BIOL CHEM, V280, P21763, DOI 10.1074/jbc.M501759200; Li YK, 2004, J BIOL CHEM, V279, P37030, DOI 10.1074/jbc.M405195200; Liang CP, 2004, J CLIN INVEST, V113, P764, DOI [10.1172/JCI200419528, 10.1172/JCI19528]; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Libby P, 2001, AM J CARDIOL, V88, p3J, DOI [DOI 10.1016/S0002-9149(01)02145-2, 10.1016/S0002-9149(01)02145-2]; Liu J, 2005, ARTERIOSCL THROM VAS, V25, P174, DOI 10.1161/01.ATV.0000148548.47755.22; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Mahajan NP, 2003, J BIOL CHEM, V278, P42596, DOI 10.1074/jbc.M305817200; Mallat Z, 2001, CIRC RES, V89, P930, DOI 10.1161/hh2201.099415; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Massari P, 2002, J IMMUNOL, V168, P1533, DOI 10.4049/jimmunol.168.4.1533; McDonald PP, 1999, J IMMUNOL, V163, P6164; Melaragno MG, 1999, TRENDS CARDIOVAS MED, V9, P250, DOI 10.1016/S1050-1738(00)00027-X; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Moreira MEC, 2004, AN ACAD BRAS CIENC, V76, P93, DOI 10.1590/S0001-37652004000100009; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; RAPP JH, 1983, J LIPID RES, V24, P1329; Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240; ROSS AC, 1984, J BIOL CHEM, V259, P815; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schaefer H E, 1981, Haematol Blood Transfus, V27, P137; Schrijvers DM, 2005, ARTERIOSCL THROM VAS, V25, P1256, DOI 10.1161/01.ATV.0000166517.18801.a7; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; SMALL DM, 1984, J CLIN INVEST, V73, P1590, DOI 10.1172/JCI111366; Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Yao PM, 2000, J BIOL CHEM, V275, P23807, DOI 10.1074/jbc.M002087200; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200	59	74	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6707	6717		10.1074/jbc.M510579200	http://dx.doi.org/10.1074/jbc.M510579200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16380374	hybrid, Green Published			2022-12-27	WOS:000236030800068
J	Mazzochi, C; Bubien, JK; Smith, PR; Benos, DJ				Mazzochi, C; Bubien, JK; Smith, PR; Benos, DJ			The carboxyl terminus of the alpha-subunit of the amiloride-sensitive epithelial sodium channel binds to F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNELS; APICAL MEMBRANE; ENAC SUBUNITS; ION-TRANSPORT; MDCK CELLS; EXPRESSION; LOCALIZATION; CYTOSKELETON; AQUAPORIN-2; SECRETION	The activity of the amiloride-sensitive epithelial sodium channel (ENaC) is modulated by F-actin. However, it is unknown if there is a direct interaction between alpha-ENaC and actin. We have investigated the hypothesis that the actin cytoskeleton directly binds to the carboxyl terminus of alpha-ENaC using a combination of confocal microscopy, co-immunoprecipitation, and protein binding studies. Confocal microscopy of Madin-Darby canine kidney cell monolayers stably transfected with wild type, rat isoforms of alpha-, beta-, and gamma-ENaC revealed co-localization of alpha-ENaC with the cortical F-actin cytoskeleton both at the apical membrane and within the subapical cytoplasm. F-actin was found to co-immunoprecipitate with alpha-ENaC from whole cell lysates of this cell line. Gel overlay assays demonstrated that F-actin specifically binds to the carboxyl terminus of alpha-ENaC. A direct interaction between F-actin and the COOH terminus of alpha-ENaC was further corroborated by F-actin co-sedimentation studies. This is the first study to report a direct and specific biochemical interaction between F-actin and ENaC.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Benos, DJ (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, MCLM 704,1918 Univ Blvd, Birmingham, AL 35294 USA.	benos@physiology.uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM BIOSC, 2005, GST GEN FUS SYST, P26; Berdiev BK, 2001, BIOPHYS J, V80, P2176, DOI 10.1016/S0006-3495(01)76190-5; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BERNSTEIN BW, 1989, NEURON, V3, P257, DOI 10.1016/0896-6273(89)90039-1; Berryman M, 2004, J BIOL CHEM, V279, P34794, DOI 10.1074/jbc.M402835200; Blazer-Yost BL, 2003, AM J PHYSIOL-CELL PH, V284, pC1645, DOI 10.1152/ajpcell.00372.2002; Blazer-Yost BL, 2001, AM J PHYSIOL-CELL PH, V281, pC624, DOI 10.1152/ajpcell.2001.281.2.C624; BlazerYost BL, 1997, AM J PHYSIOL-CELL PH, V272, pC761, DOI 10.1152/ajpcell.1997.272.3.C761; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; Bubien JK, 2001, J BIOL CHEM, V276, P8557, DOI 10.1074/jbc.M008886200; CANTIELLO HF, 1991, AM J PHYSIOL, V261, pC882, DOI 10.1152/ajpcell.1991.261.5.C882; Chasan B, 2002, EUR BIOPHYS J BIOPHY, V30, P617, DOI 10.1007/s00249-001-0188-9; Copeland SJ, 2001, AM J PHYSIOL-CELL PH, V281, pC231, DOI 10.1152/ajpcell.2001.281.1.C231; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; Denker SP, 2002, CURR OPIN CELL BIOL, V14, P214, DOI 10.1016/S0955-0674(02)00304-6; DING G, 1991, AM J PHYSIOL, V260, pC9, DOI 10.1152/ajpcell.1991.260.1.C9; Ehre C, 2005, AM J PHYSIOL-CELL PH, V288, pC46, DOI 10.1152/ajpcell.00397.2004; FECHHEIMER M, 1979, MOL IMMUNOL, V16, P881, DOI 10.1016/0161-5890(79)90086-5; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Hager H, 2001, AM J PHYSIOL-RENAL, V280, pF1093, DOI 10.1152/ajprenal.2001.280.6.F1093; Hitt AL, 2002, ANAL BIOCHEM, V310, P67, DOI 10.1016/S0003-2697(02)00280-4; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ismailov II, 1997, AM J PHYSIOL-CELL PH, V272, pC1077, DOI 10.1152/ajpcell.1997.272.4.C1077; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Khurana S, 2000, J MEMBRANE BIOL, V178, P73, DOI 10.1007/s002320010016; Loffing J, 2000, AM J PHYSIOL-RENAL, V278, pF530, DOI 10.1152/ajprenal.2000.278.4.F530; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; Morris RG, 2002, J GEN PHYSIOL, V120, P71, DOI 10.1085/jgp.20018547; Noda Y, 2004, BIOCHEM BIOPH RES CO, V322, P740, DOI 10.1016/j.bbrc.2004.07.195; PEARL M, 1983, AM J PHYSIOL, V245, pC28, DOI 10.1152/ajpcell.1983.245.1.C28; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Szaszi K, 2000, CELL PHYSIOL BIOCHEM, V10, P265, DOI 10.1159/000016358; Valentijn KM, 1999, J CELL SCI, V112, P81; VITALE ML, 1991, J CELL BIOL, V113, P1057, DOI 10.1083/jcb.113.5.1057; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200	41	88	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6528	6538		10.1074/jbc.M509386200	http://dx.doi.org/10.1074/jbc.M509386200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16356937	hybrid			2022-12-27	WOS:000236030800048
J	Kupke, T; Schwarz, W				Kupke, T; Schwarz, W			4 '-Phosphopantetheine biosynthesis in archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A BIOSYNTHESIS; BACTERIAL DFP FLAVOPROTEINS; MOLECULAR CHARACTERIZATION; PHOSPHOPANTOTHENOYLCYSTEINE SYNTHETASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; STRUCTURAL BASIS; BINDING PROTEIN; 4'-PHOSPHOPANTOTHENOYLCYSTEINE; DECARBOXYLASE	Coenzyme A as the principal acyl carrier is required for many synthetic and degradative reactions in intermediary metabolism. It is synthesized in five steps from pantothenate, and recently the CoaA biosynthetic genes of eubacteria, plants, and human were all identified and cloned. In most bacteria, the so-called Dfp proteins catalyze the synthesis of the coenzyme A precursor 4'-phosphopantetheine. Dfp proteins are bifunctional enzymes catalyzing the synthesis of 4'-phosphopantothenoylcysteine (CoaB activity) and its decarboxylation to 4'-phosphopantetheine (CoaC activity). Here, we demonstrate the functional characterization of the CoaB and CoaC domains of an archaebacterial Dfp protein. Both domains of the Methanocaldococcus jannaschii Dfp protein were purified as His tag proteins, and their enzymatic activities were then identified and characterized by site-directed mutagenesis. Although the nucleotide binding motif II of the CoaB domain resembles that of eukaryotic enzymes, Methanocaldococcus CoaB is a CTP- and not an ATP-dependent enzyme, as shown by detection of the 4'-phosphopantothenoylCMP intermediate. The proposed 4'-phosphopantothenoylcysteine binding clamp of the Methanocaldococcus CoaC activity differs significantly from those of other characterized CoaC proteins. In particular, the active site cysteine residue, which otherwise is involved in the reduction of an aminoenethiol reaction intermediate, is not present. Moreover, the conserved Asn residue of the PXMNXXMW motif, which contacts the carboxyl group of 4'-phosphopantothenoylcysteine, is exchanged for His.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15,Verfugungsgebaude, D-72076 Tubingen, Germany.	Thomas.Kupke@t-online.de	Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; Blaesse M, 2003, ACTA CRYSTALLOGR D, V59, P1414, DOI 10.1107/S0907444903011831; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CORMACK B, 1991, CURRENT PROTOCOLS MO; Genschel U, 2004, MOL BIOL EVOL, V21, P1242, DOI 10.1093/molbev/msh119; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; Kupke T, 2004, EUR J BIOCHEM, V271, P163, DOI 10.1046/j.1432-1033.2003.03916.x; Kupke T, 2003, J BIOL CHEM, V278, P38229, DOI 10.1074/jbc.M306321200; Kupke T, 2002, J BIOL CHEM, V277, P36137, DOI 10.1074/jbc.M206188200; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Kupke T, 2001, J BIOL CHEM, V276, P27597, DOI 10.1074/jbc.M103342200; Leonardi R, 2005, PROG LIPID RES, V44, P125, DOI 10.1016/j.plipres.2005.04.001; Majer F, 2002, J BACTERIOL, V184, P1234, DOI 10.1128/JB.184.5.1234-1243.2002; Manoj N, 2003, STRUCTURE, V11, P927, DOI 10.1016/S0969-2126(03)00146-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Stanitzek S, 2004, STRUCTURE, V12, P1977, DOI 10.1016/j.str.2004.08.007; Steinbacher S, 2003, J MOL BIOL, V327, P193, DOI 10.1016/S0022-2836(03)00092-5; Strauss E, 2004, BIOCHEMISTRY-US, V43, P15520, DOI 10.1021/bi048340a; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200	21	21	22	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5435	5444		10.1074/jbc.M510056200	http://dx.doi.org/10.1074/jbc.M510056200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371361	hybrid			2022-12-27	WOS:000235568900015
J	Sheldon, AL; Gonzalez, MI; Robinson, MB				Sheldon, AL; Gonzalez, MI; Robinson, MB			A carboxyl-terminal determinant of the neuronal glutamate transporter, EAAC1, is required for platelet-derived growth factor-dependent trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; PROTEIN-KINASE-C; PERINUCLEAR STORAGE COMPARTMENT; TRAUMATIC BRAIN-INJURY; GABA SYNTHESIS; AMINO; ACTIVATION; SUBTYPE; GLUT4; EXCITOTOXICITY	The neuronal glutamate transporter, EAAC1 ( excitatory amino acid carrier 1), undergoes rapid regulation after treatment with platelet-derived growth factor (PDGF) or phorbol ester in C6 glioma cells and neurons. A large intracellular pool of EAAC1 exists, from which transporters are redistributed to the cell surface in response to these signals. Here we show that PDGF had no effect on subcellular localization of the glial glutamate transporter, GLT-1, after transfection into C6 glioma cells. Chimeras consisting of domains from EAAC1 or GLT-1 were used to investigate structural motifs involved in PDGF-dependent redistribution of EAAC1. PDGF did not induce trafficking of an EAAC1 chimera containing the carboxyl- terminal domain of GLT-1; however, it did induce trafficking of a GLT-1 chimera containing the carboxyl- terminal domain of EAAC1. A truncated mutant of EAAC1 lacking 10 carboxyl-terminal amino acids was responsive to PDGF, whereas a mutant lacking 20 residues was not. Alanine substitution mutagenesis in this region revealed a short motif, (YVN504)-Y-502, necessary for regulated trafficking. This motif was also involved in protein kinase C-dependent trafficking, as mutant transporters exhibited an attenuated response to phorbol ester. Interestingly, the presence of YVN in the homologous region of a nonresponsive chimera was not sufficient to confer regulated trafficking; however, the presence of a 12-amino acid motif starting at this Tyr residue was sufficient to confer responsiveness to PDGF. These studies identify a novel motif within the carboxyl terminus of EAAC1 which is required for regulated trafficking. The possibility that this motif targets EAAC1 to an intracellular, "regulated pool" is discussed.	Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia	Robinson, MB (corresponding author), Dept Pediat, 502N Abramson Pediat Res Bldg,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@pharm.med.upenn.edu			NICHD NIH HHS [P30-HD29679] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07517] Funding Source: Medline; NIMH NIH HHS [1-F31-MH1071008-01] Funding Source: Medline; NINDS NIH HHS [NS39011, NS29868] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R13HD029679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039011, R01NS029868] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKMANN ML, 2005, NEUROPHARMACOL C, V15; Cheng CL, 2002, J NEUROSCI, V22, P10643; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Conti F, 1998, CEREB CORTEX, V8, P108, DOI 10.1093/cercor/8.2.108; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Davis KE, 1998, J NEUROSCI, V18, P2475; Diamond JS, 2001, J NEUROSCI, V21, P8328, DOI 10.1523/JNEUROSCI.21-21-08328.2001; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Fournier KM, 2004, J BIOL CHEM, V279, P34505, DOI 10.1074/jbc.M404032200; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; He Y, 2000, J COMP NEUROL, V418, P255; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; Levenson J, 2002, NAT NEUROSCI, V5, P155, DOI 10.1038/nn791; Martinez-Arca S, 2000, J CELL SCI, V113, P1705; Mathews GC, 2003, J NEUROSCI, V23, P2040; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; Palacios S, 2001, J BIOL CHEM, V276, P3371, DOI 10.1074/jbc.M006739200; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sepkuty JP, 2002, J NEUROSCI, V22, P6372; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Tsvetkov E, 2004, NEURON, V41, P139, DOI 10.1016/S0896-6273(03)00800-6; Watson RT, 2004, ENDOCR REV, V25, P177, DOI 10.1210/er.2003-0011; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018	32	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4876	4886		10.1074/jbc.M504983200	http://dx.doi.org/10.1074/jbc.M504983200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368696	hybrid			2022-12-27	WOS:000235426200038
J	Daus, ML; Landmesser, H; Schlosser, A; Muller, P; Herrmann, A; Schneider, E				Daus, ML; Landmesser, H; Schlosser, A; Muller, P; Herrmann, A; Schneider, E			ATP induces conformational changes of periplasmic loop regions of the maltose ATP-binding cassette transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC MEMBRANE-PROTEIN; LARGE-SCALE PURIFICATION; RETRACTED ARTICLE. SEE; HUMAN P-GLYCOPROTEIN; ABC TRANSPORTER; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; SUBUNIT INTERACTIONS; CRYSTAL-STRUCTURE; TRANSITION-STATE	We have studied cofactor-induced conformational changes of the maltose ATP-binding cassette transporter by employing limited proteolysis in detergent solution. The transport complex consists of one copy each of the transmembrane subunits, MalF and MalG, and of two copies of the nucleotide-binding subunit, MalK. Transport activity further requires the periplasmic maltose-binding protein, MalE. Binding of ATP to the MalK subunits increased the susceptibility of two tryptic cleavage sites in the periplasmic loops P2 of MalF and P1 of MalG, respectively. Lys(262) of MalF and Arg(73) of MalG were identified as probable cleavage sites, resulting in two N-terminal peptide fragments of 29 and 8 kDa, respectively. Trapping the complex in the transition state by vanadate further stabilized the fragments. In contrast, the tryptic cleavage profile of MalK remained largely unchanged. ATP-induced conformational changes of MalF-P2 and MalG-P1 were supported by fluorescence spectroscopy of complex variants labeled with 2-(4'-maleimidoanilino)naphthalene-6-sulfonic acid. Limited proteolysis was subsequently used as a tool to study the consequences of mutations on the transport cycle. The results suggest that complex variants exhibiting a binding protein-independent phenotype (MalF500) or containing a mutation that affects the "catalytic carboxylate" (MalKE159Q) reside in a transition state-like conformation. A similar conclusion was drawn for a complex containing a replacement of MalKQ140 in the signature sequence by leucine, whereas substitution of lysine for Gln(140) appears to lock the transport complex in the ground state. Together, our data provide the first evidence for conformational changes of the transmembrane subunits of an ATP-binding cassette import system upon binding of ATP.	Humboldt Univ, Inst Biol Bakterienphysiol, D-10115 Berlin, Germany; Charite Univ Med Berlin, Inst Med Immunol, D-10115 Berlin, Germany; Humboldt Univ, Inst Biol Biophys, D-10115 Berlin, Germany	Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Schneider, E (corresponding author), Humboldt Univ, Inst Biol Bakterienphysiol, Chausseestr 117, D-10115 Berlin, Germany.	erwin.schneider@rz.hu-berlin.de						Austermuhle MI, 2004, J BIOL CHEM, V279, P28243, DOI 10.1074/jbc.M403508200; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DASSA E, 1993, MOL MICROBIOL, V7, P39, DOI 10.1111/j.1365-2958.1993.tb01095.x; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; Dassa E., 2003, ABC PROTEINS BACTERI, P3; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; DAVIDSON AL, 1991, J BIOL CHEM, V266, P8946; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; Ehrmann M, 1998, MOL MICROBIOL, V29, P685, DOI 10.1046/j.1365-2958.1998.00915.x; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; HOLLAND EB, 2003, ABC PROTEINS BACTERI; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Horlacher R, 1998, J BACTERIOL, V180, P680, DOI 10.1128/JB.180.3.680-689.1998; Hulsmann A, 2000, J BACTERIOL, V182, P6292, DOI 10.1128/JB.182.22.6292-6301.2000; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Hunke S, 1999, FEBS LETT, V448, P131, DOI 10.1016/S0014-5793(99)00356-7; Hunke S, 2000, J BIOL CHEM, V275, P15526, DOI 10.1074/jbc.275.20.15526; Hunke S, 2000, J BACTERIOL, V182, P1432, DOI 10.1128/JB.182.5.1432-1436.2000; HUNKE S, 1995, BIOCHEM BIOPH RES CO, V216, P589, DOI 10.1006/bbrc.1995.2663; Janas E, 2003, J BIOL CHEM, V278, P26862, DOI 10.1074/jbc.M301227200; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landmesser H, 2002, BBA-BIOMEMBRANES, V1565, P64, DOI 10.1016/S0005-2736(02)00506-0; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Mannering DE, 2001, J BIOL CHEM, V276, P12362, DOI 10.1074/jbc.M011686200; MARTINEZ E, 1988, GENE, V68, P159, DOI 10.1016/0378-1119(88)90608-7; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Mourez M, 1997, MOL MICROBIOL, V26, P821, DOI 10.1046/j.1365-2958.1997.6271992.x; Mourez M, 1998, MOL MICROBIOL, V30, P353, DOI 10.1046/j.1365-2958.1998.01070.x; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Nelson BD, 1998, J BACTERIOL, V180, P2507, DOI 10.1128/JB.180.9.2507-2514.1998; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Scheffel F, 2005, FEBS LETT, V579, P2953, DOI 10.1016/j.febslet.2005.04.017; Schmees G, 1999, EUR J BIOCHEM, V266, P420, DOI 10.1046/j.1432-1327.1999.00871.x; Schmitt L, 2002, CURR OPIN STRUC BIOL, V12, P754, DOI 10.1016/S0959-440X(02)00399-8; Schneider E, 2001, RES MICROBIOL, V152, P303, DOI 10.1016/S0923-2508(01)01201-3; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; SCHNEIDER E, 2003, ABC PROTEINS BACTERI, P157; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; Sharom FJ., 2003, ABC PROTEINS BACTERI, P107; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Steinke A, 2001, J BACTERIOL, V183, P375, DOI 10.1128/JB.183.1.375-381.2001; Tapia MI, 1999, J BACTERIOL, V181, P2267, DOI 10.1128/JB.181.7.2267-2272.1999; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; WALTER C, 1992, FEBS LETT, V303, P41, DOI 10.1016/0014-5793(92)80473-T; WALTER C, 1992, J BIOL CHEM, V267, P8863; Wang GC, 1997, BIOCHEM J, V328, P897, DOI 10.1042/bj3280897; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200	59	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3856	3865		10.1074/jbc.M511953200	http://dx.doi.org/10.1074/jbc.M511953200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352608	hybrid			2022-12-27	WOS:000235275300013
J	Kaneki, H; Guo, R; Chen, D; Yao, ZQ; Schwarz, EM; Zhang, YE; Boyce, BF; Xing, LP				Kaneki, H; Guo, R; Chen, D; Yao, ZQ; Schwarz, EM; Zhang, YE; Boyce, BF; Xing, LP			Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; MURINE CLONAL OSTEOBLASTS; NF-KAPPA-B; FACTOR-ALPHA; SKELETAL-MUSCLE; BONE-FORMATION; TNF-ALPHA; MEDIATED DEGRADATION; TRANSGENIC MICE; CELL POLARITY	Tumor necrosis factor (TNF) plays an important role in the pathogenesis of inflammatory bone loss through stimulation of osteoclastic bone resorption and inhibition of osteoblastic bone formation. Compared with the well established role of TNF in osteoclastogenesis, mechanisms by which TNF inhibits osteoblast function have not been fully determined. Runx2 is an osteoblast-specific transcription factor whose steady-state protein levels are regulated by proteasomal degradation, mediated by the E3 ubiquitin ligases, Smurf1 and Smurf2. We hypothesized that TNF inhibits osteoblast function through Smurf-mediated Runx2 degradation. We treated C2C12 and 2T3 osteoblast precursor cell lines and primary osteoblasts with TNF and found that TNF, but not interleukin-1, significantly increased Smurf1 and Smurf2 expression. TNF increased the degradation of endogenous or transfected Runx2 protein, which was blocked by treating cells with a proteasomal inhibitor or by infecting cells with small interfering (si) RNA against Smurf1 or Smurf2. TNF inhibited the expression of bone morphogenetic protein and transforming growth factor-beta signaling reporter constructs, and the inhibition of each was blocked by Smurf1 siRNA and Smurf2 siRNA, respectively. Overexpression of Smurf1 and/or Smurf2 siRNAs prevented the inhibitory effect of TNF on Runx2 reporter. Consistent with these in vitro findings, bones from TNF transgenic mice or TNF-injected wild type mice had increased Smurf1 and decreased Runx2 protein levels. We propose that one of the mechanisms by which TNF inhibits bone formation in inflammatory bone disorders is by promoting Runx2 proteasomal degradation through up-regulation of Smurf1 and Smurf2 expression.	Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Dept Orthopaed, Ctr Musculoseletal Res, Rochester, NY 14642 USA; NCI, Ctr Canc Res, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Xing, LP (corresponding author), Univ Rochester, Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.	Lianping_xing@urmc.rochester.edu	Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	NATIONAL CANCER INSTITUTE [Z01BC010419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051189, R01AR048697, R03AR048920, R01AR043510] Funding Source: NIH RePORTER; Intramural NIH HHS [ZIA BC011168-01] Funding Source: Medline; NIAMS NIH HHS [R01 AR051189, R03 AR048920-02, R01 AR043510, R01 AR048697, R03 AR048920, R01 AR051189-02, AR051189, AR48697, R01 AR051189-01, AR43510] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbas S, 2003, CYTOKINE, V22, P33, DOI 10.1016/S1043-4666(03)00106-6; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo-125-3-1142; CANALIS E, 1987, ENDOCRINOLOGY, V121, P1596, DOI 10.1210/endo-121-5-1596; Datto M, 2005, CELL, V121, P2, DOI 10.1016/j.cell.2005.03.017; Dehoux MJM, 2003, FEBS LETT, V544, P214, DOI 10.1016/S0014-5793(03)00505-2; Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956; Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200; Gilbert LC, 2005, AM J PHYSIOL-ENDOC M, V288, pE1011, DOI 10.1152/ajpendo.00534.2004; Goldring SR, 2000, CURR OPIN RHEUMATOL, V12, P195, DOI 10.1097/00002281-200005000-00006; GREEN LM, 1984, J IMMUNOL METHODS, V70, P257, DOI 10.1016/0022-1759(84)90190-X; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kitajima I, 1996, J BONE MINER RES, V11, P200; Kitajima I, 1996, BONE, V19, P263, DOI 10.1016/8756-3282(96)00181-0; Lam J, 2001, J BONE MINER RES, V16, pS150; Li P, 2004, ARTHRITIS RHEUM, V50, P265, DOI 10.1002/art.11419; Li YP, 2005, FASEB J, V19, P362, DOI 10.1096/fj.04-2364com; LI YP, 1992, J IMMUNOL, V148, P788; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Nair SP, 2000, RHEUMATOLOGY, V39, P821, DOI 10.1093/rheumatology/39.8.821; Pray TR, 2002, DRUG RESIST UPDATE, V5, P249, DOI 10.1016/S1368-7646(02)00121-8; Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094; TAICHMAN RS, 1992, INFLAMMATION, V16, P587, DOI 10.1007/BF00919342; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Tsuboi M, 1999, J LAB CLIN MED, V134, P222, DOI 10.1016/S0022-2143(99)90201-9; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Ying SX, 2003, J BIOL CHEM, V278, P39029, DOI 10.1074/jbc.M301193200; Zhang Y, 2004, CELL CYCLE, V3, P391; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhao M, 2004, J BIOL CHEM, V279, P12854, DOI 10.1074/jbc.M313294200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	38	233	248	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4326	4333		10.1074/jbc.M509430200	http://dx.doi.org/10.1074/jbc.M509430200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16373342	hybrid, Green Accepted			2022-12-27	WOS:000235275300067
J	Mitchell, MS; Tozser, J; Princler, G; Lloyd, PA; Auth, A; Derse, D				Mitchell, MS; Tozser, J; Princler, G; Lloyd, PA; Auth, A; Derse, D			Synthesis, processing, and composition of the virion-associated HTLV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LEUKEMIA-VIRUS; MAMMARY-TUMOR VIRUS; COMPLETE NUCLEOTIDE-SEQUENCE; AQUATICUS DNA-POLYMERASE; PFIZER MONKEY VIRUS; POL-GENE-PRODUCTS; SUBSTRATE-SPECIFICITY; CLEAVAGE SITE; MESSENGER-RNA; TYPE-1	It is not known whether the low infectivity and low virion-associated polymerase activity of human T-cell lymphotropic virus type-1 (HTLV-1) are due to the quantity or quality of the reverse transcriptase (RT), because the protein has not yet been fully characterized. We have developed anti-RT antibodies and constructed HTLV-1 expression plasmids that express truncated or hemagglutinin-tagged Pol polyproteins to examine the maturation and composition of HTLV-1 RT. We detected virion-associated proteins corresponding to RT-integrase (IN) (pr98) and RT (p62) as well as smaller proteins containing the polymerase (p49) or RNase H domains. We have identified the amino acid sequences in the Pol polyprotein that are cleaved by HTLV-1 protease to yield RT and IN. We have also identified the cleavage sites within RT that give rise to the p49 polymerase fragment. Immunoprecipitation of an epitope-tagged p62 subunit coprecipitated p49, indicating that the HTLV-1 RT complex can exist as a p62/p49 heterodimer analogous to the RT of HIV-1 (p66/p51).	NCI, HIV Drug Resistance Program, Frederick, MD 21702 USA; Univ Debrecen, Dept Biochem, H-4012 Debrecen, Hungary; SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Debrecen; Science Applications International Corporation (SAIC); SAIC-Frederick	Derse, D (corresponding author), NCI, HIV Drug Resistance Program, POB B,Bldg 535-134, Frederick, MD 21702 USA.	derse@ncifcrf.gov	Tozser, Jozsef/A-7840-2008	Tozser, Jozsef/0000-0003-0274-0056; Tozser, Jozsef/0000-0001-5076-8729	NATIONAL CANCER INSTITUTE [ZIABC010003, Z01BC010003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram ME, 2005, J VIROL, V79, P11952, DOI 10.1128/JVI.79.18.11952-11961.2005; Agbuya PG, 2001, ARCH BIOCHEM BIOPHYS, V392, P93, DOI 10.1006/abbi.2001.2432; BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; Bukovsky A, 1996, J VIROL, V70, P6820, DOI 10.1128/JVI.70.10.6820-6825.1996; Das D, 2004, STRUCTURE, V12, P819, DOI 10.1016/j.str.2004.02.032; Derse D, 2001, J VIROL, V75, P8461, DOI 10.1128/JVI.75.18.8461-8468.2001; DICKSON C, 1979, CELL, V17, P1003, DOI 10.1016/0092-8674(79)90339-8; DICKSON C, 1983, CURR TOP MICROBIOL, V106, P1; Entin-Meer M, 2003, VIROLOGY, V310, P157, DOI 10.1016/S0042-6822(03)00113-2; Heidecker G, 2002, J VIROL, V76, P13101, DOI 10.1128/JVI.76.24.13101-13105.2002; HOSTOMSKY Z, 1992, J VIROL, V66, P3179, DOI 10.1128/JVI.66.5.3179-3182.1992; HRUSKOVAHEIDINGSFELDOVA O, 1995, J BIOL CHEM, V270, P15053, DOI 10.1074/jbc.270.25.15053; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; JACKS T, 1985, SCIENCE, V230, P1237, DOI 10.1126/science.2416054; JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; JONES MD, 1989, NUCLEIC ACIDS RES, V17, P8387, DOI 10.1093/nar/17.20.8387; JUPP RA, 1991, FEBS LETT, V283, P180, DOI 10.1016/0014-5793(91)80583-O; Kadas J, 2004, J BIOL CHEM, V279, P27148, DOI 10.1074/jbc.M401868200; LEDERER H, 1992, EMBO J, V11, P1131, DOI 10.1002/j.1460-2075.1992.tb05153.x; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; Louis JM, 1999, J BIOL CHEM, V274, P6660, DOI 10.1074/jbc.274.10.6660; MADOR N, 1989, J VIROL, V63, P2400, DOI 10.1128/JVI.63.5.2400-2404.1989; Mariani VL, 2003, BIOCHEM BIOPH RES CO, V300, P268, DOI 10.1016/S0006-291X(02)02848-6; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NAM SH, 1993, J VIROL, V67, P196, DOI 10.1128/JVI.67.1.196-203.1993; NAM SH, 1988, J VIROL, V62, P3718, DOI 10.1128/JVI.62.10.3718-3728.1988; Navarro JM, 2001, VIROLOGY, V290, P300, DOI 10.1006/viro.2001.1188; Owen SM, 1998, J VIROL, V72, P5279, DOI 10.1128/JVI.72.6.5279-5284.1998; POWER MD, 1986, SCIENCE, V231, P1567, DOI 10.1126/science.3006247; Princler GL, 2003, VIROLOGY, V317, P136, DOI 10.1016/j.virol.2003.09.010; Quillent C, 1996, VIROLOGY, V219, P29, DOI 10.1006/viro.1996.0219; RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5; RICE NR, 1985, VIROLOGY, V142, P357, DOI 10.1016/0042-6822(85)90344-7; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; ROTH MJ, 1985, J BIOL CHEM, V260, P9326; SAGATA N, 1985, P NATL ACAD SCI USA, V82, P677, DOI 10.1073/pnas.82.3.677; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHAFFER AL, 1990, ANAL BIOCHEM, V190, P292, DOI 10.1016/0003-2697(90)90196-G; SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5; Telesnitsky A., 1997, P121; TOZSER J, 1993, BIOCHEMISTRY-US, V32, P3347, DOI 10.1021/bi00064a018; Tozser J, 2000, EUR J BIOCHEM, V267, P6287, DOI 10.1046/j.1432-1327.2000.01714.x; Trentin B, 1998, J VIROL, V72, P6504, DOI 10.1128/JVI.72.8.6504-6510.1998; Werner S, 2000, J VIROL, V74, P3245, DOI 10.1128/JVI.74.7.3245-3252.2000; Wlodawer A, 2000, BBA-PROTEIN STRUCT M, V1477, P16, DOI 10.1016/S0167-4838(99)00267-8	47	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3964	3971		10.1074/jbc.M507660200	http://dx.doi.org/10.1074/jbc.M507660200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368688	hybrid			2022-12-27	WOS:000235275300024
J	Sun, MJ; Finnemann, SC; Febbraio, M; Shan, L; Annangudi, SP; Podrez, EA; Hoppe, G; Darrow, R; Organisciak, DT; Salomon, RG; Silverstein, RL; Hazen, SL				Sun, MJ; Finnemann, SC; Febbraio, M; Shan, L; Annangudi, SP; Podrez, EA; Hoppe, G; Darrow, R; Organisciak, DT; Salomon, RG; Silverstein, RL; Hazen, SL			Light-induced oxidation of photoreceptor outer segment phospholipids generates ligands for CD36-mediated phagocytosis by retinal pigment epithelium - A potential mechanism for modulating outer segment phagocytosis under oxidant stress conditons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCAVENGER RECEPTOR CD36; NITRIC-OXIDE; RCS RAT; ALPHA-V-BETA-5 INTEGRIN; OXIDIZED PHOSPHOLIPIDS; MACULAR DEGENERATION; RPE CELLS; IN-VITRO; DYSTROPHY; BINDING	Clearance by the retinal pigment epithelium (RPE) of shed photoreceptor outer segments (OSs), a tissue with one of the highest turnover rates in the body, is critical to the maintenance and normal function of the retina. We hypothesized that there is a potential role for photo-oxidation in OS uptake by RPE via scavenger receptor-mediated recognition of structurally defined lipid peroxidation products. We now demonstrate that specific structurally defined oxidized species derived from arachidonyl, linoleoyl, and docosahexanoyl phosphatidylcholine may serve as endogenous ligands on OSs for uptake by RPE via the scavenger receptor CD36. Mass spectrometry studies of retinal lipids recovered from dark-adapted rats following physiological light exposure demonstrate in vivo formation of specific oxidized phosphatidylcholine molecular species possessing a CD36 recognition motif, an oxidatively truncated sn-2 acyl group with a terminal gamma-hydroxy(or oxo)-alpha,beta-unsaturated carbonyl. Cellular studies using RPE isolated from wild-type versus CD36 null mice suggest that CD36 plays a role in engulfment, but not initial binding, of OSs via these oxidized phospholipids. Parallel increases in OS protein-bound nitrotyrosine, a post-translational modification by nitric oxide (NO)-derived oxidants, were also observed, suggesting a possible role for light-induced generation of NO-derived oxidants in the initiation of OS lipid peroxidation. Collectively, these studies suggest that intense light exposure promotes "oxidative tagging" of photoreceptor outer segments with structurally defined choline glycerophospholipids that may serve as a physiological signal for CD36-mediated phagocytosis under oxidant stress conditions.	Cleveland Clin Fdn, Ctr Cardiovas Diagnost & Prevent, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cornell Univ, Weill Med Coll, Dyson Vis Res Inst, Dept Ophthalmol,Dept Cell & Dev Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Phys & Biophys, New York, NY 10021 USA; Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44195 USA; Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45401 USA	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cornell University; Dyson; Cornell University; Cleveland Clinic Foundation; University System of Ohio; Wright State University Dayton	Hazen, SL (corresponding author), Cleveland Clin Fdn, Ctr Cardiovas Diagnost & Prevent, 9500 Euclid Ave,NE-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Annangudi, Suresh/AAD-6408-2020; Hazen, Stanley L/ABD-5845-2021; Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NEI NIH HHS [EY01959, R01 EY001959, EY13295, EY10967, R01 EY013295] Funding Source: Medline; NHLBI NIH HHS [HL46403, R01 HL061878, P01 HL046403, R01 HL070621, HL70621, P01 HL076491, P50 HL077107, HL61878, P01 HL77107] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY001959, R01EY010967, R01EY013295] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070621, P01HL046403, R01HL061878, P50HL077107, P01HL076491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Benssasson R.V., 1993, EXCITED STATES FREE, P128; BLANKS JC, 1992, INVEST OPHTH VIS SCI, V33, P2814; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; Daviet L, 1997, THROMB HAEMOSTASIS, V78, P65; DELMELLE M, 1975, EXP EYE RES, V21, P369, DOI 10.1016/0014-4835(75)90047-0; Deng YH, 1998, J ORG CHEM, V63, P7789, DOI 10.1021/jo980861e; Dillon J, 1996, PHOTOCHEM PHOTOBIOL, V63, P680, DOI 10.1111/j.1751-1097.1996.tb05673.x; Donovan M, 2001, J BIOL CHEM, V276, P23000, DOI 10.1074/jbc.M005359200; EDWARDS RB, 1977, SCIENCE, V197, P1001, DOI 10.1126/science.560718; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Finneman SC, 2001, J EXP MED, V194, P1289, DOI 10.1084/jem.194.9.1289; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x; Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555; GOUREAU O, 1993, NEUROREPORT, V5, P233, DOI 10.1097/00001756-199312000-00012; Grimm C, 2000, NAT GENET, V25, P63, DOI 10.1038/75614; Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200; Gu XR, 2003, J ORG CHEM, V68, P3749, DOI 10.1021/jo026721t; HALL MO, 1987, EXP EYE RES, V45, P907, DOI 10.1016/S0014-4835(87)80105-7; Hall MO, 2002, EXP EYE RES, V75, P391, DOI 10.1006/exer.2002.2030; Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063; LI S, 1995, ARCH OPHTHALMOL-CHIC, V113, P521, DOI 10.1001/archopht.1995.01100040143041; Miyagi M, 2002, MOL CELL PROTEOMICS, V1, P293, DOI 10.1074/mcp.M100034-MCP200; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; NABI IR, 1993, J CELL SCI, V104, P37; Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447; Nicholls SJ, 2005, METHOD ENZYMOL, V396, P245, DOI 10.1016/S0076-6879(05)96022-9; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; ORGANISCIAK DT, 1985, INVEST OPHTH VIS SCI, V26, P1580; ORGANISCIAK DT, 1994, PROG RETIN EYE RES, V13, P1, DOI 10.1016/1350-9462(94)90003-5; Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PAUTLER EL, 1994, CURR EYE RES, V13, P687, DOI 10.3109/02713689408999905; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pravenec M, 2003, PHYSIOL RES, V52, P681; Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X; ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825; Ryeom SW, 1996, J CELL SCI, V109, P387; Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Silverstein RL, 2000, CURR OPIN LIPIDOL, V11, P483, DOI 10.1097/00041433-200010000-00006; SUN M, 2003, THESIS CASE W RESERV, P262; Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383; Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198; Watson CL, 1997, CIRC RES, V81, P387, DOI 10.1161/01.RES.81.3.387; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392; Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598	58	117	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4222	4230		10.1074/jbc.M509769200	http://dx.doi.org/10.1074/jbc.M509769200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354659	Green Accepted, hybrid			2022-12-27	WOS:000235275300055
J	Wallar, BJ; Stropich, BN; Schoenherr, JA; Holman, HA; Kitchen, SM; Alberts, AS				Wallar, BJ; Stropich, BN; Schoenherr, JA; Holman, HA; Kitchen, SM; Alberts, AS			The basic region of the diaphanous-autoregulatory domain (DAD) is required for autoregulatory interactions with the diaphanous-related formin inhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN NUCLEATION; MOUSE FORMIN; RHO-GTPASE; PROTEIN; MDIA1; MECHANISM; DYNAMICS; REVEALS; ROCK; BNI1	(M) under bar ammalian (dia) under bar phanous-related (mDia) formins act as Rho GTPase effectors during cytoskeletal remodeling. Rho binding to mDia amino-terminal (G) under bar TPase-(b) under bar inding (b) under bar omains (GBDs) causes the adjacent (D) under bar ia-(i) under bar nhibitory (d) under bar omain (DID) to release the carboxyl-terminal (D) under bar ia-(a) under bar utoregulatory (DAD) domain that flanks the formin (h) under bar omology-2 (FH2) domain. The release of DAD allows the FH2 domain to then nucleate and elongate nonbranched actin filaments. DAD, initially discovered as a region of homology shared between a phylogenetically divergent set of formin proteins, is comprised of a core motif, MDXLLXL, and an adjacent region is comprised of numerous basic residues, typically RRKR in the mDia family. Here, we show that these specific amino acids within the basic region of DAD contribute to the binding of DID and therefore the maintenance of the mDia autoregulatory mechanism. In addition, expression of full-length versions of mDia2 containing amino acid substitutions in either the DAD core or basic regions causes profound changes in the F-actin architecture, including the formation of filopodia-like structures that rapidly elongate from the cell edge. These studies further refine our understanding of the molecular contribution of DAD to mDia control and the role of mDia2 in the assembly of membrane protrusions.	Grand Valley State Univ, Dept Chem, Allendale, MI 49401 USA; Grand Valley State Univ, Cell & Mol Biol Program, Allendale, MI 49401 USA; Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI 49503 USA	Grand Valley State University; Grand Valley State University; Van Andel Institute	Alberts, AS (corresponding author), 333 Bostwick Ave, Grand Rapids, MI 49503 USA.	art.alberts@vai.org			NATIONAL CANCER INSTITUTE [R21CA107529] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA107529] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 2005, J BIOL CHEM, V280, P12152, DOI 10.1074/jbc.M405073200; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Dong YQ, 2003, J CELL BIOL, V161, P1081, DOI 10.1083/jcb.200212040; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Harris ES, 2004, J BIOL CHEM, V279, P20076, DOI 10.1074/jbc.M312718200; Higgs HN, 2005, MOL BIOL CELL, V16, P1, DOI 10.1091/mbc.E04-07-0565; Kovar DR, 2004, NAT CELL BIOL, V6, P1158, DOI 10.1038/ncb1204-1158; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Otomo T, 2005, MOL CELL, V18, P273, DOI 10.1016/j.molcel.2005.04.002; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pellegrin S, 2005, CURR BIOL, V15, P129, DOI 10.1016/j.cub.2005.01.011; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Posern G, 2004, EMBO J, V23, P3973, DOI 10.1038/sj.emboj.7600404; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Rose R, 2005, NATURE, V435, P513, DOI 10.1038/nature03604; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Schirenbeck A, 2005, NAT CELL BIOL, V7, P619, DOI 10.1038/ncb1266; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yasuda S, 2004, NATURE, V428, P767, DOI 10.1038/nature02452	30	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4300	4307		10.1074/jbc.M510277200	http://dx.doi.org/10.1074/jbc.M510277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361707	hybrid			2022-12-27	WOS:000235275300064
J	Juarez-Diaz, JA; McClure, B; Vazquez-Santana, S; Guevara-Garcia, A; Leon-Mejia, P; Marquez-Guzman, J; Cruz-Garcia, F				Juarez-Diaz, JA; McClure, B; Vazquez-Santana, S; Guevara-Garcia, A; Leon-Mejia, P; Marquez-Guzman, J; Cruz-Garcia, F			A novel thioredoxin h is secreted in Nicotiana alata and reduces S-RNase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS RECEPTOR KINASE; SELF-INCOMPATIBILITY; ESCHERICHIA-COLI; PLANT THIOREDOXINS; PROTEINS; GENE; SEQUENCE; REDUCTASE; SYSTEM; IDENTIFICATION	Thioredoxins type h are classified into three subgroups. The subgroup II includes thioredoxins containing an N-terminal extension, the role of which is still unclear. Although thioredoxin secretion has been observed in animal cells, there is no evidence suggesting that any thioredoxin h is secreted in plants. In this study, we report that a thioredoxin h, subgroup II, from Nicotiana alata (NaTrxh) is secreted into the extracellular matrix of the stylar transmitting tract tissue. Fractionation studies showed that NaTrxh is extracted along with well characterized secretion proteins such as S-RNases and NaTTS (N. alata transmitting tissue-specific protein). Moreover, an NaTrxh-green fluorescent fusion protein transiently expressed in Nicotiana benthamiana and Arabidopsis thaliana leaves was also secreted, showing that NaTrxh has the required information for its secretion. We performed reduction assays in vitro to identify potential extracellular targets of NaTrxh. We found that S-RNase is one of the several potential substrates of the NaTrxh in the extracellular matrix. In addition, we proved by affinity chromatography that NaTrxh specifically interacts with S-RNase. Our findings showed that NaTrxh is a new thioredoxin h in Nicotiana that is secreted as well as in animal systems. Because NaTrxh is localized in the extracellular matrix of the stylar transmitting tract and its specific interaction with S-RNase to reduce it in vitro, we suggest that this thioredoxin h may be involved either in general pollen-pistil interaction processes or particularly in S-RNase-based self-incompatibility.	Univ Nacl Autonoma Mexico, Fac Quim, Dept Bioquim & Biol Mol Plantas, Mexico City 04510, DF, Mexico; Life Sci Ctr, Div Biochem, Columbia, MO 65211 USA; Univ Nacl Autonoma Mexico, Fac Ciencias, Dept Biol Comparada, Mexico City 04510, DF, Mexico; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Biol Mol Plantas, Cuernavaca 62250, Morelos, Mexico	Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico	Cruz-Garcia, F (corresponding author), Univ Nacl Autonoma Mexico, Fac Quim, Dept Bioquim & Biol Mol Plantas, Mexico City 04510, DF, Mexico.	fcg@servidor.unam.mx	Cruz-Garcia, Felipe/A-5817-2008; Juárez-Díaz, Javier Andrés/AAD-6398-2021	Juarez-Diaz, Javier Andres/0000-0001-9238-8564				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Baumann U, 2002, CELL MOL LIFE SCI, V59, P1042, DOI 10.1007/s00018-002-8485-8; Bendtsen JD, 2004, PROTEIN ENG DES SEL, V17, P349, DOI 10.1093/protein/gzh037; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bosch M, 2001, PLANT PHYSIOL, V125, P2180, DOI 10.1104/pp.125.4.2180; Bower MS, 1996, PLANT CELL, V8, P1641, DOI 10.1105/tpc.8.9.1641; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGIDOU C, 1993, MOL GEN GENET, V238, P285, DOI 10.1007/BF00279557; Cabrillac D, 2001, NATURE, V410, P220, DOI 10.1038/35065626; Cruz-Garcia F, 2005, PLANT J, V42, P295, DOI 10.1111/j.1365-313X.2005.02375.x; DEBLAERE R, 1985, NUCLEIC ACIDS RES, V13, P4777, DOI 10.1093/nar/13.13.4777; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; FLORENCIO FJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P496, DOI 10.1016/0003-9861(88)90282-2; Gelhaye E, 2004, P NATL ACAD SCI USA, V101, P14545, DOI 10.1073/pnas.0405282101; Gelhaye E, 2004, PLANT PHYSIOL BIOCH, V42, P265, DOI 10.1016/j.plaphy.2004.03.002; HARTMAN H, 1990, MOL BIOL EVOL, V7, P247; HODGES M, 1994, PLANT MOL BIOL, V26, P225, DOI 10.1007/BF00039534; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOOG JO, 1984, BIOSCIENCE REP, V4, P917, DOI 10.1007/BF01116889; Ishiwatari Y, 1998, PLANTA, V205, P12, DOI 10.1007/s004250050291; ISHIWATARI Y, 1995, PLANTA, V195, P456, DOI 10.1007/BF00202605; Jefferson RA., 1988, GENETIC ENG GENETIC, V10, P247, DOI DOI 10.1007/978-1-4615-7081-3_13; JOHNSON TC, 1987, PLANTA, V171, P321, DOI 10.1007/BF00398677; KALEF E, 1993, ANAL BIOCHEM, V212, P325, DOI 10.1006/abio.1993.1337; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Laloi C, 2001, P NATL ACAD SCI USA, V98, P14144, DOI 10.1073/pnas.241340898; Lind JL, 1996, SEX PLANT REPROD, V9, P75, DOI 10.1007/BF02153054; Llave C, 2000, P NATL ACAD SCI USA, V97, P13401, DOI 10.1073/pnas.230334397; Marchand C, 2004, PROTEOMICS, V4, P2696, DOI 10.1002/pmic.200400805; Mazzurco M, 2001, PLANT MOL BIOL, V45, P365, DOI 10.1023/A:1006412329934; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; Meyer Y, 1999, TRENDS PLANT SCI, V4, P388, DOI 10.1016/S1360-1385(99)01475-2; Meyer Y, 2002, METHOD ENZYMOL, V347, P394; MURFETT J, 1995, PLANT MOL BIOL, V29, P201, DOI 10.1007/BF00043646; Murfett J, 1996, PLANT CELL, V8, P943, DOI 10.1105/tpc.8.6.943; Oxley D, 1996, EUR J BIOCHEM, V242, P75, DOI 10.1111/j.1432-1033.1996.0075r.x; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANFORD JC, 1990, PHYSIOL PLANTARUM, V79, P206, DOI 10.1111/j.1399-3054.1990.tb05888.x; Schob H, 1997, MOL GEN GENET, V256, P581, DOI 10.1007/s004380050604; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Sijacic P, 2004, NATURE, V429, P302, DOI 10.1038/nature02523; Soderberg A, 2000, CANCER RES, V60, P2281; Tanudji M, 2003, AM J PHYSIOL-CELL PH, V284, pC1272, DOI 10.1152/ajpcell.00521.2002; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wu HM, 2000, PLANT J, V22, P165, DOI 10.1046/j.1365-313x.2000.00731.x; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; Yano H, 2001, P NATL ACAD SCI USA, V98, P4794, DOI 10.1073/pnas.071041998; Zurek DM, 1997, PLANT J, V11, P797, DOI 10.1046/j.1365-313X.1997.11040797.x	52	45	50	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3418	3424		10.1074/jbc.M511687200	http://dx.doi.org/10.1074/jbc.M511687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354655	hybrid			2022-12-27	WOS:000235128200050
J	Majumdar, G; Harrington, A; Hungerford, J; Martinez-Hernandez, A; Gerling, IC; Raghow, R; Solomon, S				Majumdar, G; Harrington, A; Hungerford, J; Martinez-Hernandez, A; Gerling, IC; Raghow, R; Solomon, S			Insulin dynamically regulates calmodulin gene expression by sequential O-glycosylation and phosphorylation of Sp1 and its subcellular compartmentalization in liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; NUCLEOCYTOPLASMIC PROTEINS; GLCNAC; NUCLEAR; INTERPLAY; BETA; HYPERGLYCEMIA; INHIBITION; ACTIVATION; MECHANISMS	O-Glycosylation and phosphorylation of Sp1 are thought to modulate the expression of a number of genes in normal and diabetic state. Sp1 is an obligatory transcription factor for constitutive and insulin responsive expression of the calmodulin gene(Majumdar, G., Harmon, A., Candelaria, R., Martinez-Hernandez, A., Raghow, R., and Solomon, S. S. (2003) Am. J. Physiol. 285, E584-E591). Here we report the temporal dynamics of accumulation of total, O-GlcNAc-modified, and phosphorylated Sp1 in H-411E hepatoma cells by immunohistochemistry with monospecific antibodies, confocal microscopy, and matrix-assisted laser desorption and ionization-time of flight mass spectrometry. Insulin elicited sequential and reciprocal post-translational modifications of Sp1. The O-glycosylation of Sp1 and its nuclear accumulation induced by insulin peaked early (similar to 30 min), followed by a steady decline of O-GlcNAc-modified Sp1 to negligible levels by 240 min. The accumulation of phosphorylated Sp1 in the nuclei of insulin-treated cells showed an opposite pattern, increasing steadily until reaching a maximum around 240 min after treatment. Analyses of the total, O-GlcNAc-modified, or phosphorylated Sp1 by Western blot and mass spectrometry corroborated the sequential and reciprocal control of post-translational modifications of Sp1 in response to insulin. Treatment of cells with streptozotocin ( a potent inhibitor of O-GlcNAcase) led to hyperglycosylation of Sp1 that failed to be significantly phosphorylated. The mass spectrometry data indicated that a number of common serine residues of Sp1 undergo time-dependent, reciprocal O-glycosylation and phosphorylation, paralleling its rapid translocation from cytoplasm to the nucleus. Later, changes in the steady state levels of phosphorylated Sp1 mimicked the enhanced steady state levels of calmodulin mRNA seen after insulin treatment. Thus, O-glycosylation of Sp1 appears to be critical for its localization into the nucleus, where it undergoes obligatory phosphorylation that is needed for Sp1 to activate calmodulin gene expression.	VAMC, Res Serv, Memphis, TN 38104 USA; VAMC, Med Serv, Memphis, TN 38104 USA; VAMC, Pathol Serv, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Med, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pathol, Memphis, TN 38104 USA; Univ Tennessee, Hlth Sci Ctr, Dept Pharmacol, Memphis, TN 38104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Solomon, S (corresponding author), VAMC, Res Serv, 151,1030 Jefferson Ave, Memphis, TN 38104 USA.	ssolomon@utmem.edu						Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; Keembiyehetty CN, 2002, ENDOCRINOLOGY, V143, P1512, DOI 10.1210/en.143.4.1512; Lefebvre T, 2003, BBA-GEN SUBJECTS, V1619, P167, DOI 10.1016/S0304-4165(02)00477-4; Li T, 2003, CIRC RES, V93, P1202, DOI 10.1161/01.RES.0000104085.76261.02; Liu F, 2004, P NATL ACAD SCI USA, V101, P10804, DOI 10.1073/pnas.0400348101; Majumdar G, 2004, DIABETES, V53, P3184, DOI 10.2337/diabetes.53.12.3184; Majumdar G, 2003, AM J PHYSIOL-ENDOC M, V285, pE584, DOI 10.1152/ajpendo.00140.2003; Murphy PR, 2001, ENDOCRINOLOGY, V142, P81, DOI 10.1210/en.142.1.81; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Pan XL, 2000, J LAB CLIN MED, V136, P157, DOI 10.1067/mlc.2000.108149; Pan XL, 2001, ENDOCRINOLOGY, V142, P1635, DOI 10.1210/en.142.4.1635; Parker G, 2004, J BIOL CHEM, V279, P20636, DOI 10.1074/jbc.M312139200; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Slawson C, 2003, CURR OPIN STRUC BIOL, V13, P631, DOI 10.1016/j.sbi.2003.08.003; SOLOMON SS, 1994, J LAB CLIN MED, V124, P348; SOLOMON SS, 1995, BIOCHEM BIOPH RES CO, V210, P921, DOI 10.1006/bbrc.1995.1745; Solomon SS, 1997, P ASSOC AM PHYSICIAN, V109, P470; Solomon SS, 1997, ENDOCRINOLOGY, V138, P5052, DOI 10.1210/en.138.11.5052; SOLOMON SS, 1990, BIOCHEM BIOPH RES CO, V168, P1007, DOI 10.1016/0006-291X(90)91129-G; Solomon SS, 2005, J LAB CLIN MED, V145, P275, DOI 10.1016/j.lab.2005.02.013; SOLOMON SS, 2002, RRD ENDOCRINOL 1, V3, P79; Tannu NS, 2004, ANAL BIOCHEM, V327, P222, DOI 10.1016/j.ab.2004.01.033; Villafuerte BC, 2005, J BIOL CHEM, V280, P20010, DOI 10.1074/jbc.M410817200; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wang GY, 2004, ENDOCRINOLOGY, V145, P659, DOI 10.1210/en.2003-0770; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu J, 2005, ELECTROPHORESIS, V26, P225, DOI 10.1002/elps.200406176; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhao M, 2001, FEBS LETT, V509, P405, DOI 10.1016/S0014-5793(01)03185-4	39	76	79	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3642	3650		10.1074/jbc.M511223200	http://dx.doi.org/10.1074/jbc.M511223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332679	hybrid			2022-12-27	WOS:000235128200076
J	Ogura, K; Nobuhisa, I; Yuzawa, S; Takeya, R; Torikai, S; Saikawa, K; Sumimoto, H; Inagaki, F				Ogura, K; Nobuhisa, I; Yuzawa, S; Takeya, R; Torikai, S; Saikawa, K; Sumimoto, H; Inagaki, F			NMR solution structure of the tandem Src homology 3 domains of p47(phox) complexed with a p22(phox)-derived proline-rich peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; SRC HOMOLOGY-3 DOMAINS; PHOSPHORYLATION-INDUCED ACTIVATION; RESIDUAL DIPOLAR COUPLINGS; PROTEIN-KINASE-C; SH3 DOMAINS; BINDING; RECOGNITION	The phagocyte NADPH oxidase plays a crucial role in host defense against microbial infections by generating reactive oxygen species. It is a multisubunit enzyme composed of membrane-bound flavocytochrome b(558) as well as cytosolic components, including p47(phox), which is essential for assembly of the complex. When phagocytes are activated, the cytosolic components of the NADPH oxidase translocate to flavocytochrome b558 due to binding of the tandem Src homology 3 (SH3) domains of p47(phox) to a proline-rich region in p22(phox), a subunit of flavocytochrome b558. Using NMR titration, we first identified the proline-rich region of p22(phox) that is essential for binding to the tandem SH3 domains of p47(phox). We subsequently determined the solution structure of the p47(phox) tandem SH3 domains complexed with the proline-rich peptide of p22(phox) using NMR spectroscopy. In contrast to the intertwined dimer reported for the crystal state, the solution structure is a monomer. The central region of the p22phox peptide forms a polyproline type II helix that is sandwiched by the N- and C-terminal SH3 domains, as was observed in the crystal structure, whereas the C-terminal region of the peptide takes on a short alpha-helical conformation that provides an additional binding site with the N- terminal SH3 domain. Thus, the C-terminal alpha-helical region of the p22(phox) peptide increases the binding affinity for the tandem SH3 domains of p47(phox) more than 10-fold.	Hokkaido Univ, Dept Biol Struct, Grad Sch Pharmaceut Sci, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Kyushu Univ, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan	Hokkaido University; Kyushu University; Japan Science & Technology Agency (JST)	Inagaki, F (corresponding author), Hokkaido Univ, Dept Biol Struct, Grad Sch Pharmaceut Sci, Kita Ku, N-12,W-6, Sapporo, Hokkaido 0600812, Japan.	finagaki@pharm.hokudai.ac.jp		Yuzawa, Satoru/0000-0002-1031-5781				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAVANAGH J, 1995, PROTEIN NMR SPECTROS, P478; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DINAUER MC, 1992, ANNU REV MED, V43, P117, DOI 10.1146/annurev.med.43.1.117; ElBenna J, 1996, J BIOL CHEM, V271, P6374; ELBENNA J, 1994, J BIOL CHEM, V269, P23431; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fischer MWF, 1999, BIOCHEMISTRY-US, V38, P9013, DOI 10.1021/bi9905213; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Groemping Y, 2003, CELL, V113, P343, DOI 10.1016/S0092-8674(03)00314-3; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guinier A., 1955, SMALL ANGLE SCATTERI; Heyworth PG, 2003, CURR OPIN IMMUNOL, V15, P578, DOI 10.1016/S0952-7915(03)00109-2; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Kanelis V, 2000, J BIOMOL NMR, V16, P253, DOI 10.1023/A:1008355012528; KATAOKA M, 1989, P NATL ACAD SCI USA, V86, P6944, DOI 10.1073/pnas.86.18.6944; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lapouge K, 2002, J BIOL CHEM, V277, P10121, DOI 10.1074/jbc.M112065200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; Mal TK, 2002, BIOCHEMISTRY-US, V41, P12899, DOI 10.1021/bi0264162; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; OLEJNICZAK ET, 1992, J BIOMOL NMR, V2, P655, DOI 10.1007/BF02192854; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Ottiger M, 1998, J BIOMOL NMR, V12, P361, DOI 10.1023/A:1008366116644; Roos D, 2003, MICROBES INFECT, V5, P1307, DOI 10.1016/j.micinf.2003.09.009; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Skrynnikov NR, 2000, J MOL BIOL, V295, P1265, DOI 10.1006/jmbi.1999.3430; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Sumimoto H, 2005, BIOCHEM BIOPH RES CO, V338, P677, DOI 10.1016/j.bbrc.2005.08.210; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; THRASHER AJ, 1994, BBA-MOL BASIS DIS, V1227, P1, DOI 10.1016/0925-4439(94)90100-7; UEKI T, 1985, BIOPHYS CHEM, V23, P115, DOI 10.1016/0301-4622(85)80069-7; Ulmer TS, 2002, STRUCTURE, V10, P901, DOI 10.1016/S0969-2126(02)00781-5; Wiesner S, 2002, J MOL BIOL, V324, P807, DOI 10.1016/S0022-2836(02)01145-2; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Yuzawa S, 2004, J BIOL CHEM, V279, P29752, DOI 10.1074/jbc.M401457200; Yuzawa S, 2004, GENES CELLS, V9, P443, DOI 10.1111/j.1356-9597.2004.00733.x; Yuzawa S, 2001, J MOL BIOL, V306, P527, DOI 10.1006/jmbi.2000.4396	49	59	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3660	3668		10.1074/jbc.M505193200	http://dx.doi.org/10.1074/jbc.M505193200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326715	hybrid			2022-12-27	WOS:000235128200078
J	Takeshita, J; Byun, J; Nhan, TQ; Pritchard, DK; Pennathur, S; Schwartz, SM; Chait, A; Heinecke, JW				Takeshita, J; Byun, J; Nhan, TQ; Pritchard, DK; Pennathur, S; Schwartz, SM; Chait, A; Heinecke, JW			Myeloperoxidase generates 5-chlorouracil in human atherosclerotic tissue - A potential pathway for somatic mutagenesis by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; SENESCENCE-LIKE PHENOMENON; PEROXIDE-CHLORIDE SYSTEM; ACUTE CORONARY SYNDROMES; OXIDATIVE DNA-DAMAGE; HYPOCHLOROUS ACID; HYDROGEN-PEROXIDE; MASS-SPECTROMETRY; GAS-CHROMATOGRAPHY	Somatic mutations induced by oxidative damage of DNA might play important roles in atherogenesis. However, the underlying mechanisms remain poorly understood. Myeloperoxidase, a heme protein expressed by select populations of artery wall macrophages, initiates one potentially mutagenic pathway by generating hypochlorous acid. This potent chlorinating agent reacts rapidly with primary amines to yield long-lived, selectively reactive N-chloramines. In the current studies, we demonstrate that myeloperoxidase produced by human macrophages differentiated in the presence of granulocyte macrophage colony-stimulating factor generates 5-chlorouracil, a mutagenic thymine analog. The primary amine taurine fails to block the reaction, suggesting that N-haloamines produced by macrophages might oxidize uracil. Model system studies demonstrated that N-chloramines convert uracil to 5-chlorouracil. Interestingly, the tertiary amine nicotine dramatically enhances uracil chlorination, suggesting that cigarette smoke might promote nucleobase oxidation by N-chloramines. To look for evidence that myeloperoxidase promotes uracil oxidation in vivo, we measured 5-chlorouracil levels in human aortic tissue, using isotope dilution gas chromatography-mass spectrometry. The level of 5-chlorouracil was 10-fold higher in atherosclerotic aortic tissue obtained during vascular surgery than in normal aortic tissue, suggesting that halogenated nucleobases produced by macrophages might contribute to atherogenesis. Because 5-chlorouracil can be incorporated into nuclear DNA, our observations raise the possibility that halogenation reactions initiated by phagocytes provide one pathway for mutagenesis, phenotypic modulation, and cytotoxicity during atherogenesis.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Washington University (WUSTL); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Heinecke, JW (corresponding author), Univ Washington, Div Metab, Box 356426, Seattle, WA 98195 USA.	heinecke@u.washington.edu			NHLBI NIH HHS [P01HL030086] Funding Source: Medline; NIA NIH HHS [AG19309, AG02119] Funding Source: Medline; NIDDK NIH HHS [P30DK017047] Funding Source: Medline; NIEHS NIH HHS [P30ES07083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019309] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson MM, 1997, J CLIN INVEST, V99, P424, DOI 10.1172/JCI119176; Andreassi MG, 2003, CELL CYCLE, V2, P224, DOI 10.4161/cc.2.3.403; Andreassi MG, 2003, MUTAT RES-REV MUTAT, V543, P67, DOI 10.1016/S1383-5742(02)00089-3; Baldus S, 2001, J CLIN INVEST, V108, P1759; Baldus S, 2003, CIRCULATION, V108, P1440, DOI 10.1161/01.CIR.0000090690.67322.51; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V36, P74, DOI 10.1038/clpt.1984.142; Bergt C, 2004, P NATL ACAD SCI USA, V101, P13032, DOI 10.1073/pnas.0405292101; BOOTHMAN DA, 1987, CANCER RES, V47, P2354; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Byun J, 2003, ANAL BIOCHEM, V317, P201, DOI 10.1016/S0003-2697(03)00093-9; Carr AC, 2001, FREE RADICAL BIO MED, V30, P526, DOI 10.1016/S0891-5849(00)00495-0; CHAIT A, 1982, METABOLISM, V31, P721, DOI 10.1016/0026-0495(82)90204-9; Chen HJC, 2002, CHEM RES TOXICOL, V15, P262, DOI 10.1021/tx015578g; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; ELLIS AJ, 1954, J CHEM SOC, P1750, DOI 10.1039/jr9540001750; FALK E, 1992, CIRCULATION, V86, P30; Flynn PD, 1997, BLOOD, V89, P4378, DOI 10.1182/blood.V89.12.4378; FRENKEL K, 1986, J CELL BIOCHEM, V30, P181, DOI 10.1002/jcb.240300302; GENG YJ, 1995, AM J PATHOL, V147, P251; Giese RW, 1996, METHOD ENZYMOL, V271, P504; Gottardi W, 2002, ARCH PHARM, V335, P411, DOI 10.1002/1521-4184(200212)335:9<411::AID-ARDP411>3.0.CO;2-D; GOTTO AM, 1969, CANCER RES, V29, P807; GRISHAM MB, 1984, J BIOL CHEM, V259, P404; Hale JT, 2002, BIOCHEM PHARMACOL, V64, P1493, DOI 10.1016/S0006-2952(02)01413-2; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1993, BIOCHEM J, V290, P165, DOI 10.1042/bj2900165; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HEARTLEIN MW, 1983, MUTAT RES, V107, P103, DOI 10.1016/0027-5107(83)90081-7; Heinecke J W, 1996, Curr Opin Lipidol, V7, pU131, DOI 10.1097/00041433-199608000-00020; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; Heller JI, 2000, J BIOL CHEM, V275, P9957, DOI 10.1074/jbc.275.14.9957; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson JP, 1999, REDOX REP, V4, P319, DOI 10.1179/135100099101535025; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998; Henderson JP, 2001, BIOCHEMISTRY-US, V40, P2052, DOI 10.1021/bi002015f; HIGUCHI T, 1969, J CHEM SOC B, P626, DOI 10.1039/j29690000626; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 1986, IARC MON EV CARC RIS, V38; Jiang Q, 2003, J BIOL CHEM, V278, P32834, DOI 10.1074/jbc.M304021200; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; Kiyohara C, 2002, LUNG CANCER, V37, P241, DOI 10.1016/S0169-5002(02)00107-1; Klebanoff SJ., 1988, INFLAMMATION BASIC P, P391; KOEFFLER HP, 1985, BLOOD, V65, P484; KOK RM, 1985, J CHROMATOGR, V343, P59, DOI 10.1016/S0378-4347(00)84568-5; KRISS JP, 1963, CANCER RES, V23, P260; LEARN DB, 1990, J LEUKOCYTE BIOL, V48, P174, DOI 10.1002/jlb.48.2.174; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LINDER M, 1992, NUTR BIOCH METABOLIS, P98; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; McMillen TS, 2005, CIRCULATION, V111, P2798, DOI 10.1161/CIRCULATIONAHA.104.516278; Michishita E, 2002, EXP GERONTOL, V37, P885, DOI 10.1016/S0531-5565(02)00033-5; Michishita E, 2002, BIOSCI BIOTECH BIOCH, V66, P877, DOI 10.1271/bbb.66.877; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MORRIS SM, 1993, MUTAT RES, V297, P39, DOI 10.1016/0165-1110(93)90006-9; MORRIS SM, 1991, MUTAT RES, V258, P161, DOI 10.1016/0165-1110(91)90007-I; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Nikpoor B, 2001, AM HEART J, V142, P336, DOI 10.1067/mhj.2001.116769; O'Neill J P, 1984, Basic Life Sci, V29 Pt A, P59; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; ONEILL JP, 1983, MUTAT RES, V109, P259, DOI 10.1016/0027-5107(83)90051-9; PAL BC, 1981, MUTAT RES, V91, P395, DOI 10.1016/0165-7992(81)90021-X; Pennathur S, 2004, J BIOL CHEM, V279, P42977, DOI 10.1074/jbc.M406762200; Pennathur S, 2001, J CLIN INVEST, V107, P853, DOI 10.1172/JCI11194; Peskin AV, 2001, FREE RADICAL BIO MED, V30, P572, DOI 10.1016/S0891-5849(00)00506-2; Prutz WA, 2001, ARCH BIOCHEM BIOPHYS, V393, P297, DOI 10.1006/abbi.2001.2503; Prutz WA, 1998, ARCH BIOCHEM BIOPHYS, V357, P265, DOI 10.1006/abbi.1998.0822; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; REDDY VY, 1994, J BIOL CHEM, V269, P4683; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; SHECHTER Y, 1975, BIOCHEMISTRY-US, V14, P4497, DOI 10.1021/bi00691a025; Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Suzuki T, 2002, NUCLEIC ACIDS RES, V30, P2555, DOI 10.1093/nar/30.11.2555; Suzuki T, 2002, FEBS LETT, V516, P67, DOI 10.1016/S0014-5793(02)02503-6; TAPSCOTT SJ, 1989, SCIENCE, V245, P532, DOI 10.1126/science.2547249; Thomas E L, 1986, Methods Enzymol, V132, P569; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Winterbourn CC, 2004, JPN J INFECT DIS, V57, pS31; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Wu Xifeng, 2003, Methods Mol Med, V75, P121; YU H, 1993, J BIOL CHEM, V268, P15935; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	93	77	81	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3096	3104		10.1074/jbc.M509236200	http://dx.doi.org/10.1074/jbc.M509236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326702	hybrid			2022-12-27	WOS:000235128200012
J	Helton, ES; Zhu, JH; Chen, XB				Helton, ES; Zhu, JH; Chen, XB			The unique NH2-terminally deleted (Delta N) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the Delta N variant of p63	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 TARGET GENES; DIFFERENTIAL REGULATION; FUNCTIONAL DOMAINS; GROWTH SUPPRESSION; INDUCED APOPTOSIS; DNA-DAMAGE; P73; PROTEIN; EXPRESSION; CANCER	p63, a member of the p53 family of transcription factors, is known to be involved in epithelial development. However, its role in tumorigenesis is unclear. Contributing to this uncertainty, the TP63 locus can express multiple gene products from two different promoters. Utilization of the upstream promoter results in expression of the TAp63 variant with an activation domain similar to p53. In contrast, the NH2-terminally deleted (Delta N) p63 variant, transcribed from a cryptic promoter in intron 3, lacks such an activation domain. Thus, the TAp63 and Delta Np63 variants possess a wide ranging ability to up-regulate p53 target genes. Consequentially, the disparity in transactivation potential between p63 variants has given rise to the hypothesis that the Delta Np63 variant can serve as oncoprotein by opposing the activity of the TAp63 variant and p53. However, recent studies have revealed a transcriptional activity for Delta Np63. This study was undertaken to address the transcriptional activity of the Delta Np63 variant. Here, we showed that all NH2-terminally deleted p63 isoforms retain a potential in transactivation and growth suppression. Interestingly, Delta Np63 beta possesses a remarkable ability to suppress cell proliferation and transactivate target genes, which is consistently higher than that seen with Delta Np63 alpha. In contrast, Delta Np63 gamma has a weak or undetectable activity dependent upon the cell lines used. We also demonstrate that an intact DNA-binding domain is required for Delta Np63 function. In addition, we found that the novel activation domain for the Delta Np63 variant is composed of the 14 unique Delta N residues along with the adjacent region, including a PXXP motif. Finally, we demonstrated that a PPXY motif shared by Delta Np63 alpha and Delta Np63 beta is required for optimal transactivation of target gene promoters, suggesting that the PPXY motif is requisite for Delta Np63 function.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu			NCI NIH HHS [R01 CA102188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amiel J, 2001, EUR J HUM GENET, V9, P642, DOI 10.1038/sj.ejhg.5200676; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chen XB, 2003, CANCER BIOL THER, V2, P55; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Harmes DC, 2003, ONCOGENE, V22, P7607, DOI 10.1038/sj.onc.1207129; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Koga F, 2003, CLIN CANCER RES, V9, P5501; Liefer KM, 2000, CANCER RES, V60, P4016; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; Liu G, 2003, J BIOL CHEM, V278, P17557, DOI 10.1074/jbc.M210696200; Massion PP, 2003, CANCER RES, V63, P7113; Miyazaki K, 2003, BIOCHEM BIOPH RES CO, V308, P106, DOI 10.1016/S0006-291X(03)01347-0; Nozell S, 2003, ONCOGENE, V22, P4333, DOI 10.1038/sj.onc.1206470; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shimada A, 1999, CANCER RES, V59, P2781; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; Wang Xiaojuan, 2002, Breast Cancer, V9, P216, DOI 10.1007/BF02967592; Wu GJ, 2005, CANCER RES, V65, P758; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	42	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2533	2542		10.1074/jbc.M507964200	http://dx.doi.org/10.1074/jbc.M507964200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319057	hybrid			2022-12-27	WOS:000234931800016
J	Kurschat, P; Bielenberg, D; Rossignol-Tallandier, M; Stahl, A; Klagsbrun, M				Kurschat, P; Bielenberg, D; Rossignol-Tallandier, M; Stahl, A; Klagsbrun, M			Neuron restrictive silencer factor NRSF/REST is a transcriptional repressor of neuropilin-1 and diminishes the ability of semaphorin 3A to inhibit keratinocyte migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TARGET GENES; HISTONE DEACETYLASE; IN-VIVO; VESSEL DEVELOPMENT; AXON GUIDANCE; TUMOR-CELLS; EXPRESSION; RECEPTORS; ANGIOGENESIS	Neuropilin-1 (NRP1) is expressed by endothelial cells and neurons and serves as a receptor for both vascular endothelial growth factor (VEGF), an angiogenesis factor, and semaphorin 3A (Sema3A), a mediator of axonal guidance. We show here that NRP1 is also expressed in keratinocytes in vitro and in vivo. However, nothing has been reported about the regulation or function of keratinocyte NRP1. Using NRP1 promoter constructs in HaCaT cells, a keratinocyte cell line, we could demonstrate that a neuron restrictive silencer element (NRSE) was implicated in transcriptional repression of the NRP1 gene. Electrophoretic mobility shift assays demonstrated that the neuron restrictive silencer factor (NRSF) binds to NRSE. Overexpression of NRSF in HaCaT cells decreased NRP1 RNA and protein, whereas a dominant negative NRSF increased NRP1. Furthermore, the histone deacetylase inhibitor trichostatin A, an inhibitor of NRSF silencing activity, also increased NRP1 levels. NRP2 expression was not affected. Epidermal growth factor (EGF) and heparin-binding EGF-like growth factor (HB-EGF) strongly up-regulated NRP1 expression, concomitant with downregulation of NRSF. Other keratinocyte mitogens such as keratinocyte growth factor (KGF) had no effect. To address function, HaCaT cells were exposed to two NRP1 ligands, VEGF(165) and Sema3A. Neither had an effect on proliferation, whereas Sema3A, but not VEGF(165), inhibited cell migration. Down-regulation of NRP1 by NRSF overexpression reduced Sema3A activity. It was concluded that NRSF is a transcription factor that silences NRP1 expression and thereby diminishes the Sema3A mediated inhibition of HaCaT keratinocyte migration.	Childrens Hosp, Vasc Biol Program, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Klagsbrun, M (corresponding author), Childrens Hosp, Vasc Biol Program, Dept Pathol, Karp Bldg 12210,300 Longwood Ave, Boston, MA 02115 USA.	michael.klagsbrun@childrens.harvard.edu			NCI NIH HHS [CA37392, CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037392, R01CA037392, R56CA037392, P01CA045548] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagri A, 2002, ADV EXP MED BIOL, V515, P13; BISMUTH G, 2002, SCI STKE, pRE4; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chen CY, 2005, WORLD J SURG, V29, P271, DOI 10.1007/s00268-004-7818-1; Chen ZF, 1998, NAT GENET, V20, P136, DOI 10.1038/2431; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Goishi K, 2004, CURR TOP DEV BIOL, V62, P127; Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416; He Zhigang, 2002, Sci STKE, V2002, pre1, DOI 10.1126/stke.2002.119.re1; Herzog Y, 2001, MECH DEVELOP, V109, P115, DOI 10.1016/S0925-4773(01)00518-4; Hong YK, 2002, DEV DYNAM, V225, P351, DOI 10.1002/dvdy.10163; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Jones FS, 1999, BIOESSAYS, V21, P372, DOI 10.1002/(SICI)1521-1878(199905)21:5<372::AID-BIES3>3.0.CO;2-3; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Klagsbrun M, 2002, ADV EXP MED BIOL, V515, P33; Kuwahara K, 2003, EMBO J, V22, P6310, DOI 10.1093/emboj/cdg601; Kwei S, 2004, AM J PATHOL, V164, P81, DOI 10.1016/S0002-9440(10)63099-4; le Noble F, 2004, DEVELOPMENT, V131, P361, DOI 10.1242/dev.00929; Lohela M, 2003, THROMB HAEMOSTASIS, V90, P167, DOI 10.1160/TH03-04-0200; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Miao HQ, 2000, FASEB J, V14, P2532, DOI 10.1096/fj.00-0250com; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Mukouyama YS, 2005, DEVELOPMENT, V132, P941, DOI 10.1242/dev.01675; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Neufeld G, 2002, TRENDS CARDIOVAS MED, V12, P13, DOI 10.1016/S1050-1738(01)00140-2; Neufeld G, 2005, FRONT BIOSCI-LANDMRK, V10, P751, DOI 10.2741/1569; Neufeld G, 2002, ADV EXP MED BIOL, V515, P81; Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8; PAYA CV, 1992, P NATL ACAD SCI USA, V89, P7826, DOI 10.1073/pnas.89.16.7826; Puschel AW, 2002, ADV EXP MED BIOL, V515, P71; Rossignol M, 2003, J CELL BIOCHEM, V88, P744, DOI 10.1002/jcb.10384; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Shimojo M, 2001, J BIOL CHEM, V276, P13121, DOI 10.1074/jbc.M011193200; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Su XH, 2004, MOL CELL BIOL, V24, P8018, DOI 10.1128/MCB.24.18.8018-8025.2004; Watanabe D, 2004, AM J PATHOL, V164, P1827, DOI 10.1016/S0002-9440(10)63741-8; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Woodside KJ, 2003, AM J SURG, V186, P561, DOI 10.1016/j.amjsurg.2003.07.023; Yoo JY, 2001, BIOCHEM BIOPH RES CO, V283, P928, DOI 10.1006/bbrc.2001.4857; Yoshida M, 2003, CURR MED CHEM, V10, P2351, DOI 10.2174/0929867033456602; You LR, 2005, NATURE, V435, P98, DOI 10.1038/nature03511; Yuan L, 2002, DEVELOPMENT, V129, P4797	48	55	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2721	2729		10.1074/jbc.M507860200	http://dx.doi.org/10.1074/jbc.M507860200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330548	hybrid			2022-12-27	WOS:000234931800038
J	Christmas, P; Tolentino, K; Primo, V; Berry, KZ; Murphy, RC; Chen, M; Lee, DM; Soberman, RJ				Christmas, P; Tolentino, K; Primo, V; Berry, KZ; Murphy, RC; Chen, M; Lee, DM; Soberman, RJ			Cytochrome P-4504F18 is the leukotriene B-4 omega-1/omega-2 hydroxylase in mouse polymorphonuclear leukocytes - Identification as the functional orthologue of human polymorphonuclear leukocyte CYP4F3A in the down-regulation of responses to LTB4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; DENDRITIC CELLS; ARACHIDONIC-ACID; B-4 RECEPTOR; 5-LIPOXYGENASE EXPRESSION; DIHYDRO METABOLITES; ALLOGRAFT-REJECTION; BIOLOGICAL-ACTIVITY; OMEGA-OXIDATION; HUMAN MONOCYTE	Leukotriene B-4 (LTB4) is a potent chemoattractant for polymorphonuclear leukocytes (PMN) and other cells. Human PMN inactivate LTB4 by omega-oxidation catalyzed by cytochrome P-450 (CYP) 4F3A. The contribution of the enzymatic inactivation of LTB4 by CYP4Fs to down-regulating functional responses of cells to LTB4 is unknown. To elucidate the role of CYP4F-mediated inactivation of LTB4 in terminating the responses of PMN to LTB4 and to identify a target for future genetic studies in mice, we have identified the enzyme that catalyzes the omega-1 and omega-2 oxidation of LTB4 in mouse myeloid cells as CYP4F18. As determined by mass spectrometry, this enzyme catalyzes the conversion of LTB4 to 19-OH LTB4 and to a lesser extent 18-OH LTB4. Inhibition of CYP4F18 resulted in a marked increase in calcium flux and a 220% increase in the chemotactic response of mouse PMN to LTB4. CYP4F18 expression was induced in bone marrow-derived dendritic cells by bacterial lipopolysaccharide, a ligand for TLR4, and by poly( I center dot C), a ligand for TLR3. However, when bone marrow-derived myeloid dendritic cells trafficked to popliteal lymph nodes from paw pads, the expression of CYP4F18 was down-regulated. The results identify CYP4F18 as a critical protein in the regulation of LTB4 metabolism and functional responses in mouse PMN and identify it as the functional orthologue of human PMN CYP4F3A.	Massachusetts Gen Hosp E, Renal Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp E, Dept Med, Charlestown, MA 02129 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Aurora, CO 80045 USA; Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Brigham & Women's Hospital	Soberman, RJ (corresponding author), Massachusetts Gen Hosp E, Renal Unit, Bldg 149,Navy Yard,13th St, Charlestown, MA 02129 USA.	soberman@helix.mgh.harvard.edu			NHLBI NIH HHS [5R01 HL 025785, R01 HL 25785, 5R01 HL 068256-03] Funding Source: Medline; NIAID NIH HHS [R01 AI 059746-02] Funding Source: Medline; NIAMS NIH HHS [K08 AR 02214-04] Funding Source: Medline; NIDDK NIH HHS [R03 DK 067940, DK 59991] Funding Source: Medline; NIGMS NIH HHS [GM 61823] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068256, R01HL025785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI059746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK067940, K01DK059991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061823] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; Allen DL, 1996, J PHARMACOL EXP THER, V277, P341; Baumeister B, 1996, J CLIN GASTROENTEROL, V22, P117, DOI 10.1097/00004836-199603000-00009; Berry KAZ, 2003, J BIOL CHEM, V278, P24449, DOI 10.1074/jbc.M300856200; Boerr LAR, 1996, EUR J GASTROEN HEPAT, V8, P57, DOI 10.1097/00042737-199601000-00011; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Byrum RS, 1999, J IMMUNOL, V163, P6810; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Christmas P, 1999, J BIOL CHEM, V274, P21191, DOI 10.1074/jbc.274.30.21191; Christmas P, 2003, J BIOL CHEM, V278, P25133, DOI 10.1074/jbc.M302106200; Christmas P, 2001, J BIOL CHEM, V276, P38166; Christopherson KW, 2004, SCIENCE, V305, P1000, DOI 10.1126/science.1097071; Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000; Chuang SS, 2004, J BIOL CHEM, V279, P6305, DOI 10.1074/jbc.M311830200; Cui XM, 2001, J PHARMACOL EXP THER, V296, P542; DELPRETE A, 2006, KEYST S EIC INFL CHR; FOEGH ML, 1985, ADV PROSTAG THROMB L, V13, P209; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FRETLAND D, 1995, GUT, V37, P702, DOI 10.1136/gut.37.5.702; Gao JM, 2003, J BIOL CHEM, V278, P37902, DOI 10.1074/jbc.M306061200; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Gladue RP, 1996, J EXP MED, V183, P1893, DOI 10.1084/jem.183.4.1893; Goulet JL, 2001, J IMMUNOL, V167, P6631, DOI 10.4049/jimmunol.167.11.6631; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; Harizi H, 2003, J IMMUNOL, V170, P139, DOI 10.4049/jimmunol.170.1.139; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; JUBIZ W, 1982, J BIOL CHEM, V257, P6106; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; Kruger J, 2000, J IMMUNOL, V165, P5847, DOI 10.4049/jimmunol.165.10.5847; KUMLIN M, 1990, BIOCHEM BIOPH RES CO, V170, P23, DOI 10.1016/0006-291X(90)91235-K; Lambeir AM, 2001, J BIOL CHEM, V276, P29839, DOI 10.1074/jbc.M103106200; Lasker JM, 2000, J BIOL CHEM, V275, P4118, DOI 10.1074/jbc.275.6.4118; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lowell CA, 1998, P NATL ACAD SCI USA, V95, P7580, DOI 10.1073/pnas.95.13.7580; Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; MIGLIORISI G, 1987, AM J PATHOL, V127, P157; MUERHOFF AS, 1989, J BIOL CHEM, V264, P749; MURPHY RC, 1993, HDB LIPID RES, V7, P131; NUMAO T, 1992, J IMMUNOL, V149, P3309; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; Parmentier JH, 2001, J BIOL CHEM, V276, P15704, DOI 10.1074/jbc.M011473200; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; POWELL WS, 1990, J BIOL CHEM, V265, P9131; POWELL WS, 1989, J BIOL CHEM, V264, P5364; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; RAHMAN MA, 1988, J CLIN INVEST, V81, P1945, DOI 10.1172/JCI113542; SCHMIDT C, 1995, EUR J GASTROEN HEPAT, V7, P865; SHAK S, 1985, J BIOL CHEM, V260, P3023; SHAK S, 1984, J BIOL CHEM, V259, P181; Soberman RJ, 2003, J CLIN INVEST, V111, P1107, DOI 10.1172/JCI200318338; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; SOBERMAN RJ, 1987, J BIOL CHEM, V262, P12421; Spanbroek R, 2000, BLOOD, V96, P3857, DOI 10.1182/blood.V96.12.3857.h8003857_3857_3865; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Struyf S, 1999, J IMMUNOL, V162, P4903; Subbarao K, 2004, ARTERIOSCL THROM VAS, V24, P369, DOI 10.1161/01.ATV.0000110503.16605.15; TERNOWITZ T, 1987, ACTA PATH MICRO IM C, V95, P47; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; Weringer EJ, 1999, TRANSPLANTATION, V67, P808, DOI 10.1097/00007890-199903270-00005; Wheelan P, 1996, J AM SOC MASS SPECTR, V7, P129, DOI 10.1016/1044-0305(95)00629-X; YARED A, 1991, J AM SOC NEPHROL, V2, P45; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 2001, ARCH BIOCHEM BIOPHYS, V385, P231, DOI 10.1006/abbi.2000.2168; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOKOMIZO T, 2005, KEYST S BIOACT LIP L; [No title captured]	72	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7189	7196		10.1074/jbc.M513101200	http://dx.doi.org/10.1074/jbc.M513101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16380383	hybrid			2022-12-27	WOS:000236030900035
J	Vincent, P; Priceputu, E; Kay, D; Saksela, K; Jolicoeur, P; Hanna, Z				Vincent, P; Priceputu, E; Kay, D; Saksela, K; Jolicoeur, P; Hanna, Z			Activation of p21-activated kinase 2 and its association with Nef are conserved in murine cells but are not sufficient to induce an AIDS-like disease in CD4C/HIV transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 NEF; SIMIAN-IMMUNODEFICIENCY-VIRUS; CELLULAR SERINE/THREONINE KINASE; CD4 DOWN-REGULATION; LONG-TERM SURVIVOR; PAK-RELATED KINASE; P85 BETA-PIX; HIV-1 NEF; T-CELLS; PROTEIN-KINASE	A well conserved feature of human immunodeficiency virus, type 1 (HIV-1) and simian immunodeficiency virus (SIV) Nef is the interaction with and activation of the human p21-activated kinase 2 (PAK2). The conservation of this interaction in other species and its significance for Nef pathogenesis in vivo are poorly documented. In the present study, we measured these parameters in Nef-expressing thymocytes, macrophages, and dendritic cells of a transgenic (Tg) mouse model of AIDS (CD4C/HIV). We found that Nef binds to and activates PAK2, but not PAK1 and - 3, in these three cell subsets. Nef associates with only a small fraction of PAK2. The Nef-PAK2 complex also comprises beta-PIX-COOL. The impact of the Nef-PAK2 association on disease development was also analyzed in Tg mice expressing 10 different Nef mutant alleles. CD4C/HIV Tg mice expressing Nef alleles defective in Nef-PAK2 association (P69A, P72A/P75A, R105A/R106A, Delta 56 - 66, or G2A (myristoylation site)) failed to develop disease of the non-lymphoid organs ( kidneys and lungs). Among these, only Tg mice expressing Nef(P69A) and Nef(G2A) showed some depletion of CD4(+) T cells, although a down-regulation of the CD4 surface protein was documented in all these Tg lines, except those expressing Nef Delta 56-66. Among other Tg mice expressing Nef mutants having conserved the Nef-PAK2 association (RD35AA, D174K, P147A/P150A, Delta 8-17, and Delta 25-65), only Tg mice expressing Nef(Delta 8-17) develop kidney and lung diseases, but all showed partial CD4(+) T cell depletion despite some being defective for CD4 down-regulation ( RD35AA and D174K). Therefore, Nef can activate murine PAK2 and associate with a small fraction of it, as inhuman cells. Such activation and binding of PAK2 is clearly not sufficient but may be required to induce amultiorgan AIDS-like disease in Tg mice.	Clin Res Inst Montreal, Dept Mol Biol, Montreal, PQ H2W 1R7, Canada; Univ Helsinki, Haartman Inst, Dept Virol, FIN-0014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-0014 Helsinki, Finland; Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, FIN-33014 Tampere, Finland; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University; Tampere University Hospital; Universite de Montreal; Universite de Montreal; McGill University	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Dept Mol Biol, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	jolicop@ircm.qc.ca; hannaz@ircm.umontreal.ca		Saksela, Kalle/0000-0003-0827-122X				Aiken C, 1996, VIROLOGY, V217, P293, DOI 10.1006/viro.1996.0116; Alexander L, 2000, J VIROL, V74, P4361, DOI 10.1128/JVI.74.9.4361-4376.2000; Arora VK, 2000, J VIROL, V74, P11081, DOI 10.1128/JVI.74.23.11081-11087.2000; Baba TW, 1999, NAT MED, V5, P194, DOI 10.1038/5557; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Bell I, 1998, J GEN VIROL, V79, P2717, DOI 10.1099/0022-1317-79-11-2717; BODEUS M, 1995, J GEN VIROL, V76, P1337, DOI 10.1099/0022-1317-76-6-1337; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown A, 1999, J VIROL, V73, P9899, DOI 10.1128/JVI.73.12.9899-9907.1999; Carl S, 2000, J VIROL, V74, P4155, DOI 10.1128/JVI.74.9.4155-4164.2000; Cheng H, 1999, VIROLOGY, V264, P5, DOI 10.1006/viro.1999.9937; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Cullen BR, 1996, CURR BIOL, V6, P1557, DOI 10.1016/S0960-9822(02)70770-7; CULLEN BR, 1994, VIROLOGY, V205, P1, DOI 10.1006/viro.1994.1613; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Fackler OT, 2000, MOL CELL BIOL, V20, P2619, DOI 10.1128/MCB.20.7.2619-2627.2000; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Foster JL, 2001, J VIROL, V75, P1672, DOI 10.1128/JVI.75.4.1672-1680.2001; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Geffin R, 2000, AIDS RES HUM RETROV, V16, P1855, DOI 10.1089/08892220050195810; GOLDSMITH MA, 1995, J VIROL, V69, P4112, DOI 10.1128/JVI.69.7.4112-4121.1995; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; Guatelli JC, 1997, RES VIROLOGY, V148, P34, DOI 10.1016/S0923-2516(97)81910-3; Hanna Z, 2004, VIROLOGY, V327, P273, DOI 10.1016/j.virol.2004.06.028; Hanna Z, 2001, J VIROL, V75, P9378, DOI 10.1128/JVI.75.19.9378-9392.2001; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; HANNA Z, 2006, IN PRESS VIROLOGY; Harris M, 1996, J GEN VIROL, V77, P2379, DOI 10.1099/0022-1317-77-10-2379; Harris M, 1999, CURR BIOL, V9, pR459, DOI 10.1016/S0960-9822(99)80282-6; Hua J, 1997, VIROLOGY, V231, P231, DOI 10.1006/viro.1997.8517; HUANG M, 1995, J VIROL, V69, P60, DOI 10.1128/JVI.69.1.60-68.1995; Huang ZD, 2004, MOL CELL BIOL, V24, P1582, DOI 10.1128/MCB.24.4.1582-1594.2004; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Keppler OT, 2005, J VIROL, V79, P1655, DOI 10.1128/JVI.79.3.1655-1665.2005; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Khan IH, 1998, J VIROL, V72, P5820, DOI 10.1128/JVI.72.7.5820-5830.1998; Kirchhoff F, 2004, J VIROL, V78, P6864, DOI 10.1128/JVI.78.13.6864-6874.2004; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; Krautkramer E, 2004, J VIROL, V78, P4085, DOI 10.1128/JVI.78.8.4085-4097.2004; Lafrate AJ, 2000, J VIROL, V74, P9836, DOI 10.1128/JVI.74.21.9836-9844.2000; Lama J, 1999, CURR BIOL, V9, P622, DOI 10.1016/S0960-9822(99)80284-X; Lang SM, 1997, NAT MED, V3, P860, DOI 10.1038/nm0897-860; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LeGall S, 1997, RES VIROLOGY, V148, P43, DOI 10.1016/S0923-2516(97)81912-7; Liu LX, 2000, J VIROL, V74, P5310, DOI 10.1128/JVI.74.11.5310-5319.2000; Luo TC, 1997, J VIROL, V71, P9524, DOI 10.1128/JVI.71.12.9524-9530.1997; Luo TC, 1996, J VIROL, V70, P6493, DOI 10.1128/JVI.70.9.6493-6496.1996; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; Manninen A, 1998, VIROLOGY, V250, P273, DOI 10.1006/viro.1998.9381; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mariani R, 1996, J VIROL, V70, P7752, DOI 10.1128/JVI.70.11.7752-7764.1996; Marsh JW, 1999, ARCH BIOCHEM BIOPHYS, V365, P192, DOI 10.1006/abbi.1999.1208; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NIEDERMAN TMJ, 1992, J VIROL, V66, P6213, DOI 10.1128/JVI.66.10.6213-6219.1992; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; Peter F, 1998, IMMUNITY, V9, P433, DOI 10.1016/S1074-7613(00)80626-3; Piguet V, 1999, IMMUNOL REV, V168, P51, DOI 10.1111/j.1600-065X.1999.tb01282.x; Priceputu E, 2005, J VIROL, V79, P6377, DOI 10.1128/JVI.79.10.6377-6391.2005; Pulkkinen K, 2004, J VIROL, V78, P12773, DOI 10.1128/JVI.78.23.12773-12780.2004; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Renkema GH, 1999, CURR BIOL, V9, P1407, DOI 10.1016/S0960-9822(00)80086-X; Renkema GH, 2001, J VIROL, V75, P2154, DOI 10.1128/JVI.75.5.2154-2160.2001; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Salvi R, 1998, J VIROL, V72, P3646, DOI 10.1128/JVI.72.5.3646-3657.1998; Sawai ET, 1997, RES VIROLOGY, V148, P47, DOI 10.1016/S0923-2516(97)81913-9; SAWAI ET, 1995, J BIOL CHEM, V270, P15307, DOI 10.1074/jbc.270.25.15307; Sawai ET, 1996, CURR BIOL, V6, P1519, DOI 10.1016/S0960-9822(96)00757-9; Sawai ET, 2000, J VIROL, V74, P2038, DOI 10.1128/JVI.74.4.2038-2045.2000; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Shin EY, 2004, J BIOL CHEM, V279, P1994, DOI 10.1074/jbc.M307330200; Shin EY, 2002, J BIOL CHEM, V277, P44417, DOI 10.1074/jbc.M203754200; Simard MC, 2002, J VIROL, V76, P3981, DOI 10.1128/JVI.76.8.3981-3995.2002; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; Skowronski J, 1999, COLD SPRING HARB SYM, V64, P453, DOI 10.1101/sqb.1999.64.453; Stoddart CA, 2003, J VIROL, V77, P2124, DOI 10.1128/JVI.77.3.2124-2133.2003; Swigut T, 2001, EMBO J, V20, P1593, DOI 10.1093/emboj/20.7.1593; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; Weng XD, 2004, J VIROL, V78, P5244, DOI 10.1128/JVI.78.10.5244-5257.2004; Wiskerchen M, 1996, VIROLOGY, V224, P292, DOI 10.1006/viro.1996.0531; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32	93	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6940	6954		10.1074/jbc.M512710200	http://dx.doi.org/10.1074/jbc.M512710200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407193	hybrid			2022-12-27	WOS:000236030900006
J	Bedner, P; Niessen, H; Odermatt, B; Kretz, M; Willecke, K; Harz, H				Bedner, P; Niessen, H; Odermatt, B; Kretz, M; Willecke, K; Harz, H			Selective permeability of different connexin channels to the second messenger cyclic AMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-JUNCTION CHANNELS; FUNCTIONAL EXPRESSION; MOUSE; CAMP; GENES; CELLS; SIZE	Gap junctions are intercellular conduits that are formed in vertebrates by connexin proteins and allow diffusion exchange of intracellular ions and small molecules. At least 20 different connexin genes in the human and mouse genome are cell-type specifically expressed with overlapping expression patterns. A possible explanation for this diversity could be different permeability of biologically important molecules, such as second messenger molecules. We have recently demonstrated that cyclic nucleotide-gated channels can be used to quantify gap junction-mediated diffusion of cyclic AMP. Using this method we have compared the relative permeability of gap junction channels composed of connexin 26, 32, 36, 43, 45, or 47 proteins toward the second messenger cAMP. Here we show that cAMP permeates through the investigated connexin channels with up to 30-fold different efficacy. Our results suggest that intercellular cAMP signaling in different cell types can be affected by the connexin expression pattern.	Univ Bonn, Inst Genet, Abt Mol Genet, D-53117 Bonn, Germany; Univ Munich, BioImaging Zentrum, D-82152 Martinsried, Germany	University of Bonn; University of Munich	Willecke, K (corresponding author), Univ Bonn, Inst Genet, Abt Mol Genet, Romerstr 164, D-53117 Bonn, Germany.	genetik@uni-bonn.de	Kretz, Markus/ABB-8490-2021					ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; Bedner P, 2003, EXP CELL RES, V291, P25, DOI 10.1016/S0014-4827(03)00323-9; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bukauskas FF, 2002, J GEN PHYSIOL, V119, P171, DOI 10.1085/jgp.119.2.171; Bukauskas FF, 2002, P NATL ACAD SCI USA, V99, P7113, DOI 10.1073/pnas.032062099; BUKAUSKAS FF, 1992, EXP PHYSIOL, V77, P903, DOI 10.1113/expphysiol.1992.sp003657; BUKAUSKAS FF, 1995, PFLUG ARCH EUR J PHY, V429, P870, DOI 10.1007/BF00374812; BUTTERWECK A, 1994, J MEMBRANE BIOL, V141, P247; Cao FL, 1998, J CELL SCI, V111, P31; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; Dremier S, 2003, FEBS LETT, V546, P103, DOI 10.1016/S0014-5793(03)00561-1; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; Goldberg GS, 2002, J BIOL CHEM, V277, P36725, DOI 10.1074/jbc.M109797200; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Kam Y, 1998, BBA-BIOMEMBRANES, V1372, P384, DOI 10.1016/S0005-2736(98)00075-3; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; LAWRENCE TS, 1978, NATURE, V272, P501, DOI 10.1038/272501a0; Messler P, 1996, J NEUROSCI METH, V69, P137, DOI 10.1016/S0165-0270(96)00032-5; MUNCK S, 2004, EUR J NEUROSCI, V9, P191; MURRAY SA, 1984, J CELL BIOL, V98, P1710, DOI 10.1083/jcb.98.5.1710; Nicholson BJ, 2000, BRAZ J MED BIOL RES, V33, P369, DOI 10.1590/S0100-879X2000000400002; Niessen H, 2000, J CELL SCI, V113, P1365; Nitsche JM, 2004, BIOPHYS J, V86, P2058, DOI 10.1016/S0006-3495(04)74267-8; Odermatt B, 2003, J NEUROSCI, V23, P4549; Qu Y, 2002, P NATL ACAD SCI USA, V99, P697, DOI 10.1073/pnas.022324499; Roger PP, 1995, VITAM HORM, V51, P59, DOI 10.1016/S0083-6729(08)61038-9; Sohl G, 2005, NAT REV NEUROSCI, V6, P191, DOI 10.1038/nrn1627; Sohl G, 2003, CELL COMMUN ADHES, V10, P173, DOI 10.1080/15419060390262877; Teubner B, 2000, J MEMBRANE BIOL, V176, P249, DOI 10.1007/s002320001094; Teubner B, 2001, J NEUROSCI, V21, P1117; TRAUB O, 1994, EUR J CELL BIOL, V64, P101; TSIEN RW, 1974, J PHYSIOL-LONDON, V242, pP95; Valiunas V, 1999, J PHYSIOL-LONDON, V519, P631, DOI 10.1111/j.1469-7793.1999.0631n.x; Van Der Giessen RS, 2006, J COMP NEUROL, V495, P173, DOI 10.1002/cne.20873; VEENSTRA RD, 1995, CIRC RES, V77, P1156, DOI 10.1161/01.RES.77.6.1156; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Waschke J, 2005, AM J PHYSIOL-HEART C, V288, pH1296, DOI 10.1152/ajpheart.00687.2004; Waschke J, 2004, AM J PHYSIOL-HEART C, V287, pH2427, DOI 10.1152/ajpheart.00556.2004; Weber PA, 2004, BIOPHYS J, V87, P958, DOI 10.1529/biophysj.103.036350; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	44	80	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6673	6681		10.1074/jbc.M511235200	http://dx.doi.org/10.1074/jbc.M511235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16373337	hybrid			2022-12-27	WOS:000236030800064
J	Ramos, CRR; Oliveira, CLP; Torriani, IL; Oliveira, CC				Ramos, CRR; Oliveira, CLP; Torriani, IL; Oliveira, CC			The Pyrococcus exosome complex - Structural and functional characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEXAMERIC RING STRUCTURE; SMALL-ANGLE SCATTERING; X-RAY-SCATTERING; POLYNUCLEOTIDE PHOSPHORYLASE; RNA-BINDING; RIBOSOMAL-RNA; BIOLOGICAL MACROMOLECULES; ARCHAEAL EXOSOME; YEAST EXOSOME; KH DOMAINS	The exosome is a conserved eukaryotic enzymatic complex that plays an essential role in many pathways of RNA processing and degradation. Here, we describe the structural characterization of the predicted archaeal exosome in solution using small angle x-ray scattering. The structure model calculated from the small angle x-ray scattering pattern provides an indication of the existence of a disk-shaped structure, corresponding to the "RNases PH ring" complex formed by the proteins aRrp41 and aRrp42. The RNases PH ring complex corresponds to the core of the exosome, binds RNA, and has phosphorolytic and polymerization activities. Three additional molecules of the RNA-binding protein aRrp4 are attached to the core as extended and flexible arms that may direct the substrates to the active sites of the exosome. In the presence of aRrp4, the activity of the core complex is enhanced, suggesting a regulatory role for this protein. The results shown here also indicate the participation of the exosome in RNA metabolism in Archaea, as was established in Eukarya.	Univ Sao Paulo, Inst Chem, Dept Biochem, BR-05508900 Sao Paulo, Brazil; Brazilian Synchrotron Light Lab, BR-13084971 Campinas, SP, Brazil; Univ Estadual Campinas, Inst Phys, BR-13084971 Campinas, SP, Brazil	Universidade de Sao Paulo; Laboratorio Nacional de Luz Sincrotron (LNLS); Universidade Estadual de Campinas	Oliveira, CC (corresponding author), Univ Sao Paulo, Inst Chem, Dept Biochem, Av Prof Lineu Prestes 748, BR-05508900 Sao Paulo, Brazil.	ccoliv@iq.usp.br	Oliveira, Cristiano L P/B-4403-2008; Oliveira, Carla C/F-2323-2011; Ramos, Celso R. R./H-6349-2015; Torriani, Iris L/E-5686-2010	Oliveira, Cristiano L P/0000-0002-3426-6507; Oliveira, Carla C/0000-0002-1098-9241; Ramos, Celso R. R./0000-0002-5760-8661; 				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Andrulis ED, 2002, NATURE, V420, P837, DOI 10.1038/nature01181; Cantor C. R, 1980, BIOPHYSICAL CHEM 2, P591; Cavalcanti LP, 2004, REV SCI INSTRUM, V75, P4541, DOI 10.1063/1.1804956; Chekanova JA, 2000, J BIOL CHEM, V275, P33158, DOI 10.1074/jbc.M005493200; Chekanova JA, 2002, NUCLEIC ACIDS RES, V30, P695, DOI 10.1093/nar/30.3.695; Choi JM, 2004, J BIOL CHEM, V279, P755, DOI 10.1074/jbc.M309628200; de la Torre JG, 2000, BIOPHYS J, V78, P719, DOI 10.1016/S0006-3495(00)76630-6; Estevez AM, 2003, J BIOL CHEM, V278, P34943, DOI 10.1074/jbc.M305333200; Evguenieva-Hackenberg E, 2003, EMBO REP, V4, P889, DOI 10.1038/sj.embor.embor929; GABRIEL A, 1982, NUCL INSTRUM METHODS, V201, P223, DOI 10.1016/0167-5087(82)90031-X; GLATTER O, 1982, SMALL ANGLE XRAY SCA, P422; Harlow LS, 2004, PROTEIN SCI, V13, P668, DOI 10.1110/ps.03477004; Kellermann G, 1997, J APPL CRYSTALLOGR, V30, P880, DOI 10.1107/S0021889897001829; KLEE CB, 1969, J BIOL CHEM, V244, P2558; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Koonin EV, 2001, GENOME RES, V11, P240, DOI 10.1101/gr.162001; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lorentzen E, 2005, NAT STRUCT MOL BIOL, V12, P575, DOI 10.1038/nsmb952; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Oliveira CC, 2002, NUCLEIC ACIDS RES, V30, P4186, DOI 10.1093/nar/gkf545; OLIVEIRA CLP, 2003, 012003 LAB NAC LUZ S; Raijmakers R, 2004, EUR J CELL BIOL, V83, P175, DOI 10.1078/0171-9335-00385; Raijmakers R, 2002, J MOL BIOL, V323, P653, DOI 10.1016/S0022-2836(02)00947-6; Ramos CRR, 2004, BRAZ J MED BIOL RES, V37, P1103, DOI 10.1590/S0100-879X2004000800001; Regonesi ME, 2004, NUCLEIC ACIDS RES, V32, P1006, DOI 10.1093/nar/gkh268; RUSSNAK R, 1995, MOL CELL BIOL, V15, P1689; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Stickney LM, 2005, J BACTERIOL, V187, P7214, DOI 10.1128/JB.187.21.7214-7221.2005; SULEWSKI M, 1989, BIOCHEMISTRY-US, V28, P5855, DOI 10.1021/bi00440a023; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Symmons MF, 2002, TRENDS BIOCHEM SCI, V27, P11, DOI 10.1016/S0968-0004(01)01999-5; Symmons MF, 2000, STRUCTURE, V8, P1215, DOI 10.1016/S0969-2126(00)00521-9; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Worbs M, 2001, MOL CELL, V7, P1177, DOI 10.1016/S1097-2765(01)00262-3; [No title captured]	42	31	31	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6751	6759		10.1074/jbc.M512495200	http://dx.doi.org/10.1074/jbc.M512495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407194	hybrid			2022-12-27	WOS:000236030800073
J	Rosengren, KJ; Lin, F; Bathgate, RAD; Tregear, GW; Daly, NL; Wade, JD; Craik, DJ				Rosengren, KJ; Lin, F; Bathgate, RAD; Tregear, GW; Daly, NL; Wade, JD; Craik, DJ			Solution structure and novel insights into the determinants of the receptor specificity of human relaxin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND ISOMERIZATION; HUMAN INSULIN MUTANT; NUCLEUS INCERTUS; PEPTIDE FAMILY; H3 RELAXIN; LIGAND; FIELD; LGR8; IDENTIFICATION; ACTIVATION	Relaxin- 3 is the most recently discovered member of the relaxin family of peptide hormones. In contrast to relaxin- 1 and - 2, whose main functions are associated with pregnancy, relaxin- 3 is involved in neuropeptide signaling in the brain. Here, we report the solution structure of human relaxin- 3, the first structure of a relaxin family member to be solved by NMR methods. Overall, relaxin- 3 adopts an insulin- like fold, but the structure differs crucially from the crystal structure of human relaxin- 2 near the B- chain terminus. In particular, the B- chain C terminus folds back, allowing Trp(B27) to interact with the hydrophobic-core. This interaction partly blocks the conserved RXXXRXXI motif identified as a determinant for the interaction with the relaxin receptor LGR7 and may account for the lower affinity of relaxin- 3 relative to relaxin for this receptor. This structural feature is likely important for the activation of its endogenous receptor, GPCR135.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Melbourne, Howard Florey Inst, Melbourne, Vic 3010, Australia; Univ Kalmar, Dept Chem & Biomed Sci, SE-39281 Kalmar, Sweden	University of Queensland; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Linnaeus University; University of Kalmar	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	d.craik@imb.uq.edu.au	Craik, David/B-1695-2010; Daly, Norelle L/D-4302-2013; Rosengren, K. Johan/P-4450-2016; Bathgate, Ross/ABE-6471-2020	Craik, David/0000-0003-0007-6796; Daly, Norelle L/0000-0002-4697-6602; Rosengren, K. Johan/0000-0002-5007-8434; Bathgate, Ross/0000-0001-6301-861X; Wade, John/0000-0002-1352-6568				ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALSCHMIDT P, 1992, DIABETOLOGIA, V35, pA4; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; BLUNDELL TL, 1971, NATURE, V231, P506, DOI 10.1038/231506a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bullesbach EE, 2005, J BIOL CHEM, V280, P14586, DOI 10.1074/jbc.M414443200; Bullesbach EE, 1999, BIOCHEMISTRY-US, V38, P3073, DOI 10.1021/bi982687u; Burazin TCD, 2002, J NEUROCHEM, V82, P1553, DOI 10.1046/j.1471-4159.2002.01114.x; Clausen R, 2002, EUR J ENDOCRINOL, V147, P227, DOI 10.1530/eje.0.1470227; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DEREWENDA U, 1991, J MOL BIOL, V220, P425, DOI 10.1016/0022-2836(91)90022-X; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; Garber SL, 2001, KIDNEY INT, V59, P876, DOI 10.1046/j.1523-1755.2001.059003876.x; Goto M, 2001, J COMP NEUROL, V438, P86, DOI 10.1002/cne.1303; Grey MJ, 2003, J AM CHEM SOC, V125, P14324, DOI 10.1021/ja0367389; Higgins K A, 1988, Drug Des Deliv, V3, P159; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; HUDSON P, 1984, EMBO J, V3, P2333, DOI 10.1002/j.1460-2075.1984.tb02135.x; HUDSON P, 1983, NATURE, V301, P628, DOI 10.1038/301628a0; Jorgensen AMM, 1996, J MOL BIOL, V257, P684, DOI 10.1006/jmbi.1996.0194; Keller D, 2001, BIOCHEMISTRY-US, V40, P10732, DOI 10.1021/bi0108150; Kumagai J, 2002, J BIOL CHEM, V277, P31283, DOI 10.1074/jbc.C200398200; Lin F, 2004, J PEPT SCI, V10, P257, DOI 10.1002/psc.521; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Liu CL, 2005, J BIOL CHEM, V280, P292, DOI 10.1074/jbc.M409916200; Liu CL, 2003, J BIOL CHEM, V278, P50765, DOI 10.1074/jbc.M308996200; Liu CL, 2003, J BIOL CHEM, V278, P50754, DOI 10.1074/jbc.M308995200; McGowan BMC, 2005, ENDOCRINOLOGY, V146, P3295, DOI 10.1210/en.2004-1532; OTTING G, 1993, BIOCHEMISTRY-US, V32, P3571, DOI 10.1021/bi00065a008; Sherwood O. David, 1994, P861; SMITH GD, 1984, P NATL ACAD SCI-BIOL, V81, P7093, DOI 10.1073/pnas.81.22.7093; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; Tanaka M, 2005, EUR J NEUROSCI, V21, P1659, DOI 10.1111/j.1460-9568.2005.03980.x; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; Van Der Westhuizen ET, 2005, ANN NY ACAD SCI, V1041, P332, DOI 10.1196/annals.1282.053; Wilkins DK, 1999, BIOCHEMISTRY-US, V38, P16424, DOI 10.1021/bi991765q; Wilkinson TN, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-14; Williams EJ, 2001, GUT, V49, P577, DOI 10.1136/gut.49.4.577	40	75	78	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5845	5851		10.1074/jbc.M511210200	http://dx.doi.org/10.1074/jbc.M511210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16365033	hybrid			2022-12-27	WOS:000235568900064
J	Eckstein, TM; Chandrasekaran, S; Mahapatra, S; McNeil, MR; Chatterjee, D; Rithner, CD; Ryan, PW; Belisle, JT; Inamine, JM				Eckstein, TM; Chandrasekaran, S; Mahapatra, S; McNeil, MR; Chatterjee, D; Rithner, CD; Ryan, PW; Belisle, JT; Inamine, JM			A major cell wall lipopeptide of Mycobacterium avium subspecies paratuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPID SERODIAGNOSIS; SYNTHETASE; GLYCOPEPTIDOLIPIDS; ANTIGENS; ANTIBODY	Mycobacterium avium subspecies paratuberculosis (MAP), the causative agent of Johne disease in cattle and other ruminants, is proposed to be at least one of the causes of Crohn disease in humans. MAP and Mycobacterium avium subspecies avium, a closely related opportunistic environmental bacterium, share 95% of their genes and exhibit homologies of more than 99% between these genes. The identification of molecules specific for MAP is essential for understanding its pathogenicity and for development of useful diagnostic tools. The application of gas chromatography, mass spectrometry, and nuclear magnetic resonance led to the structural identification of a major cell wall lipopeptide of MAP, termed Para-LP-01, defined as C20 fatty acyl-D-Phe-N-Me-L-Val-L-Ile-L-Phe-L-Ala methyl ester. Variations of this lipopeptide with different fatty acyl moieties (C16 fatty acyl through C17, C18, C19, C21 to C22) were also identified. Besides the specificity of this lipopeptide for MAP, the presence of an N-Me-L-valine represents the first reported N-methylated amino acid within an immunogenic lipopeptide of mycobacteria. Sera from animals with Johne disease, but not sera from uninfected cattle, reacted with this lipopeptide, indicating potential biological importance.	Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; Colorado State Univ, Macromol Res Facil, Ft Collins, CO 80523 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University; Colorado State University	Inamine, JM (corresponding author), Colorado State Univ, Dept Microbiol Immunol & Pathol, 1682 Campus Delivery, Ft Collins, CO 80523 USA.	jinamine@colostate.edu	Belisle, John T/B-8944-2017; Mahapatra, Sebabrata/D-6033-2017; McNeil, Michael/G-3325-2019	Belisle, John T/0000-0002-2539-2798; 	NIAID NIH HHS [R01 AI-51283] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051283] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER M, 1965, BIOCHEM BIOPH RES CO, V18, P469, DOI 10.1016/0006-291X(65)90775-8; BARROW WW, 1982, INFECT IMMUN, V36, P678, DOI 10.1128/IAI.36.2.678-684.1982; BARTOS M, 2005, J MICROBIOL METHODS; Behr M, 2004, PATHOGENIC MYCOBACTE, P39; BELISLE JT, 1993, J BIOL CHEM, V268, P10510; BILLICH A, 1987, BIOL CHEM H-S, V368, P521, DOI 10.1515/bchm3.1987.368.1.521; Chacon O, 2004, ANNU REV MICROBIOL, V58, P329, DOI 10.1146/annurev.micro.58.030603.123726; Chatterjee D, 2001, CELL MOL LIFE SCI, V58, P2018, DOI 10.1007/PL00000834; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; DALEINE G, 1995, TUBERCLE LUNG DIS, V76, P234, DOI 10.1016/S0962-8479(05)80011-5; deCrecyLagard V, 1997, ANTIMICROB AGENTS CH, V41, P1904, DOI 10.1128/AAC.41.9.1904; Hacker C, 2000, J BIOL CHEM, V275, P30826, DOI 10.1074/jbc.M002614200; HUSEK P, 1975, J CHROMATOGR, V113, P139, DOI 10.1016/S0021-9673(00)86962-9; LEE BY, 1991, J CLIN MICROBIOL, V29, P1026, DOI 10.1128/JCM.29.5.1026-1029.1991; Li LL, 2005, P NATL ACAD SCI USA, V102, P12344, DOI 10.1073/pnas.0505662102; Maekura R, 2001, J CLIN MICROBIOL, V39, P3603, DOI 10.1128/JCM.39.10.3603-3608.2001; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; Moody DB, 2004, SCIENCE, V303, P527, DOI 10.1126/science.1089353; Okuda Y, 2004, J CLIN MICROBIOL, V42, P1136, DOI 10.1128/JCM.42.3.1136-1141.2004; Primm TP, 2004, CLIN MICROBIOL REV, V17, P98, DOI 10.1128/CMR.17.1.98-106.2004; Riviere M, 1996, EUR J BIOCHEM, V241, P682, DOI 10.1111/j.1432-1033.1996.00682.x; Rojas-Espinosa O, 2003, Acta Leprol, V12, P112; Schauwecker F, 2000, CHEM BIOL, V7, P287, DOI 10.1016/S1074-5521(00)00103-4; Sieber SA, 2005, CHEM REV, V105, P715, DOI 10.1021/cr0301191; Stabel JR, 2005, J CLIN MICROBIOL, V43, P4744, DOI 10.1128/JCM.43.9.4744-4750.2005; Thern B, 2002, ANGEW CHEM INT EDIT, V41, P2307, DOI 10.1002/1521-3773(20020703)41:13&lt;2307::AID-ANIE2307&gt;3.0.CO;2-Y; VITOUX B, 1986, INT J PEPT PROT RES, V27, P617; vonDohren H, 1997, CHEM REV, V97, P2675, DOI 10.1021/cr9600262	28	27	30	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5209	5215		10.1074/jbc.M512465200	http://dx.doi.org/10.1074/jbc.M512465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16339155	hybrid			2022-12-27	WOS:000235426200075
J	Flaherty, DM; Monick, MM; Hinde, SL				Flaherty, DM; Monick, MM; Hinde, SL			Human alveolar macrophages are deficient in PTEN - The role of endogenous oxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-SUPPRESSOR PTEN; ACETYL-L-CYSTEINE; AP-1 DNA-BINDING; PROTEIN-KINASE-B; TRANSCRIPTION FACTOR; REDOX REGULATION; CELL-SURVIVAL; ACTIVATION; APOPTOSIS	Human alveolar macrophages play a critical role in host defense and in the development of inflammation and fibrosis in the lung. Unlike their precursor cells, blood monocytes, alveolar macrophages are long-lived and tend to be resistant to apoptotic stimuli. In this study, we examined the role of differentiation in altering baseline phosphatidylinositol ( PI) 3-kinase/Akt activity. We found that differentiation increased activity of pro-survival PI3-kinase/Akt while decreasing amounts of the negative PI3-kinase regulator, PTEN. PTEN is a lipid phosphatase with activity against phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3), the major bioactive product of PI 3-kinase. Examining in vivo differentiation of alveolar macrophages ( by comparing blood monocytes to alveolar macrophages from single donors), we found that differentiation resulted in increased baseline reactive oxygen species ( ROS) in the alveolar macrophages. This led to a deficiency in PTEN, increased activity of Akt, and prolonged survival of alveolar macrophages. These data support the hypothesis that alterations in ROS levels contribute to macrophage homeostasis by altering the balance between PI 3-kinase/Akt and the phosphatase, PTEN.	Univ Iowa, Dept Internal Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	University of Iowa	Flaherty, DM (corresponding author), Div Pulm Crit Care & Occupat Med, 100 Eckstein Med Res Bldg, Iowa City, IA 52242 USA.	dawn-flaherty@uiowa.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077431, P50HL060316, K08HL004428] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00059] Funding Source: Medline; NHLBI NIH HHS [HL-04428, HL-60316, HL-077431] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RD, 2000, GENE THER, V7, P1034, DOI 10.1038/sj.gt.3301197; Blackwell TS, 1996, J IMMUNOL, V157, P1630; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carter AB, 2004, AM J RESP CELL MOL, V31, P43, DOI 10.1165/rcmb.2003-0377OC; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Cho SH, 2004, FEBS LETT, V560, P7, DOI 10.1016/S0014-5793(04)00112-7; CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Fernandez PC, 1999, BIOL CHEM, V380, P1383, DOI 10.1515/BC.1999.178; Flaherty DM, 2001, AM J RESP CELL MOL, V25, P254, DOI 10.1165/ajrcmb.25.2.4446; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Georgescu MM, 2000, CANCER RES, V60, P7033; Han H, 2001, J BIOL CHEM, V276, P26357, DOI 10.1074/jbc.M011136200; Kaul N, 1996, FREE RADICAL BIO MED, V21, P401, DOI 10.1016/0891-5849(96)00178-5; Kim H, 2000, FREE RADICAL BIO MED, V29, P674, DOI 10.1016/S0891-5849(00)00368-3; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Monick MM, 1999, J BIOL CHEM, V274, P18075, DOI 10.1074/jbc.274.25.18075; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Pajonk F, 2002, FREE RADICAL BIO MED, V32, P536, DOI 10.1016/S0891-5849(02)00743-8; Patel L, 2001, CURR BIOL, V11, P764, DOI 10.1016/S0960-9822(01)00225-1; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Qanungo S, 2004, J BIOL CHEM, V279, P50455, DOI 10.1074/jbc.M406749200; Rasheed BKA, 1997, CANCER RES, V57, P4187; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; THOMAS ED, 1976, SCIENCE, V192, P1016, DOI 10.1126/science.775638; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Yamada KM, 2001, J CELL SCI, V114, P2375; Zhang Jiyan, 2003, Hematol J, V4, P277, DOI 10.1038/sj.thj.6200252	50	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5058	5064		10.1074/jbc.M508997200	http://dx.doi.org/10.1074/jbc.M508997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371363	hybrid			2022-12-27	WOS:000235426200060
J	Nikrodhanond, AA; Ortiga-Carvalho, TM; Shibusawa, N; Hashimoto, K; Liao, XH; Refetoff, S; Yamada, M; Mori, M; Wondisford, FE				Nikrodhanond, AA; Ortiga-Carvalho, TM; Shibusawa, N; Hashimoto, K; Liao, XH; Refetoff, S; Yamada, M; Mori, M; Wondisford, FE			Dominant role of thyrotropin-releasing hormone in the hypothalamic-pituitary-thyroid axis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA; TRANSCRIPTIONAL REGULATION; PARAVENTRICULAR NUCLEUS; TERTIARY HYPOTHYROIDISM; POSTNATAL-DEVELOPMENT; STIMULATING HORMONE; GENE-EXPRESSION; SUBUNIT GENES; ALPHA-GENE; NULL MICE	Hypothalamic thyrotropin-releasing hormone (TRH) stimulates thyroid-stimulating hormone (TSH) secretion from the anterior pituitary. TSH then initiates thyroid hormone (TH) synthesis and release from the thyroid gland. Although opposing TRH and TH inputs regulate the hypothalamic-pituitary-thyroid axis, TH negative feedback is thought to be the primary regulator. This hypothesis, however, has yet to be proven in vivo. To elucidate the relative importance of TRH and TH in regulating the hypothalamic-pituitary-thyroid axis, we have generated mice that lack either TRH, the beta isoforms of TH receptors ( TR beta KO), or both ( double KO). TR beta knock-out ( KO) mice have significantly higher TH and TSH levels compared with wild-type mice, in contrast to double KO mice, which have reduced TH and TSH levels. Unexpectedly, hypothyroid double KO mice also failed to mount a significant rise in serum TSH levels, and pituitary TSH immunostaining was markedly reduced compared with all other hypothyroid mouse genotypes. This impaired TSH response, however, was not due to a reduced number of pituitary thyrotrophs because thyrotroph cell number, as assessed by counting TSH immunopositive cells, was restored after chronic TRH treatment. Thus, TRH is absolutely required for both TSH and TH synthesis but is not necessary for thyrotroph cell development.	Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21287 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Comm Mol Metab & Nutr, Pritzker Sch Med, Chicago, IL 60637 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21000000 Rio De Janeiro, Brazil; Gunma Univ, Dept Med & Mol Sci, Grad Sch Med, Maebashi, Gumma 33922, Japan	Johns Hopkins University; Johns Hopkins Medicine; University of Chicago; University of Chicago; Universidade Federal do Rio de Janeiro; Gunma University	Wondisford, FE (corresponding author), Johns Hopkins Med Inst, Div Metab, Dept Pediat, Baltimore, MD 21287 USA.	fwondisford@jhmi.edu	Ortiga-Carvalho, Tania/F-7178-2014; Ortiga-Carvalho, Tania M/D-5093-2011; Refetoff, Samuel/ABB-1263-2021	Ortiga-Carvalho, Tania/0000-0002-0225-1132; Ortiga-Carvalho, Tania M/0000-0002-0225-1132; Refetoff, Samuel/0000-0003-0164-8231	NIDDK NIH HHS [DK20595, DK49126, DK53036] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049126, P60DK020595, R01DK053036] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 1999, J CLIN INVEST, V104, P291, DOI 10.1172/JCI6397; Abel ED, 2003, MOL ENDOCRINOL, V17, P1767, DOI 10.1210/me.2003-0109; Abel ED, 2001, J CLIN INVEST, V107, P1017, DOI 10.1172/JCI10858; Bassett JHD, 2003, MOL CELL ENDOCRINOL, V213, P1, DOI 10.1016/j.mce.2003.10.033; BECKPECCOZ P, 1985, NEW ENGL J MED, V312, P1085, DOI 10.1056/NEJM198504253121703; BRADLEY DJ, 1994, P NATL ACAD SCI USA, V91, P439, DOI 10.1073/pnas.91.2.439; COHEN RN, 2005, WERNER INGBARS THYRO, P159; DANGELO SA, 1972, NEUROENDOCRINOLOGY, V9, P197, DOI 10.1159/000122050; DELEAN A, 1977, ENDOCRINOLOGY, V100, P1496, DOI 10.1210/endo-100-6-1496; Dupre SM, 2004, ENDOCRINOLOGY, V145, P2337, DOI 10.1210/en.2003-1209; DYESS EM, 1988, ENDOCRINOLOGY, V123, P2291, DOI 10.1210/endo-123-5-2291; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; Gauthier K, 1999, EMBO J, V18, P623, DOI 10.1093/emboj/18.3.623; HARRIS ARC, 1978, J CLIN INVEST, V61, P441, DOI 10.1172/JCI108955; HINKLE PM, 1982, ENDOCRINOLOGY, V110, P1725, DOI 10.1210/endo-110-5-1725; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; KOJIMA A, 1974, ENDOCRINOLOGY, V94, P1133, DOI 10.1210/endo-94-4-1133; Lado-Abeal J, 2005, J CLIN ENDOCR METAB, V90, P1760, DOI 10.1210/jc.2004-1488; Lazar MA, 2003, J CLIN INVEST, V112, P497, DOI 10.1172/JCI200319479; LECHAN RM, 1994, ENDOCRINOLOGY, V135, P92, DOI 10.1210/en.135.1.92; Macchia PE, 2001, P NATL ACAD SCI USA, V98, P349, DOI 10.1073/pnas.011306998; Moeller LC, 2003, MOL ENDOCRINOL, V17, P2295, DOI 10.1210/me.2003-0175; Ng L, 2001, HUM MOL GENET, V10, P2701, DOI 10.1093/hmg/10.23.2701; PERRET J, 1990, BIOCHEM BIOPH RES CO, V171, P1044, DOI 10.1016/0006-291X(90)90789-P; Persani L, 2000, J CLIN ENDOCR METAB, V85, P3631, DOI 10.1210/jc.85.10.3631; Pohlenz J, 1999, THYROID, V9, P1265, DOI 10.1089/thy.1999.9.1265; SCALAN TS, 2004, NAT MED, V6, P638; SEGERSON TP, 1987, SCIENCE, V238, P78, DOI 10.1126/science.3116669; Shibusawa N, 2003, J CLIN INVEST, V112, P588, DOI 10.1172/JCI200318377; Shibusawa N, 2000, MOL ENDOCRINOL, V14, P137, DOI 10.1210/me.14.1.137; Shupnik M A, 2000, Rev Endocr Metab Disord, V1, P35, DOI 10.1023/A:1010008318961; SHUPNIK MA, 1986, J BIOL CHEM, V261, P2675; SHUPNIK MA, 1985, J BIOL CHEM, V260, P2900; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; STEINFELDER HJ, 1991, P NATL ACAD SCI USA, V88, P3130, DOI 10.1073/pnas.88.8.3130; TAYLOR T, 1989, ENDOCRINOLOGY, V125, P2198; Weiss RE, 1997, ENDOCRINOLOGY, V138, P3624, DOI 10.1210/en.138.9.3624; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; Yamada M, 1997, P NATL ACAD SCI USA, V94, P10862, DOI 10.1073/pnas.94.20.10862	41	66	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5000	5007		10.1074/jbc.M511530200	http://dx.doi.org/10.1074/jbc.M511530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16339138	hybrid			2022-12-27	WOS:000235426200052
J	Stafforini, DM; Sheller, JR; Blackwell, TS; Sapirstein, A; Yull, FE; McIntyre, TM; Bonventre, JV; Prescott, SM; Roberts, LJ				Stafforini, DM; Sheller, JR; Blackwell, TS; Sapirstein, A; Yull, FE; McIntyre, TM; Bonventre, JV; Prescott, SM; Roberts, LJ			Release of free F-2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NEOINTIMA FORMATION; LIPID-PEROXIDATION; OXIDANT STRESS; ATHEROSCLEROTIC LESIONS; OXIDATIVE MODIFICATION; PAF-ACETYLHYDROLASE; GENE-TRANSFER; CELL-DEATH; IN-VIVO	F-2-isoprostanes are produced in vivo by nonenzymatic peroxidation of arachidonic acid esterified in phospholipids. Increased urinary and plasma F-2-isoprostane levels are associated with a number of human diseases. These metabolites are regarded as excellent markers of oxidant stress in vivo. Isoprostanes are initially generated in situ, i.e. when the arachidonate precursor is esterified in phospholipids, and they are subsequently released in free form. Although the mechanism(s) responsible for the release of free isoprostanes after in situ generation in membrane phospholipids is, for the most part, unknown, this process is likely mediated by phospholipase A(2) activity(ies). Here we reported that human plasma contains an enzymatic activity that catalyzes this reaction. The activity associates with high density and low density lipoprotein and comigrates with platelet-activating factor (PAF) acetylhydrolase on KBr density gradients. Plasma samples from subjects deficient in PAF acetylhydrolase do not release F-2-isoprostanes from esterified precursors. The intracellular PAF acetylhydrolase II, which shares homology to the plasma enzyme, also catalyzes this reaction. We found that both the intracellular and plasma PAF acetylhydrolases have high affinity for esterified F-2-isoprostanes. However, the rate of esterified F-2-isoprostane hydrolysis is much slower compared with the rate of hydrolysis of other substrates utilized by these enzymes. Studies using PAF acetylhydrolase transgenic mice indicated that these animals have a higher capacity to release F-2-isoprostanes compared with nontransgenic littermates. Our results suggested that PAF acetylhydrolases play key roles in the hydrolysis of F-2- isoprostanes esterified on phospholipids in vivo.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Vanderbilt University; Vanderbilt University; Harvard University; Harvard Medical School; Cleveland Clinic Foundation	Stafforini, DM (corresponding author), Univ Utah, Huntsman Canc Inst, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	diana.stafforini@hci.utah.edu			NHLBI NIH HHS [HL44513, HL061419, HL35828] Funding Source: Medline; NIDDK NIH HHS [DK38452, DK26657] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061419, R01HL035828, R01HL044513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, P01DK038452] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed Z, 2002, BIOCHEM BIOPH RES CO, V290, P391, DOI 10.1006/bbrc.2001.6150; AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; AMES BN, 1960, J BIOL CHEM, V235, P769; Arakawa H, 2005, CIRCULATION, V111, P3302, DOI 10.1161/CIRCULATIONAHA.104.476242; Cao Y, 1998, J BIOL CHEM, V273, P4012, DOI 10.1074/jbc.273.7.4012; Connelly PW, 2005, FREE RADICAL BIO MED, V38, P164, DOI 10.1016/j.freeradbiomed.2004.10.010; Cracowski JL, 2004, CHEM PHYS LIPIDS, V128, P75, DOI 10.1016/j.chemphyslip.2003.10.006; Crankshaw DJ, 2003, MOL CELL BIOCHEM, V253, P125, DOI 10.1023/A:1026052123843; FitzGerald GA, 1997, THROMB HAEMOSTASIS, V78, P280; GOPAUL NK, 1994, BIOCHEM BIOPH RES CO, V200, P338, DOI 10.1006/bbrc.1994.1453; GOPAUL NK, 1994, FEBS LETT, V348, P297, DOI 10.1016/0014-5793(94)00628-8; Hakkinen T, 1999, ARTERIOSCL THROM VAS, V19, P2909, DOI 10.1161/01.ATV.19.12.2909; Hattori K, 1996, J BIOL CHEM, V271, P33032, DOI 10.1074/jbc.271.51.33032; HATTORI M, 1993, J BIOL CHEM, V268, P18748; Ho YS, 2002, ARCH TOXICOL, V76, P484, DOI 10.1007/s00204-002-0373-3; Hou X, 2004, FREE RADICAL BIO MED, V36, P163, DOI 10.1016/j.freeradbiomed.2003.10.024; Itabe H, 2000, ANAL BIOCHEM, V285, P151, DOI 10.1006/abio.2000.4751; Kruse S, 2000, AM J HUM GENET, V66, P1522, DOI 10.1086/302901; Leach CA, 2001, FARMACO, V56, P45, DOI 10.1016/S0014-827X(01)01011-4; LIU M, 1994, P NATL ACAD SCI USA, V91, P6035, DOI 10.1073/pnas.91.13.6035; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8; Marathe GK, 2003, J BIOL CHEM, V278, P3937, DOI 10.1074/jbc.M211126200; Matsuzawa A, 1997, J BIOL CHEM, V272, P32315, DOI 10.1074/jbc.272.51.32315; MOORE KP, 1995, CIRC RES, V77, P335, DOI 10.1161/01.RES.77.2.335; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Morrow JD, 2005, ARTERIOSCL THROM VAS, V25, P279, DOI 10.1161/01.ATV.0000152605.64964.c0; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Musiek ES, 2005, J BIOL CHEM, V280, P35562, DOI 10.1074/jbc.M504785200; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Pratico D, 2004, CHEM PHYS LIPIDS, V128, P165, DOI 10.1016/j.chemphyslip.2003.09.012; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Quarck R, 2001, CIRCULATION, V103, P2495; Reilly MP, 1998, CIRCULATION, V98, P2822, DOI 10.1161/01.CIR.98.25.2822; Roberts LJ, 2002, CELL MOL LIFE SCI, V59, P808, DOI 10.1007/s00018-002-8469-8; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Rodrigo L, 2001, BIOCHEM J, V354, P1, DOI 10.1042/0264-6021:3540001; Shimokata K, 2004, ATHEROSCLEROSIS, V172, P167, DOI 10.1016/j.atherosclerosis.2003.09.019; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; Stafforini DM, 2003, CRIT REV CL LAB SCI, V40, P643, DOI 10.1080/714037693; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; STAFFORINI DM, 1992, T ASSOC AM PHYSICIAN, V105, P44; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Subbanagounder G, 2002, J BIOL CHEM, V277, P7271, DOI 10.1074/jbc.M107602200; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; Turunen P, 2005, ATHEROSCLEROSIS, V179, P27, DOI 10.1016/j.atherosclerosis.2004.10.025; Wu XQ, 2004, J BIOL CHEM, V279, P36158, DOI 10.1074/jbc.M402454200; Yamada Y, 2000, ATHEROSCLEROSIS, V150, P209, DOI 10.1016/S0021-9150(99)00385-8; Zalewski A, 2005, ARTERIOSCL THROM VAS, V25, P923, DOI 10.1161/01.ATV.0000160551.21962.a7	53	171	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4616	4623		10.1074/jbc.M507340200	http://dx.doi.org/10.1074/jbc.M507340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371369	hybrid			2022-12-27	WOS:000235426200009
J	Tang, W; Tu, YP; Nayak, SK; Woodson, J; Jehl, M; Ross, EM				Tang, W; Tu, YP; Nayak, SK; Woodson, J; Jehl, M; Ross, EM			G beta gamma inhibits G alpha GTPase-activating proteins by inhibition of G alpha-GTP binding during stimulation by receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE C-BETA; CRYSTAL-STRUCTURE; REGULATORY COMPONENT; MEDIATED ACTIVATION; ADENYLATE-CYCLASE; COUPLED RECEPTORS; SIGNALING RGS; K+ CHANNEL; IDENTIFICATION	G beta gamma subunits modulate several distinct molecular events involved with G protein signaling. In addition to regulating several effector proteins, G beta gamma subunits help anchor G alpha subunits to the plasma membrane, promote interaction of G alpha with receptors, stabilize the binding of GDP to G alpha to suppress spurious activation, and provide membrane contact points for G protein-coupled receptor kinases. G beta gamma subunits have also been shown to inhibit the activities of GTPase-activating proteins (GAPs), both phospholipase C (PLC)-beta s and RGS proteins, when assayed in solution under single turnover conditions. We show here that G beta gamma subunits inhibit G protein GAP activity during receptor-stimulated, steady-state GTPase turnover. GDP/GTP exchange catalyzed by receptor requires G beta gamma in amounts approximately equimolar to G alpha, but GAP inhibition was observed with superstoichiometric G beta gamma. The potency of inhibition varied with the GAP and the G alpha subunit, but half-maximal inhibition of the GAP activity of PLC-beta 1 was observed with 5-10 nM G beta gamma, which is at or below the concentrations of G beta gamma needed for regulation of physiologically relevant effector proteins. The kinetics of GAP inhibition of both receptor-stimulated GTPase activity and single turnover, solution-based GAP assays suggested a competitive mechanism in which G beta gamma competes with GAPs for binding to the activated, GTP-bound G alpha subunit. An N-terminal truncation mutant of PLC-beta 1 that cannot be directly regulated by G beta gamma-remained sensitive to inhibition of its GAP activity, suggesting that the G beta gamma binding site relevant for GAP inhibition is on the G alpha subunit rather than on the GAP. Using fluorescence resonance energy transfer between cyan or yellow fluorescent protein-labeled G protein subunits and Alexa532-labeled RGS4, we found that G beta gamma directly competes with RGS4 for high-affinity binding to G alpha(i)-GDP-AlF4.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ross, EM (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Elliott.Ross@UTSouthwestern.edu			NIGMS NIH HHS [GM30355] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albsoul-Younes AM, 2001, J BIOL CHEM, V276, P12712, DOI 10.1074/jbc.M011231200; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Chidiac P, 1999, BIOCHEM PHARMACOL, V58, P39, DOI 10.1016/S0006-2952(99)00080-5; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; FUNG BKK, 1983, J BIOL CHEM, V258, P495; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Ilkaeva O, 2002, J BIOL CHEM, V277, P4294, DOI 10.1074/jbc.M109612200; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEE RH, 1987, BIOCHEMISTRY-US, V26, P3983, DOI 10.1021/bi00387a036; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; PARKER EM, 1991, J BIOL CHEM, V266, P519; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; Peleg S, 2002, NEURON, V33, P87, DOI 10.1016/S0896-6273(01)00567-0; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Ross EM, 1999, CRC METH SIG TRANS, P123; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang J, 1997, J BIOL CHEM, V272, P5732, DOI 10.1074/jbc.272.9.5732; Wang J, 1999, J BIOL CHEM, V274, P31641, DOI 10.1074/jbc.274.44.31641; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; WU DQ, 1993, J BIOL CHEM, V268, P3704	49	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4746	4753		10.1074/jbc.M510573200	http://dx.doi.org/10.1074/jbc.M510573200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16407201	hybrid			2022-12-27	WOS:000235426200024
J	Fellin, T; Pozzan, T; Carmignoto, G				Fellin, T; Pozzan, T; Carmignoto, G			Purinergic receptors mediate two distinct glutamate release pathways in hippocampal astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2X RECEPTORS; RAT HIPPOCAMPUS; SYNAPTIC-TRANSMISSION; EXTRACELLULAR CALCIUM; NUCLEOTIDE RECEPTORS; MOLECULAR PHYSIOLOGY; CULTURED ASTROCYTES; NEURONAL-ACTIVITY; NERVOUS-SYSTEM; GLIAL-CELLS	The purinergic P2X(7) receptor (P2X(7)R) can mediate glutamate release from cultured astrocytes. Using patch clamp recordings, we investigated whether P2X(7)Rs have the same action in hippocampal astrocytes in situ. We found that 2- and 3-O-(4-benzoylbenzoyl) ATP (BzATP), a potent, although unselective P2X(7)R agonist, triggers two different glutamate-mediated responses in CA1 pyramidal neurons; they are transient inward currents, which have the kinetic and pharmacological properties of previously described slow inward currents (SICs) due to Ca2+-dependent glutamate release from astrocytes, and a sustained tonic current. Although SICs were unaffected by P2X(7)Rs antagonists, the tonic current was inhibited, was amplified in low extracellular Ca2+, and was insensitive to glutamate transporter and hemichannel inhibitors. BzATP triggered in astrocytes a large depolarization that was inhibited by P2X(7)R antagonists and amplified in low Ca2+. In low Ca2+ BzATP also induced lucifer yellow uptake into a subpopulation of astrocytes and CA3 neurons. Our results demonstrate that purinergic receptors other than the P2X(7)R mediate glutamate release that evokes SICs, whereas activation of a receptor that has features similar to the P2X(7)R, mediates a sustained glutamate efflux that generates a tonic current in CA1 neurons. This sustained glutamate efflux, which is potentiated under non-physiological conditions, may have important pathological actions in the brain.	Univ Padua, CNR, Ist Neurosci, I-35121 Padua, Italy; Univ Padua, Dipartimento Sci Biomed Sperimentali, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Carmignoto, G (corresponding author), Univ Padua, CNR, Ist Neurosci, Viale G Colombo 3, I-35121 Padua, Italy.	gcarmi@bio.unipd.it	Carmignoto, Giorgio/A-8375-2018	Carmignoto, Giorgio/0000-0003-3063-6774				Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Armstrong JN, 2002, J NEUROSCI, V22, P5938; Atkinson L, 2004, NEUROSCIENCE, V123, P761, DOI 10.1016/j.neuroscience.2003.08.065; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; Bowser DN, 2004, J NEUROSCI, V24, P8606, DOI 10.1523/JNEUROSCI.2660-04.2004; Burgo A, 2003, J PHYSIOL-LONDON, V549, P537, DOI 10.1113/jphysiol.2003.041871; Cavaliere F, 2004, J CEREBR BLOOD F MET, V24, P392, DOI 10.1097/00004647-200404000-00004; Chen NS, 2000, J NEUROPHYSIOL, V84, P693, DOI 10.1152/jn.2000.84.2.693; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CHOI ESH, 1990, DEV BIOL, V142, P169, DOI 10.1016/0012-1606(90)90160-K; Coco S, 2003, J BIOL CHEM, V278, P1354, DOI 10.1074/jbc.M209454200; Deuchars SA, 2001, J NEUROSCI, V21, P7143, DOI 10.1523/JNEUROSCI.21-18-07143.2001; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Evanko DS, 2004, GLIA, V47, P233, DOI 10.1002/glia.20050; Fellin T, 2004, NEURON, V43, P729, DOI 10.1016/j.neuron.2004.08.011; Fiacco TA, 2004, J NEUROSCI, V24, P722, DOI 10.1523/JNEUROSCI.2859-03.2004; Fields RD, 2000, TRENDS NEUROSCI, V23, P625, DOI 10.1016/S0166-2236(00)01674-X; Fumagalli M, 2003, GLIA, V43, P218, DOI 10.1002/glia.10248; GERBER U, 1989, J PHYSIOL-LONDON, V417, P567, DOI 10.1113/jphysiol.1989.sp017819; GORTER JA, 1995, NEUROSCI LETT, V194, P209, DOI 10.1016/0304-3940(95)11748-L; Jeremic A, 2001, J NEUROCHEM, V77, P664, DOI 10.1046/j.1471-4159.2001.00272.x; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Kamermans M, 2001, SCIENCE, V292, P1178, DOI 10.1126/science.1060101; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; Khakh BS, 2001, NAT REV NEUROSCI, V2, P165, DOI 10.1038/35058521; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kreft M, 2004, GLIA, V46, P437, DOI 10.1002/glia.20018; Kukley M, 2004, J NEUROSCI, V24, P7128, DOI 10.1523/JNEUROSCI.2093-04.2004; Kukley M, 2001, GLIA, V36, P11, DOI 10.1002/glia.1091; Lambrecht G, 2000, N-S ARCH PHARMACOL, V362, P340, DOI 10.1007/s002100000312; Liu QS, 2004, P NATL ACAD SCI USA, V101, P3172, DOI 10.1073/pnas.0306731101; Matthias K, 2003, J NEUROSCI, V23, P1750; Mulligan SJ, 2004, NATURE, V431, P195, DOI 10.1038/nature02827; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Newman EA, 1998, J NEUROSCI, V18, P4022; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pankratov Y, 1998, EUR J NEUROSCI, V10, P3898, DOI 10.1046/j.1460-9568.1998.00419.x; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 1997, J NEUROSCI, V17, P7817; Peters O, 2003, J NEUROSCI, V23, P9888; Ralevic V, 1998, PHARMACOL REV, V50, P413; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004; Sperlagh B, 2002, J NEUROCHEM, V81, P1196, DOI 10.1046/j.1471-4159.2002.00920.x; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Ye ZC, 2003, J NEUROSCI, V23, P3588, DOI 10.1523/jneurosci.23-09-03588.2003; Zhang JM, 2003, NEURON, V40, P971, DOI 10.1016/S0896-6273(03)00717-7	57	117	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4274	4284		10.1074/jbc.M510679200	http://dx.doi.org/10.1074/jbc.M510679200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16338906	hybrid			2022-12-27	WOS:000235275300061
J	Hashikawa, N; Mizukami, Y; Imazu, H; Sakurai, H				Hashikawa, N; Mizukami, Y; Imazu, H; Sakurai, H			Mutated yeast heat shock transcription factor activates transcription independently of hyperphosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; METALLOTHIONEIN GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; GLUCOSE STARVATION; FACTOR CONTAINS; IN-VITRO; PHOSPHORYLATION; DROSOPHILA; ELEMENT	The homotrimeric heat shock transcription factor (HSF) binds to the heat shock element of target genes and regulates transcription in response to various stresses. The Hsf1 protein of Saccharomyces cerevisiae is extensively phosphorylated upon heat shock; a modification that is under positive regulation by its C-terminal regulatory domain (CTM). Hyperphosphorylation has been implicated in gene-specific transcriptional activation. Here, we surveyed genes whose heat shock response is reduced by a CTM mutation. The CTM is indispensable for transcription via heat shock elements bound by a single Hsf1 trimer but is dispensable for transcription via heat shock elements bound by Hsf1 trimers in a cooperative manner. Intragenic mutations located within or near the wing region of the winged helix-turn-helix DNA-binding domain suppress the temperature-sensitive growth phenotype associated with the CTM mutation and enable Hsf1 to activate transcription independently of hyperphosphorylation. Deletion of the wing partially restores the transcriptional defects of the unphosphorylated Hsf1. These results demonstrate a functional link between hyperphosphorylation and the wing region and suggest that this modification is involved in a conformational change of a single Hsf1 trimer to an active form.	Kanazawa Univ, Grad Sch Med Sci, Div Hlth Sci, Kanazawa, Ishikawa 920094, Japan	Kanazawa University	Sakurai, H (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Div Hlth Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 920094, Japan.	sakurai@kenroku.kanazawa-u.ac.jp		Sakurai, Hiroshi/0000-0002-0336-2301; Hashikawa, Naoya/0000-0001-8192-6881				Ahn SG, 2001, GENE DEV, V15, P2134, DOI 10.1101/gad.894801; AMIN J, 1988, MOL CELL BIOL, V8, P3761, DOI 10.1128/MCB.8.9.3761; AMIN J, 1994, J BIOL CHEM, V269, P4804; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; BONNER JJ, 1992, MOL CELL BIOL, V12, P1021, DOI 10.1128/MCB.12.3.1021; Bulman AL, 2001, J BIOL CHEM, V276, P40254, DOI 10.1074/jbc.M106301200; Chen TX, 2002, P NATL ACAD SCI USA, V99, P1200, DOI 10.1073/pnas.032681299; Chen ZD, 1998, NUCLEIC ACIDS RES, V26, P1126, DOI 10.1093/nar/26.4.1126; Cicero MP, 2001, NUCLEIC ACIDS RES, V29, P1715, DOI 10.1093/nar/29.8.1715; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; DAMBERGER FF, 1994, PROTEIN SCI, V3, P1806, DOI 10.1002/pro.5560031020; Ferguson SB, 2005, GENETICS, V169, P1203, DOI 10.1534/genetics.104.034256; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; Fernandes M, 1995, NUCLEIC ACIDS RES, V23, P4799, DOI 10.1093/nar/23.23.4799; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; Guettouche Toumy, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-4; Hahn JS, 2004, J BIOL CHEM, V279, P5169, DOI 10.1074/jbc.M311005200; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; Hardy JA, 2000, J MOL BIOL, V295, P393, DOI 10.1006/jmbi.1999.3357; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hashikawa N, 2004, MOL CELL BIOL, V24, P3648, DOI 10.1128/MCB.24.9.3648-3659.2004; HOJ A, 1994, EMBO J, V13, P2617; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Imazu H, 2005, EUKARYOT CELL, V4, P1050, DOI 10.1128/EC.4.6.1050-1056.2005; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; Lee S, 2000, MOL BIOL CELL, V11, P1753, DOI 10.1091/mbc.11.5.1753; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu Xiao-Dong, 1996, Genes and Development, V10, P592, DOI 10.1101/gad.10.5.592; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; Sakurai H, 2003, GENES CELLS, V8, P951, DOI 10.1046/j.1356-9597.2003.00689.x; Sakurai H, 2001, BIOCHEM BIOPH RES CO, V285, P696, DOI 10.1006/bbrc.2001.5234; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Tachibana T, 2002, J BIOL CHEM, V277, P22140, DOI 10.1074/jbc.M201267200; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; TORRES FAG, 1995, MOL CELL BIOL, V15, P5063; Trinklein ND, 2004, MOL BIOL CELL, V15, P1254, DOI 10.1091/mbc.E03-10-0738; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676	52	31	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3936	3942		10.1074/jbc.M510827200	http://dx.doi.org/10.1074/jbc.M510827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361698	hybrid			2022-12-27	WOS:000235275300021
J	Oh, TJ; Daniel, J; Kim, HJ; Sirakova, TD; Kolattukudy, PE				Oh, TJ; Daniel, J; Kim, HJ; Sirakova, TD; Kolattukudy, PE			Identification and characterization of Rv3281 as a novel subunit of a biotin-dependent Acyl-CoA carboxylase in Mycobacterium tuberculosis H37Rv	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A CARBOXYLASE; PURIFICATION; EXPRESSION; GROWTH; DOMAIN; GENES; ACIDS	Mycobacterium tuberculosis produces a large number of structurally diverse lipids generated from the carboxylation products of acetyl-CoA and propionyl-CoA. A biotin-dependent acyl-CoA carboxylase was purified from M. tuberculosis H37Rv by avidin affinity chromatography, and the three major protein components were determined by N-terminal sequencing to be the 63-kDa alpha 3-subunit (AccA3, Rv3285), the 59-kDa beta 5-subunit (AccD5, Rv3280), and the 56-kDa beta 4-subunit (AccD4, Rv3799). A minor protein of about 24 kDa that co-purified with the above subunits was identified by matrix-assisted laser desorption/ionization-time of flight mass spectrometry to be the product of Rv3281 that is located immediately downstream of the open reading frame encoding the beta 5-subunit. This protein displays identity over a short stretch of amino acids with the recently discovered epsilon-subunits of Streptomyces coelicolor, suggesting that it might be an epsilon-subunit of the mycobacterial acyl-CoA carboxylase. To test this hypothesis, the carboxylase subunits were expressed in Escherichia coli and purified. Acyl-CoA carboxylase activity was successfully reconstituted for the first time from purified subunits of the acyl-CoA carboxylase of M. tuberculosis. The reconstituted alpha 3-beta 5 showed higher activity with propionyl-CoA than with acetyl-CoA, and the addition of the epsilon-subunit stimulated the carboxylation by 3.2- and 6.3-fold, respectively. The alpha 3-beta 4 showed very low activity with the above substrates but carboxylated long chain acyl-CoA. This epsilon-subunit contains five sets of tandem repeats at the N terminus that are required for maximal enhancement of carboxylase activity. The Rv3281 open reading frame is co-transcribed with Rv3280 in the mycobacterial cell, and the level of epsilon-protein was highest during the log phase and decreased during the stationary phase.	Univ Cent Florida, Burnett Coll Biomed Sci, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Kolattukudy, PE (corresponding author), Univ Cent Florida, Burnett Coll Biomed Sci, BMS 136,4000 Cent Florida Blvd, Orlando, FL 32816 USA.	pk@mail.ucf.edu	kolattukudy, pappachan e/A-1350-2012	Kim, Hwa-Jung/0000-0002-1127-0909	NIAID NIH HHS [AI46582, AI35272, R01 AI046582, R01 AI035272] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046582, R01AI035272] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Attwood PV, 2002, ACCOUNTS CHEM RES, V35, P113, DOI 10.1021/ar000049+; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cronan JE, 2002, PROG LIPID RES, V41, P407, DOI 10.1016/S0163-7827(02)00007-3; Diacovich L, 2002, J BIOL CHEM, V277, P31228, DOI 10.1074/jbc.M203263200; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; HASSE FC, 1982, J BIOL CHEM, V257, P11994; HENRIKSON KP, 1979, J BIOL CHEM, V254, P5888; HUNAITI AR, 1982, ARCH BIOCHEM BIOPHYS, V216, P362, DOI 10.1016/0003-9861(82)90222-3; LAEMMLI UK, 1970, NATURE, V227, P685; Portevin D, 2005, J BIOL CHEM, V280, P8862, DOI 10.1074/jbc.M408578200; RAINWATER DL, 1982, J BACTERIOL, V151, P905, DOI 10.1128/JB.151.2.905-911.1982; Rodriguez E, 2001, APPL ENVIRON MICROB, V67, P4166, DOI 10.1128/AEM.67.9.4166-4176.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Zhang HL, 2004, P NATL ACAD SCI USA, V101, P5910, DOI 10.1073/pnas.0400891101	19	39	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3899	3908		10.1074/jbc.M511761200	http://dx.doi.org/10.1074/jbc.M511761200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354663	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000235275300017
J	Shimizu, N; Imamoto, Y; Harigai, M; Kamikubo, H; Yamazaki, Y; Kataoka, M				Shimizu, N; Imamoto, Y; Harigai, M; Kamikubo, H; Yamazaki, Y; Kataoka, M			pH-dependent equilibrium between long lived near-UV intermediates of photoactive yellow protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E46Q MUTANT; ECTOTHIORHODOSPIRA-HALOPHILA; STRUCTURAL-CHANGES; COUMARIC ACID; PHOTOCYCLE; CHROMOPHORE; PHOTOREACTION; KINETICS; I-1; DEPROTONATION	The long lived intermediate (signaling state) of photoactive yellow protein (PYPM), which is formed in the photocycle, was characterized at various pHs. PYPM at neutral pH was in equilibrium between two spectroscopically distinct states. Absorption maxima of the acidic form (PYPMacid) and alkaline form (PYPMalkali) were located at 367 and 356 nm, respectively. Equilibrium was represented by the Henderson-Hasselbalch equation, in which apparent pK(a) was 6.4. Content of alpha- and/or beta-structure of PYPMacid was significantly greater than PYPMalkali as demonstrated by the molar ellipticity at 222 nm. In addition, changes in amide I and II modes of beta-structure in the difference Fourier transform infrared spectra for formation of PYPM acid was smaller than that of PYPMalkali. The vibrational mode at 1747 cm(-1) of protonated Glu-46 was found as a small band for PYPMacid but not for PYPMalkali, suggesting that Glu-46 remains partially protonated in PYPMacid, whereas it is fully deprotonated in PYPMalkali. Small angle x-ray scattering measurements demonstrated that the radius of gyration of PYPMacid was 15.7 angstrom, whereas for PYPMalkali it was 16.2 angstrom. These results indicate that PYPMacid assumes a more ordered and compact structure than PYPMalkali. Binding of citrate shifts this equilibrium toward PYPMalkali. UV-visible absorption spectra and difference infrared spectra of the long lived intermediate formed from E46Q mutant was consistent with those of PYPMacid, indicating that the mutation shifts this equilibrium toward PYPMacid. Alterations in the nature of PYPM by pH, citrate, and mutation of Glu-46 are consistently explained by the shift of the equilibrium between PYPMacid and PYPMalkali.	Nara Inst Sci & Technol, Grad Sch Mat Sci, Ikoma, Nara 6300192, Japan	Nara Institute of Science & Technology	Imamoto, Y (corresponding author), Nara Inst Sci & Technol, Grad Sch Mat Sci, Ikoma, Nara 6300192, Japan.	imamoto@ms.naist.jp	Kataoka, Mikio/H-4402-2011					Anderson S, 2004, STRUCTURE, V12, P1039, DOI 10.1016/j.str.2004.04.008; BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; Borucki B, 2003, BIOCHEMISTRY-US, V42, P8780, DOI 10.1021/bi034315d; Brudler R, 2001, NAT STRUCT BIOL, V8, P265, DOI 10.1038/85021; Chen EF, 2003, BIOCHEMISTRY-US, V42, P2062, DOI 10.1021/bi020577o; Craven CJ, 2000, BIOCHEMISTRY-US, V39, P14392, DOI 10.1021/bi001628p; Cusanovich MA, 2003, BIOCHEMISTRY-US, V42, P4759, DOI 10.1021/bi020690e; Derix NM, 2003, BIOCHEMISTRY-US, V42, P14501, DOI 10.1021/bi034877x; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Glatter O., 1982, SMALL ANGLE XRAY SCA; Guinier A, 1955, SMALL ANGLE XRAY SCA; HARIGAI M, 2003, BIOCHEMISTRY-US, V42, P13901; Hendriks J, 1999, J BIOL CHEM, V274, P17655, DOI 10.1074/jbc.274.25.17655; Hendriks J, 2003, BIOPHYS J, V84, P1180, DOI 10.1016/S0006-3495(03)74932-7; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; Ihee H, 2005, P NATL ACAD SCI USA, V102, P7145, DOI 10.1073/pnas.0409035102; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; Imamoto Y, 1997, J BIOL CHEM, V272, P12905, DOI 10.1074/jbc.272.20.12905; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P14047, DOI 10.1021/bi961342d; Imamoto Y, 2004, FEBS LETT, V577, P75, DOI 10.1016/j.febslet.2004.09.065; Imamoto Y, 2002, BIOCHEMISTRY-US, V41, P13595, DOI 10.1021/bi0264768; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P14336, DOI 10.1021/bi010468u; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P6047, DOI 10.1021/bi002437p; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P8997, DOI 10.1021/bi010021l; Imamoto Y, 2001, BIOCHEMISTRY-US, V40, P4679, DOI 10.1021/bi002291u; Joshi CP, 2005, BIOCHEMISTRY-US, V44, P656, DOI 10.1021/bi0481141; Kandori H, 2000, BIOCHEMISTRY-US, V39, P7902, DOI 10.1021/bi000357f; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Mihara K, 1997, J BIOCHEM, V121, P876; Ohishi S, 2001, BIOCHEMISTRY-US, V40, P2854, DOI 10.1021/bi001846i; Pan DH, 2004, BIOPHYS J, V86, P2374, DOI 10.1016/S0006-3495(04)74294-0; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Rajagopal S, 2005, STRUCTURE, V13, P55, DOI 10.1016/j.str.2004.10.016; Shimizu N, 2002, J BIOCHEM, V132, P257, DOI 10.1093/oxfordjournals.jbchem.a003219; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a; Zhou Y, 2001, J PHYS CHEM A, V105, P5719, DOI 10.1021/jp004575u	42	27	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4318	4325		10.1074/jbc.M506403200	http://dx.doi.org/10.1074/jbc.M506403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368695	hybrid			2022-12-27	WOS:000235275300066
J	Szczesna-Skorupa, E; Kemper, B				Szczesna-Skorupa, E; Kemper, B			BAP31 is involved in the retention of cytochrome P4502C2 in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIMOLECULAR FLUORESCENCE COMPLEMENTATION; CASPASE CLEAVAGE PRODUCT; LIVING CELLS; MOLECULAR-INTERACTIONS; MEMBRANE-PROTEINS; GOLGI-APPARATUS; TRANSMEMBRANE; 2E1; OVERPRODUCTION; DEGRADATION	Microsomal cytochrome P450 2C2 is an integral endoplasmic reticulum ( ER) membrane protein that is directly retained in the ER and excluded from transport vesicles. We have used bimolecular fluorescence complementation and co-immunoprecipitation to show that a ubiquitous ER membrane protein (BAP31) interacts with P450 2C2 in transfected COS-1 cells. A chimera containing only the N-terminal signal anchor of P450 2C1 ( P450 2C1-(1-29)) also interacted with BAP31, which is consistent with interaction of the two proteins via their transmembrane domains. Down-regulation of BAP31 expression with small interfering RNA resulted in redistribution of green fluorescent protein-tagged P450 2C2 or P450 2C1-(1-29) from the ER into the nuclear membrane and compact perinuclear compartment structures as well as the cell surface in a small fraction of the cells. In Bap31-null embryonic stem cells, a significant fraction of P450 2C2 or P450 2C1-(1-29) was detected at the cell surface and nuclear envelope, but was redistributed to the ER by expression of BAP31. The expression level of P450 2C2 was significantly increased in COS-1 cells with repressed levels of BAP31. Formation of the pro-apoptotic p20 fragment of BAP31 was detected in transfected COS-1 cells expressing P450 2C2, and annexin V staining was consistent with the activation of an apoptotic pathway in these cells. Down-regulation of BAP31 with small interfering RNA partially reversed the apoptosis. These results suggest that interaction of P450 2C2 with BAP31 is important for its ER retention and expression level and that BAP31 may be involved in the regulation of apoptosis induced by the ER overload response to increased expression of P450.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kemper, B (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 407 S Goodwin Ave, Urbana, IL 61801 USA.	byronkem@life.uiuc.edu			NIGMS NIH HHS [GM35897] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035897] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; AHN KS, 1993, J BIOL CHEM, V268, P18726; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; Backes WL, 2003, PHARMACOL THERAPEUT, V98, P221, DOI 10.1016/S0163-7258(03)00031-7; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Correia MA, 2005, ANNU REV PHARMACOL, V45, P439, DOI 10.1146/annurev.pharmtox.45.120403.100127; Correia MA, 2003, DRUG METAB REV, V35, P107, DOI 10.1081/DMR-120023683; Ducret A, 2003, EUR J BIOCHEM, V270, P342, DOI 10.1046/j.1432-1033.2003.03395.x; Eliasson E, 1996, MOL PHARMACOL, V50, P573; Farinha CA, 2005, MOL CELL BIOL, V25, P5242, DOI 10.1128/MCB.25.12.5242-5252.2005; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Huan JY, 2004, TOXICOL APPL PHARM, V199, P332, DOI 10.1016/j.taap.2003.12.019; Kamhi-Nesher S, 2001, MOL BIOL CELL, V12, P1711, DOI 10.1091/mbc.12.6.1711; Lambert G, 2001, J BIOL CHEM, V276, P20340, DOI 10.1074/jbc.M011209200; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Mancias JD, 2005, TRAFFIC, V6, P278, DOI 10.1111/j.1600-0854.2005.00279.x; Manley HA, 2001, J HISTOCHEM CYTOCHEM, V49, P1235, DOI 10.1177/002215540104901005; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; MURAKAMI K, 1994, J BIOCHEM, V116, P164, DOI 10.1093/oxfordjournals.jbchem.a124489; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Neve EPA, 1996, ARCH BIOCHEM BIOPHYS, V333, P459, DOI 10.1006/abbi.1996.0415; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; OHKUMA M, 1995, BBA-BIOMEMBRANES, V1236, P163, DOI 10.1016/0005-2736(95)00040-A; Ozalp C, 2005, DRUG METAB DISPOS, V33, P1382, DOI 10.1124/dmd.105.005538; Paquet ME, 2004, J IMMUNOL, V172, P7548, DOI 10.4049/jimmunol.172.12.7548; Schamel WWA, 2003, P NATL ACAD SCI USA, V100, P9861, DOI 10.1073/pnas.1633363100; Stojanovic M, 2005, J BIOL CHEM, V280, P30018, DOI 10.1074/jbc.M501306200; Szczesna-Skorupa E, 2003, J BIOL CHEM, V278, P31269, DOI 10.1074/jbc.M301489200; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; Szczesna-Skorupa E, 2004, J BIOL CHEM, V279, P13953, DOI 10.1074/jbc.M312170200; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; SZCZESNASKORUPA E, 1993, J BIOL CHEM, V268, P1757; Takewaka T, 1999, J BIOCHEM-TOKYO, V125, P507, DOI 10.1093/oxfordjournals.jbchem.a022314; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Wang B, 2004, MOL CELL BIOL, V24, P2767, DOI 10.1128/MCB.24.7.2767-2778.2004; Wang B, 2003, J BIOL CHEM, V278, P14461, DOI 10.1074/jbc.M209684200; Zen K, 2004, J BIOL CHEM, V279, P44924, DOI 10.1074/jbc.M402115200; Zuppini A, 2002, BIOCHEMISTRY-US, V41, P2850, DOI 10.1021/bi015967+	43	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4142	4148		10.1074/jbc.M509522200	http://dx.doi.org/10.1074/jbc.M509522200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16332681	hybrid			2022-12-27	WOS:000235275300045
J	Wang, DS; Mangin, JM; Moonen, G; Rigo, JM; Legendre, P				Wang, DS; Mangin, JM; Moonen, G; Rigo, JM; Legendre, P			Mechanisms for picrotoxin block of alpha(2) homomeric glycine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; CHLORIDE CHANNELS; CONFORMATIONAL-CHANGE; CRAYFISH MUSCLE; NEURONS; BINDING; GABA; ZEBRAFISH; RESIDUE; RAT	It is well known that the convulsant alkaloid picrotoxin (PTX) can inhibit neuronal gamma-aminobutyric acid ( GABA) and homomeric glycine receptors (GlyR). However, the mechanism for PTX block of alpha(2) homomeric GlyR is still unclear compared with that of alpha(1) homomeric GlyR, GABA(A), and GABA(C) receptors. Furthermore, PTX effects on GlyR kinetics have been poorly explored at the single-channel level. Hence, we used the patch-clamp technique in the outside-out configuration to investigate the mechanism of PTX suppression of currents carried by alpha(2) homomeric GlyRs stably transfected into Chinese hamster ovary cells. PTX inhibited the alpha(2) homomeric GlyR current elicited by glycine in a concentration-dependent and voltage-independent manner. Both competitive and noncompetitive mechanisms were observed. PTX decreased the mean open time of the GlyR channel in a concentration-dependent manner, suggesting that PTX can block channel openings and bind to the receptor in the open channel conformation. When PTX and glycine were co-applied, a small rebound current was observed during drug washout. Application of PTX during the deactivation phase of glycine-induced currents eliminated the rebound current and accelerated the deactivation time course in a concentration-dependent manner. PTX could not bind to the unbound conformation of GlyR, but could be trapped at its binding site when the channel closed during glycine dissociation. Based on these observations, we propose a kinetic Markov model in which PTX binds to the alpha(2) homomeric GlyR in both the open channel state and the fully liganded closed state. Our data suggest a new allosteric mechanism for PTX inhibition of wild-type homomeric alpha(2) GlyR.	Univ Paris 06, CNRS, Unite Mixte Rech 7102, F-75252 Paris 05, France; Fac Med, Ctr Rech Neurobiol Cellulaire & Mol, B-4020 Liege 2, Belgium; Univ Hasselt, Ctr Biomed Res, B-3590 Diepenbeek, Belgium; Fourth Mil Med Univ, Dept Anat, Xian 710032, Peoples R China	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Hasselt University; Air Force Military Medical University	Legendre, P (corresponding author), Univ Paris 06, CNRS, Unite Mixte Rech 7102, 9 Quai St Bernard, F-75252 Paris 05, France.	pascal.legendre@snv.jussieu.fr	Rigo, Jean-Michel/E-3456-2010	Rigo, Jean-Michel/0000-0002-0031-526X; Mangin, Jean-Marie/0000-0002-7804-0251				Adelsberger H, 1998, EUR J NEUROSCI, V10, P179, DOI 10.1046/j.1460-9568.1998.00038.x; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; Buhr A, 2001, J BIOL CHEM, V276, P7775, DOI 10.1074/jbc.M008907200; Burzomato V, 2004, J NEUROSCI, V24, P10924, DOI 10.1523/JNEUROSCI.3424-04.2004; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Colquhoun D, 2004, TRENDS NEUROSCI, V27, P337, DOI 10.1016/j.tins.2004.04.010; Colquhoun David, 1995, P397; Das P, 2005, J PHARMACOL EXP THER, V314, P320, DOI 10.1124/jpet.104.080325; Dibas MI, 2002, J BIOL CHEM, V277, P9112, DOI 10.1074/jbc.M111356200; Etter A, 1999, J NEUROCHEM, V72, P318, DOI 10.1111/jnc.1999.72.1.318; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Flint AC, 1998, NEURON, V20, P43, DOI 10.1016/S0896-6273(00)80433-X; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; Gentet LJ, 2002, J PHYSIOL-LONDON, V544, P97, DOI 10.1113/jphysiol.2001.015321; Grudzinska J, 2005, NEURON, V45, P727, DOI 10.1016/j.neuron.2005.01.028; GURLEY D, 1995, RECEPTOR CHANNEL, V3, P13; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harvey RJ, 2000, EUR J NEUROSCI, V12, P994, DOI 10.1046/j.1460-9568.2000.00993.x; Hawthorne R, 2005, J BIOL CHEM, V280, P35836, DOI 10.1074/jbc.M506645200; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; KUHSE J, 1991, FEBS LETT, V283, P73, DOI 10.1016/0014-5793(91)80557-J; Legendre P, 1997, J NEUROPHYSIOL, V77, P2400, DOI 10.1152/jn.1997.77.5.2400; Legendre P, 1998, J NEUROSCI, V18, P2856; Legendre P, 2000, J NEUROSCI, V20, P140, DOI 10.1523/JNEUROSCI.20-01-00140.2000; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; LYNCH JW, 1995, J BIOL CHEM, V270, P13799, DOI 10.1074/jbc.270.23.13799; Lynch JW, 2004, PHYSIOL REV, V84, P1051, DOI 10.1152/physrev.00042.2003; MACONOCHIE DJ, 1995, J GEN PHYSIOL, V106, P113, DOI 10.1085/jgp.106.1.113; Mangin JA, 2003, J PHYSIOL-LONDON, V553, P369, DOI 10.1113/jphysiol.2003.052142; Mangin JM, 2005, MOL PHARMACOL, V67, P1783, DOI 10.1124/mol.104.007435; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; Qian HH, 2005, MOL PHARMACOL, V67, P470, DOI 10.1124/mol.104.003996; RUNDSTROM N, 1994, P NATL ACAD SCI USA, V91, P8950, DOI 10.1073/pnas.91.19.8950; Shan Q, 2001, J NEUROCHEM, V76, P1109, DOI 10.1046/j.1471-4159.2001.00124.x; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; TRILLER A, 1990, New Biologist, V2, P637; Xu M, 1995, BIOPHYS J, V69, P1858, DOI 10.1016/S0006-3495(95)80056-1; Yoon KW, 1998, NEUROSCIENCE, V87, P807, DOI 10.1016/S0306-4522(98)00158-4; ZHANG DX, 1995, P NATL ACAD SCI USA, V92, P11756, DOI 10.1073/pnas.92.25.11756; Zhorov BS, 2000, BIOPHYS J, V78, P1786, DOI 10.1016/S0006-3495(00)76729-4	41	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3841	3855		10.1074/jbc.M511022200	http://dx.doi.org/10.1074/jbc.M511022200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16344549	hybrid, Green Submitted			2022-12-27	WOS:000235275300012
J	Xie, Y; Newberry, EP; Young, SG; Robine, S; Hamilton, RL; Wong, JS; Luo, JY; Kennedy, S; Davidson, NO				Xie, Y; Newberry, EP; Young, SG; Robine, S; Hamilton, RL; Wong, JS; Luo, JY; Kennedy, S; Davidson, NO			Compensatory increase in hepatic lipogenesis in mice with conditional intestine-specific Mttp deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY LIPOPROTEINS; APOLIPOPROTEIN-B; CHOLESTEROL ABSORPTION; EMBRYONIC LETHALITY; APOBEC-1(-/-) MICE; APO-B; SECRETION; LIVER; GENE	Microsomal TG transfer protein (MTTP) is required for the assembly and secretion of TG (TG)-rich lipoproteins from both enterocytes and hepatocytes. Liver-specific deletion of Mttp produced a dramatic reduction in plasma very low density lipoprotein-TG and virtually eliminated apolipoprotein B100 (apoB100) secretion yet caused only modest reductions in plasma apoB48 and apoB48 secretion from primary hepatocytes. These observations prompted us to examine the phenotype following intestine-specific Mttp deletion because murine, like human enterocytes, secrete virtually exclusively apoB48. We generated mice with conditional Mttp deletion in villus enterocytes (Mttp-IKO), using a tamoxifen-inducible, intestine-specific Cre transgene. Villus enterocytes from chow-fed Mttp-IKO mice contained large cytoplasmic TG droplets and no chylomicron-sized particles within the secretory pathway. Chow-fed, Mttp-IKO mice manifested steatorrhea, growth arrest, and decreased cholesterol absorption, features that collectively recapitulate the phenotype associated with abetalipoproteinemia. Chylomicron secretion was reduced dramatically in vivo, in conjunction with an similar to 80% decrease in apoB48 secretion from primary enterocytes. Additionally, although plasma and hepatic cholesterol and TG content were decreased, Mttp-IKO mice demonstrated a paradoxical increase in both hepatic lipogenesis and very low density lipoprotein secretion. These findings establish distinctive features for MTTP involvement in intestinal chylomicron assembly and secretion and suggest that hepatic lipogenesis undergoes compensatory induction in the face of defective intestinal TG secretion.	Washington Univ, Sch Med, Dept Med, Div Gastroenterol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Inst Curie, F-75248 Paris 05, France; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA	Washington University (WUSTL); Washington University (WUSTL); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Davidson, NO (corresponding author), Washington Univ, Sch Med, Dept Med, Div Gastroenterol, Box 8124,660 S Euclid Ave, St Louis, MO 63110 USA.	nod@wustl.edu		Young, Stephen/0000-0001-7270-3176	NCI NIH HHS [CA103999, CA099506] Funding Source: Medline; NHLBI NIH HHS [HL-38180, R01 HL038180] Funding Source: Medline; NIAMS NIH HHS [AR050200] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341, DK-56260, P30 DK056341-05S2, R01 DK056260, DK-52574, P30 DK056341-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA103999, R01CA099506] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038180, R01HL038180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK052574, P30DK056341, R01DK056260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; Bjorkegren J, 2002, J BIOL CHEM, V277, P5476, DOI 10.1074/jbc.M108514200; Blanc V, 2003, J BIOL CHEM, V278, P1395, DOI 10.1074/jbc.R200024200; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Finck BN, 2005, CELL METAB, V1, P133, DOI 10.1016/j.cmet.2005.01.006; Gianturco S H, 1986, Methods Enzymol, V129, P319; Hamilton RL, 1998, J LIPID RES, V39, P1543; HUANG LS, 1995, J CLIN INVEST, V96, P2152, DOI 10.1172/JCI118269; Iqbal J, 2005, J LIPID RES, V46, P1491, DOI 10.1194/jlr.M500023-JLR200; Iqbal J, 2003, J BIOL CHEM, V278, P31610, DOI 10.1074/jbc.M301177200; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Jung HR, 1999, BIOCHEM J, V343, P473, DOI 10.1042/0264-6021:3430473; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Kuriyama H, 2005, CELL METAB, V1, P41, DOI 10.1016/j.cmet.2004.11.004; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Lieu HD, 2003, CIRCULATION, V107, P1315, DOI 10.1161/01.CIR.0000054781.50889.0C; LINTON MF, 1993, J LIPID RES, V34, P521; Nassir F, 2004, J LIPID RES, V45, P1649, DOI 10.1194/jlr.M300505-JLR200; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; SCANU AM, 1974, J CLIN INVEST, V53, P440, DOI 10.1172/JCI107578; Shoulders CC, 2005, CURR TOP MED CHEM, V5, P283, DOI 10.2174/1568026053544560; Wang DQH, 2001, J LIPID RES, V42, P1820; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Xie Y, 2003, AM J PHYSIOL-GASTR L, V285, pG735, DOI 10.1152/ajpgi.00202.2003; Young SG, 1995, J CLIN INVEST, V96, P2932, DOI 10.1172/JCI118365; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	31	95	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4075	4086		10.1074/jbc.M510622200	http://dx.doi.org/10.1074/jbc.M510622200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354657	hybrid			2022-12-27	WOS:000235275300037
J	Yang, Z; Cool, BH; Martin, GM; Hu, QB				Yang, Z; Cool, BH; Martin, GM; Hu, QB			A dominant role for FE65 (APBB1) in nuclear signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; ADAPTER PROTEIN; TIP60; TRANSCRIPTION; GAMMA; TRANSDUCTION; PRESENILINS; ACTIVATION	FE65 has been described as an adaptor protein; its partners include the beta-amyloid precursor protein (APP) and Tip60 ( a histone acetyltransferase). Recent evidence suggests that APP may function in a nuclear signaling pathway via formation of APP-FE65-Tip60 complexes. The evidence is largely based on experiments in which APP/Tip60 is fused to the DNA binding domain of a yeast transcriptional factor Gal4 (Gal4DB) that can activate a reporter gene only when FE65 is coexpressed. One interpretation of published experiments has not yet been tested; however, there is the possibility that FE65 itself is the dominant transcriptional activator, whereas APP and Tip60 serve merely as positive/negative modulators or bridges for connecting FE65 to Gal4DB. To test this possibility, we fused Gal4DB directly to either end of FE65 and assessed their nuclear signaling in the presence or absence of exogenous APP/Tip60 or after knockdown of endogenous APP/ Tip60. We found that FE65-Gal4DB by itself was able to trigger robust reporter activities. Increasing levels of APP could not further augment the reporter activity, but knocking down endogenous APP or interrupting FE65-APP binding reduced the signaling by up to 2-fold. The magnitudes of the reporter activities did not correlate with relative FE65 affinities for APP. Both overexpression and knockdown experiments showed that Tip60 plays a negative role. The results are consistent with the notion that FE65 is the key agent of Gal4DB-mediated transcriptional transactivation, whereas Tip60 is an FE65-associated repressor. Although APP may have modest stimulating effects, apparently there is no absolute requirement for that molecule for the nuclear signaling pathway.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Hu, QB (corresponding author), Univ Washington, Dept Pathol, 1959 NE Pacific St, Seattle, WA 98195 USA.	qhu@u.washington.edu			NATIONAL INSTITUTE ON AGING [R01AG019711, T32AG000057] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG00057, AG19711] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Annaert W, 1999, TRENDS NEUROSCI, V22, P439, DOI 10.1016/S0166-2236(99)01455-1; Bothwell M, 2000, CELL, V102, P271, DOI 10.1016/S0092-8674(00)00032-5; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Chang Y, 2003, J BIOL CHEM, V278, P51100, DOI 10.1074/jbc.M309561200; Dickson DW, 1997, NEUROBIOL AGING, V18, pS21, DOI 10.1016/S0197-4580(97)00065-1; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gaughan L, 2001, J BIOL CHEM, V276, P46841, DOI 10.1074/jbc.M103710200; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; Green MR, 2005, MOL CELL, V18, P399, DOI 10.1016/j.molcel.2005.04.017; GUENETTE S, 2006, IN PRESS EMBO J; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hass MR, 2005, J BIOL CHEM, V280, P36895, DOI 10.1074/jbc.M502861200; Hill K, 2003, J BIOL CHEM, V278, P36032, DOI 10.1074/jbc.M301632200; Hlubek F, 2001, J BIOCHEM-TOKYO, V129, P635, DOI 10.1093/oxfordjournals.jbchem.a002901; Hu QB, 2005, J BIOL CHEM, V280, P12548, DOI 10.1074/jbc.M411855200; Hu QB, 1999, J NEUROSCI RES, V58, P632, DOI 10.1002/(SICI)1097-4547(19991201)58:5<632::AID-JNR4>3.0.CO;2-P; Hu QB, 2002, HUM MOL GENET, V11, P465, DOI 10.1093/hmg/11.4.465; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kimberly WT, 2005, J NEUROSCI, V25, P5533, DOI 10.1523/JNEUROSCI.4883-04.2005; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Kinoshita A, 2003, J BIOL CHEM, V278, P41182, DOI 10.1074/jbc.M306403200; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Lu DC, 2003, J NEUROCHEM, V87, P733, DOI 10.1046/j.1471-4159.2003.02059.x; Martin GM, 2005, CELL, V120, P523, DOI 10.1016/j.cell.2005.01.031; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Perkinton MS, 2004, J BIOL CHEM, V279, P22084, DOI 10.1074/jbc.M311479200; Philpott A, 2000, SEMIN CELL DEV BIOL, V11, P7, DOI 10.1006/scdb.1999.0346; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Santiard-Baron D, 2005, J NEUROCHEM, V93, P330, DOI 10.1111/j.1471-4159.2005.03026.x; Scheinfeld MH, 2002, J BIOL CHEM, V277, P44195, DOI 10.1074/jbc.M208110200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, P NATL ACAD SCI USA, V98, P11039, DOI 10.1073/pnas.211352598; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Telese F, 2005, EMBO REP, V6, P77, DOI 10.1038/sj.embor.7400309; Wang BP, 2004, J NEUROSCI RES, V75, P12, DOI 10.1002/jnr.10834; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Zhao Q, 2003, BIOCHEMISTRY-US, V42, P3627, DOI 10.1021/bi027117f	51	45	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4207	4214		10.1074/jbc.M508445200	http://dx.doi.org/10.1074/jbc.M508445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16332686	hybrid			2022-12-27	WOS:000235275300053
J	Chia, DJ; Ono, M; Woelfle, J; Schlesinger-Massart, M; Jiang, HL; Rotwein, P				Chia, DJ; Ono, M; Woelfle, J; Schlesinger-Massart, M; Jiang, HL; Rotwein, P			Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RIBONUCLEIC-ACID; DNA-BINDING; INSULIN; PROTEINS; EXPRESSION; PROMOTER; RECEPTOR; SOCS-3; ALPHA; IDENTIFICATION	A key agent in the anabolic actions of growth hormone (GH) is insulin-like growth factor-I (IGF-I), a 70-amino acid secreted protein with direct effects on somatic growth and tissue maintenance and repair. GH rapidly and potently stimulates IGF-I gene transcription by mechanisms independent of new protein synthesis, and recent studies have linked the transcription factor Stat5b to a regulatory network connecting the activated GH receptor on the cell membrane to the IGF-I gene in the nucleus. Here we analyze two distinct conserved GH response elements in the rat IGF-I locus that contain paired Stat5b sites. Each response element binds Stat5b in vivo in a GH-dependent way, as assessed by chromatin immunoprecipitation assays, and consists of one high affinity and one lower affinity Stat5b site, as determined by both qualitative and quantitative protein-DNA binding studies. In biochemical reconstitution experiments, both response elements are able to mediate GH-stimulated and Stat5b-dependent transcription when fused to a reporter gene containing either the major IGF-I promoter or a minimal neutral promoter, although the paired Stat5b sites located in the second IGF-I intron were more than twice as effective as the response element that mapped similar to 73 kb 5' to the IGF-I exon 1. Taken together, our results define the initial molecular architecture of a complicated GH-regulated transcriptional pathway, and suggest that apparently redundant hormone response elements provide a mechanism for amplifying GH action at a physiologically important target gene.	OR Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA; Virginia Polytech Inst & State Univ, Dept Anim & Poultry Sci, Blacksburg, VA 24061 USA	Oregon Health & Science University; Virginia Polytechnic Institute & State University	Rotwein, P (corresponding author), OR Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Rd,Mail Code L224, Portland, OR 97239 USA.	rotweinp@ohsu.edu	Woellfe, joachim F/E-9406-2014; Rotwein, Peter/R-5783-2019; Massart, Mylynda/ABC-6861-2021	Massart, Mylynda/0000-0002-8835-7957; Rotwein, Peter/0000-0002-9505-1817; , Honglin/0000-0001-9540-5788; , Joachim/0000-0002-9132-6174	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD057588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK070447, R01DK069703, R01DK063073, R01DK067961] Funding Source: NIH RePORTER; NICHD NIH HHS [K12 HD057588] Funding Source: Medline; NIDDK NIH HHS [R01 DK069703, R01 DK67961, F32 DK70447, R01 DK063073] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; Bergad PL, 2000, J BIOL CHEM, V275, P8114, DOI 10.1074/jbc.275.11.8114; BICHELL DP, 1992, MOL ENDOCRINOL, V6, P1899, DOI 10.1210/me.6.11.1899; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Davey HW, 1999, MOL CELL ENDOCRINOL, V158, P111, DOI 10.1016/S0303-7207(99)00175-6; DERCOLE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P935, DOI 10.1073/pnas.81.3.935; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GULER HP, 1988, P NATL ACAD SCI USA, V85, P4889, DOI 10.1073/pnas.85.13.4889; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; Jolivet G, 1996, FEBS LETT, V389, P257, DOI 10.1016/0014-5793(96)00598-4; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Katic M, 2005, CELL MOL LIFE SCI, V62, P320, DOI 10.1007/s00018-004-4297-y; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Litterst CM, 2003, J BIOL CHEM, V278, P45340, DOI 10.1074/jbc.M303644200; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Ooi GT, 1998, MOL ENDOCRINOL, V12, P675, DOI 10.1210/me.12.5.675; Ooi GT, 1997, MOL ENDOCRINOL, V11, P997, DOI 10.1210/me.11.7.997; Paul C, 2000, EUR J BIOCHEM, V267, P5849, DOI 10.1046/j.1432-1327.2000.01395.x; Pfitzner E, 1998, MOL ENDOCRINOL, V12, P1582, DOI 10.1210/mend.12.10.0180; Pollak M, 2000, GROWTH HORM IGF RES, V10, pS6, DOI 10.1016/S1096-6374(00)90002-9; Rotwein P, 1999, CONT ENDOCRINOL, V17, P19; ROTWEIN P, 1997, J ANIM SCI, V75, P11; SALMON WD, 1957, J LAB CLIN MED, V49, P825; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tollet-Egnell P, 1999, ENDOCRINOLOGY, V140, P3693, DOI 10.1210/en.140.8.3693; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wang Y, 2005, J BIOL CHEM, V280, P10955, DOI 10.1074/jbc.M412808200; Woelfle J, 2004, AM J PHYSIOL-ENDOC M, V286, pE393, DOI 10.1152/ajpendo.00389.2003; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woelfle J, 2003, J BIOL CHEM, V278, P22696, DOI 10.1074/jbc.M301362200; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	51	66	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3190	3197		10.1074/jbc.M510204200	http://dx.doi.org/10.1074/jbc.M510204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339156	hybrid			2022-12-27	WOS:000235128200022
J	Hao, W; Takano, T; Guillemette, J; Papillon, J; Ren, GH; Cybulsky, AV				Hao, W; Takano, T; Guillemette, J; Papillon, J; Ren, GH; Cybulsky, AV			Induction of apoptosis by the Ste20-like kinase SLK, a germinal center kinase that activates apoptosis signal-regulating kinase and p38	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR EPITHELIAL-CELLS; MESSENGER-RNA STABILITY; PROTEIN-KINASE; ENDOPLASMIC-RETICULUM; STRESS-RESPONSE; STE20-RELATED KINASE; OXIDANT STRESS; PATHWAYS; DEATH; ASK1	Expression and activity of the germinal center kinase, Ste20-like kinase ( SLK), are increased during kidney development and recovery from ischemic acute renal failure. In this study, we characterize the activation and functional role of SLK. SLK underwent dimerization via the C-terminal domain, and dimerization enhanced SLK activity. In contrast, the C-terminal domain of SLK did not dimerize with a related kinase, Mst1, and did not affect Mst1 activity. Phosphorylation/ dephosphorylation of SLK were not associated with changes in kinase activity. SLK induced phosphorylation of apoptosis signal-regulating kinase-1 ( ASK1) and increased ASK1 activity, indicating that ASK1 is a substrate of SLK. Moreover, SLK stimulated phosphorylation of p38 mitogen-activated protein kinase via ASK1, but not c-Jun N-terminal kinase nor extracellular signal-regulated kinase. Chemical anoxia and recovery during re-exposure to glucose ( ischemia-reperfusion injury in cell culture) stimulated SLK activity. Overexpression of SLK enhanced anoxia/recovery-induced apoptosis, release of cytochrome c, and activities of caspase-8 and -9, and apoptosis was reduced significantly with p38 and caspase-9 inhibitors. Induction of the endoplasmic reticulum stress response by anoxia/recovery or tunicamycin ( monitored by induction of Bip or Grp94 expression, phosphorylation of eukaryotic translation initiation factor 2 alpha subunit, expression of CHOP, and activation of caspase-12) was attenuated in cells that overexpress SLK. Thus, SLK is an anoxia/recovery-dependent kinase that is activated via homodimerization and that signals via ASK1 and p38 to promote apoptosis. Attenuation of the protective aspects of the endoplasmic reticulum stress response by SLK may contribute to its proapoptotic effect.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University	Cybulsky, AV (corresponding author), Royal Victoria Hosp, Div Nephrol, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	andrey.cybulsky@mcgill.ca	Cybulsky, Andrey V./AAG-8238-2020; Ren, Guohui/E-5388-2018	Cybulsky, Andrey V./0000-0003-4348-2348; 				ATWATER JA, 1990, ANNU REV GENET, V24, P519; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Bijian K, 2004, AM J PHYSIOL-RENAL, V286, pF255, DOI 10.1152/ajprenal.00259.2003; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brinkworth RI, 2003, P NATL ACAD SCI USA, V100, P74, DOI 10.1073/pnas.0134224100; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Coers W, 1996, EXP NEPHROL, V4, P184; Cybulsky AV, 2004, AM J PHYSIOL-RENAL, V286, pF16, DOI 10.1152/ajprenal.00144.2003; Cybulsky AV, 2002, J BIOL CHEM, V277, P41342, DOI 10.1074/jbc.M204694200; CYBULSKY AV, 1995, AM J PHYSIOL-RENAL, V269, pF739, DOI 10.1152/ajprenal.1995.269.5.F739; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Demaurex N, 2003, SCIENCE, V300, P65, DOI 10.1126/science.1083628; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Galvan V, 2003, J BIOL CHEM, V278, P13325, DOI 10.1074/jbc.M211398200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kebache S, 2004, J BIOL CHEM, V279, P9662, DOI 10.1074/jbc.M310535200; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Liu JH, 2001, BIOCHEM J, V353, P79, DOI 10.1042/bj3530079; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matsukawa J, 2004, J BIOCHEM, V136, P261, DOI 10.1093/jb/mvh134; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Savill J, 1999, KIDNEY INT, V56, P1216, DOI 10.1046/j.1523-1755.1999.00707.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Song JJ, 2004, J CELL BIOCHEM, V92, P1257, DOI 10.1002/jcb.20155; SOROKIN L, 1992, KIDNEY INT, V41, P657, DOI 10.1038/ki.1992.101; Takeda K, 2003, CELL STRUCT FUNCT, V28, P23; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Van Laethem A, 2004, FASEB J, V18, P1946, DOI 10.1096/fj.04-2285fje; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Yamada E, 2000, BBA-MOL CELL RES, V1495, P250, DOI 10.1016/S0167-4889(99)00164-0; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	52	55	59	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3075	3084		10.1074/jbc.M511744200	http://dx.doi.org/10.1074/jbc.M511744200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16316999	hybrid			2022-12-27	WOS:000235128200010
J	Henage, LG; Exton, JH; Brown, HA				Henage, LG; Exton, JH; Brown, HA			Kinetic analysis of a mammalian phospholipase D - Allosteric modulation by monomeric GTPases, protein kinase C, and polyphosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION-FACTOR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MEDIATED ACTIVATION; INTERACTION SITES; BINDING; RHO; MECHANISM; IDENTIFICATION; ENZYMES; FAMILY	In mammalian cells, phospholipase D activity is tightly regulated by diverse cellular signals, including hormones, neurotransmitters, and growth factors. Multiple signaling pathways converge upon phospholipase D to modulate cellular actions, such as cell growth, shape, and secretion. We examined the kinetics of protein kinase C and G-protein regulation of mammalian phospholipase D1 (PLD1) in order to better understand interactions between PLD1 and its regulators. Activation by Arf-1, RhoA, Rac1, Cdc42, protein kinase C alpha, and phosphatidylinositol 4,5-bisphosphate displayed surface dilution kinetics, but these effectors modulated different kinetic parameters. PKC alpha activation of PLD1 involves N- and C-terminal PLD domains. Rho GTPases were binding activators, enhancing the catalytic efficiency of a purified PLD1 catalytic domain via effects on K-m. Arf-1, a catalytic activator, stimulated PLD1 by enhancing the catalytic constant, k(cat). A kinetic description of PLD1 activation by multiple modulators reveals a mechanism for apparent synergy between activators. Synergy was observed only when PLD1 was simultaneously stimulated by a binding activator and a catalytic activator. Surprisingly, synergistic activation was steeply dependent on phosphatidylinositol 4,5-bisphosphate and phosphatidylcholine. Together, these findings suggest a role for PLD1 as a signaling node, in which integration of convergent signals occurs within discrete locales of the cellular membrane.	Vanderbilt Univ, Dept Pharmacol, Inst Biol Chem, Nashville, TN 37232 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Brown, HA (corresponding author), Vanderbilt Univ, Dept Pharmacol, Inst Biol Chem, Nashville, TN 37232 USA.	alex.brown@vanderbilt.edu			NIGMS NIH HHS [GM58516, R01 GM058516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Buser CA, 1998, METH MOL B, V84, P267; Cai SM, 2001, BIOCHEM J, V355, P779, DOI 10.1042/bj3550779; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Chalifa-Caspi V, 1998, NEUROCHEM RES, V23, P589, DOI 10.1023/A:1022422418388; Du GW, 2003, J CELL BIOL, V162, P305, DOI 10.1083/jcb.200302033; Du GW, 2000, MOL BIOL CELL, V11, P4359, DOI 10.1091/mbc.11.12.4359; Dubois T, 2005, NAT CELL BIOL, V7, P353, DOI 10.1038/ncb1244; Elias M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-2; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Foster DA, 2003, MOL CANCER RES, V1, P789; Ge MT, 2001, BIOPHYS J, V81, P994, DOI 10.1016/S0006-3495(01)75757-8; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hiroyama M, 2005, J CELL BIOCHEM, V95, P149, DOI 10.1002/jcb.20351; Hodgkin MN, 2000, CURR BIOL, V10, P43, DOI 10.1016/S0960-9822(99)00264-X; Hoer A, 2000, BBA-PROTEIN STRUCT M, V1481, P189, DOI 10.1016/S0167-4838(00)00108-4; *IUPAC IUBMB, 1982, EUR J BIOCHEM, V128, P281; Jiang XJ, 2002, METHOD ENZYMOL, V345, P328; Kook S, 2005, CELL SIGNAL, V17, P1423, DOI 10.1016/j.cellsig.2005.03.003; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; Leiros I, 2004, J MOL BIOL, V339, P805, DOI 10.1016/j.jmb.2004.04.003; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Matas OB, 2004, TRAFFIC, V5, P838, DOI 10.1111/j.1600-0854.2004.00225.x; McDermott M, 2004, BIOCHEM CELL BIOL, V82, P225, DOI 10.1139/o03-079; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Nakamura SI, 1996, P NATL ACAD SCI USA, V93, P4300, DOI 10.1073/pnas.93.9.4300; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Ponting CP, 1996, PROTEIN SCI, V5, P914; Qin CB, 2002, J BIOL CHEM, V277, P49685, DOI 10.1074/jbc.M209598200; Roth MG, 2004, PHYSIOL REV, V84, P699, DOI 10.1152/physrev.00033.2003; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; Sciorra VA, 2001, BIOCHEMISTRY-US, V40, P2640, DOI 10.1021/bi002528m; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Stahelin RV, 2004, J BIOL CHEM, V279, P54918, DOI 10.1074/jbc.M407798200; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; TERUI T, 1994, J BIOL CHEM, V269, P28130; Waite M, 1999, BBA-MOL CELL BIOL L, V1439, P187, DOI 10.1016/S1388-1981(99)00094-3; Walker SJ, 2000, J BIOL CHEM, V275, P15665, DOI 10.1074/jbc.M000076200; Walker SJ, 2002, J BIOL CHEM, V277, P26260, DOI 10.1074/jbc.M201811200; Walker Stephanie J., 2003, V237, P89; Weernink PAO, 2004, EUR J PHARMACOL, V500, P87, DOI 10.1016/j.ejphar.2004.07.014; Westermann P, 1996, BIOCHEM J, V320, P651, DOI 10.1042/bj3200651; Yang HY, 2003, PROTEIN SCI, V12, P2087, DOI 10.1110/ps.03192503; Zheng L, 2002, BIOCHEMISTRY-US, V41, P4546, DOI 10.1021/bi0158775; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	56	48	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3408	3417		10.1074/jbc.M508800200	http://dx.doi.org/10.1074/jbc.M508800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339153	Green Accepted, hybrid			2022-12-27	WOS:000235128200049
J	Kramlinger, VM; Hiasa, H				Kramlinger, VM; Hiasa, H			The "GyrA-box" is required for the ability of DNA gyrase to wrap DNA and catalyze the supercoiling reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; REPLICATION IN-VITRO; ESCHERICHIA-COLI; TOPOISOMERASE-IV; A-PROTEIN; ENZYME; RECONSTITUTION; PURIFICATION; MECHANISM; SUBUNITS	DNA gyrase is the only topoisomerase that can introduce negative supercoils into DNA. It is thought that the binding of conventional type II topoisomerases, including topoisomerase IV, to DNA takes place at the catalytic domain across the DNA gate, whereas DNA gyrase binds to DNA not only at the amino-terminal catalytic domain but also at the carboxyl-terminal domain (CTD) of the GyrA subunit. The binding of the GyrA CTD to DNA allows gyrase to wrap DNA around itself and catalyze the supercoiling reaction. Recent structural studies, however, have revealed striking similarities between the GyrA CTD and the ParC CTD, as well as the ability of the ParC CTD to bind and bend DNA. Thus, the molecular basis of gyrase-mediated wrapping of DNA needs to be reexamined. Here, we have conducted a mutational analysis to determine the role of the '' GyrA-box,'' a 7-amino acid-long motif unique to the GyrA CTD, in determining the DNA binding mode of gyrase. Either a deletion of the entire GyrA-box or substitution of the GyrA-box with 7 Ala residues abolishes the ability of gyrase to wrap DNA around itself and catalyze the supercoiling reaction. However, these mutations do not affect the relaxation and decatenation activities of gyrase. Thus, the presence of a GyrA-box allows gyrase to wrap DNA and catalyze the supercoiling reaction. The consequence of the loss of the GyrA-box during evolution of bacterial type II topoisomerases is discussed.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Hiasa, H (corresponding author), 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	hiasa001@umn.edu						ADAMS DE, 1992, CELL, V71, P277, DOI 10.1016/0092-8674(92)90356-H; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Buhler C, 1998, NUCLEIC ACIDS RES, V26, P5157, DOI 10.1093/nar/26.22.5157; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Charvin G, 2005, BIOPHYS J, V89, P384, DOI 10.1529/biophysj.105.060202; Corbett KD, 2005, J MOL BIOL, V351, P545, DOI 10.1016/j.jmb.2005.06.029; Corbett KD, 2004, P NATL ACAD SCI USA, V101, P7293, DOI 10.1073/pnas.0401595101; Hiasa H, 2000, J BIOL CHEM, V275, P34780, DOI 10.1074/jbc.M001608200; HIASA H, 1994, J BIOL CHEM, V269, P2093; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; Hsieh TJ, 2004, J BIOL CHEM, V279, P55587, DOI 10.1074/jbc.M408934200; Kampranis SC, 1996, P NATL ACAD SCI USA, V93, P14416, DOI 10.1073/pnas.93.25.14416; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; Knight SW, 1999, EMBO J, V18, P4875, DOI 10.1093/emboj/18.17.4875; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; MORTON RM, 1993, METHOD ENZYMOL, V217, P270; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; Qi Y, 2002, PROTEINS, V47, P258, DOI 10.1002/prot.10090; REECE RJ, 1989, J BIOL CHEM, V264, P19648; REECE RJ, 1991, J BIOL CHEM, V266, P3540; Ruthenburg AJ, 2005, J BIOL CHEM, V280, P26177, DOI 10.1074/jbc.M502838200; Shea ME, 2000, J BIOL CHEM, V275, P14649, DOI 10.1074/jbc.275.19.14649; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Ward D, 1997, MOL MICROBIOL, V26, P897, DOI 10.1046/j.1365-2958.1997.6242005.x	29	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3738	3742		10.1074/jbc.M511160200	http://dx.doi.org/10.1074/jbc.M511160200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332690	hybrid			2022-12-27	WOS:000235128200086
J	Krueger, S; Hundertmark, T; Kalinski, T; Peitz, U; Wex, T; Malfertheiner, P; Naumann, M; Roessner, A				Krueger, S; Hundertmark, T; Kalinski, T; Peitz, U; Wex, T; Malfertheiner, P; Naumann, M; Roessner, A			Helicobacter pylori encoding the pathogenicity island activates matrix metalloproteinase 1 in gastric epithelial cells via JNK and ERK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; MATRIX-METALLOPROTEINASE SECRETION; INTERSTITIAL COLLAGENASE; PROSTAGLANDIN E-2; PROTEIN-KINASES; GENE-EXPRESSION; RHO GTPASES; IN-VITRO; INFECTION; CANCER	Helicobacter pylori colonizes the human gastric epithelium and induces an inflammatory response that is a trigger for gastric carcinogenesis. Matrix metalloproteinases ( MMPs) have recently been shown to be up-regulated in gastric epithelial cells infected with H. pylori and might contribute to the pathogenesis of peptic ulcer. The aim of this study was to extend the knowledge about the effect of H. pylori infection on MMP-1 expression by gastric epithelial cells, the kinetics of induction, the pathogenetic properties of the bacterium, and the intracellular signaling pathways required for MMP-1 up-regulation. Expression of MMP-1 was induced more than 10-fold by co-culture of AGS cells with H. pylori strains carrying the pathogenicity island (PAI(+)). H. pylori strains with mutations in the PAI and a defective type IV secretion system had no effect on MMP-1. Double immunofluorescence revealed strong MMP-1 staining in epithelial cells of gastric biopsies at sites of bacterial attachment. In vitro, MMP-1 is up-regulated by interleukin-1 beta and tumor necrosis factor-alpha, but these regulatory mechanisms are not operating in H. pylori infection as shown by inhibitory antibodies. Specific inhibitors of JNK kinase and ERK1/2 kinase were found to suppress the H. pylori-induced MMP-1 expression and activity. AGS cells treated with antisense MMP-1 showed a significantly reduced potential to degrade reconstituted basement membrane. Our results suggest that in gastric epithelial cells, H. pylori up-regulate sMMP-1 in a type IV secretion system-dependent manner via JNK and ERK1/2. Induction of MMP-1 is further implicated in complex processes induced by H. pylori, resulting in tissue degradation and remodeling of the gastric mucosa.	Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Gastroenterol Hepatol & Infect Dis, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Expt Internal Med, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Krueger, S (corresponding author), Otto Von Guericke Univ, Inst Pathol, Leipziger Str 44, D-39120 Magdeburg, Germany.	sabine.krueger@medizin.uni-magdeburg.de	Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Al-Ghoul L, 2004, BIOCHEM BIOPH RES CO, V322, P860, DOI 10.1016/j.bbrc.2004.07.199; Bebb JR, 2003, GUT, V52, P1408, DOI 10.1136/gut.52.10.1408; Bergin PJ, 2004, HELICOBACTER, V9, P201, DOI 10.1111/j.1083-4389.2004.00232.x; BLASER MJ, 1995, CANCER RES, V55, P2111; Brauchle M, 2000, EXP CELL RES, V258, P135, DOI 10.1006/excr.2000.4913; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; Churin Y, 2001, MOL MICROBIOL, V40, P815, DOI 10.1046/j.1365-2958.2001.02443.x; Cover TL, 1999, GASTROENTEROLOGY, V117, P257, DOI 10.1016/S0016-5085(99)70575-5; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; Crowe SE, 2005, CURR OPIN GASTROEN, V21, P32; Deroanne CF, 2005, J CELL SCI, V118, P1173, DOI 10.1242/jcs.01707; Gooz M, 2003, GUT, V52, P1250, DOI 10.1136/gut.52.9.1250; Gooz M, 2001, AM J PHYSIOL-GASTR L, V281, pG823, DOI 10.1152/ajpgi.2001.281.3.G823; Ho LJ, 2005, BIOCHEM PHARMACOL, V70, P200, DOI 10.1016/j.bcp.2005.04.039; Huntington JT, 2004, J BIOL CHEM, V279, P33168, DOI 10.1074/jbc.M405102200; Inoue T, 1999, INT J MOL MED, V4, P73; Keates S, 1999, J IMMUNOL, V163, P5552; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; Kida Y, 2005, CYTOKINE, V29, P159, DOI 10.1016/j.cyto.2004.10.009; Koyama S, 2004, SCAND J GASTROENTERO, V39, P1046, DOI 10.1080/00365520410003245; Krueger S, 2001, CANCER GENE THER, V8, P522, DOI 10.1038/sj.cgt.7700341; Kruger S, 1999, CANCER RES, V59, P6010; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Malfertheiner P, 2005, AM J GASTROENTEROL, V100, P2100, DOI 10.1111/j.1572-0241.2005.41688.x; Menges M, 2000, Z GASTROENTEROL, V38, P887, DOI 10.1055/s-2000-10300; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; Murray GI, 1998, GUT, V43, P791, DOI 10.1136/gut.43.6.791; Naumann M, 2005, INT J MED MICROBIOL, V295, P335, DOI 10.1016/j.ijmm.2005.06.007; Naumann M, 2004, TRENDS MICROBIOL, V12, P29, DOI 10.1016/j.tim.2003.11.005; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; OTANI Y, 1994, J GASTROENTEROL, V29, P391, DOI 10.1007/BF02361233; Otani Y, 1997, J CLIN GASTROENTEROL, V25, pS101, DOI 10.1097/00004836-199700001-00017; Pardo A, 2005, INT J BIOCHEM CELL B, V37, P283, DOI 10.1016/j.biocel.2004.06.017; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pillinger MH, 2005, J BIOL CHEM, V280, P9973, DOI 10.1074/jbc.M413522200; Pomorski T, 2001, J BIOL CHEM, V276, P804, DOI 10.1074/jbc.M003819200; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sharma SA, 1998, J IMMUNOL, V160, P2401; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Stoicov C, 2004, GENE, V341, P1, DOI 10.1016/j.gene.2004.07.023; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Wroblewski LE, 2003, J CELL SCI, V116, P3017, DOI 10.1242/jcs.00518; Yokoyama T, 2000, ALIMENT PHARM THERAP, V14, P193, DOI 10.1046/j.1365-2036.2000.014s1193.x; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	50	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2868	2875		10.1074/jbc.m511053200	http://dx.doi.org/10.1074/jbc.m511053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16321971	hybrid			2022-12-27	WOS:000234931800055
J	Jadlowiec, JA; Zhang, XY; Li, JH; Campbell, PG; Sfeir, C				Jadlowiec, JA; Zhang, XY; Li, JH; Campbell, PG; Sfeir, C			Extracellular matrix-mediated signaling by dentin phosphophoryn involves activation of the smad pathway independent of bone morphogenetic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESENCHYMAL STEM-CELLS; GENE-EXPRESSION; RAT INCISOR; NEURAL INDUCTION; MAPK PATHWAYS; BMP; DIFFERENTIATION; BETA; PHOSPHOPROTEIN; INTEGRATION	Cells have ingenious mechanisms for interpreting complex signals from their external microenvironment. Previously, we have shown that phosphophoryn (PP) regulates the expression of bone/ dentin marker genes via the integrin/MAPK signaling pathway (Jadlowiec, J., Koch, H., Zhang, X., Campbell, P. G., Seyedain, M., and Sfeir, C. ( 2004) J. Biol. Chem. 279, 53323 - 53330). We hypothesize that other signaling pathways important for mineralized tissue morphogenesis such as the Smad pathway could be involved in PP signaling. We determined activation of the Smad pathway in human adult mesenchymal stem cells following treatment with recombinant PP (rPP). We observed that PP enhanced phosphorylation of Smad1 within 30 min and Smad1 translocation to the nucleus within 1 h. PP up-regulated the expression of Smad1 target genes, Smad6, Dlx5, and Runx2. The timing of PP activation of Smad1 implies this is a direct effect; however, we also investigated the possible involvement of bone morphogenetic proteins in PP stimulation of the Smad pathway. PP was shown to up-regulate Bmp-2 gene expression 12 h post-treatment with PP, which is much later than initial detection of Smad1 phosphorylation at 30 min. Furthermore, addition of Noggin did not block Smad1 phosphorylation by PP. We propose that PP could signal via the Smad pathway by either directly stimulating the phosphorylation of Smad1 via integrins or other mechanisms. These might include integrin/bone morphogenetic protein receptor interactions or involvement of PP with other growth factors leading to the modulation of intracellular signaling. It is noteworthy that a non-transforming growth factor-beta family member activates the Smad pathway. The role of PP in regulating the Smad pathway raises very interesting questions regarding the role of PP during bone and tooth development.	Univ Pittsburgh, Sch Dent Med, Dept Oral Med & Pathol, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Inst Complex Engineered Syst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Carnegie Mellon University	Sfeir, C (corresponding author), Univ Pittsburgh, Sch Dent Med, Dept Oral Med & Pathol, 693A Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.	csfeir@pitt.edu			NIDCR NIH HHS [DE 016123-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016123] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; *APPL BIOS, 2001, US B APPL BIOS, V2; Aubin J, 2004, GENE DEV, V18, P1482, DOI 10.1101/gad.1202604; Celil AB, 2005, J CELL BIOCHEM, V95, P518, DOI 10.1002/jcb.20429; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; DEVRIES IG, 1989, HISTOCHEMISTRY, V91, P69, DOI 10.1007/BF00501914; Diefenderfer DL, 2003, CONNECT TISSUE RES, V44, P305, DOI 10.1080/03008200390181825; Ebara S, 2002, SPINE, V27, pS10, DOI 10.1097/00007632-200208151-00004; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Ganan Y, 1996, DEVELOPMENT, V122, P2349; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guha U, 2002, DEV BIOL, V249, P108, DOI 10.1006/dbio.2002.0752; Jadlowiec J, 2005, ENDOCRINOLOGY, V146, P3765, DOI 10.1210/en.2004-1351; Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; Kimura N, 2000, J BIOL CHEM, V275, P17647, DOI 10.1074/jbc.M908622199; KOCH H, 2005, IN PRESS STEM CELL D; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lai CF, 2002, J BIOL CHEM, V277, P15514, DOI 10.1074/jbc.M200794200; LINDE A, 1980, J BIOL CHEM, V255, P5931; MACDOUGALL M, 1985, BIOCHEM J, V232, P493, DOI 10.1042/bj2320493; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2003, GENE DEV, V17, P2993, DOI 10.1101/gad.1167003; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; Raftery LA, 2003, TRENDS GENET, V19, P701, DOI 10.1016/j.tig.2003.10.009; RICHARDSON WS, 1978, J BIOL CHEM, V253, P8042; Seki K, 2004, J BIOL CHEM, V279, P18544, DOI 10.1074/jbc.M311592200; Sfeir C, 1996, CONNECT TISSUE RES, V35, P215, DOI 10.3109/03008209609029194; SFEIR C, 1995, J BONE MINER RES, V10, P607; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 2002, TRENDS CELL BIOL, V12, P304, DOI 10.1016/S0962-8924(02)02300-0; Tamura Y, 2001, J BONE MINER RES, V16, P1772, DOI 10.1359/jbmr.2001.16.10.1772; URIST MARSHALL R., 1967, CLIN ORTHOP RELATED RESIN COMPLICATIONS OF ORTHOPAEDIC SURGERY, V53, P243; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Veis A, 1998, EUR J ORAL SCI, V106, P234, DOI 10.1111/j.1600-0722.1998.tb02181.x; von Bubnoff A, 2001, DEV BIOL, V239, P1, DOI 10.1006/dbio.2001.0388; Weinstein DC, 1999, ANNU REV CELL DEV BI, V15, P411, DOI 10.1146/annurev.cellbio.15.1.411; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Xiao GZ, 2005, J BIOL CHEM, V280, P30689, DOI 10.1074/jbc.M500750200; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang W, 2002, J CELL PHYSIOL, V193, P233, DOI 10.1002/jcp.10168	49	59	59	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5341	5347		10.1074/jbc.M506158200	http://dx.doi.org/10.1074/jbc.M506158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16326713	hybrid			2022-12-27	WOS:000235568900004
J	Romero, C; Desai, P; DeLillo, N; Vancura, A				Romero, C; Desai, P; DeLillo, N; Vancura, A			Expression of FLR1 transporter requires phospholipase C and is repressed by mediator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; OF-FUNCTION ALLELE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; INOSITOL PYROPHOSPHATES; MICROTUBULE FUNCTION; TRANSCRIPTIONAL ACTIVATION; DIAZABORINE RESISTANCE; DEPENDENT BINDING; PLEIOTROPIC DRUG	In budding yeast, phosphoinositide-specific phospholipase C (Plc1p encoded by PLC1 gene) is important for function of kinetochores. Deletion of PLC1 results in benomyl sensitivity, alterations in chromatin structure of centromeres, mitotic delay, and a higher frequency of chromosome loss. Here we intended to utilize benomyl sensitivity as a phenotype that would allow us to identify genes that are important for kinetochore function and are downstream of Plc1p. However, our screen identified SIN4, encoding a component of the Mediator complex of RNA polymerase II. Deletion of SIN4 gene (sin4 Delta) does not suppress benomyl sensitivity of plc1 Delta cells by improving the function of kinetochores. Instead, benomyl sensitivity of plc1 Delta cells is caused by a defect in expression of FLR1, and the suppression of benomyl sensitivity in plc1 Delta sin4 Delta cells occurs by derepression of FLR1 transcription. FLR1 encodes a plasma membrane transporter that mediates resistance to benomyl. Several other mutations in the Mediator complex also result in significant derepression of FLR1 and greatly increased resistance to benomyl. Thus, benomyl sensitivity is not a phenotype exclusively associated with mitotic spindle defect. These results demonstrate that in addition to promoter-specific transcription factors that are components of the pleiotropic drug resistance network, expression of the membrane transporters can be regulated by Plc1p, a component of a signal transduction pathway, and by Mediator, a general transcription factor. The results thus suggest another layer of complexity in regulation of pleiotropic drug resistance.	St Johns Univ, Dept Biol Sci, Queens, NY 11439 USA	Saint John's University	Vancura, A (corresponding author), St Johns Univ, Dept Biol Sci, 8000 Utopia Pkwy, Queens, NY 11439 USA.	vancuraa@stjohns.edu		Vancura, Ales/0000-0002-5895-1218	NIGMS NIH HHS [GM 62183] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM062183] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asturias FJ, 1999, SCIENCE, V283, P985, DOI 10.1126/science.283.5404.985; Balciunas D, 1999, P NATL ACAD SCI USA, V96, P376, DOI 10.1073/pnas.96.2.376; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Bhoite LT, 2001, GENE DEV, V15, P2457, DOI 10.1101/gad.921601; Broco N, 1999, YEAST, V15, P1595; Cardenas ME, 1999, CLIN MICROBIOL REV, V12, P583, DOI 10.1128/CMR.12.4.583; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; COVITZ PA, 1994, GENETICS, V138, P577; DeLillo N, 2003, MOL GENET GENOMICS, V269, P261, DOI 10.1007/s00438-003-0832-4; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Dotson MR, 2000, P NATL ACAD SCI USA, V97, P14307, DOI 10.1073/pnas.260489497; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JIANG YW, 1995, GENETICS, V140, P47; Jungwirth H, 2000, EUR J BIOCHEM, V267, P4809, DOI 10.1046/j.1432-1327.2000.01537.x; KINGSBURY J, 1991, CELL, V66, P483, DOI 10.1016/0092-8674(81)90012-X; KINGSBURY J, 1993, MOL BIOL CELL, V4, P859, DOI 10.1091/mbc.4.8.859; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; Le Crom S, 2002, MOL CELL BIOL, V22, P2642, DOI 10.1128/MCB.22.8.2642-2649.2002; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Lin H, 2002, MOL GENET GENOMICS, V267, P313, DOI 10.1007/s00438-002-0647-8; Lin HY, 2000, MOL CELL BIOL, V20, P3597, DOI 10.1128/MCB.20.10.3597-3607.2000; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; Macatee T, 1997, NUCLEIC ACIDS RES, V25, P1240, DOI 10.1093/nar/25.6.1240; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Nguyen DT, 2001, J BIOL CHEM, V276, P1138, DOI 10.1074/jbc.M008377200; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Park JM, 2000, MOL CELL BIOL, V20, P8709, DOI 10.1128/MCB.20.23.8709-8719.2000; Proft M, 1999, MOL CELL BIOL, V19, P537; REIJO RA, 1993, GENETICS, V135, P955; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 2004, SCIENCE, V306, P2101, DOI 10.1126/science.1103344; Schuller J, 2003, J MOL MICROB BIOTECH, V5, P199, DOI 10.1159/000071071; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Song WJ, 1996, MOL CELL BIOL, V16, P115; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; STEARNS T, 1990, GENETICS, V124, P251; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Tenreiro S, 2001, BIOCHEM BIOPH RES CO, V280, P216, DOI 10.1006/bbrc.2000.4100; THOMAS JH, 1985, GENETICS, V111, P715; Wehrschutz-Sigl E, 2004, EUR J BIOCHEM, V271, P1145, DOI 10.1111/j.1432-1033.2004.04018.x; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Yu YX, 2003, MOL CELL BIOL, V23, P1910, DOI 10.1128/MCB.23.6.1910-1921.2003; Zaman Z, 2001, P NATL ACAD SCI USA, V98, P2550, DOI 10.1073/pnas.041611198; Zhang F, 2004, MOL CELL BIOL, V24, P6871, DOI 10.1128/mcb.24.15.6871-6886.2004; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	63	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5677	5685		10.1074/jbc.M506728200	http://dx.doi.org/10.1074/jbc.M506728200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16352614	hybrid			2022-12-27	WOS:000235568900044
J	Yoshida, K; Liu, HS; Miki, Y				Yoshida, K; Liu, HS; Miki, Y			Protein kinase C delta regulates Ser(46) phosphorylation of p53 tumor suppressor in the apoptotic response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; PROTEOLYTIC ACTIVATION; P53-DEPENDENT APOPTOSIS; CASPASE-3; STRESS; CELLS; RADIATION; RAD9; P21	The p53 tumor suppressor is activated in the cellular response to genotoxic stress. Transactivation of p53 target genes dictates cell cycle arrest and DNA repair or induction of apoptosis; however, a molecular mechanism responsible for these distinct functions remains unclear. Recent studies revealed that phosphorylation of p53 on Ser(46) was associated with induction of p53AIP1 expression, resulting in the commitment of the cell fate into apoptotic cell death. Moreover, upon exposure to genotoxic stress, p53DINP1 was expressed and recruited a kinase(s) to p53 that specifically phosphorylated Ser46. Here, we show that the pro-apoptotic kinase, protein kinase C delta(PKC delta), is involved in phosphorylation of p53 on Ser46. PKC delta-mediated phosphorylation is required for the interaction of PKC delta with p53. The results also demonstrate that p53DINP1 associates with PKC delta upon exposure to genotoxic agents. Consistent with these results, PKC delta potentiates p53-dependent apoptosis by Ser46 phosphorylation in response to genotoxic stress. These findings indicate that PKC delta regulates p53 to induce apoptotic cell death in the cellular response to DNA damage.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU)	Yoshida, K (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	yos.mgen@mri.tmd.ac.jp						Abbas T, 2004, J BIOL CHEM, V279, P9970, DOI 10.1074/jbc.M306979200; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Johnson CL, 2002, MOL CANCER THER, V1, P861; Kamada S, 2005, J BIOL CHEM, V280, P857, DOI 10.1074/jbc.C400538200; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; Leitges M, 2001, J CLIN INVEST, V108, P1505; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Voss OH, 2005, J BIOL CHEM, V280, P17371, DOI 10.1074/jbc.M412449200; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yoshida K, 2005, CELL CYCLE, V4, P777, DOI 10.4161/cc.4.6.1746; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, J BIOL CHEM, V277, P48372, DOI 10.1074/jbc.M205485200; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yoshida K, 2001, MOL PHARMACOL, V60, P1431, DOI 10.1124/mol.60.6.1431; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	34	130	136	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5734	5740		10.1074/jbc.M512074200	http://dx.doi.org/10.1074/jbc.M512074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377624	hybrid			2022-12-27	WOS:000235568900051
J	Yu, WM; Daino, H; Chen, J; Bunting, KD; Qu, CK				Yu, WM; Daino, H; Chen, J; Bunting, KD; Qu, CK			Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUVENILE MYELOMONOCYTIC LEUKEMIA; HEMATOPOIETIC-CELL DEVELOPMENT; COLONY-STIMULATING FACTOR; TYROSINE-PHOSPHATASE; PTPN11 MUTATIONS; NOONAN-SYNDROME; SH2 DOMAINS; MOUSE MODEL; RECEPTOR; NF1	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3. However, the molecular mechanisms by which gain-of-function (GOF) mutations of SHP-2 induce hematopoietic malignancies are not fully understood. Our previous studies have shown that SHP-2 plays an essential role in IL-3 signal transduction in both catalytic-dependent and - independent manners and that overexpression (5-6-fold) of wild type (WT) SHP-2 attenuates IL-3-mediated hematopoietic cell function through accelerated dephosphorylation of STAT5. These results raised the possibility that SHP-2-associated leukemias are not solely attributed to the increased catalytic activity of GOF mutant SHP-2. GOF mutant SHP-2 must have gained additional capacities. To test this possibility, we investigated effects of a GOF mutation of SHP- 2 ( SHP- 2 E76K) on hematopoietic cell function and IL-3 signal transduction by comparing with those of overexpressed WT SHP-2. Our results showed that SHP- 2 E76K mutation caused myeloproliferative disease in mice, while overexpression of WT SHP- 2 decreased hematopoietic potential of the transduced cells in recipient animals. The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP- 2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways. In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP- 2 E76K was dampened. Furthermore, catalytically inactive SHP- 2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway. Taken together, these studies suggest that in addition to the elevated catalytic activity, fundamental changes in physical and functional interactions between GOF mutant SHP- 2 and signaling partners also play an important role in SHP- 2-related leukemigenesis.	Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Cleveland, OH 44106 USA	Case Western Reserve University	Qu, CK (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cxq6@case.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059380] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 68212] Funding Source: Medline; NIDDK NIH HHS [R01 DK059380] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Arico M, 1997, BLOOD, V90, P479, DOI 10.1182/blood.V90.2.479.479_479_488; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Birnbaum RA, 2000, MOL CELL, V5, P189, DOI 10.1016/S1097-2765(00)80415-3; Bone H, 2000, CELL SIGNAL, V12, P183, DOI 10.1016/S0898-6568(99)00088-1; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Chen J, 2004, ONCOGENE, V23, P3659, DOI 10.1038/sj.onc.1207471; Cichowski K, 2003, GENE DEV, V17, P449, DOI 10.1101/gad.1054703; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Emanuel PD, 1996, MOL MED TODAY, V2, P468, DOI 10.1016/1357-4310(96)10044-7; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Okuda K, 1999, ANN NY ACAD SCI, V872, P305, DOI 10.1111/j.1749-6632.1999.tb08474.x; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Schubbert S, 2005, BLOOD, V106, P311, DOI 10.1182/blood-2004-11-4207; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Zhang YY, 1998, J EXP MED, V187, P1893, DOI 10.1084/jem.187.11.1893	33	42	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5426	5434		10.1074/jbc.M507622200	http://dx.doi.org/10.1074/jbc.M507622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371368	hybrid			2022-12-27	WOS:000235568900014
J	Bowers, K; Piper, SC; Edeling, MA; Gray, SR; Owen, DJ; Lehner, PJ; Luzio, JP				Bowers, K; Piper, SC; Edeling, MA; Gray, SR; Owen, DJ; Lehner, PJ; Luzio, JP			Degradation of endocytosed epidermal growth factor and virally ubiquitinated major histocompatibility complex class I is independent of mammalian ESCRTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIVESICULAR BODY PATHWAY; RECEPTOR DOWN-REGULATION; SORTING COMPLEX; PROTEIN; YEAST; TRAFFICKING; TRANSPORT; ENDOSOMES; MUTANTS; ATPASE	Models for protein sorting at multivesicular bodies in the endocytic pathway of mammalian cells have relied largely on data obtained from yeast. These data suggest the essential role of four ESCRT complexes in multivesicular body protein sorting. However, the putative mammalian ESCRTII complex (hVps25p, hVps22p, and hVps36p) has no proven functional role in endosomal transport. We have characterized the human ESCRTII complex and investigated its function in endosomal trafficking. The human ESCRTII proteins interact with one another, with hVps20p (a component of ESCRTIII), and with their yeast homologues. Our interaction data from yeast two-hybrid studies along with experiments with purified proteins suggest an essential role for the N-terminal domain of hVps22p in the formation of a heterotetrameric ESCRTII complex. Although human ESCRTII is found in the cytoplasm and in the nucleus, it can be recruited to endosomes upon overexpression of dominant-negative hVps4Bp. Interestingly, we find that small interference RNA depletion of mammalian ESCRTII does not affect degradation of epidermal growth factor, a known cargo of the multivesicular body protein sorting pathway. We also show that depletion of the deubiquitinating enzymes AMSH (associated molecule with the SH3 domain of STAM (signal transducing adaptor molecule)) and UBPY (ubiquitin isopeptidase Y) have opposite effects on epidermal growth factor degradation, with UBPY depletion causing dramatic swelling of endosomes. Down-regulation of another cargo, the major histocompatibility complex class I in cells expressing the Kaposi sarcoma-associated herpesvirus protein K3, is unaffected in ESCRTII-depleted cells. Our data suggest that mammalian ESCRTII may be redundant, cargo-specific, or not required for protein sorting at the multivesicular body.	Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Med, Cambridge CB2 2XY, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Bowers, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Cambridge Inst Med Res, Dept Clin Biochem, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	kb123@cam.ac.uk	Bowers, Katherine/U-2013-2019	Bowers, Katherine/0000-0001-5085-5208; Lehner, Paul Joseph/0000-0001-9383-1054	Medical Research Council [G9310915, G0600823] Funding Source: Medline; Wellcome Trust [066438] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Amit I, 2004, GENE DEV, V18, P1737, DOI 10.1101/gad.294904; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Babst M, 2000, TRAFFIC, V1, P248, DOI 10.1034/j.1600-0854.2000.010307.x; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Bache KG, 2004, MOL BIOL CELL, V15, P4337, DOI 10.1091/mbc.E04-03-0250; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Benmerah A, 2004, CURR BIOL, V14, pR314, DOI 10.1016/j.cub.2004.03.053; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Bishop N, 2002, J CELL BIOL, V157, P91, DOI 10.1083/jcb.200112080; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x; Bowers K, 2005, BBA-MOL CELL RES, V1744, P438, DOI 10.1016/j.bbamcr.2005.04.004; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; Burke D., 2000, METHODS YEAST GENETI; Cabezas A, 2005, J CELL SCI, V118, P2625, DOI 10.1242/jcs.02382; Coscoy L, 2001, J CELL BIOL, V155, P1265, DOI 10.1083/jcb.200111010; Dupre S, 2001, MOL CELL BIOL, V21, P4482, DOI 10.1128/MCB.21.14.4482-4494.2001; Eastman SW, 2005, J BIOL CHEM, V280, P628, DOI 10.1074/jbc.M410384200; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hewitt EW, 2002, EMBO J, V21, P2418, DOI 10.1093/emboj/21.10.2418; Hierro A, 2004, NATURE, V431, P221, DOI 10.1038/nature02914; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; James P, 1996, GENETICS, V144, P1425; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; Katoh K, 2003, J BIOL CHEM, V278, P39104, DOI 10.1074/jbc.M301604200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Martin-Serrano J, 2003, P NATL ACAD SCI USA, V100, P12414, DOI 10.1073/pnas.2133846100; Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Mullock BM, 2000, MOL BIOL CELL, V11, P3137, DOI 10.1091/mbc.11.9.3137; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; PARHAM P, 1979, J IMMUNOL, V123, P342; Peck JW, 2004, BIOCHEM J, V377, P693, DOI 10.1042/bj20031347; Pelchen-Matthews A, 2004, TRENDS MICROBIOL, V12, P310, DOI 10.1016/j.tim.2004.05.004; Poupon V, 2002, J BIOL CHEM, V277, P8941, DOI 10.1074/jbc.M108385200; Raiborg C, 2003, CURR OPIN CELL BIOL, V15, P446, DOI 10.1016/S0955-0674(03)00080-2; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reaves BJ, 1996, J CELL SCI, V109, P749; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Roudier N, 2005, TRAFFIC, V6, P695, DOI 10.1111/j.1600-0854.2005.00309.x; Schmidt AE, 1999, J BIOL CHEM, V274, P21981, DOI 10.1074/jbc.274.31.21981; Schmidt MHH, 2004, MOL CELL BIOL, V24, P8981, DOI 10.1128/MCB.24.20.8981-8993.2004; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Sevrioukov EA, 2005, MOL BIOL CELL, V16, P2301, DOI 10.1091/mbc.E04-11-1013; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 1997, J BIOL CHEM, V272, P22355, DOI 10.1074/jbc.272.35.22355; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SLAGSVOLD T, 2005, J BIOL CHEM; Stauffer DR, 2001, J CELL SCI, V114, P2383; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020; Urbanowski JL, 2001, TRAFFIC, V2, P622, DOI 10.1034/j.1600-0854.2001.20905.x; Vaccari T, 2005, DEV CELL, V9, P687, DOI 10.1016/j.devcel.2005.09.019; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; Whitley P, 2003, J BIOL CHEM, V278, P38786, DOI 10.1074/jbc.M306864200; Yorikawa C, 2005, BIOCHEM J, V387, P17, DOI 10.1042/BJ20041227	82	140	141	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5094	5105		10.1074/jbc.M508632200	http://dx.doi.org/10.1074/jbc.M508632200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371348	hybrid			2022-12-27	WOS:000235426200064
J	Mas-Droux, C; Biou, V; Dumas, R				Mas-Droux, C; Biou, V; Dumas, R			Allosteric threonine synthase - Reorganization of the pyridoxal phosphate site upon asymmetric activation through S-adenosylmethionine binding to a novel site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; ROTATION; PROGRAM; MODEL	Threonine synthase (TS) is a fold-type II pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the ultimate step of threonine synthesis in plants and microorganisms. Unlike the enzyme from microorganisms, plant TS is activated by S-adenosylmethionine ( AdoMet). The mechanism of activation has remained unknown up to now. We report here the crystallographic structures of Arabidopsis thaliana TS in complex with PLP (aTS) and with PLP and AdoMet (aTS-AdoMet), which show with atomic detail how AdoMet activates TS. The aTS structure reveals a PLP orientation never previously observed for a type II PLP-dependent enzyme and explains the low activity of plant TS in the absence of its allosteric activator. The aTS-AdoMet structure shows that activation of the enzyme upon AdoMet binding triggers a large reorganization of active site loops in one monomer of the structural dimer and allows the displacement of PLP to its active conformation. Comparison with other TS structures shows that activation of the second monomer may be triggered by substrate binding. This structure also discloses a novel fold for two AdoMet binding sites located at the dimer interface, each site containing two AdoMet effectors bound in tandem. Moreover, aTS-AdoMet is the first structure of an enzyme that uses AdoMet as an allosteric effector.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; CNRS, Commissariat Energie Atom, Physiol Cellulaire Vegetale Lab, Dept Reponse & Dynam Cellulaires, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Dumas, R (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse, F-91198 Gif Sur Yvette, France.	rdumas@cea.fr	Dumas, Renaud/E-1835-2011					Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; Curien G, 1996, FEBS LETT, V390, P85, DOI 10.1016/0014-5793(96)00633-3; Curien G, 1998, BIOCHEMISTRY-US, V37, P13212, DOI 10.1021/bi980068f; Curien G, 2003, EUR J BIOCHEM, V270, P4615, DOI 10.1046/j.1432-1033.2003.03851.x; Evans P. R., 1997, RECENT ADV PHASING, P97; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Garrido-Franco M, 2002, J BIOL CHEM, V277, P12396, DOI 10.1074/jbc.M108734200; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; LABER B, 1994, BIOCHEMISTRY-US, V33, P3413, DOI 10.1021/bi00177a035; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Omi R, 2003, J BIOL CHEM, V278, P46035, DOI 10.1074/jbc.M308065200; Schneider G, 2000, STRUCT FOLD DES, V8, pR1, DOI 10.1016/S0969-2126(00)00085-X; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Thomazeau K, 2001, PROTEIN SCI, V10, P638, DOI 10.1110/ps.44301; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	28	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5188	5196		10.1074/jbc.M509798200	http://dx.doi.org/10.1074/jbc.M509798200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16319072	hybrid, Green Published			2022-12-27	WOS:000235426200073
J	Thiel, A; Heinonen, M; Rintahaka, J; Hallikainen, T; Hemmes, A; Dixon, DA; Haglund, C; Ristimaki, A				Thiel, A; Heinonen, M; Rintahaka, J; Hallikainen, T; Hemmes, A; Dixon, DA; Haglund, C; Ristimaki, A			Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3 beta in gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; POSTTRANSCRIPTIONAL CONTROL; GENE-EXPRESSION; KINASE; INTERLEUKIN-1-BETA; INHIBITION; ACTIVATION; PREVENTION	Cyclooxygenase-2 (COX-2) expression is a marker of poor prognosis in gastric cancer patients, and its inhibition suppresses gastric tumorigenesis in experimental animal models. The mechanism that leads to COX-2 overexpression in this tumor type is unknown. We have now shown that inhibition of phosphatidylinositol 3-kinase by LY294002 suppresses both basal and phorbol myristate acetate-induced COX-2 expression in TMK-1 and MKN-28 gastric cancer cells. Furthermore, inhibition of glycogen synthase kinase-3 beta (GSK-3 beta) by SB415286 induced expression of COX-2 mRNA and protein as well as the enzyme activity in the gastric cancer cells. The effect of SB415286 was confirmed by the use of two additional GSK-3 beta inhibitors, lithium chloride and SB216763. SB415286 had a modest 1.6-fold stimulatory effect on a 2-kb COX-2 promoter reporter construct, but more importantly, it was shown to block the decay of COX-2 mRNA. In contrast to modulation of phosphatidylinositol 3-kinase/Akt/GSK-3 beta pathway, inhibitors of mitogen-activated protein kinases (MEK 1/2, p38, JNK) or the mammalian target of rapamycin did not alter COX-2 expression in gastric cancer cells. Our data show that inhibition of GSK-3 beta stimulates COX-2 expression in gastric cancer cells, which seems to be primarily facilitated via an increase in mRNA stability and to a lesser extent through enhanced transcription.	Univ Helsinki, Mol & Canc Biol Res Program, Biomedicum, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00014 Helsinki, Finland; Univ S Carolina, Dept Biol Sci, Columbia, SC 29203 USA; Univ Helsinki, Cent Hosp, Dept Surg, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Helsinki; Helsinki University Central Hospital	Ristimaki, A (corresponding author), Univ Helsinki, Mol & Canc Biol Res Program, Biomedicum, Rm B512B,POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Ari.Ristimaki@hus.fi	Haglund, Caj/N-1240-2019					Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; Dannenberg AJ, 2005, J CLIN ONCOL, V23, P254, DOI 10.1200/JCO.2005.09.112; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Fan XM, 2001, J GASTROEN HEPATOL, V16, P1098, DOI 10.1046/j.1440-1746.2001.02593.x; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HORI T, 1993, FEBS LETT, V334, P331, DOI 10.1016/0014-5793(93)80705-Y; Hu PJ, 2004, GUT, V53, P195, DOI 10.1136/gut.2003.021477; Jang BC, 2000, J BIOL CHEM, V275, P39507, DOI 10.1074/jbc.M003224200; Jang TJ, 2004, VIRCHOWS ARCH, V445, P564, DOI 10.1007/s00428-004-1104-3; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Liu WV, 2003, CANCER RES, V63, P3632; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rao R, 2005, AM J PHYSIOL-RENAL, V288, pF642, DOI 10.1152/ajprenal.00287.2004; Rao R, 2004, J BIOL CHEM, V279, P3949, DOI 10.1074/jbc.M309325200; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Ristimaki A, 1997, CANCER RES, V57, P1276; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Saukkonen K, 2003, CANCER RES, V63, P3032; Saukkonen K, 2003, APMIS, V111, P915, DOI 10.1034/j.1600-0463.2003.1111001.x; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 2001, CANCER RES, V61, P2670; Shi H, 2003, WORLD J GASTROENTERO, V9, P1421, DOI 10.3748/wjg.v9.i7.1421; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Tang QB, 2001, CANCER RES, V61, P4329; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; van Rees BP, 2003, INT J CANCER, V107, P551, DOI 10.1002/ijc.11422; Wang Q, 2006, ONCOGENE, V25, P43, DOI 10.1038/sj.onc.1209004; Weaver SA, 2001, GASTROENTEROLOGY, V120, P1117, DOI 10.1053/gast.2001.23257; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Zheng Leizhen, 2004, Gastric Cancer, V7, P61	40	47	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4564	4569		10.1074/jbc.M512722200	http://dx.doi.org/10.1074/jbc.M512722200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371352	hybrid			2022-12-27	WOS:000235426200003
J	Boissier, F; Bardou, F; Guillet, VR; Uttenweiler-Joseph, S; Daffe, M; Quemard, A; Mourey, L				Boissier, F; Bardou, F; Guillet, VR; Uttenweiler-Joseph, S; Daffe, M; Quemard, A; Mourey, L			Further insight into S-adenosylmethionine-dependent methyltransferases - Structural characterization of Hma, an enzyme essential for the biosynthesis of oxygenated mycolic acids in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; CELL-WALL; CYCLOPROPANE SYNTHETASE; ISONIAZID INHIBITION; ENVELOPE; SEQUENCE; SYNTHASE; GENE; BCG; BICARBONATE	Mycolic acids are major and specific components of the cell envelope of Mycobacteria that include Mycobacterium tuberculosis, the causative agent of tuberculosis. Their metabolism is the target of the most efficient antitubercular drug currently used in therapy, and the enzymes that are involved in the production of mycolic acids represent important targets for the development of new drugs effective against multidrug-resistant strains. Among these are the S-adenosylmethionine-dependent methyltransferases (SAM-MTs) that catalyze the introduction of key chemical modifications in defined positions of mycolic acids. Some of these subtle structural variations are known to be crucial for both the virulence of the tubercle bacillus and the permeability of the mycobacterial cell envelope. We report here the structural characterization of the enzyme Hma (MmaA4), a SAM-MT that is unique in catalyzing the introduction of a methyl branch together with an adjacent hydroxyl group essential for the formation of both keto- and methoxymycolates in M. tuberculosis. Despite the high propensity of Hma to proteolytic degradation, the enzyme was produced and crystallized, and its three-dimensional structure in the apo-form and in complex with S-adenosylmethionine was solved to about 2 angstrom.. The structures show the important role played by the modifications found within mycolic acid SAM- MTs, especially the alpha 2-alpha 3motif and the chemical environment of the active site. Essential information with respect to cofactor and substrate binding, selectivity and specificity, and about the mechanism of catalytic reaction were derived.	CNRS, UMR 5089, IPBS, Dept Mecan Mol Infect Mycobacteriennes, F-31077 Toulouse 04, France; CNRS, Inst Pharmacol & Biol Struct, Dept Proteome & Cibles Therapeut, F-31077 Toulouse 04, France; CNRS, Inst Pharmacol & Biol Struct, Dept Plate Forme Prot, F-31077 Toulouse 04, France; Univ Toulouse 3, F-31077 Toulouse 04, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Mourey, L (corresponding author), CNRS, UMR 5089, IPBS, Dept Mecan Mol Infect Mycobacteriennes, 205 Route Narbonne, F-31077 Toulouse 04, France.	lionel.mourey@ipbs.fr	Mourey, Lionel/B-5662-2009	Mourey, Lionel/0000-0002-8259-1259; Uttenweiler, Sandrine/0000-0001-9019-4766; Quemard, Annaik/0000-0002-5545-3424				Asselineau C, 2002, PROG LIPID RES, V41, P501, DOI 10.1016/S0163-7827(02)00008-5; Behr MA, 2000, J BACTERIOL, V182, P3394, DOI 10.1128/JB.182.12.3394-3399.2000; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Chang YY, 2000, J BACTERIOL, V182, P4288, DOI 10.1128/JB.182.15.4288-4294.2000; Claverol S, 2003, MOL CELL PROTEOMICS, V2, P483, DOI 10.1074/mcp.T300003-MCP200; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Courtois F, 2005, BIOCHEMISTRY-US, V44, P13583, DOI 10.1021/bi051159x; DAFFE M, 1983, ANN INST PASTEUR MIC, VB134, P241, DOI 10.1016/S0769-2609(83)80037-4; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; DeLano W.L, PYMOL MOL GRAPHICS S; Dinadayala P, 2003, J BIOL CHEM, V278, P7310, DOI 10.1074/jbc.M210501200; Dubnau E, 1998, MOL MICROBIOL, V29, P1526; Dubnau E, 1997, MOL MICROBIOL, V23, P313, DOI 10.1046/j.1365-2958.1997.2301589.x; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; Gao LY, 2003, MOL MICROBIOL, V49, P1547, DOI 10.1046/j.1365-2958.2003.03667.x; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Glickman MS, 2003, J BIOL CHEM, V278, P7844, DOI 10.1074/jbc.M212458200; Glickman MS, 2001, J BIOL CHEM, V276, P2228, DOI 10.1074/jbc.C000652200; Goren M. B., 1979, TUBERCULOSIS, P63; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grogan DW, 1997, MICROBIOL MOL BIOL R, V61, P429, DOI 10.1128/.61.4.429-441.1997; Huang CC, 2002, J BIOL CHEM, V277, P11559, DOI 10.1074/jbc.M111698200; Iwig DF, 2005, J AM CHEM SOC, V127, P11612, DOI 10.1021/ja053899z; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; KURTH J, 1990, BIOL CHEM H-S, V371, P675, DOI 10.1515/bchm3.1990.371.2.675; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MINNIKIN DE, 1984, ARCH MICROBIOL, V139, P225, DOI 10.1007/BF00402005; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Potterton E, 2003, ACTA CRYSTALLOGR D, V59, P1131, DOI 10.1107/S0907444903008126; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; Quemard A, 1997, EUR J BIOCHEM, V250, P758, DOI 10.1111/j.1432-1033.1997.00758.x; QURESHI N, 1984, J BACTERIOL, V157, P46, DOI 10.1128/JB.157.1.46-52.1984; Rao V, 2005, J EXP MED, V201, P535, DOI 10.1084/jem.20041668; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; WINDER F G, 1970, Journal of General Microbiology, V63, P41; Wong HC, 2002, J BIOL CHEM, V277, P15874, DOI 10.1074/jbc.M112300200; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828	58	58	64	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4434	4445		10.1074/jbc.M510250200	http://dx.doi.org/10.1074/jbc.M510250200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356931	hybrid, Green Published			2022-12-27	WOS:000235275300079
J	Masin, M; Kerschensteiner, D; Dumke, K; Rubio, ME; Soto, F				Masin, M; Kerschensteiner, D; Dumke, K; Rubio, ME; Soto, F			Fe65 interacts with P2X(2) subunits at excitatory synapses and modulates receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PHOSPHOTYROSINE-BINDING DOMAIN; PROLINE-RICH MOTIFS; GATED ION CHANNELS; ADAPTER PROTEIN; C-TERMINUS; IONOTROPIC RECEPTOR; CYTOPLASMIC DOMAIN; SIGNALING PROTEINS; ATP RECEPTOR	Ionotropic receptors in the neuronal plasmamembrane are organized in macromolecular complexes, which assure their proper localization and regulate signal transduction. P2X receptors, the ionotropic receptors activated by extracellular ATP, have been shown to influence synaptic transmission. Using a yeast two-hybrid approach with the P2X(2) subunit C-terminal domain as bait we isolated the beta-amyloid precursor protein-binding proteins Fe65 and Fe65-like 1 as the first identified proteins interacting with neuronal P2X receptors. We confirmed the direct interaction of Fe65 and the P2X(2) C-terminal domain by glutathione S-transferase pull-down experiments. No interaction was observed between Fe65 and the naturally occurring P2X(2) splice variant P2X(2(b)), indicating that alternative splicing can regulate the receptor complex assembly. We generated two antibodies to Fe65 to determine its subcellular localization using postembedding immunogold labeling electron microscopy. We found labeling for Fe65 at the pre- and postsynaptic specialization of CA1 hippocampal pyramidal cell/Schaffer collateral synapses. By double immunogold labeling, we determined that Fe65 colocalizes with P2X(2) subunits at the postsynaptic specialization of excitatory synapses. Moreover, P2X(2) and Fe65 could be coimmunoprecipitated from brain membrane extracts, demonstrating that the interaction occurs in vivo. The assembly with Fe65 regulates the functional properties of P2X(2) receptors. Thus, the time- and activation-dependent change in ionic selectivity of P2X(2) receptors was inhibited by coexpression of Fe65, suggesting a novel role for Fe65 in regulating P2X receptor function and ATP-mediated synaptic transmission.	Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany; UCL, Dept Pharmacol, Mol Pharmacol Lab, London WC1E 6BT, England; Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA	Max Planck Society; University of London; University College London; University of Connecticut	Soto, F (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, 1402 S Grand Blvd, St Louis, MO 63104 USA.	sotof@slu.edu						Bo XN, 2003, MOL PHARMACOL, V63, P1407, DOI 10.1124/mol.63.6.1407; Boue-Grabot E, 2004, J BIOL CHEM, V279, P6967, DOI 10.1074/jbc.M307772200; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Denlinger LC, 2003, J IMMUNOL, V171, P1304, DOI 10.4049/jimmunol.171.3.1304; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; Eickhorst AN, 2002, J GEN PHYSIOL, V120, P119, DOI 10.1085/jgp.20028535; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fisher JA, 2004, J NEUROSCI, V24, P10475, DOI 10.1523/JNEUROSCI.3250-04.2004; Fujiwara Y, 2004, J PHYSIOL-LONDON, V558, P31, DOI 10.1113/jphysiol.2004.064568; Gendreau S, 2003, J CHROMATOGR B, V786, P311, DOI 10.1016/S1570-0232(02)00743-2; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Kanjhan R, 1999, J COMP NEUROL, V407, P11; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kesavapany S, 2002, NEUROSCIENCE, V115, P951, DOI 10.1016/S0306-4522(02)00422-0; Khakh BS, 2005, J BIOL CHEM, V280, P6118, DOI 10.1074/jbc.M411324200; Khakh BS, 1999, NAT NEUROSCI, V2, P322, DOI 10.1038/7233; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; McLoughlin DM, 1996, FEBS LETT, V397, P197; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Paukert M, 2001, J BIOL CHEM, V276, P21077, DOI 10.1074/jbc.M101465200; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Ruppelt A, 2001, J NEUROCHEM, V77, P1256, DOI 10.1046/j.1471-4159.2001.00348.x; Sabo SL, 2003, J NEUROSCI, V23, P5407; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Schild L, 2004, REV PHYSIOL BIOCH P, V151, P93, DOI 10.1007/s10254-004-0023-7; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; Smith FM, 1999, J PHYSIOL-LONDON, V520, P91, DOI 10.1111/j.1469-7793.1999.00091.x; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Wilson HL, 2002, J BIOL CHEM, V277, P34017, DOI 10.1074/jbc.M205120200; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128	49	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4100	4108		10.1074/jbc.M507735200	http://dx.doi.org/10.1074/jbc.M507735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16330549	hybrid			2022-12-27	WOS:000235275300040
J	Zheng, Z; Cai, CM; Omwancha, J; Chen, SY; Baslan, T; Shemshedini, L				Zheng, Z; Cai, CM; Omwancha, J; Chen, SY; Baslan, T; Shemshedini, L			SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; C-JUN; PROTEIN INHIBITOR; NUCLEAR RECEPTORS; DEPENDENT TRANSCRIPTION; INDUCED TRANSACTIVATION; MOLECULAR-GENETICS; CODON-877 MUTATION; COACTIVATOR SRC-1; BINDING PROTEIN	Androgens are important for male sexual development, which depend on the cognate receptor, the androgen receptor. The transcriptional activity of the androgen receptor, like other nuclear receptors, is regulated by accessory proteins that can have either positive or negative effects. Through a yeast functional screen, we have identified SUMO-3 as a regulator of androgen receptor activity in prostate cancer cells. SUMO-3 is one of three eukaryotic proteins that become post-translationally conjugated to their target proteins in a manner analogous to the attachment of ubiquitin. In primary prostate epithelial cells, PrEC, and the prostate cancer cells, PC-3, SUMO-3 has a weak negative effect on androgen receptor transcriptional activity. In contrast, SUMO-3 and it close relative SUMO-2 strongly enhance transactivation by endogenous androgen receptor in LNCaP cells. This positive effect is observed in both androgen-dependent and androgen-independent LNCaP cells. Interestingly, SUMO-1, unlike SUMO-3 and SUMO-2, can inhibit, but not stimulate, androgen receptor activity. Mutational analysis of the androgen receptor and SUMO-3 demonstrates that the SUMO-3-positive activity does not depend on either the sumoylation sites of the androgen receptor or the sumoylation function of SUMO-3. Stable overexpression of SUMO-3 in LNCaP cells significantly enhances the androgen-dependent proliferation of these cells. Additionally, siRNA-mediated repression of SUMO-2 significantly inhibits the growth of both androgen-dependent and androgen-independent LNCaP cells. Collectively, these results suggest (i) a novel mechanism for elevating AR activity through the switch of SUMO-3 from a weak negative regulator in normal prostate cells to a strong positive regulator in prostate cancer cells and (ii) a proliferative role for SUMO-3 and SUMO-2 in the growth of prostate cancer cells that is independent of sumoylation of the androgen receptor.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	lshemsh@uoft02.utoledo.edu	Cai, Changmeng/AAE-6835-2020; CHEN, Shaoyong/ABF-3357-2021	Cai, Changmeng/0000-0002-8701-2586	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051274] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK51274] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Alen P, 1999, MOL CELL BIOL, V19, P6085; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, V2; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bubulya A, 2001, J BIOL CHEM, V276, P44704, DOI 10.1074/jbc.M107346200; Bubulya A, 1996, J BIOL CHEM, V271, P24583, DOI 10.1074/jbc.271.40.24583; Bubulya A, 2000, ENDOCRINE, V13, P55, DOI 10.1385/ENDO:13:1:55; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; CHEN SY, 2002, THESIS U TOLEDO TOLE; Culig Z, 2003, UROLOGY, V62, P21, DOI 10.1016/S0090-4295(03)00698-8; Fu MF, 2002, MOL CELL BIOL, V22, P3373, DOI 10.1128/MCB.22.10.3373-3388.2002; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Gregory CW, 2001, CANCER RES, V61, P4315; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jarrard DF, 1998, CANCER RES, V58, P5310; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kokontis JM, 1999, VITAM HORM, V55, P219; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Le Drean Y, 2002, ENDOCRINOLOGY, V143, P3482, DOI 10.1210/en.2002-220135; Li YH, 2003, P NATL ACAD SCI USA, V100, P259, DOI 10.1073/pnas.0235361100; LINZEY J, 1994, VITAM HORM, V49, P383; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Marcelli M, 2000, CANCER RES, V60, P944; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Rosendorff A, 2004, J VIROL, V78, P367, DOI 10.1128/JVI.78.1.367-377.2004; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; SANCHEZ ER, 1994, MOL ENDOCRINOL, V8, P408, DOI 10.1210/me.8.4.408; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; Shen XQ, 1999, ENDOCRINE, V10, P281, DOI 10.1007/BF02738627; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Suzuki H, 2003, ENDOCR-RELAT CANCER, V10, P209, DOI 10.1677/erc.0.0100209; Suzuki H, 1996, PROSTATE, V29, P153, DOI 10.1002/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5; SUZUKI H, 1993, J STEROID BIOCHEM, V46, P759, DOI 10.1016/0960-0760(93)90316-O; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2004, J CELL BIOCHEM, V91, P483, DOI 10.1002/jcb.10653; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; THUMMEL C, 1995, CELL, V83, P571; Tran CP, 2002, MOL CANCER RES, V1, P113; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wen Y, 2000, CANCER RES, V60, P6841; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; YUAN SX, 1993, CANCER RES, V53, P1304	86	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4002	4012		10.1074/jbc.M509260200	http://dx.doi.org/10.1074/jbc.M509260200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361251	hybrid			2022-12-27	WOS:000235275300029
J	Cheng, CY; Chang, CH; Wu, YJ; Li, YK				Cheng, CY; Chang, CH; Wu, YJ; Li, YK			Exploration of glycosyl hydrolase family 75, a chitosanase from Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SP N174; CRYSTAL-STRUCTURE; GLYCOSIDE HYDROLASE; ACTIVE-SITE; PURIFICATION; CHITINASE; GENE; IDENTIFICATION; RESIDUES; SPECIFICITY	A powerful endo-chitosanase ( CSN) previously described for a large scale preparation of chito-oligosaccharides ( Cheng, C.-Y., and Li, Y.-K. ( 2000) Biotechnol. Appl. Biochem. 32, 197 - 203) was cloned from Aspergillus fumigatus and further identified as a member of glycosyl hydrolase family 75. We report here a study of gene expression, functional characterization, and mutation analysis of this enzyme. Gene cloning was accomplished by reverse transcription-PCR and inverse PCR. Within the 1382-bp Aspergillus gene ( Gen-Bank (TM) accession number AY190324), two introns ( 67 and 82 bp) and an open reading frame encoding a 238-residue protein containing a 17-residue signal peptide were characterized. The recombinant mature protein was overexpressed as an inclusion body in Escherichia coli, rescued by treatment with 5 M urea, and subsequently purified by cation exchange chromatography. A time course H-1 NMR study on the enzymatic formation of chito-oligosaccharides confirmed that this A. fumigatus CSN is an inverting enzyme. Tandem mass spectrum analysis of the enzymatic hydrolysate revealed that the recombinant CSN can cleave linkages of GlcNAc-GlcN and GlcN-GlcN in its substrate, suggesting that it is a subclass I chitosanase. In addition, an extensive site-directed mutagenesis study on 10 conserved carboxylic amino acids of glycosyl hydrolase family 75 was performed. This showed that among these various mutants, D160N and E169Q lost nearly all activity. Further investigation using circular dichroism measurements of D160N, E169Q, wild-type CSN, and other active mutants showed similar spectra, indicating that the loss of enzymatic activity in D160N and E169Q was not because of changes in protein structure but was caused by loss of the catalytic essential residue. We conclude that Asp(160) and Glu(169) are the essential residues for the action of A. fumigatus endo-chitosanase.	Natl Chiao Tung Univ, Dept Appl Chem, Decatur, GA 30030 USA; Natl Chiao Tung Univ, Ctr Interdisciplinary Mol Sci, Decatur, GA 30030 USA		Li, YK (corresponding author), Natl Chiao Tung Univ, Dept Appl Chem, 1001 Ta Hseh Rd, Decatur, GA 30030 USA.	ykl@cc.nctu.edu.tw	cheng, chih-yu/A-1129-2013; Cheng, Chih-yu/AAA-6921-2021	cheng, chih-yu/0000-0002-7274-416X; Cheng, Chih-yu/0000-0002-7274-416X				Adachi W, 2004, J MOL BIOL, V343, P785, DOI 10.1016/j.jmb.2004.08.028; Ak O, 1998, BIOCHEM ARCH, V14, P221; Boucher I, 1995, J BIOL CHEM, V270, P31077, DOI 10.1074/jbc.270.52.31077; Bravman T, 2003, J BIOL CHEM, V278, P26742, DOI 10.1074/jbc.M304144200; Cheng CY, 2000, BIOTECHNOL APPL BIOC, V32, P197, DOI 10.1042/BA20000063; Chiang CL, 2003, ENZYME MICROB TECH, V32, P260, DOI 10.1016/S0141-0229(02)00275-2; Chir J, 2002, BIOCHEM J, V365, P857, DOI 10.1042/BJ20020186; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Collins T, 2002, J BIOL CHEM, V277, P35133, DOI 10.1074/jbc.M204517200; FINK D, 1991, BIOTECHNOL LETT, V13, P945; Forsyth WR, 2002, PROTEINS, V48, P388, DOI 10.1002/prot.10174; FUKAMIZO T, 1995, BIOCHEM J, V311, P377, DOI 10.1042/bj3110377; FUKAMIZO T, 1994, BBA-PROTEIN STRUCT M, V1205, P183, DOI 10.1016/0167-4838(94)90232-1; Fukamizo T, 2000, CURR PROTEIN PEPT SC, V1, P105, DOI 10.2174/1389203003381450; GEBLER J, 1992, J BIOL CHEM, V267, P12559; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Hidaka M, 2002, J MOL BIOL, V322, P79, DOI 10.1016/S0022-2836(02)00746-5; Honda Y, 1998, BBA-PROTEIN STRUCT M, V1388, P53, DOI 10.1016/S0167-4838(98)00153-8; Jeon YJ, 2001, CARBOHYD POLYM, V44, P71, DOI 10.1016/S0144-8617(00)00200-9; Juffer AH, 1998, BIOCHEM CELL BIOL, V76, P198, DOI 10.1139/bcb-76-2-3-198; Kim S.J., 1998, KOREAN J FOOD SCI TE, V30, P693; MARCOTTE E, 1993, J MOL BIOL, V232, P995, DOI 10.1006/jmbi.1993.1447; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Miyanaga A, 2004, J BIOL CHEM, V279, P44907, DOI 10.1074/jbc.M405390200; MUZZARELLI RAA, 1985, CHITIN NATURE TECHNO, P209; Nishimura T, 2001, FEBS LETT, V499, P187, DOI 10.1016/S0014-5793(01)02551-0; No HK, 2002, J FOOD SCI, V67, P1511, DOI 10.1111/j.1365-2621.2002.tb10314.x; OCHMAN H, 1988, GENETICS, V120, P621; OSSWALD WF, 1994, PLANT CELL PHYSIOL, V35, P811, DOI 10.1093/oxfordjournals.pcp.a078662; Park JK, 1999, J BACTERIOL, V181, P6642, DOI 10.1128/JB.181.21.6642-6649.1999; Puchart V, 2004, BBA-GEN SUBJECTS, V1674, P239, DOI 10.1016/j.bbagen.2004.06.022; Seo WG, 2000, CANCER LETT, V159, P189, DOI 10.1016/S0304-3835(00)00551-6; Seth D, 2003, J BIOCHEM BIOPH METH, V55, P53, DOI 10.1016/S0165-022X(02)00177-X; Shahidi F, 1999, TRENDS FOOD SCI TECH, V10, P37, DOI 10.1016/S0924-2244(99)00017-5; Shimosaka M, 1996, J FERMENT BIOENG, V82, P426, DOI 10.1016/S0922-338X(97)86977-2; Somashekar D, 1996, BIORESOURCE TECHNOL, V55, P35, DOI 10.1016/0960-8524(95)00144-1; Sun LW, 1999, VIROLOGY, V263, P376, DOI 10.1006/viro.1999.9958; SUZUKI K, 1986, CARBOHYD RES, V151, P403, DOI 10.1016/S0008-6215(00)90359-8; Synstad B, 2004, EUR J BIOCHEM, V271, P253, DOI 10.1046/j.1432-1033.2003.03923.x; Tang Chuan Yi, 2003, J Bioinform Comput Biol, V1, P267, DOI 10.1142/S0219720003000095; Tsai YT, 2004, BIOINFORMATICS, V20, P2309, DOI 10.1093/bioinformatics/bth220; WANG QP, 1993, J BIOL CHEM, V268, P14096; Yun CS, 2005, APPL ENVIRON MICROB, V71, P5138, DOI 10.1128/AEM.71.9.5138-5144.2005; Zhang XY, 2000, BIOSCI BIOTECH BIOCH, V64, P1896, DOI 10.1271/bbb.64.1896; ZIKAKIS JP, 1984, CHITIN CHITOSAN RELA, P119	45	50	55	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3137	3144		10.1074/jbc.M512506200	http://dx.doi.org/10.1074/jbc.M512506200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330537	hybrid			2022-12-27	WOS:000235128200016
J	Dassler, K; Zydek, M; Wandzik, K; Kaup, M; Fuchs, H				Dassler, K; Zydek, M; Wandzik, K; Kaup, M; Fuchs, H			Release of the soluble transferrin receptor is directly regulated by binding of its ligand ferritransferrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; LEUKEMIC HL60 CELLS; HEREDITARY HEMOCHROMATOSIS; IRON-ABSORPTION; HYPOTRANSFERRINEMIC MICE; HFE PROTEIN; BODY IRON; ECTODOMAIN; ERYTHROPOIESIS; ASSOCIATION	The human transferrin receptor (TfR) is shed by an integral metalloprotease releasing a soluble form (sTfR) into serum. The sTfR reflects the iron demand of the body and is postulated as a regulator of iron homeostasis via binding to the hereditary hemochromatosis protein HFE. To study the role of transferrin in this process, we investigated TfR shedding in HL60 cells and TfR-deficient Chinese hamster ovary cells transfected with human TfR. Independent of TfR expression, sTfR release decreases with increasing ferritransferrin concentrations, whereas apo-transferrin exhibits no inhibitory effect. To investigate the underlying mechanism, we generated several TfR mutants with different binding affinities for transferrin. Shedding of TfR mutants in transfected cells correlates exactly with their binding affinity, implying that the effect of ferritransferrin on TfR shedding is mediated by a direct molecular interaction. Analysis of sTfR release from purified microsomal membranes revealed that the regulation is independent from intracellular trafficking or cellular signaling events. Our results clearly demonstrated that sTfR does not only reflect the iron demand of the cells but also the iron availability in the bloodstream, mirrored by iron saturation of transferrin, corroborating the important potential function of sTfR as a regulator of iron homeostasis.	Univ Med Berlin, Charite, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Fuchs, H (corresponding author), Univ Med Berlin, Charite, Inst Klin Chem & Pathobiochem, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	hendrik.fuchs@charite.de	Fuchs, Hendrik/AAE-7379-2019	Fuchs, Hendrik/0000-0001-9153-9594				Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; BAYNES RD, 1995, P SOC EXP BIOL MED, V209, P286; BAYNES RD, 1993, P SOC EXP BIOL MED, V204, P65; Beguin Y, 2003, CLIN CHIM ACTA, V329, P9, DOI 10.1016/S0009-8981(03)00005-6; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Brandao M, 2005, HAEMATOLOGICA, V90, P31; Buchegger F, 1996, EUR J BIOCHEM, V235, P9, DOI 10.1111/j.1432-1033.1996.0009u.x; BUYS SS, 1991, BLOOD, V78, P3288; Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x; Cazzola M, 1999, BRIT J HAEMATOL, V106, P752, DOI 10.1046/j.1365-2141.1999.01600.x; Cheng Y, 2004, CELL, V116, P565, DOI 10.1016/S0092-8674(04)00130-8; CHITAMBAR CR, 1990, J LAB CLIN MED, V116, P345; CHITAMBAR CR, 1989, BLOOD, V74, P602; COOK JD, 1990, BRIT J HAEMATOL, V75, P603, DOI 10.1111/j.1365-2141.1990.tb07806.x; COOK JD, 1993, ANNU REV MED, V44, P63, DOI 10.1146/annurev.med.44.1.63; Cook JD, 2003, BLOOD, V101, P3359, DOI 10.1182/blood-2002-10-3071; Dassler K, 2003, FEBS LETT, V536, P25, DOI 10.1016/S0014-5793(03)00004-8; Davies PS, 2004, J BIOL CHEM, V279, P25085, DOI 10.1074/jbc.M400537200; Lima Gisélia Aparecida Freire Maia de, 2003, Sao Paulo Med. J., V121, P90; Dello Sbarba P, 2002, BIOL CHEM, V383, P69; Drakesmith H, 2002, P NATL ACAD SCI USA, V99, P15602, DOI 10.1073/pnas.242614699; Dubljevic V, 1999, BIOCHEM J, V341, P11, DOI 10.1042/0264-6021:3410011; FINCH C, 1994, BLOOD, V84, P1697; Frazer DM, 2003, BLOOD CELL MOL DIS, V30, P288, DOI 10.1016/S1079-9796(03)00039-1; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; Fuchs H, 2002, BBA-GEN SUBJECTS, V1570, P19, DOI 10.1016/S0304-4165(02)00146-0; Fuchs H, 2001, BIOTECHNIQUES, V31, P584, DOI 10.2144/01313rr03; Fuchs H, 1995, J IMMUNOL METHODS, V188, P197, DOI 10.1016/0022-1759(95)00202-2; Giannetti AM, 2003, PLOS BIOL, V1, P341, DOI 10.1371/journal.pbio.0000051; Gross CN, 1998, J BIOL CHEM, V273, P22068, DOI 10.1074/jbc.273.34.22068; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HUEBERS HA, 1990, BLOOD, V75, P102; Kang TB, 2004, EXP CELL RES, V298, P285, DOI 10.1016/j.yexcr.2004.04.022; Kaup M, 2002, J BIOL CHEM, V277, P38494, DOI 10.1074/jbc.M203461200; Kaup M, 2002, BIOL CHEM, V383, P1011, DOI 10.1515/BC.2002.108; KOHGO Y, 1987, CELL BIOL INT REP, V11, P871; Lawrence CM, 1999, SCIENCE, V286, P779, DOI 10.1126/science.286.5440.779; LILIOM K, 1991, J IMMUNOL METHODS, V143, P119, DOI 10.1016/0022-1759(91)90280-S; Liu RT, 2003, BIOCHEMISTRY-US, V42, P12447, DOI 10.1021/bi0352973; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; Maes M, 1997, SCAND J CLIN LAB INV, V57, P31, DOI 10.3109/00365519709057816; Montosi G, 2000, BLOOD, V96, P1125, DOI 10.1182/blood.V96.3.1125.015k19_1125_1129; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; Raja KB, 1999, BLOOD, V94, P3185, DOI 10.1182/blood.V94.9.3185.421a20_3185_3192; Rutledge EA, 1996, J CELL PHYSIOL, V168, P284, DOI 10.1002/(SICI)1097-4652(199608)168:2<284::AID-JCP7>3.0.CO;2-L; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SKIKNE BS, 1990, BLOOD, V75, P1870; Thomas L., 2005, LABOR DIAGNOSE; Townsend A, 2002, LANCET, V359, P786, DOI 10.1016/S0140-6736(02)07885-6; Waheed A, 1999, P NATL ACAD SCI USA, V96, P1579, DOI 10.1073/pnas.96.4.1579; Weatherall DJ, 1998, BAILLIERE CLIN HAEM, V11, P127, DOI 10.1016/S0950-3536(98)80072-3; West AP, 2001, J MOL BIOL, V313, P385, DOI 10.1006/jmbi.2001.5048	59	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3297	3304		10.1074/jbc.M511341200	http://dx.doi.org/10.1074/jbc.M511341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354665	hybrid			2022-12-27	WOS:000235128200036
J	Lepesheva, GI; Zaitseva, NG; Nes, WD; Zhou, WX; Arase, M; Liu, J; Hill, GC; Waterman, MR				Lepesheva, GI; Zaitseva, NG; Nes, WD; Zhou, WX; Arase, M; Liu, J; Hill, GC; Waterman, MR			Cyp51 from Trypanosoma cruzi - A phyla-specific residue in the B ' helix defines substrate preferences of sterol 14 alpha-demethylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBTUSIFOLIOL 14-ALPHA-DEMETHYLASE; STRUCTURAL REQUIREMENTS; EXPRESSION; BIOSYNTHESIS; DEMETHYLASE; INHIBITORS; P-45014DM; PROTEIN; GENOME; PLANTS	A potential drug target for treatment of Chagas disease, sterol 14 alpha- demethylase from Trypanosoma cruzi (TCCYP51), was found to be catalytically closely related to animal/fungi-like CYP51. Contrary to the ortholog from Trypanosoma brucei ( TB), which like plant CYP51 requires C4-monomethylated sterol substrates, TCCYP51 prefers C4-dimethylsterols. Sixty-six CYP51 sequences are known from bacteria to human, their sequence homology ranging from similar to 25% between phyla to similar to 80% within a phylum. TC versus TB is the first example of two organisms from the same phylum, in which CYP51s (83% amino acid identity) have such profound differences in substrate specificity. Substitution of animal/fungi- like Ile(105) in the B' helix to Phe, the residue found in this position in all plant and the other six CYP51 sequences from Trypanosomatidae, dramatically alters substrate preferences of TCCYP51, converting it into a more plant-like enzyme. The rates of 14 alpha- demethylation of obtusifoliol and its 24- demethyl analog 4 alpha, 4 alpha- dimethylcholesta-8,24- dien-3 beta-ol( norlanosterol) increase 60- and 150- fold, respectively. Turnover of the three 4,4- dimethylated sterol substrates is reduced similar to 3.5- fold. These catalytic properties correlate with the sterol binding parameters, suggesting that Phe in this position provides necessary interactions with C4-monomethylated substrates, which Ile cannot. The CYP51 substrate preferences imply differences in the post- squalene portion of sterol biosynthesis in TC and TB. The phyla-specific residue can be used to predict preferred substrates of new CYP51 sequences and subsequently for the development of new artificial substrate analogs, which might serve as highly specific inhibitors able to kill human parasites.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Microbiol, Sch Med, Nashville, TN 37232 USA; Texas Tech Univ, Dept Chem & Biochem, Lubbock, TX 79409 USA	Vanderbilt University; Vanderbilt University; Texas Tech University System; Texas Tech University	Lepesheva, GI (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA.	galina.i.lepesheva@vanderbilt.edu	Zhou, Wenxu/T-6917-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067871, R01GM063477] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00267-32] Funding Source: Medline; NIGMS NIH HHS [GM067871, GM63477] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOYAMA Y, 1991, BIOCHEM BIOPH RES CO, V178, P1064, DOI 10.1016/0006-291X(91)91000-3; AOYAMA Y, 1987, BIOCHIM BIOPHYS ACTA, V922, P270; Araujo MSS, 2000, J ANTIMICROB CHEMOTH, V45, P819, DOI 10.1093/jac/45.6.819; Baddley JW, 2004, CLIN LAB MED, V24, P721, DOI 10.1016/j.cll.2004.05.003; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BEACH DH, 1988, MOL BIOCHEM PARASIT, V31, P149, DOI 10.1016/0166-6851(88)90166-1; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Braga MV, 2004, INT J ANTIMICROB AG, V24, P72, DOI 10.1016/j.ijantimicag.2003.12.009; Buckner F, 2003, P NATL ACAD SCI USA, V100, P15149, DOI 10.1073/pnas.2535442100; Buckner FS, 2001, ANTIMICROB AGENTS CH, V45, P1210, DOI 10.1128/AAC.45.4.1210-1215.2001; BURTON PM, 1995, BIOCHEM PHARMACOL, V50, P529, DOI 10.1016/0006-2952(95)00152-P; Cabello-Hurtado F, 1999, EUR J BIOCHEM, V262, P435, DOI 10.1046/j.1432-1327.1999.00376.x; COOPER AB, 1989, J CHEM SOC CHEM COMM, P898, DOI 10.1039/c39890000898; Coura JR, 2002, MEM I OSWALDO CRUZ, V97, P3, DOI 10.1590/S0074-02762002000100001; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Frye LL, 1999, CRIT REV BIOCHEM MOL, V34, P123, DOI 10.1080/10409239991209246; Garzoni LR, 2004, INT J ANTIMICROB AG, V23, P273, DOI 10.1016/j.ijantimicag.2003.07.020; GOAD LJ, 1985, MOL BIOCHEM PARASIT, V15, P257, DOI 10.1016/0166-6851(85)90089-1; GOTOH O, 1992, J BIOL CHEM, V267, P83; Kahn RA, 1996, J BIOL CHEM, V271, P32944, DOI 10.1074/jbc.271.51.32944; Kale P, 2005, DRUG TODAY, V41, P91, DOI 10.1358/dot.2005.41.2.882661; KREIER T, 1992, PARASITIC PROTOZOA; Kuksis A, 2001, J CHROMATOGR A, V935, P203, DOI 10.1016/S0021-9673(01)01226-2; Lamb DC, 1998, FEBS LETT, V425, P263, DOI 10.1016/S0014-5793(98)00247-6; Lepesheva GI, 2003, BIOCHEMISTRY-US, V42, P9091, DOI 10.1021/bi034663f; Lepesheva GI, 2004, MOL CELL ENDOCRINOL, V215, P165, DOI 10.1016/j.mce.2003.11.016; Lepesheva GI, 2004, BIOCHEMISTRY-US, V43, P10789, DOI 10.1021/bi048967t; Lepesheva GI, 2001, J BIOL CHEM, V276, P28413, DOI 10.1074/jbc.M102767200; Liendo A, 1999, MOL BIOCHEM PARASIT, V104, P81, DOI 10.1016/S0166-6851(99)00129-2; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Lorente SO, 2004, ANTIMICROB AGENTS CH, V48, P2937, DOI 10.1128/AAC.48.8.2937-2950.2004; Morel CM, 2003, NAT REV MICROBIOL, V1, P14, DOI 10.1038/nrmicro735; MORISAKI M, 1986, J BIOCHEM-TOKYO, V99, P597, DOI 10.1093/oxfordjournals.jbchem.a135516; NES WR, 1977, BIOCH STEROIDS OTHER, P229; O'Brien M, 2005, PLANT PHYSIOL, V139, P734, DOI 10.1104/pp.105.066639; Ortiz de Montellano P.R., 1995, CYTOCHROME P450 STRU, P305; Podust LM, 2004, STRUCTURE, V12, P1937, DOI 10.1016/j.str.2004.08.009; Quinones W, 2004, EXP PARASITOL, V106, P135, DOI 10.1016/j.exppara.2004.03.006; Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3; Rodrigues CO, 2001, J EUKARYOT MICROBIOL, V48, P588, DOI 10.1111/j.1550-7408.2001.tb00195.x; Schaller H, 2003, PROG LIPID RES, V42, P163, DOI 10.1016/S0163-7827(02)00047-4; SONODA Y, 1992, CHEM PHARM BULL, V40, P2796, DOI 10.1248/cpb.40.2796; TATON M, 1991, BIOCHEM J, V277, P483, DOI 10.1042/bj2770483; TRZASKOS JM, 1995, BIOCHEMISTRY-US, V34, P9677, DOI 10.1021/bi00030a004; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; Urbina JA, 1996, SCIENCE, V273, P969, DOI 10.1126/science.273.5277.969; Urbina JA, 2001, CURR OPIN INFECT DIS, V14, P733, DOI 10.1097/00001432-200112000-00012; Venkatramesh M, 1996, BBA-LIPID LIPID MET, V1299, P313, DOI 10.1016/0005-2760(95)00218-9; Von Wachenfeldt C, 1995, CYTOCHROME P450 STRU, P183; Waterman MR, 2005, BIOCHEM BIOPH RES CO, V338, P418, DOI 10.1016/j.bbrc.2005.08.118; Zhang WJ, 2002, DRUG METAB DISPOS, V30, P314, DOI 10.1124/dmd.30.3.314	52	111	116	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3577	3585		10.1074/jbc.M510317200	http://dx.doi.org/10.1074/jbc.M510317200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321980	hybrid			2022-12-27	WOS:000235128200069
J	Lise, MF; Wong, TP; Trinh, A; Hines, RM; Liu, LD; Kang, RJ; Hines, DJ; Lu, J; Goldenring, JR; Wang, YT; El-Husseini, A				Lise, MF; Wong, TP; Trinh, A; Hines, RM; Liu, LD; Kang, RJ; Hines, DJ; Lu, J; Goldenring, JR; Wang, YT; El-Husseini, A			Involvement of myosin Vb in glutamate receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMPA RECEPTORS; PROTEIN COMPLEX; INTERACTING PROTEIN-2; NMDA RECEPTOR; RAB GTPASES; VA; MOTOR; IDENTIFICATION; TRANSPORT; FAMILY	Myosin V motors mediate cargo transport; however, the identity of neuronal molecules transported by these proteins remains unknown. Here we show that myosin Vb is expressed in several neuronal populations and associates with the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-type glutamate receptor subunit GluR1. In developing hippocampal neurons, expression of the tail domain of myosin Vb, but not myosin Va, enhanced GluR1 accumulation in the soma and reduced its surface expression. These changes were accompanied by reduced GluR1 clustering and diminished frequency of excitatory but not inhibitory synaptic currents. Similar effects were observed upon expression of full-length myosin Vb lacking a C-terminal region required for binding to the small GTPase Rab11. In contrast, mutant myosin Vb did not change the localization of several other neurotransmitter receptors, including the glutamate receptor subunit NR1. These results reveal a novel mechanism for the transport of a specific glutamate receptor subunit in neurons mediated by a member of the myosin V family.	Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Med, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Vanderbilt Univ, Sch Med, Dept Surg, Nashville, TN 37232 USA	University of British Columbia; University of British Columbia; Vanderbilt University	El-Husseini, A (corresponding author), Univ British Columbia, Dept Psychiat, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada.	alaa@interchange.ubc.ca	Hines, Dustin/AAC-6394-2021; Hines, Rochelle/AAE-3784-2020; Wang, Yu Tian/J-8255-2015; Wang, Yu Tian/A-4729-2008	Liu, Lidong/0000-0002-7026-690X; Hines, Dustin/0000-0003-2952-9824; Wong, Tak Pan/0000-0001-8611-4911; Hines, Rochelle/0000-0002-0459-7911	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048370] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48370] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Braithwaite SP, 2000, NEUROPHARMACOLOGY, V39, P919, DOI 10.1016/S0028-3908(99)00171-9; Bredt DS, 2003, NEURON, V40, P361, DOI 10.1016/S0896-6273(03)00640-8; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Bridgman PC, 1999, J CELL BIOL, V146, P1045, DOI 10.1083/jcb.146.5.1045; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; Fan GH, 2004, MOL BIOL CELL, V15, P2456, DOI 10.1091/mbc.E03-09-0706; Fleisig H, 2004, NEUROSCIENCE, V127, P91, DOI 10.1016/j.neuroscience.2004.04.060; Fukata Y, 2005, J CELL BIOL, V169, P399, DOI 10.1083/jcb.200501121; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Guillaud L, 2003, J NEUROSCI, V23, P131; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Hales CM, 2002, J BIOL CHEM, V277, P50415, DOI 10.1074/jbc.M209270200; Hammer JA, 2002, CURR OPIN CELL BIOL, V14, P69, DOI 10.1016/S0955-0674(01)00296-4; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Jiang M, 2004, GENE THER, V11, P1303, DOI 10.1038/sj.gt.3302305; Karcher RL, 2002, TRENDS CELL BIOL, V12, P21, DOI 10.1016/S0962-8924(01)02184-5; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Langford GM, 2002, TRAFFIC, V3, P859, DOI 10.1034/j.1600-0854.2002.31202.x; Lapierre LA, 2001, MOL BIOL CELL, V12, P1843, DOI 10.1091/mbc.12.6.1843; Lee SH, 2004, NEURON, V43, P221, DOI 10.1016/j.neuron.2004.06.015; Lee SH, 2001, NEUROPHARMACOLOGY, V41, P680, DOI 10.1016/S0028-3908(01)00124-1; Malenka RC, 2003, ANN NY ACAD SCI, V1003, P1, DOI 10.1196/annals.1300.001; Man HY, 2000, CELL MOL LIFE SCI, V57, P1526, DOI 10.1007/PL00000637; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Naisbitt S, 2000, J NEUROSCI, V20, P4524, DOI 10.1523/JNEUROSCI.20-12-04524.2000; Osterweil E, 2005, J CELL BIOL, V168, P329, DOI 10.1083/jcb.200410091; Park M, 2004, SCIENCE, V305, P1972, DOI 10.1126/science.1102026; Passafaro M, 2001, NAT NEUROSCI, V4, P917, DOI 10.1038/nn0901-917; Petralia RS, 2001, EUR J NEUROSCI, V13, P1722, DOI 10.1046/j.0953-816x.2001.01553.x; Prange O, 2004, P NATL ACAD SCI USA, V101, P13915, DOI 10.1073/pnas.0405939101; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Rodriguez OC, 2002, J CELL SCI, V115, P991; Sans N, 2003, NAT CELL BIOL, V5, P520, DOI 10.1038/ncb990; Schnell E, 2001, J NEUROPHYSIOL, V85, P1498, DOI 10.1152/jn.2001.85.4.1498; Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398-9219.2004.00190.x; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Swayze RD, 2004, NEUROPHARMACOLOGY, V47, P764, DOI 10.1016/j.neuropharm.2004.07.014; Takagishi Y, 1996, NEUROSCI LETT, V215, P169, DOI 10.1016/S0304-3940(96)12967-0; Thiagarajan TC, 2005, NEURON, V47, P725, DOI 10.1016/j.neuron.2005.06.037; Tilelli CQ, 2003, NEUROSCIENCE, V121, P573, DOI 10.1016/S0306-4522(03)00546-3; Vandenberghe W, 2004, CURR OPIN CELL BIOL, V16, P134, DOI 10.1016/j.ceb.2004.01.003; Volpicelli LA, 2002, J NEUROSCI, V22, P9776, DOI 10.1523/jneurosci.22-22-09776.2002; Wakabayashi Y, 2005, P NATL ACAD SCI USA, V102, P15087, DOI 10.1073/pnas.0503702102; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Wenthold RJ, 2003, ANNU REV PHARMACOL, V43, P335, DOI 10.1146/annurev.pharmtox.43.100901.135803; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wu XF, 1998, CELL MOTIL CYTOSKEL, V40, P286, DOI 10.1002/(SICI)1097-0169(1998)40:3<286::AID-CM7>3.0.CO;2-B; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yan Q, 2005, MOL BIOL CELL, V16, P2470, DOI 10.1091/mbc.e04-11-1014; Zhao LP, 1996, P NATL ACAD SCI USA, V93, P10826, DOI 10.1073/pnas.93.20.10826	57	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3669	3678		10.1074/jbc.M511725200	http://dx.doi.org/10.1074/jbc.M511725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338934	hybrid			2022-12-27	WOS:000235128200079
J	Patel, JH; McMahon, SB				Patel, JH; McMahon, SB			Targeting of Miz-1 is essential for Myc-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITOR P15(INK4B); C-MYC; TRANSCRIPTIONAL REPRESSION; ESSENTIAL COFACTOR; GENE-REGULATION; DNA-DAMAGE; PROTEIN; ASSOCIATION; PROMOTER; SUPPRESSION	The c-Myc oncoprotein plays a central role in human cancer via its ability to either activate or repress the transcription of essential downstream targets. For many of the repressed target genes, downregulation by c-Myc relies on its ability to bind and inactivate the transcription factor Miz-1. Although Miz-1 inactivation is suspected to be essential for at least some of the biological activities of c-Myc, it has been difficult to demonstrate this requirement experimentally. Using a combination of short hairpin RNA-mediated knockdown and a previously characterized mutant of c-Myc that is defective for Miz-1 inactivation, we examined whether this inactivation is critical for three of the most central biological functions of c-Myc, cell cycle progression, transformation, and apoptosis. The results of this analysis demonstrated that in the in vitro assays utilized here, Miz-1 inactivation is dispensable for c-Myc-induced cell cycle progression and transformation. In marked contrast, the ability of c-Myc to induce apoptosis in primary diploid human fibroblasts in response to growth factor withdrawal is entirely dependent on its ability to inactivate Miz-1. These data have a significant impact on our understanding of the biochemical mechanisms dictating how c-Myc mediates opposing biological functions, such as transformation and apoptosis, and demonstrate the first requirement for Miz-1 inactivation in any of the biological functions of c-Myc.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	McMahon, SB (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	smcmahon@jwistar.org		McMahon, Steven/0000-0002-3405-1768	NCI NIH HHS [CA090465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Bowen H, 2002, J BIOL CHEM, V277, P34997, DOI 10.1074/jbc.M204232200; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Etard C, 2005, MECH DEVELOP, V122, P545, DOI 10.1016/j.mod.2004.11.010; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Izumi H, 2001, J CELL SCI, V114, P1533; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Lapham AS, 2004, BIOCHEM SOC T, V32, P1084, DOI 10.1042/BST0321084; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mao DYL, 2004, NUCLEIC ACIDS RES, V32, P3462, DOI 10.1093/nar/gkh669; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Vaque JP, 2005, J BIOL CHEM, V280, P1112, DOI 10.1074/jbc.M409503200; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102; Ziegelbauer J, 2004, P NATL ACAD SCI USA, V101, P458, DOI 10.1073/pnas.0307562100	47	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3283	3289		10.1074/jbc.M513038200	http://dx.doi.org/10.1074/jbc.M513038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16352593	hybrid			2022-12-27	WOS:000235128200034
J	Sewell, R; Backstrom, M; Dalziel, M; Gschmeissner, S; Karlsson, H; Noll, T; Gatgens, J; Clausen, H; Hansson, GC; Burchell, J; Taylor-Papadimitriou, J				Sewell, R; Backstrom, M; Dalziel, M; Gschmeissner, S; Karlsson, H; Noll, T; Gatgens, J; Clausen, H; Hansson, GC; Burchell, J; Taylor-Papadimitriou, J			The ST6GalNAc-I sialyltransferase localizes throughout the golgi and is responsible for the synthesis of the tumor-associated Sialyl-Tn O-glycan in human breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMORPHIC EPITHELIAL MUCIN; SIALOSYL-TN; LINKED GLYCOSYLATION; MAMMARY-GLAND; CHO-K1 CELLS; EXPRESSION; ANTIGEN; ADJUVANT; TRANSFERASES; INITIATION	The functional properties of glycoproteins are strongly influenced by their profile of glycosylation, and changes in this profile are seen in malignancy. In mucin-typeO- linked glycosylation these changes can result in the production of mucins such as MUC1, carrying shorter sialylated O-glycans, and with different site occupancy. Of the tumor-associated sialylated-O-glycans, the disaccharide, sialyl-Tn (sialic acid alpha 2,6GalNAc), is expressed by 30% of breast carcinomas and is the most tumor-specific. The ST6GalNAc-I glycosyltransferase, which can catalyze the transfer of sialic acid to GalNAc, shows a highly restricted pattern of expression in normal adult tissues, being largely limited to the gastrointestinal tract and absent in mammary gland. In breast carcinomas, however, a complete correlation between the expression of RNA-encoding ST6GalNAc-I and the expression of sialyl-Tn is evident, demonstrating that the expression of sialyl-Tn results from switching on expression of hST6GalNAc-I. Endogenous or exogenous expression of hST6GalNAc-I ( but not ST6GalNAc-II) always results in the expression of sialyl-Tn. This ability to override core 1/ core 2 pathways of O-linked glycosylation is explained by the localization of ST6GalNAc-I, which is found throughout the Golgi stacks. The development of a Chinese hamster ovary (CHO) cell line expressing MUC1 and ST6GalNAc-I allowed the large scale production of MUC1 carrying 83% sialyl-Tn O-glycans. The presence of ST6GalNAc-I in the CHO cells reduced the number of O-glycosylation sites occupied in MUC1, from an average of 4.3 to 3.8 per tandem repeat. The availability of large quantities of this MUC1 glycoform will allow the evaluation of its efficacy as an immunogen for immunotherapy of MUC1/ STn- expressing tumors.	Guys Hosp, Canc Res UK Breast Canc Biol Grp, London SE1 9RT, England; Gothenburg Univ, Dept Biochem Med, S-41390 Gothenburg, Sweden; Canc Res UK London Inst, Electron Microscopy Unit, London WC2A 3PX, England; Juelich GmbH, Inst Biochem Res Ctr, D-52425 Julich, Germany; Univ Copenhagen, Dept Biochem Med, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Genet Hlth Sci Fac, DK-2200 Copenhagen, Denmark	Guy's & St Thomas' NHS Foundation Trust; University of Gothenburg; Cancer Research UK; Helmholtz Association; Research Center Julich; University of Copenhagen; University of Copenhagen	Taylor-Papadimitriou, J (corresponding author), Guys Hosp, Canc Res UK Breast Canc Biol Grp, 3rd Floor, London SE1 9RT, England.	joyce.taylor-papadimitriou@cancer.org.uk	Noll, Thomas/A-3539-2012; Burchell, Joy/G-4560-2012; clausen, henrik/AAD-8016-2021; Hansson, Gunnar C/A-1236-2009; Hansson, Gunnar C./AAF-7324-2019	Noll, Thomas/0000-0003-0748-3423; Hansson, Gunnar C/0000-0002-1900-1869; Hansson, Gunnar C./0000-0002-1900-1869; Burchell, Joy/0000-0003-0413-3823; Dalziel, Martin/0000-0002-8967-6378; Clausen, Henrik/0000-0002-0915-5055				Backstrom M, 2003, BIOCHEM J, V376, P677, DOI 10.1042/BJ20031130; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Brockhausen I, 2001, BIOL CHEM, V382, P219; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; BURCHELL J, 1993, CANCER SURV, V18, P135; Burchell JM, 2001, J MAMMARY GLAND BIOL, V6, P355, DOI 10.1023/A:1011331809881; Cao Y, 1996, HISTOCHEM CELL BIOL, V106, P197, DOI 10.1007/BF02484401; Cao Y, 1999, VIRCHOWS ARCH, V434, P503, DOI 10.1007/s004280050375; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; Corfield AP, 1999, GLYCOCONJUGATE J, V16, P307, DOI 10.1023/A:1007026314792; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hakomori S, 2004, ARCH BIOCHEM BIOPHYS, V426, P173, DOI 10.1016/j.abb.2004.02.032; HANISCH FG, 1989, J BIOL CHEM, V264, P872; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hull S R, 1989, Cancer Commun, V1, P261; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Imai J, 2001, ANTICANCER RES, V21, P1327; ITZKOWITZ SH, 1989, CANCER RES, V49, P197; ITZKOWITZ SH, 1990, CANCER-AM CANCER SOC, V66, P1960, DOI 10.1002/1097-0142(19901101)66:9<1960::AID-CNCR2820660919>3.0.CO;2-X; JASS JR, 1995, J PATHOL, V176, P143, DOI 10.1002/path.1711760207; Johnson TK, 2002, CANCER, V94, P1240, DOI 10.1002/cncr.10292; Kinney AY, 1997, CANCER-AM CANCER SOC, V80, P2240, DOI 10.1002/(SICI)1097-0142(19971215)80:12<2240::AID-CNCR4>3.0.CO;2-Y; KJELDSEN T, 1988, CANCER RES, V48, P2214; Kono M, 2000, BIOCHEM BIOPH RES CO, V272, P94, DOI 10.1006/bbrc.2000.2745; Leivonen M, 2001, ONCOLOGY-BASEL, V61, P299, DOI 10.1159/000055337; Link T, 2004, J BIOTECHNOL, V110, P51, DOI 10.1016/j.jbiotec.2003.12.008; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; LONGENECKER BM, 1993, ANN NY ACAD SCI, V690, P276; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; MACLEAN GD, 1993, CANCER IMMUNOL IMMUN, V36, P215, DOI 10.1007/BF01740902; Marcos NT, 2004, CANCER RES, V64, P7050, DOI 10.1158/0008-5472.CAN-04-1921; Miles David, 2003, Clin Breast Cancer, V3 Suppl 4, pS134, DOI 10.3816/CBC.2003.s.002; MILES DW, 1994, BRIT J CANCER, V70, P1272, DOI 10.1038/bjc.1994.486; Miles DW, 1996, BRIT J CANCER, V74, P1292, DOI 10.1038/bjc.1996.532; MILES DW, 1995, BRIT J CANCER, V71, P1074, DOI 10.1038/bjc.1995.207; Muller S, 2002, J BIOL CHEM, V277, P26103, DOI 10.1074/jbc.M202921200; Mungul A, 2004, INT J ONCOL, V25, P937; Ogata S, 1998, GLYCOCONJUGATE J, V15, P29, DOI 10.1023/A:1006935331756; Olson FJ, 2005, GLYCOBIOLOGY, V15, P177, DOI 10.1093/glycob/cwh158; PEAT N, 1992, CANCER RES, V52, P1954; Rottger S, 1998, J CELL SCI, V111, P45; Samyn-Petit B, 2000, BBA-GEN SUBJECTS, V1474, P201, DOI 10.1016/S0304-4165(00)00020-9; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69; THOR A, 1986, CANCER RES, V46, P3118; Vazquez-Martin C, 2004, ONCOLOGY-BASEL, V67, P159, DOI 10.1159/000081003; VITIELLO A, 1991, J EXP MED, V173, P1007, DOI 10.1084/jem.173.4.1007; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229	50	165	177	0	20	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3586	3594		10.1074/jbc.M511826200	http://dx.doi.org/10.1074/jbc.M511826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16319059	hybrid			2022-12-27	WOS:000235128200070
J	Gareus, R; Di Nardo, A; Rybin, V; Witke, W				Gareus, R; Di Nardo, A; Rybin, V; Witke, W			Mouse profilin 2 regulates endocytosis and competes with SH3 ligand binding to dynamin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; ACTIN NUCLEOTIDE EXCHANGE; PROLINE-RICH DOMAIN; GTPASE DYNAMIN; F-ACTIN; PROTEIN; IDENTIFICATION; CYTOSKELETON; ISOFORMS; DISTINCT	Mammalian profilins are abundantly expressed actin monomerbinding proteins, highly conserved with respect to their affinities for G-actin, poly-L-proline, and phosphoinositides. Profilins associate with a large number of proline-rich proteins; the physiological significance and regulation of which is poorly understood. Here we show that profilin 2 associates with dynamin 1 via the C-terminal proline-rich domain of dynamin and thereby competes with the binding of SH3 ligands such as endophilin, amphiphysin, and Grb2, thus interfering with the assembly of the endocytic machinery. We also present a novel role for the brain-specific mouse profilin 2 as a regulator of membrane trafficking. Overexpression of profilin 2 inhibits endocytosis, whereas lack of profilin 2 in neurons results in an increase in endocytosis and membrane recycling. Phosphatidylinositol 4,5-bisphosphate releases profilin 2 from the profilin 2-dynamin 1 complex as well as from the profilin 2-actin complex, suggesting that profilin 2 is diverging the phosphoinositide signaling pathway to actin polymerization as well as endocytosis.	European Mol Biol Lab, Mouse Biol Unit, I-00016 Monterotondo, Italy; EMBL, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL)	Witke, W (corresponding author), European Mol Biol Lab, Mouse Biol Unit, Campus Adriano Buzzati Traverso, I-00016 Monterotondo, Italy.	witke@embl-monterotondo.it						BJORKEGREN C, 1993, FEBS LETT, V333, P123, DOI 10.1016/0014-5793(93)80388-B; Di Nardo A, 2000, J CELL SCI, V113, P3795; Diefenbach TJ, 1999, J NEUROSCI, V19, P9436; Dong JX, 2000, BBA-MOL CELL RES, V1497, P253, DOI 10.1016/S0167-4889(00)00056-2; Engqvist-Goldstein AEY, 2004, MOL BIOL CELL, V15, P1666, DOI 10.1091/mbc.E03-09-0639; Fabian-Fine R, 2003, J NEUROSCI, V23, P10732; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; GIESELMANN R, 1995, EUR J BIOCHEM, V229, P621, DOI 10.1111/j.1432-1033.1995.tb20506.x; Giesemann T, 2003, J NEUROSCI, V23, P8330; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; Gomez TS, 2005, NAT IMMUNOL, V6, P261, DOI 10.1038/ni1168; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; HONORE B, 1993, FEBS LETT, V330, P151, DOI 10.1016/0014-5793(93)80262-S; Hu ED, 2001, EXP NEPHROL, V9, P265; Jonckheere V, 1999, FEBS LETT, V447, P257, DOI 10.1016/S0014-5793(99)00293-8; Karakesisoglou I, 1999, J CELL BIOL, V145, P167, DOI 10.1083/jcb.145.1.167; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; KWIATKOWSKI DJ, 1990, AM J HUM GENET, V46, P559; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Lambrechts A, 2000, J BIOL CHEM, V275, P36143, DOI 10.1074/jbc.M006274200; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Lu J, 2001, MOL BIOL CELL, V12, P1161, DOI 10.1091/mbc.12.4.1161; MACHESKY LM, 1994, BIOCHEMISTRY-US, V33, P10815, DOI 10.1021/bi00201a032; Mahoney NM, 1999, NAT STRUCT BIOL, V6, P666, DOI 10.1038/10722; MALM B, 1983, J MUSCLE RES CELL M, V4, P569, DOI 10.1007/BF00712116; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Nyman T, 2002, J BIOL CHEM, V277, P15828, DOI 10.1074/jbc.M112195200; Obermann H, 2005, MOL HUM REPROD, V11, P53, DOI 10.1093/molehr/gah132; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Okamoto PM, 1997, J BIOL CHEM, V272, P11629; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Ostrander DB, 1999, EUR J BIOCHEM, V262, P26, DOI 10.1046/j.1432-1327.1999.00354.x; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Takenawa T, 2001, BBA-MOL CELL BIOL L, V1533, P190, DOI 10.1016/S1388-1981(01)00165-2; Temesvari L, 2000, MOL BIOL CELL, V11, P2019, DOI 10.1091/mbc.11.6.2019; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P533; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Wittenmayer N, 2000, EUR J BIOCHEM, V267, P5247, DOI 10.1046/j.1432-1327.2000.01600.x; Wolven AK, 2000, J CELL BIOL, V150, P895, DOI 10.1083/jcb.150.4.895; Yarar D, 2005, MOL BIOL CELL, V16, P964, DOI 10.1091/mbc.e04-09-0774; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002	60	48	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2803	2811		10.1074/jbc.M503528200	http://dx.doi.org/10.1074/jbc.M503528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319076	hybrid			2022-12-27	WOS:000234931800047
J	Kelley, GG; Kaproth-Joslin, KA; Reks, SE; Smrcka, AV; Wojcikiewicz, RJH				Kelley, GG; Kaproth-Joslin, KA; Reks, SE; Smrcka, AV; Wojcikiewicz, RJH			G-protein-coupled receptor agonists activate endogenous phospholipase C epsilon and phospholipase C beta 3 in a temporally distinct manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; VASCULAR SMOOTH-MUSCLE; RAT-1 FIBROBLASTS; DOWN-REGULATION; ANGIOTENSIN-II; EGF RECEPTOR; INS(1,4,5)P3 FORMATION; LYSOPHOSPHATIDIC-ACID; SIGNAL-TRANSDUCTION; CYCLIC-AMP	Phospholipase C epsilon (PLC epsilon) is one of the newest members of the phosphatidylinositol-specific phospholipase C (PLC) family. Previous studies have suggested that G-protein-coupled receptors (GPCRs) stimulate phosphoinositide (PI) hydrolysis by activating PLC beta isoforms through G(q) family G proteins and G beta gamma subunits. Using RNA interference to knock down PLC isoforms, we demonstrate that the GPCR agonists endothelin (ET-1), lysophosphatidic acid (LPA), and thrombin, acting through endogenous receptors, couple to both endogenous PLC epsilon and the PLC beta isoform, PLC beta 3, in Rat-1 fibroblasts. Examination of the temporal activation of these PLC isoforms, however, reveals agonist- and isoform-specific profiles. PLC beta 3 is activated acutely within the first minute of ET-1, LPA, or thrombin stimulation but does not contribute to sustained PI hydrolysis induced by LPA or thrombin and accounts for only part of ET-1 sustained stimulation. PLC epsilon, on the other hand, predominantly accounts for sustained PI hydrolysis. Consistent with this observation, reconstitution of PLC epsilon in knockdown cells dose-dependently increases sustained, but not acute, agonist- stimulated PI hydrolysis. Furthermore, combined knockdown of both PLC epsilon and PLC beta 3 additively inhibits PI hydrolysis, suggesting independent regulation of each isoform. Importantly, ubiquitination of inositol 1,4,5-trisphosphate receptors correlates with sustained, but not acute, activation of PLC epsilon or PLC beta 3. In conclusion, GPCR agonists ET-1, LPA, and thrombin activate endogenous PLC epsilon and PLC beta 3 in Rat-1 fibroblasts. Activation of these PLC isoforms displays agonist- specific temporal profiles; however, PLC beta 3 is predominantly involved in acute and PLC epsilon in sustained PI hydrolysis.	SUNY Upstate Med, Dept Med, Syracuse, NY 13210 USA; SUNY Upstate Med, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Rochester, Sch Med & Dent, Dept Pharmacol, Rochester, NY 14642 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Rochester	Kelley, GG (corresponding author), SUNY Upstate Med, Dept Med, Syracuse, NY 13210 USA.	kelleyg@upstate.edu			NIDDK NIH HHS [DK56294, R29 DK049194, R01 DK056294, DK49194, R01 DK049194] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056294, R29DK049194, R01DK049194] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alzayady KJ, 2005, J BIOL CHEM, V280, P34530, DOI 10.1074/jbc.M508890200; ALZAYADY KJ, 2005, BIOCH J; BANNO Y, 1994, J BIOL CHEM, V269, P15846; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cadwallader K, 1997, BIOCHEM J, V321, P795, DOI 10.1042/bj3210795; CHALLISS RAJ, 1991, J NEUROCHEM, V57, P1042, DOI 10.1111/j.1471-4159.1991.tb08255.x; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Duale H, 2005, EXP PHYSIOL, V90, P71, DOI 10.1113/expphysiol.2004.029173; Evellin S, 2002, J BIOL CHEM, V277, P16805, DOI 10.1074/jbc.M112024200; GUO Y, 2004, J BIOL CHEM; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Kelley GG, 2004, BIOCHEM J, V378, P129, DOI 10.1042/BJ20031370; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KELLEY GG, 2005, AFCS NATURE MOL PAGE, DOI DOI 10.1038/MP.A000046.000001; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; KOUCHI Z, 2003, J BIOL CHEM; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; MULDOON LL, 1991, AM J PHYSIOL, V260, pC1273, DOI 10.1152/ajpcell.1991.260.6.C1273; MULDOON LL, 1988, J BIOL CHEM, V263, P18834; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; PLEVIN R, 1991, BIOCHEM SOC T, V19, pS100, DOI 10.1042/bst019100s; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; SEIFERT JP, 2004, J BIOL CHEM; Shears SB, 2004, BIOCHEM J, V377, P265, DOI 10.1042/BJ20031428; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Song CH, 2002, ONCOGENE, V21, P8105, DOI 10.1038/sj.onc.1206003; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P19772, DOI 10.1074/jbc.273.31.19772; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Wojcikiewicz RJH, 2004, TRENDS PHARMACOL SCI, V25, P35, DOI 10.1016/j.tips.2003.11.008; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; Zhang JW, 1999, BIOCHEM J, V343, P541, DOI 10.1042/0264-6021:3430541; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	53	64	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2639	2648		10.1074/jbc.M507681200	http://dx.doi.org/10.1074/jbc.M507681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16314422	hybrid, Green Accepted			2022-12-27	WOS:000234931800028
J	Joklik, WK				Joklik, WK			Adventures of a biochemist in virology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							TEMPERATURE-SENSITIVE MUTANTS; REOVIRUS MESSENGER-RNAS; DOUBLE-STRANDED-RNA; VACCINIA VIRUS; GENOME SEGMENTS; PROTEIN SIGMA-1; 3 SEROTYPES; HELA CELLS; IN-VITRO; SEQUENCES		Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Duke University	Joklik, WK (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.	finch012@mc.duke.edu						ANTCZAK JB, 1992, VIROLOGY, V187, P760, DOI 10.1016/0042-6822(92)90478-8; ANTCZAK JB, 1982, VIROLOGY, V121, P307, DOI 10.1016/0042-6822(82)90170-2; BANERJEA AC, 1988, VIROLOGY, V167, P601, DOI 10.1016/0042-6822(88)90123-7; BARTLETT JA, 1988, VIROLOGY, V167, P31, DOI 10.1016/0042-6822(88)90051-7; BECKER Y, 1964, P NATL ACAD SCI USA, V51, P577, DOI 10.1073/pnas.51.4.577; BELLAMY AR, 1967, J MOL BIOL, V29, P1, DOI 10.1016/0022-2836(67)90177-5; BELLAMY AR, 1967, J MOL BIOL, V29, P19, DOI 10.1016/0022-2836(67)90178-7; BERG P, 1954, J BIOL CHEM, V210, P657; CASHDOLLAR LW, 1982, P NATL ACAD SCI-BIOL, V79, P7644, DOI 10.1073/pnas.79.24.7644; CASHDOLLAR LW, 1984, VIROLOGY, V133, P191, DOI 10.1016/0042-6822(84)90438-0; CASHDOLLAR LW, 1985, P NATL ACAD SCI USA, V82, P24, DOI 10.1073/pnas.82.1.24; FIELDS BN, 1969, VIROLOGY, V37, P335, DOI 10.1016/0042-6822(69)90217-7; GAILLARD RK, 1980, VIROLOGY, V107, P533, DOI 10.1016/0042-6822(80)90321-9; GAILLARD RK, 1985, VIROLOGY, V147, P336, DOI 10.1016/0042-6822(85)90136-9; HIZI A, 1977, J BIOL CHEM, V252, P2281; HOLOWCZAK JA, 1967, VIROLOGY, V33, P726, DOI 10.1016/0042-6822(67)90073-6; HUISMANS H, 1976, VIROLOGY, V70, P411, DOI 10.1016/0042-6822(76)90282-8; Joklik VK, 1996, FASEB J, V10, P525, DOI 10.1096/fasebj.10.4.8647352; JOKLIK WK, 1952, BRIT J EXP PATHOL, V33, P368; JOKLIK WK, 1960, VIROLOGY, V11, P202, DOI 10.1016/0042-6822(60)90062-3; Joklik WK, 1996, ARCH VIROL, V141, P969, DOI 10.1007/BF01718171; JOKLIK WK, 1972, VIROLOGY, V49, P700, DOI 10.1016/0042-6822(72)90527-2; JOKLIK WK, 1964, J MOL BIOL, V8, P277, DOI 10.1016/S0022-2836(64)80137-6; JOKLIK WK, 1966, P NATL ACAD SCI USA, V56, P558, DOI 10.1073/pnas.56.2.558; JOKLIK WK, 1961, VIROLOGY, V13, P439, DOI 10.1016/0042-6822(61)90275-6; JOKLIK WK, 1962, BIOCHIM BIOPHYS ACTA, V61, P290, DOI 10.1016/0926-6550(62)90091-9; JOKLIK WK, 1960, NATURE, V186, P992, DOI 10.1038/186992b0; JUNGWIRTH C, 1965, VIROLOGY, V27, P80, DOI 10.1016/0042-6822(65)90145-5; LAI MHT, 1973, VIROLOGY, V51, P191, DOI 10.1016/0042-6822(73)90379-6; LARSON SM, 1994, VIROLOGY, V201, P303, DOI 10.1006/viro.1994.1295; LEE PWK, 1981, VIROLOGY, V108, P156, DOI 10.1016/0042-6822(81)90535-3; LEE PWK, 1981, VIROLOGY, V108, P134, DOI 10.1016/0042-6822(81)90533-X; LUFTIG RB, 1972, VIROLOGY, V48, P170, DOI 10.1016/0042-6822(72)90124-9; MAO ZX, 1991, VIROLOGY, V185, P377, DOI 10.1016/0042-6822(91)90785-A; MATSUHISA T, 1974, VIROLOGY, V60, P380, DOI 10.1016/0042-6822(74)90333-X; MCDOWELL MJ, 1972, P NATL ACAD SCI USA, V69, P2649, DOI 10.1073/pnas.69.9.2649; MOODY MD, 1989, VIROLOGY, V173, P437, DOI 10.1016/0042-6822(89)90556-4; NEVINS JR, 1975, VIROLOGY, V63, P1, DOI 10.1016/0042-6822(75)90365-7; NICHOLS JL, 1972, VIROLOGY, V49, P562, DOI 10.1016/0042-6822(72)90507-7; ODA KI, 1967, J MOL BIOL, V27, P395, DOI 10.1016/0022-2836(67)90047-2; PICKUP DJ, 1983, VIROLOGY, V124, P215, DOI 10.1016/0042-6822(83)90309-4; PICKUP DJ, 1986, P NATL ACAD SCI USA, V83, P7698, DOI 10.1073/pnas.83.20.7698; RANKIN JT, 1989, VIROLOGY, V168, P147, DOI 10.1016/0042-6822(89)90413-3; Roner MR, 1995, P NATL ACAD SCI USA, V92, P12362, DOI 10.1073/pnas.92.26.12362; Roner MR, 2001, P NATL ACAD SCI USA, V98, P8036, DOI 10.1073/pnas.131203198; Roner MR, 1997, P NATL ACAD SCI USA, V94, P6826, DOI 10.1073/pnas.94.13.6826; RONER MR, 1990, VIROLOGY, V179, P845, DOI 10.1016/0042-6822(90)90153-I; SKEHEL JJ, 1969, VIROLOGY, V39, P822, DOI 10.1016/0042-6822(69)90019-1; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; STARNES MC, 1993, VIROLOGY, V193, P356, DOI 10.1006/viro.1993.1132; WIEBE ME, 1975, VIROLOGY, V66, P229, DOI 10.1016/0042-6822(75)90193-2; WIENER JR, 1989, VIROLOGY, V169, P293, DOI 10.1016/0042-6822(89)90154-2; WIENER JR, 1987, VIROLOGY, V161, P332, DOI 10.1016/0042-6822(87)90125-5; WIENER JR, 1988, VIROLOGY, V163, P603, DOI 10.1016/0042-6822(88)90301-7; WIENER JR, 1989, VIROLOGY, V169, P194, DOI 10.1016/0042-6822(89)90055-X; WOODSON B, 1965, P NATL ACAD SCI USA, V54, P946, DOI 10.1073/pnas.54.3.946; XU PT, 1993, VIROLOGY, V197, P726, DOI 10.1006/viro.1993.1648	57	2	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 9	2005	280	49					40385	40397		10.1074/JBC.X500005200	http://dx.doi.org/10.1074/JBC.X500005200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	989IR	16326717	hybrid			2022-12-27	WOS:000233666600001
J	Chiu, YL; Green, WC				Chiu, YL; Green, WC			APOBEC3 cytidine deaminases: Distinct antiviral actions along the retroviral life cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA-EDITING ENZYME; VIRION INFECTIVITY FACTOR; E3 UBIQUITIN LIGASE; SINGLE-STRANDED-DNA; VIRAL VIF PROTEIN; HIV-1 VIF; T-LYMPHOCYTES; IN-VIVO; ANTIRETROVIRAL DEFENSE	The field of human immunodeficiency virus ( HIV) biology has been galvanized by the discovery of innate APOBEC3 cytidine deaminases, which pose powerful barriers to the replication of HIV and other retroviruses. Rapid progress has been made in defining their action, intriguing regulation within cells, expanded range of retroviral targets, and counterstrikes utilized by retroviruses against them. Although scientifically fascinating, advances in APOBEC3 biology may lead to new antiviral drugs and improved lentiviral vectors for gene therapy.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Green, WC (corresponding author), Gladstone Inst Virol & Immunol, 1650 Owens St, San Francisco, CA 94158 USA.	wgreene@gladstone.ucsf.edu			NIAID NIH HHS [R01 AI065329] Funding Source: Medline; NICHD NIH HHS [P01 HD40543] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD040543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI065329] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Chester A, 2004, RNA, V10, P1399, DOI 10.1261/rna.7490704; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Doehle BP, 2005, VIROLOGY, V339, P281, DOI 10.1016/j.virol.2005.06.005; Doehle BP, 2005, J VIROL, V79, P8201, DOI 10.1128/JVI.79.13.8201-8207.2005; Douaisi M, 2004, BIOCHEM BIOPH RES CO, V321, P566, DOI 10.1016/j.bbrc.2004.07.005; Ducrey-Rundquist O, 2002, J VIROL, V76, P9103, DOI 10.1128/JVI.76.18.9103-9111.2002; Dutko JA, 2005, CURR BIOL, V15, P661, DOI 10.1016/j.cub.2005.02.051; Esnault C, 2005, NATURE, V433, P430, DOI 10.1038/nature03238; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Hache G, 2005, J BIOL CHEM, V280, P10920, DOI 10.1074/jbc.M500382200; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; Harris RS, 2002, MOL CELL, V10, P1247, DOI 10.1016/S1097-2765(02)00742-6; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; Kao Sandra, 2004, Retrovirology, V1, P27, DOI 10.1186/1742-4690-1-27; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; Khan MA, 2005, J VIROL, V79, P5870, DOI 10.1128/JVI.79.9.5870-5874.2005; Kobayashi M, 2004, J VIROL, V78, P8238, DOI 10.1128/JVI.78.15.8238-8244.2004; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Liddament MT, 2004, CURR BIOL, V14, P1385, DOI 10.1016/j.cub.2004.06.050; Liu BD, 2005, J VIROL, V79, P9579, DOI 10.1128/JVI.79.15.9579-9587.2005; Lochelt M, 2005, P NATL ACAD SCI USA, V102, P7982, DOI 10.1073/pnas.0501445102; Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, GENE DEV, V18, P2861, DOI 10.1101/gad.1249904; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Neil S, 2001, J VIROL, V75, P5448, DOI 10.1128/JVI.75.12.5448-5456.2001; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Okazaki I, 2003, J EXP MED, V197, P1173, DOI 10.1084/jem.20030275; Rose KM, 2004, J BIOL CHEM, V279, P41744, DOI 10.1074/jbc.M406760200; Rosler C, 2005, HEPATOLOGY, V42, P301, DOI 10.1002/hep.20801; Rosler C, 2004, SCIENCE, V305, p1403A, DOI 10.1126/science.1100464; Russell RA, 2005, J VIROL, V79, P8724, DOI 10.1128/JVI.79.14.8724-8731.2005; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Sawyer SL, 2004, PLOS BIOL, V2, P1278, DOI 10.1371/journal.pbio.0020275; Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006; Schrofelbauer B, 2005, J VIROL, V79, P10978, DOI 10.1128/JVI.79.17.10978-10987.2005; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Schumacher AJ, 2005, P NATL ACAD SCI USA, V102, P9854, DOI 10.1073/pnas.0501694102; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Suspene R, 2005, J GEN VIROL, V86, P125, DOI 10.1099/vir.0.80426-0; Suspene R, 2004, NUCLEIC ACIDS RES, V32, P2421, DOI 10.1093/nar/gkh554; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Teng BB, 1999, J LIPID RES, V40, P623; Triques K, 2004, J VIROL, V78, P5523, DOI 10.1128/JVI.78.10.5523-5527.2004; Turelli P, 2004, J BIOL CHEM, V279, P43371, DOI 10.1074/jbc.C400334200; Turelli P, 2004, SCIENCE, V305, p1403B; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; Unutmaz D, 1999, J EXP MED, V189, P1735, DOI 10.1084/jem.189.11.1735; Wichroski MJ, 2005, J BIOL CHEM, V280, P8387, DOI 10.1074/jbc.M408048200; Wiegand HL, 2004, EMBO J, V23, P2451, DOI 10.1038/sj.emboj.7600246; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang JZ, 2004, HUM MOL GENET, V13, P1785, DOI 10.1093/hmg/ddh183; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	83	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8309	8312		10.1074/jbc.R500021200	http://dx.doi.org/10.1074/jbc.R500021200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407183	hybrid			2022-12-27	WOS:000236247100002
J	Balza, RO; Misra, RP				Balza, RO; Misra, RP			Role of the serum response factor in regulating contractile apparatus gene expression and sarcomeric integrity in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; ALPHA-ACTIN GENE; SMOOTH-MUSCLE DIFFERENTIATION; EMBRYONIC STEM-CELLS; A/T-RICH ELEMENT; SKELETAL-MUSCLE; DILATED CARDIOMYOPATHY; MYOCARDIAL-INFARCTION; TRANSCRIPTION FACTORS; MOUSE EMBRYOGENESIS	The serum response factor (SRF) is a transcriptional regulator required for mesodermal development, including heart formation and function. Previous studies have described the role of SRF in controlling expression of structural genes involved in conferring the myogenic phenotype. Recent studies by us and others have demonstrated embryonic lethal cardiovascular phenotypes in SRF-null animals, but have not directly addressed the mechanistic role of SRF in controlling broad regulatory programs in cardiac cells. In this study, we used a loss-of-function approach to delineate the role of SRF in cardiomyocyte gene expression and function. In SRF-null neonatal cardiomyocytes, we observed severe defects in the contractile apparatus, including Z-disc and stress fiber formation, as well as mislocalization and/or attenuation of sarcomeric proteins. Consistent with this, gene array and reverse transcription-PCR analyses showed down-regulation of genes encoding key cardiac transcriptional regulatory factors and proteins required for the maintenance of sarcomeric structure, function, and regulation. Chromatin immunoprecipitation analysis revealed that at least a subset of these proteins are likely regulated directly by SRF. The results presented here indicate that SRF is an essential coordinator of cardiomyocyte function due to its ability to regulate expression of numerous genes ( some previously identified and at least 28 targets newly identified in this study) that are involved in multiple and disparate levels of sarcomeric function and assembly.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Misra, RP (corresponding author), Med Coll Wisconsin, Dept Biochem, 3701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	rmisra@mcw.edu			NHLBI NIH HHS [HL-62572] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062572] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alsan BH, 2002, DEVELOPMENT, V129, P1935; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Baker DL, 1998, NUCLEIC ACIDS RES, V26, P1092, DOI 10.1093/nar/26.4.1092; Barron MR, 2005, J BIOL CHEM, V280, P11816, DOI 10.1074/jbc.M412408200; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; Brancaccio M, 2003, NAT MED, V9, P68, DOI 10.1038/nm805; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Cripps RM, 2002, DEV BIOL, V246, P14, DOI 10.1006/dbio.2002.0666; Dabiri GA, 1997, P NATL ACAD SCI USA, V94, P9493, DOI 10.1073/pnas.94.17.9493; Eigenthaler M, 2003, AM J PHYSIOL-HEART C, V285, pH2471, DOI 10.1152/ajpheart.00362.2003; Ferrari S, 1997, CELL GROWTH DIFFER, V8, P23; Finsen AV, 2004, PHYSIOL GENOMICS, V16, P301, DOI 10.1152/physiolgenomics.00144.2002; Fisher SA, 1996, J MOL CELL CARDIOL, V28, P113, DOI 10.1006/jmcc.1996.0011; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; Heicklen-Klein A, 2004, DEV BIOL, V267, P490, DOI 10.1016/j.ydbio.2003.09.042; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Heineke J, 2005, P NATL ACAD SCI USA, V102, P1655, DOI 10.1073/pnas.0405488102; Hillis GS, 1998, HEART, V79, P429, DOI 10.1136/hrt.79.5.429; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Huang WY, 1997, BIOCHEM J, V327, P507, DOI 10.1042/bj3270507; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; Kim SJ, 1999, AM J PHYSIOL-HEART C, V276, pH1780, DOI 10.1152/ajpheart.1999.276.5.H1780; Kuisk IR, 1996, DEV BIOL, V174, P1, DOI 10.1006/dbio.1996.0046; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; Lange S, 2005, J MOL BIOL, V345, P289, DOI 10.1016/j.jmb.2004.10.040; Li SJ, 2005, P NATL ACAD SCI USA, V102, P1082, DOI 10.1073/pnas.0409103102; Lilly B, 2001, DEV BIOL, V240, P531, DOI 10.1006/dbio.2001.0507; Mericskay M, 2000, DEV BIOL, V226, P192, DOI 10.1006/dbio.2000.9865; Miano JM, 2004, P NATL ACAD SCI USA, V101, P17132, DOI 10.1073/pnas.0406041101; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MISRA RP, 1991, MOL CELL BIOL, V11, P4545, DOI 10.1128/MCB.11.9.4545; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; MONCMAN CL, 1995, CELL MOTIL CYTOSKEL, V32, P205, DOI 10.1002/cm.970320305; Morkin E, 2000, MICROSC RES TECHNIQ, V50, P522, DOI 10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; Nakamura M, 2001, J BIOL CHEM, V276, P18313, DOI 10.1074/jbc.M101127200; Nelson TJ, 2005, J MOL CELL CARDIOL, V39, P479, DOI 10.1016/j.yjmcc.2005.05.004; Niu Z, 2005, J BIOL CHEM, V280, P32531, DOI 10.1074/jbc.M501372200; Parlakian A, 2004, MOL CELL BIOL, V24, P5281, DOI 10.1128/MCB.24.12.5281-5289.2004; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Ramanan N, 2005, NAT NEUROSCI, V8, P759, DOI 10.1038/nn1462; Reinhold MI, 2004, J BIOL CHEM, V279, P38209, DOI 10.1074/jbc.M404855200; Schratt G, 2002, J CELL BIOL, V156, P737, DOI 10.1083/jcb.200106008; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Selvaraj A, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-13; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; Sugiura S, 1998, JPN J PHYSIOL, V48, P173, DOI 10.2170/jjphysiol.48.173; Sun GF, 2004, J CELL BIOCHEM, V92, P189, DOI 10.1002/jcb.20039; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vickers ER, 2004, MOL CELL BIOL, V24, P10340, DOI 10.1128/MCB.24.23.10340-10351.2004; Vyas DR, 1999, J BIOL CHEM, V274, P30832, DOI 10.1074/jbc.274.43.30832; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; Watt AJ, 2004, P NATL ACAD SCI USA, V101, P12573, DOI 10.1073/pnas.0400752101; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001; Zhang SX, 2005, J BIOL CHEM, V280, P19115, DOI 10.1074/jbc.M413793200; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhu XL, 2003, ANAT REC PART A, V271A, P315, DOI 10.1002/ar.a.10032	79	78	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6498	6510		10.1074/jbc.M509487200	http://dx.doi.org/10.1074/jbc.M509487200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16368687	hybrid			2022-12-27	WOS:000236030800045
J	Grau, S; Richards, PJ; Kerr, B; Hughes, C; Caterson, B; Williams, AS; Junker, U; Jones, SA; Clausen, T; Ehrmann, M				Grau, S; Richards, PJ; Kerr, B; Hughes, C; Caterson, B; Williams, AS; Junker, U; Jones, SA; Clausen, T; Ehrmann, M			The role of human HtrA1 in arthritic disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTICULAR-CARTILAGE; SERINE-PROTEASE; SYNOVIAL-FLUID; FIBRONECTIN FRAGMENTS; MATRIX METALLOPROTEINASES; RHEUMATOID-ARTHRITIS; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; EXPRESSION; IDENTIFICATION	Human HtrA1 belongs to a widely conserved family of serine proteases involved in various aspects of protein quality control and cell fate. Although HtrA1 has been implicated in the pathology of several diseases, its precise biological functions remain to be established. Through identification of potential HtrA1 targets, studies presented herein propose that within the context of arthritis pathology HtrA1 contributes to cartilage degradation. Elevated synovial HtrA1 levels were detected in fluids obtained from rheumatoid and osteoarthritis patients, with synovial fibroblasts identified as a major source of secreted HtrA1. Mass spectrometry analysis of potential HtrA1 substrates within synovial fluids identified fibronectin as a candidate target, and treatment of fibronectin with recombinant HtrA1 led to the generation of fibronectin-degradation products that may be involved in cartilage catabolism. Consistently, treatment of synovial fibroblasts with HtrA1 or HtrA1-generated fibronectin fragments resulted in the specific induction of matrix metalloprotease 1 and matrix metalloprotease 3 expression, suggesting that HtrA1 contributes to the destruction of extracellular matrix through both direct and indirect mechanisms.	Cardiff Univ, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Cardiff Univ, Rheumatol Res Lab, Cardiff CF14 4XN, S Glam, Wales; Novartis Pharmaceut, CH-4002 Basel, Switzerland; Inst Mol Pathol, A-1030 Vienna, Austria	Cardiff University; Cardiff University; Novartis; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Ehrmann, M (corresponding author), Cardiff Univ, Sch Biosci, Biosci-2, Cardiff CF10 3US, S Glam, Wales.	ehrmann@cf.ac.uk	Hughes, Clare E/A-4526-2010; Caterson, Bruce/A-8085-2010; Ehrmann, Michael/A-7307-2012; Jones, Simon Arnett/Q-7017-2018	Ehrmann, Michael/0000-0002-1927-260X; Caterson, Bruce/0000-0001-6016-0661; Kerr, Briedgeen/0000-0002-8504-7953; Jones, Simon Arnett/0000-0001-7297-9711; Hughes, Clare/0000-0003-4726-5877; Clausen, Tim/0000-0003-1582-6924				Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; BurtonWurster N, 1997, MATRIX BIOL, V15, P441, DOI 10.1016/S0945-053X(97)90018-4; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; CLEMMENSEN I, 1982, HISTOCHEMISTRY, V76, P51, DOI 10.1007/BF00493284; DAYER JM, 1976, P NATL ACAD SCI USA, V73, P945, DOI 10.1073/pnas.73.3.945; GLANT TT, 1985, HISTOCHEMISTRY, V82, P149, DOI 10.1007/BF00708199; GRIFFITHS AM, 1989, CLIN CHIM ACTA, V184, P133, DOI 10.1016/0009-8981(89)90283-0; Harnasch M, 2004, MOL MEMBR BIOL, V21, P373, DOI 10.1080/09687860400008429; HOMANDBERG GA, 1992, J BIOL CHEM, V267, P3597; Homandberg GA, 2001, OSTEOARTHR CARTILAGE, V9, P673, DOI 10.1053/joca.2001.0419; Homandberg Gene A., 1999, Frontiers in Bioscience, V4, pd713, DOI 10.2741/Homandberg; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kageyama Y, 2000, CLIN RHEUMATOL, V19, P14, DOI 10.1007/s100670050004; LOHMANDER LS, 1993, ARTHRITIS RHEUM-US, V36, P181, DOI 10.1002/art.1780360207; Mort JS, 2001, ARTHRITIS RES, V3, P337, DOI 10.1186/ar325; Muller-Ladner U, 2002, ANN RHEUM DIS, V61, P957, DOI 10.1136/ard.61.11.957; Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572; Murwantoko, 2004, BIOCHEM J, V381, P895, DOI 10.1042/BJ20040435; Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569; Richards PJ, 1999, RHEUMATOLOGY, V38, P984, DOI 10.1093/rheumatology/38.10.984; Roughley PJ, 2001, ARTHRITIS RES, V3, P342, DOI 10.1186/ar326; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; Shridhar V, 2002, CANCER RES, V62, P262; SMITH RL, 1999, FRONT BIOSCI, V4, P704; Sottile J, 2002, MOL BIOL CELL, V13, P3546, DOI 10.1091/mbc.E02-01-0048; Stanton H, 2002, BIOCHEM J, V364, P181, DOI 10.1042/bj3640181; Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257; Tolboom TCA, 2002, ANN RHEUM DIS, V61, P975, DOI 10.1136/ard.61.11.975; Tsuchiya A, 2005, BONE, V37, P323, DOI 10.1016/j.bone.2005.03.015; VANDELOOSDRECHT AA, 1991, J IMMUNOL METHODS, V141, P15, DOI 10.1016/0022-1759(91)90205-T; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; WACHTFOGEL YT, 1988, J CLIN INVEST, V81, P1310, DOI 10.1172/JCI113456; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; WURSTER NB, 1982, BIOCHEM BIOPH RES CO, V109, P1094, DOI 10.1016/0006-291X(82)91889-7; XIE DL, 1993, BLOOD, V81, P186; XIE DL, 1993, ARCH BIOCHEM BIOPHYS, V307, P110, DOI 10.1006/abbi.1993.1568; Yoshihara Y, 2000, ANN RHEUM DIS, V59, P455, DOI 10.1136/ard.59.6.455; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	42	217	231	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6124	6129		10.1074/jbc.M500361200	http://dx.doi.org/10.1074/jbc.M500361200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377621	Green Accepted, hybrid			2022-12-27	WOS:000236030800003
J	Lu, XF; Wang, MH; Qi, J; Wang, HT; Li, XN; Gupta, D; Dziarski, R				Lu, XF; Wang, MH; Qi, J; Wang, HT; Li, XN; Gupta, D; Dziarski, R			Peptidoglycan recognition proteins are a new class of human bactericidal proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; L-ALANINE AMIDASE; ANTIMICROBIAL PEPTIDES; HUMAN SKIN; STAPHYLOCOCCUS-AUREUS; INNATE IMMUNITY; DROSOPHILA-MELANOGASTER; ESCHERICHIA-COLI; INFECTION; RECEPTOR	Skin and mucous membranes come in contact with external environment and protect tissues from infections by producing antimicrobial peptides. We report that human peptidoglycan recognition proteins 3 and 4 (PGLYRP3 and PGLYRP4) are secreted as 89-115-kDa disulfide-linked homo- and heterodimers and are bactericidal against several pathogenic and nonpathogenic transient, but not normal flora, Gram-positive bacteria. PGLYRP3 and PGLYRP4 are also bacteriostatic toward all other tested bacteria, which include Gram-negative bacteria and normal flora Gram-positive bacteria. PGLYRP3 and PGLYRP4 are also active in vivo and protect mice against experimental lung infection. In contrast to antimicrobial peptides, PGLYRPs kill bacteria by interacting with their cell wall peptidoglycan, rather than permeabilizing their membranes. PGLYRP3 and PGLYRP4 are expressed in the skin, eyes, salivary glands, throat, tongue, esophagus, stomach, and intestine. Thus, we have identified the function of mammalian PGLYRP3 and PGLYRP4, and show that they are a new class of bactericidal and bacteriostatic proteins that have different structures, mechanism of actions, and expression patterns than antimicrobial peptides.	Indiana Univ, Sch Med NW, Gary, IN 46408 USA	Indiana University System; Indiana University Northwest	Dziarski, R (corresponding author), Indiana Univ, Sch Med NW, Gary, IN 46408 USA.	rdziar@iun.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI056395] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 2879, AI 56395] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bischoff V, 2004, NAT IMMUNOL, V5, P1175, DOI 10.1038/ni1123; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Brotz H, 1997, EUR J BIOCHEM, V246, P193, DOI 10.1111/j.1432-1033.1997.t01-1-00193.x; Chang CI, 2004, PLOS BIOL, V2, P1293, DOI 10.1371/journal.pbio.0020277; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; Cho JH, 2005, BLOOD, V106, P2551, DOI 10.1182/blood-2005-02-0530; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Dziarski R, 2005, INFECT IMMUN, V73, P5212, DOI 10.1128/IAI.73.8.5212-5216.2005; Dziarski R, 2003, BLOOD, V102, P689, DOI 10.1182/blood-2002-12-3853; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; ERLANDSEN SL, 1974, J HISTOCHEM CYTOCHEM, V22, P401, DOI 10.1177/22.6.401; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; GOTZ F, 1981, J BACTERIOL, V145, P74; Guan RJ, 2004, P NATL ACAD SCI USA, V101, P17168, DOI 10.1073/pnas.0407856101; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M207587200; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; Hornef MW, 2004, NAT IMMUNOL, V5, P836, DOI 10.1038/ni1094; JACOBSON ED, 1975, J BACTERIOL, V124, P445, DOI 10.1128/JB.124.1.445-448.1975; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim MS, 2003, NAT IMMUNOL, V4, P787, DOI 10.1038/ni952; Lehrer RI, 2004, NAT REV MICROBIOL, V2, P727, DOI 10.1038/nrmicro976; Leulier F, 2003, NAT IMMUNOL, V4, P478, DOI 10.1038/ni922; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Mathur P, 2004, GENOMICS, V83, P1151, DOI 10.1016/j.ygeno.2004.01.003; Mellroth P, 2003, J BIOL CHEM, V278, P7059, DOI 10.1074/jbc.M208900200; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Nekhotiaeva N, 2003, FASEB J, V17, P394, DOI 10.1096/fj.03-0449fje; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHAEFFER P, 1965, P NATL ACAD SCI USA, V54, P704, DOI 10.1073/pnas.54.3.704; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; SINHA RK, 1968, J BACTERIOL, V96, P374, DOI 10.1128/JB.96.2.374-382.1968; Takehana A, 2004, EMBO J, V23, P4690, DOI 10.1038/sj.emboj.7600466; Tydell CC, 2002, J BIOL CHEM, V277, P19658, DOI 10.1074/jbc.M200659200; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Wang ZM, 2003, J BIOL CHEM, V278, P49044, DOI 10.1074/jbc.M307758200; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Wingens M, 1998, J INVEST DERMATOL, V111, P996, DOI 10.1046/j.1523-1747.1998.00425.x; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; ZEIGER AR, 1982, INFECT IMMUN, V37, P1112, DOI 10.1128/IAI.37.3.1112-1118.1982; Zhang YO, 2005, BBA-PROTEINS PROTEOM, V1752, P34, DOI 10.1016/j.bbapap.2005.07.001	51	169	201	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5895	5907		10.1074/jbc.M511631200	http://dx.doi.org/10.1074/jbc.M511631200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16354652	hybrid			2022-12-27	WOS:000235568900070
J	Mitchell, JE; Cvetanovic, M; Tibrewal, N; Patel, V; Colamonici, OR; Li, MO; Flavell, RA; Levine, JS; Birge, RB; Ucker, DS				Mitchell, JE; Cvetanovic, M; Tibrewal, N; Patel, V; Colamonici, OR; Li, MO; Flavell, RA; Levine, JS; Birge, RB; Ucker, DS			The presumptive phosphatidylserine receptor is dispensable for innate anti-inflammatory recognition and clearance of apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; C-ELEGANS; PHAGOCYTOSIS; ENGULFMENT; ACTIVATION; REMOVAL; CORPSES; PROTEIN; LYMPHOCYTES; MACROPHAGES	The role of the presumptive phosphatidylserine receptor (PSR) in the recognition and engulfment of apoptotic cells, and the antiinflammatory response they exert, has been of great interest. Genetic deficiency of PSR in the mouse is lethal perinatally, and results to date have been ambiguous with regard to the phagocytic and inflammatory phenotypes associated with that deficiency. Recently, we found that the specific functional recognition of apoptotic cells is a ubiquitous property of virtually all cell types, including mouse embryo fibroblasts, and reflects an innate immunity that discriminates live from effete cells. Taking advantage of this property of fibroblasts, we generated PSR+/+, PSR+/-, and PSR-/- fibroblast cell lines to examine definitively the involvement of PSR in apoptotic recognition and inflammatory modulation. Our data demonstrate that PSR-deficient cells are fully competent to recognize, engulf, and respond to apoptotic cells. Signal transduction in the responder cells, including the activation of Akt and Rac1, is unimpaired in the absence of PSR. We confirm as well that PSR is localized predominantly to the nucleus. However, it does not play a role in pro-inflammatory transcription or in the anti-inflammatory modulation of that transcriptional response triggered by apoptotic cells. We conclude that PSR is not involved generally in either specific innate recognition or engulfment of apoptotic cells.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Med, Nephrol Sect, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07214 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center; Howard Hughes Medical Institute; Yale University	Ucker, DS (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol MC 790, 835 S Wolcott, Chicago, IL 60612 USA.	duck@uic.edu	Cvetanovic, Marija/B-8907-2016	li, ming/0000-0002-1383-0535	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG024234] Funding Source: NIH RePORTER; NIA NIH HHS [AG 024234] Funding Source: Medline; NIDDK NIH HHS [DK 59793] Funding Source: Medline; NIGMS NIH HHS [GM 55760] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akakura S, 2004, EXP CELL RES, V292, P403, DOI 10.1016/j.yexcr.2003.09.011; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BOSE J, 2004, J BIOL LONDON, V3, pNIL5; Chang SH, 2002, EXP CELL RES, V277, P15, DOI 10.1006/excr.2002.5539; Chung SB, 2000, NAT CELL BIOL, V2, P931, DOI 10.1038/35046585; Cikala M, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-26; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Cocco RE, 2001, MOL BIOL CELL, V12, P919, DOI 10.1091/mbc.12.4.919; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Cui P, 2004, EXP CELL RES, V293, P154, DOI 10.1016/j.yexcr.2003.09.023; Cvetanovic M, 2004, J IMMUNOL, V172, P880, DOI 10.4049/jimmunol.172.2.880; ELLIS RE, 1991, GENETICS, V129, P79; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J IMMUNOL, V161, P6250; Gumienny TL, 2001, CELL DEATH DIFFER, V8, P564, DOI 10.1038/sj.cdd.4400850; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Harvey KJ, 2001, CYTOMETRY, V43, P273, DOI 10.1002/1097-0320(20010401)43:4<273::AID-CYTO1059>3.0.CO;2-3; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hogue MJ, 1919, J EXP MED, V30, P617, DOI 10.1084/jem.30.6.617; Hong JR, 2004, DEVELOPMENT, V131, P5417, DOI 10.1242/dev.01409; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kinchen JM, 2005, NATURE, V434, P93, DOI 10.1038/nature03263; Kunisaki Y, 2004, BLOOD, V103, P3362, DOI 10.1182/blood-2003-09-3245; Li MO, 2003, SCIENCE, V302, P1560, DOI 10.1126/science.1087621; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; Patel VA, 2006, J BIOL CHEM, V281, P4663, DOI 10.1074/jbc.M508342200; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wang XC, 2003, SCIENCE, V302, P1563, DOI 10.1126/science.1087641	34	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5718	5725		10.1074/jbc.M509775200	http://dx.doi.org/10.1074/jbc.M509775200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16317002	hybrid			2022-12-27	WOS:000235568900049
J	Patel, A; Shuman, S; Mondragon, A				Patel, A; Shuman, S; Mondragon, A			Crystal structure of a bacterial type IB DNA topoisomerase reveals a preassembled active site in the absence of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION PHASE REFINEMENT; VACCINIA TOPOISOMERASE; CATALYTIC MECHANISM; MUTATIONAL ANALYSIS; COVALENT CATALYSIS; RECOMBINATION SYNAPSE; LAMBDA-INTEGRASE; DIFFRACTION DATA; PROTEIN CLAMP; SV40 DNA	Type IB DNA topoisomerases are found in all eukarya, two families of eukaryotic viruses (poxviruses and mimivirus), and many genera of bacteria. They alter DNA topology by cleaving and resealing one strand of duplex DNA via a covalent DNA-(3-phosphotyrosyl)enzyme intermediate. Bacterial type IB enzymes were discovered recently and are described as poxvirus-like with respect to their small size, primary structures, and bipartite domain organization. Here we report the 1.75-angstrom crystal structure of Deinococcus radiodurans topoisomerase IB (DraTopIB), a prototype of the bacterial clade. DraTopIB consists of an amino-terminal (N) beta-sheet domain (amino acids 1-90) and a predominantly alpha-helical carboxyl-terminal (C) domain (amino acids 91-346) that closely resemble the corresponding domains of vaccinia virus topoisomerase IB. The five amino acids of DraTopIB that comprise the catalytic pentad (Arg-137, Lys-174, Arg-239, Asn-280, and Tyr-289) are preassembled into the active site in the absence of DNA in a manner nearly identical to the pentad configuration in human topoisomerase I bound to DNA. This contrasts with the apoenzyme of vaccinia topoisomerase, in which three of the active site constituents are either displaced or disordered. The N and C domains of DraTopIB are splayed apart in an "open" conformation, in which the surface of the catalytic domain containing the active site is exposed for DNA binding. A comparison with the human topoisomerase I-DNA cocrystal structure suggests how viral and bacterial topoisomerase IB enzymes might bind DNA circumferentially via movement of the N domain into the major groove and clamping of a disordered loop of the C domain around the helix.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Northwestern University; Memorial Sloan Kettering Cancer Center	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.	a-mondragon@northwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051350] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 51350, R01 GM051350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; Benarroch D, 2006, J VIROL, V80, P314, DOI 10.1128/JVI.80.1.314-321.2006; Carey JF, 2003, P NATL ACAD SCI USA, V100, P5640, DOI 10.1073/pnas.1031537100; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1998, J BIOL CHEM, V273, P11589, DOI 10.1074/jbc.273.19.11589; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Chrencik JE, 2004, J MOL BIOL, V339, P773, DOI 10.1016/j.jmb.2004.03.007; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DeLano WL, 2002, PYMOL USERS MANUAL; DETITTA GT, 1994, ACTA CRYSTALLOGR A, V50, P203, DOI 10.1107/S0108767393008980; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Interthal H, 2004, J BIOL CHEM, V279, P2984, DOI 10.1074/jbc.M309959200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P36091, DOI 10.1074/jbc.M102609200; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; Shuman S, 1998, BBA-GENE STRUCT EXPR, V1400, P321, DOI 10.1016/S0167-4781(98)00144-4; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; Staker BL, 2005, J MED CHEM, V48, P2336, DOI 10.1021/jm049146p; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tian LG, 2005, STRUCTURE, V13, P513, DOI 10.1016/j.str.2005.02.001; Tian LG, 2004, J BIOL CHEM, V279, P39718, DOI 10.1074/jbc.M407376200; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Tian LG, 2003, MOL CELL, V12, P199, DOI 10.1016/S1097-2765(03)00263-6; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WEEKS CM, 1994, ACTA CRYSTALLOGR A, V50, P210, DOI 10.1107/S0108767393008992; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100; Yang Z, 2001, J BIOL CHEM, V276, P677, DOI 10.1074/jbc.M007593200; Zhang HL, 2001, P NATL ACAD SCI USA, V98, P10608, DOI 10.1073/pnas.191321998	66	22	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6030	6037		10.1074/jbc.M512332200	http://dx.doi.org/10.1074/jbc.M512332200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16368685	hybrid			2022-12-27	WOS:000235568900084
J	von Wronski, MA; Raju, N; Pillai, R; Bogdan, NJ; Marinelli, ER; Nanjappan, P; Ramalingam, K; Arunachalam, T; Eaton, S; Linder, KE; Yan, F; Pochon, S; Tweedle, MF; Nunn, AD				von Wronski, MA; Raju, N; Pillai, R; Bogdan, NJ; Marinelli, ER; Nanjappan, P; Ramalingam, K; Arunachalam, T; Eaton, S; Linder, KE; Yan, F; Pochon, S; Tweedle, MF; Nunn, AD			Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR VEGF; TUMOR-CELLS; 7-ENCODED DOMAIN; IN-VIVO; RECEPTORS; VEGF(165); PEPTIDE; EXPRESSION; ANGIOGENESIS; REGENERATION	Tuftsin, Thr-Lys-Pro-Arg (TKPR), is an immunostimulatory peptide with reported nervous system effects as well. We unexpectedly found that tuftsin and a higher affinity antagonist, TKPPR, bind selectively to neuropilin- 1 and block vascular endothelial growth factor ( VEGF) binding to that receptor. Dimeric and tetrameric forms of TKPPR had greatly increased affinity for neuropilin-1 based on competition binding experiments. On endothelial cells tetrameric TKPPR inhibited the VEGF(165)-induced autophosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) even though it did not directly inhibit VEGF binding to VEGFR-2. Homology between exon 8 of VEGF and TKPPR suggests that the sequence coded for by exon 8 may stabilize VEGF binding to neuropilin- 1 to facilitate signaling through VEGFR-2. Given the overlap between processes involving neuropilin- 1 and tuftsin, we propose that at least some of the previously reported effects of tuftsin are mediated through neuropilin- 1.	Bracco Res USA, Ernst Felder Labs, Princeton, NJ 08540 USA; Bracco Res SA, CH-1228 Geneva, Switzerland	Bracco; Bracco	von Wronski, MA (corresponding author), Bracco Res USA, Ernst Felder Labs, 305 Coll Rd E, Princeton, NJ 08540 USA.	mvonwron@bru.bracco.com	Tweedle, Michael/E-4221-2011					Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Bates DO, 2002, CANCER RES, V62, P4123; Beck LH, 2004, DIFFERENTIATION, V72, P162, DOI 10.1111/j.1432-0436.2004.07204004.x; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101; Caveliers V, 2001, J NUCL MED, V42, P154; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Fukahi K, 2004, CLIN CANCER RES, V10, P581, DOI 10.1158/1078-0432.CCR-0930-03; Gavazzi I, 2001, CELL TISSUE RES, V305, P275, DOI 10.1007/s004410100365; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; GOLDMAN R, 1983, ANN NY ACAD SCI, V419, P143, DOI 10.1111/j.1749-6632.1983.tb37099.x; HERMAN ZS, 1981, EXPERIENTIA, V37, P76, DOI 10.1007/BF01965580; Ikeda M, 2000, J PATHOL, V191, P426; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; LIAW L, 1993, ARTERIOSCLER THROMB, V13, P985, DOI 10.1161/01.ATV.13.7.985; Ma X, 2004, INVEST OPHTH VIS SCI, V45, P2915, DOI 10.1167/iovs.04-0128; MOORE RN, 1989, J IMMUNOL, V142, P2689; NAJJAR VA, 1989, FEBS LETT, V253, P129, DOI 10.1016/0014-5793(89)80944-5; NAJJAR VA, 1970, NATURE, V228, P672, DOI 10.1038/228672a0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; OLIVER SJ, 1995, CELL IMMUNOL, V166, P196, DOI 10.1006/cimm.1995.9978; Raju N, 2005, TETRAHEDRON LETT, V46, P1463, DOI 10.1016/j.tetlet.2005.01.026; ROBEY FA, 1987, J BIOL CHEM, V262, P7053; Shrivastava A, 2005, PROTEIN ENG DES SEL, V18, P417, DOI 10.1093/protein/gzi049; Siemion IZ, 1999, PEPTIDES, V20, P645, DOI 10.1016/S0196-9781(99)00019-4; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; THANOS S, 1993, J NEUROSCI, V13, P455; Tordjman R, 2002, NAT IMMUNOL, V3, P477, DOI 10.1038/ni789; Wang L, 2003, J BIOL CHEM, V278, P48848, DOI 10.1074/jbc.M310047200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071	35	99	104	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5702	5710		10.1074/jbc.M511941200	http://dx.doi.org/10.1074/jbc.M511941200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371354	hybrid			2022-12-27	WOS:000235568900047
J	Jarvinen, A; Keinanen, TA; Grigorenko, NA; Khomutov, AR; Uimari, A; Vepsalainen, J; Narvanen, A; Alhonen, L; Janne, J				Jarvinen, A; Keinanen, TA; Grigorenko, NA; Khomutov, AR; Uimari, A; Vepsalainen, J; Narvanen, A; Alhonen, L; Janne, J			Guide molecule-driven stereospecific degradation of alpha-methylpolyamines by polyamine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-DECARBOXYLASE; RAT-LIVER; DERIVATIVES; SPERMIDINE; INHIBITION; ANALOGS; PURIFICATION; SPECIFICITY; METABOLISM; SPECTRA	FAD-dependent polyamine oxidase (PAO; EC 1.5.3.11) is one of the key enzymes in the catabolism of polyamines spermidine and spermine. The natural substrates for the enzyme are N-1-acetylspermidine, N-1-acetylspermine, and N-1, N-12-diacetylspermine. Here we report that PAO, which normally metabolizes achiral substrates, oxidized (R)-isomer of 1-amino-8-acetamido-5-azanonane and N-1-acetylspermidine as efficiently while (S)-1-amino-8-acetamido-5-azanonane was a much less preferred substrate. It has been shown that in the presence of certain aldehydes, the substrate specificity of PAO and the kinetics of the reaction are changed to favor spermine and spermidine as substrates. Therefore, we examined the effect of several aldehydes on the ability of PAO to oxidize different enantiomers of alpha-methylated polyamines. PAO supplemented with benzaldehyde predominantly catalyzed the cleavage of (R)-isomer of alpha-methylspermidine, whereas in the presence of pyridoxal the (S)-alpha-methylspermidine was preferred. PAO displayed the same stereospecificity with both singly and doubly alpha-methylated spermine derivatives when supplemented with the same aldehydes. Structurally related ketones proved to be ineffective. This is the first time that the stereospecificity of FAD-dependent oxidase has been successfully regulated by changing the supplementary aldehyde. These findings might facilitate the chemical regulation of stereospecificity of the enzymes.	Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, FI-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FI-70211 Kuopio, Finland; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia	University of Eastern Finland; University of Eastern Finland; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Jarvinen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, POB 1627, FI-70211 Kuopio, Finland.	Juhani.Janne@uku.fi	Khomutov, Alex/G-2128-2015; Keinänen, Tuomo/AAC-5630-2019; Narvanen, Ale/A-6002-2009	Khomutov, Alex/0000-0001-6833-7855				BEY P, 1978, J MED CHEM, V21, P50, DOI 10.1021/jm00199a009; Binda C, 2001, BIOCHEMISTRY-US, V40, P2766, DOI 10.1021/bi002751j; BOLKENIUS FN, 1981, INT J BIOCHEM, V13, P287, DOI 10.1016/0020-711X(81)90080-X; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; DELLARAGIONE F, 1983, BIOCHEM J, V213, P701, DOI 10.1042/bj2130701; FOSTER RJ, 1961, J BIOL CHEM, V236, P2461; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Grigorenko N. A., 2005, Bioorganicheskaya Khimiya, V31, P200; Grigorenko N. A., 2004, Bioorganicheskaya Khimiya, V30, P441; Grigorenko NA, 2005, MENDELEEV COMMUN, V15, P142, DOI 10.1070/MC2005v015n04ABEH002120; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; HYVONEN T, 1992, J CHROMATOGR-BIOMED, V574, P17, DOI 10.1016/0378-4347(92)80093-6; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x; Jarvinen A, 2005, J BIOL CHEM, V280, P6595, DOI 10.1074/jbc.M412788200; KEINANEN TA, 1993, ANAL BIOCHEM, V208, P35, DOI 10.1006/abio.1993.1005; Khomutov AR, 2001, TETRAHEDRON LETT, V42, P2887, DOI 10.1016/S0040-4039(01)00315-X; Khomutov AR, 1996, TETRAHEDRON, V52, P13751, DOI 10.1016/0040-4020(96)00836-8; Klibanov AM, 2001, NATURE, V409, P241, DOI 10.1038/35051719; LEDBETTER JW, 1982, J PHYS CHEM-US, V86, P2449, DOI 10.1021/j100210a041; MarkovicHousley Z, 1996, EUR J BIOCHEM, V236, P1025, DOI 10.1111/j.1432-1033.1996.01025.x; MCQUATE RS, 1975, J AM CHEM SOC, V97, P5117, DOI 10.1021/ja00851a016; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; METZLER CM, 1980, J AM CHEM SOC, V102, P6075, DOI 10.1021/ja00539a017; Niiranen K, 2002, J BIOL CHEM, V277, P25323, DOI 10.1074/jbc.M203599200; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; Perez-Cano FJ, 2003, CELL IMMUNOL, V226, P86, DOI 10.1016/j.cellimm.2003.09.009; PORTER CW, 1985, CANCER RES, V45, P2050; Qu N, 2003, BIOCHEM J, V375, P465, DOI 10.1042/BJ20030382; Rasanen TL, 2002, J BIOL CHEM, V277, P39867, DOI 10.1074/jbc.M205967200; REHSE K, 1990, ARCH PHARM, V323, P287, DOI 10.1002/ardp.19903230507; Royo M, 2005, BIOCHEMISTRY-US, V44, P7079, DOI 10.1021/bi050347k; Seiler N, 2004, AMINO ACIDS, V26, P217, DOI 10.1007/s00726-004-0070-z; TABOR H, 1983, METHOD ENZYMOL, V94, P420; Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x; TSUKADA T, 1988, INT J BIOCHEM, V20, P695, DOI 10.1016/0020-711X(88)90164-4; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; WEITKAMP ELC, 1991, BIOCHEM J, V277, P643, DOI 10.1042/bj2770643; Williams K, 1997, CELL SIGNAL, V9, P1, DOI 10.1016/S0898-6568(96)00089-7; Wu TY, 2003, J BIOL CHEM, V278, P20514, DOI 10.1074/jbc.M302149200; Yoshida M, 2004, J BIOL CHEM, V279, P46008, DOI 10.1074/jbc.M404393200	41	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4589	4595		10.1074/jbc.M509959200	http://dx.doi.org/10.1074/jbc.M509959200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16354669	Green Published, hybrid			2022-12-27	WOS:000235426200006
J	Vergauwen, B; De Vos, D; Van Beeumen, JJ				Vergauwen, B; De Vos, D; Van Beeumen, JJ			Characterization of the bifunctional gamma-glutamate-cysteine ligase/glutathione synthetase (GshF) of Pasteurella multocida	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; GLYCEROL PHOSPHATE SYNTHASE; HAEMOPHILUS-INFLUENZAE RD; GLUTAMYLCYSTEINE SYNTHETASE; GLUTATHIONE SYNTHETASE; TRYPTOPHAN SYNTHASE; CRYSTAL-STRUCTURE; DIHYDROFOLATE-REDUCTASE; 3-DIMENSIONAL STRUCTURE; THYMIDYLATE SYNTHASE	Glutamate-cysteine ligase (gamma-ECL) and glutathione synthetase (GS) are the two unrelated ligases that constitute the glutathione biosynthesis pathway in most eukaryotes, purple bacteria, and cyanobacteria. gamma-ECL is a member of the glutamine synthetase family, whereas GS enzymes group together with highly diverse carboxyltoamine/thiol ligases, all characterized by the so-called two-domain ATP-grasp fold. This generalized scheme toward the formation of glutathione, however, is incomplete, as functional steady-state levels of intracellular glutathione may also accumulate solely by import, as has been reported for the Pasteurellaceae member Haemophilus influenzae, as well as for certain Gram-positive enterococci and streptococci, or by the action of a bifunctional fusion protein (termed GshF), as has been reported recently for the Gram-positive firmicutes Streptococcus agalactiae and Listeria monocytogenes. Here, we show that yet another member of the Pasteurellaceae family, Pasteurella multocida, acquires glutathione both by import and GshF-driven biosynthesis. Domain architecture analysis shows that this P. multocida GshF bifunctional ligase contains an N-terminal gamma-proteobacterial gamma-ECL-like domain followed by a typical ATP-grasp domain, which most closely resembles that of cyanophycin synthetases, although it has no significant homology with known GS ligases. Recombinant P. multocida GshF overexpresses as an similar to 85-kDa protein, which, on the basis of gel-sizing chromatography, forms dimers in solution. The gamma-ECL activity of GshF is regulated by an allosteric type of glutathione feedback inhibition (K-i = 13.6 mM). Furthermore, steady-state kinetics, on the basis of which we present a novel variant of half-of-the-sites reactivity, indicate intimate domain-domain interactions, which may explain the bifunctionality of GshF proteins.	Univ Ghent, Lab Prot Biochem & Prot Engn, B-9000 Ghent, Belgium	Ghent University	Van Beeumen, JJ (corresponding author), Univ Ghent, Lab Prot Biochem & Prot Engn, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	Jozef.Vanbeeumen@Ugent.be						Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P1, DOI 10.1016/0304-4165(75)90205-6; BELDA FF, 1982, REV ESP FISIOL, V38, P327; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CM, 1972, J APPL CHEM BIOTECHN, V22, P363, DOI 10.1002/jctb.5020220307; Chaudhuri BN, 2001, STRUCTURE, V9, P987, DOI 10.1016/S0969-2126(01)00661-X; Copley SD, 2002, GENOME BIOL, V3; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; EASTERBY JS, 1981, BIOCHEM J, V199, P155, DOI 10.1042/bj1990155; FAHEY RC, 1984, SCIENCE, V224, P70, DOI 10.1126/science.6322306; FAHEY RC, 1978, J BACTERIOL, V133, P1126, DOI 10.1128/JB.133.3.1126-1129.1978; FAN C, 1994, SCIENCE, V266, P439, DOI 10.1126/science.7939684; Ferguson GP, 1998, J BACTERIOL, V180, P4314, DOI 10.1128/JB.180.16.4314-4318.1998; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gogos A, 2002, STRUCTURE, V10, P1669, DOI 10.1016/S0969-2126(02)00906-1; Gopal S, 2005, J BACTERIOL, V187, P3839, DOI 10.1128/JB.187.11.3839-3847.2005; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; HERRIOTT RM, 1970, J BACTERIOL, V101, P513, DOI 10.1128/JB.101.2.513-516.1970; Hibi T, 2004, P NATL ACAD SCI USA, V101, P15052, DOI 10.1073/pnas.0403277101; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; HYDE CC, 1990, BIO-TECHNOL, V8, P27, DOI 10.1038/nbt0190-27; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Jahoor F, 1999, AM J PHYSIOL-ENDOC M, V276, pE205, DOI 10.1152/ajpendo.1999.276.1.E205; Janowiak BE, 2005, J BIOL CHEM, V280, P11829, DOI 10.1074/jbc.M414326200; Joyce MA, 1999, BIOCHEMISTRY-US, V38, P7273, DOI 10.1021/bi990527s; KATO H, 1994, BIOCHEMISTRY-US, V33, P4995, DOI 10.1021/bi00183a001; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; KNIGHTON DR, 1994, NAT STRUCT BIOL, V1, P186, DOI 10.1038/nsb0394-186; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; Krehenbrink M, 2004, MICROBIOL-SGM, V150, P2599, DOI 10.1099/mic.0.27140-0; Kunishima N, 2005, J MOL BIOL, V352, P212, DOI 10.1016/j.jmb.2005.07.008; Levert KL, 2000, BIOCHEMISTRY-US, V39, P4122, DOI 10.1021/bi992662a; Liang PH, 1998, BIOCHEMISTRY-US, V37, P12195, DOI 10.1021/bi9803168; Luo JL, 2000, BIOCHEM BIOPH RES CO, V275, P577, DOI 10.1006/bbrc.2000.3337; Lyons J, 2000, P NATL ACAD SCI USA, V97, P5071, DOI 10.1073/pnas.090083297; Matsuda K, 1996, PROTEIN ENG, V9, P1083, DOI 10.1093/protein/9.12.1083; May BJ, 2001, P NATL ACAD SCI USA, V98, P3460, DOI 10.1073/pnas.051634598; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Misra I, 1998, PROTEIN EXPRES PURIF, V13, P268, DOI 10.1006/prep.1998.0897; MURATA K, 1982, APPL ENVIRON MICROB, V44, P1444, DOI 10.1128/AEM.44.6.1444-1448.1982; Myers RS, 2003, BIOCHEMISTRY-US, V42, P7013, DOI 10.1021/bi034314l; Nagradova N, 2003, IUBMB LIFE, V55, P459, DOI 10.1080/15216540310001602805; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Oppermann-Sanio FB, 2002, NATURWISSENSCHAFTEN, V89, P11, DOI 10.1007/s00114-001-0280-0; Pauwels F, 2004, J BIOL CHEM, V279, P12163, DOI 10.1074/jbc.M312037200; Pauwels F, 2003, J BIOL CHEM, V278, P16658, DOI 10.1074/jbc.M300157200; Polekhina G, 1999, EMBO J, V18, P3204, DOI 10.1093/emboj/18.12.3204; SAKUDA S, 1994, BIOSCI BIOTECH BIOCH, V58, P1347, DOI 10.1271/bbb.58.1347; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Silva MS, 2005, FEBS J, V272, P2388, DOI 10.1111/j.1742-4658.2005.04632.x; Spivey HO, 1999, METHODS, V19, P306, DOI 10.1006/meth.1999.0858; STALLCUP WB, 1972, BIOCHEM BIOPH RES CO, V49, P1108, DOI 10.1016/0006-291X(72)90327-0; SUZUKI H, 1993, J BACTERIOL, V175, P6038, DOI 10.1128/JB.175.18.6038-6040.1993; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tu ZH, 1998, ARCH BIOCHEM BIOPHYS, V354, P247, DOI 10.1006/abbi.1998.0676; van den Heuvel RHH, 2003, J MOL BIOL, V330, P113, DOI 10.1016/S0022-2836(03)00522-9; Vergauwen B, 2003, J BACTERIOL, V185, P5555, DOI 10.1128/JB.185.18.5555-5562.2003; Vergauwen B, 2003, J BACTERIOL, V185, P1572, DOI 10.1128/JB.185.5.1572-1581.2003; WIEDERHOLT KM, 1994, J DAIRY SCI, V77, P1183, DOI 10.3168/jds.S0022-0302(94)77056-9; WOLODKO WT, 1981, P NATL ACAD SCI-BIOL, V78, P2140, DOI 10.1073/pnas.78.4.2140; YAMAGUCHI H, 1993, J MOL BIOL, V229, P1083, DOI 10.1006/jmbi.1993.1106; YAQUB S, 2004, TIDSSKR NOR LAEGEFOR, V214, P3194	69	47	54	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4380	4394		10.1074/jbc.M509517200	http://dx.doi.org/10.1074/jbc.M509517200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339152	hybrid			2022-12-27	WOS:000235275300074
J	Chen, YL; Law, PY; Loh, HH				Chen, YL; Law, PY; Loh, HH			Sustained activation of phosphatidylinositol 3-kinase/Akt/nuclear factor kappa B signaling mediates G protein-coupled delta-opioid receptor gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TRANSCRIPTION FACTOR; PC12 CELLS; MORPHINE-TOLERANCE; PHEOCHROMOCYTOMA CELLS; KINASE ACTIVITY; MESSENGER-RNAS; TRK RECEPTORS; PC-12 CELLS; RAT-BRAIN	Expression of the delta-opioid receptor gene ( dor) is tightly controlled during neuronal differentiation and developmental stages. Such distinct temporal and spatial expression of dor during development suggests a role for the delta-opioid receptor in early developmental events. However, little is known about intracellular signaling pathways that control dor expression. A well established cell line model for the study of gene expression during neuronal differentiation is the rat adrenal pheochromocytoma PC12 cell line. Here we found that the constitutively activated TrkA/phosphatidylinositol 3-kinase/Akt ( protein kinase B)/NF-kappa B survival cascade mediates dor expression during nerve growth factor ( NGF)-induced differentiation of PC12h cells. Biochemical experiments showed that constitutive phosphorylation of Akt and I kappa B alpha correlates with NGF-induced dor expression. Overexpression of the transcriptional activator NF-kappa B/p65 increased dor promoter activity. Overexpression of the NF-kappa B signaling super inhibitor mutant I kappa B alpha ( S32A/ S36A) abolished the effect of p65 and blocked NGF-induced activation of NF-kappa B signaling, resulting in a significant reduction in dor promoter activity. Treatment with SN50, an NF-kappa B-specific nuclear translocation peptide inhibitor, inhibited the translocation of NF-kappa B, resulting in a reduction of dor mRNA. The gel shift assay supported the fact that there exists an NF-kappa B-binding site on the dor promoter. RNA interference experiments using NF-kappa B/p65 small interfering RNA confirmed that NF-kappa B signaling is required for dor expression. Our findings not only provide a new mechanistic explanation for NGF-induced dor expression but also shed some light on the molecular mechanism of the temporal and spatial expression of dor and the roles of the delta-opioid receptor during neuronal differentiation.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Chen, YL (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	chenx112@tc.umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NATIONAL INSTITUTE ON DRUG ABUSE [R37DA001583, R01DA001583, R01DA000564, P50DA011806, K05DA070554, K05DA000513, R56DA000564] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-000564, DA-001583, K05-DA00513, DA-011806, K05-DA-70554] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ABDELHAMID EE, 1991, J PHARMACOL EXP THER, V258, P299; ABOOD ME, 1995, J PHARMACOL EXP THER, V274, P1566; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; AUGUSTIN LB, 1995, BIOCHEM BIOPH RES CO, V207, P111, DOI 10.1006/bbrc.1995.1160; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, V2; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Borlongan CV, 2004, FRONT BIOSCI-LANDMRK, V9, P3392, DOI 10.2741/1490; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Chang JH, 2003, J BIOL CHEM, V278, P42877, DOI 10.1074/jbc.M308155200; Chang SF, 2001, NEUROSCI LETT, V314, P29, DOI 10.1016/S0304-3940(01)02280-7; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen YL, 2004, CANCER RES, V64, P8723, DOI 10.1158/0008-5472.CAN-03-3091; Dermitzaki E, 2000, J NEUROCHEM, V74, P960, DOI 10.1046/j.1471-4159.2000.0740960.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Fernyhough P, 2005, J NEUROSCI, V25, P1682, DOI 10.1523/JNEUROSCI.3127-04.2005; Georges F, 1998, DEV BRAIN RES, V109, P187, DOI 10.1016/S0165-3806(98)00082-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; INOUE N, 1982, J BIOL CHEM, V257, P9238; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; Jamen F, 2002, J NEUROCHEM, V82, P1199, DOI 10.1046/j.1471-4159.2002.01124.x; Kim SS, 2005, MOL PHARMACOL, V68, P729, DOI 10.1124/mol.105.012245; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Law PY, 2004, NEUROPHARMACOLOGY, V47, P300, DOI 10.1016/j.neuropharm.2004.07.013; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEVI A, 1988, MOL NEUROBIOL, V2, P201, DOI 10.1007/BF02935346; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu HC, 1999, J BIOL CHEM, V274, P23617, DOI 10.1074/jbc.274.33.23617; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; Malek RL, 1999, J BIOL CHEM, V274, P35499, DOI 10.1074/jbc.274.50.35499; Mattson MP, 2003, NAT NEUROSCI, V6, P105, DOI 10.1038/nn0203-105; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Middleton G, 2001, DEVELOPMENT, V128, P447; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; Nie ZZ, 1999, MOL PHARMACOL, V56, P947, DOI 10.1124/mol.56.5.947; Numan S, 1998, J NEUROSCI, V18, P10700; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Patapoutian A, 2001, CURR OPIN NEUROBIOL, V11, P272, DOI 10.1016/S0959-4388(00)00208-7; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Rojo AI, 2004, J NEUROSCI, V24, P7324, DOI 10.1523/JNEUROSCI.2111-04.2004; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roy S, 2005, J NEUROSCI, V25, P3229, DOI 10.1523/JNEUROSCI.0332-05.2005; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Smith DJ, 2003, NEUROSCI LETT, V340, P103, DOI 10.1016/S0304-3940(03)00084-3; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TAPLEY P, 1992, ONCOGENE, V7, P371; Tenconi B, 1996, DEV BRAIN RES, V94, P175, DOI 10.1016/0165-3806(96)00047-8; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; YAN Q, 1989, J COMP NEUROL, V290, P585, DOI 10.1002/cne.902900411; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3; Zhu YX, 1998, J NEUROSCI, V18, P2538	64	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3067	3074		10.1074/jbc.M506721200	http://dx.doi.org/10.1074/jbc.M506721200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16316997	hybrid			2022-12-27	WOS:000235128200009
J	Arlander, SJH; Felts, SJ; Wagner, JM; Stensgard, B; Toft, DO; Karnitz, LM				Arlander, SJH; Felts, SJ; Wagner, JM; Stensgard, B; Toft, DO; Karnitz, LM			Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; VIRUS TRANSFORMING PROTEIN; 2 CELLULAR PHOSPHOPROTEINS; GLUCOCORTICOID-RECEPTOR; PROGESTERONE-RECEPTOR; RADIOSENSITIZING AGENT; REVERSE-TRANSCRIPTASE; MOLECULAR CHAPERONE; STEROID-RECEPTORS; TYROSINE KINASES	Checkpoint kinase 1 ( Chk1), a serine/threonine kinase that regulates DNA damage checkpoints, is destabilized when heat shock protein 90 (Hsp90) is inhibited, suggesting that Chk1 is an Hsp90 client. In the present work we examined the interplay between Chk1 and Hsp90 in intact cells, identified a source of unchaperoned Chk1, and report the in vitro chaperoning of Chk1 in reticulocyte lysates and with purified chaperones and co-chaperones. We find that bacterially expressed Chk1 is post-translationally chaperoned to an active kinase. This reaction minimally requires Hsp90, Hsp70, Hsp40, Cdc37, and the protein kinase CK2. The co-chaperone Hop, although not essential for the activation of Chk1 in vitro, enhanced the chaperoning process, whereas the co-chaperone p23 did not stimulate the chaperoning reaction. Additionally, we found that the C-terminal regulatory domain of Chk1 affects the association of Chk1 with Hsp90. Collectively these results provide new insights into Hsp90-dependent chaperoning of a client kinase and identify a novel, biochemically tractable model system that will be useful to further dissect the Hsp90-dependent chaperoning of this important and ubiquitous class of Hsp90 clients.	Mayo Clin & Mayo Fdn, Coll Med, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Dept Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Div Dev Oncol Res, Guggenheim 13,200 1st St SW, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu			NATIONAL CANCER INSTITUTE [R01CA104378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249] Funding Source: NIH RePORTER; NCI NIH HHS [CA104378] Funding Source: Medline; NIDDK NIH HHS [DK46249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADKINS B, 1982, J VIROL, V43, P448, DOI 10.1128/JVI.43.2.448-455.1982; ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Arlander SJH, 2003, J BIOL CHEM, V278, P52572, DOI 10.1074/jbc.M309054200; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bohen SP, 1998, MOL CELL BIOL, V18, P3330, DOI 10.1128/MCB.18.6.3330; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; Busby EC, 2000, CANCER RES, V60, P2108; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Donze O, 1999, MOL CELL BIOL, V19, P8422, DOI 10.1128/mcb.19.12.8422; Egorin MJ, 1998, CANCER RES, V58, P2385; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Farrell A, 2000, MOL CELL BIOL, V20, P749, DOI 10.1128/MCB.20.3.749-754.2000; Felts SJ, 2003, CELL STRESS CHAPERON, V8, P108, DOI 10.1379/1466-1268(2003)008<0108:PASPWC>2.0.CO;2; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Hartson SD, 2000, BIOCHEMISTRY-US, V39, P7631, DOI 10.1021/bi000315r; Hartson SD, 1998, J BIOL CHEM, V273, P8475, DOI 10.1074/jbc.273.14.8475; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Hu JM, 2004, J VIROL, V78, P13122, DOI 10.1128/JVI.78.23.13122-13131.2004; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; JOAB I, 1984, NATURE, V308, P850, DOI 10.1038/308850a0; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lee P, 2004, MOL BIOL CELL, V15, P1785, DOI 10.1091/mbc.E03-07-0480; Miyata Y, 2004, MOL CELL BIOL, V24, P4065, DOI 10.1128/MCB.24.9.4065-4074.2004; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nollen EAA, 2002, J CELL SCI, V115, P2809; Odunuga OO, 2004, BIOESSAYS, V26, P1058, DOI 10.1002/bies.20107; Oe T, 2001, DEV BIOL, V229, P250, DOI 10.1006/dbio.2000.9968; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Sakagami M, 1999, CELL STRESS CHAPERON, V4, P19, DOI 10.1054/csac.1998.0115; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Scholz GM, 2001, CELL GROWTH DIFFER, V12, P409; SCHUH S, 1985, J BIOL CHEM, V260, P4292; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Shao JY, 2003, J BIOL CHEM, V278, P38117, DOI 10.1074/jbc.C300330200; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1994, J BIOL CHEM, V269, P22157; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Uma S, 1997, J BIOL CHEM, V272, P11648; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P742, DOI 10.1021/bi00147a029; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Yorgin PD, 2000, J IMMUNOL, V164, P2915, DOI 10.4049/jimmunol.164.6.2915	64	74	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2989	2998		10.1074/jbc.M508687200	http://dx.doi.org/10.1074/jbc.M508687200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330544	hybrid			2022-12-27	WOS:000234931800069
J	Ji, YB; Neverova, I; Van Eyk, JE; Bennett, BM				Ji, YB; Neverova, I; Van Eyk, JE; Bennett, BM			Nitration of tyrosine 92 mediates the activation of rat microsomal glutathione S-transferase by peroxynitrite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFHYDRYL OXIDATION; INACTIVATION; HYDROXYLASE; BINDING	There is increasing evidence that protein function can be modified by nitration of tyrosine residue(s), a reaction catalyzed by proteins with peroxidase activity, or that occurs by interaction with peroxynitrite, a highly reactive oxidant formed by the reaction of nitric oxide with superoxide. Although there are numerous reports describing loss of function after treatment of proteins with peroxynitrite, we recently demonstrated that the microsomal glutathione S-transferase 1 is activated rather than inactivated by peroxynitrite and suggested that this could be attributed to nitration of tyrosine residues rather than to other effects of peroxynitrite. In this report, the nitrated tyrosine residues of peroxynitrite-treated microsomal glutathione S-transferase 1 were characterized by mass spectrometry and their functional significance determined. Of the seven tyrosine residues present in the protein, only those at positions 92 and 153 were nitrated after treatment with peroxynitrite. Three mutants (Y92F, Y153F, and Y92F, Y153F) were created using site-directed mutagenesis and expressed in LLC-PK1 cells. Treatment of the microsomal fractions of these cells with peroxynitrite resulted in an similar to 2-fold increase in enzyme activity in cells expressing the wild type microsomal glutathione S-transferase 1 or the Y153F mutant, whereas the enzyme activity of Y92F and double site mutant was unaffected. These results indicate that activation of microsomal glutathione S-transferase 1 by peroxynitrite is mediated by nitration of tyrosine residue 92 and represents one of the few examples in which a gain in function has been associated with nitration of a specific tyrosine residue.	Queens Univ, Fac Hlth Sci, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Queens Univ, Fac Hlth Sci, Dept Physiol, Kingston, ON K7L 3N6, Canada; Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA	Queens University - Canada; Queens University - Canada; Johns Hopkins University	Bennett, BM (corresponding author), Queens Univ, Fac Hlth Sci, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada.	brian.bennett@queensu.ca			NHLBI NIH HHS [P01 HL081427-040003, P01 HL077180-050001, P01 HL077180-020001, P01 HL081427-030003, P01 HL077180-010001, P50 HL084946-029003, P01 HL081427, P50 HL084946, P01 HL081427-010003, P50 HL084946-039003, P01 HL081427-020003, P01 HL077180-030001, P01 HL077180-040001, P01 HL077180, P50 HL084946-019003, P01 HL081427-050003] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081427, P50HL084946, P01HL077180] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON C, 1994, BBA-PROTEIN STRUCT M, V1204, P298, DOI 10.1016/0167-4838(94)90021-3; ANIYA Y, 1989, J BIOL CHEM, V264, P1998; ANIYA Y, 1992, ARCH BIOCHEM BIOPHYS, V296, P611, DOI 10.1016/0003-9861(92)90617-6; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Busenlehner LS, 2004, BIOCHEMISTRY-US, V43, P11145, DOI 10.1021/bi048716k; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Francescutti D, 1996, PROTEIN ENG, V9, P189, DOI 10.1093/protein/9.2.189; Grzelak A, 2000, SCAND J CLIN LAB INV, V60, P253, DOI 10.1080/003655100750046413; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Holm PJ, 2002, BBA-PROTEIN STRUCT M, V1594, P276, DOI 10.1016/S0167-4838(01)00311-9; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Ji YB, 2002, BIOCHEM PHARMACOL, V63, P1397, DOI 10.1016/S0006-2952(02)00879-1; Ji YB, 2003, MOL PHARMACOL, V63, P136, DOI 10.1124/mol.63.1.136; Kocis JM, 2002, FRONT BIOSCI-LANDMRK, V7, pA175, DOI 10.2741/kocis; Kuhn DM, 1999, J NEUROSCI, V19, P10289; Kuhn DM, 1999, J BIOL CHEM, V274, P29726, DOI 10.1074/jbc.274.42.29726; LUNDQVIST G, 1992, BIOCHEM PHARMACOL, V43, P1725, DOI 10.1016/0006-2952(92)90702-K; MOSIALOU E, 1989, ARCH BIOCHEM BIOPHYS, V275, P289, DOI 10.1016/0003-9861(89)90375-5; Padmaja S, 1998, ARCH BIOCHEM BIOPHYS, V349, P1, DOI 10.1006/abbi.1997.0407; Shi Q, 2005, PHARMACOL RES, V51, P303, DOI 10.1016/j.phrs.2004.10.001; Sun TH, 1997, BIOCHEM J, V326, P193, DOI 10.1042/bj3260193; Svensson R, 2004, BIOCHEMISTRY-US, V43, P8869, DOI 10.1021/bi0492511; Svensson R, 2000, BIOCHEMISTRY-US, V39, P15144, DOI 10.1021/bi001764u; Takakura K, 1999, ARCH BIOCHEM BIOPHYS, V369, P197, DOI 10.1006/abbi.1999.1374; Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532; Zou MH, 2002, J CLIN INVEST, V109, P817, DOI 10.1172/JCI200214442	27	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					1986	1991		10.1074/jbc.M509480200	http://dx.doi.org/10.1074/jbc.M509480200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314419	hybrid			2022-12-27	WOS:000234760400018
J	Shigi, N; Suzuki, T; Terada, T; Shirouzu, M; Yokoyama, S; Watanabe, K				Shigi, N; Suzuki, T; Terada, T; Shirouzu, M; Yokoyama, S; Watanabe, K			Temperature-dependent biosynthesis of 2-thioribothymidine of Thermus thermophilus tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOLATED NUCLEOSIDES PRESENT; IN-VITRO BIOSYNTHESIS; FE-S CLUSTER; EXTREME THERMOPHILE; MIAB PROTEIN; 4-THIOURIDINE; ISCS; ENZYME; THII; RESIDUES	2-Thioribothymidine (s(2)T) is a modified nucleoside of U, specifically found at position 54 of tRNAs from extreme thermophilic microorganisms. The function of the 2-thiocarbonyl group of s(2)T54 is thermostabilization of the three-dimensional structure of tRNA; however, its biosynthesis has not been clarified until now. Using an in vivo tRNA labeling experiment, we demonstrate that the sulfur atom of s(2)T in tRNA is derived from cysteine or sulfate. We attempted to reconstitute 2-thiolation of s(2)T in vitro, using a cell extract of Thermus thermophilus. Specific 2-thiolation of ribothymidine, at position 54, was observed in vitro, in the presence of ATP. Using this assay, we found a strong temperature dependence of the 2-thiolation reaction in vitro as well as expression of 2-thiolation enzymes in vivo. These results suggest that the variable content of s(2)T in vivo at different temperatures may be explained by the above characteristics of the enzymes responsible for the 2-thiolation reaction. Furthermore, we found that another posttranscriptionally modified nucleoside, 1-methyladenosine at position 58, is required for the efficient 2-thiolation of ribothymidine 54 both in vivo and in vitro.	Natl Inst Adv Ind Sci & Technol, Bio Informat Res Ctr, Koto Ku, Tokyo 1350064, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN, Harima Inst, SPring 8, Sayo, Hyogo 6795148, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 110033, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; University of Tokyo	Watanabe, K (corresponding author), Natl Inst Adv Ind Sci & Technol, Bio Informat Res Ctr, Koto Ku, 2-42 Aomi, Tokyo 1350064, Japan.	kwatanab@jbirc.aist.go.jp	Shigi, Naoki/L-7135-2018; Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016; Suzuki, Tsutomu/J-1776-2015	Shigi, Naoki/0000-0003-4452-8264; Yokoyama, Shigeyuki/0000-0003-3133-7338; Suzuki, Tsutomu/0000-0002-9731-1731				Curran J. F., 1998, MODIFICATION EDITING, P493; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; Droogmans L, 2003, NUCLEIC ACIDS RES, V31, P2148, DOI 10.1093/nar/gkg314; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; Hoseki J, 1999, J BIOCHEM-TOKYO, V126, P951, DOI 10.1093/oxfordjournals.jbchem.a022539; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; Ikeuchi Y, 2005, MOL CELL, V19, P235, DOI 10.1016/j.molcel.2005.06.007; Jager G, 2004, J BACTERIOL, V186, P750, DOI 10.1128/JB.186.3.750-757.2004; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kaneko T, 2003, EMBO J, V22, P657, DOI 10.1093/emboj/cdg066; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; KUMAGAI I, 1982, J BIOL CHEM, V257, P7388; Lauhon CT, 2004, J BIOL CHEM, V279, P19551, DOI 10.1074/jbc.M401261200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Leipuviene R, 2004, J BACTERIOL, V186, P758, DOI 10.1128/JB.186.3.758-766.2004; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Mueller EG, 1998, NUCLEIC ACIDS RES, V26, P2606, DOI 10.1093/nar/26.11.2606; Mueller EG, 1999, PROTEIN SCI, V8, P2424; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; OSHIMA T, 1971, J GEN APPL MICROBIOL, V17, P513, DOI 10.2323/jgam.17.513; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Palenchar PM, 2000, J BIOL CHEM, V275, P8283, DOI 10.1074/jbc.275.12.8283; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Pierrel F, 2004, J BIOL CHEM, V279, P47555, DOI 10.1074/jbc.M408562200; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; SCHNEIDER A, 1994, NUCLEIC ACIDS RES, V22, P3699, DOI 10.1093/nar/22.18.3699; Shigi N, 2002, J BIOL CHEM, V277, P39128, DOI 10.1074/jbc.M207323200; Soma A, 2003, MOL CELL, V12, P689, DOI 10.1016/S1097-2765(03)00346-0; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; TAKADA T, 1993, APPL ENVIRON MICROB, V59, P2737, DOI 10.1128/AEM.59.8.2737-2739.1993; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; WATANABE K, 1974, FEBS LETT, V43, P59, DOI 10.1016/0014-5793(74)81105-1; Wolfe MD, 2004, J BIOL CHEM, V279, P1801, DOI 10.1074/jbc.M310442200; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yokoyama S, 1987, Adv Biophys, V23, P115, DOI 10.1016/0065-227X(87)90006-2	43	60	62	3	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2104	2113		10.1074/jbc.M510771200	http://dx.doi.org/10.1074/jbc.M510771200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16317006	hybrid			2022-12-27	WOS:000234760400032
J	Jermy, AJ; Willer, M; Davis, E; Wilkinson, BM; Stirling, CJ				Jermy, AJ; Willer, M; Davis, E; Wilkinson, BM; Stirling, CJ			The Brl domain in Sec63p is required for assembly of functional endoplasmic reticulum translocons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-CONDUCTING CHANNEL; ER MEMBRANE; SACCHAROMYCES-CEREVISIAE; YEAST; COMPLEX; BIP; TRANSPORT; SECYEG; IDENTIFICATION; PRECURSORS	Protein translocation into the endoplasmic reticulum occurs at pore-forming structures known as translocons. In yeast, two different targeting pathways converge at a translocation pore formed by the Sec61 complex. The signal recognition particle-dependent pathway targets nascent precursors co-translationally, whereas the Sec62p-dependent pathway targets polypeptides post-translationally. In addition to the Sec61 complex, both pathways also require Sec63p, an integral membrane protein of the Hsp40 family, and Kar2p, a soluble Hsp70 located in the ER lumen. Using a series of mutant alleles, we demonstrate that a conserved Brl (Brr2-like) domain in the COOH-terminal cytosolic region of Sec63p is essential for function both in vivo and in vitro. We further demonstrate that this domain is required for assembly of two oligomeric complexes of 350 and 380 kDa, respectively. The larger of these corresponds to the heptameric "SEC complex" required for post-translational translocation. However, the 350-kDa complex represents a newly defined hexameric SEC' complex comprising Sec61p, Sss1p, Sbh1p, Sec63p, Sec71p, and Sec72p. Our data indicate that the SEC' complex is required for co-translational protein translocation across the yeast ER membrane.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Stirling, CJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	colin.stirling@manchester.ac.uk		Jermy, Andrew/0000-0002-7454-0670	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alder NN, 2005, J CELL BIOL, V168, P389, DOI 10.1083/jcb.200409174; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; Craven RA, 1996, EMBO J, V15, P2640, DOI 10.1002/j.1460-2075.1996.tb00624.x; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; Dudek J, 2002, EMBO J, V21, P2958, DOI 10.1093/emboj/cdf315; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; Haigh NG, 2002, J CELL BIOL, V156, P261, DOI 10.1083/jcb.200110074; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Meyer HA, 2000, J BIOL CHEM, V275, P14550, DOI 10.1074/jbc.275.19.14550; Misselwitz E, 1999, J BIOL CHEM, V274, P20110, DOI 10.1074/jbc.274.29.20110; Mitra K, 2005, NATURE, V438, P318, DOI 10.1038/nature04133; Noble SM, 1996, GENETICS, V143, P67; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tyedmers J, 2000, P NATL ACAD SCI USA, V97, P7214, DOI 10.1073/pnas.97.13.7214; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van Nues RW, 2001, GENETICS, V157, P1451; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; Wang X, 2005, J CELL SCI, V118, P723, DOI 10.1242/jcs.01671; Wilkinson BM, 1997, J MEMBRANE BIOL, V155, P189, DOI 10.1007/s002329900171; Willer M, 2003, BIOCHEMISTRY-US, V42, P7171, DOI 10.1021/bi034395l; Willer M, 2003, YEAST, V20, P133, DOI 10.1002/yea.954; Wittke S, 2000, MOL BIOL CELL, V11, P3859, DOI 10.1091/mbc.11.11.3859; Young BP, 2001, EMBO J, V20, P262, DOI 10.1093/emboj/20.1.262	42	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					7899	7906		10.1074/jbc.M511402200	http://dx.doi.org/10.1074/jbc.M511402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16368690	hybrid			2022-12-27	WOS:000236031000025
J	Rowland, P; Blaney, FE; Smyth, MG; Jones, JJ; Leydon, VR; Oxbrow, AK; Lewis, CJ; Tennant, MG; Modi, S; Eggleston, DS; Chenery, RJ; Bridges, AM				Rowland, P; Blaney, FE; Smyth, MG; Jones, JJ; Leydon, VR; Oxbrow, AK; Lewis, CJ; Tennant, MG; Modi, S; Eggleston, DS; Chenery, RJ; Bridges, AM			Crystal structure of human cytochrome P450 2D6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; GENETIC-POLYMORPHISM; PHARMACOPHORE MODEL; ENZYMATIC-ACTIVITY; COMBINED PROTEIN; DRUG-METABOLISM; CYP2D ISOFORMS; AMINO-ACID	Cytochrome P450 2D6 is a heme-containing enzyme that is responsible for the metabolism of at least 20% of known drugs. Substrates of 2D6 typically contain a basic nitrogen and a planar aromatic ring. The crystal structure of human 2D6 has been solved and refined to 3.0 angstrom resolution. The structure shows the characteristic P450 fold as seen in other members of the family, with the lengths and orientations of the individual secondary structural elements being very similar to those seen in 2C9. There are, however, several important differences, the most notable involving the F helix, the F-G loop, the B' helix, beta sheet 4, and part of beta sheet 1, all of which are situated on the distal face of the protein. The 2D6 structure has a well defined active site cavity above the heme group, containing many important residues that have been implicated in substrate recognition and binding, including Asp-301, Glu-216, Phe-483, and Phe-120. The crystal structure helps to explain how Asp-301, Glu-216, and Phe-483 can act as substrate binding residues and suggests that the role of Phe-120 is to control the orientation of the aromatic ring found in most substrates with respect to the heme. The structure has been compared with published homology models and has been used to explain much of the reported site-directed mutagenesis data and help understand the metabolism of several compounds.	GlaxoSmithKline, Dept Discovery Res, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Rowland, P (corresponding author), GlaxoSmithKline, Dept Discovery Res, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Paul_2_Rowland@gsk.com		Tennant, Mike/0000-0001-6083-3109				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; *ACC INC, 1999, QUANTA98 VERS 98 111; Allorge D, 2005, PROTEINS, V59, P339, DOI 10.1002/prot.20399; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Bathelt CM, 2004, ORG BIOMOL CHEM, V2, P2998, DOI 10.1039/b410729b; Bertz RJ, 1997, CLIN PHARMACOKINET, V32, P210, DOI 10.2165/00003088-199732030-00004; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Chowdry J, 2002, BRIT J CLIN PHARMACO, V53, p443P; DALY AK, 1995, HUM GENET, V95, P337; de Graaf C, 2005, J MED CHEM, V48, P2725, DOI 10.1021/jm040180d; de Groot MJ, 1999, J MED CHEM, V42, P4062, DOI 10.1021/jm991058v; de Groot MJ, 1999, J MED CHEM, V42, P1515, DOI 10.1021/jm981118h; De Rienzo F, 2000, J COMPUT AID MOL DES, V14, P93, DOI 10.1023/A:1008187802746; deGroot MJ, 1996, CHEM RES TOXICOL, V9, P1079, DOI 10.1021/tx960003i; DeLano W.L, PYMOL MOL GRAPHICS S; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; ELLIS SW, 1995, J BIOL CHEM, V270, P29055, DOI 10.1074/jbc.270.49.29055; Ellis SW, 1996, BIOCHEM J, V316, P647, DOI 10.1042/bj3160647; Ellis SW, 2002, BRIT J CLIN PHARMACO, V53, p444P; Ellis SW, 2000, BIOCHEM J, V345, P565, DOI 10.1042/0264-6021:3450565; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Flanagan JU, 2004, BIOCHEM J, V380, P353, DOI 10.1042/BJ20040062; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GOTOH O, 1992, J BIOL CHEM, V267, P83; GOUGH AC, 1990, NATURE, V347, P773, DOI 10.1038/347773a0; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Guengerich FP, 2003, BIOCHEMISTRY-US, V42, P1245, DOI 10.1021/bi027085w; Hanna IH, 2001, ARCH BIOCHEM BIOPHYS, V393, P255, DOI 10.1006/abbi.2001.2510; Hayhurst GP, 2001, BIOCHEM J, V355, P373, DOI 10.1042/0264-6021:3550373; Hiroi T, 2002, DRUG METAB DISPOS, V30, P970, DOI 10.1124/dmd.30.9.970; Keizers PHJ, 2004, BIOCHEM PHARMACOL, V68, P2263, DOI 10.1016/j.bcp.2004.08.013; Kirton SB, 2002, PROTEINS, V49, P216, DOI 10.1002/prot.10192; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KOYMANS L, 1992, CHEM RES TOXICOL, V5, P211, DOI 10.1021/tx00026a010; KOYMANS LMH, 1993, J COMPUT AID MOL DES, V7, P281, DOI 10.1007/BF00125503; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LENNARD MS, 1990, PHARMACOL TOXICOL, V67, P273, DOI 10.1111/j.1600-0773.1990.tb00830.x; Lewis D. F. V., 2002, Xenobiotica, V32, P305, DOI 10.1080/00498250110112015; Lewis DFV, 1997, XENOBIOTICA, V27, P319, DOI 10.1080/004982597240497; LEWIS DFV, 1995, XENOBIOTICA, V25, P333, DOI 10.3109/00498259509061857; Lightfoot T, 2000, XENOBIOTICA, V30, P219, DOI 10.1080/004982500237622; Lussenburg BMA, 2005, BIOCHEM PHARMACOL, V70, P1253, DOI 10.1016/j.bcp.2005.07.002; McLaughlin LA, 2005, J BIOL CHEM, V280, P38617, DOI 10.1074/jbc.M505974200; MEYER UA, 1990, PHARMACOL THERAPEUT, V46, P297, DOI 10.1016/0163-7258(90)90096-K; Modi S, 1996, BIOCHEMISTRY-US, V35, P4540, DOI 10.1021/bi952742o; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OMURA T, 1964, J BIOL CHEM, V239, P2379; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paine MJI, 2003, J BIOL CHEM, V278, P4021, DOI 10.1074/jbc.M209519200; Pritchard MP, 1997, ARCH BIOCHEM BIOPHYS, V345, P342, DOI 10.1006/abbi.1997.0265; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RICHARDSON TH, 1993, ARCH BIOCHEM BIOPHYS, V300, P510, DOI 10.1006/abbi.1993.1069; Schleinkofer K, 2005, EMBO REP, V6, P584, DOI 10.1038/sj.embor.7400420; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Smith DA, 1997, DRUG DISCOV TODAY, V2, P406, DOI 10.1016/S1359-6446(97)01081-7; Snyder R, 2002, QUANT STRUCT-ACT REL, V21, P357, DOI 10.1002/1521-3838(200210)21:4<357::AID-QSAR357>3.0.CO;2-D; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; SZCZESNASKORUPA E, 1993, ARCH BIOCHEM BIOPHYS, V304, P170, DOI 10.1006/abbi.1993.1335; Venhorst J, 2000, DRUG METAB DISPOS, V28, P1524; Venhorst J, 2003, J MED CHEM, V46, P74, DOI 10.1021/jm0209578; vonWachenfeldt C, 1997, ARCH BIOCHEM BIOPHYS, V339, P107, DOI 10.1006/abbi.1996.9859; *WAV INC, 1999, SPARTAN SGI VERS 5 1; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Williams D, 2000, PERFORM RES, V5, P131; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yano JK, 2005, NAT STRUCT MOL BIOL, V12, P822, DOI 10.1038/nsmb971; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Zhang YQ, 1999, BIOCHEM BIOPH RES CO, V258, P32, DOI 10.1006/bbrc.1999.0569	75	359	374	2	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7614	7622		10.1074/jbc.M511232200	http://dx.doi.org/10.1074/jbc.M511232200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16352597	hybrid			2022-12-27	WOS:000236030900083
J	Pei, ZT; Jia, ZZ; Watkins, PA				Pei, ZT; Jia, ZZ; Watkins, PA			The second member of the human and murine "bubblegum" family is a testis- and brainstem-specific acyl-CoA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID TRANSPORT; X-LINKED ADRENOLEUKODYSTROPHY; COENZYME-A SYNTHETASE; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; BETA-OXIDATION; RAT-LIVER; EXPRESSION; CLONING; IDENTIFICATION	Acyl-CoA synthetases that activate fatty acids to their CoA derivatives play a central role in fatty acid metabolism. ACSBG1, an acyl-CoA synthetase originally identified in the fruit fly mutant bubblegum, was hypothesized to contribute to the biochemical pathology of X-linked adrenoleukodystrophy. We looked for homologous proteins and identified ACSBG2 in humans, mice, and rats. Human ACSBG1 and ACSBG2 amino acid sequences are 50% identical. ACSBG2 expression was confined to the testis and brainstem. Immunohistochemistry and in situ hybridization studies further localized ACSBG2 expression to testicular Sertoli cells and large motoneurons in the medulla oblongata and cervical spinal cord. Full-length cDNA encoding human and mouse ACSBG2 was cloned. In transfected COS-1 cells, both human and murine ACSBG2 were detected as 75- to 80-kDa proteins by Western blot. Cells overexpressing ACSBG2 had increased ability to activate oleic acid (C18: 1 omega 9) and linoleic acid (C18:2 omega 6) but not other fatty acid substrates tested. Within a highly conserved motif known to be important for catalysis, human ACSBG2 contains a histidine residue where all other known acyl-CoA synthetases, including mouse and rat ACSBG2, contain an arginine. This substitution resulted in a shift of the human ACSBG2 pH optimum to a more acidic pH. Mutation of this histidine to arginine improved catalytic function at neutral pH by shifting the pH profile without affecting substrate specificity. Although the role of ACSBG2 in testicular and neuronal lipid metabolism remains unclear, the limited tissue expression pattern and limited substrate specificity rule out a likely role for this enzyme in X-linked adrenoleukodystrophy pathology.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Med Genet, Baltimore, MD 21205 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; Johns Hopkins University	Watkins, PA (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, 707 N Broadway, Baltimore, MD 21205 USA.	watkins@kennedykrieger.org		Watkins, Paul A./0000-0002-3246-1405	NICHD NIH HHS [HD10981, HD24061] Funding Source: Medline; NINDS NIH HHS [NS37355] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024061] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037355] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Black PN, 1997, J BIOL CHEM, V272, P4896, DOI 10.1074/jbc.272.8.4896; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; Fraisl P, 2004, BIOCHEM J, V377, P85, DOI 10.1042/BJ20031062; Gabelli SB, 2004, STRUCTURE, V12, P927, DOI 10.1016/j.str.2004.03.028; Giger RJ, 1996, J COMP NEUROL, V375, P378, DOI 10.1002/(SICI)1096-9861(19961118)375:3<378::AID-CNE3>3.0.CO;2-#; Gulick AM, 2003, BIOCHEMISTRY-US, V42, P2866, DOI 10.1021/bi0271603; Hall AM, 2005, J BIOL CHEM, V280, P11948, DOI 10.1074/jbc.M412629200; Hall AM, 2003, J BIOL CHEM, V278, P43008, DOI 10.1074/jbc.M306575200; Hisanaga Y, 2004, J BIOL CHEM, V279, P31717, DOI 10.1074/jbc.M400100200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jia ZZ, 2004, MOL GENET METAB, V83, P117, DOI 10.1016/j.ymgme.2004.06.015; Jogl G, 2004, BIOCHEMISTRY-US, V43, P1425, DOI 10.1021/bi035911a; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E400002-JLR200; Mihalik SJ, 2002, J BIOL CHEM, V277, P24771, DOI 10.1074/jbc.M203295200; Min KT, 1999, SCIENCE, V284, P1985, DOI 10.1126/science.284.5422.1985; Moriya-Sato A, 2000, BIOCHEM BIOPH RES CO, V279, P62, DOI 10.1006/bbrc.2000.3897; Moser H., 2001, METABOLIC MOL BASES, VII, P3257; OMURA S, 1986, J ANTIBIOT, V39, P1211, DOI 10.7164/antibiotics.39.1211; Pei ZT, 2003, J BIOL CHEM, V278, P47070, DOI 10.1074/jbc.M310075200; Steinberg SJ, 2000, J BIOL CHEM, V275, P35162, DOI 10.1074/jbc.M006403200; Steinberg SJ, 1999, MOL GENET METAB, V68, P32, DOI 10.1006/mgme.1999.2883; Steinberg SJ, 1999, BIOCHEM BIOPH RES CO, V257, P615, DOI 10.1006/bbrc.1999.0510; Tang PZ, 2001, P NATL ACAD SCI USA, V98, P6581, DOI 10.1073/pnas.121046998; Van Horn CG, 2005, BIOCHEMISTRY-US, V44, P1635, DOI 10.1021/bi047721l; WATKINS PA, 1991, ARCH BIOCHEM BIOPHYS, V289, P329, DOI 10.1016/0003-9861(91)90419-J; Watkins PA, 1997, PROG LIPID RES, V36, P55, DOI 10.1016/S0163-7827(97)00004-0; WATKINS PA, 1995, AM J HUM GENET, V57, P292; WATKINS PA, 1994, BBA-LIPID LIPID MET, V1214, P288, DOI 10.1016/0005-2760(94)90075-2; Zheng Y, 2005, ASIAN J ANDROL, V7, P21, DOI 10.1111/j.1745-7262.2005.00014.x; Zou ZY, 2002, J BIOL CHEM, V277, P31062, DOI 10.1074/jbc.M205034200	35	35	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6632	6641		10.1074/jbc.M511558200	http://dx.doi.org/10.1074/jbc.M511558200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16371355	hybrid			2022-12-27	WOS:000236030800060
J	Mahfoud, M; Sukumaran, S; Hulsmann, P; Grieger, K; Niederweis, M				Mahfoud, M; Sukumaran, S; Hulsmann, P; Grieger, K; Niederweis, M			Topology of the porin MspA in the outer membrane of Mycobacterium smegmatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM ANTIBIOTICS; CELL-WALL PERMEABILITY; FREEZE-SUBSTITUTION; BACTERIAL PORINS; PROTEIN; ULTRASTRUCTURE; ACID; TUBERCULOSIS; CHELONAE; BARRIER	MspA is the major porin of Mycobacterium smegmatis mediating the exchange of hydrophilic solutes across the outer membrane (OM). It is the prototype of a new family of octameric porins with a single central channel of 9.6 nm in length and consists of two hydrophobic beta-barrels of 3.7 nm in length and a more hydrophilic, globular rim domain. The length of the hydrophobic domain of MspA does not match the thicknesses of mycobacterial OMs of 5-12 nm as derived from electron micrographs. Further, the membrane topology of MspA is unknown as it is for any other mycobacterial OM protein. We used MspA as a molecular ruler to define the boundaries of the OM of M. smegmatis by surface labeling of single cysteine mutants. Seventeen mutants covered the surface of the rim domain and were biotinylated with a membrane-impermeable reagent. The label efficiencies in vitro were remarkably similar to the predicted accessibilities of the cysteines. By contrast, six of these mutants were protected from biotinylation in M. smegmatis cells. Tryptophan 21 defines a horizontal plane that dissects the surface-exposed versus the membrane-protected residues of MspA. The 8 phenylalanines at position 99 form a ring at the periplasmic end of the hydrophobic beta-barrel domain. These results indicated that (i) the membrane boundaries of MspA are defined by aromatic girdles as in porins of Gram-negative bacteria and (ii) loops and a 3.4-nm-long part of the hydrophilic rim domain are embedded into the OM of M. smegmatis. This is the first report suggesting that elements other than hydrophobic alpha-helices or beta-sheets are integrated into a lipid membrane.	Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, D-91058 Erlangen, Germany; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA	University of Erlangen Nuremberg; University of Alabama System; University of Alabama Birmingham	Niederweis, M (corresponding author), Univ Erlangen Nurnberg, Lehrstuhl Mikrobiol, Staudtstr 5, D-91058 Erlangen, Germany.	mnieder@uab.edu						Bi WL, 1998, ANAL BIOCHEM, V256, P137, DOI 10.1006/abio.1997.2516; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; CHAMBERS HF, 1995, ANTIMICROB AGENTS CH, V39, P2620, DOI 10.1128/AAC.39.12.2620; Chatterjee D, 2001, CELL MOL LIFE SCI, V58, P2018, DOI 10.1007/PL00000834; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Diederichs K, 1998, PROTEIN SCI, V7, P2413, DOI 10.1002/pro.5560071119; Engelhardt H, 2002, J BIOL CHEM, V277, P37567, DOI 10.1074/jbc.M206983200; Etienne G, 2002, MICROBIOL-SGM, V148, P3089, DOI 10.1099/00221287-148-10-3089; Faller M, 2004, SCIENCE, V303, P1189, DOI 10.1126/science.1094114; Heinz C, 2000, ANAL BIOCHEM, V285, P113, DOI 10.1006/abio.2000.4728; Heinz C, 2003, J BIOL CHEM, V278, P8678, DOI 10.1074/jbc.M212280200; Heinze M, 2004, BIOCHEMISTRY-US, V43, P931, DOI 10.1021/bi030175w; JARLIER V, 1991, ANTIMICROB AGENTS CH, V35, P1937, DOI 10.1128/AAC.35.9.1937; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaps I, 2001, GENE, V278, P115, DOI 10.1016/S0378-1119(01)00712-0; Killian JA, 1996, BIOCHEMISTRY-US, V35, P1037, DOI 10.1021/bi9519258; Koebnik R, 2000, MOL MICROBIOL, V37, P239, DOI 10.1046/j.1365-2958.2000.01983.x; KREUSCH A, 1994, J MOL BIOL, V243, P891, DOI 10.1006/jmbi.1994.1690; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; Minnikin D. E., 1982, BIOL MYCOBACTERIA, P95; Minnikin DE, 2002, CHEM BIOL, V9, P545, DOI 10.1016/S1074-5521(02)00142-4; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Niederweis M, 1999, MOL MICROBIOL, V33, P933, DOI 10.1046/j.1365-2958.1999.01472.x; Niederweis M, 2003, MOL MICROBIOL, V49, P1167, DOI 10.1046/j.1365-2958.2003.03662.x; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; PAUL TR, 1993, ZBL BAKT-INT J MED M, V279, P450; PAUL TR, 1994, INFECT IMMUN, V62, P1542, DOI 10.1128/IAI.62.5.1542-1550.1994; PAUL TR, 1992, J BACTERIOL, V174, P6508, DOI 10.1128/JB.174.20.6508-6517.1992; RAUCH G, 1994, BIOCHEM BIOPH RES CO, V200, P908, DOI 10.1006/bbrc.1994.1536; Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034; Sander P, 1996, MOL MICROBIOL, V22, P841, DOI 10.1046/j.1365-2958.1996.01532.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz GE, 1993, CURR OPIN CELL BIOL, V5, P701, DOI 10.1016/0955-0674(93)90143-E; Stahl C, 2001, MOL MICROBIOL, V40, P451, DOI 10.1046/j.1365-2958.2001.02394.x; Stephan J, 2005, MOL MICROBIOL, V58, P714, DOI 10.1111/j.1365-2958.2005.04878.x; Tieleman DP, 1998, BIOPHYS J, V74, P2786, DOI 10.1016/S0006-3495(98)77986-X; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; Ulmschneider MB, 2001, BBA-BIOMEMBRANES, V1512, P1, DOI 10.1016/S0005-2736(01)00299-1; URRY DW, 1994, BIOPOLYMERS, V34, P889, DOI 10.1002/bip.360340708; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; Wimley WC, 1996, BIOCHEMISTRY-US, V35, P5109, DOI 10.1021/bi9600153; Zachariae U, 2002, PROTEIN SCI, V11, P1309, DOI 10.1110/ps.4910102	47	36	51	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5908	5915		10.1074/jbc.M511642200	http://dx.doi.org/10.1074/jbc.M511642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16352610	hybrid			2022-12-27	WOS:000235568900071
J	Payandeh, J; Fujihashi, M; Gillon, W; Pai, EF				Payandeh, J; Fujihashi, M; Gillon, W; Pai, EF			The crystal structure of (S)-3-O-geranylgeranylglyceryl phosphate synthase reveals an ancient fold for an ancient enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHER LIPIDS; THERMOACIDOPHILIC ARCHAEON; PROTEIN STRUCTURES; BIOSYNTHESIS; EVOLUTION; MECHANISM; BACTERIA; MODEL; PRENYLTRANSFERASES; PYROPHOSPHATE	We report crystal structures of the citrate and sn-glycerol-1-phosphate (G1P) complexes of (S)-3-O-geranylgeranylglyceryl phosphate synthase from Archaeoglobus fulgidus (AfGGGPS) at 1.55 and 2.0 angstrom resolution, respectively. AfGGGPS is an enzyme that performs the committed step in archaeal lipid biosynthesis, and it presents the first triose phosphate isomerase (TIM)-barrel structure with a prenyltransferase function. Our studies provide insight into the catalytic mechanism of AfGGGPS and demonstrate how it selects for the sn-G1P isomer. The replacement of "Helix 3" by a "strand" in AfGGGPS, a novel modification to the canonical TIM-barrel fold, suggests a model of enzyme adaptation that involves a "greasy slide" and a "swinging door." We propose functions for the homologous PcrB proteins, which are conserved in a subset of pathogenic bacteria, as either prenyltransferases or being involved in lipoteichoic acid biosynthesis. Sequence and structural comparisons lead us to postulate an early evolutionary history for AfGGGPS, which may highlight its role in the emergence of Archaea.	Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Biochem, Toronto, ON, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Princess Margaret Hosp, Div Canc Genom & Proteom, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Pai, EF (corresponding author), MaRS Ctr, Div Canc Genom & Proteom, Ontario Canc Inst, Toronto Med Discovery Tower,101 Coll St,Rm 5-358, Toronto, ON M5G 1L7, Canada.	pai@hera.med.toronto.ca	Pai, Emil F/D-2526-2013; Pai, Emil/R-8908-2019	Pai, Emil/0000-0002-1162-7242	NIGMS NIH HHS [GM 008003] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn VE, 2004, EMBO J, V23, P2931, DOI 10.1038/sj.emboj.7600320; Barona-Gomez F, 2003, EMBO REP, V4, P296, DOI 10.1038/sj.embor.embor771; Boucher Y, 2004, MOL MICROBIOL, V52, P515, DOI 10.1111/j.1365-2958.2004.03992.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang SY, 2003, J BIOL CHEM, V278, P29298, DOI 10.1074/jbc.M302687200; CHEN AJ, 1993, J BIOL CHEM, V268, P21701; CHRISTOPHER JA, 1997, SPOCK STRUCTURAL PRO; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DEROSA M, 1986, MICROBIOL REV, V50, P70, DOI 10.1128/MMBR.50.1.70-80.1986; FISCHER W, 1988, ADV MICROB PHYSIOL, V29, P233, DOI 10.1016/S0065-2911(08)60349-5; Gaspar JA, 2005, PROTEIN SCI, V14, P216, DOI 10.1110/ps.041068605; Gattinger A, 2002, FEMS MICROBIOL LETT, V213, P133, DOI 10.1111/j.1574-6968.2002.tb11297.x; GOLDFINE H, 1988, TRENDS BIOCHEM SCI, V13, P217, DOI 10.1016/0968-0004(88)90087-4; Griffith OH, 1999, BBA-MOL CELL BIOL L, V1441, P237, DOI 10.1016/S1388-1981(99)00153-5; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; Hemmi H, 2004, J BIOL CHEM, V279, P50197, DOI 10.1074/jbc.M409207200; Hocker B, 2004, P NATL ACAD SCI USA, V101, P16448, DOI 10.1073/pnas.0405832101; Hocker B, 2001, NAT STRUCT BIOL, V8, P32; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jordan IK, 2005, NATURE, V433, P633, DOI 10.1038/nature03306; KATES M, 1978, Progress in the Chemistry of Fats and Other Lipids, V15, P301; KOGA Y, 1993, MICROBIOL REV, V57, P164, DOI 10.1128/MMBR.57.1.164-182.1993; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuzuyama T, 2005, NATURE, V435, P983, DOI 10.1038/nature03668; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leopoldseder S, 2004, J MOL BIOL, V337, P871, DOI 10.1016/j.jmb.2004.01.062; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; Long SB, 2002, NATURE, V419, P645, DOI 10.1038/nature00986; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mesecar AD, 2000, NATURE, V403, P614, DOI 10.1038/35001144; Nagano N, 2002, J MOL BIOL, V321, P741, DOI 10.1016/S0022-2836(02)00649-6; Nemoto N, 2003, J BIOCHEM, V133, P651, DOI 10.1093/jb/mvg083; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALTAUF F, 1994, CHEM PHYS LIPIDS, V74, P101, DOI 10.1016/0009-3084(94)90054-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; POULTER CD, 1978, J BIOL CHEM, V253, P7227; Soderberg T, 2001, BIOCHEMISTRY-US, V40, P14847, DOI 10.1021/bi0111799; Sundaresan V, 2002, PROTEIN SCI, V11, P1330, DOI 10.1110/ps.3280102; Taylor JS, 2003, EMBO J, V22, P5963, DOI 10.1093/emboj/cdg571; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Van Gelder P, 2001, PROTEIN ENG, V14, P943, DOI 10.1093/protein/14.11.943; Vega MC, 2003, CURR OPIN CHEM BIOL, V7, P694, DOI 10.1016/j.cbpa.2003.10.004; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Wu N, 2000, P NATL ACAD SCI USA, V97, P2017, DOI 10.1073/pnas.050417797; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; ZHANG DL, 1993, J AM CHEM SOC, V115, P1270, DOI 10.1021/ja00057a008	51	36	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6070	6078		10.1074/jbc.M509377200	http://dx.doi.org/10.1074/jbc.M509377200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377641	hybrid			2022-12-27	WOS:000235568900088
J	Ponchon, L; Boulanger, P; Labesse, G; Letellier, L				Ponchon, L; Boulanger, P; Labesse, G; Letellier, L			The endonuclease domain of bacteriophage terminases belongs to the resolvase/integrase/ribonuclease H superfamily - A bioinformatics analysis validated by a functional study on bacteriophage T5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA TERMINASE; LARGE SUBUNIT; ATPASE CENTER; DNA; PROTEIN; SEQUENCE; RECOGNITION; MUTATIONS; ENZYME; PURIFICATION	Bacteriophage terminases are essential molecular motors involved in the encapsidation of viral DNA. They are hetero- multimers whose large subunit encodes both ATPase and endonuclease activities. Although the ATPase domain is well characterized from sequence and functional analysis, the C- terminal region remains poorly defined. We describe sequence- structure comparisons of the endonuclease region of various bacteriophages that revealed new sequence similarities shared by this region and the Holliday junction resolvase RuvC and to a lesser extent the HIV integrase and the ribonuclease H. Extensive sequence comparison and motif refinement led to a common signature of terminases and resolvases with three conserved acidic residues engaged in catalytic activity. Sequence analyses were validated by in vivo and in vitro functional assays showing that the nuclease activity of the endonuclease domain of bacteriophage T5 terminase was abolished by mutation of any of the three predicted catalytic aspartates. Overall, these data suggest that the endonuclease domains of terminases operate autonomously and that they adopt a fold similar to that of resolvases and share the same divalent cation- dependent enzymatic mechanism.	Univ Paris Sud, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France; Univ Montpellier I, CNRS, UMR5048, INSERM,U554,Ctr Biochim Struct, F-34060 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Letellier, L (corresponding author), Univ Paris Sud, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, Batiment 430, F-91405 Orsay, France.	lucienne.letellier@biomemb.u-psud.fr		Labesse, Gilles/0000-0002-6861-3300; ponchon, Luc/0000-0002-4094-4853				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; BHATTACHARYYA SP, 1993, VIROLOGY, V196, P34, DOI 10.1006/viro.1993.1452; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; Catalano CE, 2000, CELL MOL LIFE SCI, V57, P128, DOI 10.1007/s000180050503; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; DAVIDSON AR, 1992, VIROLOGY, V189, P21, DOI 10.1016/0042-6822(92)90677-H; Dhar A, 2005, J MOL BIOL, V347, P71, DOI 10.1016/j.jmb.2004.12.041; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; DROGE A, 2005, BACTERIOPHAGE SPP1 D, P89; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; EARNSHAW WC, 1980, CELL, V21, P319, DOI 10.1016/0092-8674(80)90468-7; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; EVERETT RD, 1981, J GEN VIROL, V52, P25, DOI 10.1099/0022-1317-52-1-25; Feiss Michael, 2005, P5; Gual A, 2000, J BIOL CHEM, V275, P35311, DOI 10.1074/jbc.M004309200; Hwang Y, 1996, BIOCHEMISTRY-US, V35, P2796, DOI 10.1021/bi952322z; Hwang Y, 1996, J MOL BIOL, V261, P524, DOI 10.1006/jmbi.1996.0480; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kanamaru S, 2004, J BIOL CHEM, V279, P40795, DOI 10.1074/jbc.M403647200; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; KOONIN EV, 1993, J MOL BIOL, V229, P1165, DOI 10.1006/jmbi.1993.1115; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; Maluf NK, 2005, J MOL BIOL, V347, P523, DOI 10.1016/j.jmb.2005.01.016; MCCORQUODALE JD, 1988, VIRUSES, V1, P439; Mitchell MS, 2004, VIROLOGY, V321, P217, DOI 10.1016/j.virol.2003.11.006; Mitchell MS, 2002, NUCLEIC ACIDS RES, V30, P4009, DOI 10.1093/nar/gkf524; MORITA M, 1995, VIROLOGY, V211, P516, DOI 10.1006/viro.1995.1433; Nishino T, 2002, ONCOGENE, V21, P9022, DOI 10.1038/sj.onc.1206135; Nowotny M, 2005, CELL, V121, P1005, DOI 10.1016/j.cell.2005.04.024; PARRIS W, 1994, J BIOL CHEM, V269, P13564; Ponchon L, 2005, BBA-GEN SUBJECTS, V1724, P255, DOI 10.1016/j.bbagen.2005.04.016; Przech AJ, 2003, J VIROL, V77, P9613, DOI 10.1128/JVI.77.17.9613-9621.2003; Rao Venigalla B., 2005, P40; Rentas FJ, 2003, J MOL BIOL, V334, P37, DOI 10.1016/j.jmb.2003.09.028; RHOADES M, 1972, J MOL BIOL, V69, P187, DOI 10.1016/0022-2836(72)90224-0; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Wang JB, 2005, VIROLOGY, V332, P45, DOI 10.1016/j.virol.2004.10.049; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3	47	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5829	5836		10.1074/jbc.M511817200	http://dx.doi.org/10.1074/jbc.M511817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377618	hybrid			2022-12-27	WOS:000235568900062
J	von Otte, S; Paletta, JRJ; Becker, S; Konig, S; Fobker, M; Greb, RR; Kiesel, L; Assmann, G; Diedrich, K; Nofer, JR				von Otte, S; Paletta, JRJ; Becker, S; Konig, S; Fobker, M; Greb, RR; Kiesel, L; Assmann, G; Diedrich, K; Nofer, JR			Follicular fluid high density lipoprotein-associated sphingosine 1-phosphate is a novel mediator of ovarian angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN SKIN FIBROBLASTS; HUMAN GRANULOSA-CELLS; CORPUS-LUTEUM; PLASMA-LIPOPROTEINS; PROTEIN; CHOLESTEROL; RAT; HDL; SPHINGOSINE-1-PHOSPHATE	Angiogenesis plays an important role in the development of the ovarian follicle and its subsequent transition into the corpus luteum. Accordingly, follicular fluid is a rich source of mitogenic and angiogenic factors such as basic fibroblast growth factor and vascular endothelial growth factor secreted by granulosa cells. In the present study, we show that follicular fluid deprived of basic fibroblast growth factor or vascular endothelial growth factor by means of thermal denaturation or antibody neutralization retains its capacity to stimulate endothelial proliferation and angiogenesis. Mass spectrometric analysis of chromatographic fractions stimulating endothelial growth obtained from follicular fluid revealed that the heat-stable mitogenic activity is identical with the subfraction alpha of high density lipoproteins purified from follicular fluid (FF-HDL). Further investigations demonstrated that sphingosine 1-phosphate (S1P), one of the lysophospholipids associated with HDL, accounts for the capacity of this lipoprotein to stimulate endothelial growth and the formation of new vessels. Activation of mitogen-activated protein kinase (p42/44(ERK1/2)), protein kinase C, and protein kinase Akt represent signaling pathways utilized by FF-HDL and S1P to induce endothelial proliferation and angiogenesis. We conclude that FF-HDL represents a novel mitogenic and angiogenic factor present in follicular fluid and that S1P is one of the FF-HDL lipid components accounting for this activity.	Univ Klinikum Schleswig Holstein, Klin Frauenheilkunde & Geburtshilfe, D-23538 Lubeck, Germany; Univ Munster, Klin & Poliklin Unfall Hand & Wiederherstellungsc, D-48149 Munster, Germany; Univ Munster, Inst Klin Chem & Lab Med, D-48149 Munster, Germany; Univ Munster, Klin & Poliklin Frauenheilkunde & Geburtshilfe, D-48149 Munster, Germany; Univ Munster, Fak Med, Interdisziplinares Zentrum Klin Forsch, D-48149 Munster, Germany; Univ Munster, Leibniz Inst Arterioskleroseforsch, D-48149 Munster, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Munster; University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; University of Munster; University of Munster	von Otte, S (corresponding author), Univ Klinikum Schleswig Holstein, Klin Frauenheilkunde & Geburtshilfe, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.	svonotte@gmx.de	König, Simone/B-6504-2008; Kiesel, Ludwig/ABC-5333-2020	König, Simone/0000-0003-0672-7246; Kiesel, Ludwig/0000-0002-7247-9247				Abulafia O, 2000, AM J OBSTET GYNECOL, V182, P240, DOI 10.1016/S0002-9378(00)70519-9; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Augustin HG, 2000, BEST PRACT RES CL OB, V14, P867, DOI 10.1053/beog.2000.0132; Azhar S, 1998, J CLIN ENDOCR METAB, V83, P983, DOI 10.1210/jc.83.3.983; Bagavandoss P, 1998, J HISTOCHEM CYTOCHEM, V46, P1043, DOI 10.1177/002215549804600908; BRYANT SM, 1988, AM J OBSTET GYNECOL, V158, P1207, DOI 10.1016/0002-9378(88)90256-6; Chandras C, 2004, MOL CELL ENDOCRINOL, V222, P1, DOI 10.1016/j.mce.2004.05.008; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; FREDERICK JL, 1984, SCIENCE, V224, P389, DOI 10.1126/science.6200930; GOSPODAROWICZ D, 1985, ENDOCRINOLOGY, V117, P2383, DOI 10.1210/endo-117-6-2383; Hammadeh ME, 2004, AM J REPROD IMMUNOL, V51, P81, DOI 10.1046/j.8755-8920.2003.00121.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Hayashi KG, 2003, BIOL REPROD, V69, P2078, DOI 10.1095/biolreprod.103.017152; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jaspard B, 1997, ARTERIOSCL THROM VAS, V17, P1605, DOI 10.1161/01.ATV.17.8.1605; KAMAT BR, 1995, AM J PATHOL, V146, P157; Kimura T, 2003, ARTERIOSCL THROM VAS, V23, P1283, DOI 10.1161/01.ATV.0000079011.67194.5A; Kimura T, 2001, J BIOL CHEM, V276, P31780, DOI 10.1074/jbc.M104353200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; KOOS RD, 1986, ENDOCRINOLOGY, V119, P481, DOI 10.1210/endo-119-2-481; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Manau D, 2000, HUM REPROD, V15, P1295, DOI 10.1093/humrep/15.6.1295; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MEYER GT, 1988, ANAT REC, V222, P18, DOI 10.1002/ar.1092220105; Miura S, 2003, ARTERIOSCL THROM VAS, V23, P802, DOI 10.1161/01.ATV.0000066134.79956.58; MOLLERS C, 1995, CELL SIGNAL, V7, P695, DOI 10.1016/0898-6568(95)00041-M; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Murata N, 2000, BIOCHEM J, V352, P809, DOI 10.1042/0264-6021:3520809; Nofer JR, 2005, TRENDS CARDIOVAS MED, V15, P265, DOI 10.1016/j.tcm.2005.08.005; Nofer JR, 2001, J BIOL CHEM, V276, P34480, DOI 10.1074/jbc.M103782200; Nofer JR, 2004, J CLIN INVEST, V113, P569, DOI 10.1172/JCI200418004; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Nofer JR, 2000, BIOCHEMISTRY-US, V39, P15199, DOI 10.1021/bi001162a; Paletta JRJ, 2003, HUM REPROD, V18, P125; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; Reynolds LP, 1998, J ANIM SCI, V76, P1671; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROY R, 1992, ENDOCRINOLOGY, V131, P1390, DOI 10.1210/en.131.3.1390; Ruwisch L, 2001, N-S ARCH PHARMACOL, V363, P358, DOI 10.1007/s002100000365; Seli E, 1998, FERTIL STERIL, V69, P1145, DOI 10.1016/S0015-0282(98)00074-0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIMPSON ER, 1980, J CLIN ENDOCR METAB, V51, P1469, DOI 10.1210/jcem-51-6-1469; Svensson PA, 1999, ENDOCRINOLOGY, V140, P2494, DOI 10.1210/en.140.6.2494; Therien I, 2001, BIOL REPROD, V65, P41, DOI 10.1095/biolreprod65.1.41; Tilly JL, 2002, BBA-MOL CELL BIOL L, V1585, P135, DOI 10.1016/S1388-1981(02)00333-5; VanBlerkom J, 1997, HUM REPROD, V12, P1047; Watterson K, 2003, PROG LIPID RES, V42, P344, DOI 10.1016/S0163-7827(03)00015-8	49	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5398	5405		10.1074/jbc.M508759200	http://dx.doi.org/10.1074/jbc.M508759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16365044	hybrid			2022-12-27	WOS:000235568900011
J	Lee, HH; Yoon, JY; Kim, HS; Kang, JY; Kim, KH; Kim, DJ; Ha, JY; Mikami, B; Yoon, HJ; Suh, SW				Lee, HH; Yoon, JY; Kim, HS; Kang, JY; Kim, KH; Kim, DJ; Ha, JY; Mikami, B; Yoon, HJ; Suh, SW			Crystal structure of a metal ion-bound IS200 transposase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSERTION SEQUENCES; BINDING PROTEINS; DNA; DOMAIN; RECOGNITION; ALIGNMENT; ELEMENTS; ORIGIN; MOTIFS; SITE	IS200 transposases, present in many bacteria and Archaea, appear to be distinct from other groups of transposases. To provide a structural basis for understanding the action of IS200 transposases, we have determined the crystal structure of the SSO1474 protein from Sulfolobus solfataricus, a member of the IS200 family, in both Mn2+-bound and Mn2+-free forms. Its monomer fold is distinct from other classes of structurally characterized transposases. Two monomers form a tight dimer by exchanging the C-terminal alpha-helix and by merging the two central beta-sheets into a large beta-sheet. Glu(55), His(62), and four water molecules provide the direct coordination sphere of the catalytically essential metal ion in the Mn2+-bound structure. His(16), Asp(59), and His(60) also play important roles in maintaining the metal binding site. The catalytic site is formed at the interface between monomers. The candidate nucleophile in the transposition mechanism, strictly conserved Tyr(121) coming from the other monomer, is turned away from the active site, suggesting that a conformational change is likely to occur during the catalytic cycle.	Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea; Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Lab Qual Design & Exploitat, Uji, Kyoto 6110011, Japan	Seoul National University (SNU); Kyoto University	Suh, SW (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea.	sewonsuh@snu.ac.kr	Suh, Won/H-8306-2013; Kim, Do Jin/I-7675-2014	Suh, Won/0000-0002-1768-4635; 				Banci L, 2002, J MOL BIOL, V323, P883, DOI 10.1016/S0022-2836(02)01007-0; Bao TH, 2005, EMBO J, V24, P3325, DOI 10.1038/sj.emboj.7600787; Beuzon CR, 2004, INT MICROBIOL, V7, P3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Curcio MJ, 2003, NAT REV MOL CELL BIO, V4, P865, DOI 10.1038/nrm1241; Datta S, 2003, STRUCTURE, V11, P1369, DOI 10.1016/j.str.2003.10.001; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Devalckenaere A, 1999, FEMS MICROBIOL LETT, V176, P229, DOI 10.1111/j.1574-6968.1999.tb13666.x; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Guasch A, 2003, NAT STRUCT BIOL, V10, P1002, DOI 10.1038/nsb1017; Hickman AB, 2002, MOL CELL, V10, P327, DOI 10.1016/S1097-2765(02)00592-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ILYINA TV, 1992, NUCLEIC ACIDS RES, V20, P3279, DOI 10.1093/nar/20.13.3279; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LAM S, 1983, CELL, V34, P951, DOI 10.1016/0092-8674(83)90552-4; Mahillon J, 1998, MICROBIOL MOL BIOL R, V62, P725, DOI 10.1128/MMBR.62.3.725-774.1998; NEVERS P, 1977, NATURE, V268, P109, DOI 10.1038/268109a0; Nicholas KB, 1997, EMBNEW NEWS, V4, P14; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Ronning DR, 2005, MOL CELL, V20, P143, DOI 10.1016/j.molcel.2005.07.026; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	27	8	9	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4261	4266		10.1074/jbc.M511567200	http://dx.doi.org/10.1074/jbc.M511567200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16340015	hybrid			2022-12-27	WOS:000235275300059
J	Mouilleron, S; Badet-Denisot, MA; Golinelli-Pimpaneau, B				Mouilleron, S; Badet-Denisot, MA; Golinelli-Pimpaneau, B			Glutamine binding opens the ammonia channel and activates glucosamine-6P synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; 6-PHOSPHATE SYNTHASE; INSULIN-RESISTANCE; AMIDOTRANSFERASE; REFINEMENT; MECHANISM; ENZYME; DOMAIN; SITE	Glucosamine-6P synthase catalyzes the synthesis of glucosamine-6P from fructose-6P and glutamine and uses a channel to transfer ammonia from its glutaminase to its synthase active site. X-ray structures of glucosamine-6P synthase have been determined at 2.05 angstrom resolution in the presence of fructose-6P and at 2.35 angstrom resolution in the presence of fructose-6P and 6-diazo-5-oxo-L-norleucine, a glutamine affinity analog that covalently modifies the N-terminal catalytic cysteine, therefore mimicking the gamma-glutamylthioester intermediate formed during hydrolysis of glutamine. The fixation of the glutamine analog activates the enzyme through several major structural changes: 1) the closure of a loop to shield the glutaminase site accompanied by significant domain hinging, 2) the activation of catalytic residues involved in glutamine hydrolysis, i.e. the alpha-amino group of Cys-1 and Asn-98 that is positioned to form the oxyanion hole, and 3) a 75 degrees rotation of the Trp-74 indole group that opens the ammonia channel.	Lab Enzymol & Biochim Struct, Unite Propre Rech 9063, F-91198 Gif Sur Yvette, France; CNRS, Unite Propre Rech 2301, Inst Chim Subst Nat, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Golinelli-Pimpaneau, B (corresponding author), Lab Enzymol & Biochim Struct, Unite Propre Rech 9063, Batiment 34, F-91198 Gif Sur Yvette, France.	beatrice.golinelli@lebs.cnrs-gif.fr	Golinelli, Beatrice/ABB-8347-2021	Golinelli, Beatrice/0000-0001-8248-4704; badet-denisot, marie-ange/0000-0003-3417-6330; mouilleron, stephane/0000-0001-7977-6298				Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BADET B, 1988, BIOCHEMISTRY-US, V27, P2282, DOI 10.1021/bi00407a006; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; DENISOT MA, 1991, ARCH BIOCHEM BIOPHYS, V288, P225, DOI 10.1016/0003-9861(91)90188-O; Hebert LF, 1996, J CLIN INVEST, V98, P930, DOI 10.1172/JCI118876; Huang XY, 2001, ANNU REV BIOCHEM, V70, P149, DOI 10.1146/annurev.biochem.70.1.149; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Krahn JM, 1997, BIOCHEMISTRY-US, V36, P11061, DOI 10.1021/bi9714114; Leriche C, 1996, J AM CHEM SOC, V118, P1797, DOI 10.1021/ja953614q; MARQUES S, 1992, EUR J BIOCHEM, V206, P69, DOI 10.1111/j.1432-1033.1992.tb16902.x; Massiere F, 1998, CELL MOL LIFE SCI, V54, P205, DOI 10.1007/s000180050145; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raushel FM, 1999, BIOCHEMISTRY-US, V38, P7891, DOI 10.1021/bi990871p; Smith JL, 1998, CURR OPIN STRUC BIOL, V8, P686, DOI 10.1016/S0959-440X(98)80087-0; Teplyakov A, 2002, NAT PROD REP, V19, P60, DOI 10.1039/b103713g; Teplyakov A, 2001, J MOL BIOL, V313, P1093, DOI 10.1006/jmbi.2001.5094; Teplyakov A, 1998, STRUCTURE, V6, P1047, DOI 10.1016/S0969-2126(98)00105-1; Teplyakov A, 1999, PROTEIN SCI, V8, P596; van den Heuvel RHH, 2003, J MOL BIOL, V330, P113, DOI 10.1016/S0022-2836(03)00522-9; van den Heuvel RHH, 2004, CELL MOL LIFE SCI, V61, P669, DOI 10.1007/s00018-003-3316-0; Wells L, 2003, CELL MOL LIFE SCI, V60, P222, DOI 10.1007/s000180300017; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	27	68	70	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4404	4412		10.1074/jbc.M511689200	http://dx.doi.org/10.1074/jbc.M511689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339762	hybrid			2022-12-27	WOS:000235275300076
J	Koide, T; Asada, S; Takahara, Y; Nishikawa, Y; Nagata, K; Kitagawa, K				Koide, T; Asada, S; Takahara, Y; Nishikawa, Y; Nagata, K; Kitagawa, K			Specific recognition of the collagen triple helix by chaperone HSP47 - Minimal structural requirement and spatial molecular orientation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-PROTEIN HSP47; PEPTIDES; SITES; PROCOLLAGEN	The unique folding of procollagens in the endoplasmic reticulum is achieved with the assistance of procollagen-specific molecular chaperones. Heat-shock protein 47 (HSP47) is an endoplasmic reticulum-resident chaperone that plays an essential role in normal procollagen folding, although its molecular function has not yet been clarified. Recent advances in studies on the binding specificity of HSP47 have revealed that Arg residues at Yaa positions in collagenous Gly-Xaa-Yaa repeats are critical for its interactions (Koide, T., Takahara, Y., Asada, S., and Nagata, K. (2002) J. Biol. Chem. 277, 6178-6182; Tasab, M., Jenkinson, L., and Bulleid, N. J. (2002) J. Biol. Chem. 277, 35007-35012). In the present study, we further examined the client recognition mechanism of HSP47 by taking advantage of systems employing engineered collagen model peptides. First, in vitro binding studies using conformationally constrained collagen-like peptides revealed that HSP47 only recognized correctly folded triple helices and that the interaction with the corresponding single-chain polypeptides was negligible. Second, a binding study using heterotrimeric model clients for HSP47 demonstrated a minimal requirement for the number of Arg residues in the triple helix. Finally, a cross-linking study using photoreactive collagenous peptides provided information about the spatial orientation of an HSP47 molecule in the chaperone-collagen complex. The obtained results led to the development of a new model of HSP47-collagen complexes that differs completely from the previously proposed "flying capstan model" (Dafforn, T. R., Della, M., and Miller, A. D. ( 2001) J. Biol. Chem. 276, 49310-49319).	Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata 9502081, Japan; Univ Tokushima, Fac Engn, Tokushima 7708506, Japan; Kyoto Univ, Inst Frontier Med Sci, Kyoto 6068397, Japan	Niigata University; Tokushima University; Kyoto University	Koide, T (corresponding author), Niigata Univ Pharm & Appl Life Sci, Fac Pharmaceut Sci, Niigata 9502081, Japan.	koi@niigata-pharm.ac.jp						BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; Hatanaka Y, 1998, J AM CHEM SOC, V120, P453, DOI 10.1021/ja973056a; Kanamori T, 1997, P NATL ACAD SCI USA, V94, P485, DOI 10.1073/pnas.94.2.485; KAUER JC, 1986, J BIOL CHEM, V261, P695; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2005, TOP CURR CHEM, V247, P85, DOI 10.1007/b103820; Koide T, 2004, BIOORG MED CHEM LETT, V14, P125, DOI 10.1016/j.bmcl.2003.10.005; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Koide T, 2000, J BIOL CHEM, V275, P27957; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; Marutani T, 2004, J CELL SCI, V117, P5913, DOI 10.1242/jcs.01514; Myllyharju J, 2005, TOP CURR CHEM, V247, P115, DOI 10.1007/b103821; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Renner C, 2004, BIOPOLYMERS, V76, P34, DOI 10.1002/bip.10569; Sacca B, 2002, CHEMBIOCHEM, V3, P904, DOI 10.1002/1439-7633(20020902)3:9<904::AID-CBIC904>3.0.CO;2-I; Sacca B, 2002, J PEPT SCI, V8, P192, DOI 10.1002/psc.385; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Tasab M, 2002, J BIOL CHEM, V277, P35007, DOI 10.1074/jbc.M202782200; Thomson CA, 2003, PROTEIN SCI, V12, P1792, DOI 10.1110/ps.0236903; Walmsley AR, 1999, J BIOL CHEM, V274, P14884, DOI 10.1074/jbc.274.21.14884; Yokota SI, 2003, BIOCHEM BIOPH RES CO, V303, P413, DOI 10.1016/S0006-291X(03)00352-8	30	51	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3432	3438		10.1074/jbc.M509707200	http://dx.doi.org/10.1074/jbc.M509707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16326708				2022-12-27	WOS:000235128200052
J	Tsukahara, T; Tsukahara, R; Yasuda, S; Makarova, N; Valentine, WJ; Allison, P; Yuan, HB; Baker, DL; Li, ZG; Bittman, R; Parrill, A; Tigyi, G				Tsukahara, T; Tsukahara, R; Yasuda, S; Makarova, N; Valentine, WJ; Allison, P; Yuan, HB; Baker, DL; Li, ZG; Bittman, R; Parrill, A; Tigyi, G			Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY-DISEASE; LOW-DENSITY-LIPOPROTEIN; RABBIT CEREBRAL-CORTEX; LYSOPHOSPHATIDIC ACID; PPAR-GAMMA; NEURONAL NUCLEI; ADIPOCYTE DIFFERENTIATION; ATHEROSCLEROTIC LESIONS; AUTOMATED DOCKING; GENE-EXPRESSION	Here we showed that a naturally occurring ether analog of lysophosphatidic acid, 1-O-octadecenyl-2-hydroxy-sn-glycero-3-phosphate (AGP), is a high affinity partial agonist of the peroxisome proliferator-activated receptor gamma (PPAR gamma). Binding studies using the PPAR gamma ligand binding domain showed that [P-32]AGP and [H-3]rosiglitazone (Rosi) both specifically bind to PPAR gamma and compete with each other. [P-32]AGP bound PPAR gamma with an affinity (K-d(app) 60 nM) similar to that of Rosi. However, AGP displaced similar to 40% of bound [H-3]Rosi even when applied at a 2000-fold excess. Activation of PPAR gamma reporter gene expression by AGP and Rosi showed similar potency, yet AGP-mediated activation was similar to 40% that of Rosi. A complex between AGP and PPAR gamma was generated using molecular modeling based on a PPAR gamma crystal structure. AGP-interacting residues were compared with Rosi-interacting residues identified within the Rosi-PPAR gamma co-crystal complex. These comparisons showed that the two ligands occupy partially overlapping positions but make different hydrogen bonding and ion pairing interactions. Site-specific mutants of PPAR gamma were prepared to examine individual ligand binding. H323A and H449A mutants showed reduced binding of Rosi but maintained binding of AGP. In contrast, the R288A showed reduced AGP binding but maintained Rosi binding. Finally, alanine replacement of Tyr-473 abolished binding and activation by Rosi and AGP. These observations indicate that the endogenous lipid mediator AGP is a high affinity ligand of PPAR gamma but that it binds via interactions distinct from those involved in Rosi binding. These distinct interactions are likely responsible for the partial PPAR gamma agonism of AGP.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; Univ Memphis, Dept Chem, Memphis, TN 38152 USA; Univ Memphis, Computat Res Inst Mat, Memphis, TN 38152 USA; Univ Tennessee, Hlth Sci Ctr, Univ Tennessee Canc Inst, Dept Med, Memphis, TN 38152 USA; Univ Tennessee, Hlth Sci Ctr, Univ Tennessee Canc Inst, Vasc Biol Ctr Excellence, Memphis, TN 38152 USA; Univ Tennessee, Hlth Sci Ctr, Univ Tennessee Canc Inst, Genom & Bioinformat Ctr Excellence, Memphis, TN 38152 USA; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis; University of Memphis; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; City University of New York (CUNY) System; Queens College NY (CUNY)	Tigyi, G (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu		YASUDA, Satoshi/0000-0002-1011-0815; Baker, Daniel/0000-0003-1482-0416; Parrill, Abby/0000-0003-1658-8497; Tsukahara, Tamotsu/0000-0001-6469-920X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469, R24HL083187, R01HL079004, T32HL007641] Funding Source: NIH RePORTER; NCI NIH HHS [CA92160] Funding Source: Medline; NHLBI NIH HHS [T32 HL007641, HL083187, HL79004, HL61469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angeli W, 2003, J IMMUNOL, V170, P5295, DOI 10.4049/jimmunol.170.10.5295; Asami-Miyagishi R, 2004, BIOCHEM BIOPH RES CO, V315, P497, DOI 10.1016/j.bbrc.2004.01.074; BAKER RR, 1988, BIOCHIM BIOPHYS ACTA, V960, P390, DOI 10.1016/0005-2760(88)90047-1; Baker RR, 1998, BBA-LIPID LIPID MET, V1392, P351, DOI 10.1016/S0005-2760(98)00050-2; BAKER RR, 1990, BIOCHEM CELL BIOL, V68, P641, DOI 10.1139/o90-091; Baker RR, 2000, BBA-MOL CELL BIOL L, V1483, P58, DOI 10.1016/S1388-1981(99)00185-7; Baker RR, 1999, MOL CELL BIOCHEM, V198, P47, DOI 10.1023/A:1006933625802; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; Berger JP, 2005, INT J OBESITY, V29, pS3, DOI 10.1038/sj.ijo.0802904; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; BOCOS C, 1995, J STEROID BIOCHEM, V53, P467, DOI 10.1016/0960-0760(95)00093-F; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; *CHEM COMP GROUP, 2003, MOE VERS 2003 02; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duval C, 2002, TRENDS MOL MED, V8, P422, DOI 10.1016/S1471-4914(02)02385-7; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fujiwara Y, 2005, J BIOL CHEM, V280, P35038, DOI 10.1074/jbc.M504351200; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Ishii I, 2000, MOL PHARMACOL, V58, P895, DOI 10.1124/mol.58.5.895; Jiang WG, 2000, PROSTAG LEUKOTR ESS, V62, P119, DOI 10.1054/plef.1999.0131; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Kiec-Wilk B, 2005, J PHYSIOL PHARMACOL, V56, P149; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Knouff C, 2004, ENDOCR REV, V25, P899, DOI 10.1210/er.2003-0036; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lautamaki R, 2005, DIABETES, V54, P2787, DOI 10.2337/diabetes.54.9.2787; Lebovitz HE, 2002, DIABETES-METAB RES, V18, pS23, DOI 10.1002/dmrr.252; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LENZ ML, 1990, J LIPID RES, V31, P1043; LI Z, 2005, IN PRESS J ORG CHEM; Liu K, 2005, J MED CHEM, V48, P2262, DOI 10.1021/jm048993p; Llodra J, 2004, P NATL ACAD SCI USA, V101, P11779, DOI 10.1073/pnas.0403259101; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Medina-Gomez G, 2005, DIABETES, V54, P1706, DOI 10.2337/diabetes.54.6.1706; Minamikawa J, 1998, J CLIN ENDOCR METAB, V83, P1818, DOI 10.1210/jc.83.5.1818; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nakane S, 2001, LIPIDS, V36, P413, DOI 10.1007/s11745-001-0737-1; Negro R, 2005, DIABETES RES CLIN PR, V70, P20, DOI 10.1016/j.diabres.2005.02.012; Nicholson AC, 2004, TRENDS CARDIOVAS MED, V14, P8, DOI 10.1016/j.tcm.2003.09.004; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Rodway HA, 2004, BIOCHEM J, V382, P83, DOI 10.1042/BJ20040107; Rother E, 2003, CIRCULATION, V108, P741, DOI 10.1161/01.CIR.0000083715.37658.C4; Santini E, 2004, DIABETES, V53, pS79, DOI 10.2337/diabetes.53.suppl_3.S79; Sarafidis PA, 2005, METABOLISM, V54, P1236, DOI 10.1016/j.metabol.2005.04.010; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; Schopfer FJ, 2005, P NATL ACAD SCI USA, V102, P2340, DOI 10.1073/pnas.0408384102; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Simon MF, 2002, J BIOL CHEM, V277, P23131, DOI 10.1074/jbc.M201530200; Sugiura T, 1999, BBA-MOL CELL BIOL L, V1440, P194, DOI 10.1016/S1388-1981(99)00127-4; Sugiura T, 2002, J LIPID RES, V43, P2049, DOI 10.1194/jlr.M200242-JLR200; TOKUMURA A, 1992, J BIOL CHEM, V267, P7275; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wang G, 2005, METABOLISM, V54, P590, DOI 10.1016/j.metabol.2004.11.017; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xu HE, 2001, P NATL ACAD SCI USA, V98, P13919, DOI 10.1073/pnas.241410198; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	69	69	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3398	3407		10.1074/jbc.M510843200	http://dx.doi.org/10.1074/jbc.M510843200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321982	hybrid			2022-12-27	WOS:000235128200048
J	Wang, W; Duan, B; Xu, H; Xu, L; Xu, TL				Wang, W; Duan, B; Xu, H; Xu, L; Xu, TL			Calcium-permeable acid-sensing ion channel is a molecular target of the neurotoxic metal ion lead	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PROTEIN-KINASE-C; RAT HIPPOCAMPAL-NEURONS; SYNAPTIC PLASTICITY; SENSORY NEURONS; NA+ CHANNEL; CA2+; CONTRIBUTES; INCREASES; EXPOSURE	Acid-sensing ion channels (ASICs) are emerging as fundamental players in the regulation of neural plasticity and in pathological conditions. Here we showed that lead (Pb2+), a well known neurotoxic metal ion, reversibly and concentration-dependently inhibited ASIC currents in the acutely dissociated spinal dorsal horn and hippocampal CA1 neurons of rats. In vitro expression of ASIC subunits in combination demonstrated that both ASIC1 and -3 subunits were sensitive to Pb2+. Mechanistically, Pb2+ reduced the pH sensitivity of ASICs independent of membrane voltage change. Moreover, Pb2+ inhibited the ASIC-mediated membrane depolarization and the elevation of intracellular Ca2+ concentration. In addition, we compared the effect of Pb2+ with that of Ca2+ or amiloride to explore the possible interactions of Pb2+ and Ca2+ in regulating ASICs, and we found that Pb2+ inhibited ASIC currents independent of the amiloride/Ca2+ blockade. Because ASIC1b and -3 subunits are mainly expressed in peripheral neurons, our data identified ASIC1a-containing Ca2+-permeable ASIC as a novel central target of Pb2+ action, which may contribute to Pb2+ neurotoxicity.	Chinese Acad Sci, Lab Learning & Memory, Kunming Inst Zool, Kunming 650223, Yunnan, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Neurobiol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Xu, L (corresponding author), Chinese Acad Sci, Lab Learning & Memory, Kunming Inst Zool, 32 Jiaochang Donglu, Kunming 650223, Yunnan, Peoples R China.	lxu@vip.163.com; tlxu@ion.ac.cn	Xu, Lin/T-5531-2017; Wang, Wei/AAC-4057-2019	Xu, Lin/0000-0002-2710-3507; Wang, Wei/0000-0002-4123-8280				Babini E, 2002, J BIOL CHEM, V277, P41597, DOI 10.1074/jbc.M205877200; Baron A, 2002, J BIOL CHEM, V277, P50463, DOI 10.1074/jbc.M208848200; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Baron A, 2001, J BIOL CHEM, V276, P35361, DOI 10.1074/jbc.M105208200; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Beigel Y, 1998, NEW ENGL J MED, V339, P827, DOI 10.1056/NEJM199809173391208; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; Chu XP, 2004, J NEUROSCI, V24, P8678, DOI 10.1523/JNEUROSCI.2844-04.2004; Coric T, 2003, J BIOL CHEM, V278, P45240, DOI 10.1074/jbc.M304441200; Coyle P, 2005, AM J IND MED, V47, P172, DOI 10.1002/ajim.20123; Darboux I, 1998, J BIOL CHEM, V273, P9424, DOI 10.1074/jbc.273.16.9424; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; Deval E, 2004, J BIOL CHEM, V279, P19531, DOI 10.1074/jbc.M313078200; Ghering AB, 2005, J AM CHEM SOC, V127, P3751, DOI 10.1021/ja0464544; Gilbert ME, 1996, BRAIN RES, V736, P118, DOI 10.1016/S0006-8993(96)00665-8; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Jett DA, 1997, PHARMACOL BIOCHEM BE, V57, P271, DOI 10.1016/S0091-3057(96)00350-4; KERN M, 1995, TOXICOL APPL PHARM, V134, P111, DOI 10.1006/taap.1995.1174; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; Kuhlmann AC, 1997, NEUROSCI LETT, V233, P101, DOI 10.1016/S0304-3940(97)00633-2; Lasley SM, 2000, NEUROTOXICOLOGY, V21, P1057; Leonard AS, 2003, P NATL ACAD SCI USA, V100, P2029, DOI 10.1073/pnas.252782799; Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; MARKOVAC J, 1988, NATURE, V334, P71, DOI 10.1038/334071a0; Needleman H, 2004, ANNU REV MED, V55, P209, DOI 10.1146/annurev.med.55.091902.103653; Nihei MK, 2000, NEUROSCIENCE, V99, P233, DOI 10.1016/S0306-4522(00)00192-5; Nihei MK, 2001, NEUROTOXICOLOGY, V22, P635, DOI 10.1016/S0161-813X(01)00035-3; Page AJ, 2004, GASTROENTEROLOGY, V127, P1739, DOI 10.1053/j.gastro.2004.08.061; Paukert M, 2004, J GEN PHYSIOL, V124, P383, DOI 10.1085/jgp.200308973; Riedel G, 2003, BEHAV BRAIN RES, V140, P1, DOI 10.1016/S0166-4328(02)00272-3; Sun XY, 1999, TOXICOL APPL PHARM, V156, P40, DOI 10.1006/taap.1999.8622; Suszkiw JB, 2004, NEUROTOXICOLOGY, V25, P599, DOI 10.1016/j.neuro.2003.09.009; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Vukicevic M, 2004, AM J PHYSIOL-CELL PH, V287, pC682, DOI 10.1152/ajpcell.00127.2004; VYAS MN, 1989, J BIOL CHEM, V264, P20817; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wu LJ, 2004, J BIOL CHEM, V279, P43716, DOI 10.1074/jbc.M403557200; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100	49	53	57	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2497	2505		10.1074/jbc.M507123200	http://dx.doi.org/10.1074/jbc.M507123200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16319075	hybrid			2022-12-27	WOS:000234931800012
J	Bocharova, OV; Makarava, N; Breydo, L; Anderson, M; Salnikov, VV; Baskakov, IV				Bocharova, OV; Makarava, N; Breydo, L; Anderson, M; Salnikov, VV; Baskakov, IV			Annealing prion protein amyloid fibrils at high temperature results in extension of a proteinase K-resistant core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; CONVERSION; DOMAIN; PRPSC; CONFORMATION; AGGREGATION; MECHANISM; DISEASE; INDUCE; URE2P	Amyloids are highly ordered, rigid beta-sheet-rich structures that appear to have minimal dynamic flexibility in individual polypeptide chains. Here, we demonstrate that substantial conformational rearrangements occur within mature amyloid fibrils produced from full-length mammalian prion protein. The rearrangement results in a substantial extension of a proteinase K-resistant core and is accompanied by an increase in the beta-sheet-rich conformation. The conformational rearrangement was induced in the presence of low concentrations of Triton X-100 either by brief exposure to 80 degrees C or, with less efficacy, by prolonged incubation at 37 degrees C at pH 7.5 and is referred to here as "annealing." Upon annealing, amyloid fibrils acquired a proteinase K-resistant core identical to that found in bovine spongiform encephalopathy-specific scrapie-associated prion protein. Annealing was also observed when amyloid fibrils were exposed to high temperatures in the absence of detergent but in the presence of brain homogenate. These findings suggest that the amyloid fibrils exist in two conformationally distinct states that are separated by a high energy barrier and that yet unknown cellular cofactors may facilitate transition of the fibrils into thermodynamically more stable state. Our studies provide new insight into the complex behavior of prion polymerization and highlight the annealing process, a previously unknown step in the evolution of amyloid structures.	Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Russian Acad Sci, Kazan Inst Biochem & Biophys, Kazan 420111, Russia	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Russian Academy of Sciences; Kazan Scientific Centre of the Russian Academy of Sciences; Kazan Institute of Biochemistry & Biophysics	Baskakov, IV (corresponding author), Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu	Breydo, Leonid/E-6119-2010; Breydo, Leo/AAJ-7996-2020; Bocharova, Olga V./J-8284-2018	Bocharova, Olga V./0000-0002-5056-1506; Vadim, Salnikov/0000-0002-2367-672X; Breydo, Leonid/0000-0003-4666-2301	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045585] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 045585] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler V, 2003, J MOL BIOL, V332, P47, DOI 10.1016/S0022-2836(03)00919-7; Baxa U, 2004, J MOL BIOL, V339, P259, DOI 10.1016/j.jmb.2004.03.033; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Bousset L, 2003, J STRUCT BIOL, V141, P132, DOI 10.1016/S1047-8477(02)00606-8; Breydo L, 2005, BIOCHEMISTRY-US, V44, P15534, DOI 10.1021/bi051369+; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Chatani E, 2005, J MOL BIOL, V352, P941, DOI 10.1016/j.jmb.2005.07.043; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Cordeiro Y, 2004, J BIOL CHEM, V279, P32354, DOI 10.1074/jbc.M404295200; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Gabus C, 2001, J BIOL CHEM, V276, P19301, DOI 10.1074/jbc.M009754200; Gabus C, 2001, J MOL BIOL, V307, P1011, DOI 10.1006/jmbi.2001.4544; Gotte G, 2003, J BIOL CHEM, V278, P10763, DOI 10.1074/jbc.M213146200; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Hayashi HK, 2005, BIOCHEM BIOPH RES CO, V328, P1024, DOI 10.1016/j.bbrc.2005.01.065; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Iconomidou VA, 2000, FEBS LETT, V479, P141, DOI 10.1016/S0014-5793(00)01888-3; Kayed R, 2004, J BIOL CHEM, V279, P46363, DOI 10.1074/jbc.C400260200; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Klein TR, 1998, BIOL CHEM, V379, P655, DOI 10.1515/bchm.1998.379.6.655; Kocisko DA, 1996, BIOCHEMISTRY-US, V35, P13434, DOI 10.1021/bi9610562; Lee AS, 2003, J MOL BIOL, V327, P699, DOI 10.1016/S0022-2836(03)00175-X; Lee S, 2003, NAT STRUCT BIOL, V10, P725, DOI 10.1038/nsb961; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Liu YS, 2001, NAT STRUCT BIOL, V8, P211, DOI 10.1038/84941; Nishina K, 2004, J BIOL CHEM, V279, P40788, DOI 10.1074/jbc.M406548200; Notari S, 2004, J BIOL CHEM, V279, P16797, DOI 10.1074/jbc.M313220200; Petty SA, 2005, J AM CHEM SOC, V127, P13488, DOI 10.1021/ja054663y; Petty SA, 2005, BIOCHEMISTRY-US, V44, P4720, DOI 10.1021/bi047445a; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Si K, 2003, CELL, V115, P879, DOI 10.1016/S0092-8674(03)01020-1; Tahiri-Alaoui A, 2004, J BIOL CHEM, V279, P31390, DOI 10.1074/jbc.M401754200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yang SC, 2005, FASEB J, V19, P1778, DOI 10.1096/fj.05-4067hyp; Yutani K, 2000, BIOCHEMISTRY-US, V39, P2769, DOI 10.1021/bi991406v; Zhu M, 2004, J BIOL CHEM, V279, P24452, DOI 10.1074/jbc.M400004200	56	62	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2373	2379		10.1074/jbc.M510840200	http://dx.doi.org/10.1074/jbc.M510840200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314415	hybrid			2022-12-27	WOS:000234760400062
J	Staelens, S; Hadders, MA; Vauterin, S; Platteau, C; De Maeyer, M; Vanhoorelbeke, K; Huizinga, EG; Deckmyn, H				Staelens, S; Hadders, MA; Vauterin, S; Platteau, C; De Maeyer, M; Vanhoorelbeke, K; Huizinga, EG; Deckmyn, H			Paratope determination of the antithrombotic antibody 82D6A3 based on the crystal structure of its complex with the von Willebrand factor A3-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PLATELET-ADHESION; VWF MONOCLONAL-ANTIBODY; COLLAGEN-BINDING SITE; GLYCOPROTEIN IIB/IIIA; VONWILLEBRAND-FACTOR; VI COLLAGEN; A3 DOMAIN; I-DOMAIN; EXTRACELLULAR-MATRIX; THROMBUS FORMATION	The antithrombotic monoclonal antibody 82D6A3 is directed against amino acids Arg-963, Pro-981, Asp-1009, Arg-1016, Ser-1020, Met-1022, and His-1023 of the von Willebrand factor A3-domain (Vanhoorelbeke, K., Depraetere, H., Romijn, R. A., Huizinga, E., De Maeyer, M., and Deckmyn, H. (2003) J. Biol. Chem. 278, 37815-37821). By this, it potently inhibits the interaction of von Willebrand factor to collagens, which is a prerequisite for blood platelet adhesion to the injured vessel wall at sites of high shear. To fully understand the mode of action of 82D6A3 at the molecular level, we resolved its crystal structure in complex with the A3-domain and fine mapped its paratope by construction and characterization of 13 mutants. The paratope predominantly consists of two short sequences in the heavy chain CDR1 (Asn-31 and Tyr-32) and CDR3 (Asp-99, Pro-101, Tyr-102 and Tyr-103), forming one patch on the surface of the antibody. Trp-50 of the heavy and His-49 of the light chain, both situated adjacent to the patch, play ancillary roles in antigen binding. The crystal structure furthermore confirms the epitope location, which largely overlaps with the collagen binding site deduced from mutagenesis of the A3-domain ( Romijn, R. A., Westein, E., Bouma, B., Schiphorst, M. E., Sixma, J. J., Lenting, P. J., and Huizinga, E. G. (2003) J. Biol. Chem. 278, 15035-15039). We herewith further consolidate the location of the collagen binding site and reveal that the potent action of the antibody is due to direct competition for the same interaction site. This information allows the design of a paratope-mimicking peptide with antithrombotic properties.	IRC, Lab Thrombosis Res, B-85000 Kortrijk, Belgium; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Chem, NL-3584 CH Utrecht, Netherlands; Katholieke Univ Leuven, Lab Biomol Modeling, B-3000 Louvain, Belgium	Utrecht University; KU Leuven	Deckmyn, H (corresponding author), IRC, Lab Thrombosis Res, KU Leuven Campus Kortrijk,E Sabbelaan 53, B-85000 Kortrijk, Belgium.	Hans.Deckmyn@kuleuven-kortrijk.be	Deckmyn, Hans/L-9434-2015; Deckmyn, Hans/N-8932-2019	Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; Vanhoorelbeke, Karen/0000-0003-2288-8277				Alberio L, 1998, BRIT J HAEMATOL, V102, P1212, DOI 10.1046/j.1365-2141.1998.00923.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnes CS, 2001, SEMIN THROMB HEMOST, V27, P337, DOI 10.1055/s-2001-16887; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Cauwenberghs N, 2000, ARTERIOSCL THROM VAS, V20, P1347, DOI 10.1161/01.ATV.20.5.1347; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Clemetson KJ, 2001, THROMB HAEMOSTASIS, V86, P189; COLOMBATTI A, 1991, BLOOD, V77, P2305; Cruz CP, 2001, J VASC SURG, V34, P724, DOI 10.1067/mva.2001.116801; DENIS C, 1993, ARTERIOSCLER THROMB, V13, P398, DOI 10.1161/01.ATV.13.3.398; DORING E, 1994, MOL IMMUNOL, V31, P1059, DOI 10.1016/0161-5890(94)90101-5; Eichler J, 2004, PROTEIN PEPTIDE LETT, V11, P281, DOI 10.2174/0929866043406931; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Fairlie DP, 1998, CURR MED CHEM, V5, P29; Feng JN, 2005, IMMUNOL LETT, V98, P311, DOI 10.1016/j.imlet.2004.12.006; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; Ferns GAA, 2000, INT J EXP PATHOL, V81, P63, DOI 10.1046/j.1365-2613.2000.00143.x; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; Kageyama S, 1997, BRIT J PHARMACOL, V122, P165, DOI 10.1038/sj.bjp.0701354; Kageyama S, 2001, THROMB RES, V101, P395, DOI 10.1016/S0049-3848(00)00430-8; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1994, J BIOL CHEM, V269, P26006; Kehrel B, 1998, BLOOD, V91, P491; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; Mazzucato M, 1999, J BIOL CHEM, V274, P3033, DOI 10.1074/jbc.274.5.3033; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nishida N, 2003, NAT STRUCT BIOL, V10, P53, DOI 10.1038/nsb876; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1988, BLOOD, V71, P831; REILLY IAG, 1988, DRUGS, V35, P154, DOI 10.2165/00003495-198835020-00005; Romijn RA, 2003, J BIOL CHEM, V278, P15035, DOI 10.1074/jbc.M208977200; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; ROSS JM, 1995, BLOOD, V85, P1826, DOI 10.1182/blood.V85.7.1826.bloodjournal8571826; Sadler E, 2002, BLOOD, V99, P3491, DOI 10.1182/blood.V99.10.3491a; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; STAELENS S, 2006, IN PRESS MOL IMMUNOL; Trivedi Shivang M, 2002, J Invasive Cardiol, V14, P423; TSCHOPP TB, 1974, J LAB CLIN MED, V83, P296; vandenElsen JMH, 1997, PROTEINS, V29, P113; Vanhoorelbeke K, 2003, J BIOL CHEM, V278, P37815, DOI 10.1074/jbc.M304289200; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wu DM, 2002, ARTERIOSCL THROM VAS, V22, P323, DOI 10.1161/hq0202.102321; Wu DM, 2002, BLOOD, V99, P3623, DOI 10.1182/blood.V99.10.3623; Zou JY, 1996, ACTA CRYSTALLOGR D, V52, P833, DOI 10.1107/S0907444995016465	58	24	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2225	2231		10.1074/jbc.M508191200	http://dx.doi.org/10.1074/jbc.M508191200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16314412	Green Published, hybrid			2022-12-27	WOS:000234760400046
J	Torban, E; Dziarmaga, A; Iglesias, D; Chu, LL; Vassilieva, T; Little, M; Eccles, M; Discenza, M; Pelletier, J; Goodyer, P				Torban, E; Dziarmaga, A; Iglesias, D; Chu, LL; Vassilieva, T; Little, M; Eccles, M; Discenza, M; Pelletier, J; Goodyer, P			PAX2 activates WNT4 expression during mammalian kidney development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-COLOBOMA SYNDROME; EPITHELIAL TRANSFORMATION; METANEPHRIC MESENCHYME; APOPTOSIS; GENE; HYPOPLASIA; CELLS; MICE	The transcription factor PAX2 is expressed during normal kidney development and is thought to influence outgrowth and branching of the ureteric bud. Mice with homozygous null Pax2 mutations have developmental defects of the midbrain-hindbrain region, optic nerve, and ear and are anephric. During nephrogenesis, PAX2 is also expressed by mesenchymal cells as they cluster and reorganize to form proximal elements of each nephron, but the function of PAX2 in these cells is unknown. In this study we hypothesized that PAX2 activates expression of WNT4, a secreted glycoprotein known to be critical for successful nephrogenesis. PAX2 protein was identified in distal portions of the "S-shaped" body, and the protein persists in the emerging proximal tubules of murine fetal kidney. PAX2 activated WNT4 promoter activity 5-fold in co-transfection assays with JTC12 cells derived from the proximal tubule. Inspection of the 5'-flanking sequence of the human WNT4 gene identified three novel PAX2 recognition motifs; each exhibited specific PAX2 protein binding in electromobility shift assays. Two motifs were contained within a completely duplicated 0.66-kb cassette. Transfection of JTC12 cells with a PAX2 expression vector was associated with a 7-fold increase in endogenous WNT4 mRNA. In contrast, Wnt4 mRNA was decreased by 60% in mesenchymal cell condensates of fetal kidney from mice with a heterozygous Pax2 mutation. We speculated that a key function of PAX2 is to activate WNT4 gene expression in metanephric mesenchymal cells as they differentiate to form elements of the renal tubules.	McGill Univ, Dept Expt Med & Pediat, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 2T5, Canada; Univ Queensland, Inst Mol Sci, Brisbane, Qld, Australia; Univ Otago, Dept Pathol, Dev Genet Lab, Dunedin, New Zealand; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; University of Queensland; University of Otago; McGill University	Goodyer, P (corresponding author), Montreal Childrens Hosp, Res Inst, 4060 Sainte Catherine St W,Rm 413, Montreal, PQ H3Z 2Z3, Canada.	Paul.Goodyer@muhc.mcgill.ca	Little, Melissa H/A-6170-2010	Little, Melissa H/0000-0003-0380-2263				Bouchard M, 2002, GENE DEV, V16, P2958, DOI 10.1101/gad.240102; Brisken C, 2000, GENE DEV, V14, P650; Brophy PD, 2001, DEVELOPMENT, V128, P4747; Clark P, 2004, J AM SOC NEPHROL, V15, P299, DOI 10.1097/01.ASN.0000111248.23454.19; Cohen ED, 2002, DEV CELL, V2, P437, DOI 10.1016/S1534-5807(02)00142-9; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Dziarmaga A, 2003, J AM SOC NEPHROL, V14, P2767, DOI 10.1097/01.ASN.0000094082.11026.EE; Guo XZ, 2004, GENE DEV, V18, P2404, DOI 10.1101/gad.1230704; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hou XN, 2004, MOL ENDOCRINOL, V18, P3035, DOI 10.1210/me.2004-0259; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Hunter DD, 2004, MOL CELL NEUROSCI, V27, P477, DOI 10.1016/j.mcn.2004.08.003; IGLESIAS DM, 2004, J AM SOC NEPHROL, V15, pA58; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kispert A, 1996, DEVELOPMENT, V122, P3627; Lyons JP, 2004, EXP CELL RES, V298, P369, DOI 10.1016/j.yexcr.2004.04.036; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stayner CK, 1998, J BIOL CHEM, V273, P25472, DOI 10.1074/jbc.273.39.25472; Torban E, 2000, AM J PATHOL, V157, P833, DOI 10.1016/S0002-9440(10)64597-X; Torban E, 1998, BBA-MOL CELL RES, V1401, P53, DOI 10.1016/S0167-4889(97)00119-5; Torres M, 1995, DEVELOPMENT, V121, P4057; Wheat W, 1999, MOL CELL BIOL, V19, P2231	27	53	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12705	12712		10.1074/jbc.M513181200	http://dx.doi.org/10.1074/jbc.M513181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16368682	hybrid			2022-12-27	WOS:000237134700062
J	Pinto, LH; Lamb, RA				Pinto, LH; Lamb, RA			The M2 proton channels of influenza A and B viruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							M-2 ION-CHANNEL; INTEGRAL MEMBRANE-PROTEIN; PLANAR LIPID-BILAYERS; TRANSMEMBRANE DOMAIN; M(2) PROTEIN; NUCLEAR TRANSPORT; CELL-SURFACE; BM2 PROTEIN; AMANTADINE; SELECTIVITY		Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University; Howard Hughes Medical Institute; Northwestern University; Northwestern University	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2205 Tech Dr, Evanston, IL 60208 USA.	larry-pinto@northwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031882, R37AI020201] Funding Source: NIH RePORTER; NIAID NIH HHS [R37AI-20201, R01AI-31882] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bauer CM, 1999, VIROLOGY, V254, P196, DOI 10.1006/viro.1998.9552; Bui M, 1996, J VIROL, V70, P8391, DOI 10.1128/JVI.70.12.8391-8401.1996; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; DUFF KC, 1994, VIROLOGY, V202, P287, DOI 10.1006/viro.1994.1345; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HELENIUS A, 1992, CELL, V69, P577, DOI 10.1016/0092-8674(92)90219-3; HOLSINGER LJ, 1995, J VIROL, V69, P1219, DOI 10.1128/JVI.69.2.1219-1225.1995; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; Jackson D, 2002, J VIROL, V76, P11744, DOI 10.1128/JVI.76.22.11744-11747.2002; Kovacs FA, 2000, J MOL BIOL, V295, P117, DOI 10.1006/jmbi.1999.3322; Lamb R.A., 2001, FIELDS VIROLOGY, P1487; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; Lear JD, 2003, FEBS LETT, V552, P17, DOI 10.1016/s0014-5793(03)00778-6; Lin TI, 2001, J VIROL, V75, P3647, DOI 10.1128/JVI.75.8.3647-3656.2001; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; Mould JA, 2000, J BIOL CHEM, V275, P31038, DOI 10.1074/jbc.M003663200; Mould JA, 2000, J BIOL CHEM, V275, P8592, DOI 10.1074/jbc.275.12.8592; Mould JA, 2003, DEV CELL, V5, P175, DOI 10.1016/S1534-5807(03)00190-4; Nishimura K, 2002, BIOCHEMISTRY-US, V41, P13170, DOI 10.1021/bi0262799; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; Paterson RG, 2003, VIROLOGY, V306, P7, DOI 10.1016/S0042-6822(02)00083-1; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SHIMBO K, 1996, BIOPHYS J, V70, P1336; Shuck K, 2000, J VIROL, V74, P7755, DOI 10.1128/JVI.74.17.7755-7761.2000; Smondyrev AM, 2002, BIOPHYS J, V83, P1987, DOI 10.1016/S0006-3495(02)73960-X; Song ZY, 2000, BIOPHYS J, V79, P767, DOI 10.1016/S0006-3495(00)76334-X; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; Takeda M, 2002, J VIROL, V76, P1391, DOI 10.1128/JVI.76.3.1391-1399.2002; Tang YJ, 2002, J BIOL CHEM, V277, P39880, DOI 10.1074/jbc.M206582200; Tian CL, 2003, PROTEIN SCI, V12, P2597, DOI 10.1110/ps.03168503; Tian CL, 2002, BIOCHEMISTRY-US, V41, P11294, DOI 10.1021/bi025695q; Tobler K, 1999, J VIROL, V73, P9695, DOI 10.1128/JVI.73.12.9695-9701.1999; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; Venkataraman P, 2005, J BIOL CHEM, V280, P21463, DOI 10.1074/jbc.M412406200; Vijayvergiya V, 2004, BIOPHYS J, V87, P1697, DOI 10.1529/biophysj.104.043018; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628; Wang JF, 2001, PROTEIN SCI, V10, P2241, DOI 10.1110/ps.17901; ZHIRNOV OP, 1992, VIROLOGY, V186, P324, DOI 10.1016/0042-6822(92)90090-C; ZHIRNOV OP, 1990, VIROLOGY, V176, P274, DOI 10.1016/0042-6822(90)90253-N	48	305	321	3	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 7	2006	281	14					8997	9000		10.1074/jbc.R500020200	http://dx.doi.org/10.1074/jbc.R500020200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	027HB	16407184	hybrid			2022-12-27	WOS:000236404700002
J	Fong, SS; Nanchen, A; Palsson, BO; Sauer, U				Fong, SS; Nanchen, A; Palsson, BO; Sauer, U			Latent pathway activation and increased pathway capacity enable Escherichia coli adaptation to loss of key metabolic enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL CARBON METABOLISM; PYRIDINE-NUCLEOTIDE TRANSHYDROGENASE; GLOBAL GENE-EXPRESSION; FLUX ANALYSIS; SACCHAROMYCES-CEREVISIAE; ADAPTIVE EVOLUTION; TRANSCRIPTIONAL REGULATION; FUNCTIONAL GENOMICS; ANAEROBIC GROWTH; XYLOSE	The ability of biological systems to adapt to genetic and environmental perturbations is a fundamental but poorly understood process at the molecular level. By quantifying metabolic fluxes and global mRNA abundance, we investigated the genetic and metabolic mechanisms that underlie adaptive evolution of four metabolic gene deletion mutants of Escherichia coli (Delta pgi, Delta ppc, Delta pta, and Delta tpi) in parallel evolution experiments of each mutant. The initial response to the gene deletions was flux rerouting through local bypass reactions or normally latent pathways. The principal effect of evolution was improved capacity of already active pathways, whereas new flux distributions were not observed. Combinatorial changes in capacity and pathway activation, however, led to different intracellular flux states that enabled evolution in three of the four parallel cases tested. The molecular bases of the evolved phenotypes were then elucidated by global mRNA transcript analyses. Activation of latent pathways and flux changes in the tricarboxylic acid cycle were found to correlate well with molecular changes at the transcriptional level. Flux alterations in other central metabolic pathways, in contrast, were apparently not connected to changes in the transcriptional network. These results give new insight into the dynamics of the evolutionary process by demonstrating the flexibility of the metabolic network of E. coli to compensate for genetic perturbations and the utility of combining multiple high throughput data sets to differentiate between causal and noncausal mechanistic changes.	Virginia Commonwealth Univ, Dept Chem & Life Sci Engn, Richmond, VA 23284 USA; ETH, Inst Mol Syst Biol, CH-8093 Zurich, Switzerland; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	Virginia Commonwealth University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of California System; University of California San Diego	Fong, SS (corresponding author), Virginia Commonwealth Univ, Dept Chem & Life Sci Engn, POB 843028, Richmond, VA 23284 USA.	ssfong@vcu.edu	Sauer, Uwe/Y-3556-2019	Palsson, Bernhard/0000-0003-2357-6785				Adams J, 2004, RES MICROBIOL, V155, P311, DOI 10.1016/j.resmic.2004.01.013; Bailey JE, 1999, NAT BIOTECHNOL, V17, P616, DOI 10.1038/10794; Blank LM, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-r49; Boonstra B, 1999, J BACTERIOL, V181, P1030, DOI 10.1128/JB.181.3.1030-1034.1999; Chang DE, 1999, J BACTERIOL, V181, P6656, DOI 10.1128/JB.181.21.6656-6663.1999; CLARKE DM, 1986, EUR J BIOCHEM, V158, P647, DOI 10.1111/j.1432-1033.1986.tb09802.x; COOPER RA, 1970, FEBS LETT, V11, P273, DOI 10.1016/0014-5793(70)80546-4; Cooper TF, 2003, P NATL ACAD SCI USA, V100, P1072, DOI 10.1073/pnas.0334340100; Cora D, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-57; Daran-Lapujade P, 2004, J BIOL CHEM, V279, P9125, DOI 10.1074/jbc.M309578200; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Elena SF, 2003, NAT REV GENET, V4, P457, DOI 10.1038/nrg1088; Emmerling M, 2002, J BACTERIOL, V184, P152, DOI 10.1128/JB.184.1.152-164.2002; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Ferguson GP, 1998, ARCH MICROBIOL, V170, P209, DOI 10.1007/s002030050635; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Fischer E, 2004, ANAL BIOCHEM, V325, P308, DOI 10.1016/j.ab.2003.10.036; Fischer E, 2005, NAT GENET, V37, P636, DOI 10.1038/ng1555; Fong SS, 2004, NAT GENET, V36, P1056, DOI 10.1038/ng1432; Fong SS, 2003, J BACTERIOL, V185, P6400, DOI 10.1128/JB.185.21.6400-6408.2003; Fuhrer T, 2005, J BACTERIOL, V187, P1581, DOI 10.1128/JB.187.5.1581-1590.2005; Gonzalez R, 2002, BIOTECHNOL PROGR, V18, P6, DOI 10.1021/bp010121i; Gunnarsson N, 2004, MOL MICROBIOL, V52, P895, DOI 10.1111/j.1365-2958.2004.04028.x; Hellerstein MK, 2003, ANNU REV NUTR, V23, P379, DOI 10.1146/annurev.nutr.23.011702.073045; HOEK JB, 1988, BIOCHEM J, V254, P1; Honisch C, 2004, GENOME RES, V14, P2495, DOI 10.1101/gr.2977704; HOPPER DJ, 1972, BIOCHEM J, V128, P321, DOI 10.1042/bj1280321; Hua Q, 2003, J BACTERIOL, V185, P7053, DOI 10.1128/JB.185.24.7053-7067.2003; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Keseler IM, 2005, NUCLEIC ACIDS RES, V33, pD334, DOI 10.1093/nar/gki108; Kuyper M, 2005, FEMS YEAST RES, V5, P925, DOI 10.1016/j.femsyr.2005.04.004; Mahadevan R, 2003, METAB ENG, V5, P264, DOI 10.1016/j.ymben.2003.09.002; Neidhardt F. C., 1990, PHYSL BACTERIAL CELL, P133; Peng LF, 2004, FEMS MICROBIOL LETT, V235, P17, DOI 10.1016/j.femsle.2004.04.003; Perrenoud A, 2005, J BACTERIOL, V187, P3171, DOI 10.1128/JB.187.9.3171-3179.2005; SAIKUSA T, 1987, AGR BIOL CHEM TOKYO, V51, P1893, DOI 10.1080/00021369.1987.10868320; Sauer U, 1999, J BACTERIOL, V181, P6679, DOI 10.1128/JB.181.21.6679-6688.1999; Sauer U, 2004, CURR OPIN BIOTECH, V15, P58, DOI 10.1016/j.copbio.2003.11.001; Sauer U, 2004, J BIOL CHEM, V279, P6613, DOI 10.1074/jbc.M311657200; Sauer U, 2001, Adv Biochem Eng Biotechnol, V73, P129; Sauer U, 2005, FEMS MICROBIOL REV, V29, P765, DOI 10.1016/j.femsre.2004.11.002; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Sonderegger M, 2004, APPL ENVIRON MICROB, V70, P2307, DOI 10.1128/AEM.70.4.2307-2317.2004; Sonderegger M, 2003, APPL ENVIRON MICROB, V69, P1990, DOI 10.1128/AEM.69.4.1990-1998.2003; Wolfe AJ, 2003, MOL MICROBIOL, V48, P977, DOI 10.1046/j.1365-2958.2003.03457.x; Zamboni N, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-209; Zelder O, 2000, CURR OPIN MICROBIOL, V3, P248, DOI 10.1016/S1369-5274(00)00084-9	48	137	145	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 24	2006	281	12					8024	8033		10.1074/jbc.M510016200	http://dx.doi.org/10.1074/jbc.M510016200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BZ	16319065	hybrid			2022-12-27	WOS:000236031000039
J	Boucher, MJ; Selander, L; Carlsson, L; Edlund, H				Boucher, MJ; Selander, L; Carlsson, L; Edlund, H			Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN GENE-TRANSCRIPTION; RECEPTOR-RELATED PROTEIN-5; DNA-BINDING ACTIVITY; OXIDATIVE STRESS; FACTOR PDX-1; C-JUN; MEDIATED SUPPRESSION; UPSTREAM FACTOR-1; DIABETES-MELLITUS; PROMOTER ACTIVITY	The transcription factor IPF1/PDX1 plays a crucial role in both pancreas development and maintenance of beta-cell function. Targeted disruption of this transcription factor in beta-cells leads to diabetes, whereas reduced expression levels affect insulin expression and secretion. Therefore, it is essential to determine molecular mechanisms underlying the regulation of this key transcription factor on mRNA levels and, most importantly, on protein levels. Here we show that a minor portion of IPF1/PDX1 is phosphorylated on serine 61 and/or serine 66 in pancreatic beta-cells. This phosphorylated form of IPF1/PDX1 preferentially accumulates following proteasome inhibition, an effect that is prevented by inhibition of glycogen synthase kinase 3 (GSK3) activity. Oxidative stress, which is associated with the diabetic state, (i) increases IPF1/PDX1 Ser(61) and/or Ser(66) phosphorylation and (ii) increases the degradation rate and decreases the half-life of IPF-1/PDX-1 protein. In addition, we provide evidence that GSK3 activity participates in oxidative stress-induced effects on beta-cells. Thus, this current study uncovers a new mechanism that might contribute to diminished levels of IPF1/ PDX1 protein and beta-cell dysfunction during the progression of diabetes.	Umea Univ, Umea Ctr Mol Med, SE-90187 Umea, Sweden	Umea University	Boucher, MJ (corresponding author), Umea Univ, Umea Ctr Mol Med, SE-90187 Umea, Sweden.	marie-josee.boucher@ucmm.umu.se; helena.edlund@ucmm.umu.se		Boucher, Marie-Josee/0000-0002-7615-3121; Edlund, Helena/0000-0002-3553-7348				Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Ahren B, 1997, METABOLISM, V46, P97, DOI 10.1016/S0026-0495(97)90175-X; BrethertonWatt D, 1996, BIOCHEM J, V313, P495, DOI 10.1042/bj3130495; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; Cockburn BN, 2004, J CLIN ENDOCR METAB, V89, P971, DOI 10.1210/jc.2003-031282; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Elbein SC, 2004, DIABETES CARE, V27, P1968, DOI 10.2337/diacare.27.8.1968; Eldar-Finkelman H, 1999, DIABETES, V48, P1662, DOI 10.2337/diabetes.48.8.1662; Elrick LJ, 2001, DIABETES, V50, P2244, DOI 10.2337/diabetes.50.10.2244; Engler TA, 2005, BIOORG MED CHEM LETT, V15, P899, DOI 10.1016/j.bmcl.2004.12.063; Fernandez-Alvarez J, 2004, DIABETOLOGIA, V47, P470, DOI 10.1007/s00125-004-1332-8; Fujino T, 2003, P NATL ACAD SCI USA, V100, P229, DOI 10.1073/pnas.0133792100; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; Hani EH, 1999, J CLIN INVEST, V104, pR41, DOI 10.1172/JCI7469; Hansen L, 2000, J CLIN ENDOCR METAB, V85, P1323, DOI 10.1210/jc.85.3.1323; Harada Y, 2005, J BIOL CHEM, V280, P31714, DOI 10.1074/jbc.M506225200; Harmon JS, 2005, J BIOL CHEM, V280, P11107, DOI 10.1074/jbc.M410345200; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Henriksen EJ, 2003, AM J PHYSIOL-ENDOC M, V284, pE892, DOI 10.1152/ajpendo.00346.2002; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kaneto H, 1999, DIABETES, V48, P2398, DOI 10.2337/diabetes.48.12.2398; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kawamori D, 2003, DIABETES, V52, P2896, DOI 10.2337/diabetes.52.12.2896; Khoo S, 2003, J BIOL CHEM, V278, P32969, DOI 10.1074/jbc.M301198200; Kim AJ, 2005, J CELL SCI, V118, P89, DOI 10.1242/jcs.01562; Kishi A, 2003, AM J PHYSIOL-ENDOC M, V284, pE830, DOI 10.1152/ajpendo.00390.2002; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Lebrun P, 2005, J BIOL CHEM, V280, P38203, DOI 10.1074/jbc.M504842200; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; Matsuoka T, 1997, J CLIN INVEST, V99, P144, DOI 10.1172/JCI119126; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nikoulina SE, 2000, DIABETES, V49, P263, DOI 10.2337/diabetes.49.2.263; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Petersen HV, 1998, FEBS LETT, V431, P362, DOI 10.1016/S0014-5793(98)00776-5; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Quelo I, 2004, BIOCHEMISTRY-US, V43, P2906, DOI 10.1021/bi036256+; Rafiq I, 1998, J BIOL CHEM, V273, P23241, DOI 10.1074/jbc.273.36.23241; Redmon JB, 1996, J CLIN INVEST, V98, P2786, DOI 10.1172/JCI119105; Ring DB, 2003, DIABETES, V52, P588, DOI 10.2337/diabetes.52.3.588; Robertson RP, 2004, J BIOL CHEM, V279, P42351, DOI 10.1074/jbc.R400019200; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sayo Y, 2000, EUR J BIOCHEM, V267, P971, DOI 10.1046/j.1432-1327.2000.01080.x; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Stanojevic V, 2004, ENDOCRINOLOGY, V145, P2918, DOI 10.1210/en.2003-1188; Stanojevic V, 2005, MOL CELL ENDOCRINOL, V237, P67, DOI 10.1016/j.mce.2005.03.003; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Thomas MK, 1999, MOL CELL BIOL, V19, P8492; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wagman AS, 2004, CURR PHARM DESIGN, V10, P1105, DOI 10.2174/1381612043452668; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Wu H, 1999, BIOCHEM J, V344, P813, DOI 10.1042/0264-6021:3440813; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	66	90	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6395	6403		10.1074/jbc.M511597200	http://dx.doi.org/10.1074/jbc.M511597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407209	hybrid			2022-12-27	WOS:000236030800033
J	Gang, L; Kang, YJ; Han, JH; Herschman, HR; Stefani, E; Wang, YB				Gang, L; Kang, YJ; Han, JH; Herschman, HR; Stefani, E; Wang, YB			TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENCODED FLUORESCENT REPORTER; CARDIAC MYOCYTES; CYCLOOXYGENASE-2 EXPRESSION; INDEPENDENT ACTIVATION; LIVING CELLS; IN-VITRO; STRESS; HEART; PATHWAYS	Stress-activated mitogen-activated protein (MAP) kinase p38 mediates stress signaling in mammalian cells via threonine and tyrosine phosphorylation in its conserved TGY motif by upstream MAP kinase kinases (MKKs). In addition, p38 MAP kinase can also be activated by an MKK-independent mechanism involving TAB-1 (TAK-1-binding protein)-mediated autophosphorylation. Although TAB-1-mediated p38 activation has been implicated in ischemic heart, the biological consequences and downstream signaling of TAB-1-mediated p38 activation in cardiomyocytes is largely unknown. We show here that TAB-1 expression leads to a significant induction of p38 autophosphorylation and consequent kinase activation in cultured neonatal cardiomyocytes. In contrast to MKK3-induced p38 kinase downstream effects, TAB-1-induced p38 kinase activation does not induce expression of pro-inflammatory genes, cardiac marker gene expression, or changes in cellular morphology. Rather, TAB-1 binds to p38 and prevents p38 nuclear localization. Furthermore, TAB-1 disrupts p38 interaction with MKK3 and redirects p38 localization in the cytosol. Consequently, TAB-1 expression antagonizes the downstream activity of p38 kinase induced by MKK3 and attenuates interleukin-1 beta-induced inflammatory gene induction in cardiomyocytes. These data suggest that TAB-1 can mediate MKK-independent p38 kinase activation while negatively modulating MKK-dependent p38 function. Our study not only redefines the functional role of TAB-1 in p38 kinase-mediated signaling pathways but also provides the first evidence that intracellular localization of p38 kinase and complex interaction dictates its downstream effects. These results suggest a previously unknown mechanism for stress-MAP kinase regulation in mammalian cells.	Univ Calif Los Angeles, Dept Anesthesiol & Med, Div Mol Med, CSH,David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Pharmacol & Biol Chem, Div Mol Med, CSH,David Geffen Sch Med, Los Angeles, CA 90095 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Scripps Research Institute	Wang, YB (corresponding author), Univ Calif Los Angeles, Dept Anesthesiol & Med, Div Mol Med, CSH,David Geffen Sch Med, BH-569, Los Angeles, CA 90095 USA.	yibinwang@mednet.ucla.edu	Han, J/G-4671-2010	Wang, Yibin/0000-0003-0852-0767	NCI NIH HHS [R01 CA 84572] Funding Source: Medline; NHLBI NIH HHS [HL 62311, HL 08111] Funding Source: Medline; NIAID NIH HHS [AI 41637] Funding Source: Medline; NIGMS NIH HHS [GM 037696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogoyevitch MA, 2000, CARDIOVASC RES, V45, P826, DOI 10.1016/S0008-6363(99)00386-7; Chen CA, 2004, BBA-PROTEINS PROTEOM, V1697, P39, DOI 10.1016/j.bbapap.2003.11.012; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Degousee N, 2003, CIRC RES, V92, P757, DOI 10.1161/01.RES.0000067929.01404.03; Dinarello CA, 2001, BLOOD PURIFICAT, V19, P314, DOI 10.1159/000046960; Force T, 1999, GENE EXPRESSION, V7, P337; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Ge BX, 2003, J BIOL CHEM, V278, P2286, DOI 10.1074/jbc.M210918200; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Herschman HR, 1999, ADV EXP MED BIOL, V469, P3; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Komatsu Y, 2002, MECH DEVELOP, V119, P239, DOI 10.1016/S0925-4773(02)00391-X; Kunkel MT, 2005, J BIOL CHEM, V280, P5581, DOI 10.1074/jbc.M411534200; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10; Li MX, 2005, CIRCULATION, V111, P2494, DOI 10.1161/01.CIR.0000165117.71483.0C; Li Q, 2004, J NEUROSCI, V24, P4070, DOI 10.1523/JNEUROSCI.0346-04.2004; Liao P, 2002, CIRC RES, V90, P190, DOI 10.1161/hh0202.104220; Mann DL, 2003, ANNU REV PHYSIOL, V65, P81, DOI 10.1146/annurev.physiol.65.092101.142249; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Morrison DK, 2001, J CELL SCI, V114, P1609; Ohkusu-Tsukada K, 2004, MOL CELL BIOL, V24, P6957, DOI 10.1128/MCB.24.16.6957-6966.2004; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Schuette R, 2000, AM J PHYSIOL-HEART C, V279, pH719, DOI 10.1152/ajpheart.2000.279.2.H719; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Singhirunnusorn P, 2005, J BIOL CHEM, V280, P7359, DOI 10.1074/jbc.M407537200; Sugden PH, 2001, ANN MED, V33, P611; Tanno M, 2003, CIRC RES, V93, P254, DOI 10.1161/01.RES.0000083490.43943.85; Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang Yibin, 2001, Current Opinion in Pharmacology, V1, P134, DOI 10.1016/S1471-4892(01)00029-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Zhang J, 2001, P NATL ACAD SCI USA, V98, P14997, DOI 10.1073/pnas.211566798	39	61	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6087	6095		10.1074/jbc.M507610200	http://dx.doi.org/10.1074/jbc.M507610200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407200	hybrid			2022-12-27	WOS:000235568900090
J	Vinothkumar, KR; Raunser, S; Jung, H; Kuhlbrandt, W				Vinothkumar, KR; Raunser, S; Jung, H; Kuhlbrandt, W			Oligomeric structure of the carnitine transporter CaiT from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; PROJECTION STRUCTURE; ELECTRON-MICROSCOPY; CORYNEBACTERIUM-GLUTAMICUM; ERYTHROCYTE-MEMBRANE; QUATERNARY STRUCTURE; ANGSTROM RESOLUTION; PROTEIN; CHANNEL; IMAGES	The carnitine transporter CaiT from Escherichia coli belongs to the betaine, choline, and carnitine transporter family of secondary transporters. It acts as an L-carnitine/gamma-butyrobetaine exchanger and is predicted to span the membrane 12 times. Unlike the other members of this transporter family, it does not require an ion gradient and does not respond to osmotic stress ( Jung, H., Buchholz, M., Clausen, J., Nietschke, M., Revermann, A., Schmid, R., and Jung, K. ( 2002) J. Biol. Chem. 277, 39251-39258). The structure and oligomeric state of the protein was examined in detergent and in lipid bilayers. Blue native gel electrophoresis indicated that CaiT was a trimer in detergent solution. This result was further supported by gel filtration and cross-linking studies. Electron microscopy and single particle analysis of the protein showed a triangular structure of three masses or two parallel elongated densities. Reconstitution of CaiT into lipid bilayers yielded two-dimensional crystals that indicated that CaiT was a trimer in the membrane, similar to its homologue BetP. The implications of the trimeric structure on the function of CaiT are discussed.	Max Planck Inst Biophys, Dept Biol Struct, D-60438 Frankfurt, Germany; Univ Munich, Dept Biol 1, D-80638 Munich, Germany	Max Planck Society; University of Munich	Kuhlbrandt, W (corresponding author), Max Planck Inst Biophys, Dept Biol Struct, Max Von Laue Str 3, D-60438 Frankfurt, Germany.	werner.kuehlbrandt@mpibp-frankfurt.mpg.de	Jung, Heinrich/K-3790-2014; Raunser, Stefan/AHE-1573-2022	Jung, Heinrich/0000-0002-5450-3063; Kuhlbrandt, Werner/0000-0002-2013-4810; Raunser, Stefan/0000-0001-9373-3016				Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; CASEY JR, 1991, J BIOL CHEM, V266, P15726; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gendreau S, 2004, J BIOL CHEM, V279, P39505, DOI 10.1074/jbc.M408038200; HENDERSON R, 1986, ULTRAMICROSCOPY, V19, P147, DOI 10.1016/0304-3991(86)90203-2; Heuberger EHML, 2002, J MOL BIOL, V317, P591, DOI 10.1006/jmbi.2002.5416; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; JUNG H, 1989, BIOCHIM BIOPHYS ACTA, V1003, P270, DOI 10.1016/0005-2760(89)90232-4; Jung H, 2002, J BIOL CHEM, V277, P39251, DOI 10.1074/jbc.M206319200; Kramer R, 2004, BBA-BIOENERGETICS, V1658, P31, DOI 10.1016/j.bbabio.2004.05.006; MARABINI R, 1994, BIOPHYS J, V66, P1804, DOI 10.1016/S0006-3495(94)80974-9; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; Mindell JA, 2001, NATURE, V409, P219, DOI 10.1038/35051631; Murakami S, 2002, NATURE, V419, P587, DOI 10.1038/nature01050; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; Radermacher M, 2001, J STRUCT BIOL, V135, P26, DOI 10.1006/jsbi.2001.4395; RADERMACHER M, 1997, SCANNING MICROSCOPY, V11, P171; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Standfuss J, 2004, J BIOL CHEM, V279, P36884, DOI 10.1074/jbc.M402348200; Valiyaveetil FI, 2002, BIOCHEMISTRY-US, V41, P10771, DOI 10.1021/bi026215y; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; Veenhoff LM, 2001, EMBO J, V20, P3056, DOI 10.1093/emboj/20.12.3056; Vinothkumar KR, 2005, EMBO J, V24, P2720, DOI 10.1038/sj.emboj.7600727; WANG DN, 1993, EMBO J, V12, P2233, DOI 10.1002/j.1460-2075.1993.tb05876.x; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Ziegler C, 2004, J MOL BIOL, V337, P1137, DOI 10.1016/j.jmb.2004.02.026	32	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4795	4801		10.1074/jbc.M508993200	http://dx.doi.org/10.1074/jbc.M508993200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365043	hybrid			2022-12-27	WOS:000235426200030
J	Wu, J; Woodard, RW				Wu, J; Woodard, RW			New insights into the evolutionary links relating to the 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase subfamilies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DEOXY-D-MANNO-OCTULOSONATE 8-PHOSPHATE SYNTHASE; MONOFUNCTIONAL CHORISMATE MUTASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; SHIKIMATE METABOLITES; BACILLUS-SUBTILIS; NEISSERIA-GONORRHOEAE; ALLOSTERIC REGULATION; CRYSTAL-STRUCTURE; BIOSYNTHESIS	Bacterial 3-deoxy-d-arabino-heptulosonate 7-phosphate synthases (DAHPSs) have been divided into either of two classes ( Class I/Class II) or subfamilies (AroAI(alpha)/AroAI(alpha)). Our investigation into the biochemical properties of the unique bifunctional DAHPS from Bacillus subtilis provides new insight into the evolutionary link among DAHPS subfamilies. In the present study, the DAHPS( aroA) and chorismate mutase (aroQ) activities of B. subtilis DAHPS are separated by domain truncation. Detailed enzymatic studies with the full-length wild-type protein and the truncated domains led to our hypothesis that the aroQ domain was fused to the N terminus of aroA in B. subtilis during evolution for the purpose of feedback regulation and not for the creation of a bona fide bifunctional enzyme. In addition, examination of aroA and aroQ fusion proteins from Porphyromonas gingivalis, in which the aroQ domain is fused to the C terminus of aroA, further supports the hypothesis. These results, along with sequence structure analysis of the DAHPS families suggest that "feedback regulation" may indeed be the evolutionary link between the two classes/subfamilies. It is likely that DAHPSs evolved from a primitive unregulated member of the AroAI(beta) subfamily. During evolution, some members of the AroAI(beta) subfamily remained unregulated, whereas other members acquired an extra domain for feedback regulation. The AroAI(alpha) subfamilies, however, evolved in a more complex manner to acquire insertions/ extensions in the (beta/alpha)(8) barrel to function as regulatory elements.	Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.	rww@umich.edu		Woodard, Ronald/0000-0002-7472-3653	NIGMS NIH HHS [GM 53069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAASOV T, 1989, J BACTERIOL, V171, P6155, DOI 10.1128/jb.171.11.6155-6160.1989; Birck MR, 2001, J MOL EVOL, V52, P205, DOI 10.1007/s002390010149; DEWICK PM, 1995, NAT PROD REP, V12, P579, DOI 10.1039/np9951200579; GORISCH H, 1971, BIOCHIM BIOPHYS ACTA, V242, P617, DOI 10.1016/0005-2744(71)90154-9; Gosset G, 2001, J BACTERIOL, V183, P4061, DOI 10.1128/JB.183.13.4061-4070.2001; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P376, DOI 10.1021/bi00454a011; Hartmann M, 2003, P NATL ACAD SCI USA, V100, P862, DOI 10.1073/pnas.0337566100; Haslam E., 1993, SHIKIMIC ACID METABO; IP KM, 1979, EUR J BIOCHEM, V98, P431, DOI 10.1111/j.1432-1033.1979.tb13203.x; JENSEN RA, 1966, J BIOL CHEM, V241, P3373; Jensen RA, 2002, J MOL EVOL, V54, P416, DOI 10.1007/s00239-001-0031-z; Knaggs AR, 2003, NAT PROD REP, V20, P119, DOI 10.1039/b100399m; Knaggs AR, 2001, NAT PROD REP, V18, P334, DOI 10.1039/b001717p; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schofield LR, 2004, PROTEIN EXPRES PURIF, V34, P17, DOI 10.1016/j.pep.2003.11.008; Sheflyan GY, 1999, BIOCHEMISTRY-US, V38, P14320, DOI 10.1021/bi9829884; Shumilin IA, 2004, J MOL BIOL, V341, P455, DOI 10.1016/j.jmb.2004.05.077; Shumilin IA, 1999, STRUCTURE, V7, P865, DOI 10.1016/S0969-2126(99)80109-9; Shumilin IA, 2002, J MOL BIOL, V320, P1147, DOI 10.1016/S0022-2836(02)00545-4; STEPHENS CM, 1991, J BIOL CHEM, V266, P20810; Subramaniam PS, 1998, J BACTERIOL, V180, P119, DOI 10.1128/JB.180.1.119-127.1998; Sundaram AK, 2001, ORG LETT, V3, P21, DOI 10.1021/ol0066126; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vrana KE, 1999, NAT STRUCT BIOL, V6, P401, DOI 10.1038/8192; Wagner T, 2000, J MOL BIOL, V301, P389, DOI 10.1006/jmbi.2000.3957; Wu J, 2005, BIOCHEM J, V390, P583, DOI 10.1042/BJ20050294; Wu J, 2003, J BIOL CHEM, V278, P27525, DOI 10.1074/jbc.M304631200; Zhang S, 1996, BIOORGAN MED CHEM, V4, P1015, DOI 10.1016/0968-0896(96)00099-5; Zhang S, 2003, BIOORGAN MED CHEM, V11, P3109, DOI 10.1016/S0968-0896(03)00242-6	30	33	54	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4042	4048		10.1074/jbc.M512223200	http://dx.doi.org/10.1074/jbc.M512223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16339761	hybrid			2022-12-27	WOS:000235275300033
J	Hanson, SM; Gurevich, VV				Hanson, SM; Gurevich, VV			The differential engagement of arrestin surface charges by the various functional forms of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL ARRESTIN; CRYSTAL-STRUCTURE; BETA-ARRESTIN; PHOSPHORYLATION-RECOGNITION; BINDING; RHODOPSIN; MUTAGENESIS; MECHANISM; SELECTIVITY; TRANSITION	G- protein- coupled receptor signaling is terminated by arrestin proteins that preferentially bind to the activated phosphorylated form of the receptor. Arrestins also bind active unphosphorylated and inactive phosphorylated receptors. Binding to the non- preferred forms of the receptor is important for visual arrestin translocation in rod photoreceptors and the regulation of receptor signaling and trafficking by non- visual arrestins. Given the importance of arrestin interactions with the various functional forms of the receptor, we performed an extensive analysis of the receptor- binding surface of arrestin using site- directed mutagenesis. The data indicated that a large number of surface charges are important for arrestin interaction with all forms of the receptor. Arrestin elements involved in receptor binding are differentially engaged by the various functional forms of the receptor, each requiring a unique subset of arrestin residues in a specific spatial configuration. We identified several additional phosphate- binding elements in the N- domain and demonstrated for the first time that the active receptor preferentially engages the arrestin C- domain. We also found that the interdomain contact surface is important for arrestin interaction with the non- preferred forms of the receptor and that residues in this region play a role in arrestin transition into its high affinity receptor binding state.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Gurevich, VV (corresponding author), Vanderbilt Univ, Dept Pharmacol, 2200 Pierce Ave,PRB 418, Nashville, TN 37232 USA.	vsevolod.gurevich@vanderbilt.edu	Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097, T32GM007628] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500, R01 EY011500-10, R01 EY011500] Funding Source: Medline; NIGMS NIH HHS [GM07628, GM63097, R01 GM063097] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Dinculescu A, 2002, J BIOL CHEM, V277, P11703, DOI 10.1074/jbc.M111833200; Dinh DT, 2005, MOL PHARMACOL, V67, P375, DOI 10.1124/mol.104.004721; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 2000, METHOD ENZYMOL, V315, P422; Gurevich VV, 2003, STRUCTURE, V11, P1037, DOI 10.1016/S0969-2126(03)00184-9; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Gurevich VV, 1996, METHOD ENZYMOL, V275, P382; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; GUREVICH VV, 2005, IN PRESS PHARM THER; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Nair KS, 2005, NEURON, V46, P555, DOI 10.1016/j.neuron.2005.03.023; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; Pan L, 2003, J BIOL CHEM, V278, P11623, DOI 10.1074/jbc.M209532200; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Sutton RB, 2005, J MOL BIOL, V354, P1069, DOI 10.1016/j.jmb.2005.10.023; Vishnivetskiy SA, 2004, J BIOL CHEM, V279, P1262, DOI 10.1074/jbc.M308834200; Vishnivetskiy SA, 2002, J BIOL CHEM, V277, P43961, DOI 10.1074/jbc.M206951200; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451	32	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3458	3462		10.1074/jbc.M512148200	http://dx.doi.org/10.1074/jbc.M512148200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339758	hybrid, Green Accepted			2022-12-27	WOS:000235128200055
J	Tanaka, T; Masai, H				Tanaka, T; Masai, H			Stabilization of a stalled replication fork by concerted actions of two helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DNA-REPLICATION; PROTEIN PRIA; HOMOLOGOUS RECOMBINATION; HOLLIDAY JUNCTIONS; NASCENT DNA; RECG; PRIMOSOME; BINDING; SEQUENCE	PriA helicase plays crucial roles in restoration of arrested replication forks. It carries a " 3 terminus binding pocket" in its N- terminal DNA binding domain, which is required for high affinity binding of PriA to a fork carrying a 3 - end of a nascent leading strand at the branch. We show that the abrogation of the 3 ' terminus recognition either by a mutation in the 3 ' terminus binding pocket or by the bulky modification of the 3 '- end leads to unwinding of the unreplicated duplex arm on this fork, causing potential fork destabilization. This indicates a critical role of the 3 ' terminus binding pocket of PriA in its " stable" binding at the fork for primosome assembly. In contrast, PriA unwinds the unreplicated duplex region on a fork without a 3 '- end, potentially destabilizing the fork. However, this process is inhibited by RecG helicase, capable of regressing the fork until the 3 '- end of the nascent leading strand reaches the branch. PriA now stably binds to this regressed fork, stabilizing it. Using a model arrest- fork- substrate, we reconstitute the above process in vitro with RecG and PriA proteins. Our results present a novel mechanism by which two helicases function in a highly coordinated manner to generate a structure in which an arrested fork is stabilized for further repair and/ or replication restart.	Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Genome Dynam Project, Tokyo 1138613, Japan.	hmasai@rinshoken.or.jp						AlDeib AA, 1996, J BACTERIOL, V178, P6782, DOI 10.1128/jb.178.23.6782-6789.1996; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; Chen HW, 2004, J BIOL CHEM, V279, P38503, DOI 10.1074/jbc.M404769200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Fukuoh A, 1997, EMBO J, V16, P203, DOI 10.1093/emboj/16.1.203; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; Hishida T, 2004, GENE DEV, V18, P1886, DOI 10.1101/gad.1223804; Jones JM, 2001, J MOL BIOL, V312, P935, DOI 10.1006/jmbi.2001.4930; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1999, J BIOL CHEM, V274, P25033, DOI 10.1074/jbc.274.35.25033; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Marians KJ, 2000, CURR OPIN GENET DEV, V10, P151, DOI 10.1016/S0959-437X(00)00059-9; Marians KJ, 2000, PROG NUCLEIC ACID RE, V63, P39; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; Masai H, 1999, BIOCHIMIE, V81, P847, DOI 10.1016/S0300-9084(99)00211-4; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; McGlynn P, 2000, CELL, V101, P35, DOI 10.1016/S0092-8674(00)80621-2; McGlynn P, 2002, TRENDS GENET, V18, P413, DOI 10.1016/S0168-9525(02)02720-8; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8227, DOI 10.1073/pnas.111008698; McGlynn P, 2001, P NATL ACAD SCI USA, V98, P8235, DOI 10.1073/pnas.121007798; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Mizukoshi T, 2003, J BIOL CHEM, V278, P42234, DOI 10.1074/jbc.C300285200; Noguchi E, 2004, MOL CELL BIOL, V24, P8342, DOI 10.1128/MCB.24.19.8342-8355.2004; Noguchi E, 2003, MOL CELL BIOL, V23, P7861, DOI 10.1128/MCB.23.21.7861-7874.2003; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; OUZOUNIS CA, 1991, NUCLEIC ACIDS RES, V19, P6953, DOI 10.1093/nar/19.24.6953; Sandler SJ, 1996, GENETICS, V143, P5; Sharples GJ, 1999, J BACTERIOL, V181, P5543, DOI 10.1128/JB.181.18.5543-5550.1999; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Tanaka T, 2002, J BIOL CHEM, V277, P38062, DOI 10.1074/jbc.M204397200; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	55	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3484	3493		10.1074/jbc.M510979200	http://dx.doi.org/10.1074/jbc.M510979200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16354656	hybrid			2022-12-27	WOS:000235128200058
J	Tsakadze, NL; Sithu, SD; Sen, U; English, WR; Murphy, G; D'Souza, SE				Tsakadze, NL; Sithu, SD; Sen, U; English, WR; Murphy, G; D'Souza, SE			Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; MEMBRANE-PROXIMAL CLEAVAGE; TISSUE INHIBITOR; L-SELECTIN; PROTEOLYTIC RELEASE; SECRETASE CLEAVAGE; CELL-ADHESION; DOMAIN; METALLOPROTEINASE; DISINTEGRIN	Ectodomain shedding has emerged as an important regulatory step in the function of transmembrane proteins. Intercellular adhesion molecule-1 ( ICAM-1), an adhesion receptor that mediates inflammatory and immune responses, undergoes shedding in the presence of inflammatory mediators and phorbol 12-myristate 13-acetate ( PMA). The shedding of ICAM-1 in ICAM-1- transfected 293 cells upon PMA stimulation and in endothelial cells upon tumor necrosis factor-alpha stimulation was blocked by metalloproteinase inhibitors, whereas serine protease inhibitors were ineffective. p-Aminophenylmercuric acetate, a mercuric compound that is known to activate matrix metalloproteinases, up-regulated ICAM-1 shedding. TIMP-3 ( but not TIMP-1 or -2) effectively blocked cleavage. This profile suggests the involvement of the ADAM family of proteases in the cleavage of ICAM-1. The introduction of enzymatically active tumor necrosis factor-alpha-converting enzyme ( TACE) into ICAM-1- expressing cells up-regulated cleavage. Small interfering RNA directed against TACE blocked ICAM-1 cleavage. ICAM-1 transfected into TACE(-/-) fibroblasts did not show increased shedding over constitutive levels in the presence of PMA, whereas cleavage did occur in ICAM-1-transfected TACE(-/-) cells. These results indicate that ICAM-1shedding is mediated by TACE. Blocking the shedding of ICAM-1 altered the cell adhesive function, as ICAM-1- mediated cell adhesion was up-regulated in the presence of TACE small interfering RNA and TIMP-3, but not TIMP-1. However, cleavage was found to occur at multiple sites within the stalk domain of ICAM-1, and numerous point mutations within the region did not affect cleavage, indicating that TACE-mediated cleavage of ICAM-1 may not be sequence-specific.	Univ Louisville, Dept Physiol & Biophys, Hlth Sci Ctr, Louisville, KY 40292 USA; Cambridge Inst Med Res, Dept Oncol, Cambridge CB2 2XY, England; Cambridge Inst Med Res, Addenbrookes Hosp, Cambridge CB2 2XY, England	University of Louisville; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	D'Souza, SE (corresponding author), Univ Louisville, Dept Physiol & Biophys, Hlth Sci Ctr, A-1115,500 S Preston St, Louisville, KY 40292 USA.	sedsou01@gwise.louisville.edu			NHLBI NIH HHS [HL43721] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043721, R01HL043721] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 2002, CHEM REV, V102, P4627, DOI 10.1021/cr010202t; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BELDENT V, 1993, J BIOL CHEM, V268, P26428; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2003, BIOCHEM SOC SYMP, V70, P39, DOI 10.1042/bss0700039; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CARLOS TM, 1994, BLOOD, V84, P2068; Champagne B, 1998, J IMMUNOL, V161, P6398; CHENG HJ, 1994, MOL BIOL CELL, V5, P943, DOI 10.1091/mbc.5.9.943; Eyries M, 2001, J BIOL CHEM, V276, P5525, DOI 10.1074/jbc.M007706200; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Gardiner EE, 1997, J BIOL CHEM, V272, P15474, DOI 10.1074/jbc.272.24.15474; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; Hinkle CL, 2004, J BIOL CHEM, V279, P24179, DOI 10.1074/jbc.M312141200; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; Labarrere CA, 2000, CIRCULATION, V102, P1549, DOI 10.1161/01.CIR.102.13.1549; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Melis M, 2003, AM J RESP CRIT CARE, V167, P1131, DOI 10.1164/rccm.200207-654OC; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; MURPHY G, 1995, METHOD ENZYMOL, V248, P496; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 2001, J CELL SCI, V114, P1213; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Otto VI, 2002, J NEUROCHEM, V80, P824, DOI 10.1046/j.0022-3042.2001.00748.x; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pluskota E, 2000, J BIOL CHEM, V275, P30029, DOI 10.1074/jbc.M000240200; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; Robledo O, 2003, EUR J IMMUNOL, V33, P1351, DOI 10.1002/eji.200323195; ROTHLEIN R, 1991, J IMMUNOL, V147, P3788; Sadhukhan R, 1999, J BIOL CHEM, V274, P10511, DOI 10.1074/jbc.274.15.10511; SBARBA PD, 2002, BIOL CHEM, V383, P69; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schlondorff J, 1999, J CELL SCI, V112, P3603; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TSAKADZE ML, 2004, AM J PHYSIOL, V287, pC55; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200; Zheng YF, 2004, J BIOL CHEM, V279, P42898, DOI 10.1074/jbc.M403193200	57	130	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3157	3164		10.1074/jbc.M510797200	http://dx.doi.org/10.1074/jbc.M510797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332693	hybrid			2022-12-27	WOS:000235128200018
J	Chen, YM; Ferrar, TS; Lohmeir-Vogel, E; Morrice, N; Mizuno, Y; Berenger, B; Ng, KKS; Muench, DG; Moorhead, GBG				Chen, YM; Ferrar, TS; Lohmeir-Vogel, E; Morrice, N; Mizuno, Y; Berenger, B; Ng, KKS; Muench, DG; Moorhead, GBG			The PII signal transduction protein of Arabidopsis thaliana forms an arginine-regulated complex with plastid N-acetyl glutamate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-II PROTEIN; PUTATIVE NITROGEN SENSOR; GLNB GENE-PRODUCT; PHOSPHORYLATION; NITRATE; CARBON; PURIFICATION; EXPRESSION	The PII proteins are key mediators of the cellular response to carbon and nitrogen status and are found in all domains of life. In eukaryotes, PII has only been identified in red algae and plants, and in these organisms, PII localizes to the plastid. PII proteins perform their role by assessing cellular carbon, nitrogen, and energy status and conferring this information to other proteins through protein-protein interaction. We have used affinity chromatography and mass spectrometry to identify the PII-binding proteins of Arabidopsis thaliana. The major PII-interacting protein is the chloroplast-localized enzyme N-acetyl glutamate kinase, which catalyzes the key regulatory step in the pathway to arginine biosynthesis. The interaction of PII with N-acetyl glutamate kinase was confirmed through pull-down, gel filtration, and isothermal titration calorimetry experiments, and binding was shown to be enhanced in the presence of the downstream product, arginine. Enzyme kinetic analysis showed that PII increases N-acetyl glutamate kinase activity slightly, but the primary function of binding is to relieve inhibition of enzyme activity by the pathway product, arginine. Knowing the identity of PII-binding proteins across a spectrum of photosynthetic and non-photosynthetic organisms provides a framework for a more complete understanding of the function of this highly conserved signaling protein.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland	University of Calgary; University of Dundee	Moorhead, GBG (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	moorhead@ucalgary.ca	Ferrar, Tony S/M-6782-2015; Berenger, Byron/M-4761-2019	Ferrar, Tony S/0000-0002-4606-1613; Berenger, Byron/0000-0001-9062-6346; Ng, Kenneth K.S./0000-0001-7280-8445				Aldehni MF, 2003, J BACTERIOL, V185, P2582, DOI 10.1128/JB.185.8.2582-2591.2003; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; Burillo S, 2004, J BACTERIOL, V186, P3346, DOI 10.1128/JB.186.11.3346-3354.2004; Coruzzi GM, 2003, ARABIDOPSIS BOOK; Fernandez-Murga ML, 2004, J BACTERIOL, V186, P6142, DOI 10.1128/JB.186.18.6142-6149.2004; Ferraris S, 2005, 5 INT FOR AL SHIPS, P1; Forchhammer K, 2004, FEMS MICROBIOL REV, V28, P319, DOI 10.1016/j.femsre.2003.11.001; FORCHHAMMER K, 1994, J BACTERIOL, V176, P84, DOI 10.1128/JB.176.1.84-91.1994; Hanson TE, 1998, MICROBIOL-SGM, V144, P1537, DOI 10.1099/00221287-144-6-1537; Heinrich A, 2004, MOL MICROBIOL, V52, P1303, DOI 10.1111/j.1365-2958.2004.04058.x; Hisbergues M, 1999, FEBS LETT, V463, P216, DOI 10.1016/S0014-5793(99)01624-5; Hsieh MH, 1998, P NATL ACAD SCI USA, V95, P13965, DOI 10.1073/pnas.95.23.13965; Lee HM, 2000, EUR J BIOCHEM, V267, P591, DOI 10.1046/j.1432-1327.2000.01043.x; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Magasanik B, 2000, TRENDS MICROBIOL, V8, P447, DOI 10.1016/S0966-842X(00)01849-7; Maheswaran M, 2004, J BIOL CHEM, V279, P55202, DOI 10.1074/jbc.M410971200; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; MOFFATT B, 2002, ARABIDOPSIS BOOK; MOORHEAD G, 1995, FEBS LETT, V362, P101, DOI 10.1016/0014-5793(95)00197-H; Moorhead GBG, 2003, PLANT PHYSIOL, V133, P492, DOI 10.1104/pp.103.025627; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; Ninfa AJ, 2005, CURR OPIN MICROBIOL, V8, P168, DOI 10.1016/j.mib.2005.02.011; Palinska KA, 2002, MICROBIOL-SGM, V148, P2405, DOI 10.1099/00221287-148-8-2405; Paz-Yepes J, 2003, FEBS LETT, V543, P42, DOI 10.1016/S0014-5793(03)00384-3; Smith CS, 2004, BBA-PROTEINS PROTEOM, V1699, P145, DOI 10.1016/j.bbapap.2004.02.009; Smith CS, 2003, PLANT J, V33, P353, DOI 10.1046/j.1365-313X.2003.01634.x; Smith CS, 2002, PROTEIN EXPRES PURIF, V25, P342, DOI 10.1016/S1046-5928(02)00018-9; Sugiyama K, 2004, PLANT CELL PHYSIOL, V45, P1768, DOI 10.1093/pcp/pch199; Templeton GW, 2005, EMBO REP, V6, P723, DOI 10.1038/sj.embor.7400479; Tran HT, 2004, MOL CELL PROTEOMICS, V3, P257, DOI 10.1074/mcp.M300115-MCP200	30	84	92	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5726	5733		10.1074/jbc.M510945200	http://dx.doi.org/10.1074/jbc.M510945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377628	hybrid			2022-12-27	WOS:000235568900050
J	Dresbach, T; Torres, V; Wittenmayer, N; Altrock, WD; Zamorano, P; Zuschratter, W; Nawrotzki, R; Ziv, NE; Garner, CC; Gundelfinger, ED				Dresbach, T; Torres, V; Wittenmayer, N; Altrock, WD; Zamorano, P; Zuschratter, W; Nawrotzki, R; Ziv, NE; Garner, CC; Gundelfinger, ED			Assembly of active zone precursor vesicles - Obligatory trafficking of presynaptic cytomatrix proteins bassoon and piccolo via a trans-Golgi compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-MECHANISMS; BREFELDIN-A; NEUROTRANSMITTER RELEASE; FUNCTIONAL INTERACTION; SYNAPSES; FAMILY; RIM1; SYNAPTOGENESIS; INVOLVEMENT; MEMBRANES	\Neurotransmitter release from presynaptic nerve terminals is restricted to specialized areas of the plasma membrane, so-called active zones. Active zones are characterized by a network of cytoplasmic scaffolding proteins involved in active zone generation and synaptic transmission. To analyze the modes of biogenesis of this cytomatrix, we asked how Bassoon and Piccolo, two prototypic active zone cytomatrix molecules, are delivered to nascent synapses. Although these proteins may be transported via vesicles, little is known about the importance of a vesicular pathway and about molecular determinants of cytomatrix molecule trafficking. We found that Bassoon and Piccolo co-localize with markers of the trans-Golgi network in cultured neurons. Impairing vesicle exit from the Golgi complex, either using brefeldin A, recombinant proteins, or a low temperature block, prevented transport of Bassoon out of the soma. Deleting a newly identified Golgi-binding region of Bassoon impaired subcellular targeting of recombinant Bassoon. Overexpressing this region to specifically block Golgi binding of the endogenous protein reduced the concentration of Bassoon at synapses. These results suggest that, during the period of bulk synaptogenesis, a primordial cytomatrix assembles in a trans-Golgi compartment. They further indicate that transport via Golgi-derived vesicles is essential for delivery of cytomatrix proteins to the synapse. Paradigmatically this establishes Golgi transit as an obligatory step for subcellular trafficking of distinct cytoplasmic scaffolding proteins.	Heidelberg Univ, Inst Anat & Cell Biol, D-69120 Heidelberg, Germany; Leibniz Inst Neurobiol, Dept Neurochem & Mol Biol, D-39118 Magdeburg, Germany; Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; Technion Israel Inst Technol, Fac Med, Dept Physiol, IL-31096 Haifa, Israel	Ruprecht Karls University Heidelberg; Leibniz Institut fur Neurobiologie (LIN); Stanford University; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Gundelfinger, ED (corresponding author), Heidelberg Univ, Inst Anat & Cell Biol, Neuenheimer Feld 307, D-69120 Heidelberg, Germany.	gundelfinger@ifn-magdeburg.de	Ziv, Noam/ABA-6551-2020; Torres, Viviana/AAC-3329-2019	Ziv, Noam/0000-0001-9197-326X; Torres, Viviana/0000-0002-1220-7709; Garner, Craig/0000-0003-1970-5417	NIA NIH HHS [AG 12978-02, AG 06569-09] Funding Source: Medline; NICHD NIH HHS [P30 HD 38985-03, P50 HD 32901] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD038985] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569, R01AG012978] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmari SE, 2000, NAT NEUROSCI, V3, P445, DOI 10.1038/74814; Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Bresler T, 2004, J NEUROSCI, V24, P1507, DOI 10.1523/JNEUROSCI.3819-03.2004; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Dick O, 2003, NEURON, V37, P775, DOI 10.1016/S0896-6273(03)00086-2; Dieck ST, 2005, J CELL BIOL, V168, P825, DOI 10.1083/jcb.200408157; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Dresbach T, 2003, MOL CELL NEUROSCI, V23, P279, DOI 10.1016/S1044-7431(03)00015-0; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Gao YS, 1998, J BIOL CHEM, V273, P33825, DOI 10.1074/jbc.273.50.33825; Garner CC, 2002, TRENDS NEUROSCI, V25, P243, DOI 10.1016/S0166-2236(02)02152-5; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Jareb M, 1997, J NEUROSCI, V17, P8955; Kanaani J, 2004, J CELL SCI, V117, P2001, DOI 10.1242/jcs.01030; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Mossessova E, 2003, MOL CELL, V12, P1403, DOI 10.1016/S1097-2765(03)00475-1; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Polishchuk RS, 2004, CELL MOL LIFE SCI, V61, P146, DOI 10.1007/s00018-003-3353-8; Righter K, 1999, J COMP NEUROL, V408, P437, DOI 10.1002/(SICI)1096-9861(19990607)408:3<437::AID-CNE9>3.0.CO;2-5; Roos J, 2000, NAT NEUROSCI, V3, P415, DOI 10.1038/74773; Rosenmund C, 2003, CURR OPIN NEUROBIOL, V13, P509, DOI 10.1016/j.conb.2003.09.011; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Shapira M, 2003, NEURON, V38, P237, DOI 10.1016/S0896-6273(03)00207-1; Shewan AM, 2003, MOL BIOL CELL, V14, P973, DOI 10.1091/mbc.E02-06-0315; Spang A, 2002, CURR OPIN CELL BIOL, V14, P423, DOI 10.1016/S0955-0674(02)00346-0; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Takao-Rikitsu E, 2004, J CELL BIOL, V164, P301, DOI 10.1083/jcb.200307101; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 2002, P NATL ACAD SCI USA, V99, P14464, DOI 10.1073/pnas.182532999; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Ziv NE, 2004, NAT REV NEUROSCI, V5, P385, DOI 10.1038/nrn1370	40	71	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6038	6047		10.1074/jbc.M508784200	http://dx.doi.org/10.1074/jbc.M508784200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373352	hybrid			2022-12-27	WOS:000235568900085
J	Hanrott, K; Gudmunsen, L; O'Neill, MJ; Wonnacott, S				Hanrott, K; Gudmunsen, L; O'Neill, MJ; Wonnacott, S			d6-Hydroxydopamine- induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-3-DEPENDENT PROTEOLYTIC CLEAVAGE; DOPAMINERGIC NEURONAL CELLS; GLAND ACINAR-CELLS; PC12 CELLS; OXIDATIVE STRESS; PKC-DELTA; TYROSINE PHOSPHORYLATION; PARKINSONS-DISEASE; 6-HYDROXYDOPAMINE-INDUCED APOPTOSIS; SUBSTANTIA-NIGRA	6-Hydroxydopamine is a neurotoxin commonly used to lesion dopaminergic pathways and generate experimental models for Parkinson disease, however, the cellular mechanism of 6-hydroxydopamine-induced neurodegeneration is not well defined. In this study we have explored how 6-hydroxydopamine neurotoxicity is initiated. We have also investigated downstream signaling pathways activated in response to 6-hydroxydopamine, using a neuronal-like, catecholaminergic cell line (PC12 cells) as an in vitro model system. We have shown that 6-hydroxydopamine neurotoxicity is initiated via extracellular auto-oxidation and the induction of oxidative stress from the oxidative products generated. Neurotoxicity is completely attenuated by preincubation with catalase, suggesting that hydrogen peroxide, at least in part, evokes neuronal cell death in this model. 6-Hydroxydopamine does not initiate toxicity by dopamine transporter-mediated uptake into PC12 cells, because both GBR-12909 and nisoxetine ( inhibitors of dopamine and noradrenaline transporters, respectively) failed to reduce toxicity. 6-Hydroxydopamine has previously been shown to induce both apoptotic and necrotic cell-death mechanisms. In this study oxidative stress initiated by 6-hydroxydopamine caused mitochondrial dysfunction, activation of caspases 3/7, nuclear fragmentation, and apoptosis. We have shown that, in this model, proteolytic activation of the proapoptotic protein kinase C delta (PKC delta) is a key mediator of 6-hydroxydopamine-induced cell death. 6-Hydroxydopamine induces caspase 3-dependent cleavage of full-length PKC delta( 79 kDa) to yield a catalytic fragment ( 41 kDa). Inhibition of PKC delta ( with rottlerin or via RNA interference-mediated gene suppression) ameliorates the neurotoxicity evoked by 6-hydroxydopamine, implicating this kinase in 6-hydroxydopamine-induced neurotoxicity and Parkinsonian neurodegeneration.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Eli Lilly & Co Ltd, Windlesham GU20 6PH, Surrey, England	University of Bath; Eli Lilly	Wonnacott, S (corresponding author), Univ Bath, Dept Biol & Biochem, 4 South,Claverton Down, Bath BA2 7AY, Avon, England.	S.Wonnacott@bath.ac.uk						Anantharam V, 2002, J NEUROSCI, V22, P1738, DOI 10.1523/JNEUROSCI.22-05-01738.2002; Berretta N, 2005, NEUROTOXICOLOGY, V26, P869, DOI 10.1016/j.neuro.2005.01.014; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Blum D, 2001, BIOCHEM PHARMACOL, V62, P473, DOI 10.1016/S0006-2952(01)00680-3; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Blum D, 1997, BRAIN RES, V751, P139, DOI 10.1016/S0006-8993(96)01358-3; Blum D, 2000, NEUROSCI LETT, V283, P193, DOI 10.1016/S0304-3940(00)00948-4; BREESE GR, 1970, J PHARMACOL EXP THER, V174, P413; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chudapongse N, 2003, J PHARMACOL SCI, V93, P372, DOI 10.1254/jphs.93.372; Clement MW, 2002, J NEUROCHEM, V81, P414, DOI 10.1046/j.1471-4159.2002.00802.x; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Ding YM, 2004, J NEUROCHEM, V89, P776, DOI 10.1111/j.1471-4159.2004.02415.x; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; Elkon H, 2001, CELL MOL NEUROBIOL, V21, P771, DOI 10.1023/A:1015160323009; Eminel S, 2004, J BIOL CHEM, V279, P55385, DOI 10.1074/jbc.M405858200; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fonck C, 2001, BRAIN RES, V905, P199, DOI 10.1016/S0006-8993(01)02551-3; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Goldberg M, 1996, BIOCHEM PHARMACOL, V51, P1089, DOI 10.1016/0006-2952(96)00046-9; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Han BS, 2003, J NEUROSCI, V23, P5069; Izumi Y, 2005, J NEUROSCI RES, V79, P849, DOI 10.1002/jnr.20382; Jordan J, 2004, J NEUROCHEM, V89, P124, DOI 10.1046/j.1471-4159.2003.02299.x; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kanthasamy AG, 2003, ANTIOXID REDOX SIGN, V5, P609, DOI 10.1089/152308603770310275; Kaul S, 2005, J BIOL CHEM, V280, P28721, DOI 10.1074/jbc.M501092200; Kaul S, 2003, EUR J NEUROSCI, V18, P1387, DOI 10.1046/j.1460-9568.2003.02864.x; Kitazawa M, 2004, NEUROTOXICOLOGY, V25, P589, DOI 10.1016/j.neuro.2003.09.014; Kitazawa M, 2003, NEUROSCIENCE, V119, P945, DOI 10.1016/S0306-4522(03)00226-4; Kohda Y, 2005, J PHARMACOL SCI, V98, P49, DOI 10.1254/jphs.FP0040926; Konishi H, 1999, BIOCHEM BIOPH RES CO, V264, P840, DOI 10.1006/bbrc.1999.1579; Latchoumycandane C, 2005, J PHARMACOL EXP THER, V313, P46, DOI 10.1124/jpet.104.078469; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li LW, 1999, MOL CELL BIOL, V19, P8547; Liang QH, 2004, J NEUROSCI RES, V77, P747, DOI 10.1002/jnr.20198; Liao YF, 2005, LIFE SCI, V77, P707, DOI 10.1016/j.lfs.2005.01.010; LJUNGDAHL A, 1971, EXPERIENTIA, V27, P297, DOI 10.1007/BF02138157; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lotharius J, 1999, J NEUROSCI, V19, P1284; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mazzio EA, 2004, BRAIN RES, V1004, P29, DOI 10.1016/j.brainres.2003.12.034; Miguel BG, 2005, BBA-MOL CELL RES, V1743, P215, DOI 10.1016/j.bbamcr.2004.10.011; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Munoz AM, 2004, J NEUROSCI RES, V76, P551, DOI 10.1002/jnr.20107; Ochu EE, 1998, J NEUROCHEM, V70, P2637; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Scheel-Toellner D, 1999, EUR J IMMUNOL, V29, P2603, DOI 10.1002/(SICI)1521-4141(199908)29:08<2603::AID-IMMU2603>3.0.CO;2-L; Seth K, 2002, NEUROSCI LETT, V330, P89, DOI 10.1016/S0304-3940(02)00714-0; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Takai N, 1998, J NEUROSCI RES, V54, P214, DOI 10.1002/(SICI)1097-4547(19981015)54:2<214::AID-JNR9>3.0.CO;2-H; Tapia JA, 2003, J BIOL CHEM, V278, P35220, DOI 10.1074/jbc.M303119200; Tsao CW, 2002, NEUROIMMUNOMODULAT, V10, P328, DOI 10.1159/000071473; WALKINSHAW G, 1994, NEUROSCIENCE, V63, P975, DOI 10.1016/0306-4522(94)90566-5; Woodgate A, 1999, MOL BRAIN RES, V69, P84, DOI 10.1016/S0169-328X(99)00103-5; Yang YJ, 2004, MOL CELL NEUROSCI, V25, P406, DOI 10.1016/j.mcn.2003.11.011; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698	71	182	202	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5373	5382		10.1074/jbc.M511560200	http://dx.doi.org/10.1074/jbc.M511560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16361258	hybrid			2022-12-27	WOS:000235568900008
J	Hernandez-Gonzalez, EO; Sosnik, J; Edwards, J; Acevedo, JJ; Mendoza-Lujambio, I; Lopez-Gonzalez, I; Demarco, I; Wertheimer, E; Darszon, A; Visconti, PE				Hernandez-Gonzalez, EO; Sosnik, J; Edwards, J; Acevedo, JJ; Mendoza-Lujambio, I; Lopez-Gonzalez, I; Demarco, I; Wertheimer, E; Darszon, A; Visconti, PE			Sodium and epithelial sodium channels participate in the regulation of the capacitation-associated hyperpolarization in mouse sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PROTEIN-TYROSINE PHOSPHORYLATION; MEDIATED SIGNAL-TRANSDUCTION; SPERMATOGENIC CELLS; NA+ CHANNEL; FUNCTIONAL EXPRESSION; CA2+ CHANNELS; ION CHANNELS; ACROSOME REACTION; MAMMALIAN SPERM	In a process called capacitation, mammalian sperm gain the ability to fertilize after residing in the female tract. During capacitation the mouse sperm plasma membrane potential (E-m) hyperpolarizes. However, the mechanisms that regulate sperm E-m are not well understood. Here we show that sperm hyperpolarize when external Na+ is replaced by N-methyl-glucamine. Readdition of external Na+ restores a more depolarized E-m by a process that is inhibited by amiloride or by its more potent derivative 5-(N-ethyl-N-isopropyl)amiloride hydrochloride. These findings indicate that under resting conditions an electrogenic Na+ transporter, possibly involving an amiloride sensitive Na+ channel, may contribute to the sperm resting E-m. Consistent with this proposal, patch clamp recordings from spermatogenic cells reveal an amiloride-sensitive inward Na+ current whose characteristics match those of the epithelial Na+ channel ( ENaC) family of epithelial Na+ channels. Indeed, ENaC-alpha and -delta mRNAs were detected by reverse transcription-PCR in extracts of isolated elongated spermatids, and ENaC-alpha and -delta proteins were found on immunoblots of sperm membrane preparations. Immunostaining indicated localization of ENaC-alpha to the flagellar midpiece and of ENaC-delta to the acrosome. Incubations known to produce capacitation in vitro or induction of capacitation by cell-permeant cAMP analogs decreased the depolarizing response to the addition of external Na+. These results suggest that increases in cAMP content occurring during capacitation may inhibit ENaCs to produce a required hyperpolarization of the sperm membrane.	Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Dev Genet & Mol Physiol, Cuernavaca 62210, Morelos, Mexico; Univ Massachusetts, Dept Vet & Anim Sci, Paige Labs, Amherst, MA 01003 USA; Inst Politecn Nacl, Ctr Res & Adv Studies, Dept Cell Biol, Mexico City 07300, DF, Mexico; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22908 USA; Univ Autonoma Morelos, Sch Med, Dept Physiol & Pathophysiol, Cuernavaca 62210, Morelos, Mexico; Inst Politecn Nacl, Natl Med & Homeopathy Sch, Mol Biomed Postgrad Program, Mexico City 07320, DF, Mexico	Universidad Nacional Autonoma de Mexico; University of Massachusetts System; University of Massachusetts Amherst; Instituto Politecnico Nacional - Mexico; University of Virginia; Universidad Autonoma del Estado de Morelos; Instituto Politecnico Nacional - Mexico	Darszon, A (corresponding author), Univ Nacl Autonoma Mexico, Inst Biotechnol, Dept Dev Genet & Mol Physiol, Ave Univ 2001 Col Chamilpa, Cuernavaca 62210, Morelos, Mexico.	darszon@ibt.unam.mx	Hernández-González, Enrique/AAU-8526-2020; Sosnik, Julian/A-8310-2010; Mendoza-Lujambio, Irene/AAD-6955-2022	Sosnik, Julian/0000-0002-0528-9929; Mendoza-Lujambio, Irene/0000-0002-0677-9946; Darszon, Alberto/0000-0002-2502-0505; Lopez-Gonzalez, Ignacio/0000-0002-1536-0258; Acevedo, Juan Jose/0000-0001-8306-1690	FIC NIH HHS [R03 TW 006121] Funding Source: Medline; NICHD NIH HHS [HD 44044, HD 38082] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD038082, R01HD044044] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW006121] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; Arnoult C, 1996, P NATL ACAD SCI USA, V93, P13004, DOI 10.1073/pnas.93.23.13004; Arnoult C, 1998, MOL PHARMACOL, V53, P1104; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; Awayda MS, 2000, AM J PHYSIOL-CELL PH, V279, pC1896, DOI 10.1152/ajpcell.2000.279.6.C1896; BELLVE AR, 1993, METHOD ENZYMOL, V225, P84; Blanco G, 2003, ANN NY ACAD SCI, V986, P536, DOI 10.1111/j.1749-6632.2003.tb07245.x; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Castellano LE, 2003, FEBS LETT, V541, P69, DOI 10.1016/S0014-5793(03)00305-3; Darboux I, 1998, J BIOL CHEM, V273, P9424, DOI 10.1074/jbc.273.16.9424; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Delmas P, 2004, FASEB J, V18, P740, DOI 10.1096/fj.03-0319fje; Demarco IA, 2003, J BIOL CHEM, V278, P7001, DOI 10.1074/jbc.M206284200; ESPINOSA F, 1995, FEBS LETT, V372, P119, DOI 10.1016/0014-5793(95)00962-9; Ficarro S, 2003, J BIOL CHEM, V278, P11579, DOI 10.1074/jbc.M202325200; Florman HM, 1998, BIOL REPROD, V59, P12, DOI 10.1095/biolreprod59.1.12; Gamper N, 2000, PFLUG ARCH EUR J PHY, V441, P281, DOI 10.1007/s004240000410; Gong XD, 2001, MOL HUM REPROD, V7, P705, DOI 10.1093/molehr/7.8.705; Gonzalez-Martinez MT, 2003, J BIOL CHEM, V278, P36304, DOI 10.1074/jbc.M304479200; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hernandez-Gonzalez EO, 2000, CELL MOTIL CYTOSKEL, V46, P43, DOI 10.1002/(SICI)1097-0169(200005)46:1&lt;43::AID-CM5&gt;3.0.CO;2-1; Inagaki A, 2004, AM J PHYSIOL-CELL PH, V286, pC380, DOI 10.1152/ajpcell.00373.2003; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Ji HL, 2004, J BIOL CHEM, V279, P26939, DOI 10.1074/jbc.M401143200; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; KALAB P, 1994, J BIOL CHEM, V269, P3810; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kierszenbaum AL, 2004, MOL REPROD DEV, V67, P385, DOI 10.1002/mrd.20042; Konig J, 2001, EMBO REP, V2, P1047, DOI 10.1093/embo-reports/kve232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lievano A, 1996, FEBS LETT, V388, P150, DOI 10.1016/0014-5793(96)00515-7; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; Lopez-Gonzalez I, 2001, DEV BIOL, V236, P210, DOI 10.1006/dbio.2001.0314; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; MOORE GD, 1994, DEVELOPMENT, V120, P3313; Munoz-Garay C, 2001, DEV BIOL, V234, P261, DOI 10.1006/dbio.2001.0196; Narahashi T, 2002, MINI-REV MED CHEM, V2, P419, DOI 10.2174/1389557023405927; Patrat C, 2000, BIOL CELL, V92, P255, DOI 10.1016/S0248-4900(00)01072-8; Santi CM, 1996, AM J PHYSIOL-CELL PH, V271, pC1583, DOI 10.1152/ajpcell.1996.271.5.C1583; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; Schreiber R, 2003, J MEMBRANE BIOL, V192, P101, DOI 10.1007/s00232-002-1067-8; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Trevino CL, 2004, FEBS LETT, V563, P87, DOI 10.1016/S0014-5793(04)00257-1; Trevino CL, 2001, FEBS LETT, V509, P119, DOI 10.1016/S0014-5793(01)03134-9; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; Visconti PE, 1999, J BIOL CHEM, V274, P3235, DOI 10.1074/jbc.274.5.3235; Visconti PE, 2002, J REPROD IMMUNOL, V53, P133, DOI 10.1016/S0165-0378(01)00103-6; VISCONTI PE, 1995, DEVELOPMENT, V121, P1129; Visconti PE, 1999, DEV BIOL, V214, P429, DOI 10.1006/dbio.1999.9428; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; Wennemuth G, 2003, J GEN PHYSIOL, V122, P115, DOI 10.1085/jgp.200308839; Wright SH, 2004, ADV PHYSIOL EDUC, V28, P139, DOI 10.1152/advan.00029.2004; Yamamura H, 2004, J BIOL CHEM, V279, P12529, DOI 10.1074/jbc.M400274200; Yanagimachi R., 1994, P189; Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207; ZENG Y, 1995, DEV BIOL, V171, P554, DOI 10.1006/dbio.1995.1304	60	99	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5623	5633		10.1074/jbc.M508172200	http://dx.doi.org/10.1074/jbc.M508172200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407190	hybrid			2022-12-27	WOS:000235568900038
J	Sun, MX; Oakes, JL; Ananthanarayanan, SK; Hawley, KH; Tsien, RY; Adams, SR; Yengo, CM				Sun, MX; Oakes, JL; Ananthanarayanan, SK; Hawley, KH; Tsien, RY; Adams, SR; Yengo, CM			Dynamics of the upper 50-kDa domain of myosin V examined with fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; F-ACTIN; BINDING; MECHANISM; MOVEMENT; RELEASE; COMPLEX; CLEFT; MOTOR	The upper 50-kDa region of myosin may be critical for coupling between the nucleotide- and actin-binding regions. We introduced a tetracysteine motif in the upper 50-kDa domain ( residues 292 297) of myosin V containing a single IQ domain (MV 1IQ), allowing us to label this site with the fluorescein biarscenical hairpin-binding dye (FlAsH) (MV1IQ FlAsH). The enzymatic properties of MV 1IQ FlAsH were similar to those of unlabeled MV 1IQ except for a 3-fold reduced ADP-release rate. MV1IQ FlAsH was also capable of moving actin filaments in the in vitro motility assay. To examine rotation of the upper 50-kDa region, we determined the difference in the degree of energy transfer from N-methylanthraniloyl ( mant)-labeled nucleotides to FlAsH in both steady-state and transient kinetic experiments. The energy transfer efficiency was higher with mant-ATP (0.65 +/- 0.02) compared with mant-ADP (0.55 +/- 0.02) in the absence of actin. Stopped- flow measurements suggested that the energy transfer efficiency decreased with phosphate release (0.04 s(-1)) in the absence of actin. In contrast, upon mixing MV 1IQ FlAsH in the ADP.P-i state with actin, a decrease in the energy transfer signal was observed at a rate of 13 s(-1), similar to the ADP release rate. Our results demonstrate there was no change in the energy transfer signal upon actin-activated phosphate release and suggest that actin binding alters the dynamics of the upper 50-kDa region, which may be critical for the ability of myosin to bind tightly to both ADP and actin.	Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of North Carolina; University of North Carolina Charlotte; University of California System; University of California San Diego	Yengo, CM (corresponding author), Univ N Carolina, Dept Biol, Charlotte, NC 28223 USA.	cmyengo@email.uncc.edu						Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; CLEGG RM, 1992, METHOD ENZYMOL, V211, P353; Conibear PB, 2004, BIOCHEMISTRY-US, V43, P15404, DOI 10.1021/bi048338j; Conibear PB, 2003, NAT STRUCT BIOL, V10, P831, DOI 10.1038/nsb986; Coureux PD, 2004, EMBO J, V23, P4527, DOI 10.1038/sj.emboj.7600458; Coureux PD, 2003, NATURE, V425, P419, DOI 10.1038/nature01927; De la Cruz EM, 2000, BIOPHYS J, V79, P1524, DOI 10.1016/S0006-3495(00)76403-4; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Holmes KC, 2004, PHILOS T ROY SOC B, V359, P1819, DOI 10.1098/rstb.2004.1566; Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005; Ignatova Z, 2004, P NATL ACAD SCI USA, V101, P523, DOI 10.1073/pnas.0304533101; KRON SJ, 1991, METHOD ENZYMOL, V196, P399; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lawson JD, 2004, BIOPHYS J, V86, P3794, DOI 10.1529/biophysj.103.037390; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Robia SL, 2005, BIOCHEMISTRY-US, V44, P4302, DOI 10.1021/bi0478446; Rosenfeld SS, 2005, J BIOL CHEM, V280, P6072, DOI 10.1074/jbc.M412717200; ROSENFELD SS, 1994, J BIOL CHEM, V269, P30187; Sellers J. R., 1999, MYOSINS; Takagi Y, 2004, PHILOS T R SOC B, V359, P1913, DOI 10.1098/rstb.2004.1561; Tiago T, 2004, BIOCHEMISTRY-US, V43, P5551, DOI 10.1021/bi049910+; Volkmann N, 2000, NAT STRUCT BIOL, V7, P1147; Yengo CM, 2000, J BIOL CHEM, V275, P25481, DOI 10.1074/jbc.M002910200; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, J BIOL CHEM, V277, P24114, DOI 10.1074/jbc.M111253200; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u	35	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5711	5717		10.1074/jbc.M508103200	http://dx.doi.org/10.1074/jbc.M508103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377637	hybrid			2022-12-27	WOS:000235568900048
J	Wee, G; Koo, DB; Song, BS; Kim, JS; Kang, MJ; Moon, SJ; Kang, YK; Lee, KK; Han, YM				Wee, G; Koo, DB; Song, BS; Kim, JS; Kang, MJ; Moon, SJ; Kang, YK; Lee, KK; Han, YM			Inheritable histone H4 acetylation of somatic chromatins in cloned embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; IN-VITRO; NUCLEAR TRANSFER; DNA METHYLATION; IMPRINTED GENES; MOUSE; CELL; ABERRANT; H1	A viable cloned animal indicates that epigenetic status of the differentiated cell nucleus is reprogrammed to an embryonic totipotent state. However, molecular events regarding epigenetic reprogramming of the somatic chromatin are poorly understood. Here we provide new insight that somatic chromatins are refractory to reprogramming of histone acetylation during early development. A low level of acetylated histone H4-lysine 5 (AcH4K5) of the somatic chromatin was sustained at the pronuclear stage. Unlike in vitro fertilized (IVF) embryos, the AcH4K5 level remarkably reduced at the 8-cell stage in cloned bovine embryos. The AcH4K5 status of somatic chromatins transmitted to cloned and even recloned embryos. Differences of AcH4K5 signal intensity were more distinguishable in the metaphase chromosomes between IVF and cloned embryos. Two imprinted genes, Ndn and Xist, were aberrantly expressed in cloned embryos as compared with IVF embryos, which is partly associated with the AcH4K5 signal intensity. Our findings suggest that abnormal epigenetic reprogramming in cloned embryos may be because of a memory mechanism, the epigenetic status itself of somatic chromatins.	KRIBB, Lab Dev & Differentiat, Taejon 305806, South Korea; Chonnam Natl Univ, Dept Anim Sci, Kwangju 500757, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chonnam National University	Han, YM (corresponding author), 52 Eoeun Dong, Taejon 305806, South Korea.	ymhan@kribb.re.kr	Han, Yong-Mahn/C-1652-2011					Adenot PG, 1997, DEVELOPMENT, V124, P4615; Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; Aoki F, 1997, DEV BIOL, V181, P296, DOI 10.1006/dbio.1996.8466; BAVISTER BD, 1977, BIOL REPROD, V16, P228, DOI 10.1095/biolreprod16.2.228; Boiani M, 2002, GENE DEV, V16, P1209, DOI 10.1101/gad.966002; Bordignon V, 1999, BIOL REPROD, V61, P22, DOI 10.1095/biolreprod61.1.22; BOUNIOL C, 1995, EXP CELL RES, V218, P57, DOI 10.1006/excr.1995.1130; Bourc'his D, 2001, CURR BIOL, V11, P1542, DOI 10.1016/S0960-9822(01)00480-8; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; Clarke HJ, 1997, J CELL SCI, V110, P477; Dean W, 2001, P NATL ACAD SCI USA, V98, P13734, DOI 10.1073/pnas.241522698; Eggan K, 2000, SCIENCE, V290, P1578, DOI 10.1126/science.290.5496.1578; Gao SR, 2004, DEV BIOL, V266, P62, DOI 10.1016/j.ydbio.2003.10.003; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hu JF, 2000, ENDOCRINOLOGY, V141, P4428, DOI 10.1210/en.141.12.4428; Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399; Hyttel P, 1996, J REPROD FERTIL, V108, P263, DOI 10.1530/jrf.0.1080263; Inoue K, 2002, SCIENCE, V295, P297, DOI 10.1126/science.295.5553.297; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kang YK, 2001, NAT GENET, V28, P173, DOI 10.1038/88903; Kang YK, 2003, CURR OPIN CELL BIOL, V15, P290, DOI 10.1016/S0955-0674(03)00031-0; Kang YK, 2002, EMBO J, V21, P1092, DOI 10.1093/emboj/21.5.1092; Kim JM, 2003, J CELL BIOL, V162, P37, DOI 10.1083/jcb.200303047; KOPECNY V, 1989, Molecular Reproduction and Development, V1, P79; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; LATHAM KE, 1991, DEVELOPMENT, V112, P921; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; MacDonald HR, 1997, HUM MOL GENET, V6, P1873, DOI 10.1093/hmg/6.11.1873; Memili E, 1998, MOL REPROD DEV, V51, P36, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;36::AID-MRD4&gt;3.0.CO;2-X; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Ohgane J, 2001, GENESIS, V30, P45, DOI 10.1002/gene.1031; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Peippo JP, 2002, MOL HUM REPROD, V8, P923, DOI 10.1093/molehr/8.10.923; Pfister-Genskow M, 2005, BIOL REPROD, V72, P546, DOI 10.1095/biolreprod.104.031799; Ruddock NT, 2004, BIOL REPROD, V70, P1131, DOI 10.1095/biolreprod.103.022236; Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567; Shiels PG, 1999, NATURE, V399, P316, DOI 10.1038/20580; Svensson K, 1998, DEVELOPMENT, V125, P61; Teranishi T, 2004, DEV BIOL, V266, P76, DOI 10.1016/j.ydbio.2003.10.004; THOMPSON EM, 1995, DEVELOPMENT, V121, P3425; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Turner BM, 1998, CELL MOL LIFE SCI, V54, P21, DOI 10.1007/s000180050122; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Viuff D, 1996, MOL REPROD DEV, V43, P171, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;171::AID-MRD6&gt;3.0.CO;2-O; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WORRAD DM, 1995, DEVELOPMENT, V121, P2949; Wrenzycki C, 2001, BIOL REPROD, V65, P309, DOI 10.1095/biolreprod65.1.309; Xue F, 2002, NAT GENET, V31, P216, DOI 10.1038/ng900; Yang L, 2005, MOL REPROD DEV, V71, P431, DOI 10.1002/mrd.20311; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155; Zhang KL, 2002, MOL CELL PROTEOMICS, V1, P500, DOI 10.1074/mcp.M200031-MCP200	55	103	119	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6048	6057		10.1074/jbc.M511340200	http://dx.doi.org/10.1074/jbc.M511340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16371357	hybrid			2022-12-27	WOS:000235568900086
J	Grabolle, M; Haumann, M; Muller, C; Liebisch, P; Dau, H				Grabolle, M; Haumann, M; Muller, C; Liebisch, P; Dau, H			Rapid loss of structural motifs in the manganese complex of oxygenic photosynthesis by x-ray irradiation at 10-300 K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II MEMBRANE-PARTICLES; PHOTOSYSTEM-II; RADIATION-DAMAGE; ABSORPTION SPECTROSCOPY; CRYSTAL-STRUCTURE; PROTEIN CRYSTALS; EVOLVING COMPLEX; OXIDATION-STATE; CENTERED OXIDATION; GLASS-TRANSITION	Structural changes upon photoreduction caused by x-ray irradiation of the water-oxidizing tetramanganese complex of photosystem II were investigated by x-ray absorption spectroscopy at the manganese K-edge. Photoreduction was directly proportional to the x-ray dose. It was faster in the higher oxidized S-2 state than in S-1; seemingly the oxidizing potential of the metal site governs the rate. X-ray irradiation of the S-1 state at 15 K initially caused single-electron reduction to S-0* accompanied by the conversion of one di-mu-oxo bridge between manganese atoms, previously separated by similar to 2.7 angstrom, to a mono-mu-oxo motif. Thereafter, manganese photoreduction was 100 times slower, and the biphasic increase in its rate between 10 and 300 K with a breakpoint at similar to 200 K suggests that protein dynamics is rate-limiting the radical chemistry. For photoreduction at similar x-ray doses as applied in protein crystallography, halfway to the final Mn-4(II) state the complete loss of inter-manganese distances < 3 angstrom was observed, even at 10 K, because of the destruction of mu-oxo bridges between manganese ions. These results put into question some structural attributions from recent protein crystallography data on photosystem II. It is proposed to employ controlled x-ray photoreduction in metalloprotein research for: (i) population of distinct reduced states, (ii) estimating the redox potential of buried metal centers, and (iii) research on protein dynamics.	Free Univ Berlin, FB Phys, D-14195 Berlin, Germany	Free University of Berlin	Dau, H (corresponding author), Free Univ Berlin, FB Phys, Arnimallee 14, D-14195 Berlin, Germany.	holger.dau@physik.fu-berlin.de	MIchael, Haumann/A-7087-2013	Dau, Holger/0000-0001-6482-7494				ANGELL CA, 1995, P NATL ACAD SCI USA, V92, P6675, DOI 10.1073/pnas.92.15.6675; Baldwin MJ, 1999, INORG CHEM, V38, P4801, DOI 10.1021/ic990346e; Berglund GI, 2002, NATURE, V417, P463, DOI 10.1038/417463a; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Burmeister WP, 2000, ACTA CRYSTALLOGR D, V56, P328, DOI 10.1107/S0907444999016261; Carugo O, 2005, TRENDS BIOCHEM SCI, V30, P213, DOI 10.1016/j.tibs.2005.02.009; Chamorovsky SK, 2003, EUR BIOPHYS J BIOPHY, V32, P537, DOI 10.1007/s00249-003-0289-8; CHANCE B, 1982, ANAL BIOCHEM, V124, P248, DOI 10.1016/0003-2697(82)90035-5; Cinco RM, 2002, BIOCHEMISTRY-US, V41, P12928, DOI 10.1021/bi026569p; Dau H, 1997, J PHYS IV, V7, P607, DOI 10.1051/jp4/1997112; Dau H, 2005, PHOTOSYNTH RES, V84, P325, DOI 10.1007/s11120-004-7080-2; Dau H, 2003, ANAL BIOANAL CHEM, V376, P562, DOI 10.1007/s00216-003-1982-2; Dau H, 2004, PHYS CHEM CHEM PHYS, V6, P4781, DOI 10.1039/b408146c; Dau H, 2001, BBA-BIOENERGETICS, V1503, P24, DOI 10.1016/S0005-2728(00)00230-9; Dau H, 2005, PHYS SCRIPTA, VT115, P844; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DISMUKES GC, 1981, P NATL ACAD SCI-BIOL, V78, P274, DOI 10.1073/pnas.78.1.274; Dittmer J, 1998, J PHYS CHEM B, V102, P8196, DOI 10.1021/jp981049i; DITTMER J, 1999, THESIS CHRISTIAN ALB; DOSTER W, 1989, NATURE, V337, P754, DOI 10.1038/337754a0; FERRAND M, 1993, P NATL ACAD SCI USA, V90, P9668, DOI 10.1073/pnas.90.20.9668; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Garman E, 2003, CURR OPIN STRUC BIOL, V13, P545, DOI 10.1016/j.sbi.2003.09.013; GONZALEZ A, 1994, ACTA CRYSTALLOGR D, V50, P874, DOI 10.1107/S0907444994006311; Haumann M, 2005, BIOCHEMISTRY-US, V44, P1894, DOI 10.1021/bi048697e; Haumann M, 2005, J SYNCHROTRON RADIAT, V12, P35, DOI 10.1107/S0909049504027803; Haumann M, 2002, FEBS LETT, V512, P116, DOI 10.1016/S0014-5793(02)02237-8; HAUMANN M, 1996, OXYGENIC PHOTOSYNTHE, P213; Huang P, 2002, J INORG BIOCHEM, V91, P159, DOI 10.1016/S0162-0134(02)00394-X; Hubbell JH, 1999, PHYS MED BIOL, V44, pR1, DOI 10.1088/0031-9155/44/1/001; Iuzzolino L, 1998, BIOCHEMISTRY-US, V37, P17112, DOI 10.1021/bi9817360; JONES GDD, 1987, NATURE, V330, P772, DOI 10.1038/330772a0; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Keppler C, 2000, EUR BIOPHYS J BIOPHY, V29, P146, DOI 10.1007/s002490050260; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; Koningsberger DC, 2000, TOP CATAL, V10, P143, DOI 10.1023/A:1019105310221; Kuhn P, 2005, PHOTOSYNTH RES, V84, P317, DOI 10.1007/s11120-004-7079-8; Lee AL, 2001, NATURE, V411, P501, DOI 10.1038/35078119; Li J, 1999, INORG CHEM, V38, P929, DOI 10.1021/ic980731o; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; McEvoy JP, 2004, PHYS CHEM CHEM PHYS, V6, P4754, DOI 10.1039/b407500e; Meinke C, 2000, BIOCHEMISTRY-US, V39, P7033, DOI 10.1021/bi9924258; Messinger J, 2001, J AM CHEM SOC, V123, P7804, DOI 10.1021/ja004307+; NUGENT JHA, 2001, BIOCH BIOPHYS ACTA, V1503; Palenik GJ, 1997, INORG CHEM, V36, P4888, DOI 10.1021/ic9705554; PARAK F, 1982, J MOL BIOL, V161, P177, DOI 10.1016/0022-2836(82)90285-6; Persson P, 2001, PROTEIN SCI, V10, P2480, DOI 10.1110/ps.ps.26201; Pospisil P, 2003, BIOPHYS J, V84, P1370, DOI 10.1016/S0006-3495(03)74952-2; Ravelli RBG, 2000, STRUCTURE, V8, P315, DOI 10.1016/S0969-2126(00)00109-X; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Robblee JH, 2002, J AM CHEM SOC, V124, P7459, DOI 10.1021/ja011621a; Robblee JH, 2001, BBA-BIOENERGETICS, V1503, P7, DOI 10.1016/S0005-2728(00)00217-6; SAYGIN O, 1985, PHOTOBIOCH PHOTOBIOP, V10, P71; Schiller H, 2000, J PHOTOCH PHOTOBIO B, V55, P138, DOI 10.1016/S1011-1344(00)00036-1; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; Scott R.A, 2000, PHYS METHODS BIOINOR, P465; Sliz P, 2003, STRUCTURE, V11, P13, DOI 10.1016/S0969-2126(02)00910-3; Sole VA, 1999, J SYNCHROTRON RADIAT, V6, P174, DOI 10.1107/S0909049598017531; Teeter MM, 2001, P NATL ACAD SCI USA, V98, P11242, DOI 10.1073/pnas.201404398; Telser J, 2001, J AM CHEM SOC, V123, P5853, DOI 10.1021/ja010428d; Teng TY, 2000, J SYNCHROTRON RADIAT, V7, P313, DOI 10.1107/S0909049500008694; VASS I, 1991, BIOCHEMISTRY-US, V30, P830, DOI 10.1021/bi00217a037; Weik M, 2003, EUR PHYS J E, V12, P153, DOI 10.1140/epje/i2003-10043-5; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623; Yano J, 2005, P NATL ACAD SCI USA, V102, P12047, DOI 10.1073/pnas.0505207102; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	66	165	170	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4580	4588		10.1074/jbc.M509724200	http://dx.doi.org/10.1074/jbc.M509724200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16352605	hybrid			2022-12-27	WOS:000235426200005
J	Petrushenko, ZM; Lai, CH; Rai, R; Rybenkov, VV				Petrushenko, ZM; Lai, CH; Rai, R; Rybenkov, VV			DNA reshaping by MukB - Right-handed knotting, left-handed supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SMC PROTEINS; CHROMOSOME CONDENSATION; STRUCTURAL MAINTENANCE; ELECTRON-MICROSCOPY; MITOTIC CHROMOSOME; COHESIN COMPLEX; TOPOISOMERASE-I; ATP HYDROLYSIS; 13S CONDENSIN	MukB is a bacterial SMC (structural maintenance of chromosome) protein required for faithful chromosome segregation in Escherichia coli. We report here that purified MukB introduces right-handed knots into DNA in the presence of type-2 topoisomerase, indicating that the protein promotes intramolecular DNA condensation. The pattern of generated knots suggests that MukB, similar to eukaryotic condensins, stabilizes large right-handed DNA loops. In contrast to eukaryotic condensins, however, the net supercoiling stabilized by MukB was negative. Furthermore, DNA reshaping by MukB did not require ATP. These data establish that bacterial condensins alter the shape of double-stranded DNA in vitro and lend support to the notions that the right-handed knotting is the most conserved biochemical property of condensins. Finally, we found that MukB can be eluted from a heparin column in two distinct forms, one of which is inert in DNA binding or reshaping. Furthermore, we find that the activity of MukB is reversibly attenuated during chromatographic separation. Thus, MukB has a unique set of topological properties, compared with other SMC proteins, and is likely to exist in two different conformations.	Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of Oklahoma System; University of Oklahoma - Norman	Rybenkov, VV (corresponding author), Univ Oklahoma, Dept Chem & Biochem, 620 Parrington Oval, Norman, OK 73019 USA.	valya@ou.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063786] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63786, R01 GM063786] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi S, 2003, J BACTERIOL, V185, P3690, DOI 10.1128/JB.185.13.3690-3695.2003; Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002; Arumugam P, 2003, CURR BIOL, V13, P1941, DOI 10.1016/j.cub.2003.10.036; Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; COZZARELLI NR, 1990, DNA TOPOLOGY BIOL EF; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; delaRoche MA, 1997, ARCH BIOCHEM BIOPHYS, V344, P159, DOI 10.1006/abbi.1997.0203; DYNAN WS, 1981, J BIOL CHEM, V256, P5860; Gill G, 1997, CHEM RES TOXICOL, V10, P302, DOI 10.1021/tx960170i; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano M, 2004, EMBO J, V23, P2664, DOI 10.1038/sj.emboj.7600264; Hirano M, 2002, EMBO J, V21, P5733, DOI 10.1093/emboj/cdf575; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Holmes VF, 2000, P NATL ACAD SCI USA, V97, P1322, DOI 10.1073/pnas.040576797; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Kimura K, 1999, CELL, V98, P239, DOI 10.1016/S0092-8674(00)81018-1; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Lammens A, 2004, CURR BIOL, V14, P1778, DOI 10.1016/j.cub.2004.09.044; Losada A, 2001, CURR BIOL, V11, P268, DOI 10.1016/S0960-9822(01)00066-5; Matoba K, 2005, BIOCHEM BIOPH RES CO, V333, P694, DOI 10.1016/j.bbrc.2005.05.163; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; NIKI H, 1992, EMBO J, V11, P5101, DOI 10.1002/j.1460-2075.1992.tb05617.x; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; Sawitzke JA, 2000, P NATL ACAD SCI USA, V97, P1671, DOI 10.1073/pnas.030528397; Schleiffer A, 2003, MOL CELL, V11, P571, DOI 10.1016/S1097-2765(03)00108-4; Soppa J, 2002, MOL MICROBIOL, V45, P59, DOI 10.1046/j.1365-2958.2002.03012.x; Stray JE, 2005, J BIOL CHEM, V280, P34723, DOI 10.1074/jbc.M506589200; Stray JE, 2003, J BIOL CHEM, V278, P26238, DOI 10.1074/jbc.M302699200; Strunnikov AV, 1999, EUR J BIOCHEM, V263, P6, DOI 10.1046/j.1432-1327.1999.00509.x; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Vologodskii A, 1996, BIOPHYS J, V70, P2548, DOI 10.1016/S0006-3495(96)79826-0; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; Weitao T, 1999, MOL MICROBIOL, V34, P157, DOI 10.1046/j.1365-2958.1999.01589.x; Weitzer S, 2003, CURR BIOL, V13, P1930, DOI 10.1016/j.cub.2003.10.030; Yamanaka K, 1996, MOL GEN GENET, V250, P241; Yamazoe M, 1999, EMBO J, V18, P5873, DOI 10.1093/emboj/18.21.5873; Zechiedrich EL, 1999, METH MOL B, V94, P99	47	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4606	4615		10.1074/jbc.M504754200	http://dx.doi.org/10.1074/jbc.M504754200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16368697	Green Accepted, hybrid			2022-12-27	WOS:000235426200008
J	Deb, C; Daniel, J; Sirakova, TD; Abomoelak, B; Dubey, VS; Kolattukudy, PE				Deb, C; Daniel, J; Sirakova, TD; Abomoelak, B; Dubey, VS; Kolattukudy, PE			A novel lipase belonging to the hormone-sensitive lipase family induced under starvation to utilize stored triacylglycerol in Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FATTY-ACIDS; PERSISTENCE; EXPRESSION; ESTERASE; GENE; BIOLOGY	Twenty-four putative lipase/esterase genes of Mycobacterium tuberculosis H37Rv were expressed in Escherichia coli and assayed for long-chain triacylglycerol (TG) hydrolase activity. We show here that the product of Rv3097c (LIPY) hydrolyzed long-chain TG with high specific activity. LIPY was purified after solubilization from inclusion bodies; the enzyme displayed a K-m of 7.57 mM and V-max of 653.3 nmol/mg/min for triolein with optimal activity between pH 8.0 and pH 9.0. LIPY was inhibited by active serine-directed reagents and was inactivated at temperatures above 37 degrees C. Detergents above their critical micellar concentrations and divalent cations inhibited the activity of LIPY. The N-terminal half of LIPY showed sequence homology with the proline glutamic acid-polymorphic GC-rich repetitive sequences protein family of M. tuberculosis. The C-terminal half of LIPY possesses amino acid domains homologous with the hormone-sensitive lipase family and the conserved active-site motif GDSAG. LIPY shows low sequence identity with the annotated lipases of M. tuberculosis and with other bacterial lipases. We demonstrate that hypoxic cultures of M. tuberculosis, which had accumulated TG, hydrolyzed the stored TG when subjected to nutrient starvation. Under such conditions, lipY was induced more than all lipases, suggesting a central role for it in the utilization of stored TG. We also show that in the lipY-deficient mutant, TG utilization was drastically decreased under nutrient-deprived condition. Thus, LIPY may be responsible for the utilization of stored TG during dormancy and reactivation of the pathogen.	Univ Cent Florida, Burnett Coll Biomed Sci, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Kolattukudy, PE (corresponding author), Univ Cent Florida, Burnett Coll Biomed Sci, Orlando, FL 32816 USA.	pk@mail.ucf.edu	kolattukudy, pappachan e/A-1350-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046582, R01AI035272] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35272, R01 AI035272, AI46582, R01 AI046582] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arpigny JL, 1999, BIOCHEM J, V343, P177, DOI 10.1042/0264-6021:3430177; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; BELFRAGE P, 1969, J LIPID RES, V10, P341; Bentrup KHZ, 2001, TRENDS MICROBIOL, V9, P597, DOI 10.1016/S0966-842X(01)02238-7; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Brennan MJ, 2002, TRENDS MICROBIOL, V10, P246, DOI 10.1016/S0966-842X(02)02335-1; Canaan S, 2004, EUR J BIOCHEM, V271, P3953, DOI 10.1111/j.1432-1033.2004.04335.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Danelishvili L, 2004, FEMS MICROBIOL LETT, V239, P41, DOI 10.1016/j.femsle.2004.08.014; Daniel J, 2004, J BACTERIOL, V186, P5017, DOI 10.1128/jb.186.15.5017-5030.2004; Dannenberg Arthur M. Jr., 1994, P459; De Simone G, 2001, J MOL BIOL, V314, P507, DOI 10.1006/jmbi.2001.5152; Derbyshire KM, 2000, MOLECULAR GENETICS OF MYCOBACTERIA, P93; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Fisher MA, 2002, J BACTERIOL, V184, P4025, DOI 10.1128/JB.184.14.4025-4032.2002; Hotelier T, 2004, NUCLEIC ACIDS RES, V32, pD145, DOI 10.1093/nar/gkh141; JACKSON SK, 1989, BRIT J EXP PATHOL, V70, P435; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; KOLATTUKUDY PE, 1984, LIPASES, P47; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; Munoz-Elias EJ, 2005, NAT MED, V11, P638, DOI 10.1038/nm1252; PAZNOKAS JL, 1977, BIOCHIM BIOPHYS ACTA, V487, P405, DOI 10.1016/0005-2760(77)90212-0; Russell DG, 2003, NAT CELL BIOL, V5, P776, DOI 10.1038/ncb0903-776; SEGAL W, 1956, J BACTERIOL, V72, P132, DOI 10.1128/JB.72.2.132-141.1956; Sirakova TD, 2001, J BIOL CHEM, V276, P16833, DOI 10.1074/jbc.M011468200; Vereecke D, 2002, TRENDS MICROBIOL, V10, P485, DOI 10.1016/S0966-842X(02)02457-5; Voskuil MI, 2004, TUBERCULOSIS, V84, P256, DOI 10.1016/j.tube.2003.12.014; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139; Wei YY, 1999, NAT STRUCT BIOL, V6, P340; *WHO, 2005, GLOB ACT CANC NOW, P24; *WHO IUATLD GLOB P, 2004, ANT DRUG RES WORLD 3, P13; Zahrt TC, 2003, MICROBES INFECT, V5, P159, DOI 10.1016/S1286-4579(02)00083-7; Zhang M, 2005, PROTEIN EXPRES PURIF, V42, P59, DOI 10.1016/j.pep.2005.03.022	33	212	224	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3866	3875		10.1074/jbc.M505556200	http://dx.doi.org/10.1074/jbc.M505556200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16354661	hybrid, Green Accepted, Green Published			2022-12-27	WOS:000235275300014
J	Hallows, KR; Fitch, AC; Richardson, CA; Reynolds, PR; Clancy, JP; Dagher, PC; Witters, LA; Kolls, JK; Pilewski, JM				Hallows, KR; Fitch, AC; Richardson, CA; Reynolds, PR; Clancy, JP; Dagher, PC; Witters, LA; Kolls, JK; Pilewski, JM			Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; C-SRC; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; UPSTREAM KINASE; LUNG; EXPRESSION; CFTR; TRANSPORT; GROWTH; BETA	AMP-activatedkinase (AMPK) is a ubiquitous metabolic sensor that inhibits the cystic fibrosis (CF) transmembrane conductance regulator (CFTR). To determine whether CFTR reciprocally regulates AMPK function in airway epithelia and whether such regulation is involved in lung inflammation, AMPK localization, expression, and activity and cellular metabolic profiles were compared as a function of CFTR status in CF and non-CF primary human bronchial epithelial (HBE) cells. As compared with non-CF HBE cells, CF cells had greater and more diffuse AMPK staining and had greater AMPK activity than their morphologically matched non-CF counterparts. The cellular [AMP]/[ATP] ratio was higher in undifferentiated than in differentiated non-CF cells, which correlated with AMPK activity under these conditions. However, this nucleotide ratio did not predict AMPK activity in differentiating CF cells. Inhibiting channel activity in non-CF cells did not affect AMPK activity or metabolic status, but expressing functional CFTR in CF cells reduced AMPK activity without affecting cellular [AMP]/[ATP]. Therefore, lack of functional CFTR expression and not loss of channel activity in CF cells appears to up-regulate AMPK activity in CF HBE cells, presumably through non- metabolic effects on upstream regulatory pathways. Compared with wild-type CFTR-expressing immortalized CF bronchial epithelial (CFBE) cells, Delta F508CFTR-expressing CFBE cells had greater AMPK activity and greater secretion of tumor necrosis factor-alpha and the interleukins IL-6 and IL-8. Further pharmacologic AMPK activation inhibited inflammatory mediator secretion in both wild type- and Delta F508-expressing cells, suggesting that AMPK activation in CF airway cells is an adaptive response that reduces inflammation. We propose that therapies to activate AMPK in the CF airway may be beneficial in reducing excessive airway inflammation, a major cause of CF morbidity.	Univ Pittsburgh, Dept Med, Sch Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Ctr Environm & Occupat Hlth, Sch Med, Pittsburgh, PA 15261 USA; Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA; Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35233 USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35233 USA; Indiana Univ, Dept Med, Indianapolis, IN 46202 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Dartmouth College; Dartmouth College; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Indiana University System; Indiana University-Purdue University Indianapolis	Hallows, KR (corresponding author), Univ Pittsburgh, Dept Med, Sch Med, S976 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	hallows@pitt.edu	Pilewski, Joseph/AAF-5149-2021; Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304; Hallows, Kenneth/0000-0002-2964-2440	NHLBI NIH HHS [R01-HL067088] Funding Source: Medline; NIDDK NIH HHS [K08-DK059477, R03 DK068390-01, K08 DK059477-05, R01-DK060495, P30-DK072506, K08 DK059477, R03 DK068390-02, K08 DK059477-04, R03 DK068390, R01-DK035712] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK068390, P30DK072506, K08DK059477, R01DK035712, R01DK060495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altarejos JY, 2005, J BIOL CHEM, V280, P183, DOI 10.1074/jbc.M411810200; AU JLS, 1989, CLIN CHEM, V35, P48; Bebok Z, 2005, J PHYSIOL-LONDON, V569, P601, DOI 10.1113/jphysiol.2005.096669; Becker MN, 2004, AM J RESP CRIT CARE, V169, P645, DOI 10.1164/rccm.200207-765OC; Berger M, 2002, ALLERGY ASTHMA PROC, V23, P19; Boucher RC, 2004, EUR RESPIR J, V23, P146, DOI 10.1183/09031936.03.00057003; Bruscia E, 2002, GENE THER, V9, P683, DOI 10.1038/sj.gt.3301741; Butterworth MB, 2005, J GEN PHYSIOL, V125, P81, DOI 10.1085/jgp.2004.09124; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chmiel JF, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-8; Chmiel JF, 2002, CLIN REV ALLERG IMMU, V23, P5, DOI 10.1385/CRIAI:23:1:005; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Coyne CB, 2000, AM J RESP CELL MOL, V23, P602, DOI 10.1165/ajrcmb.23.5.4164; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Dagenais A, 2004, AM J PHYSIOL-LUNG C, V286, pL301, DOI 10.1152/ajplung.00326.2002; Dagher PC, 2000, AM J PHYSIOL-CELL PH, V279, pC1270, DOI 10.1152/ajpcell.2000.279.4.C1270; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827, DOI 10.1152/ajpcell.1999.276.4.C827; DUPUIT F, 1995, GENE THER, V2, P156; Freedman SD, 2004, NEW ENGL J MED, V350, P560, DOI 10.1056/NEJMoa021218; Giri S, 2004, J NEUROSCI, V24, P479, DOI 10.1523/JNEUROSCI.4288-03.2004; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; GRUNE T, 1991, J CHROMATOGR-BIOMED, V563, P53, DOI 10.1016/0378-4347(91)80276-I; Hallows KR, 2003, AM J PHYSIOL-CELL PH, V284, pC1297, DOI 10.1152/ajpcell.00227.2002; Hallows KR, 2005, CURR OPIN NEPHROL HY, V14, P464, DOI 10.1097/01.mnh.0000174145.14798.64; Hallows KR, 2003, J BIOL CHEM, V278, P998, DOI 10.1074/jbc.M210621200; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; Hamilton SR, 2001, FEBS LETT, V500, P163, DOI 10.1016/S0014-5793(01)02602-3; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Huang S, 2003, J BIOL CHEM, V278, P8326, DOI 10.1074/jbc.M208264200; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Kelley TJ, 2001, AM J RESP CELL MOL, V25, P732, DOI 10.1165/ajrcmb.25.6.4574; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Koehler DR, 2004, AM J RESP CELL MOL, V31, P377, DOI 10.1165/rcmb.2004-0124TR; Kreiselmeier NE, 2003, AM J PHYSIOL-LUNG C, V285, pL1286, DOI 10.1152/ajplung.00127.2003; Kube D, 2001, AM J PHYSIOL-LUNG C, V280, pL493, DOI 10.1152/ajplung.2001.280.3.L493; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; Lee JY, 2004, AM J RESP CELL MOL, V31, P234, DOI 10.1165/rcmb.2003-0447OC; Lei DC, 1996, GENE THER, V3, P427; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; McAllister F, 2005, J IMMUNOL, V175, P404, DOI 10.4049/jimmunol.175.1.404; Nath N, 2005, J IMMUNOL, V175, P566, DOI 10.4049/jimmunol.175.1.566; Picciano JA, 2003, AM J PHYSIOL-CELL PH, V285, pC1009, DOI 10.1152/ajpcell.00140.2003; Pilewski JM, 1999, PHYSIOL REV, V79, P215; Puchelle Edith, 2002, Paediatr Respir Rev, V3, P115, DOI 10.1016/S1526-0550(02)00005-7; Ribeiro CMP, 2005, J BIOL CHEM, V280, P10202, DOI 10.1074/jbc.M410317200; Ribeiro CMP, 2005, J BIOL CHEM, V280, P17798, DOI 10.1074/jbc.M410618200; Sakamoto K, 2004, AM J PHYSIOL-ENDOC M, V287, pE310, DOI 10.1152/ajpendo.00074.2004; Schwiebert LM, 1999, AM J PHYSIOL-CELL PH, V276, pC700, DOI 10.1152/ajpcell.1999.276.3.C700; Soltys J, 2002, J IMMUNOL, V168, P1903, DOI 10.4049/jimmunol.168.4.1903; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Venkatakrishnan A, 2000, AM J RESP CELL MOL, V23, P396, DOI 10.1165/ajrcmb.23.3.3949; Weber AJ, 2001, AM J PHYSIOL-LUNG C, V281, pL71, DOI 10.1152/ajplung.2001.281.1.L71; WELSH MJ, 1995, SCI AM, V273, P52, DOI 10.1038/scientificamerican1295-52; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Woollhead AM, 2005, J PHYSIOL-LONDON, V566, P781, DOI 10.1113/jphysiol.2005.088674; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200; Zou MH, 2003, J BIOL CHEM, V278, P34003, DOI 10.1074/jbc.M300215200	66	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4231	4241		10.1074/jbc.M511029200	http://dx.doi.org/10.1074/jbc.M511029200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361706	hybrid			2022-12-27	WOS:000235275300056
J	Ryo, A; Togo, T; Nakai, T; Hirai, A; Nishi, M; Yamaguchi, A; Suzuki, K; Hirayasu, Y; Kobayashi, H; Perrem, K; Liou, YC; Aoki, I				Ryo, A; Togo, T; Nakai, T; Hirai, A; Nishi, M; Yamaguchi, A; Suzuki, K; Hirayasu, Y; Kobayashi, H; Perrem, K; Liou, YC; Aoki, I			Prolyl-isomerase Pin1 accumulates in Lewy bodies of Parkinson disease and facilitates formation of alpha-synuclein inclusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BODY FORMATION; DROSOPHILA MODEL; SYNPHILIN-1; PHOSPHORYLATION; PROTEIN; UBIQUITINATION; AGGREGATION; DEGRADATION; CANCER; NEURODEGENERATION	Parkinson disease (PD) is a relatively common neurodegenerative disorder that is characterized by the loss of dopaminergic neurons and by the formation of Lewy bodies (LBs), which are cytoplasmic inclusions containing aggregates of alpha-synuclein. Although certain post-translational modifications of alpha-synuclein and its related proteins are implicated in the genesis of LBs, the specific molecular mechanisms that both regulate these processes and initiate subsequent inclusion body formation are not yet well understood. We demonstrate in our current study, however, that the prolyl-isomerase Pin1 localizes to the LBs in PD brain tissue and thereby enhances the formation of alpha-synuclein immunoreactive inclusions. Immunohistochemical analysis of brain tissue from PD patients revealed that Pin1 localizes to 50-60% of the LBs that show an intense halo pattern resembling that of alpha-synuclein. By utilizing a cellular model of alpha-synuclein aggregation, we also demonstrate that, whereas Pin1 overexpression facilitates the formation of alpha-synuclein inclusions, dominant-negative Pin1 expression significantly suppresses this process. Consistent with these observations, Pin1 overexpression enhances the protein half-life and insolubility of alpha-synuclein. Finally, we show that Pin1 binds synphilin-1, an alpha-synuclein partner, via its Ser-211-Pro and Ser-215-Pro motifs, and enhances its interaction with alpha-synuclein, thus likely facilitating the formation of alpha-synuclein inclusions. These results indicate that Pin1-mediated prolyl-isomerization plays a pivotal role in a post-translational modification pathway for alpha-synuclein aggregation and in the resultant Lewy body formations in PD.	Yokohama City Univ, Sch Med, Dept Pathol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Psychiat, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Radioisotope Res Ctr, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan; Beaumont Hosp, Royal Coll Surg Ireland, Dept Pathol, Mol Oncol Lab, Dublin 9, Ireland; Natl Univ Singapore, Dept Biochem, Singapore 117543, Singapore; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore	Yokohama City University; Yokohama City University; Yokohama City University; Kyushu University; Royal College of Surgeons - Ireland; National University of Singapore; National University of Singapore	Ryo, A (corresponding author), Yokohama City Univ, Sch Med, Dept Pathol, Kanazawa Ku, 3-9 Fuku Ura, Yokohama, Kanagawa 2360004, Japan.	aryo@yokohama-cu.ac.jp						Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baba M, 1998, AM J PATHOL, V152, P879; Chen L, 2005, NAT NEUROSCI, V8, P657, DOI 10.1038/nn1443; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Geschwind DH, 2003, NEURON, V40, P457, DOI 10.1016/S0896-6273(03)00681-0; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Goers J, 2003, BIOCHEMISTRY-US, V42, P8465, DOI 10.1021/bi0341152; GOLDMAN JE, 1983, SCIENCE, V221, P1082, DOI 10.1126/science.6308771; Iseki E, 2002, NEUROSCI LETT, V326, P211, DOI 10.1016/S0304-3940(02)00418-4; Ito T, 2003, J BIOL CHEM, V278, P29106, DOI 10.1074/jbc.M302763200; Joseph James D, 2003, Prog Cell Cycle Res, V5, P477; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee G, 2004, J BIOL CHEM, V279, P6834, DOI 10.1074/jbc.M312760200; Liani E, 2004, P NATL ACAD SCI USA, V101, P5500, DOI 10.1073/pnas.0401081101; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lindersson E, 2005, J BIOL CHEM, V280, P5703, DOI 10.1074/jbc.M410409200; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002; Lu PJ, 1999, NATURE, V399, P784; Lundvig D, 2005, MOL BRAIN RES, V134, P3, DOI 10.1016/j.molbrainres.2004.09.001; Messenger MM, 2002, J BIOL CHEM, V277, P23054, DOI 10.1074/jbc.M200111200; Nagano Y, 2003, J BIOL CHEM, V278, P51504, DOI 10.1074/jbc.M306347200; O'Farrell C, 2001, MOL BRAIN RES, V97, P94, DOI 10.1016/S0169-328X(01)00292-3; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Recchia A, 2004, FASEB J, V18, P617, DOI 10.1096/fj.03-0338rev; Ryo A, 2003, J CELL SCI, V116, P773, DOI 10.1242/jcs.00276; Ryo A, 2005, CLIN CANCER RES, V11, P7523, DOI 10.1158/1078-0432.CCR-05-0457; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Suzuki K, 2003, NEUROREPORT, V14, P551, DOI 10.1097/00001756-200303240-00004; Tanaka M, 2004, J BIOL CHEM, V279, P4625, DOI 10.1074/jbc.M310994200; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	42	69	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4117	4125		10.1074/jbc.M507026200	http://dx.doi.org/10.1074/jbc.M507026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16365047	hybrid			2022-12-27	WOS:000235275300042
J	Ma, SH; Musa, T; Bag, J				Ma, SH; Musa, T; Bag, J			Reduced stability of mitogen-activated protein kinase kinase-2 mRNA and phosphorylation of poly(A)-binding protein (PABP) in cells overexpressing PABP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; TRANSLATION INITIATION-FACTORS; IDENTIFICATION; EXPRESSION; ELEMENTS; DOMAINS; DEADENYLATION; INHIBITOR; INCREASE; REGION	The poly( A)- binding protein ( PABP) is an important regulator of mRNA translation and stability. The cellular level of PABP is controlled by regulating its mRNA translation by a feedback mechanism. The important aspect of this mechanism is that PABP binds to an adenosine-rich cis-element at the 5'-untranslated region of its own mRNA and inhibits its translation. To assess the importance of controlling the PABP level, we studied the effect of PABP overexpression on the transcription profile using the microarray technique. In PABP-overexpressing cells, 19 mRNAs showed a reduction in cellular levels due to reduced mRNA stability, and one showed an increase due to increased mRNA stability. Among these mRNAs, the MKK-2 mRNA encodes the protein kinase activator of ERK1/2 kinase, which is involved in the phosphorylation of eukaryotic initiation factor ( eIF) 4E. As a result, mRNA translation may be regulated by the cellular level of MKK-2. In this study, we show that the abundance of the MKK-2 polypeptide is reduced in PABP-overexpressing cells. In these cells, the levels of phosphorylated PABP, eIF4E, and ERK2 are also reduced. Treatment of HeLa cells with the MKK-2 inhibitor U0126 reduced PABP phosphorylation, suggesting that the phosphorylation of PABP is mediated by the MKK-2/ ERK signaling pathway. Thus, a novel signaling pathway involving MKK-2 and ERK1/2 may down-regulate the activity of PABP and eIF4E by controlling their phosphorylation and compensates for the effect of excess cellular PABP.	Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada	University of Guelph	Bag, J (corresponding author), Univ Guelph, Dept Mol & Cellular Biol, 50 Stone Rd, Guelph, ON N1G 2W1, Canada.	jbag@uoguelph.ca						ADAMOU J, 1992, EUR J BIOCHEM, V209, P803, DOI 10.1111/j.1432-1033.1992.tb17351.x; ALFONINA E, 1998, J BIOL CHEM, V273, P13015; Bag J, 1996, EUR J BIOCHEM, V237, P143, DOI 10.1111/j.1432-1033.1996.0143n.x; Bag J, 2001, J BIOL CHEM, V276, P47352, DOI 10.1074/jbc.M107676200; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BOTH GW, 1975, P NATL ACAD SCI USA, V72, P1189, DOI 10.1073/pnas.72.3.1189; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gallie DR, 1997, J BIOL CHEM, V272, P1046, DOI 10.1074/jbc.272.2.1046; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; GRANGE T, 1987, NUCLEIC ACIDS RES, V15, P4771, DOI 10.1093/nar/15.12.4771; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hornstein E, 1999, FEBS LETT, V457, P209, DOI 10.1016/S0014-5793(99)01039-X; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Jacobson A., 1996, POLY A METABOLISM TR, P451; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Khaleghpour K, 2001, MOL CELL BIOL, V21, P5200, DOI 10.1128/MCB.21.15.5200-5213.2001; Kozak M, 2004, GENE, V343, P41, DOI 10.1016/j.gene.2004.08.011; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Le H, 2000, J BIOL CHEM, V275, P17452, DOI 10.1074/jbc.M001186200; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Mangus DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-223; Melo EO, 2003, J BIOL CHEM, V278, P46357, DOI 10.1074/jbc.M307624200; Mohr E, 2001, P NATL ACAD SCI USA, V98, P7072, DOI 10.1073/pnas.111146598; NETO OPD, 1995, NUCLEIC ACIDS RES, V23, P2198, DOI 10.1093/nar/23.12.2198; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; ORNBJERG WS, 2005, MOL CELL PROTEOMICS, V4, P483; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roy G, 2002, MOL CELL BIOL, V22, P3769, DOI 10.1128/MCB.22.11.3769-3782.2002; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Sladic RT, 2004, EUR J BIOCHEM, V271, P450, DOI 10.1046/j.1432-1033.2003.03945.x; Tallada VA, 2002, YEAST, V19, P1139, DOI 10.1002/yea.902; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; THOMAS G, 1986, J CELL BIOL, V103, P2137, DOI 10.1083/jcb.103.6.2137; Thomson AM, 1999, BIOTECHNIQUES, V27, P1032, DOI 10.2144/99275rr03; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; VEDA T, 2004, MOL CELL BIOL, V24, P6539; Verlaet M, 2001, BIOCHEM BIOPH RES CO, V283, P12, DOI 10.1006/bbrc.2001.4731; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; Winzen R, 2004, MOL CELL BIOL, V24, P4835, DOI 10.1128/MCB.24.11.4835-4847.2004; Wormington M, 1996, EMBO J, V15, P900, DOI 10.1002/j.1460-2075.1996.tb00424.x; Wu J, 1998, J BIOL CHEM, V273, P34535, DOI 10.1074/jbc.273.51.34535; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137	53	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3145	3156		10.1074/jbc.M508937200	http://dx.doi.org/10.1074/jbc.M508937200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332685	hybrid			2022-12-27	WOS:000235128200017
J	Toth, A; Nickson, P; Qin, LL; Erhardt, P				Toth, A; Nickson, P; Qin, LL; Erhardt, P			Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; MITOCHONDRIAL DEATH PATHWAY; HYPOXIA-INDUCED APOPTOSIS; SMALL-MOLECULE INHIBITORS; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR MYOCYTES; P53-MDM2 INTERACTION; ENHANCED EXPRESSION; SIGNALING PATHWAYS; REPERFUSION INJURY	MDM2 is an E3 ubiquitin ligase that regulates the proteasomal degradation and activity of proteins involved in cell growth and apoptosis, including the tumor suppressors p53 and retinoblastoma and the transcription factor E2F1. Although the effect of several MDM2 targets on cardiomyocyte survival and hypertrophy has already been investigated, the role of MDM2 in these processes has not yet been established. We have, therefore, analyzed the effect of overexpression as well as inhibition of MDM2 on cardiac ischemia/reperfusion injury and hypertrophy. Here we show that isolated cardiac myocytes overexpressing MDM2 acquired resistance to hypoxia/reoxygenation-induced cell death. Conversely, inactivation of MDM2 by a peptide inhibitor resulted in elevated p53 levels and promoted hypoxia/reoxygenation-induced apoptosis. Consistent with this, decreased expression of MDM2 in a genetic mouse model was accompanied by reduced functional recovery of the left ventricles determined with the Langendorff ex vivo model of ischemia/reperfusion. In contrast to cell survival, cell hypertrophy induced by the alpha-agonists phenylephrine or endothelin-1 was inhibited by MDM2 overexpression. Collectively, our studies indicate that MDM2 promotes survival and attenuates hypertrophy of cardiac myocytes. This differential regulation of cell growth and cell survival is unique, because most other survival factors are prohypertrophic. MDM2, therefore, might be a potential therapeutic target to down-regulate both cell death and pathologic hypertrophy during remodeling upon cardiac infarction. In addition, our data also suggest that cancer treatments with MDM2 inhibitors to reactivate p53 may have adverse cardiac side effects by promoting cardiomyocyte death.	Boston Biomed Res Inst, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Erhardt, P (corresponding author), Boston Biomed Res Inst, 64 Grove St, Watertown, MA 02472 USA.	Erhardt@bbri.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068126] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-68126] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bialik S, 1997, J CLIN INVEST, V100, P1363, DOI 10.1172/JCI119656; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Condorelli G, 2002, P NATL ACAD SCI USA, V99, P12333, DOI 10.1073/pnas.172376399; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Dorn GW, 2005, J CLIN INVEST, V115, P527, DOI 10.1172/JCI200524178; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Force T, 2004, CIRCULATION, V109, P1196, DOI 10.1161/01.CIR.0000118538.21306.A9; Fotouhi N, 2005, CURR TOP MED CHEM, V5, P159, DOI 10.2174/1568026053507705; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Grazette LP, 2004, J AM COLL CARDIOL, V44, P2231, DOI 10.1016/j.jacc.2004.08.066; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hauck L, 2002, CIRC RES, V91, P782, DOI 10.1161/01.RES.0000041030.98642.41; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Iwakuma T, 2003, MOL CANCER RES, V1, P993; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kanovsky M, 2001, P NATL ACAD SCI USA, V98, P12438, DOI 10.1073/pnas.211280698; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; Klein C, 2004, BRIT J CANCER, V91, P1415, DOI 10.1038/sj.bjc.6602164; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Leri A, 1999, CIRC RES, V84, P752; Liu XW, 2004, AM J PHYSIOL-HEART C, V286, pH933, DOI 10.1152/ajpheart.00759.2003; Long XL, 1998, J CLIN INVEST, V101, P1453, DOI 10.1172/JCI345; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; LUNA RMD, 1995, NATURE, V378, P203; MacLellan WR, 2005, MOL CELL BIOL, V25, P2486, DOI 10.1128/MCB.25.6.2486-2497.2005; Maisse C, 2003, BIOCHEM PHARMACOL, V66, P1555, DOI 10.1016/S0006-2952(03)00511-2; Matsui T, 2001, CIRCULATION, V104, P330; Maulik N, 2000, FEBS LETT, V485, P7, DOI 10.1016/S0014-5793(00)02174-8; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael A, 2004, J BIOL CHEM, V279, P21383, DOI 10.1074/jbc.M401413200; Mocanu MM, 2003, FEBS LETT, V555, P302, DOI 10.1016/S0014-5793(03)01260-2; Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Regula KM, 2001, J MOL CELL CARDIOL, V33, P1435, DOI 10.1006/jmcc.2001.1405; Sanna B, 2005, MOL CELL BIOL, V25, P865, DOI 10.1128/MCB.25.3.865-878.2005; Shiojima I, 2005, J CLIN INVEST, V115, P2108, DOI 10.1172/JCI24682; Shiraishi I, 2004, CIRC RES, V94, P884, DOI 10.1161/01.RES.0000124394.01180.BE; Skurk C, 2005, J BIOL CHEM, V280, P20814, DOI 10.1074/jbc.M500528200; Soonpaa MH, 1996, AM J PHYSIOL-HEART C, V271, pH2183; Steinberg SF, 2005, CIRC RES, V96, P711, DOI 10.1161/01.RES.0000164185.96546.82; Toth A, 2003, FREE RADICAL BIO MED, V35, P1051, DOI 10.1016/S0891-5849(03)00467-2; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Webster KA, 1999, J CLIN INVEST, V104, P239; Wilkins BJ, 2004, BIOCHEM BIOPH RES CO, V322, P1178, DOI 10.1016/j.bbrc.2004.07.121; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	61	74	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3679	3689		10.1074/jbc.M509630200	http://dx.doi.org/10.1074/jbc.M509630200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339144	hybrid			2022-12-27	WOS:000235128200080
J	Safholm, A; Leandersson, K; Dejmek, J; Nielsen, CK; Villoutreix, BO; Andersson, T				Safholm, A; Leandersson, K; Dejmek, J; Nielsen, CK; Villoutreix, BO; Andersson, T			A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; BETA-CATENIN; RECEPTOR 1; ACTIVATION; EXPRESSION; PROTEINS; DIFFERENTIATION; MECHANISMS; CARCINOMA; STIFFNESS	Loss of Wnt-5a protein expression is associated with shorter recurrence-free survival in breast carcinoma patients and increased motility in mammary cell lines. Based on sequence analysis of Wnt-5a, we identified 14 peptide fragments and investigated their ability to mimic the effects of Wnt-5a on mammary cell adhesion and migration. Two of these peptides significantly increased adhesion and impaired migration in the non-tumorigenic HB2 breast epithelial cell line and in the MDA-MB468 breast cancer cell line, both of which show little endogenous expression of the Wnt-5a protein. We removed two amino acids at a time from the N terminus of the shorter of these two peptides to identify the shortest peptide that still inhibited migration. The influence on tumor cell adhesion was gradually lost and was no longer detectable when only six amino acids remained. However, formylation of the N-terminal methionine of this hexapeptide restored its effect on adhesion and reduced tumor cell motility via a Frizzled-5 receptor-dependent mechanism, even at a low pH such as encountered in breast tumor tissue. This formylated hexapeptide ligand induced a rapid cytosolic calcium signal, whereas it did not affect the cellular levels of unphosphorylated beta-catenin or active JNK. The novel formyl-Met-AspGly-Cys-Glu-Leu peptide ligand is not only a valuable experimental tool but has also a potential role in antimetastatic treatment of the 50% of human breast cancer patients that have reduced endogenous Wnt-5a protein expression.	Lund Univ, Dept Lab Med, UMAS, Malmo Univ Hosp, SE-20502 Malmo, Sweden; Univ Paris 05, INSERM U648, Struct Bioinformat Team, F-75006 Paris, France	Lund University; Skane University Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Andersson, T (corresponding author), Lund Univ, Dept Lab Med, UMAS, Malmo Univ Hosp, Entrance 78,Floor 3, SE-20502 Malmo, Sweden.	tommy.andersson@med.lu.se	Villoutreix, Bruno/I-4565-2015	Villoutreix, Bruno/0000-0002-6456-7730; Andersson, Tommy/0000-0003-4032-5769				Andersen H, 1999, P NATL ACAD SCI USA, V96, P11189, DOI 10.1073/pnas.96.20.11189; BARTEK J, 1991, P NATL ACAD SCI USA, V88, P3520, DOI 10.1073/pnas.88.9.3520; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Bhujwalla ZM, 1999, MAGN RESON MED, V41, P897, DOI 10.1002/(SICI)1522-2594(199905)41:5<897::AID-MRM7>3.0.CO;2-T; Blanc E, 2005, ONCOGENE, V24, P1277, DOI 10.1038/sj.onc.1208255; Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008-5472.CAN-05-1710; Dejmek J, 2003, INT J CANCER, V103, P344, DOI 10.1002/ijc.10752; Dejmek J, 2005, CLIN CANCER RES, V11, P520; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; HUGUET EL, 1995, J BIOL CHEM, V270, P12851, DOI 10.1074/jbc.270.21.12851; Hwang SG, 2005, FEBS LETT, V579, P4837, DOI 10.1016/j.febslet.2005.07.067; Jansson M, 2001, J CELL SCI, V114, P2043; Jonsson M, 2002, CANCER RES, V62, P409; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Nagayama M, 2004, EXP CELL RES, V300, P396, DOI 10.1016/j.yexcr.2004.07.034; Nagayama M, 2001, CELL MOTIL CYTOSKEL, V50, P173, DOI 10.1002/cm.10008; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nielsen CK, 2005, EXP CELL RES, V302, P31, DOI 10.1016/j.yexcr.2004.08.042; Pakala R, 2000, THROMB RES, V100, P89, DOI 10.1016/S0049-3848(00)00307-8; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Reshkin SJ, 2000, J BIOL CHEM, V275, P5361, DOI 10.1074/jbc.275.8.5361; Rost B, 1996, METHOD ENZYMOL, V266, P525; Schulte G, 2005, J NEUROCHEM, V92, P1550, DOI 10.1111/j.1471-4159.2004.03022.x; Sen M, 2001, ARTHRITIS RHEUM, V44, P772, DOI 10.1002/1529-0131(200104)44:4<772::AID-ANR133>3.0.CO;2-L; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Wang YS, 1996, J BIOL CHEM, V271, P4468; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Widelitz R, 2005, GROWTH FACTORS, V23, P111, DOI 10.1080/08977190500125746; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	38	87	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2740	2749		10.1074/jbc.M508386200	http://dx.doi.org/10.1074/jbc.M508386200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330545	hybrid			2022-12-27	WOS:000234931800040
J	Wang, XC; Gu, JG; Ihara, H; Miyoshi, E; Honke, K; Taniguchi, N				Wang, XC; Gu, JG; Ihara, H; Miyoshi, E; Honke, K; Taniguchi, N			Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; GLIOMA-CELL-LINE; HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODY; N-ACETYLGLUCOSAMINE; U373 MG; BINDING; OLIGOSACCHARIDES; GLYCOSYLATION; EXPRESSION	alpha 1,6-Fucosyltransferase (Fut8) catalyzes the transfer of a fucose residue to N-linked oligosaccharides on glycoproteins via an alpha 1,6-linkage to form core fucosylation in mammals. We recently found that disruption of the Fut8 gene induces severe growth retardation and early postnatal death. To investigate the molecular mechanism involved, we have established embryonic fibroblasts of Fut8(+/+) and Fut8(-/-), derived from wild-type and Fut8-null mice, respectively. Interestingly, the epidermal growth factor (EGF)-induced phosphorylation levels of the EGF receptor ( EGFR) were substantially blocked in Fut8(-/-) cells, compared with Fut8(-/-) cells, while there are no significant changes in the total activities of tyrosine phosphatase for phosphorylated EGFR between two cells. The inhibition of EGFR phosphorylation was completely restored by re-introduction of the Fut8 gene to Fut8(-/-) cells. Consistent with this, EGFR-mediated JNK or ERK activation was significantly suppressed in Fut8(-/-) cells. Finally, we found that the core fucosylation of N-glycans is required for the binding of the EGF to its receptor, whereas no effect was observed for the expression levels of EGFR on the cell surface. Collectively, these results strongly suggest that core fucosylation is essential for EGF receptor-mediated biological functions.	Osaka Univ, Dept Biochem, Grad Sch Med, Osaka, Japan; Kochi Univ, Grad Sch Med, Dept Mol Genet, Nanko Ku, Kochi 7838505, Japan	Osaka University; Kochi University	Gu, JG (corresponding author), Osaka Univ, Dept Biochem, Grad Sch Med, Osaka, Japan.	jgu@biochem.med.osaka-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; Gu, Jianguo/ABC-9257-2020; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Ihara, Hideyuki/0000-0003-0490-6355				AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; DEFIZE LHK, 1988, J CELL BIOL, V107, P939, DOI 10.1083/jcb.107.3.939; DEFIZE LHK, 1989, J CELL BIOL, V109, P2495, DOI 10.1083/jcb.109.5.2495; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; GREGORIOU M, 1984, EMBO J, V3, P929, DOI 10.1002/j.1460-2075.1984.tb01910.x; Gregoriou M, 1993, Methods Mol Biol, V14, P189; Gu JG, 2004, GLYCOBIOLOGY, V14, P177, DOI 10.1093/glycob/cwh016; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; HAZAN R, 1995, J CELL PHYSIOL, V162, P74, DOI 10.1002/jcp.1041620110; HUTCHINSON WL, 1991, HEPATOLOGY, V13, P683, DOI 10.1002/hep.1840130412; Isaji T, 2004, J BIOL CHEM, V279, P19747, DOI 10.1074/jbc.M311627200; Miyoshi E, 1999, CANCER RES, V59, P2237; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; Noda K, 2003, CANCER RES, V63, P6282; Partridge EA, 2004, SCIENCE, V306, P120, DOI 10.1126/science.1102109; Rebbaa A, 1997, J BIOL CHEM, V272, P9275; Rebbaa A, 1996, J NEUROCHEM, V67, P2265; SATO Y, 1993, NEW ENGL J MED, V328, P1802, DOI 10.1056/NEJM199306243282502; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; SHIMIZU H, 1993, J BIOCHEM-TOKYO, V114, P334, DOI 10.1093/oxfordjournals.jbchem.a124177; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; Stroop CJM, 2000, GLYCOBIOLOGY, V10, P901, DOI 10.1093/glycob/10.9.901; TAKETA K, 1993, CANCER RES, V53, P5419; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; Taniguchi N, 2001, PROTEOMICS, V1, P239; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Uozumi N, 1996, J BIOCHEM, V120, P385; Wang W, 2001, GLYCOBIOLOGY, V11, P165, DOI 10.1093/glycob/11.2.165; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; ZENG FY, 1995, MOL CELL BIOCHEM, V142, P117, DOI 10.1007/BF00928932; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325	41	242	250	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2572	2577		10.1074/jbc.M510893200	http://dx.doi.org/10.1074/jbc.M510893200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16316986	hybrid			2022-12-27	WOS:000234931800020
J	Markou, T; Yong, CS; Sugden, PH; Clerk, A				Markou, T; Yong, CS; Sugden, PH; Clerk, A			Regulation of protein kinase C delta by phorbol ester, endothelin-1, and platelet-derived growth factor in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PKC-DELTA; IN-VIVO; PHOSPHORYLATION; ACTIVATION; EXPRESSION; CARDIOMYOCYTES; STIMULATION; ISOZYMES; MUTATION; EPSILON	Protein kinase C ( PKC) delta is regulated allosterically by phosphatidylserine and diacylglycerol ( which promote its translocation to the membrane) and by phosphorylation of Ser/ Thr and Tyr residues. Although phosphorylation on Thr- 505/ Ser- 643/ Ser- 662 may simply " prime" PKC delta for activation, it could be regulatory. We examined the regulation of PKC delta in cardiac myocytes by endothelin- 1 ( G(q) protein- coupled receptor agonist) and platelet- derived growth factor ( receptor tyrosine kinase agonist) in comparison with phorbol 12- myristate 13- acetate ( PMA). All increased phosphorylation of PKC delta( Thr- 505/ Ser- 643) and of Tyr residues, although to differing extents. De novo phosphorylation occurred mainly after translocation of PKC delta to the particulate fraction, and phosphorylations of Thr- 505/ Ser- 643 versus Tyr residues were essentially independent events. Following chromatographic separation of the PKC delta subspecies, activities were correlated with immunoreactivity profiles of total and phosphorylated forms. In unstimulated cells, similar to 25% of PKC delta lacked phosphorylation of Thr- 505/ Ser- 643 and displayed minimal activity ( assayed in the presence of phosphatidylserine/ PMA following chromatography). Endothelin- 1 or PMA ( 10 min) promoted Thr- 505/ Ser- 643 phosphorylation of this pool, and this was associated with an increase in total recoverable PKC delta activity. Meanwhile, in cells exposed to endothelin- 1 or PMA, the overall pool of PKC delta translocated rapidly ( 30 s) to the particulate fraction and was phosphorylated on Tyr residues. This was associated with an increase in lipid- independent activity ( i. e. the phosphatidylserine/ PMA requirement disappeared). For endothelin- 1, Tyr phosphorylation of PKC delta and the increase in phosphatidylserine/ PMA- independent activity persisted after PKC delta retrotranslocated to the soluble fraction. We concluded that, with this physiological agonist, PKC delta becomes activated in the particulate fraction but retains activity following its retrotranslocation, presumably to phosphorylate substrates elsewhere.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst Div, London SW7 2AZ, England	Imperial College London	Sugden, PH (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst Div, Flowers Bldg,4th Floor,Armstrong Rd, London SW7 2AZ, England.	p.sugden@imperial.ac.uk; a.clerk@imperial.ac.uk		Clerk, Angela/0000-0002-5658-0708				Acs P, 2000, CARCINOGENESIS, V21, P887, DOI 10.1093/carcin/21.5.887; BOGOYEVITCH MA, 1995, BIOCHEM J, V309, P437, DOI 10.1042/bj3090437; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; CLERK A, 1995, AM J PHYSIOL-HEART C, V269, pH1087, DOI 10.1152/ajpheart.1995.269.3.H1087; Clerk A, 2006, CELL SIGNAL, V18, P225, DOI 10.1016/j.cellsig.2005.04.005; CLERK A, 1994, J BIOL CHEM, V269, P32848; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Gutcher I, 2003, CELL MOL LIFE SCI, V60, P1061, DOI 10.1007/s00018-003-2281-y; Hahn HS, 2002, CIRC RES, V91, P741, DOI 10.1161/01.RES.0000037091.64492.69; Haworth RS, 2000, J MOL CELL CARDIOL, V32, P1013, DOI 10.1006/jmcc.2000.1143; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leslie NR, 2001, CHEM REV, V101, P2365, DOI 10.1021/cr000091i; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Mayr M, 2004, AM J PHYSIOL-HEART C, V287, pH946, DOI 10.1152/ajpheart.00878.2003; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Sabri A, 2003, MOL CELL BIOCHEM, V251, P97, DOI 10.1023/A:1025490017780; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; Szallasi Z, 1996, J BIOL CHEM, V271, P18299, DOI 10.1074/jbc.271.31.18299; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498	34	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8321	8331		10.1074/jbc.M508398200	http://dx.doi.org/10.1074/jbc.M508398200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16361709	hybrid			2022-12-27	WOS:000236247100005
J	He, B; Gampe, RT; Hnat, AT; Faggart, JL; Minges, JT; French, FS; Wilson, EM				He, B; Gampe, RT; Hnat, AT; Faggart, JL; Minges, JT; French, FS; Wilson, EM			Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTION; GENE-MUTATIONS; STRUCTURAL BASIS; TRANSCRIPTIONAL ACTIVATION; TERMINAL INTERACTION; DOMAIN; SPECIFICITY; INTERDOMAIN; DEPRIVATION; PROTEIN	The androgen receptor (AR) is a ligand-activated transcription factor required for male sex development and virilization and contributes to prostate cancer initiation and progression. High affinity androgen binding triggers conformational changes required for AR transactivation. Here we characterized naturally occurring AR gene mutations in the region of activation function 2 (AF2) that decrease or increase AR transcriptional activity by altering the region bounded by AF2 and the ligand binding pocket without affecting equilibrium androgen binding affinity. In the androgen insensitivity syndrome, germ line AR mutations increase the androgen dissociation rate and reduce AR FXXLF motif binding and the recruitment of steroid receptor coactivator ( SRC)/p160 coactivator LXXLL motifs. In prostate cancer, somatic AR mutations in AF2 or near the bound ligand slow androgen dissociation and increase AR stabilization and coactivator recruitment. Crystal structures of the AR ligand binding domain bound to R1881 and FXXLF or LXXLL motif peptide indicate the mutations are proximal to the AF2 bound peptide, adjacent to the ligand pocket, or in a putative ligand gateway. The results suggest a bidirectional structural relay between bound ligand and coactivator that establishes AR functional potency in vivo.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pediat Biochem & Biophys, Reprod Biol Lab, Chapel Hill, NC 27599 USA; GlaxoSmithKline, Discovery Res, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline	Wilson, EM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pediat Biochem & Biophys, Reprod Biol Lab, Chapel Hill, NC 27599 USA.	emw@med.unc.edu			FIC NIH HHS [R03TW001234] Funding Source: Medline; NICHD NIH HHS [U54-HD35041, HD16910] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016910, R01HD016910, U54HD035041] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [R03TW001234] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Ahmed SF, 2000, J CLIN ENDOCR METAB, V85, P658, DOI 10.1210/jc.85.2.658; ANDERSON JN, 1975, ENDOCRINOLOGY, V96, P160, DOI 10.1210/endo-96-1-160; Aquilina JW, 1997, JNCI-J NATL CANCER I, V89, P689, DOI 10.1093/jnci/89.10.689; Bai SX, 2005, MOL CELL BIOL, V25, P1238, DOI 10.1128/MCB.25.4.1238-1257.2005; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Bohl CE, 2005, J BIOL CHEM, V280, P37747, DOI 10.1074/jbc.M507464200; Carlsson P, 2005, MOL ENDOCRINOL, V19, P1960, DOI 10.1210/me.2004-0203; Chang CY, 2001, CANCER RES, V61, P8712; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DEBELLIS A, 1994, J CLIN ENDOCR METAB, V78, P513, DOI 10.1210/jc.78.3.513; Duff J, 2005, MOL ENDOCRINOL, V19, P2943, DOI 10.1210/me.2005-0231; ELO JP, 1995, J CLIN ENDOCR METAB, V80, P3494, DOI 10.1210/jc.80.12.3494; Essawi M, 1997, DIS MARKERS, V13, P99; Estebanez-Perpina E, 2005, J BIOL CHEM, V280, P8060, DOI 10.1074/jbc.M407046200; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Georget V, 1998, J CLIN ENDOCR METAB, V83, P3597, DOI 10.1210/jc.83.10.3597; Glass CK, 2000, GENE DEV, V14, P121; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P4315; Gruber SB, 2003, PROSTATE, V54, P306, DOI 10.1002/pros.10195; Hara T, 2003, CANCER RES, V63, P149; HARRIS SE, 1991, MOLECULAR AND CELLULAR BIOLOGY OF PROSTATE CANCER, P315; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2002, MOL GENET METAB, V75, P293, DOI 10.1016/S1096-7192(02)00009-4; He B, 2004, J BIOL CHEM, V279, P30643, DOI 10.1074/jbc.M403117200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He B, 2003, MOL CELL BIOL, V23, P2135, DOI 10.1128/MCB.23.6.2135-2150.2003; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; HIORT O, 1993, J CLIN ENDOCR METAB, V77, P262, DOI 10.1210/jc.77.1.262; Hiort O, 1998, J PEDIATR-US, V132, P939, DOI 10.1016/S0022-3476(98)70387-7; Holterhus PM, 2000, J CLIN ENDOCR METAB, V85, P3245, DOI 10.1210/jc.85.9.3245; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; IMPERATO.J, 1974, SCIENCE, V186, P1213, DOI 10.1126/science.186.4170.1213; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; KOIVISTO P, 1995, AM J PATHOL, V147, P1608; Koivisto P, 1998, AM J PATHOL, V152, P1; Krishnan AV, 2002, ENDOCRINOLOGY, V143, P1889, DOI 10.1210/en.143.5.1889; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; MacLean Helen E, 2004, Hum Mutat, V23, P287, DOI 10.1002/humu.9221; Marcelli M, 2000, CANCER RES, V60, P944; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Matias PM, 2002, J MED CHEM, V45, P1439, DOI 10.1021/jm011072j; McDonald S, 2000, CANCER RES, V60, P2317; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Mononen N, 2000, CANCER RES, V60, P6479; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAKAO R, 1993, J CLIN ENDOCR METAB, V77, P103, DOI 10.1210/jcem.77.1.8325932; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; NEWMARK JR, 1992, P NATL ACAD SCI USA, V89, P6319, DOI 10.1073/pnas.89.14.6319; PETERZIEL H, 1995, INT J CANCER, V63, P544, DOI 10.1002/ijc.2910630415; PINSKY L, 1992, CLIN INVEST MED, V15, P456; Poujol N, 2002, J CLIN ENDOCR METAB, V87, P5793, DOI 10.1210/jc.2002-020491; Quigley CA, 2004, MECH AGEING DEV, V125, P683, DOI 10.1016/j.mad.2004.08.007; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shi XB, 2002, CANCER RES, V62, P1496; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taplin ME, 2001, J CLIN ENDOCR METAB, V86, P3467, DOI 10.1210/jc.86.8.3467; Terouanne B, 2003, MOL PHARMACOL, V63, P791, DOI 10.1124/mol.63.4.791; Tilley WD, 1996, CLIN CANCER RES, V2, P277; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WILSON EM, 1976, J BIOL CHEM, V251, P5620; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	86	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6648	6663		10.1074/jbc.M511738200	http://dx.doi.org/10.1074/jbc.M511738200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16365032	Green Published, hybrid			2022-12-27	WOS:000236030800062
J	Lafleur, MA; Mercuri, FA; Ruangpanit, N; Seiki, M; Sato, H; Thompson, EW				Lafleur, MA; Mercuri, FA; Ruangpanit, N; Seiki, M; Sato, H; Thompson, EW			Type I collagen abrogates the clathrin-mediated internalization of membrane type 1 matrix metalloproteinase (MT1-MMP) via the MT1-MMP hemopexin domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GELATINASE-A; CELL-SURFACE; MMP-2 ACTIVATION; METASTATIC PROGRESSION; MESSENGER-RNA; CANCER; INVASION; EXPRESSION; PROTEOLYSIS; PROGELATINASE	Type I collagen (Col I)-stimulated matrix metalloproteinase- 2 (MMP-2) activation via membrane type 1 MMP (MT1-MMP) involves both a transcriptional increase in MT1-MMP expression and a nontranscriptional response mediated by preexisting MT1-MMP. In order to identify which MT1-MMP domains were required for the nontranscriptional response, MCF-7 cells that lack endogenous MT1-MMP were transfected with either wild type or domain mutant MT1-MMP constructs. We observed that mutant constructs lacking the MT1-MMP cytoplasmic tail were able to activate MMP-2 in response to Col I but not a construct lacking the MT1-MMP hemopexin domain. Col I did not alter total MT1-MMP protein levels; nor did it appear to directly induce MT1-MMP oligomerization. Col I did, however, redistribute preexisting MT1-MMP to the cell periphery compared with unstimulated cells that displayed a more diffuse staining pattern. In addition, Col I blocked the internalization of MT1-MMP in a dynamin-dependent manner via clathrin-coated pit-mediated endocytosis. This mechanism of impaired internalization is different from that reported for concanavalin A, since it is not mediated by the cytoplasmic tail of MT1-MMP but rather by the hemopexin domain. In summary, upon Col I binding to its cell surface receptor, MT1-MMP internalization via clathrin-coated pit-mediated endocytosis is impaired through interactions with the hemopexin domain, thereby regulating its function and ability to activate MMP-2.	St Vincents Inst Med Res, VBCRC Invas & Metastasis Grp, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Surg, Fitzroy, Vic 3065, Australia; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Tokyo 1088639, Japan; Kanazawa Univ, Dept Mol Oncol & Virol, Kanazawa, Ishikawa 9200934, Japan	St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne; University of Tokyo; Kanazawa University	Thompson, EW (corresponding author), St Vincents Inst Med Res, VBCRC Invas & Metastasis Grp, 9 Princes St, Fitzroy, Vic 3065, Australia.	rik@medstv.unimelb.edu.au	Seiki, Motoharu/K-9443-2015; Thompson, Erik W/A-1425-2009; SATO, Hiroshi/D-8454-2015; Thompson, Erik/GPK-2067-2022	Thompson, Erik W/0000-0002-9723-4924; Thompson, Erik/0000-0002-9723-4924; Lafleur, Marc/0000-0002-8776-9773; Mercuri, Francesca/0000-0003-1026-2672				Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Benmerah A, 1999, J CELL SCI, V112, P1303; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Cao H, 2000, J CELL SCI, V113, P1993; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Carver LA, 2003, NAT REV CANCER, V3, P571, DOI 10.1038/nrc1146; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 1998, CANCER RES, V58, P5529; Gingras D, 2000, BBA-MOL CELL RES, V1497, P341, DOI 10.1016/S0167-4889(00)00071-9; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Henley JR, 1999, FASEB J, V13, pS243, DOI 10.1096/fasebj.13.9002.S243; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Lafleur Marc A, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403006628; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Nguyen M, 2000, INT J BIOCHEM CELL B, V32, P621, DOI 10.1016/S1357-2725(00)00013-3; NOEL AC, 1994, INT J CANCER, V56, P331, DOI 10.1002/ijc.2910560306; Oh J, 2004, ONCOGENE, V23, P5041, DOI 10.1038/sj.onc.1207688; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Ruangpanit N, 2001, MATRIX BIOL, V20, P193, DOI 10.1016/S0945-053X(01)00135-4; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Seiki M, 2003, CANCER METAST REV, V22, P129, DOI 10.1023/A:1023087113214; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Takino T, 2003, BIOCHEM BIOPH RES CO, V304, P160, DOI 10.1016/S0006-291X(03)00544-8; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Wang P, 2004, J BIOL CHEM, V279, P51148, DOI 10.1074/jbc.M409074200; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; YU M, 1995, CANCER RES, V55, P3272; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	55	46	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6826	6840		10.1074/jbc.M513084200	http://dx.doi.org/10.1074/jbc.M513084200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407177	Green Published, hybrid			2022-12-27	WOS:000236030800081
J	Lavery, GG; Walker, EA; Draper, N; Jeyasuria, P; Marcos, J; Shackleton, CHL; Parker, KL; White, PC; Stewart, PM				Lavery, GG; Walker, EA; Draper, N; Jeyasuria, P; Marcos, J; Shackleton, CHL; Parker, KL; White, PC; Stewart, PM			Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HYDROXYSTEROID DEHYDROGENASE; HEXOSE 6-PHOSPHATE DEHYDROGENASE; CORTISONE REDUCTASE DEFICIENCY; HEPATIC INSULIN SENSITIVITY; ENDOPLASMIC-RETICULUM; GLUCOSE-DEHYDROGENASE; SELECTIVE-INHIBITION; HYPERGLYCEMIC MICE; LIVER-MICROSOMES; RAT	The local generation of active glucocorticoid by NADPH-dependent, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) oxoreductase activity, has emerged as an important factor in regulating hepatic glucose output and visceral adiposity. We have proposed that this NADPH is generated within the endoplasmic reticulum by the enzyme hexose-6-phosphate dehydrogenase. To address this hypothesis, we generated mice with a targeted inactivation of the H6PD gene. These mice were unable to convert 11-dehydrocorticosterone (11-DHC) to corticosterone but demonstrated increased corticosterone to 11-DHC conversion consistent with lack of 11 beta-HSD1 oxoreductase and a concomitant increase in dehydrogenase activity. This increased corticosterone clearance in the knock-out mice resulted in a reduction in circulating corticosterone levels. Our studies define the critical requirement of hexose-6-phosphate dehydrogenase for 11 beta-HSD1 oxoreductase activity and add a new dimension to the investigation of 11 beta-HSD1 as a therapeutic target in patients with the metabolic syndrome.	Univ Birmingham, Dept Med, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	University of Birmingham; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Stewart, PM (corresponding author), Univ Birmingham, Dept Med, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	p.m.stewart@bham.ac.uk	Lavery, Gareth/F-9346-2010; Marcos, Josep/F-3545-2015; Jeyasuria, Pancharatnam/B-4710-2008	Marcos, Josep/0000-0002-3624-108X; Jeyasuria, Pancharatnam/0000-0002-1388-906X	MRC [G0100729] Funding Source: UKRI; Medical Research Council [G0100729] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; Alberts P, 2003, ENDOCRINOLOGY, V144, P4755, DOI 10.1210/en.2003-0344; Alberts P, 2002, DIABETOLOGIA, V45, P1528, DOI 10.1007/s00125-002-0959-6; Atanasov AG, 2004, FEBS LETT, V571, P129, DOI 10.1016/j.febslet.2004.06.065; Banhegyi G, 2004, J BIOL CHEM, V279, P27017, DOI 10.1074/jbc.M404159200; Barf T, 2002, J MED CHEM, V45, P3813, DOI 10.1021/jm025530f; BEUTLER E, 1967, J BIOL CHEM, V242, P5289; Bujalska IJ, 2005, J MOL ENDOCRINOL, V34, P675, DOI 10.1677/jme.1.01718; Clarke JL, 2003, ARCH BIOCHEM BIOPHYS, V415, P229, DOI 10.1016/S0003-9861(03)00229-7; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Gerin I, 2002, FEBS LETT, V517, P257, DOI 10.1016/S0014-5793(02)02640-6; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDULA B, 1970, ARCH BIOCHEM BIOPHYS, V141, P155, DOI 10.1016/0003-9861(70)90118-9; Mason PJ, 1999, BLOOD CELL MOL DIS, V25, P30, DOI 10.1006/bcmd.1999.0224; Masuzaki H, 2003, J CLIN INVEST, V112, P83, DOI 10.1172/JCI17845; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McCormick KL, 2006, J BIOL CHEM, V281, P341, DOI 10.1074/jbc.M506026200; Morton NM, 2001, J BIOL CHEM, V276, P41293, DOI 10.1074/jbc.M103676200; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302; Paterson JM, 2004, P NATL ACAD SCI USA, V101, P7088, DOI 10.1073/pnas.0305524101; ROMANELLI A, 1994, BIOCHEM BIOPH RES CO, V200, P1491, DOI 10.1006/bbrc.1994.1619; San Millan JL, 2005, J CLIN ENDOCR METAB, V90, P4157, DOI 10.1210/jc.2004-1523; SHACKLETON CHL, 1993, J STEROID BIOCHEM, V45, P127, DOI 10.1016/0960-0760(93)90132-G; SHACKLETON CHL, 1990, STEROIDS BILE ACID A, P297; TANAHASHI K, 1980, J HISTOCHEM CYTOCHEM, V28, P1175, DOI 10.1177/28.11.7430614; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; White PC, 2005, J CLIN ENDOCR METAB, V90, P5880, DOI 10.1210/jc.2005-0942; White PC, 1997, ENDOCR REV, V18, P135, DOI 10.1210/er.18.1.135	31	170	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6546	6551		10.1074/jbc.M512635200	http://dx.doi.org/10.1074/jbc.M512635200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16356929	hybrid			2022-12-27	WOS:000236030800050
J	Smith, BO; Picken, NC; Westrop, GW; Bromek, K; Mottram, JC; Coombs, GH				Smith, BO; Picken, NC; Westrop, GW; Bromek, K; Mottram, JC; Coombs, GH			The structure of Leishmania mexicana ICP provides evidence for convergent evolution of cysteine peptidase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; N-TERMINAL REGION; PROTEASE INHIBITOR; TRYPANOSOMA-CRUZI; STEFIN-A; CHAGASIN; PROTEINASES; BINDING; DIFFERENTIATION; IDENTIFICATION	Clan CA, family C1 cysteine peptidases ( CPs) are important virulence factors and drug targets in parasites that cause neglected diseases. Natural CP inhibitors of the I42 family, known as ICP, occur in some protozoa and bacterial pathogens but are absent from metazoa. They are active against both parasite and mammalian CPs, despite having no sequence similarity with other classes of CP inhibitor. Recent data suggest that Leishmania mexicana ICP plays an important role in host- parasite interactions. We have now solved the structure of ICP from L. mexicana by NMR and shown that it adopts a type of immunoglobulin- like fold not previously reported in lower eukaryotes or bacteria. The structure places three loops containing highly conserved residues at one end of the molecule, one loop being highly mobile. Interaction studies with CPs confirm the importance of these loops for the interaction between ICP and CPs and suggest the mechanism of inhibition. Structure- guided mutagenesis of ICP has revealed that residues in the mobile loop are critical for CP inhibition. Data- driven docking models support the importance of the loops in the ICP- CP interaction. This study provides structural evidence for the convergent evolution from an immunoglobulin fold of CP inhibitors with a cystatin- like mechanism.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immunol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Wellcome Ctr Mol Parasitol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow	Smith, BO (corresponding author), Joseph Black Bldg, Glasgow G12 8QQ, Lanark, Scotland.	b.smith@bio.gla.ac.uk	Smith, Brian/AAJ-9393-2020; Smith, Brian O/J-1899-2015	Smith, Brian/0000-0003-3363-4168; Smith, Brian O/0000-0003-3363-4168; Mottram, Jeremy/0000-0001-5574-3766; Westrop, Gareth/0000-0002-8011-6219	Medical Research Council [G0000508] Funding Source: Medline; Wellcome Trust [074875, 074875/2/04/2] Funding Source: Medline; MRC [G0000508] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alves LC, 2001, MOL BIOCHEM PARASIT, V116, P1, DOI 10.1016/S0166-6851(01)00290-0; Besteiro S, 2004, MOL MICROBIOL, V54, P1224, DOI 10.1111/j.1365-2958.2004.04355.x; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Bozic D, 2004, J BIOL CHEM, V279, P44812, DOI 10.1074/jbc.C400353200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1992, X PLOR 3 1; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Guncar G, 1999, EMBO J, V18, P793, DOI 10.1093/emboj/18.4.793; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Jenko S, 2003, J MOL BIOL, V326, P875, DOI 10.1016/S0022-2836(02)01432-8; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Markley JL, 1998, PURE APPL CHEM, V70, P117, DOI 10.1351/pac199870010117; MARTIN JR, 1994, EUR J BIOCHEM, V225, P1181, DOI 10.1111/j.1432-1033.1994.1181b.x; Monteiro ACS, 2001, J CELL SCI, V114, P3933; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Pol E, 2003, BBA-PROTEINS PROTEOM, V1645, P105, DOI 10.1016/S1570-9639(02)00526-5; Rawlings ND, 2004, NUCLEIC ACIDS RES, V32, pD160, DOI 10.1093/nar/gkp971; Rawlings ND, 2004, BIOCHEM J, V378, P705, DOI 10.1042/BJ20031825; Riekenberg S, 2005, FEBS LETT, V579, P1573, DOI 10.1016/j.febslet.2005.01.067; Rigden DJ, 2002, PROTEIN SCI, V11, P1971, DOI 10.1110/ps.0207202; Rigden DJ, 2001, FEBS LETT, V504, P41, DOI 10.1016/S0014-5793(01)02753-3; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; Sanderson SJ, 2003, FEBS LETT, V542, P12, DOI 10.1016/S0014-5793(03)00327-2; Sanderson SJ, 2000, BIOCHEM J, V347, P383, DOI 10.1042/0264-6021:3470383; Santos CC, 2005, J CELL SCI, V118, P901, DOI 10.1242/jcs.01677; SMITH BO, 2005, IN PRESS J BIOMOL NM; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449	36	37	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5821	5828		10.1074/jbc.M510868200	http://dx.doi.org/10.1074/jbc.M510868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407198	Green Accepted, hybrid			2022-12-27	WOS:000235568900061
J	Albers, M; Blume, B; Schlueter, T; Wright, MB; Kober, I; Kremoser, C; Deuschle, U; Koegl, M				Albers, M; Blume, B; Schlueter, T; Wright, MB; Kober, I; Kremoser, C; Deuschle, U; Koegl, M			A novel principle for partial agonism of liver X receptor ligands - Competitive recruitment of activators and repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; MOLECULAR DETERMINANTS; TISSUE-SPECIFICITY; CHOLESTEROL EFFLUX; LIPID-METABOLISM; GENE-EXPRESSION; BINDING DOMAIN; LXR-ALPHA; COACTIVATOR; IDENTIFICATION	Partial, selective activation of nuclear receptors is a central issue in molecular endocrinology but only partly understood. Using LXRs as an example, we show here that purely agonistic ligands can be clearly and quantitatively differentiated from partial agonists by the cofactor interactions they induce. Although a pure agonist induces a conformation that is incompatible with the binding of repressors, partial agonists such as GW3965 induce a state where the interaction not only with coactivators, but also corepressors is clearly enhanced over the unliganded state. The activities of the natural ligand 22(R)-hydroxycholesterol and of a novel quinazolinone ligand, LN6500 can be further differentiated from GW3965 and T0901317 by their weaker induction of coactivator binding. Using biochemical and cell-based assays, we show that the natural ligand of LXR is a comparably weak partial agonist. As predicted, we find that a change in the coactivator to corepressor ratio in the cell will affect NCoR recruiting compounds more dramatically than NCoR-dissociating compounds. Our data show how competitive binding of coactivators and corepressors can explain the tissue-specific behavior of partial agonists and open up new routes to a rational design of partial agonists for LXRs.	PheneX Pharmaceut AG, D-67056 Ludwigshafen, Germany; F Hoffmann La Roche & Cie AG, Dept Vasc & Metab Dis, CH-4070 Basel, Switzerland	Roche Holding	Koegl, M (corresponding author), RZPD German Resource Ctr Genome Res, Neuenheimer Feld 580, D-69120 Heidelberg, Germany.	koegl@rzpd.de		Wright, matthewwright/0000-0002-0532-3381				Albers M, 2005, MOL CELL PROTEOMICS, V4, P205, DOI 10.1074/mcp.M400169-MCP200; Bramlett KS, 2001, MOL ENDOCRINOL, V15, P909, DOI 10.1210/me.15.6.909; Chang CY, 1999, MOL CELL BIOL, V19, P8226; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chisholm JW, 2003, J LIPID RES, V44, P2039, DOI 10.1194/jlr.M300135-JLR200; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Farnegardh M, 2003, J BIOL CHEM, V278, P38821, DOI 10.1074/jbc.M304842200; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Hoerer S, 2003, J MOL BIOL, V334, P853, DOI 10.1016/j.jmb.2003.10.033; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Iannone MA, 2004, MOL ENDOCRINOL, V18, P1064, DOI 10.1210/me.2003-0432; Iannone MA, 2000, CYTOMETRY, V39, P131, DOI 10.1002/(SICI)1097-0320(20000201)39:2<131::AID-CYTO6>3.3.CO;2-L; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2003, CURR OPIN PHARMACOL, V3, P192, DOI 10.1016/S1471-4892(03)00009-2; Lala DS, 2004, IDRUGS, V7, P563; LE DB, 1996, EMBO J, V15, P6701; Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010-JLR200; Lund EG, 2003, ARTERIOSCL THROM VAS, V23, P1169, DOI 10.1161/01.ATV.0000056743.42348.59; McDonnell DP, 2003, ENDOCRINOLOGY, V144, P4237, DOI 10.1210/en.2003-0900; Miao B, 2004, J LIPID RES, V45, P1410, DOI 10.1194/jlr.M300450-JLR200; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Quinet EM, 2004, J LIPID RES, V45, P1929, DOI 10.1194/jlr.M400257-JLR200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; Stanley TB, 2003, BIOCHEMISTRY-US, V42, P9278, DOI 10.1021/bi034472c; Steffensen KR, 2004, DIABETES, V53, pS36, DOI 10.2337/diabetes.53.2007.S36; Svensson S, 2003, EMBO J, V22, P4625, DOI 10.1093/emboj/cdg456; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Wang Q, 2004, MOL ENDOCRINOL, V18, P1376, DOI 10.1210/me.2003-0421; Whitney KD, 2001, J BIOL CHEM, V276, P43509, DOI 10.1074/jbc.M106155200; Williams S, 2003, J BIOL CHEM, V278, P27138, DOI 10.1074/jbc.M302260200; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Zechel C, 2002, J RECEPT SIGNAL TR R, V22, P31, DOI 10.1081/RRS-120014587	49	76	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4920	4930		10.1074/jbc.M510101200	http://dx.doi.org/10.1074/jbc.M510101200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16354658	hybrid			2022-12-27	WOS:000235426200043
J	Eraly, SA; Vallon, V; Vaughn, DA; Gangoiti, JA; Richter, K; Nagle, M; Monte, JC; Rieg, T; Truong, DM; Long, JM; Barshop, BA; Kaler, G; Nigam, SK				Eraly, SA; Vallon, V; Vaughn, DA; Gangoiti, JA; Richter, K; Nagle, M; Monte, JC; Rieg, T; Truong, DM; Long, JM; Barshop, BA; Kaler, G; Nigam, SK			Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE PROTEIN MRP2; BETA-LACTAM ANTIBIOTICS; MOLECULAR-CLONING; RAT-KIDNEY; TRANSPORTER 1; CATION TRANSPORTERS; PARA-AMINOHIPPURATE; FUNCTIONAL-CHARACTERIZATION; SUBSTRATE-SPECIFICITY; CELLULAR PHYSIOLOGY	The "classical" organic anion secretory pathway of the renal proximal tubule is critical for the renal excretion of the prototypic organic anion, para-aminohippurate, as well as of a large number of commonly prescribed drugs among other significant substrates. Organic anion transporter 1 ( OAT1), originally identified as NKT ( Lopez-Nieto, C. E., You, G., Bush, K. T., Barros, E. J. G., Beier, D. R., and Nigam, S. K. ( 1997) J. Biol. Chem. 272, 6471-6478), has physiological properties consistent with a role in this pathway. However, several other transporters ( e. g. OAT2, OAT3, and MRP1) have also been proposed as important PAH transporters on the basis of in vitro studies; therefore, the relative contribution of OAT1 has remained unclear. We have now generated a colony of OAT1 knockout mice, permitting elucidation of the role of OAT1 in the context of these other potentially functionally redundant transporters. We find that the knock-out mice manifest a profound loss of organic anion transport ( e. g. para-aminohippurate) both ex vivo ( in isolated renal slices) as well as in vivo ( as indicated by loss of renal secretion). In the case of the organic anion, furosemide, loss of renal secretion in the knock-out results in impaired diuretic responsiveness to this drug. These results indicate a critical role for OAT1 in the functioning of the classical pathway. In addition, we have determined the levels of similar to 60 endogenous organic anions in the plasma and urine of wild-type and knock-out mice. This has led to identification of several compounds with significantly higher plasma concentrations and/or lower urinary concentrations in knock-out mice, suggesting the involvement of OAT1 in their renal secretion. We have also demonstrated in xenopus oocytes that some of these compounds interact with OAT1 in vitro. Thus, these latter compounds might represent physiological substrates of OAT1.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; San Diego Vet Affairs Healthcare Syst, Dept Med, La Jolla, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Nigam, SK (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	snigam@ucsd.edu	Rieg, Timo/W-7478-2019	Rieg, Timo/0000-0001-6082-662X; Vallon, Volker/0000-0002-9211-2063; Truong, David/0000-0002-5121-5111	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD040011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI057695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028602, R01DK056248, K08DK064839] Funding Source: NIH RePORTER; NIAID NIH HHS [AI057695] Funding Source: Medline; NICHD NIH HHS [HD40011] Funding Source: Medline; NIDDK NIH HHS [DK064839, DK28602, DK56248] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apiwattanakul N, 1999, MOL PHARMACOL, V55, P847; Bahn A, 2004, DRUG METAB DISPOS, V32, P424, DOI 10.1124/dmd.32.4.424; BEERMANN B, 1984, ACTA PHARMACOL TOX, V54, P17; BOUHAMIDI R, 1992, J STEROID BIOCHEM, V42, P345, DOI 10.1016/0960-0760(92)90138-9; BOWMAN HM, 1972, P SOC EXP BIOL MED, V141, P258; Brady KP, 1999, GENOMICS, V56, P254, DOI 10.1006/geno.1998.5722; Buist SCN, 2004, DRUG METAB DISPOS, V32, P620, DOI 10.1124/dmd.32.6.620; Buist SCN, 2003, DRUG METAB DISPOS, V31, P559, DOI 10.1124/dmd.31.5.559; Buist SCN, 2002, J PHARMACOL EXP THER, V301, P145, DOI 10.1124/jpet.301.1.145; BULLETTI C, 1988, AM J OBSTET GYNECOL, V159, P509, DOI 10.1016/S0002-9378(88)80119-4; Burckhardt BC, 2003, REV PHYSIOL BIOCH P, V146, P95, DOI 10.1007/s10254-002-0003-8; Burckhardt G, 2002, CELL BIOCHEM BIOPHYS, V36, P169, DOI 10.1385/CBB:36:2-3:169; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Cha SH, 2001, MOL PHARMACOL, V59, P1277, DOI 10.1124/mol.59.5.1277; Cihlar T, 2000, ANAL BIOCHEM, V283, P49, DOI 10.1006/abio.2000.4633; Cihlar T, 1999, MOL PHARMACOL, V56, P570, DOI 10.1124/mol.56.3.570; DALTON RN, 1988, KIDNEY INT, V34, P117, DOI 10.1038/ki.1988.153; Dantzler WH, 2003, BBA-BIOMEMBRANES, V1618, P185, DOI 10.1016/j.bbamem.2003.08.015; Dantzler WH, 2002, BBA-BIOMEMBRANES, V1566, P169, DOI 10.1016/S0005-2736(02)00599-0; DONOSO VS, 1986, J LAB CLIN MED, V107, P315; Dresser MJ, 2001, J PHARM SCI, V90, P397, DOI 10.1002/1520-6017(200104)90:4<397::AID-JPS1000>3.3.CO;2-4; Enomoto A, 2002, J PHARMACOL EXP THER, V301, P797, DOI 10.1124/jpet.301.3.797; Enomoto A, 2002, NATURE, V417, P447, DOI 10.1038/nature742; Eraly SA, 2004, MOL PHARMACOL, V65, P479, DOI 10.1124/mol.65.3.479; Eraly SA, 2004, PHYSIOL GENOMICS, V18, P12, DOI 10.1152/physiolgenomics.00014.2004; Eraly SA, 2003, CURR OPIN NEPHROL HY, V12, P551, DOI 10.1097/00041552-200309000-00011; Eraly SA, 2003, BIOCHEM BIOPH RES CO, V300, P333, DOI 10.1016/S0006-291X(02)02853-X; Eraly SA, 2002, BIOCHEM BIOPH RES CO, V297, P1159, DOI 10.1016/S0006-291X(02)02343-4; GOUGOUX A, 1989, AM J PHYSIOL, V257, pF959, DOI 10.1152/ajprenal.1989.257.6.F959; Groves CE, 1998, J PHARMACOL EXP THER, V284, P943; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HOFFMANN G, 1989, CLIN CHEM, V35, P587; Huang DY, 2004, J AM SOC NEPHROL, V15, P885, DOI 10.1097/01.ASN.0000120368.59693.A8; Illum L, 2000, EUR J PHARM SCI, V11, P1, DOI 10.1016/S0928-0987(00)00087-7; Jariyawat S, 1999, J PHARMACOL EXP THER, V290, P672; Kobayashi Y, 2002, MOL PHARMACOL, V62, P7, DOI 10.1124/mol.62.1.7; Kojima R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134848; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kumps A, 2002, CLIN CHEM, V48, P708; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Kuze K, 1999, J BIOL CHEM, V274, P1519, DOI 10.1074/jbc.274.3.1519; Leier I, 2000, KIDNEY INT, V57, P1636, DOI 10.1046/j.1523-1755.2000.00007.x; Ljubojevic M, 2004, AM J PHYSIOL-RENAL, V287, pF124, DOI 10.1152/ajprenal.00029.2004; Lopez-Nieto C. E., 1996, Journal of the American Society of Nephrology, V7, P1301; LopezNieto CE, 1996, NAT BIOTECHNOL, V14, P857, DOI 10.1038/nbt0796-857; LopezNieto CE, 1997, J BIOL CHEM, V272, P6471, DOI 10.1074/jbc.272.10.6471; Lu R, 1999, AM J PHYSIOL-RENAL, V276, pF295, DOI 10.1152/ajprenal.1999.276.2.F295; MACDOUGALL ML, 1988, J PHYSIOL-LONDON, V397, P459, DOI 10.1113/jphysiol.1988.sp017012; Monte JC, 2004, BIOCHEM BIOPH RES CO, V323, P429, DOI 10.1016/j.bbrc.2004.08.112; Mori K, 1997, FEBS LETT, V417, P371, DOI 10.1016/S0014-5793(97)01325-2; Motohashi H, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134866; Motojima M, 2002, BRIT J PHARMACOL, V135, P555, DOI 10.1038/sj.bjp.0704482; *NIH, 1996, GUID CAR US LAB AN N; Pavlova A, 2000, AM J PHYSIOL-RENAL, V278, pF635, DOI 10.1152/ajprenal.2000.278.4.F635; Pritchard JB, 1996, KIDNEY INT, V49, P1649, DOI 10.1038/ki.1996.240; RICHTERICH R, 1969, CLIN CHEM; Russel FGM, 2002, ANNU REV PHYSIOL, V64, P563, DOI 10.1146/annurev.physiol.64.081501.155913; Schomig E, 1998, FEBS LETT, V425, P79, DOI 10.1016/S0014-5793(98)00203-8; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SIMONSON GD, 1994, J CELL SCI, V107, P1065; SKOV PE, 1977, ACTA MED SCAND, V202, P81; Smeets PHE, 2004, J AM SOC NEPHROL, V15, P2828, DOI 10.1097/01.ASN.0000143473.64430.AC; Sun W, 2001, BIOCHEM BIOPH RES CO, V283, P417, DOI 10.1006/bbrc.2001.4774; Sweet DH, 2005, TOXICOL APPL PHARM, V204, P198, DOI 10.1016/j.taap.2004.10.016; Sweet DH, 2003, AM J PHYSIOL-RENAL, V284, pF763, DOI 10.1152/ajprenal.00405.2002; Sweet DH, 2002, J BIOL CHEM, V277, P26934, DOI 10.1074/jbc.M203803200; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Sykes D, 2004, AM J PHYSIOL-RENAL, V286, pF972, DOI 10.1152/ajprenal.00356.2003; Tune BM, 1997, PEDIATR NEPHROL, V11, P768, DOI 10.1007/s004670050386; Uchino H, 2000, BIOCHEM BIOPH RES CO, V270, P254, DOI 10.1006/bbrc.2000.2407; Uwai Y, 2000, J PHARMACOL EXP THER, V295, P261; Vallon V, 1998, J PHARMACOL EXP THER, V286, P1215; Vallon V, 2004, PFLUG ARCH EUR J PHY, V448, P214, DOI 10.1007/s00424-004-1239-8; Van Aubel RAMH, 2000, AM J PHYSIOL-RENAL, V279, pF216, DOI 10.1152/ajprenal.2000.279.2.F216; Van Aubel RAMH, 2000, AM J PHYSIOL-RENAL, V279, pF713, DOI 10.1152/ajprenal.2000.279.4.F713; Vormfelde SV, 2003, PHARMACOGENOMICS, V4, P701, DOI 10.1517/phgs.4.6.701.22817; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; Youngblood GL, 2004, AM J PHYSIOL-RENAL, V287, pF236, DOI 10.1152/ajprenal.00012.2004	79	171	172	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5072	5083		10.1074/jbc.M508050200	http://dx.doi.org/10.1074/jbc.M508050200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16354673	hybrid			2022-12-27	WOS:000235426200062
J	Mi, KH; Dolan, PJ; Johnson, GVW				Mi, KH; Dolan, PJ; Johnson, GVW			The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED HELICAL FILAMENTS; WNT SIGNALING PATHWAY; BETA-CATENIN; ALZHEIMERS-DISEASE; TAU-PROTEIN; CANONICAL PATHWAY; PHOSPHORYLATION; AXIN; KINASE	Glycogen synthase kinase 3 (GSK3) is a widely expressed Ser/Thr protein kinase that phosphorylates numerous substrates. This large number of substrates requires precise and specific regulation of GSK3 activity, which is achieved by a combination of phosphorylation, localization, and interactions with GSK3-binding proteins. Members of the Wnt canonical pathway have been shown to influence GSK3 activity. Through a yeast two-hybrid screen, we identified the Wnt canonical pathway co-receptor protein low density lipoprotein receptor-related protein 6 (LRP6) as a GSK3-binding protein. The interaction between the C terminus of LRP6 and GSK3 was also confirmed by in vitro GST pull-down assays and in situ coimmunoprecipitation assays. In vitro assays using immunoprecipitated proteins demonstrated that the C terminus of LRP6 significantly attenuated the activity of GSK3 beta. In situ, LRP6 significantly decreased GSK3 beta-mediated phosphorylation of tau at both primed and unprimed sites. Finally, it was also demonstrated that GSK3 beta phosphorylates the PPP(S/T) P motifs in the C terminus of LRP6. This is the first identification of a direct interaction between LRP6 and GSK3, which results in an attenuation of GSK3 activity.	Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama, Dept Psychiat, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404	NINDS NIH HHS [NS051279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS051279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraha A, 2000, J CELL SCI, V113, P3737; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Billingsley ML, 1997, BIOCHEM J, V323, P577, DOI 10.1042/bj3230577; Brennan K, 2004, ONCOGENE, V23, P4873, DOI 10.1038/sj.onc.1207642; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Cho JH, 2004, J NEUROCHEM, V88, P349, DOI 10.1046/j.1471-4159.2003.02155.x; Culbert AA, 2001, FEBS LETT, V507, P288, DOI 10.1016/S0014-5793(01)02990-8; Ferkey DM, 2002, J BIOL CHEM, V277, P16147, DOI 10.1074/jbc.M112363200; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hay E, 2005, J BIOL CHEM, V280, P13616, DOI 10.1074/jbc.M411999200; Hoffmann R, 1997, BIOCHEMISTRY-US, V36, P8114, DOI 10.1021/bi970380+; Holmen SL, 2005, BIOCHEM BIOPH RES CO, V328, P533, DOI 10.1016/j.bbrc.2005.01.009; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Johnson G V, 1999, J Alzheimers Dis, V1, P307; Johnson GVW, 1997, J NEUROCHEM, V68, P430; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Lau KF, 1999, J PEPT RES, V54, P85, DOI 10.1034/j.1399-3011.1999.00083.x; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li YH, 2004, ONCOGENE, V23, P9129, DOI 10.1038/sj.onc.1208123; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mi KH, 2005, J CELL BIOCHEM, V95, P328, DOI 10.1002/jcb.20400; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Stoothof WH, 2002, J NEUROCHEM, V83, P904, DOI 10.1046/j.1471-4159.2002.01197.x; Stoothoff WH, 2005, J BIOL CHEM, V280, P270, DOI 10.1074/jbc.M410061200; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; van Amerongen R, 2005, GENE DEV, V19, P425, DOI 10.1101/gad.326705; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Zilberberg A, 2004, J BIOL CHEM, V279, P17535, DOI 10.1074/jbc.M311292200; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8; Zou ZY, 2004, J BIOL CHEM, V279, P34302, DOI 10.1074/jbc.M405608200	52	67	84	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4787	4794		10.1074/jbc.M508657200	http://dx.doi.org/10.1074/jbc.M508657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365045	hybrid			2022-12-27	WOS:000235426200029
J	Nacak, TG; Leptien, K; Fellner, D; Augustin, HG; Kroll, J				Nacak, TG; Leptien, K; Fellner, D; Augustin, HG; Kroll, J			The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-MEDIATED CLEAVAGE; CUL3-BASED E3 LIGASE; REPEAT SUPERFAMILY; NRF2; INHIBITION; ADAPTER; ELEMENTS; COMPLEX; BINDING; BRIDGES	Members of the BTB-kelch superfamily play important roles during fundamental cellular processes, such as the regulation of cell morphology, migration, and gene expression. The BTB-kelch protein LZTR-1is deleted in the majority of DiGeorge syndrome patients and is believed to act as a transcriptional regulator. However, functional and expression profiling studies of LZTR-1 have not been performed thus far. Therefore, we examined the subcellular localization and function of LZTR-1 to gain insights into its biological role. Analysis of the primary structure of the protein revealed six N-terminal kelch motifs and two BTB/POZ domains at the C terminus within LZTR-1. Confocal analysis of the subcellular distribution of LZTR-1 using the Golgi markers GM130, Golgin-97, and TGN46 identified a localization of LZTR-1 exclusively on the cytoplasmic surface of the Golgi network that is mediated by its second BTB/POZ domain. In contrast to most other BTB-kelch proteins, LZTR-1 did not co-localize with actin. Treatment with brefeldin A did not lead to redistribution of LZTR-1 to the endoplasmic reticulum but caused its relocalization in dispersed, punctuated structures that were also positive for GM130. These data demonstrate that LZTR-1 is a Golgi matrix-associated protein. Upon induction of apoptosis, LZTR-1 was phosphorylated on tyrosine residues and subsequently degraded; that could be rescued partially by the addition of the caspase inhibitor Z-VAD-fmk and the proteasome inhibitors lactacystin and MG132. Taken together, our experiments identify LZTR-1 as the first BTB-kelch protein that exclusively localizes to the Golgi network, and the binding of LZTR-1 to the Golgi complex is mediated by its second BTB/POZ domain.	Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, D-79106 Freiburg, Germany		Kroll, J (corresponding author), Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, Breisacher Str 117, D-79106 Freiburg, Germany.	kroll@tumorbio.uni-freiburg.de	Augustin, Hellmut/AAA-5246-2020	Augustin, Hellmut/0000-0002-7173-4242				Adams J, 2000, TRENDS CELL BIOL, V10, P17, DOI 10.1016/S0962-8924(99)01673-6; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; Cullen VC, 2004, NEUROREPORT, V15, P873, DOI 10.1097/00001756-200404090-00028; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Fujimura L, 2004, CARDIOVASC RES, V64, P315, DOI 10.1016/j.cardiores.2004.07.009; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Hicks SW, 2002, J BIOL CHEM, V277, P35833, DOI 10.1074/jbc.M206280200; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Keller JN, 2000, J NEUROSCI RES, V61, P436, DOI 10.1002/1097-4547(20000815)61:4<436::AID-JNR10>3.0.CO;2-Z; Kelly KF, 2004, J CELL SCI, V117, P6143, DOI 10.1242/jcs.01541; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kroll J, 2005, MOL CELL BIOL, V25, P8531, DOI 10.1128/MCB.25.19.8531-8540.2005; KURAHASHI H, 1995, HUM MOL GENET, V4, P541, DOI 10.1093/hmg/4.4.541; Lane JD, 2002, J CELL BIOL, V156, P495, DOI 10.1083/jcb.200110007; Lindsay EA, 2001, NAT REV GENET, V2, P858, DOI 10.1038/35098574; Lowe M, 2004, J CELL SCI, V117, P1139, DOI 10.1242/jcs.00950; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Philpott KL, 1996, EUR J NEUROSCI, V8, P1906, DOI 10.1111/j.1460-9568.1996.tb01334.x; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Prag S, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-42; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; Sesso A, 1999, TISSUE CELL, V31, P357, DOI 10.1054/tice.1999.0042; Stogios PJ, 2004, TRENDS BIOCHEM SCI, V29, P634, DOI 10.1016/j.tibs.2004.10.003; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Yan W, 2004, P NATL ACAD SCI USA, V101, P7793, DOI 10.1073/pnas.0308025101; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	34	41	43	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5065	5071		10.1074/jbc.M509073200	http://dx.doi.org/10.1074/jbc.M509073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16356934	hybrid			2022-12-27	WOS:000235426200061
J	Perez-Vilar, J; Mabolo, R; McVaugh, CT; Bertozzi, CR; Boucher, RC				Perez-Vilar, J; Mabolo, R; McVaugh, CT; Bertozzi, CR; Boucher, RC			Mucin granule intraluminal organization in living mucous/goblet cells - Roles of protein post-translational modifications and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; O-GLYCOSYLATION; ION-EXCHANGE; MUC5AC MUCIN; RELEASE; EXOCYTOSIS; KINETICS; PEPTIDE; PATHWAY; CA2+	Recent studies suggest that the mucin granule lumen consists of a matrix meshwork embedded in a fluid phase. Secretory products can both diffuse, although very slowly, through the meshwork pores and interact noncovalently with the matrix. Using a green fluorescent protein-mucin fusion protein (SHGFP-MUC5AC/CK) as a FRAP (fluorescence recovery after photobleaching) probe, we have assessed in living mucous cells the relative importance of different protein post-translational modifications on the intragranular organization. Long term inhibition of mucin-type O-glycosylation, sialylation, or sulfation altered SHGFP-MUC5AC/CK characteristic diffusion time (t(1/2)), whereas all but sulfation diminished its mobile fraction. Reduction of protein disulfide bonds with tris(hydroxypropyl) phosphine resulted in virtually complete immobilization of the SHGFP-MUC5AC/CK intragranular pool. However, when activity of the vacuolar H+-ATPase was also inhibited, disulfide reduction decreased SHGFP-MUC5AC/CKt(1/2) while diminishing its intraluminal concentration. Similar FRAP profiles were observed in granules that remained in the cells after the addition of amucin secretagogue. Taken together these results suggest that: (a) the relative content of O-glycans and intragranular anionic groups is crucial for protein diffusion through the intragranular meshwork; (b) protein-protein, rather than carbohydrate-mediated, interactions are responsible for binding of SHGFP-MUC5AC/CK to the immobile fraction, although the degree of matrix O-glycosylation and sialylation affects such interactions; (c) intragranular organization does not depend on covalent multimerization of mucins or the presence of native disulfide bonds in the intragranular mucin/proteins, but rather on specific protein-mediated interactions that are important during the early stages of mucin matrix condensation; (d) alterations of the intragranular matrix precede granule discharge, which can be partial and, accordingly, does not necessarily involve the disappearance of the granule.	Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Howard Hughes Med Inst, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Perez-Vilar, J (corresponding author), Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, CB7248, Chapel Hill, NC 27599 USA.	juan_vilar@med.unc.edu			NCI NIH HHS [P50 CA89520] Funding Source: Medline; NIDDK NIH HHS [DK63030] Funding Source: Medline; NIGMS NIH HHS [GM66047] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK063030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravanis AM, 2003, NATURE, V423, P643, DOI 10.1038/nature01686; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brockhausen I, 2003, BIOCHEM SOC T, V31, P318, DOI 10.1042/BST0310318; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; Chin WC, 2004, PLANT CELL PHYSIOL, V45, P535, DOI 10.1093/pcp/pch062; Day R, 2003, TRENDS ENDOCRIN MET, V14, P10, DOI 10.1016/S1043-2760(02)00011-5; DEKKER J, 1989, J BIOL CHEM, V264, P10431; Dekker J, 2002, TRENDS BIOCHEM SCI, V27, P126, DOI 10.1016/S0968-0004(01)02052-7; Drose S, 1997, J EXP BIOL, V200, P1; Espinosa M, 2002, HUM REPROD, V17, P1964, DOI 10.1093/humrep/17.8.1964; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; Gouyer V, 2001, FRONT BIOSCI, V6, pD1235, DOI 10.2741/gouyer; Halm DR, 2000, AM J PHYSIOL-CELL PH, V278, pC212, DOI 10.1152/ajpcell.2000.278.1.C212; Han WP, 1999, J NEUROSCI, V19, P900; Hang HC, 2004, CHEM BIOL, V11, P337, DOI 10.1016/j.chembiol.2004.02.023; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Kelly ML, 2004, CELL BIOL INT, V28, P709, DOI 10.1016/j.cellbi.2004.07.005; Kepes F, 2005, INT REV CYTOL, V242, P55; Kitamura H, 1996, EUR J CANCER, V32A, P1788, DOI 10.1016/0959-8049(96)00168-2; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Lee KY, 2002, J BIOL CHEM, V277, P49341, DOI 10.1074/jbc.M209618200; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Lidell ME, 2003, J BIOL CHEM, V278, P13944, DOI 10.1074/jbc.M210069200; LOHMANDER LS, 1979, J BIOL CHEM, V254, P551; Marszalek PE, 1997, BIOPHYS J, V73, P1160, DOI 10.1016/S0006-3495(97)78148-7; Marszalek PE, 1997, BIOPHYS J, V73, P1169, DOI 10.1016/S0006-3495(97)78149-9; Molist A, 1998, EUR J BIOCHEM, V254, P371, DOI 10.1046/j.1432-1327.1998.2540371.x; NEUTRA MR, 1984, CIBA F SYMP, V109, P20, DOI 10.1002/9780470720905.ch3; Nguyen T, 1998, NATURE, V395, P908, DOI 10.1038/27686; Palfrey HC, 2003, CURR BIOL, V13, pR397, DOI 10.1016/S0960-9822(03)00320-8; Perez-Vilar J, 2004, FREE RADICAL BIO MED, V37, P1564, DOI 10.1016/j.freeradbiomed.2004.07.027; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 2005, J HISTOCHEM CYTOCHEM, V53, P1305, DOI 10.1369/jhc.5B6713.2005; Perez-Vilar J, 2005, J BIOL CHEM, V280, P16868, DOI 10.1074/jbc.M413289200; Perez-Vilar J, 2004, GLYCOBIOLOGY, V14, P325, DOI 10.1093/glycob/cwh041; Periasamy N, 1998, BIOPHYS J, V75, P557, DOI 10.1016/S0006-3495(98)77545-9; PHILLIPS TE, 1995, IN VITRO CELL DEV-AN, V31, P421, DOI 10.1007/BF02634251; Pollack GH, 2003, ADV COLLOID INTERFAC, V103, P173, DOI 10.1016/S0001-8686(02)00095-7; PUCHELLE E, 1991, BIOL CELL, V72, P159, DOI 10.1016/0248-4900(91)90090-A; Quesada I, 2003, BIOPHYS J, V85, P963, DOI 10.1016/S0006-3495(03)74535-4; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; SERAFIN WE, 1986, J BIOL CHEM, V261, P5017; Sheehan JK, 2004, J BIOL CHEM, V279, P15698, DOI 10.1074/jbc.M313241200; Sheehan JK, 2000, BIOCHEM J, V347, P37, DOI 10.1042/0264-6021:3470037; Singer M, 2004, NAT MED, V10, P193, DOI 10.1038/nm983; Snapp E.L., 2003, CURRENT PROTOCOLS CE; SPECIAN RD, 1991, AM J PHYSIOL, V260, pC183, DOI 10.1152/ajpcell.1991.260.2.C183; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TANAKA T, 1979, J CHEM PHYS, V70, P1214, DOI 10.1063/1.437602; Taraska JW, 2003, P NATL ACAD SCI USA, V100, P2070, DOI 10.1073/pnas.0337526100; Thiele C, 1998, SEMIN CELL DEV BIOL, V9, P511, DOI 10.1006/scdb.1998.0259; THORNTON DJ, 1995, ANAL BIOCHEM, V227, P162, DOI 10.1006/abio.1995.1266; Tian E, 2004, J BIOL CHEM, V279, P50382, DOI 10.1074/jbc.M406397200; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; VERDUGO P, 1991, AM REV RESPIR DIS, V144, pS33, DOI 10.1164/ajrccm/144.3_pt_2.S33; VERDUGO P, 1984, CIBA F SYMP, V109, P212, DOI 10.1002/9780470720905.ch15; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001; Wickstrom C, 2001, J BIOL CHEM, V276, P47116, DOI 10.1074/jbc.M106593200	63	25	27	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4844	4855		10.1074/jbc.M510520200	http://dx.doi.org/10.1074/jbc.M510520200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377632	hybrid			2022-12-27	WOS:000235426200035
J	Balatsos, NAA; Nilsson, P; Mazza, C; Cusack, S; Virtanen, A				Balatsos, NAA; Nilsson, P; Mazza, C; Cusack, S; Virtanen, A			Inhibition of mRNA deadenylation by the nuclear cap binding complex (CBC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC TRANSLATION INITIATION; AU-RICH ELEMENTS; POLY(A)-SPECIFIC RIBONUCLEASE; POLY(A)-BINDING PROTEIN; MAMMALIAN-CELLS; POLY(A) BINDING; IN-VITRO; SACCHAROMYCES-CEREVISIAE; CYTOPLASMIC EXTRACTS; YEAST	Poly(A)-specific ribonuclease (PARN) is a cap-interacting and poly(A)-specific 3'-exoribonuclease. Here we have investigated how the cap binding complex ( CBC) affects human PARN activity. We showed that CBC, via its 80-kDa subunit (CBP80), inhibited PARN, suggesting that CBC can regulate mRNA deadenylation. The CBC-mediated inhibition of PARN was cap-independent, and in keeping with this, the CBP80 subunit alone inhibited PARN. Our data suggested a new function for CBC, identified CBC as a potential regulator of PARN, and emphasized the importance of communication between the two extreme ends of the mRNA as a key strategy to regulate mRNA degradation. Based on our data, we have proposed a model for CBC-mediated regulation of PARN, which relies on an interaction between CBP80 and PARN. Association of CBC with PARN might have importance in the regulated recruitment of PARN to the nonsense-mediated decay pathway during the pioneer round of translation.	Uppsala Univ, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble 9, France	Uppsala University; European Molecular Biology Laboratory (EMBL)	Virtanen, A (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.	anders.virtanen@icm.uu.se		Cusack, Stephen/0000-0002-9324-0796; Balatsos, Nikolaos/0000-0002-1146-1174				ASTRON J, 1999, EMBO J, V10, P3067; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Calero G, 2002, NAT STRUCT BIOL, V9, P912, DOI 10.1038/nsb874; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chiba Y, 2004, GENE, V328, P95, DOI 10.1016/j.gene.2003.11.028; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; Coller JM, 1998, GENE DEV, V12, P3226, DOI 10.1101/gad.12.20.3226; Copeland PR, 2001, RNA, V7, P875, DOI 10.1017/S1355838201010020; Daugeron MC, 2001, NUCLEIC ACIDS RES, V29, P2448, DOI 10.1093/nar/29.12.2448; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fortes P, 2000, MOL CELL, V6, P191, DOI 10.1016/S1097-2765(00)00020-4; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Izaurralde E, 1995, COLD SPRING HARB SYM, V60, P669, DOI 10.1101/SQB.1995.060.01.072; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JAREBORG N, 1991, J GEN VIROL, V72, P2269, DOI 10.1099/0022-1317-72-9-2269; Khanna R, 2004, EMBO J, V23, P1968, DOI 10.1038/sj.emboj.7600213; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Kuhn U, 2004, BBA-GENE STRUCT EXPR, V1678, P67, DOI 10.1016/j.bbaexp.2004.03.008; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lejeune F, 2004, NAT STRUCT MOL BIOL, V11, P992, DOI 10.1038/nsmb824; Lejeune F, 2003, MOL CELL, V12, P675, DOI 10.1016/S1097-2765(03)00349-6; Maquat LE, 2004, NAT REV MOL CELL BIO, V5, P89, DOI 10.1038/nrm1310; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Mazza C, 2002, EMBO J, V21, P5548, DOI 10.1093/emboj/cdf538; Mazza C, 2001, MOL CELL, V8, P383, DOI 10.1016/S1097-2765(01)00299-4; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Niedzwiecka A, 2002, J MOL BIOL, V319, P615, DOI 10.1016/S0022-2836(02)00328-5; Ohno M, 2000, CELL, V101, P187, DOI 10.1016/S0092-8674(00)80829-6; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Ren YG, 2002, RNA, V8, P1393, DOI 10.1017/S1355838202021015; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Seal R, 2005, NUCLEIC ACIDS RES, V33, P376, DOI 10.1093/nar/gki169; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; VARNUM SM, 1992, DEV BIOL, V153, P283, DOI 10.1016/0012-1606(92)90113-U; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; Viswanathan P, 2003, J BIOL CHEM, V278, P14949, DOI 10.1074/jbc.M211794200; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wilusz CJ, 2001, RNA, V7, P1416; Worch R, 2005, RNA, V11, P1355, DOI 10.1261/rna.2850705; Wu MS, 2005, EMBO J, V24, P4082, DOI 10.1038/sj.emboj.7600869	54	51	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4517	4522		10.1074/jbc.M508590200	http://dx.doi.org/10.1074/jbc.M508590200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16317009	hybrid			2022-12-27	WOS:000235275300087
J	Eckhardt, ERM; Cai, L; Shetty, S; Zhao, ZZ; Szanto, A; Webb, NR; Van der Westhuyzen, DR				Eckhardt, ERM; Cai, L; Shetty, S; Zhao, ZZ; Szanto, A; Webb, NR; Van der Westhuyzen, DR			High density lipoprotein endocytosis by scavenger receptor SR-BII is clathrin-dependent and requires a carboxyl-terminal dileucine motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TYPE-I; SELECTIVE LIPID UPTAKE; COATED PIT FORMATION; MEDIATED ENDOCYTOSIS; CHOLESTERYL ESTERS; TRANSPORT; CELLS; METABOLISM; PROTEINS; GLYCOSPHINGOLIPIDS	The high density lipoprotein (HDL) receptor Scavenger Receptor BII (SR-BII) is encoded by an alternatively spliced mRNA from the SR-BI gene and is expressed in various tissues. SR-BII protein differs from SR-BI only in the carboxyl-terminal cytoplasmic tail, which, as we showed previously, must contain a signal that confers predominant intracellular expression and rapid endocytosis of HDL. We haveshown thatSR-BII mediates HDL endocytosis through a clathrin-dependent, caveolae-independent pathway. Two candidate amino acid motifs were identified in the tail that could mediate association with clathrin-containing endocytic vesicles: a putative dileucine motif at position 492-493 and an overlapping tyrosine-based YXXZ motif starting at position 489. Although substitution of tyrosine at position 489 with alanine or histidine did not affect endocytosis, substitution L492A resulted in increased surface binding of HDL and reduced HDL particle endocytosis. Substitution L493A had a less dramatic effect. No other regions in the carboxyl-terminal tail appeared to contain motifs required for HDL endocytosis. Substitutions of leucine at position 492 with the hydrophobic amino acids valine or phenylalanine also reduced HDL endocytosis, stressing the importance of leucine at this position. Introducing the SR-BII YTPLL motif into the carboxyl-terminal cytoplasmic tail of SR-BI converted SR-BI into an endocytic receptor resembling SR-BII. These results demonstrated that SR- BII differs from SR-BI in subcellular localization and trafficking and suggest that the two isoforms differ in the manner in which they target ligands intracellularly.	Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA; Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Univ Debrecen, Dept Biochem & Mol Biol, Res Ctr Mol Med, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary	University of Kentucky; University of Kentucky; University of Debrecen	Van der Westhuyzen, DR (corresponding author), Univ Kentucky, Grad Ctr Nutr Sci, Wethington Hlth Sci Bldg,Rm 541,900 S Limestone S, Lexington, KY 40536 USA.	dvwest1@uky.edu	Webb, Nancy/AAL-7030-2021; Szanto, Attila/B-2198-2012; Zhao, Zhenze/AAW-5870-2020; Eckhardt, Erik/G-1567-2010	Eckhardt, Erik/0000-0002-3015-5180				Azhar S, 2002, MOL CELL ENDOCRINOL, V195, P1, DOI 10.1016/S0303-7207(02)00222-8; Azhar S, 1998, J LIPID RES, V39, P1616; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Connelly MA, 2004, CURR OPIN LIPIDOL, V15, P287, DOI 10.1097/00041433-200406000-00008; Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756; Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Liu B, 2002, J BIOL CHEM, V277, P34125, DOI 10.1074/jbc.M204265200; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Mulcahy JV, 2004, BIOCHEM J, V377, P741, DOI 10.1042/bj20030307; Nieland TJF, 2005, BBA-MOL CELL BIOL L, V1734, P44, DOI 10.1016/j.bbalip.2005.02.007; Peng Y, 2004, MOL BIOL CELL, V15, P384, DOI 10.1091/mbc.e03-06-0445; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; Rigotti A, 2003, ENDOCR REV, V24, P357, DOI 10.1210/er.2001-0037; Ritsch A, 2004, J LIPID RES, V45, P214, DOI 10.1194/jlr.M300353-JLR200; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; STRACHAN AF, 1988, BIOCHEM J, V250, P203, DOI 10.1042/bj2500203; Thilakawardhana S, 2005, NEUROBIOL AGING, V26, P813, DOI 10.1016/j.neurobiolaging.2004.08.004; Trigatti BL, 2003, ARTERIOSCL THROM VAS, V23, P1732, DOI 10.1161/01.ATV.0000091363.28501.84; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Webb NR, 1997, J LIPID RES, V38, P1490; Wustner D, 2005, J BIOL CHEM, V280, P6766, DOI 10.1074/jbc.M413238200; Wustner D, 2004, J LIPID RES, V45, P427, DOI 10.1194/jlr.M300440-JLR200	37	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4348	4353		10.1074/jbc.M513154200	http://dx.doi.org/10.1074/jbc.M513154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368683	hybrid			2022-12-27	WOS:000235275300070
J	Lee, EB; Leng, LZ; Zhang, B; Kwong, L; Trojanowski, JQ; Abel, T; Lee, VMY				Lee, EB; Leng, LZ; Zhang, B; Kwong, L; Trojanowski, JQ; Abel, T; Lee, VMY			Targeting amyloid-beta peptide (A beta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A beta precursor protein (APP) transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; MOUSE MODEL; IN-VIVO; BRAIN; IMMUNOTHERAPY; MECHANISMS; DEPOSITION; CLEARANCE	Passive immunization of murine models of Alzheimer disease amyloidosis reduces amyloid-beta peptide (A beta) levels and improves cognitive function. To specifically address the role of A beta oligomers in learning and memory, we generated a novel monoclonal antibody, NAB61, that preferentially recognizes a conformational epitope present in dimeric, small oligomeric, and higher order A beta structures but not full-length amyloid-beta precursor protein or C-terminal amyloid-beta precursor protein fragments. NAB61 also recognized a subset of brain A beta deposits, preferentially mature senile plaques, and amyloid angiopathy. Using NAB61 as immunotherapy, we showed that aged Tg2576 transgenic mice treated with NAB61 displayed significant improvements in spatial learning and memory relative to control mice. These data implicated A beta oligomers as a pathologic substrate for cognitive decline in Alzheimer disease.	Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Lee, VMY (corresponding author), Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Sch Med, 3rd Fl,Maloney Bldg,3600 Spruce St, Philadelphia, PA 19104 USA.	vmylee@mail.med.upenn.edu	Abel, Ted/AAX-2825-2021; Lee, Edward/AAU-8436-2021	Abel, Ted/0000-0003-2423-4592; 	NATIONAL INSTITUTE ON AGING [P01AG011542, P50AG008012, T32AG000255] Funding Source: NIH RePORTER; NIA NIH HHS [AG11542, T32 AG00255, AG008012] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Backskai BJ, 2001, NAT MED, V7, P369, DOI 10.1038/85525; Bacskai BJ, 2002, J NEUROSCI, V22, P7873; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Bussiere T, 2004, AM J PATHOL, V165, P987, DOI 10.1016/S0002-9440(10)63360-3; Cirrito JR, 2003, J NEUROSCI, V23, P8844; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hartman RE, 2005, J NEUROSCI, V25, P6213, DOI 10.1523/JNEUROSCI.0664-05.2005; Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Kotilinek LA, 2002, J NEUROSCI, V22, P6331; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee EB, 2005, FEBS LETT, V579, P2564, DOI 10.1016/j.febslet.2005.03.070; Lee EB, 2005, J CELL BIOL, V168, P291, DOI 10.1083/jcb.200407070; Lee EB, 2003, J BIOL CHEM, V278, P4458, DOI 10.1074/jbc.M210105200; Moir RD, 2005, J BIOL CHEM, V280, P17458, DOI 10.1074/jbc.M414176200; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Neely MD, 2002, CHEM RES TOXICOL, V15, P40, DOI 10.1021/tx010115w; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Westerman MA, 2002, J NEUROSCI, V22, P1858, DOI 10.1523/JNEUROSCI.22-05-01858.2002; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Wilcock DM, 2003, J NEUROSCI, V23, P3745, DOI 10.1523/jneurosci.23-09-03745.2003; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786	44	244	283	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4292	4299		10.1074/jbc.M511018200	http://dx.doi.org/10.1074/jbc.M511018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361260	hybrid			2022-12-27	WOS:000235275300063
J	Ohyama, Y; Meaney, S; Heverin, M; Ekstrom, L; Brafman, A; Shafir, M; Andersson, U; Olin, M; Eggertsen, G; Diczfalusy, U; Feinstein, E; Bjorkhem, I				Ohyama, Y; Meaney, S; Heverin, M; Ekstrom, L; Brafman, A; Shafir, M; Andersson, U; Olin, M; Eggertsen, G; Diczfalusy, U; Feinstein, E; Bjorkhem, I			Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1) - Marked insensitivity toward different regulatory axes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; RETINOID-X-RECEPTOR; ALZHEIMERS-DISEASE; BRAIN CHOLESTEROL; APOE PROMOTER; 24S-HYDROXYLASE GENE; STEROL-METABOLISM; APOLIPOPROTEIN-E; FATTY-ACIDS; IN-VIVO	Mammalian CNS contains a disproportionally large and remarkably stable pool of cholesterol. Despite an efficient recycling there is some requirement for elimination of brain cholesterol. Conversion of cholesterol into 24S-hydroxycholesterol by the cholesterol 24-hydroxylase (CYP46A1) is the quantitatively most important mechanism. Based on the protein expression and plasma levels of 24S-hydroxycholesterol, CYP46A1 activity appears to be highly stable in adults. Here we have made a structural and functional characterization of the promoter of the human CYP46A1 gene. No canonical TATA or CAAT boxes were found in the promoter region. Moreover this region had a high GC content, a feature often found in genes considered to have a largely housekeeping function. A broad spectrum of regulatory axes using a variety of promoter constructs did not result in a significant transcriptional regulation. Oxidative stress caused a significant increase in transcriptional activity. The possibility of a substrate-dependent transcriptional regulation was explored in vivo in a sterol-deficient mouse model (Dhcr24 null) in which almost all cholesterol had been replaced with desmosterol, which is not a substrate for CYP46A1. Compared with heterozygous littermates there was no statistically significant difference in the mRNA levels of Cyp46a1. During the first 2 weeks of life in the wild-type mouse, however, a significant increase of Cyp46a1 mRNA levels was found, in parallel with an increase in 24S-hydroxycholesterol level and a reduction of cholesterol synthesis. The failure to demonstrate a significant transcriptional regulation under most conditions is discussed in relation to the turnover of brain and neuronal cholesterol.	Karolinska Univ Hosp, Dept Lab Med, Div Clin Chem, S-14186 Huddinge, Sweden; Karolinska Univ Hosp, Dept Lab Med, Div Clin Pharmacol, S-14186 Huddinge, Sweden; Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan; Quark Biotech, Fremont, CA 94555 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Hiroshima University	Bjorkhem, I (corresponding author), Karolinska Univ Hosp, Dept Lab Med, Div Clin Chem, S-14186 Huddinge, Sweden.	ingemar.bjorkhem@karolinska.se	Heverin, Maura B/J-4101-2012; Diczfalusy, Ulf/A-5336-2008; Meaney, Steve/X-9289-2019	Diczfalusy, Ulf/0000-0001-6643-3763; Meaney, Steve/0000-0002-7789-516X; Bjorkhem, Ingemar/0000-0002-0575-9425; Bjorkhem, Ingemar/0000-0001-6087-9190				Ando S, 2003, NEUROCHEM RES, V28, P5, DOI 10.1023/A:1021635826032; Beyer K, 2002, NEUROSCI LETT, V326, P187, DOI 10.1016/S0304-3940(02)00355-5; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Bjorkhem I, 2001, J BIOL CHEM, V276, P37004, DOI 10.1074/jbc.M103828200; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bogdanovica N, 2001, NEUROSCI LETT, V314, P45, DOI 10.1016/S0304-3940(01)02277-7; Borroni B, 2004, NEUROBIOL AGING, V25, P747, DOI 10.1016/j.neurobiolaging.2003.08.004; Bretillon L, 2000, J LIPID RES, V41, P840; Brown J, 2004, J BIOL CHEM, V279, P34674, DOI 10.1074/jbc.M402324200; Chalmers KA, 2004, NEUROREPORT, V15, P95, DOI 10.1097/00001756-200401190-00019; Couronne O, 2003, GENOME RES, V13, P73, DOI 10.1101/gr.762503; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Desai P, 2002, NEUROSCI LETT, V328, P9, DOI 10.1016/S0304-3940(02)00443-3; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Fu Q, 1998, J NEUROCHEM, V71, P549; Heverin M, 2004, J LIPID RES, V45, P186, DOI 10.1194/jlr.M300320-JLR200; Ingelsson M, 2004, NEUROSCI LETT, V367, P228, DOI 10.1016/j.neulet.2004.06.011; Johansson A, 2004, HUM GENET, V114, P581, DOI 10.1007/s00439-004-1107-9; Kabbara A, 2004, NEUROSCI LETT, V363, P139, DOI 10.1016/j.neulet.2004.03.066; Kolsch H, 2002, MOL PSYCHIATR, V7, P899, DOI 10.1038/sj.mp.4001109; KOTTI T, 2004, SOC NEUR ANN M SAN D, P1; Lambert JC, 1998, HUM MOL GENET, V7, P533, DOI 10.1093/hmg/7.3.533; Lambert JC, 1998, HUM MOL GENET, V7, P1511, DOI 10.1093/hmg/7.9.1511; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; Leoni V, 2004, CLIN CHEM LAB MED, V42, P186, DOI 10.1515/CCLM.2004.034; LIN YY, 1974, BIOCHIM BIOPHYS ACTA, V348, P189; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 2001, ACTA PAEDIATR, V90, P652, DOI 10.1080/080352501750258720; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mast N, 2003, BIOCHEMISTRY-US, V42, P14284, DOI 10.1021/bi035512f; Meaney S, 2002, J LIPID RES, V43, P2130, DOI 10.1194/jlr.M200293-JLR200; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Papassotiropoulos A, 2003, ARCH NEUROL-CHICAGO, V60, P29, DOI 10.1001/archneur.60.1.29; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; PITAS RE, 1987, J BIOL CHEM, V262, P14352; Quan G, 2003, DEV BRAIN RES, V146, P87, DOI 10.1016/j.devbrainres.2003.09.015; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Ryu H, 2003, J NEUROSCI, V23, P3597; Sambrook J., 2001, MOL CLONING LAB MANU; SMITH LL, 1972, J NEUROCHEM, V19, P899, DOI 10.1111/j.1471-4159.1972.tb01406.x; Sun Y, 2003, J BIOL CHEM, V278, P27688, DOI 10.1074/jbc.M300760200; Thelen KM, 2006, J PHARMACOL EXP THER, V316, P1146, DOI 10.1124/jpet.105.094136; VOLPE JJ, 1977, BIOCHIM BIOPHYS ACTA, V486, P408, DOI 10.1016/0005-2760(77)90090-X; Wang BB, 2004, NEUROSCI LETT, V369, P104, DOI 10.1016/j.neulet.2004.07.020; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776; Werner T, 1999, MAMM GENOME, V10, P168, DOI 10.1007/s003359900963; Whitney KD, 2002, MOL ENDOCRINOL, V16, P1378, DOI 10.1210/me.16.6.1378; Xie CL, 2003, J LIPID RES, V44, P1780, DOI 10.1194/jlr.M300164-JLR200; Zhang J, 1997, BIOCHEM J, V322, P175, DOI 10.1042/bj3220175	54	110	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3810	3820		10.1074/jbc.M505179200	http://dx.doi.org/10.1074/jbc.M505179200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16321981	hybrid			2022-12-27	WOS:000235275300009
J	Toleman, CA; Paterson, AJ; Kudlow, JE				Toleman, CA; Paterson, AJ; Kudlow, JE			The histone acetyltransferase NCOAT contains a zinc finger-like motif involved in substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; GCN5 TRANSCRIPTIONAL COACTIVATOR; CRYSTAL-STRUCTURE; O-GLCNACASE; PHD FINGER; MECHANISM; PROTEIN; DOMAIN; PURIFICATION; SUPERFAMILY	Nuclear cytoplasmic O-GlcNAcase and acetyltransferase (NCOAT) is a bifunctional enzyme with both glycoside hydrolase and alkyltransferase activity. Its O-GlcNAcase active site lies in the N terminus of the enzyme and its histone acetyltransferase (HAT) domain lies in the C terminus. Whereas the HAT domain of the enzyme is catalytically and structurally similar to other acetyltransferases across subfamilies, NCOAT has a motif resembling a zinc finger-like domain unique to the MYST family of HATs. Among the MYST family, this zinc finger, or zinc finger-like domain, is responsible for making contacts with the histone tails within nucleosomes for the HAT to catalyze its respective reaction. Here, we show that NCOAT has the ability to directly associate with both an acetylated and unacetylated histone H4 tail in vitro, and a potential zinc finger-like motif found in NCOAT is implicated in this nucleosomal contact, and is necessary for fully efficient enzymatic activity. Subsequent to the catalysis of acetyltransfer to lysine 8 of histone H4 for the enzyme, however, the substrate is released and NCOAT can no longer bind H4 in our assays. Furthermore, this finger domain by itself is sufficient to bind histone H4.	Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kudlow, JE (corresponding author), Univ Alabama, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA.	kudlow@uab.edu						Akhtar A, 2001, EMBO REP, V2, P113, DOI 10.1093/embo-reports/kve022; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; DONG DLY, 1994, J BIOL CHEM, V269, P19321; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Kalkhoven E, 2002, MOL CELL BIOL, V22, P1961, DOI 10.1128/MCB.22.7.1961-1970.2002; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Pelletier N, 2003, METHODS, V31, P24, DOI 10.1016/S1046-2023(03)00084-7; Poux AN, 2002, P NATL ACAD SCI USA, V99, P14065, DOI 10.1073/pnas.222373899; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schultz J, 2002, FEBS LETT, V529, P179, DOI 10.1016/S0014-5793(02)03322-7; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Simpson RJY, 2003, J BIOL CHEM, V278, P28011, DOI 10.1074/jbc.M211146200; Takechi S, 1999, BIOCHEM BIOPH RES CO, V266, P405, DOI 10.1006/bbrc.1999.1836; Tanner KG, 2000, BIOCHEMISTRY-US, V39, P11961, DOI 10.1021/bi001272h; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Toleman C, 2004, J BIOL CHEM, V279, P53665, DOI 10.1074/jbc.M410406200; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Wolf E, 2002, J MOL BIOL, V317, P215, DOI 10.1006/jmbi.2001.5371; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3	24	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3918	3925		10.1074/JBC.m510485200	http://dx.doi.org/10.1074/JBC.m510485200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356930	hybrid			2022-12-27	WOS:000235275300019
J	Yan, H; Zareen, N; Levinger, L				Yan, H; Zareen, N; Levinger, L			Naturally occurring mutations in human mitochondrial pre-tRNA(Ser(UCN)) can affect the transfer ribonuclease Z cleavage site, processing kinetics, and substrate secondary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA PRECURSORS; POLYADENYLATION FACTOR CPSF-73; CANCER SUSCEPTIBILITY GENE; TRNA(SER(UCN)) GENE; TRNASE-Z; PAIRED SUBSTITUTIONS; THERMOTOGA-MARITIMA; POINT MUTATION; ACCEPTOR STEM; DNA MUTATION	tRNAs are transcribed as precursors with a 5' end leader and a 3' end trailer. The 5' end leader is processed by RNase P, and in most organisms in all three kingdoms, transfer ribonuclease (tRNase) Z can endonucleolytically remove the 3' end trailer. Long ((L)) and short ((S)) forms of the tRNase Z gene are present in the human genome. tRNase Z(L) processes a nuclear-encoded pre-tRNA similar to 1600-fold more efficiently than tRNase Z(S) and is predicted to have a strong mitochondrial transport signal. tRNase Z(L) could, thus, process both nuclear-and mitochondrially encoded pre-tRNAs. More than 150 pathogenesis-associated mutations have been found in the mitochondrial genome, most of them in the 22 mitochondrially encoded tRNAs. All the mutations investigated in human mitochondrial tRNA(Ser(UCN)) affect processing efficiency, and some affect the cleavage site and secondary structure. These changes could affect tRNase Z processing of mutant pre-tRNAs, perhaps contributing to mitochondrial disease.	CUNY, York Coll, Dept Nat Sci Biol, Riyadh 11451, Saudi Arabia		Levinger, L (corresponding author), CUNY, York Coll, Dept Nat Sci Biol, 94-20 Guy R Brewer Blvd, Riyadh 11451, Saudi Arabia.	louie@york.cuny.edu	Yan, Hua/E-5305-2011		NIGMS NIH HHS [S06GM08153] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008153] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Baillat D, 2005, CELL, V123, P265, DOI 10.1016/j.cell.2005.08.019; BROWN MD, 1992, AM J HUM GENET, V51, P378; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; CHEN JY, 1988, J BIOL CHEM, V263, P13677; Chen Y, 2005, BMC MOL BIOL, V6, DOI 10.1186/1471-2199-6-12; de la Sierra-Gallay IL, 2005, NATURE, V433, P657, DOI 10.1038/nature03284; Dominski Z, 2005, CELL, V123, P37, DOI 10.1016/j.cell.2005.08.002; Dominski Z, 2005, MOL CELL BIOL, V25, P1489, DOI 10.1128/MCB.25.4.1489-1500.2005; Dubrovsky EB, 2004, NUCLEIC ACIDS RES, V32, P255, DOI 10.1093/nar/gkh182; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Fechter P, 1998, FEBS LETT, V436, P99, DOI 10.1016/S0014-5793(98)01096-5; Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868; Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUTCHIN T, 1993, NUCLEIC ACIDS RES, V21, P4174, DOI 10.1093/nar/21.18.4174; Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692; Ishii R, 2005, J BIOL CHEM, V280, P14138, DOI 10.1074/jbc.M500355200; Leontis NB, 2002, NUCLEIC ACIDS RES, V30, P3497, DOI 10.1093/nar/gkf481; Levinger L, 1998, J BIOL CHEM, V273, P1015, DOI 10.1074/jbc.273.2.1015; Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884; Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008; LEVINGER L, 1995, J BIOL CHEM, V270, P18903, DOI 10.1074/jbc.270.32.18903; Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282; Levinger L, 2001, NUCLEIC ACIDS RES, V29, P4334, DOI 10.1093/nar/29.21.4334; Li ZW, 2002, RNA, V8, P97, DOI 10.1017/S1355838202014929; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Marchfelder A, 1996, J BIOL CHEM, V271, P1898, DOI 10.1074/jbc.271.4.1898; MARCHFELDER A, 1990, NUCLEIC ACIDS RES, V18, P1401, DOI 10.1093/nar/18.6.1401; Minagawa A, 2005, CANCER LETT, V222, P211, DOI 10.1016/j.canlet.2004.09.013; Minagawa A, 2004, J BIOL CHEM, V279, P15688, DOI 10.1074/jbc.M313951200; Mohan A, 2000, J MOL BIOL, V303, P605, DOI 10.1006/jmbi.2000.4162; Mohan A, 1999, RNA, V5, P245, DOI 10.1017/S1355838299981256; MONTOYA J, 1981, NATURE, V290, P465, DOI 10.1038/290465a0; Morl M, 2001, EMBO REP, V2, P17, DOI 10.1093/embo-reports/kve006; NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260; Nashimoto M, 1999, BIOCHEMISTRY-US, V38, P12089, DOI 10.1021/bi9911942; NASHIMOTO M, 1992, NUCLEIC ACIDS RES, V20, P3737, DOI 10.1093/nar/20.14.3737; Nashimoto M, 1997, NUCLEIC ACIDS RES, V25, P1148, DOI 10.1093/nar/25.6.1148; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; Pandya A, 1999, AM J HUM GENET, V65, P1803, DOI 10.1086/302658; Pellegrini O, 2003, EMBO J, V22, P4534, DOI 10.1093/emboj/cdg435; Perez-Iratxeta C, 2005, FEBS LETT, V579, P1795, DOI 10.1016/j.febslet.2005.02.020; Reid FM, 1997, HUM MOL GENET, V6, P443, DOI 10.1093/hmg/6.3.443; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; Ryan K, 2004, RNA, V10, P565, DOI 10.1261/rna.5214404; Schiffer S, 2003, BIOL CHEM, V384, P333, DOI 10.1515/BC.2003.039; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; Sprinzl M, 2005, NUCLEIC ACIDS RES, V33, pD139, DOI 10.1093/nar/gki012; Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905; Takaku H, 2004, NUCLEIC ACIDS RES, V32, P4429, DOI 10.1093/nar/gkh774; Takaku H, 2003, NUCLEIC ACIDS RES, V31, P2272, DOI 10.1093/nar/gkg337; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; THOMANN HU, 1989, J MOL BIOL, V209, P505, DOI 10.1016/0022-2836(89)90590-1; Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200; Vogel A, 2004, BIOCHEMISTRY-US, V43, P10379, DOI 10.1021/bi049703+; Xiao SH, 2002, ANNU REV BIOCHEM, V71, P165, DOI 10.1146/annurev.biochem.71.110601.135352; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2; Zareen N, 2005, J MOL BIOL, V350, P189, DOI 10.1016/j.jmb.2005.04.073	61	44	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3926	3935		10.1074/jbc.M509822200	http://dx.doi.org/10.1074/jbc.M509822200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361254	hybrid			2022-12-27	WOS:000235275300020
J	Yu, Q; Sandmeier, J; Xu, HP; Zou, YF; Bi, X				Yu, Q; Sandmeier, J; Xu, HP; Zou, YF; Bi, X			Mechanism of the long range anti-silencing function of targeted histone acetyltransferases in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESOLUTION STRUCTURAL-ANALYSIS; SACCHAROMYCES-CEREVISIAE; HYPERACETYLATED CHROMATIN; EXCLUDES NUCLEOSOMES; GENE-EXPRESSION; HETEROCHROMATIN; ACETYLATION; COMPLEX; TRANSCRIPTION; DNA	Transcriptionally silent chromatin in Saccharomyces cerevisiae is associated with histone hypoacetylation and is formed through the action of the Sir histone deacetylase complex. A histone acetyltransferase (HAT) targeted near silent chromatin can overcome silencing at a distance by increasing histone acetylation in a sizable region. However, how a tethered HAT acetylates distant nucleosomes has not been resolved. We demonstrate here that targeting the histone H3-specific HAT Gcn5p promotes acetylation of not only histone H3 but also histone H4 in a broad region. We also show that long range anti-silencing and histone acetylation by targeted HATs can be blocked by nucleosome-excluding sequences. These results are consistent with the contention that a tethered HAT promotes step-wise propagation of histone acetylation along the chromatin. Because histone hypoacetylation is key to the formation and maintenance of transcriptionally silent chromatin, it is believed that acetylation promoted by a targeted HAT disrupts silent chromatin thereby overcoming silencing. However, we show that the acetylated and transcriptionally active region created by a tethered HAT retains structural hallmarks of Sir-dependent silent chromatin and remains associated with Sir proteins indicating that tethered HATs overcome silencing without completely dismantling silent chromatin.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Bi, X (corresponding author), Univ Rochester, Dept Biol, 601 Elmwood Ave, Rochester, NY 14627 USA.	xinbi@mail.rochester.edu			NIGMS NIH HHS [R01-GM62484] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062484] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Bi X, 1999, P NATL ACAD SCI USA, V96, P11934, DOI 10.1073/pnas.96.21.11934; Bi X, 2004, MOL CELL BIOL, V24, P2118, DOI 10.1128/MCB.24.5.2118-2131.2004; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; Boudreault AA, 2003, GENE DEV, V17, P1415, DOI 10.1101/gad.1056603; Bulger M, 2005, J BIOL CHEM, V280, P21689, DOI 10.1074/jbc.R500004200; Carmen AA, 2002, J BIOL CHEM, V277, P4778, DOI 10.1074/jbc.M110532200; Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; Chiu YH, 2003, GENETICS, V165, P115; Deckert J, 2002, MOL CELL BIOL, V22, P6458, DOI 10.1128/MCB.22.18.6458-6470.2002; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Donze D, 2001, EMBO J, V20, P520, DOI 10.1093/emboj/20.3.520; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hassan AH, 2002, CELL, V111, P369, DOI 10.1016/S0092-8674(02)01005-X; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Katan-Khaykovich Y, 2005, EMBO J, V24, P2138, DOI 10.1038/sj.emboj.7600692; Kirkpatrick DT, 1999, MOL CELL BIOL, V19, P7661; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Liou GG, 2005, CELL, V121, P515, DOI 10.1016/j.cell.2005.03.035; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Pirrotta V, 2005, MOL CELL, V18, P395, DOI 10.1016/j.molcel.2005.04.013; Ravindra A, 1999, MOL CELL BIOL, V19, P7944; Reimer SK, 1997, CHROMOSOMA, V106, P136, DOI 10.1007/s004120050233; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rusche LN, 2003, ANNU REV BIOCHEM, V72, P481, DOI 10.1146/annurev.biochem.72.121801.161547; Rusche LN, 2001, GENE DEV, V15, P955; Sekinger EA, 1999, EMBO J, V18, P7041, DOI 10.1093/emboj/18.24.7041; Sendra R, 2000, J BIOL CHEM, V275, P24928, DOI 10.1074/jbc.M003783200; SIMPSON RT, 1979, NUCLEIC ACIDS RES, V6, P1387, DOI 10.1093/nar/6.4.1387; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sutton A, 2001, MOL CELL BIOL, V21, P3514, DOI 10.1128/MCB.21.10.3514-3522.2001; Wang YH, 1996, P NATL ACAD SCI USA, V93, P8863, DOI 10.1073/pnas.93.17.8863; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yang Y, 2003, NOVON, V13, P153, DOI 10.2307/3393581; Zeng L, 2002, FEBS LETT, V513, P124, DOI 10.1016/S0014-5793(01)03309-9	50	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3980	3988		10.1074/jbc.M510140200	http://dx.doi.org/10.1074/jbc.M510140200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16368686	hybrid			2022-12-27	WOS:000235275300026
J	Zhang, DW; Graf, GA; Gerard, RD; Cohen, JC; Hobbs, HH				Zhang, DW; Graf, GA; Gerard, RD; Cohen, JC; Hobbs, HH			Functional asymmetry of nucleotide-binding domains in ABCG5 and ABCG8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN-1; BILIARY CHOLESTEROL SECRETION; GLYCOPROTEIN ATPASE ACTIVITY; MYOSIN MOTOR DOMAIN; P-GLYCOPROTEIN; DIETARY-CHOLESTEROL; GLUTAMATE RESIDUES; ESCHERICHIA-COLI; CATALYTIC CYCLE; TRANSPORTER	The ATP-binding cassette half-transporters ABCG5 (G5) and ABCG8 (G8) promote secretion of neutral sterols into bile, a major pathway for elimination of sterols. Mutations in either ABCG5 or ABCG8 cause sitosterolemia, a recessive disorder characterized by impaired biliary and intestinal sterol secretion, sterol accumulation, and premature atherosclerosis. The mechanism by which the G5G8 heterodimer couples ATP hydrolysis to sterol transport is not known. Here we examined the roles of the Walker A, Walker B, and signature motifs in the nucleotide-binding domains (NBD) of G5 and G8 using recombinant adenoviruses to reconstitute biliary sterol transport in G5G8-deficient mice. Mutant forms of each half-transporter were co-expressed with their wild-type partners. Mutations at crucial residues in the Walker A and Walker B domains of G5 prevented biliary sterol secretion, whereas mutations of the corresponding residues in G8 did not. The opposite result was obtained when mutations were introduced into the signature motif; mutations in the signature domain of G8 prevented sterol transport, but substitution of the corresponding residues in G5 did not. Taken together, these findings indicate that the NBDs of G5 and G8 are not functionally equivalent. The integrity of the canonical NBD formed by the Walker A and Walker B motifs of G5 and the signature motif of G8 is essential for G5G8-mediated sterol transport. In contrast, mutations in key residues of the NBD formed by the Walker A and B motifs of G8 and the signature sequence of G5 did not affect sterol secretion.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hobbs, HH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	helen.hobbs@utsouthwestern.edu	Zhang, Dawei/ABD-8990-2022	Zhang, Dawei/0000-0001-8279-8041; Graf, Gregory/0000-0002-0130-9929	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072304, P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01HL-20948, R01HL-72304] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Berger AL, 2005, P NATL ACAD SCI USA, V102, P455, DOI 10.1073/pnas.0408575102; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Chen M, 2004, J BIOL CHEM, V279, P46073, DOI 10.1074/jbc.M404042200; Davidson AL, 2004, ANNU REV BIOCHEM, V73, P241, DOI 10.1146/annurev.biochem.73.011303.073626; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Graf GA, 2003, J BIOL CHEM, V278, P48275, DOI 10.1074/jbc.M310223200; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Lapinski PE, 2001, J BIOL CHEM, V276, P7526, DOI 10.1074/jbc.M009448200; Lapinski PE, 2003, J BIOL CHEM, V278, P8229, DOI 10.1074/jbc.M208930200; Lee MH, 2001, NAT GENET, V27, P79, DOI 10.1038/83799; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Melin P, 2004, BIOCHEM PHARMACOL, V67, P2187, DOI 10.1016/j.bcp.2004.02.022; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Payen LF, 2003, J BIOL CHEM, V278, P38537, DOI 10.1074/jbc.M305786200; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Reyes CL, 2005, SCIENCE, V308, P1028, DOI 10.1126/science.1107733; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; Sauna ZE, 2004, J BIOL CHEM, V279, P48855, DOI 10.1074/jbc.M408849200; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szakacs G, 2001, BIOCHEM J, V356, P71, DOI 10.1042/0264-6021:3560071; Tombline G, 2004, J BIOL CHEM, V279, P31212, DOI 10.1074/jbc.M404689200; Tombline G, 2004, J BIOL CHEM, V279, P5363, DOI 10.1074/jbc.M311964200; Tombline G, 2004, J BIOL CHEM, V279, P46518, DOI 10.1074/jbc.M408052200; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; Vergani P, 2005, NATURE, V433, P876, DOI 10.1038/nature03313; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zhang DW, 2003, J BIOL CHEM, V278, P46052, DOI 10.1074/jbc.M308403200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200	47	38	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4507	4516		10.1074/jbc.M512277200	http://dx.doi.org/10.1074/jbc.M512277200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352607	hybrid			2022-12-27	WOS:000235275300086
J	Jenkins, HT; Mark, L; Ball, G; Persson, J; Lindahl, G; Uhrin, D; Blom, AM; Barlow, PN				Jenkins, HT; Mark, L; Ball, G; Persson, J; Lindahl, G; Uhrin, D; Blom, AM; Barlow, PN			Human C4b-binding protein, structural basis for interaction with streptococcal M protein, a major bacterial virulence factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN C4-BINDING PROTEIN; C4B BINDING-PROTEIN; SURFACE-PROTEINS; ALPHA-CHAIN; COMPLEMENT ACTIVATION; SEQUENCE HOMOLOGY; SERUM RESISTANCE; 2 PARTS; RECEPTOR; C3B	Human C4b-binding protein (C4BP) protects host tissue, and those pathogens able to hijack this plasma glycoprotein, from complement-mediated destruction. We now show that the first two complement control protein (CCP) modules of the C4BP alpha-chain, plus the four residues connecting them, are necessary and sufficient for binding a bacterial virulence factor, the Streptococcus pyogenes M4 (Arp4) protein. Structure determination by NMR reveals two tightly coupled CCP modules in an elongated arrangement within this region of C4BP. Chemical shift perturbation studies demonstrate that the N-terminal, hypervariable region of M4 binds to a site including strand 1 of CCP module 2. This interaction is accompanied by an intermodular reorientation within C4BP. We thus provide a detailed picture of an interaction whereby a pathogen evades complement.	Univ Edinburgh, Sch Chem, Edinburgh Biol NMR Unit, Edinburgh EH9 3JJ, Midlothian, Scotland; Lund Univ, Dept Lab Med, Sect Clin Chem, Malmo Univ Hosp, S-20502 Malmo, Sweden; Lund Univ, Dept Lab Med, Div Med Microbiol, SE-22362 Lund, Sweden	University of Edinburgh; Lund University; Skane University Hospital; Lund University	Barlow, PN (corresponding author), Univ Edinburgh, Sch Chem, Edinburgh Biol NMR Unit, Joseph Black Chem Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	Paul.Barlow@ed.ac.uk	Jenkins, Huw/E-1094-2011; Barlow, Paul N/G-2853-2011; Blom, Anna/AFS-7369-2022; Persson, Jenny J/H-1796-2012; Blom, Anna/B-9607-2009	Jenkins, Huw/0000-0002-3302-6966; Persson, Jenny J/0000-0002-1075-4346; Blom, Anna/0000-0002-1348-1734; Ball, Graeme/0000-0002-6526-2306	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Accardo P, 1996, J IMMUNOL, V157, P4935; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Berggard K, 2001, EUR J IMMUNOL, V31, P2771, DOI 10.1002/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO;2-0; Blom AM, 2000, J IMMUNOL, V164, P5328, DOI 10.4049/jimmunol.164.10.5328; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Blom AM, 1999, J BIOL CHEM, V274, P19237, DOI 10.1074/jbc.274.27.19237; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Brodeur SR, 2003, IMMUNITY, V18, P837, DOI 10.1016/S1074-7613(03)00149-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlsson F, 2003, J EXP MED, V198, P1057, DOI 10.1084/jem.20030543; Cockburn IA, 2004, P NATL ACAD SCI USA, V101, P272, DOI 10.1073/pnas.0305306101; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; FUJITA T, 1979, J EXP MED, V150, P267, DOI 10.1084/jem.150.2.267; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; Fukui A, 2002, J BIOCHEM, V132, P719, DOI 10.1093/oxfordjournals.jbchem.a003279; Ganesh VK, 2004, P NATL ACAD SCI USA, V101, P8924, DOI 10.1073/pnas.0400744101; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; Hammel M, 2002, J MOL BIOL, V321, P85, DOI 10.1016/S0022-2836(02)00621-6; Heiring C, 2001, PROTEIN ENG, V14, P183, DOI 10.1093/protein/14.3.183; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; Jarva H, 2005, J IMMUNOL, V174, P6299, DOI 10.4049/jimmunol.174.10.6299; Kask L, 2004, J BIOL CHEM, V279, P23869, DOI 10.1074/jbc.C400159200; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Lancefield RC, 1928, J EXP MED, V47, P91, DOI 10.1084/jem.47.1.91; Meri T, 2004, INFECT IMMUN, V72, P6633, DOI 10.1128/IAI.72.11.6633-6641.2004; Morfeldt E, 2001, J IMMUNOL, V167, P3870, DOI 10.4049/jimmunol.167.7.3870; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Nordstrom T, 2004, J IMMUNOL, V173, P4598, DOI 10.4049/jimmunol.173.7.4598; Prasadarao NV, 2002, J IMMUNOL, V169, P6352, DOI 10.4049/jimmunol.169.11.6352; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; SCHARFSTEIN J, 1978, J EXP MED, V148, P207, DOI 10.1084/jem.148.1.207; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; Smith BO, 2002, CELL, V108, P769, DOI 10.1016/S0092-8674(02)00672-4; Soares DC, 2005, PROTEIN ENG DES SEL, V18, P379, DOI 10.1093/protein/gzi039; STENBERG L, 1994, J BIOL CHEM, V269, P13458; Stevens DL., 2000, STREPTOCOCCAL INFECT; THERN A, 1995, J IMMUNOL, V154, P375; Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189; Uhrinova S, 2003, P NATL ACAD SCI USA, V100, P4718, DOI 10.1073/pnas.0730844100; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; [No title captured]	49	45	48	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3690	3697		10.1074/jbc.M511563200	http://dx.doi.org/10.1074/jbc.M511563200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330538	hybrid			2022-12-27	WOS:000235128200081
J	Voss, E; Wehkamp, J; Wehkamp, K; Stange, EF; Schroder, JM; Harder, J				Voss, E; Wehkamp, J; Wehkamp, K; Stange, EF; Schroder, JM; Harder, J			NOD2/CARD15 mediates induction of the antimicrobial peptide human beta-defensin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN BETA-DEFENSINS; ANTIINFLAMMATORY SESQUITERPENE LACTONE; INTESTINAL EPITHELIAL-CELLS; INNATE IMMUNE-RESPONSE; TOLL-LIKE RECEPTORS; HUMAN BETA-DEFENSIN-2; CROHNS-DISEASE; STAPHYLOCOCCUS-AUREUS; HELICOBACTER-PYLORI	Production of inducible antimicrobial peptides offers a first and rapid defense response of epithelial cells against invading microbes. Human beta-defensin-2 (hBD-2) is an antimicrobial peptide induced in various epithelia upon extracellular as well as intracellular bacterial challenge. Nucleotide-binding oligomerization domain protein 2 (NOD2/CARD15) is a cytosolic protein involved in intracellular recognition of microbes by sensing peptidoglycan fragments ( e. g. muramyl dipeptide). We used luciferase as a reporter gene for a 2.3-kb hBD-2 promoter to test the hypothesis that NOD2 mediates the induction of hBD-2. Activation of NOD2 in NOD2-overexpressing human embryonic kidney 293 cells through its ligand muramyl dipeptide ( MDP) induced hBD-2 expression. In contrast, overexpression of NOD2 containing the 3020insC frameshift mutation, the most frequent NOD2 variant associated with Crohn disease, resulted in defective induction of hBD-2 through MDP. Luciferase gene reporter analyses and site-directed mutagenesis experiments demonstrated that functional binding sites for NF-kappa B and AP-1 in the hBD-2 promoter are required for NOD2-mediated induction of hBD-2 through MDP. Moreover, the NF-kappa B inhibitor Helenalin as well as a super-repressor form of the NF-kappa B inhibitor I kappa B strongly inhibited NOD2-mediated hBD-2 promoter activation. Expression of NOD2 was detected in primary keratinocytes, and stimulation of these cells with MDP induced hBD-2 peptide release. In contrast, small interference RNA-mediated downregulation of NOD2 expression in primary keratinocytes resulted in a defective induction of hBD-2 upon MDP treatment. Together, these data suggest that NOD2 serves as an intracellular pattern recognition receptor to enhance host defense by inducing the production of antimicrobial peptides such as hBD-2.	Univ Hosp Schleswig Holstein, Dept Dermatol, D-24105 Kiel, Germany; Univ Calif Davis, Sch Med, Dept Med Microbiol & Immunol, Davis, CA 95616 USA; Robert Bosch Krankenhaus, Dept Internal Med 1, D-70376 Stuttgart, Germany	University of Kiel; Schleswig Holstein University Hospital; University of California System; University of California Davis; Bosch; Robert Bosch Krankenhaus	Harder, J (corresponding author), Univ Hosp Schleswig Holstein, Dept Dermatol, Campus Kiel,Schittenhelmstr 7, D-24105 Kiel, Germany.	jharder@dermatology.uni-kiel.de	Wehkamp, Jan/B-7319-2011; Schroeder, Jens M/B-3994-2009; Harder, Jürgen/B-3162-2010	Wehkamp, Jan/0000-0001-6788-841X; Harder, Jurgen/0000-0002-4075-4603				Boman HG, 2003, J INTERN MED, V254, P197, DOI 10.1046/j.1365-2796.2003.01228.x; Chung WO, 2004, INFECT IMMUN, V72, P352, DOI 10.1128/IAI.72.1.352-358.2004; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Donnarumma G, 2004, EXP DERMATOL, V13, P748, DOI 10.1111/j.0906-6705.2004.00218.x; Fournier B, 2005, CLIN MICROBIOL REV, V18, P521, DOI 10.1128/CMR.18.3.521-540.2005; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 2004, J INVEST DERMATOL, V123, P522, DOI 10.1111/j.0022-202X.2004.23234.x; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Huang GTJ, 2002, HUM GENE THER, V13, P2017, DOI 10.1089/10430340260395875; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Kao CY, 2004, J IMMUNOL, V173, P3482, DOI 10.4049/jimmunol.173.5.3482; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Krisanaprakornkit S, 2002, J IMMUNOL, V168, P316, DOI 10.4049/jimmunol.168.1.316; Kulms D, 2000, J BIOL CHEM, V275, P15060, DOI 10.1074/jbc.M910113199; Lala S, 2003, GASTROENTEROLOGY, V125, P47, DOI 10.1016/S0016-5085(03)00661-9; Lehmann J, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-20; Liu LD, 2003, J IMMUNOL, V170, P575, DOI 10.4049/jimmunol.170.1.575; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Lyss G, 1997, BIOL CHEM, V378, P951, DOI 10.1515/bchm.1997.378.9.951; Mathews M, 1999, INFECT IMMUN, V67, P2740, DOI 10.1128/IAI.67.6.2740-2745.1999; McDermott AM, 2003, INVEST OPHTH VIS SCI, V44, P1859, DOI 10.1167/iovs.02-0787; Menzies BE, 2005, INFECT IMMUN, V73, P5241, DOI 10.1128/IAI.73.8.5241-5244.2005; Niyonsaba F, 2004, IMMUNOLOGY, V111, P273, DOI 10.1111/j.0019-2805.2004.01816.x; Nomura I, 2003, J IMMUNOL, V171, P3262, DOI 10.4049/jimmunol.171.6.3262; O'Neil DA, 2000, INFECT IMMUN, V68, P5412, DOI 10.1128/IAI.68.9.5412-5415.2000; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ogushi K, 2001, J BIOL CHEM, V276, P30521, DOI 10.1074/jbc.M011618200; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200; Pallen MJ, 2003, CURR OPIN MICROBIOL, V6, P519, DOI 10.1016/j.mib.2003.09.005; Philpott DJ, 2004, MOL IMMUNOL, V41, P1099, DOI 10.1016/j.molimm.2004.06.012; Proud D, 2004, J IMMUNOL, V172, P4637, DOI 10.4049/jimmunol.172.7.4637; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; Schroder JM, 1999, CELL MOL LIFE SCI, V56, P32, DOI 10.1007/s000180050004; Sorensen OE, 2005, J IMMUNOL, V174, P4870, DOI 10.4049/jimmunol.174.8.4870; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tsutsumi-Ishii Y, 2003, J IMMUNOL, V170, P4226, DOI 10.4049/jimmunol.170.8.4226; Tsutsumi-Ishii Y, 2002, J LEUKOCYTE BIOL, V71, P154; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Vora P, 2004, J IMMUNOL, V173, P5398, DOI 10.4049/jimmunol.173.9.5398; Wada A, 1999, BIOCHEM BIOPH RES CO, V263, P770, DOI 10.1006/bbrc.1999.1452; Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805; Wehkamp J, 2004, INFECT IMMUN, V72, P5750, DOI 10.1128/IAI.72.10.5750-5758.2004; Wehkamp J, 2005, J LEUKOCYTE BIOL, V77, P460, DOI 10.1189/jlb.0904543; Wehkamp J, 2003, INFLAMM BOWEL DIS, V9, P215, DOI 10.1097/00054725-200307000-00001; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Wolk K, 2004, IMMUNITY, V21, P241, DOI 10.1016/j.immuni.2004.07.007; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	63	251	265	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 27	2006	281	4					2005	2011		10.1074/jbc.M511044200	http://dx.doi.org/10.1074/jbc.M511044200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	004NV	16319062	hybrid			2022-12-27	WOS:000234760400021
J	Hakansson, P; Dahl, L; Chilkova, O; Domkin, V; Thelander, L				Hakansson, P; Dahl, L; Chilkova, O; Domkin, V; Thelander, L			The Schizosaccharomyces pombe replication inhibitor spd1 regulates ribonucleotide reductase activity and dNTPs by binding to the large Cdc22 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE INHIBITOR; FISSION YEAST; DNA-DAMAGE; RECOMBINANT MOUSE; CELL-CYCLE; CHECKPOINT; LOCALIZATION; PURIFICATION; MUTAGENESIS; PROTEIN	Ribonucleotide reductase (RNR) is an essential enzyme that provides the cell with a balanced supply of deoxyribonucleoside triphosphates for DNA replication and repair. Mutations that affect the regulation of RNR in yeast and mammalian cells can lead to genetic abnormalities and cell death. We have expressed and purified the components of the RNR system in fission yeast, the large subunit Cdc22p, the small subunit Suc22p, and the replication inhibitor Spd1p. It was proposed (Liu, C., Powell, K. A., Mundt, K., Wu, L., Carr, A. M., and Caspari, T. ( 2003) Genes Dev. 17, 1130 1140) that Spd1 is an RNR inhibitor, acting by anchoring the Suc22p inside the nucleus during G(1) phase. Using in vitro assays with highly purified proteins we have demonstrated that Spd1 indeed is a very efficient inhibitor of fission yeast RNR, but acting on Cdc22p. Furthermore, biosensor technique showed that Spd1p binds to the Cdc22p with a K-D of 2.4 mu M, whereas the affinity to Suc22p is negligible. Therefore, Spd1p inhibits fission yeast RNR activity by interacting with the Cdc22p. Similar to the situation in budding yeast, logarithmically growing fission yeast increases the dNTP pools 2-fold after 3 h of incubation in the UV mimetic 4-nitroquinoline-N-oxide. This increase is smaller than the increase observed in budding yeast but of the same order as the dNTP pool increase when synchronous Schizosaccharomyces pombe cdc10 cells are going from G(1) to S-phase.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Hakansson, P (corresponding author), Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden.	pelle.hakanson@medchem.umu.se		Hakansson, Pelle/0000-0003-0421-2433; Shilkova, Olga/0000-0001-8607-4008				Bondar T, 2004, J BIOL CHEM, V279, P9937, DOI 10.1074/jbc.M312570200; Borgne A, 2000, J CELL SCI, V113, P4341; Chabes A, 2003, CELL, V112, P391, DOI 10.1016/S0092-8674(03)00075-8; Chabes A, 2000, P NATL ACAD SCI USA, V97, P2474, DOI 10.1073/pnas.97.6.2474; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Domkin V, 2002, J BIOL CHEM, V277, P18574, DOI 10.1074/jbc.M201553200; ENGSTROM Y, 1988, EMBO J, V7, P1615, DOI 10.1002/j.1460-2075.1988.tb02987.x; ENGSTROM Y, 1984, EMBO J, V3, P863, DOI 10.1002/j.1460-2075.1984.tb01897.x; ENGSTROM Y, 1979, BIOCHEMISTRY-US, V18, P2941, DOI 10.1021/bi00581a004; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P42; Hofer A, 1998, J BIOL CHEM, V273, P34098, DOI 10.1074/jbc.273.51.34098; Holmberg C, 2005, GENE DEV, V19, P853, DOI 10.1101/gad.329905; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Koc A, 2003, J BIOL CHEM, V278, P9345, DOI 10.1074/jbc.M213013200; KUNZ BA, 1991, ANNU REV GENET, V25, P339, DOI 10.1146/annurev.ge.25.120191.002011; Liu C, 2003, GENE DEV, V17, P1130, DOI 10.1101/gad.1090803; LIU C, 2005, IN PRESS EMBO J; MANN GJ, 1991, BIOCHEMISTRY-US, V30, P1939, DOI 10.1021/bi00221a030; Mundt KE, 1999, CURR BIOL, V9, P1427, DOI 10.1016/S0960-9822(00)80091-3; Nielsen O, 2003, CURR BIOL, V13, pR565, DOI 10.1016/S0960-9822(03)00475-5; Nilssen EA, 2003, P NATL ACAD SCI USA, V100, P10758, DOI 10.1073/pnas.1833769100; Rova U, 1999, J BIOL CHEM, V274, P23746, DOI 10.1074/jbc.274.34.23746; ROVA U, 1995, BIOCHEMISTRY-US, V34, P4267, DOI 10.1021/bi00013a016; SARABIA MJF, 1993, MOL GEN GENET, V238, P241, DOI 10.1007/BF00279553; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Uchiki T, 2004, J BIOL CHEM, V279, P11293, DOI 10.1074/jbc.M309751200; Woollard A, 1996, EMBO J, V15, P4603, DOI 10.1002/j.1460-2075.1996.tb00838.x; Yao RJ, 2003, P NATL ACAD SCI USA, V100, P6628, DOI 10.1073/pnas.1131932100; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2000, MOL CELL BIOL, V20, P9076, DOI 10.1128/MCB.20.23.9076-9083.2000	32	52	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 20	2006	281	3					1778	1783		10.1074/jbc.M511716200	http://dx.doi.org/10.1074/jbc.M511716200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	002ZS	16317005	hybrid			2022-12-27	WOS:000234652000059
J	Kassavetis, GA; Steiner, DF				Kassavetis, GA; Steiner, DF			Nhp6 is a transcriptional initiation fidelity factor for RNA polymerase III transcription in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; START-SITE; MUTATIONAL ANALYSIS; GENE-TRANSCRIPTION; YEAST TFIIIB; DNA; COMPLEXES; UPSTREAM; ORGANIZATION	The binding of the RNA polymerase III (pol III) transcription factor TFIIIC to the box A intragenic promoter element of tRNA genes specifies the placement of TFIIIB on upstream-lying DNA. In turn, TFIIIB recruits pol III to the promoter and specifies transcription initiating 17 - 19 base pairs upstream of boxA. The resolution of the pol III transcription apparatus into recombinant TFIIIB, highly purified TFIIIC, and pol III is accompanied by a loss of precision in specifying where transcription initiation occurs due to heterogeneous placement of TFIIIB. In this paper we show that Nhp6a, an abundant high mobility group B ( HMGB) family, non-sequence-specific DNA-binding protein in Saccharomyces cerevisiae restores transcriptional initiation fidelity to this highly purified in vitro system. Restoration of initiation fidelity requires the presence of Nhp6a prior to TFIIIB-DNA complex formation. Chemical nuclease footprinting of TFIIIC- and TFIIIB-TFIIIC-DNA complexes reveals that Nhp6a markedly alters the TFIIIC footprint over box A and reduces the size of the TFIIIB footprint on upstream DNA sequence. Analyses of unprocessed tRNAs from yeast lacking Nhp6a and its closely related paralogue Nhp6b demonstrate that Nhp6 is required for transcriptional initiation fidelity of some but not all tRNA genes, in vivo.	Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kassavetis, GA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gak@biomail.ucsd.edu						Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; Andrau JC, 2001, EUR J BIOCHEM, V268, P5167, DOI 10.1046/j.0014-2956.2001.02445.x; Bachman N, 2004, GENOME RES, V14, P1232, DOI 10.1101/gr.2052904; BAKER RE, 1986, J BIOL CHEM, V261, P5275; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1989, P NATL ACAD SCI USA, V86, P2530, DOI 10.1073/pnas.86.8.2530; Brewster NK, 2001, MOL CELL BIOL, V21, P3491, DOI 10.1128/MCB.21.10.3491-3502.2001; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; DIECI G, 1993, J BIOL CHEM, V268, P11199; Eriksson P, 2004, MOL CELL BIOL, V24, P6419, DOI 10.1128/MCB.24.14.6419-6429.2004; FABRIZIO P, 1987, P NATL ACAD SCI USA, V84, P8763, DOI 10.1073/pnas.84.24.8763; Formosa T, 2001, EMBO J, V20, P3506, DOI 10.1093/emboj/20.13.3506; FRUSCOLONI P, 1995, NUCLEIC ACIDS RES, V23, P2914, DOI 10.1093/nar/23.15.2914; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Giuliodori S, 2003, J MOL BIOL, V333, P1, DOI 10.1016/j.jmb.2003.08.016; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Huet J, 1996, METHOD ENZYMOL, V273, P249; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; Kassavetis GA, 2005, P NATL ACAD SCI USA, V102, P15406, DOI 10.1073/pnas.0507653102; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; KASSAVETIS GA, 1992, J MOL BIOL, V226, P47, DOI 10.1016/0022-2836(92)90123-2; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Kruppa M, 2001, MOL CELL, V7, P309, DOI 10.1016/S1097-2765(01)00179-4; Kufel J, 2003, RNA, V9, P202, DOI 10.1261/rna.2145103; Kumar A, 1997, MOL CELL BIOL, V17, P1868, DOI 10.1128/MCB.17.4.1868; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LEVEILLARD T, 1993, J BIOL CHEM, V268, P3594; Lopez S, 2001, MOL CELL BIOL, V21, P3096, DOI 10.1128/MCB.21.9.3096-3104.2001; Martin MP, 2001, MOL CELL BIOL, V21, P6429, DOI 10.1128/MCB.21.19.6429-6439.2001; Masse JE, 2002, J MOL BIOL, V323, P263, DOI 10.1016/S0022-2836(02)00938-5; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NICHOLS M, 1989, J BIOL CHEM, V264, P17084; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; Persinger J, 1999, MOL CELL BIOL, V19, P5218; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; SHARP SJ, 1985, CRC CR REV BIOCH MOL, V19, P107, DOI 10.3109/10409238509082541; WHITE RJ, 2002, RNA POLYM 3 TRANSCRI; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1; Zecherle GN, 1996, MOL CELL BIOL, V16, P5801; Ziehler WA, 2000, BIOCHEMISTRY-US, V39, P9909, DOI 10.1021/bi000603n	47	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7445	7451		10.1074/jbc.M512810200	http://dx.doi.org/10.1074/jbc.M512810200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407207	hybrid			2022-12-27	WOS:000236030900066
J	Shah, M; Patel, K; Mukhopadhyay, S; Xu, F; Guo, G; Sehgal, PB				Shah, M; Patel, K; Mukhopadhyay, S; Xu, F; Guo, G; Sehgal, PB			Membrane-associated STAT3 and PY-STAT3 in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING ENDOSOME HYPOTHESIS; RESONANCE ENERGY-TRANSFER; PLASMA-MEMBRANE; CYTOSOLIC COMPLEXES; CLATHRIN EXCHANGE; PROTEIN; GROWTH; ACTIVATION; TRANSPORT; INTERNALIZATION	Signal transduction from the plasma membrane to the nucleus by STAT proteins is widely represented as exclusively a soluble cytosolic process. Using cell-fractionation methods, we observed that similar to 5% of cytoplasmic STAT3 was constitutively associated with the purified early endosome (EE) fraction in human Hep3B liver cells. By 15 - 30 min after interleukin-6 (IL-6) treatment, up to two-thirds of cytoplasmic Tyr-phosphorylated STAT3 can be associated with the purified early endosome fraction (Rab-5-, EEA1-, transferrin receptor-, and clathrin-positive fraction). Electron microscopy, immunofluorescence, and detergent dissection approaches confirmed the association of STAT3 and PY-STAT3 with early endosomes. STAT3 was constitutively associated with clathrin heavy chain in membrane and in the 1- to 2-MDa cytosolic complexes. The membrane association was dynamic in that, within 15 min of treatment with the vicinal-thiol cross-linker phenylarsine oxide, there was a dramatic increase in bulk STAT3 association with sedimentable membranes. The functional contribution of PY-STAT3 association with the endocytic pathway was evaluated in transient transfection assays using IL-6-inducible STAT3-reporter-luciferase constructs and selective regulators of this pathway. STAT3-transcriptional activation was inhibited by expression constructs for dominant negative dynamin K44A, epsin 2a, amphiphysin A1, and clathrin light chain but enhanced by that for the active dynamin species MxA. Taken together, these studies emphasize the contribution of the endocytic pathway to productive IL-6/ STAT3 signaling.	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Sehgal, PB (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Rm 201,Basic Sci Bldg, Valhalla, NY 10595 USA.	pravin_sehgal@nymc.edu		Mukhopadhyay, Somshuvra/0000-0002-3420-7830	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073301] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 73301] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; Beattie EC, 1996, COLD SPRING HARB SYM, V61, P389; Bild AH, 2002, EMBO J, V21, P3255, DOI 10.1093/emboj/cdf351; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Braunstein J, 2003, J BIOL CHEM, V278, P34133, DOI 10.1074/jbc.M304531200; COFFER PJ, 1995, BIOCHEM BIOPH RES CO, V210, P74, DOI 10.1006/bbrc.1995.1629; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; HOLTZMAN E, 1966, J MOL BIOL, V17, P131, DOI 10.1016/S0022-2836(66)80099-2; Howe CL, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742-4682-2-43; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; JHUN BH, 1991, J BIOL CHEM, V266, P22260; Jiang RF, 2000, J BIOL CHEM, V275, P8439, DOI 10.1074/jbc.275.12.8439; KALEF E, 1994, METHOD ENZYMOL, V233, P395; Kochs G, 2002, J BIOL CHEM, V277, P14172, DOI 10.1074/jbc.M200244200; Kojima H, 2005, P NATL ACAD SCI USA, V102, P4524, DOI 10.1073/pnas.0500679102; Kretzschmar AK, 2004, BIOCHEM J, V377, P289, DOI 10.1042/BJ20030708; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; MANDERS EMM, 1993, J MICROSC-OXFORD, V169, P375, DOI 10.1111/j.1365-2818.1993.tb03313.x; MANDERS EMM, 1992, J CELL SCI, V103, P857; Mao X, 2005, MOL CELL, V17, P761, DOI 10.1016/j.molcel.2005.02.021; Minoguchi M, 2003, J BIOL CHEM, V278, P11182, DOI 10.1074/jbc.M211230200; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Ota N, 2004, NAT IMMUNOL, V5, P208, DOI 10.1038/ni1032; Parker MS, 2002, EUR J PHARMACOL, V452, P279, DOI 10.1016/S0014-2999(02)02339-7; PENMAN S, 1966, J MOL BIOL, V17, P117, DOI 10.1016/S0022-2836(66)80098-0; Rayala SK, 2006, J BIOL CHEM, V281, P4395, DOI 10.1074/jbc.M510368200; Rayanade RJ, 1997, J BIOL CHEM, V272, P4659, DOI 10.1074/jbc.272.8.4659; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Saxena S, 2005, MOL CELL NEUROSCI, V28, P571, DOI 10.1016/j.mcn.2004.11.011; Schroder M, 2004, J LEUKOCYTE BIOL, V75, P792, DOI 10.1189/jlb.1003496; Scoles DR, 2002, HUM MOL GENET, V11, P3179, DOI 10.1093/hmg/11.25.3179; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Sehgal PB, 2003, ACTA BIOCHIM POL, V50, P583; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; Sehgal PB, 2003, SIGNAL TRANSDUCERS A, P1; Shah M, 2005, AM J PHYSIOL-CELL PH, V288, pC850, DOI 10.1152/ajpcell.00327.2004; Shah M, 2002, J BIOL CHEM, V277, P45662, DOI 10.1074/jbc.M205935200; Sorkin A, 2004, CURR OPIN CELL BIOL, V16, P392, DOI 10.1016/j.ceb.2004.06.001; Thiel S, 2000, FEBS LETT, V470, P15, DOI 10.1016/S0014-5793(00)01276-X; Thiel S, 1998, FEBS LETT, V441, P231, DOI 10.1016/S0014-5793(98)01559-2; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; Watanabe K, 2004, BIOCHEM BIOPH RES CO, V324, P1264, DOI 10.1016/j.bbrc.2004.09.187; Wu XF, 2003, MOL BIOL CELL, V14, P516, DOI 10.1091/mbc.E02-06-0353; Wu XF, 2001, J CELL BIOL, V155, P291, DOI 10.1083/jcb.200104085; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; Yeung YG, 2003, MOL CELL PROTEOMICS, V2, P1143, DOI 10.1074/mcp.R300009-MCP200; Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200; Zhong MH, 2005, P NATL ACAD SCI USA, V102, P3966, DOI 10.1073/pnas.0501063102	60	66	67	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7302	7308		10.1074/jbc.M508527200	http://dx.doi.org/10.1074/jbc.M508527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407171	hybrid			2022-12-27	WOS:000236030900048
J	Tian, XJ; Feig, LA				Tian, XJ; Feig, LA			Age-dependent participation of Ras-GRF proteins in coupling calcium-permeable AMPA glutamate receptors to Ras/Erk signaling in cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; SYNAPTIC PLASTICITY; PYRAMIDAL NEURONS; COMPLEX-FORMATION; MAP KINASE; TRAFFICKING; SPECIFICITY; ACTIVATION; CREB; PHOSPHORYLATION	alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors (AMPARs) are ligand-gated sodium channels. Through their ability to mediate the majority of rapid excitatory transmission in the central nervous system, these neurotransmitter receptors have been shown to influence synaptic plasticity. Some of these receptors are also calcium-permeable (CP), and they also have been implicated in regulating synaptic plasticity, particularly in interneurons where their concentration is highest. However, the biochemical pathways emanating from CP-AMPARs that mediate these effects have not been well characterized. In this paper, we show that CP-AMPARs are the predominant AMPAR class responsible for activating the Ras/Erk kinase signaling cascade and the cAMP-response element-binding protein (CREB) transcription factor in the cortex of mature mice. Activation of Ras and Erk, but not CREB, occurs through the calcium/calmodulin regulated Ras-GRF1 and Ras-GRF2 exchange factors, which form AMPA-induced complexes with CP-AMPARs but not calcium-impermeable (CI) AMPARs in vivo. Furthermore, we show that CP-AMPARs are also the major AMPAR type to activate Ras/Erk signaling in pubescent mice; however, at this developmental stage Ras-GRF (guanine nucleotide-releasing factor) proteins are not involved. Finally, in neonatal animals CI-AMPARs, but not CP-AMPARs, are the predominant AMPAR type that activates Ras-Erk signaling and CREB in cortical neurons. This occurs indirectly through activation of L-type voltage-dependent calcium channels, an event that is also Ras-GRF-independent. Thus, Ras/Erk signaling and CREB activity induced by AMPARs occur through age-dependent mechanisms that likely make unique developmentally dependent contributions to synaptic function.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA	Tufts University; Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.	larry.feig@tufts.edu			NCI NIH HHS [R01 CA 47391] Funding Source: Medline; NIDDK NIH HHS [P3 DK 3498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047391] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Connolly BA, 2005, MOL CELL BIOL, V25, P4602, DOI 10.1128/MCB.25.11.4602-4614.2005; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Goldberg JH, 2003, NEURON, V40, P807, DOI 10.1016/S0896-6273(03)00714-1; HOLLMANN M, 1994, RENAL PHYSIOL BIOCH, V17, P182; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; Krapivinsky G, 2003, NEURON, V40, P775, DOI 10.1016/S0896-6273(03)00645-7; Kumar SS, 2002, J NEUROSCI, V22, P3005, DOI 10.1523/JNEUROSCI.22-08-03005.2002; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; Malenka RC, 2003, ANN NY ACAD SCI, V1003, P1, DOI 10.1196/annals.1300.001; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Ogoshi F, 2003, J NEUROSCI, V23, P10521; Perkinton MS, 1999, J NEUROSCI, V19, P5861, DOI 10.1523/JNEUROSCI.19-14-05861.1999; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Tian XJ, 2004, EMBO J, V23, P1567, DOI 10.1038/sj.emboj.7600151; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Vanhoutte P, 1999, MOL CELL BIOL, V19, P136; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	26	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7578	7582		10.1074/jbc.M512060200	http://dx.doi.org/10.1074/jbc.M512060200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16407208	hybrid			2022-12-27	WOS:000236030900079
J	Wu, YZ; Manevich, Y; Baldwin, JL; Dodia, C; Yu, K; Feinstein, SI; Fisher, AB				Wu, YZ; Manevich, Y; Baldwin, JL; Dodia, C; Yu, K; Feinstein, SI; Fisher, AB			Interaction of surfactant protein a with peroxiredoxin 6 regulates phospholipase A(2) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT; RAT LUNG; II CELLS; LAMELLAR BODIES; ALVEOLAR DPPC; KAPPA-B; DIPALMITOYLPHOSPHATIDYLCHOLINE; MEMBRANE; IDENTIFICATION; RECOGNITION	Peroxiredoxin 6 (Prdx6) is a "moonlighting" protein with both GSH peroxidase and phospholipase A(2) (PLA(2)) activities. This protein is responsible for degradation of internalized dipalmitoylphosphatidylcholine, the major phospholipid component of lung surfactant. The PLA(2) activity is inhibited by surfactant protein A (SP-A). We postulate that SP-A regulates the PLA(2) activity of Prdx6 through direct protein-protein interaction. Recombinant human Prdx6 and SP-A isolated from human alveolar proteinosis fluid were studied. Measurement of kinetic constants at pH 4.0 (maximal PLA(2) activity) showed K-m 0.35 mM and V-max 138 nmol/min/mg of protein. SP-A inhibited PLA(2) activity non-competitively with K-i 10 mu g/ml and was Ca2+-independent. Activity at pH 7.4 was similar to 50% less, and inhibition by SP-A was partially dependent on Ca2+. Interaction of SP-A and Prdx6 at pH 7.4 was shown by Prdx6-mediated inhibition of SP-A binding to agarose beads, a pull-down assay using His-tagged Prdx6 and Ni2+-chelating beads, co-immunoprecipitation from lung epithelial cells and from a binary mixture of the two proteins, binding after treatment with a trifunctional cross-linker, and size-exclusion chromatography. Analysis by static light scattering and surface plasmon resonance showed calcium-independent SP-A binding to Prdx6 at pH 4.0 and partial Ca2+ dependence of binding at pH 7.4. These results indicate a direct interaction between SP-A and Prdx6, which provides a mechanism for regulation of the PLA(2) activity of Prdx6 by SP-A.	Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Fisher, AB (corresponding author), Univ Penn, Inst Environm Med, 1 John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	abf@mail.med.upenn.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akiba S, 1998, COMP BIOCHEM PHYS B, V120, P393, DOI 10.1016/S0305-0491(98)10046-9; Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; Bi XH, 2001, BIOCHEMISTRY-US, V40, P13659, DOI 10.1021/bi011188h; Casals C, 2001, PEDIATR PATHOL MOL M, V20, P249, DOI 10.1080/152279501750412216; CHANDER A, 1986, J BIOL CHEM, V261, P6126; CHINOY MR, 1993, AM J PHYSIOL, V264, pL300, DOI 10.1152/ajplung.1993.264.3.L300; FISHER AB, 1994, AM J PHYSIOL, V267, pL335, DOI 10.1152/ajplung.1994.267.3.L335; Fisher AB, 2005, J LIPID RES, V46, P1248, DOI 10.1194/jlr.M400499-JLR200; FISHER AB, 1994, BBA-LIPID LIPID MET, V1211, P256, DOI 10.1016/0005-2760(94)90148-1; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V280, pL748, DOI 10.1152/ajplung.2001.280.4.L748; Fisher AB, 1996, J LIPID RES, V37, P1057; HAAGSMAN HP, 1989, AM J PHYSIOL, V257, pL421, DOI 10.1152/ajplung.1989.257.6.L421; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; Jain D, 2003, AM J PHYSIOL-LUNG C, V284, pL759, DOI 10.1152/ajplung.00200.2002; KALINA M, 1995, AM J PHYSIOL-LUNG C, V268, pL144, DOI 10.1152/ajplung.1995.268.1.L144; Kim TS, 1998, AM J PHYSIOL-LUNG C, V274, pL750, DOI 10.1152/ajplung.1998.274.5.L750; Kim TS, 1997, J BIOL CHEM, V272, P2542; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; Manevich Y, 2004, P NATL ACAD SCI USA, V101, P3780, DOI 10.1073/pnas.0400181101; Manevich Y, 2002, P NATL ACAD SCI USA, V99, P11599, DOI 10.1073/pnas.182384499; Morrow MR, 2003, BIOPHYS J, V85, P2397, DOI 10.1016/S0006-3495(03)74663-3; Mulugeta S, 2002, J BIOL CHEM, V277, P22147, DOI 10.1074/jbc.M201812200; Piboonpocanun S, 2005, J BIOL CHEM, V280, P9, DOI 10.1074/jbc.M411570200; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; RIDER ED, 1991, J BIOL CHEM, V266, P22522; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; VANGOLDE LMG, 1988, PHYSIOL REV, V68, P374, DOI 10.1152/physrev.1988.68.2.374; WALI A, 1993, AM J PHYSIOL, V264, pL431, DOI 10.1152/ajplung.1993.264.5.L431; Weaver TE, 2002, SEMIN CELL DEV BIOL, V13, P263, DOI 10.1016/S1084952102000551; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; Wu YZ, 2003, AM J RESP CRIT CARE, V168, P692, DOI 10.1164/rccm.200304-467OC; YOUNG SL, 1991, AM J PHYSIOL, V260, pL161, DOI 10.1152/ajplung.1991.260.2.L161; Zen K, 1998, AM J PHYSIOL-LUNG C, V275, pL172, DOI 10.1152/ajplung.1998.275.1.L172	35	66	70	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7515	7525		10.1074/jbc.M504525200	http://dx.doi.org/10.1074/jbc.M504525200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16330552	hybrid			2022-12-27	WOS:000236030900073
J	Vinolo, E; Sebban, H; Chaffotte, A; Israel, A; Courtois, G; Veron, M; Agou, F				Vinolo, E; Sebban, H; Chaffotte, A; Israel, A; Courtois, G; Veron, M; Agou, F			A point mutation in NEMO associated with anhidrotic ectodermal dysplasia with immunodeficiency pathology results in destabilization of the oligomer and reduces lipopolysaccharide- and tumor necrosis factor-mediated NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; HELICAL COILED-COILS; GAMMA IKK-GAMMA; KINASE COMPLEX; ZINC-FINGER; HYDROPHOBIC INTERACTIONS; TYROSINATE FLUORESCENCE; INCONTINENTIA PIGMENTI; CIRCULAR-DICHROISM; ALPHA	The NEMO (NF-kappa B essential modulator) protein plays a crucial role in the canonical NF-kappa B pathway as the regulatory component of the IKK (I kappa B kinase) complex. The human disease anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) has been recently linked to mutations in NEMO. We investigated the effect of an alanine to glycine substitution found in the NEMO polypeptide of an EDA-ID patient. This pathogenic mutation is located within the minimal oligomerization domain of the protein, which is required for the IKK activation in response to diverse stimuli. The mutation does not dramatically change the native-like state of the trimer, but temperature-induced unfolding studied by circular dichroism showed that it leads to an important loss in the oligomer stability. Furthermore, fluorescence studies showed that the tyrosine located in the adjacent zinc finger domain, which is possibly required for NEMO ubiquitination, exhibits an alteration in its spectral properties. This is probably due to a conformational change of this domain, providing evidence for a close interaction between the oligomerization domain and the zinc finger. In addition, functional complementation assays using NEMO-deficient pre-B and T lymphocytes showed that the pathogenic mutation reduced TNF-alpha and LPS-induced NF-kappa B activation by altering the assembly of the IKK complex. Altogether, our findings provide understanding as to how a single point mutation in NEMO leads to the observed EDA-ID phenotype in relation to the NEMO-dependent mechanism of IKK activation.	Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2185, Unite Repliement & Modelisat Prot, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2582, Unite Signalisat Mol & Activat Cellulaire, F-75724 Paris 15, France; Hop St Louis, INSERM, U697, F-75475 Paris 10, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Agou, F (corresponding author), Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, 25-28 Rue Dr Roux, F-75724 Paris 15, France.	fagou@pasteur.fr	, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595				Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Aradhya S, 2001, HUM MOL GENET, V10, P2171, DOI 10.1093/hmg/10.19.2171; Boice JA, 1996, BIOCHEMISTRY-US, V35, P14480, DOI 10.1021/bi961831d; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; Courtois G, 2005, CELL MOL LIFE SCI, V62, P1682, DOI 10.1007/s00018-005-5031-5; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dragan AI, 2002, J MOL BIOL, V321, P891, DOI 10.1016/S0022-2836(02)00699-X; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; Fusco F, 2004, HUM MOL GENET, V13, P1763, DOI 10.1093/hmg/ddh192; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Harding S. E., 1992, ANAL ULTRACENTRIFUGA; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HENNESSEY JP, 1982, ANAL BIOCHEM, V125, P177, DOI 10.1016/0003-2697(82)90400-6; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; JASANOFF A, 1992, J MOL BIOL, V225, P1035, DOI 10.1016/0022-2836(92)90103-Q; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; Kohsaka T, 1999, HUM MUTAT, V14, P466, DOI 10.1002/(SICI)1098-1004(199912)14:6<466::AID-HUMU4>3.3.CO;2-Y; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Lachenmann MJ, 2002, J MOL BIOL, V316, P969, DOI 10.1006/jmbi.2001.5335; Liew CK, 2000, STRUCTURE, V8, P1157, DOI 10.1016/S0969-2126(00)00527-X; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Matthews JM, 2000, EUR J BIOCHEM, V267, P1030, DOI 10.1046/j.1432-1327.2000.01095.x; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Muller KM, 2000, METHOD ENZYMOL, V328, P261; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; PUNDAK S, 1984, BIOCHEMISTRY-US, V23, P1549, DOI 10.1021/bi00302a032; Receveur V, 2000, PROTEINS, V38, P226, DOI 10.1002/(SICI)1097-0134(20000201)38:2<226::AID-PROT10>3.0.CO;2-H; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; Smahi A, 2000, NATURE, V405, P466; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; SZABO AG, 1978, FEBS LETT, V94, P249, DOI 10.1016/0014-5793(78)80948-X; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang F, 2004, J IMMUNOL, V172, P2446, DOI 10.4049/jimmunol.172.4.2446; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	60	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6334	6348		10.1074/jbc.M510118200	http://dx.doi.org/10.1074/jbc.M510118200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16379012	hybrid			2022-12-27	WOS:000236030800027
J	Barends, TRM; Polderman-Tijmes, JJ; Jekel, PA; Williams, C; Wybenga, G; Janssen, DB; Dijkstra, BW				Barends, TRM; Polderman-Tijmes, JJ; Jekel, PA; Williams, C; Wybenga, G; Janssen, DB; Dijkstra, BW			Acetobacter turbidans alpha-amino acid ester hydrolase - How a single mutation improves an antibiotic-producing enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLYL DIPEPTIDYL AMINOPEPTIDASE; ACYL TRANSFER; SUBSTRATE-SPECIFICITY; PENICILLIN ACYLASE; XANTHOMONAS-CITRI; IDENTIFICATION; RESIDUES; SEQUENCE; KINETICS; PROGRAM	The alpha- amino acid ester hydrolase ( AEH) from Acetobacter turbidans is a bacterial enzyme catalyzing the hydrolysis and synthesis of beta- lactam antibiotics. The crystal structures of the native enzyme, both unliganded and in complex with the hydrolysis product D- phenylglycine are reported, as well as the structures of an inactive mutant ( S205A) complexed with the substrate ampicillin, and an active site mutant ( Y206A) with an increased tendency to catalyze antibiotic production rather than hydrolysis. The structure of the native enzyme shows an acyl binding pocket, in which D- phenylglycine binds, and an additional space that is large enough to accommodate the beta- lactam moiety of an antibiotic. In the S205A mutant, ampicillin binds in this pocket in a non- productive manner, making extensive contacts with the side chain of Tyr(112), which also participates in oxyanion hole formation. In the Y206A mutant, the Tyr(112) side chain has moved with its hydroxyl group toward the catalytic serine. Because this changes the properties of the beta- lactam binding site, this could explain the increased beta- lactam transferase activity of this mutant.	Univ Groningen, Biophys Chem Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Biochem Lab, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Biophys Chem Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	b.w.dijkstra@rug.nl	Dijkstra, Bauke W./H-4308-2019	Dijkstra, Bauke W./0000-0001-9731-6586				Alkema WBL, 2002, EUR J BIOCHEM, V269, P2093, DOI 10.1046/j.1432-1033.2002.02857.x; ALKEMA WBL, 2002, THESIS U GRONINGIN G, P142; Barends TRM, 2003, ACTA CRYSTALLOGR D, V59, P2237, DOI 10.1107/S0907444903020729; Barends TRM, 2003, J BIOL CHEM, V278, P23076, DOI 10.1074/jbc.M302246200; BLINKOVSKY AM, 1993, ENZYME MICROB TECH, V15, P965, DOI 10.1016/0141-0229(93)90173-Y; Bruggink A, 1998, ORG PROCESS RES DEV, V2, P128, DOI 10.1021/op9700643; CHICH JF, 1992, FEBS LETT, V314, P139, DOI 10.1016/0014-5793(92)80960-O; ESNOUSF BM, 1997, J MOL GRAPHICS, V15, P138; Fernandez-Lafuente R, 2001, J MOL CATAL B-ENZYM, V11, P633, DOI 10.1016/S1381-1177(00)00065-5; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; KATO K, 1980, AGR BIOL CHEM TOKYO, V44, P1083, DOI 10.1080/00021369.1980.10864077; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen NA, 2002, NAT STRUCT BIOL, V9, P17, DOI 10.1038/nsb742; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAM DH, 1985, BIOTECHNOL BIOENG, V27, P953, DOI 10.1002/bit.260270705; Nardini M, 1999, CURR OPIN STRUC BIOL, V9, P732, DOI 10.1016/S0959-440X(99)00037-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polderman-Tijmes JJ, 2002, J BIOL CHEM, V277, P28474, DOI 10.1074/jbc.M204143200; Polderman-Tijmes JJ, 2002, APPL ENVIRON MICROB, V68, P211, DOI 10.1128/AEM.68.1.211-218.2002; Rigolet P, 2002, STRUCTURE, V10, P1383, DOI 10.1016/S0969-2126(02)00851-1; SINGER PT, 1993, SCIENCE, V261, P621, DOI 10.1126/science.261.5121.621; TAKAHASHI T, 1972, J AM CHEM SOC, V94, P4035, DOI 10.1021/ja00766a076; TAKAHASHI T, 1974, BIOCHEM J, V137, P497, DOI 10.1042/bj1370497; Topf M, 2002, PROTEINS, V47, P357, DOI 10.1002/prot.10097; Turner JM, 2002, BIOCHEMISTRY-US, V41, P12297, DOI 10.1021/bi026131p; Van der Laan J-M, 2002, WO Patent, Patent No. [W002086111, C12N15/55, C12N9/18, (IPC1-7): C 12N9/00.2002, 02086111]; Yeates TO, 1997, METHOD ENZYMOL, V276, P344, DOI 10.1016/S0076-6879(97)76068-3; Youshko MI, 2002, BBA-PROTEINS PROTEOM, V1599, P134, DOI 10.1016/S1570-9639(02)00413-2	32	21	26	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5804	5810		10.1074/jbc.M511187200	http://dx.doi.org/10.1074/jbc.M511187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377627	hybrid, Green Published			2022-12-27	WOS:000235568900059
J	Ignatiuk, A; Quickfall, JP; Hawrysh, AD; Chamberlain, MD; Anderson, DH				Ignatiuk, A; Quickfall, JP; Hawrysh, AD; Chamberlain, MD; Anderson, DH			The smaller isoforms of ankyrin 3 bind to the p85 subunit of phosphatidylinositol 3 '-kinase and enhance platelet-derived growth factor receptor down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF-BETA-RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE KINASES; P85-ALPHA SUBUNIT; RAB PROTEINS; GENE FAMILY; SH2 DOMAINS; INTERNALIZATION; ENDOSOMES; 3-KINASE	The Src homology 2 (SH2) domains of the p85 subunit of phosphatidylinositol 3'-kinase have been shown to bind to the tyrosine-phosphorylated platelet-derived growth factor receptor (PDGFR). Previously, we have demonstrated that p85 SH2 domains can also bind to the serine/threonine kinase A-Raf via a unique phosphorylation-independent interaction. In this report, we describe a new phosphotyrosine-independent p85 SH2-binding protein, ankyrin 3 (Ank3). In general, ankyrins serve a structural role by binding to both integral membrane proteins at the plasma membrane and spectrin/fodrin proteins of the cytoskeleton. However, smaller isoforms of Ank3 lack the membrane domain and are localized to late endosomes and lysosomes. We found that p85 binds directly to these smaller 120- and 105-kDa Ank3 isoforms. Both the spectrin domain and the regulatory domain of Ank3 are involved in binding to p85. At least two domains of p85 can bind to Ank3, and the interaction involving the p85 C-SH2 domain was found to be phosphotyrosine-independent. Overexpression of the 120- or 105-kDa Ank3 proteins resulted in significantly enhanced PDGFR degradation and a reduced ability to proliferate in response to PDGF. Ank3 overexpression also differentially regulated signaling pathways downstream from the PDGFR. Chloroquine, an inhibitor of lysosomal-mediated degradation pathways, blocked the ability of Ank3 to enhance PDGFR degradation. Immunofluorescence experiments demonstrated that both small Ank3 isoforms colocalized with the lysosomal-associated membrane protein and with p85 and the PDGFR. These results suggest that Ank3 plays an important role in lysosomal-mediated receptor down-regulation, likely through a p85-Ank3 interaction.	Saskatoon Canc Agcy, Canc Res Unit, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 535, Canada; Univ Saskatchewan, Dept Oncol, Saskatoon, SK S7N 535, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Anderson, DH (corresponding author), Saskatoon Canc Agcy, Canc Res Unit, Hlth Res Div, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	deborah.anderson@scf.sk.ca	Chamberlain, Michael/A-9107-2016; Chamberlain, Michael Dean/AAX-1670-2021	Chamberlain, Michael/0000-0003-1813-8545; Chamberlain, Michael Dean/0000-0003-1813-8545				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Anderson DH, 1998, ONCOGENE, V16, P2321, DOI 10.1038/sj.onc.1201780; Armstrong J, 2000, INT J BIOCHEM CELL B, V32, P303, DOI 10.1016/S1357-2725(99)00112-0; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Chamberlain MD, 2004, J BIOL CHEM, V279, P48607, DOI 10.1074/jbc.M409769200; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; Fang Y, 2002, BIOCHEM BIOPH RES CO, V290, P1267, DOI 10.1006/bbrc.2002.6347; HELDIN CH, 1982, J BIOL CHEM, V257, P4216; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hoock TC, 1997, J CELL BIOL, V136, P1059, DOI 10.1083/jcb.136.5.1059; IINO T, 1986, J GEN VIROL, V67, P1373, DOI 10.1099/0022-1317-67-7-1373; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; King TR, 2000, J BIOL CHEM, V275, P36450, DOI 10.1074/jbc.M004720200; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Siegal G, 1998, J MOL BIOL, V276, P461, DOI 10.1006/jmbi.1997.1562; Sorkin A, 2000, J CELL SCI, V113, P4375; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Stenmark H, 2001, GENOME BIOL, V2; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5956	5964		10.1074/jbc.M510032200	http://dx.doi.org/10.1074/jbc.M510032200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377635	hybrid			2022-12-27	WOS:000235568900076
J	Drees, JC; Chitteni-Pattu, S; McCaslin, DR; Inman, RB; Cox, MM				Drees, JC; Chitteni-Pattu, S; McCaslin, DR; Inman, RB; Cox, MM			Inhibition of RecA protein function by the RdgC protein from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; GENETIC-RECOMBINATION; COPROTEASE ACTIVITIES; BINDING-PROTEIN; ATP HYDROLYSIS; C-TERMINUS; IN-VITRO; FILAMENT; EXCHANGE; REPAIR	The Escherichia coli RdgC protein is a potential negative regulator of RecA function. RdgC inhibits RecA protein-promoted DNA strand exchange, ATPase activity, and RecA-dependent LexA cleavage. The primary mechanism of RdgC inhibition appears to involve a simple competition for DNA binding sites, especially on duplex DNA. The capacity of RecA to compete with RdgC is improved by the DinI protein. RdgC protein can inhibit DNA strand exchange catalyzed by RecA nucleoprotein filaments formed on single-stranded DNA by binding to the homologous duplex DNA and thereby blocking access to that DNA by the RecA nucleoprotein filaments. RdgC protein binds to single-stranded and double-stranded DNA, and the protein can be visualized on DNA using electron microscopy. RdgC protein exists in solution as a mixture of oligomeric states in equilibrium, most likely as monomers, dimers, and tetramers. This concentration-dependent change of state appears to affect its mode of binding to DNA and its capacity to inhibit RecA. The various species differ in their capacity to inhibit RecA function.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Cox JM, 2005, PLOS BIOL, V3, P231, DOI 10.1371/journal.pbio.0030052; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2002, MUTAT RES-FUND MOL M, V510, P107, DOI 10.1016/S0027-5107(02)00256-7; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Drees JC, 2004, J BIOL CHEM, V279, P52991, DOI 10.1074/jbc.M409050200; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; HOWARDFLANDERS P, 1987, DNA REPLICATION RECO, P609; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLE JW, 1991, BIOCHIMIE, V73, P411, DOI 10.1016/0300-9084(91)90108-D; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; MARRIONE PE, 1995, BIOCHEMISTRY-US, V34, P9809, DOI 10.1021/bi00030a019; Moore T, 2004, J BACTERIOL, V186, P870, DOI 10.1128/JB.186.3.870-874.2004; Moore T, 2003, EMBO J, V22, P735, DOI 10.1093/emboj/cdg048; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Ryder L, 1996, GENETICS, V143, P1101; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; Tessmer I, 2005, J MOL BIOL, V350, P254, DOI 10.1016/j.jmb.2005.04.043; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Voloshin ON, 2001, GENE DEV, V15, P415, DOI 10.1101/gad.862901; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Yasuda T, 1998, EMBO J, V17, P3207, DOI 10.1093/emboj/17.11.3207; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yoshimasu M, 2003, NUCLEIC ACIDS RES, V31, P1735, DOI 10.1093/nar/gkg256; Yu VPCC, 2000, GENE DEV, V14, P1400; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L	45	36	37	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4708	4717		10.1074/jbc.M513592200	http://dx.doi.org/10.1074/jbc.M513592200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377615	hybrid			2022-12-27	WOS:000235426200019
J	Ong, CT; Cheng, HT; Chang, LW; Ohtsuka, T; Kageyama, R; Stormo, GD; Kopan, R				Ong, CT; Cheng, HT; Chang, LW; Ohtsuka, T; Kageyama, R; Stormo, GD; Kopan, R			Target selectivity of vertebrate notch proteins - Collaboration between discrete domains and CSL-binding site architecture determines activation probability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLIT COMPLEX GENES; INTRACELLULAR DOMAIN; MAMMALIAN NOTCH; TRANSCRIPTIONAL ACTIVATION; PHYSICAL INTERACTION; SIGNALING PATHWAY; DROSOPHILA NOTCH; ANKYRIN REPEATS; HES PROMOTERS; YIN YANG-1	All four mammalian Notch proteins interact with a single DNA-binding protein (RBP-j kappa), yet they are not equivalent in activating target genes. Parallel assays of three Notch-responsive promoters in several cell lines revealed that relative activation strength is dependent on protein module and promoter context more than the cellular context. Each Notch protein reads binding site orientation and distribution on the promoter differently; Notch1 performs extremely well on paired sites, and Notch3 prefers single sites in conjunction with a proximal zinc finger transcription factor. Although head-head sites can elicit a Notch response on their own, use of CBS (CSL binding site) in tail-tail orientation is context-dependent. Bias for specific DNA elements is achieved by interplay between the N-terminal RAM (RBP-j kappa-associated molecule/ankyrin region), which interprets CBS proximity and orientation, and the C-terminal transactivation domain that interacts specifically with the transcription machinery or nearby factors. To confirm the prediction that modular design underscores the evolution of functional divergence between Notch proteins, we generated a synthetic Notch protein (Notch1 ankyrin with Notch3 transactivation domain) that displayed superior signaling strength on the hes5 promoter. Consistent with the prediction that "preferred" targets (Hes1) should respond faster and at lower Notch concentration than other targets, we showed that Hes5-GFP was extinguished fast and recovered slowly, whereas Hes1-GFP was inhibited late and recovered quickly after a pulse of DAPT in metanephroi cultures.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO 63110 USA; Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Kyoto University	Kopan, R (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA.	kopan@wustl.edu	Kopan, Raphael/AFG-3275-2022; Kopan, Raphael/AAF-1357-2022; Stormo, Gary D/C-5367-2013; CHENG, HUI-TENG/AAD-9899-2020	Stormo, Gary D/0000-0001-6896-1850; CHENG, HUI-TENG/0000-0003-1544-7473; Kopan, Raphael/0000-0002-0350-2730	NICHD NIH HHS [HD44056] Funding Source: Medline; NIGMS NIH HHS [GM55479-09] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055479] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; AUSEBEL FM, 2000, CURRENT PROTOCOLS MO, V2; BAILEY AM, 1995, GENE DEV, V9, P2609, DOI 10.1101/gad.9.21.2609; Ball Douglas W, 2003, Cancer Treat Res, V115, P95; Beatus P, 2001, MECH DEVELOP, V104, P3, DOI 10.1016/S0925-4773(01)00373-2; Beatus P, 1999, DEVELOPMENT, V126, P3925; Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324; Bray S, 2005, DEV CELL, V8, P279, DOI 10.1016/j.devcel.2004.11.020; Cave JW, 2005, CURR BIOL, V15, P94, DOI 10.1016/j.cub.2004.12.070; Cheng HT, 2003, DEVELOPMENT, V130, P5031, DOI 10.1242/dev.00697; CONLON RA, 1995, DEVELOPMENT, V121, P1533; Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904; DOU QP, 1991, P NATL ACAD SCI USA, V88, P1157, DOI 10.1073/pnas.88.4.1157; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Furriols M, 2001, CURR BIOL, V11, P60, DOI 10.1016/S0960-9822(00)00044-0; Furriols M, 2000, DEV BIOL, V227, P520, DOI 10.1006/dbio.2000.9923; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; HSIEH JJD, 1995, SCIENCE, V268, P560, DOI 10.1126/science.7725102; Hsieh JJD, 1997, J VIROL, V71, P1938, DOI 10.1128/JVI.71.3.1938-1945.1997; Itoh F, 2004, EMBO J, V23, P541, DOI 10.1038/sj.emboj.7600065; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENNINGS B, 1995, DEVELOPMENT, V121, P3745; Kim J, 1996, NATURE, V382, P133, DOI 10.1038/382133a0; Kovall RA, 2004, EMBO J, V23, P3441, DOI 10.1038/sj.emboj.7600349; Krebs LT, 2003, GENESIS, V37, P139, DOI 10.1002/gene.10241; Krebs LT, 2000, GENE DEV, V14, P1343; Kuroda K, 2003, IMMUNITY, V18, P301, DOI 10.1016/S1074-7613(03)00029-3; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Le Gall M, 2004, J BIOL CHEM, V279, P29418, DOI 10.1074/jbc.M404589200; LECOURTOIS M, 1995, GENE DEV, V9, P2598, DOI 10.1101/gad.9.21.2598; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Liang YY, 2002, GENE DEV, V16, P1977, DOI 10.1101/gad.996502; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Lubman OY, 2005, PROTEIN SCI, V14, P1274, DOI 10.1110/ps.041184105; Lubman OY, 2004, MOL CELL, V13, P619, DOI 10.1016/S1097-2765(04)00120-0; Maekawa Y, 2003, IMMUNITY, V19, P549, DOI 10.1016/S1074-7613(03)00270-X; Maier MM, 2000, BIOCHEM BIOPH RES CO, V275, P652, DOI 10.1006/bbrc.2000.3354; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; McCright B, 2001, DEVELOPMENT, V128, P491; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nellesen DT, 1999, DEV BIOL, V213, P33, DOI 10.1006/dbio.1999.9324; Ohtsuka T, 2006, MOL CELL NEUROSCI, V31, P109, DOI 10.1016/j.mcn.2005.09.006; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; Parr C, 2004, INT J MOL MED, V14, P779; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Pirot P, 2004, BIOCHEM BIOPH RES CO, V322, P526, DOI 10.1016/j.bbrc.2004.07.157; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; Raya A, 2003, GENE DEV, V17, P1213, DOI 10.1101/gad.1084403; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Saxena MT, 2001, J BIOL CHEM, V276, P40268, DOI 10.1074/jbc.M107234200; SAXENA MT, 2001, THESIS WASHINGTON U; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Shimizu K, 2002, BIOCHEM BIOPH RES CO, V291, P775, DOI 10.1006/bbrc.2002.6528; Shimizu K, 2000, BIOCHEM BIOPH RES CO, V276, P385, DOI 10.1006/bbrc.2000.3469; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Solway J, 1998, AM J RESP CRIT CARE, V158, pS100, DOI 10.1164/ajrccm.158.supplement_2.13tac500; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2997, DOI 10.1093/nar/10.9.2997; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Sweeney C, 2004, FASEB J, V18, P1421, DOI 10.1096/fj.04-1700fje; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Takizawa T, 2003, NUCLEIC ACIDS RES, V31, P5723, DOI 10.1093/nar/gkg778; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tani S, 2001, NUCLEIC ACIDS RES, V29, P1373, DOI 10.1093/nar/29.6.1373; Vardar D, 2003, BIOCHEMISTRY-US, V42, P7061, DOI 10.1021/bi034156y; VASSEUR-COGNET M, 1993, P NATL ACAD SCI USA, V90, P7312, DOI 10.1073/pnas.90.15.7312; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zweifel ME, 2003, PROTEIN SCI, V12, P2622, DOI 10.1110/ps.03279003	82	176	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5106	5119		10.1074/jbc.M506108200	http://dx.doi.org/10.1074/jbc.M506108200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16365048	hybrid			2022-12-27	WOS:000235426200065
J	Patel, VA; Longacre, A; Hsiao, K; Fan, HL; Meng, F; Mitchell, JE; Rauch, J; Ucker, DS; Levine, JS				Patel, VA; Longacre, A; Hsiao, K; Fan, HL; Meng, F; Mitchell, JE; Rauch, J; Ucker, DS; Levine, JS			Apoptotic cells, at all stages of the death process, trigger characteristic signaling events that are divergent from and dominant over those triggered by necrotic cells - Implications for the delayed clearance model of autoimmunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; IMPAIRED UPTAKE; PRONE MICE; MACROPHAGES; PHAGOCYTOSIS; DYSREGULATION; DISEASE; KINASE; TRANSDUCTION; INFLAMMATION	Current models of autoimmunity suggest that delayed clearance of apoptotic cells leads to the presentation of apoptotic antigens in the context of inflammatory signals, with resultant autoimmunity. These models implicitly assume that, in contrast to early apoptotic cells (that retain membrane integrity), late apoptotic cells (with compromised membranes) act like necrotic cells (which also lack intact membranes), possibly because of the release of proinflammatory intracellular contents. We showed previously that early apoptotic and necrotic cells induce distinct mitogen-activated protein kinase modules in macrophages with which they interact. Exposure to apoptotic cells led to nearly complete inhibition of both basal and macrophage colony-stimulating factor-induced ERK1/2 by macrophages. In contrast, necrotic cells induced ERK1/2. We show here that apoptotic cells also strongly induced both c-Jun N-terminal kinase and p38, whereas necrotic cells had no detectable effect on c-Jun N-terminal kinase and p38. We also compared the signaling events induced in macrophages by exposure to early apoptotic cells, late apoptotic cells, and necrotic cells. The signaling events induced by late apoptotic cells were identical to and just as potent as those induced by early apoptotic cells. Thus, apoptotic cells are functionally equivalent throughout the cell death process, irrespective of membrane integrity. Moreover, the effects of both early and late apoptotic cells on signaling were dominant over those of necrotic cells. These data show that apoptotic cells do not become proinflammatory upon the loss of membrane integrity and are inconsistent with the notion that delayed clearance alone can lead to autoimmunity.	Univ Illinois, Dept Med, Div Nephrol, Coll Med, Chicago, IL 60612 USA; Promega Corp, Madison, WI 53711 USA; McGill Univ, Ctr Hlth, Dept Med, Div Rheumatol, Montreal, PQ H3G 1A4, Canada; Univ Illinois, Dept Immunol & Microbiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Promega Corporation; McGill University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Levine, JS (corresponding author), Univ Illinois, Dept Med, Div Nephrol, Coll Med, MC793,820 S Wood St, Chicago, IL 60612 USA.	jslevine@uic.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL069722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG024234] Funding Source: NIH RePORTER; Canadian Institutes of Health Research [42391] Funding Source: Medline; NHLBI NIH HHS [HL69722] Funding Source: Medline; NIA NIH HHS [AG024234, R21 AG024234] Funding Source: Medline; NIDDK NIH HHS [DK59793, R01 DK059793] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albert ML, 2004, NAT REV IMMUNOL, V4, P223, DOI 10.1038/nri11308; Barker RN, 2002, CLIN EXP IMMUNOL, V127, P220, DOI 10.1046/j.1365-2249.2002.01774.x; Baumann I, 2002, ARTHRITIS RHEUM-US, V46, P191, DOI 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K; Cocco RE, 2001, MOL BIOL CELL, V12, P919, DOI 10.1091/mbc.12.4.919; Cohen PL, 2002, J EXP MED, V196, P135, DOI 10.1084/jem.20012094; Cvetanovic M, 2004, J IMMUNOL, V172, P880, DOI 10.4049/jimmunol.172.2.880; Devitt A, 2004, J CELL BIOL, V167, P1161, DOI 10.1083/jcb.200410057; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Fan HL, 2006, J LEUKOCYTE BIOL, V79, P155, DOI 10.1189/jlb.0705408; Fan HL, 2004, J IMMUNOL, V172, P4834, DOI 10.4049/jimmunol.172.8.4834; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Gaipl US, 2005, AUTOIMMUN REV, V4, P189, DOI 10.1016/j.autrev.2004.10.007; Giles KM, 2001, J IMMUNOL, V167, P976, DOI 10.4049/jimmunol.167.2.976; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H; Hugues S, 2002, IMMUNITY, V16, P169, DOI 10.1016/S1074-7613(02)00273-X; Koh JS, 2000, J IMMUNOL, V165, P4190, DOI 10.4049/jimmunol.165.8.4190; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEVINE JS, 1993, EUR J IMMUNOL, V23, P2951, DOI 10.1002/eji.1830231134; Longacre A, 2004, J LEUKOCYTE BIOL, V76, P971, DOI 10.1189/jlb.0604346; MAJNO G, 1995, AM J PATHOL, V146, P3; Mitchell DA, 2002, J IMMUNOL, V168, P2538, DOI 10.4049/jimmunol.168.5.2538; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Sinha D, 2005, AM J PHYSIOL-RENAL, V288, pF703, DOI 10.1152/ajprenal.00189.2004; Skoberne M, 2005, CURR TOP MICROBIOL, V289, P259; Stuart LM, 2005, J IMMUNOL, V174, P3220, DOI 10.4049/jimmunol.174.6.3220; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wu XW, 2001, ARTHRITIS RHEUM, V44, P2642, DOI 10.1002/1529-0131(200111)44:11<2642::AID-ART444>3.0.CO;2-8	32	116	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4663	4670		10.1074/jbc.M508342200	http://dx.doi.org/10.1074/jbc.M508342200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16377620	Green Accepted, hybrid			2022-12-27	WOS:000235426200014
J	Plummer, LJ; Hildebrandt, ER; Porter, SB; Rogers, VA; McCracken, J; Schmidt, WK				Plummer, LJ; Hildebrandt, ER; Porter, SB; Rogers, VA; McCracken, J; Schmidt, WK			Mutational analysis of the Ras converting enzyme reveals a requirement for glutamate and histidine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOPRENYLATED PROTEIN ENDOPROTEASE; A-FACTOR PRECURSOR; SACCHAROMYCES-CEREVISIAE; TOPOLOGY PREDICTION; MEMBRANE-PROTEINS; MATING PHEROMONE; CAAX PROTEASES; YEAST; STE24P; RCE1	The Ras converting enzyme (RCE) promotes a proteolytic activity that is required for the maturation of Ras, the yeast a-factor mating pheromone, and certain other proteins whose precursors bear a C-terminal CAAX tetrapeptide motif. Despite the physiological importance of RCE, the enzymatic mechanism of this protease remains undefined. In this study, we have evaluated the substrate specificity of RCE orthologs from yeast (Rce1p), worm, plant, and human and have determined the importance of conserved residues toward enzymatic activity. Our findings indicate that RCE orthologs have conserved substrate specificity, cleaving CVIA, CTLM, and certain other CAAX motifs, but not the CASQ motif, when these motifs are placed in the context of the yeast a-factor precursor. Our mutational studies of residues conserved between the orthologs indicate that an alanine substitution at His(194) completely inactivates yeast Rce1p enzymatic activity, whereas a substitution at Glu(156) or His(248) results in marginal activity. We have also determined that residues Glu(157), Tyr(160), Phe(190), and Asn(252) impact the substrate selectivity of Rce1p. Computational methods predict that residues influencing Rce1p function are all near or within hydrophobic segments. Combined, our data indicate that yeast Rce1p function requires residues that are invariably conserved among an extended family of prokaryotic and eukaryotic enzymes and that these residues are likely to lie within or immediately adjacent to the transmembrane segments of this membrane-localized enzyme.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Schmidt, WK (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, 120 Green St, Athens, GA 30602 USA.	wschmidt@bmb.uga.edu		McCracken, D. Jay/0000-0001-6305-707X	NIGMS NIH HHS [R01 GM067092-01A2, R01 GM067092] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067092] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baum Charles, 2003, Curr Oncol Rep, V5, P99, DOI 10.1007/s11912-003-0096-5; Bergo MO, 2004, J BIOL CHEM, V279, P4729, DOI 10.1074/jbc.M310081200; Bergo MO, 2002, MOL CELL BIOL, V22, P171, DOI 10.1128/MCB.22.1.171-181.2002; Bergo MO, 2002, P NATL ACAD SCI USA, V99, P13049, DOI 10.1073/pnas.192460799; Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Brachmann CB, 1998, YEAST, V14, P115; Bzymek KP, 2004, J BIOL CHEM, V279, P31018, DOI 10.1074/jbc.M404035200; Cadinanos J, 2003, J BIOL CHEM, V278, P42091, DOI 10.1074/jbc.M306700200; Cadinanos J, 2003, BIOCHEM J, V370, P1047, DOI 10.1042/BJ20021514; Chen YL, 1996, BIOCHEMISTRY-US, V35, P3227, DOI 10.1021/bi952529s; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Corrigan DP, 2005, BIOCHEM J, V387, P129, DOI 10.1042/BJ20041359; Dolence JM, 2000, BIOCHEMISTRY-US, V39, P4096, DOI 10.1021/bi9923611; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Freije JMP, 1999, GENOMICS, V58, P270, DOI 10.1006/geno.1999.5834; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; Fujinaga M, 2004, P NATL ACAD SCI USA, V101, P3364, DOI 10.1073/pnas.0400246101; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Hollander I, 2000, ANAL BIOCHEM, V286, P129, DOI 10.1006/abio.2000.4795; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; Kim H, 2003, J BIOL CHEM, V278, P10208, DOI 10.1074/jbc.M300163200; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LEMOUAL H, 1993, FEBS LETT, V324, P196, DOI 10.1016/0014-5793(93)81392-D; MA YT, 1993, BIOCHEMISTRY-US, V32, P2386, DOI 10.1021/bi00060a033; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; Maske CP, 2003, J CELL BIOL, V162, P1223, DOI 10.1083/jcb.200303113; MICHAELIS S, 1988, MOL CELL BIOL, V8, P1309, DOI 10.1128/MCB.8.3.1309; Nijbroek GL, 1998, METHOD ENZYMOL, V292, P193; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Otto JC, 1999, J BIOL CHEM, V274, P8379, DOI 10.1074/jbc.274.13.8379; Pei JM, 2001, TRENDS BIOCHEM SCI, V26, P275, DOI 10.1016/S0968-0004(01)01813-8; Pendas AM, 2002, NAT GENET, V31, P94, DOI 10.1038/ng871; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; Schmidt WK, 2000, J BIOL CHEM, V275, P6227, DOI 10.1074/jbc.275.9.6227; SIKORSKI RS, 1989, GENETICS, V122, P19; Tam A, 2001, J BIOL CHEM, V276, P46798, DOI 10.1074/jbc.M106150200; Tam A, 1998, J CELL BIOL, V142, P635, DOI 10.1083/jcb.142.3.635; Trueblood CE, 2000, MOL CELL BIOL, V20, P4381, DOI 10.1128/MCB.20.12.4381-4392.2000; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Vazeux G, 1996, J BIOL CHEM, V271, P9069, DOI 10.1074/jbc.271.15.9069; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; YOUNG SG, 2001, ENZYMES, P155, DOI DOI 10.1016/01874-6047(0)180020-2; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhu Kuichun, 2003, Curr Opin Investig Drugs, V4, P1428	49	38	39	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4596	4605		10.1074/jbc.M506284200	http://dx.doi.org/10.1074/jbc.M506284200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361710	hybrid, Green Accepted			2022-12-27	WOS:000235426200007
J	Smal, C; Vertommen, D; Bertrand, L; Ntamashimikiro, S; Rider, MH; Van Den Neste, E; Bontemps, F				Smal, C; Vertommen, D; Bertrand, L; Ntamashimikiro, S; Rider, MH; Van Den Neste, E; Bontemps, F			Identification of in vivo phosphorylation sites on human deoxycytidine kinase - Role of Ser-74 in the control of enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NUCLEOSIDE ANALOGS; PURINE ANALOGS; CELL LEUKEMIA; DNA-SYNTHESIS; ACTIVATION; RESISTANCE; PROTEIN; 2-CHLORO-2'-DEOXYADENOSINE	Deoxycytidine kinase (dCK) catalyzes the rate-limiting step of the deoxyribonucleoside salvage pathway in mammalian cells and plays a key role in the activation of numerous nucleoside analogues used in anti-cancer and antiviral chemotherapy. Although compelling evidence indicated that dCK activity might be regulated by phosphorylation/ dephosphorylation, direct demonstration was lacking. Here we showed that dCK overexpressed in HEK 293T cells was labeled after incubating the cells with [P-32] orthophosphate. Sorbitol, which was reported to decrease dCK activity, also decreased the labeling of dCK. These results indicated that dCK may exist as a phosphoprotein in vivo and that its activity can be correlated with its phosphorylation level. After purification of P-32-labeled dCK, digestion by trypsin, and analysis of the radioactive peptides by tandem mass spectrometry, the following four in vivo phosphorylation sites were identified: Thr-3, Ser-11, Ser-15, and Ser-74, the latter being the major phosphorylation site. Site-directed mutagenesis and use of an anti-phospho-Ser-74 antibody demonstrated that Ser-74 phosphorylation was crucial for dCK activity in HEK 293T cells, whereas phosphorylation of other identified sites did not seem essential. Phosphorylation of Ser-74 was also detected on endogenous dCK in leukemic cells, in which the Ser-74 phosphorylation state was increased by agents that enhanced dCK activity. Our study provided direct evidence that dCK activity can be controlled by phosphorylation in intact cells and highlights the importance of Ser-74 for dCK activity.	Catholic Univ Louvain, ICP 7539, Christian de Duve Inst Cellular Pathol, Physiol Chem Lab, B-1200 Brussels, Belgium; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, Hormone & Metab Res Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, Clin Univ St Luc, Div Cardiol, B-1200 Brussels, Belgium; Catholic Univ Louvain, Clin Univ St Luc, Dept Hematol, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Bontemps, F (corresponding author), Catholic Univ Louvain, ICP 7539, Christian de Duve Inst Cellular Pathol, Physiol Chem Lab, 75 Av Hippocrate, B-1200 Brussels, Belgium.	bontemps@bchm.ucl.ac.be		Bertrand, Luc/0000-0003-0655-7099; Vertommen, Didier/0000-0001-7648-8282				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Arner ESJ, 1996, LEUKEMIA LYMPHOMA, V21, P225, DOI 10.3109/10428199209067604; Blackstock AW, 2001, CLIN CANCER RES, V7, P3263; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardoen S, 2001, CLIN CANCER RES, V7, P3559; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; Csapo Z, 2003, BIOCHEM PHARMACOL, V65, P2031, DOI 10.1016/S0006-2952(03)00182-5; Csapo Z, 2001, BIOCHEM PHARMACOL, V61, P191, DOI 10.1016/S0006-2952(00)00534-7; De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jcv.2004.02.009; Galmarini CM, 2002, LANCET ONCOL, V3, P415, DOI 10.1016/S1470-2045(02)00788-X; Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114; Goodman GR, 2003, CURR OPIN HEMATOL, V10, P258, DOI 10.1097/00062752-200307000-00002; Hatzis P, 1998, J BIOL CHEM, V273, P30239, DOI 10.1074/jbc.273.46.30239; JOHANSSON M, 1995, BIOCHEM PHARMACOL, V50, P163, DOI 10.1016/0006-2952(95)00129-N; KAWASAKI H, 1993, BLOOD, V81, P597; Keszler G, 2004, BIOCHEM PHARMACOL, V67, P947, DOI 10.1016/j.bcp.2003.10.019; Koenig M, 2004, BIOINFORMATICS, V20, P3620, DOI 10.1093/bioinformatics/bth455; Mansson E, 2003, BIOCHEM PHARMACOL, V65, P237, DOI 10.1016/S0006-2952(02)01484-3; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; ORR RM, 1995, CLIN CANCER RES, V1, P391; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; PLUNKETT W, 1997, NUCLEOSIDE ANALOGS C, P1; Robak T, 2005, TRANSFUS APHER SCI, V32, P33, DOI 10.1016/j.transci.2004.10.004; Sabini E, 2003, NAT STRUCT BIOL, V10, P513, DOI 10.1038/nsb942; Sasvari-Szekely M, 1998, BIOCHEM PHARMACOL, V56, P1175, DOI 10.1016/S0006-2952(98)00108-7; Smal C, 2004, BIOCHEM PHARMACOL, V68, P95, DOI 10.1016/j.bcp.2004.02.031; Spasokoukotskaja T, 2000, ADV EXP MED BIOL, V486, P281; Spasokoukotskaja T, 1999, EUR J CANCER, V35, P1862, DOI 10.1016/S0959-8049(99)00223-3; STEGMANN APA, 1995, ANN HEMATOL, V71, P41, DOI 10.1007/s002770050081; Van den Neste E, 2003, BIOCHEM PHARMACOL, V65, P573, DOI 10.1016/S0006-2952(02)01559-9; VERHOEF V, 1981, CANCER RES, V41, P4478; Veuger MJT, 2000, BLOOD, V96, P1517, DOI 10.1182/blood.V96.4.1517.h8001517_1517_1524; WANG LM, 1994, BBA-MOL CELL RES, V1224, P161, DOI 10.1016/0167-4889(94)90186-4; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Woods A, 2003, J BIOL CHEM, V278, P28434, DOI 10.1074/jbc.M303946200	38	48	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4887	4893		10.1074/jbc.M512129200	http://dx.doi.org/10.1074/jbc.M512129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16361699	hybrid			2022-12-27	WOS:000235426200039
J	Parnis, A; Rawet, M; Regev, L; Barkan, B; Rotman, M; Gaitner, M; Cassel, D				Parnis, A; Rawet, M; Regev, L; Barkan, B; Rotman, M; Gaitner, M; Cassel, D			Golgi localization determinants in ArfGAP1 and in new tissue-specific ArfGAP1 Isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; NONCATALYTIC DOMAIN; MEMBRANE CURVATURE; SECRETORY FUNCTION; DEPENDENT BINDING; VESICLE FORMATION; KDEL RECEPTOR; COPI VESICLES	The Arf1-directed GTPase-activating protein ArfGAP1 is a Golgi-localized protein that controls the dynamics of the COPI coat of carriers that mediate transport in the endoplasmic reticulum-Golgi shuttle. Previously the interaction of ArfGAP1 with the Golgi was allocated to a portion of the non-catalytic, carboxyl part of the protein, but the mechanism of this interaction has not been established. In this study we identify a short stretch in the non-catalytic part of ArfGAP1 (residues 204-214) in which several hydrophobic residues contribute to Golgi localization. Even single alanine replacement of two of these residues (Leu-207 and Trp-211) strongly diminished Golgi localization. Mutations in the hydrophobic residues also diminished the in vitro activity of ArfGAP1 on Arf1 bound to Golgi membranes. The stretch containing the hydrophobic residues was recently shown to mediate the binding of ArfGAP1 to loosely packed lipids of highly curved liposomes (Bigay, J., Casella, J. F., Drin, G., Mesmin, B., and Antonny, B. ( 2005) EMBO J. 24, 2244-2253). Whereas short fragments containing the hydrophobic stretch were not Golgi-localized, a proximal 10-residue in-frame insertion that is present in new ArfGAP1 isoforms that we identified in brain and heart tissues could confer Golgi localization on these fragments. This localization was abrogated by alanine replacement of residues Phe-240 or Trp-241 of the insertion sequence but not by their replacement with leucines. Our findings indicate that ArfGAP1 interacts with the Golgi through multiple hydrophobic motifs and that alternative modes of interaction may exist in tissue-specific ArfGAP1 isoforms.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Technion Israel Institute of Technology	Cassel, D (corresponding author), Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel.	danc@tx.technion.ac.il						Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Aoe T, 1999, J BIOL CHEM, V274, P20545, DOI 10.1074/jbc.274.29.20545; Aoe T, 1997, EMBO J, V16, P7305, DOI 10.1093/emboj/16.24.7305; Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; Hirst J, 2003, MOL BIOL CELL, V14, P625, DOI 10.1091/mbc.E02-09-0552; Holthuis JCM, 2003, DEV CELL, V5, P821, DOI 10.1016/S1534-5807(03)00366-6; Huber I, 1998, J BIOL CHEM, V273, P24786, DOI 10.1074/jbc.273.38.24786; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Lanoix J, 1999, EMBO J, V18, P4935, DOI 10.1093/emboj/18.18.4935; Lee MCS, 2004, ANNU REV CELL DEV BI, V20, P87, DOI 10.1146/annurev.cellbio.20.010403.105307; Lee SY, 2005, J CELL BIOL, V168, P281, DOI 10.1083/jcb.200404008; Lippincott-Schwartz J, 2003, NATURE, V426, P507, DOI 10.1038/426507a; Litvak V, 2005, NAT CELL BIOL, V7, P225, DOI 10.1038/ncb1221; Liu W, 2005, J CELL BIOL, V168, P1053, DOI 10.1083/jcb.200410142; Liu XQ, 2001, FEBS LETT, V490, P79, DOI 10.1016/S0014-5793(01)02134-2; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; McMahon HT, 2004, CURR OPIN CELL BIOL, V16, P379, DOI 10.1016/j.ceb.2004.06.009; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Poon PP, 1999, EMBO J, V18, P555, DOI 10.1093/emboj/18.3.555; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; Szafer E, 2000, J BIOL CHEM, V275, P23615, DOI 10.1074/jbc.M003171200; Szafer E, 2001, J BIOL CHEM, V276, P47834, DOI 10.1074/jbc.M106000200; Watson PJ, 2004, TRAFFIC, V5, P79, DOI 10.1111/j.1600-0854.2004.00158.x; Wong TA, 2005, P NATL ACAD SCI USA, V102, P12777, DOI 10.1073/pnas.0506156102; Yanagisawa LL, 2002, MOL BIOL CELL, V13, P2193, DOI 10.1091/mbc.01-11-0563; Yang JS, 2002, J CELL BIOL, V159, P69, DOI 10.1083/jcb.200206015; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; Yu S, 2002, MOL BIOL CELL, V13, P2559, DOI 10.1091/mbc.E02-04-0189; Zhang CG, 2000, GENOMICS, V63, P400, DOI 10.1006/geno.1999.6095; Zhao LY, 1999, J BIOL CHEM, V274, P14198, DOI 10.1074/jbc.274.20.14198	42	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					3785	3792		10.1074/jbc.M508959200	http://dx.doi.org/10.1074/jbc.M508959200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16316994	hybrid			2022-12-27	WOS:000235275300006
J	Rayala, SK; den Hollander, P; Balasenthil, S; Molli, PR; Bean, AJ; Vadlamudi, RK; Wang, RA; Kumar, R				Rayala, SK; den Hollander, P; Balasenthil, S; Molli, PR; Bean, AJ; Vadlamudi, RK; Wang, RA; Kumar, R			Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; NONGENOMIC ACTIVITY; PROTEIN-KINASE; PHOSPHORYLATION; DOMAIN; MONOUBIQUITINATION; INVOLVEMENT; ENDOCYTOSIS	PELP1 (proline-, glutamic acid-, and leucine- rich protein-1) (also known as the modulator of nongenomic activity of estrogen receptor) plays a role in genomic functions of the estrogen receptor via histone interactions and in nongenomic functions via its influence on the MAPK-Src pathway. However, recent studies have shown that differential compartmentalization of PELP1 could play a crucial role in modulating the status of nongenomic signaling by using molecular mechanisms that remain poorly understood. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) is an early endosomal protein that plays a role in regulating the trafficking of growth factor-receptor complexes through early endosomes. By using a yeast two-hybrid screen, we identified HRS as a novel PELP1-binding protein providing evidence of a physiologic interaction between HRS and PELP1. The noted HRS-PELP1 interaction was accompanied by inhibition of the basal coactivator function of PELP1 upon estrogen receptor transactivation. HRS was found to sequester PELP1 in the cytoplasm, leading to the activation of MAPK in a manner that is dependent on the epidermal growth factor receptor but independent of the estrogen receptor, Shc, and Src. In addition, stimulation of MAPK and the subsequent activation of its downstream effector pathway, Elk-1, by HRS or PELP1 were found to depend on the presence of endogenous PELP1 or HRS. Furthermore, HRS was overexpressed and correlated well with the cytoplasmic PELP1, increased MAPK, and EGFR status in breast tumors. These findings highlight a novel role of HRS in up-regulating MAPK, presumably involving interaction with PELP1.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, Dept Genet, New Orleans, LA 70112 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Messier, Claude/A-2322-2008; Wang, Brian/HGA-9535-2022	Messier, Claude/0000-0002-4791-1763; Wang, Rui-An/0000-0003-2320-1211; Rayala, Suresh/0000-0003-4394-4450	NATIONAL CANCER INSTITUTE [R01CA098823, R01CA090970] Funding Source: NIH RePORTER; NCI NIH HHS [CA90970, CA98823] Funding Source: Medline; NIMH NIH HHS [MH05892] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Asao H, 1997, J BIOL CHEM, V272, P32785, DOI 10.1074/jbc.272.52.32785; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haugh Jason M, 2002, Mol Interv, V2, P292, DOI 10.1124/mi.2.5.292; Ishihara H, 1998, BIOCHEM BIOPH RES CO, V252, P139, DOI 10.1006/bbrc.1998.9621; Jekely G, 2003, EMBO REP, V4, P1163, DOI 10.1038/sj.embor.7400019; KOMADA M, 1995, MOL CELL BIOL, V15, P6213; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 2001, BIOCHEM BIOPH RES CO, V281, P1065, DOI 10.1006/bbrc.2001.4441; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; Kwong J, 2000, J CELL SCI, V113, P2273; Manavathi B, 2005, CANCER RES, V65, P5571, DOI 10.1158/0008-5472.CAN-04-4664; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Morino C, 2004, EXP CELL RES, V297, P380, DOI 10.1016/j.yexcr.2004.03.038; Nair SS, 2004, CANCER RES, V64, P6416, DOI 10.1158/0008-5472.CAN-04-1786; PELICCI G, 1995, ONCOGENE, V11, P899; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Sasaki Y, 2001, J BIOL CHEM, V276, P29943, DOI 10.1074/jbc.M104230200; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Urbe S, 2000, MOL CELL BIOL, V20, P7685, DOI 10.1128/MCB.20.20.7685-7692.2000; Vadlamudi RK, 2005, CANCER RES, V65, P7724, DOI 10.1158/0008-5472.CAN-05-0614; Vadlamudi RK, 2005, HUM PATHOL, V36, P670, DOI 10.1016/j.humpath.2005.03.016; Vadlamudi RK, 2004, J CLIN ENDOCR METAB, V89, P6130, DOI 10.1210/jc.2004-0909; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Wong CW, 2002, P NATL ACAD SCI USA, V99, P14783, DOI 10.1073/pnas.192569699	32	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4395	4403		10.1074/jbc.M510368200	http://dx.doi.org/10.1074/jbc.M510368200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16352611	hybrid			2022-12-27	WOS:000235275300075
J	Xie, ZL; O'Rourke, KI; Dong, ZQ; Jenny, AL; Langenberg, JA; Belay, ED; Schonberger, LB; Petersen, RB; Zou, WQ; Kong, QZ; Gambetti, P; Chen, SG				Xie, ZL; O'Rourke, KI; Dong, ZQ; Jenny, AL; Langenberg, JA; Belay, ED; Schonberger, LB; Petersen, RB; Zou, WQ; Kong, QZ; Gambetti, P; Chen, SG			Chronic wasting disease of elk and deer and Creutzfeldt-Jakob disease - Comparative analysis of the scrapie prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPTIVE MULE DEER; BOVINE SPONGIFORM ENCEPHALOPATHY; ODOCOILEUS-HEMIONUS; VARIANT CJD; TRANSMISSION; HUMANS; NEUROPATHOLOGY; CLASSIFICATION; IDENTIFICATION; PATTERNS	Chronic wasting disease (CWD), a transmissible prion disease that affects elk and deer, poses new challenges to animal and human health. Although the transmission of CWD to humans has not been proven, it remains a possibility. If this were to occur, it is important to know whether the "acquired" human prion disease would show a phenotype including the scrapie prion protein (PrPSc) features that differ from those associated with human sporadic prion disease. In this study, we have compared the pathological profiles and PrPSc characteristics in brains of CWD-affected elk and deer with those in subjects with sporadic Creutzfeldt-Jakob disease (CJD), as well as CJD-affected subjects who might have been exposed to CWD, using histopathology, immunohistochemistry, immunoblotting, conformation stability assay, and N-terminal protein sequencing. Spongiform changes and intense PrPSc staining were present in several brain regions of CWD-affected animals. Immunoblotting revealed three proteinase K (PK)-resistant bands in CWD, representing different glycoforms of PrPSc. The unglycosylated PK-resistant PrPSc of CWD migrated at 21 kDa with an electrophoretic mobility similar to that of type 1 human PrPSc present in sporadic CJD affecting subjects homozygous for methionine at codon 129 (sCJDMM1). N-terminal sequencing showed that the PK cleavage site of PrPSc in CWD occurred at residues 82 and 78, similar to that of PrPSc in sCJDMM1. Conformation stability assay also showed no significant difference between elk CWD PrPSc and the PrPSc species associated with sCJDMM1. However, there was a major difference in glycoform ratio of PrPSc between CWD and sCJDMM1 affecting both subjects potentially exposed to CWD and non-exposed subjects. Moreover, PrPSc of CWD exhibited a distinct constellation of glycoforms distinguishable from that of sCJDMM1 in two-dimensional immunoblots. These findings underline the importance of detailed PrPSc characterization in trying to detect novel forms of acquired prion disease.	Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Natl Pr Dis Pathol Surveillance Ctr, Cleveland, OH 44106 USA; Washington State Univ, USDA ARS, Anim Dis Res Unit, Pullman, WA 99164 USA; USDA, Natl Vet Serv Labs, Ames, IA 50010 USA; Wisconsin Dept Nat Resources, Wildlife Hlth Program, Bur Wildlife Management, Madison, WI 53707 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA	Case Western Reserve University; Case Western Reserve University; United States Department of Agriculture (USDA); Washington State University; United States Department of Agriculture (USDA); Centers for Disease Control & Prevention - USA	Chen, SG (corresponding author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	shu.chen@case.edu	Belay, Ermias/A-8829-2013; Petersen, Robert/B-5075-2011; Chen, Shu G./AAK-7301-2021; Chen, Shu G./O-4750-2014; Zou, Wenquan/ABF-2875-2020; Chen, Shu/Z-2943-2019; Zou, Wenquan/GWQ-3489-2022	Petersen, Robert/0000-0002-3154-0072; Chen, Shu G./0000-0001-7180-3001; Chen, Shu G./0000-0001-7180-3001; DONG, ZHIQIAN/0000-0002-8748-4532; Belay, Ermias/0000-0002-9837-0960	NATIONAL INSTITUTE ON AGING [P01AG014359] Funding Source: NIH RePORTER; NIA NIH HHS [AG-14359, P01 AG014359] Funding Source: Medline; PHS HHS [UR8/CCU515004-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bartz JC, 1998, VIROLOGY, V251, P297, DOI 10.1006/viro.1998.9427; Belay ED, 2004, EMERG INFECT DIS, V10, P977, DOI 10.3201/eid1006.031082; BOLTON DC, 1987, ARCH BIOCHEM BIOPHYS, V258, P579, DOI 10.1016/0003-9861(87)90380-8; Bunk S, 2004, PLOS BIOL, V2, P427, DOI 10.1371/journal.pbio.0020121; Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; Chen SG, 1997, NAT MED, V3, P1009, DOI 10.1038/nm0997-1009; Collinge J, 1997, NATURE, V389, P526, DOI 10.1038/39116; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Gambetti P, 2003, BRIT MED BULL, V66, P213, DOI 10.1093/bmb/66.1.213; Head MW, 2004, ANN NEUROL, V55, P851, DOI 10.1002/ana.20127; Ironside JW, 1996, BRAIN PATHOL, V6, P379, DOI 10.1111/j.1750-3639.1996.tb00869.x; Kong QZ, 2005, J NEUROSCI, V25, P7944, DOI 10.1523/JNEUROSCI.2467-05.2005; Liberski PP, 2001, ACTA NEUROPATHOL, V102, P496; Marsh RF, 2005, J VIROL, V79, P13794, DOI 10.1128/JVI.79.21.13794-13796.2005; Miller MW, 2003, NATURE, V425, P35, DOI 10.1038/425035a; Miller MW, 2004, CURR TOP MICROBIOL, V284, P193; Parchi P, 2000, P NATL ACAD SCI USA, V97, P10168, DOI 10.1073/pnas.97.18.10168; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 1996, ANN NEUROL, V39, P767, DOI 10.1002/ana.410390613; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Peters J, 2000, J VET DIAGN INVEST, V12, P579, DOI 10.1177/104063870001200618; Prusiner Stanley B., 2004, VVolume 41, P545; Race RE, 2002, J VIROL, V76, P12365, DOI 10.1128/JVI.76.23.12365-12368.2002; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SCOTT M, 2004, PRION BIOL DIS, P434; Scott MR, 1999, P NATL ACAD SCI USA, V96, P15137, DOI 10.1073/pnas.96.26.15137; Sigurdson CJ, 2001, J GEN VIROL, V82, P2327, DOI 10.1099/0022-1317-82-10-2327; Spraker TR, 2002, VET PATHOL, V39, P546, DOI 10.1354/vp.39-5-546; Spraker TR, 2002, VET PATHOL, V39, P110, DOI 10.1354/vp.39-1-110; WELLS GAH, 1995, BRAIN PATHOL, V5, P91, DOI 10.1111/j.1750-3639.1995.tb00580.x; Will RG, 2003, BRIT MED BULL, V66, P255, DOI 10.1093/bmb/66.1.255; Will Robert G., 2004, VVolume 41, P629; WILLIAMS ES, 1993, VET PATHOL, V30, P36, DOI 10.1177/030098589303000105; Williams ES, 2002, REV SCI TECH OIE, V21, P305, DOI 10.20506/rst.21.2.1340; WILLIAMS ES, 1980, J WILDLIFE DIS, V16, P89, DOI 10.7589/0090-3558-16.1.89; Williams ES, 2003, CLIN LAB MED, V23, P139, DOI 10.1016/S0272-2712(02)00040-9; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812; Zou WQ, 2004, P NATL ACAD SCI USA, V101, P1380, DOI 10.1073/pnas.0307825100; Zou WQ, 2003, J BIOL CHEM, V278, P40429, DOI 10.1074/jbc.M308550200	40	29	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4199	4206		10.1074/jbc.M509052200	http://dx.doi.org/10.1074/jbc.M509052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16338930	Green Accepted, hybrid			2022-12-27	WOS:000235275300052
J	Caunt, CJ; Finch, AR; Sedgley, KR; Oakley, L; Luttrell, LM; McArdle, CA				Caunt, CJ; Finch, AR; Sedgley, KR; Oakley, L; Luttrell, LM; McArdle, CA			Arrestin-mediated ERK activation by gonadotropin-releasing hormone receptors - Receptor-specific activation mechanisms and compartmentalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MAP KINASE KINASE; DYNAMIN-DEPENDENT INTERNALIZATION; SIGNAL-REGULATED KINASE; GROWTH-FACTOR RECEPTOR; BETA-ARRESTIN; NUCLEAR TRANSLOCATION; RAPID DESENSITIZATION; C-SRC; CELLS	Activation of seven-transmembrane region receptors typically causes their phosphorylation with consequent arrestin binding and desensitization. Arrestins also act as scaffolds, mediating signaling to Raf and ERK and, for some receptors, inhibiting nuclear translocation of ERK. GnRH receptors (GnRHRs) act via G(q/11) to stimulate the phospholipase C/Ca2+/protein kinase C (PKC) cascade and the Raf/MEK/ERK cassette. Uniquely, type I mammalian GnRHRs lack the C-tails that are found in other seven-\transmembrane region receptors ( including nonmammalian GnRHRs) and are implicated in arrestin binding. Here we have compared ERK signaling by human GnRHRs (hGnRHRs) and Xenopus GnRHRs (XGnRHRs). In HeLa cells, XGnRHRs underwent rapid and arrestin-dependent internalization and caused arrestin/green fluorescent protein (GFP) translocation to the membrane and endosomes, whereas hGnRHRs did not. Internalized XGnRHRs were co-localized with arrestin-GFP, whereas hGnRHRs were not. Both receptors mediated transient ERK phosphorylation and nuclear translocation (revealed by immunohistochemistry or by imaging of co-transfected ERK2-GFP), and for both, ERK phosphorylation was reduced by PKC inhibition but not by inhibiting epidermal growth factor receptor autophosphorylation. In the presence of PKC inhibitor, Delta arrestin-(319 - 418) blocked XGnRHR-mediated, but not hGnRHR- mediated, ERK phosphorylation. When receptor number was varied, hGnRHRs activated phospholipase C and ERK more efficiently than XGnRHRs but were less efficient at causing ERK2-GFP translocation. At high receptor number, XGnRHRs and hGnRHRs both caused ERK2-GFP translocation to the nucleus, but at low receptor number, XGnRHRs caused ERK2-GFP translocation, whereas hGnRHRs did not. Thus, experiments with XGnRHRs have revealed the first direct evidence of arrestin-mediated (probably G protein-independent) GnRHR signaling, whereas those with hGnRHRs imply that scaffolds other than arrestins can determine GnRHR effects on ERK compartmentalization.	Univ Bristol, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol BS1 3NY, Avon, England; Med Univ S Carolina, Dept Med Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	University of Bristol; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	McArdle, CA (corresponding author), Univ Bristol, Henry Wellcome Labs Integrat Neurosci & Endocrino, Whitson St, Bristol BS1 3NY, Avon, England.	craig.mcardle@bris.ac.uk	McArdle, Craig/AAQ-5660-2021	McArdle, Craig/0000-0003-4836-5351; Luttrell, Louis/0000-0003-2805-6949	Medical Research Council [G9721484] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9721484] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Caunt CJ, 2004, ENDOCRINOLOGY, V145, P3594, DOI 10.1210/en.2004-0092; CONN PM, 1994, ANNU REV MED, V45, P391, DOI 10.1146/annurev.med.45.1.391; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; Davidson L, 2004, J BIOL CHEM, V279, P1980, DOI 10.1074/jbc.M309827200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Finch AR, 2004, J CLIN ENDOCR METAB, V89, P1823, DOI 10.1210/jc.2003-030787; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Ge L, 2003, J BIOL CHEM, V278, P34418, DOI 10.1074/jbc.M300573200; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Harris D, 2003, ENDOCRINOLOGY, V144, P612, DOI 10.1210/en.2002-220690; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; Heding A, 2000, ENDOCRINOLOGY, V141, P299, DOI 10.1210/en.141.1.299; Hislop JN, 2005, J MOL ENDOCRINOL, V35, P177, DOI 10.1677/jme.1.01809; Hislop JN, 2001, J BIOL CHEM, V276, P39685, DOI 10.1074/jbc.M104542200; Hislop JN, 2000, ENDOCRINOLOGY, V141, P4564, DOI 10.1210/en.141.12.4564; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Liu FJ, 2002, MOL ENDOCRINOL, V16, P419, DOI 10.1210/me.16.3.419; Luttrell DK, 2003, ASSAY DRUG DEV TECHN, V1, P327, DOI 10.1089/15406580360545143; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McArdle CA, 1996, J BIOL CHEM, V271, P23711, DOI 10.1074/jbc.271.39.23711; McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001; MCARDLE CA, 1995, ENDOCRINOLOGY, V136, P4864, DOI 10.1210/en.136.11.4864; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Shah BH, 2003, J BIOL CHEM, V278, P19118, DOI 10.1074/jbc.M212932200; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Whitehurst A, 2004, MOL CELL BIOL, V24, P10145, DOI 10.1128/MCB.24.23.10145-10150.2004; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; Willars GB, 2001, J BIOL CHEM, V276, P3123, DOI 10.1074/jbc.M008916200; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301; Zhang T, 2001, J BIOL CHEM, V276, P45604, DOI 10.1074/jbc.M107075200	47	49	51	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2701	2710		10.1074/jbc.M507242200	http://dx.doi.org/10.1074/jbc.M507242200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16314413	hybrid			2022-12-27	WOS:000234931800036
J	Dimova, EY; Kietzmann, T				Dimova, EY; Kietzmann, T			Cell type-dependent regulation of the hypoxia-responsive plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; TRANSCRIPTION FACTOR USF; NONCANONICAL E-BOX; HELIX-LOOP-HELIX; RAT HEPATOCYTES; TATA BOX; PROMOTER; EXPRESSION; BINDING; ELEMENT	Transcriptional regulation of the plasminogen activator inhibitor type-1 (PAI-1) gene is an important issue since PAI-1 plays a crucial role in various pathological conditions. The transcription factor USF-2 was shown to be a negative regulator for rat PAI-1 expression, and therefore it was the aim of this study to evaluate the role of USF-2 for human PAI-1 expression. We found in human hepatoma cells (HepG2) that USF-2 induced human PAI-1 expression via two classical E-boxes and the hypoxia-responsive element (HRE) within the promoter. Gel-shift analyses showed that E-box 4 and E-box 5 bound USFs, and although the HRE contributed to the USF-dependent effects, it did not bind them. By contrast, USF-2 inhibited PAI-1 promoter activity in primary rat hepatocytes suggesting that PAI-1 expression depends on either the promoter context or USF activity which might be cell type-specific. Cotransfection of human or rat PAI-1 promoter luciferase constructs with expression vectors for wild-type USF-2 or USF-2 mutants in human HepG2 and rat H4IIE cells as well as in primary rat hepatocytes revealed that the effects of USF on PAI-1 expression depend on the cell type rather than the promoter context and that the USF-specific region domain of USF accounts for the observed cell type-specific effects.	Univ Kaiserslautern, Fac Chem, Dept Biochem, D-67663 Kaiserslautern, Germany	University of Kaiserslautern	Dimova, EY (corresponding author), Univ Kaiserslautern, Fac Chem, Dept Biochem, Erwin Schrodinger Str 54, D-67663 Kaiserslautern, Germany.	edimova@gwdg.de		Dimova, Elitsa/0000-0003-2745-8145; Kietzmann, Thomas/0000-0003-0242-8636				Allen RR, 2005, J CELL PHYSIOL, V203, P156, DOI 10.1002/jcp.20211; BUNGERT J, 1992, J MOL BIOL, V223, P885, DOI 10.1016/0022-2836(92)90250-N; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; Chen YH, 2001, J BIOL CHEM, V276, P47658, DOI 10.1074/jbc.M108678200; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; COLLEN D, 1991, BLOOD, V78, P3114; Coulson JM, 2003, BIOCHEM J, V369, P549, DOI 10.1042/BJ20021176; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimova EY, 2005, THROMB HAEMOSTASIS, V93, P1176, DOI 10.1160/TH04-11-0761; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fink T, 2002, BLOOD, V99, P2077, DOI 10.1182/blood.V99.6.2077; Goueli BS, 2003, ONCOGENE, V22, P8042, DOI 10.1038/sj.onc.1206847; Harris VK, 2000, J BIOL CHEM, V275, P28539, DOI 10.1074/jbc.M001677200; Henrion AA, 1996, MAMM GENOME, V7, P803, DOI 10.1007/s003359900241; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; Jiang B, 2003, MOL CELL BIOL, V23, P6117, DOI 10.1128/MCB.23.17.6117-6128.2003; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kietzmann T, 1997, BIOCHEM J, V321, P17, DOI 10.1042/bj3210017; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Levens D, 2002, P NATL ACAD SCI USA, V99, P5757, DOI 10.1073/pnas.102173199; LIJNEN HR, 1988, ENZYME, V40, P90, DOI 10.1159/000469150; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; Luo X, 1996, MOL CELL BIOL, V16, P1367; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Samoylenko A, 2001, BLOOD, V97, P2657, DOI 10.1182/blood.V97.9.2657; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; Scholtz B, 1996, J BIOL CHEM, V271, P32375, DOI 10.1074/jbc.271.50.32375; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Smih F, 2002, DIABETES, V51, P293, DOI 10.2337/diabetes.51.2.293; Takahashi Y, 1997, J BIOL CHEM, V272, P30025, DOI 10.1074/jbc.272.48.30025; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Virolle T, 2002, NUCLEIC ACIDS RES, V30, P1789, DOI 10.1093/nar/30.8.1789; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716	39	34	34	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 3	2006	281	5					2999	3005		10.1074/jbc.M512078200	http://dx.doi.org/10.1074/jbc.M512078200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	006XT	16330554	hybrid			2022-12-27	WOS:000234931800070
J	Samuel, CE				Samuel, CE			Virus-host interaction minireview series: Human immunodeficiency virus, hepatitis C virus, and influenza virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							ANTIVIRAL ACTIONS		Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Biomol Sci & Engn Program, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Samuel, CE (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.	samuel@lifesci.ucsb.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020611, R01AI012520, R37AI012520] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-20611, AI-12520] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appel N, 2006, J BIOL CHEM, V281, P9833, DOI 10.1074/jbc.R500026200; Chiu YL, 2006, J BIOL CHEM, V281, P8309, DOI 10.1074/jbc.R500021200; Knipe D.M., 2001, FIELDS VIROLOGY; Pinto LH, 2006, J BIOL CHEM, V281, P8997, DOI 10.1074/jbc.R500020200; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Samuel CE, 2002, P NATL ACAD SCI USA, V99, P11555, DOI 10.1073/pnas.202448899	6	7	7	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8305	8307		10.1074/jbc.R500032200	http://dx.doi.org/10.1074/jbc.R500032200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16407181	hybrid			2022-12-27	WOS:000236247100001
J	Qasimi, P; Ming-Lum, A; Ghanipour, A; Ong, CJ; Cox, ME; Ihle, J; Cacalano, N; Yoshimura, A; Mui, ALF				Qasimi, P; Ming-Lum, A; Ghanipour, A; Ong, CJ; Cox, ME; Ihle, J; Cacalano, N; Yoshimura, A; Mui, ALF			Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor alpha and nitric oxide production by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; LIPOPOLYSACCHARIDE-INDUCED ACTIVATION; CYTOKINE SIGNALING-3; TYROSINE PHOSPHORYLATION; CHRONIC ENTEROCOLITIS; INDEPENDENT PATHWAYS; NEGATIVE REGULATION; MOUSE MACROPHAGES; J774 MACROPHAGES; HUMAN MONOCYTES	The cytokine interleukin-10 (IL-10) potently inhibits macrophage function through activation of the transcription factor STAT3. The expression of SOCS3 ( suppressor of cytokine signaling-3) has been shown to be induced by IL-10 in a STAT3-dependent manner. However, the relevance of SOCS3 expression to the anti-inflammatory effect of IL-10 on macrophages has been controversial. Through kinetic analysis of the requirement for SOCS3 in IL-10 inhibition of lipopolysaccharide (LPS)-stimulated tumor necrosis factor-alpha(TNF alpha) transcription and translation, SOCS3 was found to be necessary for TNF alpha expression during the early phase, but not the late phase of IL-10 action. SOCS3 was essential for IL-10 inhibition of LPS-stimulated production of iNOS ( inducible nitric-oxide synthase) protein and nitric oxide ( NO). To determine the domains of SOCS3 protein important in mediating these effects, SOCS3(-/-) macrophages were reconstituted with SOCS3 mutated for the SH2, KIR, SOCS box domains, and tyrosines 204 (Tyr(204)) and 221 (Tyr(221)). The SH2 domain, SOCS box, and both Tyr(204) and Tyr(221) were required for IL-10 inhibition of TNF alpha mRNA and protein expression, but interestingly the KIR domain was necessary only for IL-10 inhibition of TNF alpha protein expression. In contrast, Tyr204 and Tyr221 were the only structural features of SOCS3 that were necessary in mediating IL-10 inhibition of iNOS protein expression and NO production. These data define SOCS3 as an important mediator of IL-10 inhibition of macrophage activation and that SOCS3 interferes with distinct LPS-stimulated signal transduction events through differing mechanisms.	Univ British Columbia, Dept Surg, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Coastal Hlth Res Inst, Immun & Infect Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Coastal Hlth Res Inst, Prostate Canc Res Ctr, Vancouver, BC V6H 3Z6, Canada; St Jude Childrens Hosp, Memphis, TN 38105 USA; Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90095 USA; Kyushu Univ, Div Mol & Cellular Immunol, Fukuoka 8128582, Japan	University of British Columbia; Vancouver Coastal Health Research Institute; Vancouver Coastal Health Research Institute; St Jude Children's Research Hospital; University of California System; University of California Los Angeles; Kyushu University	Mui, ALF (corresponding author), Univ British Columbia, Dept Surg, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	amui@interchange.ubc.ca	Yoshimura, Akihiko/K-5515-2013					Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Alexander WS, 2004, ANNU REV IMMUNOL, V22, P503, DOI 10.1146/annurev.immunol.22.091003.090312; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; Berlato C, 2002, J IMMUNOL, V168, P6404, DOI 10.4049/jimmunol.168.12.6404; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; BROMBERG JS, 1995, CURR OPIN IMMUNOL, V7, P639, DOI 10.1016/0952-7915(95)80070-0; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Campbell J, 2004, J IMMUNOL, V173, P6928, DOI 10.4049/jimmunol.173.11.6928; Crespo A, 2002, EUR J IMMUNOL, V32, P710, DOI 10.1002/1521-4141(200203)32:3<710::AID-IMMU710>3.0.CO;2-T; de Veer MJ, 2003, EUR J IMMUNOL, V33, P2822, DOI 10.1002/eji.200324128; Denys A, 2002, J IMMUNOL, V168, P4837, DOI 10.4049/jimmunol.168.10.4837; DING AH, 1988, J IMMUNOL, V141, P2407; Ding YZ, 2003, J IMMUNOL, V170, P1383, DOI 10.4049/jimmunol.170.3.1383; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gao JJ, 1998, J IMMUNOL, V161, P4803; Gingras S, 2004, J BIOL CHEM, V279, P54702, DOI 10.1074/jbc.M411043200; Goldman M, 1996, ANN NY ACAD SCI, V796, P282, DOI 10.1111/j.1749-6632.1996.tb32590.x; Haan S, 2003, J BIOL CHEM, V278, P31972, DOI 10.1074/jbc.M303170200; Hanada T, 2001, J BIOL CHEM, V276, P40746, DOI 10.1074/jbc.M106139200; Hattori Y, 1996, BIOCHEM MOL BIOL INT, V40, P889; Heine Holger, 2005, V86, P99, DOI 10.1159/000086654; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Imai K, 2003, FEMS IMMUNOL MED MIC, V39, P173, DOI 10.1016/S0928-8244(03)00231-1; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Jacobs AT, 2001, J BIOL CHEM, V276, P47950, DOI 10.1074/jbc.M106639200; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Krebs DL, 2000, J CELL SCI, V113, P2813; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; Lang R, 2003, NAT IMMUNOL, V4, P546, DOI 10.1038/ni932; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Niemand C, 2003, J IMMUNOL, V170, P3263, DOI 10.4049/jimmunol.170.6.3263; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Oberholzer A, 2001, SHOCK, V16, P83, DOI 10.1097/00024382-200116020-00001; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Okugawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC399, DOI 10.1152/ajpcell.00026.2003; PENNLINE KJ, 1994, CLIN IMMUNOL IMMUNOP, V71, P169, DOI 10.1006/clin.1994.1068; Peraldi P, 2001, J BIOL CHEM, V276, P24614, DOI 10.1074/jbc.M102209200; RENNICK D, 1995, CLIN IMMUNOL IMMUNOP, V76, pS174, DOI 10.1016/S0090-1229(95)90144-2; Rennick DM, 1997, J LEUKOCYTE BIOL, V61, P389, DOI 10.1002/jlb.61.4.389; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; Riley SG, 2002, AM J KIDNEY DIS, V39, P985, DOI 10.1053/ajkd.2002.32772; Sasaki A, 2000, J BIOL CHEM, V275, P29338, DOI 10.1074/jbc.M003456200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Shames BD, 1998, SHOCK, V10, P389, DOI 10.1097/00024382-199812000-00002; Sitko JC, 2004, J BIOL CHEM, V279, P37662, DOI 10.1074/jbc.M404007200; Stoiber D, 2001, J IMMUNOL, V166, P466, DOI 10.4049/jimmunol.166.1.466; Suhrbier A, 2003, TRENDS IMMUNOL, V24, P165, DOI 10.1016/S1471-4906(03)00065-6; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Walker J M, 1994, Methods Mol Biol, V32, P5; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Williams LM, 2004, IMMUNOLOGY, V113, P281, DOI 10.1111/j.1365-2567.2004.01988.x; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	77	76	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6316	6324		10.1074/jbc.M508608200	http://dx.doi.org/10.1074/jbc.M508608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16352613	hybrid			2022-12-27	WOS:000236030800025
J	Tian, Y; Sohar, I; Taylor, JW; Lobel, P				Tian, Y; Sohar, I; Taylor, JW; Lobel, P			Determination of the substrate specificity of tripeptidyl-peptidase I using combinatorial peptide libraries and development of improved fluorogenic substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; MITOCHONDRIAL ATP SYNTHASE; SOLID-PHASE SYNTHESIS; LYSOSOMAL DEGRADATION; BATTEN-DISEASE; PARTIAL-PURIFICATION; TARGETED DISRUPTION; MOUSE-BRAIN; SUBUNIT C; PROTEIN	Classical late-infantile neuronal ceroid lipofuscinosis is a fatal neurodegenerative disease caused by mutations in CLN2, the gene encoding the lysosomal protease tripeptidyl-peptidase I (TPP I). The natural substrates for TPP I and the pathophysiological processes associated with lysosomal storage and disease progression are not well understood. Detailed characterization of TPP I substrate specificity should provide insights into these issues and also aid in the development of improved clinical and biochemical assays. To this end, we constructed fluorogenic and standard combinatorial peptide libraries and analyzed them using fluorescence and mass spectrometry-based activity assays. The fluorogenic group 7-amino-4-carbamoylmethylcoumarin was incorporated into a series of 7-amino-4-carbamoylmethylcoumarin tripeptide libraries using a design strategy that allowed systematic evaluation of the P1, P2, and P3 positions. TPP I digestion of these substrates liberates the fluorescence group and results in a large increase in fluorescence that can be used to calculate kinetic parameters and to derive the substrate specificity constant k(cat)/K-M. In addition, we implemented amass spectrometry-based assay to measure the hydrolysis of individual peptides in peptide pools and thus expand the scope of the analysis. Nonfluorogenic tetrapeptide and pentapeptide libraries were synthesized and analyzed to evaluate P1' and P2' residues. Together, this analysis allowed us to predict the relative specificity of TPP I toward a wide range of potential biological substrates. In addition, we evaluated a variety of new fluorogenic peptides with a P3 Arg residue, and we demonstrated their superiority compared with the widely used substrate Ala-Ala-Phe-AMC for selectively measuring TPP I activity in biological specimens.	Rutgers State Univ, CABM, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lobel, P (corresponding author), Rutgers State Univ, CABM, 679 Hoes Lane, Piscataway, NJ 08854 USA.	lobel@cabm.rutgers.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037918] Funding Source: NIH RePORTER; NCRR NIH HHS [RR017992] Funding Source: Medline; NINDS NIH HHS [NS37918] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bernardini F, 2002, BIOCHEM J, V366, P521, DOI 10.1042/BJ20020467; Berry-Kravis E, 2000, ANN NEUROL, V47, P254, DOI 10.1002/1531-8249(200002)47:2<254::AID-ANA19>3.0.CO;2-7; Comellas-Bigler M, 2002, STRUCTURE, V10, P865, DOI 10.1016/S0969-2126(02)00772-4; DOEBBER TW, 1978, ENDOCRINOLOGY, V103, P1794, DOI 10.1210/endo-103-5-1794; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; Ezaki J, 2000, J BIOCHEM-TOKYO, V128, P509, DOI 10.1093/oxfordjournals.jbchem.a022781; FEARNLEY IM, 1990, BIOCHEM J, V268, P751, DOI 10.1042/bj2680751; Goebel H, 1999, NEURONAL CEROID LIPO; Golabek AA, 2004, J BIOL CHEM, V279, P31058, DOI 10.1074/jbc.M400700200; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Herva R, 2000, BRAIN PATHOL, V10, P215, DOI 10.1111/j.1750-3639.2000.tb00255.x; HOLTZMAN E, 1989, LYSOSOMES, P73; Junaid M A, 2001, Eur J Paediatr Neurol, V5 Suppl A, P63, DOI 10.1053/ejpn.2000.0437; Junaid MA, 1999, CLIN CHIM ACTA, V281, P169, DOI 10.1016/S0301-2115(98)00333-9; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; Kleijer WJ, 2001, PRENATAL DIAG, V21, P99, DOI 10.1002/1097-0223(200102)21:2<99::AID-PD988>3.0.CO;2-F; Kopan S, 2004, BIOCHEM BIOPH RES CO, V319, P58, DOI 10.1016/j.bbrc.2004.04.142; Lin CC, 2001, ASIA PAC J OPER RES, V18, P165; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lukacs Z, 2003, CLIN CHEM, V49, P509, DOI 10.1373/49.3.509; Maly DJ, 2002, J ORG CHEM, V67, P910, DOI 10.1021/jo016140o; MCDONALD JK, 1985, BIOCHEM BIOPH RES CO, V126, P63, DOI 10.1016/0006-291X(85)90571-6; MCGEEHAN GM, 1995, METHOD ENZYMOL, V248, P35; Mitchison HM, 1999, NEUROBIOL DIS, V6, P321, DOI 10.1006/nbdi.1999.0267; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Oyama H, 2005, J BIOCHEM, V138, P127, DOI 10.1093/jb/mvi110; Palmer DN, 1997, NEUROPEDIATRICS, V28, P45, DOI 10.1055/s-2007-973666; PALMER DN, 1992, AM J MED GENET, V42, P561, DOI 10.1002/ajmg.1320420428; PALMER DN, 1986, J BIOL CHEM, V261, P1773; PALMER DN, 1989, J BIOL CHEM, V264, P5736; Rawlings ND, 1999, BBA-PROTEIN STRUCT M, V1429, P496, DOI 10.1016/S0167-4838(98)00238-6; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Sleat D E, 2001, Eur J Paediatr Neurol, V5 Suppl A, P57, DOI 10.1053/ejpn.2000.0436; Sleat DE, 1999, AM J HUM GENET, V64, P1511, DOI 10.1086/302427; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Sleat DE, 2004, J NEUROSCI, V24, P9117, DOI 10.1523/JNEUROSCI.2729-04.2004; Sleat DE, 1998, BIOCHEM J, V334, P547, DOI 10.1042/bj3340547; Sohar I, 2000, CLIN CHEM, V46, P1005; Sohar I, 1999, J NEUROCHEM, V73, P700, DOI 10.1046/j.1471-4159.1999.0730700.x; SOHAR I, 2003, HDB PROTEOLYTIC ENZY, P1893; Tian Y, 2002, J PEPT RES, V59, P264, DOI 10.1034/j.1399-3011.2002.02988.x; Tyynela J, 1997, J NEUROPATH EXP NEUR, V56, P369, DOI 10.1097/00005072-199704000-00005; Vines DJ, 1999, FEBS LETT, V443, P131, DOI 10.1016/S0014-5793(98)01683-4; Warburton MJ, 2002, NEUROSCI LETT, V331, P99, DOI 10.1016/S0304-3940(02)00841-8; Warburton MJ, 2001, FEBS LETT, V500, P145, DOI 10.1016/S0014-5793(01)02608-4; WATANABE Y, 1992, BIOCHEM INT, V27, P869; Wlodawer A, 2001, NAT STRUCT BIOL, V8, P442, DOI 10.1038/87610; Wlodawer Alexander, 2003, BMC Struct Biol, V3, P8, DOI 10.1186/1472-6807-3-8	48	30	35	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6559	6572		10.1074/jbc.M507336200	http://dx.doi.org/10.1074/jbc.M507336200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16339154	hybrid			2022-12-27	WOS:000236030800052
J	Tu, Z; Prajapati, S; Park, KJ; Kelly, NJ; Yamamoto, Y; Gaynor, RB				Tu, Z; Prajapati, S; Park, KJ; Kelly, NJ; Yamamoto, Y; Gaynor, RB			IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; BREAST-CANCER CELLS; GENE-EXPRESSION; KINASE-ALPHA; FAMILY-MEMBERS; DIFFERENTIAL REGULATION; RETINOBLASTOMA PROTEIN; LIVER DEGENERATION; DEPENDENT KINASES; MICE LACKING	The I kappa B kinase (IKK) complex consists of the catalytic subunits IKK alpha and IKK beta and a regulatory subunit, IKK gamma/NEMO. Even though IKK alpha and IKK beta share significant sequence similarity, they have distinct biological roles. It has been demonstrated that IKKs are involved in regulating the proliferation of both normal and tumor cells, although the mechanisms by which they function in this process remain to be better defined. In this study, we demonstrate that IKK alpha, but not IKK beta, is important for estrogen-induced cell cycle progression by regulating the transcription of the E2F1 gene as well as other E2F1-responsive genes, including thymidine kinase 1, proliferating cell nuclear antigen, cyclin E, and cdc25A. The role of IKK alpha in regulating E2F1 was not the result of reduced levels of cyclin D1, as overexpression of this gene could not overcome the effects of IKK alpha knock-down. Furthermore, estrogen treatment increased the association of endogenous IKK alpha and E2F1, and this interaction occurred on promoters bound by E2F1. IKK alpha also potentiated the ability of p300/CBP-associated factor to acetylate E2F1. Taken together, these data suggest a novel mechanism by which IKK alpha can influence estrogen-mediated cell cycle progression through its regulation of E2F1.	Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA	Eli Lilly	Yamamoto, Y (corresponding author), Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA.	yamamoto_yumi@lilly.com; gaynor_richard@lilly.com						Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Altucci L, 1996, ONCOGENE, V12, P2315; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cress WD, 1996, MOL CELL BIOL, V16, P2119; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Foster JS, 1996, MOL ENDOCRINOL, V10, P488, DOI 10.1210/me.10.5.488; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Gruber CJ, 2004, TRENDS ENDOCRIN MET, V15, P73, DOI 10.1016/j.tem.2004.01.008; Hartman J, 2004, ONCOGENE, V23, P8826, DOI 10.1038/sj.onc.1208139; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Inari A, 2004, J BIOL CHEM, V279, P30830, DOI 10.1074/jbc.M402403200; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Krutzfeldt M, 2005, MOL CELL, V18, P213, DOI 10.1016/j.molcel.2005.03.009; Kwak YT, 2005, J BIOL CHEM, V280, P33945, DOI 10.1074/jbc.M506206200; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Ngwenya S, 2003, ENDOCRINOLOGY, V144, P1675, DOI 10.1210/en.2002-0009; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Ren H, 2002, J IMMUNOL, V168, P3721, DOI 10.4049/jimmunol.168.8.3721; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	55	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6699	6706		10.1074/jbc.M512439200	http://dx.doi.org/10.1074/jbc.M512439200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16407216	hybrid			2022-12-27	WOS:000236030800067
J	Andersson, FI; Blakytny, R; Kirstein, J; Turgay, K; Bukau, B; Mogk, A; Clarke, AK				Andersson, FI; Blakytny, R; Kirstein, J; Turgay, K; Bukau, B; Mogk, A; Clarke, AK			Cyanobacterial ClpC/HSP100 protein displays intrinsic chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; DEPENDENT CLP PROTEASE; ESCHERICHIA-COLI; MOLECULAR CHAPERONE; BACILLUS-SUBTILIS; STRESS TOLERANCE; LISTERIA-MONOCYTOGENES; ACTIVATED ATPASE; ADAPTER PROTEIN; HIGHER-PLANTS	HSP100 proteins are molecular chaperones that belong to the broader family of AAA+ proteins ( ATPases associated with a variety of cellular activities) known to promote protein unfolding, disassembly of protein complexes and translocation of proteins across membranes. The ClpC form of HSP100 is an essential, highly conserved, constitutively expressed protein in cyanobacteria and plant chloroplasts, and yet little is known regarding its specific activity as a molecular chaperone. To address this point, ClpC from the cyanobacterium Synechococcus elongatus (SyClpC) was purified using an Escherichia coli-based overexpression system. Recombinant SyClpC showed basal ATPase activity, similar to that of other types of HSP100 protein in non-photosynthetic organisms but different to ClpC in Bacillus subtilis. SyClpC also displayed distinct intrinsic chaperone activity in vitro, first by preventing aggregation of unfolded polypeptides and second by resolubilizing and refolding aggregated proteins into their native structures. The refolding activity of SyClpC was enhanced 3-fold in the presence of the B. subtilis ClpC adaptor protein MecA. Overall, the distinctive ClpC protein in photosynthetic organisms indeed functions as an independent molecular chaperone, and it is so far unique among HSP100 proteins in having both "holding" and disaggregase chaperone activities without the need of other chaperones or adaptor proteins.	Univ Gothenburg, Inst Bot, S-40530 Gothenburg, Sweden; Fachklin Hornheide, Dept Canc Res, D-48157 Munster, Germany; Free Univ Berlin, Inst Pflanzenphysiol & Mikrobiol, Fachbereich Biol, D-14195 Berlin, Germany; Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany	University of Gothenburg; Free University of Berlin; Ruprecht Karls University Heidelberg	Clarke, AK (corresponding author), Univ Gothenburg, Inst Bot, Box 461, S-40530 Gothenburg, Sweden.	adrian.clarke@botany.gu.se	Turgay, Kürsad/D-4828-2011; Turgay, Kürşad/Q-5285-2019	Turgay, Kürsad/0000-0002-8959-492X; Turgay, Kürşad/0000-0002-8959-492X; Bukau, Bernd/0000-0003-0521-7199; Kirstein, Janine/0000-0003-4990-2497				Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Clarke AK, 1999, ANN BOT-LONDON, V83, P593, DOI 10.1006/anbo.1999.0878; Clarke AK, 2005, PHYSIOL PLANTARUM, V123, P406, DOI 10.1111/j.1399-3054.2005.00452.x; Clarke AK, 1996, PLANT MOL BIOL, V31, P721, DOI 10.1007/BF00019460; Clarke AK, 1998, PLANT MOL BIOL, V37, P791, DOI 10.1023/A:1006016302074; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; DUBNAU D, 1990, J BACTERIOL, V172, P4048, DOI 10.1128/jb.172.7.4048-4055.1990; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Guo FS, 2002, J BIOL CHEM, V277, P46753, DOI 10.1074/jbc.M208104200; Hattendorf DA, 2002, EMBO J, V21, P12, DOI 10.1093/emboj/21.1.12; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Jarvis P, 2001, BBA-MOL CELL RES, V1541, P64, DOI 10.1016/S0167-4889(01)00147-1; Kaneko T, 1996, DNA Res, V3, P109; Kim KI, 1998, BIOCHEM J, V333, P671, DOI 10.1042/bj3330671; KRUGER E, 1994, J BACTERIOL, V176, P3360; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lau GW, 2001, MOL MICROBIOL, V40, P555, DOI 10.1046/j.1365-2958.2001.02335.x; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Lupas AN, 2003, J STRUCT BIOL, V141, P77, DOI 10.1016/S1047-8477(02)00582-8; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; MSADEK T, 1994, P NATL ACAD SCI USA, V91, P5788, DOI 10.1073/pnas.91.13.5788; Muffler A, 1996, EMBO J, V15, P1333, DOI 10.1002/j.1460-2075.1996.tb00475.x; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Nimura K, 2001, J BACTERIOL, V183, P1320, DOI 10.1128/JB.183.4.1320-1328.2001; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Persuh M, 1999, MOL MICROBIOL, V33, P886, DOI 10.1046/j.1365-2958.1999.01544.x; Persuh M, 2002, J BACTERIOL, V184, P2310, DOI 10.1128/JB.184.8.2310-2313.2002; RIGGS P, 1990, CURRENT PROTOCOLS MO, P1; Rouquette C, 1996, MOL MICROBIOL, V21, P977, DOI 10.1046/j.1365-2958.1996.641432.x; Rouquette C, 1998, MOL MICROBIOL, V27, P1235, DOI 10.1046/j.1365-2958.1998.00775.x; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlothauer T, 2003, P NATL ACAD SCI USA, V100, P2306, DOI 10.1073/pnas.0535717100; SEOL JH, 1994, J BIOL CHEM, V269, P29468; Sjogren LLE, 2004, PLANT PHYSIOL, V136, P4114, DOI 10.1104/pp.104.053835; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Turgay K, 1997, GENE DEV, V11, P119, DOI 10.1101/gad.11.1.119; Weibezahn J, 2003, J BIOL CHEM, V278, P32608, DOI 10.1074/jbc.M303653200; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zeth K, 2002, NAT STRUCT BIOL, V9, P906, DOI 10.1038/nsb869; Zheng B, 2002, PHYSIOL PLANTARUM, V114, P92, DOI 10.1034/j.1399-3054.2002.1140113.x; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	52	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5468	5475		10.1074/jbc.M509661200	http://dx.doi.org/10.1074/jbc.M509661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16361263	Green Submitted, hybrid			2022-12-27	WOS:000235568900019
J	Grimsley, CM; Lu, MJ; Haney, LB; Kinchen, JM; Ravichandran, KS				Grimsley, CM; Lu, MJ; Haney, LB; Kinchen, JM; Ravichandran, KS			Characterization of a novel interaction between ELMO1 and ERM proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F-ACTIN BINDING; CELL-ADHESION; EZRIN/RADIXIN/MOESIN PROTEINS; EPITHELIAL-CELLS; PLASMA-MEMBRANE; CULTURED-CELLS; ACTIVATES RAC1; THREONINE 558; IN-VITRO; EZRIN	ERMs are closely related proteins involved in cell migration, cell adhesion, maintenance of cell shape, and formation of microvilli through their ability to cross-link the plasma membrane with the actin cytoskeleton. ELMO proteins are also known to regulate actin cytoskeleton reorganization through activation of the small GTP-binding protein Rac via the ELMO-Dock180 complex. Here we showed that ERM proteins associate directly with ELMO1 as purified recombinant proteins in vitro and at endogenous levels in intact cells. We mapped ERM binding on ELMO1 to the N-terminal 280 amino acids, which overlaps with the region required for binding to the GTPase RhoG, but is distinct from the C-terminal Dock180 binding region. Consistent with this, ELMO1 could simultaneously bind both radixin and Dock180, although radixin did not alter Rac activation via the Dock180-ELMO complex. Most interestingly, radixin binding did not affect ELMO binding to active RhoG and a trimeric complex of active RhoG-ELMO-radixin could be detected. Moreover, the three proteins colocalized at the plasma membrane. Finally, in contrast to most other ERM-binding proteins, ELMO1 binding occurred independently of the state of radixin C-terminal phosphorylation, suggesting an ELMO1 interaction with both the active and inactive forms of ERM proteins and implying a possible role of ELMO in localizing or retaining ERM proteins in certain cellular sites. Together these data suggest that ELMO1-mediated cytoskeletal changes may be coordinated with ERM protein cross-linking activity during dynamic cellular functions.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Ravichandran, KS (corresponding author), Univ Virginia, Carter Immunol Ctr, MR4 Rm 4072D,Box 801386,Lane Rd, Charlottesville, VA 22908 USA.	Ravi@virginia.edu	Lu, Mingjian/AGK-0751-2022; Lu, Mingjian/AAO-6179-2021; Kinchen, Jason/ABC-5663-2021	Lu, Mingjian/0000-0001-9328-4935; Kinchen, Jason/0000-0001-8430-2265	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064709] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 064709] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allenspach EJ, 2001, IMMUNITY, V15, P739, DOI 10.1016/S1074-7613(01)00224-2; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; BERRYMAN M, 1993, J CELL SCI, V105, P1025; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Blangy A, 2000, J CELL SCI, V113, P729; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cao XW, 2005, J BIOL CHEM, V280, P13584, DOI 10.1074/jbc.M411941200; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; DeBakker CD, 2004, CURR BIOL, V14, P2208, DOI 10.1016/j.cub.2004.12.029; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; FRANCK Z, 1993, J CELL SCI, V105, P219; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Gobel V, 2004, DEV CELL, V6, P865, DOI 10.1016/j.devcel.2004.05.018; Granes F, 2000, J CELL SCI, V113, P1267; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hayashi K, 1999, J CELL SCI, V112, P1149; Heiska L, 1998, J BIOL CHEM, V273, P21893, DOI 10.1074/jbc.273.34.21893; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1999, J BIOL CHEM, V274, P12803, DOI 10.1074/jbc.274.18.12803; Ishikawa H, 2001, J MOL BIOL, V310, P973, DOI 10.1006/jmbi.2001.4818; Iwase A, 2004, J BIOL CHEM, V279, P11898, DOI 10.1074/jbc.M212737200; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Kikuchi S, 2002, NAT GENET, V31, P320, DOI 10.1038/ng905; Kitajiri S, 2004, J CELL BIOL, V166, P559, DOI 10.1083/jcb.200402007; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; Manchanda N, 2005, J BIOL CHEM, V280, P12517, DOI 10.1074/jbc.C400583200; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SATO N, 1992, J CELL SCI, V103, P131; SCHWARTZALBIEZ R, 1995, EUR J CELL BIOL, V67, P189; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 2002, J CELL SCI, V115, P2569; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	56	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5928	5937		10.1074/jbc.M510647200	http://dx.doi.org/10.1074/jbc.M510647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377631	hybrid			2022-12-27	WOS:000235568900073
J	Krementsova, EB; Hodges, AR; Lu, HL; Trybus, KM				Krementsova, EB; Hodges, AR; Lu, HL; Trybus, KM			Processivity of chimeric class V myosins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEAK BINDING; ACTIN; MOTOR; COORDINATION; MECHANISM; MOVEMENT; KINETICS; DOMAIN	Unconventional myosin V takes many 36-nm steps along an actin filament before it dissociates, thus ensuring its ability to move cargo intracellularly over long distances. In the present study we assessed the structural features that affect processive run length by analyzing the properties of chimeras of mouse myosin V and a non-processive class V myosin from yeast (Myo4p) (Reck-Peterson, S. L., Tyska, M. J., Novick, P. J., and Mooseker, M. S. (2001) J. Cell Biol. 153, 1121-1126). Surprisingly a chimera containing the yeast motor domain on the neck and rod of mouse myosin V (Y-MD) showed longer run lengths than mouse wild type at low salt. Run lengths of mouse myosin V showed little salt dependence, whereas those of Y-MD decreased steeply with ionic strength, similar to a chimera containing yeast loop 2 in the mouse myosin V backbone. Loop 2 binds to acidic patches on actin in the weak binding states of the cycle (Volkmann, N., Liu, H., Hazelwood, L., Krementsova, E. B., Lowey, S., Trybus, K. M., and Hanein, D. (2005) Mol. Cell 19, 595-605). Constructs containing yeast loop 2, which has no net charge compared with +6 for wild type, showed a higher K-m for actin in steady-state ATPase assays. The results imply that a positively charged loop 2 and a high affinity for actin are important to maintain processivity near physiologic ionic strength.	Univ Vermont, Dept Mol Physiol & Biophys, Burlington, VT 05405 USA	University of Vermont	Trybus, KM (corresponding author), Univ Vermont, Dept Mol Physiol & Biophys, 149 Beaumont Ave, Burlington, VT 05405 USA.	kathleen.trybus@uvm.edu	lu, hailong/C-7754-2009		NHLBI NIH HHS [HL 38113] Funding Source: Medline; NIAMS NIH HHS [AR 47906] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038113, R29HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR047906] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JE, 2004, P NATL ACAD SCI USA, V101, P5542, DOI 10.1073/pnas.0307247101; Buss F, 2004, ANNU REV CELL DEV BI, V20, P649, DOI 10.1146/annurev.cellbio.20.012103.094243; De la Cruz EM, 2000, BIOCHEMISTRY-US, V39, P14196, DOI 10.1021/bi001701b; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De La Cruz EM, 2004, CURR OPIN CELL BIOL, V16, P61, DOI 10.1016/j.ceb.2003.11.011; Furch M, 1998, BIOCHEMISTRY-US, V37, P6317, DOI 10.1021/bi972851y; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 2001, MECH MOTOR PROTEINS, P95; Joel PB, 2003, BIOCHEMISTRY-US, V42, P9160, DOI 10.1021/bi034415j; Krementsov DN, 2004, J CELL BIOL, V164, P877, DOI 10.1083/jcb.200310065; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Purcell TJ, 2005, P NATL ACAD SCI USA, V102, P13873, DOI 10.1073/pnas.0506441102; Reck-Peterson SL, 2000, BBA-MOL CELL RES, V1496, P36, DOI 10.1016/S0167-4889(00)00007-0; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; Rosenfeld SS, 2004, J BIOL CHEM, V279, P40100, DOI 10.1074/jbc.M402583200; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Toth J, 2005, J BIOL CHEM, V280, P30594, DOI 10.1074/jbc.M505209200; Vale RD, 2003, J CELL BIOL, V163, P445, DOI 10.1083/jcb.200308093; Veigel C, 2005, NAT CELL BIOL, V7, P861, DOI 10.1038/ncb1287; Veigel C, 2002, NAT CELL BIOL, V4, P59, DOI 10.1038/ncb732; Volkmann N, 2005, MOL CELL, V19, P595, DOI 10.1016/j.molcel.2005.07.015; WORK SS, 1992, ANAL BIOCHEM, V202, P275, DOI 10.1016/0003-2697(92)90106-H; Yengo CM, 2004, BIOCHEMISTRY-US, V43, P2605, DOI 10.1021/bi035510v; Yengo CM, 2002, BIOCHEMISTRY-US, V41, P8508, DOI 10.1021/bi015969u	26	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					6079	6086		10.1074/jbc.M510041200	http://dx.doi.org/10.1074/jbc.M510041200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16377634	hybrid			2022-12-27	WOS:000235568900089
J	LeBlanc, SE; Jang, SW; Ward, RM; Wrabetz, L; Svaren, J				LeBlanc, SE; Jang, SW; Ward, RM; Wrabetz, L; Svaren, J			Direct regulation of myelin protein zero expression by the Egr2 transactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHWANN-CELL DIFFERENTIATION; PERIPHERAL NERVOUS-SYSTEM; TRANSCRIPTION FACTOR SOX10; GENE-EXPRESSION; NEURAL CREST; NGFI-A; INHERITED NEUROPATHIES; AXONAL REGULATION; NAB PROTEINS; GLYCOPROTEIN	During myelination of the peripheral nervous system, the myelin protein zero (Mpz) gene is induced to produce the most abundant protein component (P-0) of mature myelin. Although the basal embryonic expression of Mpz in Schwann cells has been attributed to regulation by Sox10, the molecular mechanism for the profound up-regulation of this gene during myelination has not been established. In this study, we have identified a highly conserved element within the first intron of the Mpz gene, which contains binding sites for the early growth response 2 (Egr2/Krox20) transcription factor, a critical regulator of peripheral nerve myelination. Egr2 can transactivate the intron element, and the induction is blocked by two known repressors of Egr2 activity. Using chromatin immunoprecipitation assays, we find that Egr2 binds in vivo to the intron element, but not to the Mpz promoter. Known inducers of Mpz expression such as forskolin and insulin-like growth factor-1 also activate the element in an Egr2-dependent manner. In addition, we found that Egr2 can act synergistically with Sox10 to activate this intron element, suggesting a model in which cooperative interactions between Egr2 and Sox10 mediate a large increase in Mpz expression to the high levels found in myelinating Schwann cells.	Univ Wisconsin, Sch Vet Med, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Grad Program Cellular & Mol Biol, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Comparat Biosci, Madison, WI 53706 USA; San Raffaele Sci Inst, Dipartimento Ric Biol & Technol, I-20132 Milan, Italy	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Svaren, J (corresponding author), Univ Wisconsin, Sch Vet Med, Mol & Cellular Pharmacol Program, 2015 Linden Dr, Madison, WI 53706 USA.	jpsvaren@wisc.edu	Svaren, John/A-1605-2010	Svaren, John/0000-0003-2963-7921	NICHD NIH HHS [R01 HD041590, P30 HD 03352, HD 41590] Funding Source: Medline; NIGMS NIH HHS [T32 GM 08688] Funding Source: Medline; NINDS NIH HHS [NS 045630, NS 055256, NS 043560] Funding Source: Medline; Telethon [GGP030074] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD003352] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD041590] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045630, R01NS055256, R01NS043560] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BHATTACHARYYA A, 1991, NEURON, V7, P831, DOI 10.1016/0896-6273(91)90285-8; Blanchard AD, 1996, J NEUROSCI RES, V46, P630, DOI 10.1002/(SICI)1097-4547(19961201)46:5<630::AID-JNR11>3.0.CO;2-0; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; Brown AM, 1997, J BIOL CHEM, V272, P28939, DOI 10.1074/jbc.272.46.28939; Cheng HL, 1999, ENDOCRINOLOGY, V140, P4478, DOI 10.1210/en.140.10.4478; Colosimo A, 1999, BIOTECHNIQUES, V26, P870, DOI 10.2144/99265bm15; Denarier E, 2005, J NEUROSCI, V25, P11210, DOI 10.1523/JNEUROSCI.2596-05.2005; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; Feltri ML, 1999, EUR J NEUROSCI, V11, P1577, DOI 10.1046/j.1460-9568.1999.00568.x; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; FRANZ T, 1993, DEV BRAIN RES, V72, P99, DOI 10.1016/0165-3806(93)90163-5; Ghislain J, 2002, DEVELOPMENT, V129, P155; Ghislain J, 2003, DEVELOPMENT, V130, P941, DOI 10.1242/dev.00318; GIESE KP, 1992, CELL, V71, P565, DOI 10.1016/0092-8674(92)90591-Y; Gillian AL, 2004, J BIOL CHEM, V279, P9056, DOI 10.1074/jbc.M309308200; GREENFIELD S, 1973, J NEUROCHEM, V20, P1207, DOI 10.1111/j.1471-4159.1973.tb00089.x; Hai M, 2002, J NEUROSCI RES, V69, P497, DOI 10.1002/jnr.10327; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; KNIGHT RM, 1993, J NEUROSCI RES, V35, P38, DOI 10.1002/jnr.490350106; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Le N, 2005, NAT NEUROSCI, V8, P932, DOI 10.1038/nn1490; Le N, 2005, P NATL ACAD SCI USA, V102, P2596, DOI 10.1073/pnas.0407836102; LeBlanc SE, 2005, J NEUROCHEM, V93, P737, DOI 10.1111/j.1471-4159.2005.03056.x; Lee MJ, 1997, MOL CELL NEUROSCI, V8, P336, DOI 10.1006/mcne.1996.0589; Lee SL, 1996, MOL CELL BIOL, V16, P4566; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, DEVELOPMENT, V102, P499; Li YW, 2001, MOL CELL NEUROSCI, V17, P761, DOI 10.1006/mcne.2000.0967; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Mandemakers W, 2000, EMBO J, V19, P2992, DOI 10.1093/emboj/19.12.2992; Maurel P, 2000, J NEUROSCI, V20, P4635, DOI 10.1523/JNEUROSCI.20-12-04635.2000; Maycox PR, 1997, MOL CELL NEUROSCI, V8, P405, DOI 10.1006/mcne.1997.0600; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nagarajan R, 2002, P NATL ACAD SCI USA, V99, P8998, DOI 10.1073/pnas.132080999; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Ogata T, 2004, J NEUROSCI, V24, P6724, DOI 10.1523/JNEUROSCI.5520-03.2004; Parkinson DB, 2003, MOL CELL NEUROSCI, V23, P13, DOI 10.1016/S1044-7431(03)00024-1; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Shy ME, 2005, PERIPHERAL NEUROPATH, P1681; Slutsky SG, 2003, J BIOL CHEM, V278, P8960, DOI 10.1074/jbc.M210569200; STAHL N, 1990, MOL BRAIN RES, V8, P209, DOI 10.1016/0169-328X(90)90018-9; Stewart HJS, 1996, EUR J NEUROSCI, V8, P553, DOI 10.1111/j.1460-9568.1996.tb01240.x; Suter U, 2003, NAT REV NEUROSCI, V4, P714, DOI 10.1038/nrn1196; Svaren J, 1996, MOL CELL BIOL, V16, P3545; SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275; Takeda Yasuo, 2001, Keio Journal of Medicine, V50, P240; Taveggia C, 2005, NEURON, V47, P681, DOI 10.1016/j.neuron.2005.08.017; Taveggia C, 2004, J NEUROCHEM, V91, P813, DOI 10.1111/j.1471-4159.2004.02745.x; TODA K, 1994, J NEUROCHEM, V63, P1646; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Verheijen MHG, 2003, GENE DEV, V17, P2450, DOI 10.1101/gad.1116203; Warner LE, 1999, HUM MOL GENET, V8, P1245, DOI 10.1093/hmg/8.7.1245; Wegner M, 2000, GLIA, V31, P1, DOI 10.1002/(SICI)1098-1136(200007)31:1<1::AID-GLIA10>3.0.CO;2-V; Wight PA, 2004, CELL MOL LIFE SCI, V61, P810, DOI 10.1007/s00018-003-3309-z; WRABETZ L, 2004, MYELIN BIOL DISORDER, P905; ZHANG SM, 1995, J NEUROSCI RES, V40, P241, DOI 10.1002/jnr.490400213; Zorick TS, 1999, DEVELOPMENT, V126, P1397; Zorick TS, 1996, MOL CELL NEUROSCI, V8, P129, DOI 10.1006/mcne.1996.0052	64	75	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5453	5460		10.1074/jbc.M512159200	http://dx.doi.org/10.1074/jbc.M512159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16373334	hybrid			2022-12-27	WOS:000235568900017
J	Gong, QM; Jones, MA; Zhou, ZF				Gong, QM; Jones, MA; Zhou, ZF			Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; POTASSIUM CHANNEL; INTRACELLULAR-TRANSPORT; QUALITY-CONTROL; CALNEXIN INTERACTION; PROTEIN TRAFFICKING; CARDIAC-ARRHYTHMIA; WILD-TYPE; DOMAIN; MUTATIONS	Long QT syndrome type 2 is caused by mutations in the human ether-a-go-go-related gene (hERG). We previously reported that the N470D mutation is retained in the endoplasmic reticulum ( ER) but can be rescued to the plasma membrane by hERG channel blocker E-4031. The mechanisms of ER retention and how E-4031 rescues the N470D mutant are poorly understood. In this study, we investigated the interaction of hERG channels with the ER chaperone protein calnexin. Using coimmunoprecipitation, we showed that the immature forms of both wild type hERG and N470D associated with calnexin. The association required N-linked glycosylation of hERG channels. Pulse-chase analysis revealed that N470D had a prolonged association with calnexin compared with wild type hERG and E-4031 shortened the time course of calnexin association with N470D. To test whether the prolonged association of N470D with calnexin is due to defective folding of mutant channels, we studied hERG channel folding using the trypsin digestion method. We found that N470D and the immature form of wild type hERG were more sensitive to trypsin digestion than the mature form of wild type hERG. In the presence of E-4031, N470D became more resistant to trypsin even when its ER-to-Golgi transport was blocked by brefeldin A. These results suggest that defective folding of N470D contributes to its prolonged association with calnexin and ER retention and that E-4031 may restore proper folding of the N470D channel leading to its cell surface expression.	Oregon Hlth & Sci Univ, Div Cardiovasc Med, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University	Zhou, ZF (corresponding author), Oregon Hlth & Sci Univ, Div Cardiovasc Med, Dept Med, NRC3,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	zhouzh@ohsu.edu			NHLBI NIH HHS [R01 HL068854, HL68854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersson H, 1996, FEBS LETT, V397, P321, DOI 10.1016/S0014-5793(96)01207-0; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bellocq C, 2004, MOL PHARMACOL, V66, P1093, DOI 10.1124/mol.104.001065; Bernier V, 2004, TRENDS ENDOCRIN MET, V15, P222, DOI 10.1016/j.tem.2004.05.003; Chugh SS, 2004, J AM COLL CARDIOL, V43, P1625, DOI 10.1016/j.jacc.2003.11.052; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Delisle BP, 2004, CIRC RES, V94, P1418, DOI 10.1161/01.RES.0000128561.28701.ea; Deprez P, 2005, MOL CELL, V19, P183, DOI 10.1016/j.molcel.2005.05.029; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Fodstad H, 2004, ANN MED, V36, P53, DOI 10.1080/17431380410032689; Gong QM, 2005, J BIOL CHEM, V280, P19419, DOI 10.1074/jbc.M502327200; Gong QM, 2004, J MOL CELL CARDIOL, V37, P1225, DOI 10.1016/j.yjmcc.2004.10.002; Gong QM, 2004, AM J PHYSIOL-HEART C, V287, pH652, DOI 10.1152/ajpheart.00052.2004; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Higgins MK, 2003, BBA-BIOMEMBRANES, V1610, P124, DOI 10.1016/S0005-2736(02)00715-0; January CT, 2000, J CARDIOVASC ELECTR, V11, P1413, DOI 10.1046/j.1540-8167.2000.01413.x; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; Khanna R, 2004, J CELL SCI, V117, P2897, DOI 10.1242/jcs.01141; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; LOO TW, 1994, J BIOL CHEM, V269, P28683; Manganas LN, 2004, BIOCHEM BIOPH RES CO, V322, P577, DOI 10.1016/j.bbrc.2004.06.182; Manganas LN, 2001, J BIOL CHEM, V276, P49427, DOI 10.1074/jbc.M109325200; Morello JP, 2001, BIOCHEMISTRY-US, V40, P6766, DOI 10.1021/bi002699r; Nagaya N, 1999, RECEPTOR CHANNEL, V6, P229; Paulussen A, 2002, J BIOL CHEM, V277, P48610, DOI 10.1074/jbc.M206569200; PIND S, 1994, J BIOL CHEM, V269, P12784; Popov M, 1999, J BIOL CHEM, V274, P17635, DOI 10.1074/jbc.274.25.17635; Rossenbacker T, 2005, CIRCULATION, V111, P961, DOI 10.1161/01.CIR.0000156327.35255.D8; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Schulein R, 2004, REV PHYSIOL BIOCH P, V151, P45, DOI 10.1007/s10254-004-0022-8; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; TESTER DJ, 2005, HEART RHYTHM, V2; Thomas D, 2003, CARDIOVASC RES, V60, P235, DOI 10.1016/j.cardiores.2003.08.002; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Zhang DC, 2000, BLOOD, V96, P2925; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	43	66	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4069	4074		10.1074/jbc.M511765200	http://dx.doi.org/10.1074/jbc.M511765200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16361248	Green Accepted, hybrid			2022-12-27	WOS:000235275300036
J	Gregoire, S; Tremblay, AM; Xiao, L; Yang, Q; Ma, KW; Nie, JY; Mao, ZX; Wu, ZG; Giguere, V; Yang, XJ				Gregoire, S; Tremblay, AM; Xiao, L; Yang, Q; Ma, KW; Nie, JY; Mao, ZX; Wu, ZG; Giguere, V; Yang, XJ			Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCYTE-ENHANCER FACTOR-2; ACTIVATED PROTEIN-KINASE; DNA-BINDING ACTIVITY; HISTONE DEACETYLASES; SUMO-1 MODIFICATION; MADS-BOX; CALCINEURIN; P300; REPRESSES; APOPTOSIS	A eukaryotic protein is often subject to regulation by multiple modifications like phosphorylation, acetylation, ubiquitination, and sumoylation. How these modifications are coordinated in vivo is an important issue that is poorly understood but is relevant to many biological processes. We recently showed that human MEF2D (myocyte enhancer factor 2D) is sumoylated on Lys-439. Adjacent to the sumoylation motif is Ser-444, which like Lys-439 is highly conserved among MEF2 proteins from diverse species. Here we presented several lines of evidence to demonstrate that Ser-444 of MEF2D is required for sumoylation of Lys-439. Histone deacetylase 4 (HDAC4) stimulated this modification by acting through Ser-444. In addition, phosphorylation of Ser-444 by Cdk5, a cyclin-dependent kinase known to inhibit MEF2 transcriptional activity, stimulated sumoylation. Opposing the actions of HDAC4 and Cdk5, calcineurin (also known as protein phosphatase 2B) dephosphorylated Ser-444 and inhibited sumoylation of Lys-439. This phosphatase, however, exerted minimal effects on the phosphorylation catalyzed by ERK5, an extracellular signal-regulated kinase known to activate MEF2D. These results identified an essential role for Ser-444 in MEF2D sumoylation and revealed a novel mechanism by which calcineurin selectively "edits" phosphorylation at different sites, thereby reiterating that interplay between different modifications represents a general mechanism for coordinated regulation of eukaryotic protein functions in vivo.	MUHC, RVH, Mol Oncol Grp, Dept Med, Montreal, PQ H3A 1A1, Canada; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	McGill University; Royal Victoria Hospital; Emory University; Emory University; Hong Kong University of Science & Technology	Yang, XJ (corresponding author), MUHC, RVH, Mol Oncol Grp, Dept Med, Rm H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca		Giguere, Vincent/0000-0001-9567-3694				Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cox DM, 2003, J BIOL CHEM, V278, P15297, DOI 10.1074/jbc.M211312200; De Angelis L, 1998, P NATL ACAD SCI USA, V95, P12358, DOI 10.1073/pnas.95.21.12358; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gong XM, 2003, NEURON, V38, P33, DOI 10.1016/S0896-6273(03)00191-0; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 2000, TRENDS CARDIOVAS MED, V10, P19, DOI 10.1016/S1050-1738(00)00039-6; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Heidenreich KA, 2004, MOL NEUROBIOL, V29, P155, DOI 10.1385/MN:29:2:155; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Li MT, 2001, J NEUROSCI, V21, P6544, DOI 10.1523/JNEUROSCI.21-17-06544.2001; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Linseman DA, 2003, J NEUROCHEM, V85, P1488, DOI 10.1046/j.1471-4159.2003.09799.x; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Lynch J, 2005, J CELL BIOL, V170, P37, DOI 10.1083/jcb.200412156; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Mao ZX, 1999, J BIOL CHEM, V274, P31102, DOI 10.1074/jbc.274.43.31102; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Naya FJ, 2002, NAT MED, V8, P1303, DOI 10.1038/nm789; Okamoto S, 2002, P NATL ACAD SCI USA, V99, P3974, DOI 10.1073/pnas.022036399; Prima V, 2005, LEUKEMIA, V19, P806, DOI 10.1038/sj.leu.2403684; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tang XL, 2005, J NEUROSCI, V25, P4823, DOI 10.1523/JNEUROSCI.1331-05.2005; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; Wang XM, 2005, J BIOL CHEM, V280, P16705, DOI 10.1074/jbc.M501819200; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016; Yamashita D, 2004, GENES CELLS, V9, P1017, DOI 10.1111/j.1365-2443.2004.00786.x; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang XJ, 2005, MOL CELL BIOL, V25, P2873, DOI 10.1128/MCB.25.8.2873-2884.2005; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao M, 1999, MOL CELL BIOL, V19, P21; Zhao X, 2005, MOL CELL BIOL, V25, P8456, DOI 10.1128/MCB.25.19.8456-8464.2005; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056; Zhu BM, 2005, J BIOL CHEM, V280, P28749, DOI 10.1074/jbc.M502491200; Zhu BM, 2004, MOL CELL BIOL, V24, P8264, DOI 10.1128/MCB.24.18.8264-8275.2004	80	130	134	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 17	2006	281	7					4423	4433		10.1074/jbc.M509471200	http://dx.doi.org/10.1074/jbc.M509471200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	011NN	16356933	hybrid			2022-12-27	WOS:000235275300078
J	Eckelman, BP; Salvesen, GS				Eckelman, BP; Salvesen, GS			The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; BIR DOMAIN; SIGNALING COMPLEX; NMR STRUCTURE; CYTOCHROME-C; CELL-DEATH; XIAP; IAP; SMAC; SURVIVIN	cIAPs (cellular inhibitor of apoptosis proteins) 1 and 2 are able to regulate apoptosis when ectopically expressed in recipient cells and probably also in vivo. Previous work suggested that this is at least partially due to direct caspase inhibition, mediated by two of the three baculovirus IAP repeat (BIR) domains that are contained in these proteins. In support of this we show that the BIR domains 2 and 3 of the two cIAPs are able to bind caspases-7 and -9. However, we demonstrate that neither of these BIR domains is able to inhibit caspases because of critical substitutions in the regions that target caspase inhibition in the X-linked IAP, a tight binding caspase inhibitor. The cIAP BIR domains can be converted to tight binding caspase inhibitors by substituting these critical residues with XIAP residues. Thus, cIAPs maintain protein scaffolds suitable for direct caspase inhibition but have lost or never acquired specific caspase inhibitory interaction sites. Consequently, although the binding function of the cIAP BIRs may be important for their physiologic function, caspase inhibition is not.	Univ Calif San Diego, Program Cell Death & Apoptosis Res, Burnham Inst Med Res, La Jolla, CA 92037 USA; Univ Calif San Diego, Program Cell Death & Apoptosis Res, Grad Program Mol Pathol, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Salvesen, GS (corresponding author), Univ Calif San Diego, Program Cell Death & Apoptosis Res, Burnham Inst Med Res, La Jolla, CA 92037 USA.	gsalvesen@burnham.org			NCI NIH HHS [2T32CA77109] Funding Source: Medline; NIA NIH HHS [AG15402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA077109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Davoodi J, 2004, J BIOL CHEM, V279, P40622, DOI 10.1074/jbc.M405963200; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Duckett Colin S, 2005, Biochem J, V385, pe1; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Orth R, 1997, J BIOL CHEM, V272, P8841; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Shin H, 2005, BIOCHEM J, V385, P1, DOI 10.1042/BJ20041107; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simons M, 1999, J NEUROCHEM, V72, P292, DOI 10.1046/j.1471-4159.1999.0720292.x; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Tenev T, 2005, NAT CELL BIOL, V7, P70, DOI 10.1038/ncb1204; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Verhagen AM, 2001, GENOME BIOL, V2; Vucic D, 2005, BIOCHEM J, V385, P11, DOI 10.1042/BJ20041108; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	45	274	291	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3254	3260		10.1074/jbc.M510863200	http://dx.doi.org/10.1074/jbc.M510863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16339151	hybrid			2022-12-27	WOS:000235128200030
J	Ferguson, AD; Labunskyy, VM; Fomenko, DE; Arac, D; Chelliah, Y; Amezcua, CA; Rizo, J; Gladyshev, VN; Deisenhofer, J				Ferguson, AD; Labunskyy, VM; Fomenko, DE; Arac, D; Chelliah, Y; Amezcua, CA; Rizo, J; Gladyshev, VN; Deisenhofer, J			NMR structures of the selenoproteins Sep15 and SelM reveal redox activity of a new thioredoxin-like family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN GLUCOSYLTRANSFERASE; FUNCTIONAL-CHARACTERIZATION; MAMMALIAN SELENOPROTEIN; SPERM MATURATION; UDP-GLUCOSE; SELENIUM; SEQUENCE; DOMAIN	Selenium has significant health benefits, including potent cancer prevention activity and roles in immune function and the male reproductive system. Selenium- containing proteins, which incorporate this essential micronutrient as selenocysteine, are proposed to mediate the positive effects of dietary selenium. Presented here are the solution NMR structures of the selenoprotein SelM and an ortholog of the selenoprotein Sep15. These data reveal that Sep15 and SelM are structural homologs that establish a new thioredoxinlike protein family. The location of the active-site redox motifs within the fold together with the observed localized conformational changes after thiol-disulfide exchange and measured redox potential indicate that they have redox activity. In mammals, Sep15 expression is regulated by dietary selenium, and either decreased or increased expression of this selenoprotein alters redox homeostasis. A physiological role for Sep15 and SelM as thiol- disulfide oxidoreductases and their contribution to the quality control pathways of the endoplasmic reticulum are discussed.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Nebraska System; University of Nebraska Lincoln	Deisenhofer, J (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA.	Johann.Deisenhofer@utsouthwestern.edu	Labunskyy, Vyacheslav/AAC-8489-2020; Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Gladyshev, Vadim/0000-0002-0372-7016; Labunskyy, Vyacheslav/0000-0001-9317-1076	NCI NIH HHS [CA080946] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080946] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alanen HI, 2003, J BIOL CHEM, V278, P28912, DOI 10.1074/jbc.M304598200; Anelli T, 2002, EMBO J, V21, P835, DOI 10.1093/emboj/21.4.835; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; Brockmann C, 2004, STRUCTURE, V12, P1645, DOI 10.1016/j.str.2004.06.021; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delano W.L, 2002, PYMOL USERS MANUAL; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Fomenko DE, 2003, BIOCHEMISTRY-US, V42, P11214, DOI 10.1021/bi034459s; Frickel EM, 2002, P NATL ACAD SCI USA, V99, P1954, DOI 10.1073/pnas.042699099; Gladyshev VN, 1998, J BIOL CHEM, V273, P8910, DOI 10.1074/jbc.273.15.8910; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Habeck Michael, 2004, Methods Mol Biol, V278, P379; HILL KE, 1992, BIOCHEM BIOPH RES CO, V185, P260, DOI 10.1016/S0006-291X(05)80984-2; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Holm L, 2000, BIOINFORMATICS, V16, P566, DOI 10.1093/bioinformatics/16.6.566; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; Huber-Wunderlich M, 1998, FOLD DES, V3, P161, DOI 10.1016/S1359-0278(98)00024-8; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; Ip C, 2002, CANCER METAST REV, V21, P281, DOI 10.1023/A:1021263027659; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korotkov KV, 2002, MOL CELL BIOL, V22, P1402, DOI 10.1128/MCB.22.5.1402-1411.2002; Korotkov KV, 2001, J BIOL CHEM, V276, P15330, DOI 10.1074/jbc.M009861200; Kryukov GV, 2004, EMBO REP, V5, P538, DOI 10.1038/sj.embor.7400126; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Labunskyy VM, 2005, J BIOL CHEM, V280, P37839, DOI 10.1074/jbc.M508685200; Lappi AK, 2004, J MOL BIOL, V335, P283, DOI 10.1016/j.jmb.2003.10.051; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Martin-Romero FJ, 2001, J BIOL CHEM, V276, P29798, DOI 10.1074/jbc.M100422200; Meunier L, 2002, MOL BIOL CELL, V13, P4456, DOI 10.1091/mbc.E02-05-0311; Mossner E, 1998, PROTEIN SCI, V7, P1233; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Poirot O, 2004, NUCLEIC ACIDS RES, V32, pW37, DOI 10.1093/nar/gkh382; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; Qi Y, 2005, PROTEINS, V58, P376, DOI 10.1002/prot.20329; SAARINEN M, 1995, STRUCTURE, V3, P1097, DOI 10.1016/S0969-2126(01)00245-3; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Su D, 2005, J BIOL CHEM, V280, P26491, DOI 10.1074/jbc.M503638200; Su D, 2004, BIOCHEMISTRY-US, V43, P12177, DOI 10.1021/bi048478t; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009; Zhang ZH, 1997, BIOL TRACE ELEM RES, V57, P147, DOI 10.1007/BF02778198; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	55	153	159	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3536	3543		10.1074/jbc.M511386200	http://dx.doi.org/10.1074/jbc.M511386200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16319061	hybrid, Green Published			2022-12-27	WOS:000235128200064
J	Lee, CH; Kim, HJ; Lee, JH; Cho, HJ; Kim, J; Chung, KC; Jung, S; Paik, SR				Lee, CH; Kim, HJ; Lee, JH; Cho, HJ; Kim, J; Chung, KC; Jung, S; Paik, SR			Dequalinium-induced protofibril formation of alpha-synuclein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA COMPONENT; PROTEIN-KINASE-C; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; IN-VITRO; INHIBITS FIBRILLATION; SELF-OLIGOMERIZATION; PRECURSOR PROTEIN; AMYLOID FORMATION; LEWY BODIES	alpha- Synuclein is the major constituent of Lewy bodies, a pathological signature of Parkinson disease, found in the degenerating dopaminergic neurons of the substantia nigra pars compacta. Amyloidosis generating the insoluble fibrillar protein deposition has been considered to be responsible for the cell death observed in the neurodegenerative disorder. In order to develop a controlling strategy toward the amyloid formation, 1,1 -( 1,10- decanediyl)- bis-[ 4- amino2- methylquinolinium] ( dequalinium), was selected and examined in terms of its specific molecular interaction with alpha- synuclein. The protein was self- oligomerized by dequalinium, which gave rise to the ladder formation on N-[ 2- hydroxy- 1,1bis( hydroxymethyl) ethyl] glycine/ SDS- PAGE in the presence of a coupling reagent of N-( ethoxycarbonyl)- 2- ethoxy- 1,2- dihydroquinoline. The double- headed structure of dequalinium with the two cationic 4- aminoquinaldinium rings was demonstrated to be critical for the protein self- oligomerization. The dequalinium-binding site was located on the acidic C- terminal region of the protein with an approximate dissociation constant of 5.5 mu M. The protein self- oligomerization induced by the compound has resulted in the protofibril formation of alpha- synuclein before it has developed into amyloids. The protofibrils were demonstrated to affect the membrane intactness of liposomes, and they have also been shown to influence cell viability of human neuroblastoma cells. In addition, dequalinium treatment of the alpha- synuclein- overexpressing cells exerted a significant cell death. Therefore, it is pertinent to consider that dequalinium could be used as amolecular probe to assess toxic mechanisms related to the amyloid formation of alpha- synuclein. Ultimately, the compound could be employed to develop therapeutic and preventive strategies toward alpha- synucleinopathies including Parkinson disease.	Seoul Natl Univ, Sch Chem & Biol Engn, Coll Engn, Seoul 151744, South Korea; Inha Univ, Dept Biochem, Coll Med, Inchon 402751, South Korea; Yonsei Univ, Dept Microbiol, Coll Med, Seoul 120752, South Korea; Yonsei Univ, Dept Biol, Coll Sci, Seoul 120752, South Korea; Konkuk Univ, Dept Microbial Engn, Seoul 143701, South Korea; Konkuk Univ, Biomol Binformat Ctr, Seoul 143701, South Korea	Seoul National University (SNU); Inha University; Yonsei University; Yonsei University Health System; Yonsei University; Konkuk University; Konkuk University	Paik, SR (corresponding author), Seoul Natl Univ, Sch Chem & Biol Engn, Coll Engn, San 56-1, Seoul 151744, South Korea.	srpaik@snu.ac.kr		Kim, Jongsun/0000-0002-3149-669X				Bernstein SL, 2004, J AM SOC MASS SPECTR, V15, P1435, DOI 10.1016/j.jasms.2004.05.003; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BODDEN WL, 1986, BIOCHEM BIOPH RES CO, V135, P574, DOI 10.1016/0006-291X(86)90032-X; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chesebro B, 2005, SCIENCE, V308, P1435, DOI 10.1126/science.1110837; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dickson DW, 2001, CURR OPIN NEUROL, V14, P423, DOI 10.1097/00019052-200108000-00001; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Kim J, 1997, MOL CELLS, V7, P78; Kim YS, 2001, BRAIN RES, V908, P93, DOI 10.1016/S0006-8993(01)02575-6; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee D, 2002, J NEUROCHEM, V82, P1007, DOI 10.1046/j.1471-4159.2002.01024.x; Lee D, 2001, EUR J BIOCHEM, V268, P295, DOI 10.1046/j.1432-1327.2001.01877.x; Lee EN, 2004, BIOCHEMISTRY-US, V43, P3704, DOI 10.1021/bi0356707; Lee JH, 1998, NEUROCHEM RES, V23, P1427, DOI 10.1023/A:1020711025418; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lee SS, 2003, NEUROBIOL AGING, V24, P687, DOI 10.1016/S0197-4580(02)00196-3; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Li J, 2004, CHEM BIOL, V11, P1513, DOI 10.1016/j.chembiol.2004.08.025; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Paik SR, 1997, ARCH BIOCHEM BIOPHYS, V344, P325, DOI 10.1006/abbi.1997.0207; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; Paik SR, 2003, FEBS LETT, V537, P63, DOI 10.1016/S0014-5793(03)00081-4; Paik SR, 1998, FEBS LETT, V421, P73, DOI 10.1016/S0014-5793(97)01537-8; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; Qin DH, 2000, J MED CHEM, V43, P1413, DOI 10.1021/jm990340z; ROTENBERG SA, 1990, CANCER RES, V50, P677; Serpell LC, 1997, CELL MOL LIFE SCI, V53, P871, DOI 10.1007/s000180050107; Shin HJ, 2000, BBA-PROTEIN STRUCT M, V1481, P139, DOI 10.1016/S0167-4838(00)00106-0; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Sullivan RM, 2000, MOL PHARMACOL, V58, P729, DOI 10.1124/mol.58.4.729; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Uversky VN, 2001, FEBS LETT, V500, P105, DOI 10.1016/S0014-5793(01)02597-2; Uversky VN, 2001, FEBS LETT, V509, P31, DOI 10.1016/S0014-5793(01)03121-0; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; WEISS MJ, 1987, P NATL ACAD SCI USA, V84, P5444, DOI 10.1073/pnas.84.15.5444; Wersinger C, 2003, NEUROSCI LETT, V342, P124, DOI 10.1016/S0304-3940(03)00212-X; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795; Zhu M, 2004, J BIOL CHEM, V279, P26846, DOI 10.1074/jbc.M403129200; ZHUO SQ, 1988, BIOCHEM BIOPH RES CO, V152, P968, DOI 10.1016/S0006-291X(88)80378-4; ZHUO SQ, 1993, BIOCHEMISTRY-US, V32, P2219, DOI 10.1021/bi00060a013; Zourlidou A, 2003, NEUROSCI LETT, V340, P234, DOI 10.1016/S0304-3940(03)00081-8	74	24	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3463	3472		10.1074/jbc.M505307200	http://dx.doi.org/10.1074/jbc.M505307200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16330551	hybrid			2022-12-27	WOS:000235128200056
J	Leuranguer, V; Papadopoulos, S; Beam, KG				Leuranguer, V; Papadopoulos, S; Beam, KG			Organization of calcium channel beta(1a) subunits in triad junctions in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR BETA-1A SUBUNIT; DIHYDROPYRIDINE RECEPTOR; CA2+ CURRENT; ABSENCE; COMPLEX; DOMAIN; INVOLVEMENT; COMPONENTS; TERMINUS	In skeletal muscle, dihydropyridine receptors ( DHPRs) in the plasma membrane interact with the type 1 ryanodine receptor ( RyR1) at junctions with the sarcoplasmic reticulum. This interaction organizes junctional DHPRs into groups of four termed tetrads. In addition to the principle alpha(1S) subunit, the beta(1a) subunit of the DHPR is also important for the interaction with RyR1. To probe this interaction, we measured fluorescence resonance energy transfer ( FRET) of beta(1a) subunits labeled with cyan fluorescent protein ( CFP) and/ or yellow fluorescent protein ( YFP). Expressed in dysgenic (alpha(1S)- null) myotubes, YFP-beta(1a)- CFP and CFP- beta(1a)- YFP were diffusely distributed in the cytoplasm and highly mobile as indicated by fluorescence recovery after photobleaching. Thus, beta(1a) does not appear to bind to other cellular proteins in the absence of alpha(1S). FRET efficiencies for these cytoplasmic beta(1a) subunits were similar to 6 - 7%, consistent with the idea that < 10 nm separates the N and C termini. After coexpression with unlabeled alpha(1S) ( in dysgenic or beta(1)- null myotubes), both constructs produced discrete fluorescent puncta, which correspond to assembled DHPRs in junctions and that did not recover after photobleaching. In beta(1)- null myotubes, FRET efficiencies of doubly labeled beta(1a) in puncta were similar to those of the same constructs diffusely distributed in the cytoplasm and appeared to arise intramolecularly, since no FRET was measured when mixtures of singly labeled beta(1a) ( CFP or YFP at the N or C terminus) were expressed in beta 1- null myotubes. Thus, DHPRs in tetrads may be arranged such that the N and C termini of adjacent beta(1a) subunits are located > 10 nm from one another.	Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA; Hannover Med Sch, D-30625 Hannover, Germany	Colorado State University; Hannover Medical School	Beam, KG (corresponding author), Colorado State Univ, Dept Biomed Sci, 1617 Campus Delivery, Ft Collins, CO 80523 USA.	kbeam@lamar.colostate.edu						Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Beam KG, 1997, METHOD CELL BIOL, V52, P283, DOI 10.1016/S0091-679X(08)60384-2; Beurg M, 1999, BIOPHYS J, V76, P1744, DOI 10.1016/S0006-3495(99)77336-4; Beurg M, 1999, BIOPHYS J, V77, P2953, DOI 10.1016/S0006-3495(99)77128-6; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; Neuhuber B, 1998, P NATL ACAD SCI USA, V95, P5015, DOI 10.1073/pnas.95.9.5015; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Paolini C, 2004, J MOL BIOL, V342, P145, DOI 10.1016/j.jmb.2004.07.035; Papadopoulos S, 2004, J BIOL CHEM, V279, P44046, DOI 10.1074/jbc.M405317200; Sheridan DC, 2004, BIOPHYS J, V87, P929, DOI 10.1529/biophysj.104.043810; SIEGEL RM, 2000, SCI STKE, pPL1; Strube C, 1996, BIOPHYS J, V71, P2531, DOI 10.1016/S0006-3495(96)79446-8; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Wolf M, 2003, J MOL BIOL, V332, P171, DOI 10.1016/S0022-2836(03)00899-4	18	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3521	3527		10.1074/jbc.M509566200	http://dx.doi.org/10.1074/jbc.M509566200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16317008	hybrid			2022-12-27	WOS:000235128200062
J	Peignon, G; Thenet, S; Schreider, C; Fouquet, S; Ribeiro, A; Dussaulx, E; Chambaz, J; Cardot, P; Pincon-Raymond, M; Le Beyec, J				Peignon, G; Thenet, S; Schreider, C; Fouquet, S; Ribeiro, A; Dussaulx, E; Chambaz, J; Cardot, P; Pincon-Raymond, M; Le Beyec, J			E-cadherin-dependent transcriptional control of apolipoprotein A-IV gene expression in intestinal epithelial cells - A role for the hepatic nuclear factor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-CADHERIN; EXTRACELLULAR-MATRIX; PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIAL EXPRESSION; SUCRASE-ISOMALTASE; DOWN-REGULATION; MESSENGER-RNA; CACO-2 CELLS; FACTOR HNF-4	Cell-matrix and cell-cell adhesion play a central role in the control of cell proliferation, differentiation, and gene expression. Integrins and E- cadherin are the key components involved in these processes in epithelial cells. We recently showed that integrin-dependent adhesion to the extracellular matrix reinforces the formation of E-cadherin-actin complexes inducing the polarization of Caco-2 enterocytes and increases the expression of a marker of enterocyte differentiation, the apolipoprotein A-IV (apoA-IV) gene. By impairing or enhancing E-cadherin-dependent cell adhesion, we demonstrate in the present study its involvement in the transcriptional activation of the apoA-IV gene in Caco- 2 cells. This control requires the regulatory sequence that we have previously identified as necessary and sufficient to drive and restrict apoA-IV gene expression in enterocytes in vivo. Furthermore, using chimeric E-cadherin-Fc homophilic ligand-coated surfaces, we show that a direct activation of E-cadherin triggers the transcriptional activation of the apoA-IV promoter. Finally, E- cadherin- dependent cellcell adhesion controls the nuclear abundance of the transcription factor hepatic nuclear factor 4 alpha, which is involved in the enterocytespecific expression of apoA- IV gene. Altogether, our results suggest that E-cadherin controls enterocyte- specific expression of genes, such as the apoA-IV gene, through the control of hepatic nuclear factor 4 alpha nuclear abundance.	Univ Paris 06, INSERM, UMRS 505, F-75006 Paris, France; Ecole Prat Hautes Etud, Pharmacol Cellulaire & Mol Lab, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE)	Le Beyec, J (corresponding author), Univ Paris 06, INSERM, UMRS 505, 15 Rue Ecole Med, F-75006 Paris, France.	jlebihan@bhdc.jussieu.fr	Ribeiro, Agnès/Q-9702-2017; Thenet, Sophie/GQY-5726-2022	Ribeiro, Agnès/0000-0003-2063-6084; Thenet, Sophie/0000-0002-0336-2942; Le Beyec - Le Bihan, johanne/0000-0002-5647-2002				Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; [Anonymous], 2001, NUCL RECEPTORS GENET; Archer A, 2005, MOL ENDOCRINOL, V19, P2320, DOI 10.1210/me.2004-0462; Beaulieu JF, 1997, PROG HISTOCHEM CYTOC, V31, P1; BEAULIEU JF, 1999, FRONT BIOSCI, V4, P310; Bissell MJ, 1999, CANCER RES, V59, p1757S; Booth C, 2000, J CLIN INVEST, V105, P1493, DOI 10.1172/JCI10229; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Carriere V, 2005, J BIOL CHEM, V280, P5406, DOI 10.1074/jbc.M408002200; CHANTRET I, 1994, J CELL SCI, V107, P213; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DARMOUL D, 1992, J BIOL CHEM, V267, P4824; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Escaffit F, 2005, EXP CELL RES, V302, P206, DOI 10.1016/j.yexcr.2004.08.033; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; Fouquet S, 2004, J BIOL CHEM, V279, P43061, DOI 10.1074/jbc.M405095200; Gavard J, 2004, J BIOL CHEM, V279, P36795, DOI 10.1074/jbc.M401705200; GeorgeWeinstein M, 1997, DEV BIOL, V185, P14, DOI 10.1006/dbio.1997.8542; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Hirokane H, 2004, J BIOL CHEM, V279, P45685, DOI 10.1074/jbc.M404255200; Hirota K, 2003, J BIOL CHEM, V278, P13056, DOI 10.1074/jbc.C200553200; Hodin R A, 1997, J Gastrointest Surg, V1, P433, DOI 10.1016/S1091-255X(97)80130-8; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOLT CE, 1994, P NATL ACAD SCI USA, V91, P10844, DOI 10.1073/pnas.91.23.10844; Hong YH, 2003, J BIOL CHEM, V278, P27495, DOI 10.1074/jbc.M304112200; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Kandikonda S, 1996, CELL ADHES COMMUN, V4, P13, DOI 10.3109/15419069609010760; Kedinger M, 1998, PHILOS T R SOC B, V353, P847, DOI 10.1098/rstb.1998.0249; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; KNUDSEN KA, 1990, EXP CELL RES, V188, P175, DOI 10.1016/0014-4827(90)90157-6; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lambert M, 2000, J CELL SCI, V113, P2207; Laprise P, 2002, J BIOL CHEM, V277, P8226, DOI 10.1074/jbc.M110235200; Le Beyec J, 1999, J BIOL CHEM, V274, P4954, DOI 10.1074/jbc.274.8.4954; LeBeyec J, 1997, EXP CELL RES, V236, P311; Leclerc I, 2001, DIABETES, V50, P1515, DOI 10.2337/diabetes.50.7.1515; Lelievre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lussier C, 2000, MICROSC RES TECHNIQ, V51, P169; Mariadason JM, 2001, CANCER RES, V61, P3465; MEGE RM, 1992, J CELL SCI, V103, P897; Orian-Rousseau V, 1998, J CELL SCI, V111, P1993; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Parviz F, 2002, GENESIS, V32, P130, DOI 10.1002/gene.10058; PINTO M, 1983, BIOL CELL, V47, P323; Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Rodolosse A, 1998, BIOCHEM J, V336, P115, DOI 10.1042/bj3360115; Ruse MD, 2002, MOL CELL BIOL, V22, P1626, DOI 10.1128/MCB.22.6.1626-1638.2002; Sauvaget D, 2002, J BIOL CHEM, V277, P34540, DOI 10.1074/jbc.M206074200; Schreider C, 2002, J CELL SCI, V115, P543; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; TELLER IC, 2001, EXPERT REV MOL MED, P1; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yamada A, 2004, GENES CELLS, V9, P843, DOI 10.1111/j.1365-2443.2004.00768.x; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 2003, J CELL BIOL, V160, P11, DOI 10.1083/jcb.200208156; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	79	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3560	3568		10.1074/jbc.M506360200	http://dx.doi.org/10.1074/jbc.M506360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16338932	hybrid			2022-12-27	WOS:000235128200067
J	Ying, MY; Xu, R; Wu, XH; Zhu, HX; Zhuang, Y; Han, M; Xu, T				Ying, MY; Xu, R; Wu, XH; Zhu, HX; Zhuang, Y; Han, M; Xu, T			Sodium butyrate ameliorates histone hypoacetylation and neurodegenerative phenotypes in a mouse model for DRPLA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; BULBAR MUSCULAR-ATROPHY; CREB-BINDING PROTEIN; HUNTINGTONS-DISEASE; EXPANDED POLYGLUTAMINE; REPRESSES TRANSCRIPTION; MICE; DEACETYLASE; REPEATS; PATHOGENESIS	Dentatorubral-pallidoluysian atrophy ( DRPLA) is a progressive neurodegenerative disease caused by polyglutamine expansion within the Atrophin-1 protein. To study the mechanism of this disease and to test potential therapeutic methods, we established Atro-118Q transgenic mice, which express in neurons a mutant human Atrophin-1 protein that contains an expanded stretch of 118 glutamines. Consistent with the results from previous studies on transgenic mice that expressed mutant Atrophin-1 with 65 glutamines, Atro-118Q mice exhibited several neurodegenerative phenotypes that are commonly seen in DRPLA patients, including ataxia, tremors, and other motor defects. Overexpression of wild-type human Atrophin-1 could not rescue the motor and survival defects in Atro-118Q mice, indicating that the mutant protein with polyglutamine expansion does not simply function in a dominant negative manner. Biochemical analysis of Atro-118Q mice revealed hypoacetylation of histone H3 in brain tissues and thus suggested that global gene repression is an underlying mechanism for neurodegeneration in this mouse model. We further show that intraperitoneal administration of sodium butyrate, a histone deacetylase inhibitor, ameliorated the histone acetylation defects, significantly improved motor performance, and extended the average life span of Atro-118Q mice. These results support the hypothesis that transcription deregulation plays an important role in the pathogenesis of polyglutamine expansion diseases and suggest that reversion of transcription repression with small molecules such as sodium butyrate is a feasible approach to treating DRPLA symptoms.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Fudan Univ, Inst Dev Biol & Mol Med, Morgan Tan Int Ctr Life Sci, Shanghai 200433, Peoples R China; Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Howard Hughes Medical Institute; Yale University; Yale University; Fudan University; Duke University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Xu, T (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 295 Congress Ave,BCMM236, New Haven, CT 06510 USA.	tian.xu@yale.edu		zhuang, yuan/0000-0002-2964-3654				Adachi H, 2003, J NEUROSCI, V23, P2203; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Becher MW, 1997, MOVEMENT DISORD, V12, P519, DOI 10.1002/mds.870120408; Bodai L, 2003, CURR MED CHEM, V10, P2577, DOI 10.2174/0929867033456530; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, P53; Dunah AW, 2002, SCIENCE, V296, P2238, DOI 10.1126/science.1072613; Ferrante RJ, 2003, J NEUROSCI, V23, P9418; Hockly E, 2003, P NATL ACAD SCI USA, V100, P2041, DOI 10.1073/pnas.0437870100; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Lalonde R, 1996, NEUROBIOL LEARN MEM, V65, P113, DOI 10.1006/nlme.1996.0013; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Li SH, 2002, MOL CELL BIOL, V22, P1277, DOI 10.1128/MCB.22.5.1277-1287.2002; Luthi-Carter R, 2002, HUM MOL GENET, V11, P1927, DOI 10.1093/hmg/11.17.1927; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Minamiyama M, 2004, HUM MOL GENET, V13, P1183, DOI 10.1093/hmg/ddh131; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NAGY A, 2002, MANIPULATING MOUSE E, P289; NAITO H, 1982, NEUROLOGY, V32, P798, DOI 10.1212/WNL.32.8.798; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; ONODERA O, 1995, AM J HUM GENET, V57, P1050; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ross CA, 1998, PROG BRAIN RES, V117, P397; Ross CA, 1997, BRAIN PATHOL, V7, P1003, DOI 10.1111/j.1750-3639.1997.tb00898.x; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Sakata T, 1993, Rinsho Shinkeigaku, V33, P777; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; Sato T, 1999, HUM MOL GENET, V8, P99, DOI 10.1093/hmg/8.1.99; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Schilling G, 2001, NEUROBIOL DIS, V8, P405, DOI 10.1006/nbdi.2001.0385; Shahbazian MD, 2002, NEURON, V35, P243, DOI 10.1016/S0896-6273(02)00768-7; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Takahashi H, 1999, Rinsho Shinkeigaku, V39, P1279; Takeda S, 1992, No To Shinkei, V44, P111; UYAMA E, 1995, J NEUROL SCI, V130, P146, DOI 10.1016/0022-510X(95)00019-X; VAN LC, 1996, GENE EXPRESSION, V5, P245; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Yanagisawa H, 2000, HUM MOL GENET, V9, P1433, DOI 10.1093/hmg/9.9.1433; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4; Zoltewicz JS, 2004, DEVELOPMENT, V131, P3, DOI 10.1242/dev.00908	51	72	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	2006	281	18					12580	12586		10.1074/jbc.M511677200	http://dx.doi.org/10.1074/jbc.M511677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	037GI	16407196	hybrid			2022-12-27	WOS:000237134700047
J	DeLisser, HM; Helmke, BP; Cao, GY; Egan, PM; Taichman, D; Fehrenbach, M; Zaman, A; Cui, Z; Mohan, GS; Baldwin, HS; Davies, PF; Savani, RC				DeLisser, HM; Helmke, BP; Cao, GY; Egan, PM; Taichman, D; Fehrenbach, M; Zaman, A; Cui, Z; Mohan, GS; Baldwin, HS; Davies, PF; Savani, RC			Loss of PECAM-1 function impairs alveolarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; PLATELET; THALIDOMIDE; INHIBITION; EXPRESSION; MIGRATION; SURVIVAL	The final stage of lung development in humans and rodents occurs principally after birth and involves the partitioning of the large primary saccules into smaller air spaces by the inward protrusion of septae derived from the walls of the saccules. Several observations in animal models implicate angiogenesis as critical to this process of alveolarization, but all anti-angiogenic treatments examined to date have resulted in endothelial cell (EC) death. We therefore targeted the function of platelet endothelial cell adhesion molecule, (PECAM-1), an EC surface molecule that promotes EC migration and has been implicated in in vivo angiogenesis. Administration of an anti-PECAM-1 antibody that inhibits EC migration, but not proliferation or survival in vitro, disrupted normal alveolar septation in neonatal rat pups without reducing EC content. Three-dimensional reconstruction of lungs showed that pups treated with a blocking PECAM-1 antibody had remodeling of more proximal branches resulting in large tubular airways. Subsequent studies in PECAM-1-null mice confirmed that the absence of PECAM-1 impaired murine alveolarization, without affecting EC content, proliferation, or survival. Further, cell migration was reduced in lung endothelial cells isolated from these mice. These data suggest that the loss of PECAM-1 function compromises postnatal lung development and provide evidence that inhibition of EC function, in contrast to a loss of viable EC, inhibits alveolarization.	Univ Penn, Childrens Hosp Philadelphia, Sch Med,Abramson Res Ctr, Dept Pediat,Div Neonatol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Med,Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat,Div Cardiol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Savani, RC (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med,Abramson Res Ctr, Dept Pediat,Div Neonatol, 3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	rsavani@mail.med.upenn.edu	DeLisser, Horace/AFM-1942-2022; Rashmin C. Savani, MBChB/AAG-2041-2021; Mohan, Gopi/AAP-5976-2020	Rashmin C. Savani, MBChB/0000-0002-9533-5422; 	NHLBI NIH HHS [HL62868, HL62472, HL075930, HL10058] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062868, R01HL075930, R01HL062472, F32HL010058] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albelda SM, 2004, AM J RESP CELL MOL, V31, P246, DOI 10.1165/rcmb.2003-0404OC; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Bowden RA, 2002, CIRC RES, V90, P562, DOI 10.1161/01.RES.0000013835.53611.97; BURRI PH, 1997, LUNG GROWTH DEV, P1035; Cao GY, 2002, AM J PHYSIOL-CELL PH, V282, pC1181, DOI 10.1152/ajpcell.00524.2001; Carrithers M, 2005, AM J PATHOL, V166, P185, DOI 10.1016/S0002-9440(10)62243-2; COALSON JJ, 2000, LUNG BIOL HEALTH DIS, V137, P85; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; COONEY TP, 1982, THORAX, V37, P572, DOI 10.1136/thx.37.8.572; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DeLisser HM, 1997, AM J PATHOL, V151, P671; deMello DE, 1997, AM J RESP CELL MOL, V16, P568, DOI 10.1165/ajrcmb.16.5.9160839; Duncan GS, 1999, J IMMUNOL, V162, P3022; Gao CJ, 2003, BLOOD, V102, P169, DOI 10.1182/blood-2003-01-0003; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Gratzinger D, 2003, FASEB J, V17, P1458, DOI 10.1096/fj.02-1040com; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Ilan N, 2003, CURR OPIN CELL BIOL, V15, P515, DOI 10.1016/S0955-0674(03)00100-5; Jackson DE, 2003, FEBS LETT, V540, P7, DOI 10.1016/S0014-5793(03)00224-2; Jakkula M, 2000, AM J PHYSIOL-LUNG C, V279, pL600, DOI 10.1152/ajplung.2000.279.3.L600; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; Lammert E, 2001, SCIENCE, V294, P564, DOI 10.1126/science.1064344; Maas M, 2005, AM J PHYSIOL-HEART C, V288, pH159, DOI 10.1152/ajpheart.00500.2004; Maniscalco WM, 2002, AM J PHYSIOL-LUNG C, V282, pL811, DOI 10.1152/ajplung.00325.2001; MASSARO D, 1986, AM J PHYSIOL, V251, pR218, DOI 10.1152/ajpregu.1986.251.2.R218; MASSARO D, 1986, ANNU REV PHYSIOL, V58, P73; Massaro GD, 1997, NAT MED, V3, P675, DOI 10.1038/nm0697-675; Massaro GD, 2000, AM J PHYSIOL-LUNG C, V278, pL955, DOI 10.1152/ajplung.2000.278.5.L955; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Nakada MT, 2000, J IMMUNOL, V164, P452, DOI 10.4049/jimmunol.164.1.452; Newman PJ, 2003, ARTERIOSCL THROM VAS, V23, P953, DOI 10.1161/01.ATV.0000071347.69358.D9; O'Brien CD, 2004, AM J PHYSIOL-CELL PH, V287, pC1103, DOI 10.1152/ajpcell.00573.2003; Schachtner SK, 2000, AM J RESP CELL MOL, V22, P157, DOI 10.1165/ajrcmb.22.2.3766; Schenkel AR, 2004, J IMMUNOL, V173, P6403, DOI 10.4049/jimmunol.173.10.6403; Solowiej A, 2003, AM J PATHOL, V162, P953, DOI 10.1016/S0002-9440(10)63890-4; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Thompson RD, 2001, BLOOD, V97, P1854, DOI 10.1182/blood.V97.6.1854; Zhou Z, 1999, Angiogenesis, V3, P181, DOI 10.1023/A:1009092107382	43	73	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 31	2006	281	13					8724	8731		10.1074/jbc.M511798200	http://dx.doi.org/10.1074/jbc.M511798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	025EC	16377626	hybrid			2022-12-27	WOS:000236247100050
J	Forouhar, F; Hussain, M; Farid, R; Benach, J; Abashidze, M; Edstrom, WC; Vorobiev, SM; Xiao, R; Acton, TB; Fu, ZJ; Kim, JJP; Miziorko, HM; Montelione, GT; Hunt, JF				Forouhar, F; Hussain, M; Farid, R; Benach, J; Abashidze, M; Edstrom, WC; Vorobiev, SM; Xiao, R; Acton, TB; Fu, ZJ; Kim, JJP; Miziorko, HM; Montelione, GT; Hunt, JF			Crystal structures of two bacterial 3-hydroxy-3-methylglutaryl-CoA lyases suggest a common catalytic mechanism among a family of TIM barrel metalloenzymes cleaving carbon-carbon bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCURATE DOCKING; MOLECULAR-BASIS; PROTEIN; DEFICIENCY; ALIGNMENT; ACIDURIA; PROGRAM; RESIDUE; PREDICTION; INSIGHTS	The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase catalyzes the terminal steps in ketone body generation and leucine degradation. Mutations in this enzyme cause a human autosomal recessive disorder called primary metabolic aciduria, which typically kills victims because of an inability to tolerate hypoglycemia. Here we present crystal structures of the HMG-CoA lyases from Bacillus subtilis and Brucella melitensis at 2.7 and 2.3 angstrom resolution, respectively. These enzymes share greater than 45% sequence identity with the human orthologue. Although the enzyme has the anticipated triose-phosphate isomerase (TIM) barrel fold, the catalytic center contains a divalent cation-binding site formed by a cluster of invariant residues that cap the core of the barrel, contrary to the predictions of homology models. Surprisingly, the residues forming this cation-binding site and most of their interaction partners are shared with three other TIM barrel enzymes that catalyze diverse carbon-carbon bond cleavage reactions believed to proceed through enolate intermediates (4-hydroxy-2-ketovalerate aldolase, 2-isopropylmalate synthase, and transcarboxylase 5S). We propose the name "DRE-TIM metallolyases" for this newly identified enzyme family likely to employ a common catalytic reaction mechanism involving an invariant Asp-Arg-Glu (DRE) triplet. The Asp ligates the divalent cation, while the Arg probably stabilizes charge accumulation in the enolate intermediate, and the Glu maintains the precise structural alignment of the Asp and Arg. We propose a detailed model for the catalytic reaction mechanism of HMG-CoA lyase based on the examination of previously reported product complexes of other DRE-TIM metallolyases and induced fit substrate docking studies conducted using the crystal structure of human HMG-CoA lyase (reported in the accompanying paper by Fu, et al. (2006) J. Biol. Chem. 281, 7526-7532). Our model is consistent with extensive mutagenesis results and can guide subsequent studies directed at definitive experimental elucidation of this enzyme's reaction mechanism.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Columbia Univ, NE Struct Genom Consortium, New York, NY 10027 USA; Schrodinger Inc, New York, NY 10036 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; NE Struct Genom Consortium, Piscataway, NJ 08854 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Missouri, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	Columbia University; Columbia University; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Medical College of Wisconsin; University of Missouri System; University of Missouri Kansas City	Hunt, JF (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	jfhunt@biology.columbia.edu		Montelione, Gaetano/0000-0002-9440-3059	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM074958, P50GM062413] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM 62413, U54 GM 074958] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cardoso ML, 2004, MOL GENET METAB, V82, P334, DOI 10.1016/j.ymgme.2004.06.003; Casals N, 2003, J BIOL CHEM, V278, P29016, DOI 10.1074/jbc.M304276200; Doublie S, 1996, FEBS LETT, V384, P219, DOI 10.1016/0014-5793(96)00316-X; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Fu ZJ, 2006, J BIOL CHEM, V281, P7526, DOI 10.1074/jbc.M506880200; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s; Hall PR, 2004, EMBO J, V23, P3621, DOI 10.1038/sj.emboj.7600373; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; HRUZ PW, 1993, BIOCHIM BIOPHYS ACTA, V1162, P149, DOI 10.1016/0167-4838(93)90141-D; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jorgensen WL, 2004, SCIENCE, V303, P1813, DOI 10.1126/science.1096361; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kontoyianni M, 2004, J MED CHEM, V47, P558, DOI 10.1021/jm0302997; Koon N, 2004, P NATL ACAD SCI USA, V101, P8295, DOI 10.1073/pnas.0400820101; KRAULIS PJ, 1994, J MOL BIOL, V243, P696, DOI 10.1016/0022-2836(94)90042-6; Krovat EM, 2005, CURR COMPUT-AID DRUG, V1, P93, DOI 10.2174/1573409052952314; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; Manjasetty BA, 2003, P NATL ACAD SCI USA, V100, P6992, DOI 10.1073/pnas.1236794100; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MITCHELL GA, 1995, PRENATAL DIAG, V15, P725, DOI 10.1002/pd.1970150807; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perola E, 2004, PROTEINS, V56, P235, DOI 10.1002/prot.20088; Pie J, 2003, J PHYSIOL BIOCHEM, V59, P311, DOI 10.1007/BF03179889; Pospisilova E, 2003, J INHERIT METAB DIS, V26, P433, DOI 10.1023/A:1025169210121; Puisac B, 2005, BIOPHYS CHEM, V115, P241, DOI 10.1016/j.bpc.2004.12.031; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; Roberts JR, 1996, J BIOL CHEM, V271, P24604, DOI 10.1074/jbc.271.40.24604; ROBERTS JR, 1995, J BIOL CHEM, V270, P17311, DOI 10.1074/jbc.270.29.17311; SHERMAN W, 2006, IN PRESS J MED CHEM; Standley DM, 2001, PROTEINS, P133; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tuinstra RL, 2004, BIOCHEMISTRY-US, V43, P5287, DOI 10.1021/bi0499765; Tuinstra RL, 2003, J BIOL CHEM, V278, P37092, DOI 10.1074/jbc.M304472200; Tuinstra RL, 2002, ARCH BIOCHEM BIOPHYS, V408, P286, DOI 10.1016/S0003-9861(02)00584-2; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Xu L, 2004, J BIOL CHEM, V279, P50555, DOI 10.1074/jbc.M406801200	47	28	29	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					7533	7545		10.1074/jbc.M507996200	http://dx.doi.org/10.1074/jbc.M507996200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BY	16330546	hybrid			2022-12-27	WOS:000236030900075
J	Kontaridis, MI; Swanson, KD; David, FS; Barford, D; Neel, BG				Kontaridis, MI; Swanson, KD; David, FS; Barford, D; Neel, BG			PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; NOONAN-SYNDROME; CRYSTAL-STRUCTURE; LEUKEMIA; MUTANTS; HEART; GENE; DIFFERENTIATION; LEUKEMOGENESIS; VALVULOGENESIS	Multiple lentigines/LEOPARD syndrome (LS) is a rare, autosomal dominant disorder characterized by Lentigines, Electrocardiogram abnormalities, Ocular hypertelorism, Pulmonic valvular stenosis, Abnormalities of genitalia, Retardation of growth, and Deafness. Like the more common Noonan syndrome (NS), LS is caused by germ line missense mutations in PTPN11, encoding the protein-tyrosine phosphatase Shp2. Enzymologic, structural, cell biological, and mouse genetic studies indicate that NS is caused by gain-of-function PTPN11 mutations. Because NS and LS share several features, LS has been viewed as an NS variant. We examined a panel of LS mutants, including the two most common alleles. Surprisingly, we found that in marked contrast to NS, LS mutants are catalytically defective and act as dominant negative mutations that interfere with growth factor/Erk-mitogen-activated protein kinase-mediated signaling. Molecular modeling and biochemical studies suggest that LS mutations contort the Shp2 catalytic domain and result in open, inactive forms of Shp2. Our results establish that the pathogenesis of LS and NS is distinct and suggest that these disorders should be distinguished by mutational analysis rather than clinical presentation.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Neel, BG (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Canc Biol Program, 330 Brookline Ave, Boston, MA 02215 USA.	bneel@bidmc.harvard.edu	Kontaridis, Maria/AAN-9781-2021	Kontaridis, Maria/0000-0002-6121-0533; David, Frank/0000-0002-8025-4427	PHS HHS [R37 49152] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLANSON JE, 1985, AM J MED GENET, V21, P507, DOI 10.1002/ajmg.1320210313; Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Armstrong EJ, 2004, CIRC RES, V95, P459, DOI 10.1161/01.RES.0000141146.95728.da; Barford D, 1998, STRUCTURE, V6, P249, DOI 10.1016/S0969-2126(98)00027-6; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Denu JM, 1996, CELL, V87, P361, DOI 10.1016/S0092-8674(00)81356-2; Digilio MC, 2002, AM J HUM GENET, V71, P389, DOI 10.1086/341528; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; GORLIN RJ, 1969, AM J DIS CHILD, V117, P652, DOI 10.1001/archpedi.1969.02100030654006; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Keren B, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.021451; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Krenz M, 2005, CIRC RES, V97, P813, DOI 10.1161/01.RES.0000186194.06514.b0; Lakkis MM, 1998, DEVELOPMENT, V125, P4359; Legius E, 2002, J MED GENET, V39, P571, DOI 10.1136/jmg.39.8.571; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Merks JHM, 2005, AM J MED GENET A, V134A, P132, DOI 10.1002/ajmg.a.30603; MOHI MG, 2005, CANCER CELL, V7, P1; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Niihori T, 2005, J HUM GENET, V50, P192, DOI 10.1007/s10038-005-0239-7; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Pannifer ADB, 1998, J BIOL CHEM, V273, P10454, DOI 10.1074/jbc.273.17.10454; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Salvi M, 2004, CELL MOL LIFE SCI, V61, P2393, DOI 10.1007/s00018-004-4211-z; Sarkozy A, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.013466; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schoenwaelder SM, 2000, CURR BIOL, V10, P1523, DOI 10.1016/S0960-9822(00)00831-9; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; Tartaglia M, 2004, BLOOD, V104, P307, DOI 10.1182/blood-2003-11-3876; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002	42	225	235	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6785	6792		10.1074/jbc.M513068200	http://dx.doi.org/10.1074/jbc.M513068200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16377799	hybrid			2022-12-27	WOS:000236030800077
J	Tang, J; Hu, G; Hanai, J; Yadlapalli, G; Lin, YF; Zhang, B; Galloway, J; Bahary, N; Sinha, S; Thisse, B; Thisse, C; Jin, JP; Zon, LI; Sukhatme, VP				Tang, J; Hu, G; Hanai, J; Yadlapalli, G; Lin, YF; Zhang, B; Galloway, J; Bahary, N; Sinha, S; Thisse, B; Thisse, C; Jin, JP; Zon, LI; Sukhatme, VP			A critical role for calponin 2 in vascular development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; ZEBRAFISH EMBRYOS; EXPRESSION; H2-CALPONIN; BINDING; CLONING; VASCULOGENESIS	Calponin 2 (h2 calponin, CNN2) is an actin-binding protein implicated in cytoskeletal organization. We have found that the expression of calponin 2 is relatively restricted to vasculature from 16 to 30 h post-fertilization during zebrafish ( Danio rerio) development. Forty-eight hours after injecting antisense morpholino oligos against calponin 2 into embryos at the 1 - 4-cell stage, zebrafish demonstrated various cardiovascular defects, including sluggish axial and head circulation, absence of circulation in intersegmental vessels and in the dorsal longitudinal anastomotic vessel, enlarged cerebral ventricles, and pericardial edema, in addition to an excess bending, spiraling tail and twisting of the caudal fin. Knockdown of calponin 2 in the Tg(fli1: EGFP)(y1) zebrafish line ( in which a fli1 promoter drives vascular-specific enhanced green fluorescent protein expression) indicated that diminished calponin 2 expression blocked the proper migration of endothelial cells during formation of intersegmental vessels. In vitro studies showed that basic fibroblast growth factor-induced human umbilical vein endothelial cell migration was down-regulated by knockdown of calponin 2 expression using an antisense adenovirus, and overexpression of calponin 2 enhanced migration and hastened wound healing. These events were correlated with activation of mitogen-activated protein kinase; moreover, inhibition of this pathway blocked the promigratory effect of calponin 2. Collectively, these data suggest that calponin 2 plays an important role in the migration of endothelial cells both in vivo and in vitro and that its expression is critical for proper vascular development.	Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Ctr Study Tumor Microenvironm, Boston, MA 02215 USA; Childrens Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; Univ Strasbourg 1, INSERM, CNRS, Inst Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU de Strasbour, France; Northwestern Univ, Feinberg Sch Med, Evanston Northwestern Healthcare, Sect Mol Cardiol, Evanston, IL 60201 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15261 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Boston Children's Hospital; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; NorthShore University Health System; Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sukhatme, VP (corresponding author), Beth Israel Deaconess Med Ctr, Div Renal, 330 Brookline Ave,RW 563, Boston, MA 02215 USA.	vsukhatm@bidmc.harvard.edu	Sukhatme, Vikas/W-2776-2019	Jin, JP/0000-0001-9932-1063; THISSE, Christine/0000-0002-8684-1681				Abr?moff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; Childs S, 2002, DEVELOPMENT, V129, P973; Danninger C, 2000, J CELL SCI, V113, P3725; ElMezgueldi M, 1996, BIOCHEMISTRY-US, V35, P3654, DOI 10.1021/bi952027e; Fujii T, 1997, J BIOCHEM, V122, P344; Fukui Y, 1997, J DERMATOL SCI, V14, P29, DOI 10.1016/S0923-1811(96)00545-2; Galloway JL, 2005, DEV CELL, V8, P109, DOI 10.1016/j.devcel.2004.12.001; GIMONA M, 1996, BIOCH SMOOTH MUSCLE, P91; Graceffa P, 1996, J BIOL CHEM, V271, P30336, DOI 10.1074/jbc.271.48.30336; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hossain MM, 2005, J BIOL CHEM, V280, P42442, DOI 10.1074/jbc.M509952200; Hossain MM, 2003, AM J PHYSIOL-CELL PH, V284, pC156, DOI 10.1152/ajpcell.00233.2002; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Je HD, 2001, J PHYSIOL-LONDON, V537, P567, DOI 10.1111/j.1469-7793.2001.00567.x; Jin JP, 2003, PROTEIN EXPRES PURIF, V31, P231, DOI 10.1016/S1046-5928(03)00185-2; JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Lee P, 2002, P NATL ACAD SCI USA, V99, P10470, DOI 10.1073/pnas.162366299; Leinweber B, 2000, J BIOL CHEM, V275, P40329, DOI 10.1074/jbc.M008257200; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Liang D, 1998, BBA-GENE STRUCT EXPR, V1397, P14, DOI 10.1016/S0167-4781(97)00233-9; Lyons MS, 1998, DEV DYNAM, V212, P133, DOI 10.1002/(SICI)1097-0177(199805)212:1<133::AID-AJA12>3.0.CO;2-8; Mabuchi K, 1997, J BIOL CHEM, V272, P22662, DOI 10.1074/jbc.272.36.22662; Masuda H, 1996, J BIOCHEM-TOKYO, V120, P415; Menice CB, 1997, J BIOL CHEM, V272, P25157, DOI 10.1074/jbc.272.40.25157; Morgan KG, 2001, J APPL PHYSIOL, V91, P953, DOI 10.1152/jappl.2001.91.2.953; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; Ransom DG, 1996, DEVELOPMENT, V123, P311; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Roman BL, 2000, BIOESSAYS, V22, P882; Sakihara C, 1996, BIOCHEM BIOPH RES CO, V222, P195, DOI 10.1006/bbrc.1996.0721; Samaj J, 2004, J EXP BOT, V55, P189, DOI 10.1093/jxb/erh012; Seth P, 2005, BIOCHEM BIOPH RES CO, V332, P533, DOI 10.1016/j.bbrc.2005.03.250; Szymanski PT, 1997, BIOCHEM J, V321, P519, DOI 10.1042/bj3210519; SZYMANSKI PT, 1993, FEBS LETT, V334, P378; TAKAHASHI K, 1988, J HYPERTENS, V6, pS40, DOI 10.1097/00004872-198812040-00008; Thisse B, 2004, METHOD CELL BIOL, V77, P505; Thompson MA, 1998, DEV BIOL, V197, P248, DOI 10.1006/dbio.1998.8887; Tsakiridis T, 1998, J BIOL CHEM, V273, P28322, DOI 10.1074/jbc.273.43.28322; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; Westerfield M., 1993, ZEBRAFISH BOOK GUIDE	48	46	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 10	2006	281	10					6664	6672		10.1074/jbc.M506991200	http://dx.doi.org/10.1074/jbc.M506991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	022BX	16317011	hybrid			2022-12-27	WOS:000236030800063
J	Cunningham, P; Afzal-Ahmed, I; Naftalin, RJ				Cunningham, P; Afzal-Ahmed, I; Naftalin, RJ			Docking studies show that D-glucose and quercetin slide through the transporter GLUT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUGAR-TRANSPORT; ISOLATED RAT ADIPOCYTES; DEHYDROASCORBIC ACID; ESCHERICHIA-COLI; BINDING-SITE; 3-DIMENSIONAL STRUCTURE; LACTOSE PERMEASE; MEMBRANE; MODEL; FLAVONOIDS	On a three- dimensional templated model of GLUT1 ( Protein Data Bank code 1SUK), a molecular recognition program, AUTODOCK 3, reveals nine hexose- binding clusters spanning the entire " hydrophilic" channel. Five of these cluster sites are within 3 - 5 angstrom of 10 glucose transporter deficiency syndrome missense mutations. Another three sites are within 8 angstrom of two other missense mutations. D- Glucose binds to five sites in the external channel opening, with increasing affinity toward the pore center and then passes via a narrow channel into an internal vestibule containing four lower affinity sites. An external site, not adjacent to any mutation, also binding phloretin but recognizing neither D- fructose nor L- glucose, may be the main threading site for glucose uptake. Glucose exit from human erythrocytes is inhibited by quercetin ( K-i = 2.4 mu M) but not anionic quercetin- semiquinone. Quercetin influx is retarded by extracellular D- glucose ( 50 mM) but not by phloretin and accelerated by intracellular D- glucose. Quercetin docking sites are absent from the external opening but fill the entire pore center. In the inner vestibule, Glu(254) and Lys(256) hydrogen- bond quercetin ( K-i = 10 mu M) but not quercetin- semiquinone. Consistent with the kinetics, this site also binds D- glucose, so quercetin displacement by glucose could accelerate quercetin influx, whereas quercetin binding here will competitively inhibit glucose efflux. beta- D- Hexoses dock twice as frequently as their alpha- anomers to the 23 aromatic residues in the transport pathway, suggesting that endocyclic hexose hydrogens, as with maltosaccharides in maltoporins, form pi- bonds with aromatic rings and slide between sites instead of being translocated via a single alternating site.	Kings Coll London, Dept Physiol, London SE1 1UL, England; Kings Coll London, London SE1 9NH, England	University of London; King's College London; University of London; King's College London	Naftalin, RJ (corresponding author), Kings Coll London, Dept Physiol, Guys Campus, London SE1 1UL, England.	richard.naftalin@kcl.ac.uk	Naftalin, Richard J/F-1112-2010	Naftalin, Richard/0000-0001-8783-390X				Abramson J, 2003, FEBS LETT, V555, P96, DOI 10.1016/S0014-5793(03)01087-1; Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Afzal I, 2002, BIOCHEM J, V365, P707, DOI 10.1042/BJ20011624; BAKER GF, 1973, J PHYSIOL-LONDON, V231, P143, DOI 10.1113/jphysiol.1973.sp010225; BAKER GF, 1979, BIOCHIM BIOPHYS ACTA, V550, P474, DOI 10.1016/0005-2736(79)90150-0; Barrett MP, 1999, CURR OPIN CELL BIOL, V11, P496, DOI 10.1016/S0955-0674(99)80072-6; Blodgett DM, 2005, BIOCHEMISTRY-US, V44, P2650, DOI 10.1021/bi048247m; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P10411, DOI 10.1021/bi953077m; Cohen NR, 1996, BIOCHEM J, V315, P971, DOI 10.1042/bj3150971; Corchado JC, 2004, J AM CHEM SOC, V126, P7311, DOI 10.1021/ja0398767; Dutzler R, 2002, STRUCTURE, V10, P1273, DOI 10.1016/S0969-2126(02)00811-0; Fernandez MD, 2005, J AM CHEM SOC, V127, P7379, DOI 10.1021/ja051020+; Galati G, 2002, TOXICOLOGY, V177, P91, DOI 10.1016/S0300-483X(02)00198-1; GECK P, 1971, BIOCHIM BIOPHYS ACTA, V241, P462, DOI 10.1016/0005-2736(71)90045-9; Heard KS, 2000, BIOCHEMISTRY-US, V39, P3005, DOI 10.1021/bi991931u; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; JANOSHAZI A, 1993, J MEMBRANE BIOL, V132, P167; Kasahara T, 2000, FEBS LETT, V471, P103, DOI 10.1016/S0014-5793(00)01371-5; Klepper J, 2005, BIOCHEMISTRY-US, V44, P12621, DOI 10.1021/bi051079t; LEFEVRE PG, 1962, AM J PHYSIOL, V203, P286, DOI 10.1152/ajplegacy.1962.203.2.286; Levine KB, 1998, BIOCHEMISTRY-US, V37, P12221, DOI 10.1021/bi980585y; LOWE AG, 1986, BIOCHIM BIOPHYS ACTA, V857, P146, DOI 10.1016/0005-2736(86)90342-1; Martin HJ, 2003, CHEM-BIOL INTERACT, V146, P225, DOI 10.1016/j.cbi.2003.06.001; Metodiewa D, 1999, FREE RADICAL BIO MED, V26, P107, DOI 10.1016/S0891-5849(98)00167-1; MIWA I, 1988, BIOCHEM INT, V16, P111; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mueckler M, 2004, J BIOL CHEM, V279, P46876, DOI 10.1074/jbc.M408632200; Naftalin RJ, 2003, BRIT J PHARMACOL, V140, P487, DOI 10.1038/sj.bjp.0705460; NAFTALIN RJ, 1994, BBA-BIOMEMBRANES, V1191, P65, DOI 10.1016/0005-2736(94)90234-8; Naftalin RJ, 2002, J MEMBRANE BIOL, V186, P113, DOI 10.1007/s00232-001-0140-z; Naftalin RJ, 1997, BBA-BIOMEMBRANES, V1328, P13, DOI 10.1016/S0005-2736(97)00062-X; Park JB, 2000, J NUTR, V130, P1297, DOI 10.1093/jn/130.5.1297; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; SALTER DW, 1978, J MEMBRANE BIOL, V40, P67, DOI 10.1007/BF01909739; Seatter MJ, 1998, BIOCHEMISTRY-US, V37, P1322, DOI 10.1021/bi972322u; Song J, 2002, J BIOL CHEM, V277, P15252, DOI 10.1074/jbc.M110496200; Strobel P, 2005, BIOCHEM J, V386, P471, DOI 10.1042/BJ20040703; Sujatha MS, 2005, BIOCHEMISTRY-US, V44, P8554, DOI 10.1021/bi050298b; Uldry M, 2002, FEBS LETT, V524, P199, DOI 10.1016/S0014-5793(02)03058-2; Van Gelder P, 2002, J BACTERIOL, V184, P2994, DOI 10.1128/JB.184.11.2994-2999.2002; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wang D, 2005, ANN NEUROL, V57, P111, DOI 10.1002/ana.20331	46	87	89	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5797	5803		10.1074/jbc.M509422200	http://dx.doi.org/10.1074/jbc.M509422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16407180	hybrid			2022-12-27	WOS:000235568900058
J	DeRossi, C; Bode, L; Eklund, EA; Zhang, FR; Davis, JA; Westphal, V; Wang, L; Borowsky, AD; Freeze, HH				DeRossi, C; Bode, L; Eklund, EA; Zhang, FR; Davis, JA; Westphal, V; Wang, L; Borowsky, AD; Freeze, HH			Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROLOGOUS EXPRESSION; CLONING; GLYCOSYLATION; HYPOGLYCEMIA; GLYCOLYSIS; DEFICIENCY; METABOLISM; INGESTION; THERAPY; IB	MPI encodes phosphomannose isomerase, which interconverts fructose 6-phosphate and mannose 6-phosphate (Man-6-P), used for glycoconjugate biosynthesis. MPI mutations in humans impair protein glycosylation causing congenital disorder of glycosylation Ib (CDG-Ib), but oral mannose supplements normalize glycosylation. To establish a mannose-responsive mouse model for CDG-Ib, we ablated Mpi and provided dams with mannose to rescue the anticipated defective glycosylation. Surprisingly, although glycosylation was normal, Mpi(-/-) embryos died around E11.5. Mannose supplementation even hastened their death, suggesting that mannose was toxic. Mpi(-/-) embryos showed growth retardation and placental hyperplasia. More than 90% of Mpi(-/-) embryos failed to form yolk sac vasculature, and 35% failed chorioallantoic fusion. We generated primary embryonic fibroblasts to investigate the mechanisms leading to embryonic lethality and found that mannose caused a concentration- and time-dependent accumulation of Man-6-P in Mpi(-/-) fibroblasts. In parallel, ATP decreased by more than 70% after 24 h compared with Mpi(+/+) controls. In cell lysates, Man-6- P inhibited hexokinase (70%), phosphoglucose isomerase (65%), and glucose-6-phosphate dehydrogenase (85%), but not phosphofructokinase. Incubating intact Mpi(-/-) fibroblasts with 2-[H-3]deoxyglucose confirmed mannose-dependent hexokinase inhibition. Our results in vitro suggest that mannose toxicity in Mpi(-/-) embryos is caused by Man-6-P accumulation, which inhibits glucose metabolism and depletes intracellular ATP. This was confirmed in E10.5 Mpi(-/-) embryos where Man-6-P increased more than 10 times, and ATP decreased by 50% compared with Mpi(+/+) littermates. Because Mpi ablation is embryonic lethal, a murine CDG-Ib model will require hypomorphic Mpi alleles.	Burnham Inst Med Res, Glycobiol & Carbohydrate Chem Program, La Jolla, CA 92037 USA; Univ Calif Davis, Davis, CA 95616 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Davis	Freeze, HH (corresponding author), Burnham Inst Med Res, Glycobiol & Carbohydrate Chem Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	hudson@burnham.org	Borowsky, Alexander D/S-5404-2017	Freeze, Hudson/0000-0001-6316-0501	NIDDK NIH HHS [R01 DK 065091] Funding Source: Medline; NIGMS NIH HHS [R01 GM 55695] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055695] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman DM, 2000, GENE DEV, V14, P3191, DOI 10.1101/gad.853700; Alton G, 1997, BIOCHEM MOL MED, V60, P127, DOI 10.1006/bmme.1997.2574; Alton G, 1998, GLYCOBIOLOGY, V8, P285, DOI 10.1093/glycob/8.3.285; Babovic-Vuksanovic D, 1999, J PEDIATR-US, V135, P775, DOI 10.1016/S0022-3476(99)70103-4; BUCHANAN T, 1985, J CLIN INVEST, V75, P1927, DOI 10.1172/JCI111908; COPP AJ, 1995, TRENDS GENET, V11, P87, DOI 10.1016/S0168-9525(00)89008-3; Davis JA, 2002, GLYCOBIOLOGY, V12, P435, DOI 10.1093/glycob/cwf060; Davis JA, 2001, BBA-GEN SUBJECTS, V1528, P116, DOI 10.1016/S0304-4165(01)00183-0; de Lonlay P, 1999, J PEDIATR-US, V135, P379, DOI 10.1016/S0022-3476(99)70139-3; DELAFUENTE M, 1986, BIOCHEM BIOPH RES CO, V140, P51, DOI 10.1016/0006-291X(86)91056-9; DELAFUENTE M, 1988, BRIT J CANCER, V58, P567, DOI 10.1038/bjc.1988.260; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; Freeze HH, 2001, GLYCOBIOLOGY, V11, p129R, DOI 10.1093/glycob/11.12.129R; FREINKEL N, 1984, NEW ENGL J MED, V310, P223, DOI 10.1056/NEJM198401263100404; Harms HK, 2002, ACTA PAEDIATR, V91, P1065, DOI 10.1080/080352502760311566; Joyner AL, 1993, GENE TARGETING PRACT; Kelly A, 1996, DEV DYNAM, V207, P300; Kelly A, 2002, GENESIS, V33, P29, DOI 10.1002/gene.10085; Marquardt T, 2003, EUR J PEDIATR, V162, P359, DOI 10.1007/s00431-002-1136-0; MOORE DCP, 1987, LIFE SCI, V41, P1885, DOI 10.1016/0024-3205(87)90739-9; NICHOLS EA, 1973, BIOCHEM GENET, V8, P47, DOI 10.1007/BF00485556; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Oehler R, 1996, ANAL BIOCHEM, V241, P269, DOI 10.1006/abio.1996.0412; Packer NH, 1998, GLYCOCONJUGATE J, V15, P737, DOI 10.1023/A:1006983125913; PAYTON MA, 1991, J BACTERIOL, V173, P2006, DOI 10.1128/jb.173.6.2006-2010.1991; Pitkanen JP, 2004, J BIOL CHEM, V279, P55737, DOI 10.1074/jbc.M410619200; PROUDFOOT AEI, 1994, EUR J BIOCHEM, V219, P415, DOI 10.1111/j.1432-1033.1994.tb19954.x; Sapin V, 2001, TRANSGENIC RES, V10, P377, DOI 10.1023/A:1012085713898; SMITH DJ, 1995, YEAST, V11, P301, DOI 10.1002/yea.320110402; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; Sola-Penna M, 2002, J BIOCHEM BIOPH METH, V50, P129, DOI 10.1016/S0165-022X(01)00180-4; SOLS A, 1960, SCIENCE, V131, P297, DOI 10.1126/science.131.3396.297; Stanford WL, 2001, NAT REV GENET, V2, P756, DOI 10.1038/35093548; STOCCHI V, 1987, ANAL BIOCHEM, V167, P181, DOI 10.1016/0003-2697(87)90150-3; Westphal V, 2001, MOL GENET METAB, V73, P77, DOI 10.1006/mgme.2001.3161; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	36	64	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5916	5927		10.1074/jbc.M511982200	http://dx.doi.org/10.1074/jbc.M511982200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16339137	hybrid			2022-12-27	WOS:000235568900072
J	Halenius, A; Momburg, F; Reinhard, H; Bauer, D; Lobigs, M; Hengel, H				Halenius, A; Momburg, F; Reinhard, H; Bauer, D; Lobigs, M; Hengel, H			Physical and functional interactions of the cytomegalovirus US6 glycoprotein with the transporter associated with antigen processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; INHIBITS PEPTIDE TRANSLOCATION; ENDOPLASMIC-RETICULUM; VACCINIA VIRUS; PROTEIN ICP47; BINDING-SITE; CELL-LINE; TAP; DOMAINS	The endoplasmic reticulum-resident human cytomegalovirus glycoprotein US6 (gpUS6) inhibits peptide translocation by the transporter associated with antigen processing ( TAP) to prevent loading of major histocompatibility complex class I molecules and antigen presentation to CD8+ T cells. TAP is formed by two subunits, TAP1 and TAP2, each containing one multispanning transmembrane domain (TMD) and a cytosolic nucleotide binding domain. Here we reported that the blockade of TAP by gpUS6 is species-restricted, i.e. gpUS6 inhibits human TAP but not rat TAP. Co-expression of human and rat subunits of TAP demonstrates independent binding of gpUS6 to human TAP1 and TAP2, whereas gpUS6 does not bind to rat TAP subunits. gpUS6 associates with preformed TAP1/2 heterodimers but not with unassembled TAP subunits. To locate domains of TAP required for gpUS6 binding and function, we took advantage of reciprocal human/rat intrachain TAP chimeras. Each TAP subunit forms two contact sites within its TMD interacting with gpUS6. The dominant gpUS6-binding site on TAP2 maps to an N-terminal loop, whereas inhibition of peptide transport is mediated by a C-terminal loop of the TMD. For TAP1, two gpUS6 binding domains are formed by loops of the C-terminal TMD. The domain required for TAP inactivation is built by a distal loop of the C-terminal TMD, indicating a topology of TAP1 comprising 10 endoplasmic reticulum transmembrane segments. By forming multimeric complexes, gpUS6 reaches the distant target domains to arrest peptide transport. The data revealed a nonanalogous multipolar bridging of the TAP TMDs by gpUS6.	Robert Koch Inst, Div Viral Infect, D-13353 Berlin, Germany; German Canc Res Ctr, Div Mol Immunol, D-69120 Heidelberg, Germany; Australian Natl Univ, John Curtin Sch Med Res, Div Immunol & Genet, Acton, ACT 0200, Australia; Univ Dusseldorf, Inst Virol, D-40225 Dusseldorf, Germany	Robert Koch Institute; Helmholtz Association; German Cancer Research Center (DKFZ); Australian National University; John Curtin School of Medical Research; Heinrich Heine University Dusseldorf	Hengel, H (corresponding author), Robert Koch Inst, Div Viral Infect, Nordurfer 20, D-13353 Berlin, Germany.	hartmut.hengel@uni-duesseldorf.de	lobigs, mario/ABC-5711-2020					Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn K, 1996, EMBO J, V15, P3247, DOI 10.1002/j.1460-2075.1996.tb00689.x; ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Armandola EA, 1996, EUR J IMMUNOL, V26, P1748, DOI 10.1002/eji.1830260813; ARNOLD B, 1984, CELL, V38, P79, DOI 10.1016/0092-8674(84)90528-2; Arora S, 2001, P NATL ACAD SCI USA, V98, P7241, DOI 10.1073/pnas.131132198; Atalay R, 2002, J VIROL, V76, P8596, DOI 10.1128/JVI.76.17.8596-8608.2002; BANKS TA, 1994, VIROLOGY, V200, P236, DOI 10.1006/viro.1994.1181; Benz C, 2001, J GEN VIROL, V82, P2061, DOI 10.1099/0022-1317-82-9-2061; Bouvier M, 2003, MOL IMMUNOL, V39, P697, DOI 10.1016/S0161-5890(02)00261-4; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Hengel H, 1998, TRENDS MICROBIOL, V6, P190, DOI 10.1016/S0966-842X(98)01255-4; Hengel H, 1996, J GEN VIROL, V77, P2287, DOI 10.1099/0022-1317-77-9-2287; Hengel H, 1997, IMMUNITY, V6, P623, DOI 10.1016/S1074-7613(00)80350-7; Hewitt EW, 2001, EMBO J, V20, P387, DOI 10.1093/emboj/20.3.387; HILL A, 1995, NATURE, V375, P411, DOI 10.1038/375411a0; JOLY E, 1994, IMMUNOGENETICS, V40, P45, DOI 10.1007/BF00163963; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLAR D, 1989, EMBO J, V8, P475, DOI 10.1002/j.1460-2075.1989.tb03400.x; Koch J, 2004, J BIOL CHEM, V279, P10142, DOI 10.1074/jbc.M312816200; Koopmann JO, 2000, IMMUNITY, V13, P117, DOI 10.1016/S1074-7613(00)00013-3; Koopmann JO, 1996, EUR J IMMUNOL, V26, P1720, DOI 10.1002/eji.1830260809; Kyritsis C, 2001, J BIOL CHEM, V276, P48031, DOI 10.1074/jbc.M108528200; Lehner PJ, 1997, P NATL ACAD SCI USA, V94, P6904, DOI 10.1073/pnas.94.13.6904; LIVNEH E, 1986, J CELL BIOL, V103, P327, DOI 10.1083/jcb.103.2.327; LOBIGS M, 1995, IMMUNOL CELL BIOL, V73, P181, DOI 10.1038/icb.1995.29; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Misaghi S, 2004, J VIROL, V78, P413, DOI 10.1128/JVI.78.1.413-423.2004; Momburg F, 2002, CURR TOP MICROBIOL, V269, P57; Momburg F, 2002, MOL IMMUNOL, V39, P217, DOI 10.1016/S0161-5890(02)00103-7; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; Momburg F, 1998, ADV IMMUNOL, V68, P191, DOI 10.1016/S0065-2776(08)60560-X; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Nijenhuis M, 1996, J IMMUNOL, V157, P5467; Nijenhuis M, 1996, J IMMUNOL, V156, P2186; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; RUSS G, 1995, J BIOL CHEM, V270, P21312, DOI 10.1074/jbc.270.36.21312; Tomazin R, 1998, J VIROL, V72, P2560, DOI 10.1128/JVI.72.3.2560-2563.1998; Tomazin R, 1996, EMBO J, V15, P3256, DOI 10.1002/j.1460-2075.1996.tb00690.x; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; van Endert PM, 2002, TRENDS BIOCHEM SCI, V27, P454, DOI 10.1016/S0968-0004(02)02090-X; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; VOLKMER H, 1987, J EXP MED, V166, P668, DOI 10.1084/jem.166.3.668; Vos JC, 1999, J IMMUNOL, V163, P6679; Vos JC, 2000, CURR BIOL, V10, P1, DOI 10.1016/S0960-9822(99)00257-2	49	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5383	5390		10.1074/jbc.M510223200	http://dx.doi.org/10.1074/jbc.M510223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16356928	hybrid			2022-12-27	WOS:000235568900009
J	Williams, KJ; Halkes, KM; Kamerling, JP; DeAngelis, PL				Williams, KJ; Halkes, KM; Kamerling, JP; DeAngelis, PL			Critical elements of oligosaccharide acceptor substrates for the Pasteurella multocida hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 ACTIVE-SITES; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CHEMOENZYMATIC SYNTHESIS; CHONDROITIN SYNTHASE; HEPAROSAN SYNTHASE; IDENTIFICATION; ENZYME; GLYCOSYLTRANSFERASES; BIOSYNTHESIS	Three-dimensional structures are not available for polysaccharide synthases and only minimal information on the molecular basis for catalysis is known. The Pasteurella multocida hyaluronan synthase (PmHAS) catalyzes the polymerization of the alternating beta 1,3-N-acetylglucosamine-beta 1,4-glucuronic acid sugar chain by the sequential addition of single monosaccharides to the non-reducing terminus. Therefore, PmHAS possesses both GlcNAc-transferase and glucuronic acid (GlcUA)-transferase activities. The recombinant Escherichia coli-derived PmHAS enzyme will elongate exogenously supplied hyaluronan chains in vitro with either a single monosaccharide or a long chain depending on the UDP-sugar availability. Competition studies using pairs of acceptors with distinct termini ( where one oligosaccharide is a substrate that may be elongated, whereas the other cannot) were performed here; the lack of competition suggests that PmHAS contains at least two distinct acceptor sites. We hypothesize that the size of the acceptor binding pockets of the enzyme corresponds to the size of the smallest high efficiency substrates; thus we tested the relative activity of a series of authentic hyaluronan oligosaccharides and related structural analogs. The GlcUA-transferase site readily elongates ( GlcNAc-GlcUA) 2, whereas the GlcNAc-transferase elongates GlcUA-GlcNAc- GlcUA. The minimally sized oligosaccharides, elongated with high efficiency, both contain a trisaccharide with two glucuronic acid residues that enabled the identification of a synthetic, artificial acceptor for the synthase. PmHAS behaves as a fusion of two complete glycosyltransferases, each containing a donor site and an acceptor site, in one polypeptide. Overall, this information advances the knowledge of glycosaminoglycan biosynthesis as well as assists the creation of various therapeutic sugars for medical applications in the future.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Utrecht, Bijvoet Ctr, Dept Bioorgan Chem, NL-3508 TB Utrecht, Netherlands	University of Oklahoma System; University of Oklahoma Health Sciences Center; Utrecht University	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu						DeAngelis PL, 2000, J BIOL CHEM, V275, P24124, DOI 10.1074/jbc.M003385200; DeAngelis PL, 1998, J BIOL CHEM, V273, P8454, DOI 10.1074/jbc.273.14.8454; DeAngelis PL, 2004, J BACTERIOL, V186, P8529, DOI 10.1128/JB.186.24.8529-8532.2004; Deangelis PL, 2003, J BIOL CHEM, V278, P35199, DOI 10.1074/jbc.M306431200; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DeAngelis PL, 1999, J BIOL CHEM, V274, P26557, DOI 10.1074/jbc.274.37.26557; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; DeAngelis PL, 2002, J BIOL CHEM, V277, P7209, DOI 10.1074/jbc.M112130200; HADFIELD AT, 1994, J MOL BIOL, V243, P856, DOI 10.1006/jmbi.1994.1688; Halkes KM, 1998, CARBOHYD RES, V309, P161, DOI 10.1016/S0008-6215(98)00116-5; Jing W, 2000, GLYCOBIOLOGY, V10, P883, DOI 10.1093/glycob/10.9.883; Jing W, 2004, J BIOL CHEM, V279, P42345, DOI 10.1074/jbc.M402744200; Jing W, 2003, GLYCOBIOLOGY, V13, P661, DOI 10.1093/glycob/cwg085; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Leemhuis H, 2002, J BIOL CHEM, V277, P1113, DOI 10.1074/jbc.M106667200; Negishi M, 2003, BIOCHEM BIOPH RES CO, V303, P393, DOI 10.1016/S0006-291X(03)00356-5; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Pedersen LC, 2002, J BIOL CHEM, V277, P21869, DOI 10.1074/jbc.M112343200; RUPLEY JA, 1967, P NATL ACAD SCI USA, V57, P496, DOI 10.1073/pnas.57.3.496	20	32	35	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 3	2006	281	9					5391	5397		10.1074/jbc.M510439200	http://dx.doi.org/10.1074/jbc.M510439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	015RQ	16361253	hybrid, Green Published			2022-12-27	WOS:000235568900010
J	Appleton, BA; Brooks, J; Loregian, A; Filman, DJ; Coen, DM; Hogle, JM				Appleton, BA; Brooks, J; Loregian, A; Filman, DJ; Coen, DM; Hogle, JM			Crystal structure of the cytomegalovirus DNA polymerase subunit UL44 in complex with the C terminus from the catalytic subunit - Differences in structure and function relative to unliganded UL44	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLEX-VIRUS TYPE-1; ACCESSORY PROTEIN UL44; CLAMP LOADER COMPLEX; CELL NUCLEAR ANTIGEN; PROCESSIVITY FACTOR; BINDING PROTEIN; TRANSIENT COMPLEMENTATION; FLAP ENDONUCLEASE-1; VIRAL REPLICATION; PRIMER-TEMPLATE	The human cytomegalovirus DNA polymerase is composed of a catalytic subunit, UL54, and an accessory protein, UL44, which has a structural fold similar to that of other processivity factors, including herpes simplex virus UL42 and homotrimeric sliding clamps such as proliferating cell nuclear antigen. Several specific residues in the C-terminal region of UL54 and in the "connector loop" of UL44 are required for the association of these proteins. Here, we describe the crystal structure of residues 1-290 of UL44 in complex with a peptide from the extreme C terminus of UL54, which explains this interaction at a molecular level. The UL54 peptide binds to structural elements similar to those used by UL42 and the sliding clamps to associate with their respective binding partners. However, the details of the interaction differ from those of other processivity factor-peptide complexes. Crucial residues include a three-residue hydrophobic "plug" from the UL54 peptide and Ile(135) of UL44, which forms a critical intramolecular hydrophobic anchor for interactions between the connector loop and the peptide. As was the case for the unliganded UL44 structure, the UL44-peptide complex forms a head-to-head dimer that could potentially form a C-shaped clamp on DNA. However, the peptide-bound structure displays subtle differences in the relative orientation of the two subdomains of the protein, resulting in a more open clamp, which we predicted would affect its association with DNA. Indeed, filter binding assays revealed that peptide-bound UL44 binds DNA with higher affinity. Thus, interaction with the catalytic subunit appears to affect both the structure and function of UL44.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Comm Virol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Summer Honors Undergrad Res Program, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Hogle, JM (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Bldg C-2,240 Longwood Ave, Boston, MA 02115 USA.	jhogle@hms.harvard.edu	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504; filman, david/0000-0002-8714-1644; LOREGIAN, ARIANNA/0000-0002-8900-861X; Appleton, Brent/0000-0003-1136-5649	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019838, U01AI032480, R01AI032480] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19838, AI32480, R01 AI019838] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Appleton BA, 2004, MOL CELL, V15, P233, DOI 10.1016/j.molcel.2004.06.018; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Bridges KG, 2001, J VIROL, V75, P4990, DOI 10.1128/JVI.75.11.4990-4998.2001; Bridges KG, 2000, J BIOL CHEM, V275, P472, DOI 10.1074/jbc.275.1.472; Bruning JB, 2004, STRUCTURE, V12, P2209, DOI 10.1016/j.str.2004.09.018; Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Burnouf DY, 2004, J MOL BIOL, V335, P1187, DOI 10.1016/j.jmb.2003.11.049; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chen XL, 2004, J BIOL CHEM, V279, P28375, DOI 10.1074/jbc.M400032200; Cihlar T, 1997, PROTEIN EXPRES PURIF, V11, P209, DOI 10.1006/prep.1997.0781; Coen DM, 2003, NAT REV DRUG DISCOV, V2, P278, DOI 10.1038/nrd1065; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; DIGARD P, 1995, P NATL ACAD SCI USA, V92, P1456, DOI 10.1073/pnas.92.5.1456; DIGARD P, 1993, J VIROL, V67, P398, DOI 10.1128/JVI.67.1.398-406.1993; ERTL PF, 1992, J VIROL, V66, P4126, DOI 10.1128/JVI.66.7.4126-4133.1992; GALLO ML, 1988, J VIROL, V62, P2874, DOI 10.1128/JVI.62.8.2874-2883.1988; GIBSON W, 1981, VIROLOGY, V111, P251, DOI 10.1016/0042-6822(81)90669-3; GOTTLIEB J, 1994, J VIROL, V68, P4937, DOI 10.1128/JVI.68.8.4937-4945.1994; GOTTLIEB J, 1990, J VIROL, V64, P5976, DOI 10.1128/JVI.64.12.5976-5987.1990; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; HEILBRONN R, 1987, J VIROL, V61, P119, DOI 10.1128/JVI.61.1.119-124.1987; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOUZARIDES T, 1987, J VIROL, V61, P125, DOI 10.1128/JVI.61.1.125-133.1987; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Loregian A, 2004, J VIROL, V78, P9084, DOI 10.1128/JVI.78.17.9084-9092.2004; Loregian A, 2004, J VIROL, V78, P158, DOI 10.1128/JVI.78.1.158-167.2004; Loregian A, 2003, J VIROL, V77, P8336, DOI 10.1128/JVI.77.15.8336-8344.2003; LOREGIAN A, 2006, IN PRESS CHEM BIOL; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Makhov AM, 2004, J BIOL CHEM, V279, P40358, DOI 10.1074/jbc.M408733200; MAR EC, 1985, J VIROL, V56, P846, DOI 10.1128/JVI.56.3.846-851.1985; Matsumiya S, 2002, GENES CELLS, V7, P911, DOI 10.1046/j.1365-2443.2002.00572.x; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NISHIYAMA Y, 1983, VIROLOGY, V124, P221, DOI 10.1016/0042-6822(83)90339-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pages V, 2002, ONCOGENE, V21, P8957, DOI 10.1038/sj.onc.1206006; PARI GS, 1993, J VIROL, V67, P2575, DOI 10.1128/JVI.67.5.2575-2582.1993; PARI GS, 1993, J VIROL, V67, P6979, DOI 10.1128/JVI.67.12.6979-6988.1993; PARRIS DS, 1988, J VIROL, V62, P818, DOI 10.1128/JVI.62.3.818-825.1988; Pilger BD, 2004, CHEM BIOL, V11, P647, DOI 10.1016/j.chembiol.2004.01.018; Randell JCW, 2004, J MOL BIOL, V335, P409, DOI 10.1016/j.jmb.2003.10.064; RIPALTI A, 1995, J VIROL, V69, P2047, DOI 10.1128/JVI.69.4.2047-2057.1995; Sakurai S, 2005, EMBO J, V24, P683, DOI 10.1038/sj.emboj.7600519; Shamoo Y, 1999, CELL, V99, P155, DOI 10.1016/S0092-8674(00)81647-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thornton KE, 2000, VIROLOGY, V275, P373, DOI 10.1006/viro.2000.0506; Vivona JB, 2003, FEBS LETT, V546, P167, DOI 10.1016/S0014-5793(03)00622-7; WEILAND KL, 1994, VIRUS RES, V34, P191, DOI 10.1016/0168-1702(94)90124-4; Weisshart K, 1999, J VIROL, V73, P55, DOI 10.1128/JVI.73.1.55-66.1999; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	60	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5224	5232		10.1074/jbc.M506900200	http://dx.doi.org/10.1074/jbc.M506900200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371349	Green Published, hybrid			2022-12-27	WOS:000235426200077
J	Campos, LS; Decker, L; Taylor, V; Skarnes, W				Campos, LS; Decker, L; Taylor, V; Skarnes, W			Notch, epidermal growth factor receptor, and beta 1-integrin pathways are coordinated in neural stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIAL GLIAL IDENTITY; LIPID RAFTS; SIGNALING PATHWAY; EPITHELIAL-CELLS; PRECURSOR CELLS; EGF-RECEPTOR; INTEGRIN; DIFFERENTIATION; ACTIVATION; PROLIFERATION	Notch1 and beta 1-integrins are cell surface receptors involved in the recognition of the niche that surrounds stem cells through cell-cell and cell-extracellular matrix interactions, respectively. Notch1 is also involved in the control of cell fate choices in the developing central nervous system (Lewis, J. (1998) Semin. Cell Dev. Biol. 9, 583-589). Here we report that Notch and beta 1-integrins are co-expressed and that these proteins cooperate with the epidermal growth factor receptor in neural progenitors. We describe data that suggests that beta 1-integrins may affect Notch signaling through 1) physical interaction (sequestration) of the Notch intracellular domain fragment by the cytoplasmic tail of the beta 1-integrin and 2) affecting trafficking of the Notch intracellular domain via caveolin-mediated mechanisms. Our findings suggest that caveolin 1-containing lipid rafts play a role in the coordination and coupling of beta 1-integrin, Notch1, and tyrosine kinase receptor signaling pathways. We speculate that this will require the presence of the adequate beta 1-activating extracellular matrix or growth factors in restricted regions of the central nervous system and namely in neurogenic niches.	INSERM, Ecole Normale Super, U368, Paris, France; Max Planck Inst Immunobiol, Dept Mol Embryol, D-7800 Freiburg, Germany; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Max Planck Society; Wellcome Trust Sanger Institute	Campos, LS (corresponding author), INSERM, Ecole Normale Super, U368, Paris, France.	lsc@sanger.ac.uk		Taylor, Verdon/0000-0003-3497-5976	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akai J, 2003, CELL, V115, P510, DOI 10.1016/S0092-8674(03)00936-X; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Aszodi A, 2003, GENE DEV, V17, P2465, DOI 10.1101/gad.277003; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Baron W, 2003, CURR BIOL, V13, P151, DOI 10.1016/S0960-9822(02)01437-9; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Billon N, 2002, J CELL SCI, V115, P3657, DOI 10.1242/jcs.00049; Blair SS, 2004, CURR BIOL, V14, pR570, DOI 10.1016/j.cub.2004.07.015; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Campos LS, 2004, J NEUROSCI RES, V78, P761, DOI 10.1002/jnr.20333; Campos LS, 2004, DEVELOPMENT, V131, P3433, DOI 10.1242/dev.01199; Campos LS, 2001, J NEUROSCI RES, V64, P590, DOI 10.1002/jnr.1111.abs; Campos LS, 2005, BIOESSAYS, V27, P698, DOI 10.1002/bies.20256; Capela A, 2002, NEURON, V35, P865, DOI 10.1016/S0896-6273(02)00835-8; Chojnacki A, 2003, J NEUROSCI, V23, P1730; Collins AT, 2001, J CELL SCI, V114, P3865; Culi J, 2001, DEVELOPMENT, V128, P299; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Decker L, 2004, J NEUROSCI, V24, P3816, DOI 10.1523/JNEUROSCI.5725-03.2004; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; DRAGO J, 1991, EXP CELL RES, V196, P246, DOI 10.1016/0014-4827(91)90258-V; Faux CH, 2001, J NEUROSCI, V21, P5587, DOI 10.1523/JNEUROSCI.21-15-05587.2001; Flores GV, 2000, CELL, V103, P75, DOI 10.1016/S0092-8674(00)00106-9; Forster E, 2002, P NATL ACAD SCI USA, V99, P13178, DOI 10.1073/pnas.202035899; Franklin JL, 1999, CURR BIOL, V9, P1448, DOI 10.1016/S0960-9822(00)80114-1; Gaiano N, 2002, ANNU REV NEUROSCI, V25, P471, DOI 10.1146/annurev.neuro.25.030702.130823; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Georges-Labouesse E, 1998, CURR BIOL, V8, P983, DOI 10.1016/S0960-9822(98)70402-6; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Golub T, 2004, CURR OPIN NEUROBIOL, V14, P542, DOI 10.1016/j.conb.2004.08.003; Gotz M, 2005, NEURON, V46, P369, DOI 10.1016/j.neuron.2005.04.012; Grandbarbe L, 2003, DEVELOPMENT, V130, P1391, DOI 10.1242/dev.00374; Hart A, 2003, DEV DYNAM, V228, P185, DOI 10.1002/dvdy.10368; Hitoshi S, 2002, GENE DEV, V16, P846, DOI 10.1101/gad.975202; Jacques TS, 1998, DEVELOPMENT, V125, P3167; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; Lai EC, 2003, J CELL BIOL, V162, P365, DOI 10.1083/jcb.200307087; Leitinger B, 2002, J CELL SCI, V115, P963; Leone DP, 2005, J CELL SCI, V118, P2589, DOI 10.1242/jcs.02396; Leong KG, 2002, MOL CELL BIOL, V22, P2830, DOI 10.1128/MCB.22.8.2830-2841.2002; Lewis J, 1998, SEMIN CELL DEV BIOL, V9, P583, DOI 10.1006/scdb.1998.0266; Lillien L, 2000, DEVELOPMENT, V127, P4993; Liour SS, 2003, GLIA, V42, P109, DOI 10.1002/glia.10202; Lundell MJ, 2003, DEVELOPMENT, V130, P4109, DOI 10.1242/dev.00593; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Martens DJ, 2000, J NEUROSCI, V20, P1085, DOI 10.1523/JNEUROSCI.20-03-01085.2000; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Prince JM, 2002, DEV DYNAM, V223, P497, DOI 10.1002/dvdy.10070; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Seugnet L, 1997, DEV BIOL, V192, P585, DOI 10.1006/dbio.1997.8723; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SVENDSEN CN, 1995, EXP BRAIN RES, V102, P407; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang WD, 2004, DEVELOPMENT, V131, P5367, DOI 10.1242/dev.01413; Watanabe N, 2003, J BONE MINER METAB, V21, P344, DOI 10.1007/s00774-003-0428-4; Watt FM, 2002, J DERMATOL SCI, V28, P173, DOI 10.1016/S0923-1811(02)00003-8; Yanagisawa M, 2004, GENES CELLS, V9, P801, DOI 10.1111/j.1365-2443.2004.00764.x; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Yoon KJ, 2004, J NEUROSCI, V24, P9497, DOI 10.1523/JNEUROSCI.0993-04.2004; Zhong WM, 1997, DEVELOPMENT, V124, P1887; Zine A, 2001, J NEUROSCI, V21, P4712, DOI 10.1523/JNEUROSCI.21-13-04712.2001	79	120	128	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5300	5309		10.1074/jbc.M511886200	http://dx.doi.org/10.1074/jbc.M511886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16332675	hybrid			2022-12-27	WOS:000235426200084
J	Kreiner, L; Lee, A				Kreiner, L; Lee, A			Endogenous and exogenous Ca2+ buffers differentially modulate Ca2+-dependent inactivation of Ca(V)2.1 Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; PURKINJE-CELLS; P-TYPE; CA2+/CALMODULIN-DEPENDENT FACILITATION; SYNAPTIC-TRANSMISSION; FOREBRAIN NEURONS; PARVALBUMIN; CALMODULIN; CALBINDIN-D-28K; CURRENTS	Voltage-gated Ca2+ channels undergo a negative feedback regulation by Ca2+ ions, Ca2+-dependent inactivation, which is important for restricting Ca2+ signals in nerve and muscle. Although the molecular details underlying Ca2+-dependent inactivation have been characterized, little is known about how this process might be modulated in excitable cells. Based on previous findings that Ca2+-dependent inactivation of Ca(v)2.1 (P/Q-type) Ca2+ channels is suppressed by strong cytoplasmic Ca2+ buffering, we investigated how factors that regulate cellular Ca2+ levels affect inactivation of Ca(v)2.1 Ca2+ currents in transfected 293T cells. We found that inactivation of Ca(v)2.1 Ca2+ currents increased exponentially with current amplitude with low intracellular concentrations of the slow buffer EGTA (0.5 mM), but not with high concentrations of the fast Ca2+ buffer BAPTA ( 10 mM). However, when the concentration of BAPTA was reduced to 0.5 mM, inactivation of Ca2+ currents was significantly greater than with an equivalent concentration of EGTA, indicating the importance of buffer kinetics in modulating Ca2+-dependent inactivation of Ca(v)2.1. Cotransfection of Ca(v)2.1 with the EF-hand Ca2+-binding proteins, parvalbumin and calbindin, significantly altered the relationship between Ca2+ current amplitude and inactivation in ways that were unexpected from behavior as passive Ca2+ buffers. We conclude that Ca2+-dependent inactivation of Ca(v)2.1 depends on a subplasmalemmal Ca2+ microdomain that is affected by the amplitude of the Ca2+ current and differentially modulated by distinct Ca2+ buffers.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Ctr Neurodegenerat Dis, Atlanta, GA 30322 USA	Emory University; Emory University	Lee, A (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, 5123 Rollins Res Bldg,1510 Clifton Rd, Atlanta, GA 30322 USA.	alee@pharm.emory.edu		Lee, Amy/0000-0001-8021-0443	NINDS NIH HHS [NS044922, F31NS049757] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS049757, R01NS044922] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bodding M, 1999, PFLUG ARCH EUR J PHY, V439, P27, DOI 10.1007/s004240051124; Borst JGG, 1998, J PHYSIOL-LONDON, V513, P149, DOI 10.1111/j.1469-7793.1998.149by.x; BREHM P, 1978, SCIENCE, V202, P1203, DOI 10.1126/science.103199; Cavelier P, 2002, J PHYSIOL-LONDON, V540, P57, DOI 10.1113/jphysiol.2001.013294; Chaudhuri D, 2005, J NEUROSCI, V25, P8282, DOI 10.1523/JNEUROSCI.2253-05.2005; Chaudhuri D, 2004, J NEUROSCI, V24, P6334, DOI 10.1523/JNEUROSCI.1712-04.2004; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; Cuttle MF, 1998, J PHYSIOL-LONDON, V512, P723, DOI 10.1111/j.1469-7793.1998.723bd.x; Dargan SL, 2003, J PHYSIOL-LONDON, V553, P775, DOI 10.1113/jphysiol.2003.054247; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Ferreira G, 1997, J GEN PHYSIOL, V109, P449, DOI 10.1085/jgp.109.4.449; Fierro L, 1996, J PHYSIOL-LONDON, V496, P617, DOI 10.1113/jphysiol.1996.sp021713; Forsythe ID, 1998, NEURON, V20, P797, DOI 10.1016/S0896-6273(00)81017-X; GILLIS JM, 1982, J MUSCLE RES CELL M, V3, P377, DOI 10.1007/BF00712090; Hackney CM, 2005, J NEUROSCI, V25, P7867, DOI 10.1523/JNEUROSCI.1196-05.2005; HAIECH J, 1979, BIOCHEMISTRY-US, V18, P2752, DOI 10.1021/bi00580a010; Hartley DM, 1996, MOL BRAIN RES, V40, P285, DOI 10.1016/0169-328X(96)00066-6; HOU TT, 1991, J PHYSIOL-LONDON, V441, P285, DOI 10.1113/jphysiol.1991.sp018752; John LM, 2001, J PHYSIOL-LONDON, V535, P3, DOI 10.1111/j.1469-7793.2001.t01-2-00003.x; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; KADOWAKI K, 1993, NEUROSCI LETT, V153, P80, DOI 10.1016/0304-3940(93)90082-V; KOSAKA T, 1993, EXP BRAIN RES, V93, P483; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee SH, 2000, J PHYSIOL-LONDON, V525, P419, DOI 10.1111/j.1469-7793.2000.t01-2-00419.x; Lee SH, 2000, J PHYSIOL-LONDON, V525, P405, DOI 10.1111/j.1469-7793.2000.t01-3-00405.x; LI ZH, 1995, J PHYSIOL-LONDON, V488, P601, DOI 10.1113/jphysiol.1995.sp020993; Li-Smerin YY, 2001, J PHYSIOL-LONDON, V533, P729, DOI 10.1111/j.1469-7793.2001.t01-1-00729.x; LLINAS R, 1992, TRENDS NEUROSCI, V15, P351, DOI 10.1016/0166-2236(92)90053-B; Lutz W, 2003, BIOCHEM BIOPH RES CO, V303, P1186, DOI 10.1016/S0006-291X(03)00499-6; Maetzler W, 2004, EXP NEUROL, V186, P78, DOI 10.1016/j.expneurol.2003.10.014; Meuth SG, 2005, PFLUG ARCH EUR J PHY, V450, P111, DOI 10.1007/s00424-004-1377-z; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; Miyazaki T, 2004, J NEUROSCI, V24, P1734, DOI 10.1523/JNEUROSCI.4208-03.2004; Muller A, 2005, J NEUROSCI, V25, P558, DOI 10.1523/JNEUROSCI.3799-04.2005; Nagerl UV, 2000, BIOPHYS J, V79, P3009, DOI 10.1016/S0006-3495(00)76537-4; Nagerl UV, 2000, J NEUROSCI, V20, P1831; PAULS TL, 1993, J BIOL CHEM, V268, P20897; PAULS TL, 1994, BIOCHEMISTRY-US, V33, P10393, DOI 10.1021/bi00200a021; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PLOGMANN D, 1993, BRAIN RES, V600, P273, DOI 10.1016/0006-8993(93)91383-4; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Rousset M, 2004, J BIOL CHEM, V279, P14619, DOI 10.1074/jbc.M313284200; Schmidt H, 2005, P NATL ACAD SCI USA, V102, P5850, DOI 10.1073/pnas.0407855102; Schmidt H, 2003, J PHYSIOL-LONDON, V551, P13, DOI 10.1113/jphysiol.2002.035824; Schmidt H, 2003, BIOPHYS J, V84, P2599, DOI 10.1016/S0006-3495(03)75065-6; Schwaller B, 1999, AM J PHYSIOL-CELL PH, V276, pC395, DOI 10.1152/ajpcell.1999.276.2.C395; Soong TW, 2002, J NEUROSCI, V22, P10142; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; Stout AK, 1996, J PHYSIOL-LONDON, V492, P641, DOI 10.1113/jphysiol.1996.sp021334; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Van den Bosch L, 2002, EXP NEUROL, V174, P150, DOI 10.1006/exnr.2001.7858; Wheeler DB, 1996, J NEUROSCI, V16, P2226; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	59	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4691	4698		10.1074/jbc.M511971200	http://dx.doi.org/10.1074/jbc.M511971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373336	hybrid			2022-12-27	WOS:000235426200017
J	Ku, MC; Howard, S; Ni, WH; Lagna, G; Hata, A				Ku, MC; Howard, S; Ni, WH; Lagna, G; Hata, A			OAZ regulates bone morphogenetic protein signaling through Smad6 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEOBOX GENE; PATHWAY; TARGET; OSTEOBLAST; DIFFERENTIATION; NEUROGENESIS; ANGIOGENESIS; RESISTANCE; INHIBITOR; MUTATIONS	The intensity and duration of activation of a signal transduction system are important determinants of the specificity of the cellular response to the stimulus. It is unclear how different cells can generate a signal of varying intensity and duration in response to the same cytokine. We investigated the role of the transcriptional activator and Smad1/4 cofactor OAZ in regulating bone morphogenetic protein (BMP) signaling. We demonstrate that upon BMP4 stimulation, an OAZ-Smad1/4 complex binds to and activates the gene encoding Smad6, a specific inhibitor of the BMP pathway. Removal of endogenous OAZ from pluripotent embryonal carcinoma cells prevents the induction of Smad6 by BMP4 and extends the period of detection of phosphorylated Smad1 after BMP stimulation. Conversely, in cells that do not normally express OAZ, such as myoblasts and smooth muscle cells, forced OAZ expression leads to faster and higher Smad6 induction in response to BMP4, decrease of Smad1 phosphorylation, and attenuation of BMP-mediated responses. Our results demonstrate that OAZ can alter the intensity and duration of the BMP stimulus through Smad6 and indicate that the tissue-specific expression of OAZ is a critical determinant of the cellular response to the BMP signal.	Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Hata, A (corresponding author), Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	akiko.hata@tufts.edu						Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Attisano L., 2001, GENOME BIOL, V2, p3010.3011, DOI [DOI 10.1186/GB-2001-2-8-REVIEWS3010, 10.1186/gb-2001-2-8-reviews3010]; BONBUBNOFF A, 2005, DEV BIOL, V281, P210; Bond HM, 2004, BLOOD, V103, P2062, DOI 10.1182/blood-2003-07-2388; Chang H, 1999, DEVELOPMENT, V126, P1631; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Eddahibi S, 2002, EUR RESPIR J, V20, P1559, DOI 10.1183/09031936.02.00081302; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hentges KE, 2005, ONCOGENE, V24, P1220, DOI 10.1038/sj.onc.1208243; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; Horiki M, 2004, J CELL BIOL, V165, P433, DOI 10.1083/jcb.200311015; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Karaulanov E, 2004, EMBO J, V23, P844, DOI 10.1038/sj.emboj.7600101; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Ku MC, 2005, MOL CELL BIOL, V25, P7144, DOI 10.1128/MCB.25.16.7144-7157.2005; Ku MC, 2003, BIOCHEM BIOPH RES CO, V311, P702, DOI 10.1016/j.bbrc.2003.10.053; Ladher R, 1996, DEVELOPMENT, V122, P2385; Lechleider RJ, 2001, DEV BIOL, V240, P157, DOI 10.1006/dbio.2001.0469; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Machado RD, 2001, AM J HUM GENET, V68, P92, DOI 10.1086/316947; Mandegar M, 2004, CARDIOL CLIN, V22, P417, DOI 10.1016/j.ccl.2004.04.005; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Naeije R, 2004, Bull Mem Acad R Med Belg, V159, P219; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nakayama T, 1998, GENES CELLS, V3, P387, DOI 10.1046/j.1365-2443.1998.00196.x; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; Onichtchouk D, 1998, DEVELOPMENT, V125, P1447; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Seki K, 2004, J BIOL CHEM, V279, P18544, DOI 10.1074/jbc.M311592200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Takase M, 1998, BIOCHEM BIOPH RES CO, V244, P26, DOI 10.1006/bbrc.1998.8200; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thomson JR, 2000, J MED GENET, V37, P741, DOI 10.1136/jmg.37.10.741; von Bubnoff N, 2005, CELL CYCLE, V4, P400, DOI 10.4161/cc.4.3.1560; Warming S, 2004, ONCOGENE, V23, P2727, DOI 10.1038/sj.onc.1207452; Wilson PA, 1997, DEVELOPMENT, V124, P3177; Yang X, 1999, DEVELOPMENT, V126, P1571; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang S, 2003, AM J PHYSIOL-LUNG C, V285, pL740, DOI 10.1152/ajplung.00284.2002; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	49	33	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					5277	5287		10.1074/jbc.M510004200	http://dx.doi.org/10.1074/jbc.M510004200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16373339	hybrid			2022-12-27	WOS:000235426200082
J	Sher, RB; Aoyama, C; Huebsch, KA; Ji, SN; Kerner, J; Yang, Y; Frankel, WN; Hoppel, CL; Wood, PA; Vance, DE; Cox, GA				Sher, RB; Aoyama, C; Huebsch, KA; Ji, SN; Kerner, J; Yang, Y; Frankel, WN; Hoppel, CL; Wood, PA; Vance, DE; Cox, GA			A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARNITINE PALMITOYLTRANSFERASE-I; CHOLINE/ETHANOLAMINE KINASE; MEMBRANE-REPAIR; NERVOUS-SYSTEM; MOUSE MODELS; RAT-LIVER; SKELETAL; GENE; DISRUPTION; DYSFERLIN	Muscular dystrophies include a diverse group of genetically heterogeneous disorders that together affect 1 in 2000 births worldwide. The diseases are characterized by progressive muscle weakness and wasting that lead to severe disability and often premature death. Rostrocaudal muscular dystrophy (rmd) is a new recessive mouse mutation that causes a rapidly progressive muscular dystrophy and a neonatal forelimb bone deformity. The rmd mutation is a 1.6-kb intragenic deletion within the choline kinase beta (Chkb) gene, resulting in a complete loss of CHKB protein and enzymatic activity. CHKB is one of two mammalian choline kinase (CHK) enzymes (alpha and beta) that catalyze the phosphorylation of choline to phosphocholine in the biosynthesis of the major membrane phospholipid phosphatidylcholine. While mutant rmd mice show a dramatic decrease of CHK activity in all tissues, the dystrophy is only evident in skeletal muscle tissues in an unusual rostral-to-caudal gradient. Minor membrane disruption similar to dysferlinopathies suggest that membrane fusion defects may underlie this dystrophy, because severe membrane disruptions are not evident as determined by creatine kinase levels, Evans Blue infiltration, and unaltered levels of proteins in the dystrophin-glycoprotein complex. The rmd mutant mouse offers the first demonstration of a defect in a phospholipid biosynthetic enzyme causing muscular dystrophy, representing a unique model for understanding mechanisms of muscle degeneration.	Jackson Lab, Bar Harbor, ME 04609 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 252, Canada; Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA; Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Louis Stokes Vet Affairs Med Ctr, Cleveland, OH 44106 USA	Jackson Laboratory; University of Alberta; University of Alabama System; University of Alabama Birmingham; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	Cox, GA (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	gac@jax.org			NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR002599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049043] Funding Source: NIH RePORTER; NCI NIH HHS [CA34196] Funding Source: Medline; NCRR NIH HHS [R01-RR-02599] Funding Source: Medline; NIAMS NIH HHS [AR-49043] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI K, 1994, EXP MOL PATHOL, V61, P134, DOI 10.1006/exmp.1994.1032; ANDERSON JE, 1991, BIOCHEM CELL BIOL, V69, P835, DOI 10.1139/o91-124; Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001; Aoyama C, 2000, J LIPID RES, V41, P452; Aoyama C, 2002, BIOCHEM J, V363, P777, DOI 10.1042/0264-6021:3630777; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; BAKKER E, 1998, NEUROMUSCULAR DISORD, P59; Balci B, 2005, NEUROMUSCULAR DISORD, V15, P271, DOI 10.1016/j.nmd.2005.01.013; Bansal D, 2004, TRENDS CELL BIOL, V14, P206, DOI 10.1016/j.tcb.2004.03.001; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Bergo MO, 2002, J BIOL CHEM, V277, P47701, DOI 10.1074/jbc.M207734200; Boas FE, 1998, P NATL ACAD SCI USA, V95, P3077, DOI 10.1073/pnas.95.6.3077; Boon JM, 2002, MED RES REV, V22, P251, DOI 10.1002/med.10009; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; Connor WE, 1997, J LIPID RES, V38, P2516; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Devaux PF, 2004, TRAFFIC, V5, P241, DOI 10.1111/j.1600-0854.2004.0170.x; Emery AEH, 2002, NEUROMUSCULAR DISORD, V12, P343, DOI 10.1016/S0960-8966(01)00303-0; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; EUSEBI F, 1986, BIOCHIM BIOPHYS ACTA, V855, P197, DOI 10.1016/0005-2736(86)90206-3; FOLCH J, 1957, J BIOL CHEM, V226, P497; Grewal PK, 2003, HUM MOL GENET, V12, pR259, DOI 10.1093/hmg/ddg272; Hanshaw RG, 2005, BIOORGAN MED CHEM, V13, P5035, DOI 10.1016/j.bmc.2005.04.071; Hayashi YK, 2003, LANCET, V362, P843, DOI 10.1016/S0140-6736(03)14346-2; Ho M, 2004, HUM MOL GENET, V13, P1999, DOI 10.1093/hmg/ddh212; Hoppel CL, 1998, J BIOL CHEM, V273, P23495, DOI 10.1074/jbc.273.36.23495; Ilkovski B, 2001, AM J HUM GENET, V68, P1333, DOI 10.1086/320605; Infante JP, 1999, MOL CELL BIOCHEM, V195, P155, DOI 10.1023/A:1006972315739; Ishidate K, 1997, BBA-LIPID LIPID MET, V1348, P70, DOI 10.1016/S0005-2760(97)00118-5; ISHIDATE K, 1992, METHOD ENZYMOL, V209, P121; Kiss Z, 1999, CELL SIGNAL, V11, P149, DOI 10.1016/S0898-6568(98)00057-6; Le Rumeur E, 2003, J BIOL CHEM, V278, P5993, DOI 10.1074/jbc.M207321200; Liu J, 1998, NAT GENET, V20, P31, DOI 10.1038/1682; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MACBRINN MC, 1968, J LIPID RES, V9, P552; Manno S, 2002, P NATL ACAD SCI USA, V99, P1943, DOI 10.1073/pnas.042688399; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; McNeil PL, 2003, P NATL ACAD SCI USA, V100, P4592, DOI 10.1073/pnas.0736739100; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; MOGGIO M, 1994, MUSCLE NERVE, V17, P485, DOI 10.1002/mus.880170503; MYHER JJ, 1989, LIPIDS, V24, P408, DOI 10.1007/BF02535148; NISHIJIMA M, 1984, J BIOL CHEM, V259, P7101; O'Brien KF, 2001, MOL GENET METAB, V74, P75, DOI 10.1006/mgme.2001.3220; OBrien TP, 1996, GENETICS, V143, P447; Pan HJ, 2005, DIABETES, V54, P1854, DOI 10.2337/diabetes.54.6.1854; Pereira J, 1999, THROMB HAEMOSTASIS, V82, P1318; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; Rodriguez-Gonzalez A, 2005, INT J ONCOL, V26, P999; *SAS I, 2004, JMP STAT GRAPH GUID; Sasarman F, 2002, HUM MOL GENET, V11, P1669, DOI 10.1093/hmg/11.14.1669; Sharma U, 2003, NMR BIOMED, V16, P213, DOI 10.1002/nbm.832; Sharma U, 2003, MAGN RESON IMAGING, V21, P145, DOI 10.1016/S0730-725X(02)00646-X; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; TANDLER B, 1986, ANN NY ACAD SCI, V488, P65; Tandler B, 2002, ULTRASTRUCT PATHOL, V26, P177, DOI 10.1080/01913120290076847; van der Leij FR, 2002, J BIOL CHEM, V277, P26994, DOI 10.1074/jbc.M203189200; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; Wu H, 1996, BIOCHEMISTRY-US, V35, P12602, DOI 10.1021/bi960168q; Yamazaki N, 2000, J BIOL CHEM, V275, P31739, DOI 10.1074/jbc.M006322200; Yamazaki N, 2003, J BIOCHEM, V133, P523, DOI 10.1093/jb/mvg069; Yang Y, 2003, HUM MOL GENET, V12, P975, DOI 10.1093/hmg/ddg118	66	88	96	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 24	2006	281	8					4938	4948		10.1074/jbc.M512578200	http://dx.doi.org/10.1074/jbc.M512578200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	013RF	16371353	hybrid			2022-12-27	WOS:000235426200045
J	Angelo, PF; Lima, AR; Alves, FM; Blaber, SI; Scarisbrick, IA; Blaber, M; Juliano, L; Juliano, MA				Angelo, PF; Lima, AR; Alves, FM; Blaber, SI; Scarisbrick, IA; Blaber, M; Juliano, L; Juliano, MA			Substrate specificity of human kallikrein 6 - Salt and glycosaminoglycan activation effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TISSUE KALLIKREIN; MOUSE SUBMANDIBULAR-GLAND; PROSTATE-SPECIFIC ANTIGEN; SERINE-PROTEASE; ZYME/PROTEASE M/NEUROSIN; CHONDROITIN SULFATE; MOLECULAR-CLONING; GENE FAMILY; IDENTIFICATION; TRYPSIN	Human kallikrein 6 ( hK6) is abundantly expressed in the central nervous system and is implicated in demyelinating disease. This study provided biochemical data about the substrate specificity and activation of hK6 by glycosaminoglycans and by kosmotropic salts, which followed the Hofmeister series. The screening of fluorescence resonance energy transfer ( FRET) peptide families derived from Abz-KLRSSKQ-EDDnp resulted in the finding that Abz-AFRFSQ- EDDnp ( where Abz is ortho-aminobenzoic acid and EDDnp is N-[2,4-dinitrophenyl]ethylenediamine)) is the best synthetic substrate described so far for hK6 ( k(cat)/K-m = 38,667 s(-1)mM(-1)). It is noteworthy that the AFRFS sequence was found as a motif in the amino-terminal domain of seven human ionotropic glutamate receptor subunits. We also examined the hK6 hydrolytic activity on FRET peptides derived from human myelin basic protein, precursor of the A beta amyloid peptide, reactive center loop of alpha(1)-antichymotrypsin, plasminogen, and maturation and inactivation cleavage sites of hK6, which were described earlier as natural substrates for hK6. The best substrates were derived from myelin basic protein. The hK6 maturation cleavage site was poorly hydrolyzed, and no evidence was found to support a two-step self-activation process reported previously. Finally, we assayed FRET peptides derived from sequences that span the cleavage sites for activation of protease-activated receptors ( PAR) 1 - 4, and only the substrate with the PAR 2 sequence was hydrolyzed. These results further supported the hypothesis that hK6 expressed in the central nervous system is involved in normal myelin turnover/demyelination processes, but it is unlikely to self-activate. This report also suggested the possible modulation of ionotropic glutamate receptors and activation of PAR 2 by hK6.	Univ Fed Sao Paulo, Dept Biofis Escola Paulista Med, BR-04044020 Sao Paulo, Brazil; Florida State Univ, Coll Med, Dept Biomed Sci, Tallahassee, FL 32306 USA; Mayo Med Rochester, Dept Neurol, Mayo Clin & Grad Sch, Rochester, MN 55905 USA; Mayo Med Rochester, Dept Phys Med, Mayo Clin & Grad Sch, Rochester, MN 55905 USA; Mayo Med Rochester, Dept Rehabil, Mayo Clin & Grad Sch, Rochester, MN 55905 USA	Universidade Federal de Sao Paulo (UNIFESP); State University System of Florida; Florida State University; Mayo Clinic; Mayo Clinic; Mayo Clinic	Juliano, MA (corresponding author), Univ Fed Sao Paulo, Dept Biofis Escola Paulista Med, Rua Tres Maio 100, BR-04044020 Sao Paulo, Brazil.	juliano.biof@epm.br	Juliano, Luiz/D-7204-2012; Blaber, Michael/N-1083-2019; Blaber, Michael/E-7478-2011; Messier, Claude/A-2322-2008; Blaber, Michael/ABA-5031-2021	Juliano, Luiz/0000-0002-5589-2822; Blaber, Michael/0000-0002-6856-1643; Messier, Claude/0000-0002-4791-1763; 				Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; Axen R., 1966, BIOCHEM BIOPH RES CO, V5, P353; Back SA, 2005, NAT MED, V11, P966, DOI 10.1038/nm1279; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267, DOI 10.1152/physrev.2000.80.4.1267; Bayes A, 2004, BIOL CHEM, V385, P517, DOI 10.1515/BC.2004.061; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; BLABER M, 1989, BIOCHEMISTRY-US, V28, P7813, DOI 10.1021/bi00445a043; Blaber SI, 2004, FASEB J, V18, P920, DOI 10.1096/fj.03-1212fje; Blaber SI, 2002, BIOCHEMISTRY-US, V41, P1165, DOI 10.1021/bi015781a; Borgono CA, 2004, NAT REV CANCER, V4, P876, DOI 10.1038/nrc1474; BOTHWELL MA, 1979, J BIOL CHEM, V254, P7287; Bourgeois L, 1997, J BIOL CHEM, V272, P29590, DOI 10.1074/jbc.272.47.29590; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Cacace MG, 1997, Q REV BIOPHYS, V30, P241, DOI 10.1017/S0033583597003363; CHAGAS JR, 1992, BIOCHEMISTRY-US, V31, P4969, DOI 10.1021/bi00136a008; CHAGAS JR, 1995, BIOCHEM J, V306, P63, DOI 10.1042/bj3060063; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DELNERY E, 1995, BIOCHEM J, V312, P233, DOI 10.1042/bj3120233; Deperthes D, 1996, J ANDROL, V17, P659; Diamandis EP, 2000, CLIN BIOCHEM, V33, P579, DOI 10.1016/S0009-9120(00)00182-X; Dietrich CP, 1998, CELL MOL BIOL, V44, P417; ElMoujahed A, 1997, EUR J BIOCHEM, V247, P652; EVANS B, 1983, J BIOL CHEM, V258, P227; Felber LM, 2005, BIOL CHEM, V386, P291, DOI 10.1515/BC.2005.035; Fiedler F, 1979, Adv Exp Med Biol, V120A, P261; Fogaca SE, 2004, BIOCHEM J, V380, P775, DOI 10.1042/BJ20031047; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; Ghosh MC, 2004, TUMOR BIOL, V25, P193, DOI 10.1159/000081102; Gomis-Ruth FX, 2002, J BIOL CHEM, V277, P27273, DOI 10.1074/jbc.M201534200; Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200; Hirata IY, 1995, LETT PEPT SCI, V1, P299, DOI DOI 10.1007/BF00119771; HOSOI K, 1994, J BIOCHEM-TOKYO, V115, P137, DOI 10.1093/oxfordjournals.jbchem.a124288; Huang XY, 2001, BIOCHEMISTRY-US, V40, P11734, DOI 10.1021/bi010364j; Hutchinson S, 2003, CLIN CHEM, V49, P746, DOI 10.1373/49.5.746; JAMESON GW, 1973, BIOCHEM J, V131, P107, DOI 10.1042/bj1310107; Jelesarov I, 1998, BIOCHEMISTRY-US, V37, P7539, DOI 10.1021/bi972977v; KIM WS, 1991, J BIOL CHEM, V266, P19283; Laxmikanthan G, 2005, PROTEINS, V58, P802, DOI 10.1002/prot.20368; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Lerma J, 2003, NAT REV NEUROSCI, V4, P481, DOI 10.1038/nrn1118; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Magklara A, 2003, BIOCHEM BIOPH RES CO, V307, P948, DOI 10.1016/S0006-291X(03)01271-3; MASON AJ, 1983, NATURE, V303, P300, DOI 10.1038/303300a0; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; Melo RL, 2001, BIOCHEMISTRY-US, V40, P5226, DOI 10.1021/bi002003u; Mitsui S, 2002, ANN NY ACAD SCI, V977, P216, DOI 10.1111/j.1749-6632.2002.tb04818.x; Ni X, 2004, BRIT J CANCER, V91, P725, DOI 10.1038/sj.bjc.6602041; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Oswald RE, 2004, ADV PROTEIN CHEM, V68, P313; Pimenta DC, 1999, BIOCHEM J, V339, P473, DOI 10.1042/0264-6021:3390473; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Rehault S, 2002, BBA-PROTEIN STRUCT M, V1596, P55, DOI 10.1016/S0167-4838(02)00204-2; Rehault S, 2001, EUR J BIOCHEM, V268, P2960, DOI 10.1046/j.1432-1327.2001.02185.x; Rhodes KE, 2004, J ANAT, V204, P33, DOI 10.1111/j.1469-7580.2004.00261.x; Scarisbrick IA, 2000, GLIA, V30, P219, DOI 10.1002/(SICI)1098-1136(200005)30:3<219::AID-GLIA2>3.0.CO;2-2; Scarisbrick IA, 2002, BRAIN, V125, P1283, DOI 10.1093/brain/awf142; Scarisbrick IA, 2001, J COMP NEUROL, V431, P347; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; SmithSwintosky VL, 1997, J NEUROCHEM, V69, P1890; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Striggow F, 2001, EUR J NEUROSCI, V14, P595, DOI 10.1046/j.0953-816x.2001.01676.x; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WINES DR, 1989, J BIOL CHEM, V264, P7653; WINES DR, 1991, J MOL EVOL, V32, P476, DOI 10.1007/BF02102650; Wollmuth LP, 2004, TRENDS NEUROSCI, V27, P321, DOI 10.1016/j.tins.2004.04.005; Yamanaka H, 1999, MOL BRAIN RES, V71, P217, DOI 10.1016/S0169-328X(99)00187-4; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184; Zani ML, 2001, BBA-PROTEIN STRUCT M, V1547, P387, DOI 10.1016/S0167-4838(01)00208-4; Zarghooni M, 2002, CLIN BIOCHEM, V35, P225, DOI 10.1016/S0009-9120(02)00292-8	75	89	91	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3116	3126		10.1074/jbc.M510096200	http://dx.doi.org/10.1074/jbc.M510096200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16321973	hybrid			2022-12-27	WOS:000235128200014
J	Khan, MT; Wagner, L; Yule, DI; Bhanumathy, C; Joseph, SK				Khan, MT; Wagner, L; Yule, DI; Bhanumathy, C; Joseph, SK			Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; TRISPHOSPHATE RECEPTOR; CALCIUM-RELEASE; IP3 RECEPTOR; INTRACELLULAR CALCIUM; ENDOPLASMIC-RETICULUM; RAT HEPATOCYTES; APOPTOSIS; TYPE-1; CELLS	A consensus RXRXX(S/T) substrate motif for Akt kinase is conserved in the C-terminal tail of all three inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) isoforms. We have shown that IP3R can be phosphorylated by Akt kinase in vitro and in vivo. Endogenous IP(3)Rs in Chinese hamster ovary T-cells were phosphorylated in response to Akt activation by insulin. LnCAP cells, a prostate cancer cell line with constitutively active Akt kinase, also showed a constitutive phosphorylation of endogenous type I IP(3)Rs. In all cases, the IP3R phosphorylation was diminished by the addition of LY294002, an inhibitor of phosphatidylinositol 3-kinase. Mutation of IP3R serine 2681 in the Akt substrate motif to alanine (S2681A) or glutamate (S2681E) prevented IP3R phosphorylation in COS cells transfected with constitutively active Akt kinase. Analysis of the Ca2+ flux properties of these IP3R mutants expressed in COS cell microsomes or in DT40 triple knock-out (TKO) cells did not reveal any modification of channel function. However, staurosporine-induced caspase-3 activation in DT40 TKO cells stably expressing the S2681A mutant was markedly enhanced when compared with wild-type or S2681E IP(3)Rs. We conclude that IP3 receptors are in vivo substrates for Akt kinase and that phosphorylation of the IP3R may provide one mechanism to restrain the apoptotic effects of calcium.	Thomas Jefferson Univ, Dept Pathol & Cell Biol, Sch Med, Philadelphia, PA 19107 USA; Univ Rochester, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	Jefferson University; University of Rochester	Joseph, SK (corresponding author), Thomas Jefferson Univ, Dept Pathol & Cell Biol, Sch Med, Rm 230A JAH,1020 Locust St, Philadelphia, PA 19107 USA.	suresh.joseph@mail.tju.edu			NIDCR NIH HHS [DE14756] Funding Source: Medline; NIDDK NIH HHS [DK34804, DK54568] Funding Source: Medline; NINDS NIH HHS [R21-NS051822] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034804, R56DK054568, R01DK054568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS051822] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Assefa Z, 2004, J BIOL CHEM, V279, P43227, DOI 10.1074/jbc.M403872200; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carson JP, 1999, CANCER RES, V59, P1449; Chen R, 2004, J CELL BIOL, V166, P193, DOI 10.1083/jcb.200309146; Cui J, 2004, J BIOL CHEM, V279, P16311, DOI 10.1074/jbc.M400206200; Dufner A, 1999, MOL CELL BIOL, V19, P4525; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hang LS, 2000, J NEUROCHEM, V75, P1852; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Lawlor MA, 2001, J CELL SCI, V114, P2903; Malathi K, 2003, J CELL BIOCHEM, V90, P1186, DOI 10.1002/jcb.10720; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Nakayama T, 2004, BIOCHEM J, V377, P299, DOI 10.1042/BJ20030599; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Ozeki M, 2004, MOL CELL BIOCHEM, V259, P169, DOI 10.1023/B:MCBI.0000021369.17958.f4; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patterson RL, 2004, ANNU REV BIOCHEM, V73, P437, DOI 10.1146/annurev.biochem.73.071403.161303; Ravichandran LV, 2001, MOL ENDOCRINOL, V15, P1768, DOI 10.1210/me.15.10.1768; Rizzuto Rosario, 2004, Sci STKE, V2004, pre1, DOI 10.1126/stke.2152004re1; Rooney TA, 1996, J BIOL CHEM, V271, P19817, DOI 10.1074/jbc.271.33.19817; Sato M, 2003, NAT CELL BIOL, V5, P1016, DOI 10.1038/ncb1054; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Soulsby MD, 2004, FEBS LETT, V557, P181, DOI 10.1016/S0014-5793(03)01487-X; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tantral L, 2004, CELL BIOCHEM FUNCT, V22, P35, DOI 10.1002/cbf.1050; Tsunoda T, 2005, ONCOGENE, V24, P1396, DOI 10.1038/sj.onc.1208313; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Wagner LE, 2004, J BIOL CHEM, V279, P46242, DOI 10.1074/jbc.M405849200; Wagner LE, 2003, J BIOL CHEM, V278, P45811, DOI 10.1074/jbc.M306270200; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678	49	112	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3731	3737		10.1074/jbc.M509262200	http://dx.doi.org/10.1074/jbc.M509262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16332683	hybrid			2022-12-27	WOS:000235128200085
J	Kulikowicz, T; Shapiro, TA				Kulikowicz, T; Shapiro, TA			Distinct genes encode type II topoisomerases for the nucleus and mitochondrion in the protozoan parasite Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOFLAGELLATE LEISHMANIA-DONOVANI; HUMAN AFRICAN TRYPANOSOMIASIS; KINETOPLAST DNA MINICIRCLES; CRITHIDIA-FASCICULATA; CELL-CYCLE; RNA INTERFERENCE; EXPRESSION; CLONING; GENOME; TARGET	Topoisomerases are essential for orderly nucleic acid metabolism and cell survival and are proven targets for clinically useful antimicrobial and anticancer drugs. Interest in the topologically intricate mitochondrial DNA ( kinetoplast or kDNA) of Trypanosoma brucei brucei and related kinetoplastid protozoan parasites has led to many reports of type II topoisomerases that participate in kDNA metabolism ( we term the T. brucei brucei gene TbTOP2mt). We have now identified and characterized two new genes for type II topoisomerases in T. brucei brucei, termed TbTOP2 alpha and TbTOP2 beta. Phylogenetically, they share a common node with other nuclear topoisomerases, clearly distinct from a clade that includes the previously reported kinetoplastid genes, all of which are homologs of TbTOP2mt. Southern blot analysis reveals the new genes are single copy and positioned similar to 1.7 kb apart. Cognate mRNAs are expressed in African trypanosomes, but only a single message is detected in Leishmania or Crithidia. TbTOP2 alpha encodes an ATP-dependent topoisomerase that appears as a single similar to 170kDa band on immunoblots and localizes to the nucleus; RNA interference leads to pleomorphic nuclear ( but not kDNA) abnormalities and early growth arrest. The role of TbTOP2 beta is unclear. Although transcribed in trypanosomes, TbTOP2 beta is not detected by beta-specific antiserum, and RNAi silencing results in no obvious phenotype. These studies indicate that African trypanosomes and related kinetoplastid human pathogens are unusual in having independent topoisomerase II genes to service their nuclear and mitochondrial genomes, and they highlight TbTOP2 alpha as a promising target for the development of much-needed new therapies.	Johns Hopkins Univ, Sch Med, Div Pharmacol, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Pharmacol, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Shapiro, TA (corresponding author), Johns Hopkins Univ, Sch Med, Div Pharmacol, Dept Med, 303 Hunterian Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	tshapiro@jhmi.edu			NIAID NIH HHS [AI28855] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028855, R56AI028855] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; Bakshi RP, 2004, MOL BIOCHEM PARASIT, V136, P249, DOI 10.1016/j.molbiopara.2004.04.006; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Bingle LEH, 2001, MICROBIOL-SGM, V147, P3231, DOI 10.1099/00221287-147-12-3231; BODLEY AL, 1995, J INFECT DIS, V172, P1157, DOI 10.1093/infdis/172.4.1157; BORST P, 1982, MOL BIOCHEM PARASIT, V6, P13, DOI 10.1016/0166-6851(82)90049-4; BRUN R, 1979, ACTA TROP, V36, P289; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CHAKRABORTY AK, 1987, MOL BIOCHEM PARASIT, V26, P215, DOI 10.1016/0166-6851(87)90074-0; CHAKRABORTY AK, 1991, BIOCHEM BIOPH RES CO, V180, P279, DOI 10.1016/S0006-291X(05)81289-6; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Das A, 2001, NUCLEIC ACIDS RES, V29, P1844, DOI 10.1093/nar/29.9.1844; De Sousa JMA, 2003, SCAND J INFECT DIS, V35, P826, DOI 10.1080/00365540310017023; Djikeng A, 1998, GENE, V221, P93, DOI 10.1016/S0378-1119(98)00427-2; DOUCRASY S, 1988, BIOL CELL, V64, P145, DOI 10.1016/0248-4900(88)90074-3; Ersfeld K, 1999, PARASITOL TODAY, V15, P58, DOI 10.1016/S0169-4758(98)01378-7; Field MC, 2004, MICROSC MICROANAL, V10, P621, DOI 10.1017/S1431927604040942; FRAGOSO SP, 1992, MOL BIOCHEM PARASIT, V55, P127, DOI 10.1016/0166-6851(92)90133-5; Fragoso SP, 1998, MOL BIOCHEM PARASIT, V94, P197, DOI 10.1016/S0166-6851(98)00066-8; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Gibson W, 1999, ADV PARASIT, V43, P1, DOI 10.1016/S0065-308X(08)60240-7; Grab DJ, 2004, J PARASITOL, V90, P970, DOI 10.1645/GE-287R; Hanke T, 2003, NUCLEIC ACIDS RES, V31, P4917, DOI 10.1093/nar/gkg671; Hsiung Y, 1996, CANCER RES, V56, P91; Huang W M, 1994, Adv Pharmacol, V29A, P201; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; Low RL, 2003, EUR J BIOCHEM, V270, P4173, DOI 10.1046/j.1432-1033.2003.03814.x; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; MELENDY T, 1989, J BIOL CHEM, V264, P1870; Mirabella A, 1997, EMBO J, V16, P523, DOI 10.1093/emboj/16.3.523; Moore AC, 2002, NEW ENGL J MED, V346, P2069, DOI 10.1056/NEJMcpc010056; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; PARSONS M, 1984, CELL, V38, P309, DOI 10.1016/0092-8674(84)90552-X; PASION SG, 1992, MOL BIOCHEM PARASIT, V50, P57, DOI 10.1016/0166-6851(92)90244-E; Ploubidou A, 1999, J CELL SCI, V112, P4641; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950; SHAPIRO TA, 1989, J BIOL CHEM, V264, P4173; Shlomai J, 2004, CURR MOL MED, V4, P623, DOI 10.2174/1566524043360096; SHLOMAI J, 1984, ADV EXP MED BIOL, V179, P409; Simpson L, 2003, RNA, V9, P265, DOI 10.1261/rna.2178403; Smith DH, 1998, BRIT MED BULL, V54, P341, DOI 10.1093/oxfordjournals.bmb.a011692; Stich A, 2002, BRIT MED J, V325, P203, DOI 10.1136/bmj.325.7357.203; STRAUSS PR, 1990, MOL BIOCHEM PARASIT, V38, P141, DOI 10.1016/0166-6851(90)90214-7; STUART KD, 1971, J CELL BIOL, V49, P189, DOI 10.1083/jcb.49.1.189; Swofford D.L., 2002, PHYLOGENETIC ANAL US; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tu XM, 2005, EUKARYOT CELL, V4, P755, DOI 10.1128/EC.4.4.755-764.2005; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang ZF, 2002, EMBO J, V21, P4998, DOI 10.1093/emboj/cdf482; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	57	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3048	3056		10.1074/jbc.M505977200	http://dx.doi.org/10.1074/jbc.M505977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16316982	hybrid			2022-12-27	WOS:000235128200007
J	Rendic, D; Linder, A; Paschinger, K; Borth, N; Wilson, IBH; Fabini, GV				Rendic, D; Linder, A; Paschinger, K; Borth, N; Wilson, IBH; Fabini, GV			Modulation of neural carbohydrate epitope expression in Drosophila melanogaster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE ALPHA-1,3-LINKED FUCOSE; N-GLYCAN ANALYSIS; HORSERADISH-PEROXIDASE; LINKED CARBOHYDRATE; GENE-EXPRESSION; ANTIBODIES; CLONING; OLIGOSACCHARIDES; IDENTIFICATION; GLYCOPROTEINS	Neural pathways in invertebrates are often tracked using anti-horseradish peroxidase, a cross-reaction due to the presence of core alpha 1,3-fucosylated N-glycans. In order to investigate the molecular basis of this epitope in a cellular context, we compared two Drosophila melanogaster cell lines: the S2 and the neuronal-like BG2-c6 cell lines. As shown by mass spectrometric and chromatographic analyses, only the BG2-c6 cell line expresses alpha 1,3/alpha 1,6-difucosylated N-glycans, a result that correlates with anti-horseradish peroxidase binding. Of all four alpha 1,3-fucosyltransferase homologues previously identified, the core alpha 1,3-fucosyltransferase (FucTA; EC 2.4.1.214) is expressed in the neuronal cell line as well as throughout fly development and in heads and bodies of flies of both sexes. This pattern is distinctive in comparison with the expression of the other three alpha 1,3-fucosyltransferase homologues (FucTB, FucTC, and FucTD). Furthermore, only transfection of FucTA cDNA into S2 cells resulted in expression of the anti-horseradish peroxidase epitope, a result compatible with its substrate specificity in vitro. Finally, silencing of FucTA by RNAi in the neuronal cell line led to a significant reduction of anti-horseradish peroxidase binding. The present study, in conjunction with our previous in vitro data, thereby shows that FucTA is indispensable for expression of the neural carbohydrate epitope in Drosophila cells.	Univ Bodenkultur Wien, Dept Chem, A-1190 Vienna, Austria; Univ Bodenkultur Wien, Dept Biotechnol, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna	Rendic, D (corresponding author), Univ Bodenkultur Wien, Dept Chem, Muthgasse 18, A-1190 Vienna, Austria.	dubravko.rendic@boku.ac.at	Rendic, Dubravko/A-9368-2010; Wilson, Iain/B-3326-2009	Wilson, Iain/0000-0001-8996-1518; Paschinger, Katharina/0000-0002-3594-7136; Borth, Nicole/0000-0001-6324-9338				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Bencurova M, 2004, GLYCOBIOLOGY, V14, P457, DOI 10.1093/glycob/cwh058; Bouyain S, 2002, J BIOL CHEM, V277, P22566, DOI 10.1074/jbc.M202825200; Breton C, 1998, GLYCOBIOLOGY, V8, P87, DOI 10.1093/glycob/8.1.87; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; Haase A, 2001, DEV GENES EVOL, V211, P428, DOI 10.1007/s004270100173; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; Haslam SM, 2000, GLYCOBIOLOGY, V10, P223, DOI 10.1093/glycob/10.2.223; Ivey-Hoyle M, 1991, Curr Opin Biotechnol, V2, P704, DOI 10.1016/0958-1669(91)90038-7; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KATZ F, 1988, EMBO J, V7, P3471, DOI 10.1002/j.1460-2075.1988.tb03222.x; Kim YK, 2005, BIOTECHNOL BIOENG, V92, P452, DOI 10.1002/bit.20605; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; KUBELKA V, 1995, GLYCOCONJUGATE J, V12, P77, DOI 10.1007/BF00731872; KUBELKA V, 1994, ARCH BIOCHEM BIOPHYS, V308, P148, DOI 10.1006/abbi.1994.1021; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; Leiter H, 1999, J BIOL CHEM, V274, P21830, DOI 10.1074/jbc.274.31.21830; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; Parisi M, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r40; Paschinger K, 2004, J BIOL CHEM, V279, P49588, DOI 10.1074/jbc.M408978200; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Seppo A, 2003, DEVELOPMENT, V130, P1439, DOI 10.1242/dev.00347; SIDDIQUI SS, 1991, J NEUROGENET, V7, P193, DOI 10.3109/01677069109167433; SNOW PM, 1987, J NEUROSCI, V7, P4137; Tsitilou SG, 2003, BIOCHEM BIOPH RES CO, V312, P1372, DOI 10.1016/j.bbrc.2003.11.059; UI K, 1994, IN VITRO CELL DEV-AN, V30A, P209; WANG X, 1994, INSECT BIOCHEM MOLEC, V24, P233, DOI 10.1016/0965-1748(94)90002-7; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Worby C A, 2001, Sci STKE, V2001, ppl1, DOI 10.1126/stke.2001.95.pl1	34	40	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 10	2006	281	6					3343	3353		10.1074/jbc.M508334200	http://dx.doi.org/10.1074/jbc.M508334200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	009QV	16314421	hybrid			2022-12-27	WOS:000235128200042
